PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lin, SH; Nishino, M; Luo, WP; Aumais, JP; Galfione, M; Kuang, J; Yu-Lee, LY				Lin, SH; Nishino, M; Luo, WP; Aumais, JP; Galfione, M; Kuang, J; Yu-Lee, LY			Inhibition of prostate tumor growth by overexpression of NudC, a microtubule motor-associated protein	ONCOGENE			English	Article						NudC; dynein; microtubule; mitosis; prostate cancer	NUCLEAR MIGRATION GENE; CARCINOMA CELL-LINE; CYTOPLASMIC DYNEIN; MOVEMENT PROTEIN; ASPERGILLUS-NIDULANS; DYNACTIN REVEALS; HUMAN HOMOLOG; LIS1; LOCALIZATION; EXPRESSION	Microtubules play a central role in coordinating various cellular functions that are orchestrated by their interaction with molecular motors. Anticancer drugs that target microtubule dynamics have been shown to be effective in cancer treatment. However, the effect of microtubule motor-associated molecules on cancer cell proliferation is not clear. Here, we investigated the role of NudC, a nuclear movement protein associated with the microtubule motor dynein, on prostate tumorigenesis. Recombinant adenovirus expressing NudC (Ad-NudC) was used to examine the effects of NudC on the tumorigenicity of prostate cancer cells. Expression of NudC in LNCaP cells inhibited their anchorage-independent growth in a soft agar colony assay. Expression of NudC in DU145 or PC-3 cells inhibited tumor growth in a subcutaneous xenograft model. At the cellular level, expression of NudC in DU145 and PC-3 cells inhibited cell proliferation at 48 h after Ad-NudC infection. FACS analysis of cell cycle distribution showed that 50-60% of Ad-NudC-infected PC-3 cells have a G2/M-phase DNA content compared to about 16-19% in Ad-Luciferase (Ad-Luc)-infected control cells, suggesting that NudC overexpression resulted in aberrant cell cycle progression. Immunofluorescence microscopy revealed a significant increase in cells with a single enlarged nucleus and cells exhibiting multiple nuclei, along with a concomitant increase in cell size in Ad-NudC-infected cells. These results suggest that NudC overexpression led to a block in cell division of prostate cancer cells, and that Ad-NudC may provide a new anticancer drug approach targeting the function of a microtubule motor-associated protein.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Baylor Coll Med, Cell & Mol Biol Program, Houston, TX 77030 USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	Yu-Lee, LY (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.	yulee@bcm.tmc.edu		Nishino, Michiya/0000-0003-4692-4981	NCI NIH HHS [R01 CA86342] Funding Source: Medline; NIDDK NIH HHS [R01 DK53176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angus SP, 2002, EXP CELL RES, V276, P201, DOI 10.1006/excr.2002.5510; Aumais JP, 2003, J CELL SCI, V116, P1991, DOI 10.1242/jcs.00412; Aumais JP, 2000, MOL BIOL CELL, V11, p353A; Aumais JP, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0002.2001; AXTELL SM, 1995, MOL ENDOCRINOL, V9, P312, DOI 10.1210/me.9.3.312; Baas PW, 1999, NEURON, V22, P23, DOI 10.1016/S0896-6273(00)80675-3; Banks JD, 2001, CURR BIOL, V11, pR128, DOI 10.1016/S0960-9822(01)00059-8; Beaudouin J, 2002, CELL, V108, P83, DOI 10.1016/S0092-8674(01)00627-4; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Chen JG, 2002, CANCER RES, V62, P1935; Chiu YH, 1997, MOL BIOL CELL, V8, P1735, DOI 10.1091/mbc.8.9.1735; Coquelle FM, 2002, MOL CELL BIOL, V22, P3089, DOI 10.1128/MCB.22.9.3089-3102.2002; Dujardin DL, 2002, CURR OPIN CELL BIOL, V14, P44, DOI 10.1016/S0955-0674(01)00292-7; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Gartel AL, 2002, MOL CANCER THER, V1, P639; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gocke CD, 2000, HISTOCHEM CELL BIOL, V114, P293; Gocke CD, 2000, LEUKEMIA LYMPHOMA, V39, P447, DOI 10.3109/10428190009113375; Han GS, 2001, CURR BIOL, V11, P719, DOI 10.1016/S0960-9822(01)00200-7; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; KAIGHN ME, 1979, INVEST UROL, V17, P16; Karki S, 1998, J CELL BIOL, V142, P1023, DOI 10.1083/jcb.142.4.1023; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; Lin SH, 1999, ANTICANCER RES, V19, P337; Miller BA, 1999, EXP HEMATOL, V27, P742, DOI 10.1016/S0301-472X(98)00074-5; Moreau N, 2001, INT J DEV BIOL, V45, P839; Morris NR, 2000, J CELL BIOL, V148, P1097, DOI 10.1083/jcb.148.6.1097; Morris SM, 1998, EXP CELL RES, V238, P23, DOI 10.1006/excr.1997.3822; Morris SM, 1997, MOL ENDOCRINOL, V11, P229, DOI 10.1210/me.11.2.229; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; OSMANI AH, 1990, J CELL BIOL, V111, P543, DOI 10.1083/jcb.111.2.543; Peterson JR, 2002, CHEM BIOL, V9, P1275, DOI 10.1016/S1074-5521(02)00284-3; Quintyne NJ, 1999, J CELL BIOL, V147, P321, DOI 10.1083/jcb.147.2.321; Quintyne NJ, 2002, J CELL BIOL, V159, P245, DOI 10.1083/jcb.200203089; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Salina D, 2002, CELL, V108, P97, DOI 10.1016/S0092-8674(01)00628-6; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Straight AF, 2000, CURR BIOL, V10, pR760, DOI 10.1016/S0960-9822(00)00746-6; Tai CY, 2002, J CELL BIOL, V156, P959, DOI 10.1083/jcb.200109046; Talcott B, 2000, J BIOL CHEM, V275, P10099, DOI 10.1074/jbc.275.14.10099; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Yan XM, 2003, MOL CELL BIOL, V23, P1239, DOI 10.1128/MCB.23.4.1239-1250.2003; Zhang MY, 2002, EXP CELL RES, V273, P73, DOI 10.1006/excr.2001.5414; Zhou T, 2003, DEV CELL, V5, P127, DOI 10.1016/S1534-5807(03)00186-2	52	26	28	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2499	2506		10.1038/sj.onc.1207343	http://dx.doi.org/10.1038/sj.onc.1207343			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676831				2022-12-28	WOS:000220558000007
J	Willis, A; Jung, EJ; Wakefield, T; Chen, XB				Willis, A; Jung, EJ; Wakefield, T; Chen, XB			Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes	ONCOGENE			English	Article						p53; mutant p53; cell cycle arrest; transcription	CELL-CYCLE ARREST; TUMOR-SUPPRESSOR P53; GAIN-OF-FUNCTION; FUNCTION MUTATIONS; TERMINAL DOMAIN; HUMAN CANCER; DNA-BINDING; APOPTOSIS; PROTEIN; ACTIVATION	Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer. A majority of these mutations are missense mutations in the DNA-binding domain. As a result, the mutated p53 gene encodes a full-length protein incapable of transactivating its target genes. In addition to this loss of function, mutant p53 can have a dominant negative effect over wild-type p53 and/or gain of function activity independently of the wild-type protein. To better understand the nature of the tumorigenic activity of mutant p53, we have investigated the mechanism by which mutant p53 can exert a dominant negative effect. We have established several stable cell lines capable of inducibly expressing a p53 mutant alone, wild-type p53 alone, or both proteins concurrently. In this context, we have used chromatin immunoprecipitation to determine the ability of wild-type p53 to bind to its endogenous target genes in the presence of various p53 mutants. We have found that p53 missense mutants markedly reduce the binding of wild-type p53 to the p53 responsive element in the target genes of p21, MDM2, and PIG3. These findings correlate with the reduced ability of wild-type p53 in inducing these and other endogenous target genes and growth suppression in the presence of mutant p53. We also showed that mutant p53 suppresses the ability of wild-type p53 in inducing cell cycle arrest. This highlights the sensitivity and utility of the dual inducible expression system because in previous studies, p53-mediated cell cycle arrest is not affected by transiently overexpressed p53 mutants. Together, our data showed that mutant p53 exerts its dominant negative activity by abrogating the DNA binding, and subsequently the growth suppression, functions of wild-type p53.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, UAB Comprehens Canc Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660,1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		Amara, Amy/0000-0003-0762-9656	NCI NIH HHS [2 R01 CA076069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076069] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atema A, 2002, CANCER LETT, V185, P103, DOI 10.1016/S0304-3835(02)00318-X; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Birch JM, 1998, ONCOGENE, V17, P1061, DOI 10.1038/sj.onc.1202033; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN XB, 1995, CANCER RES, V55, P4257; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; Hussain SP, 1998, CANCER RES, V58, P4023; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1995, ONCOGENE, V10, P2387; Liu G, 2000, P NATL ACAD SCI USA, V97, P4174, DOI 10.1073/pnas.97.8.4174; Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Marutani M, 1999, CANCER RES, V59, P4765; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; Monti P, 2002, ONCOGENE, V21, P1641, DOI 10.1038/sj.onc.1205250; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nicholls CD, 2002, J BIOL CHEM, V277, P12937, DOI 10.1074/jbc.M108815200; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Prives C, 1999, J PATHOL, V187, P112; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; ROLLEY N, 1995, ONCOGENE, V11, P763; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Willis AC, 2003, ONCOGENE, V22, P5481, DOI 10.1038/sj.onc.1206505; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhu JH, 1998, CANCER RES, V58, P5061	55	214	221	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2330	2338		10.1038/sj.onc.1207396	http://dx.doi.org/10.1038/sj.onc.1207396			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743206				2022-12-28	WOS:000220427700007
J	Weeraratna, AT; Becker, D; Carr, KM; Duray, PH; Rosenblatt, KP; Yang, S; Chen, YD; Bittner, M; Strausberg, RL; Riggins, GJ; Wagner, U; Kallioniemi, OP; Trent, JM; Morin, PJ; Meltzer, PS				Weeraratna, AT; Becker, D; Carr, KM; Duray, PH; Rosenblatt, KP; Yang, S; Chen, YD; Bittner, M; Strausberg, RL; Riggins, GJ; Wagner, U; Kallioniemi, OP; Trent, JM; Morin, PJ; Meltzer, PS			Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome	ONCOGENE			English	Article						SAGE; melanoma; tissue microarray; CD74; calpain; Wnt5a	GENE-EXPRESSION; SERIAL ANALYSIS; MALIGNANT-MELANOMA; GASTRIC-CANCER; CELL-LINES; PROTEINS; TUMOR; MUTATIONS; BINDING; FAMILY	In this study, we generated three SAGE libraries from melanoma tissues. Using bioinformatics tools usually applied to microarray data, we identified several genes, including novel transcripts, which are preferentially expressed in melanoma. SAGE results converged with previous microarray analysis on the importance of intracellular calcium and G- protein signaling, and the Wnt/ Frizzled family. We also examined the expression of CD74, which was specifically, albeit not abundantly, expressed in the melanoma libraries using a melanoma progression tissue microarray, and demonstrate that this protein is expressed by melanoma cells but not by benign melanocytes. Many genes involved in intracellular calcium and G- protein signaling were highly expressed in melanoma, results we had observed earlier from microarray studies ( Bittner et al., 2000). One of the genes most highly expressed in our melanoma SAGE libraries was a calcium-regulated gene, calpain 3 ( p94). Immunohistochemical analysis demonstrated that calpain 3 moves from the nuclei of non- neoplastic cells to the cytoplasm of malignant cells, suggesting activation of this intracellular proteinase. Our SAGE results and the clinical validation data demonstrate how SAGE profiles can highlight specific links between signaling pathways as well as associations with tumor progression. This may provide insights into new genes that may be useful for the diagnosis and therapy of melanoma.	NIA, Immunol Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; NCI, Bethesda, MD 20892 USA; NHGRI, Bethesda, MD 20892 USA; Translat Genom Res Inst, Phoenix, AZ USA; Inst Genom Res, Rockville, MD USA; Johns Hopkins Univ, Dept Neurosurg, Baltimore, MD USA; Univ Basel, Inst Pathol, Basel, Switzerland; Univ Turku, Turku, Finland; Tech Res Ctr Finland, Med Biotechnol Grp, Turku, Finland	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Translational Genomics Research Institute; J. Craig Venter Institute; Johns Hopkins University; University of Basel; University of Turku; VTT Technical Research Center Finland	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr,Box 21, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov; pmeltzer@nhgri.nih.gov	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000186] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000442, Z01AG000512, ZIAAG000442] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Datson NA, 1999, NUCLEIC ACIDS RES, V27, P1300, DOI 10.1093/nar/27.5.1300; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dejmek J, 2003, INT J CANCER, V103, P344, DOI 10.1002/ijc.10752; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; DEMETRICK DJ, 1992, J NATL CANCER I, V84, P422, DOI 10.1093/jnci/84.6.422; Desmond RA, 2003, SURG CLIN N AM, V83, P1, DOI 10.1016/S0039-6109(02)00092-0; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Eisenberg CA, 1997, DEVELOPMENT, V124, P525; El-Rifai W, 2002, CANCER RES, V62, P6823; Hodgkinson JL, 2000, J MUSCLE RES CELL M, V21, P115, DOI 10.1023/A:1005697301043; Hough CD, 2000, CANCER RES, V60, P6281; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Ishigami S, 2001, CANCER LETT, V168, P87, DOI 10.1016/S0304-3835(01)00503-1; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; MARTI GE, 1992, LEUKEMIA LYMPHOMA, V7, P497, DOI 10.3109/10428199209049807; O'Rourke FA, 2003, BIOCHEM J, V373, P133, DOI 10.1042/BJ20030013; OHNO S, 1990, CYTOGENET CELL GENET, V53, P225, DOI 10.1159/000132937; Ong GL, 1999, IMMUNOLOGY, V98, P296; PFAFFSMITH, 2004, IN PRESS CANC BIOL T; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449; Porter DA, 2001, CANCER RES, V61, P5697; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Ribe A, 2003, MODERN PATHOL, V16, P505, DOI 10.1097/01.MP.0000071128.67149.FD; Richard I, 1999, AM J HUM GENET, V64, P1524, DOI 10.1086/302426; ROSS AH, 1983, ARCH BIOCHEM BIOPHYS, V225, P370, DOI 10.1016/0003-9861(83)90042-5; Saitoh T, 2002, INT J MOL MED, V9, P515; Sakai C, 1997, MELANOMA RES, V7, P83, DOI 10.1097/00008390-199704000-00001; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Smedley D, 2000, GENE CHROMOSOME CANC, V28, P121, DOI 10.1002/(SICI)1098-2264(200005)28:1<121::AID-GCC14>3.0.CO;2-O; Taniguchi S, 2001, CANCER RES, V61, P7627; VANRUISSEN F, 1995, GENOMICS, V79, P671; Velculescu VE, 2000, TRENDS GENET, V16, P423, DOI 10.1016/S0168-9525(00)02114-4; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wang CY, 2001, NEURON, V32, P99, DOI 10.1016/S0896-6273(01)00434-2; Weeraratna AT, 2003, PIGM CELL RES, V16, P183, DOI 10.1034/j.1600-0749.2003.00042.x; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	45	55	57	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2264	2274		10.1038/sj.onc.1207337	http://dx.doi.org/10.1038/sj.onc.1207337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14755246				2022-12-28	WOS:000220280900017
J	Peirce, SK; Chen, WY				Peirce, SK; Chen, WY			Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice	ONCOGENE			English	Article						prolactin antagonist; bax; bcl-2; cytochrome c; breast cancer; apoptosis	MAMMARY-GLAND; APOPTOSIS; GROWTH; FAMILY; PROMOTER	To gain insight into the molecular mechanisms involved in human prolactin receptor antagonist (hPRL-G129R)induced apoptosis, we used real-time reverse transcription - polymerase chain reaction to measure bax and bcl-2 gene expression in 11 human breast cancer cell lines following treatment with hPRL and hPRL-G129R. We also measured bax and bcl-2 gene expression in the mammary glands of transgenic mice expressing hPRL or hPRL-G129R. A time-course study of hPRL and antagonist treatment in T-47D cells indicated changing bax/bcl-2 mRNA ratios beginning at 24 h. We found that bax/bcl-2 mRNA ratios were significantly elevated in seven of the 11 hPRL-G129R-treated cell lines, as well as in the hPRL-G129R transgenic mice. To confirm these results, Bax and Bcl-2 proteins were analysed by Western blot methods in mammary gland tissue homogenates of transgenic mice. Bax/Bcl-2 ratios were highest in the 6-month group of hPRL-G129R transgenics, and lowest in the 6-month group of hPRL transgenics. We expanded our findings by examining the release of a downstream Bax-induced protein, cytochrome c, a hallmark protein of apoptosis, in transgenic mice. Again, cytochrome c levels were highest in the 6-month hPRL-G129R transgenic group. Thus, hPRL-G129R-induced breast cancer cell and/or mammary gland apoptosis is mediated, at least in part, through the regulation of Bax and Bcl-2 gene expression.	Greenville Hosp Syst, Oncol Res Inst, Greenville, SC 29605 USA; Clemson Univ, Dept Biol Sci, Clemson, SC 29630 USA; Clemson Univ, Dept Biochem & Genet, Clemson, SC 29630 USA	Greenville Health System; Clemson University; Clemson University	Chen, WY (corresponding author), Greenville Hosp Syst, Oncol Res Inst, 900 W Faris Rd, Greenville, SC 29605 USA.	wchen@ghs.org			NCI NIH HHS [CA87093] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087093] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Beck MT, 2002, ONCOGENE, V21, P5047, DOI 10.1038/sj.onc.1205637; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; Bhatavdekar JM, 2000, EUR J SURG ONCOL, V26, P540, DOI 10.1053/ejso.2000.0943; Binart N, 2000, ADV EXP MED BIOL, V480, P85; Binder C, 1996, ANN ONCOL, V7, P129; BLACKWELL RE, 1999, HORMONAL CONTROL NOR, P3; Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774; Chen NY, 2002, INT J ONCOL, V20, P813; Chen WY, 1999, CLIN CANCER RES, V5, P3583; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Corbacho AM, 2002, J ENDOCRINOL, V173, P219, DOI 10.1677/joe.0.1730219; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; GINSBURG E, 1995, CANCER RES, V55, P2591; Green DR, 1999, CANC DRUG DISC DEV, V5, P157; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Krumenacker JS, 1998, ENDOCRINE, V9, P163, DOI 10.1385/ENDO:9:2:163; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Kuo CB, 2002, CELL TISSUE RES, V309, P429, DOI 10.1007/s00441-002-0598-8; Marti A, 1997, EUR J CELL BIOL, V73, P158; NAGASAWA H, 1985, EXP CLIN ENDOCRINOL, V86, P357, DOI 10.1055/s-0029-1210509; Peirce SK, 2001, J ENDOCRINOL, V171, pR1, DOI 10.1677/joe.0.171R001; Schorr K, 1999, CANCER RES, V59, P2541; Vonderhaar BK, 1998, PHARMACOL THERAPEUT, V79, P169, DOI 10.1016/S0163-7258(98)00017-5; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	31	43	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1248	1255		10.1038/sj.onc.1207245	http://dx.doi.org/10.1038/sj.onc.1207245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647416				2022-12-28	WOS:000188892200009
J	Stoner, M; Wormke, M; Saville, B; Samudio, I; Qin, CH; Abdelrahim, M; Safe, S				Stoner, M; Wormke, M; Saville, B; Samudio, I; Qin, CH; Abdelrahim, M; Safe, S			Estrogen regulation of vascular endothelial growth factor gene expression in ZR-75 breast cancer cells through interaction of estrogen receptor alpha and SP proteins	ONCOGENE			English	Article						estrogen; VEGF; transactivation; ER alpha/Sp1; ER alpha/Sp3	PERMEABILITY FACTOR EXPRESSION; NECROSIS-FACTOR-ALPHA; CATHEPSIN-D GENE; TRANSCRIPTIONAL ACTIVATION; FACTOR VEGF; PROGESTERONE-RECEPTOR; HORMONAL-REGULATION; RESPONSIVE ELEMENT; GLIOMA-CELLS; TUMOR-GROWTH	Vascular endothelial growth factor (VEGF) is expressed in multiple hormone-dependent cancer cells/tumors. Treatment of ZR-75 breast cancer cells with 17beta-estradiol (E2) induced a greater than fourfold increase of VEGF mRNA levels. ZR-75 breast cancer cells were transfected with pVEGF1, a construct containing a -2018 to +50 VEGF prom oter insert, and E2 induced reporter gene (luciferase) activity. Deletion and mutation analysis of the VEGF gene promoter identified a GC-rich region (-66 to -47) which was required for E2-induced transactivation of pVEGF5, a construct containing the minimal promoter (-66 to +54) that exhibited E2-responsiveness. Interactions of nuclear proteins from ZR-75 cells with the proximal GC-rich region of the VEGF gene promoter were investigated by electrophoretic mobility shift and chromatin immunoprecipitation assays. The results demonstrate that both Sp1 and Sp3 proteins bound the GC-rich motif (-66 to +47), and estrogen receptor alpha (ERalpha) interactions were confirmed by chromatin immunoprecipitation. Moreover, E2-dependent activation of constructs containing proximal and distal GC/GT-rich regions of the VEGF promoter was inhibited in ZR-75 cells transfected with small inhibitory RNAs for Sp1 and Sp3. These results were consistent with a mechanism of hormone activation of VEGF through ERalpha/Sp1 and ERalpha/Sp3 interactions with GC-rich motifs.	Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Safe, S (corresponding author), Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.	ssafe@cvm.tamu.edu	Samudio, Ismael/D-3581-2013	Samudio, Ismael/0000-0001-8676-1035	NATIONAL CANCER INSTITUTE [R01CA076636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009106, R01ES004176] Funding Source: NIH RePORTER; NCI NIH HHS [CA076636] Funding Source: Medline; NIEHS NIH HHS [ES04176, ES09106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bae DG, 2000, J BIOL CHEM, V275, P13588, DOI 10.1074/jbc.275.18.13588; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; Bogin L, 2002, CANCER RES, V62, P1948; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Brekken RA, 2000, CANCER RES, V60, P5117; BROWN LF, 1993, AM J PATHOL, V143, P1255; Buteau-Lozano H, 2002, CANCER RES, V62, P4977; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; CAVAILLES V, 1989, MOL ENDOCRINOL, V3, P552, DOI 10.1210/mend-3-3-552; CAVAILLES V, 1993, P NATL ACAD SCI USA, V90, P203, DOI 10.1073/pnas.90.1.203; Classen-Linke I, 2000, STEROIDS, V65, P763, DOI 10.1016/S0039-128X(00)00180-X; CULLINANBOVE K, 1993, ENDOCRINOLOGY, V133, P829, DOI 10.1210/en.133.2.829; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981; Enholm B, 1997, ONCOGENE, V14, P2475, DOI 10.1038/sj.onc.1201090; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Gillesby BE, 1997, BIOCHEMISTRY-US, V36, P6080, DOI 10.1021/bi962131b; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Harborth J, 2001, J CELL SCI, V114, P4557; Hyder SM, 1997, CANCER LETT, V120, P165, DOI 10.1016/S0304-3835(97)00306-6; Hyder SM, 1998, CANCER RES, V58, P392; Hyder SM, 1996, CANCER RES, V56, P3954; Hyder SM, 2000, CANCER RES, V60, P3183; Kimura H, 2001, J BIOL CHEM, V276, P2292, DOI 10.1074/jbc.M008398200; KLOTZ DM, 1995, BIOCHEM BIOPH RES CO, V210, P609, DOI 10.1006/bbrc.1995.1702; Laitinen M, 1997, ENDOCRINOLOGY, V138, P4748, DOI 10.1210/en.138.11.4748; Linderholm BK, 2001, CANCER RES, V61, P2256; Monte D, 1998, J BIOL CHEM, V273, P4585, DOI 10.1074/jbc.273.8.4585; Mueller MD, 2000, P NATL ACAD SCI USA, V97, P10972, DOI 10.1073/pnas.200377097; Nakamura J, 1996, ENDOCRINOLOGY, V137, P5589, DOI 10.1210/en.137.12.5589; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Pipaon C, 1999, MOL CELL BIOL, V19, P2734; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Ruohola JK, 1999, MOL CELL ENDOCRINOL, V149, P29, DOI 10.1016/S0303-7207(99)00003-9; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Samudio I, 2001, ENDOCRINOLOGY, V142, P1000, DOI 10.1210/en.142.3.1000; Sathya G, 1997, MOL ENDOCRINOL, V11, P1994, DOI 10.1210/me.11.13.1994; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Scheidegger KJ, 2000, J BIOL CHEM, V275, P38921, DOI 10.1074/jbc.M004691200; Schlaeppi JM, 1999, CANCER METAST REV, V18, P473, DOI 10.1023/A:1006358220123; Shi Q, 2001, CANCER RES, V61, P4143; Simmen RCM, 1999, ENDOCRINOLOGY, V140, P2517, DOI 10.1210/en.140.6.2517; Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; Wormke M, 2003, MOL CELL BIOL, V23, P1843, DOI 10.1128/MCB.23.6.1843-1855.2003; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Yoshiji H, 1997, CANCER RES, V57, P3924; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	63	114	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1052	1063		10.1038/sj.onc.1207201	http://dx.doi.org/10.1038/sj.onc.1207201			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647449				2022-12-28	WOS:000188749900004
J	Dan, HC; Jiang, K; Coppola, D; Hamilton, A; Nicosia, SV; Sebti, SM; Cheng, JQ				Dan, HC; Jiang, K; Coppola, D; Hamilton, A; Nicosia, SV; Sebti, SM; Cheng, JQ			Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis	ONCOGENE			English	Article						Akt; PI3K; survivin; GGTI; apoptosis; ovarian cancer	NF-KAPPA-B; HUMAN OVARIAN-CANCER; WILD-TYPE P53; X-LINKED INHIBITOR; V-HA-RAS; FARNESYLTRANSFERASE INHIBITOR; GERANYLGERANYLATED RHOB; GROWTH-FACTORS; UP-REGULATION; CELLS	Geranylgeranyltransferase I inhibitors (GGTIs) represent a new class of anticancer drugs. However, the mechanism by which GGTIs inhibit tumor cell growth is still unclear. Here, we demonstrate that GGTI-298 and GGTI-2166 induce apoptosis in both cisplatin-sensitive and -resistant human ovarian epithelial cancer cells by inhibition of PI3K/AKT and survivin pathways. Following GGTI-298 or GGTI-2166 treatment, kinase levels of PI3K and AKT were decreased and survivin expression was significantly reduced. Ectopic expression of constitutively active AKT2 and/or survivin significantly rescue human cancer cells from GGTI-298-induced apoptosis. Previous studies have shown that Akt mediates growth factor-induced survivin, whereas p53 inhibits survivin expression. However, constitutively active AKT2 failed to rescue the GGTIs downregulation of survivin. Further, GGTIs suppress survivin expression and induce programmed cell death in both wild-type p53 and p53-deficient ovarian cancer cell lines. These data indicate that GGTI-298 and GGTI-2166 induce apoptosis by targeting PI3K/AKT and survivin parallel pathways independent of p53. Owing to the fact that upregulation of Akt and survivin as well as inactivation of p53 are frequently associated with chemoresistance, GGTIs could be valuable agents to overcome antitumor drug resistance.	Univ S Florida, Coll Med, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Drug Discovery Program, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06511 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), Univ S Florida, Coll Med, Dept Pathol, 12901 Bruce B Downs Blvd,MDC11, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu; jcheng@hsc.usf.edu			NATIONAL CANCER INSTITUTE [R01CA089242, U19CA067771, R01CA085709] Funding Source: NIH RePORTER; NCI NIH HHS [CA89242, CA085709, CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Arboleda MJ, 2003, CANCER RES, V63, P196; Bolick SCE, 2003, LEUKEMIA, V17, P451, DOI 10.1038/sj.leu.2402832; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Clark AS, 2002, MOL CANCER THER, V1, P707; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du W, 1999, MOL CELL BIOL, V19, P1831; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Liu AX, 1998, CANCER RES, V58, P2973; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Ozes ON, 1999, NATURE, V401, P82; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Sasaki H, 2000, CANCER RES, V60, P5659; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Sebti SM, 1997, PHARMACOL THERAPEUT, V74, P103, DOI 10.1016/S0163-7258(97)00014-4; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; Song KM, 1997, ONCOL RES, V9, P603; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sun JZ, 1999, CANCER RES, V59, P4919; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	41	87	94	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					706	715		10.1038/sj.onc.1207171	http://dx.doi.org/10.1038/sj.onc.1207171			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737105				2022-12-28	WOS:000188304900009
J	Ionov, Y; Nowak, N; Perucho, M; Markowitz, S; Cowell, JK				Ionov, Y; Nowak, N; Perucho, M; Markowitz, S; Cowell, JK			Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability	ONCOGENE			English	Article						NMD; microsatellite instability; p300	MESSENGER-RNA DECAY; COLORECTAL-CANCER; MAMMALIAN-CELLS; SURVEILLANCE; RETINOBLASTOMA; TRANSLATION; EXPRESSION; INACTIVATION; SEQUENCES; MECHANISM	Cancer cells showing microsatellite instability (MSI) demonstrate a high frequency of acquired frameshift mutations that result in the generation of nonsense mutations. RNA transcripts carrying these nonsense mutations are usually targeted for degradation through the nonsense mediated decay (NMD) pathway. Blocking this pathway with drugs such as emitine, results in the 'stabilization' of these mutant transcripts, which can now be detected on cDNA arrays. Unfortunately, emetine also induces a stress response that results in upregulation of additional transcripts which contribute to the analysis of the array. As a result, identifying which genes truly carry nonsense mutations is made more difficult. To overcome this, we have combined the emetine treatment with actinomycin D, which effectively prevents the upregulation of stress response genes while still stabilizing mutant transcripts. When we applied this modified approach to the analysis of MSI-positive colon cancer cells, we identified mutations in the UVRAG and p300 genes.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Burnham Inst, La Jolla Canc Ctr, La Jolla, CA 92037 USA; Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Roswell Park Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; University Hospitals of Cleveland	Ionov, Y (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	Yurij.Ionov@RoswellPark.org		Perucho, Manuel/0000-0002-2169-2662; Cowell, John/0000-0002-2079-5950				BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COWELL JK, 2001, MOL GENETICS CANC; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Iida A, 2000, HUM GENET, V106, P277, DOI 10.1007/s004390051038; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Jiang W, 1997, BIOCHEMISTRY-US, V36, P14786, DOI 10.1021/bi9717892; KIM HG, 1994, AM J PATHOL, V145, P148; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Laurila IP, 1999, AGR FOOD SCI FINLAND, V8, P1; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Perucho M, 1996, BIOL CHEM, V377, P675; Salahshor S, 1999, GENE CHROMOSOME CANC, V26, P247, DOI 10.1002/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.3.CO;2-8; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Sun XL, 2000, RNA, V6, P1, DOI 10.1017/S1355838200991660; TEITZ T, 1990, GENE, V87, P295, DOI 10.1016/0378-1119(90)90316-J; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498	28	130	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	2004	23	3					639	645		10.1038/sj.onc.1207178	http://dx.doi.org/10.1038/sj.onc.1207178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737099				2022-12-28	WOS:000188304900002
J	Wang, HC; Boecker, W; Wang, HY; Wang, X; Guan, J; Thompson, LH; Nickoloff, JA; Iliakis, G				Wang, HC; Boecker, W; Wang, HY; Wang, X; Guan, J; Thompson, LH; Nickoloff, JA; Iliakis, G			Caffeine inhibits homology-directed repair of I-SceI-induced DNA double-strand breaks	ONCOGENE			English	Article						caffeine; DNA; double-strand breaks (DSB); repair; homology-directed repair; homologous recombination; nonhomologous end joining	IRRADIATED HELA-CELLS; MAMMALIAN-CELLS; IONIZING-RADIATION; PROTEIN-KINASE; INDUCED RADIOSENSITIZATION; CHROMOSOME BREAKS; DAMAGE CHECKPOINT; RAD51 PARALOGS; CULTURED HUMAN; X-IRRADIATION	We recently reported that two Chinese hamster mutants deficient in the RAD51 paralogs XRCC2 and XRCC3 show reduced radiosensitization after treatment with caffeine, thus implicating homology-directed repair (HDR) of DNA double- strand breaks (DSBs) in the mechanism of caffeine radiosensitization. Here, we investigate directly the effect of caffeine on HDR initiated by DSBs induced by a rare cutting endonuclease (I-SceI) into one of two direct DNA repeats. The results demonstrate a strong inhibition by caffeine of HDR in wild-type cells, and a substantial reduction of this effect in HDR-deficient XRCC3 mutant cells. Inhibition of HDR and cell radiosensitization to killing shows similar dependence on caffeine concentration suggesting a cause - effect relationship between these effects. UCN-01, a kinase inhibitor that effectively abrogates checkpoint activation in irradiated cells, has only a small effect on HDR, indicating that similar to radiosensitization, inhibition of checkpoint signaling is not sufficient for HDR inhibition. Recombination events occurring during treatment with caffeine are characterized by rearrangements reminiscent to those previously reported for the XRCC3 mutant, and immunofluorescence microscopy demonstrates significantly reduced formation of IR-specific RAD51 foci after caffeine treatment. In summary, our results identify inhibition of HDR as a significant contributor to caffeine radiosensitization.	Univ Duisburg Gesamthsch, Essen Med Sch, Inst Med Radiat Biol, D-45122 Essen, Germany; Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of Duisburg Essen; Jefferson University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of New Mexico	Iliakis, G (corresponding author), Univ Duisburg Gesamthsch, Essen Med Sch, Inst Med Radiat Biol, IG1 Bldg,Room A4-37, D-45122 Essen, Germany.	Georg.Iliakis@uni-essen.de			NCI NIH HHS [CA56706, CA77693, CA42026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077693, R01CA056706, R01CA042026] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; BEETHAM KL, 1984, RADIAT RES, V100, P104, DOI 10.2307/3576526; BEETHAM KL, 1986, RADIAT RES, V107, P272, DOI 10.2307/3576814; BEETHAM KL, 1984, RADIAT RES, V100, P585, DOI 10.2307/3576421; BEETHAM KL, 1982, J CELL PHYSIOL, V113, P385, DOI 10.1002/jcp.1041130306; Bernhard EJ, 1996, INT J RADIAT BIOL, V69, P575, DOI 10.1080/095530096145580; Bill CA, 2001, MUTAT RES-DNA REPAIR, V487, P41; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Busby EC, 2000, CANCER RES, V60, P2108; BUSSE PM, 1977, RADIAT RES, V71, P666, DOI 10.2307/3574634; BUSSE PM, 1978, RADIAT RES, V76, P292, DOI 10.2307/3574780; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; DOMON M, 1969, RADIAT RES, V39, P207, DOI 10.2307/3572642; FAN SJ, 1995, CANCER RES, V55, P1649; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; FURCINITTI PS, 1983, RADIAT RES, V95, P197, DOI 10.2307/3576085; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; GRIFFITHS TD, 1978, INT J RADIAT BIOL, V33, P493, DOI 10.1080/09553007814550401; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARVEY AN, 1994, MUTAT RES, V304, P203, DOI 10.1016/0027-5107(94)90212-7; ILIAKIS G, 1983, INT J RADIAT BIOL, V43, P649, DOI 10.1080/09553008314550741; ILIAKIS G, 1983, RADIAT RES, V95, P87, DOI 10.2307/3576074; ILIAKIS G, 1991, BIOESSAYS, V13, P641; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; Johnson RD, 2001, BIOCHEM SOC T, V29, P196, DOI 10.1042/BST0290196; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JUNG T, 1992, INT J RADIAT BIOL, V62, P161, DOI 10.1080/09553009214551971; KASTAN MB, 1991, CANCER RES, V51, P6304; KIHLMAN BA, 1977, CAFFEINE CHROMOSOMES, P1; KIMLER BF, 1982, INT J RADIAT BIOL, V41, P47, DOI 10.1080/09553008214550041; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 2002, NUCLEIC ACIDS RES, V30, P1009, DOI 10.1093/nar/30.4.1009; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LUCKEHUHLE C, 1983, INT J RADIAT BIOL, V43, P123, DOI 10.1080/09553008314550131; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; MURNANE JP, 1980, NATURE, V285, P326, DOI 10.1038/285326a0; MURNANE JP, 1995, CANCER METAST REV, V14, P17, DOI 10.1007/BF00690208; MUSK SRR, 1991, RADIAT RES, V125, P262, DOI 10.2307/3578108; MUSK SRR, 1990, INT J RADIAT BIOL, V57, P1105, DOI 10.1080/09553009014551221; PAINTER RB, 1980, J MOL BIOL, V143, P289, DOI 10.1016/0022-2836(80)90191-6; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; Peterson SR, 1997, J BIOL CHEM, V272, P10227; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; POWELL SN, 1995, CANCER RES, V55, P1643; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Raderschall E, 2002, J CELL SCI, V115, P153; Ribeiro JCC, 1999, INT J RADIAT BIOL, V75, P481, DOI 10.1080/095530099140410; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sarkaria JN, 1999, CANCER RES, V59, P4375; Shinomiya N, 1997, CYTOMETRY, V27, P365, DOI 10.1002/(SICI)1097-0320(19970401)27:4<365::AID-CYTO8>3.3.CO;2-F; STACKHOUSE MA, 1993, RADIAT RES, V136, P241, DOI 10.2307/3578617; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tambini CE, 1997, GENOMICS, V41, P84, DOI 10.1006/geno.1997.4636; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; TAYLOR YC, 1993, INT J RADIAT BIOL, V64, P57, DOI 10.1080/09553009314551111; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; THOMPSON LH, 2003, EUKARYOTIC DNA DAMAG; TIMSON J, 1977, MUTAT RES, V47, P1, DOI 10.1016/0165-1110(77)90016-1; TOLMACH LJ, 1980, RADIAT RES, V82, P374, DOI 10.2307/3575387; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; TOMASOVIC SP, 1978, RADIAT RES, V74, P112, DOI 10.2307/3574761; TSO POP, 1964, P NATL ACAD SCI USA, V51, P17, DOI 10.1073/pnas.51.1.17; Valenzuela MT, 2000, RADIOTHER ONCOL, V54, P261, DOI 10.1016/S0167-8140(99)00180-2; WALDREN CA, 1978, RADIAT RES, V73, P95, DOI 10.2307/3574576; WALTERS RA, 1974, BIOPHYS J, V14, P99, DOI 10.1016/S0006-3495(74)70002-9; Wang HC, 2003, RADIAT RES, V159, P420, DOI 10.1667/0033-7587(2003)159[0420:CCNESH]2.0.CO;2; Wang HC, 2001, ONCOGENE, V20, P2212, DOI 10.1038/sj.onc.1204350; Wang X, 2003, RADIAT RES, V159, P426, DOI 10.1667/0033-7587(2003)159[0426:CIRIIO]2.0.CO;2; Wiese C, 2002, NUCLEIC ACIDS RES, V30, P1001, DOI 10.1093/nar/30.4.1001; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	84	47	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					824	834		10.1038/sj.onc.1207168	http://dx.doi.org/10.1038/sj.onc.1207168			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737117				2022-12-28	WOS:000188304900021
J	Kim, EH; Kim, SU; Shin, DY; Choi, KS				Kim, EH; Kim, SU; Shin, DY; Choi, KS			Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; roscovitine; apoptosis; glioma	X-LINKED INHIBITOR; CYCLIN-DEPENDENT KINASES; PROSTATE-CANCER CELLS; GLIAL-CELLS; PHASE-II; EXPRESSION; PROTEIN; LIGAND; CLEAVAGE; FAMILY	The cytotoxic effect of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is limited in many glioma cell lines. However, treatment with TRAIL in combination with subtoxic doses of roscovitine, a specific inhibitor of Cdc2 and Cdk2, induced rapid apoptosis in TRAIL-resistant glioma cells. Roscovitine could sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells, but not human astrocytes, to TRAIL-induced apoptosis, offering an attractive strategy for safely treating resistant gliomas. Treatment with roscovitine significantly inhibited Cdc2 activity, and expression of a dominant-negative Cdc2 mutant sensitized glioma cells to TRAIL-induced apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in U87MG and T98 glioma cells, treatment with roscovitine recovered TRAIL-induced activation of caspases very efficiently in these cells. We found that treatment with roscovitine or expression of a dominant-negative Cdc2 mutant downregulated the protein levels of survivin and XIAP, two major caspase inhibitors. Overexpression of survivin or XIAP attenuated the apoptosis induced by roscovitine and TRAIL. Taken together, these results suggest that downregulation of survivin and XIAP by subtoxic doses of roscovitine contributes to the amplification of caspase cascades, thereby overcoming glioma cell resistance to TRAIL-mediated apoptosis.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea; Dankook Univ Coll Med, Dept Microbiol, Cheonan 330714, South Korea	Ajou University; Ajou University; Dankook University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Asselin E, 2001, CANCER RES, V61, P1862; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Gazzaniga P, 2003, ANN ONCOL, V14, P85, DOI 10.1093/annonc/mdg002; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Grant S, 2003, DRUG RESIST UPDATE, V6, P15, DOI 10.1016/S1368-7646(02)00141-3; Griffith TS, 2002, CANCER RES, V62, P3093; Hao CH, 2001, CANCER RES, V61, P1162; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Legler JM, 1999, JNCI-J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Nagane M, 2000, CANCER RES, V60, P847; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Sehgal A, 1998, SEMIN SURG ONCOL, V14, P3; Shapiro GI, 2001, CLIN CANCER RES, V7, P1590; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Weber RG, 2001, INT J CANCER, V91, P213, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1036>3.3.CO;2-D; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	44	116	124	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					446	456		10.1038/sj.onc.1207025	http://dx.doi.org/10.1038/sj.onc.1207025			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724573				2022-12-28	WOS:000188098300015
J	Conlan, LA; McNees, CJ; Heierhorst, J				Conlan, LA; McNees, CJ; Heierhorst, J			Proteasome-dependent dispersal of PML nuclear bodies in response to alkylating DNA damage	ONCOGENE			English	Article						PML; Sp100; DNA alkylation; proteasome	PROTEIN; LOCALIZATION; P53	Promyelocytic leukemia protein (PML) nuclear bodies (NBs) are present in variable number in most human cell types and have been linked to various cellular functions, including roles as depots for DNA repair proteins. Here, we show that treatment of human cells with DNA methylating agents leads to redistribution of PML from NBs to a diffuse nuclear localization. Biochemically, this correlates with a specific reduction of PML levels in the nuclear matrix fraction without affecting total PML levels. Similar results were obtained for the other major PML NB component, the Sp100 protein, indicating that DNA methylating agents lead to a general disassembly of PML NBs. Similar to the dispersal of PML NBs in response to some viral infections, PML redistribution after DNA damage was inhibited by the proteasome inhibitor MG132. We propose that the regulated dispersal of PML NBs may facilitate the enhanced release of DNA repair proteins from NB depots in order to respond adequately to extensive DNA damage.	Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia	St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; University of Melbourne; St Vincent's Hospital Melbourne; University of Melbourne	Heierhorst, J (corresponding author), Univ Melbourne, St Vincents Hosp, St Vincents Inst Med Res, 9 Princes St, Fitzroy, Vic 3065, Australia.	heier@ariel.its.unimelb.edu.au						Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; De Lucia F, 2001, BIOCHEM J, V358, P447, DOI 10.1042/0264-6021:3580447; Everett RD, 1999, J CELL SCI, V112, P3443; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Venere M, 2002, NAT CELL BIOL, V4, pE255, DOI 10.1038/ncb1102-e255; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869	16	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					307	310		10.1038/sj.onc.1207119	http://dx.doi.org/10.1038/sj.onc.1207119			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712236				2022-12-28	WOS:000187895300033
J	Wright, KO; Messing, EM; Reeder, JE				Wright, KO; Messing, EM; Reeder, JE			DBCCR1 mediates death in cultured bladder tumor cells	ONCOGENE			English	Article						bladder neoplasm; DBCCR1; tumor suppressor gene; chromosme 9	HOMOZYGOUS DELETION; SUPPRESSOR REGION; CANCER; 9Q32-33; GENE; DEFINITION; EXPRESSION; CARCINOMA; GROWTH; LOCUS	Chromosome 9, which is often partially or fully reduced to homozygosity in bladder cancer cells, harbors several tumor suppressor loci including deleted in bladder cancer chromosome region 1 (DBCCR1) at 9q32-33. To study DBCCR1 function, stable cell lines, inducible for DBCCR1 expression by tetracycline, were made, but the DBCCR1 protein was not expressed at detectable levels. To understand the fate of DBCCR1-expressing cells, human bladder tumor cells were transiently transfected with an expression vector containing DBCCR1 fused to enhanced green fluorescent protein (EGFP). Initially, DBCCR1-expressing cells demonstrated diffuse cytoplasmic green fluorescence with nuclear exclusion patterns. After time, the intensity level of green fluorescence increased and a granular distribution of protein became visible in the cells. At this point, cells rounded up and detached from the tissue culture dish. Cells transfected with a control vector, containing only EGFP, and partial DBCCR1-EGFP fusion constructs did not demonstrate this behavior. DBCCR1-mediated cell death in cultured tumor cells was independent of caspase-3 activation and did not result in detectable DNA strand breaks by TUNEL staining that are hallmarks of the classical apoptotic pathway.	Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Dept Urol, Rochester, NY USA	University of Rochester; University of Rochester	Reeder, JE (corresponding author), Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14642 USA.	Jay_Reeder@urmc.patholo-gy.rochester.edu		Reeder, Jay/0000-0002-7125-6893	NCI NIH HHS [CA33148-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033148] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1993, ONCOGENE, V8, P1083; COMPTON M, 1992, CANCER METAST REV, V2, P105; CREAGH E, 2001, BIOCH SOC T, V29; DEVLIN J, 1994, ONCOGENE, V9, P2757; Easton RM, 1997, J NEUROSCI, V17, P9656; Fujiwara H, 2001, J HUM GENET, V46, P372, DOI 10.1007/s100380170056; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Habuchi T, 1997, HUM MOL GENET, V6, P913, DOI 10.1093/hmg/6.6.913; Habuchi T, 2001, ONCOGENE, V20, P531, DOI 10.1038/sj.onc.1204122; Howard CM, 2000, CANCER RES, V60, P2737; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KEEN AJ, 1994, ONCOGENE, V9, P2083; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li WW, 1997, CANCER RES, V57, P2193; MICKEY D, 1982, J UROLOGY, V27, P23307; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nishiyama H, 1999, GENE CHROMOSOME CANC, V26, P171, DOI 10.1002/(SICI)1098-2264(199910)26:2<171::AID-GCC10>3.3.CO;2-2; Nishiyama H, 2001, ONCOGENE, V20, P2956, DOI 10.1038/sj.onc.1204432; RUPPERT JM, 1993, CANCER RES, V53, P5093; Sowden MP, 1998, NUCLEIC ACIDS RES, V26, P1644, DOI 10.1093/nar/26.7.1644; Stadler WM, 2001, CLIN CANCER RES, V7, P1676; Tang Dean G, 1996, Pathol Oncol Res, V2, P117; Weng LP, 1999, CANCER RES, V59, P5808	25	28	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					82	90		10.1038/sj.onc.1206642	http://dx.doi.org/10.1038/sj.onc.1206642			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712213				2022-12-28	WOS:000187895300009
J	Aebersold, DM; Landt, O; Berthou, S; Gruber, G; Beer, KT; Greiner, RH; Zimmer, Y				Aebersold, DM; Landt, O; Berthou, S; Gruber, G; Beer, KT; Greiner, RH; Zimmer, Y			Prevalence and clinical impact of Met Y1253D-activating point mutation in radiotherapy-treated squamous cell cancer of the oropharynx	ONCOGENE			English	Article						Met receptor; activating mutation; radiotherapy; head and neck cancer	GROWTH-FACTOR RECEPTOR; SOMATIC MUTATIONS; FACTOR PROTECTS; SCATTER FACTOR; C-MET; RADIATION; DNA; CARCINOMAS; ONCOGENE; KINASE	Aberrant signalling through the hepatocyte growth factor/scatter factor receptor Met has been implicated in various aspects of the development of human cancer including the promotion of tumour invasion, angiogenesis and metastasis. Moreover, experimental data indicate that activation of the Met receptor may be involved in cellular resistance towards antineoplastic treatments such as chemotherapy and ionizing radiation. We determined the prevalence and clinical impact of the Met-activating mutation Y1253D in patients with squamous cell cancer of the oropharynx treated by radical radiotherapy. To screen archival tissue for the presence of a low-abundance point mutation, we developed a sensitive screening method using real-time polymerase chain reaction along with peptide nucleic acid-based DNA clamping and melting curve analysis. By this approach, Met Y1253D was detected in tumours of 15 out of 138 patients (10.9%). Both univariate and multivariate survival analysis revealed Met Y1253D to be significantly associated with impaired local tumour control. Our results provide evidence that the Met-activating mutation Y1253D is present in a notable subset of patients with oropharyngeal cancer and indicate that it may interfere with radioresponsiveness of these tumours, supporting the notion of aberrant Met signalling as a potential target for radiosensitization.	Univ Bern, Dept Clin Res, CH-3010 Bern, Switzerland; MOLBIOL, TIB, Berlin, Germany; Inselspital, Dept Radiat Oncol, Bern, Switzerland	University of Bern; University of Bern; University Hospital of Bern	Zimmer, Y (corresponding author), Univ Bern, Dept Clin Res, Murtenstr 35-D-809, CH-3010 Bern, Switzerland.		Aebersold, Daniel Matthias/C-2946-2013	Aebersold, Daniel Matthias/0000-0002-9493-3834				Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Bowers DC, 2000, CANCER RES, V60, P4277; CHIARA F, 2003, J BIOL CHEM, V12, P12; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Lindel K, 2001, CANCER-AM CANCER SOC, V92, P805, DOI 10.1002/1097-0142(20010815)92:4<805::AID-CNCR1386>3.0.CO;2-9; Lorenzato A, 2002, CANCER RES, V62, P7025; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Park WS, 1999, CANCER RES, V59, P307; Pietras RJ, 1999, CANCER RES, V59, P1347; Raben David, 2002, Expert Rev Anticancer Ther, V2, P461, DOI 10.1586/14737140.2.4.461; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Sun XY, 2002, NAT BIOTECHNOL, V20, P186, DOI 10.1038/nbt0202-186; To CTT, 1998, ONCOL REP, V5, P1013; Turner BC, 1997, CANCER RES, V57, P3079	19	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8519	8523		10.1038/sj.onc.1206968	http://dx.doi.org/10.1038/sj.onc.1206968			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627992				2022-12-28	WOS:000186650300015
J	Jhabvala-Romero, F; Evans, A; Guo, SH; Denton, M; Clinton, GM				Jhabvala-Romero, F; Evans, A; Guo, SH; Denton, M; Clinton, GM			Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2	ONCOGENE			English	Article						herstatin; heregulin; HER-2; HER-3; tamoxifen; breast cancer	NEU DIFFERENTIATION FACTOR; TYROSINE KINASE; ESTROGEN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; HORMONAL-THERAPY; HER2/NEU ERBB-2; EXPRESSION; PROTEIN; PATHWAY	Ligands of the ErbB family of receptors and estrogens control the proliferation of breast cancer cells. Overexpression of human EGF receptor HER-2 (erbB2) leads to amplified heregulin (HRG) signaling, promoting more aggressive breast cancer that is nonresponsive to estrogen and the antiestrogenic drug tamoxifen. Herstatin (Hst), a secreted HER-2 gene product, binds to the HER-2 receptor ectodomain blocking receptor activation. The aim of this study was to investigate the impact of this HER-2 inhibitor on HRG-induced signaling, proliferation, and sensitivity to tamoxifen in breast cancer cells with and without HER-2 overexpression. The expression of Hst in MCF7 cells eliminated HRG signaling through both mitogen-activated protein kinase and Akt pathways and prevented HRG-mediated proliferation. The loss in signaling corresponded to downregulation of the HRG receptors, HER-3 and HER-4, whereas HER-2 overexpression strongly stimulated the levels of both HRG receptors. Although Hst blocked HRG signaling in both parental and HER-2 transfected cells, it enhanced sensitivity to tamoxifen only in the MCF7 cells that overexpressed HER-2. To evaluate further the efficacy of Hst as an anticancer agent, His-tagged Hst was expressed in transfected insect cells, purified, and added to the breast cancer cells. As in the transfected cells, purified Hst inhibited HER-3 levels and suppressed HRG-induced proliferation of MCF7 and BT474 breast cancer cells. In contrast, the HER-2 monoclonal antibody, herceptin, downregulated HER-2, but not HER-3. These results suggest the potential use of Hst against HRG-mediated growth of breast cancers with high and low levels of HER-2 and against tamoxifen resistance in HER-2 overexpressing breast cancer.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA	Oregon Health & Science University	Clinton, GM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	clinton@ohsu.edu		Evans, Adam/0000-0002-4250-2127				Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2001, SEMIN ONCOL, V28, P30, DOI 10.1053/sonc.2001.29722; Azios NG, 2001, ONCOGENE, V20, P5199, DOI 10.1038/sj.onc.1204555; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Christianson TA, 1998, CANCER RES, V58, P5123; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Dowsett M, 2001, ENDOCR-RELAT CANCER, V8, P191, DOI 10.1677/erc.0.0080191; Dowsett M, 2001, CANCER RES, V61, P8452; Gilbertson RJ, 1998, CANCER RES, V58, P3932; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Heldin Carl-Henrik, 1996, Cytokine and Growth Factor Reviews, V7, P3, DOI 10.1016/1359-6101(96)00002-0; Hijazi MM, 2000, INT J ONCOL, V17, P629; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JESCHKE M, 1995, INT J CANCER, V60, P730, DOI 10.1002/ijc.2910600527; Justman QA, 2002, J BIOL CHEM, V277, P20618, DOI 10.1074/jbc.M111359200; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kurokawa H, 2000, CANCER RES, V60, P5887; Lewis GD, 1996, CANCER RES, V56, P1457; Lopez GN, 2001, J BIOL CHEM, V276, P22177, DOI 10.1074/jbc.M010718200; Mazumdar A, 2001, CANCER RES, V61, P400; Nicholson BP, 2000, SEMIN ONCOL, V27, P33, DOI 10.1053/sonc.2000.19897; Pegram M, 2000, SEMIN ONCOL, V27, P13; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Pinkas-Kramarski R, 1998, MOL CELL BIOL, V18, P6090, DOI 10.1128/MCB.18.10.6090; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Ram TG, 2000, J CELL PHYSIOL, V183, P301, DOI 10.1002/(SICI)1097-4652(200006)183:3<301::AID-JCP2>3.0.CO;2-W; READ LD, 1990, CANCER RES, V50, P3947; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; SCHLESSINGER J, 1988, COLD SPRING HARB SYM, V53, P515, DOI 10.1101/SQB.1988.053.01.059; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Tan M, 1999, CANCER RES, V59, P1620; Tang CK, 1996, CANCER RES, V56, P3350; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Xiong SB, 2001, CANCER RES, V61, P1727	48	26	33	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8178	8186		10.1038/sj.onc.1206912	http://dx.doi.org/10.1038/sj.onc.1206912			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603258				2022-12-28	WOS:000186403400012
J	Wan, XL; Helman, LJ				Wan, XL; Helman, LJ			Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells	ONCOGENE			English	Article						Akt; phosphorylation; PTEN	TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-II; INTEGRIN-LINKED KINASE; SIGNAL-TRANSDUCTION; PROSTATE-CANCER; GLIOMA-CELLS; ACTIVATION; INSULIN; INHIBITION; EXPRESSION	Constitutive activation of Akt has been found in many types of human cancer, and is believed to promote proliferation and increased cell survival thereby contributing to cancer progression. In this study, we examined Akt phosphorylation on Ser473 and Thr308 in seven IGF-II-overexpressing rhabdomyosarcomas (RMS) cells. All the RMS cell lines tested had high levels of Akt phosphorylation on Thr308, whereas three cell lines (Rh5, Rh18, and CTR) had a much lower level of Akt phosphorylation on Ser473. To determine whether the difference in Akt phosphorylation on Ser473, but not on Thr308, observed among cell lines is a cell-specific phenomenon or due to other factors, which possibly downregulate Akt phosphorylation, we examined expression of PTEN protein, which acts as a negative regulator of the PI3K/Akt signaling pathway through its ability to dephosphorylate phosphatidylinositol 3,4,5-triphosphate (PIP3). The levels of PTEN expression inversely correlate with Akt phosphorylation on Ser473, but not on Thr308. Consistent with this finding, transfection of wild-type PTEN into RMS and mouse myoblast C2C12 cells resulted in reduced Akt phosphorylation on Ser473, but not on Thr308. Our data suggest that Ser473 may be a key target residue for PTEN to modulate the effects of IGF-II on activating the PI3K/Akt pathway in RMS cells. A better understanding of the pathway in RMS will likely contribute to insights into the biology of the RMS tumorigenesis and hopefully lead to novel therapeutic options.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH, Bldg 10,Rm 13N240, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [ZIASC006892, Z01SC006892] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brodbeck D, 2001, J BIOL CHEM, V276, P29550, DOI 10.1074/jbc.M104633200; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Davies MA, 1998, CANCER RES, V58, P5285; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; ELBADRY OM, 1991, J CLIN INVEST, V87, P648, DOI 10.1172/JCI115042; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Ghosh AK, 1999, GENE, V235, P85, DOI 10.1016/S0378-1119(99)00206-1; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Tsatsanis C, 2000, INT J MOL MED, V5, P583; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	53	96	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8205	8211		10.1038/sj.onc.1206878	http://dx.doi.org/10.1038/sj.onc.1206878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603261				2022-12-28	WOS:000186403400015
J	Scotto, KW				Scotto, KW			Transcriptional regulation of ABC drug transporters	ONCOGENE			English	Review						drug resistance; gene regulation; MDR; MRP; promoter	MULTIDRUG-RESISTANCE GENE; HUMAN MDR1 GENE; P-GLYCOPROTEIN EXPRESSION; BINDING-PROTEIN YB-1; HEAT-SHOCK; MULTIDRUG-RESISTANCE-1 GENE; 5'-FLANKING REGION; UP-REGULATION; BILE-SALT; RAT-LIVER	P-glycoprotein, the founding member of the ATP-binding cassette (ABC) family of drug transporters, was first identified almost three decades ago and shown to confer resistance to multiple chemotherapeutic agents when overexpressed in human tumors. Subsequent years have witnessed a tremendous effort to characterize the function and regulation of P-glycoprotein, initially spurred by the hope that its inhibition was the key to overcoming clinical resistance to multiple anticancer agents. However, the identification of MRP1, another member of the ABC drug transporter family, led to the realization that the multidrug resistance (MDR) phenotype is considerably more complex than initially believed. Indeed, at the present time at least 10 members of the ABC transporter family have been implicated in an MDR phenotype, and it is likely that more will be added to this list as studies progress. With this complexity comes the imperative to improve our understanding of the function of individual transporters, as well as to delineate the mechanisms underlying their expression in normal and tumor cells, particularly those that may be amenable to therapeutic intervention. Several articles within this volume address the structure and function of drug transporters. This review will focus on our current understanding of the regulation of ABC drug transporters at the level of transcription.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Scotto, KW (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	KW_Scotto@fccc.edu			NCPDCID CDC HHS [NCI R01 CA 57307, NCI R01 CA 95792, NCI P30 CA 08748] Funding Source: Medline	NCPDCID CDC HHS		Abolhoda A, 1999, CLIN CANCER RES, V5, P3352; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Bahr O, 2001, J CLIN INVEST, V107, P643, DOI 10.1172/JCI12415; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bartsevich VV, 2000, MOL PHARMACOL, V58, P1; Belinsky MG, 2002, CANCER RES, V62, P6172; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; BHUSHAN A, 1992, MOL PHARMACOL, V42, P69; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Bright-Thomas RM, 2003, EUR J SURG ONCOL, V29, P107, DOI 10.1053/ejso.2002.1331; Brown JM, 1998, CANCER RES, V58, P1408; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brugger D, 2002, ANTICANCER RES, V22, P4229; Bush JA, 2002, CARCINOGENESIS, V23, P1603, DOI 10.1093/carcin/23.10.1603; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; Chen ZS, 2002, CANCER RES, V62, P3144; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; COMBATES NJ, 1994, J BIOL CHEM, V269, P29715; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; CORNWELL MM, 1990, CELL GROWTH DIFFER, V1, P607; CORNWELL MM, 1993, J BIOL CHEM, V268, P19505; Courtois A, 1999, FEBS LETT, V459, P381, DOI 10.1016/S0014-5793(99)01295-8; Daschner PJ, 1999, BREAST CANCER RES TR, V53, P229, DOI 10.1023/A:1006138803392; Davis W, 2003, NUCLEIC ACIDS RES, V31, P1097, DOI 10.1093/nar/gkg192; Dean M, 2001, J BIOENERG BIOMEMBR, V33, P475, DOI 10.1023/A:1012823120935; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; Denson LA, 2000, J BIOL CHEM, V275, P8835, DOI 10.1074/jbc.275.12.8835; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Egan D. A., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P324; EGAN DA, 1997, THESIS CORNELL U NEW; El-Osta A, 2001, BIOCHEM BIOPH RES CO, V289, P733, DOI 10.1006/bbrc.2001.6023; El-Osta A, 2002, MOL CELL BIOL, V22, P1844, DOI 10.1128/MCB.22.6.1844-1857.2002; Fardel O, 1996, BIOCHEM PHARMACOL, V51, P1427, DOI 10.1016/0006-2952(96)00081-0; Freedman LP, 1999, J CELL BIOCHEM, P103; Friedman D, 2002, CANCER RES, V62, P3377; Fromm MF, 2002, TOXICOLOGY, V181, P299, DOI 10.1016/S0300-483X(02)00297-4; FROMM MF, 2002, TOXICOLOGY, V27, P181; Fukushima Y, 1999, EUR J CANCER, V35, P935, DOI 10.1016/S0959-8049(99)00035-0; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P1897; Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200; GEKELER V, 1988, BIOCHEM BIOPH RES CO, V155, P754, DOI 10.1016/S0006-291X(88)80559-X; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; Guo YP, 2003, J BIOL CHEM, V278, P29509, DOI 10.1074/jbc.M304059200; Hill BA, 1996, CARCINOGENESIS, V17, P451, DOI 10.1093/carcin/17.3.451; Hirose Masao, 1999, Journal of Medical Investigation, V46, P130; HU XF, 1995, BRIT J CANCER, V71, P931, DOI 10.1038/bjc.1995.180; Hu Z, 2000, J BIOL CHEM, V275, P2979, DOI 10.1074/jbc.275.4.2979; Ichihashi N, 2001, BRIT J DERMATOL, V144, P745, DOI 10.1046/j.1365-2133.2001.04129.x; Ihnat MA, 1997, CLIN CANCER RES, V3, P1339; IKEGUCHI M, 1991, DNA CELL BIOL, V10, P639, DOI 10.1089/dna.1991.10.639; Ince TA, 1996, CANCER RES, V56, P2021; INCE TA, 1995, GENE, V156, P287, DOI 10.1016/0378-1119(94)00907-A; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2003, ANN NY ACAD SCI, V983, P213, DOI 10.1111/j.1749-6632.2003.tb05976.x; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kalebic T, 2003, ANN NY ACAD SCI, V983, P278, DOI 10.1111/j.1749-6632.2003.tb05982.x; Kao HH, 2003, J BIOMED SCI, V10, P98, DOI 10.1159/000068078; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kauffmann HM, 2001, TOXICOLOGY, V167, P25, DOI 10.1016/S0300-483X(01)00455-3; Kim RB, 2002, TOXICOLOGY, V181, P291, DOI 10.1016/S0300-483X(02)00296-2; KIM RS, 1994, CANCER RES, V54, P4958; Kim SH, 1997, CANCER LETT, V115, P9, DOI 10.1016/S0304-3835(97)04725-3; KIOKA N, 1992, FEBS LETT, V301, P37, DOI 10.1016/0014-5793(92)80205-U; Knutsen T, 1998, GENE CHROMOSOME CANC, V23, P44, DOI 10.1002/(SICI)1098-2264(199809)23:1<44::AID-GCC7>3.0.CO;2-6; KOHNO K, 1990, J BIOL CHEM, V265, P19690; KOHNO K, 1989, BIOCHEM BIOPH RES CO, V165, P1415, DOI 10.1016/0006-291X(89)92761-7; Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844; Kuo MT, 2002, ONCOGENE, V21, P1945, DOI 10.1038/sj.onc.1205117; Kurz EU, 2001, BIOCHEM BIOPH RES CO, V285, P981, DOI 10.1006/bbrc.2001.5262; Labialle S, 2002, BIOCHEM PHARMACOL, V64, P943, DOI 10.1016/S0006-2952(02)01156-5; Lamba JK, 2003, HUM MOL GENET, V12, P99, DOI 10.1093/hmg/ddg011; Lecureur V, 1996, CARCINOGENESIS, V17, P1157, DOI 10.1093/carcin/17.5.1157; Lee G, 2001, CAN J PHYSIOL PHARM, V79, P876, DOI 10.1139/cjpp-79-10-876; Leonard Gregory D, 2002, Curr Opin Investig Drugs, V3, P1652; Liu ZL, 2002, CANCER CHEMOTH PHARM, V49, P391, DOI 10.1007/s00280-001-0411-5; MADDEN MJ, 1993, J BIOL CHEM, V268, P8290; Marthinet E, 2000, GENE THER, V7, P1224, DOI 10.1038/sj.gt.3301231; Mathieu MC, 2001, J BIOL CHEM, V276, P4819, DOI 10.1074/jbc.M008495200; McCoy C, 1999, CELL GROWTH DIFFER, V10, P377; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; Meier PJ, 2002, ANNU REV PHYSIOL, V64, P635, DOI 10.1146/annurev.physiol.64.082201.100300; Mickley LA, 1997, J CLIN INVEST, V99, P1947, DOI 10.1172/JCI119362; MICKLEY LA, 1989, J BIOL CHEM, V264, P18031; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MIYAZAKI M, 1992, BIOCHEM BIOPH RES CO, V187, P677, DOI 10.1016/0006-291X(92)91248-O; NAKATSUKASA H, 1993, HEPATOLOGY, V18, P1202; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Neely KE, 2002, BBA-REV CANCER, V1603, P19, DOI 10.1016/S0304-419X(02)00067-7; NGUYEN KT, 1994, ONCOL RES, V6, P71; Oda Y, 2003, J PATHOL, V199, P251, DOI 10.1002/path.1282; Ogretmen B, 2000, BIOCHEMISTRY-US, V39, P194, DOI 10.1021/bi991943f; Ogretmen B, 1999, BIOCHEMISTRY-US, V38, P2189, DOI 10.1021/bi982236+; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Potocnik U, 2002, J MED GENET, V39, P340, DOI 10.1136/jmg.39.5.340; REDFERN CP, 1995, EUR J CANCER, V31, P496; Redinger RN, 2003, CAN J GASTROENTEROL, V17, P265, DOI 10.1155/2003/190784; ROHLFF C, 1995, CELL SIGNAL, V7, P431, DOI 10.1016/0898-6568(95)00018-K; Rohlff C, 1998, INT J ONCOL, V12, P383; Rund D, 1999, ADV EXP MED BIOL, V457, P71; Saji H, 2003, CANCER LETT, V190, P191, DOI 10.1016/S0304-3835(02)00590-6; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Schrenk D, 2001, TOXICOL LETT, V120, P51, DOI 10.1016/S0378-4274(01)00306-X; SCHRENK D, 1994, CARCINOGENESIS, V15, P2541, DOI 10.1093/carcin/15.11.2541; Scott IAW, 2001, MOL ECOL NOTES, V1, P117, DOI 10.1046/j.1471-8278.2001.00037.x; Scotto KW, 1998, CYTOTECHNOLOGY, V27, P257, DOI 10.1023/A:1008032716628; SCOTTO KW, 2000, BASIC SCI CANC, P108; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shannon BA, 2001, CANCER LETT, V167, P91, DOI 10.1016/S0304-3835(01)00431-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; STEIN U, 1994, EUR J CANCER, V30A, P1541, DOI 10.1016/0959-8049(94)00287-F; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stockel B, 2000, EUR J BIOCHEM, V267, P1347, DOI 10.1046/j.1432-1327.2000.01106.x; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; Suzuki H, 2002, ADV DRUG DELIVER REV, V54, P1311, DOI 10.1016/S0169-409X(02)00075-3; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Takada T, 2000, BIOCHEM BIOPH RES CO, V270, P728, DOI 10.1006/bbrc.2000.2507; Tanaka T, 1999, HEPATOLOGY, V30, P1507, DOI 10.1002/hep.510300617; TEETER LD, 1991, DNA CELL BIOL, V10, P433, DOI 10.1089/dna.1991.10.433; TEETER LD, 1991, CELL GROWTH DIFFER, V2, P429; THAYER S, 1996, P AM ASSOC CANC RES, P324; THAYER SP, 1999, THESIS CORNELL U NEW; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; VANGROENIGEN M, 1993, BIOCHIM BIOPHYS ACTA, V1172, P138, DOI 10.1016/0167-4781(93)90280-Q; Vilaboa NE, 2000, J BIOL CHEM, V275, P24970, DOI 10.1074/jbc.M909136199; Vulevic B, 2001, CANCER RES, V61, P3339; Wang QJ, 1998, CANCER RES, V58, P5762; Yague E, 2003, J BIOL CHEM, V278, P10344, DOI 10.1074/jbc.M211093200; Yamada T, 2003, CANCER RES, V63, P895; Yamada T, 2000, CANCER RES, V60, P4761; Yang JM, 2001, MOL PHARMACOL, V60, P674; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200; YU LJ, 1995, CELL GROWTH DIFFER, V6, P1505; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAO JY, 1993, ENDOCRINOLOGY, V133, P521, DOI 10.1210/en.133.2.521; Zhu QC, 1996, DNA CELL BIOL, V15, P105, DOI 10.1089/dna.1996.15.105	153	323	339	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7496	7511		10.1038/sj.onc.1206950	http://dx.doi.org/10.1038/sj.onc.1206950			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576854				2022-12-28	WOS:000186112500019
J	Zhao, RB; Goldman, ID				Zhao, RB; Goldman, ID			Resistance to antifolates	ONCOGENE			English	Review						antifolates; folates; folic acid; leucovorin; MRP; PGP; BCRP; exporters; polyglutamate; methotrexate; raltitrexed reduced folate carrier; folate receptors; thymidylate synthase; dihydrofolate reductase; folylpolyglutamate synthetase; GAR transforylase; membrane transport	REDUCED FOLATE CARRIER; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHINESE-HAMSTER OVARY; THYMIDYLATE SYNTHASE INHIBITOR; ORGANIC ANION TRANSPORTER; HUMAN DIHYDROFOLATE-REDUCTASE; GAMMA-GLUTAMATE SYNTHETASE; BREAST-CANCER-CELLS; RECEPTOR-TYPE-BETA; CCRF-CEM CELLS	The antifolates were the first class of antimetabolites to enter the clinics more than 50 years ago. Over the following decades, a full understanding of their mechanisms of action and chemotherapeutic potential evolved along with the mechanisms by which cells develop resistance to these drugs. These principals served as a basis for the subsequent exploration and understanding of the mechanisms of resistance to a variety of diverse antineoplastics with different cellular targets. This section describes the bases for intrinsic and acquired antifolate resistance within the context of the current understanding of the mechanisms of actions and cytotoxic determinants of these agents. This encompasses impaired drug transport into cells, augmented drug export, impaired activation of antifolates through polyglutamylation, augmented hydrolysis of antifolate polyglutamates, increased expression and mutation of target enzymes, and the augmentation of cellular tetrahydrofolate-cofactor pools in cells. This chapter also describes how these insights are being utilized to develop gene therapy approaches to protect normal bone marrow progenitor cells as a strategy to improve the efficacy of bone marrow transplantation. Finally, clinical studies are reviewed that correlate the cellular pharmacology of methotrexate with the clinical outcome in children with neoplastic diseases treated with this antifolate.	Yeshiva Univ Albert Einstein Coll Med, Dept Med & Mol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Goldman, ID (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med & Mol, Chanin 2,Room 209,1300 Morris Pk Ave, Bronx, NY 10461 USA.	igoldman@aecom.yu.edu						Abe T, 2001, GASTROENTEROLOGY, V120, P1689, DOI 10.1053/gast.2001.24804; Aghi M, 1999, J NATL CANCER I, V91, P1233, DOI 10.1093/jnci/91.14.1233; Alati T, 1996, CANCER RES, V56, P2331; ALBRECHT AM, 1972, CANCER RES, V32, P1539; ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; ALLEGRA CJ, 1986, J BIOL CHEM, V261, P6478; ALLEGRA CJ, 1985, J BIOL CHEM, V260, P9720; ALLEGRA CJ, 1987, J BIOL CHEM, V262, P13520; Allen JD, 2002, CANCER RES, V62, P2294; Andreassi JL, 2002, BIOCHEMISTRY-US, V41, P226, DOI 10.1021/bi015644d; APPLEMAN JR, 1988, J BIOL CHEM, V263, P10304; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ARKIN H, 1989, CANCER RES, V49, P6556; Assaraf YG, 1999, BIOCHEM PHARMACOL, V58, P1321, DOI 10.1016/S0006-2952(99)00227-0; ASSARAF YG, 1989, J NATL CANCER I, V81, P290, DOI 10.1093/jnci/81.4.290; Assaraf YG, 1998, J BIOL CHEM, V273, P8106, DOI 10.1074/jbc.273.14.8106; Assaraf YG, 1997, J BIOL CHEM, V272, P17460, DOI 10.1074/jbc.272.28.17460; BAGGOTT JE, 1986, BIOCHEM J, V236, P193, DOI 10.1042/bj2360193; BALINSKA M, 1991, ARCH BIOCHEM BIOPHYS, V284, P219, DOI 10.1016/0003-9861(91)90287-S; BANERJEE D, 1994, GENE, V139, P269, DOI 10.1016/0378-1119(94)90768-4; Banerjee R, 1999, INDIAN J BIOCHEM BIO, V36, P107; BARAM J, 1987, J CLIN INVEST, V79, P692, DOI 10.1172/JCI112872; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; Barnes MJ, 1999, CLIN CANCER RES, V5, P2548; BARREDO JC, 1994, BLOOD, V84, P564; BAUGH CM, 1973, BIOCHEM BIOPH RES CO, V52, P27, DOI 10.1016/0006-291X(73)90949-2; Belkov VM, 1999, BLOOD, V93, P1643, DOI 10.1182/blood.V93.5.1643.405k06_1643_1650; BERTINO JR, 1977, SEMIN ONCOL, V4, P203; Boritzki TJ, 1996, INVEST NEW DRUG, V14, P295, DOI 10.1007/BF00194533; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; BRIGLE KE, 1991, J BIOL CHEM, V266, P17243; BRIGLE KE, 1994, BIOCHEM PHARMACOL, V47, P337, DOI 10.1016/0006-2952(94)90025-6; BRIGLE KE, 1995, J BIOL CHEM, V270, P22974, DOI 10.1074/jbc.270.39.22974; Calvert H, 2002, SEMIN ONCOL, V29, P3, DOI 10.1016/S0093-7754(02)70209-1; CAMPBELL IG, 1991, CANCER RES, V51, P5329; Capiaux GM, 2003, HUM GENE THER, V14, P435, DOI 10.1089/104303403321467207; CHABNER BA, 1985, J CLIN INVEST, V76, P907, DOI 10.1172/JCI112088; Chancy CD, 2000, J BIOL CHEM, V275, P20676, DOI 10.1074/jbc.M002328200; Chango A, 2000, MOL GENET METAB, V70, P310, DOI 10.1006/mgme.2000.3034; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2003, CANCER RES, V63, P4048; Chiao JH, 1997, J BIOL CHEM, V272, P11165, DOI 10.1074/jbc.272.17.11165; Chu E, 1996, ADV ENZYME REGUL, V36, P143, DOI 10.1016/0065-2571(95)00004-6; CHU E, 1994, MOL CELL BIOL, V14, P207, DOI 10.1128/MCB.14.1.207; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1990, J BIOL CHEM, V265, P8470; CHUNG KN, 1993, J CLIN INVEST, V91, P1289, DOI 10.1172/JCI116327; Cole PD, 2001, CANCER RES, V61, P4599; CONEY LR, 1991, CANCER RES, V51, P6125; COWAN KH, 1984, J BIOL CHEM, V259, P793; CURT GA, 1985, J CLIN INVEST, V76, P1323, DOI 10.1172/JCI112106; CURT GA, 1983, NEW ENGL J MED, V308, P199, DOI 10.1056/NEJM198301273080406; DeGraaf D, 1996, P NATL ACAD SCI USA, V93, P1238, DOI 10.1073/pnas.93.3.1238; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEUTSCH JC, 1989, ARCH BIOCHEM BIOPHYS, V274, P327, DOI 10.1016/0003-9861(89)90446-3; DICKER AP, 1993, P NATL ACAD SCI USA, V90, P11797, DOI 10.1073/pnas.90.24.11797; DICKER AP, 1990, J BIOL CHEM, V265, P8317; Ding BC, 2001, BIOCHEM PHARMACOL, V61, P665; DIXON KH, 1991, CANCER COMMUN-US, V3, P357, DOI 10.3727/095535491820873687; DIXON KH, 1992, J BIOL CHEM, V267, P24140; DIXON KH, 1994, J BIOL CHEM, V269, P17; DOLNICK BJ, 1979, J CELL BIOL, V83, P394, DOI 10.1083/jcb.83.2.394; DOMIN BA, 1982, MOL PHARMACOL, V21, P231; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Drake JC, 1996, BIOCHEM PHARMACOL, V51, P1349, DOI 10.1016/0006-2952(96)00057-3; Drori S, 2000, J BIOL CHEM, V275, P30855, DOI 10.1074/jbc.M003988200; Dudeja PK, 1997, AM J PHYSIOL-GASTR L, V272, pG1408, DOI 10.1152/ajpgi.1997.272.6.G1408; Ercikan E, 1993, Adv Exp Med Biol, V338, P537; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; FABRE I, 1984, CANCER RES, V44, P3190; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Ferguson PL, 1999, J BIOL CHEM, V274, P16269, DOI 10.1074/jbc.274.23.16269; FLASSHOVE M, 1995, LEUKEMIA, V9, pS34; FLASSHOVE M, 1995, BLOOD, V85, P566; FLINTOFF WF, 1976, SOMAT CELL GENET, V2, P245, DOI 10.1007/BF01538963; FREEMANTLE SJ, 1995, BRIT J CANCER, V71, P925, DOI 10.1038/bjc.1995.179; FRY DW, 1982, J BIOL CHEM, V257, P1890; FRY DW, 1983, CANCER RES, V43, P1087; FRY DW, 1982, CANCER RES, V42, P2532; FRY DW, 1980, CANCER RES, V40, P3669; FYFE MJ, 1973, J BIOL CHEM, V248, P5067; Galipeau J, 1997, HUM GENE THER, V8, P1773, DOI 10.1089/hum.1997.8.15-1773; Galivan J, 2000, PHARMACOL THERAPEUT, V85, P207, DOI 10.1016/S0163-7258(99)00063-7; Galpin AJ, 1997, MOL PHARMACOL, V52, P155, DOI 10.1124/mol.52.1.155; Gifford AJ, 1998, INT J CANCER, V78, P176, DOI 10.1002/(SICI)1097-0215(19981005)78:2<176::AID-IJC10>3.3.CO;2-F; Gifford AJ, 2002, LEUKEMIA, V16, P2379, DOI 10.1038/sj.leu.2402655; GOKER E, 1993, LEUKEMIA, V7, P1000; GOLDIE JH, 1980, EUR J CANCER, V16, P1539, DOI 10.1016/0014-2964(80)90026-2; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1974, MOL PHARMACOL, V10, P257; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Guo W, 1999, CLIN CANCER RES, V5, P621; HABECK LL, 1995, MOL PHARMACOL, V48, P326; HAKALA MT, 1965, BIOCHIM BIOPHYS ACTA, V102, P210, DOI 10.1016/0926-6585(65)90214-1; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; HENDERSON GB, 1981, BIOCHEM BIOPH RES CO, V99, P163, DOI 10.1016/0006-291X(81)91727-7; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1990, BIOCHEM PHARMACOL, V39, P2019, DOI 10.1016/0006-2952(90)90624-T; HENDERSON GB, 1982, BIOCHEM BIOPH RES CO, V104, P474, DOI 10.1016/0006-291X(82)90661-1; HENDERSON GB, 1982, BIOCHEM INT, V4, P493; HENDERSON GB, 1984, J BIOL CHEM, V259, P1526; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HILL BT, 1979, CANCER RES, V39, P2440; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Honjo Y, 2001, CANCER RES, V61, P6635; Hooijberg JH, 2003, BIOCHEM PHARMACOL, V65, P765, DOI 10.1016/S0006-2952(02)01615-5; Hooijberg JH, 1999, CANCER RES, V59, P2532; HORNE DW, 1990, BIOCHIM BIOPHYS ACTA, V1023, P47, DOI 10.1016/0005-2736(90)90008-C; Horne DW, 2001, ARCH BIOCHEM BIOPHYS, V394, P39, DOI 10.1006/abbi.2001.2528; HORNS RC, 1984, J CLIN ONCOL, V2, P2, DOI 10.1200/JCO.1984.2.1.2; HOUGHTON PJ, 1992, CANCER RES, V52, P558; HSUEH CT, 1994, BIOCHEM PHARMACOL, V47, P1019, DOI 10.1016/0006-2952(94)90413-8; Huang W, 1997, INVEST OPHTH VIS SCI, V38, P1578; Ito K, 2001, J BIOL CHEM, V276, P38108; JACKMAN AL, 1991, CANCER RES, V51, P5579; Jackman AL, 1997, CLIN CANCER RES, V3, P911; JACKMAN AL, 1995, BRIT J CANCER, V71, P914, DOI 10.1038/bjc.1995.178; JACKSON RC, 1977, ARCH BIOCHEM BIOPHYS, V182, P646, DOI 10.1016/0003-9861(77)90545-8; JACKSON RC, 1976, CANCER RES, V36, P1991; JACKSON RC, 1984, ADV ENZYME REGUL, V22, P187, DOI 10.1016/0065-2571(84)90014-1; JACKSON RC, 1973, ARCH BIOCHEM BIOPHYS, V158, P827, DOI 10.1016/0003-9861(73)90579-1; JANSEN G, 1990, CANCER RES, V50, P7544; JANSEN G, 1989, CANCER RES, V49, P1959; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, MOL PHARMACOL, V55, P761; JOHNSON TB, 1988, CANCER RES, V48, P2426; JOLIVET J, 1983, J CLIN INVEST, V72, P773, DOI 10.1172/JCI111048; JOLIVET J, 1982, J CLIN INVEST, V70, P351, DOI 10.1172/JCI110624; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KANE MA, 1986, J BIOL CHEM, V261, P44; KATES RE, 1976, BIOCHEM PHARMACOL, V25, P1485, DOI 10.1016/0006-2952(76)90065-4; KAUFMAN RJ, 1979, P NATL ACAD SCI USA, V76, P5669, DOI 10.1073/pnas.76.11.5669; Khokhar NZ, 2001, CLIN CANCER RES, V7, P3199; KIM JS, 1993, J BIOL CHEM, V268, P21680; Kitchens ME, 1999, J BIOL CHEM, V274, P12544, DOI 10.1074/jbc.274.18.12544; Kitchens ME, 1999, MOL PHARMACOL, V56, P1063, DOI 10.1124/mol.56.5.1063; KOIZUMI S, 1985, J CLIN INVEST, V75, P1008, DOI 10.1172/JCI111761; KOIZUMI S, 1990, JPN J CANCER RES, V81, P1162, DOI 10.1111/j.1349-7006.1990.tb02529.x; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kuhnel JM, 2000, J CELL PHYSIOL, V184, P364, DOI 10.1002/1097-4652(200009)184:3<364::AID-JCP11>3.0.CO;2-N; Kumar CK, 1998, AM J PHYSIOL-CELL PH, V274, pC289, DOI 10.1152/ajpcell.1998.274.1.C289; KUMAR P, 1989, BIOCHEM PHARMACOL, V38, P541, DOI 10.1016/0006-2952(89)90397-3; Kusuhara H, 1998, AM J PHYSIOL-GASTR L, V275, pG789, DOI 10.1152/ajpgi.1998.275.4.G789; LAINI E, 2003, INT J CANCER, V103, P587; Leamon CP, 2001, DRUG DISCOV TODAY, V6, P44, DOI 10.1016/S1359-6446(00)01594-4; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; LI WW, 1992, CANCER RES, V52, P1434; LI WW, 1992, CANCER RES, V52, P3908; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Liu XY, 2001, BIOCHEM J, V358, P511, DOI 10.1042/0264-6021:3580511; Liu XY, 2002, BBA-BIOMEMBRANES, V1564, P333, DOI 10.1016/S0005-2736(02)00467-4; Longley DB, 2001, CLIN CANCER RES, V7, P3533; Longo GSA, 1997, ONCOL RES, V9, P259; LU K, 1995, BIOCHEM PHARMACOL, V50, P391, DOI 10.1016/0006-2952(95)00135-M; Lu YJ, 2002, ADV DRUG DELIVER REV, V54, P675, DOI 10.1016/S0169-409X(02)00042-X; Mahdavian E, 1999, ARCH BIOCHEM BIOPHYS, V368, P257, DOI 10.1006/abbi.1999.1319; Masson E, 1996, J CLIN INVEST, V97, P73, DOI 10.1172/JCI118409; Masuda M, 1997, CANCER RES, V57, P3506; Masuda S, 1999, MOL PHARMACOL, V55, P743; MATHERLY LH, 1993, BIOCHEM PHARMACOL, V46, P2185, DOI 10.1016/0006-2952(93)90608-Y; MATHERLY LH, 1995, BLOOD, V85, P500; MATHERLY LH, 1986, CANCER RES, V46, P588; MATHERLY LH, 1983, CANCER RES, V43, P2694; MATHERLY LH, 1984, CANCER RES, V44, P2325; MATHERLY LH, 1990, CANCER RES, V50, P3262; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; Matherly LH, 2003, VITAM HORM, V66, P403, DOI 10.1016/S0083-6729(03)01012-4; MATHERLY LH, 1990, BIOCHEM PHARMACOL, V39, P2005, DOI 10.1016/0006-2952(90)90622-R; Matherly LH, 2001, PROG NUCLEIC ACID RE, V67, P131, DOI 10.1016/S0079-6603(01)67027-2; Mauritz R, 2002, BIOCHEM PHARMACOL, V63, P105, DOI 10.1016/S0006-2952(01)00824-3; MCBURNEY MW, 1974, CELL, V2, P173, DOI 10.1016/0092-8674(74)90091-9; MCCLOSKEY DE, 1991, J BIOL CHEM, V266, P6181; McGuire JJ, 1998, ONCOL RES, V10, P193; McGuire JJ, 1995, ONCOL RES, V7, P535; MCIVOR RS, 1990, NUCLEIC ACIDS RES, V18, P7025, DOI 10.1093/nar/18.23.7025; MELERA PW, 1984, MOL CELL BIOL, V4, P38, DOI 10.1128/MCB.4.1.38; MELERA PW, 1988, J BIOL CHEM, V263, P1978; Merickel A, 1997, J BIOL CHEM, V272, P5403, DOI 10.1074/jbc.272.9.5403; Mineo C, 2001, HISTOCHEM CELL BIOL, V116, P109; MINI E, 1985, CANCER RES, V45, P317; MIOTTI S, 1995, INT J CANCER, V63, P395, DOI 10.1002/ijc.2910630316; MIYACHI H, 1995, CANCER LETT, V88, P93, DOI 10.1016/0304-3835(94)03616-Q; MORAN RG, 1976, J BIOL CHEM, V251, P3569; MOSCOW JA, 1995, CANCER RES, V55, P3790; NIETHAMMER D, 1975, EUR J CANCER, V11, P845, DOI 10.1016/0014-2964(75)90083-3; NIMEC Z, 1983, ARCH BIOCHEM BIOPHYS, V226, P671, DOI 10.1016/0003-9861(83)90337-5; Niyikiza C, 2002, MOL CANCER THER, V1, P545; Norris MD, 1996, INT J CANCER, V65, P613; OCONNOR BM, 1992, CANCER RES, V52, P1137; Pan XQ, 2002, BLOOD, V100, P594, DOI 10.1182/blood.V100.2.594; Pisters KMW, 1996, CLIN CANCER RES, V2, P1819; PIZZORNO G, 1995, CANCER RES, V55, P566; PIZZORNO G, 1988, CANCER RES, V48, P2149; PIZZORNO G, 1989, CANCER RES, V49, P5275; PIZZORNO G, 1991, MOL PHARMACOL, V39, P85; POSER RG, 1981, CANCER RES, V41, P4441; PRASAD PD, 1995, BIOCHEM BIOPH RES CO, V206, P681, DOI 10.1006/bbrc.1995.1096; PRIEST DG, 1989, CANCER RES, V49, P4204; RAGOUSSIS J, 1992, GENOMICS, V14, P423, DOI 10.1016/S0888-7543(05)80236-8; Rajgopal A, 2001, AM J PHYSIOL-CELL PH, V281, pC1579, DOI 10.1152/ajpcell.2001.281.5.C1579; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; Reddy JA, 1999, BLOOD, V93, P3940, DOI 10.1182/blood.V93.11.3940.411k09_3940_3948; Reilly RT, 1997, ARCH BIOCHEM BIOPHYS, V342, P338, DOI 10.1006/abbi.1997.0116; RHEE MS, 1993, CANCER RES, V53, P2227; RHEE MS, 1990, CANCER RES, V50, P3979; Roberts JD, 2000, CANCER CHEMOTH PHARM, V45, P103, DOI 10.1007/s002800050017; ROSENBLATT DS, 1978, MOL PHARMACOL, V14, P210; ROSENBLATT DS, 1978, MOL PHARMACOL, V14, P1143; Rosowsky A, 1998, J MED CHEM, V41, P5310, DOI 10.1021/jm980477+; Rosowsky A, 2000, PHARMACOL THERAPEUT, V85, P191, DOI 10.1016/S0163-7258(99)00055-8; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; Ross JF, 1999, CANCER-AM CANCER SOC, V85, P348, DOI 10.1002/(SICI)1097-0142(19990115)85:2<348::AID-CNCR12>3.0.CO;2-4; ROSS JF, 1994, CANCER-AM CANCER SOC, V73, P2432, DOI 10.1002/1097-0142(19940501)73:9<2432::AID-CNCR2820730929>3.0.CO;2-S; Rothem L, 2003, J BIOL CHEM, V278, P8935, DOI 10.1074/jbc.M209578200; Rothem L, 2002, BIOCHEM J, V367, P741, DOI 10.1042/BJ20020801; Rots MG, 1999, BLOOD, V94, P3121, DOI 10.1182/blood.V94.9.3121.421k08_3121_3128; Roy K, 1998, J BIOL CHEM, V273, P2526, DOI 10.1074/jbc.273.5.2526; Roy K, 1997, J BIOL CHEM, V272, P6903, DOI 10.1074/jbc.272.11.6903; Russel FGM, 2002, ANNU REV PHYSIOL, V64, P563, DOI 10.1146/annurev.physiol.64.081501.155913; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SAHINTOTH M, 1992, P NATL ACAD SCI USA, V89, P10547, DOI 10.1073/pnas.89.21.10547; SAIKAWA Y, 1993, J BIOL CHEM, V268, P5293; Saito H, 1996, J BIOL CHEM, V271, P20719, DOI 10.1074/jbc.271.34.20719; Sanghani SP, 1999, J BIOL CHEM, V274, P27018, DOI 10.1074/jbc.274.38.27018; Sanghani SP, 1997, BIOCHEMISTRY-US, V36, P10506, DOI 10.1021/bi970825u; Sauerbrey A, 1999, HUM GENE THER, V10, P2495, DOI 10.1089/10430349950016834; Saxena M, 1996, BIOCHEM PHARMACOL, V51, P975, DOI 10.1016/0006-2952(96)00051-2; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; SCHILSKY RL, 1980, P NATL ACAD SCI-BIOL, V77, P2919, DOI 10.1073/pnas.77.5.2919; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCHLEMMER SR, 1992, J BIOL CHEM, V267, P14746; SCHLEMMER SR, 1995, BIOCHEM PHARMACOL, V49, P1427, DOI 10.1016/0006-2952(95)00069-C; Schmitz JC, 2001, CANCER METAST REV, V20, P33, DOI 10.1023/A:1013100306315; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Schultz RM, 1999, SEMIN ONCOL, V26, P68; SEITHER RL, 1989, J BIOL CHEM, V264, P17016; SEITHER RL, 1991, J BIOL CHEM, V266, P4112; SELHUB J, 1983, PHARMACOL THERAPEUT, V20, P397, DOI 10.1016/0163-7258(83)90034-7; Sharif KA, 1998, BIOCHEM PHARMACOL, V55, P1683, DOI 10.1016/S0006-2952(98)00039-2; Sharina IG, 2001, MOL PHARMACOL, V59, P1022, DOI 10.1124/mol.59.5.1022; SHEN F, 1995, BIOCHEMISTRY-US, V34, P5660, DOI 10.1021/bi00016a042; SHEN F, 1994, BIOCHEMISTRY-US, V33, P1209, DOI 10.1021/bi00171a021; Shih C, 1997, CANCER RES, V57, P1116; Sierra EE, 1997, BIOCHEM PHARMACOL, V53, P223, DOI 10.1016/S0006-2952(96)00730-7; Sierra EE, 1998, BIOCHEM PHARMACOL, V55, P1505, DOI 10.1016/S0006-2952(97)00673-4; SIMONSEN CC, 1983, P NATL ACAD SCI-BIOL, V80, P2495, DOI 10.1073/pnas.80.9.2495; SIROTNAK FM, 1981, CANCER RES, V41, P4447; SIROTNAK FM, 1981, CANCER RES, V41, P3944; SIROTNAK FM, 1981, CANCER RES, V41, P966; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1978, CANCER RES, V38, P345; SIROTNAK FM, 1974, CANCER RES, V34, P3332; Sirotnak FM, 2000, CLIN CANCER RES, V6, P3705; SIROTNAK FM, 1968, CANCER RES, V28, P75; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; Sorrentino B P, 1999, Prog Exp Tumor Res, V36, P143; Spencer HT, 1996, LEUKEMIA, V10, P439; SPINELLA MJ, 1995, J BIOL CHEM, V270, P7842, DOI 10.1074/jbc.270.14.7842; SRIMATKANDADA S, 1989, J BIOL CHEM, V264, P3524; Stark M, 2003, MOL PHARMACOL, V64, P220, DOI 10.1124/mol.64.2.220; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Sun W, 2001, BIOCHEM BIOPH RES CO, V283, P417, DOI 10.1006/bbrc.2001.4774; Sun XL, 1998, P NATL ACAD SCI USA, V95, P6647, DOI 10.1073/pnas.95.12.6647; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Takebe N, 2001, MOL THER, V3, P88, DOI 10.1006/mthe.2000.0236; Takebe N, 2000, CANCER GENE THER, V7, P910, DOI 10.1038/sj.cgt.7700199; Theti DS, 2003, CANCER RES, V63, P3612; Tong YZ, 1998, J BIOL CHEM, V273, P11611, DOI 10.1074/jbc.273.19.11611; Tong YZ, 1998, J BIOL CHEM, V273, P31209, DOI 10.1074/jbc.273.47.31209; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; TRENT DF, 1991, J BIOL CHEM, V266, P5445; TRENT JM, 1984, J CLIN ONCOL, V2, P8, DOI 10.1200/JCO.1984.2.1.8; Tse A, 1998, J BIOL CHEM, V273, P25953, DOI 10.1074/jbc.273.40.25953; Tse A, 1998, J BIOL CHEM, V273, P25944, DOI 10.1074/jbc.273.40.25944; van der Wilt CL, 2001, CANCER RES, V61, P3675; VANDERVEER LJ, 1989, LEUKEMIA RES, V13, P981, DOI 10.1016/0145-2126(89)90005-2; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Volk EL, 2000, CANCER RES, V60, P3514; Volk EL, 2002, CANCER RES, V62, P5035; Wang H, 2000, BLOOD, V96, P3529; WANG X, 1992, BIOCHEM PHARMACOL, V44, P1898; Wang YH, 2003, BIOCHEM PHARMACOL, V65, P1163, DOI 10.1016/S0006-2952(03)00007-8; Wang YH, 2001, BBA-BIOMEMBRANES, V1513, P49, DOI 10.1016/S0005-2736(01)00340-6; Webber S, 1996, CANCER CHEMOTH PHARM, V37, P509, DOI 10.1007/s002800050422; Wedge SR, 1995, CLIN CANCER RES, V1, P1479; WEITMAN SD, 1994, J NEURO-ONCOL, V21, P107, DOI 10.1007/BF01052894; WEITMAN SD, 1992, CANCER RES, V52, P3396; WEITMAN SD, 1992, CANCER RES, V52, P6708; Welsh SJ, 2000, CLIN CANCER RES, V6, P2538; WERKHEISER W, 1961, J BIOL CHEM, V236, P888; WESTERHOF GR, 1991, CANCER RES, V51, P5507; WESTERHOF GR, 1995, MOL PHARMACOL, V48, P459; Whetstine JR, 2001, CLIN CANCER RES, V7, P3416; WHITE JC, 1981, J BIOL CHEM, V256, P5722; WHITE JC, 1976, MOL PHARMACOL, V12, P711; WHITE JC, 1975, MOL PHARMACOL, V11, P287; WHITE JC, 1979, J BIOL CHEM, V254, P889; Whitehead VM, 1998, LEUKEMIA LYMPHOMA, V31, P507, DOI 10.3109/10428199809057610; WHITEHEAD VM, 1992, BLOOD, V80, P1316; WHITEHEAD VM, 1990, BLOOD, V76, P44; Whitehead VM, 1998, CLIN CANCER RES, V4, P183; Whitehead VM, 2001, LEUKEMIA, V15, P1081, DOI 10.1038/sj.leu.2402165; WHITEHEAD VM, 1977, CANCER RES, V37, P408; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wong SC, 1999, J BIOL CHEM, V274, P10388, DOI 10.1074/jbc.274.15.10388; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Worzalla JF, 1998, ANTICANCER RES, V18, P3235; Wright JE, 2000, BIOCHEM PHARMACOL, V60, P41, DOI 10.1016/S0006-2952(00)00294-X; Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277; Wu M, 1999, CANCER EPIDEM BIOMAR, V8, P775; YALOWICH JC, 1982, CANCER RES, V42, P3648; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; Yang R, 2003, CLIN CANCER RES, V9, P837; YU MH, 1993, CANCER RES, V53, P6031; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 2000, CANCER RES, V60, P4779; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274; Zhang L, 1998, CLIN CANCER RES, V4, P2169; Zhao R, 2000, CLIN CANCER RES, V6, P3304; Zhao R, 1998, J BIOL CHEM, V273, P19065, DOI 10.1074/jbc.273.30.19065; Zhao RB, 2000, CLIN CANCER RES, V6, P3687; Zhao RB, 2000, J BIOL CHEM, V275, P26599, DOI 10.1074/jbc.M002580200; Zhao RB, 1999, BIOCHEM PHARMACOL, V58, P1615, DOI 10.1016/S0006-2952(99)00257-9; Zhao RB, 2003, BBA-BIOMEMBRANES, V1613, P49, DOI 10.1016/S0005-2736(03)00136-6; Zhao RB, 1998, J BIOL CHEM, V273, P7873, DOI 10.1074/jbc.273.14.7873; Zhao RB, 1999, MOL PHARMACOL, V56, P68, DOI 10.1124/mol.56.1.68; Zhao RB, 2000, MOL PHARMACOL, V57, P317; Zhao RB, 2002, AM J PHYSIOL-CELL PH, V282, pC1512, DOI 10.1152/ajpcell.00547.2001; Zhao RB, 1997, J BIOL CHEM, V272, P21207, DOI 10.1074/jbc.272.34.21207; Zhao RB, 2001, BIOCHEM PHARMACOL, V61, P857, DOI 10.1016/S0006-2952(01)00532-9; Zhao RB, 2001, J BIOL CHEM, V276, P1114, DOI 10.1074/jbc.M007919200	345	205	210	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7431	7457		10.1038/sj.onc.1206946	http://dx.doi.org/10.1038/sj.onc.1206946			27	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576850				2022-12-28	WOS:000186112500015
J	Wang, L; Soria, JC; Chang, YS; Lee, HY; Wei, QY; Mao, L				Wang, L; Soria, JC; Chang, YS; Lee, HY; Wei, QY; Mao, L			Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer	ONCOGENE			English	Article						minisatellite; tandem repeats; VNTR; hTERT; lung cancer	REVERSE-TRANSCRIPTASE; HTERT EXPRESSION; DNA; CELL; REARRANGEMENTS; POLYMORPHISMS; REPAIR; INSTABILITY; CARCINOMAS; EPITHELIUM	Chemoprevention has been widely explored as a promising strategy for controlling the incidence of lung cancer, the leading cause of cancer-related death. To maximize the benefit of lung cancer chemoprevention, it is important to identify individuals at high risk for the disease. The genetic background has been shown to play an important role in one's risk of developing lung cancer. We report here the identification of a polymorphic tandem repeats minisatellite (termed MNS16A) in the downstream region of the human telomerase gene. This minisatellite is located upstream of an antisense transcript from the human telomerase gene locus and was demonstrated to have promoter activity. The promoter activity was significantly lower in the construct containing the shorter repeats, suggesting that the MNS16A variant may have a relevance of functionality. To explore the role of this novel polymorphism in lung cancer, we conducted a pilot hospital-based case-control study by identifying the MNS16A genotype with genomic DNA from 53 lung cancer patients and 72 cancer-free controls. We found four different alleles and classified them as shorter (S) or longer (L) on the functional basis of the length of the repeats in the controls. The MNS16A genotype distributions of the SS, SL, and LL genotypes were 11, 32, and 57%, respectively, in the cases, and 14, 40, and 46%, respectively, in the controls. Compared with the SS+SL genotype, the LL genotype was associated with greater than twofold increased risk of lung cancer (odds ratio = 2.18; 95% confidence interval = 0.92, 5.20) after adjustment for age, sex, ethnicity, and smoking status, suggesting a potential role of MNS16A in lung cancer susceptibility. Larger studies are needed to verify our findings.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mao, L (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 432,1515 Holcombe Blvd, Houston, TX 77030 USA.	lmao@mdanderson.org	Soria, Jean-Charles/F-3619-2014; Mao, Li/C-7570-2011	Mao, Li/0000-0001-7263-3358; Chang, Yoon Soo/0000-0003-3340-4223; Lee, Ho-Young/0000-0001-7556-9312	NATIONAL CANCER INSTITUTE [P01CA091844, U01CA086390] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; *AM CANC SOC INC, 2003, CANC FACTS FIG 2003, P2; Bouchardy C, 2001, LUNG CANCER-J IASLC, V32, P109, DOI 10.1016/S0169-5002(00)00215-4; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; Dhaene K, 2000, VIRCHOWS ARCH, V437, P1, DOI 10.1007/s004280000189; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HOFFOLSEN P, 1995, HUM MUTAT, V5, P329, DOI 10.1002/humu.1380050410; HONMA M, 1994, MUTAT RES, V304, P167, DOI 10.1016/0027-5107(94)90208-9; Imai H, 1997, P NATL ACAD SCI USA, V94, P10817, DOI 10.1073/pnas.94.20.10817; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1987, NUCLEIC ACIDS RES, V15, P2823, DOI 10.1093/nar/15.7.2823; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaplanski C, 1997, INT J CANCER, V72, P248, DOI 10.1002/(SICI)1097-0215(19970717)72:2<248::AID-IJC8>3.0.CO;2-R; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEDWITH BJ, 1995, CARCINOGENESIS, V16, P1167, DOI 10.1093/carcin/16.5.1167; LEDWITH BJ, 1990, CANCER RES, V50, P5245; Leem SH, 2002, ONCOGENE, V21, P769, DOI 10.1038/sj.onc.1205122; MATSUMURA Y, 1992, CANCER RES, V52, P2174; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; PAQUETTE B, 1992, CANCER RES, V52, P5788; Shen HB, 2002, CANCER RES, V62, P4992; Soria JC, 2001, JNCI-J NATL CANCER I, V93, P1257, DOI 10.1093/jnci/93.16.1257; Spitz MR, 2001, CANCER RES, V61, P1354; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; THEIN SL, 1987, BRIT J CANCER, V55, P353, DOI 10.1038/bjc.1987.71; Wang L, 2002, CLIN CANCER RES, V8, P2883; Wei QY, 2000, J NATL CANCER I, V92, P1764; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yashima K, 1997, CANCER RES, V57, P2373	35	52	54	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7123	7129		10.1038/sj.onc.1206852	http://dx.doi.org/10.1038/sj.onc.1206852			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562040				2022-12-28	WOS:000185955000003
J	Hall, EJ; Hei, TK				Hall, EJ; Hei, TK			Genomic instability and bystander effects induced by high-LET radiation	ONCOGENE			English	Article						alpha-particles; microbeam; bystander effects; gene amplification; allelic imbalance	BRONCHIAL EPITHELIAL-CELLS; ALPHA-PARTICLES; GENE AMPLIFICATION; MAMMALIAN-CELLS; LOW FLUENCES; IONIZING-RADIATION; IN-VITRO; TRANSFORMATION; MICROBEAM; CORRELATE	An understanding of the radiobiological effects of high-linear energy transfer (LET) radiation is essential for radiation protection and human risk assessment. Ever since the discovery of X-rays was made by Rontgen more than a century ago, it has always been accepted that the deleterious effects of ionizing radiation, such as mutation and carcinogenesis, are due mainly to direct damage to DNA. With the availability of a precision single-particle microbeam, it is possible to demonstrate, unequivocally, the presence of a bystander effect with many biological end points. These studies provide clear evidence that irradiated cells can induce a bystander mutagenic response in neighboring cells not directly traversed by alpha-particles, and that cell-cell communication processes play a critical role in mediating the bystander phenomenon. Following exposure to high-LET radiation, immortalized human bronchial (BEP2D) and breast (MCF-10F) cells have been shown to undergo malignant transformation through a series of successive steps, before becoming tumorigenic in nude mice. There is a progressive increase in genomic instability, determined either by gene amplification or allelic imbalance, with the highest incidence observed among established tumor cell lines, relative to transformed, nontumorigenic and control cell lines.	Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Columbia University	Hall, EJ (corresponding author), Columbia Univ, Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.	ejh1@Columbia.edu			NCI NIH HHS [CA 49062] Funding Source: Medline; NCRR NIH HHS [RR 11623] Funding Source: Medline; NIEHS NIH HHS [ES 07890, ES 10349] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049062] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011623] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007890, P42ES010349] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Calaf GM, 2000, CARCINOGENESIS, V21, P769, DOI 10.1093/carcin/21.4.769; Cheng TL, 1999, BRIT J CANCER, V79, P1378, DOI 10.1038/sj.bjc.6690221; Cohen BL, 2002, AM J ROENTGENOL, V179, P1137, DOI 10.2214/ajr.179.5.1791137; Dale Walter M., 1943, BRIT JOUR RADIOL, V16, P171; Dale Walter M., 1942, BIOCHEM JOUR, V36, P80; Dale WM, 1940, BIOCHEM J, V34, P1367, DOI 10.1042/bj0341367; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINENDEGEN LE, 1998, PHYS SOC, V27, P4; Hall E, 2000, RAD BIOL RADIOLOGIST; HEI TK, 1996, ADV SPACE RES-SERIES, V18, P137, DOI 10.1016/0273-1177(95)00800-T; Hei TK, 2001, ADV SPACE RES-SERIES, V27, P411, DOI 10.1016/S0273-1177(01)00009-6; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; Hei TK, 1997, P NATL ACAD SCI USA, V94, P3765, DOI 10.1073/pnas.94.8.3765; HEI TK, 1996, RADIAT ONCOL INVEST, V3, P398; International Commission on Radiological Protection, 1991, 60 ICRP 60 ICRP; KOTVAL JP, 1947, J GENET, V48, P135, DOI 10.1007/BF02989375; Lea D., 1944, PARASITOLOGY, V36, P110, DOI 10.1017/S003118200001204X; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 2003, P NATL ACAD SCI USA, V100, P776, DOI 10.1073/pnas.0334858100; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MITCHELL SA, 2003, MICR PROB CELL RAD R; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Nagar S, 2003, CANCER RES, V63, P324; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Nagasawa H, 2002, MUTAT RES-FUND MOL M, V508, P121, DOI 10.1016/S0027-5107(02)00193-8; NAGASAWA H, 1992, CANCER RES, V52, P6394; NCRP 116. National Council on Radiation Protection and Measurements, 1993, 116 NCRP; Piao CQ, 2001, RADIAT RES, V155, P263, DOI 10.1667/0033-7587(2001)155[0263:GAAMII]2.0.CO;2; Piao CQ, 1999, CARCINOGENESIS, V20, P1529, DOI 10.1093/carcin/20.8.1529; Prise KM, 2002, ADV SPACE RES, V30, P871, DOI 10.1016/S0273-1177(02)00408-8; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Roy D, 2001, MOL CARCINOGEN, V31, P192, DOI 10.1002/mc.1054; Roy D, 2001, CARCINOGENESIS, V22, P1685, DOI 10.1093/carcin/22.10.1685; Sawant SG, 2002, RADIAT RES, V157, P361, DOI 10.1667/0033-7587(2002)157[0361:TRIBEF]2.0.CO;2; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; SOULE HD, 1990, CANCER RES, V50, P6075; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; Weaver DA, 1997, CARCINOGENESIS, V18, P1251, DOI 10.1093/carcin/18.6.1251; Weaver DA, 2000, CARCINOGENESIS, V21, P205, DOI 10.1093/carcin/21.2.205; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798	47	115	126	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7034	7042		10.1038/sj.onc.1206900	http://dx.doi.org/10.1038/sj.onc.1206900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557808				2022-12-28	WOS:000185903900008
J	Matsubara, S; Ozawa, M				Matsubara, S; Ozawa, M			Expression of alpha-catenin in alpha-catenin-deficient cells results in a reduced proliferation in three-dimensional multicellular spheroids but not in two-dimensional monolayer cultures	ONCOGENE			English	Article						alpha-catenin; cadherin; proliferation; compaction; multicellular spheroids	ANCHORAGE-INDEPENDENT GROWTH; E-CADHERIN FUNCTION; BETA-CATENIN; CONTACT INHIBITION; ALKYLATING-AGENTS; ADHESION COMPLEX; EPITHELIAL-CELLS; DEPENDENT KINASE; CARCINOMA-CELLS; PROSTATE-CANCER	alpha-Catenin is an intracellular protein that associates with the carboxy-terminal region of cadherin, a cell adhesion molecule, via beta-catenin or gamma-catenin (plakoglobin). Linkage of cadherin to the cytoskeleton by catenins is required for full cadherin activity. Following transfection of an alpha-catenin-deficient colon carcinoma cell line with a series of alpha-catenin constructs, we discovered that the restoration of alpha-catenin expression results in reduced proliferation in three-dimensional multicellular spheroids, but not in two-dimensional monolayer cultures. The cellular function of alpha-catenin has not been compared between cells in three- and two-dimensional culture; this is the first evidence that growth regulation in three- dimensional cultures requires signaling mediated by alpha-catenin. Two classes of constructs, containing deletions in either the central segment or the COOH terminus of the molecule, both induced morphological changes, including cell compaction, and suppressed cell growth in three- dimensional cultures. In alpha-catenin-expressing cells, inhibition of cadherin cell adhesion by treatment with anti-E-cadherin antibodies resulted in a similar phenotype as that observed following the loss of alpha-catenin. Therefore, both the homophilic interaction of the cadherin extracellular domain and the linkage of the cadherin cytoplasmic domain to the actin cytoskeleton by alpha-catenin are necessary for growth control in three- dimensional culture.	Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 8908544, Japan	Kagoshima University	Matsubara, S (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Biochem & Mol Biol, Kagoshima 8908544, Japan.	shmlmcbd@m.kufm.kagoshima-u.ac.jp						ALLEY MC, 1988, CANCER RES, V48, P589; Anttila M, 1998, J CLIN ONCOL, V16, P2591, DOI 10.1200/JCO.1998.16.8.2591; Bracke ME, 1997, EUR J CELL BIOL, V74, P342; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Che XM, 1999, ONCOLOGY-BASEL, V57, P131, DOI 10.1159/000012020; Espada J, 1999, J CELL BIOL, V146, P967, DOI 10.1083/jcb.146.5.967; EWING CM, 1995, CANCER RES, V55, P4813; FUKAZAWA H, 1995, ANAL BIOCHEM, V228, P83, DOI 10.1006/abio.1995.1318; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; KEMLER R, 1977, P NATL ACAD SCI USA, V74, P4449, DOI 10.1073/pnas.74.10.4449; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lampugnani MG, 2003, J CELL BIOL, V161, P793, DOI 10.1083/jcb.200209019; Maeno Y, 1999, AM J PATHOL, V154, P1323, DOI 10.1016/S0002-9440(10)65385-0; Matsubara S, 2001, J CELL BIOL, V154, P573, DOI 10.1083/jcb.200103097; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x; Obama H, 1997, J BIOL CHEM, V272, P11017; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Ozawa M, 1998, J BIOL CHEM, V273, P29524, DOI 10.1074/jbc.273.45.29524; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Raftopoulos I, 1998, J SURG ONCOL, V68, P92, DOI 10.1002/(SICI)1096-9098(199806)68:2<92::AID-JSO4>3.0.CO;2-F; Roe S, 1998, CELL ADHES COMMUN, V5, P283, DOI 10.3109/15419069809040298; Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10; Shimazui T, 1997, INT J CANCER, V74, P523, DOI 10.1002/(SICI)1097-0215(19971021)74:5<523::AID-IJC8>3.0.CO;2-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; SURANI MAH, 1980, EXP CELL RES, V125, P275, DOI 10.1016/0014-4827(80)90123-8; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Umbas R, 1997, INT J CANCER, V74, P374, DOI 10.1002/(SICI)1097-0215(19970822)74:4<374::AID-IJC2>3.0.CO;2-S; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Winston J, 1996, J BIOL CHEM, V271, P11253, DOI 10.1074/jbc.271.19.11253; Woodfield RJ, 2001, BIOCHEM J, V360, P335, DOI 10.1042/0264-6021:3600335	47	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2694	2702		10.1038/sj.onc.1207423	http://dx.doi.org/10.1038/sj.onc.1207423			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755240				2022-12-28	WOS:000220714900011
J	Palecek, E; Brazda, V; Jagelska, E; Pecinka, P; Karlovska, L; Brazdova, M				Palecek, E; Brazda, V; Jagelska, E; Pecinka, P; Karlovska, L; Brazdova, M			Enhancement of p53 sequence-specific binding by DNA supercoiling	ONCOGENE			English	Article						competition assay; p53; DNA sequence-specific binding; supercoiled DNA; cruciform extrusion	TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; CORE DOMAIN; MONOCLONAL-ANTIBODIES; CONSENSUS SEQUENCE; RESPONSE ELEMENT; ELISA TECHNIQUE; PROTEIN; CONFORMATION; MICROSCOPY	Using a new competition assay, we investigated the effect of DNA negative supercoiling on the DNA sequence-specific binding ( SSDB) of human wild- type ( wt) p53 protein. We found that supercoiled ( sc) pBluescript DNAs with different inserted p53 target sequences were stronger competitors than a mixture of scDNA pBluescript with the given 20- mer target oligodeoxynucleotide. ScDNAs were always better competitors than their linearized or relaxed forms. Two DNAs with extruded cruciforms within the target sequence were the best competitors; removal of the cruciforms resulted in a decrease of competitor strength. In contrast to the full- length wt p53, the deletion mutant p53CDelta30 and the p53 core domain ( 93 - 312 aa) showed no enhancement of p53 SSDB to scDNA, suggesting that, in addition to the p53 core domain, the C- terminal was involved in this binding. We conclude that cruciforms and DNA bends contribute to the enhancement of p53 SSDB to scDNA and that the DNA supercoiling is an important determinant in the p53 sequence-specific binding. Supercoiling may thus play a significant role in the complex p53- regulatory network.	Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Palecek, E (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CS-61265 Brno, Czech Republic.	palecek@ibp.cz	Brazdova, Marie/H-1924-2014; Palecek, Emil/C-1075-2013; Václav, Brázda/F-9582-2011; Pečinka, Petr/H-8493-2014; Jagelská, Eva Brázdová -/H-1915-2014; Brazda, Vaclav/ABH-9460-2020	Palecek, Emil/0000-0003-2561-8336; Václav, Brázda/0000-0003-2837-4226; Brazda, Vaclav/0000-0003-2837-4226; Pecinka, Petr/0000-0003-1270-3646				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BATES AD, 1993, DNA TOPOLOGY; Brazda V, 2000, BIOCHEM BIOPH RES CO, V267, P934, DOI 10.1006/bbrc.1999.2056; Brazdova M, 2002, NUCLEIC ACIDS RES, V30, P4966, DOI 10.1093/nar/gkf616; Cherny DI, 1999, J MOL BIOL, V294, P1015, DOI 10.1006/jmbi.1999.3299; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; GOHLER T, 2002, J BIOL CHEM, V8, P8; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jagelska E, 2002, J IMMUNOL METHODS, V267, P227, DOI 10.1016/S0022-1759(02)00182-5; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jett SD, 2000, J MOL BIOL, V299, P585, DOI 10.1006/jmbi.2000.3759; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Krasilnikov AS, 1999, J MOL BIOL, V292, P1149, DOI 10.1006/jmbi.1999.3117; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mazur SJ, 1999, J MOL BIOL, V292, P241, DOI 10.1006/jmbi.1999.3064; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Palecek E, 1999, ONCOGENE, V18, P3617, DOI 10.1038/sj.onc.1202710; Palecek E, 2001, EUR J BIOCHEM, V268, P573, DOI 10.1046/j.1432-1327.2001.01898.x; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Pospisilova S, 2000, J IMMUNOL METHODS, V237, P51, DOI 10.1016/S0022-1759(99)00246-X; Stros M, 2000, J BIOL CHEM, V275, P35699, DOI 10.1074/jbc.M007167200; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Zhou HJ, 2001, J MOL BIOL, V306, P227, DOI 10.1006/jmbi.2000.4370	41	36	36	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2004	23	12					2119	2127		10.1038/sj.onc.1207324	http://dx.doi.org/10.1038/sj.onc.1207324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14755248				2022-12-28	WOS:000220280900001
J	Ko, JS; Shin, SM; Oh, YM; Lee, YS; Ryoo, ZY; Lee, YH; Na, DS; Kim, JW				Ko, JS; Shin, SM; Oh, YM; Lee, YS; Ryoo, ZY; Lee, YH; Na, DS; Kim, JW			Transgenic mouse model for breast cancer: induction of breast cancer in novel oncogene HCCR-2 transgenic mice	ONCOGENE			English	Article						breast cancer; HCCR-2; p53; transgenic mouse	EMBRYO FIBROBLASTS; C-MYC; IDENTIFICATION; AMPLIFICATION; INVOLVEMENT; GENES; CELLS; DNA	Transgenic mice containing novel oncogene HCCR-2 were generated to analyse the phenotype and to characterize the role of HCCR-2 in cellular events. Mice transgenic for HCCR-2 developed breast cancers and metastasis. The level of p53 in HCCR-2 transgenic mice was elevated in most tissues including breast, brain, heart, lung, liver, stomach, kidney, spleen, and lymph node. We examined whether stabilized p53 is functional in HCCR-2 transgenic mice. Defective induction of p53 responsive genes including p21(WAF1), MDM2, and bax indicates that stabilized p53 in HCCR-2 transgenic mice exists in an inactive form. These results suggest that HCCR-2 represents an oncoprotein that is related to breast cancer development and regulation of the p53 tumor suppressor.	Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea; Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Internal Med, Seoul 138736, South Korea; Catholic Univ Korea, Coll Med, Dept Obstet & Gynecol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Dept Clin Pathol, Seoul 137040, South Korea; Catholic Univ Korea, Coll Med, Lab Anim Sci, Seoul 137040, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea	Catholic University of Korea; University of Ulsan; University of Ulsan; Catholic University of Korea; Catholic University of Korea; Catholic University of Korea; Yeungnam University; University of Ulsan	Kim, JW (corresponding author), Catholic Univ Korea, Coll Med, Mol Genet Lab, Seoul 137040, South Korea.	jinwoo@catholic.ac.kr	RYOO, ZAEYOUNG/AAQ-1573-2020					BERNS EMJJ, 1992, CANCER RES, V52, P1107; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BYRNE JA, 1995, CANCER RES, V55, P2896; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Dickson C, 2000, ONCOGENE, V19, P1097, DOI 10.1038/sj.onc.1203267; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; Kim J, 1996, AM J PHYSIOL-RENAL, V270, pF575, DOI 10.1152/ajprenal.1996.270.4.F575; Ko J, 2003, ONCOGENE, V22, P4679, DOI 10.1038/sj.onc.1206624; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; NEBERT DW, 1991, MUTAT RES, V247, P267, DOI 10.1016/0027-5107(91)90022-G; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Proux V, 1996, J BIOL CHEM, V271, P30790, DOI 10.1074/jbc.271.48.30790; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUURING E, 1992, CANCER RES, V52, P5229; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Smith JB, 1998, J NATL CANCER I, V90, P1146, DOI 10.1093/jnci/90.15.1146	19	32	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1950	1953		10.1038/sj.onc.1207356	http://dx.doi.org/10.1038/sj.onc.1207356			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14691448				2022-12-28	WOS:000220129500017
J	Li, HX; Seth, A				Li, HX; Seth, A			An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein	ONCOGENE			English	Article						RNF11; AMSH; smurf2; TGF-beta; breast cancer; RING-H2-finger domain; PY motif	TGF-BETA RECEPTOR; BREAST-CANCER; LIGASE; EPS15; DEGRADATION; ENDOCYTOSIS; PATHWAY; TARGETS; ENDOSOMES; BRCA1	RING-finger proteins play crucial roles in ubiquitination events involved in diverse cellular processes including signal transduction, differentiation and apoptosis. Most of the RING-finger proteins have E3-ubiquitin ligase activity. RNF11 is a small RING-finger protein and harbors a RING-H2 domain and a PY motif that could facilitate protein: protein interaction(s) involved in oncogenesis. To isolate RNF11 protein partners and determine its role in normal and cancer cells, we performed yeast two-hybrid screening. Among 18 in-frame positive clones, three were found to be ZBRK1, Eps15 and AMSH ( associated molecule with the SH3 domain of STAM). ZBRK1 is a KRAB domain containing Zinc-finger protein and is known to repress target gene transcription in a BRCA1-dependent manner. Eps15 is monoubiquitinated and is part of an essential complex involved in the endocytosis of plasma membrane receptors via the clathrin-mediated internalization pathway. Recent studies have shown that AMSH protein is involved in BMP/TGF-beta signaling pathway by binding to Smad6 and Smad7. The association of RNF11 with these binding partners suggests that it would be involved in biological processes such as gene transcription, BMP/TGF-beta signaling and ubiquitination-associated events. Previously, we have shown that RNF11 interacts with the HECT-type E3 ligases AIP4 and Smurf2. Here, we show that RNF11 binds to AMSH in mammalian cells and that this interaction is independent of the RNF11 RING-finger domain and the PY motif. Our results also demonstrate that AMSH is ubiquitinated by Smurf2 E3 ligase in the presence of RNF11 and that a consequent reduction in its steady-state level requires both RNF11 and Smurf2. RNF11 therefore recruits AMSH to Smurf2 for ubiquitination, leading to its degradation by the 26S proteasome. The potential functions of RNF11-mediated degradation of AMSH in breast cancer are discussed.	Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Seth, A (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Lab Mol Pathol, Rm E-423B,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	arun.seth@utoronto.ca						Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bean AJ, 2000, J BIOL CHEM, V275, P15271, DOI 10.1074/jbc.275.20.15271; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Burger A, 1998, ONCOGENE, V16, P327, DOI 10.1038/sj.onc.1201517; Carbone R, 1997, CANCER RES, V57, P5498; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Ishii N, 2001, MOL CELL BIOL, V21, P8626, DOI 10.1128/MCB.21.24.8626-8637.2001; Itoh F, 2001, EMBO J, V20, P4132, DOI 10.1093/emboj/20.15.4132; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KITCHING R, 2003, UNPUB BIOCH BIOPHYS; Nuber U, 1999, J BIOL CHEM, V274, P7576, DOI 10.1074/jbc.274.11.7576; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Salcini AE, 1999, INT J BIOCHEM CELL B, V31, P805, DOI 10.1016/S1357-2725(99)00042-4; Sorkina T, 1999, J CELL SCI, V112, P317; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Tanaka N, 1999, J BIOL CHEM, V274, P19129, DOI 10.1074/jbc.274.27.19129; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	23	48	59	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1801	1808		10.1038/sj.onc.1207319	http://dx.doi.org/10.1038/sj.onc.1207319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755250				2022-12-28	WOS:000220129500001
J	Han, SU; Kim, HT; Seong, DH; Kim, YS; Park, YS; Bang, YJ; Yang, HK; Kim, SJ				Han, SU; Kim, HT; Seong, DH; Kim, YS; Park, YS; Bang, YJ; Yang, HK; Kim, SJ			Loss of the Smad3 expression increases susceptibility to tumorigenicity in human gastric cancer	ONCOGENE			English	Article						TGF-b; Smad3; gastric cancer; tumorigenicity; gene expression	GROWTH-FACTOR-BETA; TUMOR-SUPPRESSOR GENE; II RECEPTOR GENE; TGF-BETA; E-CADHERIN; CARCINOMA-CELLS; MICROSATELLITE INSTABILITY; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; COLON	Loss of the tumor suppressive effect of transforming growth factor-beta (TGF-beta) has been commonly found at later stages in carcinogenic progression. Although the genes encoding TGF-beta receptors and Smads have been found genetically altered in certain human cancers, no mutation in Smad3 has been observed. Therefore, suppression of Smad3 expression may mediate key oncogenic properties of TGF-beta. First, we observed that 37.5% of human gastric cancer tissues showed low to undetectable levels of Smad3 and that in nine human gastric cancer cell lines examined, two showed deficient Smad3 expression. Introduction of Smad3 into human gastric cancer cells that did not express Smad3, restored TGF-beta responsiveness: induction of p21 and p15 gene expression, and growth inhibition in response to TGF-beta. Furthermore, these Smad3-expressing cells showed markedly decreased and delayed tumorigenicity in vivo. These findings suggest that Smad3 expression may have a critical role in tumor suppression in the early stages of gastric carcinogenesis.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Hanyang Univ, Coll Med, Dept Biochem, Seoul 133791, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea; Seoul Natl Univ, Coll Med, Dept Gen Surg, Seoul 110744, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hanyang University; Seoul National University (SNU); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Room B1106, Bethesda, MD 20892 USA.	kims@mail.nih.gov	Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597	NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chang J, 1997, CANCER RES, V57, P2856; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Datto MB, 1999, MOL CELL BIOL, V19, P2495; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fink SP, 2001, CANCER RES, V61, P256; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Harada H, 1999, CANCER RES, V59, P3783; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jong HS, 2002, BIOCHEM BIOPH RES CO, V292, P383, DOI 10.1006/bbrc.2002.6666; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Keller G., 2002, Pathologica (Genoa), V94, P229, DOI 10.1007/s102420200037; KIESER A, 1994, ONCOGENE, V9, P963; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee DK, 2002, J BIOL CHEM, V277, P33766, DOI 10.1074/jbc.M200150200; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; MYEROFF LL, 1995, CANCER RES, V55, P5545; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; Powell SM, 1997, CANCER RES, V57, P4221; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Schutte M, 1999, ANN ONCOL, V10, P56, DOI 10.1023/A:1008336703450; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shattuck TM, 2002, J CLIN ENDOCR METAB, V87, P3911, DOI 10.1210/jc.87.8.3911; Shitara Y, 1999, JPN J CLIN ONCOL, V29, P3, DOI 10.1093/jjco/29.1.3; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Takagi Y, 1998, BRIT J CANCER, V78, P1152, DOI 10.1038/bjc.1998.645; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; WALL NA, 1994, CURR OPIN GENET DEV, V4, P517, DOI 10.1016/0959-437X(94)90066-C; Xiangming C, 2001, CLIN CANCER RES, V7, P277; Yanagisawa K, 2000, ONCOGENE, V19, P2305, DOI 10.1038/sj.onc.1203591; Yang HK, 1999, ONCOGENE, V18, P2213, DOI 10.1038/sj.onc.1202535; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	64	104	111	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1333	1341		10.1038/sj.onc.1207259	http://dx.doi.org/10.1038/sj.onc.1207259			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647420				2022-12-28	WOS:000189035800001
J	Ijichi, H; Otsuka, M; Tateishi, K; Ikenoue, T; Kawakami, T; Kanai, F; Arakawa, Y; Seki, N; Shimizu, K; Miyazono, K; Kawabe, T; Omata, M				Ijichi, H; Otsuka, M; Tateishi, K; Ikenoue, T; Kawakami, T; Kanai, F; Arakawa, Y; Seki, N; Shimizu, K; Miyazono, K; Kawabe, T; Omata, M			Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta	ONCOGENE			English	Article						p21/WAF1; TGF-beta; Smad4-independent signaling; Smad2/3-dependent signaling; pancreatic cancer	HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR GENE; SIGNALING PATHWAYS; SMAD PROTEINS; RECEPTOR; EXPRESSION; ACTIVATION; CELLS; DPC4; INACTIVATION	The transforming growth factor-beta (TGF-beta)-Smad signaling pathway inhibits the growth of human epithelial cells and plays a role in tumor suppression. The Smad4 gene is mutated or deleted in 50% of pancreatic cancers. In this study, the Smad4-null pancreatic cancer cell line BxPC-3 was transfected with either the Smad4 expression vector or the empty vector and incubated in the presence or absence of TGF-beta. The cells were analysed using a cDNA microarray, which included 2280 named genes to screen for target genes regulated by TGF-beta in either a Smad4-dependent or -independent manner. The microarray and subsequent quantitative RT-PCR analysis demonstrated that the Smad4-independent and -dependent signaling pathways driven by TGF-beta upregulated only one of the 2280 genes, respectively, suggesting that Smad4-independent signaling downstream of TGF-beta might be as widespread as Smad4-dependent signaling. In this study, we demonstrated that the cyclin-dependent kinase inhibitor p21/WAF1, which has been considered the major effector of the Smad-dependent growth inhibitory signal of TGF-beta, is upregulated in a Smad4-independent manner. The upregulation occurs through Smad2/3-dependent transcriptional activation of the p21/WAF1 promoter region. These results suggest a novel mechanism of gene regulation, that is, a novel signal mediator other than Smad4.	Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan; Helix Res Inst, Biol Technol Lab, Chiba 2920812, Japan; Asahi Life Fdn, Inst Adult Dis, Div Gastroenterol, Tokyo 1600023, Japan; Tokyo Univ Hosp, Clin Res Ctr, Tokyo 1138655, Japan; Kirin Brewery Co Ltd, Div Pharmaceut, Takasaki, Gumma 3701295, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo 1130033, Japan	University of Tokyo; Asahi Life Foundation; University of Tokyo; Kirin Brewery Company Limited; University of Tokyo	Ijichi, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	ijichi-2im@h.u-tokyo.ac.jp	Otsuka, Motoyuki/H-9067-2019; IJICHI, Hideaki/AGZ-2874-2022; Ijichi, Hideaki/AAE-6692-2022; Ijichi, Hideaki/V-2720-2019	Otsuka, Motoyuki/0000-0003-2869-2881; IJICHI, Hideaki/0000-0002-2379-7986; Ijichi, Hideaki/0000-0002-2379-7986; 				Akiyoshi S, 2001, JPN J CANCER RES, V92, P257, DOI 10.1111/j.1349-7006.2001.tb01090.x; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DERYNCK R, 1987, CANCER RES, V47, P707; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grady WM, 1999, CANCER RES, V59, P320; Grau AM, 1997, CANCER RES, V57, P3929; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Ijichi H, 2001, BIOCHEM BIOPH RES CO, V289, P350, DOI 10.1006/bbrc.2001.5988; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Otsuka M, 2001, BIOCHEM BIOPH RES CO, V289, P876, DOI 10.1006/bbrc.2001.6047; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Schutte M, 1996, CANCER RES, V56, P2527; Simeone DM, 2000, ANN SURG, V232, P73, DOI 10.1097/00000658-200007000-00011; Togo G, 1996, CANCER RES, V56, P5620; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; Wang D, 2000, CANCER RES, V60, P4507; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398	39	60	68	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1043	1051		10.1038/sj.onc.1207222	http://dx.doi.org/10.1038/sj.onc.1207222			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762439				2022-12-28	WOS:000188749900003
J	Dohoney, KM; Guillerm, C; Whiteford, C; Elbi, C; Lambert, PF; Hager, GL; Brady, JN				Dohoney, KM; Guillerm, C; Whiteford, C; Elbi, C; Lambert, PF; Hager, GL; Brady, JN			Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage	ONCOGENE			English	Article						p53; PP2A; phosphatase; DNA damage; serine 37	PROTEIN PHOSPHATASE 2A; CELL-CYCLE CHECKPOINT; CATALYTIC SUBUNIT; BINDING-SITE; OKADAIC ACID; T-ANTIGEN; MDM2; TRANSACTIVATION; INHIBITION; EXPRESSION	The p53 tumor suppressor protein plays a critical role in mediating cellular response to stress. Upon DNA damage, post-translational modifications stabilize and activate this nuclear phosphoprotein. To determine the effect of phosphorylation site mutants in the context of the whole p53 protein, we performed reporter assays in p53 and MDM2 knockout mouse embryonic fibroblasts transfected with full-length p53 constructs. We show that mutation of S37 causes a decrease in p53 transcriptional activity compared to wild-type p53. Our data further suggest that the dephosphorylation of p53 at S37 is a regulated event involving protein phosphatase 2A (PP2A). Coimmunoprecipitation and immunofluorescence microscopy studies demonstrate that PP2A and p53 associate with one another in vivo following gamma-irradiation. Consistent with these observations, phosphorylated S37 accumulates in cell extracts prepared from gamma-irradiated Molt-4 cells in the presence of okadaic acid. Furthermore, in vitro phosphatase assays show that PP2A dephosphorylates p53 at S37. These results suggest that dephosphorylation of p53 at S37 plays a role in the transcriptional regulation of the p53 protein in response to DNA damage.	NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bethesda, MD 20892 USA; NCI, Ctr Adv Technol, Ctr Canc Res, Gaithersburg, MD 20892 USA; NCI, Lab Receptor Biol & Gene Express, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Flinders Univ S Australia, Sch Med, Bedford Pk, SA 5042, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Flinders University South Australia	Brady, JN (corresponding author), NCI, Basic Res Lab, Virus Tumor Biol Sect, NIH, Bldg 41,Room B 201,41 Lib Dr MSC 5055, Bethesda, MD 20892 USA.	bradyj@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010308, Z01BC005450, ZIABC005450, ZIABC005691, Z01BC005691, Z01BC010308] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; COHEN P, 1989, J BIOL CHEM, V264, P21435; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Elbi C, 2002, MOL BIOL CELL, V13, P2001, DOI 10.1091/mboc.13.6.mk0602002001; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gotz J, 1998, P NATL ACAD SCI USA, V95, P12370, DOI 10.1073/pnas.95.21.12370; GUY GR, 1992, J BIOL CHEM, V267, P1846; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; MIYASHITA T, 1995, CELL, V80, P293; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; RUEDIGER R, 1991, MOL CELL BIOL, V11, P4282, DOI 10.1128/MCB.11.8.4282; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHONTHAL AH, 1998, FRONT BIOSCI, V3, P1262; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; vanSteensel B, 1996, J CELL SCI, V109, P787; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yan Y, 1997, J BIOL CHEM, V272, P15220, DOI 10.1074/jbc.272.24.15220; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	47	53	56	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					49	57		10.1038/sj.onc.1207005	http://dx.doi.org/10.1038/sj.onc.1207005			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712210				2022-12-28	WOS:000187895300006
J	Liu, YN; Kang, BB; Chen, JH				Liu, YN; Kang, BB; Chen, JH			Transcriptional regulation of human osteopontin promoter by C/EBP alpha and AML-1 in metastatic cancer cells	ONCOGENE			English	Article						gene expression; metastasis; OPN; C/EBP alpha; AML-1	BINDING; EXPRESSION; PROTEINS; FUSION; DOMAIN	Osteopontin (OPN) is a secreted glycoprotein produced by osteoclasts, macrophages, T cells, hematopoietic cells, and vascular smooth muscle cells. It contributes to macrophage homing and cellular immunity. It also mediates neovascularization, inhibits apoptosis, and plays important roles in extracellular matrix remodeling and angiogenesis. These properties are also characteristics of metastatic cancer cells. Consequently, the OPN gene was found to be upregulated among various metastatic cancer cells. This suggests that OPN is involved in tumor metastasis. How the OPN gene is upregulated in metastatic cancer cells remains to be illustrated. Thus, we investigated the transcriptional activation of the OPN promoter in the human metastatic cancer cell line A2058. We cloned the OPN promoter, and serial deletion analysis of the OPN promoter showed that the region between -170 and -127 may act as an enhancer to control the OPN gene in metastatic tumor cells. This region was found to contain overlapped AML-1 and C/EBP binding site motifs. Gel-mobility-shift assays using the A2058 nuclear extract and AML-1a or C/EBPalpha (CCAAT/enhancer binding protein alpha) recombinant protein indicated that these two transcription factors can bind to the overlapped AML-1/C/EBP binding site motifs on the OPN regulatory sequence from -147 to -127. Surprisingly, the gel-shift experiments did not show supershift complex formation between AML-1 and C/EBPalpha. Functional analysis showed that the C/EBPalpha was more potent than the complex of AML-1 and its cofactor CBFbeta to upregulate the OPN promoter. In addition, AML-1 and C/EBPalpha did not exhibit transactivation additively or synergistically. Our results suggest that AML-1 and C/EBPalpha play an important role in the upregulation of the OPN gene in metastatic tumor cells.	Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien, Taiwan; Tzu Chi Univ, Grad Inst Human Genet, Hualien, Taiwan; Tzu Chi Univ, Coll Med, Dept Med Technol, Hualien, Taiwan	Tzu Chi University; Tzu Chi University; Tzu Chi University	Chen, JH (corresponding author), Tzu Chi Univ, Grad Inst Mol & Cell Biol, 701 Chung Yang Rd Sec 3, Hualien, Taiwan.	jhc@mail.tcu.edu.tw						ANNA T, 1998, INT J CANCER, V77, P82; Baiker A, 2000, NAT CELL BIOL, V2, P182, DOI 10.1038/35004061; BROWN LF, 1994, AM J PATHOL, V145, P610; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crawford HC, 1998, CANCER RES, V58, P5206; DIPAK PR, 2002, BIOCHEM J, V365, P561; DONGYAN W, 2000, ONCOGENE, V19, P5801; FUMIYUKI T, 2002, INT J CANCER, V98, P707; Gang X, 2001, AM J KIDNEY DIS, V37, P374, DOI 10.1053/ajkd.2001.21316; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HELMUT P, 2003, NAT REV MOL CELL BIO, V4, P33; JOHN DD, 1983, NUCLEIC ACIDS RES, V11, P1475; Kaartinen MT, 1999, J BIOL CHEM, V274, P1729, DOI 10.1074/jbc.274.3.1729; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lorsbach RB, 2001, INT J HEMATOL, V74, P258, DOI 10.1007/BF02982058; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621; MIKALA E, 2002, NAT REV CANCER, V2, P163; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Nau GJ, 1999, INFECT IMMUN, V67, P4223, DOI 10.1128/IAI.67.8.4223-4230.1999; PER A, 1995, BIOCHEM BIOPH RES CO, V215, P106; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rittling SR, 2002, J BIOL CHEM, V277, P9175, DOI 10.1074/jbc.M109028200; Rudland PS, 2002, CANCER RES, V62, P3417; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Shi XM, 2001, J BIOL CHEM, V276, P850, DOI 10.1074/jbc.M005955200; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; SUBHA P, 2001, J BIOL CHEM, V276, P44926; Tomizawa M, 2002, INT J MOL MED, V9, P597; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	38	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					278	288		10.1038/sj.onc.1207022	http://dx.doi.org/10.1038/sj.onc.1207022			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712233				2022-12-28	WOS:000187895300029
J	Pak, BJ; Lee, J; Thai, BL; Fuchs, SY; Shaked, Y; Ronai, Z; Kerbel, RS; Ben-David, Y				Pak, BJ; Lee, J; Thai, BL; Fuchs, SY; Shaked, Y; Ronai, Z; Kerbel, RS; Ben-David, Y			Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase	ONCOGENE			English	Article						radiation resistance; malignant melanoma; DOPAchrome tautomerase; mitogen-activated protein kinase	TYROSINASE-RELATED PROTEIN-2; CISPLATIN-INDUCED APOPTOSIS; JUN NH2-TERMINAL KINASE; DNA MISMATCH REPAIR; DRUG-RESISTANCE; CANCER CELLS; FRIEND-VIRUS; ACTIVATION; EXPRESSION; CIS-DIAMMINEDICHLOROPLATINUM(II)	While melanomas are resistant to the cytotoxic effects of radiotherapy, little is known about the molecular mechanisms underlying this intrinsic resistance. Here, we describe the utilization of retroviral insertional mutagenesis to facilitate the analysis of genetic changes that are associated with radioresistance in human melanoma. A radial growth phase human melanoma cell line, WM35, was infected with a replication-defective amphotropic murine retrovirus and subsequently selected for X-ray radiation-resistant variants. Several radiation-resistant clones were independently isolated and characterized. Interestingly, these clones also displayed resistance to ultraviolet radiation and to the chemotherapeutic drug cis-diamminedichloroplatinum(II) (CDDP). By Northern and Western analyses, we showed that the expression of DOPAchrome tautomerase (DCT), also known as tyrosinase-related protein 2 (TYRP2), an enzyme that functions in eumelanin synthesis, was significantly elevated in the radiation-resistant clones relative to the parental WM35 cells. Moreover, the levels of DCT in a variety of human melanoma cell lines correlated with their relative levels of radioresistance and the enforced expression of DCT conferred increased resistance to UV(B) treatment. An analysis of stress signaling induced by radiation as well other cytotoxic stressors showed that resistance associated with DCT overexpression applied specifically to treatments that activate the ERK/MAPK pathway. Indeed, DCT overexpression in a melanoma cell line resulted in increased ERK activity. Moreover, ectopic expression of dominant-active MEK in this melanoma cell line conferred UV(B) resistance suggesting that the ERK/MAPK pathway downstream of DCT may play a critical role in radiation and drug resistance. Overall, given that each gamma- and UV(B)-resistant cell line also exhibited resistance to CDDP and that CDDP-resistant clones showed increased resistance to UV(B) irradiation, these results suggest a common mechanism underlying radio- and chemoresistance, which is mediated by DCT expression.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY USA; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Icahn School of Medicine at Mount Sinai; University of Toronto	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto Sunnybrook Reg Canc Ctr, Res Bldg,S Wing Rm S-218,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca		RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41233] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bani MR, 1996, CANCER RES, V56, P3075; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; Chu W, 2000, ONCOGENE, V19, P395, DOI 10.1038/sj.onc.1203315; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; DACQUISTO F, 1995, LIFE SCI, V57, pPL401, DOI 10.1016/0024-3205(95)02244-2; DAVID YB, 1988, ONCOGENE, V3, P179; Donovan JCH, 2001, J BIOL CHEM, V276, P40888, DOI 10.1074/jbc.M106448200; Fang D, 2001, PIGM CELL RES, V14, P132, DOI 10.1034/j.1600-0749.2001.140209.x; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Hayakawa J, 2003, J BIOL CHEM, V278, P20582, DOI 10.1074/jbc.M210992200; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; JARA JR, 1990, BIOCHIM BIOPHYS ACTA, V1035, P276, DOI 10.1016/0304-4165(90)90089-F; KUBODA H, 1991, INT J CANCER, V47, P732; Lin XJ, 1999, MOL PHARMACOL, V56, P390, DOI 10.1124/mol.56.2.390; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; LU SJ, 1995, CANCER RES, V55, P1139; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MAZZONI A, 1990, ONCOLOGY, V47, P488; Memoli S, 1997, BBA-LIPID LIPID MET, V1346, P61, DOI 10.1016/S0005-2760(97)00018-0; Merienne K, 2000, ONCOGENE, V19, P4221, DOI 10.1038/sj.onc.1203712; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; Nehme A, 1997, CANCER RES, V57, P3253; Nishioka E, 1999, MELANOMA RES, V9, P433, DOI 10.1097/00008390-199910000-00002; Olivares C, 2001, BIOCHEM J, V354, P131, DOI 10.1042/0264-6021:3540131; Pak BJ, 2000, MELANOMA RES, V10, P499, DOI 10.1097/00008390-200010000-00013; Pillaire MJ, 2000, BIOCHEM BIOPH RES CO, V278, P724, DOI 10.1006/bbrc.2000.3877; Rosengren E, 1998, MELANOMA RES, V8, P469, DOI 10.1097/00008390-199810000-00013; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; WOLF CR, 1987, INT J CANCER, V39, P695, DOI 10.1002/ijc.2910390607; YAN MH, 1994, J BIOL CHEM, V269, P19067	36	55	58	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					30	38		10.1038/sj.onc.1207007	http://dx.doi.org/10.1038/sj.onc.1207007			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712208				2022-12-28	WOS:000187895300004
J	Dow, LE; Brumby, AM; Muratore, R; Coombe, ML; Sedelies, KA; Trapani, JA; Russell, SM; Richardson, HE; Humbert, PO				Dow, LE; Brumby, AM; Muratore, R; Coombe, ML; Sedelies, KA; Trapani, JA; Russell, SM; Richardson, HE; Humbert, PO			hScrib is a functional homologue of the Drosophila tumour suppressor Scribble	ONCOGENE			English	Article						hScrib; Scribble; polarity; cell cycle; tumour suppressor; Drosophila; discs large	CELL POLARITY; GENE-EXPRESSION; PROTEIN; DLG; IDENTIFICATION; PROLIFERATION; PROGRESSION; EPITHELIA; GROWTH; CANCER	Scribble (scrib), discs large (dlg) and lethal giant larvae (lgl) encode proteins that regulate cell polarity and have been identified as neoplastic tumour suppressor genes in Drosophila melanogaster. Here, we have used the Drosophila model system to provide the first functional evidence that human Scribble (hScrib) can act as a tumour suppressor. We show that hScrib protein displays highly polarized localization in mammalian epithelial cells and colocalizes with mammalian Dlg, similar to D. melanogaster Scribble (DmScrib) distribution in Drosophila epithelium. Furthermore, hScrib can rescue the polarity and tumorous overgrowth defects of scrib mutant Drosophila. hScrib therefore can act as an effective tumour suppressor in vivo, regulating both apical-basal polarity and cellular proliferation in a manner similar to that of DmScrib in Drosophila. These data demonstrate that hScrib is a functional homologue of DmScrib and therefore predict an important role for hScrib in the suppression of mammalian tumorigenesis.	Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3005, Australia; Peter MacCallum Canc Ctr, Cell Cycle & Dev Lab, Melbourne, Vic 3002, Australia; Peter MacCallum Canc Ctr, Canc Cell Death Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3005, Australia; Peter MacCallum Canc Ctr, Immune Signaling Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3005, Australia	Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, St Andrews Pl, Melbourne, Vic 3002, Australia.		Richardson, Helena E/A-8080-2013; Russell, Sarah M/B-9341-2009; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Russell, Sarah M/0000-0001-5826-9641; Humbert, Patrick O/0000-0002-1366-6691; Trapani, Joseph/0000-0003-0983-1532; Dow, Lukas/0000-0001-7048-1418				BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Boussioutas A, 2003, CANCER RES, V63, P2569; BRAND AH, 1993, DEVELOPMENT, V118, P401; GATEFF E, 1994, INT J DEV BIOL, V38, P565; Huang JHY, 2003, GENE EXPR PATTERNS, V3, P3, DOI 10.1016/s1567-133X(02)00096-0; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Liu LX, 2002, WORLD J GASTROENTERO, V8, P580, DOI 10.3748/wjg.v8.i4.580; Ludford-Menting MJ, 2002, J BIOL CHEM, V277, P4477, DOI 10.1074/jbc.M108479200; Makino K, 1997, ONCOGENE, V14, P2425, DOI 10.1038/sj.onc.1201087; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Mathew D, 2002, CURR BIOL, V12, P531, DOI 10.1016/S0960-9822(02)00758-3; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods DF, 1996, J CELL BIOL, V134, P1469, DOI 10.1083/jcb.134.6.1469; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X	25	93	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9225	9230		10.1038/sj.onc.1207154	http://dx.doi.org/10.1038/sj.onc.1207154			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681682				2022-12-28	WOS:000187400400004
J	Wolff, L; Garin, MT; Koller, R; Bies, J; Liao, W; Malumbres, M; Tessarollo, L; Powell, D; Perella, C				Wolff, L; Garin, MT; Koller, R; Bies, J; Liao, W; Malumbres, M; Tessarollo, L; Powell, D; Perella, C			Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-defficient mice	ONCOGENE			English	Article						tumor suppressor; myeloid leukemia; hypermethylation; retrovirus; Ink4b	KINASE INHIBITOR P15(INK4B); TUMOR-SUPPRESSOR; C-MYB; METHYLATION; INACTIVATION; P16(INK4A); EXPRESSION; P19(ARF); CELLS; ASSAY	The Ink4b gene (Cdkn2b) encodes p15(Ink4b), a cyclin-dependent kinase inhibitor. It has been implicated in playing a role in the development of acute myeloid leukemia (AML) in man, since it is hypermethylated with high frequency. We provide evidence that the gene is a tumor suppressor for myeloid leukemia in mice. The evidence is twofold: (1) retrovirus-induced myeloid leukemias of the myelomonocytic phenotype were found to have hypermethylation of the 5' CpG island of the Ink4b gene, and this could be correlated with reduced mRNA expression, as demonstrated by TaqMan real-time PCR. p15(Ink4b) mRNA expression in a leukemia cell line, with hypermethylation at the locus, was induced following treatment with 5-aza-2'-deoxycytidine.(2) Targeted deletion of one allele in mice by removal of exon 2 increases their susceptibility to retrovirus-induced myeloid leukemia. Mice deficient in both alleles were not more susceptible to myeloid disease than those deficient in one allele, raising the possibility that there are opposing forces related to the development of myeloid leukemia in Ink4b null mice.	NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; NCI, SAIC Frederick, Bethesda, MD 20892 USA; NCI, Data Management Serv, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Ctr Canc Res, NIH, Bldg 37,Room 4124A,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	lwolff@helix.nih.gov	Malumbres, Marcos/E-8834-2011	Malumbres, Marcos/0000-0002-0829-6315				Amanullah A, 2000, BLOOD, V96, P475; Bonin A, 2000, METH MOL B, V158, P121; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Fekete E, 1938, AM J PATHOL, V14, P557; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P16; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; NAZAROV V, 1994, VIROLOGY, V205, P479, DOI 10.1006/viro.1994.1668; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schmidt M, 2001, ONCOGENE, V20, P6205, DOI 10.1038/sj.onc.1204821; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stirewalt DEREK L., 2000, Hematology, V5, P15; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Tessarollo L, 2000, METH MOL B, V158, P47; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Wolff L, 2001, BLOOD CELL MOL DIS, V27, P483, DOI 10.1006/bcmd.2001.0409	31	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9265	9274		10.1038/sj.onc.1207092	http://dx.doi.org/10.1038/sj.onc.1207092			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681685				2022-12-28	WOS:000187400400008
J	Oliveira, C; Pinto, M; Duval, A; Brennetot, C; Domingo, E; Espin, E; Armengol, M; Yamamoto, H; Hamelin, R; Seruca, R; Schwartz, S				Oliveira, C; Pinto, M; Duval, A; Brennetot, C; Domingo, E; Espin, E; Armengol, M; Yamamoto, H; Hamelin, R; Seruca, R; Schwartz, S			BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency	ONCOGENE			English	Article						genomic instability; BRAF; K-Ras; DNA mismatch repair; mutator phenotype; gastrointestinal cancer	MICROSATELLITE MUTATOR PHENOTYPE; TARGET GENES; GASTROINTESTINAL CANCER; SOMATIC MUTATIONS; COLORECTAL-CANCER; INSTABILITY; SEQUENCES; FEATURES	Genes from the RAF family are Ras-regulated kinases involved in growth cellular responses. Recently, a V599E hotspot mutation within the BRAF gene was reported in a high percentage of colorectal tumors and significantly associated to defective mismatch repair (MMR). Additionally, BRAF mutations were described only in K-Ras-negative colon carcinomas, suggesting that BRAF/K-Ras activating mutations might be alternative genetic events in colon cancer. We have addressed to what extent the tumorigenic-positive selection exerted by BRAF mutations seen in colorectal MMR-deficient tumors was also involved in the tumorigenesis of gastric cancer. Accordingly, BRAF mutations were detected in 34% (25/74) of colorectal MMR-deficient tumors and in 5% (7/142) of MMR-proficient colorectal cases (P = 0.0001). All mutations found in the MSI cases corresponded to the previously reported hotspot V599E. Two D593K and a K600E additional mutations were also detected in three MSS cases. However, only one mutation of BRAF was found within 124 MSS gastric tumors and none in 37 MSI gastric tumors, clearly suggesting that BRAF mutations are not involved in gastric tumorigenesis. Nonetheless, a high incidence of mutations of K-Ras was found within the MSI gastric group of tumors (P = 0.0005), suggesting that the activation of K-Ras-dependent pathways contributes to the tumorigenesis of gastric cancers with MMR deficiency. Accordingly, our results show evidences that BRAF mutations characterize colon but not gastric tumors with MMR deficiency and are not involved in the tumorigenesis of gastric cancer of the mutator phenotype pathway.	Ctr Invest Bioquim & Biol Mol CIBBIM, Mol Pathol Program, Barcelona 08035, Spain; Ctr Etud Polymorphisme Humain, INSERM, U434, F-75010 Paris, France; Univ Porto, Inst Patol & Imunol Mol, P-4200465 Oporto, Portugal	Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade do Porto	Schwartz, S (corresponding author), Ctr Invest Bioquim & Biol Mol CIBBIM, Mol Pathol Program, Passeig Vall hebron 119-129, Barcelona 08035, Spain.		Oliveira, Carla/F-8188-2011; Domingo, Enric/A-9099-2018; seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012	Oliveira, Carla/0000-0001-8340-2264; Domingo, Enric/0000-0003-4390-8767; LOUIS, Caroline/0000-0002-4952-3828; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Espin-Basany, Eloy/0000-0002-9139-4548; Pinto, Mafalda/0000-0003-4684-4797; Armengol, Manuel/0000-0002-3211-3195				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Boland CR, 1998, CANCER RES, V58, P5248; BRENNETOT C, IN PRESS GASTROENTER; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Duval A, 2002, CANCER RES, V62, P2447; Fukushima H, 2001, J EXP CLIN CANC RES, V20, P553; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Hoang JM, 1997, CANCER RES, V57, P300; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Oliveira C, 1998, AM J PATHOL, V153, P1211, DOI 10.1016/S0002-9440(10)65665-9; Perucho M, 1996, BIOL CHEM, V377, P675; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Schwartz S, 1999, CANCER RES, V59, P2995; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Yamamoto H, 1999, GASTROENTEROLOGY, V116, P1348, DOI 10.1016/S0016-5085(99)70499-3; Yamamoto H, 1997, CANCER RES, V57, P4420; Yuen ST, 2002, CANCER RES, V62, P6451	17	114	121	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9192	9196		10.1038/sj.onc.1207061	http://dx.doi.org/10.1038/sj.onc.1207061			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668801				2022-12-28	WOS:000187149100010
J	Hirose, T; Sowa, Y; Takahashi, S; Saito, S; Yasuda, C; Shindo, N; Furuichi, K; Sakai, T				Hirose, T; Sowa, Y; Takahashi, S; Saito, S; Yasuda, C; Shindo, N; Furuichi, K; Sakai, T			p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y	ONCOGENE			English	Article						HDAC inhibitor; Gadd45; Oct-1; CCAAT; promoter	WAF1/CIP1 GENE PROMOTER; SP1 SITES; IN-VIVO; P53; BUTYRATE; ACETYLATION; ACTIVATION; EXPRESSION; BINDING; ARREST	Histone deacetylase ( HDAC) inhibitors cause growth arrest at the G1 and/ or G2/M phases, and induce differentiation and/ or apoptosis in a wide variety of tumour cells. The growth arrest at G1 phase by HDAC inhibitors is thought to be highly dependent on the upregulation of p21/WAF1, but the precise mechanism by which HDAC inhibitors cause G2/M arrest or apoptosis in tumour cells is unknown. Gadd45 causes cell cycle arrest at the G2/M phase transition and participates in genotoxic stress-induced apoptosis. We show here that it is also induced by a typical HDAC inhibitor, trichostatin A (TSA), through its promoter, in a p53-independent manner. To identify the mechanism of activation of the gadd45 promoter, we performed luciferase reporter analyses and electrophoretic mobility shift assays. These revealed that both the Oct-1 and CCAAT sites are needed for the full activation by TSA. We also found that the transcription factors Oct-1 and NF-Y specifically bind to each site. Thus, HDAC inhibitors can induce Gadd45 through its promoter without the need for functional p53, and both the Oct-1 and NF-Y concertedly participate in TSA-induced activation of the gadd45 promoter.	Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Mol Med Labs, Tsukuba, Ibaraki 3058585, Japan	Kyoto Prefectural University of Medicine; Astellas Pharmaceuticals	Sowa, Y (corresponding author), Kyoto Prefectural Univ Med, Dept Prevent Med, Kamigyo Ku, Kyoto 6028566, Japan.	ysowa@basic.kpu-m.ac.jp						Adachi N, 2000, GENE, V245, P49, DOI 10.1016/S0378-1119(00)00040-8; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; Blagosklonny MV, 2001, CANCER RES, V61, P4301; CHANDAR N, 1992, BRIT J CANCER, V65, P208, DOI 10.1038/bjc.1992.43; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kakizawa T, 2001, J BIOL CHEM, V276, P9720, DOI 10.1074/jbc.M008531200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kojima H, 1999, J IMMUNOL, V162, P5063; Kramer OH, 2001, TRENDS ENDOCRIN MET, V12, P294, DOI 10.1016/S1043-2760(01)00438-6; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; SAKAI T, 1996, JPN J HYG, V50, P1036; SAMBROOK J, 2001, MOL CLONING, pCH17; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takahashi S, 2001, CANCER RES, V61, P1187; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Xu Y, 2001, GENE, V269, P141, DOI 10.1016/S0378-1119(01)00445-0; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang W, 2001, INT J ONCOL, V18, P749	48	100	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7762	7773		10.1038/sj.onc.1207091	http://dx.doi.org/10.1038/sj.onc.1207091			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586402				2022-12-28	WOS:000186240200006
J	Hazlehurst, LA; Landowski, TH; Dalton, WS				Hazlehurst, LA; Landowski, TH; Dalton, WS			Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death	ONCOGENE			English	Review						drug resistance; adhesion; integains; microenvironment	FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; MARROW STROMAL CELLS; U266 MYELOMA CELLS; FAMILY MEMBER BIM; CAM-DR; CYCLE PROGRESSION; ENDOTHELIAL-CELLS; MULTIPLE-MYELOMA; TYROSINE KINASE	The emergence of clinical drug resistance continues to be an obstacle for the successful treatment of cancer. Our current understanding of mechanisms associated with drug resistance has been ascertained by investigating drug-resistant models created by exposing a parental population to increasing concentrations of a cytotoxic. These unicellular drug-resistant models have been critical in elucidating drug-resistant mechanism and in some cases have aided in the identification of drug targets. However, these models do not address resistance mechanisms that contribute to de novo drug resistance. We propose that specific niches within the tumor microenvironment may provide a sanctuary for subpopulations of tumors cells that affords a survival advantage following initial drug exposure and may facilitate the acquisition of acquired drug resistance. More specifically, we propose that the bone marrow microenvironment is a sanctuary for hematopoietic cancers. This review will focus on the bone marrow microenvironment and its role in conferring resistance to cytotoxics and physiological mediators of cell death.	Univ S Florida, H Lee Moffitt Canc Ctr, Clin Invest Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Dalton, WS (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Clin Invest Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.							Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Astier A, 1997, J BIOL CHEM, V272, P228; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Blagosklonny MV, 2002, LEUKEMIA, V16, P570, DOI 10.1038/sj.leu.2402409; BOHNSACK JF, 1994, BLOOD, V83, P543; Bouillet P, 2002, J CELL SCI, V115, P1567; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CherbonnelLasserre C, 1996, ONCOGENE, V13, P1489; Coll ML, 2002, ONCOGENE, V21, P2908, DOI 10.1038/sj.onc.1205388; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; DALTON WS, 1992, HEMATOL ONCOL CLIN N, V6, P383, DOI 10.1016/S0889-8588(18)30351-4; Damiano JS, 2000, LEUKEMIA LYMPHOMA, V38, P71, DOI 10.3109/10428190009060320; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; DURAND RE, 1972, EXP CELL RES, V71, P75, DOI 10.1016/0014-4827(72)90265-0; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Fortney JE, 2001, LEUKEMIA RES, V25, P901, DOI 10.1016/S0145-2126(01)00051-0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HAMDAN HF, 1992, ONCOL RES, V4, P210; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; Hazlehurst LA, 2001, CANCER METAST REV, V20, P43, DOI 10.1023/A:1013156407224; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hochhaus A, 2001, SCIENCE, V293, P2163; Hoyt DG, 1996, CANCER RES, V56, P4146; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hurley RW, 1997, EXP HEMATOL, V25, P321; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; JENSEN GS, 1993, AM J HEMATOL, V43, P29, DOI 10.1002/ajh.2830430108; Jiang YH, 2000, BLOOD, V95, P846, DOI 10.1182/blood.V95.3.846.003k31_846_854; Jones CB, 2001, MOL PHARMACOL, V59, P69, DOI 10.1124/mol.59.1.69; KOOPMAN G, 1994, J IMMUNOL, V152, P3760; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lundell BI, 1996, BLOOD, V87, P2450, DOI 10.1182/blood.V87.6.2450.bloodjournal8762450; MacGillivray MK, 2000, J BIOL CHEM, V275, P23509, DOI 10.1074/jbc.M003186200; NEFEDOVA Y, ASH ABSTR, V2983; Ohmori T, 1998, EXP CELL RES, V245, P350, DOI 10.1006/excr.1998.4261; Oloumi A, 2000, CANCER RES, V60, P5747; Oshiro MM, 2001, CLIN CANCER RES, V7, P4262; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sawyers CL, 2001, SCIENCE, V294, P1834; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; St Croix B, 1998, CANCER LETT, V131, P35, DOI 10.1016/S0304-3835(98)00199-2; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; StCroix B, 1996, NAT MED, V2, P1204; Taylor ST, 2000, J NATL CANCER I, V92, P18, DOI 10.1093/jnci/92.1.18; TEICHER BA, 1990, SCIENCE, V247, P1457, DOI 10.1126/science.2108497; Teicher BA, 1997, IN VIVO, V11, P463; Tiberio R, 2002, FEBS LETT, V524, P139, DOI 10.1016/S0014-5793(02)03040-5; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Wang MWJ, 1998, CELL GROWTH DIFFER, V9, P105; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028	70	160	177	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7396	7402		10.1038/sj.onc.1206943	http://dx.doi.org/10.1038/sj.onc.1206943			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576847				2022-12-28	WOS:000186112500012
J	Kruh, GD				Kruh, GD			Introduction to resistance to anticancer agents	ONCOGENE			English	Editorial Material						chemosensitivity; apoptosis; targeted therapy			Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruh, GD (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [U01CA073728, P30CA006927, R01CA073728] Funding Source: NIH RePORTER; NCI NIH HHS [CA 06927, CA 73728] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHU E, 2001, CANC PRINCIPLES PRAC, P289; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031	2	68	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7262	7264		10.1038/sj.onc.1206932	http://dx.doi.org/10.1038/sj.onc.1206932			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576836				2022-12-28	WOS:000186112500001
J	Cervi, D; Truong, AHL; Lee, JS; Sukhai, N; Li, YJ; Koki, A; Ben-David, Y				Cervi, D; Truong, AHL; Lee, JS; Sukhai, N; Li, YJ; Koki, A; Ben-David, Y			Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to Celecoxib	ONCOGENE			English	Article						erythroleukemia; celecoxib; c-Kit phosphorylation; p53 status; resistance	MULV-INDUCED-ERYTHROLEUKEMIAS; CYCLOOXYGENASE-2 EXPRESSION; ERYTHROID PROLIFERATION; TUMOR-GROWTH; CANCER; APOPTOSIS; SULINDAC; GENE; DIFFERENTIATION; CHEMOPREVENTION	It is well established that selective COX-2 inhibitors exhibit potent effects against progression of select solid tumours. However, their effects on liquid tumours have not been fully established. By taking advantage of murine Friend Disease we have shown a strong antileukemic effect of celecoxib by determining novel in vitro targets. Western blot analyses revealed the expression of COX-2 in a panel of Friend Virus-transformed, splenic-derived primary erythroleukemic blasts and established cell lines generated in our laboratory. We have shown that celecoxib at concentrations as low as 20 muM significantly suppresses proliferation of the selected murine erythroleukemia cell line HB60-5. The greatest proliferative inhibition was seen at 40 muM of celecoxib, resulting in apoptosis. Our results also demonstrate that treatment of the established murine erythroleukemia cell line HB60-5 with celecoxib results in suppression of c-Kit and erythropoietin receptor (Epo-R) phosphorylation resulting in apoptosis, likely through decreased levels of survival factors. However, upon overexpression of c-Kit alone in these cells a significant increase in survival and twofold increase in proliferation in the presence of celecoxib were observed (P < 0.05). Finally, since responsiveness of our murine erythroleukemia cell lines to celecoxib is above the reported physiologically achievable levels in vivo, we have provided in vitro evidence to suggest that reduced sensitivity of erythroleukemic cells to lower doses of celecoxib may be a consequence of the loss of wild-type p53. These findings are pivotal in addressing potential discrepancies associated with sensitivity of murine erythroleukemic cells to celecoxib in vitro versus in vivo.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Div Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Med Biophys, Div Mol & Cellular Biol, Res Bldg,Room S-216,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	bendavid@srcl.sunnybrook.utoronto.ca						Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; BeazerBarclay Y, 1996, CARCINOGENESIS, V17, P1757, DOI 10.1093/carcin/17.8.1757; BEN-DAVID Y, 1990, New Biologist, V2, P1015; Berman KS, 2002, CLIN CANCER RES, V8, P354; Bittorf T, 2001, CELL SIGNAL, V13, P673, DOI 10.1016/S0898-6568(01)00189-9; Chan G, 1999, CANCER RES, V59, P991; DuBois RN, 1996, GASTROENTEROL CLIN N, V25, P773, DOI 10.1016/S0889-8553(05)70274-0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Harris RE, 2000, CANCER RES, V60, P2101; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; Howard JC, 2001, ONCOGENE, V20, P2291, DOI 10.1038/sj.onc.1204348; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Li YJ, 2001, MOL CELL BIOL, V21, P73, DOI 10.1128/MCB.21.1.73-80.2001; Lim JTE, 1999, BIOCHEM PHARMACOL, V58, P1097, DOI 10.1016/S0006-2952(99)00200-2; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Mekori YA, 2001, J CLIN IMMUNOL, V21, P171, DOI 10.1023/A:1011083031272; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; Nakanishi Y, 2001, EUR J CANCER, V37, P1570, DOI 10.1016/S0959-8049(01)00160-5; Sachinidis A, 1999, BRIT J PHARMACOL, V128, P1761, DOI 10.1038/sj.bjp.0702969; Shamma A, 2000, CLIN CANCER RES, V6, P1229; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 2000, CANCER RES, V60, P6045; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	32	7	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2305	2314		10.1038/sj.onc.1207400	http://dx.doi.org/10.1038/sj.onc.1207400			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743207				2022-12-28	WOS:000220427700004
J	Woo, JH; Lim, JH; Kim, YH; Suh, SI; Min, DS; Chang, JS; Lee, YH; Park, JW; Kwon, TK				Woo, JH; Lim, JH; Kim, YH; Suh, SI; Min, DS; Chang, JS; Lee, YH; Park, JW; Kwon, TK			Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction	ONCOGENE			English	Article						resveratrol; matrix metalloproteinase-9; NF-kappa B; PMA; PKC; JNK	ACTIVATED PROTEIN-KINASE; IV COLLAGENASE GENE; MECHANISM; METALLOPROTEINASES; PHOSPHORYLATION; SURFACE; ERK	Proteolytic degradation of the extracellular matrix and tumor metastasis correlate with the expression of endopeptidases known as matrix metalloproteinases (MMPs). The expression of MMPs is regulated by cytokines and signal transduction pathways, including those activated by phorbol myristate acetate (PMA). We found that resveratrol, a phytoalexin present in grapes, significantly inhibits the PMA-induced increase in MMP-9 expression and activity. These effects of resveratrol are dose dependent and correlate with the suppression of MMP-9 mRNA expression levels. PMA caused about a 23-fold increase in MMP-9 promoter activity, which was suppressed by resveratrol. Transient transfection utilizing MMP-9 constructs, in which specific transcriptional factors were mutagenized, indicated that the effects of PMA and resveratrol were mediated via an activator protein-1 and nuclear factor-kappaB response element. Resveratrol inhibited PMA-mediated activation of c-Jun N-terminal kinase (JNK) and protein kinase C (PKC)-delta activation. Therefore, we conclude that the MMP-9 inhibition activity of resveratrol and its inhibition of JNK and PKC-delta may have a therapeutic potential, given that a novel means of controlling growth and invasiveness of tumors.	Keimyung Univ, Sch Med, Dept Immunol, Taegu, South Korea; Keimyung Univ, Sch Med, Dept Microbiol, Taegu 700712, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Daejin Univ, Dept Life Sci, Pochon Gun, Kyeonggido, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Taegu, South Korea	Keimyung University; Keimyung University; Catholic University of Korea; Daejin University; Yeungnam University	Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, 194 DongSan Dong, Taegu, South Korea.	kwontk@dsmc.or.kr						Baek WK, 2002, GENE, V295, P117, DOI 10.1016/S0378-1119(02)00827-2; Banerjee S, 2002, CANCER RES, V62, P4945; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; Fauconneau B, 1997, LIFE SCI, V61, P2103, DOI 10.1016/S0024-3205(97)00883-7; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Godichaud S, 2000, HEPATOLOGY, V31, P922, DOI 10.1053/he.2000.5848; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; JANG M, 1999, CANC CHEMOTHER PHA S, V43, pS42; Lee PPH, 2000, ENDOCRINOLOGY, V141, P3764, DOI 10.1210/en.141.10.3764; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; OHagan RC, 1996, ONCOGENE, V13, P1323; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; PaceAsciak CR, 1996, CLIN CHIM ACTA, V246, P163, DOI 10.1016/0009-8981(96)06236-5; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SATO H, 1993, ONCOGENE, V8, P395; Simon C, 1998, CANCER RES, V58, P1135; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; Waas ET, 2002, BRIT J CANCER, V86, P1876, DOI 10.1038/sj.bjc.6600366; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; ZUCKER S, 1993, CANCER RES, V53, P140	30	181	187	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1845	1853		10.1038/sj.onc.1207307	http://dx.doi.org/10.1038/sj.onc.1207307			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14661062				2022-12-28	WOS:000220129500006
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine	ONCOGENE			English	Article						pancreatic adenocarcinoma; cancer; gemcitabine; ribonucleotide reductase; siRNA; RNA interference	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; GENE AMPLIFICATION; CELL-LINES; CANCER; RESISTANCE; MOUSE; OVEREXPRESSION; HYDROXYUREA; EXPRESSION	Ribonucleotide reductase is emerging as an important determinant of gemcitabine chemoresistance in human cancers. Activity of this enzyme, which catalyses conversion of ribonucleotide 5'-diphosphates to their 2'-deoxynucleotides, is modulated by levels of its M2 subunit (RRM2). Here we show that RRM2 overexpression is associated with gemcitabine chemoresistance in pancreatic adenocarcinoma cells, and that suppression of RRM2 expression using RNA interference mediated by small interfering RNA (siRNA) enhances gemcitabine-induced cytotoxicity in vitro. We demonstrate the ability of systemically administered RRM2 siRNA to suppress tumoral RRM2 expression in an orthotopic xenograft model of pancreatic adenocarcinoma. Synergism between RRM2 siRNA and gemcitabine results in markedly suppressed tumor growth, increased tumor apoptosis and inhibition of metastasis. Our findings confirm the importance of RRM2 in pancreatic adenocarcinoma gemcitabine chemoresistance. This is the first demonstration that systemic delivery of siRNA-based therapy can enhance the efficacy of an anticancer nucleoside analog.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Adjei AA, 2003, CLIN CANCER RES, V9, P115; [Anonymous], 2003, NAT CELL BIOL, V5, P489, DOI 10.1038/ncb0603-490; Aoki Y, 2003, CLIN EXP PHARMACOL P, V30, P96, DOI 10.1046/j.1440-1681.2003.03801.x; Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390; Bergman AM, 2002, DRUG RESIST UPDATE, V5, P19, DOI 10.1016/S1368-7646(02)00002-X; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Calzado MA, 2000, CLIN EXP IMMUNOL, V120, P317, DOI 10.1046/j.1365-2249.2000.01203.x; CORY JG, 1997, BIOCH CLIN CORRELATI, P489; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ERIKSSON S, 1981, J BIOL CHEM, V256, P9436; Fan HZ, 1996, P NATL ACAD SCI USA, V93, P14036, DOI 10.1073/pnas.93.24.14036; Filleur S, 2003, CANCER RES, V63, P3919; Fujioka S, 2003, CLIN CANCER RES, V9, P346; Goan YG, 1999, CANCER RES, V59, P4204; GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935; GRANT CE, 1994, CANCER RES, V54, P357; Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200; HEINEMANN V, 1988, CANCER RES, V48, P4024; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jong AY, 1998, J BIOMED SCI, V5, P62, DOI 10.1007/BF02253357; Jung CP, 2001, CLIN CANCER RES, V7, P2527; Kelley JR, 2001, SURGERY, V130, P280, DOI 10.1067/msy.2001.115899; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lee Y, 2003, CANCER RES, V63, P2802; LI K, 2003, CANCER RES, V63, P3953; MCCLARTY GA, 1987, BIOCHEMISTRY-US, V26, P8004, DOI 10.1021/bi00398a068; Monteith DK, 1997, ANTI-CANCER DRUG DES, V12, P421; Muerkoster S, 2003, INT J CANCER, V104, P469, DOI 10.1002/ijc.10963; Nieth C, 2003, FEBS LETT, V545, P144, DOI 10.1016/S0014-5793(03)00523-4; PAVLOFF N, 1992, J DNA SEQUENCING MAP, V2, P227; PESSARA U, 1990, MOL CELL BIOL, V10, P4146, DOI 10.1128/MCB.10.8.4146; Plunkett W, 1996, SEMIN ONCOL, V23, P3; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; RAITANO AB, 1990, PANCREAS, V5, P267, DOI 10.1097/00006676-199005000-00005; Reichard P, 1985, Basic Life Sci, V31, P33; REICHARD P, 1978, FED PROC, V37, P9; SCALABAS GM, 2003, INT J GASTROINT CANC, V33, P15; Shen Z, 2002, BIOTECHNIQUES, V32, P1168, DOI 10.2144/02325dd07; Sun FX, 2003, CANCER RES, V63, P80; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; THELANDER M, 1985, J BIOL CHEM, V260, P2737; WRIGHT JA, 1987, SOMAT CELL MOLEC GEN, V13, P155, DOI 10.1007/BF01534695; Zhou B, 2001, CYTOGENET CELL GENET, V95, P34, DOI 10.1159/000057014; ZHOU BS, 1995, CANCER RES, V55, P1328; Zhou BS, 1998, CLIN EXP METASTAS, V16, P43	50	200	225	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1539	1548		10.1038/sj.onc.1207272	http://dx.doi.org/10.1038/sj.onc.1207272			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14661056				2022-12-28	WOS:000189219500007
J	Politi, K; Kljuic, A; Szabolcs, M; Fisher, P; Ludwig, T; Efstratiadis, A				Politi, K; Kljuic, A; Szabolcs, M; Fisher, P; Ludwig, T; Efstratiadis, A			'Designer' tumors in mice	ONCOGENE			English	Article						breast cancer; sarcoma; animal models of cancer; gene expression profiling	MIDDLE-T-ONCOGENE; AMINO-TERMINAL DOMAIN; TRANSGENIC MICE; MESSENGER-RNA; SINGLE-COPY; K-RAS; EXPRESSION; VIRUS; ACTIN; MOUSE	We have developed and tested successfully a general method based on Cre-mediated recombination that can be used for ubiquitous or tissue-specific expression of protein products, including tumor-inducing oncoproteins. Depending on the specificity of a chosen promoter driving cre expression, tumors develop by design in bitransgenic mouse progeny derived by crossing Cre-producing mice with partners carrying a dormant oncogenic transgene (targeted into the 3' noncoding region of the cytoplasmic beta-actin locus) that becomes functional after excision of a 'floxed' DNA segment. To provide proof-of-principle, we have used as models transgenes encoding the polyomavirus middle T antigen (PVMT) and the T antigens of the SV40 early region (SVER). Cre-dependent activation of widespread SVER expression resulted in hyperplasias or invasive tumors affecting particular visceral smooth muscles, whereas Cre-dependent, mammary gland-specific expression of PVMT-induced adenocarcinomas, according to plan. Unexpectedly, we also encountered spontaneous (Cre-independent) oncogene expression occurring as a rare event, which simulates the initiation of sporadic tumors and leads to PVMT-induced hemangiomas and mammary carcinomas or SVER-induced disseminated sarcomas, thus, revealing particular tissue susceptibilities to the actions of these oncoproteins.	Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University	Efstratiadis, A (corresponding author), Columbia Univ, Dept Genet & Dev, Berrie Med Sci Pavil,1150 St Nicholas Ave, New York, NY 10032 USA.	arg@cancercenter.columbia.edu	Ludwig, Thomas/Q-6484-2016	Ludwig, Thomas/0000-0003-3461-2585	NATIONAL CANCER INSTITUTE [P01CA075553, T32CA009503, P01CA097403] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA75553, P01 CA97403, T32 CA09503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1992, PROG CLIN BIOL RES, V376, P1; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; Berns A, 2001, NATURE, V410, P1043, DOI 10.1038/35074238; Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; CHOI YW, 1988, MOL CELL BIOL, V8, P3382, DOI 10.1128/MCB.8.8.3382; DARBY I, 1990, LAB INVEST, V63, P21; Dietrich P, 2000, MAMM GENOME, V11, P196, DOI 10.1007/s003350010037; Dorer DR, 1997, TRANSGENIC RES, V6, P3, DOI 10.1023/A:1018460413680; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; ELDER PK, 1988, MOL CELL BIOL, V8, P480, DOI 10.1128/MCB.8.1.480; Eyden B, 2001, ULTRASTRUCT PATHOL, V25, P39, DOI 10.1080/019131201300004672; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hollies CR, 2001, EUR J HUM GENET, V9, P143, DOI 10.1038/sj.ejhg.5200590; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Mao XH, 1999, P NATL ACAD SCI USA, V96, P5037, DOI 10.1073/pnas.96.9.5037; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; POLITI K, 2004, IN PRESS AM J PATHOL, V164; Ratineau C, 2000, GASTROENTEROLOGY, V119, P1305, DOI 10.1053/gast.2000.19278; SEPERACK PK, 1988, P NATL ACAD SCI USA, V85, P189, DOI 10.1073/pnas.85.1.189; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Wallace H, 2000, NUCLEIC ACIDS RES, V28, P1455, DOI 10.1093/nar/28.6.1455; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; WILLIAMS RL, 1988, CELL, V52, P121; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x	34	13	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1558	1565		10.1038/sj.onc.1207275	http://dx.doi.org/10.1038/sj.onc.1207275			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14661057				2022-12-28	WOS:000189219500009
J	Kumar, D; Gokhale, P; Broustas, C; Chakravarty, D; Ahmad, I; Kasid, U				Kumar, D; Gokhale, P; Broustas, C; Chakravarty, D; Ahmad, I; Kasid, U			Expression of SCC-S2, an antiapoptotic molecule, correlates with enhanced proliferation and tumorigenicity of MDA-MB 435 cells	ONCOGENE			English	Article						SCC-S2; subcellular localization; cell growth regulation in vitro and in vivo	NF-KAPPA-B; DEATH-EFFECTOR DOMAIN; NECROSIS-FACTOR-ALPHA; FLICE-INHIBITORY PROTEIN; DISEASE TUMOR-CELLS; C-FLIP; PANCREATIC ADENOCARCINOMA; CONSTITUTIVE ACTIVATION; MEDIATED APOPTOSIS; RADIATION RESPONSE	SCC-S2/GG2-1/NDED is a recently discovered antiapoptotic molecule induced by the activation of the transcription factor NF-kappaB. Here we have examined a role of SCC-S2 in cell growth regulation in vitro and in vivo. Western blotting using an antipeptide antibody revealed endogenous SCC-S2 as a similar to21kDa cytosolic protein in human breast cancer cells (MDA-MB 231) and renal carcinoma cells (RCC-RS). The immunofluorescence detection method showed the cytosolic localization of FLAG-tagged human SCC-S2 in COS-1 transfectants. MDA-MB 435 human cancer cells stably transfected with the FLAG-tagged SCC-S2 cDNA exhibited increased growth rate as compared to control vector transfectants, as measured by the cell viability (>twofold; n=3; P<0.005) and thymidine-labeling procedures (similar to sixfold; n=3; P<0.0001). SCC-S2 transfectants also displayed an increase in cell migration in collagen I as compared to control transfectants (similar totwofold; n=3; P<0.005). In athymic mice, SCC-S2 transfectants showed significantly enhanced tumor growth as compared to control transfectants (mean tumor volumes, day 16: control, 56.86 +/- 19.82 mm(3); SCC-S2, 127.54 +/- 18.78 mm(3); n=5; P<0.03). The examination of a limited number of clinical specimens revealed higher expression levels of SCC-S2 protein in certain human tumor tissues as compared to the matched normal adjacent tissues. Taken together, the present studies demonstrate SCC-S2 as a novel oncogenic factor in cancer cells.	Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Lombardi Canc Ctr, Washington, DC 20057 USA; Neopharm Inc, Lake Forest, IL 60045 USA	Georgetown University; Georgetown University	Kasid, U (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Lombardi Canc Ctr, E208,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	kasidu@georgetown.edu		Chakravarty, Debyani/0000-0001-8629-5732; Broustas, Constantinos/0000-0001-7169-807X	NCI NIH HHS [P01 CA74175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Keleg Shereen, 2003, Mol Cancer, V2, P14, DOI 10.1186/1476-4598-2-14; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LEUNG SW, 1993, CANCER-AM CANCER SOC, V71, P2276, DOI 10.1002/1097-0142(19930401)71:7<2276::AID-CNCR2820710718>3.0.CO;2-7; Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Mori N, 1999, BLOOD, V93, P2360; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Scaife CL, 2002, CANCER RES, V62, P6870; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tibbetts MD, 2003, NAT IMMUNOL, V4, P404, DOI 10.1038/ni0503-404; Wajant H, 2002, SCIENCE, V296, P1635, DOI 10.1126/science.1071553; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Xiao CW, 2003, ENDOCRINOLOGY, V144, P623, DOI 10.1210/en.2001-211024; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	39	100	117	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					612	616		10.1038/sj.onc.1207123	http://dx.doi.org/10.1038/sj.onc.1207123			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724590				2022-12-28	WOS:000188098300033
J	Chikumi, H; Barac, A; Behbahani, B; Gao, Y; Teramoto, H; Zheng, Y; Gutkind, JS				Chikumi, H; Barac, A; Behbahani, B; Gao, Y; Teramoto, H; Zheng, Y; Gutkind, JS			Homo- and hetero-oligomerization of PDZ-RhoGEF, LARG and p115RhoGEF by their C-terminal region regulates their in vivo Rho GEF activity and transforming potential	ONCOGENE			English	Article						Rho; guanine-nucleotide exchange factor; transformation; GTPases; G proteins	NUCLEOTIDE EXCHANGE FACTORS; VAV PROTOONCOGENE PRODUCT; HETEROTRIMERIC G-PROTEINS; LEUKEMIA-ASSOCIATED RHO; TYROSINE PHOSPHORYLATION; GUANOSINE TRIPHOSPHATASES; CELLULAR-TRANSFORMATION; DEPENDENT ACTIVATION; P115 RHOGEF; DBL FAMILY	PDZ-RhoGEF, LARG, and p115RhoGEF are members of a newly identified family of Rho-guanine nucleotide exchange factors (GEFs) exhibiting a unique structural feature consisting of the presence of an area of similarity to regulators of G protein signaling (RGS). This RGS-like (RGL) domain provides a functional motif by which Galpha(12) and Galpha(13) can bind and regulate the activity of these RhoGEFs, thus providing a direct link from these heterotrimeric G proteins to Rho. PDZ-RhoGEF and LARG can also be phosphorylated by tyrosine kinases, including FAK, and associate with Plexin B, a semaphorin receptor, which controls axon guidance during development, through their PDZ domain, thereby stimulating Rho. Interestingly, while characterizing a PDZ-RhoGEF antiserum, we found that a transfected PDZ-RhoGEF construct associated with the endogenous PDZ-RhoGEF. Indeed, we observed that PDZ-RhoGEF and LARG can form homo- and hetero-oligomers, whereas p115RhoGEF can only homo-oligomerize, and that this intermolecular interaction was mediated by their unique C-terminal regions. Deletion of the C-terminal tail of PDZ-RhoGEF had no significant effect on the GEF catalytic activity towards Rho in vitro, but resulted in a drastic increase in the ability to stimulate a serum response element reporter and the accumulation of the GTP-bound Rho in vivo. Furthermore, removal of the C-termini of each of the three RGL-containing GEFs unleashed their full transforming potential. Together, these findings suggest the existence of a novel mechanism controlling the activity of PDZ-RhoGEF, LARG, and p115RhoGEF, which involves homo- and hetero-oligomerization through their inhibitory C-terminal region.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Zheng, Yi/J-7235-2015	Gutkind, J. Silvio/0000-0002-5150-4482; Zheng, Yi/0000-0001-7089-6074; Barac, Ana/0000-0002-9935-8904	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fukuhara S, 2001, ONCOGENE, V20, P1661, DOI 10.1038/sj.onc.1204182; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sakabe K, 2002, FEBS LETT, V511, P15, DOI 10.1016/S0014-5793(01)03264-1; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taya S, 2001, J CELL BIOL, V155, P809, DOI 10.1083/jcb.200106139; Teramoto H, 1997, J BIOL CHEM, V272, P10751; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	36	83	84	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					233	240		10.1038/sj.onc.1207012	http://dx.doi.org/10.1038/sj.onc.1207012			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712228				2022-12-28	WOS:000187895300024
J	Esteller, M; Herman, JG				Esteller, M; Herman, JG			Generating mutations but providing chemosensitivity: the role of O-6-methylguanine DNA methyltransferase in human cancer	ONCOGENE			English	Review						O-6-methylguanine DNA methyltransferase; MGMT; CpG island hypermethylation; transition mutations; alkylating agents	TUMOR-SUPPRESSOR GENES; HMLH1 PROMOTER HYPERMETHYLATION; N-NITROSO COMPOUNDS; CELL LUNG-CANCER; REPAIR GENE; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CPG ISLAND; K-RAS; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; MESSENGER-RNA	O-6-methylguanine DNA methyltransferase (MGMT) is a key enzyme in the DNA repair network. MGMT removes mutagenic and cytotoxic adducts from O-6-guanine in DNA, the preferred point of attack of many carcinogens (i.e. methylnitrosourea) and alkylating chemotherapeutic agents (i.e. BCNU, temozolamide, etc.). Hypermethylation of the CpG island located in the promoter region of MGMT is primarily responsible for the loss of MGMT function in many tumor types. The methylation-mediated silencing of MGMT has two consequences for cancer. First, tumors with MGMT methylation have a new mutator phenotype characterized by the generation of transition point mutations in genes involved in cancer etiology, such as the tumor suppressor p53 and the oncogene K-ras. Second, MGMT hypermethylation demonstrates the possibility of pharmacoepigenomics: methylated tumors are more sensitive to the killing effects of alkylating drugs used in chemotherapy. These recent results underscore the importance of MGMT in basic and translational cancer research.	Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Canc Epigenet Lab, Madrid 28029, Spain; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr Johsn Hopkins, Baltimore, MD 21231 USA	Centro Nacional de Investigaciones Oncologicas (CNIO); Johns Hopkins University; Johns Hopkins Medicine	Esteller, M (corresponding author), Spanish Natl Canc Ctr CNIO, Mol Pathol Program, Canc Epigenet Lab, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mesteller@cnio.es; hermanji@jhmi.edu	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093	NATIONAL CANCER INSTITUTE [P50CA058184, U01CA084986] Funding Source: NIH RePORTER; NCI NIH HHS [CA84986, P50CA58184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AQUILINA G, 1992, CANCER RES, V52, P6471; Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTSCH H, 1990, MUTAT RES, V238, P255, DOI 10.1016/0165-1110(90)90017-6; Belanich M, 1996, CANCER RES, V56, P783; Biswas T, 1999, ONCOGENE, V18, P525, DOI 10.1038/sj.onc.1202320; BOCKER T, 1999, BIOCHIM BIOPHYS ACTA, V1423, P1; BONFANTI M, 1991, NUCLEIC ACIDS RES, V19, P5739, DOI 10.1093/nar/19.20.5739; BOS JL, 1989, CANCER RES, V49, P4682; Brabender J, 2003, CLIN CANCER RES, V9, P223; CAI Y, 2001, CANCER RES, V60, P5464; Cai YN, 1999, CANCER RES, V59, P3059; CECCOTTI S, 1993, BIOCHEMISTRY-US, V32, P13664, DOI 10.1021/bi00212a035; Choy KW, 2002, INVEST OPHTH VIS SCI, V43, P1344; CITRON M, 1992, J NATL CANCER I, V84, P337, DOI 10.1093/jnci/84.5.337; COLVIN M, 1981, CANCER TREAT REP, V65, P89; COSTELLO JF, 1996, CANCER RES, V271, P13916; COULONDRE C, 1977, J MOL BIOL, V117, P577, DOI 10.1016/0022-2836(77)90059-6; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Dolan ME, 1997, CLIN CANCER RES, V3, P837; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Edara S, 1996, CANCER RES, V56, P5571; Egyhazi S, 2002, Hum Mutat, V20, P408, DOI 10.1002/humu.9078; Engelbergs J, 1998, P NATL ACAD SCI USA, V95, P1635, DOI 10.1073/pnas.95.4.1635; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; Esteller M, 1999, CANCER RES, V59, P67; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2001, CANCER RES, V61, P3225; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Esteller M, 2000, CANCER RES, V60, P2368; Esteller M, 2002, J NATL CANCER I, V94, P26; Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8; Fleisher AS, 1999, CANCER RES, V59, P1090; FORNACE AJ, 1990, CANCER RES, V50, P7908; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249; Friedman HS, 1999, CANCER CHEMOTH PHARM, V43, P80; Gamcsik MP, 1999, CURR PHARM DESIGN, V5, P587; Gerson SL, 2002, J CLIN ONCOL, V20, P2388, DOI 10.1200/JCO.2002.06.110; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; Harris LC, 1996, CANCER RES, V56, P2029; Hayashi H, 2002, JPN J CANCER RES, V93, P184, DOI 10.1111/j.1349-7006.2002.tb01257.x; HEPBURN PA, 1991, J BIOL CHEM, V266, P7985; Herfarth KKF, 1999, MOL CARCINOGEN, V24, P90, DOI 10.1002/(SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hongeng S, 1997, CLIN CANCER RES, V3, P2459; HORSFALL MJ, 1990, ENVIRON MOL MUTAGEN, V15, P107, DOI 10.1002/em.2850150208; Hussain SP, 1998, RECENT RES CANCER, V154, P22; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; IMAI Y, 1995, CARCINOGENESIS, V16, P2441; Inoue R, 2000, PHARMACOGENETICS, V10, P59, DOI 10.1097/00008571-200002000-00008; Jaeckle KA, 1998, J CLIN ONCOL, V16, P3310, DOI 10.1200/JCO.1998.16.10.3310; Kane MF, 1997, CANCER RES, V57, P808; Kawate H, 2000, CARCINOGENESIS, V21, P301, DOI 10.1093/carcin/21.2.301; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kohya N, 2003, INT J MOL MED, V11, P65; Kohya N, 2002, ANN SURG ONCOL, V9, P371, DOI 10.1245/aso.2002.9.4.371; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; KROES RA, 1995, CARCINOGENESIS, V16, P2255, DOI 10.1093/carcin/16.9.2255; KUNKEL TA, 1993, NATURE, V362, P709; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Liu LL, 1999, CARCINOGENESIS, V20, P279, DOI 10.1093/carcin/20.2.279; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; LUDLUM DB, 1990, MUTAT RES, V233, P117, DOI 10.1016/0027-5107(90)90156-X; Markowitz S, 2000, J CLIN ONCOL, V18, p75S; Maruyama R, 2002, CLIN CANCER RES, V8, P514; Mattern J, 1998, INT J CANCER, V77, P919, DOI 10.1002/(SICI)1097-0215(19980911)77:6<919::AID-IJC20>3.0.CO;2-V; Middleton MR, 2003, LANCET ONCOL, V4, P37, DOI 10.1016/S1470-2045(03)00959-8; MITRA G, 1989, P NATL ACAD SCI USA, V86, P8650, DOI 10.1073/pnas.86.22.8650; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Palmisano WA, 2000, CANCER RES, V60, P5954; Park TJ, 2001, CANCER, V92, P2760, DOI 10.1002/1097-0142(20011201)92:11<2760::AID-CNCR10123>3.0.CO;2-8; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Paz MF, 2003, CANCER RES, V63, P1114; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PEGG AE, 1990, CANCER RES, V50, P6119; Pfeifer GP, 2000, MUTAT RES-FUND MOL M, V450, P155, DOI 10.1016/S0027-5107(00)00022-1; PHEAR G, 1987, P NATL ACAD SCI USA, V84, P4450, DOI 10.1073/pnas.84.13.4450; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Pourquier P, 2001, CANCER RES, V61, P53; Qian XLC, 1997, CANCER RES, V57, P3672; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Rosas SLB, 2001, CANCER RES, V61, P939; ROWLAND IR, 1991, CARCINOGENESIS, V12, P1395, DOI 10.1093/carcin/12.8.1395; Rusin M, 1999, Hum Mutat, V14, P269, DOI 10.1002/(SICI)1098-1004(1999)14:3<269::AID-HUMU13>3.0.CO;2-6; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Silber JR, 1998, CANCER RES, V58, P1068; SILBER JR, 1993, CANCER RES, V53, P3416; Smith-Sorensen B, 2002, ONCOGENE, V21, P8878, DOI 10.1038/sj.onc.1205978; Srivenugopal KS, 2002, ONCOGENE, V21, P5940, DOI 10.1038/sj.onc.1205762; Srivenugopal KS, 2000, CANCER RES, V60, P282; Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205; STRAUSS BS, 1992, CANCER RES, V52, P249; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Teicher Beverly A., 1997, P405; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Toyooka S, 2001, MOL CANCER THER, V1, P61; Virmani AK, 2001, CLIN CANCER RES, V7, P584; Wang L, 1997, INT J CANCER, V71, P719, DOI 10.1002/(SICI)1097-0215(19970529)71:5<719::AID-IJC5>3.0.CO;2-U; WARD FW, 1989, FOOD CHEM TOXICOL, V27, P445, DOI 10.1016/0278-6915(89)90030-6; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Weinstein JN, 2000, NEW ENGL J MED, V343, P1408, DOI 10.1056/NEJM200011093431910; WHITE GRM, 1986, CARCINOGENESIS, V7, P2077, DOI 10.1093/carcin/7.12.2077; Whitehall VLJ, 2001, CANCER RES, V61, P827; Wolf P, 2001, CANCER RES, V61, P8113; Yin D, 2003, MOL CARCINOGEN, V36, P23, DOI 10.1002/mc.10094; ZAIDI NH, 1995, CARCINOGENESIS, V16, P451, DOI 10.1093/carcin/16.3.451; Zhang YJ, 2003, INT J CANCER, V103, P440, DOI 10.1002/ijc.10852	117	231	246	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					1	8		10.1038/sj.onc.1207316	http://dx.doi.org/10.1038/sj.onc.1207316			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712205				2022-12-28	WOS:000187895300001
J	Rengifo-Cam, W; Konishi, A; Morishita, N; Matsuoka, H; Yamori, T; Nada, S; Okada, M				Rengifo-Cam, W; Konishi, A; Morishita, N; Matsuoka, H; Yamori, T; Nada, S; Okada, M			Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis	ONCOGENE			English	Article						Src; Csk; colon cancer; integrin	PROTEIN-TYROSINE KINASE; TERMINAL SRC KINASE; ADVANCED COLORECTAL CANCERS; C-SRC; FAMILY KINASES; CODON 531; E-CADHERIN; ACTIVATION; PP60C-SRC; GENE	Progression of human colon cancer is often associated with elevated expression and activity of the Src family tyrosine kinase (SFK). SFK is ordinarily in equilibrium between inactive and primed states by a balance of negative regulatory kinase Csk and its counteracting tyrosine phosphatase(s), both of which act on the regulatory C-terminal tyrosine of SFK. To evaluate the contribution of the regulatory system of SFK in cancer progression, we here modulated the equilibrium status of SFK by introducing wild-type or dominant-negative Csk in human epithelial colon cancer cells, HCT15 and HT29. Overexpression of wild-type Csk induced decreased SFK activation, increased cell-cell contacts mediated by E-cadherin, decreased the number of focal contacts and decreased cell adhesion/migration and in vitro invasiveness. Conversely, expression of a dominant-negative Csk resulted in elevated SFK activation, enhanced phosphorylation of FAK and paxilllin, enhanced cell scattering, an increased number of focal contacts, dramatic rearrangement of actin cytoskeleton and increased cell adhesion/migration and in vitro invasiveness. In these scattered cells, however, localization, expression and phosphorylation of either E-cadherin or beta-catenin were not significantly affected, suggesting that the E-cadherin-mediated cell-cell contact is indirectly regulated by SFK. Furthermore, all these events occurred absolutely dependent on integrin-mediated cell adhesion. These findings demonstrate that Csk defines the ability of integrin-SFK-mediated cell adhesion signaling that influences the metastatic potential of cancer cells.	Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Osaka 5650871, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Toshima Ku, Tokyo 1708455, Japan	Osaka University; Japanese Foundation for Cancer Research	Okada, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Osaka 5650871, Japan.	okadam@biken.osaka-u.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; BOARDMAN LA, 1995, GASTROENTEROLOGY, V108, P291, DOI 10.1016/0016-5085(95)90037-3; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Daigo Y, 1999, CANCER RES, V59, P4222; Dan S, 2002, CANCER RES, V62, P1139; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Irby RB, 2002, CANCER RES, V62, P2669; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakagawa T, 2000, INT J CANCER, V88, P384, DOI 10.1002/1097-0215(20001101)88:3<384::AID-IJC10>3.3.CO;2-2; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Nilbert M, 2000, CANCER GENET CYTOGEN, V121, P94, DOI 10.1016/S0165-4608(00)00226-0; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; RENGIFOCAM W, 2001, CANCER, V92, P61; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Suen PW, 1999, J CELL SCI, V112, P4067; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5	36	36	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					289	297		10.1038/sj.onc.1207041	http://dx.doi.org/10.1038/sj.onc.1207041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712234				2022-12-28	WOS:000187895300030
J	Aglipay, JA; Lee, SW; Okada, S; Fujiuchi, N; Ohtsuka, T; Kwak, JC; Wang, Y; Johnstone, RW; Deng, CX; Qin, J; Ouchi, T				Aglipay, JA; Lee, SW; Okada, S; Fujiuchi, N; Ohtsuka, T; Kwak, JC; Wang, Y; Johnstone, RW; Deng, CX; Qin, J; Ouchi, T			A member of the Pyrin family, IFI16, is a novel BRCA1-associated protein involved in the p53-mediated apoptosis pathway	ONCOGENE			English	Article						BRCA1; IFI16; p53; apoptosis	CELL-CYCLE; BRCA1; PHOSPHORYLATION; CANCER; TRANSCRIPTION; BREAST; DOMAIN; P53; CHECKPOINT; MUTATION	We identified IFI16 as a BRCA1-associated protein involved in p53-mediated apoptosis. IFI16 contains the Pyrin/PAAD/DAPIN domain, commonly found in cell death-associated proteins. BRCA1 (aa 502-802) interacted with the IFI16 Pyrin domain (aa 1-130). We found that IFI16 was localized in the nucleoplasm and nucleoli. Clear nucleolar IFI16 localization was not observed in HCC1937 BRCA1 mutant cells, but reintroduction of wild-type BRCA1 restored IFI16 nuclear relocalization following IR (ionizing radiation). Coexpression of IFI16 and BRCA1 enhanced DNA damage-induced apoptosis in mouse embryonic fibroblasts from BRCA1 mutant mice expressing wild-type p53, although mutant IFI16 deficient in binding to BRCA1 did not induce apoptosis. Furthermore, tetracycline-induced IFI16 collaborated in inducing apoptosis when adenovirus p53 was expressed in DNA-damaged p53-deficient EJ cells. These results indicate a BRCA1-IFI16 role in p53-mediated transmission of DNA damage signals and apoptosis.	NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Beth Israel Deaconess Med Ctr, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic, Australia; NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD USA	Icahn School of Medicine at Mount Sinai; New York University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Baylor College of Medicine; Baylor College of Medicine; Peter Maccallum Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ouchi, T (corresponding author), NYU, Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	Toru.Ouchi@mssm.edu	deng, chuxia/N-6713-2016; Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237	NCI NIH HHS [CA80058, CA84199, CA78356, CA90631, CA79892] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084199, R01CA090631, R01CA079892, R01CA078356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Johnstone RW, 1998, J BIOL CHEM, V273, P17172, DOI 10.1074/jbc.273.27.17172; Johnstone RW, 2000, ONCOGENE, V19, P6033, DOI 10.1038/sj.onc.1204005; Johnstone RW, 1999, MOL CELL BIOL, V19, P5833; KAELIN WG, 1994, CELL, V644, P521; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Martinon F, 2001, CURR BIOL, V11, pR118, DOI 10.1016/S0960-9822(01)00056-2; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pawlowski K, 2001, TRENDS BIOCHEM SCI, V26, P85, DOI 10.1016/S0968-0004(00)01729-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Staub E, 2001, TRENDS BIOCHEM SCI, V26, P83, DOI 10.1016/S0968-0004(00)01717-5; Tomlinson GE, 1998, CANCER RES, V58, P3237; TRAPANI JA, 1992, IMMUNOGENETICS, V36, P369; Wang Y, 2000, GENE DEV, V14, P927; Xu B, 2002, CANCER RES, V62, P4588; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7	35	105	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8931	8938		10.1038/sj.onc.1207057	http://dx.doi.org/10.1038/sj.onc.1207057			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654789				2022-12-28	WOS:000186982200014
J	Liston, P; Fong, WG; Korneluk, RG				Liston, P; Fong, WG; Korneluk, RG			The inhibitors of apoptosis: there is more to life than Bcl2	ONCOGENE			English	Review						IAP; apoptosis; cancer; xaf1; Smac; caspase	X-LINKED INHIBITOR; UBIQUITIN-PROTEIN LIGASE; CASPASE-MEDIATED CLEAVAGE; SPINAL MUSCULAR-ATROPHY; HUMAN OVARIAN-CANCER; PROMOTES CELL-DEATH; IAP FAMILY PROTEINS; NEURONS IN-VIVO; FACTOR-KAPPA-B; SERINE-PROTEASE	The inhibitor of apoptosis (IAP) genes constitute a highly conserved family found in organisms as diverse as insects and mammals. These genes encode proteins that directly bind and inhibit caspases, and thus play a critical role in deciding cell fate. The IAPs are in turn regulated by endogenous proteins ( second mitochondrial activator of caspases and Omi) that are released from the mitochondria during apoptosis. Overexpression of the IAPs, particularly the X-chromosome-linked IAP, has been shown to be protective in a variety of experimental animal models of human neurodegenerative diseases. Furthermore, overexpression of one or more of the IAPs in cancer cell lines and primary tumor samples appears to be a frequent event. IAP gene amplification and translocation events provide genetic evidence that further strengthens the case for classifying the IAPs as oncogenes. Therapeutic strategies that interfere with IAP expression or function are under investigation as an adjuvant to conventional chemotherapy- and radiation-based cancer therapy. This paper reviews the structure and function of the IAP family members and their inhibitors, and surveys the available evidence for IAP dysregulation in cancer.	Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Korneluk, RG (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	bob@mgcheo.med.uottawa.ca						Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clem RJ, 2001, J BIOL CHEM, V276, P7602, DOI 10.1074/jbc.M010259200; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; Crocker SJ, 2003, NEUROBIOL DIS, V12, P150, DOI 10.1016/S0969-9961(02)00020-7; Crocker SJ, 2001, EUR J NEUROSCI, V14, P391, DOI 10.1046/j.0953-816x.2001.01653.x; Dai ZY, 2003, HUM MOL GENET, V12, P791, DOI 10.1093/hmg/ddg083; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gendron N H, 1999, Curr Opin Neurol, V12, P137, DOI 10.1097/00019052-199904000-00002; Growney JD, 2000, GENOME RES, V10, P1158, DOI 10.1101/gr.10.8.1158; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Huang HK, 2000, J BIOL CHEM, V275, P26661; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Imoto I, 2002, CANCER RES, V62, P4860; Imoto I, 2001, CANCER RES, V61, P6629; Inohara N, 2001, ONCOGENE, V20, P6473, DOI 10.1038/sj.onc.1204787; Johnson DE, 2000, CANCER RES, V60, P1818; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Karran L, 2001, CRIT REV EUKAR GENE, V11, P269; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lagace M, 2001, GENOMICS, V77, P181, DOI 10.1006/geno.2001.6635; Lee RT, 2001, CIRC RES, V88, P262, DOI 10.1161/01.RES.88.3.262; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu HX, 2001, LANCET, V357, P39, DOI 10.1016/S0140-6736(00)03571-6; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Los M, 2001, TRENDS IMMUNOL, V22, P31, DOI 10.1016/S1471-4906(00)01814-7; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; MCCARREY JR, 1987, NATURE, V326, P501, DOI 10.1038/326501a0; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Mouhamad S, 2002, EUR CYTOKINE NETW, V13, P439; Pandey P, 2000, ONCOGENE, V19, P3941, DOI 10.1038/sj.onc.1203751; Perrelet D, 2000, EUR J NEUROSCI, V12, P2059, DOI 10.1046/j.1460-9568.2000.00098.x; Perrelet D, 2002, NAT CELL BIOL, V4, P175, DOI 10.1038/ncb751; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Richter BWM, 2001, MOL CELL BIOL, V21, P4292, DOI 10.1128/MCB.21.13.4292-4301.2001; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sanna MG, 2002, J BIOL CHEM, V277, P30454, DOI 10.1074/jbc.M203312200; Sasaki H, 2000, CANCER RES, V60, P5659; Savopoulos JW, 2000, PROTEIN EXPRES PURIF, V19, P227, DOI 10.1006/prep.2000.1240; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Song ZW, 2000, MOL CELL BIOL, V20, P2907, DOI 10.1128/MCB.20.8.2907-2914.2000; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vaughan ATM, 2002, APOPTOSIS, V7, P173, DOI 10.1023/A:1014374717773; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yang LL, 2003, CANCER RES, V63, P831; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yaraghi Z, 1998, GENOMICS, V51, P107, DOI 10.1006/geno.1998.5378; Zou H, 2003, J BIOL CHEM, V278, P8091, DOI 10.1074/jbc.M204783200	113	349	382	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8568	8580		10.1038/sj.onc.1207101	http://dx.doi.org/10.1038/sj.onc.1207101			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634619				2022-12-28	WOS:000186720000003
J	McBride', K; Charron, F; Lefebvre, C; Nemer, M				McBride', K; Charron, F; Lefebvre, C; Nemer, M			Interaction with GATA transcription factors provides a mechanism for cell-specific effects of c-Fos	ONCOGENE			English	Article						c-Fos; GATA factors; AP-1; transcription	GENE-EXPRESSION; COOPERATIVE INTERACTION; CARDIAC TRANSCRIPTION; LEUKEMIA GENE; DOCKING SITES; MICE LACKING; JUN; ACTIVATION; PROTEINS; RECEPTOR	c-Fos is a multifunctional transcription factor that is involved in cellular proliferation, differentiation and apoptosis. c-Fos is rapidly induced by a variety of hormones, growth factors and other extracellular stimuli, resulting in cell-specific responses. One potential mechanism underlying the cell-specific effects of c-Fos may be its ability to regulate gene expression through interaction with tissue-restricted transcription factors. We report here that c-Fos interacts with the cell-specific GATA proteins to potentiate their ability to transactivate target promoters, via GATA-binding sites. c-Fos is recruited to GATA proteins through direct interaction with their N-terminal activation domain. Neither the leucine zipper nor the DNA-binding domain of c-Fos is required for physical interaction with GATA proteins. Instead, a C-terminal domain located between amino acids 235 and 296, which is conserved in FosB but not in the nontransforming Fos family members, FosB/SF or Fra-1, is essential for c-Fos-GATA interaction. These data suggest that c-Fos may act as an inducible cofactor for cell-specific transcription factors and unravel a novel mechanism for transcriptional regulation by c-Fos, independent of the well-studied AP-1 pathway. The results also raise the possibility that dysregulated interaction with cell-specific transcription factors may be an important component in cellular transformation by nuclear oncogenes.	Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, Montreal, PQ H2W 1R7, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University	Nemer, M (corresponding author), Inst Rech Clin Montreal, Lab Dev & Differenciat Cardiaques, 110 Ave Pins Ouest, Montreal, PQ H2W 1R7, Canada.		Charron, Frederic/O-8017-2019	Charron, Frederic/0000-0003-3483-8672				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhalla SS, 2001, J BIOL CHEM, V276, P11439, DOI 10.1074/jbc.M100208200; Bockamp EO, 1998, J BIOL CHEM, V273, P29032, DOI 10.1074/jbc.273.44.29032; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Charron F, 1999, MOL CELL BIOL, V19, P4355; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Ciapponi L, 2001, GENE DEV, V15, P1540, DOI 10.1101/gad.886301; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Depre C, 1998, NAT MED, V4, P1269, DOI 10.1038/3253; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fox AH, 1998, J BIOL CHEM, V273, P33595, DOI 10.1074/jbc.273.50.33595; Gottgens B, 2002, GENOME RES, V12, P749, DOI 10.1101/gr.45502; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; Kataoka K, 1996, ONCOGENE, V12, P53; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; McBride K, 2001, CAN J PHYSIOL PHARM, V79, P673, DOI 10.1139/cjpp-79-8-673; McBride K, 1998, MOL CELL BIOL, V18, P5073, DOI 10.1128/MCB.18.9.5073; Miyamoto T, 2001, BLOOD, V98, P2544, DOI 10.1182/blood.V98.8.2544; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Nemer G, 2003, DEV BIOL, V254, P131, DOI 10.1016/S0012-1606(02)00026-X; Nemer G, 1999, MAMM GENOME, V10, P993, DOI 10.1007/s003359901146; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PANDEY KN, 1986, BIOCHEM BIOPH RES CO, V138, P399, DOI 10.1016/0006-291X(86)90295-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wenzel A, 2002, J NEUROCHEM, V80, P1089, DOI 10.1046/j.0022-3042.2002.00807.x; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	58	20	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8403	8412		10.1038/sj.onc.1206877	http://dx.doi.org/10.1038/sj.onc.1206877			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627981				2022-12-28	WOS:000186650300004
J	Moore, L; Venkatachalam, S; Vogel, H; Watt, JC; Wu, CL; Steinman, H; Jones, SN; Donehower, LA				Moore, L; Venkatachalam, S; Vogel, H; Watt, JC; Wu, CL; Steinman, H; Jones, SN; Donehower, LA			Cooperativity of p19(ARF), Mdm2, and p53 in murine tumorigenesis	ONCOGENE			English	Article						19(ARF); Mdm2; p53; mouse cancer model; tumor suppressor	CARCINOGEN-INDUCED TUMORIGENESIS; SOFT-TISSUE SARCOMAS; ARF TUMOR-SUPPRESSOR; MDM2-DEFICIENT MICE; EMBRYONIC LETHALITY; STABILIZES P53; INK4A LOCUS; CANCER; APOPTOSIS; OVEREXPRESSION	The p19(ARF) gene product responds to oncogenic stresses by interfering with the inhibitory effects of Mdm2 on p53, thus enhancing p53 activity and its antiproliferative functions. The absence of p19(ARF) in the mouse leads to early tumor susceptibility, presumably in part due to decreased p53 activity. To examine the tumorigenic cooperativity of p19(ARF), Mdm2, and p53 in vivo, p19(ARF)-deficient mice were crossed first to p53-deficient mice and then to Mdm2 transgenic mice. The progeny were monitored for tumors. Cooperativity between p19(ARF) and p53 deficiencies in accelerating tumor formation was observed for most genotypes except p53 -/- p19(ARF) -/- mice. p53 -/- p19(ARF) -/- mice had a tumor incidence similar to p53 -/- mice. In this context, tumor suppression by ARF appears to be primarily p53 dependent. The majority of the p19(ARF) +/- tumors deleted the wildtype p19(ARF) allele, in agreement with the previous studies, suggesting that p19(ARF) is a classic 'two hit' tumor suppressor. In a p53+/- background, however, all p19(ARF) +/ - tumors retained a wildtype ARF allele and most also retained wildtype p53. In the second cross between p19(ARF)-deficient and Mdm2 transgenic mice, cooperativity in tumor incidence between Mdm2 overexpression and ARF deficiency was observed, consistent with the role of p19(ARF) in negatively regulating Mdm2 activity. These experiments further demonstrate in vivo the inter-relationships of the p19(ARF)-Mdm2-p53 signaling axis in tumor suppression.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Tennessee, Dept Biochem & Cell & Mol Biol, Knoxville, TN 37996 USA; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA	Baylor College of Medicine; Baylor College of Medicine; University of Tennessee System; University of Tennessee Knoxville; Stanford University; University of Massachusetts System; University of Massachusetts Worcester	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.			Vogel, Otto Hannes/0000-0002-0960-3508				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Foster CJ, 2002, ONCOGENE, V21, P3525, DOI 10.1038/sj.onc.1205441; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kuo ML, 2003, CANCER RES, V63, P1046; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; LUNA RMD, 1995, NATURE, V378, P203; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Tsuji K, 2002, BIOCHEM BIOPH RES CO, V295, P621, DOI 10.1016/S0006-291X(02)00723-4; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weber HO, 2002, ONCOGENE, V21, P3207, DOI 10.1038/sj.onc.1205429; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7831	7837		10.1038/sj.onc.1206985	http://dx.doi.org/10.1038/sj.onc.1206985			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586409	Bronze			2022-12-28	WOS:000186240200013
J	Marquez, N; Chappell, SC; Sansom, OJ; Clarke, AR; Court, J; Errington, RJ; Smith, PJ				Marquez, N; Chappell, SC; Sansom, OJ; Clarke, AR; Court, J; Errington, RJ; Smith, PJ			Single cell tracking reveals that Msh2 is a key component of an early-acting DNA damage-activated G2 checkpoint	ONCOGENE			English	Article						G2 checkpoint; Msh2; mouse embryonic fibroblasts; time-lapse microscopy; event analysis	REPAIR PROTEINS MSH2; MISMATCH REPAIR; DRUG-RESISTANCE; TUMOR-CELLS; APOPTOSIS; CISPLATIN; MUTATION; ARREST; P53; EXPRESSION	Dysfunction of cell-cycle checkpoints in DNA mismatch repair (MMR)- deficient cells in response to DNA damage has implications for anticancer therapy and genetic instability. We have studied the cell-cycle effects of MMR deficiency (Msh2(-/-)) in primary mouse embryonic fibroblasts (MEFs) exposed to cisplatin (10 muM x 1 h) using time-lapse microscopy. Kinetic responses of MEFs from different embryos and passage ages varied, but we report a consistent drug-induced inhibition of mitotic entry (approx. 50%). There was a loss of an early-acting (<5 h) delay in G2 to M transition in Msh2(-/-) cells, although a later-acting G2 arrest was apparently normal. This suggests that Msh2 primarily acts to delay mitotic entry of cells already in G2, that is, DNA damage incurred during G2 does not influence the cell once committed to mitotic traverse. Irrespective of Msh2 status, cisplatin treatment and the incurred DNA damage did not effect mitotic traverse or show any evidence for early ( within 24 h) cell death. The results indicate that Msh2(-/-) status can result in the premature commitment to mitosis of a cell subpopulation, determined by the fraction residing in G2 at the time of damage induction. The findings suggest a new route to MMR-driven genetic instability that does not rely primarily on the integrity of the late-acting checkpoint.	Cardiff Univ, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales; Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Velindre NHS Trust, Canc Res Wales Lab, Cardiff CF14 2TL, S Glam, Wales; Cardiff Univ, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University; Cardiff University	Smith, PJ (corresponding author), Cardiff Univ, Dept Pathol, Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	smithpj2@cardiff.ac.uk	t, lf/AAJ-4924-2020; clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X; Sansom, Owen J./0000-0001-9540-3010; Chapell, Sally/0000-0003-2712-2617				Aebi S, 1997, CLIN CANCER RES, V3, P1763; Aquilina G, 1999, CARCINOGENESIS, V20, P2317, DOI 10.1093/carcin/20.12.2317; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Christmann M, 2002, NUCLEIC ACIDS RES, V30, P1959, DOI 10.1093/nar/30.9.1959; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; delasAlas MM, 1997, J NATL CANCER I, V89, P1537, DOI 10.1093/jnci/89.20.1537; EPSTEIN RJ, 1988, CYTOMETRY, V9, P349, DOI 10.1002/cyto.990090412; EVANS DL, 1993, CANCER RES, V53, P2133; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hirose Y, 2001, CANCER RES, V61, P1957; Karran P, 1999, FR MOLEC B, V22, P66; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Kravtsov VD, 1999, AM J PATHOL, V155, P1327, DOI 10.1016/S0002-9440(10)65235-2; Lage H, 1999, INT J CANCER, V80, P744, DOI 10.1002/(SICI)1097-0215(19990301)80:5<744::AID-IJC19>3.0.CO;2-5; LIN X, 2001, CANCER RES, V15, P1508; Moreland NJ, 1999, CANCER RES, V59, P2102; Nehme A, 1999, BRIT J CANCER, V79, P1104, DOI 10.1038/sj.bjc.6690176; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; SORENSON CM, 1988, CANCER RES, V48, P6703; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Therneau TM, 2000, MODELING SURVIVAL DA; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yan T, 2001, CANCER RES, V61, P8290; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	34	21	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7642	7648		10.1038/sj.onc.1206876	http://dx.doi.org/10.1038/sj.onc.1206876			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576827				2022-12-28	WOS:000186113000012
J	Perkins, ND				Perkins, ND			Oncogenes, tumor suppressors and p52 NF-kappa B	ONCOGENE			English	Editorial Material						NF-kappa B2; Lyt-10; NIK; IKK; P53; cyclin D1	HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING; CYCLIN D1; TRANSCRIPTIONAL ACTIVATION; NF-KAPPA-B2 P100; IKK-ALPHA; T-CELLS; EXPRESSION; BCL-3; GENE	A role for the p52 NF-kappaB subunit in tumorigenesis has been steadily emerging since its discovery as a gene associated with chromosomal translocations in B- and T-cell lymphomas. Now Eliopoulos and co-workers have extended these studies to examine the effect of the Epstein - Barr virus (EBV)-encoded latent infection membrane protein 1 (LMP1) on p52. They find that LMP1 stimulates the processing of p100 to p52 NF-kappaB. Moreover, nuclear p52 is also associated with LMP1 expression in tumor tissue biopsies. They also demonstrate that the pathway leading to p100/p52 processing is distinct from that engaged by LMP1 to activate other NF-kappaB subunits through IkappaBalpha degradation. A clearer picture is now developing of the important role that p52 NF-kappaB plays during normal cell growth and how subverting its function can contribute to oncogenesis.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk						Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; THAKUR S, 1994, ONCOGENE, V9, P2335; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805	43	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7553	7556		10.1038/sj.onc.1207139	http://dx.doi.org/10.1038/sj.onc.1207139			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576816				2022-12-28	WOS:000186113000001
J	Ambudkar, SV; Kimchi-Sarfaty, C; Sauna, ZE; Gottesman, MM				Ambudkar, SV; Kimchi-Sarfaty, C; Sauna, ZE; Gottesman, MM			P-glycoprotein: from genomics to mechanism	ONCOGENE			English	Review						ABC transporter; multidrug resistance; P-glycoprotein; drug transport; ATP hydrolysis; catalytic cycle; polymorphism	ATP-BINDING CASSETTE; MDR1 GENE POLYMORPHISMS; ACUTE MYELOID-LEUKEMIA; MULTIDRUG-RESISTANCE GENE; BREAST-CANCER RESISTANCE; MYOSIN MOTOR DOMAIN; ABC TRANSPORTER; CATALYTIC CYCLE; DRUG-BINDING; ESCHERICHIA-COLI	Resistance to chemically different natural product anticancer drugs ( multidrug resistance, or MDR) results from decreased drug accumulation, resulting from expression of one or more ATP-dependent efflux pumps. The first of these to be identified was P-glycoprotein (P-gp), the product of the human MDR1 gene, localized to chromosome 7q21. P-gp is a member of the large ATP-binding cassette (ABC) family of proteins. Although its crystallographic 3-D structure is yet to be determined, sequence analysis and comparison to other ABC family members suggest a structure consisting of two transmembrane (TM) domains, each with six TM segments, and two nucleotide-binding domains. In the epithelial cells of the gastrointestinal tract, liver, and kidney, and capillaries of the brain, testes, and ovaries, P-gp acts as a barrier to the uptake of xenobiotics, and promotes their excretion in the bile and urine. Polymorphisms in the MDR1 gene may affect the pharmacokinetics of many commonly used drugs, including anticancer drugs. Substrate recognition of many different drugs occurs within the TM domains in multiple-overlapping binding sites. We have proposed a model for how ATP energizes transfer of substrates from these binding sites on P-gp to the outside of the cell, which accounts for the apparent stoichiometry of two ATPs hydrolysed per molecule of drug transported. Understanding of the biology, genetics, and biochemistry of P-gp promises to improve the treatment of cancer and explain the pharmacokinetics of many commonly used drugs.	NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ambudkar, SV (corresponding author), NCI, Cell Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 1A-09, Bethesda, MD 20892 USA.	ambudkar@helix.nih.gov	Ambudkar, Suresh V/B-5964-2008; Sauna, Zuben E./AAA-7149-2019; Ambudkar, Suresh V/L-1317-2016	Kimchi-Sarfaty, Chava/0000-0002-9355-8585	NATIONAL CANCER INSTITUTE [Z01BC010030, ZIABC010030] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allikmets R, 1998, CANCER RES, V58, P5337; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; Ambudkar SV, 1997, J BIOL CHEM, V272, P21160, DOI 10.1074/jbc.272.34.21160; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Ameyaw MM, 2001, PHARMACOGENETICS, V11, P217, DOI 10.1097/00008571-200104000-00005; Andrus MB, 2000, BIOORG MED CHEM LETT, V10, P2275, DOI 10.1016/S0960-894X(00)00439-X; Belinsky MG, 1999, BRIT J CANCER, V80, P1342, DOI 10.1038/sj.bjc.6690527; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Borchers C, 2002, MOL PHARMACOL, V61, P1366, DOI 10.1124/mol.61.6.1366; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Brangi M, 1999, CANCER RES, V59, P5938; Brinkmann U, 2001, DRUG DISCOV TODAY, V6, P835, DOI 10.1016/S1359-6446(01)01892-X; BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; Brumme ZL, 2003, AIDS, V17, P201, DOI 10.1097/00002030-200301240-00010; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; Calado RT, 2002, HAEMATOLOGICA, V87, P564; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; CHEN CJ, 1990, J BIOL CHEM, V265, P506; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Chen ZS, 2003, MOL PHARMACOL, V63, P351, DOI 10.1124/mol.63.2.351; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Childs S, 1998, CANCER RES, V58, P4160; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DALE MP, 1987, BIOCHEMISTRY-US, V26, P8365, DOI 10.1021/bi00399a051; De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282; Dean M, 2001, J LIPID RES, V42, P1007; Decleves X, 2000, HUM MUTAT, V15; Demeule M, 1998, BIOCHEMISTRY-US, V37, P18110, DOI 10.1021/bi981992c; Demmer A, 1999, EUR J BIOCHEM, V264, P800, DOI 10.1046/j.1432-1327.1999.00702.x; Demmer A, 1997, J BIOL CHEM, V272, P20913, DOI 10.1074/jbc.272.33.20913; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Drescher S, 2002, BRIT J CLIN PHARMACO, V53, P526, DOI 10.1046/j.1365-2125.2002.01591.x; Ecker G, 1999, MOL PHARMACOL, V56, P791; Ecker GF, 2002, MOL PHARMACOL, V61, P637, DOI 10.1124/mol.61.3.637; Ejendal KFK, 2002, CURR PROTEIN PEPT SC, V3, P503, DOI 10.2174/1389203023380521; Evans WE, 2003, NEW ENGL J MED, V348, P538, DOI 10.1056/NEJMra020526; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FOJO AT, 1987, J CLIN ONCOL, V5, P1922, DOI 10.1200/JCO.1987.5.12.1922; FORD JM, 1990, PHARMACOL REV, V42, P155; Furuno T, 2002, PHARMACOGENETICS, V12, P529, DOI 10.1097/00008571-200210000-00004; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; Goh BC, 2002, J CLIN ONCOL, V20, P3683, DOI 10.1200/JCO.2002.01.025; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; Goto M, 2002, PHARMACOGENETICS, V12, P451, DOI 10.1097/00008571-200208000-00005; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; Gottesman MM, 2001, J BIOENERG BIOMEMBR, V33, P453, DOI 10.1023/A:1012866803188; GOTTESMAN MM, 1988, J NATL CANCER I, V80, P1352, DOI 10.1093/jnci/80.17.1352; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gottesman MM, 1996, CURR OPIN GENET DEV, V6, P610, DOI 10.1016/S0959-437X(96)80091-8; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Gribar JJ, 2000, J MEMBRANE BIOL, V173, P203, DOI 10.1007/s002320001020; Hitzl M, 2001, PHARMACOGENETICS, V11, P293, DOI 10.1097/00008571-200106000-00003; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Honjo Y, 2001, CANCER RES, V61, P6635; Horinouchi M, 2002, PHARMACEUT RES, V19, P1581, DOI 10.1023/A:1020433422259; Hrycyna CA, 1998, J BIOL CHEM, V273, P16631, DOI 10.1074/jbc.273.27.16631; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hrycyna CA, 2001, SEMIN CELL DEV BIOL, V12, P247, DOI 10.1006/scdb.2000.0250; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Illmer T, 2002, CANCER RES, V62, P4955; Isenberg B, 2001, EUR J BIOCHEM, V268, P2629, DOI 10.1046/j.1432-1327.2001.02155.x; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; Ito S, 2001, PHARMACOGENETICS, V11, P175, DOI 10.1097/00008571-200103000-00008; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Jedlitschky G, 1996, CANCER RES, V56, P988; Johne A, 2002, CLIN PHARMACOL THER, V72, P584, DOI 10.1067/mcp.2002.129196; Johnson DR, 2001, CANCER RES, V61, P1469; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Kerb R, 2001, PHARMACOGENOMICS, V2, P51, DOI 10.1517/14622416.2.1.51; Kerb R., 2001, Pharmacogenomics Journal, V1, P204; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Kim RB, 2001, CLIN PHARMACOL THER, V70, P189, DOI 10.1067/mcp.2001.117412; Kimchi-Sarfaty C, 2002, MOL PHARMACOL, V62, P1, DOI 10.1124/mol.62.1.1; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; Komatani H, 2001, CANCER RES, V61, P2827; Konings WN, 2002, IUBMB LIFE, V53, P213, DOI 10.1080/15216540212646; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kurata Y, 2002, CLIN PHARMACOL THER, V72, P209, DOI 10.1067/mcp.2002.126177; Laing NM, 1998, CANCER RES, V58, P1332; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; Lecureur V, 2000, MOL PHARMACOL, V57, P24; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Leith CP, 1999, BLOOD, V94, P1086; LELONG IH, 1994, BIOCHEMISTRY-US, V33, P8921, DOI 10.1021/bi00196a009; Leonard Gregory D, 2002, Curr Opin Investig Drugs, V3, P1652; List AF, 2001, BLOOD, V98, P3212, DOI 10.1182/blood.V98.12.3212; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2000, J CELL SCI, V113, P2011; Liu CE, 1997, J BIOL CHEM, V272, P21883, DOI 10.1074/jbc.272.35.21883; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loe DW, 1998, CANCER RES, V58, P5130; Loo TW, 1999, BIOCHEM CELL BIOL, V77, P11, DOI 10.1139/bcb-77-1-11; Loo TW, 1999, J BIOL CHEM, V274, P24759, DOI 10.1074/jbc.274.35.24759; Loo TW, 2002, J BIOL CHEM, V277, P44332, DOI 10.1074/jbc.M208433200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Maliepaard M, 2001, CANCER RES, V61, P3458; Mayer U, 1996, BRIT J PHARMACOL, V119, P1038, DOI 10.1111/j.1476-5381.1996.tb15775.x; Mickley LA, 1998, BLOOD, V91, P1749, DOI 10.1182/blood.V91.5.1749.1749_1749_1756; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; Miyake K, 1999, CANCER RES, V59, P8; Moriya Y, 2002, BIOL PHARM BULL, V25, P1356, DOI 10.1248/bpb.25.1356; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nooter K, 1995, CLIN CANCER RES, V1, P1301; Paulusma CC, 1997, HEPATOLOGY, V25, P1539, DOI 10.1002/hep.510250635; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Potocnik U, 2001, PFLUG ARCH EUR J PHY, V442, pR182, DOI 10.1007/s004240100017; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rayment I, 1996, J BIOL CHEM, V271, P15850, DOI 10.1074/jbc.271.27.15850; REPKE KRH, 1982, ANN NY ACAD SCI, V402, P272, DOI 10.1111/j.1749-6632.1982.tb25747.x; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; Roberts R. L., 2002, Pharmacogenomics Journal, V2, P191, DOI 10.1038/sj.tpj.6500099; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Saito S, 2002, J HUM GENET, V47, P38, DOI 10.1007/s10038-002-8653-6; Sakaeda T, 2001, PHARMACEUT RES, V18, P1400, DOI 10.1023/A:1012244520615; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; SCHINKEL AH, 1993, INT J CANCER, V55, P478, DOI 10.1002/ijc.2910550326; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schwab M, 2003, ANNU REV PHARMACOL, V43, P285, DOI 10.1146/annurev.pharmtox.43.100901.140233; Seelig A, 1998, EUR J BIOCHEM, V251, P252, DOI 10.1046/j.1432-1327.1998.2510252.x; Seelig A, 1998, INT J CLIN PHARM TH, V36, P50; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Shapiro AB, 1998, EUR J BIOCHEM, V254, P189, DOI 10.1046/j.1432-1327.1998.2540189.x; Sharma S, 2000, J BACTERIOL, V182, P6570, DOI 10.1128/JB.182.23.6570-6576.2000; SHAROM FJ, 1995, BIOCHEM J, V308, P381, DOI 10.1042/bj3080381; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; Shen DW, 1998, CANCER RES, V58, P268; Siddiqui A, 2003, NEW ENGL J MED, V348, P1442, DOI 10.1056/NEJMoa021986; Siegsmund M, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019412.87412.BC; Sinues B, 2003, ONCOLOGY-BASEL, V64, P183, DOI 10.1159/000067770; SLEEP JA, 1980, J BIOL CHEM, V255, P4094; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Struk B, 2000, J MOL MED, V78, P282, DOI 10.1007/s001090000114; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Tanabe M, 2001, J PHARMACOL EXP THER, V297, P1137; Tang K, 2002, PHARMACOGENETICS, V12, P437, DOI 10.1097/00008571-200208000-00004; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; Volk EL, 2002, CANCER RES, V62, P5035; von Ahsen N, 2001, CLIN CHEM, V47, P1048; Vulevic B, 2001, CANCER RES, V61, P3339; Wang RX, 2001, P NATL ACAD SCI USA, V98, P2011, DOI 10.1073/pnas.031465498; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Wu Q, 1998, BIOCHEMISTRY-US, V37, P11272, DOI 10.1021/bi980598b; YAMADA S, 1980, J BIOL CHEM, V255, P3108; Yamauchi A, 2002, TRANSPLANTATION, V74, P571, DOI 10.1097/00007890-200208270-00024; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	183	833	887	2	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7468	7485		10.1038/sj.onc.1206948	http://dx.doi.org/10.1038/sj.onc.1206948			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576852	Bronze			2022-12-28	WOS:000186112500017
J	Horn, S; Meyer, J; Stocking, C; Ostertag, W; Jucker, M				Horn, S; Meyer, J; Stocking, C; Ostertag, W; Jucker, M			An increase in the expression and total activity of endogenous p60(c-Src) in several factor-independent mutants of a human GM-CSF-dependent leukemia cell line (TF-1)	ONCOGENE			English	Article						p(60c-Src); GM-CSF; acute myeloid leukemia; TF-1	COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; V-SRC ONCOGENE; NIH 3T3 CELLS; ACUTE MYELOBLASTIC-LEUKEMIA; HEMATOPOIETIC GROWTH-FACTOR; COMMON BETA-SUBUNIT; ROUS-SARCOMA-VIRUS; TYROSINE KINASE; AUTOCRINE GROWTH	Growth factor independence of hematopoietic cells can be induced by ectopic expression of a variety of oncogenes encoding receptor or cytoplasmic tyrosine kinases. To examine whether the activation of tyrosine kinases occurs in factor-independent mutants in vivo, the tyrosine-phosphorylated proteins from 14 factor-independent mutants of a GM-CSF-dependent cell line (TF-1) were analysed. These mutants did not secrete any growth-stimulating activity for TF-1 cells, suggesting that activation of intracellular signaling rather than an autocrine stimulation by secreted growth factors is responsible for their factor-independent growth. In 11 out of 14 GM-CSF-independent mutants analysed, a constitutively tyrosine-phosphorylated protein of 60 kDa was detected, which was subsequently identified as p60(c-Src). The kinase activity of p60(c-Src) was increased up to 12-fold in these mutants, which was at least in part due to overexpression of the c-src gene on the RNA and protein level. The Src substrate Sam68 showed an increased phosphorylation in mutants with high Src activity, suggesting that p60(c-Src) triggers downstream signaling in these cells. Treatment of the factor-independent mutants with the Src kinase inhibitor PP2 resulted in a reduced proliferation, demonstrating that Src kinases are essential for these cells for maximal proliferation. Further analysis of factor-independent mutants with low or undetectable Src activity revealed a constitutive phosphorylation of the common beta chain of the GM-CSF receptor and STAT5. Our data indicate an increase in the expression and total activity of endogenous p60(c-Src) in several GM-CSF-independent TF-1 mutants, further underlining the role of Src in the process of autonomous growth of hematopoietic cells.	Univ Hamburg, Klinikum Eppendorf, Zentrum Expt Med, Inst Biochem & Mol Biol 1, D-20246 Hamburg, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Abt Zell & Virusgenet, D-20251 Hamburg, Germany	University of Hamburg; Heinrich Pette Institute; University of Hamburg	Jucker, M (corresponding author), Univ Hamburg, Klinikum Eppendorf, Zentrum Expt Med, Inst Biochem & Mol Biol 1, Martinistr 52, D-20246 Hamburg, Germany.							ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANDERSON SM, 1990, ONCOGENE, V5, P317; ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; CHANG JM, 1989, BLOOD, V73, P1487; Chao JR, 1997, ONCOGENE, V14, P721, DOI 10.1038/sj.onc.1200884; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DUHRSEN U, 1990, EMBO J, V9, P1087, DOI 10.1002/j.1460-2075.1990.tb08214.x; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GABERT JA, 1994, LEUKEMIA, V8, P1359; GRIFFIN JD, 1986, BLOOD, V68, P1185; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HANNEMANN J, 1995, MOL CELL BIOL, V15, P2402; HEBERLEIN C, 1990, ONCOGENE, V5, P1799; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JUCKER M, 1991, BLOOD, V77, P2413; JUCKER M, 1992, ONCOGENE, V7, P943; Jucker M, 1997, J BIOL CHEM, V272, P2104; JUCKER M, 1995, J BIOL CHEM, V270, P27817; Jucker M, 1997, BLOOD, V89, P2024, DOI 10.1182/blood.V89.6.2024; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; KATZAV S, 1989, ONCOGENE, V4, P1129; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kitayama H, 1996, BLOOD, V88, P995; Klein JB, 2000, J IMMUNOL, V164, P4286, DOI 10.4049/jimmunol.164.8.4286; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LACONIQUE V, 1997, SCIENCE, V278, P1309; LAKER C, 1987, P NATL ACAD SCI USA, V84, P8458, DOI 10.1073/pnas.84.23.8458; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOWENBERG B, 1993, NEW ENGL J MED, V328, P614, DOI 10.1056/NEJM199303043280904; McCormack MP, 1997, BLOOD, V90, P1471, DOI 10.1182/blood.V90.4.1471.1471_1471_1481; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MECKLINGGILL KA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P65, DOI 10.1016/0167-4889(92)90101-G; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Nijhuis E, 2002, J LEUKOCYTE BIOL, V71, P115; NORI M, 1991, MOL CELL BIOL, V11, P2812, DOI 10.1128/MCB.11.5.2812; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; Ostermeyer AG, 1996, EXP HEMATOL, V24, P176; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; PIERCE JH, 1984, P NATL ACAD SCI-BIOL, V81, P2374, DOI 10.1073/pnas.81.8.2374; Prassolov V, 2001, EXP HEMATOL, V29, P756, DOI 10.1016/S0301-472X(01)00648-8; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; SCHRADER JW, 1983, P NATL ACAD SCI-BIOL, V80, P6892, DOI 10.1073/pnas.80.22.6892; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; Steelman LS, 1996, LEUKEMIA, V10, P528; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STOCKING C, 1989, CURR TOP MICROBIOL, V149, P117; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VANBOKHOVEN A, 1992, MOL BIOL REP, V16, P17, DOI 10.1007/BF00788749; WATSON JD, 1987, J IMMUNOL, V139, P123; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; WHEELER EF, 1986, NATURE, V324, P377, DOI 10.1038/324377a0; YOUNG DC, 1986, BLOOD, V68, P1178; ZHOU H, 1990, P NATL ACAD SCI USA, V87, P9128, DOI 10.1073/pnas.87.23.9128	70	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7170	7180		10.1038/sj.onc.1206856	http://dx.doi.org/10.1038/sj.onc.1206856			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562045				2022-12-28	WOS:000185955000008
J	Luo, XQ; Huang, Y; Sheikh, MS				Luo, XQ; Huang, Y; Sheikh, MS			Cloning and characterization of a novel gene PDRG that is differentially regulated by p53 and ultraviolet radiation	ONCOGENE			English	Article						ultraviolet radiation; p53; DNA damage; cell growth; promoter activity	TUMOR-SUPPRESSOR PROTEIN; INDUCED DNA-DAMAGE; WILD-TYPE P53; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; INDUCIBLE CDNA; BINDING; PHOSPHORYLATION; IDENTIFICATION; EXPRESSION	We report the cloning and characterization of a novel p53 and DNA damage-regulated gene (PDRG). The human and mouse PDRG sequences are highly homologous and contain open reading frames of 133 amino acids each with molecular masses of 15.5 and 15.3 kDa, respectively. PDRG codes for a novel protein that does not show similarity to any known protein in the databases. Human PDRG is predominantly expressed in normal testis and exhibits reduced but detectable expression in other organs. GFP-tagged PDRG was predominantly detected as aggregates that appeared to reside in a distinct subcellular compartment. PDRG mRNA was upregulated by ultraviolet radiation (UV) but downregulated by tumor suppressor p53. UV is known to transcriptionally upregulate the expression of certain genes by activating the transcription factor Oct-1, while p53 has been reported to suppress transcription of certain genes by directly binding to a novel head-to-tail response element. Cloning and sequence analysis of PDRG promoter revealed the presence of Oct-1-binding element and a putative head-to-tail-type p53-binding site. Indeed, UV as well as exogenous Oct-1 independently increased PDRG promoter activity, suggesting that UV could mediate PDRG upregulation via Oct-1. Exogenous wild-type p53 was found to downregulate the PDRG promoter activity indicating that wild-type p53 transcriptionally suppresses the expression of PDRG and may mediate its effect via the putative head-to-tail response element. Furthermore, stable expression of exogenous PDRG was found to decrease the clonogenic survival after UV irradiation, which highlights the significance of PDRG in facilitating UV-induced killing.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 12310 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.				NATIONAL CANCER INSTITUTE [R01CA086945, R21CA089043] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER; NCI NIH HHS [CA86945, CA89043] Funding Source: Medline; NIDDK NIH HHS [DK062136] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Desdouets C, 1996, FEBS LETT, V385, P34, DOI 10.1016/0014-5793(96)00330-4; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontanini G, 1999, CLIN CANCER RES, V5, P155; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; Friedberg EC, 2003, NATURE, V421, P436, DOI 10.1038/nature01408; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottifredi V, 2001, MOL CELL BIOL, V21, P1066, DOI 10.1128/MCB.21.4.1066-1076.2001; GU W, 1997, NATURE, V387, P318; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang Y, 2001, CANCER RES, V61, P6918; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Latchman DS, 1999, J CELL PHYSIOL, V179, P126; Lopez CD, 2000, MOL CELL BIOL, V20, P8018, DOI 10.1128/MCB.20.21.8018-8025.2000; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Seker H, 2003, ONCOGENE, V22, P1620, DOI 10.1038/sj.onc.1206140; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1997, J BIOL CHEM, V272, P26720, DOI 10.1074/jbc.272.42.26720; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; Takahashi S, 2001, CANCER RES, V61, P1187; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Wong J, 2002, J BIOL CHEM, V277, P26699, DOI 10.1074/jbc.M203020200; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; Zhao HC, 2000, CANCER RES, V60, P6276; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	50	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7247	7257		10.1038/sj.onc.1207010	http://dx.doi.org/10.1038/sj.onc.1207010			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562055				2022-12-28	WOS:000185955000018
J	Ruivenkamp, CAL; Csikos, T; Klous, AM; van Wezel, T; Demant, P				Ruivenkamp, CAL; Csikos, T; Klous, AM; van Wezel, T; Demant, P			Five new mouse susceptibility to colon cancer loci, Scc11-Scc15	ONCOGENE			English	Article						susceptibility genes; colon cancer; genetic mapping; mouse genetics; AOM	TUMOR-SUSCEPTIBILITY; LINKAGE; MODELS; GENES	Although several genes causing familial cancer syndromes have been identified, susceptibility to sporadic cancer remains unsolved. Animal experiments have demonstrated a large number of quantitative trait loci affecting cancer susceptibility. Previously, we described in mouse strain CcS-19/Dem five susceptibility to colon cancer (Scc) loci, Scc1-Scc5 controlling tumor numbers. In the present study, we performed an independent identical mouse cross using a distinct carcinogen, azoxymethane, to induce colon tumors. We confirmed all five originally described Scc loci and detected five additional new Scc loci; Scc11 Scc15. All these loci were detected in two-way interactions.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Demant, P (corresponding author), Leiden Univ, Med Ctr, Dept Human & Clin Genet, POB 9600, NL-2300 RC Leiden, Netherlands.		van Wezel, Tom/A-9599-2008; van Wezel, Tom/AAL-5626-2021; van Wezel, Tom/Z-3092-2019	van Wezel, Tom/0000-0001-5773-7730; van Wezel, Tom/0000-0001-5773-7730				Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Demant P, 1992, Semin Cancer Biol, V3, P159; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; MOEN CJA, 1992, ONCOGENE, V7, P563; MOEN CJA, 1991, MAMM GENOME, V1, P217, DOI 10.1007/BF00352328; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; van Wezel T, 1999, CANCER RES, V59, P4216; vanWezel T, 1996, NAT GENET, V14, P468, DOI 10.1038/ng1296-468	12	21	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7258	7260		10.1038/sj.onc.1207096	http://dx.doi.org/10.1038/sj.onc.1207096			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562056				2022-12-28	WOS:000185955000019
J	He, Q; Huang, Y; Sheikh, MS				He, Q; Huang, Y; Sheikh, MS			Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells	ONCOGENE			English	Article						Apo2L/TRAIL; death receptor 5; caspases; Bax; proteasome inhibitor cytochrome c; Smac	TRAIL-INDUCED APOPTOSIS; DEPLETION-INDUCED APOPTOSIS; DECOY RECEPTORS; HUMAN COLON; IN-VIVO; AGENTS; FAMILY; LIGAND; DOMAIN; MITOCHONDRIAL	Apo2L/TRAIL (tumor necrosis factor-related apoptosis inducing ligand ( TRAIL), also known as Apo2L) is a potentially important anticancer agent awaiting clinical trials. Unfortunately, however, some cancer cells exhibit resistance to Apo2L/TRAIL, which could limit the use of this potentially promising anticancer agent. Although the molecular basis of the inherent or acquired resistance to Apo2L/TRAIL remains unclear, previous studies indicate that Bax deficiency can confer resistance to Apo2L/TRAIL. Proteasome inhibition is also emerging as a promising therapeutic strategy to manage human malignancies. Here, we report that proteasome inhibitor MG132 upregulates Apo2L/TRAIL death receptor 5 expression in both Bax-proficient and -deficient HCT116 cells. MG132 effectively cooperated with Apo2L/TRAIL to induce apoptosis in both Bax-proficient and -deficient cells that was coupled with caspases-8 and -3 activation and Bid cleavage. Although both agents in combination also induced cytochrome c and Smac release from mitochondria into cytosol and activated caspase-9 in Bax-proficient cells, their effects on these events were significantly diminished in Bax-deficient cells. These results suggest that Bax is not absolutely required for death receptor 5-dependent apoptotic signals and MG132 by upregulating DR5 effectively cooperates with Apo2L/TRAIL to overcome Bax deficiency-induced resistance to Apo2L/TRAIL. Our results have important clinical implications in that the use of Apo2L/TRAIL and proteasome inhibitors in combination could prove to be a novel therapeutic strategy to manage the Apo2L/TRAIL-resistant tumors.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA89043, CA86945] Funding Source: Medline; NIDDK NIH HHS [DK062136] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043, R01CA086945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK062136] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2000, ONCOGENE, V19, P6687, DOI 10.1038/sj.onc.1204088; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Burns TF, 2001, J BIOL CHEM, V276, P37879; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; He Q, 2003, ONCOGENE, V22, P2674, DOI 10.1038/sj.onc.1206363; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; He Q, 2002, ONCOGENE, V21, P2623, DOI 10.1038/sj.onc.1205345; Huang Y, 2001, CANCER RES, V61, P6918; Korsmeyer SJ, 1999, COLD SPRING HARB SYM, V64, P343, DOI 10.1101/sqb.1999.64.343; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagane M, 2000, CANCER RES, V60, P847; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nimmanapalli R, 2001, CANCER RES, V61, P759; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Singh A, 1998, J INTERF CYTOK RES, V18, P439, DOI 10.1089/jir.1998.18.439; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yamaguchi H, 2003, CANCER RES, V63, P1483; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	41	97	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2554	2558		10.1038/sj.onc.1207351	http://dx.doi.org/10.1038/sj.onc.1207351			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691451				2022-12-28	WOS:000220558000013
J	Jang, ER; Lim, SJ; Lee, ES; Jeong, G; Kim, TY; Bang, YJ; Lee, JS				Jang, ER; Lim, SJ; Lee, ES; Jeong, G; Kim, TY; Bang, YJ; Lee, JS			The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen	ONCOGENE			English	Article						estrogen receptor alpha, beta; tamoxifen responsiveness; HDAC inhibitor; ER alpha-negative breast cancer	ER-BETA; TRANSCRIPTIONAL REPRESSION; ACTIVATION FUNCTION-2; BRCA1 INHIBITION; GENE-EXPRESSION; COACTIVATORS; ACETYLATION; MODULATION; PREVENTION; ESTRADIOL	Many cases of breast cancer show loss of estrogen receptor (ER) alpha expression, which leads to unresponsiveness to antihormonal treatment even though there is no loss of the structurally and biochemically similar ER beta. ER activity is positively and negatively regulated by transcriptional regulators such as histone deacetylase (HDAC), which is known to be a negative ER regulator. Here, we evaluated using ER beta as an alternative target for tamoxifen therapy by treating ER alpha-negative, beta-positive breast cancer cells with the HDAC inhibitor trichostatin A (TSA), and testing whether tamoxifen responsiveness increased following upregulation of ER beta. TSA enhanced the overall ER transcriptional activity in these cells, as visualized by estrogen response element-regulated reporter and the expression of progesterone receptor, a known ER target, without ER alpha restoration. Additionally, TSA induced the expression and nuclear translocation of ER beta but not alpha, suggesting that these actions leading to increase of ER transcriptional activity are mediated through ER beta rather than alpha. Furthermore, following treatment with TSA, the formerly unresponsive MDA-MB-231 and Hs578T breast cancer cells became responsive to tamoxifen. However, reduction of ER beta expression by short interfering RNA abrogated this TSA-induced sensitization effect in these cells. Together, these results show that the HDAC inhibitor TSA sensitized ER alpha-negative, antihormone-unresponsive breast cancer cells to tamoxifen treatment possibly by upregulating ER beta activity.	Natl Canc Ctr, Hosp, Goyang Si 411764, Gyeonggi Do, South Korea; Seoul Natl Univ, Coll Nat Sci, Seoul 110799, South Korea; Seoul Natl Univ, Natl Res Lab Canc Epigenet, Inst Canc Res, Coll Med, Seoul 110799, South Korea	National Cancer Center - Korea (NCC); Seoul National University (SNU); Seoul National University (SNU)	Lee, JS (corresponding author), Natl Canc Ctr, Res Inst, 809 Madu 1 Dong, Goyang Si 411764, Gyeonggi Do, South Korea.	leejs@ncc.re.kr	Kim, Tae-You/J-2750-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				Acevedo ML, 2003, MOL CELL BIOL, V23, P335, DOI 10.1128/MCB.23.1.335-348.2003; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chang J, 2000, CLIN CANCER RES, V6, P616; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Ghoshal K, 2002, MOL CELL BIOL, V22, P8302, DOI 10.1128/MCB.22.23.8302-8319.2002; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HEDDEN A, 1995, ANN NY ACAD SCI, V761, P109, DOI 10.1111/j.1749-6632.1995.tb31373.x; Jensen EV, 2001, P NATL ACAD SCI USA, V98, P15197, DOI 10.1073/pnas.211556298; Jordan VC, 2001, ANN NY ACAD SCI, V949, P72; Jung DJ, 2001, J BIOL CHEM, V276, P37280, DOI 10.1074/jbc.M106860200; Kaaks R, 2002, CANCER EPIDEM BIOMAR, V11, P1531; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Levenson AS, 2002, CANCER RES, V62, P4419; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Matsuda KI, 2002, MOL ENDOCRINOL, V16, P2215, DOI 10.1210/me.2002-0110; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Noh EJ, 2003, BIOCHEM BIOPH RES CO, V310, P267, DOI 10.1016/j.bbrc.2003.09.013; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7; Powles TJ, 2002, NAT REV CANCER, V2, P787, DOI 10.1038/nrc908; Scott GK, 2002, MOL CANCER THER, V1, P385; Shi YH, 2001, GENE DEV, V15, P1140, DOI 10.1101/gad.871201; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; Weihua Z, 2002, P NATL ACAD SCI USA, V99, P13589, DOI 10.1073/pnas.162477299; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yang XW, 2001, CANCER RES, V61, P7025; Yang XW, 2000, CANCER RES, V60, P6890	42	138	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1724	1736		10.1038/sj.onc.1207315	http://dx.doi.org/10.1038/sj.onc.1207315			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14676837				2022-12-28	WOS:000220029300008
J	Efimova, EV; Al-Zoubi, AM; Martinez, O; Kaithamana, S; Lu, SF; Arima, T; Prabhakar, BS				Efimova, EV; Al-Zoubi, AM; Martinez, O; Kaithamana, S; Lu, SF; Arima, T; Prabhakar, BS			IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs	ONCOGENE			English	Article						IG20; MADD; DENN-SV; apoptosis; mRNA splicing; tumor	NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; DEATH DOMAIN PROTEIN; KINASE RIP; SIGNALING COMPLEX; NEOPLASTIC-CELLS; TNF; ACTIVATION; ALPHA; MECHANISM	We identified seven putative splice variants of the human IG20 gene. Four variants namely, IG20, MADD, IG20-SV2 and DENN-SV are expressed in human tissues. While DENN-SV is constitutively expressed in all tissues, expression of IG20 appears to be regulated. Interestingly, overexpression of DENN-SV enhanced cell replication and resistance to treatments with TNFalpha, vinblastine, etoposide and gamma-radiation. In contrast, IG20 expression suppressed cell replication and increased susceptibility to the above treatments. Moreover, cells that were resistant and susceptible to TNFalpha-induced apoptosis exclusively expressed endogenous DENN-SV and IG20, respectively. When PA-1 ovarian cancer cells that are devoid of endogenous IG20 variant, but express higher levels of DENN-SV, were transfected with IG20, they showed reduced cell proliferation and increased susceptibility to apoptosis induced by TNFalpha, TRAIL and gamma-radiation. This indicated that overexpression of IG20 can override endogenous DENN-SV function. CrmA reversed the effects of IG20, but not DENN-SV. In contrast, dominant-negative-I-kappa B reversed the effects of DENN-SV, but not IG20, and showed that DENN-SV most likely exerted its effects through NFkappaB activation. Together, our data show that IG20 gene can play a novel and significant role in regulating cell proliferation, survival and death through alternative mRNA splicing.	Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Miltenyi Biotec Inc, Div Mol Biol, Auburn, CA 95602 USA; Human Genome Sci Inc, Dept Lead Dev & Characterizat, Gaithersburg, MD 20878 USA; MeridianLink Inc, Costa Mesa, CA 92626 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; GlaxoSmithKline; Human Genome Sciences Inc	Prabhakar, BS (corresponding author), Univ Illinois, Dept Microbiol & Immunol, M-C 790,Room E-709,Bldg 935,835 S Wolcott Ave, Chicago, IL 60612 USA.	bprabhak@uic.edu		Martinez, Osvaldo/0000-0001-7335-4342				Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Brown TL, 1998, CURR BIOL, V8, pR191; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chow VTK, 1998, GENOME, V41, P543, DOI 10.1139/gen-41-4-543; Chow VTK, 1996, DNA SEQUENCE, V6, P263, DOI 10.3109/10425179609020873; Cunningham SJ, 1996, THESIS U TEXAS MED B; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; GOTO Y, 1992, J BIOL CHEM, V267, P15252; Herbert A, 1999, NAT GENET, V21, P265, DOI 10.1038/6780; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iwasaki K, 2000, EMBO J, V19, P4806, DOI 10.1093/emboj/19.17.4806; Jiang ZH, 1999, P SOC EXP BIOL MED, V220, P64, DOI 10.1046/j.1525-1373.1999.d01-11.x; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Levivier E, 2001, BIOCHEM BIOPH RES CO, V287, P688, DOI 10.1006/bbrc.2001.5652; Lim KM, 2002, MOL CARCINOGEN, V35, P110, DOI 10.1002/mc.10082; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Murakami-Mori K, 1999, J IMMUNOL, V162, P3672; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Schievella AR, 1997, J BIOL CHEM, V272, P12069, DOI 10.1074/jbc.272.18.12069; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Smrcka M, 2003, PHYSIOL RES, V52, P117; Telliez JB, 2000, BBA-PROTEIN STRUCT M, V1478, P280, DOI 10.1016/S0167-4838(00)00029-7; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Varfolomeev EE, 1996, J EXP MED, V183, P1271, DOI 10.1084/jem.183.3.1271; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zhang Y, 1998, P NATL ACAD SCI USA, V95, P2586, DOI 10.1073/pnas.95.5.2586	38	33	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1076	1087		10.1038/sj.onc.1207210	http://dx.doi.org/10.1038/sj.onc.1207210			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14716293				2022-12-28	WOS:000188749900006
J	Wang, W; Ungermannova, D; Jin, JP; Harper, JW; Liu, XD				Wang, W; Ungermannova, D; Jin, JP; Harper, JW; Liu, XD			Negative regulation of SCFSkp2 ubiquitin ligase by TGF-beta signaling	ONCOGENE			English	Article						Skp2; p27(Kip1); TGF-beta; protein degradation; ubiquitin; Cdc34 and Cks1	ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE ARREST; BOX PROTEIN SKP2; DEPENDENT KINASE; GROWTH-INHIBITION; MAMMALIAN-CELLS; CDK INHIBITORS; HUMAN CUL-1; S-PHASE; DEGRADATION	TGF-beta is a multifunctional growth factor whose best-known function is to inhibit cell growth and suppress tumor formation. TGF-beta causes cells to accumulate in mid-to-late G1 phase by blocking the transition from G1 to S. It has been shown that TGF-beta inhibits Cdk2-cyclin E kinase activity by promoting the binding of cell cycle inhibitor p27(Kip1) to the kinase complexes. Here, we show that TGF-beta treatment leads to stabilization of p27(Kip1) during G1 to S transition. We found that TGF-beta negatively regulates components of the SCF complex, which degrades the p27(Kip1) during the G1 to S transition, through two distinct mechanisms. Using a pulse-chase analysis, we demonstrated that the stability of Skp2 decreases in the presence of TGF-beta. Destabilization of Skp2 by ubiquitin-mediated proteolysis was also demonstrated that in an in vitro degradation system, using cell extracts prepared from TGF-beta-treated cultured cells. In addition, TGF-beta treatment decreases the levels of Cks1 mRNA. The deficiency of Cks1 in TGF-beta-treated cells likely contributes to the stabilization of p27(Kip1) and destabilization of Skp2, because in the absence of Cks1, SCFSkp2 cannot ubiquitinate p27(Kip1); instead, self-ubiquitination of Skp2 occurs. Thus, stabilization of the cell cycle inhibitor p27(Kip1) and cell growth inhibition in response to TGF-beta occur in part through limiting the threshold of the SCFSkp2 ubiquitin ligase by transcriptional and post-transcriptional mechanisms.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA	University of Colorado System; University of Colorado Boulder; Baylor College of Medicine	Liu, XD (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.	xuedong.liu@colorado.edu	Jin, Jianping/K-5002-2018	Jin, Jianping/0000-0003-4175-9104; LIU, XUEDONG/0000-0001-7209-4964; Harper, Jeffrey/0000-0002-6944-7236	NCI NIH HHS [CA95527-01, R01 CA095527] Funding Source: Medline; NIA NIH HHS [R01 AG011085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095527] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; Dow R, 2001, J BIOL CHEM, V276, P45945, DOI 10.1074/jbc.M103593200; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Iavarone A, 1997, NATURE, V387, P417; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Liu XD, 2000, ANAL BIOCHEM, V280, P20, DOI 10.1006/abio.2000.4478; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Lyapina SA, 1998, P NATL ACAD SCI USA, V95, P7451, DOI 10.1073/pnas.95.13.7451; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakayama K, 2001, BIOCHEM BIOPH RES CO, V282, P853, DOI 10.1006/bbrc.2001.4627; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; SIMON KE, 1995, CELL GROWTH DIFFER, V6, P1261; Sitry D, 2002, J BIOL CHEM, V277, P42233, DOI 10.1074/jbc.M205254200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2003, J BIOL CHEM, V278, P32390, DOI 10.1074/jbc.M305241200; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	59	39	40	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1064	1075		10.1038/sj.onc.1207204	http://dx.doi.org/10.1038/sj.onc.1207204			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14676846				2022-12-28	WOS:000188749900005
J	Sugihara, E; Kanai, M; Matsui, A; Onodera, M; Schwab, M; Miwa, M				Sugihara, E; Kanai, M; Matsui, A; Onodera, M; Schwab, M; Miwa, M			Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells	ONCOGENE			English	Article						MYCN; centrosome; micronuclei; DNA damage	GENETIC INSTABILITY; N-MYC; AMPLIFICATION; CYCLE; P53; OVERDUPLICATION; ABNORMALITIES; DUPLICATION; DEFECTS; ABSENCE	Centrosomes play important roles in cell polarity, regulation of cell cycle and chromosomal stability. Centrosome abnormality is frequently found in many cancers and contributes to chromosomal instability (including aneuploidy, tetraploidy, and/or micronuclei) in daughter cells through the assembly of multipolar or monopolar spindles during mitosis. It has recently been reported that loss of tumor suppressor genes or overexpression of oncogenes causes centrosome hyperamplification. Amplification and overexpression of the MYCN oncogene is found in a subgroup of neuroblastomas. In this study, we examined whether overexpression of MYCN causes centrosome hyperamplification in neuroblastoma cells. We show that ectopic expression of MYCN alone in a neuroblastoma cell line did not cause centrosome hyperamplification. However, centrosome hyperamplification and micronuclei formation were seen in these cells after DNA damage. These findings suggest that overexpression of MYCN abrogates the regulation of the centrosome cycle after DNA damage.	Univ Tsukuba, Inst Basic Med Sci, Dept Biochem & Mol Oncol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 305, Japan; Deutsch Krebsforschungszentrum, Dept Tumour Genet B030, D-69120 Heidelberg, Germany; Univ Tsukuba, Inst Clin Med, Dept Hematol, Tsukuba, Ibaraki 305, Japan	University of Tsukuba; University of Tsukuba; Helmholtz Association; German Cancer Research Center (DKFZ); University of Tsukuba	Miwa, M (corresponding author), Univ Tsukuba, Inst Basic Med Sci, Dept Biochem & Mol Oncol, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058575, Japan.	m-miwa@md.tsukuba.ac.jp	Sugihara, Eiji/J-8058-2013	Sugihara, Eiji/0000-0002-3233-1045				BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chernova OB, 1998, MOL CELL BIOL, V18, P536, DOI 10.1128/MCB.18.1.536; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Fukasawa K, 2002, ONCOGENE, V21, P6140, DOI 10.1038/sj.onc.1205771; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GILBERT F, 1982, CANCER GENET CYTOGEN, V7, P33, DOI 10.1016/0165-4608(82)90105-4; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lutz W, 1996, ONCOGENE, V13, P803; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Pihan GA, 1998, CANCER RES, V58, P3974; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; Sato N, 2000, ONCOGENE, V19, P5281, DOI 10.1038/sj.onc.1203902; Sato N, 1999, CLIN CANCER RES, V5, P963; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Suzuki A, 2002, J NEUROCHEM, V82, P953, DOI 10.1046/j.1471-4159.2002.01048.x; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Wartiovaara K, 2002, J NEUROSCI, V22, P815, DOI 10.1523/JNEUROSCI.22-03-00815.2002; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	33	15	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1005	1009		10.1038/sj.onc.1207216	http://dx.doi.org/10.1038/sj.onc.1207216			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647433				2022-12-28	WOS:000188486600017
J	Cuenco, GM; Ren, RB				Cuenco, GM; Ren, RB			Both AML1 and EVI1 oncogenic components are required for the cooperation of AML1/MDS1/EVI1 with BCR/ABL in the induction of acute myelogenous leukemia in mice	ONCOGENE			English	Article						acute myelogenous leukemia (AML); AML1/MDS1/EVI1; BCR/ABL; EVI1; RUNX1	ACUTE MYELOID-LEUKEMIA; T(3/21) FUSION PRODUCT; TRANSCRIPTION FACTOR; BCR-ABL; MYELOPROLIFERATIVE DISEASE; GROWTH-INHIBITION; GENE CBFB-MYH11; RAPID INDUCTION; PR DOMAIN; EXPRESSION	We have previously shown that BCR/ABL, a fusion protein generated by the t(9;22)(q34;q11) translocation found in the vast majority of chronic myelogenous leukemia (CML), cooperates with AML1/MDS1/EVI1 (AME), a fusion transcription factor generated by a t(3;21)(q26;q22) translocation identified as a secondary mutation in some cases of CML during the blast phase (CML-BC), in the rapid induction of an acute myelogenous leukemia (AML) in mice. In this study, we evaluated the leukemogenic potential of EVI1-, MDS1/EVI1- and AML1-related oncoproteins (AML1Delta, AML1/MDS1). We found that ectopic expression of either EVI1 or MDS1/EVI1 impaired hematopoiesis. However, neither EVI1 nor MDS1/EVI1 was sufficient for inducing AML in mice, although EVI1 did induce some hematologic neoplasia other than AML with a low efficiency. In addition, unlike AME, none of the EVI1- or AML1-related oncoproteins examined were capable of fully cooperating with BCR/ABL in the induction of AML. The results indicate that both the AML1 and EVI1 oncogenic components are required for the leukemogenic potential of AME and for the cooperation of AME and BCR/ABL in the induction of AML.	Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA.	ren@brandeis.edu			NCI NIH HHS [CA68008] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; ERICKSON PF, 1994, CANCER RES, V54, P1782; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fears S, 1996, P NATL ACAD SCI USA, V93, P1642, DOI 10.1073/pnas.93.4.1642; FIALKOW PJ, 1991, BLOOD, V77, P1415; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Izutsu K, 2002, ONCOGENE, V21, P2695, DOI 10.1038/sj.onc.1205356; JACOBS A, 1991, LEUKEMIA, V5, P277; Kojima K, 1999, BRIT J HAEMATOL, V106, P720, DOI 10.1046/j.1365-2141.1999.01588.x; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; Kurokawa M, 1998, BLOOD, V92, P4003, DOI 10.1182/blood.V92.11.4003.423a56_4003_4012; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Langabeer SE, 2001, BRIT J HAEMATOL, V112, P208, DOI 10.1046/j.1365-2141.2001.02569.x; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Louz D, 2000, LEUKEMIA, V14, P1876, DOI 10.1038/sj.leu.2401887; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; Myint H, 1997, LEUKEMIA RES, V21, P473, DOI 10.1016/S0145-2126(97)00070-2; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; Nucifora G, 1997, LEUKEMIA, V11, P2022, DOI 10.1038/sj.leu.2400880; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Phillips RL, 2000, SCIENCE, V288, P1635, DOI 10.1126/science.288.5471.1635; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; Scandura JM, 2002, ONCOGENE, V21, P3422, DOI 10.1038/sj.onc.1205315; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	41	40	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					569	579		10.1038/sj.onc.1207143	http://dx.doi.org/10.1038/sj.onc.1207143			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724585				2022-12-28	WOS:000188098300028
J	Nony, P; Gaude, H; Rossel, M; Fournier, L; Rouault, JP; Billaud, M				Nony, P; Gaude, H; Rossel, M; Fournier, L; Rouault, JP; Billaud, M			Stability of the Peutz-Jeghers syndrome kinase LKB1 requires its binding to the molecular chaperones Hsp90/Cdc37	ONCOGENE			English	Article						LKB1; Peutz-Jeghers; tumor suppressor; Hsp90	SERINE/THREONINE PROTEIN-KINASE; TUMOR-SUPPRESSOR; GENE LKB1; CANCER; HSP90; IDENTIFICATION; MUTATIONS; CHIP; LKB1/STK11; DESTABILIZATION	Peutz-Jeghers syndrome (PJS) is an autosomal dominant disorder characterized by the presence of multiple gastrointestinal polyps and an increased risk for various types of cancers. Inactivating germline mutations of the LKB1 gene, which encodes a serine/threonine kinase, are responsible for the majority of PJS cases. Here, we show that the heteromeric complex containing the molecular chaperones Hsp90 and Cdc37/p50 interacts with the kinase domain of LKB1. Treatment of cells with either geldanamycin or novobiocin, two pharmacological inhibitors of Hsp90 causes the destabilization of LKB1. Furthermore, geldanamycin treatment leads to the ubiquitination and the rapid degradation of LKB1 by the proteasome-dependent pathway. In addition, we found that a LKB1 point mutation identified in a sporadic testicular cancer, weakens the interaction of LKB1 with both Hsp90 and Cdc37/p50 and enhances its sensitivity to the destabilizing effect of geldanamycin. Collectively, our results demonstrate that the Hsp90/Cdc37 complex is a major regulator of the stability of the LKB1 tumor suppressor. Furthermore, these data draw attention to the possible adverse consequences of antitumor drugs that target Hsp90, such as antibiotics related to geldanamycin, which could disrupt LKB1 function and promote the development of polyps and carcinomatous lesions.	Lab Genet & Canc, FRE 2692, F-69373 Lyon 08, France; Hop Debrousse, INSERM, U418, INRA UA 953,Lab Commun Cellulaires & Differenciat, F-69322 Lyon 05, France; Ecole Prat Hautes Etud, INSERM, E0343, Lab Biol Cellulaire Quantit, F-34095 Montpellier 05, France	CHU Lyon; INRAE; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Universite de Montpellier	Billaud, M (corresponding author), Lab Genet & Canc, FRE 2692, Domaine Rockefeller,8 Ave Rockefeller, F-69373 Lyon 08, France.	billaud@univ-lvon1.fr	Billaud, Marc N/M-6954-2013	Rossel, Mireille/0000-0003-2275-0817				Avizienyte E, 1999, AM J PATHOL, V154, P677, DOI 10.1016/S0002-9440(10)65314-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Blumer JB, 2003, J BIOL CHEM, V278, P23217, DOI 10.1074/jbc.C200686200; BOUDEAU J, 2002, BIOCHEM J, V19, P849; Ciechanover A, 1998, P NATL ACAD SCI USA, V95, P2727, DOI 10.1073/pnas.95.6.2727; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hunter T, 1997, TRENDS CELL BIOL, V7, P157, DOI 10.1016/S0962-8924(97)01027-1; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jishage K, 2002, P NATL ACAD SCI USA, V99, P8903, DOI 10.1073/pnas.122254599; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Liu WK, 2003, J BIOMED SCI, V10, P242, DOI 10.1159/000068708; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Miyata Y, 2001, J BIOL CHEM, V276, P21841, DOI 10.1074/jbc.M010944200; Miyoshi H, 2002, CANCER RES, V62, P2261; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Olschwang S, 2001, J MED GENET, V38, P356, DOI 10.1136/jmg.38.6.356; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Perdew GH, 1997, BIOCHEMISTRY-US, V36, P3600, DOI 10.1021/bi9612529; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Smith DP, 1999, HUM MOL GENET, V8, P1479, DOI 10.1093/hmg/8.8.1479; Smith DP, 2001, HUM MOL GENET, V10, P2869, DOI 10.1093/hmg/10.25.2869; SPIGELMAN AD, 1989, GUT, V30, P1588, DOI 10.1136/gut.30.11.1588; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; TOFT DO, 1999, CONTROL HORMONE RECE; Watts JL, 2000, DEVELOPMENT, V127, P1467; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Ylikorkala A, 1999, HUM MOL GENET, V8, P45, DOI 10.1093/hmg/8.1.45; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	55	45	46	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2003	22	57					9165	9175		10.1038/sj.onc.1207179	http://dx.doi.org/10.1038/sj.onc.1207179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668798	Bronze			2022-12-28	WOS:000187149100007
J	Smith, SL; Watson, SG; Ratschiller, D; Gugger, M; Betticher, DC; Heighway, J				Smith, SL; Watson, SG; Ratschiller, D; Gugger, M; Betticher, DC; Heighway, J			Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions	ONCOGENE			English	Article						serpin; maspin; immunohistochemistry; lung cancer; preneoplastic	CELL CARCINOMA ANTIGEN; TUMOR-SUPPRESSOR; BREAST-CANCER; OVEREXPRESSION; INHIBITION; P53; METASTASIS; EPITHELIA; HEADPIN	Maspin, SCCA1/2 and hurpin were identified by cDNA microarray analyses as dramatically differentially expressed transcripts in primary non-small cell lung cancer (NSCLC). These sequences are located within a 10-gene serpin cluster on 18q21.3. Using comparative RT-PCR, we have investigated the expression of each of these serpins, including their flanking loci, in an independent NSCLC series. Whereas six of the genes (maspin, SCCA1, SCCA2, hurpin, megsin and pAI-2) were commonly differentially expressed in primary lesions, each significantly more often in squamous cell tumours, maspin was identified as the most frequently over-represented sequence in both squamous cell carcinoma and adenocarcinoma. Using a well-characterized monoclonal antibody, we have shown strong maspin expression in tumour protein extracts, detected multiple isoforms of the 42 kDa protein and shown that maspin is localized specifically to the tumour cells within neoplastic lesions. In contrast, most cells in non-neoplastic lung tissue appear not to express the gene, with the exception of the multipotent basal epithelial cells that line the bronchial airway. These reserve cells generally show strong predominantly nuclear localization of maspin. Strong nuclear expression of maspin within primary tumour cells is correlated with increased survival (P = 0.05) and a longer remission duration (P = 0.02) in resectable-staged patients. However, within the airways of cancer patients and somewhat in contrast to this observation, such expression was more frequently detected in the superficial cells of preneoplastic over non-neoplastic epithelia (P < 0.0001), consistent with a role for the protein in early neoplasia.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, Liverpool L3 9TA, Merseyside, England; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland	University of Liverpool; University of Bern	Heighway, J (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, 200 London Rd, Liverpool L3 9TA, Merseyside, England.	heighwayj@roycastle.liv.ac.uk	Betticher, Daniel C/G-5849-2013					Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Bass R, 2002, J BIOL CHEM, V277, P46845, DOI 10.1074/jbc.C200532200; Betticher DC, 1997, BRIT J CANCER, V75, P1761, DOI 10.1038/bjc.1997.300; Biliran H, 2001, CANCER RES, V61, P8676; Borner MM, 1999, BRIT J CANCER, V79, P952, DOI 10.1038/sj.bjc.6690152; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Cataltepe S, 2000, J HISTOCHEM CYTOCHEM, V48, P113, DOI 10.1177/002215540004800112; Champelovier P, 2001, EUR UROL, V39, P343, DOI 10.1159/000052465; Duggan C, 1997, BRIT J CANCER, V76, P622, DOI 10.1038/bjc.1997.435; Fujita T, 1999, INT J ONCOL, V15, P927; HAMADA K, 2001, BIOCHIM BIOPHYS ACTA, V19, P124; Heighway J, 2002, ONCOGENE, V21, P7749, DOI 10.1038/sj.onc.1205979; Heighway Jim, 2003, Methods Mol Med, V75, P291; Jayakumar A, 2003, ARCH BIOCHEM BIOPHYS, V409, P367, DOI 10.1016/S0003-9861(02)00635-5; Kato H., 1992, SEROLOGICAL CANC MAR, P437; Kishimoto H, 2001, INT J ONCOL, V18, P297; Maass N, 2001, J PATHOL, V195, P321; Maass N, 2001, CLIN BIOCHEM, V34, P303, DOI 10.1016/S0009-9120(01)00220-X; Miyata T, 2002, J CLIN INVEST, V109, P585, DOI 10.1172/JCI200214336; Mohsin SK, 2003, J PATHOL, V199, P432, DOI 10.1002/path.1319; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; Murakami A, 2000, TUMOR BIOL, V21, P224, DOI 10.1159/000030128; Nakashima T, 2000, BBA-GENE STRUCT EXPR, V1492, P441, DOI 10.1016/S0167-4781(00)00100-7; PEMBERTON PA, 1995, J BIOL CHEM, V270, P15832, DOI 10.1074/jbc.270.26.15832; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Pierson CR, 2002, PROSTATE, V53, P255, DOI 10.1002/pros.10107; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Ratschiller D, 2003, J CLIN ONCOL, V21, P2085, DOI 10.1200/JCO.2003.03.103; Reis JS, 2002, J PATHOL, V197, P272, DOI 10.1002/path.1104; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; SCHNEIDER SS, 1995, P NATL ACAD SCI USA, V92, P3147, DOI 10.1073/pnas.92.8.3147; Shi HY, 2001, CANCER RES, V61, P6945; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Stenman J, 2001, INT J CANCER, V95, P39, DOI 10.1002/1097-0215(20010120)95:1<39::AID-IJC1007>3.0.CO;2-N; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; Travis WD, 1999, HISTOLOGICAL TYPING; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; VERSPAGET HW, 1995, EUR J CANCER, V31A, P1105, DOI 10.1016/0959-8049(95)00170-N; Yasumatsu R, 2001, HEAD NECK-J SCI SPEC, V23, P962, DOI 10.1002/hed.1139; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	60	68	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8677	8687		10.1038/sj.onc.1207127	http://dx.doi.org/10.1038/sj.onc.1207127			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647462				2022-12-28	WOS:000186844900005
J	Mishra, S; Reichert, A; Cunnick, J; Senadheera, D; Hemmeryckx, B; Heisterkamp, N; Groffen, J				Mishra, S; Reichert, A; Cunnick, J; Senadheera, D; Hemmeryckx, B; Heisterkamp, N; Groffen, J			Protein kinase CKII alpha interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cells	ONCOGENE			English	Article						Bcr; Bcr/Abl P190; CKII alpha; acute lymphoblastic leukemia; TBB	ABL ONCOPROTEIN; TRANSGENIC MICE; OLIGOMERIZATION DOMAIN; CATALYTIC SUBUNIT; TYROSINE KINASES; CASEIN KINASE-2; II-ALPHA; CK2; TRANSFORMATION; LEUKEMIA	The Bcr protein was originally identified because of its fusion to Abl as a consequence of the Philadelphia chromosome translocation found in chronic myelogenous and acute lymphoblastic leukemias. The Bcr moiety is essential for the transforming activity of the Bcr/Abl oncogene. In search of physiologically relevant Bcr and Bcr/Abl-interacting proteins, we performed an interaction screen in yeast using the entire Bcr protein as bait. We here report that the alpha catalytic subunit of protein kinase CKII strongly and specifically forms a complex with Bcr in yeast in mouse lysates. The region in Bcr responsible for CKIIalpha binding was localized to residues 242-413. CKIIalpha was previously shown to be involved in leukemogenesis and tumorigenesis using different experimental approaches including mouse models. Inhibition of Bcr/Abl P190 in lymphoma cells from Bcr/Abl transgenic mice using imatinib reduced CKIIalpha activity. A highly selective inhibitor of CKIIalpha, 4,5,6,7-tetrabromo-2-benzotriazole, inhibited the growth of murine lymphoid cells with induced P210 Bcr/Abl expression and of P190 lymphoma cells. Our results demonstrate that CKIIalpha plays an important role in the proliferation of Bcr/Abl expressing cells, and suggests that inhibitors of CKIIalpha may have therapeutic potential in the treatment of Bcr/Abl-positive leukemia patients.	Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Groffen, J (corresponding author), Childrens Hosp Los Angeles, Res Inst, Div Hematol Oncol, Sect Mol Carcinogenesis, Ms 54,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Cunnick, Jess/F-1715-2018; Hemmeryckx, Bianca/AAR-2360-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273	NATIONAL CANCER INSTITUTE [R01CA090321, R01CA050248] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50248, CA 90321] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Battistutta R, 2001, PROTEIN SCI, V10, P2200, DOI 10.1110/ps.19601; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; De Langhe S, 2002, INT J MOL MED, V9, P451; Deininger MWN, 2003, J CLIN ONCOL, V21, P1637, DOI 10.1200/JCO.2003.11.143; Donella-Deana A, 2003, BIOCHEM J, V372, P841, DOI 10.1042/BJ20021905; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; FIORETOS T, 1995, CELL MOL BIOL RES, V41, P97; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Guerra B, 1999, FEBS LETT, V462, P353, DOI 10.1016/S0014-5793(99)01553-7; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Haataja L, 1998, INT J MOL MED, V1, P665; Hawk N, 2002, CANCER RES, V62, P386; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 2001, CHRONIC MYELOID LEUK, P3; Heriche JK, 1998, ONCOGENE, V17, P13, DOI 10.1038/sj.onc.1201900; Kaartinen V, 2001, DEVELOPMENT, V128, P4217; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Landesman-Bollag E, 1998, ONCOGENE, V16, P2965, DOI 10.1038/sj.onc.1201854; Laurent E, 2001, CANCER RES, V61, P2343; Lebrin F, 2001, ONCOGENE, V20, P2010, DOI 10.1038/sj.onc.1204307; Ling XY, 2003, CANCER RES, V63, P298; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Ma GZ, 1997, ONCOGENE, V14, P2367, DOI 10.1038/sj.onc.1201053; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Orlandini M, 1998, J BIOL CHEM, V273, P21291, DOI 10.1074/jbc.273.33.21291; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Pinna LA, 2003, ACCOUNTS CHEM RES, V36, P378, DOI 10.1021/ar020164f; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rifkin IR, 1998, J IMMUNOL, V161, P5164; Rudert F, 1996, GENE, V169, P281, DOI 10.1016/0378-1119(95)00820-9; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; SELDIN DC, 1995, SCIENCE, V267, P894, DOI 10.1126/science.7846532; Senadheera D, 2001, INT J MOL MED, V8, P127; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1992, CANCER RES, V52, P4534; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang Y, 2001, CANCER RES, V61, P138; Xu X, 1999, NAT GENET, V23, P118, DOI 10.1038/12729; Xu X, 1999, MOL CELL BIOCHEM, V191, P65, DOI 10.1023/A:1006866412652; Zhao X, 2002, NAT STRUCT BIOL, V9, P117	46	41	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8255	8262		10.1038/sj.onc.1207156	http://dx.doi.org/10.1038/sj.onc.1207156			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614449				2022-12-28	WOS:000186541500004
J	Denizot, Y; Gainant, A; Guglielmi, L; Bouvier, S; Cubertafond, P; Mathonnet, M				Denizot, Y; Gainant, A; Guglielmi, L; Bouvier, S; Cubertafond, P; Mathonnet, M			Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients	ONCOGENE			English	Article						acetylhydrolase activity; colorectal carcinoma; phospholipase A2; platelet-activating factor; receptor	HUMAN BREAST-CANCER; FACTOR ACETYLHYDROLASE; FACTOR RECEPTOR; TUMOR-CELLS; FACTOR PAF; EXPRESSION; PROLIFERATION; ANGIOGENESIS; METABOLISM; PROTEIN	The lipid mediator platelet-activating factor (PAF) plays a role in cancer. We investigated its presence in human colon carcinoma by assessing the levels of tissue phospholipase A(2) (PLA(2), the key enzyme in the generation of the lyso-PAF precursor), lyso-PAF, PAF and acetylhydrolase activity (AHA, the key enzyme in PAF degradation) in colorectal cancer patients and by correlating them with Dukes' classification. The results highlighted that the tumour tissues of Dukes' A and B patients had significantly higher PLA(2), lyso-PAF, PAF and AHA levels as compared with nontumour tissues. Dukes' C patients had higher PLA(2), lyso-PAF and AHA levels but unchanged PAF. Dukes' D patients had higher AHA levels but unchanged PLA(2), lyso-PAF and PAF. A pathophysiological role for PAF is suggested in human colon carcinoma.	Fac Med Limoges, CNRS, UMR 6101, Immunol Lab, F-87025 Limoges, France; Serv Chirurg Digest Endocrinienne & Gen, F-87042 Limoges, France	Centre National de la Recherche Scientifique (CNRS)	Denizot, Y (corresponding author), Fac Med Limoges, CNRS, UMR 6101, Immunol Lab, 2 Rue Dr Marcland, F-87025 Limoges, France.		Mathonnet, Muriel/ABD-3021-2020; Denizot, Yves/H-9769-2016	Mathonnet, Muriel/0000-0002-9127-3068; Guglielmi, Laurence/0000-0003-2517-4616				Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; CAPASSO F, 1991, DRUG EXP CLIN RES, V17, P351; Chaux P, 1996, LAB INVEST, V74, P975; DENIZOT Y, 1997, HDB EXPT PHARM PLATE, P483; Dueck DA, 1996, MOL CELL BIOCHEM, V162, P97; Dupuis F, 1997, BBA-MOL CELL RES, V1359, P241, DOI 10.1016/S0167-4889(97)00106-7; Ellis L M, 2000, Oncologist, V5 Suppl 1, P11; Fallani A, 2002, PROSTAG OTH LIPID M, V70, P209, DOI 10.1016/S0090-6980(02)00109-0; HENDRICKSE CW, 1995, BRIT J SURG, V82, P475, DOI 10.1002/bjs.1800820415; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; Kald B, 1996, DIGESTION, V57, P472, DOI 10.1159/000201376; Kennedy BP, 1998, CANCER RES, V58, P500; Ko HM, 2002, CANCER RES, V62, P1809; MAGGI M, 1994, CANCER RES, V54, P4777; Mannori G, 2000, CLIN EXP METASTAS, V18, P89, DOI 10.1023/A:1026548700247; Montrucchio G, 1998, AM J PATHOL, V153, P1589, DOI 10.1016/S0002-9440(10)65747-1; Ono T, 2000, AM J GASTROENTEROL, V95, P1062; Shetye J, 1998, CLIN CANCER RES, V4, P1921; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TRIPATHI YB, 1991, LIFE SCI, V49, P1761, DOI 10.1016/0024-3205(91)90319-7; Wang HM, 2003, ONCOGENE, V22, P2186, DOI 10.1038/sj.onc.1206348; Youlyouz I, 2002, MEDIAT INFLAMM, V11, P329, DOI 10.1080/09629350210000015755	24	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7222	7224		10.1038/sj.onc.1207032	http://dx.doi.org/10.1038/sj.onc.1207032			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562051				2022-12-28	WOS:000185955000014
J	Seales, EC; Jurado, GA; Singhal, A; Bellis, SL				Seales, EC; Jurado, GA; Singhal, A; Bellis, SL			Ras oncogene directs expression of a differentially sialylated, functionally altered beta 1 integrin	ONCOGENE			English	Article						integrin; ras; collagen; glycosylation; sialic acid	CELL-ADHESION RECEPTORS; INTEGRIN ACTIVATION; FIBRONECTIN RECEPTORS; HA-RAS; BETA(1) INTEGRINS; EPITHELIAL-CELLS; N-GLYCOSYLATION; CANCER CELLS; R-RAS; SIALYLTRANSFERASE	Intense investigation has centered on understanding the regulation of integrin cell adhesion receptors. In the present study, we propose that variant N-glycosylation represents an important mechanism for regulation of beta1, but not beta3 or beta5 integrins. We find that expression of oncogenic ras in HD3 colonocytes causes increased alpha2-6 sialylation of b1 integrins, whereas expression of dominant-negative ras induces decreased alpha2-6 sialylation, relative to cells with wild-type ras. In contrast, neither beta3 nor beta5 integrins are alpha2-6 sialylated, regardless of the state of ras activation. Results from RT-PCR analyses suggest that differential integrin sialylation is due to a ras-dependent alteration in the expression of ST6Gal I, the enzyme that adds alpha2-6-linked sialic acids. Cells that express differentially sialylated beta1 integrins exhibit altered adhesion to collagen I (a beta ligand), but not to vitronectin (a beta3 or beta5 ligand). Similarly, the enzymatic removal of cell surface sialic acids from control cells alters binding to collagen, but not to vitronectin. Finally, using a cell-free receptor/ligand-binding assay, we show that purified, desialylated alpha1beta1 integrins have diminished collagen-binding capability, providing strong evidence that sialic acids play a causal role in regulating b1 integrin function.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Bellis, SL (corresponding author), Univ Alabama, Dept Physiol & Biophys, Room 982A MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.				NCI NIH HHS [R01CA84248] Funding Source: Medline; NIAMS NIH HHS [5 P60 AR20614-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKIYAMA SK, 1989, J BIOL CHEM, V264, P18011; Aplin AE, 1998, PHARMACOL REV, V50, P197; Asada M, 1997, CANCER RES, V57, P1073; Bellis SL, 1999, J CELL PHYSIOL, V181, P33, DOI 10.1002/(SICI)1097-4652(199910)181:1<33::AID-JCP4>3.0.CO;2-#; Braut-Boucher F, 1998, LEUKEMIA RES, V22, P947, DOI 10.1016/S0145-2126(98)00094-0; DALLOLIO F, 1989, INT J CANCER, V44, P434; EASTON EW, 1991, J BIOL CHEM, V266, P21674; Gangopadhyay A, 1998, HYBRIDOMA, V17, P117, DOI 10.1089/hyb.1998.17.117; GESSNER P, 1993, CANCER LETT, V75, P143, DOI 10.1016/0304-3835(93)90056-F; Guo HB, 2002, CANCER RES, V62, P6837; HEINO J, 1989, J BIOL CHEM, V264, P380; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Jasiulionis MG, 1996, CANCER RES, V56, P1682; KIM LT, 1992, J CELL SCI, V103, P743; Kinashi T, 2000, J BIOL CHEM, V275, P22590, DOI 10.1074/jbc.M000633200; LEMARER N, 1995, GLYCOBIOLOGY, V5, P219, DOI 10.1093/glycob/5.2.219; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LENTER M, 1994, J BIOL CHEM, V269, P12263; LEPPA S, 1995, CELL GROWTH DIFFER, V6, P853; LI M, 1995, CLIN SCI, V89, P397, DOI 10.1042/cs0890397; Lise M, 2000, HYBRIDOMA, V19, P281, DOI 10.1089/027245700429828; Ma JY, 1999, J BIOL CHEM, V274, P8046, DOI 10.1074/jbc.274.12.8046; MOSS L, 1994, GLYCOBIOLOGY, V4, P567, DOI 10.1093/glycob/4.5.567; OZ OK, 1989, INT J CANCER, V44, P343, DOI 10.1002/ijc.2910440226; Praetorius J, 2002, EXP CELL RES, V276, P52, DOI 10.1006/excr.2002.5516; Pretzlaff RK, 2000, CELL ADHES COMMUN, V7, P491, DOI 10.3109/15419060009040306; Recchi MA, 1998, CANCER RES, V58, P4066; SATA T, 1991, AM J PATHOL, V139, P1435; Semel AC, 2002, J BIOL CHEM, V277, P32830, DOI 10.1074/jbc.M202493200; SYMINGTON BE, 1989, J BIOL CHEM, V264, P13258; VANDAMME V, 1992, BIOCHIMIE, V74, P89, DOI 10.1016/0300-9084(92)90188-K; VANDEWATER L, 1988, CANCER RES, V48, P5730; VEIGA SS, 1995, INT J CANCER, V61, P420, DOI 10.1002/ijc.2910610324; VONLAMPE B, 1993, GUT, V34, P829, DOI 10.1136/gut.34.6.829; WADSWORTH S, 1993, J IMMUNOL, V150, P847; Woodside DG, 2001, THROMB HAEMOSTASIS, V86, P316, DOI 10.1055/s-0037-1616229; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHENG MZ, 1994, J BIOL CHEM, V269, P12325; Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8	40	105	111	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7137	7145		10.1038/sj.onc.1206834	http://dx.doi.org/10.1038/sj.onc.1206834			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562042				2022-12-28	WOS:000185955000005
J	Lee, M; Daniels, MJ; Venkitararnan, AR				Lee, M; Daniels, MJ; Venkitararnan, AR			Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression	ONCOGENE			English	Article						BRCA2; polo; DNA repair; mitosis	CANCER SUSCEPTIBILITY GENE; HUMAN BREAST-CANCER; CELL-CYCLE; PROGNOSTIC-SIGNIFICANCE; PROTEIN-KINASE; RAD51 PROTEIN; EXPRESSION; RECOMBINATION; ACTIVATION; PROPHASE	The breast cancer susceptibility protein, BRCA2, preserves chromosomal stability through roles in the repair of DNA double-strand breaks, and possibly, cell division. Post-translational modifications that may coordinate these functions remain poorly characterized. Here, we report that BRCA2 is a substrate for the mitotic Polo-like kinase, Plk1. BRCA2 undergoes phosphorylation in cells synchronously passing through the G2/M phases of cell cycle, when Plk1 expression and activity are maximal. Depletion of Plk1 by RNA interference suppresses BRCA2 modification. BRCA2 and Plk1 interact with one another in cell lysates, through a conserved region in BRCA2, which spans the eight BRC repeat motifs essential for its function in DNA repair. Within this. region, residues positioned between BRC repeats - but not the repeat motifs themselves - are phosphorylated by Plk1. Interestingly, Plk1-mediated modification of BRCA2 during the G2/M phases is inhibited by treatment with the radiomimetic agent, adriamycin. Thus, our findings define a regulatory circuit for BRCA2 phosphorylation by Plk1 that is responsive to DNA damage as well as mitotic progression.	Univ Cambridge, CR UK Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, MRC, Canc Cell Unit, Hutchison MRC Res Ctr, Cambridge CB2 2XZ, England	University of Cambridge; University of Cambridge	Venkitararnan, AR (corresponding author), Univ Cambridge, CR UK Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	arv22@cam.ac.uk	Lee, MiYoung/G-3748-2014	Daniels, Matthew/0000-0002-9250-6214				Abrieu A, 1998, J CELL SCI, V111, P1751; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bertwistle D, 1998, CURR OPIN GENET DEV, V8, P14, DOI 10.1016/S0959-437X(98)80056-7; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Milner J, 2000, ONCOGENE, V19, P4441, DOI 10.1038/sj.onc.1203793; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Takahashi T, 2003, CANCER SCI, V94, P148, DOI 10.1111/j.1349-7006.2003.tb01411.x; Takai N, 2001, CANCER LETT, V169, P41, DOI 10.1016/S0304-3835(01)00522-5; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Venkitaraman AR, 2000, PHILOS T R SOC B, V355, P191, DOI 10.1098/rstb.2000.0558; Weitzer S, 2002, DEV CELL, V2, P381, DOI 10.1016/S1534-5807(02)00155-7; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu KJ, 2003, J BIOL CHEM, V278, P15652, DOI 10.1074/jbc.M211297200; Yu VPCC, 2000, GENE DEV, V14, P1400	41	67	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					865	872		10.1038/sj.onc.1207223	http://dx.doi.org/10.1038/sj.onc.1207223			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647413				2022-12-28	WOS:000188486600001
J	Joo, A; Aburatani, H; Morii, E; Iba, H; Yoshimura, A				Joo, A; Aburatani, H; Morii, E; Iba, H; Yoshimura, A			STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression	ONCOGENE			English	Article						MITF; STAT3; c-fos; cellular transformation	MICROPHTHALMIA TRANSCRIPTION FACTOR; TYROSINE KINASE; MAST-CELLS; GENE-REGULATION; ACTIVATION; PROTEIN; MELANOMA; TRANSACTIVATION; DIFFERENTIATION; TARGET	The signal transducer and activator of transcription ( STAT) family proteins are transcription factors critical in mediating cytokine signaling. Among them, STAT3 is frequently activated in a number of human cancers and transformed cell lines and is implicated in tumorigenesis. However, although constitutively activated STAT3 mutant (STAT3C) leads to cellular transformation, its transformation potential such as colony-forming activity in soft-agar is much weaker than that of v-src. To identify tumorigenic factors that cooperatively induce cellular transformation with STAT3C, we screened the retroviral cDNA library. We found that the microphthalmia-associated transcription factor ( MITF), an essential transcription factor for melanocyte development and pigmentation, induces anchorage-independent growth of NIH-3T3 cells in cooperation with STAT3C. Micro array analysis revealed that c-fos is highly expressed in transformants expressing STAT3C and MITF. Promoter analysis and chromatin immunoprecipitation assay suggested that both STAT3 and MITF can cooperatively upregulate the c-fos gene. In addition, the transformation of NIH-3T3 cells by both MITF and STAT3C was significantly suppressed by a dominant-negative AP-1 retrovirus. These data indicate that MITF and STAT3 cooperatively induce c-fos, resulting in cellular transformation.	Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Div Genome Sci, Meguro Ku, Tokyo 1538904, Japan; Osaka Univ, Sch Med, Dept Pathol, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan	Kyushu University; University of Tokyo; Osaka University; University of Tokyo	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURD PR, 1989, J EXP MED, V170, P245, DOI 10.1084/jem.170.1.245; Carreira S, 2000, J BIOL CHEM, V275, P21920, DOI 10.1074/jbc.M000035200; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; HATAKEYAMA M, 1992, P NATL ACAD SCI USA, V89, P2022, DOI 10.1073/pnas.89.6.2022; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Kamaraju AK, 2002, J BIOL CHEM, V277, P15132, DOI 10.1074/jbc.M200004200; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Kim DS, 2003, J CELL SCI, V116, P1699, DOI 10.1242/jcs.00366; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kitamura Y, 2002, MOL IMMUNOL, V38, P1173, DOI 10.1016/S0161-5890(02)00058-5; KOBAYASHI T, 1994, J BIOL CHEM, V269, P29198; KULMBURG PA, 1992, J EXP MED, V176, P1773, DOI 10.1084/jem.176.6.1773; Levy C, 2002, J BIOL CHEM, V277, P1962, DOI 10.1074/jbc.M109236200; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P295; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Morii E, 1996, BLOOD, V88, P2488, DOI 10.1182/blood.V88.7.2488.bloodjournal8872488; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nakayama K, 2002, EMBO J, V21, P6174, DOI 10.1093/emboj/cdf596; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172; Ogihara H, 2001, BLOOD, V97, P645, DOI 10.1182/blood.V97.3.645; ONG EK, 1993, GENE, V134, P235, DOI 10.1016/0378-1119(93)90099-O; Sasaki A, 2003, J BIOL CHEM, V278, P2432, DOI 10.1074/jbc.C200608200; Sato M, 1999, BIOCHEM BIOPH RES CO, V254, P384, DOI 10.1006/bbrc.1998.9918; Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x; SHIBUYA H, 1994, MOL CELL BIOL, V14, P5812, DOI 10.1128/MCB.14.9.5812; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Tachibana M, 1997, PIGM CELL RES, V10, P25, DOI 10.1111/j.1600-0749.1997.tb00462.x; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Ui M, 2000, BIOCHEM BIOPH RES CO, V278, P97, DOI 10.1006/bbrc.2000.3777; Vachtenheim J, 2001, J INVEST DERMATOL, V117, P1505, DOI 10.1046/j.0022-202x.2001.01563.x; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zanocco-Marani T, 1999, CANCER RES, V59, P5331	43	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					726	734		10.1038/sj.onc.1207174	http://dx.doi.org/10.1038/sj.onc.1207174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737107				2022-12-28	WOS:000188304900011
J	Manohar, CF; Bray, JA; Salwen, HR; Madafiglio, J; Cheng, A; Flemming, C; Marshall, GM; Norris, MD; Haber, M; Cohn, SL				Manohar, CF; Bray, JA; Salwen, HR; Madafiglio, J; Cheng, A; Flemming, C; Marshall, GM; Norris, MD; Haber, M; Cohn, SL			MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma	ONCOGENE			English	Article						neuroblastoma; MYCN; MRP1; gene regulation	RESISTANCE-ASSOCIATED PROTEIN; MULTIDRUG-RESISTANCE; GENE-EXPRESSION; N-MYC; LUNG-CANCER; CELL-LINE; DNA-BINDING; P53; ONCOGENE; DIFFERENTIATION	In the childhood cancer neuroblastoma ( NB), the level of expression of the multidrug resistance-associated protein (MRP1) gene is strongly correlated with expression of the MYCN oncogene in primary NB tumors, suggesting that MRP1 may be a target for MYCN-mediated gene regulation. In this study, we show that MYCN induction in human NB cells results in increased MRP1 mRNA and protein levels, which in turn is accompanied by increased drug resistance and enhanced MRP1-mediated drug efflux. Furthermore, luciferase activity from MRP1 promoter/luciferase gene reporter constructs was significantly increased in NB cells with exogenous overexpression of MYCN, whereas activity was decreased in NB cells stably transfected with MYCN-antisense vectors. Decreased luciferase activity was observed with promoter constructs that lacked one or two E-box sequences or had E-box double point mutations, while a truncated MRP1 promoter lacking all three E-boxes exhibited only basal levels of activity. Specific electrophoretic mobility shifts of MRP1 E-box sequences were detected with nuclear extracts from NB cells with MYCN overexpression, and complex formation was inhibited with the addition of antibodies directed against MYCN or MYC. These findings indicate that by interacting with E-box elements within the promoter, MYCN can upregulate MRP1 expression and modulate drug resistance in NB.	Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Children's Cancer Institute; Children's Medical Research Institute - Australia; Northwestern University; Feinberg School of Medicine	Cohn, SL (corresponding author), Childrens Mem Hosp, Div Hematol Oncol, Box 30,2300 Childrens Plaza, Chicago, IL 60614 USA.	scohn@northwestern.edu	Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650; Haber, Michelle/0000-0003-2036-8817; Norris, Murray/0000-0002-0632-4589	NCI NIH HHS [5P30CA60553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bader P, 1999, ONCOL REP, V6, P1143; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blanc E, 2003, AM J PATHOL, V163, P321, DOI 10.1016/S0002-9440(10)63656-5; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; BORDOW SB, 1994, CANCER RES, V54, P5036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 2001, PRINCIPLES PRACTICE, P895; CHAN HSL, 1991, NEW ENGL J MED, V325, P1608, DOI 10.1056/NEJM199112053252304; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; FAVROT M, 1991, BRIT J CANCER, V64, P233, DOI 10.1038/bjc.1991.282; GOLDSTEIN LJ, 1990, J CLIN ONCOL, V8, P128, DOI 10.1200/JCO.1990.8.1.128; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; Haber M, 2000, NEUROBLASTOMA, P207; HABER M, 1989, J NATL CANCER I, V81, P1250, DOI 10.1093/jnci/81.16.1250; Haber M, 1997, EUR J CANCER, V33, P2031, DOI 10.1016/S0959-8049(97)00229-3; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; Keshelava N, 2001, CANCER RES, V61, P6185; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; Kurz EU, 2001, BIOCHEM BIOPH RES CO, V285, P981, DOI 10.1006/bbrc.2001.5262; Kuss BJ, 2002, INT J CANCER, V98, P128, DOI 10.1002/ijc.10159; Lutz W, 1996, ONCOGENE, V13, P803; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; Matsunaga T, 1998, JPN J CANCER RES, V89, P1276, DOI 10.1111/j.1349-7006.1998.tb00524.x; NAKAGAWARA A, 1990, CANCER RES, V50, P3043; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; Norris MD, 1996, NEW ENGL J MED, V334, P231, DOI 10.1056/NEJM199601253340405; Norris MD, 1997, EUR J CANCER, V33, P1911, DOI 10.1016/S0959-8049(97)00284-0; Oshika Y, 1998, MODERN PATHOL, V11, P1059; Peaston AE, 2001, BRIT J CANCER, V85, P1564, DOI 10.1054/bjoc.2001.2144; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Shohet JM, 2002, CANCER RES, V62, P1123; Sullivan GF, 2000, J CLIN INVEST, V105, P1261, DOI 10.1172/JCI9290; Tweddle DA, 2003, CANCER LETT, V197, P93, DOI 10.1016/S0304-3835(03)00088-0; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; VOGAN K, 1993, CANCER RES, V53, P5269; Wang QJ, 1998, CANCER RES, V58, P5762; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Xiao WH, 1997, P NATL ACAD SCI USA, V94, P7227, DOI 10.1073/pnas.94.14.7227; Young LC, 1999, CLIN CANCER RES, V5, P673; Zhu QC, 1996, DNA CELL BIOL, V15, P105, DOI 10.1089/dna.1996.15.105; ZHU QC, 1994, CANCER RES, V54, P4488	51	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					753	762		10.1038/sj.onc.1207151	http://dx.doi.org/10.1038/sj.onc.1207151			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737110				2022-12-28	WOS:000188304900014
J	Xia, WL; Liu, LH; Ho, P; Spector, NL				Xia, WL; Liu, LH; Ho, P; Spector, NL			Truncated ErbB2 receptor (p95(ErbB2)) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016	ONCOGENE			English	Article						truncated ErbB2; heterodimers; ErbB3; tyrosine kinase; heregulin	GROWTH-FACTOR RECEPTORS; HUMAN-BREAST; EXTRACELLULAR DOMAIN; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; STRUCTURAL ALTERATIONS; PROTOONCOGENE PRODUCT; MONOCLONAL-ANTIBODY; SIGNAL-TRANSDUCTION; HER2 ECTODOMAIN	The expression of the NH2 terminally truncated ErbB2 receptor (p95(ErbB2)) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185(ErbB2). We now show that heregulin (HRG), but not EGF, stimulates p95(ErbB2) phosphorylation in BT474 breast cancer cells. Furthermore, phospho-p95(ErbB2) forms heterodimers with ErbB3, but not EGFR, while p185(ErbB2) heterodimerizes with both EGFR and ErbB3. The predilection of p95(ErbB2) to heterodimerize with ErbB3 provides an explanation for its regulation by HRG, an ErbB3 ligand. GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95(ErbB2) phosphorylation in BT474 cells and tumor xenografts. Inhibition of p95(ErbB2), p185(ErbB2), and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels. Increased phosphorylation of p95(ErbB2) and AKT in response to HRG was abrogated to varying degrees by GW572016. In contrast, trastuzumab did not inhibit p95(ErbB2) phosphorylation or the expression of downstream phospho-Erk1/2, phospho-AKT, or cyclin D. It is tempting to speculate that trastuzumab resistance may be mediated in part by the selection of p95(ErbB2)-expressing breast cancer cells capable of exerting potent growth and prosurvival signals through p95(ErbB2)-ErbB3 heterodimers. Thus, p95(ErbB2) represents a target for therapeutic intervention, and one that is sensitive to GW572016 therapy.	GlaxoSmithKline, Dept Discovery Med, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline	Spector, NL (corresponding author), GlaxoSmithKline, Dept Discovery Med, 5 Moore Dr, Res Triangle Pk, NC 27709 USA.	Neil.L.Spector@gsk.com						ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BrandtRauf PW, 1995, MUTAT RES-FUND MOL M, V333, P203, DOI 10.1016/0027-5107(95)00146-8; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Christianson TA, 1998, CANCER RES, V58, P5123; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cockerill S, 2001, BIOORG MED CHEM LETT, V11, P1401, DOI 10.1016/S0960-894X(01)00219-0; Codony-Servat J, 1999, CANCER RES, V59, P1196; Colomer R, 2000, CLIN CANCER RES, V6, P2356; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; KANDL H, 1994, BRIT J CANCER, V70, P739, DOI 10.1038/bjc.1994.387; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Klapper LN, 2000, ADV CANCER RES, V77, P25; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; Levkowitz G, 1996, ONCOGENE, V12, P1117; LIN YZJ, 1991, ONCOGENE, V6, P639; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUPA SM, 1993, ONCOGENE, V8, P2917; RAJIKUMAR T, 1994, BREAST CANC RES TREA, V29, P3; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rusnak DW, 2001, MOL CANCER THER, V1, P85; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yakes FM, 2002, CANCER RES, V62, P4132; Yamauchi H, 1997, J CLIN ONCOL, V15, P2518, DOI 10.1200/JCO.1997.15.7.2518; ZABRECKY JR, 1991, J BIOL CHEM, V266, P1716	52	193	220	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					646	653		10.1038/sj.onc.1207166	http://dx.doi.org/10.1038/sj.onc.1207166			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737100				2022-12-28	WOS:000188304900003
J	Al Moustafa, AE; Foulkes, WD; Benlimame, N; Wong, A; Yen, L; Bergeron, J; Batist, G; Alpert, L; Alaoui-Jamali, MA				Al Moustafa, AE; Foulkes, WD; Benlimame, N; Wong, A; Yen, L; Bergeron, J; Batist, G; Alpert, L; Alaoui-Jamali, MA			E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells	ONCOGENE			English	Article						ErbB-2; E6/E7 of HPV; oral epithelial cells; transformation	GROWTH-FACTOR RECEPTOR; ADHESION MOLECULE UVOMORULIN; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; ACTIVATED NEU; E-CADHERIN; CYCLIN D1; CLINICAL-IMPLICATIONS; SIGNALING NETWORK; CANCER	Head and neck squamous cell carcinomas (HNSCC) are characterized by a marked propensity for local invasion and spread to cervical lymph nodes, with distant metastases developing in 30-40% of cases. HPV-16 is an important risk factor for HNSCC. How HPV enhances susceptibility to HNSCC is not fully understood, but seems to involve cofactors. In this study, we examined the effect of the cooperation between HPV-16 and the tyrosine kinase receptor ErbB-2 on E-cadherin/catenin complex patterns and neoplastic transformation of human normal oral epithelial (NOE) cells. We report that overexpression of ErbB-2 or E6/E7 alone does not affect E-cadherin/catenin complex patterns nor does it induce cell transformation of NOE cells. In contrast, coexpression of E6/E7 and ErbB-2 downregulates E-cadherin and catenin expression. This is accompanied by cytoplasmic localization of E-cadherin, as well as nuclear translocation of alpha, beta, and gamma-catenins. Furthermore, we demonstrate that E6/E7 cooperate with overexpressed ErbB-2 to induce tumor formation in nude mice and to upregulate cyclin D1 and c-myc expression. Our data suggest that E6/E7 cooperate with ErbB-2 in head and neck carcinogenesis, at least in part, via the conversion of beta-catenin from a cell adhesion to a nuclear function, that is, to act as a potential transcriptional regulator. This conversion leads to the upregulation of cyclin D1, c-myc and other oncoproteins necessary for alteration of the E-cadherin/catenin complex and cell transformation of NOE cells.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pathol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Pharmacol, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Therapeut, Montreal, PQ H3T 1E2, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Ctr Translat Res Canc, Montreal, PQ H3T 1E2, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Oncol, Program Canc Genet, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Program Canc Genet, Montreal, PQ, Canada	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; McGill University; McGill University	Foulkes, WD (corresponding author), Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Dept Med, Room A-803,3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada.	william.foulkes@mcgill.ca	Foulkes, William D./AAR-9586-2021	Foulkes, William D./0000-0001-7427-4651				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Al Moustafa AE, 2002, LUNG CANCER, V37, P49, DOI 10.1016/S0169-5002(02)00025-9; Al Moustafa AE, 1999, CLIN CANCER RES, V5, P681; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Eckert RL, 2000, INT J ONCOL, V16, P853; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Franceschi S, 1996, CANCER EPIDEM BIOMAR, V5, P567; Galipeau J, 1999, CANCER RES, V59, P2384; Galloway DA, 1996, SEMIN CANCER BIOL, V7, P309, DOI 10.1006/scbi.1996.0040; Gillison Maura L., 1999, Current Opinion in Oncology, V11, P191, DOI 10.1097/00001622-199905000-00010; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Ke LD, 1999, ORAL ONCOL, V35, P415, DOI 10.1016/S1368-8375(99)00015-9; Klapper LN, 2000, ADV CANCER RES, V77, P25; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397; McDougall J K, 1994, Curr Top Microbiol Immunol, V186, P101; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Ninomiya I, 2000, INT J CANCER, V85, P757, DOI 10.1002/(SICI)1097-0215(20000315)85:6<757::AID-IJC3>3.0.CO;2-O; Niv A, 2000, J LARYNGOL OTOL, V114, P41, DOI 10.1258/0022215001903870; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Orr MS, 2000, J NATL CANCER I, V92, P987, DOI 10.1093/jnci/92.12.987; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; Rapp L, 1998, BBA-REV CANCER, V1378, pF1, DOI 10.1016/S0304-419X(98)00009-2; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Wilding J, 1996, CANCER RES, V56, P5285; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Xia WY, 1999, CLIN CANCER RES, V5, P4164; XIE YM, 1995, ONCOGENE, V10, P2409; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972	46	87	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					350	358		10.1038/sj.onc.1207148	http://dx.doi.org/10.1038/sj.onc.1207148			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724563				2022-12-28	WOS:000188098300004
J	Roos, W; Baumgartner, M; Kaina, B				Roos, W; Baumgartner, M; Kaina, B			Apoptosis triggered by DNA damage O-6-methylguanine in human lymphocytes requires DNA replication and is mediated by p53 and Fas/CD95/Apo-1	ONCOGENE			English	Article						apoptosis; DNA damage; DNA repair; alkyltransferase; lymphocytes; Fas; p53	MISMATCH REPAIR; METHYLTRANSFERASE MGMT; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CHROMOSOMAL-ABERRATIONS; METHYLATING AGENTS; ALKYLATING-AGENTS; BCL-2 DECLINE; CELL-DEATH; V79 CELLS; EXPRESSION	Various tumor-therapeutic drugs and environmental carcinogens alkylate DNA inducing O-6-methylguanine (O(6)MeG) that provokes cell death by apoptosis. In rodent fibroblasts, apoptosis triggered by O(6)MeG is executed via the mitochondrial damage pathway. Conversion of O(6)MeG into critical downstream lesions requires mismatch repair (MMR). This is thought to signal apoptosis upon binding to O(6)MeG lesions mispaired with thymine. Alternatively, O(6)MeG lesions might be processed by MMR giving rise to DNA double-strand breaks (DSBs) during replication that finally provoke apoptosis. To test this, we examined apoptosis triggered by O(6)MeG in human peripheral lymphocytes in which O-6-methylguanine-DNA methyltransferase (MGMT) had been inactivated by O-6-benzylguanine (O(6)BG) and which were not proliferating or proliferating upon CD3/CD28 stimulation. Treatment with N-methyl-N#8242;-nitro-N-nitrosoguanidine (MNNG) or the anticancer drug temozolomide induced apoptosis only in proliferating, but not resting cells. With exceptional high alkylation doses (greater than or equal to15 muM of MNNG), apoptosis was also observed in resting lymphocytes, albeit at a lower level than in proliferating cells. This response was not affected by O(6)BG, suggesting that replication-independent apoptosis at high dose levels is caused by lesions other than O(6)MeG. O(6)MeG-triggered apoptosis in proliferating lymphocytes was preceded by a wave of DSBs, which coincided with p53 and Fas receptor upregulation, while Fas ligand, Bax and Bcl-2 expression was not altered. Treatment with anti-Fas neutralizing antibody attenuated MNNG-induced apoptosis in MGMT-depleted proliferating lymphocytes. The data suggest that O(6)MeG is converted by MMR and DNA replication into DSBs that trigger apoptosis by p53 stabilization and Fas/CD95/Apo-1 upregulation. This is supported by the finding that ionizing radiation, inducing DSBs on its own, provokes apoptosis in lymphocytes in a replication-independent way. The strict proliferation dependence of apoptosis triggered by O(6)MeG may explain the specific killing response of MGMT-deficient proliferating cells, including tumors, to O(6)MeG generating anticancer drugs and suggests that tumor proliferation rate, Fas responsiveness, MGMT and MMR status are important prognosis parameters.	Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany		Kaina, B (corresponding author), Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	Kaina@mail.uni-mainz.de	Roos, Wynand/B-4846-2008	Roos, Wynand/0000-0002-0474-7414				Becker K, 1996, CANCER RES, V56, P3244; Becker R, 2002, BRIT J CANCER, V86, P130, DOI 10.1038/sj.bjc.6600027; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRENNAND J, 1986, P NATL ACAD SCI USA, V83, P6292, DOI 10.1073/pnas.83.17.6292; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; Dosch J, 1996, ONCOGENE, V13, P1927; Dosch J, 1998, CARCINOGENESIS, V19, P567, DOI 10.1093/carcin/19.4.567; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; Dunkern TR, 2002, MOL BIOL CELL, V13, P348, DOI 10.1091/mbc.01-05-0225; Dunkern TR, 2001, MUTAT RES-DNA REPAIR, V486, P249, DOI 10.1016/S0921-8777(01)00095-7; DUNKERN TR, 2003, IN PRESS MUTATION RE; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; GALLOWAY SM, 1995, MUTAT RES LETT, V346, P231, DOI 10.1016/0165-7992(95)90040-3; Gerson SL, 1996, BLOOD, V88, P1649; Hammond LA, 1999, J CLIN ONCOL, V17, P2604, DOI 10.1200/JCO.1999.17.8.2604; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; Janssen K, 2001, ARCH TOXICOL, V75, P306, DOI 10.1007/s002040100226; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; KAINA B, 1985, MUTAT RES, V142, P49, DOI 10.1016/S0165-7992(85)80012-9; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; KARRAN P, 1990, MUTAT RES, V236, P269, DOI 10.1016/0921-8777(90)90010-3; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Marra G, 2001, P NATL ACAD SCI USA, V98, P7164, DOI 10.1073/pnas.121136498; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; MORITZ T, 1995, CANCER RES, V55, P2608; MOSCHEL RC, 1992, J MED CHEM, V35, P4486, DOI 10.1021/jm00101a028; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Ochs K, 2000, CANCER RES, V60, P5815; Ochs K, 2002, CANCER RES, V62, P1524; OLIVE PL, 1991, CANCER RES, V51, P4671; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I	46	99	103	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					359	367		10.1038/sj.onc.1207080	http://dx.doi.org/10.1038/sj.onc.1207080			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724564				2022-12-28	WOS:000188098300005
J	Pfahl, M; Piedrafita, FJ				Pfahl, M; Piedrafita, FJ			Retinoid targets for apoptosis induction	ONCOGENE			English	Article						retinoids; apoptosis; MKP-1	CYTOCHROME-C RELEASE; PROTEIN-KINASE-C; KAPPA-B KINASE; CARBOXYLIC-ACID; N-(4-HYDROXYPHENYL)RETINAMIDE-INDUCED APOPTOSIS; POSTTRANSCRIPTIONAL REGULATION; RETRO-RETINOIDS; CARCINOMA CELLS; LEUKEMIA-CELLS; GROWTH ARREST	Certain synthetic retinoid-related molecules induce apoptosis in cancer cells through a novel mechanism of retinoid action that is independent of the nuclear retinoid receptors. These compounds target protein kinases and protein phosphatases to trigger signal transduction pathways that lead to apoptosis. Whereas retinoid agonists such as CD437 activate stress kinases via inhibition of the phosphatase MKP-1, the retinoid antagonist MX781 inhibits the survival kinase IKK. These retinoid-mediated signaling pathways converge at the mitochondria, where they cause the release of cytochrome c and subsequent Apaf-1-dependent activation of caspases. Identification of the retinoid targets that mediate their apoptotic activity will enhance our understanding of the mechanism of this novel retinoid action, to allow appropriate optimization of currently available compounds to advance into the clinic as novel anticancer agents.	Incyte San Diego Inc, San Diego, CA 92121 USA; Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA	Incyte	Pfahl, M (corresponding author), Incyte San Diego Inc, 10835 Altman Row, San Diego, CA 92121 USA.	pfahl@incyte.com						Adachi H, 1998, CELL DEATH DIFFER, V5, P973, DOI 10.1038/sj.cdd.4400445; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen YQ, 1999, CANCER RES, V59, P3985; Degos L, 2001, ONCOGENE, V20, P7140, DOI 10.1038/sj.onc.1204763; DELIA D, 1993, CANCER RES, V53, P6036; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; DELIA D, 1995, BLOOD, V85, P359, DOI 10.1182/blood.V85.2.359.bloodjournal852359; Denkert C, 2002, INT J CANCER, V102, P507, DOI 10.1002/ijc.10746; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hail N, 2001, CANCER RES, V61, P6698; Hoyos B, 2002, J BIOL CHEM, V277, P23949, DOI 10.1074/jbc.M110750200; Hoyos B, 2000, J EXP MED, V192, P835, DOI 10.1084/jem.192.6.835; Hsieh TC, 1995, BIOCHEM MOL BIOL INT, V37, P499; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Imam A, 2001, FASEB J, V15, P28; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; KALEMKERIAN GP, 1995, J NATL CANCER I, V87, P1674, DOI 10.1093/jnci/87.22.1674; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Korichneva I, 1999, J CELL SCI, V112, P2521; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Lopez-Hernandez FJ, 2003, MOL CANCER THER, V2, P255; LOPEZHERNANDEZ FJ, 2003, IN PRESS CELL DEATH; Lu XP, 1997, NAT MED, V3, P686, DOI 10.1038/nm0697-686; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Marchetti P, 1999, CANCER RES, V59, P6257; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Merritt G, 2001, CANCER LETT, V164, P15, DOI 10.1016/S0304-3835(00)00714-X; Mologni L, 1999, BLOOD, V93, P1045, DOI 10.1182/blood.V93.3.1045.403k22_1045_1061; OConnell MJ, 1996, J EXP MED, V184, P549, DOI 10.1084/jem.184.2.549; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; Ortiz MA, 2001, CANCER RES, V61, P8504; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Piedrafita FJ, 1997, MOL CELL BIOL, V17, P6348, DOI 10.1128/MCB.17.11.6348; Ponzanelli I, 2000, BLOOD, V95, P2672; PONZONI M, 1995, CANCER RES, V55, P853; Rishi AK, 1999, NUCLEIC ACIDS RES, V27, P3111, DOI 10.1093/nar/27.15.3111; Sakaue M, 1999, MOL PHARMACOL, V55, P668; Simeone AM, 2002, MOL CANCER THER, V1, P1009; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sun SY, 2000, MOL PHARMACOL, V58, P508, DOI 10.1124/mol.58.3.508; Sun SY, 1999, ONCOGENE, V18, P3894, DOI 10.1038/sj.onc.1202771; Sun SY, 1999, CANCER RES, V59, P2829; Sun SY, 1999, CANCER RES, V59, P2493; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vicent Silvestre, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P360; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang HT, 2001, CANCER RES, V61, P5102; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang TTY, 1996, CANCER LETT, V107, P65, DOI 10.1016/0304-3835(96)04344-3; Wu JM, 2001, APOPTOSIS, V6, P377, DOI 10.1023/A:1011342220621; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang JM, 2001, CANCER RES, V61, P4901; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350	64	62	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9058	9062		10.1038/sj.onc.1207109	http://dx.doi.org/10.1038/sj.onc.1207109			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663484				2022-12-28	WOS:000187043600009
J	Discenza, MT; He, SJ; Lee, TH; Chu, LL; Bolon, B; Goodyer, P; Eccles, M; Pelletier, J				Discenza, MT; He, SJ; Lee, TH; Chu, LL; Bolon, B; Goodyer, P; Eccles, M; Pelletier, J			WT1 is a modifier of the Pax2 mutant phenotype: cooperation and interaction between WT1 and Pax2	ONCOGENE			English	Article						WT1; Pax2; kidney development; protein-protein interactions	TUMOR SUPPRESSOR GENE; WILMS-TUMOR; KIDNEY DEVELOPMENT; UROGENITAL DEVELOPMENT; EXPRESSION; RECEPTOR; REPRESSION; INHIBITION; MUTATIONS; FAMILY	Metanephric kidney development requires an inductive interaction between the ureteric bud and progenitor mesenchyme, where the early expression of two genes, Wilms' tumour 1 (WT1) and paired box 2 (Pax2), establishes critical but unknown developmental pathways. Indeed, transgenic mice with deregulated overexpression of Pax2 exhibit structural kidney defects and impaired renal function, as do mice harboring targeted disruptions and/or spontaneous mutations of either the Pax2 or WT1 genes. WT1 and Pax2 are thought to regulate each other's expression during renal development. To better de. ne the relationship between WT1 and Pax2, we generated mouse embryos containing heterozygous mutations in both genes. WT1(+/-)/Pax2(1Neu/+) kidneys were 50% smaller than wildtype kidneys. They were characterized by severe attenuation of the renal medulla, and reduced development of calyces and the renal pelvis. Renal cortex development in compound heterozygotes culminated in fewer nephrons than in WT1(+/-), Pax2(1Neu/+) or wild-type mice. Only minor variations in the mesenchymal expression pattern of Pax2 protein, and the mRNA expression levels of Pax2 and WT1, were noted in mutant kidneys. We show that WT1 and Pax2 proteins interact in vitro and in vivo, demonstrating that WT1 and Pax2 can form a molecular complex. Our data suggest that WT1 is a modifier of the Pax2 mutant phenotype.	Univ Otago, Dept Pathol, Dunedin 9015, New Zealand; McGill Univ, Dept Biochem, Montreal, PQ, Canada; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, McGill Canc Ctr, Montreal, PQ, Canada	University of Otago; McGill University; Amgen; McGill University; McGill University	Eccles, M (corresponding author), Univ Otago, Dept Pathol, Hercus Bldg,Hanover St,POB 913, Dunedin 9015, New Zealand.		Lee, Tae Ho/AAT-1721-2020					Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bruening W, 1996, J BIOL CHEM, V271, P8646, DOI 10.1074/jbc.271.15.8646; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; Dehbi M, 1996, ONCOGENE, V13, P447; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Eccles MR, 1998, PEDIATR NEPHROL, V12, P712, DOI 10.1007/s004670050533; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EVERS P, 1994, J HISTOCHEM CYTOCHEM, V42, P1555, DOI 10.1177/42.12.7983356; Favor J, 1996, P NATL ACAD SCI USA, V93, P13870, DOI 10.1073/pnas.93.24.13870; GNARRA JR, 1995, CANCER RES, V55, P4092; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Herzer U, 1999, CURR BIOL, V9, P837, DOI 10.1016/S0960-9822(99)80369-8; Kim J, 2000, FEBS LETT, V474, P121, DOI 10.1016/S0014-5793(00)01590-8; Kreidberg JA, 1999, MOL REPROD DEV, V52, P366, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;366::AID-MRD5&gt;3.0.CO;2-Y; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee TH, 2002, J BIOL CHEM, V277, P44826, DOI 10.1074/jbc.M205667200; Lee TH, 2001, PHYSIOL GENOMICS, V7, P187, DOI 10.1152/physiolgenomics.00046.2001; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; McConnell MJ, 1997, ONCOGENE, V14, P2689, DOI 10.1038/sj.onc.1201114; Moore AW, 1999, DEVELOPMENT, V126, P1845; MURATOVSKA A, 2003, IN PRESS ONCOGENE; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; Porteous S, 2000, HUM MOL GENET, V9, P1, DOI 10.1093/hmg/9.1.1; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Torres M, 1995, DEVELOPMENT, V121, P4057; WERNER H, 1995, MOL CELL BIOL, V15, P3516; WERNER H, 1995, INT J BIOCHEM CELL B, V27, P987, DOI 10.1016/1357-2725(95)00074-Y; Wheat W, 1999, MOL CELL BIOL, V19, P2231	39	27	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8145	8155		10.1038/sj.onc.1206997	http://dx.doi.org/10.1038/sj.onc.1206997			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603255				2022-12-28	WOS:000186403400009
J	Bravo, SB; Pampin, S; Cameselle-Teijeiro, J; Carneiro, C; Dominguez, F; Barreiro, F; Alvarez, CV				Bravo, SB; Pampin, S; Cameselle-Teijeiro, J; Carneiro, C; Dominguez, F; Barreiro, F; Alvarez, CV			TGF-beta-induced apoptosis in human thyrocytes is mediated by p27(kip1) reduction and is overridden in neoplastic thyrocytes by NF-kappa B activation	ONCOGENE			English	Article						TGF-beta; thyroid cancer; p27; apoptosis; NF-kappa B	THYROID-TUMORS; PROLIFERATIVE ACTIVITY; MESSENGER-RNA; GROWTH; CELLS; EXPRESSION; QUIESCENCE; RESISTANCE; RECEPTOR; MODEL	Millions of people worldwide suffer goiter, a proliferative disease of the follicular cells of the thyroid that may become neoplastic. Thyroid neoplasms have low proliferative index, low apoptotic index and a high incidence of metastasis. TGF-beta is overexpressed in thyroid follicular tumor cells. To investigate the role of TGF-beta in thyroid tumor progression, we established cultures of human thyrocytes from different proliferative pathologies ( Grave's disease, multinodular goiter, follicular adenoma, papillary carcinoma), lymph node metastasis, and a normal thyroid sample. All cultures maintained the thyrocyte phenotype. TGF-beta induced cell-cycle arrest in all cultures, in contrast with results reported for other epithelial tumors. In deprived medium, TGF-beta induced apoptosis in normal thyrocyte cultures and all neoplastic cultures except the metastatic cultures. This apoptosis was mediated by a reduction in p27(kip1) levels, inducing cell-cycle initiation. Antisense p27 expression induced apoptosis in the absence of TGF-beta. By contrast, in cells in which p27 was overexpressed, TGF-beta had a survival effect. In growth medium, a net survival effect occurs in neoplastic thyrocytes only, not normal thyrocytes, due to activation of the NF-kappaB survival program. Together, these findings suggest that (a) thyroid neoplasms are due to reduced apoptosis, not increased division, in line with the low proliferative index of these pathologies, and (b) TGF-beta induces apoptosis in normal thyrocytes via p27 reduction, but that in neoplastic thyrocytes this effect is overridden by activation of the NF-kappaB program.	Univ Santiago de Compostela, Sch Med, Dept Physiol, Santiago De Compostela 15782, Spain; Hosp Clin Univ, Dept Pathol, Santiago De Compostela 15706, Spain; Hosp Clin Univ, Dept Surg, Santiago De Compostela 15706, Spain	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela	Alvarez, CV (corresponding author), Univ Santiago de Compostela, Sch Med, Dept Physiol, San Francisco S-N, Santiago De Compostela 15782, Spain.	fscralvi@usc.es	Lopez, Susana Belén Bravo/F-8487-2016; Alvarez, Clara V/AAN-4173-2020	Lopez, Susana Belén Bravo/0000-0001-7615-3079; Alvarez, Clara V/0000-0003-1500-4058				Achenbach TV, 2000, CLIN CANCER RES, V6, P3006; ASA SL, 2001, CANC HDB, pCH9; Asmis LM, 1996, J ENDOCRINOL, V149, P485, DOI 10.1677/joe.0.1490485; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Blaydes JP, 1996, INT J CANCER, V65, P525, DOI 10.1002/(SICI)1097-0215(19960208)65:4<525::AID-IJC22>3.3.CO;2-G; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Chan JKC, 2000, DIAGNOSTIC HISTOPATH, P959; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Derwahl M, 2002, TRENDS ENDOCRIN MET, V13, P23, DOI 10.1016/S1043-2760(01)00519-7; Derwahl M, 2000, BEST PRACT RES CL EN, V14, P577, DOI 10.1053/beem.2000.0104; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eymin B, 1999, ONCOGENE, V18, P1411, DOI 10.1038/sj.onc.1202437; Freitas JE, 2000, SEMIN NUCL MED, V30, P88, DOI 10.1053/nm.2000.4597; Goretzki PE, 2000, WORLD J SURG, V24, P913, DOI 10.1007/s002680010174; GRUBECKLOEBENSTEIN B, 1989, J CLIN INVEST, V83, P764, DOI 10.1172/JCI113955; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kammori M, 2002, EXP GERONTOL, V37, P513, DOI 10.1016/S0531-5565(01)00178-4; KATOH R, 1995, HUM PATHOL, V26, P139, DOI 10.1016/0046-8177(95)90029-2; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; Kimura ET, 1999, THYROID, V9, P119, DOI 10.1089/thy.1999.9.119; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; Lazzereschi D, 1997, CANCER RES, V57, P2071; LEE TK, 1985, HUM PATHOL, V16, P1042, DOI 10.1016/S0046-8177(85)80282-3; Levy O, 1998, J BIOL CHEM, V273, P22657, DOI 10.1074/jbc.273.35.22657; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Matthews P, 2001, J PATHOL, V194, P183, DOI 10.1002/path.848; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Moore D, 1998, HISTOPATHOLOGY, V32, P35; MORTENSEN JD, 1955, J CLIN ENDOCR METAB, V15, P1270, DOI 10.1210/jcem-15-10-1270; Mothersill C, 1995, Methods Mol Biol, V43, P25; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sgambato A, 2000, J CELL PHYSIOL, V183, P18, DOI 10.1002/(SICI)1097-4652(200004)183:1<18::AID-JCP3>3.0.CO;2-S; SOARES P, 1994, CANCER, V73, P2879, DOI 10.1002/1097-0142(19940601)73:11<2879::AID-CNCR2820731135>3.0.CO;2-E; Sreelekha TT, 2000, THYROID, V10, P117, DOI 10.1089/thy.2000.10.117; Urbano AG, 2000, ENDOCRINOLOGY, V141, P1893, DOI 10.1210/en.141.5.1893; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Yoshida A, 1999, SURG TODAY, V29, P204	45	44	44	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7819	7830		10.1038/sj.onc.1207029	http://dx.doi.org/10.1038/sj.onc.1207029			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586408				2022-12-28	WOS:000186240200012
J	Smith, MR				Smith, MR			Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance	ONCOGENE			English	Review						antibody dependent cellular cytotoxicity; non-Hodgkin's lymphoma; B-cell receptor signaling; apoptosis	CHRONIC LYMPHOCYTIC-LEUKEMIA; FC-GAMMA-RIIIA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; NON-HODGKINS-LYMPHOMA; MULTICENTER PHASE-II; REFRACTORY LOW-GRADE; B-CELL RECEPTOR; IN-VITRO; FOLLICULAR LYMPHOMA; COMPLEMENT ACTIVATION	Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, was the first monoclonal antibody to be approved for therapeutic use. Treatment with rituximab at standard weekly dosing is effective in more than 50% of patients with relapsed or refractory CD20-positive follicular non-Hodgkin's lymphoma, but is not curative. It is less effective in other subtypes of CD20-positive lymphoma and for retreatment, even with CD20 still expressed. Thus, binding of rituximab to CD20 is not sufficient to kill many lymphoma cells, indicating that there are mechanisms of resistance. Mechanisms of cell destruction that have been demonstrated to be activated by rituximab binding to CD20 include direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. The relative importance of each of these mechanisms in determining clinical response to rituximab treatment remains a matter of conjecture. Thus, the role of various resistance pathways, some documented in experimental systems and others still hypothetical, remains uncertain. Resistance could potentially be mediated by alterations in CD20 expression or signaling, elevated apoptotic threshold, modulation of complement activity or diminished cellular cytotoxicity. As the first of an expanding class of anticancer agents, lessons learned regarding the mechanism of rituximab action and resistance will be of increasing importance.	Fox Chase Canc Ctr, Lymphoma Serv, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Smith, MR (corresponding author), Fox Chase Canc Ctr, Lymphoma Serv, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	M_smith@fccc.edu		Smith, Mitchell/0000-0003-1428-8765				Alas S, 2002, CLIN CANCER RES, V8, P836; ANDERSON KC, 1984, BLOOD, V63, P1424, DOI 10.1182/blood.V63.6.1424.1424; Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Bellosillo B, 2001, BLOOD, V98, P2771, DOI 10.1182/blood.V98.9.2771; Berinstein NL, 1998, ANN ONCOL, V9, P995, DOI 10.1023/A:1008416911099; Bladergroen BA, 2002, BLOOD, V99, P232, DOI 10.1182/blood.V99.1.232; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; Byrd JC, 2001, J CLIN ONCOL, V19, P2153, DOI 10.1200/JCO.2001.19.8.2153; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Campbell K S, 2001, Int Rev Immunol, V20, P333, DOI 10.3109/08830180109054413; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; CHARLES J, 1999, WINTROBES CLIN HEMAT, V1, P1191; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Colombat P, 2001, BLOOD, V97, P101, DOI 10.1182/blood.V97.1.101; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; Czuczman MS, 2001, ANN ONCOL, V12, P109, DOI 10.1023/A:1008395214584; Davis TA, 2000, J CLIN ONCOL, V18, P3135, DOI 10.1200/JCO.2000.18.17.3135; Davis TA, 1999, CLIN CANCER RES, V5, P611; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Deans JP, 2002, IMMUNOLOGY, V107, P176, DOI 10.1046/j.1365-2567.2002.01495.x; Di Gaetano N, 2001, BRIT J HAEMATOL, V114, P800, DOI 10.1046/j.1365-2141.2001.03014.x; Donin N, 2003, CLIN EXP IMMUNOL, V131, P254, DOI 10.1046/j.1365-2249.2003.02066.x; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; Foran JM, 2001, BRIT J HAEMATOL, V114, P881, DOI 10.1046/j.1365-2141.2001.03019.x; Foran JM, 2000, BRIT J HAEMATOL, V109, P81, DOI 10.1046/j.1365-2141.2000.01965.x; Friedberg JW, 2002, BRIT J HAEMATOL, V117, P828, DOI 10.1046/j.1365-2141.2002.03535.x; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Ghielmini Michele, 2002, Blood, V100, P604; Golay J, 2000, BLOOD, V95, P3900; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; GOLAY JT, 1985, J IMMUNOL, V135, P3795; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grillo-Lopez AJ, 2000, SEMIN ONCOL, V27, P9, DOI 10.1053/sonc.2000.20444; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Harjunpaa A, 2001, LEUKEMIA LYMPHOMA, V42, P731, DOI 10.3109/10428190109099335; HARRIS NL, 1994, BLOOD, V84, P1361; Hofmeister JK, 2000, BLOOD CELL MOL DIS, V26, P133, DOI 10.1006/bcmd.2000.0287; HOOIJBERG E, 1995, CANCER RES, V55, P2627; Keating MJ, 2002, BLOOD, V99, P3554, DOI 10.1182/blood.V99.10.3554; Keating MJ, 2002, SEMIN ONCOL, V29, P70, DOI 10.1053/sonc.2002.30142; Kennedy AD, 2003, BLOOD, V101, P1071, DOI 10.1182/blood-2002-03-0876; Kennedy GA, 2002, BRIT J HAEMATOL, V119, P412, DOI 10.1046/j.1365-2141.2002.03843.x; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Leonard JP, 2002, SEMIN ONCOL, V29, P81, DOI 10.1053/sonc.2002.30149; Manches O, 2003, BLOOD, V101, P949, DOI 10.1182/blood-2002-02-0469; Mathas S, 2000, CANCER RES, V60, P7170; McLaughlin P, 1998, J CLIN ONCOL, V16, P2825, DOI 10.1200/JCO.1998.16.8.2825; O'Keefe TL, 1998, IMMUNOGENETICS, V48, P125, DOI 10.1007/s002510050412; Osterborg A, 1997, J CLIN ONCOL, V15, P1567, DOI 10.1200/JCO.1997.15.4.1567; Pedersen IM, 2002, BLOOD, V99, P1314, DOI 10.1182/blood.V99.4.1314; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Pichert G, 2001, Clin Lymphoma, V1, P293, DOI 10.3816/CLM.2001.n.004; Piro LD, 1999, ANN ONCOL, V10, P655, DOI 10.1023/A:1008389119525; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Reff M E, 1994, Blood, V83, P435; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Selenko N, 2002, J CLIN IMMUNOL, V22, P124, DOI 10.1023/A:1015463811683; Shan D, 1998, BLOOD, V91, P1644, DOI 10.1182/blood.V91.5.1644.1644_1644_1652; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; TEDDER TF, 1985, J IMMUNOL, V135, P973; Treon SP, 2001, J IMMUNOTHER, V24, P263, DOI 10.1097/00002371-200105000-00011; van der Kolk LE, 2002, LEUKEMIA, V16, P693, DOI 10.1038/sj.leu.2402424; Vose JM, 2000, J CLIN ONCOL, V18, P1316, DOI 10.1200/JCO.2000.18.6.1316; Warren T L, 2000, Clin Lymphoma, V1, P57, DOI 10.3816/CLM.2000.n.005; Weng WK, 2001, BLOOD, V98, P1352, DOI 10.1182/blood.V98.5.1352; Witzig TE, 2002, J CLIN ONCOL, V20, P3262, DOI 10.1200/JCO.2002.11.017; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616	70	563	613	5	105	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7359	7368		10.1038/sj.onc.1206939	http://dx.doi.org/10.1038/sj.onc.1206939			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576843				2022-12-28	WOS:000186112500008
J	Prise, KM; Folkard, M; Michael, BD				Prise, KM; Folkard, M; Michael, BD			Bystander responses induced by low LET radiation	ONCOGENE			English	Article						bystander response; low LET; cell signalling; microbeam	CHARGED-PARTICLE MICROBEAM; INDUCED GENOMIC INSTABILITY; EARLY DNA-DAMAGE; IONIZING-RADIATION; HUMAN FIBROBLASTS; ALPHA-PARTICLES; IN-VIVO; X-RAY; UNIRRADIATED CELLS; INTERCELLULAR COMMUNICATION	Radiation-induced bystander responses are observed when cells respond to their neighbours being irradiated. Considerable evidence is now available regarding the importance of these responses in cell and tissue models. Most studies have utilized two approaches where either a media-transferable factor has been assessed or cells have been exposed to low fluences of charged particles, where only a few percent are exposed. The development of microbeams has allowed nontargeted responses such as bystander effects to be more carefully analysed. As well as charged particle microbeams, X-ray microprobes have been developed, and several groups are also developing electron microbeams. Using the Gray Cancer Institute soft X-ray microprobe, it has been possible to follow the response of individual cells to targeted low doses of carbon-characteristic soft X-rays. Studies in human fibroblasts have shown evidence of a significant radiation quality-dependent bystander effect, measured as chromosomal damage in the form of micronuclei which is radiation quality dependent. Other studies show that even under conditions when only a single cell is targeted with soft X-rays, significant bystander-mediated cell killing is observed. The observation of bystander responses with low LET radiation suggests that these may be important in understanding radiation risk from background levels of radiation, where cells observe only single electron track traversals. Also, the indirect evidence for these responses in vivo indicates that they may have a role to play in current radiotherapy approaches and future novel strategies involving modulating nontargeted responses.	Mt Vernon Hosp, Gray Canc Inst, Cell & Mol Biophys Grp, Northwood HA6 2RN, Middx, England	University of Oxford	Prise, KM (corresponding author), Mt Vernon Hosp, Gray Canc Inst, Cell & Mol Biophys Grp, POB 100, Northwood HA6 2RN, Middx, England.		Prise, Kevin/N-7872-2015; Michael, Barry D/C-7126-2008	Prise, Kevin/0000-0001-6134-7946; 				AUCLAIR C, 1990, ARCH BIOCHEM BIOPHYS, V278, P238, DOI 10.1016/0003-9861(90)90253-U; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Belyakov OV, 1999, INT J RADIAT BIOL, V75, P985, DOI 10.1080/095530099139746; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; BISHAYEE A, 2000, RADIAT RES, V155, P1; BRABY LA, 1992, SCANNING MICROSCOPY, V6, P164; Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V; Camphausen K, 2003, CANCER RES, V63, P1990; Denning C, 1997, HUM GENE THER, V8, P1825, DOI 10.1089/hum.1997.8.15-1825; Emerit I, 1996, P NATL ACAD SCI USA, V93, P12799, DOI 10.1073/pnas.93.23.12799; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; EMERIT I, 1991, FREE RADICAL BIO MED, V10, P371, DOI 10.1016/0891-5849(91)90045-5; Engels H, 1999, STRAHLENTHER ONKOL, V175, P47, DOI 10.1007/BF03038888; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 2001, RADIAT RES, V156, P796, DOI 10.1667/0033-7587(2001)156[0796:AFUXRM]2.0.CO;2; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; HICKMAN AW, 1994, CANCER RES, V54, P5797; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; Iyer R, 2002, MUTAT RES-FUND MOL M, V503, P1, DOI 10.1016/S0027-5107(02)00068-4; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; KORYSTOV YN, 1993, RADIAT RES, V134, P301, DOI 10.2307/3578189; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; McMasters RA, 1998, HUM GENE THER, V9, P2253, DOI 10.1089/hum.1998.9.15-2253; Mesnil M, 1996, P NATL ACAD SCI USA, V93, P1831, DOI 10.1073/pnas.93.5.1831; Miller JH, 2000, RADIAT ENVIRON BIOPH, V39, P173, DOI 10.1007/s004110000057; Miller RC, 1999, P NATL ACAD SCI USA, V96, P19, DOI 10.1073/pnas.96.1.19; Moiseenko VV, 2000, INT J RADIAT ONCOL, V48, P1539, DOI 10.1016/S0360-3016(00)00802-6; MORGAN GW, 1995, INT J RADIAT ONCOL, V31, P361, DOI 10.1016/0360-3016(94)00477-3; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Nagar S, 2003, CANCER RES, V63, P324; NAGASAWA H, 1992, CANCER RES, V52, P6394; Obedian E, 2000, J CLIN ONCOL, V18, P2406, DOI 10.1200/JCO.2000.18.12.2406; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Prise KM, 2000, ADV SPACE RES, V25, P2095, DOI 10.1016/S0273-1177(99)01060-1; PRISE KM, 2000, RADIAT RES, V2, P174; Ramesh R, 1996, EXP HEMATOL, V24, P829; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Schettino G, 2002, RADIAT PROT DOSIM, V99, P287, DOI 10.1093/oxfordjournals.rpd.a006786; Schettino G, 2001, RADIAT RES, V156, P526, DOI 10.1667/0033-7587(2001)156[0526:LDHICH]2.0.CO;2; SCHETTINO G, UNPUB; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 2001, J RADIAT RES, V42, P305, DOI 10.1269/jrr.42.305; Watson GE, 2000, CANCER RES, V60, P5608; Wilson WE, 2001, RADIAT RES, V155, P89, DOI 10.1667/0033-7587(2001)155[0089:MOAKEM]2.0.CO;2; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699	55	75	77	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7043	7049		10.1038/sj.onc.1206991	http://dx.doi.org/10.1038/sj.onc.1206991			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557809				2022-12-28	WOS:000185903900009
J	Levchenko, T; Bratt, A; Arbiser, JL; Holmgren, L				Levchenko, T; Bratt, A; Arbiser, JL; Holmgren, L			Angiomotin expression promotes hemangioendothelioma invasion	ONCOGENE			English	Article						angiostatin; angiomotin; angiogenesis; motility	ENDOTHELIAL-CELL MIGRATION; TRACTIONAL FORCES; TUMOR INVASION; ANGIOGENESIS; PROTEIN; PROTEOLYSIS; ANGIOSTATIN; MECHANISMS; GROWTH	Angiomotin was identified by its ability to bind angiostatin and has been shown to mediate its activity in vitro. The family of angiomotin-like protein consists of three members that have coiled-coil domains and conserved c-terminal PDZ-binding motifs. We show here that expression of angiomotin in mouse aortic endothelial (MAE) cells results in stabilization of tubes in the Matrigel assay. Control tubes start to regress after 72 h, whereas MAE-angiomotin ( MAE Amot) tubes were stable for over 30 days. In contrast, cells expressing a functional mutant lacking the PDZ protein interaction motif did not migrate and form tubes. Cells from the established tubes invaded into the solidified matrigel. We therefore tested whether angiomotin promotes endothelial invasion. In microcarrier-based invasion in vitro assay, angiomotin-expressing cells invaded collagen matrix and formed tube-like branches. This was confirmed in vivo as injection of MAE-Amot cells promoted tumor growth and invasion into surrounding muscle tissue. Injection of cells transfected with the functional mutant resulted in establishment of noninvasive tumors surrounded by a capsule of fibrous tissue. These tumors remained in constant size or dormant over 3 weeks. Zymogel analysis of the transfected cells did not reveal any differences in proteolytic activity. However, time-lapse photography showed a significant increase in random motility in MAE-Amot cells. We conclude that angiomotin may promote angiogenesis by both stimulating invasion as well as stabilizing established tubes.	Karolinska Inst, Ctr Canc, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA	Karolinska Institutet; Emory University	Holmgren, L (corresponding author), Karolinska Hosp, CCK,R8-03, S-17176 Stockholm, Sweden.	lars.holmgren@cck.ki.se		Tegnebratt, Tetyana/0000-0003-4298-2295	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR044947, P30AR042687] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR44947, AR42687, AR02030] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Auerbach R, 2003, CLIN CHEM, V49, P32, DOI 10.1373/49.1.32; Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Bratt A, 2002, GENE, V298, P69, DOI 10.1016/S0378-1119(02)00928-9; Edwards DR, 1998, NATURE, V394, P527, DOI 10.1038/28961; Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Holmgren L, 1996, CANCER METAST REV, V15, P241, DOI 10.1007/BF00437478; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Lawler J, 2002, J CELL MOL MED, V6, P1, DOI 10.1111/j.1582-4934.2002.tb00307.x; Levchenko T, 2003, J CELL SCI, V116, P3803, DOI 10.1242/jcs.00694; LIOTTA LA, 1984, AM J PATHOL, V117, P339; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Nyberg P, 2003, J BIOL CHEM, V278, P22404, DOI 10.1074/jbc.M210325200; Parker KK, 2002, FASEB J, V16, DOI 10.1096/fj.02-0038com; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Pintucci Giuseppe, 1996, Seminars in Thrombosis and Hemostasis, V22, P517, DOI 10.1055/s-2007-999054; Serini G, 2003, EMBO J, V22, P1771, DOI 10.1093/emboj/cdg176; Staff AC, 2001, SCAND J CLIN LAB INV, V61, P257, DOI 10.1080/00365510152378978; Troyanovsky B, 2001, J CELL BIOL, V152, P1247, DOI 10.1083/jcb.152.6.1247; Vouret-Craviari V, 1998, MOL BIOL CELL, V9, P2639, DOI 10.1091/mbc.9.9.2639; Wang N, 2002, CELL MOTIL CYTOSKEL, V52, P97, DOI 10.1002/cm.10037; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F	24	38	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1469	1473		10.1038/sj.onc.1207264	http://dx.doi.org/10.1038/sj.onc.1207264			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14730344				2022-12-28	WOS:000189035800014
J	der-Sarkissian, H; Bacchetti, S; Cazes, L; Londono-Vallejo, JA				der-Sarkissian, H; Bacchetti, S; Cazes, L; Londono-Vallejo, JA			The shortest telomeres drive karyotype evolution in transformed cells	ONCOGENE			English	Article						telomere length heterogeneity; chromosome instability; tumorigenesis	CHROMOSOME INSTABILITY; REPLICATIVE SENESCENCE; LENGTH; IMMORTALIZATION; DYSFUNCTION; CANCER; HETEROGENEITY; DYNAMICS; CRISIS; HUMANS	Maintenance of telomeres is essential for chromosome stability. In the absence of telomerase, telomeres shorten with cell division until they approach a stability threshold, at which point cells enter senescence. When senescence-signaling pathways are inactive, further telomere shortening leads to chromosome instability characterized by telomeric fusions and breakage-fusion-bridge (BFB) cycles. Since the distribution of telomere lengths among chromosome extremities is heterogeneous, we wondered about the impact of such variability on the stability of particular chromosome arms. We correlated the initial length of individual telomeres in telomerase-negative-transformed cells with the stability of the corresponding chromosome arms during the precrisis period. We show that arms carrying the shortest telomeres are the first to become unstable and this instability affects the chromosome homologues with shorter telomeres almost exclusively. The analysis of several postcrisis cell populations, which had stabilized their telomeres by re-expressing telomerase, showed that the karyotypic outcome is strongly influenced by the initial telomere length heterogeneity. The timing of telomerase re-expression also seems to play a role in limiting the extent of karyotypic changes, probably by reducing the frequency of telomeric fusions and hence BFB. Since the distribution of telomere lengths within somatic cells is proper to every individual, our results predict that the risk for a particular chromosome arm of becoming unstable early in tumorigenesis will differ between individuals and contribute directly to the heterogeneity of chromosome aberrations found in tumors.	Ctr Etud Polymorphisme Humain, F-75010 Paris, France; Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy; INSERM, U434, F-75010 Paris, France	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Institut National de la Sante et de la Recherche Medicale (Inserm)	Londono-Vallejo, JA (corresponding author), Ctr Etud Polymorphisme Humain, 27 Rue Julliette Dodu, F-75010 Paris, France.	londono@cephb.fr	Londono-Vallejo, Arturo/ABH-5555-2020	Londono-Vallejo, Arturo/0000-0003-3535-7563				Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; ALLSOPP RC, 1995, EXP CELL RES, V220, P194, DOI 10.1006/excr.1995.1306; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Baird DM, 2003, NAT GENET, V33, P203, DOI 10.1038/ng1084; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; CHERIF D, 1993, GENE CHROMOSOME CANC, V6, P107, DOI 10.1002/gcc.2870060207; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; Der-Sarkissian H, 2002, GENOME RES, V12, P1673, DOI 10.1101/gr.322802; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Duncan EL, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1263; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Graakjaer J, 2003, MECH AGEING DEV, V124, P629, DOI 10.1016/S0047-6374(03)00081-2; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; Henderson S, 1996, J CELL BIOL, V134, P1, DOI 10.1083/jcb.134.1.1; Ishikawa F, 1997, BIOCHEM BIOPH RES CO, V230, P1, DOI 10.1006/bbrc.1996.5928; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Lansdorp PM, 2000, MECH AGEING DEV, V118, P23, DOI 10.1016/S0047-6374(00)00151-2; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Londono-Vallejo JA, 2001, NUCLEIC ACIDS RES, V29, P3164, DOI 10.1093/nar/29.15.3164; Martens UM, 1998, NAT GENET, V18, P76, DOI 10.1038/ng0198-018; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; Stewart SA, 2003, NAT GENET, V33, P492, DOI 10.1038/ng1127; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	33	78	80	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1221	1228		10.1038/sj.onc.1207152	http://dx.doi.org/10.1038/sj.onc.1207152			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14716292				2022-12-28	WOS:000188892200006
J	Koh, EY; Chen, T; Daley, GQ				Koh, EY; Chen, T; Daley, GQ			Genetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation	ONCOGENE			English	Article						expression cloning; cytokine signaling; tyrosine kinase; myeloproliferative disease	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLONY-STIMULATING FACTOR; HOMEOBOX GENE; PROTEIN-KINASE; MYELODYSPLASTIC SYNDROMES; DIFFERENTIAL EXPRESSION; TRANSCRIPTION FACTORS; TRANSFORMING GENE; MYELOID-LEUKEMIA	Molecular evidence suggests a multistep process in the development of acute leukemia. Since inappropriate activation of cytokine signaling cascades is a recurring theme in human leukemia, we performed expression screens to identify genes that transform cytokine-dependent cells. Using retroviral cDNA libraries derived from peripheral blood mononuclear cells of patients with myeloproliferative disorders, we isolated numerous genes that genetically complement cytokine requirements for proliferation of BaF/3 and TF-1 cells. The majority of recovered genes represent members of the kinase family, including several previously linked to leukemogenesis. Our unbiased screen highlights the central role of kinase activation in hematopoietic cell proliferation and identifies a number of potential leukemic oncoproteins.	Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA; Harvard Univ, Sch Med,Childrens Hosp, Dept Biol Chem & Mol Pharmacol, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Daley, GQ (corresponding author), Whitehead Inst, Cambridge Ctr 9, Cambridge, MA 02142 USA.	daley@wi.mit.edu			NATIONAL CANCER INSTITUTE [R29CA076418, R01CA086991, T32CA009541] Funding Source: NIH RePORTER; NCI NIH HHS [CA09541, CA76418, CA86991] Funding Source: Medline; NIGMS NIH HHS [T32 GM007753, GM07753-22] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ALLEN JD, 1995, J IMMUNOL, V154, P1531; ALLEN JD, 1993, BLOOD, V81, P3242; AOKI M, 1993, J BIOL CHEM, V268, P22723; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; BAKER DA, 1994, LEUKEMIA, V8, P141; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108; Bourette RP, 1992, GROWTH FACTORS, V7, P315, DOI 10.3109/08977199209046414; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; CHAN AML, 1993, ONCOGENE, V8, P1329; Cillo C, 1999, EXP CELL RES, V248, P1, DOI 10.1006/excr.1999.4451; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Deguchi K, 2002, LEUKEMIA, V16, P740, DOI 10.1038/sj.leu.2402500; DEGUCHI Y, 1992, J BIOL CHEM, V267, P8222; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAMPE A, 1982, CELL, V30, P775, DOI 10.1016/0092-8674(82)90282-3; Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5; Hanada M, 1998, FEBS LETT, V437, P172, DOI 10.1016/S0014-5793(98)01229-0; Hansen GM, 1999, ONCOGENE, V18, P6531, DOI 10.1038/sj.onc.1203023; Hariharan I K, 1988, Oncogene Res, V3, P387; Ho JMY, 1999, BLOOD, V93, P4354, DOI 10.1182/blood.V93.12.4354.412k30_4354_4364; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Koh EY, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf142; KOH EY, 2001, CHRONIC MYELOID LEUK, P56; Kulkarni S, 2000, CANCER RES, V60, P3592; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Magli MC, 1997, J CELL PHYSIOL, V173, P168, DOI 10.1002/(SICI)1097-4652(199711)173:2<168::AID-JCP16>3.0.CO;2-C; MANFIOLETTI G, 1995, BLOOD, V85, P1237, DOI 10.1182/blood.V85.5.1237.bloodjournal8551237; MCARTHUR GA, 1994, BLOOD, V83, P972; McCubrey JA, 1998, LEUKEMIA, V12, P1903, DOI 10.1038/sj.leu.2401215; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peters DG, 2001, ONCOGENE, V20, P2636, DOI 10.1038/sj.onc.1204374; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Tabrizi M, 1998, LEUKEMIA, V12, P200, DOI 10.1038/sj.leu.2400949; TOBAL K, 1990, LEUKEMIA, V4, P486; TRUS MD, 1982, J BIOL CHEM, V257, P2730; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Yates KE, 1996, STEM CELLS, V14, P117, DOI 10.1002/stem.140117	61	8	8	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1214	1220		10.1038/sj.onc.1207209	http://dx.doi.org/10.1038/sj.onc.1207209			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647454				2022-12-28	WOS:000188892200005
J	Ismail, IH; Martensson, S; Moshinsky, D; Rice, A; Tang, C; Howlett, A; McMahon, G; Hammarsten, O				Ismail, IH; Martensson, S; Moshinsky, D; Rice, A; Tang, C; Howlett, A; McMahon, G; Hammarsten, O			SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization	ONCOGENE			English	Article						radiotherapy; DNA-PK; radio sensitizer; ATM	SEVERE COMBINED IMMUNODEFICIENCY; CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN TUMOR-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; MAMMALIAN DNA; HISTONE H2AX; PHOSPHORYLATION; WORTMANNIN	Loss of the DNA-dependent protein kinase (DNA-PK) results in increased sensitivity to ionizing radiation due to inefficient repair of DNA double-strand breaks. Overexpression of DNA-PK in tumor cells conversely results in resistance to ionizing radiation. It is therefore possible that inhibition of DNA-PK will enhance the preferential killing of tumor cells by radiotherapy. Available inhibitors of DNA-PK, like wortmannin, are cytotoxic and stop the cell cycle because they inhibit phoshatidylinositol-3-kinases at 100-fold lower concentrations required to inhibit DNA-PK. In an effort to develop a specific DNA-PK inhibitor, we have characterized SU11752, from a three-substituted indolin-2-ones library. SU11752 and wortmannin were equally potent inhibitors of DNA-PK. In contrast, inhibition of the phoshatidylinositol-3-kinase p110gamma required 500-fold higher concentration of SU11752. Thus, SU11752 was a more selective inhibitor of DNA-PK than wortmannin. Inhibition kinetics and a direct assay for ATP binding showed that SU11752 inhibited DNA-PK by competing with ATP. SU11752 inhibited DNA double-strand break repair in cells and gave rise to a five-fold sensitization to ionizing radiation. At concentrations of SU11752 that inhibited DNA repair, cell cycle progression was still normal and ATM kinase activity was not inhibited. We conclude that SU11752 defines a new class of drugs that may serve as a starting point for the development of specific DNA-PK inhibitors.	Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden; SUGEN Inc, San Francisco, CA 94080 USA	Sahlgrenska University Hospital; University of Gothenburg; Pfizer	Hammarsten, O (corresponding author), Gothenburg Univ, Sahlgrens Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.	ola.hammarsten@clinchem.gu.se	Hammarsten, Ola/A-2791-2012	Ismail, Ismail Hassan/0000-0002-5526-6063				Ahn JY, 2000, CANCER RES, V60, P5934; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Boulton S, 1996, CARCINOGENESIS, V17, P2285, DOI 10.1093/carcin/17.11.2285; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chernikova SB, 1999, RADIAT RES, V151, P159, DOI 10.2307/3579766; Christodoulopoulos G, 1998, CANCER RES, V58, P1789; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; Cospedal R, 1999, CARDIOVASC RES, V41, P708, DOI 10.1016/S0008-6363(98)00232-6; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Dibiase SJ, 2000, CANCER RES, V60, P1245; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Elmroth K, 2000, INT J RADIAT BIOL, V76, P1501, DOI 10.1080/09553000050176261; Elmroth K, 2003, DNA REPAIR, V2, P363, DOI 10.1016/S1568-7864(02)00235-5; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frit P, 1999, MOL PHARMACOL, V56, P141, DOI 10.1124/mol.56.1.141; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammarsten O, 2000, J BIOL CHEM, V275, P1541, DOI 10.1074/jbc.275.3.1541; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; Izzard RA, 1999, CANCER RES, V59, P2581; Jackson SP, 2001, BIOCHEM SOC T, V29, P655, DOI 10.1042/BST0290655; Kemp CJ, 1999, CARCINOGENESIS, V20, P2051, DOI 10.1093/carcin/20.11.2051; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Martensson S, 2002, J BIOL CHEM, V277, P3020, DOI 10.1074/jbc.M106711200; Martensson S, 2003, RADIAT RES, V160, P291, DOI 10.1667/0033-7587(2003)160[0291:AOTDPK]2.0.CO;2; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mizuta R, 1997, INT IMMUNOL, V9, P1607, DOI 10.1093/intimm/9.10.1607; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; NIAS AHW, 1998, INTRO RADIOBIOLOGY, P116; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Puglianiello A, 2000, J ENDOCRINOL, V165, P123, DOI 10.1677/joe.0.1650123; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; RUBIN P, 1993, CLIN ONCOLOGY MULTID, P71; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shen HX, 1997, ONCOL RES, V9, P295; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shin EK, 1997, J IMMUNOL, V158, P3565; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; Stenerlow B, 2003, RADIAT RES, V159, P502, DOI 10.1667/0033-7587(2003)159[0502:MOPDDS]2.0.CO;2; Stockley M, 2001, BIOORG MED CHEM LETT, V11, P2837, DOI 10.1016/S0960-894X(01)00537-6; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TAKE Y, 1995, BIOCHEM BIOPH RES CO, V215, P41, DOI 10.1006/bbrc.1995.2431; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Tounekti O, 2001, BRIT J CANCER, V84, P1272, DOI 10.1054/bjoc.2001.1786; Vaganay-Juery S, 2000, BRIT J CANCER, V83, P514, DOI 10.1054/bjoc.2000.1258; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang HC, 2001, CANCER RES, V61, P270; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; Williams CJ, 2001, MOL CELL BIOL, V21, P400, DOI 10.1128/MCB.21.2.400-413.2001; XU W, 2002, NAT CELL BIOL, V2, P339; Zhao HJ, 2000, CLIN CANCER RES, V6, P1073	67	72	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					873	882		10.1038/sj.onc.1207303	http://dx.doi.org/10.1038/sj.onc.1207303			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661061				2022-12-28	WOS:000188486600002
J	Sukhai, MA; Wu, XM; Xuan, YL; Zhang, T; Reis, PP; Dube, K; Rego, EM; Bhaumik, M; Bailey, DJ; Wells, RA; Kamel-Reid, S; Pandolfi, PP				Sukhai, MA; Wu, XM; Xuan, YL; Zhang, T; Reis, PP; Dube, K; Rego, EM; Bhaumik, M; Bailey, DJ; Wells, RA; Kamel-Reid, S; Pandolfi, PP			Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; NuMA-RAR alpha; transgenic model; immunophenotype	ACID RECEPTOR-ALPHA; CHROMOSOMAL-ABNORMALITIES; PML/RAR-ALPHA; T(15-17) TRANSLOCATION; VARIANT TRANSLOCATION; PMLRAR-ALPHA; BONE-MARROW; PROTEIN; FUSION; APL	Acute promyelocytic leukemia (APL) is characterized by the accumulation of abnormal promyelocytes in the bone marrow (BM), and by the presence of a reciprocal chromosomal translocation involving retinoic acid receptor alpha (RARalpha). To date, five RARalpha partner genes have been identified in APL. NuMA-RARalpha was identified in a pediatric case of APL carrying a translocation t(11;17)(q13;q21). Using a construct containing the NuMA-RARalpha fusion gene driven by the human cathepsin G promoter (hCG-NuMA-RARalpha), two transgenic mouse lines were generated. Transgenic mice were observed to have a genetic myeloproliferation (increased granulopoiesis in BM) at an early age, and rapidly developed a myeloproliferative disease-like myeloid leukemia. This leukemia was morphologically and immunophenotypically indistinguishable from human APL, with a penetrance of 100%. The phenotype of transgenic mice was consistent with a blockade of neutrophil differentiation. NuMA-RARalpha is therefore sufficient for disease development in this APL model.	Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON, Canada; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol & Dev Biol Lab, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Univ Hlth Network, Ontario Canc Inst, Dept Pathol, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Kamel-Reid, S (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Room 9-622,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	s.kamel.reid@utoronto.ca	Rego, Eduardo M./Y-5572-2019; Rego, Eduardo/AFS-7973-2022; dos Reis, Patricia Pintor/F-4701-2012; Rego, Eduardo M/A-1058-2012	Rego, Eduardo M./0000-0003-1567-4086; Rego, Eduardo/0000-0003-1567-4086; dos Reis, Patricia Pintor/0000-0003-3775-3797; Rego, Eduardo M/0000-0003-1567-4086; Kamel-Reid, Suzanne/0000-0002-4386-0292	NATIONAL CANCER INSTITUTE [R01CA074031, U01CA084292, R01CA071692] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84292, R01 CA74031, R01 CA71692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; de Botton S, 2000, BRIT J HAEMATOL, V111, P801, DOI 10.1046/j.1365-2141.2000.02442.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; GRIGNANI F, 1994, BLOOD, V83, P10; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; HARMON DC, 1991, LEUKEMIAS, P399; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lane AA, 2002, BLOOD, V100, p538A; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Okubo T, 2000, CELL STRUCT FUNCT, V25, P133, DOI 10.1247/csf.25.133; PAIETTA E, 1994, LEUKEMIA, V8, P1108; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; Rizzatti EG, 2002, AM J CLIN PATHOL, V118, P31, DOI 10.1309/6U82-2WNG-4KX3-HBMA; ROWLEY JD, 1977, INT J CANCER, V20, P869, DOI 10.1002/ijc.2910200608; ROWLEY JD, 1977, LANCET, V1, P549; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Vickers M, 2000, LEUKEMIA, V14, P722, DOI 10.1038/sj.leu.2401722; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Weir EG, 2001, SEMIN HEMATOL, V38, P124, DOI 10.1053/shem.2001.21924; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Westervelt P, 1998, BLOOD, V92, p211A; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	48	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					665	678		10.1038/sj.onc.1207073	http://dx.doi.org/10.1038/sj.onc.1207073			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737102				2022-12-28	WOS:000188304900005
J	Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE				Duxbury, MS; Ito, H; Zinner, MJ; Ashley, SW; Whang, EE			CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells	ONCOGENE			English	Article						anoikis; pancreatic cancer; adenocarcinoma; CEACAM6; RNA interference; metastasis	CARCINOEMBRYONIC ANTIGEN FAMILY; INTEGRIN-LINKED KINASE; GPI-ANCHORED PROTEINS; COLON-CANCER CELLS; DUCTAL ADENOCARCINOMA; BILIARY GLYCOPROTEIN; MELANOMA-CELLS; TUMOR-GROWTH; CEA FAMILY; N-DOMAINS	Anoikis is the apoptotic response induced in normal cells by inadequate or inappropriate adhesion to substrate. It is postulated that resistance to anoikis facilitates tumorigenesis and metastasis. Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is an immunoglobulin superfamily member overexpressed in a number of human cancers and implicated in anoikis resistance. We tested the effect of CEACAM6 gene silencing on anoikis in pancreatic adenocarcinoma cell lines. Anoikis was induced in PANC1, Capan2, MiaPaCa2 and Mia(AR) (a MiaPaCa2-derived anoikis-resistant subline) by culture in poly-2-hydroxyethylmethacrylate-coated wells. Anoikis was quantified by YO-PRO-1/propidium iodide staining and flow cytometry. The role of caspase activation was determined using fluorometric profiling and the caspase inhibitor Z-Val-Ala-Asp-fluoromethyl ketone (Z-VAD-fmk). CEACAM6 expression was suppressed by RNA interference. Using a nude mouse orthotopic xenograft model, we assessed the effect of this treatment on in vivo metastatic ability. Anoikis resistance was associated with increased CEACAM6 expression. CEACAM6-specific short interfering ribonucleic acid (siRNA), but not control siRNA, increased susceptibility to caspase-mediated anoikis, an effect abrogated by Z-VAD-fmk, and decreased Akt phosphorylation (Ser-473) under anchorage-independent conditions. CEACAM6 gene silencing reversed the acquired anoikis resistance of Mia(AR) and inhibited its in vivo metastatic ability. CEACAM6 warrants further investigation as a novel therapeutic target for the treatment of pancreatic adenocarcinoma.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Whang, EE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, 75 Francis St, Boston, MA 02115 USA.	ewhang1@partners.org						Arvelo Francisco, 2001, Acta Cientifica Venezolana, V52, P304; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Beauchemin N, 1999, EXP CELL RES, V252, P243; Bouvet M, 2002, CANCER RES, V62, P1534; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; CHEVINSKY AH, 1991, SEMIN SURG ONCOL, V7, P162, DOI 10.1002/ssu.2980070309; COURNOYER D, 1988, CANCER RES, V48, P3153; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Farrell TJ, 1997, ANN SURG, V226, P66, DOI 10.1097/00000658-199707000-00009; Fidler I J, 1978, Adv Cancer Res, V28, P149, DOI 10.1016/S0065-230X(08)60648-X; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gardner-Thorpe J, 2002, BIOCHEM BIOPH RES CO, V293, P391, DOI 10.1016/S0006-291X(02)00237-1; GORELIK E, 1993, CLIN EXP METASTAS, V11, P439, DOI 10.1007/BF00054935; HASEGAWA T, 1993, BRIT J CANCER, V67, P58, DOI 10.1038/bjc.1993.9; Ilantzis C, 2002, NEOPLASIA, V4, P151, DOI 10.1038/sj.neo.7900201; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim HRC, 1999, CANCER RES, V59, P4148; KODERA Y, 1993, BRIT J CANCER, V68, P130, DOI 10.1038/bjc.1993.300; Kunath T, 1995, ONCOGENE, V11, P2375; Kuroki M, 2001, J LEUKOCYTE BIOL, V70, P543; Malek T R, 1994, Semin Immunol, V6, P105, DOI 10.1006/smim.1994.1015; MAYNE KM, 1993, BRIT J HAEMATOL, V83, P30, DOI 10.1111/j.1365-2141.1993.tb04627.x; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miknyoczki SJ, 1999, CLIN CANCER RES, V5, P2205; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; Ordonez C, 2000, CANCER RES, V60, P3419; Perugini RA, 2000, J SURG RES, V90, P39, DOI 10.1006/jsre.2000.5833; Qiao L, 1996, CANCER LETT, V107, P83, DOI 10.1016/0304-3835(96)04346-7; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; RAZ A, 1983, SCIENCE, V221, P1307, DOI 10.1126/science.6612347; ROBINSON P, 1994, BRAZ J MED BIOL RES, V27, P263; Scholzel S, 2000, AM J PATHOL, V156, P595, DOI 10.1016/S0002-9440(10)64764-5; Semba S, 2003, PANCREAS, V26, P250, DOI 10.1097/00006676-200304000-00008; Shanmugathasan M, 2000, PATHOL INT, V50, P273, DOI 10.1046/j.1440-1827.2000.01047.x; Skubitz KM, 2001, J PEPT RES, V58, P515, DOI 10.1034/j.1399-3011.2001.00931.x; Soeth E, 2001, CLIN CANCER RES, V7, P2022; Stanners CP, 1998, CELL ADHES COMMUN S, V5, P57; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; TAN MH, 1985, TUMOUR BIOL, V6, P89; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; Wang WX, 2001, ANTICANCER RES, V21, P1789; Wirth T, 2002, CLIN EXP METASTAS, V19, P155, DOI 10.1023/A:1014566127493; Yao Z, 2002, PANCREAS, V24, P42, DOI 10.1097/00006676-200201000-00006; Yawata A, 1998, ONCOGENE, V16, P2681, DOI 10.1038/sj.onc.1201792; Zhu ZY, 2001, CANCER RES, V61, P1707	50	151	168	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					465	473		10.1038/sj.onc.1207036	http://dx.doi.org/10.1038/sj.onc.1207036			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724575				2022-12-28	WOS:000188098300017
J	Faast, R; White, J; Cartwright, P; Crocker, L; Sarcevic, B; Dalton, S				Faast, R; White, J; Cartwright, P; Crocker, L; Sarcevic, B; Dalton, S			Cdk6-cyclin D3 activity in murine ES cells is resistant to inhibition by p16(INK4a)	ONCOGENE			English	Article						ES cells; cyclin D; p16; differentiation	DEPENDENT KINASE CDK6; CYCLIN D1 EXPRESSION; EMBRYONIC STEM-CELLS; TUMOR-SUPPRESSOR; REPLICATIVE SENESCENCE; STRUCTURAL BASIS; INK4 FAMILY; MOUSE; GENE; PROTEIN	Through a screen aimed at identifying genes that are specifically upregulated in embryomic stem (ES) cells but not primitive ectoderm, we identified cyclin D3. This was surprising since cyclin D activity is generally believed to be inactive in ES cells even though retinoblastoma tumor suppressor protein (pRb) accumulates in a predominantly hyperphosphorylated state. Cdk6 is the major catalytic partner for cyclin D3 in ES cells and exhibits robust pRb kinase activity that is downregulated during the early stages of ES embryoid body differentiation. To investigate the basis underlying the insensitivity of ES cells to ectopic p16 expression, we show that Cdk6-cyclin D3 complexes are not subject to inhibition by p16, similar to Cdk-viral cyclin complexes. These observations show that specificity exists between Cdk4/6-cyclin D complexes and their ability to be targeted by p16. Our data suggest that Cdk6-cyclin D3 activity in other cell types, including tumors, may also be refractory to p16-mediated growth inhibition and raises the possibility of additional specificity within the INK4 family.	Univ Georgia, Rhodes Ctr, Athens, GA 30602 USA; Univ Adelaide, Ctr Mol Genet Dev, Bresagen Cell Therapy Program, Dept Mol Biosci, Adelaide, SA, Australia; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	University System of Georgia; University of Georgia; University of Adelaide; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Dalton, S (corresponding author), Univ Georgia, Rhodes Ctr, 425 River Rd, Athens, GA 30602 USA.	sdalton@uga.edu		Sarcevic, Boris/0000-0002-8063-1050; Wright, Josephine/0000-0003-4588-8827; Dalton, Stephen/0000-0002-3450-1263				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burdon T, 2002, TRENDS CELL BIOL, V12, P432, DOI 10.1016/S0962-8924(02)02352-8; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Fahraeus R, 1999, EMBO J, V18, P2106, DOI 10.1093/emboj/18.8.2106; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Gabrielli BG, 1999, J BIOL CHEM, V274, P13961, DOI 10.1074/jbc.274.20.13961; GARDNER RL, 1988, J CELL SCI, P11; GARDNER RL, 1979, J EMBRYOL EXP MORPH, V52, P141; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; Grossel MJ, 1999, J BIOL CHEM, V274, P29960, DOI 10.1074/jbc.274.42.29960; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Halaban R, 1999, CANCER METAST REV, V18, P333, DOI 10.1023/A:1006396104073; Hara E, 1996, MOL CELL BIOL, V16, P859; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HAUB O, 1991, DEVELOPMENT, V112, P397; Humbert PO, 2000, MOL CELL, V6, P281, DOI 10.1016/S1097-2765(00)00029-0; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; JIANG H, 1998, MOL CELL BIOL, V130, P755; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lake JA, 2000, J CELL SCI, V113, P555; Laman H, 2000, CURR OPIN GENET DEV, V10, P70, DOI 10.1016/S0959-437X(99)00045-3; Lin J, 2001, ONCOGENE, V20, P2000, DOI 10.1038/sj.onc.1204375; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pelton TA, 1998, REPROD FERT DEVELOP, V10, P535, DOI 10.1071/RD98084; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Pratt T, 2000, DEV BIOL, V228, P19, DOI 10.1006/dbio.2000.9935; QUELLE DE, 1995, ONCOGENE, V11, P635; Rathjen J, 1999, J CELL SCI, V112, P601; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROGERS MB, 1991, DEVELOPMENT, V113, P815; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sarcevic B, 1997, J BIOL CHEM, V272, P33327, DOI 10.1074/jbc.272.52.33327; Savatier P, 1996, ONCOGENE, V12, P309; SAVATIER P, 1994, ONCOGENE, V9, P809; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; SOLTER D, 1971, EXP CELL RES, V64, P331, DOI 10.1016/0014-4827(71)90084-X; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Swanton C, 1999, TRENDS BIOCHEM SCI, V24, P116, DOI 10.1016/S0968-0004(99)01354-7; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	60	89	91	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					491	502		10.1038/sj.onc.1207133	http://dx.doi.org/10.1038/sj.onc.1207133			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724578				2022-12-28	WOS:000188098300020
J	Huang, Y; Rangwala, F; Fulkerson, PC; Ling, B; Reed, E; Cox, AD; Kamholz, J; Ratner, N				Huang, Y; Rangwala, F; Fulkerson, PC; Ling, B; Reed, E; Cox, AD; Kamholz, J; Ratner, N			Role of TC/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells	ONCOGENE			English	Article						Schwann cell; TC21; neurofibromin; chemotaxis; R-Ras; Ras	FARNESYL-PROTEIN TRANSFERASE; NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEINS; R-RAS; TYPE-1 GENE; FARNESYLTRANSFERASE INHIBITORS; CYTOPLASMIC DOMAINS; TRANSGENIC MICE; N-RAS; H-RAS	The neurofibromatosis type 1 tumor suppressor protein neurofibromin, is a GTPase activating protein for H-, N-, K-, R-Ras and TC21/R-Ras2 proteins. We demonstrate that Schwann cells derived from Nf1-null mice have enhanced chemokinetic and chemotactic migration in comparison to wild-type controls. Surprisingly, this migratory phenotype is not inhibited by a farnesyltransferase inhibitor or dominant-negative (dn) (N17)H-Ras (which inhibits H-, N-, and K-Ras activation). We postulated that increased activity of R-Ras and/or TC21/R-Ras2, due to loss of Nf1, contributes to increased migration. Mouse Schwann cells (MSCs) express R-Ras and TC21/R-Ras2 and their specific guanine exchange factors, C3G and AND-34. Infection of Nf1-null MSCs with a dn(43N)R-Ras adenovirus (to inhibit both R-Ras and TC21/R-Ras2 activation) decreases migration by approximately 50%. Conversely, expression of activated (72L)TC21/R-Ras2, but not activated (38V)R-Ras, increases migration, suggesting a role of TC21/R-Ras2 activation in the migration of neurofibromin-deficient Schwann cells. TC21/R-Ras2 preferentially couples to the phosphatidylinositol 3-kinase (PI3-kinase) and MAP kinase pathways. Treatment with a PI3-kinase or MAP kinase inhibitor reduces Nf1-null Schwann cell migration, implicating these TC21 effectors in Schwann cell migration. These data reveal a key role for neurofibromin regulation of TC21/R-Ras2 in Schwann cells, a cell type critical to NF1 tumor pathogenesis.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Wayne State Univ, Dept Neurol, Detroit, MI 48201 USA	University System of Ohio; University of Cincinnati; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Wayne State University	Ratner, N (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 3125 Eden Ave, Cincinnati, OH 45267 USA.	nancy.ratner@uc.edu		Cox, Adrienne D./0000-0002-4901-2454; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS028840, NS-28840, R01 NS028840-09] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CARBONI JM, 1995, ONCOGENE, V10, P1905; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COX AD, 1994, ONCOGENE, V9, P3281; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Gotoh T, 2000, J BIOL CHEM, V275, P30118, DOI 10.1074/jbc.M003074200; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Graham SM, 2001, METHOD ENZYMOL, V333, P203; Guha A, 1996, ONCOGENE, V12, P507; Gutmann DH, 2001, HUM MOL GENET, V10, P3009, DOI 10.1093/hmg/10.26.3009; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huff SY, 1997, ONCOGENE, V14, P133, DOI 10.1038/sj.onc.1200815; Huson SM, 1994, NEUROFIBROMATOSES; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; KIM HA, 1995, ONCOGENE, V11, P325; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Kluwe L, 1999, GENE CHROMOSOME CANC, V24, P283, DOI 10.1002/(SICI)1098-2264(199903)24:3<283::AID-GCC15>3.0.CO;2-K; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; Movilla N, 1999, ONCOGENE, V18, P5860, DOI 10.1038/sj.onc.1202968; MUIR D, 1995, CLIN EXP METASTAS, V13, P303, DOI 10.1007/BF00133486; Murphy GA, 2002, J BIOL CHEM, V277, P9966, DOI 10.1074/jbc.M109059200; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Omer CA, 2000, CANCER RES, V60, P2680; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; REY I, 1994, ONCOGENE, V9, P685; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Serra E, 2001, NAT GENET, V28, P294, DOI 10.1038/90148; SHEELA S, 1990, J CELL BIOL, V111, P645, DOI 10.1083/jcb.111.2.645; Sherman LS, 2000, J BIOL CHEM, V275, P30740, DOI 10.1074/jbc.M001702200; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200; YAN N, 1995, CANCER RES, V55, P3569; Yu Y, 2002, ONCOGENE, V21, P7557, DOI 10.1038/sj.onc.1205961; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	64	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					368	378		10.1038/sj.onc.1207075	http://dx.doi.org/10.1038/sj.onc.1207075			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724565	Green Accepted, Green Submitted			2022-12-28	WOS:000188098300006
J	Reiter, R; Oh, AS; Wellstein, A; Riegel, AT				Reiter, R; Oh, AS; Wellstein, A; Riegel, AT			Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta 3 on estrogenic ligands with different intrinsic activity	ONCOGENE			English	Article						AIB1; coactivator; estrogen; ER	BREAST-CANCER; ER-ALPHA; TISSUE DISTRIBUTION; EXPRESSION; GROWTH; BETA; HORMONE; MAMMARY; COREGULATORS; SPECIFICITY	The nuclear receptor coactivator amplified in breast cancer 1 (AIB1) and its more active isoform AIB1-Delta3 are overexpressed in breast cancer and preneoplastic breast tissue. However, the impact of these proteins on the transcriptional activity of natural estrogens or selective estrogen receptor modulators (SERMs) has not been determined. Here we show that AIB1-Delta3 causes a significant increase in the efficacy of 17beta-estradiol at both estrogen receptor-alpha (ER-alpha) and ER-beta in ovarian, breast and endometrial cancer cell lines. AIB1-Delta3 also significantly increased the efficacy of the natural estrogen genistein at both ER-alpha and ER-beta, whereas AIB1 had no effect on either the potency or efficacy of genistein at either receptor. The estrogenic efficacy of the partial agonist tamoxifen was significantly increased in all cell lines at ER-alpha by overexpression of AIB1-Delta3 both on transfected and endogenous estrogen responsive genes. In contrast, overexpression of AIB1 or AIB1-Delta3 had no effect on the potency or efficacy of the SERM raloxifene. We conclude that overexpression of the AIB1-Delta3 isoform will increase the estrogenicity of a variety of natural and pharmacologic compounds in tissues that develop hormone-dependent neoplasias and overexpression of these cofactors may be a contributing factor to the hormone-driven development of neoplasia and to antiestrogen resistance of breast cancers.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg,Room E307, Washington, DC 20057 USA.	ariege01@georgetown.edu		Wellstein, Anton/0000-0002-0570-4950; Oh, Annabell S./0000-0002-0676-1164	NCI NIH HHS [P50 CA58185] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058185] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; AUGEREAU P, 1994, MOL ENDOCRINOL, V8, P693, DOI 10.1210/me.8.6.693; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Couse JF, 1997, ENDOCRINOLOGY, V138, P4613, DOI 10.1210/en.138.11.4613; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; Glass CK, 2000, GENE DEV, V14, P121; Guan XY, 1996, CANCER RES, V56, P3446; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurebayashi J, 2000, CLIN CANCER RES, V6, P512; Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; Liu H, 2002, J BIOL CHEM, V277, P9189, DOI 10.1074/jbc.M108335200; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Murphy LC, 2000, CANCER RES, V60, P6266; Nilsson S, 2002, CRIT REV BIOCHEM MOL, V37, P1, DOI 10.1080/10409230290771438; ONATE SA, 1995, SCIENCE, V270, P1354; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Roger P, 2001, CANCER RES, V61, P2537; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tikkanen MK, 2000, P NATL ACAD SCI USA, V97, P12536, DOI 10.1073/pnas.220427297; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Watanabe T, 1998, MOL CELL BIOL, V18, P442, DOI 10.1128/MCB.18.1.442; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498	39	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					403	409		10.1038/sj.onc.1207202	http://dx.doi.org/10.1038/sj.onc.1207202			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14691461				2022-12-28	WOS:000188098300010
J	Guo, JC; Kleeff, J; Li, JS; Ding, JY; Hammer, J; Zhao, YP; Giese, T; Korc, M; Buchler, MW; Friess, H				Guo, JC; Kleeff, J; Li, JS; Ding, JY; Hammer, J; Zhao, YP; Giese, T; Korc, M; Buchler, MW; Friess, H			Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; CDC25B; pancreatic ductal adenocarcinoma	RANDOMIZED CONTROLLED TRIAL; HUMAN COLORECTAL-CARCINOMA; TGF-BETA RESPONSIVENESS; COLO-357 CELLS; UP-REGULATION; CANCER-CELLS; PHOSPHATASE; OVEREXPRESSION; RECEPTOR; ACTIVATION	Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related deaths. Deregulation of cell-cycle control is thought to be a crucial event in malignant transformation, and CDC25 phosphatases are a family of cyclin-dependent kinase activators, which act at different points of the cell cycle, including G1-S and G2-M transition. Here, we investigated the expression and functional significance of CDC25s in PDAC. CDC25B mRNA expression levels in human pancreatic tissue samples were analysed by cDNA array, quantitative PCR and Northern blotting. Immunohistochemistry was carried out to localize and quantify CDC25B expression. Two specific CDC25B inhibitors were utilized to determine the functional relevance of CDC25B. By quantitative RT-PCR, CDC25B mRNA was overexpressed in pancreatic cancer (7.5-fold) in comparison to the normal pancreas. Strong nuclear CDC25B immunoreactivity was present in both pancreatic and metastatic cancer samples, and there was a marked increase of the percentage of positive cells in primary cancer (48.6+/-16.3%) and metastatic tissues (71.7+/-3.1%) compared to normal samples (8.3+/-1.8%). Two CDC25B inhibitors reduced the growth of pancreatic cancer cell lines, resulting in the accumulation of phosphorylated CDC2 and G2/M arrest. These findings demonstrate an important role of CDC25B in cell-cycle progression, raising the possibility that inhibition of CDC25B may have therapeutic potential in pancreatic cancer.	Univ Heidelberg, Dept Gen Surg, D-69120 Heidelberg, Germany; Beijing Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China; Hoffmann La Roche Inc, Roche Genom & Informat Sci, Nutley, NJ 07110 USA; Univ Heidelberg, Inst Immunol, D-69120 Heidelberg, Germany; Univ Calif Irvine, Dept Med Biol Chem & Pharmacol, Div Endocrinol Diabet & Metab, Irvine, CA USA	Ruprecht Karls University Heidelberg; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Roche Holding; Ruprecht Karls University Heidelberg; University of California System; University of California Irvine	Friess, H (corresponding author), Univ Heidelberg, Dept Gen Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	helmut_friess@med.uni-heidelberg.de	Kleeff, Jorg/B-2124-2009	Kleeff, Jorg/0000-0003-3432-6669; Guo, Junchao/0000-0002-7878-8315	NATIONAL CANCER INSTITUTE [R01CA040162] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40162] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldin V, 2002, J BIOL CHEM, V277, P35176, DOI 10.1074/jbc.M204430200; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Broggini M, 2000, ANTICANCER RES, V20, P4835; Davezac N, 2000, ONCOGENE, V19, P2179, DOI 10.1038/sj.onc.1203545; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Friess H, 2001, ANN SURG, V234, P769, DOI 10.1097/00000658-200112000-00008; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Ito Y, 2002, BRIT J CANCER, V86, P1909, DOI 10.1038/sj.bjc.6600364; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Kleeff J, 1998, J BIOL CHEM, V273, P7495, DOI 10.1074/jbc.273.13.7495; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; Kleeff J, 1999, PANCREAS, V18, P364, DOI 10.1097/00006676-199905000-00006; Koliopanos A, 2001, CANCER RES, V61, P4655; Kudo Y, 1997, JPN J CANCER RES, V88, P947, DOI 10.1111/j.1349-7006.1997.tb00313.x; Lal G, 2000, GENE CHROMOSOME CANC, V27, P358, DOI 10.1002/(SICI)1098-2264(200004)27:4<358::AID-GCC4>3.0.CO;2-O; Lammer C, 1998, J CELL SCI, V111, P2445; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Miyata H, 2001, CANCER RES, V61, P3188; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2001, ANN SURG, V234, P758, DOI 10.1097/00000658-200112000-00007; Ngan ESW, 2003, ONCOGENE, V22, P734, DOI 10.1038/sj.onc.1206121; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Sasaki H, 2001, CANCER LETT, V173, P187, DOI 10.1016/S0304-3835(01)00669-3; Sato Y, 2001, JPN J CLIN ONCOL, V31, P428, DOI 10.1093/jjco/hye093; Schutte M, 1996, CANCER RES, V56, P2527; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Takemasa I, 2000, CANCER RES, V60, P3043; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tureci O, 2003, FASEB J, V17, P376, DOI 10.1096/fj.02-0478com; Ulloa L, 2001, J BIOL CHEM, V276, P21397, DOI 10.1074/jbc.M010783200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wagner M, 1998, INT J CANCER, V78, P255, DOI 10.1002/(SICI)1097-0215(19981005)78:2<255::AID-IJC21>3.0.CO;2-8; WU S, 1995, DEV BIOL, V170, P195, DOI 10.1006/dbio.1995.1207	50	68	73	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					71	81		10.1038/sj.onc.1206926	http://dx.doi.org/10.1038/sj.onc.1206926			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712212				2022-12-28	WOS:000187895300008
J	Steinman, HA; Sluss, HK; Sands, AT; Pihan, G; Jones, SN				Steinman, HA; Sluss, HK; Sands, AT; Pihan, G; Jones, SN			Absence of p21 partially rescues Mdm4 loss and uncovers an antiproliferative effect of Mdm4 on cell growth	ONCOGENE			English	Article						Mdm4; p21; Mdm2; p53; mice	EMBRYONIC LETHALITY; TRANSCRIPTION FACTOR; MDM2-DEFICIENT MICE; P53; PROTEIN; DELETION	Mdm4 (MdmX) is a p53-binding protein that shares structural similarities with Mdm2 and has been proposed to be a negative regulator of p53 function. Like Mdm2, the absence of Mdm4 has recently been found to induce embryonic lethality in mice that is rescued by p53 deletion. Mdm4-null embryos are reduced in size and die at mid-gestation, and Mdm4-deficient embryos and embryonic fibroblasts displayed reduced rates of cell proliferation. The p53-induced, cyclin-dependent kinase inhibitor p21 is strongly upregulated in Mdm4-null embryos and cells. Here, we report that deletion of p21 delays the mid-gestation lethality observed in Mdm4-null mice, suggesting that Mdm4 downregulates p53-mediated suppression of cell growth. Surprisingly, the absence of p21 also uncovers an antiproliferative effect of Mdm4 on cell growth in vitro and in Mdm4-heterozygous mice. These results indicate that p21 is a downstream modifier of Mdm4, and provides genetic evidence that Mdm4 can function to regulate cell growth both positively and negatively.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Lexicon Genet, The Woodlands, TX 77381 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; Lexicon Pharmaceuticals; University of Massachusetts System; University of Massachusetts Worcester	Jones, SN (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.	stephen.jones@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA077735, R56CA077735] Funding Source: NIH RePORTER; NCI NIH HHS [CA77735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Finch RA, 2002, CANCER RES, V62, P3221; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1996, P NATL ACAD SCI USA, V93, P14106, DOI 10.1073/pnas.93.24.14106; LUNA RMD, 1995, NATURE, V378, P203; Luna RMD, 1997, NAT GENET, V16, P336; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Strachan GD, 2003, J CELL BIOCHEM, V88, P557, DOI 10.1002/jcb.10318; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	17	29	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					303	306		10.1038/sj.onc.1206925	http://dx.doi.org/10.1038/sj.onc.1206925			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712235				2022-12-28	WOS:000187895300032
J	Voz, ML; Mathys, J; Hensen, K; Pendeville, H; Van Valckenborgh, I; Van Huffel, C; Chavez, M; Van Damme, B; De Moor, B; Moreau, Y; Van de Ven, WJM				Voz, ML; Mathys, J; Hensen, K; Pendeville, H; Van Valckenborgh, I; Van Huffel, C; Chavez, M; Van Damme, B; De Moor, B; Moreau, Y; Van de Ven, WJM			Microarray screening for target genes of the proto-oncogene PLAG1	ONCOGENE			English	Article						PLAG1 gene; oligonucleotide microarray; target genes; pleomorphic adenoma; salivary gland	BINDING PROTEIN-II; PLEOMORPHIC ADENOMAS; SALIVARY-GLANDS; P57/KIP2 PROTEIN; RETINOIC ACID; IGF-II; EXPRESSION; GROWTH; FAMILY; P57(KIP2)	PLAG1 is a proto-oncogene whose ectopic expression can trigger the development of pleomorphic adenomas of the salivary glands and of lipoblastomas. As PLAG1 is a transcription factor, able to activate transcription through the binding to the consensus sequence GRGGC(N)(6-8)GGG, its ectopic expression presumably results in the deregulation of target genes, leading to uncontrolled cell proliferation. The identification of PLAG1 target genes is therefore a crucial step in understanding the molecular mechanisms involved in PLAG1-induced tumorigenesis. To this end, we analysed the changes in gene expression caused by the conditional induction of PLAG1 expression in fetal kidney 293 cell lines. Using oligonucleotide microarray analyses of about 12000 genes, we consistently identified 47 genes induced and 12 genes repressed by PLAG1. One of the largest classes identified as upregulated PLAG1 targets consists of growth factors such as the insulin-like growth factor II and the cytokine-like factor 1. The in silico search for PLAG1 consensus sequences in the promoter of the upregulated genes reveals that a large proportion of them harbor several copies of the PLAG1-binding motif, suggesting that they represent direct PLAG1 targets. Our approach was complemented by the comparison of the expression profiles of pleomorphic adenomas induced by PLAG1 versus normal salivary glands. Concordance between these two sets of experiments pinpointed 12 genes that were significantly and consistently upregulated in pleomorphic adenomas and in PLAG1-expressing cells, identifying them as putative PLAG1 targets in these tumors.	Univ Liege, Lab Biol Mol & Genie Genet, Inst Chim, B-4000 Sart Tilman Par Liege, Belgium; Katholieke Univ Leuven, Ctr Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv, Inst Biotechnol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, ESAT SCD, B-3001 Louvain, Belgium; Starlab NV SA, Dept Gen, B-1180 Brussels, Belgium; Katholieke Univ Leuven, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	University of Liege; KU Leuven; KU Leuven; KU Leuven	Voz, ML (corresponding author), Univ Liege, Lab Biol Mol & Genie Genet, Inst Chim, B6, B-4000 Sart Tilman Par Liege, Belgium.	mvoz@ulg.ac.be		Van Huffel, Christophe/0000-0001-6127-3027; Moreau, Yves/0000-0002-4647-6560				Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; Astrom AK, 1999, CANCER RES, V59, P918; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Burns JL, 2001, DEVELOPMENT, V128, P3819; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9; Coppock D, 2000, BIOCHEM BIOPH RES CO, V269, P604, DOI 10.1006/bbrc.2000.2324; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Debiec-Rychter M, 2001, LAB INVEST, V81, P1289, DOI 10.1038/labinvest.3780342; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DULL TJ, 1984, NATURE, V310, P777, DOI 10.1038/310777a0; Elson GCA, 1998, J IMMUNOL, V161, P1371; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Frade Gonzalez C., 2001, ACTA OTORRINOLARINGO, V52, P456; Grosso LE, 1996, J ORAL PATHOL MED, V25, P5, DOI 10.1111/j.1600-0714.1996.tb01215.x; Hartmann W, 2000, AM J PATHOL, V157, P1393, DOI 10.1016/S0002-9440(10)64652-4; Hensen K, 2002, CANCER RES, V62, P1510; Hibbard MK, 2000, CANCER RES, V60, P4869; Ito Y, 2002, LIVER, V22, P145, DOI 10.1034/j.1600-0676.2002.01532.x; Ito Y, 2002, INT J MOL MED, V9, P373; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kusafuka K, 1998, VIRCHOWS ARCH, V432, P247, DOI 10.1007/s004280050162; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Oya M, 2000, BRIT J CANCER, V83, P626, DOI 10.1054/bjoc.2000.1298; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; Schwienbacher C, 2000, P NATL ACAD SCI USA, V97, P5445, DOI 10.1073/pnas.090087497; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHRESTHA P, 1994, ORAL ONCOL, V30B, P393; SUNARDHIWIDYAPUTRA S, 1993, PATHOL RES PRACT, V189, P138, DOI 10.1016/S0344-0338(11)80083-X; SunardhiWidyaputra S, 1995, PATHOL RES PRACT, V191, P1186, DOI 10.1016/S0344-0338(11)81124-6; Toretsky JA, 1996, J ENDOCRINOL, V149, P367, DOI 10.1677/joe.0.1490367; Vo HP, 1998, ANTICANCER RES, V18, P217; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Zhu Q, 1997, ORAL ONCOL, V33B, P29, DOI 10.1016/S0964-1955(96)00038-3	41	88	92	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					179	191		10.1038/sj.onc.1207013	http://dx.doi.org/10.1038/sj.onc.1207013			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712223	Green Submitted			2022-12-28	WOS:000187895300019
J	Lefevre, G; Calipel, A; Mouriaux, F; Hecquet, C; Malecaze, F; Mascarelli, F				Lefevre, G; Calipel, A; Mouriaux, F; Hecquet, C; Malecaze, F; Mascarelli, F			Opposite long-term regulation of c-Myc and p27(Kip1)through overactivation of Raf-1 and the MEK/ERK module in proliferating human choroidal melanoma cells	ONCOGENE			English	Article						choroidal melanoma; proliferation; Raf-1; antisense strategy	ACTIVATED PROTEIN-KINASE; UVEAL MELANOMA; UP-REGULATION; IN-VITRO; APOPTOSIS; GROWTH; CYCLE; INHIBITION; EXPRESSION; MUTATIONS	Although there is no current evidence for ras gene mutation in choroidal melanoma, there is an increasing body of evidence indicating that deregulated intracellular signalling pathways are involved in choroidal melanoma pathogenesis. The various components of the linear Raf/MEK/ERK signalling pathway have been implicated in various tumours. We therefore investigated the role of Raf-1 and the MEK/ERK module in the proliferation of human normal choroidal melanocytes (NCM) and cells from the ocular choroidal melanoma (OCM-1) cell line. OCM-1 cells proliferated four times faster than NCM. High basal activation of the MEK/ERK module was observed in unstimulated OCM-1 cells, whereas rapid and persistent activation was detected after serum stimulation, throughout the 24-h period of culture. In contrast, the activation of MEK/ERK was barely detectable in unstimulated NCM and occurred late (6 h) after the stimulation of cell proliferation. Inhibition of Raf-1 and MEK1/2 activation by pharmacological approaches and of the production of Raf-1 and ERK1/2 by antisense oligonucleotide approaches demonstrated that Raf-1 and the MEK/ERK module controlled proliferation in OCM-1 cells, but not in NCM. OCM-1 cells produced very low levels of p27(Kip1), whereas NCM produced constant, high levels of p27(Kip1). The inhibition of Raf-1 or MEK1/2 induced a large increase in p27(Kip1) in OCM-1 cells, associated with an arrest of cell proliferation. Levels of c-Myc production were high and constant in OCM-1 cells and low in NCM, in contrast to what was observed for p27(Kip1). The inhibition of both Raf-1 and MEK1/2 induced a decrease in c-Myc production and downregulated c-Myc activity by preventing c-Myc phosphorylation in OCM-1 cells. We conclude that Raf-1 and the MEK/ERK module control the production of both p27(Kip1) and c-Myc, and the activation of c-Myc for OCM-1 cell proliferation.	Inst Biomed Cordeliers, IFR58, INSERM, U450, F-75006 Paris, France; CHRU, Hop Purpan, Serv Ophtalmol, F-31000 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; CHU de Toulouse	Mascarelli, F (corresponding author), Inst Biomed Cordeliers, IFR58, INSERM, U450, 15 Rue Ecole Med, F-75006 Paris, France.	fmascar@infobiogen.fr	Mouriaux, Frederic/T-1440-2019; Mascarelli, Frederic/L-8916-2018					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barry OP, 2001, J BIOL CHEM, V276, P15537, DOI 10.1074/jbc.M010847200; Casagrande F, 1998, FEBS LETT, V422, P385, DOI 10.1016/S0014-5793(98)00043-X; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHUANG CF, 1994, FEBS LETT, V346, P229, DOI 10.1016/0014-5793(94)00480-3; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Guise S, 2001, J NEUROSCI RES, V63, P257, DOI 10.1002/1097-4547(20010201)63:3<257::AID-JNR1019>3.0.CO;2-T; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; KANMITCHELL J, 1989, INVEST OPHTH VIS SCI, V30, P829; Kimura A, 1999, CANCER RES, V59, P5133; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; MARSHALL CJ, 1995, METHOD ENZYMOL, V255, P273; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; MOOY CM, 1991, BRIT J CANCER, V64, P411, DOI 10.1038/bjc.1991.319; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mouriaux F, 1998, INVEST OPHTH VIS SCI, V39, P876; Mouriaux F, 2000, INVEST OPHTH VIS SCI, V41, P2837; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; Pyrhonen S, 1998, EUR J CANCER, V34, pS27; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOPARKER CN, 1993, INVEST OPHTH VIS SCI, V34, P2203; Volmat V, 2001, BIOL CELL, V93, P71, DOI 10.1016/S0248-4900(01)01129-7; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev	34	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8813	8822		10.1038/sj.onc.1207099	http://dx.doi.org/10.1038/sj.onc.1207099			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654778				2022-12-28	WOS:000186982200002
J	Conte, N; Delaval, B; Ginestier, C; Ferrand, A; Isnardon, D; Larroque, C; Prigent, C; Seraphin, B; Jacquemier, J; Birnbaum, D				Conte, N; Delaval, B; Ginestier, C; Ferrand, A; Isnardon, D; Larroque, C; Prigent, C; Seraphin, B; Jacquemier, J; Birnbaum, D			TACC1-chTOG-Aurora A protein complex in breast cancer	ONCOGENE			English	Article						Aurora kinase; breast cancer; cell division; chTOG protein; microtubule; SM proteins; TACC protein; tissue microarray; RNAi	DROSOPHILA AURORA-A; SM-LIKE PROTEIN; MESSENGER-RNA; COILED-COIL; TRANSLATIONAL CONTROL; D-TACC; SERINE/THREONINE KINASE; EXPRESSION ANALYSIS; TUMOR SUPPRESSOR; GENE FAMILY	The three human TACC (transforming acidic coiled-coil) genes encode a family of proteins with poorly defined functions that are suspected to play a role in oncogenesis. A Xenopus TACC homolog called Maskin is involved in translational control, while Drosophila D-TACC interacts with the microtubule-associated protein MSPS (Mini SPindleS) to ensure proper dynamics of spindle pole microtubules during cell division. We have delineated here the interactions of TACC1 with four proteins, namely the microtubule-associated chTOG (colonic and hepatic tumor-overexpressed gene) protein (ortholog of Drosophila MSPS), the adaptor protein TRAP (tudor repeat associator with PCTAIRE2), the mitotic serine/threonine kinase Aurora A and the mRNA regulator LSM7 (Like-Sm protein 7). To measure the relevance of the TACC1-associated complex in human cancer we have examined the expression of the three TACC, chTOG and Aurora A in breast cancer using immunohistochemistry on tissue microarrays. We show that expressions of TACC1, TACC2, TACC3 and Aurora A are significantly correlated and downregulated in a subset of breast tumors. Using siRNAs, we further show that depletion of chTOG and, to a lesser extent of TACC1, perturbates cell division. We propose that TACC proteins, which we also named 'Taxins', control mRNA translation and cell division in conjunction with microtubule organization and in association with chTOG and Aurora A, and that these complexes and cell processes may be affected during mammary gland oncogenesis.	Inst J Paoli I Calmettes, INSERM, U119, IFR57,Dept Mol Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Imaging Core Facil, F-13009 Marseille, France; CRLC Val Aurelle Paul Lamarque, INSERM, E229, Montpellier, France; Fac Med, CNRS, UMR 6061, IFR 97,Lab Cycle Cellulaire, Rennes, France; Ctr Genet Mol, Gif Sur Yvette, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, INSERM, U119, IFR57,Dept Mol Oncol, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017	Ginestier, Christophe/0000-0002-7477-3837; Birnbaum, Daniel/0000-0001-7920-9883; Conte, Nathalie/0000-0002-1010-3121; Seraphin, Bertrand/0000-0002-5168-1921				Aitola M, 2003, J HISTOCHEM CYTOCHEM, V51, P455, DOI 10.1177/002215540305100407; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Barbarese E, 2002, J NEUROCHEM, V81, P93; Barbee SA, 2002, CURR BIOL, V12, P1502, DOI 10.1016/S0960-9822(02)01111-9; Berdnik D, 2002, CURR BIOL, V12, P640, DOI 10.1016/S0960-9822(02)00766-2; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blagden SP, 2003, NAT CELL BIOL, V5, P505, DOI 10.1038/ncb0603-505; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Charrasse S, 1998, J CELL SCI, V111, P1371; CHARRASSE S, 1995, EUR J BIOCHEM, V234, P406, DOI 10.1111/j.1432-1033.1995.406_b.x; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chen HM, 2000, MOL BIOL CELL, V11, P1357, DOI 10.1091/mbc.11.4.1357; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cremet JY, 2003, MOL CELL BIOCHEM, V243, P123, DOI 10.1023/A:1021608012253; Cullen CF, 2001, NAT CELL BIOL, V3, P637, DOI 10.1038/35083025; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gergely F, 2000, EMBO J, V19, P241, DOI 10.1093/emboj/19.2.241; Gergely F, 2000, P NATL ACAD SCI USA, V97, P14352, DOI 10.1073/pnas.97.26.14352; Giet R, 2002, J CELL BIOL, V156, P437, DOI 10.1083/jcb.200108135; Giet R, 1999, J CELL SCI, V112, P3591; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GREGELY F, 2003, GENE DEV, V17, P336; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Hao ZL, 2002, MOL REPROD DEV, V63, P291, DOI 10.1002/mrd.90012; Hirose T, 1997, EUR J BIOCHEM, V249, P481, DOI 10.1111/j.1432-1033.1997.t01-1-00481.x; Hirose T, 2000, EUR J BIOCHEM, V267, P2113, DOI 10.1046/j.1432-1327.2000.01218.x; Huang XQ, 1999, GENOME RES, V9, P868, DOI 10.1101/gr.9.9.868; Huang YS, 2002, EMBO J, V21, P2139, DOI 10.1093/emboj/21.9.2139; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; Lappin TR, 2002, LEUKEMIA LYMPHOMA, V43, P1455, DOI 10.1080/1042819022386644; Lauffart B, 2003, GENOMICS, V81, P192, DOI 10.1016/S0888-7543(02)00039-3; Lauffart B, 2002, BIOCHEM J, V363, P195, DOI 10.1042/0264-6021:3630195; Lee MJ, 2001, NAT CELL BIOL, V3, P643, DOI 10.1038/35083033; Line A, 2002, CANCER GENET CYTOGEN, V139, P78, DOI 10.1016/S0165-4608(02)00607-6; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mack GJ, 2000, MICROSC RES TECHNIQ, V49, P409, DOI 10.1002/(SICI)1097-0029(20000601)49:5<409::AID-JEMT2>3.0.CO;2-V; McKeveney PJ, 2001, BRIT J HAEMATOL, V112, P1016, DOI 10.1046/j.1365-2141.2001.02644.x; Mendez R, 2002, EMBO J, V21, P1833, DOI 10.1093/emboj/21.7.1833; Mendez R, 2001, NAT REV MOL CELL BIO, V2, P521, DOI 10.1038/35080081; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nonet GH, 2001, CANCER RES, V61, P1250; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Popovici C, 2001, BIOCHEM BIOPH RES CO, V288, P362, DOI 10.1006/bbrc.2001.5794; Pu JJ, 2001, CYTOKINE, V13, P129, DOI 10.1006/cyto.2000.0812; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter JD, 2001, P NATL ACAD SCI USA, V98, P7069, DOI 10.1073/pnas.111146498; Roghi C, 1998, J CELL SCI, V111, P557; Sadek CM, 2000, MECH DEVELOP, V97, P13, DOI 10.1016/S0925-4773(00)00415-9; Sadek CM, 2003, GENE EXPR PATTERNS, V3, P203, DOI 10.1016/S1567-133X(02)00066-2; Salgado-Garrido J, 1999, EMBO J, V18, P3451, DOI 10.1093/emboj/18.12.3451; Schweinfest CW, 1997, CANCER RES, V57, P2961; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Spittle C, 2000, J BIOL CHEM, V275, P20748, DOI 10.1074/jbc.M002597200; STEADMAN BT, 2002, J BIOL CHEM, V363, P195; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Still IH, 1999, ONCOGENE, V18, P4032, DOI 10.1038/sj.onc.1202801; Still IH, 1999, GENOMICS, V58, P165, DOI 10.1006/geno.1999.5829; Tharun S, 2000, NATURE, V404, P515, DOI 10.1038/35006676; Theurkauf WE, 2001, NAT CELL BIOL, V3, pE159, DOI 10.1038/35083110; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	71	78	87	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8102	8116		10.1038/sj.onc.1206972	http://dx.doi.org/10.1038/sj.onc.1206972			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603251				2022-12-28	WOS:000186403400005
J	Benelli, R; Peissel, B; Manenti, G; Gariboldi, M; Vanzetto, C; Albini, A; Dragani, TA				Benelli, R; Peissel, B; Manenti, G; Gariboldi, M; Vanzetto, C; Albini, A; Dragani, TA			Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration	ONCOGENE			English	Article						cancer modifier genes; genetic susceptibility; polymorphism skin cancer	EXTRACELLULAR-MATRIX; TUMOR INVASION; PTHRP; PEPTIDE; BREAST; EXPRESSION; MOTILITY; RECEPTOR; LINE	The mouse parathyroid hormone-like hormone Pthlh(Pro) and Pthlh(Thr) variants are linked with susceptibility and resistance to skin carcinogenesis of Car-S and Car-R mice, respectively, and with in vitro effects ( Oncogene, 19: 5324 - 5328, 2000). We have identified an additional Pthlh variant, consisting of Thr and three amino-acid changes in the C-terminus (Pthlh(SerAspTyr)), carried by an evolutionarily distant Mus spretus (SPRET/Ei) inbred strain. When transfected into NCI-H520 tumor cells, this Pthlh(SerAspTyr) variant did not stimulate tumor growth in nude mice. Analysis of cell adhesion, migration, and invasion patterns of Pthlh(Pro)-, Pthlh(Thr)-, and Pthlh(SerAspTyr)- transfected NCI-H520 cells revealed a 1.5-fold decrease in adhesion efficiency on both collagen type I and Matrigel, and a 5-6-fold increase in migration capability in Pthlh(Pro) transfectants as compared to nontransfected, vector-transfected, Pthlh(Thr)-, or Pthlh(SerAspTyr)- transfected cells. These findings suggest that the cancer modifier effects of the mouse Pthlh gene are mediated by differential cell adhesion and migration effects of PTHrP variants.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Ist Nazl Ric Canc, Mol Biol Lab, I-16132 Genoa, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Genoa; IRCCS AOU San Martino IST	Dragani, TA (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.		Manenti, Giacomo/J-3339-2017; Benelli, Roberto/AAF-3143-2019; Peissel, Bernard/E-8187-2017; Dragani, Tommaso A./K-4493-2016; Gariboldi, Manuela/K-4744-2016	Manenti, Giacomo/0000-0002-4887-4482; Benelli, Roberto/0000-0002-9769-0954; Peissel, Bernard/0000-0001-9233-3571; Dragani, Tommaso A./0000-0001-5915-4598; Albini, Adriana/0000-0002-9624-5103; Gariboldi, Manuela/0000-0001-8406-165X				Akino K, 2000, ENDOCRINOLOGY, V141, P4313, DOI 10.1210/en.141.11.4313; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1998, Pathol Oncol Res, V4, P230; Bakre MM, 2002, NAT MED, V8, P995, DOI 10.1038/nm753; Boccellino M, 2000, J CELL PHYSIOL, V183, P254, DOI 10.1002/(SICI)1097-4652(200005)183:2<254::AID-JCP12>3.0.CO;2-U; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; Conlan LA, 2002, FEBS LETT, V527, P71, DOI 10.1016/S0014-5793(02)03164-2; De Miguel F, 2001, ENDOCRINOLOGY, V142, P4096, DOI 10.1210/en.142.9.4096; Fassina G, 1996, INT J ONCOL, V8, P253; Goomer RS, 2000, ENDOCRINOLOGY, V141, P4613, DOI 10.1210/en.141.12.4613; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Luparello C, 1999, FEBS LETT, V463, P265, DOI 10.1016/S0014-5793(99)01635-X; Manenti G, 2000, ONCOGENE, V19, P5324, DOI 10.1038/sj.onc.1203916; Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; POSTLETHWAITE AE, 1976, J EXP MED, V144, P1188, DOI 10.1084/jem.144.5.1188; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Rabbani SA, 2000, INT J ONCOL, V16, P197; Sepulveda VAT, 2002, ENDOCRINOLOGY, V143, P596, DOI 10.1210/en.143.2.596; Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306; Ye YM, 2001, REGUL PEPTIDES, V101, P19, DOI 10.1016/S0167-0115(01)00259-2	22	8	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7711	7715		10.1038/sj.onc.1207088	http://dx.doi.org/10.1038/sj.onc.1207088			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586397				2022-12-28	WOS:000186240200001
J	Black, EJ; Clair, T; Delrow, J; Neiman, P; Gillespie, DAF				Black, EJ; Clair, T; Delrow, J; Neiman, P; Gillespie, DAF			Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun	ONCOGENE			English	Article						v-Jun; autotaxin; microarray; lysophospholipase; angiogenesis	HYPOXIA-INDUCIBLE FACTOR-1; ESTROGEN RECEPTOR CHIMERA; C-JUN; TRANSCRIPTIONAL ACTIVATION; GROWTH; GENE; PROTEIN; DNA; FIBROBLASTS; EXPRESSION	We have used chicken cDNA microarrays to investigate gene-expression changes induced during transformation of chick embryo fibroblasts (CEF) by the viral Jun oncoprotein encoded by ASV17. This analysis reveals that v-Jun induces increases and decreases of varying magnitude in the expression of genes involved in diverse cellular functions, most of which have not been detected in previous screens for putative v-Jun targets. In all, 27 individual genes were identified, whose expression is increased threefold or more in v-Jun-transformed cells, including genes involved in energy generation, protein synthesis, and gene transcription. Interestingly, this group includes the hypoxia-inducible factor-1 alpha (Hif-1alpha) transcription factor and the glycolytic enzyme enolase, suggesting that adaptation to hypoxia could play a role in tumorigenesis by v-Jun. We also identified 32 genes whose expression is decreased threefold or more, including chaperones, components of the cytoskeleton, and, unexpectedly, DNA replication factors. The gene whose expression is upregulated most dramatically (similar to100-fold) encodes Autotaxin (ATX), a secreted tumor motility-promoting factor with lysophospholipase D activity. Strikingly, v-Jun-transformed CEF secrete catalytically active ATX and chemotactic activity, which can be detected in conditioned medium. ATX is not detectably expressed in normal CEF or CEF transformed by the v-Src or v-Myc oncoproteins, indicating that induction of this putative autocrine/paracrine factor is a specific consequence of cell transformation by v-Jun. ATX has been implicated in both angiogenesis and invasion, and could therefore play an important role in tumorigenesis by v-Jun in vivo.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Glasgow G61 1BD, Lanark, Scotland; NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Dept Human Biol, Seattle, WA 98109 USA	University of Glasgow; Beatson Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Gillespie, DAF (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland.	d.gillespie@beatson.gla.ac.uk	Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544	NATIONAL CANCER INSTITUTE [R01CA020068] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA20068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bader AG, 2001, ONCOGENE, V20, P7524, DOI 10.1038/sj.onc.1204938; Bates S, 1996, ONCOGENE, V13, P1103; Beere H M, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.93.re1; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Clark W, 2000, MOL CELL BIOL, V20, P2529, DOI 10.1128/MCB.20.7.2529-2542.2000; Clark W, 1997, CELL GROWTH DIFFER, V8, P371; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dunn CA, 2003, BBA-GENE STRUCT EXPR, V1628, P147, DOI 10.1016/S0167-4781(03)00136-2; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gao MH, 1996, CANCER RES, V56, P4229; Hadman M, 1996, ONCOGENE, V12, P135; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Inohara N, 1998, J BIOL CHEM, V273, P8705, DOI 10.1074/jbc.273.15.8705; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kilbey A, 1996, ONCOGENE, V12, P2409; Koh E, 2003, CANCER RES, V63, P2042; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; MORGAN IM, 1993, ONCOGENE, V8, P1135; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; Nam SW, 2001, CANCER RES, V61, P6938; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; NISHIMURA T, 1988, ONCOGENE, V3, P659; Salnikow K, 2002, MOL CELL BIOL, V22, P1734, DOI 10.1128/MCB.22.6.1734-1741.2002; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; WONG WY, 1992, ONCOGENE, V7, P2077	46	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2357	2366		10.1038/sj.onc.1207377	http://dx.doi.org/10.1038/sj.onc.1207377			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691447	Bronze			2022-12-28	WOS:000220427700010
J	Krauer, KG; Burgess, A; Buck, M; Flanagan, J; Gabrielli, B				Krauer, KG; Burgess, A; Buck, M; Flanagan, J; Gabrielli, B			The EBNA-3 gene family proteins disrupt the G2/M checkpoint	ONCOGENE			English	Article						EBV; EBNA-3; G2/M checkpoint; chk2	EPSTEIN-BARR-VIRUS; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; NUCLEAR ANTIGEN 3C; HISTONE DEACETYLASE; TYROSINE DEPHOSPHORYLATION; MONOCLONAL-ANTIBODY; B-LYMPHOCYTES; J KAPPA; ACTIVATION	The Epstein - Barr nuclear antigens (EBNA), EBNA-3, -4 and - 6, have previously been shown to act as transcriptional regulators, however, this study identifies another function for these proteins, disruption of the G2/M checkpoint. Lymphoblastoid cell lines (LCLs) treated with a G2/M initiating drug azelaic bishydroxamine ( ABHA) did not show a G2/M checkpoint response, but rather they display an increase in cell death, a characteristic of sensitivity to the cytotoxic effects of the drug. Cell cycle analysis demonstrated that the individual expression of EBNA-3, - 4 or - 6 are capable of disrupting the G2/M checkpoint response induced by ABHA resulting in increased toxicity, whereas EBNA-2, and - 5 were not. EBNA-3 gene family protein expression also disrupted the G2/M checkpoint initiated in response to the genotoxin etoposide and the S phase inhibitor hydroxyurea. The G2 arrest in response to these drugs were sensitive to caffeine, suggesting that ATM/ATR signalling in these checkpoint responses may be blocked by the EBNA-3 family proteins. The function of EBNA-3, - 4 and - 6 proteins appears to be more complex than anticipated and these data suggest a role for these proteins in disrupting the host cell cycle machinery.	Univ Queensland, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Univ Queensland, Joint Oncol Program, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Mol & Cellular Pathol, Brisbane, Qld, Australia	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland; University of Queensland	Krauer, KG (corresponding author), Univ Queensland, Queensland Inst Med Res, Post Off Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	keniaK@qimr.edu.au	Burgess, Andrew/H-3339-2019; Burgess, Andrew/C-7952-2009; Gabrielli, Brian G/B-3655-2011	Burgess, Andrew/0000-0003-4536-9226; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651; Flanagan, James/0000-0003-4955-1383				BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Cannell EJ, 1996, ONCOGENE, V13, P1413; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Connell M. J. O., 2000, TRENDS CELL BIOL, V10, P296; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; Floettmann JE, 1996, VIROLOGY, V223, P29, DOI 10.1006/viro.1996.0452; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; Grundhoff AT, 1999, J BIOL CHEM, V274, P19136, DOI 10.1074/jbc.274.27.19136; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Kaykas A, 2000, ONCOGENE, V19, P1400, DOI 10.1038/sj.onc.1203365; Kienzle N, 1996, BIOTECHNIQUES, V20, P612; Kienzle N, 1996, VIROLOGY, V224, P167, DOI 10.1006/viro.1996.0518; Krauer KG, 1996, VIROLOGY, V226, P346, DOI 10.1006/viro.1996.0662; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LOCK RB, 1992, CANCER RES, V52, P1817; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MARSHALL D, 1995, J VIROL, V69, P3624, DOI 10.1128/JVI.69.6.3624-3630.1995; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MAUNDERS MJ, 1994, J GEN VIROL, V75, P769, DOI 10.1099/0022-1317-75-4-769; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Parker GA, 1996, ONCOGENE, V13, P2541; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; PETTI L, 1990, VIROLOGY, V176, P563, DOI 10.1016/0042-6822(90)90027-O; PINES J, 1987, EMBO J, V6, P2987, DOI 10.1002/j.1460-2075.1987.tb02604.x; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCULLEY TB, 1984, J VIROL, V52, P88, DOI 10.1128/JVI.52.1.88-93.1984; Sculley TB, 2002, TRANSPLANTATION, V73, P271, DOI 10.1097/00007890-200201270-00021; Shieh SY, 2000, GENE DEV, V14, P289; SILINS SL, 1994, VIROLOGY, V202, P16, DOI 10.1006/viro.1994.1317; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SINCLAIR AJ, 1992, CELL GROWTH DIFFER, V3, P557; Sinclair AJ, 1998, HISTOL HISTOPATHOL, V13, P461, DOI 10.14670/HH-13.461; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Villa LL, 1997, ADV CANCER RES, V71, P321, DOI 10.1016/S0065-230X(08)60102-5; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	54	48	50	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1342	1353		10.1038/sj.onc.1207253	http://dx.doi.org/10.1038/sj.onc.1207253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14716295				2022-12-28	WOS:000189035800002
J	Gan, DD; Khalili, K				Gan, DD; Khalili, K			Interaction between JCV large T-antigen and beta-catenin	ONCOGENE			English	Article						human polyomavirus; T-antigen; Wnt pathway; beta-catenin; medulloblastoma	BRAIN-TUMORS; VIRUS; IDENTIFICATION; MUTATION; PROTEIN; TARGET; GENE	Expression of the JCV early protein T-antigen in transgenic mice leads to the development of cerebellar primitive neuroectodermal tumors (PNETs). In light of earlier reports on the association of JCV with PNETs in humans and the involvement of the Wnt signaling pathway in the development of cerebellar tumors, we investigated the interplay between T-antigen and beta-catenin, the key protein of the Wnt pathway. Our results demonstrate the physical interaction of T-antigen with beta-catenin through the central domain of T-antigen spanning residues 82-628, and the C-terminus of beta-catenin located between amino acids 695 and 781. The association of T-antigen with beta-catenin elevates the level of beta-catenin in the cells due to increased in the stability of the protein. In the presence of T-antigen, beta-catenin was found in the nuclei of cells, suggesting that the interaction of beta-catenin with T-antigen facilitates its nuclear import. In cells expressing mutant T-antigen with no nuclear localization domain, beta-catenin was found in the cytoplasm. Coexpression of T-antigen with beta-catenin increased the transcription of the c-myc promoter, a known downstream target of beta-catenin, and artificial promoter whose activity is beta-catenin dependent. These observations ascribe a new oncogenic pathway for T-antigen, and offer an alternative mechanism for the deregulation of the Wnt pathway through stabilization of beta-catenin upon its association with the viral oncoprotein.	Temple Univ, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu						AGOSTINI HT, 2001, HUMAN POLYOMAVIRUSES, P491; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Berger JR, 1999, SEMIN NEUROL, V19, P193, DOI 10.1055/s-2008-1040837; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Eberhart CG, 2000, J NEUROPATH EXP NEUR, V59, P333, DOI 10.1093/jnen/59.4.333; Fujimuro M, 2003, NAT MED, V9, P300, DOI 10.1038/nm829; Gallia GL, 1998, J NEUROVIROL, V4, P175, DOI 10.3109/13550289809114517; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Polakis P, 2000, GENE DEV, V14, P1837; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; RAJ GV, 1995, INT J ONCOL, V7, P801; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Walker D L, 1983, Prog Clin Biol Res, V105, P99; Weiner HL, 2002, CANCER RES, V62, P6385; Xu LF, 2000, GENE DEV, V14, P585	27	59	62	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					483	490		10.1038/sj.onc.1207018	http://dx.doi.org/10.1038/sj.onc.1207018			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724577				2022-12-28	WOS:000188098300019
J	Claij, N; Riele, HT				Claij, N; Riele, HT			Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells	ONCOGENE			English	Article						mismatch repair; MSH2; cisplatin; Cre-Lox	DNA MISMATCH REPAIR; TUMOR-CELLS; MICROSATELLITE INSTABILITY; DRUG-RESISTANCE; METHYLATION TOLERANCE; REPLICATIVE BYPASS; IN-VITRO; DAMAGE; P53; CANCER	Several reports have suggested that a defect in the DNA mismatch repair (MMR) system not only causes resistance to methylating agents but also confers low-level resistance to the chemotherapeutic drug cisplatin. Here we report that in a clonogenic assay, mouse embryonic stem (ES) cells deficient for the MMR protein MSH2 respond similarly as wild-type cells to cisplatin. Furthermore, restoring MSH2 expression in a cisplatin-resistant subclone selected from an Msh2(-/-) cell population did not sensitize cells to cisplatin. To ascertain that our observations were not the result of a mutation in the Msh2(-/-) cells that obscured the contribution of a defective MMR machinery to cisplatin resistance, we made use of the Cre-lox system to create a cell line in which the Msh2 gene can be conditionally inactivated. However, while de novo inactivation of Msh2 rendered cells tolerant to the methylating drug N-methyl-N'-nitro-N-nitrosoguanidine as expected, it did not alter the sensitivity to cisplatin. In addition, we were not able to derive cisplatin-resistant subclones from this freshly generated MMR-deficient cell line. Thus, in ES cells we did not find evidence for direct involvement of MMR deficiency in cisplatin resistance.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Riele, HT (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	h.t.riele@nki.nl						Aebi S, 1996, CANCER RES, V56, P3087; Anthoney DA, 1996, CANCER RES, V56, P1374; Aquilina G, 2000, CLIN CANCER RES, V6, P671; Branch P, 2000, ONCOGENE, V19, P3138, DOI 10.1038/sj.onc.1203668; Buermeyer AB, 1999, CANCER RES, V59, P538; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; Claij N, 2002, ONCOGENE, V21, P2873, DOI 10.1038/sj.onc.1205395; de Wind N, 1998, CANCER RES, V58, P248; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Fink D, 1998, BRIT J CANCER, V77, P703, DOI 10.1038/bjc.1998.116; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1997, CANCER RES, V57, P1841; Gong JG, 1999, NATURE, V399, P806; HAWN MT, 1995, CANCER RES, V55, P3721; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KOI M, 1994, CANCER RES, V54, P4308; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; MAMENTA EL, 1994, CANCER RES, V54, P3500; Massey A, 2003, DNA REPAIR, V2, P73, DOI 10.1016/S1568-7864(02)00187-8; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Nehme A, 1997, CANCER RES, V57, P3253; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; Samimi G, 2000, CLIN CANCER RES, V6, P1415; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sergent C, 2002, CANCER CHEMOTH PHARM, V49, P445, DOI 10.1007/s00280-002-0450-6; Siddik ZH, 1998, CANCER RES, V58, P698; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Vaisman A, 1998, CANCER RES, V58, P3579; Watanabe Y, 2001, BRIT J CANCER, V85, P1064, DOI 10.1054/bjoc.2001.2037; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	37	30	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					260	266		10.1038/sj.onc.1207015	http://dx.doi.org/10.1038/sj.onc.1207015			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712231				2022-12-28	WOS:000187895300027
J	Wu, YZ; Diab, I; Zhang, XP; Izmailova, ES; Zehner, ZE				Wu, YZ; Diab, I; Zhang, XP; Izmailova, ES; Zehner, ZE			Stat3 enhances vimentin gene expression by binding to the antisilencer element and interacting with the repressor protein, ZBP-89	ONCOGENE			English	Article						Stat3; ZBP-89; Sp1; repressor; activator	TRANSCRIPTION FACTOR ZBP-89; BREAST-CANCER CELLS; ZINC-FINGER PROTEIN; C-JUN; GROWTH-REGULATION; TUMOR-CELLS; PROMOTER; ACTIVATION; SP1; IDENTIFICATION	Vimentin exhibits a complex pattern of developmental- and tissue-specific expression and is aberrantly expressed in most metastatic tumors. The human vimentin promoter contains multiple DNA elements, some of which enhance gene expression and one that inhibits. A silencer element (at -319) binds the repressor ZBP-89. Further upstream (at <LF>-757) is an element, which acts positively in the presence of the silencer element and, thus, is referred to as an antisilencer (ASE). Previously, we showed that Stat1alpha binds to this element upon induction by IFN-gamma. However, substantial binding and reporter gene activity was still present in nontreated cells. Here, we have found that Stat3 binds to the ASE element in vitro. Transfection experiments in COS-1 cells with various vimentin promoter-reporter constructs show that gene activity is dependent upon the cotransfection and activation of Stat3. Moreover, activated Stat3 can overcome ZBP-89 repression. Coimmunoprecipitation studies demonstrate that Stat3 and ZBP-89 can interact and confocal microscopy detects these factors to be colocalized in the nucleus. Moreover, a correlation exists between the presence of activated Stat3 and vimentin expression in MDA-MB-231 cells, which is lacking in MCF7 cells where vimentin is not expressed. In the light of these results, we propose that the interaction of Stat3 and ZBP-89 may be crucial for overcoming the effects of the repressor ZBP-89, which suggests a novel mode for Stat3 gene activation.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.	zezehner@vcu.edu		Izmailova, Elena/0000-0002-7150-1748; Diab, Iman/0000-0002-4017-5804	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45422] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Bai LG, 2001, MOL CELL BIOL, V21, P4670, DOI 10.1128/MCB.21.14.4670-4683.2001; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; BUSSEMAKERS MJG, 1992, BIOCHEM BIOPH RES CO, V182, P1254, DOI 10.1016/0006-291X(92)91866-O; CAREY I, 1995, CELL GROWTH DIFFER, V6, P899; Chen JH, 1996, ONCOGENE, V13, P1667; Cheng PY, 2000, BIOCHEMISTRY-US, V39, P4347, DOI 10.1021/bi992298f; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobretsova A, 1999, J NEUROCHEM, V72, P2227, DOI 10.1046/j.1471-4159.1999.0722227.x; DUPREY P, 1995, INT J DEV BIOL, V39, P443; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FRANKE WW, 1979, EXP CELL RES, V123, P25, DOI 10.1016/0014-4827(79)90418-X; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gilles C, 2003, CANCER RES, V63, P2658; GILLES C, 1996, BREAST J, V2, P83; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; HSIEH TC, 1995, EXP CELL RES, V218, P137, DOI 10.1006/excr.1995.1140; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; Keates AC, 2001, J BIOL CHEM, V276, P43713, DOI 10.1074/jbc.M107838200; Law DJ, 1998, MAMM GENOME, V9, P165, DOI 10.1007/s003359900711; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; Malone CS, 2001, GENE, V268, P9, DOI 10.1016/S0378-1119(01)00430-9; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Meyer T, 2002, EXP CELL RES, V272, P45, DOI 10.1006/excr.2001.5405; NIELSEN DA, 1983, P NATL ACAD SCI-BIOL, V80, P5198, DOI 10.1073/pnas.80.17.5198; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; Passantino R, 1998, J BIOL CHEM, V273, P484, DOI 10.1074/jbc.273.1.484; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Remington MC, 1997, BIOCHEM BIOPH RES CO, V237, P230, DOI 10.1006/bbrc.1997.7119; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1989, CANCER RES, V49, P4258; SOMMERS CL, 1992, CANCER RES, V52, P190; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1992, MOL CELL BIOL, V12, P2230, DOI 10.1128/MCB.12.5.2230; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Wu YZ, 2003, ONCOGENE, V22, P8891, DOI 10.1038/sj.onc.1206898; Yamada A, 2001, J BIOL CHEM, V276, P18082, DOI 10.1074/jbc.M008387200; Ye S, 1999, FEBS LETT, V450, P268, DOI 10.1016/S0014-5793(99)00509-8; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang XP, 2003, NUCLEIC ACIDS RES, V31, P2900, DOI 10.1093/nar/gkg380	63	49	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					168	178		10.1038/sj.onc.1207003	http://dx.doi.org/10.1038/sj.onc.1207003			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712222				2022-12-28	WOS:000187895300018
J	Afaq, F; Ahmad, N; Mukhtar, H				Afaq, F; Ahmad, N; Mukhtar, H			Suppression of UVB-induced phosphorylation of mitogen-activated protein kinases and nuclear factor kappa B by green tea polyphenol in SKH-1 hairless mice	ONCOGENE			English	Article						photochemopreventive; UVB; GTP; MAPKs; NF-kappa B; SKH-1	HUMAN EPIDERMAL-KERATINOCYTES; C-JUN; GROWTH-FACTOR; MOUSE SKIN; GENE-EXPRESSION; (-)-EPIGALLOCATECHIN-3-GALLATE TREATMENT; SIGNAL-TRANSDUCTION; MEDIATED ACTIVATION; DENDRITIC CELLS; MAP KINASES	Studies from our laboratory have shown that epigallocatechin-3-gallate, the major polyphenol present in green tea, inhib its ultraviolet (UV)B-exposure-mediated phosphorylation of mitogen-activated protein kinases (MAPKs) (Toxicol. Appl. Pharmacol. 176: 110-117, 2001) and activation of nuclear factor kappa B (NF-kappaB) (Oncogene 22: 1035-1044,2003) pathways in normal human epidermal keratinocytes. This study was designed to investigate the relevance of these findings to the in vivo situations in SKH-1 hairless mouse model, which is regarded to have relevance to human situations. SKH-1 hairless mice were topically treated with GTP (5 mg/0.2 ml acetone/mouse) and were exposed to UVB 30 min later (180 mJ/cm(2)). These treatments were repeated every alternate day for 2 weeks, for a total of seven treatments. The animals were killed 24 h after the last UVB exposure. Topical application of GTP resulted in significant decrease in UVB-induced bifold-skin thickness, skin edema and infiltration of leukocytes. Employing Western blot analysis and immunohistochemical studies, we found that GTP resulted in inhibition of UVB-induced: (i) phosphorylation of extracellular-signal-regulated kinases (ERK1/2),(ii) c-Jun N-terminal kinases, and (iii) p38 protein expression. Since NF-kappaB plays a major role in inflammation and cell proliferation, we assessed the effect of GTP on UVB-mediated modulations in the NF-kappaB pathway. Our data demonstrated that GTP inhibited UVB-induced: (i) activation of NF-kappaB,(ii) activation of IKKalpha, and (iii) phosphorylation and degradation of IkappaBalpha. Our data suggest that GTP protects against the adverse effects of UV radiation via modulations in MAPK and NF-kappaB signaling pathways, and provides molecular basis for the photochemopreventive effect of GTP in an in vivo animal model system.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206; Afaq F, 2003, TOXICOL APPL PHARM, V186, P28, DOI 10.1016/S0041-008X(02)00014-5; Afaq F, 2002, SKIN PHARMACOL APPL, V15, P297, DOI 10.1159/000064533; Afaq F, 2002, FRONT BIOSCI-LANDMRK, V7, pD784, DOI 10.2741/afaq; AGARWAL R, 1992, CANCER RES, V52, P3582; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Bachelor MA, 2002, ONCOGENE, V21, P7092, DOI 10.1038/sj.onc.1205855; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Balasubramanian S, 1999, ONCOGENE, V18, P1297, DOI 10.1038/sj.onc.1202417; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Chen YC, 2002, J CELL BIOCHEM, V86, P331, DOI 10.1002/jcb.10230; Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072; Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dhar A, 2002, MOL CELL BIOCHEM, V234, P185, DOI 10.1023/A:1015948505117; Dubois B, 2001, CELL IMMUNOL, V214, P173, DOI 10.1006/cimm.2001.1898; Elmets CA, 2001, J AM ACAD DERMATOL, V44, P425, DOI 10.1067/mjd.2001.112919; F'guyer S, 2003, PHOTODERMATOL PHOTO, V19, P56, DOI 10.1034/j.1600-0781.2003.00019.x; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; GENSLER HL, 1992, CARCINOGENESIS, V13, P9, DOI 10.1093/carcin/13.1.9; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hildesheim J, 2002, CANCER RES, V62, P7305; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1998, P NATL ACAD SCI USA, V95, P156, DOI 10.1073/pnas.95.1.156; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Iordanov MS, 2002, MOL CELL BIOL, V22, P5380, DOI 10.1128/MCB.22.15.5380-5394.2002; Jemal A, 2000, JNCI-J NATL CANCER I, V92, P811, DOI 10.1093/jnci/92.10.811; Kang S, 2003, J INVEST DERMATOL, V120, P835, DOI 10.1046/j.1523-1747.2003.12122.x; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Katiyar SK, 2000, CLIN CANCER RES, V6, P3864; Katiyar SK, 2001, TOXICOL APPL PHARM, V176, P110, DOI 10.1006/taap.2001.9276; Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287; KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855; Katiyar SK, 2001, J LEUKOCYTE BIOL, V69, P719; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; KATIYAR SK, 1992, CANCER RES, V52, P6890; Kaufman CK, 2000, J CELL BIOL, V149, P999, DOI 10.1083/jcb.149.5.999; Kim J, 2001, SKIN PHARMACOL APPL, V14, P11, DOI 10.1159/000056329; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LEARN DB, 1993, PHOTODERMATOL PHOTO, V9, P147; Lefort K, 2001, ONCOGENE, V20, P7375, DOI 10.1038/sj.onc.1204923; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nghiem DX, 2002, J INVEST DERMATOL, V119, P600, DOI 10.1046/j.1523-1747.2002.01845.x; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; She QB, 2002, J BIOL CHEM, V277, P24039, DOI 10.1074/jbc.M109907200; Stahl W, 2002, SKIN PHARMACOL APPL, V15, P291, DOI 10.1159/000064532; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Vink AA, 1997, P NATL ACAD SCI USA, V94, P5255, DOI 10.1073/pnas.94.10.5255; WANG ZY, 1991, CARCINOGENESIS, V12, P1527, DOI 10.1093/carcin/12.8.1527; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Yang TY, 2002, IEEE T ADV PACKAGING, V25, P54, DOI 10.1109/TADVP.2002.1017686; Zhu WH, 2002, AM J PATHOL, V161, P823, DOI 10.1016/S0002-9440(10)64242-3	72	105	107	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9254	9264		10.1038/sj.onc.1207035	http://dx.doi.org/10.1038/sj.onc.1207035			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681684				2022-12-28	WOS:000187400400007
J	Tullo, A; Mastropasqua, G; Bourdon, JC; Centonze, P; Gostissa, M; Costanzo, A; Levrero, M; Del Sal, G; Saccone, C; Sbisa, E				Tullo, A; Mastropasqua, G; Bourdon, JC; Centonze, P; Gostissa, M; Costanzo, A; Levrero, M; Del Sal, G; Saccone, C; Sbisa, E			Adenosine deaminase, a key enzyme in DNA precursors control, is a new p73 target	ONCOGENE			English	Article						p73; p53; adenosine deaminase; p53 family; purine metabolism	CANCER CELL-LINE; P53 HOMOLOG; FUNCTIONAL IMPLICATIONS; GENE-EXPRESSION; BINDING-SITE; P63; APOPTOSIS; FAMILY; IDENTIFICATION; ACTIVATION	The discovery of the p73 and p63 genes, homologous to p53 tumor suppressor has uncovered a family of transcription factors and widened the scenario of cell cycle control and apoptosis. We have identified a putative p53-responsive element in the human adenosine deaminase (ADA) gene, an important enzyme involved in nucleotide metabolism, the deficit of which causes the inhibition of DNA synthesis and repair. Here, we demonstrate that the ectopic expression of p73 isoforms leads to the ADA gene upregulation, showing for the first time a correlation between p73 and ADA. W e found that p73 promotes ADA gene expression following a dNTP unbalance generated by ADA enzyme deficiency and 2' deoxyadenosine accumulation. The abrogation of p73 transcriptional activity by the specific dominant-negative p73DD abolishes ADA induction. By contrast, the ADA gene does not appear to be a functional p53 target in the physiological conditions we tested. On the whole, our results contribute to the emerging picture that p73 could play a different role from p53 in normal growth and development by inducing alternative target genes, which are not shared by p53.	CNR, Sez Bari Bioinformat & Genom, Ist Tecnol Biomed, I-70126 Bari, Italy; Univ Bari, Dipartimento Biochim & Biol Mol, I-70125 Bari, Italy; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Consorzio Interuniv Biotecnol, Lab Nazl, Trieste, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Gene Express Lab, Rome, Italy; Univ Roma Tor Vergata, Dept Dermatol, I-00161 Rome, Italy; Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34100 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomembrane e Bioenergetica (IBBE-CNR); Universita degli Studi di Bari Aldo Moro; University of Dundee; Sapienza University Rome; University of Rome Tor Vergata; University of Trieste	Tullo, A (corresponding author), CNR, Sez Bari Bioinformat & Genom, Ist Tecnol Biomed, Via Amendola 165-A, I-70126 Bari, Italy.		MASTROPASQUA, Mauro/AAK-8813-2020; JC, Bourdon/A-4439-2008; Sbisa', Elisabetta/AAW-9727-2020; Costanzo, Antonio/D-3896-2012; Costanzo, Antonio/GZG-2433-2022; Tullo, Apollonia/AAX-1079-2020; Levrero, Massimo/G-5680-2016	MASTROPASQUA, Mauro/0000-0002-8306-0839; JC, Bourdon/0000-0003-4623-9386; Costanzo, Antonio/0000-0001-9697-2557; Tullo, Apollonia/0000-0002-5081-4745; DEL SAL, GIANNINO/0000-0003-2185-6003; Levrero, Massimo/0000-0002-4978-0875				ARONOW BJ, 1992, MOL CELL BIOL, V12, P4170, DOI 10.1128/MCB.12.9.4170; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bemi V, 1998, INT J CANCER, V75, P713, DOI 10.1002/(SICI)1097-0215(19980302)75:5<713::AID-IJC9>3.0.CO;2-1; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; Bian JH, 1996, CARCINOGENESIS, V17, P2559, DOI 10.1093/carcin/17.12.2559; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; CAMICI M, 1995, INT J CANCER, V62, P176, DOI 10.1002/ijc.2910620212; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; Cristalli G, 2001, MED RES REV, V21, P105, DOI 10.1002/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U; D'Erchia A. M., 2003, Current Genomics, V4, P13, DOI 10.2174/1389202033350173; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Duriez C, 2000, ONCOGENE, V19, P2461, DOI 10.1038/sj.onc.1203580; Dusing MR, 1997, J BIOL CHEM, V272, P26634, DOI 10.1074/jbc.272.42.26634; DUSING MR, 1994, NUCLEIC ACIDS RES, V22, P669, DOI 10.1093/nar/22.4.669; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; GIBLETT ER, 1972, LANCET, V2, P1067; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HE YP, 1993, J NUTR, V123, P1017; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIZAKI H, 1988, J IMMUNOL, V141, P1652; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Lohrum MAE, 2000, TRENDS CELL BIOL, V10, P197, DOI 10.1016/S0962-8924(00)01736-0; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moriwaki Y, 1999, HISTOL HISTOPATHOL, V14, P1321, DOI 10.14670/HH-14.1321; Nagaich AK, 1997, J BIOL CHEM, V272, P14842, DOI 10.1074/jbc.272.23.14842; Saccone C, 2002, GENE, V300, P195, DOI 10.1016/S0378-1119(02)01036-3; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Sciacchitano S, 2002, MOL ENDOCRINOL, V16, P1577, DOI 10.1210/me.16.7.1577; Shi DQ, 1997, J BIOL CHEM, V272, P2334, DOI 10.1074/jbc.272.4.2334; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Vikhanskaya F, 2001, CANCER RES, V61, P935; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WAKADE AR, 1995, J BIOL CHEM, V270, P17986, DOI 10.1074/jbc.270.30.17986; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zheng XJ, 2001, FEBS LETT, V489, P4, DOI 10.1016/S0014-5793(00)02437-6; Zhou HJ, 2001, J MOL BIOL, V306, P227, DOI 10.1006/jmbi.2000.4370	51	18	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8738	8748		10.1038/sj.onc.1206967	http://dx.doi.org/10.1038/sj.onc.1206967			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647469				2022-12-28	WOS:000186844900012
J	Aki, T; Yamaguchi, K; Fujimiya, T; Mizukami, Y				Aki, T; Yamaguchi, K; Fujimiya, T; Mizukami, Y			Phosphoinositide 3-kinase accelerates autophagic cell death during glucose deprivation in the rat cardiomyocyte-derived cell line H9c2	ONCOGENE			English	Article						phosphoinositide 3-kinase; autophagy; glucose deprivation; cell death	PROTEIN-DEGRADATION; 3T3-L1 ADIPOCYTES; DISEASE; KINASE; HEPATOCYTES; MECHANISMS; MORPHOLOGY; APOPTOSIS; TRANSPORT; VACUOLES	We investigated cell death during glucose deprivation in rat cardiomyocyte-derived H9c2 cells. Electron microscopic analysis revealed accumulation of autophagic vacuoles during glucose deprivation. The addition of 3-methyladenine or LY294002, which are known to inhibit autophagosome formation, reduced cell death while Z-VAD-FMK, a caspase inhibitor, slightly affected cell death. Thus, cell death during glucose deprivation is not type I programmed cell death (apoptotic cell death) but type 11 programmed cell death (autophagic cell death). Moreover, we found that both insulin-like growth factor-I and the adenovirus-mediated overexpression of wild-type class I PI 3-kinase accelerated cell death as well as accumulation of autophagic vacuoles during glucose deprivation while dominant-negative PI 3-kinase reduced these phenomena. The results indicate that IGF-I/PI 3-kinase accelerates the accumulation of autophagic vacuoles and subsequent autophagic cell death during glucose deprivation, revealing the opposing role of IGF-I/PI 3-kinase in two distinct types of programmed cell death (apoptotic and autophagic cell death).	Yamaguchi Univ, Ctr Gene Res, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Inst Lab Anim, Ube, Yamaguchi 7558505, Japan; Yamaguchi Univ, Sch Med, Dept Legal Med, Ube, Yamaguchi 7558505, Japan	Yamaguchi University; Yamaguchi University; Yamaguchi University	Aki, T (corresponding author), Yamaguchi Univ, Ctr Gene Res, 1-1-1 Minamikoguchi, Ube, Yamaguchi 7558505, Japan.			Mizukami, Yoichi/0000-0002-3290-0754				Aki T, 2001, BIOCHEM J, V358, P481, DOI 10.1042/0264-6021:3580481; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Bursch W, 2001, CELL DEATH DIFFER, V8, P569, DOI 10.1038/sj.cdd.4400852; Chi SJ, 1999, ONCOGENE, V18, P2281, DOI 10.1038/sj.onc.1202538; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; Izuishi K, 2000, CANCER RES, V60, P6201; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Katagiri H, 1997, AM J PHYSIOL-ENDOC M, V272, pE326, DOI 10.1152/ajpendo.1997.272.2.E326; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; KEGAL BK, 2000, J NEUROSCI, V20, P7268; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Munafo DB, 2001, J CELL SCI, V114, P3619; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Nixon RA, 2000, NEUROCHEM RES, V25, P1161, DOI 10.1023/A:1007675508413; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHWEICHEL JU, 1973, TERATOLOGY, V7, P253, DOI 10.1002/tera.1420070306; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; ZAKERI Z, 1995, CELL DEATH DIFFER, V2, P87	31	109	117	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8529	8535		10.1038/sj.onc.1207197	http://dx.doi.org/10.1038/sj.onc.1207197			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627994				2022-12-28	WOS:000186650300017
J	Das, S; El-Deiry, WS; Somasundaram, K				Das, S; El-Deiry, WS; Somasundaram, K			Efficient growth inhibition of HPV 16 E6-expressing cells by an adenovirus-expressing p53 homologue p73 beta	ONCOGENE			English	Article						p53; p73; human papilloma virus; cervical cancer; E6; gene therapy	HUMAN-PAPILLOMAVIRUS; DNA-BINDING; GENE; APOPTOSIS; DEGRADATION; SUPPRESSION; CARCINOMA; PROMOTES; PROTEIN; ARREST	Tumor suppressor p53 functions are downregulated in most cervical cancers, because the product of human papilloma virus (HPV) oncogene E6 binds to and inactivates p53 by promoting its degradation. p73, a p53 homologue, is similar to p53 in structure and function but yet not degraded by HPV E6 gene product. In this study, we have developed a replication-deficient recombinant adenovirus, which expresses p73beta (Ad-p73). Infection of human cancer cells with Ad-p73 results in several fold increase of p73beta levels as well as its known target genes like p21(WAF1/CIP1). Ad-p73-infected cells showed reduced cellular DNA synthesis, arrest in G1 phase of cell cycle and induction of apoptosis. Ad-p73 inhibited the growth of cancer cells of different types. More importantly, Ad-p73 inhibited the growth of cell tines carrying HPV E6 gene, which was introduced by stable integration, more efficiently in comparison to an Ad-p53. Furthermore, Ad-p73 also inhibited the growth of HeLa cells, a cell line derived from cervical cancer, very efficiently. The ability of Ad-p73 to inhibit the growth of HPV E6-expressing cells and HeLa cells correlated with the stable expression of functional p73 in the presence of E6. These results suggest that Ad-p73 could be used as a potential gene therapy agent against cervical cancer.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Indian Institute of Science (IISC) - Bangalore; Howard Hughes Medical Institute; University of Pennsylvania	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in	El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Das, Sanjeev/0000-0002-3594-1033				BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; BRINTON LA, 1992, EPIDEMIOLOGY CERVICA, P3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hamada K, 1996, CANCER RES, V56, P3047; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huh WK, 2001, GYNECOL ONCOL, V83, P370, DOI 10.1006/gyno.2001.6403; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNGU O, 1995, OBSTET GYNECOL, V85, P337, DOI 10.1016/0029-7844(94)00399-X; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Orlow I, 1999, AM J PATHOL, V155, P105, DOI 10.1016/S0002-9440(10)65105-X; Prabhu NS, 1996, CLIN CANCER RES, V2, P1221; Prabhu NS, 1998, INT J ONCOL, V13, P5; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304, DOI 10.1128/JCM.35.6.1304-1310.1997; ROSE PG, 2000, COMBINED MODALITY TR; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Yatabe N, 2002, CANCER GENE THER, V9, P624, DOI 10.1038/sj.cgt.7700479; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	36	32	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8394	8402		10.1038/sj.onc.1206908	http://dx.doi.org/10.1038/sj.onc.1206908			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627980				2022-12-28	WOS:000186650300003
J	Mao, JH; Wu, D; Perez-Losada, J; Nagase, H; DelRosario, R; Balmain, A				Mao, JH; Wu, D; Perez-Losada, J; Nagase, H; DelRosario, R; Balmain, A			Genetic interactions between Pten and p53 in radiation-induced lymphoma development	ONCOGENE			English	Article						Pten; p53; loss of heterozygosity; intragenic deletion; radiation induced lymphoma	TUMOR-SUPPRESSOR GENE; MUTATIONS; TRANSCRIPTION; INACTIVATION; IRRADIATION; LOCUS; MDM2; FORM	Genetic analysis of radiation-induced lymphomas from p53 heterozygous or null mice has revealed a high frequency of genetic alterations on mouse chromosome 19. Detailed microsatellite analysis of chromosome 19 deletions identified three independent regions of loss of heterozygosity, one of which was refined to a 0.3 Mb interval that contained the Pten tumor suppressor gene. More than 50% of radiation-induced tumors from p53+/- and p53-/- mice showed heterozygous loss of one Pten allele. In most cases, the remaining allele was wild type and expressed, suggesting that Pten is a haploinsufficient tumor suppressor gene for mouse lymphoma development. This conclusion was supported by the detection of specific intragenic deletions in Pten in tumors that retained one wild-type allele. Pten heterozygous mice were just as sensitive as p53+/- mice to induction of tumors by radiation, and surprisingly, the double p53+/-Pten+/- mice were equivalent to p53 null mice in radiation sensitivity. Despite the fact that Pten appears to be a haploinsufficient tumor suppressor gene, most tumors from both the single and double heterozygous mice had lost the remaining wild-type allele. The mechanism of loss in all cases involved the complete chromosome, suggesting that it is driven by other tumor suppressor genes on this chromosome. This sensitized screen therefore identified complementary roles for Pten and p53 pathways in suppression of tumor development induced by radiation exposure.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; Roswell Park Cancer Institute	Balmain, A (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022; Pérez-Losada, Jesús/A-5883-2019	Mao, Jian-Hua/0000-0001-9320-6021; Pérez-Losada, Jesús/0000-0003-2400-624X	NCI NIH HHS [U01 CA84244] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Butler MP, 1999, GENE CHROMOSOME CANC, V24, P322, DOI 10.1002/(SICI)1098-2264(199904)24:4<322::AID-GCC5>3.0.CO;2-9; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Gronbaek K, 1998, BLOOD, V91, P4388; Herranz M, 2000, LEUKEMIA, V14, P1325, DOI 10.1038/sj.leu.2401813; Izumoto S, 2001, J NEURO-ONCOL, V53, P21, DOI 10.1023/A:1011839920176; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Kwabi-Addo B, 2001, P NATL ACAD SCI USA, V98, P11563, DOI 10.1073/pnas.201167798; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Mayo LD, 2002, J BIOL CHEM, V277, P5484, DOI 10.1074/jbc.M108302200; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; Santos J, 2002, ONCOGENE, V21, P6680, DOI 10.1038/sj.onc.1205846; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Shin KH, 2002, INT J ONCOL, V21, P997; Sjoling A, 2003, GENE CHROMOSOME CANC, V36, P70, DOI 10.1002/gcc.10143; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774	32	39	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8379	8385		10.1038/sj.onc.1207083	http://dx.doi.org/10.1038/sj.onc.1207083			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627978				2022-12-28	WOS:000186650300001
J	Denison, SR; Wang, F; Becker, NA; Schule, B; Kock, N; Phillips, LA; Klein, C; Smith, DI				Denison, SR; Wang, F; Becker, NA; Schule, B; Kock, N; Phillips, LA; Klein, C; Smith, DI			Alterations in the common fragile site gene Parkin in ovarian and other cancers	ONCOGENE			English	Article						common fragile sites; Parkinson's disease; ovarian cancer	RECESSIVE JUVENILE PARKINSONISM; UBIQUITIN-PROTEIN LIGASE; FHIT GENE; MUTATIONS; DISEASE; FRA16D; INSTABILITY; SUPPRESSOR; REGION; WWOX	The cloning and characterization of the common fragile site (CFS) FRA6E (6q26) identified Parkin, the gene involved in the pathogenesis of many cases of juvenile, early-onset and, rarely, late-onset Parkinson's disease, as the third large gene to be localized within a large CFS. Initial analyses of Parkin indicated that in addition to playing a role in Parkinson's disease, it might also be involved in the development and/or progression of ovarian cancer. These analyses also indicated striking similarities among the large CFS-locus genes: fragile histidine triad gene (FHIT; 3p14.2), WW domain-containing oxidoreductase gene (WWOX; 16q23), and Parkin (6q26). Analyses of FHIT and WWOX in a variety of different cancer types have identified the presence of alternative transcripts with whole exon deletions. Interestingly, various whole exon duplications and deletions have been identified for Parkin in juvenile and early-onset Parkinson's patients. Therefore, we performed mutational/exon rearrangement analysis of Parkin in ovarian cancer cell lines and primary tumors. Four (66.7%) cell lines and four (18.2%) primary tumors were identified as being heterozygous for the duplication or deletion of a Parkin exon. Additionally, three of 23 (13.0%) nonovarian tumor-derived cell lines were also identified as having a duplication or deletion of one or more Parkin exons. Analysis of Parkin protein expression with antibodies revealed that most of the ovarian cancer cell lines and primary tumors had diminished or absent Parkin expression. While functional analyses have not yet been performed for Parkin, these data suggest that like FHIT and WWOX, Parkin may represent a tumor suppressor gene.	Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Expt Pathol, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Med Univ Lubeck, Dept Neurol, D-23538 Lubeck, Germany; Med Univ Lubeck, Dept Human Genet, D-23538 Lubeck, Germany	Mayo Clinic; University of Lubeck; University of Lubeck	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, Mayo Clin Canc Ctr, Div Expt Pathol, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		Schuele, Birgitt/0000-0002-9952-5776; Klein, Christine/0000-0003-2102-3431	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2002, GENE CHROMOSOME CANC, V33, P82, DOI 10.1002/gcc.10000; Becker NA, 2002, ONCOGENE, V21, P8713, DOI 10.1038/sj.onc.1205950; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Corbin S, 2002, CANCER RES, V62, P3477; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Druck T, 1997, CANCER RES, V57, P504; Druck T, 1998, ONCOL RES, V10, P341; Feany MB, 2003, NEURON, V38, P13, DOI 10.1016/S0896-6273(03)00201-0; GAMMA A, 1997, CANCER RES, V57, P1435; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hedrich K, 2002, NEUROLOGY, V58, P1239, DOI 10.1212/WNL.58.8.1239; Hedrich K, 2001, HUM MOL GENET, V10, P1649, DOI 10.1093/hmg/10.16.1649; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hoenicka J, 2002, ARCH NEUROL-CHICAGO, V59, P966, DOI 10.1001/archneur.59.6.966; Horowitz JM, 2001, J CHEM NEUROANAT, V21, P75, DOI 10.1016/S0891-0618(00)00111-3; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Ishii H, 2001, JAMA-J AM MED ASSOC, V286, P2441, DOI 10.1001/jama.286.19.2441; Kahns S, 2002, J BIOL CHEM, V277, P15303, DOI 10.1074/jbc.M111534200; Kann M, 2002, ANN NEUROL, V51, P621, DOI 10.1002/ana.10179; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Krummel KA, 2002, GENE CHROMOSOME CANC, V34, P154, DOI 10.1002/gcc.10047; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mangelsdorf M, 2000, CANCER RES, V60, P1683; Nichols WC, 2002, J MED GENET, V39, P489, DOI 10.1136/jmg.39.7.489; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Paige AJW, 2000, CANCER RES, V60, P1690; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; Shiraishi T, 2001, P NATL ACAD SCI USA, V98, P5722, DOI 10.1073/pnas.091095898; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Smith DI, 1998, INT J ONCOL, V12, P187; Staropoli JF, 2003, NEURON, V37, P735, DOI 10.1016/S0896-6273(03)00084-9; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Tanaka K, 2001, J MOL MED, V79, P482, DOI 10.1007/s001090100242; Verma RS., 1995, HUMAN CHROMOSOMES PR, V2; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	45	171	174	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8370	8378		10.1038/sj.onc.1207072	http://dx.doi.org/10.1038/sj.onc.1207072			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614460				2022-12-28	WOS:000186541500015
J	Zhao, LY; Liu, Y; Bertos, NR; Yang, XJ; Liao, DQ				Zhao, LY; Liu, Y; Bertos, NR; Yang, XJ; Liao, DQ			PCAF is a coactivator for p73-mediated transactivation	ONCOGENE			English	Article						transcription coactivator; PCAF; p73; tumor suppressor; acetyltransferase; protein-protein interaction	P53 HOMOLOG P73; KINASE C-ABL; DNA-DAMAGE; INDUCE APOPTOSIS; TRANSCRIPTIONAL ACTIVITIES; P53-RELATED PROTEIN; TUMOR-SUPPRESSOR; BINDING-PROTEIN; TERMINAL DOMAIN; TARGET GENES	The tumor suppressor p53-related p73 shares significant amino-acid sequence identity with p53. Like p53, p73 recognizes canonical p53 DNA-binding sites and activates p53-responsive target genes and induces apoptosis. Moreover, transcription coactivator p300/CBP binds to and coactivates with both p53 and p73 in stimulating the expression of their target genes. Here, we report that coactivator PCAF binds to p73. The N-terminal transactivation domain (TAD) and the conserved oligomerization domain (OD) of p73 are both required for its interaction with PCAF. Conversely, PCAF's HAT-domain is required for and both the N-terminal region and Bromo domain enhance binding of PCAF to p73. Significantly, PCAF stimulates p73-mediated transactivation, and binding of PCAF to p73 is necessary for p73's transactivation activity. PCAF-specific siRNA dramatically reduces p73-mediated transactivation. Stimulation of p73-mediated transactivation by PCAF requires the HAT domain of PCAF and the p53-binding site within the p21 promoter. In vivo, coexpression of wild-type, but not HAT-deficient PCAF with p73beta markedly increases p21 expression. Furthermore, cotransfection of PCAF and p73 leads to increased apoptosis and reduced colony formation. Collectively, these data suggest that p73 recruit PCAF to specific promoters to activate the transcription of p73 target genes.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Sherbrooke, Fac Med, Dept Microbiol & Infect Dis, Sherbrooke, PQ, Canada; McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, Montreal, PQ, Canada; Univ Florida, UF Shands Canc Ctr, Gainesville, FL USA	State University System of Florida; University of Florida; University of Sherbrooke; McGill University; State University System of Florida; University of Florida	Liao, DQ (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Arch Rd, Gainesville, FL 32610 USA.		Liao, Daiqing/A-8941-2008		NATIONAL CANCER INSTITUTE [R01CA092236] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA92236] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; Arrowsmith CH, 1999, CELL DEATH DIFFER, V6, P1169, DOI 10.1038/sj.cdd.4400619; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bres V, 2002, EMBO J, V21, P6811, DOI 10.1093/emboj/cdf669; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Gong JG, 1999, NATURE, V399, P806; Gu JJ, 2001, ONCOGENE, V20, P3519, DOI 10.1038/sj.onc.1204454; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; Huang SM, 2000, EMBO J, V19, P6792, DOI 10.1093/emboj/19.24.6792; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; James P, 1996, GENETICS, V144, P1425; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Liu Y, 2000, MOL CELL BIOL, V20, P5540, DOI 10.1128/MCB.20.15.5540-5553.2000; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Ozaki T, 1999, CANCER RES, V59, P5902; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; Prabhu NS, 1998, INT J ONCOL, V13, P5; Prives C, 1999, J PATHOL, V187, P112; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SCHILTZ RL, 2000, BIOCHIM BIOPHYS ACTA, V1470, P37; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Ueda Y, 2001, BIOCHEM J, V356, P859, DOI 10.1042/0264-6021:3560859; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2001, J BIOL CHEM, V276, P48, DOI 10.1074/jbc.C000722200; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 2001, ONCOGENE, V20, P4050, DOI 10.1038/sj.onc.1204516; Zhu JH, 1998, CANCER RES, V58, P5061	63	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8316	8329		10.1038/sj.onc.1206916	http://dx.doi.org/10.1038/sj.onc.1206916			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614455				2022-12-28	WOS:000186541500010
J	Burger, M; Glodek, A; Hartmann, T; Schmitt-Graff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA				Burger, M; Glodek, A; Hartmann, T; Schmitt-Graff, A; Silberstein, LE; Fujii, N; Kipps, TJ; Burger, JA			Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells	ONCOGENE			English	Article						chemokine receptor; lung cancer; signal transduction; integrin activation; adhesion; migration	CHEMOKINE RECEPTOR CXCR4; LEUKEMIA B-CELLS; BONE-MARROW; TRANSENDOTHELIAL MIGRATION; HEMATOPOIETIC PROGENITORS; SIGNAL-TRANSDUCTION; CD34(+) CELLS; STEM-CELLS; VLA-4; FIBRONECTIN	Small-cell lung cancer (SCLC) is an aggressive, rapidly metastasizing neoplasm. The chemokine stromal cell-derived factor-1 (SDF-1/CXCL12) is constitutively secreted by marrow stromal cells and plays a key role for homing of hematopoietic cells to the marrow. Here, we report that tumor cells from patients with SCLC express high levels of functional CXCR4 receptors for the chemokine CXCL12. Reverse transcriptase-polymerase chain reaction and flow cytometry demonstrated CXCR4 mRNA and CXCR4 surface expression in SCLC cell lines. Immunohistochemistry of primary tumor samples from SCLC patients revealed high expression of CXCR4. CXCL12 elicited CXCR4 receptor endocytosis, actin polymerization, and a robust activation of phospho-p44/42 mitogen-activated protein kinase in SCLC cells. Furthermore, CXCL12 induced SCLC cell invasion into extracellular matrix and firm adhesion to marrow stromal cells. Stromal cell adhesion of SCLC cells was significantly inhibited by the specific CXCR4 antagonist T140, pertussis toxin, antivascular cell adhesion molecule-1(VCAM-1) antibodies, and CS-1 peptide, demonstrating the importance of CXCR4 chemokine receptor activation and alpha4beta1 integrin binding, respectively. In addition, CXCL12 enhanced the adhesion of SCLC cells to immobilized VCAM-1, demonstrating that CXCR4 chemokine receptors can induce integrin activation on SCLC cells. As SCLC has a high propensity for bone marrow involvement, our findings suggest that CXCR4 chemokine receptors and alpha4beta1 integrins play a critical role in the interaction of SCLC cells with stromal cells in the tumor microenvironment.	Freiburg Univ Hosp, Dept Internal Med, Freiburg, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Freiburg Univ Hosp, Dept Pathol, Freiburg, Germany; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto, Japan; Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA	University of Freiburg; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Freiburg; Kyoto University; University of California System; University of California San Diego	Burger, JA (corresponding author), Freiburg Univ Hosp, Dept Med, Div Hematol Oncol, Hugstetterstr 55, D-79106 Freiburg, Germany.	burger@mm11.ukl.uni-freiburg.de	Hartmann, Tanja Nicole/AAA-6735-2020; Hartmann, Tanja Nicole/C-9345-2017; Hartmann, Tanja Nicole/C-9345-2017	Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-0377-7179; Hartmann, Tanja Nicole/0000-0002-2633-7301				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BARAK LS, 1980, P NATL ACAD SCI-BIOL, V77, P980, DOI 10.1073/pnas.77.2.980; Boyle DL, 2000, CELL IMMUNOL, V200, P1, DOI 10.1006/cimm.2000.1610; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 1999, BLOOD, V94, P3658, DOI 10.1182/blood.V94.11.3658.423k11_3658_3667; Burger JA, 2001, J CLIN INVEST, V107, P305, DOI 10.1172/JCI11092; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Hidalgo A, 2001, EXP HEMATOL, V29, P345, DOI 10.1016/S0301-472X(00)00668-8; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; IHDE D, 1993, CANC PRINCIPLES PRAC, P591; IHDE DC, 1992, NEW ENGL J MED, V327, P1434; Imai K, 1999, BLOOD, V93, P149, DOI 10.1182/blood.V93.1.149.401a02_149_156; Kijima T, 2002, CANCER RES, V62, P6304; Kristensen CA, 1996, CRIT REV ONCOL HEMAT, V22, P27, DOI 10.1016/1040-8428(94)00170-7; LASSEN U, 1995, J CLIN ONCOL, V13, P1215, DOI 10.1200/JCO.1995.13.5.1215; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; MASN DY, 2001, TISSUE ANTIGENS, V58, P425; Mohle R, 1998, BLOOD, V91, P4523, DOI 10.1182/blood.V91.12.4523.412k04_4523_4530; Moore MAS, 2001, BIOESSAYS, V23, P674, DOI 10.1002/bies.1095; Moser B, 1998, Int Rev Immunol, V16, P323, DOI 10.3109/08830189809043000; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy PM, 2001, NEW ENGL J MED, V345, P833, DOI 10.1056/NEJM200109133451113; Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nebreda AR, 1999, SCIENCE, V286, P1309, DOI 10.1126/science.286.5443.1309; PAPAYANNOPOULOU T, 1995, P NATL ACAD SCI USA, V92, P9647, DOI 10.1073/pnas.92.21.9647; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Sanz-Rodriguez F, 2001, BLOOD, V97, P346, DOI 10.1182/blood.V97.2.346; Schraufstatter IU, 2001, AM J PHYSIOL-LUNG C, V280, pL1094, DOI 10.1152/ajplung.2001.280.6.L1094; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; SIMMONS PJ, 1992, BLOOD, V80, P388; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Taichman RS, 2002, CANCER RES, V62, P1832; Tamamura H, 1998, BIOCHEM BIOPH RES CO, V253, P877, DOI 10.1006/bbrc.1998.9871; TEIXIDO J, 1992, J CLIN INVEST, V90, P358, DOI 10.1172/JCI115870; Verfaillie CM, 1998, BLOOD, V92, P2609, DOI 10.1182/blood.V92.8.2609; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	44	219	230	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8093	8101		10.1038/sj.onc.1207097	http://dx.doi.org/10.1038/sj.onc.1207097			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603250				2022-12-28	WOS:000186403400004
J	Kuga, H; Morisaki, T; Nakamura, K; Onishi, H; Noshiro, H; Uchiyama, A; Tanaka, M; Katano, M				Kuga, H; Morisaki, T; Nakamura, K; Onishi, H; Noshiro, H; Uchiyama, A; Tanaka, M; Katano, M			Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model	ONCOGENE			English	Article						TGF-beta; IFN-gamma; gastric carcinoma; three-dimensional culture; Smad	UROKINASE PLASMINOGEN-ACTIVATOR; BREAST-CANCER CELLS; TGF-BETA; IN-VITRO; GENE-EXPRESSION; NUCLEAR-LOCALIZATION; HUMAN-FIBROBLASTS; SKIN FIBROBLASTS; GLIOMA INVASION; COLLAGEN GELS	We reconstituted a three-dimensional gastric carcinoma model similar to invasive gastric carcinoma tissue. This model consists of a human gastric carcinoma cell line, GCTM-1, a human fibroblast cell line, TIG-1-20, and transforming growth factor-beta (TGF-beta)-containing type I collagen gel. Using this model, we were able to observe the growth of the two cell types, especially carcinoma cell invasive growth, in real time for more than 30 days. TGF-beta and TIG-1-20 were essential for GCTM-1 invasive growth and proliferation, respectively. TGF-beta induced the enhanced expression of matrix metalloproteinase 9 (MMP9) and urokinase-type plasminogen activator (uPA) in GCTM-1 at both the protein and enzymatic activity levels. The TGF-beta-induced invasion of GCTM-1 was inhibited by MMP9- or uPA-antisense (AS) oligonucleotide transfection to GCTM-1. When exogenous interferon-gamma (IFN-gamma) was added to this model, TGF-beta-dependent GCTM-1 invasion was significantly inhibited, concomitant with the decreased expression of MMP9 and uPA. The intracellular signal transduction of Smad was examined to analyse the mechanism of the inhibitory effect of IFN-gamma. TGF-beta accelerated the phosphorylation of Smad2/3 and nuclear translocation of the Smad2/3 Smad4 complex in GCTM-1, but these TGF-beta-induced effects were significantly inhibited by IFN-gamma-induced Smad7 expression. When GCTM-1 was cotransfected with AS oligonucleotide of Smad2 and Smad3, the TGF-beta-induced invasion of GCTM-1 disappeared. In addition, the inhibitory effect of IFN-gamma on TGF-beta-dependent GCTM-1 invasion vanished by the AS oligonucleotide of Smad7 transfection. These results indicate that IFN-gamma inhibits TGF-beta-dependent GCTM-1 invasion through cross-talk in the Smad pathway. IFN-gamma may be a new therapeutic tool for TGF-beta-expressed invasive carcinomas.	Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Clin Oncol & Surg, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University; Kyushu University	Katano, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Canc Therapy & Res, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							ALBINI A, 1987, CANCER RES, V47, P3239; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANKRAPP DP, 1993, CANCER RES, V53, P3399; [Anonymous], GENOME BIOL; ARNOLETTI JP, 1995, CANCER, V76, P998, DOI 10.1002/1097-0142(19950915)76:6<998::AID-CNCR2820760613>3.0.CO;2-0; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bauman GS, 1999, INT J DEV NEUROSCI, V17, P643, DOI 10.1016/S0736-5748(99)00023-4; Bell HS, 1999, J NEUROSURG, V91, P989, DOI 10.3171/jns.1999.91.6.0989; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; Chen SJ, 2000, J CELL PHYSIOL, V183, P381, DOI 10.1002/(SICI)1097-4652(200006)183:3<381::AID-JCP11>3.0.CO;2-O; COFFEY RJ, 1988, CANCER RES, V48, P1596; DAVID M, 1995, PHARMACOL THERAPEUT, V65, P149, DOI 10.1016/0163-7258(94)00050-D; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Ellenrieder V, 2001, INT J CANCER, V93, P204, DOI 10.1002/ijc.1330; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; Festuccia C, 2000, INT J CANCER, V85, P407, DOI 10.1002/(SICI)1097-0215(20000201)85:3<407::AID-IJC18>3.0.CO;2-8; Fink SP, 2001, CANCER RES, V61, P256; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; GURUJEYALAKSHMI G, 1995, EXP LUNG RES, V21, P791, DOI 10.3109/01902149509050842; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HLATKY L, 1994, CANCER RES, V54, P6083; HOFLAND LJ, 1995, INT J CANCER, V60, P93, DOI 10.1002/ijc.2910600114; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KESKIOJA J, 1988, J CELL BIOL, V106, P451, DOI 10.1083/jcb.106.2.451; Kikuchi S, 2000, HEPATO-GASTROENTEROL, V47, P1256; Kunz-Schughart LA, 2001, EXP CELL RES, V266, P74, DOI 10.1006/excr.2001.5210; Leivonen SK, 2002, J BIOL CHEM, V277, P46338, DOI 10.1074/jbc.M206535200; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; MAHARA K, 1994, BRIT J CANCER, V69, P777, DOI 10.1038/bjc.1994.147; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Matrisian LM, 2001, CANCER RES, V61, P3844; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Montgomery E, 2001, AM J PATHOL, V158, P537, DOI 10.1016/S0002-9440(10)63995-8; Mori Y, 2000, EXP CELL RES, V258, P374, DOI 10.1006/excr.2000.4930; Morisaki T, 2000, ANTICANCER RES, V20, P3363; Morrissey D, 1999, CLIN EXP METASTAS, V17, P77; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Nakamura M, 1998, BRIT J CANCER, V78, P1373, DOI 10.1038/bjc.1998.687; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; Rossi L, 2000, INT J CANCER, V85, P667, DOI 10.1002/(SICI)1097-0215(20000301)85:5<667::AID-IJC12>3.0.CO;2-1; Saito H, 1999, CANCER, V86, P1455, DOI 10.1002/(SICI)1097-0142(19991015)86:8<1455::AID-CNCR11>3.0.CO;2-L; Sandusky G, 2002, J BIOL CHEM, V277, P49815, DOI 10.1074/jbc.C200543200; Sehgal I, 1996, CANCER RES, V56, P3359; SHIPLEY GD, 1986, CANCER RES, V46, P2068; Shyu RY, 2000, J SURG ONCOL, V75, P122, DOI 10.1002/1096-9098(200010)75:2<122::AID-JSO9>3.0.CO;2-4; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Teti A, 1997, INT J CANCER, V72, P1013; TORREAMIONE G, 1990, P NATL ACAD SCI USA, V87, P1486, DOI 10.1073/pnas.87.4.1486; Tredget EE, 2000, J INTERF CYTOK RES, V20, P143, DOI 10.1089/107999000312540; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; URA H, 1991, CANCER RES, V51, P3550; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Yashiro M, 1996, BRIT J CANCER, V74, P1096, DOI 10.1038/bjc.1996.496; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	66	25	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7838	7847		10.1038/sj.onc.1207046	http://dx.doi.org/10.1038/sj.onc.1207046			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586410				2022-12-28	WOS:000186240200014
J	Mor, O; Nativ, O; Stein, A; Novak, L; Lehavi, D; Shiboleth, Y; Rozen, A; Berent, E; Brodsky, L; Feinstein, E; Rahav, A; Morag, K; Rothenstein, D; Persi, N; Mor, Y; Skaliter, R; Regev, A				Mor, O; Nativ, O; Stein, A; Novak, L; Lehavi, D; Shiboleth, Y; Rozen, A; Berent, E; Brodsky, L; Feinstein, E; Rahav, A; Morag, K; Rothenstein, D; Persi, N; Mor, Y; Skaliter, R; Regev, A			Molecular analysis of transitional cell carcinoma using cDNA microarray	ONCOGENE			English	Article						transitional cell carcinoma; cDNA microarray; molecular markers; expression profiling; tumor classification	BLADDER-CANCER; GENE-EXPRESSION; URINARY-BLADDER; CATHEPSIN-E; CLASSIFICATION; IDENTIFICATION; PATTERNS; MARKERS; TUMORS; GROWTH	The incidence of transitional cell carcinoma (TCC), the fourth most common neoplasm diagnosed in men, is rising. Despite the development of several noninvasive diagnostic tests, none have gained full recognition by the clinicians. Gene expression pro. ling of tumors can identify new molecular markers for early diagnosis and disease follow-up. It also allows the classification of tumors into subclasses assisting in disease diagnosis and prognosis, as well as in treatment selection. In this paper, we employed expression pro. ling for molecular analysis of TCC. A TCC-derived cDNA microarray was constructed and hybridized with 19 probes from normal urothelium and TCC tissues. Hierarchical clustering analysis identified all normal urothelium samples to be tightly clustered and separated from the TCC samples, with 29 of the genes significantly induced (t-test, P<10(-5)) in noninvasive TCC compared to normal urothelium. The identified genes are involved in epithelial cells' functions, tumorigenesis or apoptosis, and could become molecular tools for noninvasive TCC diagnosis. Principal components analysis of the noninvasive and invasive TCC expression profiles further revealed sets of genes that are specifically induced in different tumor subsets, thus providing molecular fingerprints that expand the information gained from classical staging and grading.	QBI Enterprises Ltd, IL-70400 Ness Ziona, Israel; Bnei Zion Med Ctr, Dept Urol, Haifa, Israel; Carmel Hosp, Dept Urol, Haifa, Israel; Chaim Sheba Med Ctr, Dept Urol, IL-52621 Ramat Gan, Israel	Bnai Zion Medical Center; Clalit Health Services; Carmel Medical Center; Chaim Sheba Medical Center	Mor, O (corresponding author), QBI Enterprises Ltd, POB 4071, IL-70400 Ness Ziona, Israel.			Stein, Avi/0000-0002-7886-2458; Shiboleth, Yoel/0000-0001-5941-4978				Bayer-Garner IB, 2000, AM J DERMATOPATH, V22, P119, DOI 10.1097/00000372-200004000-00005; Bieller A, 2001, DNA CELL BIOL, V20, P555, DOI 10.1089/104454901317094963; Brown FM, 2000, UROL CLIN N AM, V27, P25, DOI 10.1016/S0094-0143(05)70231-7; Burchardt M, 2000, CLIN CHEM, V46, P595; Choudry GA, 2001, BRIT J CANCER, V85, P1137, DOI 10.1054/bjoc.2001.2056; Dobra K, 2000, EXP CELL RES, V258, P12, DOI 10.1006/excr.2000.4915; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Dyrskjot L, 2003, NAT GENET, V33, P90, DOI 10.1038/ng1061; Engel LS, 2002, AM J EPIDEMIOL, V156, P95, DOI 10.1093/aje/kwf018; Feroze-Merzoug F, 2002, BIOTECHNIQUES, V32, P776, DOI 10.2144/02324st03; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Giroldi Laurence A., 2000, Morphologie, V84, P31; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kataoka H, 2000, CANCER LETT, V148, P127, DOI 10.1016/S0304-3835(99)00322-5; Kausch I, 2002, EUR UROL, V41, P15, DOI 10.1016/S0302-2838(01)00007-0; Koenig F, 2000, CLIN CHIM ACTA, V297, P191, DOI 10.1016/S0009-8981(00)00246-1; KWAK MK, 2002, J BIOL CHEM, V27, P27; Levy A, 1999, GENE CHROMOSOME CANC, V24, P42, DOI 10.1002/(SICI)1098-2264(199901)24:1<42::AID-GCC6>3.0.CO;2-F; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; Liu NF, 2001, CANCER RES, V61, P5207; Liu YX, 2001, CHINESE MED J-PEKING, V114, P35; Macgregor PF, 2002, CLIN CHEM, V48, P1170; Menard S, 1998, BREAST CANCER RES TR, V52, P137, DOI 10.1023/A:1006171403765; Mohr S, 2002, J CLIN ONCOL, V20, P3165, DOI 10.1200/JCO.2002.12.073; Mota F, 1997, AM J PATHOL, V150, P1223; Rotem D, 2000, EUR UROL, V37, P601, DOI 10.1159/000020199; Schamhart DHJ, 2000, EUR UROL, V37, P16, DOI 10.1159/000052388; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Southgate J, 1999, HISTOL HISTOPATHOL, V14, P657, DOI 10.14670/HH-14.657; Thykjaer T, 2001, CANCER RES, V61, P2492; Turner KJ, 2002, BRIT J CANCER, V86, P1276, DOI 10.1038/sj.bjc.6600215; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vila MR, 2000, CANCER, V89, P152; Weiner HL, 2000, NEUROSURGERY, V47, P1400, DOI 10.1097/00006123-200012000-00028; Yamamoto S, 1996, VIRCHOWS ARCH, V427, P589; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41	39	43	45	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7702	7710		10.1038/sj.onc.1207039	http://dx.doi.org/10.1038/sj.onc.1207039			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576834				2022-12-28	WOS:000186113000019
J	Dorothee, G; Echchakir, H; Chansac, BL; Vergnon, I; El Hage, F; Moretta, A; Bensussan, A; Chouaib, S; Mami-Chouaib, F				Dorothee, G; Echchakir, H; Chansac, BL; Vergnon, I; El Hage, F; Moretta, A; Bensussan, A; Chouaib, S; Mami-Chouaib, F			Functional and molecular characterization of a KIR3DL2/p140 expressing tumor-specific cytotoxic T lymphocyte clone infiltrating a human lung carcinoma	ONCOGENE			English	Article						TIL; KIR3DL2; CTL; TCR	CLASS-I MOLECULES; CELL-MEDIATED CYTOTOXICITY; NATURAL-KILLER-CELLS; INHIBITORY RECEPTOR; DIFFERENTIAL EXPRESSION; KIR2DL4 CD158D; LYTIC ACTIVITY; NK CELLS; HLA-A; ANTIGEN	T lymphocytes infiltrating a human lung carcinoma stimulated in vitro with autologous tumor cell line showed a TCRVbeta13.6(+) T-cell expansion. This subset was isolated using TCRVbeta-specific antibody and several T-cell clones were generated. All these clones expressed a unique Vbeta13.6-Jbeta2.7 TCR with the same junctional region strongly suggesting that they derived from the same cell. They were CD8(+)/CD28(-) and expressed the MHC class I binding killer cell Ig-like receptor (KIR)3DL2/p140, but not KIR3DL1/p70, KIR2DL1/p58.1 and KIR2DL2/3/p58.2. Sequence analysis indicated that KIR3DL2/p140 cDNA was identical to the previously reported 3DL2*002 allele except for two nucleic acid substitutions. Functional studies showed that KIR3DL2/p140(+) CTL secrete a significant level of IFNgamma and mediate an HLA-A2-restricted cytotoxicity against the autologous and some allogeneic tumor cells but not towards the autologous EBV-B cells. Strikingly, both the lytic and the cytokine secretion activities induced upon specific cell interactions were unaffected by anti-KIR3DL2/p140 antibody. In addition, crosslinking KIR3DL2/p140 molecules on CTL did not result into the modi. cation of cytotoxicity and cytokine production triggered by anti-CD3 antibody. These results strongly suggest that, as opposed to distinct KIR expressed by CTL, the in vitro KIR3DL2/p140 engagement does not result into inhibitory (nor activatory) effects on tumor-specific CTL.	Inst Gustave Roussy, INSERM, U487, Lab Cytokines & Immunol Tumeurs Humaines, F-94805 Villejuif, France; Univ Genoa, Ctr Eccellenza Ric Biomed, I-16132 Genoa, Italy; Univ Genoa, Dipartimento Med Sperimentale, Sez Istol, I-16132 Genoa, Italy; Fac Med Creteil, INSERM, U448, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; University of Genoa; University of Genoa; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Mami-Chouaib, F (corresponding author), Inst Gustave Roussy, INSERM, U487, Lab Cytokines & Immunol Tumeurs Humaines, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.		DOROTHEE, Guillaume/O-9760-2016; Bensussan, Armand/E-5434-2017; Chouaib, Salem/F-7939-2016; Mami-Chouaib, Fathia/E-5267-2016	DOROTHEE, Guillaume/0000-0001-5763-3632; Bensussan, Armand/0000-0002-0409-2497				Asselin-Paturel C, 1998, INT J CANCER, V77, P7, DOI 10.1002/(SICI)1097-0215(19980703)77:1<7::AID-IJC2>3.0.CO;2-Y; AZUMA M, 1993, J IMMUNOL, V150, P1147; Bagot M, 2001, BLOOD, V97, P1388, DOI 10.1182/blood.V97.5.1388; Bakker ABH, 1998, J IMMUNOL, V160, P5239; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Colonna M, 1997, J EXP MED, V186, P1809, DOI 10.1084/jem.186.11.1809; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; Dohring C, 1996, J IMMUNOL, V156, P3098; Echchakir H, 2001, CANCER RES, V61, P4078; Echchakir H, 2002, P NATL ACAD SCI USA, V99, P9358, DOI 10.1073/pnas.142308199; Echchakir H, 2000, INT IMMUNOL, V12, P537, DOI 10.1093/intimm/12.4.537; Faure M, 2002, J IMMUNOL, V168, P6208, DOI 10.4049/jimmunol.168.12.6208; FERRINI S, 1994, EUR J IMMUNOL, V24, P2294, DOI 10.1002/eji.1830241005; Fry AM, 1996, J EXP MED, V184, P295, DOI 10.1084/jem.184.1.295; Gardiner CM, 2001, J IMMUNOL, V166, P2992, DOI 10.4049/jimmunol.166.5.2992; Gati A, 2001, CANCER RES, V61, P3240; Guerra N, 2000, BLOOD, V95, P2883, DOI 10.1182/blood.V95.9.2883.009k22_2883_2889; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Le Drean E, 1998, EUR J IMMUNOL, V28, P264, DOI 10.1002/(SICI)1521-4141(199801)28:01<264::AID-IMMU264>3.0.CO;2-O; MINGARI MC, 1995, INT IMMUNOL, V7, P697, DOI 10.1093/intimm/7.4.697; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; Noppen C, 1998, EUR J IMMUNOL, V28, P1134, DOI 10.1002/(SICI)1521-4141(199804)28:04<1134::AID-IMMU1134>3.0.CO;2-G; Pende D, 1996, J EXP MED, V184, P505, DOI 10.1084/jem.184.2.505; PHILLIPS JH, 1995, SCIENCE, V268, P403, DOI 10.1126/science.7716542; Rajagopalan S, 2001, J IMMUNOL, V167, P1877, DOI 10.4049/jimmunol.167.4.1877; Shilling HG, 2002, J IMMUNOL, V168, P2307, DOI 10.4049/jimmunol.168.5.2307; Speiser DE, 1999, J EXP MED, V190, P775, DOI 10.1084/jem.190.6.775; STORKUS WJ, 1991, P NATL ACAD SCI USA, V88, P5989, DOI 10.1073/pnas.88.14.5989; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; Young NT, 2001, J IMMUNOL, V166, P3933, DOI 10.4049/jimmunol.166.6.3933; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	32	21	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7192	7198		10.1038/sj.onc.1206627	http://dx.doi.org/10.1038/sj.onc.1206627			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562047				2022-12-28	WOS:000185955000010
J	Gulbins, E; Kolesnick, R				Gulbins, E; Kolesnick, R			Raft ceramide in molecular medicine	ONCOGENE			English	Article						ceramide; acid sphingomyelinase (ASM); radiation; bacteria; rafts; membrane platforms	RADIATION-INDUCED APOPTOSIS; RICH MEMBRANE RAFTS; HEREDITARY SENSORY NEUROPATHY; ACID SPHINGOMYELINASE; SERINE PALMITOYLTRANSFERASE; CELL-MEMBRANES; IN-VIVO; FAS; DEATH; MICE	Ceramide, generated by the action of acid sphingomyelinase (ASM), has emerged as a biochemical mediator of stimuli as diverse as ionizing radiation, chemotherapy, UVA light, heat, CD95, reperfusion injury, as well as infection with some pathogenic bacteria and viruses. ASM activity is also crucial for developmental programmed cell death of oocytes by apoptosis. Recently, we proposed a comprehensive model that might explain these diverse functions of ceramide: Upon contacting the relevant stimuli, ASM translocates into and generates ceramide within distinct plasma membrane sphingolipid-enriched microdomains termed rafts. Ceramide, which manifests a unique biophysical property, the capability to self-associate through hydrogen bonding, provides the driving force that results in the coalescence of microscopic rafts into large-membrane macrodomains. These structures serve as platforms for protein concentration and oligomerization, transmitting signals across the plasma membrane. Preliminary data suggest that manipulation of ceramide metabolism and/or the function of ceramide-enriched membrane platforms may present novel therapeutic opportunities for the treatment of cancer, degenerative disorders, pathogenic infections or cardiovascular diseases.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	University of Duisburg Essen; Memorial Sloan Kettering Cancer Center	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufelandstr 55, D-45122 Essen, Germany.	erich.gulbins@uni-essen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				Bejaoui K, 2001, NAT GENET, V27, P261, DOI 10.1038/85817; Bini L, 2003, BIOCHEM J, V369, P301, DOI 10.1042/BJ20020503; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Charles R, 2000, CIRC RES, V87, P282, DOI 10.1161/01.RES.87.4.282; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chung HS, 2003, EXP MOL MED, V35, P181, DOI 10.1038/emm.2003.25; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CREMESTI A, 2003, UNPUB FAS ACTIVATION; Dawkins JL, 2001, NAT GENET, V27, P309, DOI 10.1038/85879; Esen M, 2001, APOPTOSIS, V6, P431, DOI 10.1023/A:1012445925628; FANZO JC, 2003, CANCER BIOL THER, V2, pE55; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; Hauck CR, 2000, FEBS LETT, V478, P260, DOI 10.1016/S0014-5793(00)01851-2; Holopainen JM, 1998, BIOCHEMISTRY-US, V37, P17562, DOI 10.1021/bi980915e; Huang HW, 1999, BIOPHYS J, V77, P1489, DOI 10.1016/S0006-3495(99)76996-1; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Jan JT, 2000, J VIROL, V74, P6425, DOI 10.1128/JVI.74.14.6425-6432.2000; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Lucci A, 1998, ANTICANCER RES, V18, P475; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; Michael JM, 1997, CANCER RES, V57, P3600; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nurminen TA, 2002, J AM CHEM SOC, V124, P12129, DOI 10.1021/ja017807r; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Paris F, 2001, J BIOL CHEM, V276, P8297, DOI 10.1074/jbc.M008732200; Pena LA, 2000, CANCER RES, V60, P321; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwartz GK, 1997, CLIN CANCER RES, V3, P537; Seino KI, 1997, GASTROENTEROLOGY, V113, P1315, DOI 10.1053/gast.1997.v113.pm9322527; Selzner M, 2001, CANCER RES, V61, P1233; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Spinedi A, 1998, CELL DEATH DIFFER, V5, P785, DOI 10.1038/sj.cdd.4400428; tenGrotenhuis E, 1996, BIOPHYS J, V71, P1389, DOI 10.1016/S0006-3495(96)79341-4; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Wang HT, 2001, CANCER RES, V61, P5102; WANG ZQ, 1994, EUR J IMMUNOL, V24, P1549, DOI 10.1002/eji.1830240714; Yu ZF, 2000, J MOL NEUROSCI, V15, P85, DOI 10.1385/JMN:15:2:85; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200	56	328	336	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7070	7077		10.1038/sj.onc.1207146	http://dx.doi.org/10.1038/sj.onc.1207146			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557812				2022-12-28	WOS:000185903900012
J	Deshayes, F; Lapree, G; Portier, A; Richard, Y; Pencalet, P; Mahieu-Caputo, D; Horellou, P; Tsapis, A				Deshayes, F; Lapree, G; Portier, A; Richard, Y; Pencalet, P; Mahieu-Caputo, D; Horellou, P; Tsapis, A			Abnormal production of the TNF-homologue APRIL increases the proliferation of human malignant glioblastoma cell lines via a specific receptor	ONCOGENE			English	Article						glioblastomas; APRIL; proliferation; APRIL receptor; malignancy	NECROSIS-FACTOR FAMILY; MATURATION ANTIGEN; BCMA GENE; GROWTH; MEMBER; TACI; LIGAND; SUPERFAMILY; SYSTEM; DEATH	A proliferation-inducing ligand (APRIL) of the tumour necrosis factor (TNF) family is produced in small amounts in many tissues and more abundantly in tumours. APRIL has been reported to promote cell growth in vivo and in vitro. It was recently shown that the production of APRIL in some glioblastoma cell lines does not lead to an increase in cell growth. In this study, we investigated the production of APRIL and its ability to increase the proliferation of eight human glioblastoma cell lines. We found that APRIL was produced in the eight human glioblastoma cell lines tested but not in the normal embryonic astrocyte counterparts of glioblastomas. Flow cytometry demonstrated the presence of a specific APRIL-binding receptor on the cell surface in all the glioblastoma cell lines tested. This receptor was also present on normal embryonic and adult astrocytes and embryonic neural progenitor cells. Moreover, the addition of recombinant human APRIL resulted in an increase in proliferation rate of normal adult astrocytes and in four of eight cell lines tested. Addition of the soluble recombinant TNF-receptor-homologue B-cell maturation (BCMA) chimeric protein, which binds APRIL, confirmed the involvement of APRIL in the growth of malignant glioblastoma cell lines.	INSERM, U131, F-92140 Clamart, France; Hop Foch, Serv Neurochirurg, F-92150 Suresnes, France; Hop Antoine Beclere, INSERM, F-92140 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Hospital Foch; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Tsapis, A (corresponding author), INSERM, U131, 32 Rue Carnets, F-92140 Clamart, France.	andreas.tsapis@ipsc.u-psud.fr	Horellou, Philippe/B-4290-2019; RICHARD, Yolande/B-7926-2008	Horellou, Philippe/0000-0003-2467-8177; RICHARD, Yolande/0000-0001-8560-9250				Barbero S, 2003, CANCER RES, V63, P1969; CHAMAK B, 1989, DEVELOPMENT, V106, P483; DAVIES LG, 1986, BASIC METHODS MOL BI; Goswami S, 1998, J NEUROCHEM, V71, P1837; Gravestein LA, 1998, SEMIN IMMUNOL, V10, P423, DOI 10.1006/smim.1998.0144; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Held-Feindt J, 2003, J NEURO-ONCOL, V63, P117, DOI 10.1023/A:1023943405292; Kelly K, 2000, CANCER RES, V60, P1021; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LAABI Y, 1994, NUCLEIC ACIDS RES, V22, P1147, DOI 10.1093/nar/22.7.1147; Lopez-Fraga M, 2001, EMBO REP, V2, P945, DOI 10.1093/embo-reports/kve198; Madry C, 1998, INT IMMUNOL, V10, P1693, DOI 10.1093/intimm/10.11.1693; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; MILOUX B, 1994, GENE, V149, P341, DOI 10.1016/0378-1119(94)90173-2; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ridet JL, 1999, HUM GENE THER, V10, P271, DOI 10.1089/10430349950019057; Roth W, 2001, CELL DEATH DIFFER, V8, P403, DOI 10.1038/sj.cdd.4400827; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Wu YM, 2000, J BIOL CHEM, V275, P35478, DOI 10.1074/jbc.M005224200; Xia XZ, 2000, J EXP MED, V192, P137, DOI 10.1084/jem.192.1.137; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	27	47	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3005	3012		10.1038/sj.onc.1207350	http://dx.doi.org/10.1038/sj.onc.1207350			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14691452				2022-12-28	WOS:000220845200004
J	Kadaja, L; Laos, S; Maimets, T				Kadaja, L; Laos, S; Maimets, T			Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF	ONCOGENE			English	Article						CD43; p53; p19ARF	WISKOTT-ALDRICH SYNDROME; T-CELL-ACTIVATION; SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODIES; COLON ADENOMA; FEEDBACK LOOP; MDM2; PHOSPHORYLATION; LEUKOSIALIN; EXPRESSION	CD43 or leukosialin is a transmembrane sialoglycoprotein, whose extracellular domain participates in cell adhesiveness and the cytoplasmic tail regulates a variety of intracellular signal transduction pathways involved in cell proliferation. CD43 is abundantly expressed on the surface of hematopoietic cells, but CD43 expression is also frequently found in the tumor cells of nonhematopoietic origin. In the early stages of some tumors, the accumulation of tumor suppressor protein p53 has been described. Here, we show that the expression of CD43 causes the induction of functionally active p53 protein. Moreover, we found that the activation of p53 by CD43 is mediated by tumor suppressor protein ARF. The coexpression of CD43 and ARF in ARF-null mouse embryonic fibroblasts resulted in programmed cell death, but that was not the case when CD43 alone was expressed in these cells. These data provide the first evidence of the connection between p53- and CD43-dependent pathways.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Tartu; University of Gothenburg	Kadaja, L (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, 23 Riia St, EE-51010 Tartu, Estonia.	lkadaja@ebc.ee	Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				ANDERSSON LC, 1978, BLOOD, V52, P57; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAZARS R, 1991, ONCOGENE, V6, P1685; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; Miura Y, 2001, BIOCHEM BIOPH RES CO, V288, P80, DOI 10.1006/bbrc.2001.5729; Ostberg JR, 1996, J IMMUNOL, V157, P4876; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Rosenstein Y, 1999, IMMUNOL RES, V20, P89, DOI 10.1007/BF02786465; Sambrook J., 2002, MOL CLONING LAB MANU; Santamaria M, 1996, CANCER RES, V56, P3526; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sikut R, 1999, INT J CANCER, V82, P52, DOI 10.1002/(SICI)1097-0215(19990702)82:1<52::AID-IJC10>3.0.CO;2-C; Sikut R, 1997, BIOCHEM BIOPH RES CO, V238, P612, DOI 10.1006/bbrc.1997.7334; Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang WM, 2000, CELL IMMUNOL, V205, P34, DOI 10.1006/cimm.2000.1716; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	2004	23	14					2523	2530		10.1038/sj.onc.1207359	http://dx.doi.org/10.1038/sj.onc.1207359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676827				2022-12-28	WOS:000220558000009
J	Candeias, SM; Mancini, SJC; Touvrey, C; Borel, E; Jouvin-Marche, E; Marche, PN				Candeias, SM; Mancini, SJC; Touvrey, C; Borel, E; Jouvin-Marche, E; Marche, PN			p53-dependent and p53-independent pathways for radiation-induced immature thymocyte differentiation	ONCOGENE			English	Article						p53; ionizing radiation; T lymphocyte survival; differentiation; DNA-PK	DEPENDENT PROTEIN-KINASE; T-CELL RECEPTOR; TCRA GENE REARRANGEMENT; DNA-DAMAGE; PRE-TCR; V(D)J RECOMBINATION; TRANSCRIPTIONAL REPRESSION; MOUSE THYMOCYTES; DEFICIENT MICE; SCID MICE	The pre-T-cell receptor (TCR) delivers essential survival/differentiation signals to the developing thymocytes. Severe combined immunodeficient (SCID) and recombination-activating gene (RAG)-deficient mice are unable to assemble antigen receptor genes, and therefore cannot express a pre-TCR. Consequently, T lymphocyte differentiation is arrested at an early stage in the thymus of these animals, and immature thymocytes are eliminated through apoptotic processes. This maturation arrest can be relieved and thymocyte differentiation rescued after the exposure of these mice to whole-body gamma-irradiation. Whereas the promotion of immature thymocyte survival/differentiation was shown to require p53 activity in irradiated SCID mice, it was suggested, on the other hand, that p53 activation prevents immature thymocytes survival/differentiation in irradiated RAG-deficient mice. However, SCID mice have impaired responses to ionizing radiation. In this paper, we analysed p53 requirement in radiation-induced thymocyte differentiation in CD3epsilon(Delta5/Delta5) mice, where pre-TCR deficiency also results in an early block of lymphocyte development. Our results show at the cellular and molecular levels that, in this DNA repair-proficient model, irradiation-induced thymocyte differentiation proceeds either by a p53-dependent or by a p53-independent pathway, which differ in their sensitivity to the radiation dose delivered.	Univ Grenoble 1, Dept Reponse & Dynam Cellulaire, Commissariat Energie Atom Grenoble, Lab Immunochim,INSERM,U548, F-38054 Grenoble, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Candeias, SM (corresponding author), Univ Grenoble 1, Dept Reponse & Dynam Cellulaire, Commissariat Energie Atom Grenoble, Lab Immunochim,INSERM,U548, 17 Rue Martyrs, F-38054 Grenoble, France.	immuno@dsvsud.cea.fr	TOUVREY, Cedric/G-4126-2011; Marche, Patrice N/K-5060-2013; Mancini, Stéphane J/R-4109-2016; JOUVIN MARCHE, Evelyne/L-8648-2013	Marche, Patrice N/0000-0002-8930-9340; Mancini, Stéphane J/0000-0001-9255-4606; JOUVIN MARCHE, Evelyne/0000-0001-8616-138X; Borel Meneroud, eve/0000-0002-9638-578X; Candeias, Serge/0000-0003-2257-5529				Araki R, 1997, P NATL ACAD SCI USA, V94, P2438, DOI 10.1073/pnas.94.6.2438; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Candeias SM, 1997, BIOCHIMIE, V79, P607, DOI 10.1016/S0300-9084(97)82010-X; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DeJarnette JB, 1998, P NATL ACAD SCI USA, V95, P14909, DOI 10.1073/pnas.95.25.14909; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; Gallagher M, 1998, EUR J IMMUNOL, V28, P3878, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3878::AID-IMMU3878&gt;3.0.CO;2-C; GUIDOS CJ, 1995, J EXP MED, V181, P1187, DOI 10.1084/jem.181.3.1187; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haks MC, 1999, IMMUNITY, V11, P91, DOI 10.1016/S1074-7613(00)80084-9; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; HUGO P, 1991, EUR J IMMUNOL, V21, P835, DOI 10.1002/eji.1830210346; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Mancini S, 1999, J IMMUNOL, V163, P6053; Mancini SJC, 2001, J IMMUNOL, V167, P4485, DOI 10.4049/jimmunol.167.8.4485; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; Nacht M, 1998, CELL GROWTH DIFFER, V9, P131; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Newton K, 2000, EMBO J, V19, P931, DOI 10.1093/emboj/19.5.931; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; Wang BP, 1998, J EXP MED, V188, P1375, DOI 10.1084/jem.188.7.1375; Wang BP, 1999, J IMMUNOL, V162, P88; Zhao RB, 2000, GENE DEV, V14, P981; ZUNIGAPFLUCKER JC, 1994, J EXP MED, V180, P1517, DOI 10.1084/jem.180.4.1517	38	5	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1922	1929		10.1038/sj.onc.1207320	http://dx.doi.org/10.1038/sj.onc.1207320			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755249				2022-12-28	WOS:000220129500014
J	Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T				Kim, M; Tezuka, T; Tanaka, K; Yamamoto, T			Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation	ONCOGENE			English	Article						Cbl family; v-Src; transformation; ubiquitination	MEDIATED TYROSINE PHOSPHORYLATION; D-ASPARTATE RECEPTOR; DOWN-REGULATION; NEGATIVE REGULATOR; LIGASE ACTIVITY; KINASE; ACTIVATION; ZAP-70; CELLS; PROLIFERATION	The Cbl family proteins Cbl, Cbl- b, and Cbl-c/Cbl-3 are thought to regulate signaling through protein-tyrosine kinases, positively as scaffold proteins and negatively as ubiquitin ligases. However, the precise signaling pathways and target proteins for each Cbl family member are not well understood. Here we show that Src is a preferential target of Cbl- c for degradation. Although exogenous expression of all Cbl family proteins suppressed the anchorage-independent growth of v-Src-transformed NIH3T3 cells, only Cbl- c caused reversion of the refractile morphology. The level of v-Src protein was reduced by Cbl- c, possibly through a lysosome-dependent pathway. The TKB domain and RING finger of Cbl- c were important for its antioncogenic activity. Wild-type Cbl- c promoted ubiquitination of Src in 293T cells, whereas a RING finger mutant did not. Cbl- c bound specifically to Src phosphorylated at Tyr419. Furthermore, Cbl- c together with UbcH5 induced ubiquitination of Src in vitro. Importantly, the Tyr419 nonphosphorylated form of Src was not ubiquitinated by Cbl- c. Therefore, activated Src may be a direct target of Cbl- c in vivo. Our results suggest that Cbl and Cbl- b suppress v-Src-induced transformation through mechanisms distinct from that of Cbl- c.	Univ Tokyo, Inst Med Sci, Div Oncol, Dept Canc Biol,Minato Ku, Tokyo 1088639, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan	University of Tokyo; Tokyo Metropolitan Institute of Medical Science	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Dept Canc Biol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	tyamamot@ims.u-tokyo.ac.jp		Kim, Minsoo/0000-0001-8536-8653				Astarie-Dequeker C, 2002, J CELL SCI, V115, P81; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Howlett CJ, 2002, ONCOGENE, V21, P1707, DOI 10.1038/sj.onc.1205228; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kim M, 1999, GENE, V239, P145, DOI 10.1016/S0378-1119(99)00356-X; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; ODAJIMA J, 2000, J BIOL CHEM, V11, P11; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tezuka T, 1999, P NATL ACAD SCI USA, V96, P435, DOI 10.1073/pnas.96.2.435; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yasuda T, 2002, J EXP MED, V196, P51, DOI 10.1084/jem.20020068; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200	33	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1645	1655		10.1038/sj.onc.1207298	http://dx.doi.org/10.1038/sj.onc.1207298			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14661060				2022-12-28	WOS:000220029300001
J	Ueda, R; Iizuka, Y; Yoshida, K; Kawase, T; Kawakami, Y; Toda, M				Ueda, R; Iizuka, Y; Yoshida, K; Kawase, T; Kawakami, Y; Toda, M			Identification of a human glioma antigen, SOX6, recognized by patients' sera	ONCOGENE			English	Article						glioma; tumor antigen; CT antigen; SOX6; SEREX; IgG response	IMMUNE-RESPONSES; NERVOUS-SYSTEM; BRAIN-TUMORS; GENE SOX6; PROTEIN; TESTIS; SRY; LYMPHOCYTES; EXPRESSION; MOUSE	To identify tumor antigens for glioma, a human testis cDNA library was screened by serological identification of antigens by recombinant expression cloning with sera from glioma patients. In this screening, the most frequently isolated antigen was SOX6, an Sry-related high-mobility group (HMG) box-containing gene. SOX6 is a transcriptional factor that is specifically expressed in the developing central nervous system and in the early stages of chondrogenesis in mouse embryos. IgG antibodies against SOX6 were detected in sera from 12 of 36 glioma patients (33.3%), 0 of 14 patients with other brain disease (0%), and one of 54 other cancer patients (1.9%). In sera from 37 healthy individuals, no IgG responses against SOX6 were detected, except in an elderly female. Furthermore, Western blot and ELISA analyses with sera from glioma patients revealed that the DNA-binding domain, the HMG box of SOX6, might be a dominant epitope of IgGs against SOX6. RT-PCR and Northern blot analysis revealed that the SOX6 gene was more highly expressed in glioma tissues than in normal adult tissues, except testis. Western blot analysis with an anti-SOX6 antibody demonstrated that the SOX6 protein was expressed in glioma tissues, but not in normal adult brain tissue. Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analysed expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in non-neoplastic tissues from the cerebral cortex. In summary, these results indicate that the developmentally regulated transcription factor SOX6 is aberrantly expressed in glioma and specifically recognized by IgGs from glioma patients' sera.	Keio Univ, Sch Med, Dept Neurosurg, Neuroimmunol Res Grp,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Inst Adv Med Res, Div Cellular Signaling,Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Neuroimmunol Res Grp, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University; Keio University	Toda, M (corresponding author), Keio Univ, Sch Med, Dept Neurosurg, Neuroimmunol Res Grp,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	todam@sc.itc.keio.ac.jp	nakamura, asuka/S-7235-2016; Toda, Masahiro/L-2268-2013; Kawakami, Yutaka/E-7429-2013; Yoshida, Kazunari/L-2255-2013	Kawakami, Yutaka/0000-0003-4836-2855; 				Almqvist PM, 2002, J HISTOCHEM CYTOCHEM, V50, P147, DOI 10.1177/002215540205000203; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Cohen-Barak G, 2001, GENE, V265, P157, DOI 10.1016/S0378-1119(01)00346-8; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327; Fischer U, 2001, CLIN EXP IMMUNOL, V126, P206, DOI 10.1046/j.1365-2249.2001.01635.x; Hagiwara N, 2000, P NATL ACAD SCI USA, V97, P4180, DOI 10.1073/pnas.97.8.4180; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Narahara M, 2002, BIOL PHARM BULL, V25, P705, DOI 10.1248/bpb.25.705; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PRADOS MD, 1992, INT J RADIAT ONCOL, V23, P3, DOI 10.1016/0360-3016(92)90537-R; ROBBINS PF, 1994, CANCER RES, V54, P3124; Sahin U, 2000, CLIN CANCER RES, V6, P3916; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Southard-Smith EM, 1998, NAT GENET, V18, P60, DOI 10.1038/ng0198-60; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; TAKAHASHI K, 1995, CANCER RES, V55, P3478; Toda M, 2001, GLIA, V34, P1, DOI 10.1002/glia.1034; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; Xia Y, 2000, CANCER RES, V60, P6303; Yamashita A, 2000, FEBS LETT, V481, P147, DOI 10.1016/S0014-5793(00)01987-6	33	51	56	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1420	1427		10.1038/sj.onc.1207252	http://dx.doi.org/10.1038/sj.onc.1207252			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14691456	Green Submitted			2022-12-28	WOS:000189035800009
J	Zhou, XL; Thorgeirsson, SS; Popescu, NC				Zhou, XL; Thorgeirsson, SS; Popescu, NC			Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells	ONCOGENE			English	Article						DLC-1 function; cell growth inhibition; cell migration inhibition; apoptosis reduction of tumorigenicity	CHROMOSOME 8P DELETION; RHO GTPASES; IN-VIVO; METASTASIS; PROTEINS; LINES; DISEASE; DOMAIN; START; DEATH	The gene deleted in liver cancer-1 (DLC-1) is located on human chromosome 8p21-22, a region thought to harbor tumor suppressor genes on the basis of its frequent deletion or loss of heterozygosity in a variety of human cancers, including hepatocellular carcinoma (HCC). Deletion or altered expression of DLC-1 is common in HCC. In the current study, the subcellular localization of Dlc-1 protein was determined by immunostaining with antibody to DLC-1 and the possible tumor growth suppressor activity of DLC-1 was investigated by examining the effects of of DLC-1 cDNA transfection in two human HCC cell lines lacking expression of the endogenous gene. The results show that Dlc-1protein is localized in the cell cytoplasm, and the restoration of DLC-1 expression in HCC cells resulted in caspase-3-mediated apoptosis, inhibition of cell growth and invasiveness in vitro as well as in reduction of the ability of the cells to form tumors in athymic nude mice. These observations thus support the notion that Dlc-1 protein is involved in hepatocarcinogenesis and has oncosuppressive activity in HCC.	NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bldg 37,Room 4128,37 Convent Dr,MSC 4264, Bethesda, MD 20892 USA.	popescun@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010038, Z01BC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Euer N, 2002, ANTICANCER RES, V22, P733; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kahng YS, 2003, J GASTROEN HEPATOL, V18, P430, DOI 10.1046/j.1440-1746.2003.02997.x; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Keck CL, 1999, CANCER GENET CYTOGEN, V111, P37, DOI 10.1016/S0165-4608(98)00210-6; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Ng IOL, 2000, CANCER RES, V60, P6581; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	27	123	139	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1308	1313		10.1038/sj.onc.1207246	http://dx.doi.org/10.1038/sj.onc.1207246			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647417				2022-12-28	WOS:000188892200016
J	Theoleyre, O; Deguillien, M; Moriniere, M; Starck, J; Moreau-Gachelin, F; Morle, F; Baklouti, F				Theoleyre, O; Deguillien, M; Moriniere, M; Starck, J; Moreau-Gachelin, F; Morle, F; Baklouti, F			Spi-l/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythroleukemia cells	ONCOGENE			English	Article						alternative splicing; erythroleukemia; Spi-l/PU.1; Fli-1; protein 4.1R; erythroid differentiation	INSERTION DELETION MUTATIONS; ACTIN-BINDING DOMAIN; TRANSCRIPTION FACTOR; PU.1 TRANSCRIPTION; MOLECULAR ANALYSIS; TERNARY COMPLEX; DIFFERENTIATION; PROTEIN-4.1; SPI-1/PU.1; SPECTRIN	The inclusion of exon 16 in mature protein 4.1R mRNA arises from a stage-specific splicing event that occurs during late erythroid development. We have shown that mouse erythroleukemia (MEL) cells reproduce this erythroid-specific splicing event upon induction of differentiation. We here found that this splicing event is regulated specifically in erythroleukemic cells that have the potential to differentiate and produce hemoglobin, regardless of the nature of the differentiation inducer. Knowing that dysregulated expression of spi-1/pu.1 and fli-1 oncogenes is involved in MEL cell differentiation arrest, we looked at their effect on exon 16 erythroid splicing. We found that exon 16 inclusion requires Spi-1/ PU.1 shutdown in MEL cells, and that enforced expression of Spi-1/PU.1 inhibits exon selection, regardless of the presence or absence of a chemical inducer. By contrast, endogenous overexpression or enforced expression of Fli-1 has no effect on exon selection. We further showed that Spi-1/PU.1 acts similarly on the endogenous and on a transfected exon 16, suggesting a promoter-independent effect of Spi-1/PU.1 on splicing regulation. This study provides the first evidence that Spi-1/PU.1 displays the unique property, not shared with Fli-1, to inhibit erythroid-specific pre-mRNA splicing in erythroleukemia cell context.	Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Inst Curie, INSERM, U528, Lab Transduct Signal & Oncogenese, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Baklouti, F (corresponding author), Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 16 Rue R Dubois, F-69622 Villeurbanne, France.	baklouti@univ-lyon1.fr	BAKLOUTI, Faouzi/E-7670-2013	BAKLOUTI, Faouzi/0000-0002-2830-292X				Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bolduc L, 2001, J BIOL CHEM, V276, P17597, DOI 10.1074/jbc.M011769200; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CONBOY J, 1990, J CLIN INVEST, V86, P524, DOI 10.1172/JCI114739; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DELGADO MD, 1994, ONCOGENE, V9, P1723; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HANSPAL M, 1992, BLOOD, V80, P530; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; HORNE WC, 1993, BLOOD, V82, P2558; LORENZO F, 1994, J CLIN INVEST, V94, P1651, DOI 10.1172/JCI117508; Maillet P, 1999, HUM MUTAT, V14, P145, DOI 10.1002/(SICI)1098-1004(1999)14:2<145::AID-HUMU6>3.0.CO;2-L; MARCHESI SL, 1990, J CLIN INVEST, V86, P516, DOI 10.1172/JCI114738; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; Starck J, 1999, MOL CELL BIOL, V19, P121; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	32	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					920	927		10.1038/sj.onc.1207206	http://dx.doi.org/10.1038/sj.onc.1207206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647452				2022-12-28	WOS:000188486600007
J	Wichert, A; Stege, A; Midorikawa, Y; Holm, PS; Lage, H				Wichert, A; Stege, A; Midorikawa, Y; Holm, PS; Lage, H			Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells	ONCOGENE			English	Article						drug resistance; mitoxantrone; glypicans; ribozymes; gastric carcinoma	HEPARAN-SULFATE PROTEOGLYCANS; DEVELOPMENTALLY-REGULATED TRANSCRIPT; BEHMEL OVERGROWTH SYNDROME; DNA TOPOISOMERASE-II; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; BREAST-CANCER; MELANOMA-CELLS; IN-VITRO; EXPRESSION	Elevated expression of the heparan sulphate proteoglycan glypican-3 (GPC3) was found on mRNA and protein levels in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV, which was established by in vitro selection against mitoxantrone. In order to elucidate a putative role of GPC3 in the drug-resistant phenotype, the mitoxantrone-resistant cell line EPG85-257RNOV was transfected with an expression vector construct carrying an anti-GPC3 hammerhead ribozyme. It could be demonstrated that in anti-GPC3 ribozyme-transfected cell clones, the GPC3-specific mRNA and corresponding protein expression levels were decreased to levels that are similar to those observed in nonresistant, parental cells. The anti-GPC3 ribozyme-containing clones reduced the mitoxantrone resistance level up to 21% of the original resistance and the crossresistance against etoposide to 33% of the original value. This reversal of drug resistance was accompanied by an increased cellular mitoxantrone accumulation in the anti-GPC3 ribozyme-expressing cells. In conclusion, it was verified that GPC3 is involved in the cellular protection against mitoxantrone in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV.	Humboldt Univ, Inst Pathol, Charite, D-10117 Berlin, Germany; Univ Tokyo, Genome Sci Div, Meguro Ku, Tokyo 1538944, Japan	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Tokyo	Lage, H (corresponding author), Humboldt Univ, Inst Pathol, Charite, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	hermann.lage@charite.de		Stege, Alexandra/0000-0001-9659-1930				AlHaideri M, 1997, BIOCHEMISTRY-US, V36, P12766, DOI 10.1021/bi9631024; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DIETEL M, 1990, CANCER RES, V50, P6100; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; Eggenschwiler J, 1997, GENE DEV, V11, P3128, DOI 10.1101/gad.11.23.3128; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; Hsu HC, 1997, CANCER RES, V57, P5179; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; HYAFIL F, 1993, CANCER RES, V53, P4595; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kellner U, 1997, INT J CANCER, V71, P817, DOI 10.1002/(SICI)1097-0215(19970529)71:5<817::AID-IJC20>3.0.CO;2-3; Kowalski P, 2002, CANCER GENE THER, V9, P579, DOI 10.1038/sj.cgt.7700471; Lage H, 2003, INT J ANTIMICROB AG, V22, P188, DOI 10.1016/S0924-8579(03)00203-6; Lage H, 2000, BRIT J CANCER, V82, P488, DOI 10.1054/bjoc.1999.0947; Lage H, 1997, GENE, V188, P151, DOI 10.1016/S0378-1119(96)00689-0; Lage H, 1998, INT J CLIN PHARM TH, V36, P58; Lage H, 2002, J CANCER RES CLIN, V128, P349, DOI 10.1007/s00432-002-0349-y; Lage H, 2001, FEBS LETT, V503, P179, DOI 10.1016/S0014-5793(01)02722-3; Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3; Lage H, 2000, Lancet Oncol, V1, P169, DOI 10.1016/S1470-2045(00)00032-2; Lin HC, 1999, CANCER RES, V59, P807; Midorikawa Y, 2003, INT J CANCER, V103, P455, DOI 10.1002/ijc.10856; Mulder M, 1998, HAEMOSTASIS, V28, P174; Murthy SS, 2000, ONCOGENE, V19, P410, DOI 10.1038/sj.onc.1203322; Olofsson AM, 1999, J CLIN INVEST, V104, P885, DOI 10.1172/JCI6671; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; Saikali Z, 2000, INT J CANCER, V89, P418; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; WALKER PR, 1991, CANCER RES, V51, P1078; Wells MJ, 1998, J BIOL CHEM, V273, P23440, DOI 10.1074/jbc.273.36.23440; Wichert A, 1999, CANCER GENE THER, V6, P263, DOI 10.1038/sj.cgt.7700045; Xiang YY, 2001, ONCOGENE, V20, P7408, DOI 10.1038/sj.onc.1204925	47	30	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					945	955		10.1038/sj.onc.1207237	http://dx.doi.org/10.1038/sj.onc.1207237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661052				2022-12-28	WOS:000188486600010
J	Zou, MX; Butcher, DT; Sadikovic, B; Groves, TC; Yee, SP; Rodenhiser, DI				Zou, MX; Butcher, DT; Sadikovic, B; Groves, TC; Yee, SP; Rodenhiser, DI			Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region	ONCOGENE			English	Article						neurofibromatosis; promoter; transcription; methylation	DNA METHYLATION; TRANSCRIPTION FACTOR; GENE; BINDING; ACTIVATION; PROTEIN; CANCER; FAMILY; CREB; SP1	An essential requirement to understand how genes contribute to genetic disease is the thorough knowledge of the transcriptional regulation of gene expression. Here, we have characterized transcription factor binding sites within the type 1 neurofibromatosis (NF1) proximal regulatory region, and addressed the molecular mechanisms that regulate NF1 transcription. Overlapping regions of the NF1 proximal promoter have been cloned and characterized for use in luciferase reporter assays. These assays have identified a 500 bp region displaying activities up to 80-fold higher than control reporter levels. Mutations at putative CRE and SP1-binding sites immediately 5' to the transcription start site have dramatic effects that lead to a 70-90% decrease in reporter activity in all cell lines tested. Gelshift assays confirm binding of CREB and SP1/KLF family members to their putative recognition sequences, and provide the first evidence identifying functional sites likely involved in regulating NF1 transcription. These assays have also revealed a putative repressor region within the NF1 promoter region corresponding to CCCTC-rich sequences between the transcription and translation start sites. This work provides new information concerning the transcriptional regulation of the NF1 gene, and is the most thorough attempt to date to map functionally relevant regions within the NF1 proximal promoter region.	Univ Western Ontario, London Reg Canc Ctr, London, ON N6A 4L6, Canada; Univ Western Ontario, Child Hlth Res Inst, London, ON, Canada; Univ Western Ontario, Dept Biochem, London, ON, Canada; Univ Western Ontario, Dept Paediat, London, ON, Canada; Univ Western Ontario, Dept Oncol, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Rodenhiser, DI (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Room A4-134,Victoria Res Tower,790 Commissioners, London, ON N6A 4L6, Canada.	drodenhi@uwo.ca						Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Guha A, 1998, CAN J NEUROL SCI, V25, P267, DOI 10.1017/S0317167100034272; HAJRA A, 1994, GENOMICS, V21, P649, DOI 10.1006/geno.1994.1328; HOFMAN KJ, 1994, J PEDIATR-US, V124, pS1, DOI 10.1016/S0022-3476(05)83163-4; Horan MP, 2000, HUM GENET, V107, P33, DOI 10.1007/s004390050007; Jiang JG, 2000, BIOCHEM BIOPH RES CO, V272, P882, DOI 10.1006/bbrc.2000.2848; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kim HA, 2001, J NEUROSCI, V21, P1110; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Luijten M, 2000, EUR J HUM GENET, V8, P939, DOI 10.1038/sj.ejhg.5200565; Mancini DN, 1999, ONCOGENE, V18, P4108, DOI 10.1038/sj.onc.1202764; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MANCINIDINARDO DN, 2001, ONCOGENE, V20, P5331; Plass C, 2002, EUR J HUM GENET, V10, P6, DOI 10.1038/sj.ejhg.5200768; Reed N, 2001, TRENDS MOL MED, V7, P157, DOI 10.1016/S1471-4914(01)01955-4; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; RUBENSTEIN A, 1990, NEUROFIBROMATOSIS HD; STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; ZOLLER M, 1995, ACTA DERM-VENEREOL, V75, P136	30	15	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					330	339		10.1038/sj.onc.1207053	http://dx.doi.org/10.1038/sj.onc.1207053			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647436				2022-12-28	WOS:000188098300002
J	Celetti, A; Cerrato, A; Merolla, F; Vitagliano, D; Vecchio, G; Grieco, M				Celetti, A; Cerrato, A; Merolla, F; Vitagliano, D; Vecchio, G; Grieco, M			H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization	ONCOGENE			English	Article						H4(D10S170); RET/PTC1; ERK; apoptosis; stress; carcinogenesis; thyroid; TUNEL	FACTOR RECEPTOR-BETA; IN-VIVO; CELLS; PROTOONCOGENE; BAX; ACTIVATION; APOPTOSIS; ONCOGENE; PROTEINS; TUMORS	Human thyroid papillary carcinomas are characterized by rearrangements of the RET protooncogene with a number of heterologous genes, which generate the RET/papillary thyroid carcinoma (PTC) oncogenes. One of the most frequent variants of these recombination events is the fusion of the intracellular kinase-encoding domain of RET to the first 101 amino acids of a gene named H4(D10S170). We have characterized the H4(D10S170) gene product, showing that it is a ubiquitously expressed 55 KDa nuclear and cytosolic protein that is phosphorylated following serum stimulation. This phosphorylation was found to depend on mitogen-activated protein kinase (MAPK) Erk1/2 activity and to be associated to the relocation of H4(D10S170) from the nucleus to the cytosol. Overexpression of the H4(D10S170) gene was able to induce apoptosis of thyroid follicular epithelial cells; conversely a carboxy-terminal truncated H4(D10S170) mutant H4(1-101), corresponding to the portion included in the RET/PTC1 oncoprotein, behaved as dominant negative on the proapoptotic function and nuclear localization of H4(D10S170). Furthermore, conditional expression of the H4(D10S170)-dominant negative truncated mutant protected cells from stress-induced apoptosis. The substitution of serine 244 with alanine abrogated the apoptotic function of H4(D10S170). These data suggest that loss of the H4(D10S170) gene function might have a role in thyroid carcinogenesis by impairing apoptosis.	Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Policlin Materdomini, I-88100 Catanzaro, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ist Endocrinol & Oncol Sperimentale, Naples, Italy	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II	Grieco, M (corresponding author), Magna Graecia Univ Catanzaro, Dipartimento Med Sperimentale & Clin, Policlin Materdomini, Via T Campanella 115, I-88100 Catanzaro, Italy.	mgrieco@unicz.it	Cerrato, Aniello/AAY-1484-2020; vitagliano, donata/B-8976-2012; Celetti, Angela/AAY-7172-2020	Grieco, Michele/0000-0002-4212-7814				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Bouillet P, 2002, J CELL SCI, V115, P1567; Bounacer A, 1997, BIOCHIMIE, V79, P619, DOI 10.1016/S0300-9084(97)82012-3; Bounacer A, 1997, ONCOGENE, V15, P1263, DOI 10.1038/sj.onc.1200206; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Castellone MD, 2003, ONCOGENE, V22, P246, DOI 10.1038/sj.onc.1206112; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; ITO T, 1993, CANCER RES, V53, P2940; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Jossart GH, 1996, CYTOGENET CELL GENET, V75, P254, DOI 10.1159/000134495; Kulkarni S, 2000, CANCER RES, V60, P3592; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mitchell KO, 2000, CANCER RES, V60, P6318; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; Nikiforova MN, 2000, SCIENCE, V290, P138, DOI 10.1126/science.290.5489.138; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Portella G, 1996, ONCOGENE, V13, P2021; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Sakakura C, 1996, INT J CANCER, V67, P101, DOI 10.1002/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; Schlumberger M, 1999, CR ACAD SCI III-VIE, V322, P205, DOI 10.1016/S0764-4469(99)80045-6; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; Sheils OM, 2000, J PATHOL, V192, P32; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tong Q, 1997, J BIOL CHEM, V272, P9043; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuttle RM, 2000, SEMIN NUCL MED, V30, P133, DOI 10.1053/nm.2000.5412; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Wang JW, 2003, MOL ENDOCRINOL, V17, P1425, DOI 10.1210/me.2003-0041; ZHAN QM, 1994, ONCOGENE, V9, P3743	39	48	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					109	121		10.1038/sj.onc.1206981	http://dx.doi.org/10.1038/sj.onc.1206981			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712216				2022-12-28	WOS:000187895300012
J	Fromigue, O; Louis, K; Dayem, M; Milanini, J; Pages, G; Tartare-Deckert, S; Ponzio, G; Hofman, P; Barbry, P; Auberger, P; Mari, B				Fromigue, O; Louis, K; Dayem, M; Milanini, J; Pages, G; Tartare-Deckert, S; Ponzio, G; Hofman, P; Barbry, P; Auberger, P; Mari, B			Gene expression profiling of normal human pulmonary fibroblasts following coculture with non-small-cell lung cancer cells reveals alterations related to matrix degradation, angiogenesis, cell growth and survival	ONCOGENE			English	Article						tumor-stroma; fibroblast; coculture; cDNA arrays; desmoplasia; stromelysin-3	EPITHELIAL-MESENCHYMAL INTERACTIONS; HUMAN BREAST CARCINOMAS; MESSENGER-RNA; PLASMINOGEN-ACTIVATOR; TUMOR PROGRESSION; STROMAL CELLS; OVER-EXPRESSION; RETINOIC ACID; ID PROTEINS; HUMAN COLON	Increasing evidence supports a major role for the microenvironment in carcinoma formation and progression. The influence of the stroma is partly mediated by signalling between epithelial tumor cells and neighboring fibroblasts. However, the molecular mechanisms underlying these interactions are largely unknown. To mimic the initial steps of invasive carcinoma in which tumor cells come in contact with normal stromal cells, we used a coculture model of non-small-cell lung cancer tumor cells and normal pulmonary fibroblasts. Using DNA filter arrays, we first analysed the overall modification of gene expression profile after a 24 h period of coculture. Next, we focused our interest on the transcriptome of the purified fibroblastic fraction of coculture using both DNA filter arrays and a laboratory-made DNA microarray. These experiments allowed the identification of a set of modulated genes coding for growth and survival factors, angiogenic factors, proteases and protease inhibitors, transmembrane receptors, kinases and transcription regulators that can potentially affect the regulation of matrix degradation, angiogenesis, invasion, cell growth and survival. This study represents to our knowledge the first attempt to dissect early global gene transcription occurring in a tumor-stroma coculture model and should help to understand better some of the molecular mechanisms involved in heterotypic signalling between epithelial tumor cells and fibroblasts.	Fac Med Pasteur, INSERM U526, F-06107 Nice 2, France; Fac Med Pasteur, INSERM EPI0215, F-06107 Nice 2, France; Fac Med Pasteur, INSERM U385, F-06107 Nice 2, France; Ctr Antoine Lacassagne, CNRS, UNSA UMR 6543, F-06054 Nice, France; IPMC, CNRS, UNSA UMR 6097, Sophia Antipolis, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Mari, B (corresponding author), Fac Med Pasteur, INSERM U526, Ave Valombrose,IFR 50, F-06107 Nice 2, France.	bmari@unice.fr	Ponzio, Gilles/Q-1256-2016; Hofman, Paul/P-7654-2018; Fromigue, Olivia/B-8225-2013; TARTARE-DECKERT, Sophie/P-6057-2015; Mari, Bernard P/F-8960-2013; AUBERGER, Patrick/G-1491-2013; Pages, Gilles/N-7135-2017; Mari, Bernard/Q-5832-2019; Barbry, Pascal/O-5021-2016; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022	Ponzio, Gilles/0000-0003-2741-0248; Hofman, Paul/0000-0003-0431-9353; Fromigue, Olivia/0000-0002-3050-6155; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Mari, Bernard P/0000-0002-0422-9182; AUBERGER, Patrick/0000-0002-2481-8275; Mari, Bernard/0000-0002-0422-9182; Barbry, Pascal/0000-0001-9632-6483; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Milanini, Julie/0000-0002-5861-2830				Ahmed W, 1998, CONNECT TISSUE RES, V37, P263, DOI 10.3109/03008209809002444; ANDERSON IC, 1995, CANCER RES, V55, P4120; Anderson IC, 2000, CANCER RES, V60, P269; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; Birckbichler PJ, 2000, CANCER-AM CANCER SOC, V89, P412, DOI 10.1002/1097-0142(20000715)89:2<412::AID-CNCR29>3.0.CO;2-O; Blom IE, 2002, MATRIX BIOL, V21, P473, DOI 10.1016/S0945-053X(02)00055-0; Borchers AH, 1997, MOL CARCINOGEN, V19, P258, DOI 10.1002/(SICI)1098-2744(199708)19:4<258::AID-MC7>3.0.CO;2-8; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Christensen L, 1996, INT J CANCER, V66, P441; Cursio R, 2001, FASEB J, V15, P93, DOI 10.1096/fj.01-0279fje; Dayem MA, 2003, COMP FUNCT GENOM, V4, P47, DOI 10.1002/cfg.239; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GIOANNI J, 1988, EUR J CANCER CLIN ON, V24, P1445, DOI 10.1016/0277-5379(88)90335-5; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hanamura N, 1997, INT J CANCER, V73, P10, DOI 10.1002/(SICI)1097-0215(19970926)73:1<10::AID-IJC2>3.0.CO;2-4; He C, 2001, J CANCER RES CLIN, V127, P180, DOI 10.1007/s004320000192; Heppner KJ, 1996, AM J PATHOL, V149, P273; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; Ingber DE, 2002, DIFFERENTIATION, V70, P547, DOI 10.1046/j.1432-0436.2002.700908.x; ITO A, 1995, BRIT J CANCER, V71, P1039, DOI 10.1038/bjc.1995.200; Jaques G, 1997, ENDOCRINOLOGY, V138, P1767, DOI 10.1210/en.138.4.1767; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kim SH, 2002, ONCOGENE, V21, P8741, DOI 10.1038/sj.onc.1205987; Kleeff J, 1998, INT J CANCER, V77, P860, DOI 10.1002/(SICI)1097-0215(19980911)77:6<860::AID-IJC11>3.0.CO;2-5; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lee HY, 2002, CANCER RES, V62, P3530; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Linder C, 1997, BREAST CANCER RES TR, V42, P207, DOI 10.1023/A:1005769622570; LINGE C, 1989, EXP CELL RES, V185, P519, DOI 10.1016/0014-4827(89)90320-0; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; Mari BP, 1998, J BIOL CHEM, V273, P618, DOI 10.1074/jbc.273.1.618; Mascaux C, 2002, ANTICANCER RES, V22, P1273; Matrisian LM, 2001, CANCER RES, V61, P3844; Maulon L, 2001, ONCOGENE, V20, P1964, DOI 10.1038/sj.onc.1204266; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; MITSIADIS TA, 1995, J CELL BIOL, V130, P407, DOI 10.1083/jcb.130.2.407; Moorehead RA, 2003, ONCOGENE, V22, P853, DOI 10.1038/sj.onc.1206188; NOEL AC, 1994, INT J CANCER, V56, P331, DOI 10.1002/ijc.2910560306; Ohga E, 1996, BIOCHEM BIOPH RES CO, V228, P391, DOI 10.1006/bbrc.1996.1672; Ohtani H, 1998, PATHOL INT, V48, P1, DOI 10.1111/j.1440-1827.1998.tb03820.x; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Porte H, 1998, CLIN CANCER RES, V4, P1375; Rabbani SA, 1998, IN VIVO, V12, P135; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; ROUYER N, 1994, INVAS METAST, V14, P269; Sampson MT, 2002, BIOCHEM SOC T, V30, P201, DOI 10.1042/bst0300201; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SESLAR SP, 1993, CANCER RES, V53, P1233; Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X; Tureci O, 1998, P NATL ACAD SCI USA, V95, P7608, DOI 10.1073/pnas.95.13.7608; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umeda T, 1997, J PATHOL, V183, P388; Vitolo D, 2001, J PATHOL, V195, P197, DOI 10.1002/path.938; Wang K, 2002, ONCOGENE, V21, P7598, DOI 10.1038/sj.onc.1205953; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Wojtukiewicz MZ, 1999, THROMB HAEMOSTASIS, V82, P1659; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Wu EX, 2001, J CELL BIOCHEM, V82, P549, DOI 10.1002/jcb.1181; Wu-Wong J Ruth, 2002, Curr Opin Investig Drugs, V3, P1234; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	77	40	41	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8487	8497		10.1038/sj.onc.1206918	http://dx.doi.org/10.1038/sj.onc.1206918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627989				2022-12-28	WOS:000186650300012
J	Shteper, PJ; Zcharia, E; Ashhab, Y; Peretz, T; Vlodavsky, I; Ben-Yehuda, D				Shteper, PJ; Zcharia, E; Ashhab, Y; Peretz, T; Vlodavsky, I; Ben-Yehuda, D			Role of promoter methylation in regulation of the mammalian heparanase gene	ONCOGENE			English	Article						promoter methylation; epigenetic regulation; 5-azacytidine; 5-aza-2 ' deoxycytidine; mammalian heparanase; tumour metastasis	DNA METHYLATION; TUMOR-METASTASIS; EXTRACELLULAR-MATRIX; ABL1 METHYLATION; CPG METHYLATION; EXPRESSION; CANCER; CLONING; HYPERMETHYLATION; INHIBITION	Mammalian heparanase (endo-beta-glucuronidase) degrades heparan sulfate proteoglycans and is an important modulator of the extracellular matrix and associated factors. The enzyme is preferentially expressed in neoplastic tissues and contributes to tumour metastasis and angiogenesis. To investigate the epigenetic regulation of the heparanase locus, methylation-specific and bisulfite PCR were performed on a panel of 22 human cancer cell lines. Cytosine methylation of the heparanase promoter was associated with inactivation of the affected allele. Despite lack of sequence homology, extensively methylated CpG islands were found both in human choriocarcinoma (JAR) and rat glioma (C-6) cells which lack heparanase activity. Treatment of these cells with demethylating agents (5-azacytidine, 5-aza-2'-deoxycytidine) resulted in stable dose- and time-dependant promoter hypomethylation accompanied by reappearance of heparanase mRNA, protein and enzymatic activity. An inhibitor of histone deacetylase, Trichostatin A, failed to induce either of these effects. Upregulation of heparanase expression and activity by demethylating drugs was associated with a marked increase in lung colonization by pretreated C-6 rat glioma cells. The increased metastatic potential in vivo was inhibited in mice treated with laminaran sulfate, a potent inhibitor of heparanase activity. We propose a model wherein expression of mammalian heparanase gene is modulated by the interplay between trans-activating genetic and cis-inhibitory epigenetic elements in its promoter.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hadassah Hebrew Univ Med Ctr, Dept Hematol, IL-91120 Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Oncol, IL-91120 Jerusalem, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il	Ashhab, Yaqoub/AAC-8789-2019		NATIONAL CANCER INSTITUTE [R21CA087085] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andela VB, 2000, CANCER RES, V60, P6557; Asimakopoulos FA, 1999, BLOOD, V94, P2452, DOI 10.1182/blood.V94.7.2452.419k23_2452_2460; Ben-Porath I, 2000, CURR OPIN GENET DEV, V10, P550, DOI 10.1016/S0959-437X(00)00126-X; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bitan M, 2002, EXP HEMATOL, V30, P34, DOI 10.1016/S0301-472X(01)00766-4; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Esteller M, 2001, CANCER RES, V61, P3225; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1999, SEMIN CANCER BIOL, V9, P339, DOI 10.1006/scbi.1999.0134; Koliopanos A, 2001, CANCER RES, V61, P4655; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lu WC, 2003, ONCOGENE, V22, P919, DOI 10.1038/sj.onc.1206201; Lynch Catherine A, 2002, Mol Cancer, V1, P2, DOI 10.1186/1476-4598-1-2; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Melki JR, 1999, CANCER RES, V59, P3730; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Miyakura Y, 2003, GENE CHROMOSOME CANC, V36, P17, DOI 10.1002/gcc.10134; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; RACHMILEWITZ J, 1995, ONCOGENE, V11, P863; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Shteper PJ, 2001, LEUKEMIA, V15, P575, DOI 10.1038/sj.leu.2402026; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Song JZ, 2002, ONCOGENE, V21, P1048, DOI 10.1038/sj.onc.1205153; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Toyota M, 1999, SEMIN CANCER BIOL, V9, P349, DOI 10.1006/scbi.1999.0135; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; VanLint C, 1996, GENE EXPRESSION, V5, P245; Velinov M, 2000, MOL GENET METAB, V69, P81, DOI 10.1006/mgme.1999.2941; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yokomori N, 1998, MOL ENDOCRINOL, V12, P1241, DOI 10.1210/me.12.8.1241; YOKOMORI N, 1995, MOL CELL BIOL, V15, P5355	72	92	97	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7737	7749		10.1038/sj.onc.1207056	http://dx.doi.org/10.1038/sj.onc.1207056			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586400				2022-12-28	WOS:000186240200004
J	Zhao, CY; Lam, EWF; Sunters, A; Enmark, E; De Bella, MT; Coombes, RC; Gustafsson, JA; Dahlman-Wright, K				Zhao, CY; Lam, EWF; Sunters, A; Enmark, E; De Bella, MT; Coombes, RC; Gustafsson, JA; Dahlman-Wright, K			Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation	ONCOGENE			English	Article						ER beta; DNA methylation; mRNA isoform; breast cancer	MESSENGER-RNA EXPRESSION; QUANTITATIVE-ANALYSIS; CPG ISLANDS; WILD-TYPE; ER-BETA; ALPHA; CLONING; PROMOTER; PROSTATE; GENE	Two novel estrogen receptor beta (ERbeta) mRNA isoforms that diverge in their 5'-untranslated regions, ERbeta mRNA (0K-1) and ERbeta mRNA (0N-1), have recently been identified. This indicates that transcription of the human ERbeta gene occurs from at least two different promoters, named promoter 0K and promoter 0N. The aim of this study was to investigate the expression of ERbeta isoforms in primary cultures of normal breast epithelial cells, a panel of breast cancer cell lines and in normal breast and breast cancer tissues; and to examine whether methylation of the two ERbeta promoters is involved in regulation of ERbeta gene expression. Using quantitative real-time PCR techniques, we found that ERbeta mRNA levels were significantly lower in breast cancer cell lines than in primary cultures of normal breast epithelial cells. Bisulfite genomic sequencing analysis revealed that two promoters of the ERbeta gene exhibit distinct methylation patterns. Promoter 0N was unmethylated in normal breast epithelial cells, but extensively methylated in breast cancer cell lines. In contrast, promoter 0K was unmethylated in both normal and malignant breast epithelial cells. We demonstrated a significant correlation between promoter 0N hypermethylation and loss of ERbeta mRNA expression in breast cancer cell lines. Treatment of breast cancer cells with demethylating agent effectively reactivated the expression of ERbeta mRNA. The observations from the cell lines were also reflected in primary breast cancer tumors. Thus, expression of ERbeta mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N. Our results suggest that a decreased level of ERbeta mRNA may be associated with breast tumorigenesis, and that DNA methylation is an important mechanism for ERbeta gene silencing in breast cancer.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Sect Canc Cell Biol, London W12 0NN, England	Karolinska Institutet; Cancer Research UK; Imperial College London; Imperial College London	Zhao, CY (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Coombes, Raoul Charles/0000-0002-4811-1100				Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Dotzlaw H, 1999, CANCER RES, V59, P529; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Fuqua SAW, 1999, CANCER RES, V59, P5425; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; Gustafsson JA, 2000, J STEROID BIOCHEM, V74, P245, DOI 10.1016/S0960-0760(00)00130-8; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirata S, 2001, J STEROID BIOCHEM, V78, P33, DOI 10.1016/S0960-0760(01)00071-1; Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lewandowski S, 2002, FEBS LETT, V524, P1, DOI 10.1016/S0014-5793(02)03015-6; Leygue E, 1999, CANCER RES, V59, P1175; Leygue E, 1998, CANCER RES, V58, P3197; Li LC, 2000, BIOCHEM BIOPH RES CO, V275, P682, DOI 10.1006/bbrc.2000.3363; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Omoto Y, 2002, EUR J CANCER, V38, P380, DOI 10.1016/S0959-8049(01)00383-5; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Sasaki M, 2002, J NATL CANCER I, V94, P384; Skliris GP, 2001, BRIT J CANCER, V84, P1095, DOI 10.1054/bjoc.2001.1721; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473	31	129	136	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7600	7606		10.1038/sj.onc.1207100	http://dx.doi.org/10.1038/sj.onc.1207100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576822				2022-12-28	WOS:000186113000007
J	Jechlinger, M; Grunert, S; Tamir, IH; Janda, E; Ludemann, S; Waerner, T; Seither, P; Weith, A; Beug, H; Kraut, N				Jechlinger, M; Grunert, S; Tamir, IH; Janda, E; Ludemann, S; Waerner, T; Seither, P; Weith, A; Beug, H; Kraut, N			Expression profiling of epithelial plasticity in tumor progression	ONCOGENE			English	Article						epithelial-mesenchymal transition; microarray; ras; TGF beta	GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MESENCHYMAL TRANSITIONS; SIGNALING PATHWAYS; CELL PLASTICITY; BETA-CATENIN; E-CADHERIN; HA-RAS; GENE; METASTASIS	Epithelial-to-mesenchymal transition (EMT), a switch of polarized epithelial cells to a migratory, fibroblastoid phenotype, is increasingly considered as an important event during malignant tumor progression and metastasis. To identify molecular players involved in EMT and metastasis, we performed expression pro. ling of a set of combined in vitro/in vivo cellular models, based on clonal, fully polarized mammary epithelial cells. Seven closely related cell pairs were used, which were modified by defined oncogenes and/or external factors and showed specific aspects of epithelial plasticity relevant to cell migration, local invasion and metastasis. Since mRNA levels do not necessarily reflect protein levels in cells, we used an improved expression pro. ling method based on polysome-bound RNA, suitable to analyse global gene expression on Affymetrix chips. A substantial fraction of all regulated genes was found to be exclusively controlled at the translational level. Further more, pro. ling of the above multiple cell pairs allowed one to identify small numbers of genes by cluster analysis, specifically correlating gene expression with EMT, metastasis, scattering and/or oncogene function. A small set of genes specifically regulated during EMT was identified, including key regulators and signaling pathways involved in cell proliferation, epithelial polarity, survival and trans-differentiation to mesenchymal-like cells with invasive behavior.	Res Inst Mol Pathol, IMP, A-1030 Vienna, Austria; Boehringer Ingelheim Pharma KG, Genom Grp, D-88397 Biberach, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Boehringer Ingelheim	Beug, H (corresponding author), Res Inst Mol Pathol, IMP, Dr Bohrgasse 7, A-1030 Vienna, Austria.		Gruenert, Stefan/B-7598-2016; Jechlinger, Martin/AAC-9442-2020; Janda, Elzbieta/AAD-5126-2022; Gruenert, Stefan/T-7755-2019; Janda, Elzbieta/AFQ-7061-2022	Gruenert, Stefan/0000-0003-0241-9297; Janda, Elzbieta/0000-0002-6787-7291; Gruenert, Stefan/0000-0003-0241-9297; Janda, Elzbieta/0000-0002-6787-7291; Jechlinger, Martin/0000-0002-3710-4466				Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Berquin IM, 1996, ADV EXP MED BIOL, V389, P281; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; De Jong JS, 1998, J PATHOL, V184, P44; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay ED, 1995, ACTA ANAT, V154, P8; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Kiemer AK, 2001, ONCOGENE, V20, P6679, DOI 10.1038/sj.onc.1204872; Kumar S, 1999, CANCER RES, V59, P856; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Mikulits W, 2000, FASEB J, V14, P1641, DOI 10.1096/fj.14.11.1641; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; ZHANG H, 1995, MECH DEVELOP, V50, P119, DOI 10.1016/0925-4773(94)00329-L; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	50	226	250	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7155	7169		10.1038/sj.onc.1206887	http://dx.doi.org/10.1038/sj.onc.1206887			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562044				2022-12-28	WOS:000185955000007
J	Rangel, LBA; Sherman-Baust, CA; Wernyj, RP; Schwartz, DR; Cho, KR; Morin, PJ				Rangel, LBA; Sherman-Baust, CA; Wernyj, RP; Schwartz, DR; Cho, KR; Morin, PJ			Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression	ONCOGENE			English	Article						ovarian cancer; biomarkers; HOST; gene expression; SAGE	EPITHELIAL-CELLS; MESSENGER-RNA; TUMOR; OVEREXPRESSION; CARCINOMA; STAGE; H19; COTRANSPORTER; CYSTADENOMAS; PATTERNS	A better understanding of changes in gene expression during ovarian tumorigenesis and the identification of specific tumor markers may lead to novel strategies for diagnosis and therapy for this disease. Using our serial analysis of gene expression ( SAGE) data, as well as public SAGE databases that contained a total of 137 SAGE libraries representing a wide variety of normal and neoplastic tissues, we identified five novel SAGE tags specifically expressed in ovarian cancer. Database analysis, cloning and, sequencing of the corresponding expressed sequence tags revealed details about these transcripts that we named human ovarian cancer-specific transcripts (HOSTs). HOST1 was found to be identical to the gene encoding ovarian marker CA125 (MUC16). HOST2 is a novel gene containing multiple copies of retroviral-related sequences without an obvious open reading frame. HOST3 encodes the tight-junction protein claudin-16 (CLDN16). HOST4 encodes a poorly characterized proteoglycan link protein (LP), and HOST5 codes for a type II sodium-dependent phosphate transporter (SLC34A2). Except for MUC16, these genes have not previously been shown to be expressed in ovarian or other cancers. Northern blot analysis confirmed that HOST genes are rarely expressed in normal tissues or nonovarian cancers, but are frequently expressed in ovarian cancer-derived cell lines and primary tumors. Moreover, HOST genes are upregulated in all four major subtypes of ovarian cancer compared to cultivated ovarian surface epithelial cells, as concluded by real-time reverse transcription (RT)-PCR using a panel of microdissected ovarian tumors. The sodium-dependent phosphate transporter (HOST5/SLC34A2) expression was associated with increased differentiation in ovarian serous tumors. While the roles of HOSTs in ovarian malignant transformation remain unclear, we propose that HOSTs may represent alternative targets for diagnosis and therapy and of this deadly disease.	NIA, Cellular & Mol Biol Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Fed Rio de Janeiro, Dept Basic & Clin Pharmacol, Rio De Janeiro, Brazil; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Michigan System; University of Michigan; Universidade Federal do Rio de Janeiro; Johns Hopkins University; Johns Hopkins Medicine	Morin, PJ (corresponding author), NIA, Cellular & Mol Biol Lab, Gerontol Res Ctr, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	morinp@grc.nia.nih.gov	Rangel, Leticia B/E-6241-2018	Rangel, Leticia B/0000-0002-6150-4064; Cho, Kathleen/0000-0003-0500-9998	NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Bast RC, 1998, INT J BIOL MARKER, V13, P179, DOI 10.1177/172460089801300402; Berek JS, 1999, ANN ONCOL, V10, P87, DOI 10.1023/A:1008323922057; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Erdmann VA, 2000, NUCLEIC ACIDS RES, V28, P197, DOI 10.1093/nar/28.1.197; Folz RJ, 2000, BIOTECHNIQUES, V29, P762, DOI 10.2144/00294st01; Gregoire L, 1998, IN VITRO CELL DEV-AN, V34, P636; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Hashimoto M, 2000, AM J PATHOL, V157, P21, DOI 10.1016/S0002-9440(10)64512-9; Hellstrom I, 2003, CANCER RES, V63, P3695; Hoskins WJ, 1995, J CELL BIOCHEM, P189; Hough CD, 2001, CANCER RES, V61, P3869; Hough CD, 2000, CANCER RES, V60, P6281; Ismail RS, 2000, CANCER RES, V60, P6744; Lal A, 1999, CANCER RES, V59, P5403; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo MP, 1997, GYNECOL ONCOL, V67, P277, DOI 10.1006/gyno.1997.4880; MAKAR AP, 1995, GYNECOL ONCOL, V56, P175, DOI 10.1006/gyno.1995.1027; MANN WJ, 1988, J NATL CANCER I, V80, P208, DOI 10.1093/jnci/80.3.208; Mashima H, 2001, DIABETES, V50, pS39, DOI 10.2337/diabetes.50.2007.S39; Mazurek A, 1998, EUR J CANCER PREV, V7, P23; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; OZOLS RF, 1980, CANCER-AM CANCER SOC, V45, P572, DOI 10.1002/1097-0142(19800201)45:3<572::AID-CNCR2820450325>3.0.CO;2-3; Petricoin EF, 2002, LANCET, V359, P572, DOI 10.1016/S0140-6736(02)07746-2; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; RIGGINS GJ, 2002, GENETIC BASIS HUMAN, P131; Sawiris GP, 2002, CANCER RES, V62, P2923; Schummer M, 1999, GENE, V238, P375, DOI 10.1016/S0378-1119(99)00342-X; Schwartz DR, 2002, CANCER RES, V62, P4722; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Shimizu Y, 1998, CANCER-AM CANCER SOC, V82, P893, DOI 10.1002/(SICI)1097-0142(19980301)82:5<893::AID-CNCR14>3.0.CO;2-W; Shridhar V, 2001, CANCER RES, V61, P5895; Simon DB, 1999, SCIENCE, V285, P103, DOI 10.1126/science.285.5424.103; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yousef GM, 2003, CANCER RES, V63, P2223	37	106	136	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7225	7232		10.1038/sj.onc.1207008	http://dx.doi.org/10.1038/sj.onc.1207008			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562052				2022-12-28	WOS:000185955000015
J	Kobayashi, K; Nishioka, M; Kohno, T; Nakamoto, M; Maeshima, A; Aoyagi, K; Sasaki, H; Takenoshita, S; Sugimura, H; Yokota, J				Kobayashi, K; Nishioka, M; Kohno, T; Nakamoto, M; Maeshima, A; Aoyagi, K; Sasaki, H; Takenoshita, S; Sugimura, H; Yokota, J			Identification of genes whose expression is upregulated in lung adenocarcinoma cells in comparison with type II alveolar cells and bronchiolar epithelial cells in vivo	ONCOGENE			English	Article						lung adenocarcinoma; type II alveolar cells; bronchiolar epithelial cells; laser capture microdissection; cDNA microarray	LASER CAPTURE MICRODISSECTION; MATRIX METALLOPROTEINASES; DIFFERENTIAL EXPRESSION; TISSUE LOCALIZATION; MESSENGER-RNA; MICROARRAY ANALYSIS; DNA TOPOISOMERASES; TUMOR-CELLS; CARCINOMAS; CANCER	To identify genes whose expression is upregulated in lung adenocarcinoma (AdC) cells in comparison with noncancerous peripheral lung epithelial cells, type II alveolar cells and bronchiolar epithelial cells, as well as AdC cells, were isolated by laser capture microdissection, and subjected to cDNA microarray analysis of 637 human cancer-related genes. Each of the component cells was obtained from several different individuals and analysed independently. As a comparison, two lung AdC cell lines and two primarily cultured normal lung epithelial cell lines were also subjected to cDNA microarray analysis. Four genes, TOP2A, MMP15, MX2 and KOC1, were commonly upregulated in microdissected AdC cells in comparison with microdissected epithelial cells. Hierarchical clustering analysis revealed that differences in gene-expression profiles were more evident between cultured and uncultured cells than between cancerous and noncancerous cells. To further identify the common molecular targets of AdC cells in vivo, quantitative real-time RT-PCR was performed against the four genes upregulated by cDNA microarray analysis. The TOP2A, MMP15, MX2 and KOC1 genes were overexpressed in 10/10 (100%), 8/10 (80%), 5/10 (50%) and 3/10 (30%) microdissected AdC cell samples, respectively, in comparison with any of nine independently microdissected noncancerous epithelial cell samples. The TOP2A gene was commonly overexpressed in lung AdC cells, as previously reported. In addition, the MMP15 and MX2 genes were identified, for the first time, as being commonly overexpressed in lung AdC cells. These results strongly indicate that the MMP15 and MX2 genes could be novel markers for molecular diagnosis and therapy of lung AdC.	Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan; Fukushima Med Univ, Sch Med, Dept Surg 2, Fukushima 9601295, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuo Ku, Tokyo 1040045, Japan; Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Shizuoka 4313192, Japan	National Cancer Center - Japan; Fukushima Medical University; National Cancer Center - Japan; National Cancer Center - Japan; Hamamatsu University School of Medicine	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@gan2.ncc.go.jp						Aoyagi K, 2003, BIOCHEM BIOPH RES CO, V300, P915, DOI 10.1016/S0006-291X(02)02967-4; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Crnogorac-Jurcevic Tatjana, 2002, Methods Mol Biol, V193, P197; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giaccone G, 1995, BBA-GENE STRUCT EXPR, V1264, P337, DOI 10.1016/0167-4781(95)00171-9; Goodwin LO, 2001, ANN CLIN LAB SCI, V31, P369; JENSEN SM, 1994, INT J CANCER, V58, P629, DOI 10.1002/ijc.2910580503; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Melen K, 1996, J BIOL CHEM, V271, P23478, DOI 10.1074/jbc.271.38.23478; Mirski SEL, 2000, LAB INVEST, V80, P787, DOI 10.1038/labinvest.3780083; Miura K, 2002, CANCER RES, V62, P3244; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Nakada M, 1999, AM J PATHOL, V154, P417, DOI 10.1016/S0002-9440(10)65288-1; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; PHELPS DS, 1988, AM REV RESPIR DIS, V137, P939, DOI 10.1164/ajrccm/137.4.939; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; POLLETE M, 1996, VIRCHOWS ARCH, V428, P29; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sobin LH, 2002, TNM CLASSIFICATION M, P97; Sugita M, 2002, CANCER RES, V62, P3971; Syahruddin E, 1998, JPN J CANCER RES, V89, P855, DOI 10.1111/j.1349-7006.1998.tb00640.x; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; Travis WD, 1999, WHO HISTOLOGICAL TYP; Ueno H, 1997, CANCER RES, V57, P2055; Vaarala MH, 2000, LAB INVEST, V80, P1259, DOI 10.1038/labinvest.3780134; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wang T, 2003, BRIT J CANCER, V88, P887, DOI 10.1038/sj.bjc.6600806; Wang T, 2000, ONCOGENE, V19, P1519, DOI 10.1038/sj.onc.1203457; Wang TT, 2001, ONCOGENE, V20, P7699, DOI 10.1038/sj.onc.1204939; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Yoshimi I, 2003, JPN J CLIN ONCOL, V33, P98, DOI 10.1093/jjco/hyg019	36	38	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 15	2004	23	17					3089	3096		10.1038/sj.onc.1207433	http://dx.doi.org/10.1038/sj.onc.1207433			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14755238				2022-12-28	WOS:000220845200013
J	Eger, A; Stockinger, A; Park, J; Langkopf, E; Mikula, M; Gotzmann, J; Mikulits, W; Beug, H; Foisner, R				Eger, A; Stockinger, A; Park, J; Langkopf, E; Mikula, M; Gotzmann, J; Mikulits, W; Beug, H; Foisner, R			beta-Catenin and TGF beta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition	ONCOGENE			English	Article						carcinogenesis; catenins; cell adhesion; TGF beta; E-cadherin; LEF/TCF	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; HA-RAS; WNT; BINDING; ACTIVATION; EXPRESSION; SMAD; PROMOTER	Several signalling pathways contribute to the regulation of epithelial to mesenchymal transition (EMT), either during developmentally regulated processes or in cancer progression and metastasis. Induction of EMT in fully polarized mouse mammary epithelial cells (EpH4) by an inducible c-fos estrogen receptor (FosER) oncoprotein involves loss of E-cadherin expression, nuclear translocation of beta-catenin, and autocrine production of TGFbeta. Reporter assays demonstrate that both beta-catenin/LEF-TCF- and TGFbeta-Smad-dependent signalling activities are upregulated, probably coregulating mesenchymal-specific gene expression during EMT. Stable expression of E-cadherin in mesenchymal FosER cells decreased beta-catenin activity and reduced cell proliferation. However, these cells still exhibited a defect in epithelial polarization and expressed E-cadherin/beta-catenin complexes in the entire plasma membrane. On the other hand, inhibition of TGFbeta-Smad signalling in mesenchymal FosER cells induced. at, cobblestone-like clusters of cells, which relocalized beta-catenin to the plasma membrane but still lacked detectable E-cadherin. Interestingly, inhibition of TGFbeta signalling in the E-cadherin-expressing mesenchymal FosER cells caused their reversion to a polarized epithelial phenotype, in which E-cadherin, beta-catenin, and ZO-1 were localized at their correct lateral plasma membrane domains. These results demonstrate that loss of E-cadherin can contribute to increased LEF/TCF-beta-catenin signalling, which in turn cooperates with autocrine TGFbeta signalling to maintain an undifferentiated mesenchymal phenotype.	Univ Vienna, Vienna Bioctr, Dept Med Biochem, Univ Dept,Max F Perutz Labs, A-1030 Vienna, Austria; Boehringer Ingelheim PharmaGmbHKG, Biberach, Germany; Univ Vienna, Inst Canc Res, A-1010 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Boehringer Ingelheim; University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Foisner, R (corresponding author), Univ Vienna, Vienna Bioctr, Dept Med Biochem, Univ Dept,Max F Perutz Labs, Dr Bohrgasse 9, A-1030 Vienna, Austria.	roland.foisner@univie.ac.at	Mikulits, Wolfgang/AAH-4043-2021; Foisner, Roland/AAD-1833-2019	Mikula, Mario/0000-0001-5782-0681; Mikulits, Wolfgang/0000-0003-4612-7106; Foisner, Roland/0000-0003-4734-4647; Gotzmann, Josef/0000-0001-6392-2115				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barker N, 2001, TRENDS MOL MED, V7, P535, DOI 10.1016/S1471-4914(01)02215-8; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier C, 1996, ACTA ANAT, V156, P217; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Duband JL, 1995, ACTA ANAT, V154, P63; Eger A, 2000, PROTOPLASMA, V211, P125; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Gotzmann J, 2002, J CELL SCI, V115, P1189; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Iavarone A, 1997, NATURE, V387, P417; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Naishiro Y, 2001, CANCER RES, V61, P2751; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Orsulic S, 1999, J CELL SCI, V112, P1237; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tian YC, 2002, AM J PATHOL, V160, P1619, DOI 10.1016/S0002-9440(10)61109-1; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Vallin J, 2001, J BIOL CHEM, V276, P30350, DOI 10.1074/jbc.M103167200; Viebahn C, 1995, ACTA ANAT, V154, P79; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940	54	126	131	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2672	2680		10.1038/sj.onc.1207416	http://dx.doi.org/10.1038/sj.onc.1207416			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755243				2022-12-28	WOS:000220714900009
J	Montano, MM; Deng, HY; Liu, M; Sun, XY; Singal, R				Montano, MM; Deng, HY; Liu, M; Sun, XY; Singal, R			Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications	ONCOGENE			English	Article						estrogen receptor; antiestrogens; glutathione-S-transferase; gamma-glutamylcysteine synthetase	GLUTATHIONE-S-TRANSFERASE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; QUINONE REDUCTASE GENE; BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; SUBUNIT GENE; P1 GENE; TELOMERASE ACTIVITY; DRUG-RESISTANCE; EXPRESSION	We previously reported that antiestrogen-liganded estrogen receptor beta (ERbeta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR)(NAD(P) H:-quinone oxidoreductase). Our studies also indicate that upregulation of QR, either by overexpression or induction by tamoxifen, can protect breast cells against oxidative DNA damage caused by estrogen metabolites. We now report on the upregulation of glutathione S-transferases Pi (GST-Pi) and gamma-glutamylcysteine synthetase heavy subunit (GCSh) expression by antiestrogens. Studies indicate the regulation of GST-Pi and GCSh transcriptional activity by ER. While ER regulation is mediated by an electrophile response element (EpRE), we identified mechanistic differences in the involvement of other transcription factors. Regardless of these differences, ERbeta-mediated regulation of GST-Pi and GCSh point towards an important role for ERbeta in cellular protection against oxidative stress. A protective role is supported by our observation of inhibition of estrogen-induced DNA damage upon upregulation of GST-Pi and GCSh expression.	Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44102 USA; Univ Miami, Dept Med, Miami, FL 33136 USA	Case Western Reserve University; University of Miami	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg W307,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu			NCI NIH HHS [CA80959] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Bianco NR, 2002, ONCOGENE, V21, P5233, DOI 10.1038/sj.onc.1205645; CHA YN, 1982, CANCER RES, V42, P2609; Dahl EL, 2001, TOXICOL SCI, V61, P265, DOI 10.1093/toxsci/61.2.265; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Esteller M, 1998, CANCER RES, V58, P4515; Gamcsik MP, 2002, BIOCHEM PHARMACOL, V63, P843, DOI 10.1016/S0006-2952(01)00931-5; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hellriegel ET, 1996, BIOCHEM PHARMACOL, V52, P1561, DOI 10.1016/S0006-2952(96)00560-6; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Jhaveri MS, 1998, GENE, V210, P1, DOI 10.1016/S0378-1119(98)00021-3; Jhaveri MS, 1998, BBA-GENE STRUCT EXPR, V1396, P179, DOI 10.1016/S0167-4781(97)00187-5; Kyo S, 1999, CANCER RES, V59, P5917; Liu RM, 1998, AM J PHYSIOL-LUNG C, V275, pL861, DOI 10.1152/ajplung.1998.275.5.L861; Matsumoto M, 2000, BIOCHEM J, V349, P225, DOI 10.1042/0264-6021:3490225; Maugard CM, 2001, INT J CANCER, V91, P334, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1057>3.0.CO;2-H; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229; Mizutani K, 2000, J HYPERTENS, V18, P1833, DOI 10.1097/00004872-200018120-00018; MOFFAT GJ, 1994, J BIOL CHEM, V269, P16397; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Montano MM, 2000, J BIOL CHEM, V275, P34306, DOI 10.1074/jbc.M003880200; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; MORROW CS, 1990, GENE, V88, P215, DOI 10.1016/0378-1119(90)90034-O; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nanni S, 2002, J CLIN INVEST, V110, P219, DOI 10.1172/JCI200215552; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; PRESTERA T, 1993, ADV ENZYME REGUL, V33, P281; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067, DOI 10.1152/ajplung.1999.277.6.L1067; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; STRANGE RC, 2001, MUTAT RES, V82, P21; TALALAY P, 1989, ADV ENZYME REGUL, V28, P237; TEW KD, 1994, CANCER RES, V54, P4313; Walsh AC, 2001, TOXICOL SCI, V61, P218, DOI 10.1093/toxsci/61.2.218; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wilkinson J, 1998, BIOCHEM BIOPH RES CO, V253, P855, DOI 10.1006/bbrc.1998.9804; XIA CL, 1993, BIOCHEM J, V292, P845, DOI 10.1042/bj2920845; Yoshida T, 2000, CARCINOGENESIS, V21, P2193, DOI 10.1093/carcin/21.12.2193; Zhang Y, 2003, J STEROID BIOCHEM, V85, P401, DOI 10.1016/S0960-0760(03)00230-9	44	58	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2442	2453		10.1038/sj.onc.1207358	http://dx.doi.org/10.1038/sj.onc.1207358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676828				2022-12-28	WOS:000220558000002
J	Gilmore, TD; Kalaitzidis, D; Liang, MC; Starczynowski, DT				Gilmore, TD; Kalaitzidis, D; Liang, MC; Starczynowski, DT			The c-Rel transcription factor and B-cell proliferation: a deal with the devil	ONCOGENE			English	Review						c-Rel; Rel; NF-kappa B; B cell; lymphoma; gene amplification	NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION; BRUTONS TYROSINE KINASE; CHICKEN SPLEEN-CELLS; V-REL; GENE-EXPRESSION; MICE LACKING; MARGINAL ZONE; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE	Activation of the Rel/NF-kappaB signal transduction pathway has been associated with a variety of animal and human malignancies. However, among the Rel/NF-kappaB family members, only c-Rel has been consistently shown to be able to malignantly transform cells in culture. In addition, c-rel has been activated by a retroviral promoter insertion in an avian B-cell lymphoma, and amplifications of REL (human c-rel) are frequently seen in Hodgkin's lymphomas and diffuse large B-cell lymphomas, and in some follicular and mediastinal B-cell lymphomas. Phenotypic analysis of c-rel knockout mice demonstrates that c-Rel has a normal role in B-cell proliferation and survival; moreover, c-Rel nuclear activity is required for B-cell development. Few mammalian model systems are available to study the role of c-Rel in oncogenesis, and it is still not clear what features of c-Rel endow it with its unique oncogenic activity among the Rel/NF-kappaB family. In any event, REL may provide an appropriate therapeutic target for certain human lymphoid cell malignancies.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu		Liang, Mei-Chih/0000-0002-7389-2455				Agresti A, 2002, MOL IMMUNOL, V38, P849, DOI 10.1016/S0161-5890(01)00121-3; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; AvetLoiseau H, 1997, BRIT J HAEMATOL, V97, P119, DOI 10.1046/j.1365-2141.1997.d01-2140.x; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Bentz M, 1996, BLOOD, V88, P1437, DOI 10.1182/blood.V88.4.1437.bloodjournal8841437; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cabatingan MS, 2002, J IMMUNOL, V169, P6795, DOI 10.4049/jimmunol.169.12.6795; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Cheng SH, 2003, ONCOGENE, V22, P8472, DOI 10.1038/sj.onc.1206917; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Doerre S, 1999, J IMMUNOL, V163, P269; Donnelly GB, 2001, BLOOD, V98, p302A; Dyer MJS, 2003, INT J HEMATOL, V77, P315, DOI 10.1007/BF02982637; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; FAN Y, 2003, IN PRESS ONCOGENE; Fields ER, 2000, J IMMUNOL, V164, P4762, DOI 10.4049/jimmunol.164.9.4762; Forsyth NR, 2002, DIFFERENTIATION, V69, P188, DOI 10.1046/j.1432-0436.2002.690412.x; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2003, VIROLOGY, V316, P9, DOI 10.1016/S0042-6822(03)00562-2; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; GILMORE TD, 2003, REL NF KAPPA B TRANS; Glineur C, 2000, BIOCHEM J, V352, P583, DOI 10.1042/0264-6021:3520583; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GRUMONT RJ, 1993, CELL GROWTH DIFFER, V4, P731; GRUMONT RJ, 1994, CELL GROWTH DIFFER, V5, P1321; Harling-McNabb L, 1999, INT IMMUNOL, V11, P1431, DOI 10.1093/intimm/11.9.1431; Harnett M, 1996, IMMUNOL TODAY, V17, P4, DOI 10.1016/0167-5699(96)80558-5; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; Houldsworth J, 1996, BLOOD, V87, P25; HOULDSWORTH J, 2003, IN PRESS BLOOD; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Hu CJ, 2001, IMMUNITY, V15, P545, DOI 10.1016/S1074-7613(01)00219-9; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; Jin JP, 2003, CANCER CELL, V3, P517, DOI 10.1016/S1535-6108(03)00145-4; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kaku H, 2002, INT IMMUNOL, V14, P1055, DOI 10.1093/intimm/dxf072; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; Kim HG, 2002, EXP CELL RES, V272, P199, DOI 10.1006/excr.2001.5420; Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100; Kistler B, 1998, J IMMUNOL, V160, P2308; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Liou HC, 2003, BIOESSAYS, V25, P767, DOI 10.1002/bies.10306; Liou HC, 1999, INT IMMUNOL, V11, P361, DOI 10.1093/intimm/11.3.361; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; LU D, 1991, ONCOGENE, V6, P1235; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mao X, 2003, GENE CHROMOSOME CANC, V37, P176, DOI 10.1002/gcc.10184; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Martinez-Climent JA, 2003, BLOOD, V101, P3109, DOI 10.1182/blood-2002-07-2119; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Moscat J, 2003, EMBO REP, V4, P31, DOI 10.1038/sj.embor.embor704; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; NEUMANN M, 1992, ONCOGENE, V7, P2095; Newton K, 2003, CURR BIOL, V13, P1247, DOI 10.1016/S0960-9822(03)00458-5; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; Popescu NC, 2002, J CELL MOL MED, V6, P151, DOI 10.1111/j.1582-4934.2002.tb00183.x; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Sachdev S, 1997, ONCOGENE, V14, P2585, DOI 10.1038/sj.onc.1201108; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Schmidt CS, 2003, J EXP MED, V197, P51, DOI 10.1084/jem.20020617; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Suzuki H, 2003, NAT IMMUNOL, V4, P280, DOI 10.1038/ni890; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tam WF, 2001, MOL CELL BIOL, V21, P4837, DOI 10.1128/MCB.21.14.4837-4846.2001; Tamura A, 2001, CANCER GENET CYTOGEN, V129, P1, DOI 10.1016/S0165-4608(01)00436-8; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; Tolnay M, 2002, J IMMUNOL, V169, P6236, DOI 10.4049/jimmunol.169.11.6236; Tsuboi K, 2000, LEUKEMIA, V14, P449, DOI 10.1038/sj.leu.2401696; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; WEIH F, 1994, ONCOGENE, V9, P3289; Werner CA, 1997, AM J PATHOL, V151, P335; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297; White DW, 1996, ONCOGENE, V13, P891; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Xue LQ, 2003, NAT IMMUNOL, V4, P857, DOI 10.1038/ni963; Yamazaki T, 2003, NAT IMMUNOL, V4, P780, DOI 10.1038/ni949; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhou MX, 2003, ONCOGENE, V22, P8137, DOI 10.1038/sj.onc.1206911; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	151	115	118	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2275	2286		10.1038/sj.onc.1207410	http://dx.doi.org/10.1038/sj.onc.1207410			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14755244				2022-12-28	WOS:000220427700001
J	Chien, J; Staub, J; Hu, SI; Erickson-Johnson, MR; Couch, FJ; Smith, DI; Crowl, RM; Kaufmann, SH; Shridhar, V				Chien, J; Staub, J; Hu, SI; Erickson-Johnson, MR; Couch, FJ; Smith, DI; Crowl, RM; Kaufmann, SH; Shridhar, V			A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer	ONCOGENE			English	Article						serine protease; HtrA; ovarian cancer; down-regulation; loss of heterozygosity	SERINE-PROTEASE; EPITHELIAL TUMORS; CELL-DEATH; GENE; DMBT1; IDENTIFICATION; APOPTOSIS; GROWTH; EXPRESSION; INHIBITOR	We report here that HtrA1, a candidate tumor suppressor, is downregulated in ovarian cancer. Expression of HtrA1 is downregulated in five of seven ovarian cancer cell lines. In total, 59% of primary ovarian tumors have either a complete absence or markedly reduced levels of HtrA1 expression compared to the brushings of ovarian surface epithelium. Primary ovarian tumors show high frequencies of loss of an allele at microsatellite markers near htrA1 locus on 10q26. Downregulation of HtrA1 in SKOV3 by antisense transfection promotes anchorage-independent growth, while exogenous expression of HtrA1 in OV202 induces cell death. HtrA1-induced cell death is not inhibited by the broad caspase inhibitor, zVAD(O-Me) fmk, but instead reflects serine protease activity associated with HtrA1. These observations raise the possibility of HtrA1 as a candidate tumor suppressor involved in promoting serine-protease-mediated cell death and that downregulation of HtrA1 in ovarian cancer may contribute to malignant phenotype.	Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, Rochester, MN 55905 USA; Mayo Clin Canc Ctr, Rochester, MN 55905 USA; Novartis Pharmaceut, Arthrit Biol Unit, E Hanover, NJ 07936 USA; Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Novartis; Mayo Clinic	Shridhar, V (corresponding author), Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, 200 1st St SW, Rochester, MN 55905 USA.	shridv@exrch.mayo.edu	Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374; Kaufmann, Scott/0000-0002-4900-7145				Albarosa R, 1996, AM J HUM GENET, V58, P1260; Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911; Clausen T, 2002, MOL CELL, V10, P443, DOI 10.1016/S1097-2765(02)00658-5; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Deichmann M, 2002, ONCOLOGY-BASEL, V63, P166, DOI 10.1159/000063802; ENOMOTO T, 1991, AM J PATHOL, V139, P777; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kato MV, 2000, MOL MED, V6, P126, DOI 10.1007/BF03401780; KATSAROS D, 1995, ANTICANCER RES, V15, P1501; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LI SB, 1991, J NATL CANCER I, V83, P637, DOI 10.1093/jnci/83.9.637; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Mueller W, 2002, ONCOGENE, V21, P5956, DOI 10.1038/sj.onc.1205733; Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Ross JS, 1999, AM J CLIN PATHOL, V111, P311; Sasaki H, 2002, CANCER RES, V62, P1790; Schwartz DI, 1999, BREAST CANCER RES TR, V58, P25, DOI 10.1023/A:1006237031070; Shridhar V, 2002, CANCER RES, V62, P262; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	32	136	145	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1636	1644		10.1038/sj.onc.1207271	http://dx.doi.org/10.1038/sj.onc.1207271			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716297				2022-12-28	WOS:000189219500019
J	Davies, ML; Roberts, GT; Spiller, DG; Wakeman, JA				Davies, ML; Roberts, GT; Spiller, DG; Wakeman, JA			Density-dependent location and interactions of truncated APC and beta-catenin	ONCOGENE			English	Article						adenomatous polyposis coli; beta-catenin; cell density; E-cadherin; tumour progression	TUMOR-SUPPRESSOR; E-CADHERIN; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; CYCLIN D1; TARGET; IDENTIFICATION; MUTATIONS; GENES; TRANSACTIVATION	Adenomatous polyposis coli (APC) is a multifunctional tumour suppressor protein, central to development and the mature organism. It is mutated in most cases of colorectal cancer, rendering it ineffective in mediating beta-catenin degradation. We show that localization of full-length APC in colon carcinoma and noncancer cell lines is independent of cell density. However, the location of truncated APC is a function of cell density and in high-density cells truncated APC is predominantly not nuclear. Although the distribution of truncated APC and beta-catenin is closely linked in subconfluent SW480 cells, at high cell density they are not colocalized. We postulated that in this cell line this could be due to an increase in beta-catenin bound to E-cadherin with formation of adherens junctions at high cell density. However, while in coimmunoprecipitation assays we observe an increase in binding between beta-catenin and E-cadherin and a corresponding decrease in binding between beta-catenin and APC at high cell density, we did not observe a strict colocalization of beta-catenin and E-cadherin at the membrane of all cells.	Univ Wales Bangor, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England	Bangor University; University of Liverpool	Wakeman, JA (corresponding author), Univ Wales Bangor, Sch Biol Sci, Deiniol Rd, Bangor LL57 2UW, Gwynedd, Wales.	j.a.wakeman@bangor.ac.uk	Spiller, David G/I-3645-2012	Spiller, David Geoffrey/0000-0003-2502-6787; Wakeman, Jane/0000-0002-7561-634X				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Allan V, 2001, NAT CELL BIOL, V3, pE226, DOI 10.1038/ncb1001-e226; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dietrich C, 2002, BIOCHEM BIOPH RES CO, V292, P195, DOI 10.1006/bbrc.2002.6625; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, EMBO REP, V1, P519; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Orsulic S, 1999, J CELL SCI, V112, P1237; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	37	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1412	1419		10.1038/sj.onc.1207266	http://dx.doi.org/10.1038/sj.onc.1207266			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647421				2022-12-28	WOS:000189035800008
J	Bauvois, B				Bauvois, B			Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis?	ONCOGENE			English	Review						ACE; ADAM; APN; DPPIV; MT-MMP; TACE	NECROSIS-FACTOR-ALPHA; ANGIOTENSIN-CONVERTING ENZYME; MEMBRANE-TYPE-MATRIX; DIPEPTIDYL PEPTIDASE-IV; MICROVASCULAR ENDOTHELIAL-CELLS; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; TNF-ALPHA; AMINOPEPTIDASE-N; TISSUE LOCALIZATION	Transmembrane proteases (TPs) are proteins anchored in the plasma membrane with their catalytic site exposed to the external surface of the membrane. TPs are widely expressed, and their dysregulated expression is associated with cancer, infection, inflammation, autoimmune and cardiovascular diseases, all diseases where angiogenesis is part of the pathology. TPs participate in extracellular proteolysis (degradation of extracellular matrix components, regulation of chemokine activity, release of membrane-anchored cytokines, cytokine receptors and adhesion molecules) and influence cell functions (growth, secretion of angiogenic molecules, motility). Recent attention has been focused on the ADAM-17 (a disintegrin and metalloprotease)/TACE/CD156q, the MT1-MMP (membrane-type-1 matrix metallo proteinase)/MMP-14, and the ectopeptidases aminopeptidase N (APN/CD13), dipeptidyl peptidase IV (DPPIV/CD26) and angiotensin-converting enzyme (ACE/CD143), that appear to have a critical role in angiogenesis. This article summarizes current knowledge on these TPs, and reviews recent investigations that document their participation during angiogenic-related events. Through their multiple roles, TPs may thereby provide critical links in angiogenesis.	Hop Necker Enfants Malad, INSERM, U507, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bauvois, B (corresponding author), Hop Necker Enfants Malad, INSERM, U507, Batiment Lavoisier,161 Rue Sevres, F-75015 Paris, France.	bauvois@necker.fr	Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922				Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X; AHMAD S, 1990, J PHARMACOL EXP THER, V252, P643; ALHENCGELAS F, 1997, CELL SURFACE PEPTIDA, P119; Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Antczak C, 2001, BIOESSAYS, V23, P251, DOI 10.1002/1521-1878(200103)23:3<251::AID-BIES1035>3.3.CO;2-F; Antczak C, 2001, J BIOL REG HOMEOS AG, V15, P130; Asher J R, 2000, Curr Hypertens Rep, V2, P384, DOI 10.1007/s11906-000-0042-y; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Bauvois B, 2001, J LEUKOCYTE BIOL, V70, P11; Beckner ME, 1999, CANCER INVEST, V17, P594, DOI 10.3109/07357909909032845; Bermpohl F, 1998, FEBS LETT, V428, P152, DOI 10.1016/S0014-5793(98)00515-8; Bernardi C, 1998, B BELG MATH SOC-SIM, V5, P7; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Bhagwat SV, 2001, BLOOD, V97, P652, DOI 10.1182/blood.V97.3.652; Bischof P, 2002, J REPROD IMMUNOL, V55, P3, DOI 10.1016/S0165-0378(01)00142-5; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brinckerhoff CE, 2000, CLIN CANCER RES, V6, P4823; Bueno C, 2002, J IMMUNOL METHODS, V264, P77, DOI 10.1016/S0022-1759(02)00083-2; BURNETT JC, 1999, J HYPERTENS S1, V17, P537; Burrell LM, 2000, AM J HYPERTENS, V13, P1110, DOI 10.1016/S0895-7061(00)01185-7; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Cambien Francois, 1995, P1667; Cerretti DP, 1999, BIOCHEM SOC T, V27, P219, DOI 10.1042/bst0270219; Chan VT, 1998, J INVEST DERMATOL, V111, P1153, DOI 10.1046/j.1523-1747.1998.00416.x; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chen WT, 2003, CANCER METAST REV, V22, P259, DOI 10.1023/A:1023055600919; CHOMARAT P, 1995, J IMMUNOL, V155, P3645; Collen A, 2003, BLOOD, V101, P1810, DOI 10.1182/blood-2002-05-1593; Colon AL, 2001, CYTOKINE, V16, P220, DOI 10.1006/cyto.2001.0969; Comte L, 1997, EUR J CLIN INVEST, V27, P788, DOI 10.1046/j.1365-2362.1997.1980737.x; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Constantinescu CS, 1998, IMMUNOL LETT, V62, P25, DOI 10.1016/S0165-2478(98)00025-X; Conway JG, 2001, J PHARMACOL EXP THER, V298, P900; Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; d'Ortho MP, 1998, FEBS LETT, V421, P159, DOI 10.1016/S0014-5793(97)01555-X; Danilov S, 1996, J HYPERTENS, V14, P719, DOI 10.1097/00004872-199606000-00007; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; DIAZFLORES L, 1994, HISTOL HISTOPATHOL, V9, P807; Doggrell SA, 2002, EXPERT OPIN INV DRUG, V11, P1003, DOI 10.1517/13543784.11.7.1003; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellenrieder V, 2000, INT J CANCER, V85, P14, DOI 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.3.CO;2-F; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellis LM, 2001, SEMIN ONCOL, V28, P94, DOI 10.1053/sonc.2001.28560; Emanueli C, 2002, AM J HYPERTENS, V15, P410, DOI 10.1016/S0895-7061(01)02332-9; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; Franzke CW, 2002, EMBO J, V21, P5026, DOI 10.1093/emboj/cdf532; FUJII H, 1995, CLIN EXP METASTAS, V13, P337; Glicklich D, 1999, TRANSPLANTATION, V68, P62, DOI 10.1097/00007890-199907150-00012; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Gonzalez-Gronow M, 2001, BIOCHEM J, V355, P397, DOI 10.1042/0264-6021:3550397; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hadjadj S, 2001, J AM SOC NEPHROL, V12, P541, DOI 10.1681/ASN.V123541; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Harada T, 1998, J HEPATOL, V28, P231, DOI 10.1016/0168-8278(88)80010-2; Hashida H, 2002, GASTROENTEROLOGY, V122, P376, DOI 10.1053/gast.2002.31095; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hiscox S, 1997, IN VIVO, V11, P125; HOCKEL M, 1993, ARCH SURG-CHICAGO, V128, P423; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Honda S, 2001, CLIN EXP IMMUNOL, V126, P131, DOI 10.1046/j.1365-2249.2001.01624.x; Hooper NM, 2002, CURR MED CHEM, V9, P1107, DOI 10.2174/0929867023370121; Isacke CM, 2002, INT J BIOCHEM CELL B, V34, P718, DOI 10.1016/S1357-2725(01)00166-2; Ishigaki S, 1999, JPN J CANCER RES, V90, P516, DOI 10.1111/j.1349-7006.1999.tb00778.x; Ishii K, 2001, BIOL PHARM BULL, V24, P226, DOI 10.1248/bpb.24.226; ISHII N, 1994, ENZYME PROTEIN, V48, P174, DOI 10.1159/000474984; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Karkkainen I, 2000, MOL CELL NEUROSCI, V15, P547, DOI 10.1006/mcne.2000.0848; Kawai M, 2003, CLIN CHIM ACTA, V330, P141, DOI 10.1016/S0009-8981(03)00002-0; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Kitagawa Y, 1998, J UROLOGY, V160, P1540, DOI 10.1016/S0022-5347(01)62609-0; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Koike T, 2002, J CELL BIOCHEM, V86, P748, DOI 10.1002/jcb.10257; Korom S, 1999, TRANSPLANT P, V31, P873, DOI 10.1016/S0041-1345(98)01812-0; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Kuro T, 2000, BIOL PHARM BULL, V23, P820; Kuroi K, 2001, INT J BIOL MARKER, V16, P5, DOI 10.1177/172460080101600102; Lafleur MA, 2002, J CELL SCI, V115, P3427; Laurent S, 2000, HYPERTENSION, V35, P1148, DOI 10.1161/01.HYP.35.5.1148; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; Li L, 1998, BBA-MOL CELL RES, V1405, P110, DOI 10.1016/S0167-4889(98)00091-3; Lohn M, 2002, LEUKEMIA LYMPHOMA, V43, P407, DOI 10.1080/10428190290006233; Lucas A, 1998, CARDIOVASC RES, V38, P237, DOI 10.1016/S0008-6363(97)00315-5; Ludwig A, 2002, J LEUKOCYTE BIOL, V72, P183; Marguet D, 2000, P NATL ACAD SCI USA, V97, P6874, DOI 10.1073/pnas.120069197; Mattei MG, 1997, GENOMICS, V40, P168, DOI 10.1006/geno.1996.4559; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; McClean DR, 2001, AM J CARDIOL, V87, P565, DOI 10.1016/S0002-9149(00)01432-6; Meissner A, 1999, MOL HUM REPROD, V5, P252, DOI 10.1093/molehr/5.3.252; Mishima Y, 2002, J NATL CANCER I, V94, P1020; Moehler TM, 2001, ANN HEMATOL, V80, P695, DOI 10.1007/s00277-001-0398-3; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Napoleone E, 2000, CIRC RES, V86, P139, DOI 10.1161/01.RES.86.2.139; Neal B, 2000, LANCET, V356, P1955; NEWTON RC, 2001, ANN RHEUM DIS     S3, V60, P25; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohta S, 2001, J RHEUMATOL, V28, P1756; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Opdenakker G, 2002, Verh K Acad Geneeskd Belg, V64, P105; Pap T, 2000, ARTHRITIS RHEUM, V43, P1226, DOI 10.1002/1529-0131(200006)43:6<1226::AID-ANR5>3.0.CO;2-4; Papies B, 1991, Cor Vasa, V33, P218; Pasqualini R, 2000, CANCER RES, V60, P722; Patel IR, 1998, J IMMUNOL, V160, P4570; Phillips M Ian, 2002, Curr Opin Investig Drugs, V3, P569; PIEPHO RW, 2000, AM J HEALTH-SYST PH, V57, P53; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Proost P, 2000, BLOOD, V96, P1674, DOI 10.1182/blood.V96.5.1674.h8001674a_1674_1680; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Prud'homme GJ, 2000, J AUTOIMMUN, V14, P23, DOI 10.1006/jaut.1999.0339; Rajavashisth TB, 1999, CIRCULATION, V99, P3103, DOI 10.1161/01.CIR.99.24.3103; Ribatti D, 2000, J HEMATOTH STEM CELL, V9, P13, DOI 10.1089/152581600319577; Riemann D, 1999, IMMUNOL TODAY, V20, P83, DOI 10.1016/S0167-5699(98)01398-X; Rouleau JL, 2000, LANCET, V356, P615, DOI 10.1016/S0140-6736(00)02602-7; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; SAIKI I, 1993, INT J CANCER, V54, P137, DOI 10.1002/ijc.2910540122; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; SANTOS A, 2000, THROMB HAEMOSTASIS, V78, P497; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; SCHEELTOELLNER D, 1995, LAB INVEST, V73, P685; Schonermarck U, 2000, CLIN EXP RHEUMATOL, V18, P457; Schwartz JD, 1998, SURGERY, V124, P232, DOI 10.1067/msy.1998.90566; Seifert T, 2002, MULT SCLER, V8, P447, DOI 10.1191/1352458502ms830oa; Seiki M, 2003, CANCER SCI, V94, P569, DOI 10.1111/j.1349-7006.2003.tb01484.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Silvestre JS, 2001, CIRC RES, V89, P678, DOI 10.1161/hh2001.097691; Simpson K, 2000, DRUGS, V59, P1149, DOI 10.2165/00003495-200059050-00012; Skopinski P, 2001, INT J CLIN PHARM RES, V21, P73; Skovronsky DM, 2001, J NEUROBIOL, V49, P40, DOI 10.1002/neu.1064; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; Soderstrom M, 2001, APMIS, V109, P305, DOI 10.1034/j.1600-0463.2001.d01-125.x; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Takeshita S, 2001, CARDIOVASC RES, V52, P314, DOI 10.1016/S0008-6363(01)00372-8; Thathiah A, 2003, J BIOL CHEM, V278, P3386, DOI 10.1074/jbc.M208326200; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Trifilieff A, 2002, BRIT J PHARMACOL, V135, P1655, DOI 10.1038/sj.bjp.0704616; Tschesche H, 2000, ADV EXP MED BIOL, V477, P217; Ueno H, 1997, CANCER RES, V57, P2055; Vivian EM, 2002, CLIN THER, V24, P1741, DOI 10.1016/S0149-2918(02)80076-5; Volpert OV, 1996, J CLIN INVEST, V98, P671, DOI 10.1172/JCI118838; Vranes D, 1995, J DIABETES COMPLICAT, V9, P296, DOI 10.1016/1056-8727(95)80026-B; WANG DH, 1990, HYPERTENSION, V15, P68, DOI 10.1161/01.HYP.15.1.68; Wesley UV, 1999, J EXP MED, V190, P311, DOI 10.1084/jem.190.3.311; WRIGHT JW, 1991, BRAIN RES BULL, V27, P545, DOI 10.1016/0361-9230(91)90027-H; Xu P, 2002, J CLIN ENDOCR METAB, V87, P1353, DOI 10.1210/jc.87.3.1353; Xue CB, 2001, J MED CHEM, V44, P2636, DOI 10.1021/jm010127e; Yamamoto S, 1999, IMMUNOL TODAY, V20, P278, DOI 10.1016/S0167-5699(99)01464-4; Yamanaka H, 2000, LAB INVEST, V80, P677, DOI 10.1038/labinvest.3780071; Yoshiji H, 2002, INT J ONCOL, V20, P1227; Yoshiji H, 2002, ANTI-CANCER DRUG, V13, P221, DOI 10.1097/00001813-200203000-00003; Yoshiji H, 2001, CLIN CANCER RES, V7, P1073; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhang XY, 1999, J MASS SPECTROM, V34, P255, DOI 10.1002/(SICI)1096-9888(199904)34:4<255::AID-JMS752>3.3.CO;2-Z; Zhao JS, 2001, DEV BIOL, V232, P204, DOI 10.1006/dbio.2001.0176; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968; Zukowska Z, 2003, CAN J PHYSIOL PHARM, V81, P89, DOI 10.1139/Y03-006; Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187; 2000, LANCET, V356, P1955	170	136	146	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					317	329		10.1038/sj.onc.1207124	http://dx.doi.org/10.1038/sj.onc.1207124			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724562				2022-12-28	WOS:000188098300001
J	Zhao, WD; Hisamuddin, IM; Nandan, MO; Babbin, BA; Lamb, NE; Yang, VW				Zhao, WD; Hisamuddin, IM; Nandan, MO; Babbin, BA; Lamb, NE; Yang, VW			Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer	ONCOGENE			English	Article						gut-enriched Kruppel-like factor; GKLF; KLF4; loss of heterozygosity; methylation; point mutation; colon cancer; tumor suppressor	KRUPPEL-LIKE FACTOR; COLONIC CELL-GROWTH; ZINC-FINGER PROTEIN; EPITHELIAL-CELLS; MUTATIONS OCCUR; LINE RKO; EXPRESSION; TUMORIGENESIS; FACTOR-4; METHYLATION	Kruppel-like factor 4 (KLF4 or GKLF) is an inhibitor of the cell cycle. The gene encoding KLF4 is localized on chromosome 9q, previously shown to exhibit allelic loss in colorectal cancer (CRC). In this study, we show that the mean level of KLF4 mRNA in a panel of 30 CRC was 52% that of paired normal colonic tissues. Similarly, the levels of KLF4 mRNA and protein in a panel of six established CRC cell lines were significantly lower than those of an untransformed colonic epithelial cell line. Using highly polymorphic DNA markers that flank the KLF4 locus, we found evidence for loss of heterozygosity (LOH) in two of eight surgically resected CRC specimens. In addition, LOH was observed in five of six CRC cell lines with one additional cell line exhibiting hemizygous deletion in the KLF4 gene. We also found that the 5'-untranslated region of KLF4 was hypermethylated in a subset of resected CRC specimens and cell lines. Lastly, the open-reading frame of KLF4 in two of three CRC cell lines examined contained several point mutations that resulted in a diminished ability to activate the p21(WAF1#47;Cip1) promoter. These findings indicate that KLF4 is a potential tumor suppressor gene in CRC.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Human Genet, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu		Mandayam, Nandan/0000-0002-4061-9348	NCI NIH HHS [R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [DK64399, R24 DK064399, DK52230, R01 DK052230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R24DK064399, R01DK052230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM CANC SOC, 2003, CANC FACTS FIG; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bird AP, 1996, CANCER SURV, V28, P87; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2002, J BIOL CHEM, V277, P46831, DOI 10.1074/jbc.M204816200; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Dang DT, 2003, ONCOGENE, V22, P3424, DOI 10.1038/sj.onc.1206413; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Goel A, 2003, CANCER RES, V63, P1608; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Gryfe R, 1997, CURR PROB CANCER, V21, P238, DOI 10.1016/S0147-0272(97)80003-7; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ilyas M, 1999, EUR J CANCER, V35, P1986, DOI 10.1016/S0959-8049(99)00298-1; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jubb AM, 2001, J PATHOL, V195, P111, DOI 10.1002/path.923; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Stone CD, 2002, FEBS LETT, V530, P147, DOI 10.1016/S0014-5793(02)03449-X; Sun RG, 2001, J BIOL CHEM, V276, P6897, DOI 10.1074/jbc.C000870200; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8; Yang V W, 1999, Curr Gastroenterol Rep, V1, P449, DOI 10.1007/s11894-999-0028-0; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	42	251	278	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					395	402		10.1038/sj.onc.1207067	http://dx.doi.org/10.1038/sj.onc.1207067			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724568	Green Accepted			2022-12-28	WOS:000188098300009
J	Keshamouni, VG; Reddy, RC; Arenberg, DA; Joel, B; Thannickal, VJ; Kalemkerian, GP; Standiford, TJ				Keshamouni, VG; Reddy, RC; Arenberg, DA; Joel, B; Thannickal, VJ; Kalemkerian, GP; Standiford, TJ			Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer	ONCOGENE			English	Article						PPAR-gamma; NSCLC; Erk1/2; differentiation	HUMAN BREAST-CANCER; PROTEASOME-DEPENDENT DEGRADATION; PPAR-GAMMA; ESTROGEN-RECEPTOR; RETINOIC ACID; MAP KINASE; MEDIATED PROTEOLYSIS; PROTEIN-KINASE; COLON-CANCER; OXIDIZED LDL	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors and a crucial regulator of cellular differentiation. Differentiation-inducing and antiproliferative effects of PPAR-gamma suggest that PPAR-gamma agonists might be useful as effective anticancer agents. Few studies have examined the efficacy of these agonists in animal models of tumorigenesis, and their mechanism(s) of action are still not clear. Our studies indicate higher PPAR-gamma expression in primary tumors from non-small-cell lung cancer (NSCLC) patients when compared to normal surrounding tissue. The expression of PPAR-gamma was also observed in several NSCLC lines. The treatment of lung adenocarcinoma cells (A549) with troglitazone (Tro), a PPAR-gamma ligand, enhanced PPAR-gamma transcriptional activity and induced a dose-dependent inhibition of A549 cell growth. The observed growth arrest was predominantly due to the inhibition of cell proliferation without significant induction of apoptosis. Cell cycle analysis of Tro-treated cells revealed a cell cycle arrest at G(0)/G(1) with concomitant downregulation of G(0)/G(1) cyclins D and E. In addition, Tro treatment stimulated sustained Erk1/2 activation in A549 cells, suggesting the activation of a differentiation-inducing pathway. Furthermore, treatment of A549 tumor-bearing SCID mice with Tro or Pio inhibited primary tumor growth by 66.7% and significantly inhibited the number of spontaneous lung metastatic lesions. Collectively, our data demonstrate that activation of PPAR-gamma impedes lung tumor progression and suggest that PPAR-gamma ligands may serve as potential therapeutic agents for NSCLC.	Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Standiford, TJ (corresponding author), Univ Michigan, Med Ctr, Div Pulm & Crit Care Med, 6301 MSRB III,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	tstandif@med.umich.edu	Arenberg, Douglas/P-7251-2014	Arenberg, Douglas/0000-0001-7707-5092; Keshamouni, Venkateshwar/0000-0003-1947-791X	NCI NIH HHS [R01 CA094121, R01 CA094121-02, R01 CA094121-01A1] Funding Source: Medline; NHLBI NIH HHS [P050 HL60289, HL57243, K08 HL070068] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057243, K08HL070068, P50HL060289] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018; BLOCH A, 1984, CANCER TREAT REP, V68, P199; Chang TH, 2000, CANCER RES, V60, P1129; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; El Khissiin A, 1999, FEBS LETT, V448, P160, DOI 10.1016/S0014-5793(99)00343-9; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; Gurdon JB, 1998, CELL, V95, P159, DOI 10.1016/S0092-8674(00)81747-X; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; Heaney AP, 2002, NAT MED, V8, P1281, DOI 10.1038/nm784; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KRANENBURG O, 1995, ONCOGENE, V10, P87; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; Mandell JW, 1998, AM J PATHOL, V153, P1411, DOI 10.1016/S0002-9440(10)65728-8; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Panigrahy D, 2002, J CLIN INVEST, V110, P923, DOI 10.1172/JCI200215634; PIERCE GB, 1988, CANCER RES, V48, P1996; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Sarraf P, 1999, MOL CELL, V3, P799, DOI 10.1016/S1097-2765(01)80012-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Syvala H, 1998, LIFE SCI, V63, P1505, DOI 10.1016/S0024-3205(98)00417-2; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Wang CG, 2001, MOL CELL BIOL, V21, P3057, DOI 10.1128/MCB.21.9.3057-3070.2001; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Watkins PB, 1998, NEW ENGL J MED, V338, P916, DOI 10.1056/NEJM199803263381314; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807	45	173	181	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					100	108		10.1038/sj.onc.1206885	http://dx.doi.org/10.1038/sj.onc.1206885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712215				2022-12-28	WOS:000187895300011
J	Kumar, R; Angelini, S; Hemminki, K				Kumar, R; Angelini, S; Hemminki, K			Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9	ONCOGENE			English	Article						BRAF; N-ras; melanoma; mutation; FAL; SSCP	MALIGNANT-MELANOMA; TUMOR PROGRESSION; CDKN2A MUTATIONS; B-RAF; GENE; FREQUENCY; CANCER; HETEROZYGOSITY; PATHWAYS; COMMON	We searched and report mutations in the BRAF and N-ras genes in 22 out of 35 (63 percent) primary sporadic melanomas. In three melanomas, mutations were concomitantly present in both genes. In all, 10 out of 12 mutations in the BRAF gene involved the 'hot spot' codon 600 (In all communications on mutations in the BRAF gene, the nucleotide and codon numbers have been based on the NCBI gene bank nucleotide sequence NM_004333. However, according to NCBI gene bank sequence with accession number NT_007914, there is a discrepancy of one codon (three nucleotides) in exon 1 in the sequence with accession number NM_004333. The sequence analysis of exon 1 of the BRAF gene in our laboratory has shown that the sequence derived from NT_007914 is correct (Kumar et al., 2003). Due to the correctness of the latter, sequence numbering of codons and nucleotides after exon 1 are changed by +1 and +3, respectively.), one tandem CT1789-90TC base change represented a novel mutation and another mutation caused a G466R amino-acid change within the glycine-rich loop in the kinase domain. Mutations in the N-ras gene in 11 melanomas were at codon 61 whereas two melanomas carried mutations in codon 12 including a tandem mutation GG>AA. We observed an inverse association between BRAF/N-ras mutations and the frequency of loss of heterozygosity (LOH) on chromosome 9 at 10 different loci. Melanomas with BRAF/N-ras mutations showed a statistically significant decreased frequency of LOH on chromosome 9 compared with cases without mutations (mean fractional allelic loss (FAL) = 0.29 +/- 0.23 vs 0.72 +/- 0.33; t-test, P = 0.0001). Difference in the FAL value between tumours with and without BRAF/N-ras mutations on 33 loci on five other chromosomes was not statistically significant (mean FAL 0.17 +/- 0.19 vs 0.25 +/- 0.22; t-test, P = 0.24). Melanoma cases with BRAF/N-ras mutations were also associated with lower age at diagnosis than cases without mutations (mean age 80.38 +/- 7.24 vs 65.77 +/- 19.79 years; t-test, P = 0.02). Our data suggest that the occurrence of BRAF/N-ras mutations compensate the requirement for the allelic loss at chromosome 9, which is one of the key events in melanoma.	German Canc Res Ctr, Div Mol Genet Epidemiol, D-69210 Heidelberg, Germany; Karolinska Inst, Novum, Ctr Nutr & Toxicol, Dept Biosci, S-14157 Huddinge, Sweden	Helmholtz Association; German Cancer Research Center (DKFZ); Karolinska Institutet	Kumar, R (corresponding author), German Canc Res Ctr, Div Mol Genet Epidemiol, Neuenheimer Feld 580 TP3, D-69210 Heidelberg, Germany.	kumar@cnt.ki.se	Kumar, Rajiv/H-6431-2019; angelini, Sabrina/AAB-5220-2022; ravegnini, gloria/K-1330-2016	Kumar, Rajiv/0000-0002-6093-0395; ravegnini, gloria/0000-0002-7774-402X; Angelini, Sabrina/0000-0002-1609-0421				Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Bolshakov S, 2003, CLIN CANCER RES, V9, P228; Brose MS, 2002, CANCER RES, V62, P6997; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1998, GENE DEV, V12, P3467, DOI 10.1101/gad.12.22.3467; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Eskandarpour M, 2003, J NATL CANCER I, V95, P790, DOI 10.1093/jnci/95.11.790; Funk JO, 1998, J CUTAN PATHOL, V25, P291, DOI 10.1111/j.1600-0560.1998.tb01748.x; Gilchrest BA, 1999, NEW ENGL J MED, V340, P1341, DOI 10.1056/NEJM199904293401707; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Hemminki K, 2001, MELANOMA RES, V11, P133, DOI 10.1097/00008390-200104000-00007; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Kumar R, 1999, MELANOMA RES, V9, P138, DOI 10.1097/00008390-199904000-00005; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Kumar R, 1998, INT J CANCER, V75, P193, DOI 10.1002/(SICI)1097-0215(19980119)75:2<193::AID-IJC5>3.3.CO;2-5; Kumar R, 2001, INT J CANCER, V95, P388, DOI 10.1002/1097-0215(20011120)95:6<388::AID-IJC1069>3.0.CO;2-6; KUMAR R, 2003, IN PRESS CLIN CANC R; Laud K, 2003, CANCER RES, V63, P3061; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Naoki K, 2002, CANCER RES, V62, P7001; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Pollock PM, 2001, CANCER RES, V61, P1154; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 2002, CANCER CELL, V2, P5, DOI 10.1016/S1535-6108(02)00089-2; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Saida T, 2001, J DERMATOL SCI, V26, P1, DOI 10.1016/S0923-1811(01)00085-8; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharpless NE, 2003, ONCOGENE, V22, P3092, DOI 10.1038/sj.onc.1206461; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smeds J, 2000, MUTAGENESIS, V15, P257, DOI 10.1093/mutage/15.3.257; vanElsas A, 1997, MELANOMA RES, V7, pS107; Walker GJ, 2002, J INVEST DERMATOL, V119, P783, DOI 10.1046/j.1523-1747.2002.00217.x; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928; Yang FC, 2001, SEMIN CANCER BIOL, V11, P261, DOI 10.1006/scbi.2000.0376; Yuen ST, 2002, CANCER RES, V62, P6451; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429	42	75	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9217	9224		10.1038/sj.onc.1206909	http://dx.doi.org/10.1038/sj.onc.1206909			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681681				2022-12-28	WOS:000187400400003
J	Schiller, M; Verrecchia, F; Mauviel, A				Schiller, M; Verrecchia, F; Mauviel, A			Cyclic adenosine 3 ',5 '-monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD3/4-dependent transcription via a protein kinase A-dependent mechanism	ONCOGENE			English	Article						cAMP; CREB; gene regulation; PAI-1; PKA; SMAD signaling; TGF-beta	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; TGF-BETA; GENE-EXPRESSION; ANTISENSE OLIGONUCLEOTIDE; DERMAL FIBROBLASTS; PROSTAGLANDIN E-2; FACTOR CREB; C-JUN; COACTIVATOR	Transforming growth factor-beta (TGF-beta) plays complex roles in carcinogenesis, as it may exert both tumor suppressor and pro-oncogenic activities depending on the stage of the tumor. SMAD proteins transduce signals from the TGF-beta receptors to regulate the transcription of specific target genes. Crosstalks with other signaling pathways may contribute to the speci. city of TGF-beta effects. In this report, we have investigated the effects of cyclic adenosine 3',5'-monophosphate (cAMP), a key second messenger in the cellular response to various hormones, on SMAD-dependent signaling in human HaCaT keratinocytes. Using either an artificial SMAD3/4-dependent reporter construct or the natural TGF-beta target, plasminogen activator inhibitor-1, we show that membrane-permeable dibutyryl cAMP, and other intracellular cAMP-elevating agents such as the phosphodiesterase inhibitor isobutyl-methylxanthine, the adenylate cyclase activator forskolin, or exogenous prostaglandin E-2 (PGE(2)), interfere with TGF-beta-induced SMAD-specific gene transactivation. Inhibition of protein kinase A (PKA), the main downstream effector of cAMP, with H-89, suppressed cAMP-dependent repression of SMAD-driven gene expression. Inversely, coexpression of either an active PKA catalytic subunit or that of the cAMP response element (CRE)-binding protein (CREB) blocked SMAD-driven gene transactivation. cAMP-elevating agents did not inhibit nuclear translocation and DNA binding of SMAD3/4complexes, but abolished the interactions of SMAD3 with the transcription coactivators CREB-binding protein (CBP) and p300 in a PKA-dependent manner. These results suggest that suppression of TGF-beta/SMAD signaling and resulting gene transactivation by cAMP-inducing agents occurs via PKA-dependent, CREB-mediated, disruption of SMAD-CBP/p300 complexes.	Univ Paris 07, Hop St Louis, Inst Rech Peau, INSERM,U532, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Mauviel, A (corresponding author), Hop St Louis, Inst Rech Peau, INSERM, U532, Pavillon Bazin,1 Ave Claude Vellefaux, F-75475 Paris 10, France.	mauviel@chu-stlouis.fr	Verrecchia, Franck/G-5535-2018; MAUVIEL, Alain/F-6251-2013	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Atfi A, 1997, J BIOL CHEM, V272, P24731, DOI 10.1074/jbc.272.40.24731; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bianco C, 2000, CLIN CANCER RES, V6, P4343; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Corley DA, 2003, GASTROENTEROLOGY, V124, P47, DOI 10.1053/gast.2003.50008; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hottiger MO, 1998, EMBO J, V17, P3124, DOI 10.1093/emboj/17.11.3124; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Johnson TW, 2002, CANCER EPIDEM BIOMAR, V11, P1586; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; Rodeck U, 1999, CANCER RES, V59, P547; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Smalley W, 1999, ARCH INTERN MED, V159, P161, DOI 10.1001/archinte.159.2.161; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Tortora G, 2002, ANN NY ACAD SCI, V968, P139, DOI 10.1111/j.1749-6632.2002.tb04332.x; Tortora G, 1997, P NATL ACAD SCI USA, V94, P12586, DOI 10.1073/pnas.94.23.12586; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Verrecchia F, 2000, J BIOL CHEM, V275, P30226, DOI 10.1074/jbc.M005310200; Verrecchia F, 2003, J BIOL CHEM, V278, P1585, DOI 10.1074/jbc.M206927200; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	44	53	54	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8881	8890		10.1038/sj.onc.1206871	http://dx.doi.org/10.1038/sj.onc.1206871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654784				2022-12-28	WOS:000186982200009
J	Catto, JWF; Azzouzi, AR; Amira, N; Rehman, I; Feeley, KM; Cross, SS; Fromont, G; Sibony, M; Hamdy, FC; Cussenot, O; Meuth, M				Catto, JWF; Azzouzi, AR; Amira, N; Rehman, I; Feeley, KM; Cross, SS; Fromont, G; Sibony, M; Hamdy, FC; Cussenot, O; Meuth, M			Distinct patterns of microsatellite instability are seen in tumours of the urinary tract	ONCOGENE			English	Article						microsatellite instability; HNPCC; bladder cancer; upper urinary tract cancer	TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; TETRANUCLEOTIDE REPEATS; COLORECTAL-CANCER; YOUNG-PATIENTS; HMLH1; PHENOTYPES; EXPRESSION; MUTATIONS; COLON	To date, two forms of microsatellite instability (MSI) have been described in human cancer. MSI typical of hereditary nonpolyposis colon cancer (HNPCC), is due to deficient DNA mismatch repair (MMR) and is defined with mono- and dinucleotide repeat microsatellites. A second variety of instability is best seen at selective tetranucleotide repeats (EMAST; elevated microsatellite alterations at select tetranucleotides). While MSI occurs infrequently in bladder cancers, EMAST is common. Sporadic tumours with the largest proportion showing MSI are those found most frequently in HNPCC kindreds. While bladder cancer is not frequently seen in HNPCC, upper urinary tract tumours (UTTs) are. Having previously found a low frequency of MSI in bladder cancer, we sought to determine the relative levels of MSI and EMAST in transitional cell carcinoma (TCC) of the upper and lower urinary tracts. Microsatellite analysis was performed at 10 mono- and dinucleotide and eight tetranucleotide loci, in 89 bladder and 71 UTT TCC. Contrasting patterns of instability were seen in urinary tumours. In bladder cancer, MSI was rare and EMAST was common. The presence of EMAST was not related to tumour grade, stage, subsequent outcome or immunohistochemical expression of the MMR proteins. In UTT, while MSI occurred frequently, EMAST was seen less frequently than in bladder cancer. When TCC of the upper and lower urinary tracts are compared, MSI-H is more frequent in UTT and EMAST more frequent in bladder cancer. Our findings show that, as for colorectal cancer, the pattern of MSI varies with location in the urinary tract. In addition, we have confirmed that MSI and EMAST are discrete forms of MSI, and that the presence of EMAST does not affect tumour phenotype.	Univ Sheffield, Inst Canc Studies, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Acad Urol Unit, Sheffield S10 2TN, S Yorkshire, England; Fac Med, Dept Urol, CeRePP EA3104, Paris, France; Royal Hallamshire Hosp, Dept Pathol, Sheffield S10 2JF, S Yorkshire, England; Univ Sheffield, Acad Pathol Unit, Sheffield S10 2TN, S Yorkshire, England; Inst Mutualiste Montsouris, Serv Anatomopathol, Paris, France; Hop Tenon, Serv Anatomopathol, F-75970 Paris, France	University of Sheffield; University of Sheffield; University of Sheffield; University of Sheffield; Institute Mutualiste Montsouris; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Catto, JWF (corresponding author), Royal Hallamshire Hosp, Acad Urol Unit, I Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.		fromont, gaelle/N-8708-2016	catto, james/0000-0003-2787-8828; Hamdy, Freddie/0000-0003-2627-2154; Cross, Simon/0000-0003-2044-1754; cussenot, olivier/0000-0002-9912-0533				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahrendt SA, 2000, CANCER RES, V60, P2488; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Boland CR, 1998, CANCER RES, V58, P5248; Bonnal C, 2000, UROLOGY, V55, P287, DOI 10.1016/S0090-4295(99)00399-4; Catto JWF, 2003, INT J CANCER, V105, P484, DOI 10.1002/ijc.11109; Christensen M, 1998, INT J CANCER, V79, P396, DOI 10.1002/(SICI)1097-0215(19980821)79:4<396::AID-IJC15>3.0.CO;2-3; Danaee H, 2002, ONCOGENE, V21, P4894, DOI 10.1038/sj.onc.1205619; Dietmaier W, 1997, CANCER RES, V57, P4749; Furihata M, 2000, INT J ONCOL, V16, P491; Furihata M, 2001, J UROLOGY, V165, P1760, DOI 10.1016/S0022-5347(05)66409-9; Gleeson CM, 1996, CANCER RES, V56, P259; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201; Hartmann A, 2002, CANCER RES, V62, P6796; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; Li MM, 1996, AM J PATHOL, V149, P229; LINNENBACH AJ, 1994, NATURE, V367, P419, DOI 10.1038/367419b0; MAO L, 1994, P NATL ACAD SCI USA, V91, P9871, DOI 10.1073/pnas.91.21.9871; Ottini L, 1997, CANCER RES, V57, P4523; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Slebos RJC, 2002, CANCER RES, V62, P6052; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Xu LH, 2001, INT J CANCER, V91, P200, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1031>3.0.CO;2-0	28	106	107	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8699	8706		10.1038/sj.onc.1206964	http://dx.doi.org/10.1038/sj.onc.1206964			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647464	Bronze			2022-12-28	WOS:000186844900007
J	Denkert, C; Furstenberg, A; Daniel, PT; Koch, I; Kobel, M; Weichert, W; Siegert, A; Hauptmann, S				Denkert, C; Furstenberg, A; Daniel, PT; Koch, I; Kobel, M; Weichert, W; Siegert, A; Hauptmann, S			Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference	ONCOGENE			English	Article						cyclooxygenase; ovarian carcinoma; NS-398; RNA interference	COLON-CANCER CELLS; CULTURED-MAMMALIAN-CELLS; CYCLOOXYGENASE-2 EXPRESSION; CHEMOTHERAPY RESISTANCE; PROGNOSTIC-SIGNIFICANCE; GROWTH-INHIBITION; BREAST-CANCER; UP-REGULATION; COX-2; APOPTOSIS	Cyclooxygenases, particularly COX-2, play an important role in tumor development and progression. We have previously shown that COX-2 expression is an independent prognostic factor in human ovarian carcinoma. In this study, we investigated the effects of the inhibition of COX isoforms by the NSAID NS-398 as well as by COX-isoform-specific RNA interference (RNAi) in the human ovarian carcinoma cell lines OVCAR-3 and SKOV-3. OVCAR-3 cells showed a constitutive expression of COX-1 and an induction of high levels of COX-2 and PGE(2) after stimulation with interleukin-1beta. In contrast, SKOV-3 cells were negative for both COX isoforms. In OVCAR-3 cells, PGE(2) production was inhibited by NS-398 in concentrations of 1 muM and by a COX-2-specific silencing RNA ( siRNA), while a COX-1-specific siRNA did not have an effect. This suggests that COX-2 is the major source of PGE(2) in this cell line. To dissociate COX-2-specific and non-COX-2-specific effects on cell proliferation, a proliferation assay was performed after incubation of cells with NS-398 and COX siRNAs. NS-398 induced an inhibition of cell proliferation at concentrations of 50-500 muM, which are above the concentrations needed for the inhibition of PGE(2) production. This inhibitory effect was present in the COX-positive cell line OVCAR-3 as well as in the COX-negative cell line SKOV-3 and could not be reverted by addition of exogenous PGE(2). Neither COX-1- nor COX-2-specific siRNAs had an effect on cell proliferation of OVCAR-3 cells. Cell cycle analysis showed an increased accumulation of cells in the G0/G1 phase after treatment with NS-398, but not with COX siRNAs. These experiments suggest that NS-398 reduced cell proliferation in ovarian carcinoma cells by induction of G0/G1 cell cycle arrest independent of COX-2 inhibition. Our study shows that specific inhibition of COX isoforms by RNAi could be used to dissociate effects of NSAIDs. Furthermore, our results suggest that cell cycle arrest is one of the primary mechanisms responsible for the antiproliferative effects of NS-398 on ovarian carcinoma cells.	Humboldt Univ, Charite Hosp, Inst Pathol, D-10117 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Univ Halle Wittenberg, Inst Pathol, Halle Saale, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Martin Luther University Halle Wittenberg	Denkert, C (corresponding author), Humboldt Univ, Charite Hosp, Inst Pathol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.		Köbel, Martin/A-7373-2011; Denkert, Carsten/AHE-2675-2022	Denkert, Carsten/0000-0002-2249-0982; Kobel, Martin/0000-0002-6615-2037				Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Denkert C, 2002, AM J PATHOL, V160, P893, DOI 10.1016/S0002-9440(10)64912-7; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Ferrandina G, 2002, J CLIN ONCOL, V20, P973, DOI 10.1200/JCO.20.4.973; Ferrandina G, 2002, ANN ONCOL, V13, P1205, DOI 10.1093/annonc/mdf207; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fogh J., 1975, HUMAN TUMOR CELLS IN, P115, DOI 10.1007/978-1-4757-1647-4_5; Goldberg Y, 1996, ONCOGENE, V12, P893; HAMILTON TC, 1983, CANCER RES, V43, P5379; Harborth J, 2001, J CELL SCI, V114, P4557; Huang M, 1998, CANCER RES, V58, P1208; Hung WC, 2000, MOL PHARMACOL, V58, P1398, DOI 10.1124/mol.58.6.1398; Khuder SA, 2001, BRIT J CANCER, V84, P1188, DOI 10.1054/bjoc.2000.1709; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ristimaki A, 2002, CANCER RES, V62, P632; Rodriguez-Burford C, 2002, CLIN CANCER RES, V8, P202; Shono T, 2001, CANCER RES, V61, P4375; THOMPSON HJ, 1995, J NATL CANCER I, V87, P1259; THUN MJ, 1994, CANCER METAST REV, V13, P269, DOI 10.1007/BF00666097; Toyoshima T, 2002, BRIT J CANCER, V86, P1150, DOI 10.1038/sj/bcj/6600183; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Yip-Schneider MT, 2001, J PHARMACOL EXP THER, V298, P976; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C	31	85	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8653	8661		10.1038/sj.onc.1206920	http://dx.doi.org/10.1038/sj.onc.1206920			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647459				2022-12-28	WOS:000186844900002
J	Fassl, S; Leisser, C; Huettenbrenner, S; Maier, S; Rosenberger, G; Strasser, S; Grusch, M; Fuhrmann, G; Leuhuber, K; Polgar, D; Stani, J; Tichy, B; Nowotny, C; Krupitza, G				Fassl, S; Leisser, C; Huettenbrenner, S; Maier, S; Rosenberger, G; Strasser, S; Grusch, M; Fuhrmann, G; Leuhuber, K; Polgar, D; Stani, J; Tichy, B; Nowotny, C; Krupitza, G			Transferrin ensures survival of ovarian carcinoma cells when apoptosis is induced by TNF alpha, FasL, TRAIL, or Myc	ONCOGENE			English	Article						transferrin; apoptosis; TNF alpha; myc; survival; ovarian cancer	TUMOR-NECROSIS-FACTOR; PYRIDOXAL ISONICOTINOYL HYDRAZONE; FERRITIN HEAVY-CHAIN; C-MYC; HEMATOPOIETIC-CELLS; H-FERRITIN; RIBONUCLEOTIDE REDUCTASE; BENZAMIDE RIBOSIDE; GENE-EXPRESSION; GROWTH-FACTOR	The activation of Myc induces apoptosis of human ovarian adenocarcinoma N.1 cells when serum factors are limited. However, the downstream mechanism that is triggered by Myc is unknown. Myc-activation and treatment with the proapoptotic ligands TNFalpha, FasL, and TRAIL induced H-ferritin expression under serum-deprived conditions. H-ferritin chelates intracellular iron and also intracellular iron sequestration by deferoxamine-induced apoptosis of N.1 cells. Supplementation of serum-free medium with holo-transferrin blocked apoptosis of N.1 cells that was induced by Myc-activation or by treatment with TNFalpha, FasL, and TRAIL, whereas apotransferrin did not prevent apoptosis. This suggests that intracellular iron depletion was a trigger for apoptosis and that transferrin-bound iron rescued N.1 cells. Furthermore, apoptosis of primary human ovarian carcinoma cells, which was induced by TNFalpha, FasL, and TRAIL, was also inhibited by holotransferrin. The data suggest that Myc-activation, FasL, TNFalpha, and TRAIL disturbed cellular iron homeostasis, which triggered apoptosis of ovarian carcinoma cells and that transferrin iron ensured survival by re-establishing this homeostasis.	Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria; Univ Vienna, Inst Zool, A-1090 Vienna, Austria; Univ Vienna, Dept Obstet & Gynaecol, A-1090 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna	Krupitza, G (corresponding author), Univ Vienna, Inst Clin Pathol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Grusch, Michael/C-1183-2008	Grusch, Michael/0000-0001-5486-9340; Krupitza, Georg/0000-0003-2949-7906				Alcantara O, 2001, EXP HEMATOL, V29, P1060, DOI 10.1016/S0301-472X(01)00683-X; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baik MG, 1998, INT J MOL MED, V2, P39; BARNES D, 1979, NATURE, V281, P388, DOI 10.1038/281388a0; Buss JL, 2003, BIOCHEM PHARMACOL, V65, P161, DOI 10.1016/S0006-2952(02)01512-5; Davidson MG, 1998, EXP EYE RES, V66, P207, DOI 10.1006/exer.1997.0413; Desole MS, 1998, NEUROSCI LETT, V247, P1, DOI 10.1016/S0304-3940(98)00260-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ferreira C, 2001, BLOOD, V98, P525, DOI 10.1182/blood.V98.3.525; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; Grusch M, 1999, CELL DEATH DIFFER, V6, P736, DOI 10.1038/sj.cdd.4400546; Grusch M, 2002, CELL DEATH DIFFER, V9, P169, DOI 10.1038/sj.cdd.4400937; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Honda KI, 2001, INT J MOL MED, V8, P135; Hua WH, 1995, J STEROID BIOCHEM, V55, P279, DOI 10.1016/0960-0760(95)00187-5; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawabata H, 2001, BLOOD, V98, P1949, DOI 10.1182/blood.V98.6.1949; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kovar J, 1997, PATHOBIOLOGY, V65, P61, DOI 10.1159/000164105; Kovar J, 2001, IN VITRO CELL DEV-AN, V37, P450; Krupitza G, 1998, CELL DEATH DIFFER, V5, P758, DOI 10.1038/sj.cdd.4400417; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; Kyriakou D, 1998, EUR J HAEMATOL, V60, P21; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Leardi A, 1998, BRIT J HAEMATOL, V102, P746, DOI 10.1046/j.1365-2141.1998.00834.x; Lesnikov V, 2001, EXP HEMATOL, V29, P477, DOI 10.1016/S0301-472X(00)00687-1; Leung Y. M., 1993, Biological Signals, V2, P117; Lin FB, 1998, ARCH BIOCHEM BIOPHYS, V352, P51, DOI 10.1006/abbi.1998.0588; Lok CN, 1998, BIOL SIGNAL RECEPT, V7, P157; Maclean K, 2001, J CELL BIOCHEM, V82, P171, DOI 10.1002/jcb.1111; MILLER LL, 1991, P NATL ACAD SCI USA, V88, P4946, DOI 10.1073/pnas.88.11.4946; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NAYLOR MS, 1993, J CLIN INVEST, V91, P2194, DOI 10.1172/JCI116446; Pang JHS, 1996, J CLIN INVEST, V97, P2204, DOI 10.1172/JCI118661; Quirk SM, 2000, BIOL REPROD, V63, P49, DOI 10.1095/biolreprod63.1.49; Richardson DR, 1997, BLOOD, V89, P3025, DOI 10.1182/blood.V89.8.3025; Rollet-Labelle E, 1998, FREE RADICAL BIO MED, V24, P563, DOI 10.1016/S0891-5849(97)00292-X; Rosenberger G, 2000, LIFE SCI, V67, P3131, DOI 10.1016/S0024-3205(00)00901-2; ROUAULT TA, 1987, P NATL ACAD SCI USA, V84, P6335, DOI 10.1073/pnas.84.18.6335; SALMERON A, 1995, J IMMUNOL, V154, P1675; Shi YF, 1997, J IMMUNOL, V159, P5318; Simonitsch I, 1998, BRIT J CANCER, V78, P862, DOI 10.1038/bjc.1998.594; SLOTMAN BJ, 1988, ANTICANCER RES, V8, P417; Sunstrom NAS, 2000, BIOTECHNOL PROGR, V16, P698, DOI 10.1021/bp000102t; Szekeres T, 1997, CRIT REV CL LAB SCI, V34, P503, DOI 10.3109/10408369709006424; Tanaka T, 1997, BBA-MOL CELL RES, V1357, P91, DOI 10.1016/S0167-4889(97)00016-5; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; TSUJI Y, 1991, J BIOL CHEM, V266, P7257; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; WU S, 1992, AM J OBSTET GYNECOL, V166, P997, DOI 10.1016/0002-9378(92)91379-O; WU S, 1993, CANCER RES, V53, P1939; Yuan XM, 1999, FREE RADICAL RES, V30, P221, DOI 10.1080/10715769900300241	56	28	31	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8343	8355		10.1038/sj.onc.1207047	http://dx.doi.org/10.1038/sj.onc.1207047			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614458				2022-12-28	WOS:000186541500013
J	Zhou, MX; Gu, LB; Zhu, NX; Woods, WG; Findley, HW				Zhou, MX; Gu, LB; Zhu, NX; Woods, WG; Findley, HW			Transfection of a dominant-negative mutant NF-kappa B inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53	ONCOGENE			English	Article						IkB; p53; apoptosis; leukemia	CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; CANCER-CELLS; ALPHA; DEGRADATION; EXPRESSION; RESISTANCE; LYMPHOMA; GROWTH; PROLIFERATION	To investigate the possible role of inhibiting NF-kB activation in sensitizing tumor cells to chemotherapy-induced apoptosis, we transfected the dominant-negative mutant inhibitor of NF-kB (IkBm) into the EU-1 cell line, an acute lymphoblastic leukemia (ALL) line with constitutive NF-kB activation. Overexpression of IkBm significantly reduced constitutive NF-kB activity in EU-1 cells, resulting in decreased cell growth. In response to apoptosis induced by chemotherapeutic drugs, IkBm-transfected cells (EU-1/IkBm) exhibited increased sensitivity to vincristine (VCR), whereas sensitivity to doxorubicin (Dox) was not changed as compared to neo-transfected control (EU-1/neo) cells. To further evaluate the link between IkBm and sensitivity to Dox and VCR, we demonstrated that both endogenous IkBalpha and ectopic IkBm bind to p53. In response to Dox, the cytosolic p53. IkBalpha complex rapidly dissociated due to downregulation of IkBalpha. However, the p53. IkBm complex did not dissociate under these conditions. Although treatment of EU-1/IkBm cells with Dox increased the expression of p53, the nondissociating p53. IkBm complex resulted in decreased p53 function, as demonstrated by absence of cell-cycle arrest and induction of p53 target genes. Contrastingly, VCR-induced cell death neither down-regulated IkBalpha nor induced p53, as shown by the lack of NF-kB activation and p53-mediated gene expression in VCR-treated cells. Our data suggest that IkBm simultaneously downregulates NF-kB activation and sequesters p53 in the cytoplasm, thus enhancing NF-kB-regulated apoptosis but blocking p53-dependent apoptosis.	Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, Atlanta, GA 30322 USA	Emory University	Zhou, MX (corresponding author), Emory Univ, Sch Med, Div Pediat Hematol Oncol BMT, Dept Pediat, 2040 Ridgewood Dr NE, Atlanta, GA 30322 USA.	mzhou@emory.edu			NATIONAL CANCER INSTITUTE [R01CA082323] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA82323] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Bentires-Alj M, 1999, CANCER RES, V59, P811; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Conway RM, 1998, EUR J CANCER, V34, P1741, DOI 10.1016/S0959-8049(98)00234-2; Doerre S, 1999, J IMMUNOL, V163, P269; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Findley HW, 1997, BLOOD, V89, P2986, DOI 10.1182/blood.V89.8.2986; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Groninger E, 2000, BRIT J HAEMATOL, V111, P875, DOI 10.1046/j.1365-2141.2000.02420.x; Gugasyan R, 2000, IMMUNOL REV, V176, P134; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; JORDAN MA, 1991, CANCER RES, V51, P2212; Kawai H, 1999, CANCER RES, V59, P6038; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Lorenzo E, 2002, J BIOL CHEM, V277, P10883, DOI 10.1074/jbc.M107442200; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Orlowski RZ, 1998, CANCER RES, V58, P4342; Post A, 1998, J NEUROSCI, V18, P8236; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Schauer SL, 1998, J IMMUNOL, V160, P4398; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VAN AD, 1996, SCIENCE, V274, P787; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WU HY, 1994, J BIOL CHEM, V269, P20067; ZHOU MX, 1994, LEUKEMIA, V8, P659	45	49	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8137	8144		10.1038/sj.onc.1206911	http://dx.doi.org/10.1038/sj.onc.1206911			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603254				2022-12-28	WOS:000186403400008
J	DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, SJ; Freeman, JW				DeArmond, D; Brattain, MG; Jessup, JM; Kreisberg, J; Malik, S; Zhao, SJ; Freeman, JW			Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines	ONCOGENE			English	Article						growth factors; ErbB-2; cell signaling; pancreatic cancer	CYCLIN D1; FACTOR-ALPHA; CONSTITUTIVE ACTIVATION; BREAST-CANCER; SIGNAL TRANSDUCERS; TYROSINE KINASES; CDK INHIBITORS; ABERRANT REGULATION; DEPENDENT KINASE; FACTOR RECEPTORS	Pancreatic ductal adenocarcinoma (PDAC) cell lines, MIA PaCa-2, and UK Pan-1, were used to investigate the role of ErbB2 in PDAC oncogenesis. Both these cell lines exhibit exogenous growth factor-independent proliferation that was attributed to the production of autocrine growth factors and/or overexpression of growth factor receptors. The exogenous growth factor-independent phenotype displayed by these PDAC cell lines was dependent on ErbB2 kinase activity since treatment of cells with tyrphostin AG879 prevented serum-free media (SFM) induction of cell proliferation. We determined that ErbB2 kinase contributed to aberrant cell cycle regulation in PDAC through the induction of cyclin D1 levels and the suppression of p21(Cip1) and p27(Kip1). Inhibition of ErbB2 kinase led to cell cycle arrest marked by an increased association of p27(Kip1) with cdk2 and reduced levels of phosphorylated pRb. We further observed constitutive STAT3 activation in the PDAC cell lines and an increase in STAT3 activation upon stimulating quiescent cells with SFM. Inhibitors of ErbB2 kinase blocked STAT3 activation, whereas inhibition of EGFR kinase led to a slight reduction of STAT3 activation. STAT3 was coimmunoprecipitated with ErbB2. SFM stimulation caused an increase in the association of ErbB2 and STAT3, which was blocked by inhibition of ErbB2 kinase. Expression of a STAT3 dominant negative prevented SFM-stimulated cell proliferation of MIA PaCa-2 cells, suggesting that activation of STAT3 by ErbB2 is required for a growth factor-independent phenotype of these cells. Consistent with this observation in PDAC cell lines, we found that most PDAC tumor specimens ( 10 of 11) showed constitutive activation of STAT3 and that ErbB2 was readily detected in most of these tumors ( nine of 11). We believe that these findings indicate a novel mechanism of oncogenesis in PDAC and may suggest future therapeutic strategies in the treatment of PDAC.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Surg, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Adm Med Ctr, Res & Dev, San Antonio, TX 78229 USA; Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Georgetown Univ, Med Ctr, Dept Surg, Washington, DC 20007 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Roswell Park Cancer Institute; Georgetown University	Freeman, JW (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Med Oncol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NCI NIH HHS [R01 CA69122, P30 CA 54174] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069122, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALLRED DC, 1992, HUM PATHOL, V23, P974, DOI 10.1016/0046-8177(92)90257-4; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bartkova J, 1997, Prog Cell Cycle Res, V3, P211; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brennan PJ, 2000, ONCOGENE, V19, P6093, DOI 10.1038/sj.onc.1203967; Burke WM, 2001, ONCOGENE, V20, P7925, DOI 10.1038/sj.onc.1204990; Busse D, 2000, SEMIN ONCOL, V27, P3, DOI 10.1053/sonc.2000.19891; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Dugan MC, 1997, PANCREAS, V14, P229, DOI 10.1097/00006676-199704000-00003; Fernandes A, 1999, INT J CANCER, V83, P564, DOI 10.1002/(SICI)1097-0215(19991112)83:4<564::AID-IJC20>3.0.CO;2-Q; Fralix KD, 2000, CANCER, V88, P2010, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2010::AID-CNCR5>3.0.CO;2-5; FREEMAN JW, 1995, J CELL PHYSIOL, V165, P155, DOI 10.1002/jcp.1041650118; Friess H, 1999, ANN SURG, V230, P767, DOI 10.1097/00000658-199912000-00005; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Gartel AL, 2000, ONCOGENE, V19, P961, DOI 10.1038/sj.onc.1203411; Gjoerup O, 1998, J BIOL CHEM, V273, P18812, DOI 10.1074/jbc.273.30.18812; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; HALL PA, 1990, J PATHOL, V161, P195, DOI 10.1002/path.1711610305; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JASKIEWICZ K, 1994, ANTICANCER RES, V14, P1919; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Klapper LN, 2000, ADV CANCER RES, V77, P25; KLOPPEL G, 1985, HISTOPATHOLOGY, V9, P841, DOI 10.1111/j.1365-2559.1985.tb02870.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Mack L, 1997, HUM PATHOL, V28, P974, DOI 10.1016/S0046-8177(97)90014-9; Masuda M, 2002, CANCER RES, V62, P3351; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; SATOH K, 1993, CANCER, V72, P51, DOI 10.1002/1097-0142(19930701)72:1<51::AID-CNCR2820720112>3.0.CO;2-O; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; SOMERVILLE JE, 1992, J CLIN PATHOL, V45, P16, DOI 10.1136/jcp.45.1.16; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Worsley SD, 1997, GYNECOL ONCOL, V64, P189, DOI 10.1006/gyno.1996.4569; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMANAKA Y, 1993, HUM PATHOL, V24, P1127, DOI 10.1016/0046-8177(93)90194-L; Yeh TC, 1999, CELL MOL LIFE SCI, V55, P1523, DOI 10.1007/s000180050392; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	70	50	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7781	7795		10.1038/sj.onc.1206966	http://dx.doi.org/10.1038/sj.onc.1206966			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586404				2022-12-28	WOS:000186240200008
J	Fixemer, T; Wissenbach, U; Flockerzi, V; Bonkhoff, H				Fixemer, T; Wissenbach, U; Flockerzi, V; Bonkhoff, H			Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression	ONCOGENE			English	Article						prostate cancer; TRPV6; in situ hybridization; prognostic marker; TRP cation channel	CALCIUM-CHANNEL; GLEASON SCORE; PREDICT; BIOPSY; ANTIGEN; STAGE	Members of the TRP superfamily of cation channels have homeostatic and regulatory functions in cells and changes in their expression may contribute to malignant growth. Previously, we have demonstrated that the gene of the Ca2+-selective cation channel CaT-L or TRPV6 is not expressed in benign prostate tissues including benign prostate hyperplasia, but is upregulated in prostate cancer. Here, we report on the differential expression of TRPV6 mRNA in prostate tissue obtained from 140 patients with prostate cancer. Using in situ hybridization, TRPV6 transcripts were undetectable in benign prostate tissue, high-grade prostatic intraepithelial neoplasia (n = 57), incidental adenocarcinoma and all tumors less than 2.3 cubic centimeter (cc). In prostatectomy specimens from 97 clinically organ-confined tumors, TRPV6 expression correlated significantly with the Gleason score (P = 0.032), pathological stage (P<0.001) and extraprostatic extension (P = 0.025). Lymph node metastasis (n = 17) and androgen-insensitive tumors (n = 27) revealed TRPV6 expression in 63 and 67% of cases, respectively. The latter, however, revealed markedly and significantly decreased levels when compared with untreated tumors (P = 0.044). In summary, the data demonstrate that TRPV6 expression is associated with prostate cancer progression. Accordingly, TRPV6 represents a prognostic marker and, as a plasma membrane Ca2+ channel, a promising target for new therapeutic strategies to treat advanced prostate cancer.	Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany; Univ Saarland, Inst Allgemeine & Spezielle Pathol, D-66421 Homburg, Germany	Saarland University; Saarland University	Flockerzi, V (corresponding author), Univ Saarland, Inst Expt & Klin Pharmakol & Toxikol, D-66421 Homburg, Germany.							Bonkhoff H, 1999, AM J PATHOL, V155, P641, DOI 10.1016/S0002-9440(10)65160-7; CUPP MR, 1995, J UROLOGY, V153, P1543, DOI 10.1016/S0022-5347(01)67458-5; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Mariot P, 2002, J BIOL CHEM, V277, P10824, DOI 10.1074/jbc.M108754200; NARAYAN P, 1995, UROLOGY, V46, P205, DOI 10.1016/S0090-4295(99)80195-2; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Steinberg DM, 1997, AM J SURG PATHOL, V21, P566, DOI 10.1097/00000478-199705000-00010; Toyota M, 1999, CANCER RES, V59, P4535; Wills ML, 1998, UROLOGY, V51, P759, DOI 10.1016/S0090-4295(98)00011-9; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200	12	177	192	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7858	7861		10.1038/sj.onc.1206895	http://dx.doi.org/10.1038/sj.onc.1206895			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586412				2022-12-28	WOS:000186240200016
J	Levy-Nissenbaum, O; Sagi-Assif, O; Kapon, D; Hantisteanu, S; Burg, T; Raanani, P; Avigdor, A; Ben-Bassat, I; Witz, IP				Levy-Nissenbaum, O; Sagi-Assif, O; Kapon, D; Hantisteanu, S; Burg, T; Raanani, P; Avigdor, A; Ben-Bassat, I; Witz, IP			Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells	ONCOGENE			English	Article						Pyst2; leukemia; dual-specificity phosphatases; DNA microarray; cell activation; differentiation	MAP KINASE PHOSPHATASE; SIGNAL-TRANSDUCTION; IN-VIVO; CYCLE REGULATION; FX ENZYME; PROTEIN; DIFFERENTIATION; LINES; CDC25; GENE	Northern blotting confirmed previous results indicating that the mitogen-activated protein kinase ( MAPK) phosphatase Pyst2-L was highly expressed in leukocytes obtained from acute myeloid leukemia (AML) patients. High levels of Pyst2-L mRNA were expressed in bone marrow ( BM) and peripheral leukocytes from nine AML and acute lymphoblastic leukemia ( ALL) patients. BM from healthy individuals expressed very low levels of Pyst2-L. Whereas high levels of Pyst2-L mRNA and protein were detected in several leukemia cell lines, Pyst2-L mRNA was detected neither in 33/34 samples of normal peripheral blood mononuclear cells (PBMC) nor in leukocyte fractions enriched with CD34(+) cells. Certain solid tumor and lymphoblastoid cell lines expressed high levels of Pyst2-L mRNA. In view of the association of Pyst2-L to MAPK signaling cascades, we tested if cell activation, a process involving MAPK signaling, influences Pyst2-L expression. Indeed, activation of T cells and endothelial cells increased Pyst2-L in these cells. Furthermore, TPA, a known MAPK activator, induces the expression of both Pyst2-L mRNA as well as the Pyst2-L protein in leukemia cells. This induction was partially inhibited by PD098059, an Mek1/2-specific inhibitor. Based on the results of this and previous studies, we hypothesize that the high levels of Pyst2-L detected in the active state of AML and ALL diseases and in other types of cancer reflect an altered MAPK signaling pathway in such malignant processes. This alteration may be the result of a failed attempt to counter the constitutive activation of MAPK in transformed cells or alternatively, may represent the activated state of such cells.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Ela Kodesz Inst Res Canc Dev & Prevent, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Inst Hematol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Witz, IP (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel.	ipwitz@post.tau.ac.il						ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; Andersen JN, 2001, BIOCHEM J, V354, P581, DOI 10.1042/0264-6021:3540581; Babcock GJ, 2000, IMMUNITY, V13, P497, DOI 10.1016/S1074-7613(00)00049-2; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Beghini A, 2000, HUM MOL GENET, V9, P2297, DOI 10.1093/oxfordjournals.hmg.a018921; Berndt N., 1999, FRONT BIOSCI, V4, pD22, DOI DOI 10.2741/BERNDT;PMID:9872729; Biethahn S, 1999, EXP HEMATOL, V27, P885, DOI 10.1016/S0301-472X(99)00017-X; CHORVATH B, 1983, NEOPLASMA, V30, P273; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dickinson RJ, 2002, BIOCHEM J, V364, P145, DOI 10.1042/bj3640145; Dowd S, 1998, J CELL SCI, V111, P3389; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eckstein JW, 2000, INVEST NEW DRUG, V18, P149, DOI 10.1023/A:1006377913494; Eshel R, 2001, CELL IMMUNOL, V213, P141, DOI 10.1006/cimm.2001.1872; Eshel R, 2000, J BIOL CHEM, V275, P12833, DOI 10.1074/jbc.275.17.12833; Frearson JA, 1996, IMMUNOL TODAY, V17, P385, DOI 10.1016/0167-5699(96)10026-8; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Geller RB, 1997, LEUKEMIA RES, V21, P387, DOI 10.1016/S0145-2126(96)00107-5; Gopalakrishna R, 1999, CANCER LETT, V136, P143, DOI 10.1016/S0304-3835(98)00315-2; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; Hantisteanu S, 2002, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON TUMOR MICROENVIRONMENT PROGRESSION, THERAPY & PREVENTION, P95; HASS R, 1989, EUR J CELL BIOL, V48, P282; He HC, 1999, CELL GROWTH DIFFER, V10, P307; Hernandez S, 1998, CANCER RES, V58, P1762; Horn S, 2001, LEUKEMIA, V15, P112, DOI 10.1038/sj.leu.2401990; Hwang PH, 2001, CANCER LETT, V172, P83, DOI 10.1016/S0304-3835(01)00632-2; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Johnson TR, 2000, J BIOL CHEM, V275, P31755, DOI 10.1074/jbc.M004182200; KEYSE SM, 1993, TRENDS BIOCHEM SCI, V18, P377, DOI 10.1016/0968-0004(93)90092-2; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KOEFFLER HP, 1981, CANCER RES, V41, P919; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Levy-Nissenbaum O, 2002, PROCEEDINGS OF THE 2ND INTERNATIONAL CONFERENCE ON TUMOR MICROENVIRONMENT PROGRESSION, THERAPY & PREVENTION, P11; LEVYNISSENBAUM O, 2003, IN PRESS METHODS ENZ; LEVYNISSENBAUM O, 2003, IN PRESS CANC LETT; LEVYNISSENBAUM O, 2003, UNPUB GENES CHROMOSO; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; Mercurius KO, 2001, BMC CELL BIOL, V2, part. no., DOI 10.1186/1471-2121-2-18; Molla A, 2000, CELL GROWTH DIFFER, V11, P83; Moore S, 2000, LEUKEMIA LYMPHOMA, V38, P211, DOI 10.3109/10428190009087013; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Ofek P, 2003, J BIOL CHEM, V278, P14299, DOI 10.1074/jbc.M211699200; Parsons Ramon, 1998, Current Opinion in Oncology, V10, P88, DOI 10.1097/00001622-199801000-00014; Pestell KE, 2000, ONCOGENE, V19, P6607, DOI 10.1038/sj.onc.1204084; Poetsch M, 2001, CANCER GENET CYTOGEN, V125, P21, DOI 10.1016/S0165-4608(00)00353-8; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; Sambrook J, 1989, MOL CLONING; Sano K, 2000, BLOOD, V95, P1066, DOI 10.1182/blood.V95.3.1066.003k11_1066_1068; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Sebolt-Leopold JS, 2000, ONCOGENE, V19, P6594, DOI 10.1038/sj.onc.1204083; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shi G, 1996, CYTOGENET CELL GENET, V74, P295, DOI 10.1159/000134439; Shin DY, 1997, ONCOGENE, V14, P2633, DOI 10.1038/sj.onc.1201106; STEINITZ M, 1977, NATURE, V269, P420, DOI 10.1038/269420a0; Tanuma N, 2000, J BIOL CHEM, V275, P28216; Theodosiou A, 2002, GENOME BIOL, V3; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; WEINSTEIN R, 1989, BLOOD, V73, P111; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wu WG, 1998, CANCER RES, V58, P4082; Yamamoto M, 1999, LEUKEMIA, V13, P595, DOI 10.1038/sj.leu.2401372	65	26	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7649	7660		10.1038/sj.onc.1206971	http://dx.doi.org/10.1038/sj.onc.1206971			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576828				2022-12-28	WOS:000186113000013
J	El-Deiry, WS				El-Deiry, WS			The role of p53 in chemosensitivity and radiosensitivity	ONCOGENE			English	Review						p53; apoptosis; cancer; chemotherapy; tissue specificity; CP-31398; prima1; MDM2; p73; Parc; Pirh2; HAUSP; ASPP1; BRCA1; PAC1; p300; ONYX-015; toxicity; stability; transcription	WILD-TYPE P53; IN-VIVO; TUMOR-SUPPRESSOR; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL REPRESSION; ANTICANCER DRUG; CANCER-THERAPY; MUTANT P53; P53-INDUCED APOPTOSIS	The role of p53 as a central mediator of the DNA damage and other cellular stress responses is well established. The ultimate growth-suppressive function of p53 in part explains its ability to confer chemosensitivity and radiosensitivity upon tumor cells. Recent work in the field has added complexity to our understanding, in terms of identifying novel regulators of p53 stability and function, elucidation of the importance of the p53 family towards p53 function, a growing list of transcriptional targets as well as transcription-independent apoptotic effects and mechanisms, tissue specificity of the p53 response, a molecular understanding of p53-dependent therapeutic sensitization, and efforts towards molecular targeting of the p53 pathway. p53 remains an attractive target for drug development in cancer because its alteration provides a fundamental difference between normal and cancer cells. Strategies are emerging for the identification of mutant p53-specific therapies, therapies targeted at mutant p53-expressing tumors, as well as therapies that target various aspects of the p53 life cycle to enhance chemosensitization. The tools of molecular imaging are beginning to accelerate the pace of discovery and preclinical testing of p53 in animal models. The future holds promise for specific, individualized targeting of mutant or wild-type p53, or its transcriptional targets, in combination therapies with other cancer-specific drugs, to maximize tumor cell killing while protecting normal cells from toxic side effects.	Univ Penn, Sch Med, Dept Med Hematol Oncol Genet Pharmacol, Abramson Comprehens Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med Hematol Oncol Genet Pharmacol, Abramson Comprehens Canc Ctr, 415 Curie Blvd,CRB 437A, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Amundson SA, 2002, CANCER BIOL THER, V1, P145, DOI 10.4161/cbt.59; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Blagosklonny MV, 1996, INT J CANCER, V67, P386, DOI 10.1002/(SICI)1097-0215(19960729)67:3<386::AID-IJC13>3.0.CO;2-6; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Bottger V, 1996, ONCOGENE, V13, P2141; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; Burns Timothy F, 2003, Cancer Treat Res, V115, P319; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Deb SP, 2002, FRONT BIOSCI, V7, pD235, DOI 10.2741/deb; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doubrovin M, 2001, P NATL ACAD SCI USA, V98, P9300, DOI 10.1073/pnas.161091198; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; El-Deiry WS, 2002, CANCER BIOL THER, V1, P490, DOI 10.4161/cbt.1.5.162; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fei PW, 2002, CANCER RES, V62, P7316; Finch RA, 2002, CANCER RES, V62, P3221; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hamid O, 2003, J CLIN ONCOL, V21, P1498, DOI 10.1200/JCO.2003.09.114; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Herbert BS, 2003, CANCER RES, V63, P1914; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kastan MB, 2003, CELL, V112, P1, DOI 10.1016/S0092-8674(02)01281-3; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2003, J BIOL CHEM, V278, P15465, DOI 10.1074/jbc.C300011200; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Laxman B, 2002, P NATL ACAD SCI USA, V99, P16551, DOI 10.1073/pnas.252644499; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Manfredi JJ, 2003, MOL CELL, V11, P552, DOI 10.1016/S1097-2765(03)00106-0; Massoud TF, 2003, GENE DEV, V17, P545, DOI 10.1101/gad.1047403; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Nishizaki M, 2001, CLIN CANCER RES, V7, P2887; OConnor PM, 1997, CANCER RES, V57, P4285; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Peng YH, 2003, ONCOGENE, V22, P4478, DOI 10.1038/sj.onc.1206777; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Slee EA, 2003, TOXICOL LETT, V139, P81, DOI 10.1016/S0378-4274(02)00421-6; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Soussi T, 2003, CANCER CELL, V3, P303, DOI 10.1016/S1535-6108(03)00081-3; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Takimoto R, 2002, CANCER BIOL THER, V1, P177, DOI 10.4161/cbt.65; Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Velculescu VE, 1996, CLIN CHEM, V42, P858; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wang WG, 2003, CANCER BIOL THER, V2, P196, DOI 10.4161/cbt.2.2.347; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Wu GS, 1996, CLIN CANCER RES, V2, P623; Yin YX, 2003, NATURE, V422, P527, DOI 10.1038/nature01519; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	104	279	289	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7486	7495		10.1038/sj.onc.1206949	http://dx.doi.org/10.1038/sj.onc.1206949			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576853				2022-12-28	WOS:000186112500018
J	Gupta, S; Hastak, K; Afaq, F; Ahmad, N; Mukhtar, H				Gupta, S; Hastak, K; Afaq, F; Ahmad, N; Mukhtar, H			Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappaB and induction of apoptosis	ONCOGENE			English	Article						green tea; epigallocatechin-3-gallate; caspases; apoptosis; nuclear factor-kappa B	TEA CONSTITUENT (-)-EPIGALLOCATECHIN-3-GALLATE; PROSTATE CARCINOMA-CELLS; EPIGALLOCATECHIN GALLATE; CANCER-THERAPY; CYCLE ARREST; DEATH; PROTEASE; GROWTH; PATHWAYS; ACTIVATION	Green tea constituent (-) epigallocatechin-3-gallate (EGCG) has shown remarkable cancer-preventive and some cancer-therapeutic effects. This is partially because of its ability to induce apoptosis in cancer cells without affecting normal cells. Previous studies from our laboratory have shown the involvement of NF-kappaB pathway in EGCG-mediated cell-cycle deregulation and apoptosis of human epidermoid carcinoma A431 cells. Here we show the essential role of caspases in EGCG-mediated inhibition of NF-kappaB and its subsequent apoptosis. Treatment of A431 cells with EGCG (10-40 mug/ml) resulted in dose-dependent inhibition of NF-kappaB/p65, induction of DNA breaks, cleavage of poly(ADP-ribose) polymerase (PARP) and morphological changes consistent with apoptosis. EGCG treatment of cells also resulted in significant activation of caspases, as shown by the dose- and time-dependent increase in DEVDase activity, and protein expression of caspase-3, -8 and -9. EGCG-mediated caspase activation induces proteolytic cleavage of NF-kappaB/p65 subunit, leading to the loss of transactivation domains, and driving the cells towards apoptosis. EGCG-mediated induction of apoptosis was significantly blocked by the caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp(OMe)-fluoromethylketone (Z-VAD-FMK), and moderately blocked by the specific caspase-3 inhibitor Z-DEVD-FMK. Further, pretreatment of cells with Z-VAD-FMK was found to suppress the cleavage of NF-kappaB/p65 subunit, thereby increasing nuclear translocation, DNA binding and transcriptional activity, thus protecting the cells from EGCG-induced apoptosis. Taken together, these studies for the first time demonstrate that EGCG-mediated activation of caspases is critical, at least in part, for inhibition of NF-kappaB and subsequent apoptosis.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA; Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA	University of Wisconsin System; University of Wisconsin Madison; Case Western Reserve University; Case Western Reserve University	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Gupta, Sanjay/0000-0002-9492-3249	NCI NIH HHS [R01 CA 78809] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078809] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2000, BIOCHEM PHARMACOL, V60, P1033, DOI 10.1016/S0006-2952(00)00393-2; Ahmad N, 2000, ARCH BIOCHEM BIOPHYS, V376, P338, DOI 10.1006/abbi.2000.1742; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chung JH, 2003, FASEB J, V17, P1913, DOI 10.1096/fj.02-0914fje; Chung LY, 2001, LIFE SCI, V68, P1207, DOI 10.1016/S0024-3205(00)01020-1; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Clement MV, 1998, BLOOD, V92, P996; Ferreira CG, 2002, CLIN CANCER RES, V8, P2024; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9; Hastak K, 2003, ONCOGENE, V22, P4851, DOI 10.1038/sj.onc.1206708; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; Islam S, 2000, BIOCHEM BIOPH RES CO, V270, P793, DOI 10.1006/bbrc.2000.2536; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kong ANT, 2001, MUTAT RES-FUND MOL M, V480, P231, DOI 10.1016/S0027-5107(01)00182-8; Kuo PL, 2003, J BIOMED SCI, V10, P219, DOI 10.1159/000068711; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Masuda M, 2001, CLIN CANCER RES, V7, P4220; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Ravi R, 1998, CANCER RES, V58, P882; Schwartz SA, 1999, SURG ONCOL, V8, P143, DOI 10.1016/S0960-7404(00)00012-8; Singh AK, 2002, ARCH BIOCHEM BIOPHYS, V401, P29, DOI 10.1016/S0003-9861(02)00013-9; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Yu R, 1998, CANCER RES, V58, P402; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	41	168	182	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2507	2522		10.1038/sj.onc.1207353	http://dx.doi.org/10.1038/sj.onc.1207353			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676829				2022-12-28	WOS:000220558000008
J	Marani, M; Hancock, D; Lopes, R; Tenev, T; Downward, J; Lemoine, NR				Marani, M; Hancock, D; Lopes, R; Tenev, T; Downward, J; Lemoine, NR			Role of Bim in the survival pathway induced by Raf in epithelial cells	ONCOGENE			English	Article						Bim; anoikis; phosphorylation; EGF receptor	GROWTH-FACTOR RECEPTOR; BCL-2 FAMILY; PROTEIN BIM; PROAPOPTOTIC ACTIVITY; DEPENDENT PATHWAY; SIGNALING PATHWAY; BH3-ONLY PROTEIN; KINASE PATHWAY; MOTOR COMPLEX; ACTIVATION	Selective and sustained activation of the Raf/MAP kinase pathway in MCF-10A DeltaRaf-ER cells, a spontaneously immortalized human mammary epithelial cell line, was previously shown to protect these cells from suspension-induced cell death, a critical feature of the Ras-transformed phenotype. Although autocrine signalling through the EGF receptor is crucial for the protection induced by Raf in these cells, we report here the existence of an additional, more direct survival mechanism, linking Raf activation to the inhibition of a proapoptotic member of the Bcl-2 family, Bim. While detachment from the matrix results in transcriptional induction of two variants of this BH3-only protein, BimEL and BimL, activation of the Raf/ERK signalling both prevents Bim upregulation specifically and leads to phosphorylation and degradation of the BimEL isoform. This represents an important route to protect epithelial cells from the proapoptotic effect of Bim.	Hammersmith Hosp, Imperial Coll London, Canc Res UK Mol Oncol Unit, London W12 0NN, England; Canc Res UK London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Inst Canc Res, Chester Beatty Labs, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England	Cancer Research UK; Imperial College London; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Lemoine, NR (corresponding author), Hammersmith Hosp, Imperial Coll London, Canc Res UK Mol Oncol Unit, DuCane Rd, London W12 0NN, England.	nick.lemoine@cancer.org.uk	Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729; Tenev, Tencho/0000-0001-8762-1069				Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BOS JL, 1989, CANCER RES, V49, P4682; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2002, J BIOL CHEM, V277, P27643, DOI 10.1074/jbc.M108863200; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; LEI K, 2003, P NATL ACAD SCI USA, V18, P18; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schulze A, 2001, GENE DEV, V15, P981, DOI 10.1101/gad.191101; Streuli CH, 1999, J MAMMARY GLAND BIOL, V4, P183, DOI 10.1023/A:1018729308878; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261	36	93	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2431	2441		10.1038/sj.onc.1207364	http://dx.doi.org/10.1038/sj.onc.1207364			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676826				2022-12-28	WOS:000220558000001
J	Gerard, A; Favre, C; Garcon, F; Nemorin, JG; Duplay, P; Pastor, S; Collette, Y; Olive, D; Nunes, JA				Gerard, A; Favre, C; Garcon, F; Nemorin, JG; Duplay, P; Pastor, S; Collette, Y; Olive, D; Nunes, JA			Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase	ONCOGENE			English	Article						Dok adaptor proteins; Tec tyrosine kinase; signal transduction; tumor suppressors; T cells	CHRONIC MYELOGENOUS LEUKEMIA; CELL ANTIGEN RECEPTOR; T-CELLS; P62(DOK); FAMILY; PHOSPHORYLATION; RECRUITMENT; ABL	The Dok adaptor family of proteins binding to RasGAP, consisting of Dok-1 and Dok-2, are critical regulators in cell proliferation. These molecules are partners and/or substrates of different protein tyrosine kinases considered as oncoproteins. Here, we show that Dok-1 and Dok-2 are the major tyrosine-phosphorylated proteins associated to Tec, a protein tyrosine kinase expressed in T cells. Furthermore, we evaluate the effect of Dok-1 or Dok-2 on Tec-mediated signalling pathways in T cells. Here, we provide evidence that Dok-1 and Dok-2 proteins are involved in a negative feedback regulation of Tec via a downregulation of its tyrosine phosphorylation and downstream signalling pathways including the Ras pathway. Either Dok-1 or Dok-2 therefore represents a mean of potent retrograde control for protein tyrosine kinase signalling, and then possibly of tumor development.	Univ Mediterranee, Inst Canc & Immunol Marseille, INSERM, U119, F-13009 Marseille, France; Univ Quebec, Inst Armand Frappier, Inst Natl Rech Sci, Laval, PQ, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Quebec; Institut national de la recherche scientifique (INRS)	Nunes, JA (corresponding author), Univ Mediterranee, Inst Canc & Immunol Marseille, INSERM, U119, 27 Bd Lei Roure, F-13009 Marseille, France.	nunes@marseille.inserm.fr	COLLETTE, Yves/F-2270-2013; NUNES, Jacques A/F-4952-2013	COLLETTE, Yves/0000-0001-5359-7099; NUNES, Jacques A/0000-0003-4865-0400				Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CLARKSON B, 1993, LEUKEMIA, V7, P1683; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Gugasyan R, 2002, J CELL BIOL, V158, P115, DOI 10.1083/jcb.200112066; Guy GR, 2002, CELL SIGNAL, V14, P11, DOI 10.1016/S0898-6568(01)00227-3; IZQUIERDO M, 1993, J EXP MED, V178, P1199, DOI 10.1084/jem.178.4.1199; Jones N, 1999, CURR BIOL, V9, P1057, DOI 10.1016/S0960-9822(99)80458-8; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Master Z, 2003, J BIOL CHEM, V278, P30170, DOI 10.1074/jbc.M301339200; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Nelms K, 1998, IMMUNITY, V9, P13, DOI 10.1016/S1074-7613(00)80584-1; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Nunes JA, 1996, J BIOL CHEM, V271, P1591, DOI 10.1074/jbc.271.3.1591; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; van Dijk TB, 2000, BLOOD, V96, P3406; Yamanashi Y, 2000, GENE DEV, V14, P11; Yang WC, 2000, INT IMMUNOL, V12, P1547, DOI 10.1093/intimm/12.11.1547; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yang WC, 2000, IMMUNITY, V12, P373, DOI 10.1016/S1074-7613(00)80189-2; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199	23	32	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1594	1598		10.1038/sj.onc.1207283	http://dx.doi.org/10.1038/sj.onc.1207283			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647425				2022-12-28	WOS:000189219500013
J	Vega, A; Salas, A; Gamborino, E; Sobrido, MJ; Macaulay, V; Carracedo, A				Vega, A; Salas, A; Gamborino, E; Sobrido, MJ; Macaulay, V; Carracedo, A			MtDNA mutations in tumors of the central nervous system reflect the neutral evolution of mtDNA in populations	ONCOGENE			English	Article						mtDNA; CNS tumors; neutral evolution; instability; hotspots	MITOCHONDRIAL-DNA MUTATIONS; MICROSATELLITE INSTABILITY; SOMATIC MUTATIONS; CONTROL REGION; CANCER; CARCINOMA; GENOME; HETEROPLASMY; FREQUENCY; SEQUENCES	Mitochondrial DNA ( mtDNA) instability has been observed in different types of cancer, including colorectal, breast, and gastric cancer. The relationship between the occurrence of such alteration and the nuclear microsatellite instability (nMI) status of the neoplastic cells remains controversial. In an attempt to clarify this issue, we sequenced the first and second mtDNA hypervariable regions, and typed the mitochondrial ( CA)(n) dinucleotide polymorphism in 69 patients with primary tumors of the central nervous system (CNS), previously screened for nMI. Tumor samples showed 27 D-loop sequence changes (39.1%) compared to the corresponding blood samples. Microsatellite homoplasmic allele mutations were detected in four cases (5.8%). We did not find significant associations of the mtDNA instability status with clinicopathological parameters including sex, age, tumor size, and duration of clinical course. Neither did we find any association between mtDNA and nuclear instabilities, indicating that, at least in CNS tumors, they respond to different DNA repair mechanisms. We have also compiled the mtDNA instabilities previously reported by other authors for several types of tumors, comparing them to mtDNA polymorphisms in human populations. Most of the tumor-associated changes are common human polymorphisms and mutational hotspots. To explain the molecular behavior of mtDNA instability in tumors, we propose a model also common to other biological situations.	Univ Santiago de Compostela, Fac Med, Unidad Genet Forense, Galica, Spain; Univ Santiago de Compostela, Hosp Clin Univ, Unidad Mol Med, Galica, Spain; Univ Santiago de Compostela, Hosp Clin Univ, Serv Cirugia, Galica, Spain; Hosp San Rafael, La Coruna, Galica, Spain; Univ Oxford, Dept Stat, Oxford OX1 3TG, England; Univ Glasgow, Dept Stat, Glasgow, Lanark, Scotland	Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; University of Oxford; University of Glasgow	Salas, A (corresponding author), Univ Santiago de Compostela, Fac Med, Unidad Genet Forense, Galica, Spain.	apimlase@usc.es	Salas, Antonio/E-3977-2012; Carracedo, Angel/D-4257-2012	Salas, Antonio/0000-0002-2336-702X; Carracedo, Angel/0000-0003-1085-8986				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779; BANDELT HJ, 1995, GENETICS, V141, P743; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Bandelt HJ, 2002, AM J HUM GENET, V71, P1150, DOI 10.1086/344397; Bodenteich Angelika, 1992, Human Molecular Genetics, V1, P140, DOI 10.1093/hmg/1.2.140-a; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; FIELD JK, 1995, BRIT J CANCER, V71, P1065, DOI 10.1038/bjc.1995.205; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Forster L, 2002, P NATL ACAD SCI USA, V99, P13950, DOI 10.1073/pnas.202400499; GALL K, 1993, INT J EXP PATHOL, V74, P333; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Habano W, 2000, GASTROENTEROLOGY, V118, P835, DOI 10.1016/S0016-5085(00)70169-7; Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798; KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287; Kirches E, 1999, GENE CHROMOSOME CANC, V26, P80, DOI 10.1002/(SICI)1098-2264(199909)26:1<80::AID-GCC11>3.0.CO;2-4; Maca-Meyer N, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-13; Malyarchuk BA, 2002, HUM GENET, V111, P46, DOI 10.1007/s00439-002-0740-4; Maximo V, 2000, GASTROENTEROLOGY, V119, P1808, DOI 10.1016/S0016-5085(00)70044-8; Meyer S, 1999, GENETICS, V152, P1103; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Richards M, 2001, AM J HUM GENET, V68, P1315, DOI 10.1086/320615; RISINGER JI, 1993, CANCER RES, V53, P5100; Salas A, 2002, AM J HUM GENET, V71, P1082, DOI 10.1086/344348; Salas A, 2001, INT J LEGAL MED, V114, P186, DOI 10.1007/s004140000164; Sobrido MJ, 2000, J NEUROL NEUROSUR PS, V69, P369, DOI 10.1136/jnnp.69.3.369; Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; TULLY G, 2003, UNPUB FORENSIC SCI I; Vega A, 2001, CANCER, V92, P2920, DOI 10.1002/1097-0142(20011201)92:11<2920::AID-CNCR10110>3.3.CO;2-J; YEE CJ, 1994, CANCER RES, V54, P1641	37	38	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1314	1320		10.1038/sj.onc.1207214	http://dx.doi.org/10.1038/sj.onc.1207214			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647457				2022-12-28	WOS:000188892200017
J	Walters, DK; Jelinek, DF				Walters, DK; Jelinek, DF			A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells	ONCOGENE			English	Article						Jak1; Tyk2; ErbB3; interferon-alpha; multiple myeloma	TYROSINE KINASE; BREAST-CANCER; MULTIPLE-MYELOMA; RECEPTOR; EXPRESSION; LEUKEMIA; OVEREXPRESSION; INTERLEUKIN-6; ACTIVATION; RESPONSES	Receptor crosstalk is an emerging and recurrent theme in cytokine and growth factor signaling; however, insight into the mechanism(s) underlying these interactions remains limited. Recently, we reported that crosstalk occurs between ErbB3 and the interferon alpha (IFN-alpha) signaling complex in the myeloma cell line KAS-6/1 and that this crosstalk contributes to the regulation of cell proliferation. In this study, we examined the mechanism underlying the transactivation of ErbB3 in the IFN-alpha growth-responsive KAS-6/1 cells. The examination of IFN-alpha receptor 1 and 2 (IFNAR1 and IFNAR2) levels revealed that the KAS-6/1 cell line overexpresses IFNAR1 relative to other myeloma cell lines that are growth arrested by IFN-alpha. Subsequent investigation of Tyk2, which is constitutively associated with IFNAR1, demonstrated that Tyk2 activation is uniquely sustained in the KAS-6/1 cell line following IFN-alpha stimulation. Interestingly, silencing of Tyk2 expression via siRNA resulted in attenuation of ErbB3 transactivation. However, inhibit ion of Jak1 expression also decreased IFN-alpha-induced tyrosine phosphorylation of ErbB3. Finally, siRNA downregulation of Tyk2 and Jak1 was found to decrease IFN-alpha-stimulated proliferation. These findings validate our previous report of ErbB3 involvement in IFN-alpha-induced proliferation and further suggest that both Janus kinase members, Tyk2 and Jak1, play a role in the transactivation of ErbB3 in this model system.	Mayo Clin & Mayo Fdn, Mayo Grad Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Immunol, Tumor Biol Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Jelinek, DF (corresponding author), 200 1st St SW, Rochester, MN 55905 USA.	jelinek.diane@mayo.edu			NCI NIH HHS [CA62228, CA62242] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062228, R55CA062228, P01CA062242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arora T, 1999, J IMMUNOL, V162, P3289; BLADE J, 1991, BRIT J HAEMATOL, V79, P523, DOI 10.1111/j.1365-2141.1991.tb08068.x; BOUNDY V, 2002, NEOPLASMA, V49, P349; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; BUHRING HJ, 1995, BLOOD, V86, P1916, DOI 10.1182/blood.V86.5.1916.bloodjournal8651916; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; DiGiovanna MP, 2002, CANCER RES, V62, P6667; Dondi E, 2001, J BIOL CHEM, V276, P47004, DOI 10.1074/jbc.M104316200; Dumont JE, 2001, CELL SIGNAL, V13, P457, DOI 10.1016/S0898-6568(01)00168-1; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hill SM, 1998, ANAT REC, V253, P42, DOI 10.1002/(SICI)1097-0185(199804)253:2<42::AID-AR7>3.0.CO;2-G; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; JELINEK DF, 2003, HEMATOL J, V4, pS37; JOURDAN M, 1991, J IMMUNOL, V147, P4402; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; Kuhn DJ, 2003, J CELL BIOCHEM, V89, P824, DOI 10.1002/jcb.10557; Long IS, 2003, MOL CANCER RES, V1, P393; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; McManus MT, 2002, J IMMUNOL, V169, P5754, DOI 10.4049/jimmunol.169.10.5754; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; SAWAMURA M, 1992, BRIT J HAEMATOL, V82, P631, DOI 10.1111/j.1365-2141.1992.tb06484.x; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Walters DK, 2003, ONCOGENE, V22, P3598, DOI 10.1038/sj.onc.1206512; Walters DK, 2002, ANTISENSE NUCLEIC A, V12, P411, DOI 10.1089/108729002321082483; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369	30	6	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1197	1205		10.1038/sj.onc.1207203	http://dx.doi.org/10.1038/sj.onc.1207203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647450				2022-12-28	WOS:000188892200003
J	Bahar, A; Bicknell, JE; Simpson, DJ; Clayton, RN; Farrell, WE				Bahar, A; Bicknell, JE; Simpson, DJ; Clayton, RN; Farrell, WE			Loss of expression of the growth inhibitory gene GADD45 gamma, in human pituitary adenomas, is associated with CpG island methylation	ONCOGENE			English	Article						GADD45 gamma; CpG island methylation; pituitary adenomas	DNA METHYLATION; MAMMALIAN-CELLS; BREAST-CANCER; P16 GENE; TUMORS; HYPERMETHYLATION; INACTIVATION; TUMORIGENESIS; PATHOGENESIS; DELETION	Inappropriate expression of cell-cycle regulatory genes and/or their protein products are a frequent finding in pituitary tumours; however, genetic changes associated with or responsible for their dysregulation are in general uncommon. In a search for novel genes, and employing eDNA-representational difference analysis, the gene encoding GADD45gamma was recently isolated and identified as being under-represented in pituitary adenomas. GADD45gamma is a member of a family of genes that are induced by DNA damage and function in the negative regulation of cell growth. In this study, we further confirm this initial report that the majority of pituitary adenomas (22 of 33; 67%) do not express GADD45gamma as determined by RT-PCR analysis. Loss of expression was not associated with either loss of heterozygosity or mutations within the coding region of this gene. In marked contrast, epigenetic change, namely methylation of the GADD45gamma genes CpG island, was a frequent finding (19 of 33 adenoma; 58%) and was significantly associated with tumours in which GADD45gamma transcript was not expressed (18 of 22; 82%; P = 0.002). In common with the primary tumours, methylation-associated gene silencing of the GADD45gamma gene was also found in the pituitary tumour cell line AtT20. The treatment of AtT20 cells with the demethylating agent, 5-Aza-2'-deoxycytidine, induced the re-expression of this gene. These findings show that silencing of the GADD45gamma gene in pituitary tumours is primarily associated with methylation of the genes CpG island. Methylation has functional importance since reversal of this epigenetic change in a pituitary-derived cell line is associated with reexpression. Silencing of GADD45gamma, a negative regulator of cell growth, is most likely responsible for conferring a selective growth advantage during tumour evolution and outgrowth.	Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust	Farrell, WE (corresponding author), Keele Univ, N Staffordshire Hosp, Sch Med, Stoke On Trent ST4 7QB, Staffs, England.	w.e.farrell@keele.ac.uk						Asa SL, 1998, ENDOCR REV, V19, P798, DOI 10.1210/er.19.6.798; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; Bates AS, 1997, J CLIN ENDOCR METAB, V82, P818, DOI 10.1210/jc.82.3.818; Baylin SB, 1998, ADV CANCER RES, V72, P141; BOGGILD MD, 1994, J CLIN ENDOCR METAB, V78, P387, DOI 10.1210/jc.78.2.387; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Davis JRE, 2001, REPRODUCTION, V121, P363, DOI 10.1530/rep.0.1210363; Esteller M, 2001, CANCER RES, V61, P3225; Farrell WE, 2000, FRONT NEUROENDOCRIN, V21, P174, DOI 10.1006/frne.1999.0195; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Frost SJ, 1999, MOL ENDOCRINOL, V13, P1801, DOI 10.1210/me.13.11.1801; Grigg GW, 1996, DNA SEQUENCE, V6, P189, DOI 10.3109/10425179609008443; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hibberts NA, 1999, CLIN CANCER RES, V5, P2133; Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459; Jaffrain-Rea ML, 1999, CLIN ENDOCRINOL, V51, P317; Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952; Korabiowska M, 1999, IN VIVO, V13, P483; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Ruebel KH, 2001, ENDOCR PATHOL, V12, P281, DOI 10.1385/EP:12:3:281; Seemann N, 2001, J PATHOL, V193, P491, DOI 10.1002/path.833; Simpson DJ, 1999, GENE CHROMOSOME CANC, V24, P328; Simpson DJ, 2002, ONCOGENE, V21, P1217, DOI 10.1038/sj.onc.1205195; Simpson DJ, 2001, CARCINOGENESIS, V22, P1149, DOI 10.1093/carcin/22.8.1149; Simpson DJ, 2000, CANCER RES, V60, P1211; SIMPSON DJ, 1999, CANCER RES, V59, P2703; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; TERADA T, 1995, ENDOCR PATHOL, V6, P301, DOI 10.1007/BF02738730; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wan YS, 2000, INT J MOL MED, V6, P683; Woloschak M, 1997, MOL CARCINOGEN, V19, P221, DOI 10.1002/(SICI)1098-2744(199708)19:4<221::AID-MC1>3.0.CO;2-F; Yan PS, 2000, CLIN CANCER RES, V6, P1432; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885; Zhang W, 2001, INT J ONCOL, V18, P749; Zhang X, 2002, J CLIN ENDOCR METAB, V87, P1262, DOI 10.1210/jc.87.3.1262; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761	38	73	80	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					936	944		10.1038/sj.onc.1207193	http://dx.doi.org/10.1038/sj.onc.1207193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647444				2022-12-28	WOS:000188486600009
J	Nassif, NT; Lobo, GP; Wu, XJ; Henderson, CJA; Morrison, CD; Eng, C; Jalaludin, B; Segelov, E				Nassif, NT; Lobo, GP; Wu, XJ; Henderson, CJA; Morrison, CD; Eng, C; Jalaludin, B; Segelov, E			PTEN mutations are common in sporadic microsatellite stable colorectal cancer	ONCOGENE			English	Article						PTEN; sporadic colorectal cancer; mutation; microsatellite instability; loss of heterozygosity; immunohistochemistry	TUMOR-SUPPRESSOR GENE; PTEN/MMAC1 GENE; COWDEN-DISEASE; SOMATIC MUTATIONS; ADJUVANT CHEMOTHERAPY; PHOSPHATASE-ACTIVITY; GERMLINE MUTATIONS; INSTABILITY; ENDOMETRIAL; EXPRESSION	The tumour suppressor gene PTEN, located at chromosome sub-band 10q23.3, encodes a dual-specificity phosphatase that negatively regulates the phosphatidylinositol 3'-kinase (PI3K)/Akt-dependent cellular survival pathway. PTEN is frequently inactivated in many tumour types including glioblastoma, prostate and endometrial cancers. While initial studies reported that PTEN gene mutations were rare in colorectal cancer, more recent reports have shown an approximate 18% incidence of somatic PTEN mutations in colorectal tumours exhibiting microsatellite instability (MSI+). To verify the role of this gene in colorectal tumorigenesis, we analysed paired normal and tumour DNA from 41 unselected primary sporadic colorectal cancers for PTEN inactivation by mutation and/or allelic loss. We now report PTEN gene mutations in 19.5% (8/41) of tumours and allele loss, including all or part of the PTEN gene, in a further 17% (7/41) of the cases. Both PTEN alleles were affected in over half (9/15) of these cases showing PTEN genetic abnormalities. Using immunohistochemistry, we have further shown that all tumours harbouring PTEN alterations have either reduced or absent PTEN expression and this correlated strongly with later clinical stage of tumour at presentation (P=0.02). In contrast to previous reports, all but one of the tumours with PTEN gene mutations were microsatellite stable (MSI-), suggesting that PTEN is involved in a distinct pathway of colorectal tumorigenesis that is separate from the pathway of mismatch repair deficiency. This work therefore establishes the importance of PTEN in primary sporadic colorectal cancer.	Univ New S Wales, Liverpool Hosp, SW Sydney Clin Sch, Canc Res Labs, Liverpool, NSW 2170, Australia; Liverpool Hosp, Dept Anat Pathol, SW Area Pathol Serv, Liverpool, NSW 2170, Australia; Ohio State Univ, Ctr Comprehens Canc, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Columbus, OH 43210 USA; Univ Cambridge, Canc Res UK Human Canc Genet Res Grp, Cambridge CB2 2XZ, England; Univ New S Wales, Liverpool Hosp, Sch Publ Hlth & Community Med, Epidemiol Unit, Liverpool, NSW 2170, Australia	Liverpool Hospital; University of New South Wales Sydney; Liverpool Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Cambridge; Liverpool Hospital; University of New South Wales Sydney	Nassif, NT (corresponding author), Univ Technol Sydney, Dept Cell & Mol Biol, St Leonards Campus,Cnr Pacific Hwy & Westbourne S, Gore Hill, NSW 2065, Australia.	Najah.Nassif@uts.edu.au; e.segelov@unsw.edu.au	Segelov, Eva/Q-7611-2019; Nassif, Najah T/G-6214-2012; Lobo, Glenn P./AAI-9736-2020	Segelov, Eva/0000-0002-4410-6144; Nassif, Najah T/0000-0003-2675-8322; Eng, Charis/0000-0002-3693-5145				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; BEAHRS OH, 1997, AM JOINT COMMITTEE C, P83; Biesecker LG, 2001, LANCET, V358, P2079, DOI 10.1016/S0140-6736(01)07109-4; Boland CR, 1998, CANCER RES, V58, P5248; Bonneau D, 2000, HUM MUTAT, V16, P109, DOI 10.1002/1098-1004(200008)16:2<109::AID-HUMU3>3.0.CO;2-0; Cairns P, 1997, CANCER RES, V57, P4997; Chang JG, 1999, EUR J CANCER, V35, P647, DOI 10.1016/S0959-8049(98)00411-0; Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507; Dahia PLM, 1997, CANCER RES, V57, P4710; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dicuonzo G, 2001, CLIN CANCER RES, V7, P4049; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Elsaleh H, 2000, ONCOLOGY-BASEL, V58, P52, DOI 10.1159/000012079; Elsaleh H, 2001, GASTROENTEROLOGY, V121, P230, DOI 10.1053/gast.2001.26044; Elsaleh H, 2001, CLIN CANCER RES, V7, P1343; Elsaleh H, 2001, GASTROENTEROLOGY, V120, P1309; Eng C, 1998, NAT GENET, V19, P223, DOI 10.1038/897; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Feilotter HE, 1998, ONCOGENE, V16, P1743, DOI 10.1038/sj.onc.1200205; Frayling IM, 1997, CANCER GENET CYTOGEN, V97, P64, DOI 10.1016/S0165-4608(97)00011-3; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Giraud S, 1997, J CLIN ENDOCR METAB, V82, P3487, DOI 10.1210/jc.82.10.3487; Guanti G, 2000, HUM MOL GENET, V9, P283, DOI 10.1093/hmg/9.2.283; Guldberg P, 1997, CANCER RES, V57, P3660; Han SY, 2000, CANCER RES, V60, P3147; Hansen L, 2001, DIABETOLOGIA, V44, P237, DOI 10.1007/s001250051605; Ilyas M, 1999, EUR J CANCER, V35, P335, DOI 10.1016/S0959-8049(98)00431-6; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kahnoski K, 2003, J MED GENET, V40, P511, DOI 10.1136/jmg.40.7.511; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Kurose K, 1998, JPN J CANCER RES, V89, P842, DOI 10.1111/j.1349-7006.1998.tb00638.x; Kurose K, 2000, GENE CHROMOSOME CANC, V29, P166, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1025>3.3.CO;2-D; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li J, 1998, CANCER RES, V58, P5667; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lin WM, 1998, CLIN CANCER RES, V4, P2577; Liu Q, 1994, PCR Methods Appl, V4, P97; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Marsh DJ, 1999, HUM MOL GENET, V8, P1461, DOI 10.1093/hmg/8.8.1461; Maxwell GL, 2000, CLIN CANCER RES, V6, P2999; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Mutter GL, 2001, CANCER RES, V61, P4311; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Negoro K, 2000, DIS COLON RECTUM, V43, pS29, DOI 10.1007/BF02237223; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Okami K, 1998, CANCER RES, V58, P509; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rhei E, 1997, CANCER RES, V57, P3657; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; Sato K, 2002, VIRCHOWS ARCH, V440, P160, DOI 10.1007/s004280100499; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Singh B, 1998, GENE CHROMOSOME CANC, V21, P166, DOI 10.1002/(SICI)1098-2264(199802)21:2<166::AID-GCC13>3.3.CO;2-V; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Taniyama K, 2001, J PATHOL, V194, P341, DOI 10.1002/path.908; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Wang SI, 1997, CANCER RES, V57, P4183; Wang ZJ, 1998, AM J PATHOL, V153, P363, DOI 10.1016/S0002-9440(10)65579-4; Watanabe T, 2001, NEW ENGL J MED, V344, P1196, DOI 10.1056/NEJM200104193441603; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5; Zhou XP, 1999, INT J CANCER, V84, P150, DOI 10.1002/(SICI)1097-0215(19990420)84:2<150::AID-IJC10>3.0.CO;2-#; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9; Zhou XP, 2002, HUM MOL GENET, V11, P445, DOI 10.1093/hmg/11.4.445	77	114	125	0	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					617	628		10.1038/sj.onc.1207059	http://dx.doi.org/10.1038/sj.onc.1207059			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724591	Green Submitted			2022-12-28	WOS:000188098300034
J	Chopin, V; Toillon, RA; Jouy, N; Le Bourhis, X				Chopin, V; Toillon, RA; Jouy, N; Le Bourhis, X			P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells	ONCOGENE			English	Article						apoptosis; breast cancer; butyrate; cell cycle; PCNA; P21(waf1/cip1)	HISTONE DEACETYLASE INHIBITOR; HUMAN COLON-CANCER; BINDING PROTEIN-3 PROMOTER; NUCLEOTIDE EXCISION-REPAIR; GROWTH ARREST; CARCINOMA CELLS; NUCLEAR ANTIGEN; IN-VIVO; TRANSCRIPTIONAL REPRESSION; INDUCIBLE EXPRESSION	Sodium butyrate (NaB) has been proposed as a potential anticancer agent. However, its mechanism of action is not totally elucidated. Here, we showed that NaB-induced cell cycle arrest and apoptosis were associated with an increase of P21(waf1/cip1) in MCF-7 breast cancer cells. This increase was more important in the nuclei, as revealed by immunofluorescence analysis. Transient transfections of MCF-7 cells with p21 deficient for interaction with CDK, but not with p21 deficient for interaction with PCNA <LF>(p21PCNA-), abrogated NaB-induced cell cycle arrest. This indicated that cell cycle blockage involved the interaction of P21(waf1/cip1) with CDK. However, P21(waf1/cip1) was dispensable, since p21 antisense did not modify cell cycle arrest. On the other hand, NaB-induced apoptosis was abolished by p21 antisense or p21PCNA-. In addition, NaB decreased PCNA levels, but increased the association of PCNA with P21(waf1/cip1). These results suggested that NaB-induced apoptosis required P21(waf1/cip1) and its interaction with PCNA.	Univ Sci & Technol Lille, Equipe Facteurs Croissance, Dev Biol Lab, UPRES 1033, F-59655 Villeneuve Dascq, France; Inst Rech Canc Lille, Inst Rech, Inst Med Predict & Rech Therapeut, IMPRT, F-59045 Lille, France	Universite de Lille - ISITE; Universite de Lille	Le Bourhis, X (corresponding author), Univ Sci & Technol Lille, Equipe Facteurs Croissance, Dev Biol Lab, UPRES 1033, IFR 118, F-59655 Villeneuve Dascq, France.	Xuefen.lebourhis@univ-lille1.fr	Le+Bourhis, Xuefen/AAL-5141-2021; Toillon, Robert-Alain/Q-2286-2018	Toillon, Robert-Alain/0000-0001-5483-2118				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN IT, 1995, ONCOGENE, V11, P1931; Chen ZX, 2002, CANCER LETT, V188, P127, DOI 10.1016/S0304-3835(02)00322-1; Chopin V, 2002, BRIT J PHARMACOL, V135, P79, DOI 10.1038/sj.bjp.0704456; Cooper MP, 1999, MOL BIOL CELL, V10, P2119, DOI 10.1091/mbc.10.7.2119; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923; Della Ragione F, 2001, FEBS LETT, V499, P199, DOI 10.1016/S0014-5793(01)02539-X; Demary K, 2001, CANCER LETT, V163, P103, DOI 10.1016/S0304-3835(00)00676-5; Derjuga A, 2001, J BIOL CHEM, V276, P37815; Detjen KM, 2003, EXP CELL RES, V282, P78, DOI 10.1016/S0014-4827(02)00011-3; Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7; Galfi P, 2002, CANCER LETT, V188, P141, DOI 10.1016/S0304-3835(02)00347-6; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; Gilbert J, 2001, CLIN CANCER RES, V7, P2292; Gregory DJ, 2002, CELL CYCLE, V1, P343, DOI 10.4161/cc.1.5.153; HALL PA, 1995, ONCOGENE, V10, P2427; Han ZY, 2002, J BIOL CHEM, V277, P17154, DOI 10.1074/jbc.M112401200; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Ito N, 2001, NEUROSURGERY, V49, P430, DOI 10.1097/00006123-200108000-00031; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; Mattock H, 2001, EXP CELL RES, V265, P234, DOI 10.1006/excr.2001.5160; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Patnaik A, 2002, CLIN CANCER RES, V8, P2142; Pellizzaro C, 2001, INT J CANCER, V91, P654, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1117>3.0.CO;2-I; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Peschiaroli A, 2002, ONCOGENE, V21, P8114, DOI 10.1038/sj.onc.1206010; Qiao L, 2002, HEPATOLOGY, V36, P39, DOI 10.1053/jhep.2002.33899; Qin LF, 2001, CANCER LETT, V172, P7, DOI 10.1016/S0304-3835(01)00701-7; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Ritt MG, 2000, CANCER LETT, V158, P73, DOI 10.1016/S0304-3835(00)00507-3; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sawa H, 2001, Brain Tumor Pathol, V18, P109, DOI 10.1007/BF02479423; Schwartz B, 1998, MOL CELL BIOCHEM, V188, P21, DOI 10.1023/A:1006831330340; Scott M, 2001, J CELL SCI, V114, P3455; Shibata MA, 2001, CANCER GENE THER, V8, P23, DOI 10.1038/sj.cgt.7700275; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 2000, BIOFACTORS, V12, P283, DOI 10.1002/biof.5520120142; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Takahashi S, 2001, CANCER RES, V61, P1187; Terao Y, 2001, INT J CANCER, V94, P257, DOI 10.1002/ijc.1448; Tian H, 2000, CANCER RES, V60, P679; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; Tsubaki J, 2002, ENDOCRINOLOGY, V143, P1778, DOI 10.1210/en.143.5.1778; Tsubaki J, 2001, J ENDOCRINOL, V169, P97, DOI 10.1677/joe.0.1690097; Vaziri C, 1998, CELL GROWTH DIFFER, V9, P465; Velazquez OC, 1996, JPEN-PARENTER ENTER, V20, P243, DOI 10.1177/0148607196020004243; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wang XM, 1999, ANTICANCER RES, V19, P2901; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Zhan QM, 1998, MOL CELL BIOL, V18, P2768, DOI 10.1128/MCB.18.5.2768; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	65	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					21	29		10.1038/sj.onc.1207020	http://dx.doi.org/10.1038/sj.onc.1207020			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712207				2022-12-28	WOS:000187895300003
J	Lionneton, F; Lelievre, E; Baillat, D; Stehelin, D; Soncin, F				Lionneton, F; Lelievre, E; Baillat, D; Stehelin, D; Soncin, F			Characterization and functional analysis of the p42Ets-1 variant of the mouse Ets-1 transcription factor	ONCOGENE			English	Article						Ets-1; endothelium; VE-cadherin; gene promoter	DNA-BINDING MOTIF; CHICK-EMBRYO; MURINE ETS-1; PROTEIN INTERACTIONS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; C-ETS-1; PROMOTER; DOMAIN; PHOSPHORYLATION	We have identified the mouse exon VII splice variant of the Ets-1 transcription factor. The variant is expressed in all cell lines which express ets-1, at lower levels, it is also expressed in the mouse embryo in vivo. The corresponding protein, p42Ets-1, is a transcription factor as it is able to bind to specific DNA sequences and to transactivate a bona. de ETS reporter vector. A comparison of optimal DNA-binding sites shows that p42Ets-1 binds to more various DNA sequences than p51Ets-1; p42Ets-1 recognizes the same optimal consensus sequence as p51Ets-1, but also many variations of it, mainly at base -1, which is located just prior to the GGAA/T core sequence. The binding differences were quantified by surface plasmon resonance analyses and the protein region responsible for the differences in DNA sequence recognition located in the Val(280)-Glu(302) fragment, which is encoded by exon VII. The specific DNA-binding properties of each isoform translates into clear differences in activity, p42Ets-1 transactivates the natural VE-cadherin gene promoter through both ETS-binding site (EBS)2 and EBS4 whereas p51Ets-1 is mainly active on EBS4. Altogether, our data suggest that p42Ets-1 acts as a distinct transcription factor from p51Ets-1.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS)	Soncin, F (corresponding author), Inst Biol Lille, CNRS, UMR 8526, 1 Rue Calmette, F-59021 Lille, France.		SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673; Lelievre, Etienne/0000-0003-0452-1578				Anderson MK, 1999, DEVELOPMENT, V126, P3131; Baillat D, 2002, J BIOL CHEM, V277, P29386, DOI 10.1074/jbc.M200088200; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BELLACOSA A, 1994, J VIROL, V68, P2320, DOI 10.1128/JVI.68.4.2320-2330.1994; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Bradford AP, 1996, J BIOL CHEM, V271, P24639, DOI 10.1074/jbc.271.40.24639; Bradford AP, 1997, MOL CELL BIOL, V17, P1065, DOI 10.1128/MCB.17.3.1065; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; Calmels TPG, 1995, BIOL CELL, V84, P53, DOI 10.1016/0248-4900(96)81318-9; Castellano R, 2002, J BIOL CHEM, V277, P42841, DOI 10.1074/jbc.M207689200; Cowley DO, 2000, GENE DEV, V14, P366; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FISHER RJ, 1991, ONCOGENE, V6, P2249; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Garvie CW, 2002, J BIOL CHEM, V277, P45529, DOI 10.1074/jbc.M206327200; Garvie CW, 2001, MOL CELL, V8, P1267, DOI 10.1016/S1097-2765(01)00410-5; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, V1, P29; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; Huang CC, 1997, ONCOGENE, V15, P851, DOI 10.1038/sj.onc.1201408; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; JORCYK CL, 1991, ONCOGENE, V6, P523; KOIZUMI S, 1990, ONCOGENE, V5, P675; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Lelievre E, 2002, J BIOL CHEM, V277, P25143, DOI 10.1074/jbc.M201628200; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Lelievre E, 2000, ONCOGENE, V19, P2438, DOI 10.1038/sj.onc.1203563; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; Lionneton F, 2001, PROTEIN EXPRES PURIF, V21, P492, DOI 10.1006/prep.2001.1405; Liu H, 2002, MOL BIOL CELL, V13, P4497, DOI 10.1091/mbc.E02-03-0149; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mo Y, 2000, NAT STRUCT BIOL, V7, P292; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; QUEVA C, 1993, ONCOGENE, V8, P2511; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAYGALLET D, 1995, ONCOGENE, V11, P303; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218	53	13	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9156	9164		10.1038/sj.onc.1207241	http://dx.doi.org/10.1038/sj.onc.1207241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668797				2022-12-28	WOS:000187149100006
J	Germani, A; Prabel, A; Mourah, S; Podgorniak, MP; Di Carlo, A; Ehrlich, R; Gisselbrecht, S; Varin-Blank, N; Calvo, F; Bruzzoni-Giovanelli, H				Germani, A; Prabel, A; Mourah, S; Podgorniak, MP; Di Carlo, A; Ehrlich, R; Gisselbrecht, S; Varin-Blank, N; Calvo, F; Bruzzoni-Giovanelli, H			SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway	ONCOGENE			English	Article						SIAH-1; CtIP; p21(Waf-1/Cip-1); protein degradation; transcription; ubiquitin; E3 ligase	TRANSCRIPTIONAL REPRESSOR; CHROMOSOME ALIGNMENT; TUMOR SUPPRESSION; BINDING-PROTEIN; DNA-DAMAGE; BRCA1; CTBP; COREPRESSOR; MECHANISM; XKID	SIAH-1 and SIAH-2 are the human members of an evolutionary highly conserved E3 ligase family. SIAH-1 is a p53 and p21(Waf-1/Cip-1) induced gene during apoptosis and tumor suppression. In stable-transfected clones of MCF-7 cells, SIAH-1 overexpression was associated with apoptosis, mitotic alterations and p21(Waf-1/Cip-1) induction of expression. Using a two-hybrid screening, we identified here the transcriptional corepressor CtBP-interacting protein (CtIP) as a SIAH-1-interacting protein. CtIP has been proposed as a regulator of p21(Waf-1/Cip-1) gene transcription through a protein complex involving BRCA1. We demonstrate that SIAH-1 associates with CtIP both in vitro and in vivo. This interaction led to CtIP degradation by the ubiquitin-proteasome pathway. As expected, SIAH-1 induced p21(Waf-1/Cip-1) transcription in Jurkat-T cell. Surprisingly, a SIAH protein deleted of its RING finger, SIAH-1DeltaN, which is able to interact with CtIP but does not promote its degradation, also induced transcription from the p21(Waf-1) promoter in a similar extent as did SIAH-1. Our results suggest that p21(Waf-1/Cip-1) induction by SIAH-1 could not be mediated by CtIP degradation.	Hop St Louis, INSERM, EMI 0334, Inst Genet Mol,Lab Pharmacol Expt & Clin, F-75010 Paris, France; Ctr Cardiol Fdn I Monzino, IRCCS, Lab Vasc Biol & Gene Therapy, I-20138 Milan, Italy; Univ Paris 05, Hop Cochin, Inst Cochin, Dept Hematol,CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Fac Ciencias, Secc Bioquim, Montevideo, Uruguay	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; IRCCS Centro Cardiologico Monzino; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad de la Republica, Uruguay	Bruzzoni-Giovanelli, H (corresponding author), Hop St Louis, INSERM, EMI 0334, Inst Genet Mol,Lab Pharmacol Expt & Clin, 27 Rue Juliette Dodu, F-75010 Paris, France.		Di Carlo, Anna/AAY-4368-2021; Varin-Blank, Nadine/G-4396-2013	Di Carlo, Anna/0000-0002-6037-6160; calvo, fabien/0000-0002-0298-7633; VARIN-BLANK, Nadine/0000-0003-2769-018X				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Koipally J, 2002, J BIOL CHEM, V277, P23143, DOI 10.1074/jbc.M202079200; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	26	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8845	8851		10.1038/sj.onc.1206994	http://dx.doi.org/10.1038/sj.onc.1206994			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654780				2022-12-28	WOS:000186982200005
J	Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Ramos, MA; Nunez, MD; Campos, J; Lacal, JC				Rodriguez-Gonzalez, A; de Molina, AR; Fernandez, F; Ramos, MA; Nunez, MD; Campos, J; Lacal, JC			Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells	ONCOGENE			English	Article						choline kinase inhibitors; new therapies; signal transduction; specificity; apoptosis	NIH 3T3 FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; GROWTH-FACTORS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; PHOSPHOLIPID-METABOLISM; ANTITUMOR STRATEGY; DRUG DISCOVERY; RAS ONCOGENE; ACTIVATION; STIMULATION	Cancer treatment is in the need of selective drugs that can interfere specifically with signalling pathways affected during the carcinogenic process. Identification of new potential molecular targets is the key event in the design of new anticancer strategies. Once identified, attempts for the generation of specific molecules to regulate their function can be achieved. The relevance of deregulation of choline kinase (ChoK, E.C. 2.7.1.32) in oncogene-driven cell transformation has been previously demonstrated. Here we provide strong evidence that MN58b, a selective inhibitor of ChoK, is rather specific to this enzyme, with no effect on a variety of oncogene-activated signalling pathways involved in the regulation of cell proliferation. MN58b does not affect MAPKs, PI3K, and other enzymes involved in the regulation of phospholipid metabolism such as phospholipases C, D, and A2, CTP:phosphocholine cytidylyltransferase, or diacylglycerol choline-phosphotransferase. Consistent with this specificity, ectopic expression of ChoK resulted in resistance to its inhibitor. Finally, nontransformed cells were able to resume cell proliferation after removal of the drug, while transformed cells were irreversibly affected. These results indicate that inhibition of ChoK is a rather specific strategy for the cytotoxic treatment of transformed cells.	CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, E-28029 Madrid, Spain; Fac Farm, Dept Quim Organ, E-18071 Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Dept Mol & Cellular Biol Canc, Arturo Duperier 4, E-28029 Madrid, Spain.		Lacal, Juan Carlos/AAL-2235-2020; del Carmen Nuñez-Carretero, M/L-7150-2014; de Molina, Ana Ramirez/AAA-3848-2019; Rosa, Joaquín/L-8436-2014; Lacal, Juan Carlos/N-9064-2015	Rosa, Joaquín/0000-0002-9035-8123; Lacal, Juan Carlos/0000-0002-1908-2777				Aboagye EO, 1999, CANCER RES, V59, P80; ANSELL GB, 1974, J NEUROCHEM, V22, P1153, DOI 10.1111/j.1471-4159.1974.tb04352.x; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Bhakoo KK, 1996, CANCER RES, V56, P4630; CANNON JG, 1994, MED RES REV, V14, P505, DOI 10.1002/med.2610140503; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARNERO A, 1994, ONCOGENE, V9, P1387; Chung TW, 2000, CELL SIGNAL, V12, P279, DOI 10.1016/S0898-6568(00)00065-6; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2002, ONCOGENE, V21, P4317, DOI 10.1038/sj.onc.1205556; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; De molina AR, 2001, INT J ONCOL, V19, P5; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; Finney RE, 2000, CANCER RES, V60, P5204; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Friend SH, 1998, NEW ENGL J MED, V338, P125, DOI 10.1056/NEJM199801083380211; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; Kiss Z, 1996, BIOCHEM BIOPH RES CO, V218, P505, DOI 10.1006/bbrc.1996.0090; KO KWS, 1986, J BIOL CHEM, V261, P7846; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; OIKAWA T, 1991, P NATL ACAD SCI USA, V88, P3057, DOI 10.1073/pnas.88.8.3057; Ramirez de Molina A, 2002, BIOCHEM BIOPH RES CO, V296, P580, DOI 10.1016/S0006-291X(02)00920-8; Ramirez de Molina A, 2002, ONCOGENE, V21, P937, DOI 10.1038/sj.onc.1205144; RATMANT JC, 1995, ARCH BIOCHEM BIOPHYS, V323, P313; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; TEEGARDEN D, 1990, J BIOL CHEM, V265, P6042; Ting YLT, 1996, ANTICANCER RES, V16, P1381; Uchida T, 1996, BBA-LIPID LIPID MET, V1304, P89, DOI 10.1016/S0005-2760(96)00109-9; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WARDEN CH, 1985, J BIOL CHEM, V260, P6006; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WIEPRECHT M, 1994, BIOCHEM J, V297, P241, DOI 10.1042/bj2970241; YANG W, 1990, J BIOL CHEM, V265, P13553; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	48	75	76	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8803	8812		10.1038/sj.onc.1207062	http://dx.doi.org/10.1038/sj.onc.1207062			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654777				2022-12-28	WOS:000186982200001
J	Rassool, FV; North, PS; Mufti, GJ; Hickson, ID				Rassool, FV; North, PS; Mufti, GJ; Hickson, ID			Constitutive DNA damage is linked to DNA replication abnormalities in Bloom's syndrome cells	ONCOGENE			English	Article						Bloom's syndrome; DNA damage; double-strand break repair; timing of replication	SYNDROME GENE-PRODUCT; DEFENDING GENOME INTEGRITY; SISTER-CHROMATID EXCHANGES; WERNERS-SYNDROME GENES; RECQ FAMILY HELICASES; STRAND BREAK REPAIR; COMMON FRAGILE SITE; SYNDROME PROTEIN; S-PHASE; TOPOISOMERASE-III	Bloom's syndrome (BS) is an autosomal recessive disorder associated with an elevated incidence of cancers. The gene mutated in BS, BLM, encodes a RecQ helicase family member. BS cells exhibit genomic instability, including excessive homologous recombination and chromosomal aberrations. W e reported previously that BS cells also demonstrate increased error-prone nonhomologous end-joining, which could contribute to genomic instability in these cells. Here, we show that BS cells display an abnormality in the timing of replication of both early-replicating genes and late-replicating loci such as chromosomal fragile sites. This delayed replication is associated with a constitutively increased frequency of sites of DNA damage and repair, as determined by the presence of DNA repair factors such as RAD51 and Ku86. In addition, another RecQ family helicase, WRN, also localizes to these repair sites. The presence of these repair sites correlates with the temporal appearance of cyclin B1 expression, indicative of the cells having progressed beyond mid-S phase in the cell division cycle. Critically, these defects in BS cells are the direct result of loss of BLM function, because BS cells phenotypically 'reverted' following transfection with the BLM cDNA no longer show such defects. Thus, our data indicate that constitutive DNA damage is coupled to delayed DNA replication in BS cells.	Guys Kings & Thomas Sch Med, Rayne Inst, Leukaemia Sci Labs, Dept Haematol Med, London SE5 9NU, England; Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Labs, Oxford OX3 9DS, England	University of London; King's College London; Cancer Research UK; University of Oxford	Rassool, FV (corresponding author), Guys Kings & Thomas Sch Med, Rayne Inst, Leukaemia Sci Labs, Dept Haematol Med, 123 Coldharbour Lane, London SE5 9NU, England.	feyruz.rassool@kcl.ac.uk	Hickson, Ian/AAJ-7548-2020	Hickson, Ian/0000-0002-0583-566X				Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2002, EMBO J, V21, P5577, DOI 10.1093/emboj/cdf554; Cooper MP, 2000, GENE DEV, V14, P907; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, J CELL SCI, V113, P2641; Gaymes TJ, 2002, ONCOGENE, V21, P2525, DOI 10.1038/sj.onc.1205331; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Glover TW, 1998, RECENT RES CANCER, V154, P185; GLOVER TW, 1987, AM J HUM GENET, V41, P882; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Langland G, 2002, CANCER RES, V62, P2766; LANGLOIS RG, 1989, P NATL ACAD SCI USA, V86, P670, DOI 10.1073/pnas.86.2.670; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Li BM, 2000, J BIOL CHEM, V275, P39800; Li BM, 2001, J BIOL CHEM, V276, P9896, DOI 10.1074/jbc.M008575200; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; LONN U, 1990, CANCER RES, V50, P3141; Moens PB, 2000, J CELL SCI, V113, P663; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Oakley TJ, 2002, DNA REPAIR, V1, P175, DOI 10.1016/S1568-7864(02)00002-2; Orren DK, 2001, NUCLEIC ACIDS RES, V29, P1926, DOI 10.1093/nar/29.9.1926; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Wang Y, 2000, GENE DEV, V14, P927; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; Wu L, 2001, CELL MOL LIFE SCI, V58, P894, DOI 10.1007/PL00000909; Wu L, 2000, COLD SPRING HARB SYM, V65, P573, DOI 10.1101/sqb.2000.65.573; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733; YUNIS JJ, 1987, ONCOGENE, V1, P59	45	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8749	8757		10.1038/sj.onc.1206970	http://dx.doi.org/10.1038/sj.onc.1206970			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647470	Bronze			2022-12-28	WOS:000186844900013
J	Hideshima, T; Chauhan, D; Hayashi, T; Akiyama, M; Mitsiades, N; Mitsiades, C; Podar, K; Munshi, NC; Richardson, PG; Anderson, KC				Hideshima, T; Chauhan, D; Hayashi, T; Akiyama, M; Mitsiades, N; Mitsiades, C; Podar, K; Munshi, NC; Richardson, PG; Anderson, KC			Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; proteasome inhibitor; IL-6; gp130; caspase	ACTIVATED PROTEIN-KINASE; MARROW STROMAL CELLS; DEXAMETHASONE-INDUCED APOPTOSIS; NF-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE/AKT; THERAPEUTIC APPLICATIONS; MOLECULAR-MECHANISMS; DRUG-RESISTANCE; UP-REGULATION; PLASMA-CELLS	Proteasome inhibitor PS-341 is one of the most promising novel agents against multiple myeloma (MM). We have previously shown that PS-341 inhibits IL-6 triggered phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 (also known as p42/44 mitogen-activated protein kinases) in MM cells. In this study, we further examined whether clinically achievable concentrations of PS-341 could inhibit IL-6 triggered signaling cascades in MM. We found that PS-341 inhibited not only ERK, but also signal transducers and activators of transcription (STAT) 3 as well as Akt phosphorylation. Since gp130 (CD130) dimerizes and is phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be involved in PS-341-induced blockade of signaling cascades mediating MM cell growth, survival, and drug resistance in the bone marrow (BM) microenvironment. In this study, we first demonstrate that PS-341 induces downregulation of gp130 in a time- and dose-dependent manner in vitro, prior to MM cell death. Conversely, downregulation of gp130 is completely abrogated by the pan-caspase inhibitor Z-VAD-FMK, suggesting that downregulation of gp130 is mediated via caspase activation. Z-VAD-FMK also abrogates the inhibitory effect of PS-341 on IL-6-triggered signaling cascades. Importantly, we demonstrate that phosphorylation of ERK, STAT3, and Akt in MM.1S cells induced by either exogenous IL-6 or by binding of MM cells to BM stromal cells is abrogated by PS-341. These studies, therefore, define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Mayer 557,44 Binney St, Boston, MA 02115 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [R0-1 CA 50947] Funding Source: Medline; PHS HHS [P0-1 78378] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; CHAUHAN D, 1995, J EXP MED, V182, P1801, DOI 10.1084/jem.182.6.1801; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2003, BLOOD, V101, P703, DOI 10.1182/blood-2002-06-1874; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, MOL CANCER THER, V1, P539; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KLEIN B, 1989, BLOOD, V73, P517; Kurth I, 1999, J IMMUNOL, V162, P1480; LeBlanc R, 2002, CANCER RES, V62, P4996; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; NISHIMOTO N, 1994, J EXP MED, V179, P1343, DOI 10.1084/jem.179.4.1343; Ogata A, 1997, J IMMUNOL, V159, P2212; Ogawa M, 2000, CANCER RES, V60, P4262; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Richardson PG, 2001, BLOOD, V98, p774A; Semenov I, 2002, LEUKEMIA RES, V26, P271, DOI 10.1016/S0145-2126(01)00103-5; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733	44	140	155	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8386	8393		10.1038/sj.onc.1207170	http://dx.doi.org/10.1038/sj.onc.1207170			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627979				2022-12-28	WOS:000186650300002
J	Jin, SQ; Mazzacurati, L; Zhu, XC; Tong, T; Song, YM; Shao, SJ; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM				Jin, SQ; Mazzacurati, L; Zhu, XC; Tong, T; Song, YM; Shao, SJ; Petrik, KL; Rajasekaran, B; Wu, M; Zhan, QM			Gadd45a contributes to p53 stabilization in response to DNA damage	ONCOGENE			English	Article						p53; Gadd45a; DNA damage	CELL-CYCLE CHECKPOINT; P53-REGULATED PROTEIN GADD45; TUMOR-SUPPRESSOR P53; INDUCED PHOSPHORYLATION; ATAXIA-TELANGIECTASIA; KINASE-ACTIVITY; ACTIVATES P53; MDM2; ARREST; INHIBITION	p53 is an important molecule in cellular response to DNA damage. After genotoxic stress, p53 protein stabilizes transiently and accumulates in the nucleus, where it functions as a transcription factor and upregulates multiple downstream-targeted genes, including p21(Waf1/Cip1), Gadd45a and Bax. However, regulation of p53 stabilization is complex and may mainly involve post-translational modification of p53, such as phosphorylation and acetylation. Using mouse embryonic fibroblasts (MEFs) derived from Gadd45a knockouts, we found that disruption of Gadd45a greatly abolished p53 protein stabilization following UVB treatment. Phosphorylation of p53 at Ser-15 was substantially reduced in Gadd45a-/- MEFs. In addition, p53 induction by UVB was shown to be greatly abrogated in the presence of p38 kinase inhibitor, but not c-Jun N-terminal kinase (JNK) and extracellular-signal regulated kinase (ERK), suggesting that p38 protein kinase is involved in the regulation of p53 induction. Along with the findings presented above, inducible expression of Gadd45a enhanced p53 accumulation after cell exposure to UVB. Taken together, the current study demonstrates that Gadd45a, a conventional downstream gene of p53, may play a role as an upstream effector in p53 stabilization following DNA damage, and thus has defined a positive feedback signal in the activation of the p53 pathway.	Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA; Chinese Acad Med Sci, Inst Canc, State Key Lab Mol Oncol, Beijing 100021, Peoples R China	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Medical Sciences - Peking Union Medical College	Zhan, QM (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Dept Radiat Oncol, Sch Med, UPCI Res Pavil,Suite G5,5117 Ctr Ave, Pittsburgh, PA 15213 USA.			mazzacurati, lucia/0000-0002-8336-8032; song, yongmei/0000-0002-7789-0158	NATIONAL CANCER INSTITUTE [R01CA083874] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-83874] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2003, MOL CELL BIOL, V23, P3859, DOI 10.1128/MCB.23.11.3859-3871.2003; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hildesheim J, 2002, CANCER RES, V62, P7305; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jin SQ, 2002, ONCOGENE, V21, P8696, DOI 10.1038/sj.onc.1206034; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEARSEY JM, 1995, ONCOGENE, V11, P1675; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MIYASHITA T, 1995, CELL, V80, P293; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Sablina AA, 2001, ONCOGENE, V20, P899, DOI 10.1038/sj.onc.1204156; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; Zhang XH, 2001, TRIBOL LETT, V11, P15, DOI 10.1023/A:1016677321278; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906	48	76	79	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8536	8540		10.1038/sj.onc.1206907	http://dx.doi.org/10.1038/sj.onc.1206907			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627995				2022-12-28	WOS:000186650300018
J	Perani, M; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH				Perani, M; Ingram, CJE; Cooper, CS; Garrett, MD; Goodwin, GH			Conserved SNH domain of the proto-oncoprotein SYT interacts with components of the human chromatin remodelling complexes, while the QPGY repeat domain forms homo-oligomers	ONCOGENE			English	Article						SYT; SYT-SSX; synovial sarcoma; BRM; BRG1; chromatin remodelling	HUMAN SYNOVIAL SARCOMA; MAMMALIAN SWI/SNF COMPLEXES; CHIMERIC PROTEIN; DNA-BINDING; TRANSCRIPTIONAL ACTIVATOR; CHROMOSOME-TRANSLOCATION; SH3 DOMAINS; CELL-CYCLE; SSX; FUSION	Many studies have now established that the SWI/SNF chromatin remodelling complexes are involved in activation and repression of a variety of genes. In mammalian cells, these complexes contain the BRM and BRG1 helicase-like proteins that are thought to be responsible for nucleosome remodelling. The proto-oncoprotein SYT, involved in the unique translocation t(X;18) found in synovial sarcoma, is known to interact with human BRM (hBRM), thus providing a link between chromatin remodelling factors and human cancer. In this work, we address how SYT interacts with hBRM and BRG1. We demonstrate that the conserved N-terminal SNH domain of SYT, which is also present in the oncoproteins SYT-SSX, binds to both hBRM and BRG1. We have also found that in vivo the C-terminus transactivation QPGY region of SYT can interact with itself. This results in an amplified interaction with hBRM and highlights a possible regulatory function of this domain in cells.	Inst Canc Res, BLB, Sect Mol Carcinogenesis, Sutton SM 5NG, Surrey, England; Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Perani, M (corresponding author), Inst Canc Res, BLB, Sect Mol Carcinogenesis, 15 Cotswold Rd, Sutton SM 5NG, Surrey, England.	michela.perani@icr.ac.uk		Ingram, Catherine/0000-0003-2863-8930	Worldwide Cancer Research [99-0108] Funding Source: Medline	Worldwide Cancer Research		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dallas PB, 2000, MOL CELL BIOL, V20, P3137, DOI 10.1128/MCB.20.9.3137-3146.2000; Dallas PB, 1998, MOL CELL BIOL, V18, P3596, DOI 10.1128/MCB.18.6.3596; de Bruijn DRH, 2001, ONCOGENE, V20, P3281, DOI 10.1038/sj.onc.1204419; deBruijn DRH, 1996, ONCOGENE, V13, P643; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; dos Santos NR, 2000, EXP CELL RES, V256, P192, DOI 10.1006/excr.2000.4813; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eid JE, 2000, CELL, V102, P839, DOI 10.1016/S0092-8674(00)00072-6; Fisher C, 1998, Ann Diagn Pathol, V2, P401, DOI 10.1016/S1092-9134(98)80042-7; Gure AO, 1997, INT J CANCER, V72, P965, DOI 10.1002/(SICI)1097-0215(19970917)72:6<965::AID-IJC8>3.0.CO;2-N; Hurlstone AFL, 2002, BIOCHEM J, V364, P255, DOI 10.1042/bj3640255; Kato H, 2002, J BIOL CHEM, V277, P5498, DOI 10.1074/jbc.M108702200; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lim FL, 1998, ONCOGENE, V17, P2013, DOI 10.1038/sj.onc.1202122; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; O'Neill D, 1999, P NATL ACAD SCI USA, V96, P349, DOI 10.1073/pnas.96.2.349; OHNO T, 1993, CANCER RES, V53, P5859; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; SMITH S, 1987, CANCER GENET CYTOGEN, V26, P179, DOI 10.1016/0165-4608(87)90147-6; Soulez M, 1999, ONCOGENE, V18, P2739, DOI 10.1038/sj.onc.1202613; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; TREICH I, 1995, MOL CELL BIOL, V15, P4240; Tureci O, 1996, CANCER RES, V56, P4766; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Xie YT, 2002, CANCER RES, V62, P3861	41	43	44	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8156	8167		10.1038/sj.onc.1207031	http://dx.doi.org/10.1038/sj.onc.1207031			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603256				2022-12-28	WOS:000186403400010
J	Charrasse, S; Comunale, F; Gilbert, E; Delattre, O; Gauthier-Rouviere, C				Charrasse, S; Comunale, F; Gilbert, E; Delattre, O; Gauthier-Rouviere, C			Variation in cadherins and catenins expression is linked to both proliferation and transformation of Rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; cadherins; catenins; transformation	GROWTH-FACTOR-II; SERUM RESPONSE FACTOR; MOUSE C2C12 MYOBLASTS; RHO-FAMILY GTPASES; N-CADHERIN; CELL-ADHESION; MYOGENIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; BREAST-CANCER; PEDIATRIC RHABDOMYOSARCOMA	Cadherins are a family of transmembrane glycoproteins that mediate Ca2+-dependent homophilic cell-cell adhesion and play a crucial role in cell differentiation. E-cadherin-mediated cell-cell adhesion is lost during the development of most epithelial cancers. This study examines cadherin-dependent adhesion in cell lines derived from rhabdomyosarcoma (RMS), a highly malignant soft-tissue tumor committed to the myogenic lineage, but arrested prior to terminal differentiation. We analysed the expression of cadherins and associated catenins at the mRNA and protein levels as well as their localization in nine RMS-derived cell lines relative to normal myoblasts. We show a decrease in the expression of cadherins and catenins in all RMS-derived cell lines compared to control cells. This decrease in the expression of N- and M-cadherin was confirmed in RMS biopsies. In contrast, R-cadherin is found expressed in RMS, whereas it is normally absent in normal myoblasts. We show that a decrease of R-cadherin expression using RNA interference inhibits cell proliferation of the RD cell line. In addition to their diminished expression, cadherins and catenins do not localize to intercellular contacts in embryonal RMS (ERMS), whereas specific persistent localization is seen in alveolar RMS (ARMS)-derived cell lines. Thus, RMS exhibit defects in the expression of molecules of the cadherin family. Defects in the localization of these adhesion molecules at the sites of cell-cell contact are specifically observed in the ERMS subtype. In addition, our data suggest that R-cadherin is a specific diagnostic marker for RMS and is also an important factor of RMS cell proliferation.	CNRS, UPR 1086, CRBM, F-34293 Montpellier, France; Inst Curie, INSERM,U509, Sect Rech, Lab Pathol Mol Canc, F-75248 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Gauthier-Rouviere, C (corresponding author), CNRS, UPR 1086, CRBM, 1919 Route Mende, F-34293 Montpellier, France.	gauthier@crbm.cnrs-mop.fr		GAUTHIER-ROUVIERE, Cecile/0000-0002-8364-3882; delattre, olivier/0000-0002-8730-2276; Comunale, Franck/0000-0001-8838-2151				Barr FG, 1999, CANCER RES, V59, p1711S; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chalmers IJ, 2001, CANCER GENET CYTOGEN, V126, P39, DOI 10.1016/S0165-4608(00)00376-9; CHARDIN P, 1985, INT J CANCER, V35, P647, DOI 10.1002/ijc.2910350513; Charrasse S, 2002, J CELL BIOL, V158, P953, DOI 10.1083/jcb.200202034; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Daniel JM, 1999, MOL CELL BIOL, V19, P3614; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DUBAND JL, 1987, J CELL BIOL, V104, P1361, DOI 10.1083/jcb.104.5.1361; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Eusebi V, 2000, AM J SURG PATHOL, V24, P223, DOI 10.1097/00000478-200002000-00008; Ferracini R, 1996, ONCOGENE, V12, P1697; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; GARSON JA, 1986, LANCET, V1, P1496; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; GeorgeWeinstein M, 1997, DEV BIOL, V185, P14, DOI 10.1006/dbio.1997.8542; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Hajra KM, 2002, CANCER RES, V62, P1613; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; HATTA K, 1987, DEV BIOL, V120, P215, DOI 10.1016/0012-1606(87)90119-9; KALEBIC T, 1994, CANCER RES, V54, P5531; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KIMURA Y, 1995, DEV BIOL, V169, P347, DOI 10.1006/dbio.1995.1149; Knudsen KA, 1990, CURR OPIN CELL BIOL, V2, P902, DOI 10.1016/0955-0674(90)90090-2; Ko K, 2000, AM J PHYSIOL-CELL PH, V279, pC147, DOI 10.1152/ajpcell.2000.279.1.C147; Kumar S, 2000, MODERN PATHOL, V13, P988, DOI 10.1038/modpathol.3880179; Linask KK, 1998, DEV BIOL, V202, P85, DOI 10.1006/dbio.1998.9025; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Marucci G., 2000, Pathologica (Genoa), V92, P198; Meriane M, 2002, ONCOGENE, V21, P2901, DOI 10.1038/sj.onc.1205396; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINNITI CP, 1994, AM J CLIN PATHOL, V101, P198, DOI 10.1093/ajcp/101.2.198; Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ostrovsky O, 2002, J BIOL CHEM, V277, P40043, DOI 10.1074/jbc.M205494200; Pinkerton R, 1998, B CANCER, V85, P1015; Pohar-Marinsek Z, 2002, ANAL QUANT CYTOL, V24, P212; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Proulx AA, 1997, CELL GROWTH DIFFER, V8, P533; Prowse DM, 1997, CELL BIOL INT, V21, P833, DOI 10.1006/cbir.1997.0202; Puri PL, 2000, GENE DEV, V14, P574; Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rosenberg P, 1997, DEV BIOL, V187, P55, DOI 10.1006/dbio.1997.8602; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; SOLER AP, 1993, EXP CELL RES, V208, P84, DOI 10.1006/excr.1993.1225; STRATTON MR, 1989, CANCER RES, V49, P6324; Suzuki H, 1996, GENE CHROMOSOME CANC, V17, P225, DOI 10.1002/(SICI)1098-2264(199612)17:4<225::AID-GCC4>3.0.CO;2-5; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Visser M, 1997, ONCOGENE, V15, P1309, DOI 10.1038/sj.onc.1201302; WANG NP, 1995, AM J PATHOL, V147, P1799; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; ZESCHNIGK M, 1995, J CELL SCI, V108, P2973; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang LJ, 1996, CANCER RES, V56, P1367	64	26	26	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2420	2430		10.1038/sj.onc.1207382	http://dx.doi.org/10.1038/sj.onc.1207382			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691446				2022-12-28	WOS:000220427700016
J	Lewis, MD; Roberts, BJ				Lewis, MD; Roberts, BJ			Role of the C-terminal alpha-helical domain of the von Hippel-Lindau protein in its E3 ubiquitin ligase activity	ONCOGENE			English	Article						VHL; HIF; ubiquitin; cancer	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVITY; PROLYL HYDROXYLATION/; REGULATE HIF; DISEASE; MUTATIONS; VHL; GENE; HYDROXYPROLINE	In the present study, the role of the C-terminal alpha-helical domain (amino acid (aa) 195-208) of the von Hippel Lindau (VHL) tumour suppressor was investigated. Deletions of the VHL C-terminus up to the naturally occurring 195-Gln-Term resulted in hypoxia-inducible factor (HIF)-1alpha downregulation in renal cell carcinoma (RCC)4 cells during normoxia, suggesting that this domain is not an absolute requirement for the ubiquitination of HIF-1alpha. However, detailed investigation of the ubiquitin protein isopeptide ligase ubiquitin ligase properties of VHL revealed C-terminal deletions to cause a significant impairment of HIF-1alpha ubiquitination, which is shown to be due to a loss in high-affinity binding to the target substrate. When VHL regulation of both HIF-1alpha N- and C-terminal oxygen-dependent degradation domains (HIF-ODDD) was investigated, it was found that only ubiquitination of the C-terminal HIF-ODDD was affected by the deletion of the VHL C-terminus. When RCC4 cells expressing C-terminal truncations of VHL were exposed to graded hypoxia, differences in the induction of HIF-1alpha were observed in comparison with full-length VHL, with a shift in the maximal induction of HIF-1alpha to a higher oxygen tension. These changes were accompanied by increased glucose transporter 1 expression, p300 CH1 domain binding and HIF-mediated reporter activity. We have thus defined a role for the C-terminal alpha-helical domain of VHL in the regulation of HIF-1alpha.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Reid Bldg,Frome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au	Lewis, Martin/A-8489-2008; Lewis, Martin/A-3881-2010	Lewis, Martin/0000-0002-3332-3776				Clifford SC, 2001, ADV CANCER RES, V82, P85, DOI 10.1016/S0065-230X(01)82003-0; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 1999, MOL MED TODAY, V5, P257, DOI 10.1016/S1357-4310(99)01481-1; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Roberts BJ, 1999, J BIOL CHEM, V274, P36351, DOI 10.1074/jbc.274.51.36351; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; WHALEY JM, 1994, AM J HUM GENET, V55, P1092; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	23	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2315	2323		10.1038/sj.onc.1207384	http://dx.doi.org/10.1038/sj.onc.1207384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14691445				2022-12-28	WOS:000220427700005
J	Kang, DC; Gopalkrishnan, RV; Lin, L; Randolph, A; Valerie, K; Pestka, S; Fisher, PB				Kang, DC; Gopalkrishnan, RV; Lin, L; Randolph, A; Valerie, K; Pestka, S; Fisher, PB			Expression analysis and genomic characterization of human melanoma differentiation associated gene-5, mda-5: a novel type I interferon-responsive apoptosis-inducing gene	ONCOGENE			English	Article						helicard; CARD; RNA helicase; terminal differentiation	HUMAN POLYNUCLEOTIDE PHOSPHORYLASE; TRANS-RETINOIC ACID; TERMINAL DIFFERENTIATION; PROTEIN FAMILY; ALPHA-INTERFERON; GAMMA-INTERFERON; GROWTH ARREST; CANCER CELLS; HYBRIDIZATION; IDENTIFICATION	Melanoma differentiation associated gene-5 (mda-5) was identified by subtraction hybridization as a novel upregulated gene in HO-1 human melanoma cells induced to terminally differentiate by treatment with IFN-beta + MEZ. Considering its unique structure, consisting of a caspase recruitment domain (CARD) and an RNA helicase domain, it was hypothesized that mda-5 contributes to apoptosis occurring during terminal differentiation. We have currently examined the expression pattern of mda-5 in normal tissues, during induction of terminal differentiation and after treatment with type I IFNs. In addition, we have defined its genomic structure and chromosomal location. IFN-beta, a type I IFN, induces mda-5 expression in a biphasic and dose-dependent manner. Based on its temporal kinetics of induction and lack of requirement for prior protein synthesis mda-5 is an early type I IFN-responsive gene. The level of mda-5 mRNA is in low abundance in normal tissues, whereas expression is induced in a spectrum of normal and cancer cells by IFN-beta. Expression of mda-5 by means of a replication incompetent adenovirus, Ad. mda-5, induces apoptosis in HO-1 cells as confirmed by morphologic, biochemical and molecular assays. Additionally, the combination of Ad.mda-5+MEZ further augments apoptosis as observed in Ad. null or uninfected HO-1 cells induced to terminally differentiate by treatment with IFN-beta+MEZ. The mda-5 gene is located on human chromosome 2q24 and consists of 16 exons, without pseudogenes, and is conserved in the mouse genome. Present data documents that mda-5 is a novel type I IFN-inducible gene, which may contribute to apoptosis induction during terminal differentiation and during IFN treatment. The conserved genomic and protein structure of mda-5 in human and mouse will permit analysis of the evolution and developmental aspects of this gene.	Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA; Columbia Univ Coll Phys & Surg, Dept Neurosurg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Urol, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA	Columbia University; Virginia Commonwealth University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Herbert Irving Comprehens Canc Ctr, BB-1501,630 W 168th St, New York, NY 10032 USA.	pbf1@columbia.edu	Valerie, Kristoffer/AAL-8299-2021		NATIONAL CANCER INSTITUTE [R01CA098712, R01CA035675, R01CA097318] Funding Source: NIH RePORTER; NCI NIH HHS [CA35675, CA97318, CA98712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akesson E, 2002, GENES IMMUN, V3, P279, DOI 10.1038/sj.gene.6363866; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf139; Chien G, 2001, CANCER GENET CYTOGEN, V126, P63, DOI 10.1016/S0165-4608(00)00392-7; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Du Plessis L, 1999, CANCER RES, V59, P1877; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Friesen H J, 1981, Methods Enzymol, V78, P430; Fusenig N E, 1995, Recent Results Cancer Res, V139, P1; Garattini Enrico, 2001, Current Opinion in Pharmacology, V1, P358, DOI 10.1016/S1471-4892(01)00062-5; Gopalkrishnan RV, 2000, ONCOGENE, V19, P4405, DOI 10.1038/sj.onc.1203767; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Huang F, 1999, GENE, V236, P125, DOI 10.1016/S0378-1119(99)00244-9; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Jackson DP, 2003, MELANOMA RES, V13, P219, DOI 10.1097/00008390-200306000-00001; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Jia SF, 1999, J INTERF CYTOK RES, V19, P617, DOI 10.1089/107999099313758; JIANG H, 1994, MOL CELL DIFFER, V2, P22139; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 2000, P NATL ACAD SCI USA, V97, P12684, DOI 10.1073/pnas.220431297; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; JIANG HP, 1995, ONCOGENE, V10, P1855; Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kovacsovics M, 2002, CURR BIOL, V12, P838, DOI 10.1016/S0960-9822(02)00842-4; Kumon K, 2001, JPN J CANCER RES, V92, P854, DOI 10.1111/j.1349-7006.2001.tb01172.x; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Levy DE, 2002, J INTERF CYTOK RES, V22, P87, DOI 10.1089/107999002753452692; Lin JJ, 1998, GENE, V207, P105, DOI 10.1016/S0378-1119(97)00562-3; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; Lovat PE, 1997, EUR J CANCER, V33, P2075, DOI 10.1016/S0959-8049(97)00242-6; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; PACKER RJ, 1991, NEUROL CLIN, V9, P405, DOI 10.1016/S0733-8619(18)30293-7; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; Peng Zhihai, 2002, Zhonghua Wai Ke Za Zhi, V40, P776; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Pestka S, 2000, BIOPOLYMERS, V55, P254, DOI 10.1002/1097-0282(2000)55:4<254::AID-BIP1001>3.0.CO;2-1; PESTKA S, 1997, SEMIN ONCOL, V24; Petersen OW, 1998, ADV CANCER RES, V75, P135, DOI 10.1016/S0065-230X(08)60741-1; Raffray M, 1997, PHARMACOL THERAPEUT, V75, P153, DOI 10.1016/S0163-7258(97)00037-5; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Saunders LR, 2003, FASEB J, V17, P961, DOI 10.1096/fj.02-0958rev; Scott RE, 1997, PHARMACOL THERAPEUT, V73, P51, DOI 10.1016/S0163-7258(96)00120-9; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tanabe T, 2000, J NEURO-ONCOL, V48, P225, DOI 10.1023/A:1006476408190; Tapper J, 1998, CANCER RES, V58, P2715; Toida M, 2001, CANCER GENET CYTOGEN, V127, P34, DOI 10.1016/S0165-4608(00)00410-6; Wang Q, 1998, GENE, V222, P83, DOI 10.1016/S0378-1119(98)00476-4; Wang Z Y, 2000, Lancet Oncol, V1, P101, DOI 10.1016/S1470-2045(00)00017-6; Will CL, 2002, EMBO J, V21, P4978, DOI 10.1093/emboj/cdf480; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; Zhang JW, 2000, J BIOSCIENCES, V25, P275, DOI 10.1007/BF02703936; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	74	142	152	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1789	1800		10.1038/sj.onc.1207300	http://dx.doi.org/10.1038/sj.onc.1207300			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14676839				2022-12-28	WOS:000220029300014
J	Dirsch, VM; Kirschke, SO; Estermeier, M; Steffan, B; Vollmar, AM				Dirsch, VM; Kirschke, SO; Estermeier, M; Steffan, B; Vollmar, AM			Apoptosis signaling triggered by the marine alkaloid ascididemin is routed via caspase-2 and JNK to mitochondria	ONCOGENE			English	Article						apoptosis; ascididemin; caspase-2; mitochondria	CYTOCHROME-C RELEASE; HUMAN PROMYELOLEUKEMIC CELLS; DEATH; ACTIVATION; PROTEIN; DNA; INHIBITION; GENERATION; INDUCTION; THYMOCYTE	The marine alkaloid ascididemin (ASC) was shown to exert cytotoxicity even against multidrug-resistant cancer cells. Here, we address the signaling pathways utilized by ASC to trigger apoptosis in Jurkat leukemia T cells. We show that ASC (0.5-20 muM) induces a mitochondrial pathway that requires the activation of the initiator caspase-2 upstream of mitochondria. ASC-triggered apoptosis occurred independent of CD95, but required mitochondrial dysfunction. The activation of caspase-2 was shown to precede the processing of caspase-8, -9 and -3. The specific caspase-2 inhibitor zVDVADfmk abrogated ASC-induced DNA fragmentation almost completely. Overexpression of Bcl-x(L) blocked caspase-8 but not caspase-2 processing. Conversely, caspase-2 inhibition strongly reduced caspase-9 activation. As a possible link between caspase-2 and mitochondrial dysfunction, Bid was found to be cleaved by ASC. In addition, JNK was activated by ASC upstream of mitochondria via reactive oxygen species. The specific JNK inhibitor SP600125 partially inhibited caspase-2 and -9 processing as well as cytochrome c release and DNA fragmentation indicating that JNK contributes to, but is not necessary for ASC-mediated apoptosis. Thus, ASC triggers a pathway in which early activation of caspase-2 provides a possible link between its DNA-damaging activity and the induction of mitochondrial dysfunction. The activation of JNK contributes to this signaling upstream of mitochondria.	Univ Munich, Ctr Drug Res, Dept Pharm, D-81377 Munich, Germany; Univ Munich, Dept Chem, D-81377 Munich, Germany	University of Munich; University of Munich	Dirsch, VM (corresponding author), Univ Munich, Ctr Drug Res, Dept Pharm, Butenandstr 5-13, D-81377 Munich, Germany.	Verena.Dirsch@cup.uni-muenchen.de		Dirsch, Verena/0000-0002-9261-5293				Antlsperger DSM, 2003, ONCOGENE, V22, P582, DOI 10.1038/sj.onc.1206161; Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Beck WT, 2001, BIOCHEM SOC T, V29, P702, DOI 10.1042/0300-5127:0290702; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; BONNARD I, 1995, ANTI-CANCER DRUG DES, V10, P333; BRACHER F, 1993, J HETEROCYCLIC CHEM, V30, P157, DOI 10.1002/jhet.5570300128; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Dassonneville L, 2000, BIOCHEM PHARMACOL, V60, P527, DOI 10.1016/S0006-2952(00)00351-8; Dirsch VM, 2001, CANCER RES, V61, P5817; Dirsch VM, 1998, MOL PHARMACOL, V53, P402, DOI 10.1124/mol.53.3.402; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Harvey NL, 1996, GENES CELLS, V1, P673, DOI 10.1046/j.1365-2443.1996.00255.x; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KOBAYASHI J, 1988, TETRAHEDRON LETT, V29, P1177, DOI 10.1016/S0040-4039(00)86681-2; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leist M, 1998, MOL PHARMACOL, V54, P789, DOI 10.1124/mol.54.5.789; LINDSAY BS, 1995, BIOORG MED CHEM LETT, V5, P739, DOI 10.1016/0960-894X(95)00106-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsumoto SS, 2003, CHEM RES TOXICOL, V16, P113, DOI 10.1021/tx025618w; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; O'Reilly LA, 2002, CELL DEATH DIFFER, V9, P832, DOI 10.1038/sj.cdd.4401033; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stefanis L, 1998, J NEUROSCI, V18, P9204; Walczak H, 2000, CANCER RES, V60, P3051; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	38	37	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1586	1593		10.1038/sj.onc.1207281	http://dx.doi.org/10.1038/sj.onc.1207281			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716300				2022-12-28	WOS:000189219500012
J	Bonner, AE; Lemon, WJ; Devereux, TR; Lubet, RA; You, M				Bonner, AE; Lemon, WJ; Devereux, TR; Lubet, RA; You, M			Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas	ONCOGENE			English	Article						lung cancer; expression profiling; mouse model; human; lung development	OLIGONUCLEOTIDE ARRAYS; EXPRESSION; TUMORIGENESIS	We have performed oligonucleotide array analysis on various murine lung tissues [normal lungs, lung adenomas, and lung adenocarcinomas (ACs)] using Affymetrix U74Av2 GeneChips to examine the complex genetic changes occurring during lung carcinogenesis. Analysis yielded 20 novel genes differentially expressed in both lung adenomas and ACs versus normal lungs, including the tumor suppressor APC2 and the oncogene Ros 1. In addition, 50 genes were found to be differentially expressed in lung adenomas versus lung ACs, including the differentiation factor Hox C6, the oncogene Ets 2, and the Ras nuclear transport factor, nuclear transport factor 2. To understand the potential relationship between genes expressed in murine lung tumors and its relationship to altered gene expression observed during embryogenesis and postnatal development, tissues from embryonic lungs and from lungs of mice up to 4 weeks following birth were examined using Affymetrix U74Av2 GeneChips. From this analysis, approximately 1300 genes were determined to exhibit differential expression in fetal lung versus postnatal lung. When we compared lung adenomas, lung ACs, and normal lung parenchyma, 24 developmentally regulated genes were found aberrantly expressed in lung tumors; these included the cell cycle control factor CDC5, the cellular differentiation factor TEA domain 4, and the proapoptotic factor BNIP 2. Finally, we compared the murine lung tumor gene expression data to the expression of genes in human lung cancer, in order to assess the relevance of murine lung cancer models in the study of human AC formation. When the 17 human lung ACs and six human lung large cell carcinomas were examined, it was found that 13 of the 17 human lung ACs clustered tightly together in a pattern that was different from the remaining four human lung ACs and six large cell carcinomas, which exhibited a different pattern. Interestingly, the mouse lung adenomas appeared similar to 13 clustered ACs, while mouse lung ACs appeared more similar in pattern to the group consisting of four ACs and six large-cell carcinomas (LCCs). Nevertheless, when compared with the combined human ACs, 39 genes with similar expression changes in murine lung tumors and human ACs/LCCs were identified, such as the oncogene-related BCL7B, the cell cycle regulator CDK4, and the proapoptotic Endophilin B1. Overall, we have determined, for the first time, the expression profiles during murine lung tumor progression and have established, at the molecular level, an association between murine lung tumorigenesis and lung development. We have also attempted to compare the expression profiles found in mouse lung cancers and those in human lung ACs.	Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA; Ohio State Univ, Ctr Comprehens Canc, Div Human Canc Genet, Columbus, OH 43210 USA; Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63110 USA; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; NCI, Chemoprevent Agent Dev Res Grp, Bethesda, MD 20892 USA	Washington University (WUSTL); James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Siteman Cancer Center; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	You, M (corresponding author), Washington Univ, Sch Med, Dept Surg, 660 S Euclid Ave, St Louis, MO 63110 USA.	youm@msnotes.wustl.edu			NCI NIH HHS [R01CA78797, R01CA58554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078797, R01CA058554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonner AE, 2003, J MED GENET, V40, P408, DOI 10.1136/jmg.40.6.408; Chen J, 2003, GENE, V302, P103, DOI 10.1016/S0378-1119(02)01095-8; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MALKINSON AM, 1992, CANCER RES, V52, pS2670; Miura K, 2002, CANCER RES, V62, P3244; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; Travis W. D., 1999, WHO INT HISTOLOGICAL; Virtanen C, 2002, P NATL ACAD SCI USA, V99, P12357, DOI 10.1073/pnas.192240599; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wurzer G, 2001, J CELL BIOCHEM, P1; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2000, CANCER RES, V60, P901	16	75	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1166	1176		10.1038/sj.onc.1207234	http://dx.doi.org/10.1038/sj.onc.1207234			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647414				2022-12-28	WOS:000188749900015
J	Cho, NH; Hong, KP; Hong, SH; Kang, S; Chung, KY; Cho, SH				Cho, NH; Hong, KP; Hong, SH; Kang, S; Chung, KY; Cho, SH			MMP expression profiling in recurred stage IB lung cancer	ONCOGENE			English	Article						recurred stage IB lung cancer; MMP-10; MMP-12; c-DNA array; real-time RT-PCR	MATRIX METALLOPROTEINASES; CARCINOMAS; GENES; METASTASIS; INHIBITORS; OVEREXPRESSION; STROMELYSIN-2; COLLAGENASE; GELATINASE; TUMORS	We aimed to clarify the prime role of recurrence in stage I lung cancer. To determine the expression profiles, quantitative RT - PCR and real-time PCR were performed subsequently to evaluate the validity of meaningful molecules identified by 0.12K c-DNA array experiment surveys. In all, 10 lung cancer patients presenting with recurrence of stage IB were selected and compared with 10 stage IB lung cancer patients without recurrence since biopsied 3 years previously. On c-DNA microarray data analysis using pairs of recurred and the corresponding nonrecurred patients, the following genes were found to be upregulated in the recurred cases: matrix metalloproteinase (MMP)-10 in five cases, MMP-12 in two cases, MMP-11, MMP-14, MMP-15, fos, cyclin E2, E2F3, TGF-alpha in each one case. The most frequently upregulated genes in recurred lung cancers were MMP-10 (stromelysin-2) and MMP-12 ( macrophage elastase). On transcriptional assay by quantitative RT - PCR and real-time RT - PCR analysis to validate those molecules, both transcripts of MMP-10 and MMP-12 were significantly more upregulated in recurred stage IB lung cancer than in the non-recurred stage IB lung cancer ( P = 0.004). Transcript levels were identical to c-DNA array data. The protein levels of these entities were also evaluated by immunohistochemistry of archival slides. By immunohistochemistry, MMP-10 monoclonal antibody showed more intense immunoreactivity in the recurred stage IB lung cancer than in the nonrecurred stage IB lung cancer ( P = 0.0313). Our approach revealed that MMP-10 plays an important role in the recurrence in stage IB lung cancer, irrespective of the histologic type.	Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Thorac Surg, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Cho, SH (corresponding author), Yonsei Univ, Coll Med, Dept Pathol, Shinchon Dong 134, Seoul, South Korea.	shjo@yumc.yonsei.ac.kr		KANG, SUKI/0000-0002-9957-3479; jo, namhun/0000-0002-0045-6441				Bolon I, 1997, AM J PATHOL, V150, P1619; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Cai M, 2002, CLIN CANCER RES, V8, P1152; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Curran S, 2000, EUR J CANCER, V36, P1621, DOI 10.1016/S0959-8049(00)00156-8; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Fong KM, 1996, CLIN CANCER RES, V2, P1369; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Kerkela E, 2001, BRIT J CANCER, V84, P659, DOI 10.1054/bjoc.2000.1634; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; MARTINI N, 1977, J THORAC CARDIOV SUR, V74, P499; MARTINI N, 1995, J THORAC CARDIOV SUR, V109, P120, DOI 10.1016/S0022-5223(95)70427-2; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 2001, J PATHOL, V195, P135, DOI 10.1002/1096-9896(200109)195:2<135::AID-PATH939>3.0.CO;2-G; NAGAKAWA H, 1994, JPN J CANCER RES, V85, P934; NAGASE H, 1998, STROMELYSINS 1 2, P43; Nawrocki B, 1997, INT J CANCER, V72, P556, DOI 10.1002/(SICI)1097-0215(19970807)72:4<556::AID-IJC2>3.3.CO;2-#; OHORI NP, 1992, AM J SURG PATHOL, V16, P675, DOI 10.1097/00000478-199207000-00006; Passlick B, 2000, CLIN CANCER RES, V6, P3944; Rechardt O, 2000, J INVEST DERMATOL, V115, P778, DOI 10.1046/j.1523-1747.2000.00135.x; SHAPIRO SD, 1998, MATRIX METALLOPROTEI, P185; SOINI Y, 1993, AM J PATHOL, V142, P1622; SREENATH T, 1992, CANCER RES, V52, P4942; Thomas P, 2000, J PATHOL, V190, P150; TOKURAKU M, 1995, INT J CANCER, V64, P355, DOI 10.1002/ijc.2910640513; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434	27	48	53	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					845	851		10.1038/sj.onc.1207140	http://dx.doi.org/10.1038/sj.onc.1207140			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647437				2022-12-28	WOS:000188304900024
J	Langley, B; Thomas, M; McFarlane, C; Gilmour, S; Sharma, M; Kambadur, R				Langley, B; Thomas, M; McFarlane, C; Gilmour, S; Sharma, M; Kambadur, R			Myostatin inhibits rhabdomyosarcoma cell proliferation through an Rb-independent pathway	ONCOGENE			English	Article						myostatin; NPAT; rhabdomyosarcoma; retinoblastoma; histone	TRANSFORMING-GROWTH-FACTOR; HISTONE GENE-TRANSCRIPTION; CYCLIN-DEPENDENT KINASES; PAX3-FKHR FUSION PROTEIN; BETA SUPERFAMILY MEMBER; ALVEOLAR RHABDOMYOSARCOMA; EMBRYONAL RHABDOMYOSARCOMA; MUSCLE GROWTH; MYOD FAMILY; S-PHASE	Rhabdomyosarcoma (RMS) tumors are the most common soft-tissue sarcomas in childhood. In this investigation, we show that myostatin, a skeletal muscle-specific inhibitor of growth and differentiation is expressed and translated in the cultured RMS cell line, RD. The addition of exogenous recombinant myostatin inhibits the proliferation of RD cells cultured in growth media, consistent with the role of myostatin in normal myoblast proliferation inhibition. However, unlike normal myoblasts, upregulation of p21 was not observed. Rather, myostatin signalling resulted in the specific downregulation of both Cdk2 and its cognate partner, cyclin-E. The analysis of Rb reveals that there was no change in its phosphorylation status with myostatin treatment, consistent with D-type-cyclin-Cdk4/6 complexes being active in the absence of p21. Moreover, the activity of Rb appeared to be unchanged between treated and nontreated RD cells, as determined by the ability of Rb to bind E2F1. The examination of NPAT, a substrate of cyclin-E-Cdk2 involved in the transcriptional activation of replication-dependent histone gene expression, revealed that it undergoes a loss of phosphorylation with myostatin treatment. Supporting this, a downregulation in H4-histone gene expression was observed. These results suggest that myostatin could potentially be used as an inhibitor of RMS proliferation and define a previously uncharacterized, Rb-independent mechanism for the inhibition of muscle precursor cell proliferation by myostatin.	AgRes, Anim Genom, Hamilton, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand	AgResearch - New Zealand; University of Auckland	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123,East St, Hamilton, New Zealand.	Ravi.Kambadur@agresearch.co.nz	McFarlane, Craig/R-2968-2019; Langley, Brett C/P-7207-2017	McFarlane, Craig/0000-0002-7056-8887; Langley, Brett C/0000-0003-4009-2109				AGUANNO S, 1990, CANCER RES, V50, P3377; Albig W, 1997, HUM GENET, V101, P284, DOI 10.1007/s004390050630; Arthur PF, 1995, AUST J AGR RES, V46, P1493, DOI 10.1071/AR9951493; BENNICELLI JL, 1995, ONCOGENE, V11, P119; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; Dagher R, 1999, Oncologist, V4, P34; DAVIS RJ, 1994, CANCER RES, V54, P2869; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Ewen ME, 2000, GENE DEV, V14, P2265, DOI 10.1101/gad.842100; Feinberg AP, 1999, CANCER RES, V59, p1743S; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Grobet L, 1998, MAMM GENOME, V9, P210, DOI 10.1007/s003359900727; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; Hofmann F, 1996, GENE DEV, V10, P851, DOI 10.1101/gad.10.7.851; HOUGHTON JA, 1981, INT J CANCER, V28, P409, DOI 10.1002/ijc.2910280403; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Ji SQ, 1998, AM J PHYSIOL-REG I, V275, pR1265, DOI 10.1152/ajpregu.1998.275.4.R1265; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; NIGGLI FK, 1994, BRIT J CANCER, V69, P1106, DOI 10.1038/bjc.1994.217; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OLIVER MH, 1989, J CELL SCI, V92, P513; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; Otten AD, 1997, CELL GROWTH DIFFER, V8, P1151; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pandita Ajay, 1999, Neoplasia (New York), V1, P262, DOI 10.1038/sj.neo.7900036; PAPPO AS, 1993, J CLIN ONCOL, V11, P1901, DOI 10.1200/JCO.1993.11.10.1901; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Puri PL, 2000, GENE DEV, V14, P574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SHAPIRO DN, 1991, J CLIN ONCOL, V9, P159, DOI 10.1200/JCO.1991.9.1.159; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Sharma M, 1999, J CELL PHYSIOL, V180, P1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEIN G S, 1992, Current Opinion in Cell Biology, V4, P166, DOI 10.1016/0955-0674(92)90028-B; Szabo G, 1998, MAMM GENOME, V9, P671, DOI 10.1007/s003359900843; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Yang JZ, 2001, MOL REPROD DEV, V60, P351, DOI 10.1002/mrd.1097; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456; Zhu XL, 2000, FEBS LETT, V474, P71, DOI 10.1016/S0014-5793(00)01570-2	61	45	50	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					524	534		10.1038/sj.onc.1207144	http://dx.doi.org/10.1038/sj.onc.1207144			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724580				2022-12-28	WOS:000188098300023
J	Surace, EI; Haipek, CA; Gutmann, DH				Surace, EI; Haipek, CA; Gutmann, DH			Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function	ONCOGENE			English	Article						merlin; schwannomin; ERM proteins; FERM; Protein 4.1; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; CELL EXTENSION ACTIVITY; ERM PROTEINS; PLASMA-MEMBRANE; TERMINAL DOMAIN; EZRIN; MOESIN; BINDING; ASSOCIATION; GROWTH	The neurofibromatosis 2 (NF2) tumor suppressor gene product, merlin, belongs to the ezrin-radixin-moesin (ERM) subgroup of the Protein 4.1 family, which links cell surface glycoproteins to the actin cytoskeleton. Previous studies have suggested that phosphorylation of merlin, similar to other ERM proteins, may regulate its function. To determine whether merlin phosphorylation has functional consequences for merlin suppression of cell growth and motility, we generated doxycycline-regulatable RT4 schwannoma cell lines that inducibly express full-length merlin with mutations at two potential phosphorylation sites (amino-acid residues S518 and T576). Whereas a mutation at S518 that mimics constitutive phosphorylation (S518D) abrogates the ability of merlin to suppress cell growth and motility, the S518A merlin mutant, which mimics nonphosphorylated merlin, functions equivalently to wild-type merlin. Similar mutations involving T576, the analogous phosphorylation site in ERM proteins important for regulating their function, had no effect. In contrast to other functionally inactive missense merlin mutants, the regulated overexpression of S518D merlin resulted in dramatic changes in cell shape and the elaboration of filopodial extensions. These results provide the first direct demonstration that the S518D merlin mutation, which mimics merlin phosphorylation, impairs not only merlin growth and motility suppression but also leads to an acquisition of a novel phenotype previously ascribed to ERM proteins.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035848] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35848] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerley S, 2003, J CELL BIOL, V161, P489, DOI 10.1083/jcb.200303138; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bretscher A, 1995, BIOCHEMISTRY-US, V34, P16830, DOI 10.1021/bi00051a034; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; CHEN J, 1995, P NATL ACAD SCI USA, V92, P7495, DOI 10.1073/pnas.92.16.7495; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gautreau A, 2002, CURR OPIN CELL BIOL, V14, P104, DOI 10.1016/S0955-0674(01)00300-3; Gautreau A, 2000, J CELL BIOL, V150, P193, DOI 10.1083/jcb.150.1.193; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; Gopalbhai K, 2003, J BIOL CHEM, V278, P8118, DOI 10.1074/jbc.M211870200; Gutmann DH, 1998, HUM MOL GENET, V7, P335, DOI 10.1093/hmg/7.3.335; Gutmann DH, 2001, HUM MOL GENET, V10, P1519, DOI 10.1093/hmg/10.14.1519; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; MARTIN M, 1995, J CELL BIOL, V128, P1081, DOI 10.1083/jcb.128.6.1081; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sherman LS, 2001, TRENDS CELL BIOL, V11, P442, DOI 10.1016/S0962-8924(01)02128-6; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497	41	71	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					580	587		10.1038/sj.onc.1207142	http://dx.doi.org/10.1038/sj.onc.1207142			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724586				2022-12-28	WOS:000188098300029
J	Pendino, F; Dudognon, C; Delhommeau, F; Sahraoui, T; Flexor, M; Bennaceur-Griscelli, A; Lanotte, M; Segal-Bendirdjian, E				Pendino, F; Dudognon, C; Delhommeau, F; Sahraoui, T; Flexor, M; Bennaceur-Griscelli, A; Lanotte, M; Segal-Bendirdjian, E			Retinoic acid receptor alpha and retinoid-X receptor-specific agonists synergistically target telomerase expression and induce tumor cell death	ONCOGENE			English	Article						telomerase; hTERT; retinoids; RAR; RXR; nuclear receptors	ACUTE PROMYELOCYTIC LEUKEMIA; CATALYTIC SUBUNIT GENE; SELECTIVE RETINOIDS; CANCER-THERAPY; RNA COMPONENT; IDENTIFICATION; MATURATION; RESISTANCE; LINE; NB4	Retinoids modulate growth and differentiation of cancer cells through activation of gene transcription via the nuclear retinoic-acid receptors (RAR) and retinoid-X receptors (RXR). Their use in differentiation therapy of acute promyelocytic leukemia (APL) represents a model concept for reprogramming cancer cells. However, they also regulate antiproliferative genes whose functions do not mechanistically concur to this program. Recently, we have shown that, independently of maturation, a long-term all-trans retinoic acid (ATRA) treatment of the maturation-resistant APL cell line (NB4-LR1) represses telomerase (hTERT), leading to telomere shortening and death. Using retinoid-receptor-specific agonists, we demonstrate herein that cross-talk between RARalpha and RXR dual-liganded to their respective agonists resulted in strong synergistic downregulation of hTERT and subsequent cell death. Importantly, unlike ATRA, this synergy was obtained at very low agonist concentrations and occurred in other ATRA maturation-resistant APL cells. These findings provide the first demonstration that dual-liganded RXR and RARalpha signaling should allow efficient targeting of telomerase in differentiation-resistant tumor cells. Such a combination therapy might hold promise in clinic to avoid side effects of ATRA whose administration can indiscriminately activate all RARs. Given the tissue-specific expression of RARs, a tissue-selective therapy targeting telomerase in tumor cells by synthetic agonists can be envisioned.	Hop St Louis, INSERM, U496, Inst Hematol, F-75475 Paris 10, France; Inst Gustave Roussy, INSERM, U362, F-94800 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy	Segal-Bendirdjian, E (corresponding author), Hop St Louis, INSERM, U496, Inst Hematol, 1 Ave Claude Vellefaux, F-75475 Paris 10, France.	esegal@jupiter.chu-stlouis.fr	PENDINO, Frederic/G-6630-2017	bennaceur griscelli, annelise/0000-0002-3557-4499; Delhommeau, Francois/0000-0002-4915-0734; Segal-Bendirdjian, Evelyne/0000-0001-9813-4880				AMOS B, 1990, METHOD ENZYMOL, V190, P217; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI14064; DE LUCA LM, 1991, FASEB J, V5, P2924; DELESCLUSE C, 1991, MOL PHARMACOL, V40, P556; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; DUPREZ E, 1992, LEUKEMIA, V6, P1281; Fenaux P, 2001, SEMIN HEMATOL, V38, P13, DOI 10.1053/shem.2001.20862; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gallagher RE, 2002, LEUKEMIA, V16, P1940, DOI 10.1038/sj.leu.2402719; Germain P, 2002, NATURE, V415, P187, DOI 10.1038/415187a; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Helder MN, 2002, CANCER INVEST, V20, P82, DOI 10.1081/CNV-120000370; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LANOTTE M, 1991, BLOOD, V77, P1080; LEHMANN JM, 1991, CANCER RES, V51, P4804; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mergny JL, 2002, NUCLEIC ACIDS RES, V30, P839, DOI 10.1093/nar/30.4.839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; ROY DY, 1995, MOL CELL BIOL, V15, P6481; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sun SY, 2000, CLIN CANCER RES, V6, P1563; URBACH J, 1994, BIOCHEM J, V299, P459, DOI 10.1042/bj2990459; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; Weinberg RA, 1998, NATURE, V396, P23, DOI 10.1038/23825; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Xu D, 1996, LEUKEMIA, V10, P1354; Xu DW, 2000, BLOOD, V96, P4313, DOI 10.1182/blood.V96.13.4313.h8004313_4313_4318; Zusi FC, 2002, DRUG DISCOV TODAY, V7, P1165, DOI 10.1016/S1359-6446(02)02526-6	40	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2003	22	57					9142	9150		10.1038/sj.onc.1207093	http://dx.doi.org/10.1038/sj.onc.1207093			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668795				2022-12-28	WOS:000187149100004
J	Watamoto, K; Towatari, M; Ozawa, Y; Miyata, Y; Okamoto, M; Abe, A; Naoe, T; Saito, H				Watamoto, K; Towatari, M; Ozawa, Y; Miyata, Y; Okamoto, M; Abe, A; Naoe, T; Saito, H			Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation	ONCOGENE			English	Article						GATA-1; HDAC; differentiation; MEL	TRANSCRIPTION FACTOR GATA-1; HISTONE ACETYLTRANSFERASE ACTIVITY; ERYTHROID-DIFFERENTIATION; ERYTHROLEUKEMIC CELLS; HEMATOPOIETIC-CELLS; NUCLEOSOMAL DNA; SOMATIC HYBRIDS; FINGER PROTEIN; STEM-CELLS; IN-VITRO	The transcription factor GATA-1 plays a significant role in erythroid differentiation and association with CBP stimulates its activity by acetylation. It is possible that histone deacetylases (HDACs) repress the activity of GATA-1. In the present study, we investigated whether class I and class II HDACs interact with GATA-1 to regulate its function and indeed, GATA-1 is directly associated with HDAC3, HDAC4 and HDAC5. The expression pro. ling and our previous observation that GATA-2 interacts with members of the HDAC family prompted us to investigate further the biological relevance of the interaction between GATA-1 and HDAC5. Coexpression of HDAC5 suppressed the transcriptional potential of GATA-1. Our results demonstrated that GATA-1 and HDAC5 colocalized to the nucleus of murine erythroleukemia (MEL) cells. Furthermore, a portion of HDAC5 moved to the cytoplasm concomitant with MEL cell erythroid differentiation, which was induced by treatment with N,N'-hexamethylenebisacetamide. These observations support the suggestion that control of the HDAC5 nucleocytoplasmic distribution might be associated with MEL cell differentiation, possibly through regulated GATA-1 transactivation.	Nagoya Univ, Dept Mol Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Natl Nagoya Hosp, Nagoya, Aichi 4600001, Japan	Nagoya University	Towatari, M (corresponding author), Nagoya Univ, Dept Mol Med, Grad Sch Med, Nagoya, Aichi 4668550, Japan.		Naoe, Tomoki/I-1888-2012					Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; BRIEGEL K, 1993, GENE DEV, V7, P1097, DOI 10.1101/gad.7.6.1097; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CONSCIENCE JF, 1977, EXP CELL RES, V105, P401, DOI 10.1016/0014-4827(77)90137-9; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Crispino JD, 1999, MOL CELL, V3, P219, DOI 10.1016/S1097-2765(00)80312-3; CROTTA S, 1990, NUCLEIC ACIDS RES, V18, P6863, DOI 10.1093/nar/18.23.6863; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; HEBERLEIN C, 1992, MOL CELL BIOL, V12, P1815, DOI 10.1128/MCB.12.4.1815; HONG L, 1993, J BIOL CHEM, V268, P305; Hu E, 2000, J BIOL CHEM, V275, P15254, DOI 10.1074/jbc.M908988199; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LEONARD MW, 1993, DEVELOPMENT, V119, P519; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ORKIN SH, 1992, BLOOD, V80, P575; ORKIN SH, 1975, P NATL ACAD SCI USA, V72, P98, DOI 10.1073/pnas.72.1.98; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; TSAI FY, 1994, NATURE, V371, P221, DOI 10.1038/371221a0; Tsai FY, 1997, BLOOD, V89, P3636, DOI 10.1182/blood.V89.10.3636.3636_3636_3643; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang AH, 1999, MOL CELL BIOL, V19, P7816; WEISS MJ, 1995, EXP HEMATOL, V23, P99; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; Weiss MJ, 1997, MOL CELL BIOL, V17, P1642, DOI 10.1128/MCB.17.3.1642; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; Zhang P, 2000, BLOOD, V96, P2641; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	59	68	68	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9176	9184		10.1038/sj.onc.1206902	http://dx.doi.org/10.1038/sj.onc.1206902			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668799				2022-12-28	WOS:000187149100008
J	Bernardi, R; Pandolfi, PP				Bernardi, R; Pandolfi, PP			Role of PML and the PML-nuclear body in the control of programmed cell death	ONCOGENE			English	Article						apoptosis; PML-nuclear body; tumor suppression; transcription; transcription factors; cancer; APL	ACUTE PROMYELOCYTIC LEUKEMIA; INTERACTING PROTEIN KINASE-2; DNA-DAMAGE; TELOMERE MAINTENANCE; INDUCED APOPTOSIS; PREMATURE SENESCENCE; TRANSGENIC MICE; ONCOGENIC RAS; MRE11 COMPLEX; P53	PML is a tumor suppressor implicated in leukemia and cancer pathogenesis. PML epitomizes a multiprotein nuclear structure, the PML-nuclear body (PML-NB), whose proper formation and function depends on PML. Studies in knockout (KO) mic e and cells unraveled an essential pleiotropic role for PML in multiple p53-dependent and -independent apoptotic pathways. As a result, Pml(-/-) mice and cells are protected from apoptosis triggered by a number of stimuli such as ionizing radiation, interferon, ceramide, Fas and TNF. It is becoming apparent that PML and the PML-NB act as molecular hubs for the induction and/or reinforcement of programmed cell death through a selective and dynamic regulation of proapoptotic transcriptional events. In addition, recent observations propose a role for PML in checkpoint responses upon DNA damage. Moreover, PML and the PML-NB have also been implicated in the control of genomic stability and DNA repair. Here, we will discuss the molecular mechanisms by which PML regulates these processes and the implication of these findings for cancer pathogenesis and therapy.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Pathol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, 1275 York Ave, New York, NY 10021 USA.	p-pandol.@ski.mskcc.org	bernardi, rosa/B-1650-2013	bernardi, rosa/0000-0002-3607-6336				Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; Changou AC, 2001, BLOOD, V98, p99A; Chehab NH, 2000, GENE DEV, V14, P278; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Grande MA, 1996, J CELL BIOCHEM, V63, P280, DOI 10.1002/(SICI)1097-4644(19961201)63:3<280::AID-JCB3>3.0.CO;2-T; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Haber JE, 1998, CELL, V95, P583, DOI 10.1016/S0092-8674(00)81626-8; Hanada K, 1997, P NATL ACAD SCI USA, V94, P3860, DOI 10.1073/pnas.94.8.3860; Harmon FG, 1998, GENE DEV, V12, P1134, DOI 10.1101/gad.12.8.1134; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LAVAU C, 1995, ONCOGENE, V11, P871; Le S, 1999, GENETICS, V152, P143; LEBEAU MM, 2003, BLOOD           0410; Lendvay TS, 1996, GENETICS, V144, P1399; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lombard DB, 2000, CANCER RES, V60, P2331; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Michaelson JS, 1999, GENE DEV, V13, P1918, DOI 10.1101/gad.13.15.1918; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Mirzoeva OK, 2003, MOL CANCER RES, V1, P207; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pandolfi PP, 2001, ONCOGENE, V20, P5726, DOI 10.1038/sj.onc.1204600; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rego EM, 2001, J EXP MED, V193, P521, DOI 10.1084/jem.193.4.521; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707; Stadler M, 1995, ONCOGENE, V11, P2565; TERRIS B, 1995, CANCER RES, V55, P1590; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Wang XW, 2001, J BIOL CHEM, V276, P32948, DOI 10.1074/jbc.M103298200; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wiesmeijer K, 2002, J STRUCT BIOL, V140, P180, DOI 10.1016/S1047-8477(02)00529-4; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yeager TR, 1999, CANCER RES, V59, P4175; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	69	151	160	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9048	9057		10.1038/sj.onc.1207106	http://dx.doi.org/10.1038/sj.onc.1207106			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663483				2022-12-28	WOS:000187043600008
J	Stupack, DG; Cheresh, DA				Stupack, DG; Cheresh, DA			Apoptotic cues from the extracellular matrix: regulators of angiogenesis	ONCOGENE			English	Article						angiogenesis; apoptosis; endothelial cell; extracellular matrix; integrin	ENDOTHELIAL GROWTH-FACTOR; FOCAL ADHESION KINASE; SURVIVAL FACTOR; CELL-SURVIVAL; BREAST-CANCER; TUMOR-GROWTH; IN-VIVO; GLANZMANN THROMBASTHENIA; INTEGRIN ALPHA(V)BETA(3); ALPHA-V-BETA-3	A variety of factors cooperate to regulate neovessel formation and persistence. Proangiogenic growth factors have remained an area of intense interest due to their capacity to promote endothelial cell (EC) proliferation and to initiate the angiogenic program. These growth factors are associated with increased cell survival, yet paradoxically, angiogenic ECs are more susceptible to apoptosis than quiescent ECs. Survival is regulated by cooperation between growth factor receptors and integrins, which are in turn governed by the composition of the local extracellular matrix (ECM). Integrin-mediated signaling is altered or disrupted by the presence of soluble, rather than matrix-bound ligands, thus providing a means by which ECM remodeling can influence both integrin- and growth factor-mediated events. Ultimately, the collaboration of these factors determines whether ECs survive or die, thereby regulating neovascularization.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cheresh@scripps.edu			NCI NIH HHS [R01 CA107263] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abramovitch R, 1998, FEBS LETT, V425, P441, DOI 10.1016/S0014-5793(98)00283-X; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; Brassard DL, 1999, EXP CELL RES, V251, P33, DOI 10.1006/excr.1999.4559; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chen H, 2000, MATRIX BIOL, V19, P597, DOI 10.1016/S0945-053X(00)00107-4; CHERESH DA, 1991, CANCER METAST REV, V10, P3, DOI 10.1007/BF00046839; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; COLLER BS, 1991, BLOOD, V77, P75; CRAFT PS, 1994, ANN ONCOL, V5, P305, DOI 10.1093/oxfordjournals.annonc.a058829; Dickson SE, 2001, J ENDOCRINOL, V168, P409, DOI 10.1677/joe.0.1680409; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Eliceiri BP, 1998, J CELL BIOL, V140, P1255, DOI 10.1083/jcb.140.5.1255; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; Hirschi K K, 1997, EXS, V79, P419; Hodivala-Dilke KM, 1999, J CLIN INVEST, V103, P229, DOI 10.1172/JCI5487; Hood JD, 2002, SCIENCE, V296, P2404, DOI 10.1126/science.1070200; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang SL, 2001, CANCER RES, V61, P3373; ILLC D, 1995, NATURE, V377, P539; Ingber D E, 1992, Semin Cancer Biol, V3, P57; Ingber DE, 2002, CIRC RES, V91, P877, DOI 10.1161/01.RES.0000039537.73816.E5; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Jones Peter Lloyd, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P137; Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Keshet E, 1999, J CLIN INVEST, V104, P1497, DOI 10.1172/JCI8849; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kim S, 2002, J CLIN INVEST, V110, P933, DOI 10.1172/JCI200214268; Klement G, 2002, CLIN CANCER RES, V8, P221; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li LM, 2002, MOL CELL BIOL, V22, P1203, DOI 10.1128/MCB.22.4.1203-1217.2002; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mitchell CA, 1998, DEV DYNAM, V213, P322, DOI 10.1002/(SICI)1097-0177(199811)213:3<322::AID-AJA8>3.0.CO;2-E; Mitsiades N, 2001, EXPERT OPIN INV DRUG, V10, P1075, DOI 10.1517/13543784.10.6.1075; Moldovan NI, 2003, ADV EXP MED BIOL, V522, P99; Myers C, 2002, AM J PATHOL, V161, P2099, DOI 10.1016/S0002-9440(10)64488-4; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; OREILLY MS, 1994, COLD SPRING HARB SYM, V59, P471, DOI 10.1101/SQB.1994.059.01.052; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petitclerc E, 2000, J BIOL CHEM, V275, P8051, DOI 10.1074/jbc.275.11.8051; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Ruegg C, 1998, NAT MED, V4, P408, DOI 10.1038/nm0498-408; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Stromblad S, 2002, J BIOL CHEM, V277, P13371, DOI 10.1074/jbc.C200044200; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Walsh DA, 2001, ARTHRITIS RES, V3, P147, DOI 10.1186/ar292; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249	79	98	104	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9022	9029		10.1038/sj.onc.1207110	http://dx.doi.org/10.1038/sj.onc.1207110			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663480				2022-12-28	WOS:000187043600005
J	Berken, A; Abel, J; Unfried, K				Berken, A; Abel, J; Unfried, K			beta 1-integrin mediates asbestos-induced phosphorylation of AKT and ERK1/2 in a rat pleural mesothelial cell line	ONCOGENE			English	Article						asbestos; integrin; mesothelioma; ERK1/2; AKT; FAK	SIGNAL-REGULATED KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED CARCINOGENESIS; CROCIDOLITE ASBESTOS; INTEGRINS; FIBRONECTIN; ACTIVATION; PATHWAYS; ADHESION; FAK	Integrin-mediated signalling has been implicated in asbestos-induced carcinogenesis. In studies here, we examined signal transduction events associated with integrin-directed cell reactions triggered by crocidolite asbestos in the pleural mesothelial cell line 4/4 RM-4. Crocidolite fibres induced a significant time- and dose-dependent activation of the extracellular-signal-regulated kinases ERK1 and ERK2. ERK activation was specifically inhibited by integrin-blocking agents, that are integrin-binding peptides containing the sequence arginine-glycine-aspartic acid (RGD), and monoclonal antibodies against the integrin B1-chain. Integrin-dependent activation of ERK1/2 in response to asbestos appeared to be independent of focal adhesion kinase pp125(FAK) (FAK) since FAK autophosphorylation remained unaffected in crocidolite-exposed mesothelial cells. Instead, we observed striking similarities in the kinetics of asbestos-induced ERK1/2 responses and phosphorylation of protein kinase B (AKT) at serine 473, a possible target residue for integrin-linked kinase. As with ERK activation, asbestos-induced AKT stimulation was significantly blocked by both the RGD-peptide and the B1-integrin antibodies. These studies are the first to establish that in mesothelial cells ERK1/2 and AKT are simultaneously phosphorylated upon asbestos exposure in a B1-integrin-dependent manner.	Univ Dusseldorf, Inst Umweltmed Forsch, Dept Toxicol, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Unfried, K (corresponding author), Univ Dusseldorf, Inst Umweltmed Forsch, Dept Toxicol, Hennekamp 50, D-40225 Dusseldorf, Germany.	Klaus.Unfried@uni-duesseldorf.de						Albrecht C, 2002, TOXICOL APPL PHARM, V184, P37, DOI 10.1006/taap.2002.9500; Aplin AE, 1998, PHARMACOL REV, V50, P197; ARONSON JF, 1981, AM J RESP CELL MOL B, V15, P141; BOYLAN AM, 1995, J CLIN INVEST, V96, P1987, DOI 10.1172/JCI118246; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coffer PJ, 1998, BIOCHEM J, V335, P1; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KUWAHARA M, 1994, AM J RESP CELL MOL, V10, P167, DOI 10.1165/ajrcmb.10.2.8110473; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Levy Y, 2003, J BIOL CHEM, V278, P14533, DOI 10.1074/jbc.M207380200; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Liu WH, 2000, AM J RESP CELL MOL, V23, P371, DOI 10.1165/ajrcmb.23.3.4094; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Roller M, 1996, EXP TOXICOL PATHOL, V48, P3, DOI 10.1016/S0940-2993(96)80084-4; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sandhu H, 2000, INHAL TOXICOL, V12, P337, DOI 10.1080/08958378.2000.11463243; Sandhu H, 2000, CARCINOGENESIS, V21, P1023, DOI 10.1093/carcin/21.5.1023; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Unfried K, 2000, INHAL TOXICOL, V12, P149, DOI 10.1080/08958378.2000.11463208; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684	30	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8524	8528		10.1038/sj.onc.1207195	http://dx.doi.org/10.1038/sj.onc.1207195			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627993				2022-12-28	WOS:000186650300016
J	Florensa, R; Bachs, O; Agell, N				Florensa, R; Bachs, O; Agell, N			ATM/ATR-independent inhibition of cyclin B accumulation in response to hydroxyurea in nontransformed cell lines is altered in tumour cell lines	ONCOGENE			English	Article						hydroxyurea; ATM; ATR; caffeine; cyclin B1; replication checkpoint	DNA-DAMAGE; S-PHASE; REPLICATION CHECKPOINT; POLYMERASE-ALPHA; G2/M TRANSITION; PROTEIN-KINASE; ATR; ACTIVATION; PHOSPHORYLATION; MITOSIS	The DNA replication checkpoint is an inhibitory pathway ensuring that mitosis occurs only after completion of DNA synthesis. Its function may be relevant to the stability of the genome. The essential elements of this checkpoint are ATM/ATR kinases that indirectly lead to the phosphorylation and inhibition of the mitosis-promoting factor (Cdc2/cyclin B1). The function of this checkpoint was analysed in diverse nontransformed and tumour-derived cell lines. All cell lines tested arrested mitosis entry when DNA synthesis was inhibited by hydroxyurea (HU) treatment. But, unlike what has been described in yeast and Xenopus, in normal rat kidney (NRK) cells and NIH 3T3 fibroblasts, the arrest induced by HU treatment was not abrogated by caffeine, an ATM and ATR inhibitor. This indicated the presence of an ATM/ATR-independent response to DNA synthesis inhibition in these nontransformed mammalian cell lines. Interestingly, the behaviour of different tumour cell lines after caffeine treatment varied. While SW480, NP29, NP18 and HeLa cells did not enter mitosis in the presence of caffeine after HU treatment, in CaCo2, DLD1, HCT116 and HT29 caffeine abrogated the checkpoint response. In nontransformed cell lines, lack of cyclin B1 accumulation was observed when DNA synthesis was inhibited. This response was not abrogated by caffeine. In the tumour cell lines, a good correlation between the ability to arrest cell cycle when DNA synthesis was inhibited in the presence of caffeine and the lack of cyclin B1 accumulation was observed. Thus, there is an ATM/ATR-independent checkpoint response that leads to a decrease in cyclin B1 accumulation. However, this response is not functional in some tumour cell lines. Using inhibitors of p38alpha and beta, Mek1, 2 and p53-/- knocked-out fibroblasts, we showed that these proteins were also not involved in this particular checkpoint response. Lack of cyclin B1 accumulation after DNA synthesis inhibition in NRK cells was not due to increased degradation of the protein, but correlated with a decrease in mRNA accumulation.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi i Sunyer IDIBAPS, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi i Sunyer IDIBAPS, E-08036 Barcelona, Spain.	agell@medicina.ub.es	Agell, Neus/E-9640-2016	Agell, Neus/0000-0002-1205-6074				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bulavin DV, 2002, CURR OPIN GENET DEV, V12, P92, DOI 10.1016/S0959-437X(01)00270-2; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; DURSO G, 1995, J CELL SCI, V108, P3109; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hwang A, 1998, J BIOL CHEM, V273, P31505, DOI 10.1074/jbc.273.47.31505; HWANG A, 1995, J BIOL CHEM, V270, P28419; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KREK W, 1992, NEW BIOL, V4, P323; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Rhind N, 1998, MOL CELL BIOL, V18, P3782, DOI 10.1128/MCB.18.7.3782; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Sarkaria JN, 1999, CANCER RES, V59, P4375; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; Stokes MP, 2002, J CELL BIOL, V158, P863, DOI 10.1083/jcb.200204127; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Ye X S, 1997, Prog Cell Cycle Res, V3, P221; You ZZ, 2002, J BIOL CHEM, V277, P27088, DOI 10.1074/jbc.M204120200; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	56	14	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8283	8292		10.1038/sj.onc.1207159	http://dx.doi.org/10.1038/sj.onc.1207159			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614452				2022-12-28	WOS:000186541500007
J	Izumiyama, K; Nakagawa, M; Yonezumi, M; Kasugai, Y; Suzuki, R; Suzuki, H; Tsuzuki, S; Hosokawa, Y; Asaka, M; Seto, M				Izumiyama, K; Nakagawa, M; Yonezumi, M; Kasugai, Y; Suzuki, R; Suzuki, H; Tsuzuki, S; Hosokawa, Y; Asaka, M; Seto, M			Stability and subcellular localization of API2-MALT1 chimeric protein involved in t(11;18) (q21;q21) MALT lymphoma	ONCOGENE			English	Article						MALT lymphoma; chromosome trans location; API2; MALT1; API2-MALT1	B-CELL LYMPHOMA; TISSUE LYMPHOMA; LOW-GRADE; GENE; APOPTOSIS; T(11-18)(Q21-Q21); INHIBITOR; FUSION; LIGASE; BCL10	t(11;18) (q21;q21) is a chromosomal aberration specific to low-grade mucosa-associated lymphoid tissue (MALT) lymphoma, and generates the chimeric product apoptosis inhibitor 2 (API2)-MALT1, which has been suggested to play an important role in MALT lymphomagenesis. However, little is known about the characteristics of API2, MALT1, and API2-MALT1 proteins. We therefore investigated the subcellular localization and stability of these products. API2 was localized in the nucleus and the cytoplasm, and MALT1 and API2-MALT1 in the cytoplasm only. Western blot analysis showed that the products of API2 and MALT1 were unstable, while the API2-MALT1 product was stable. The API2 deletion mutants at the end of the C-terminal and the MALT1 deletion mutants at the end of the N-terminal were stable compared with the full-length products. These results indicate that the domains responsible for protein instability are located in the end of the C-terminal of API2 and in that of the N-terminal of MALT1, and also that API2-MALT1 became stable because it lacks these domains. It has been suggested that NF-kappaB activation plays an important role in the tumorigenesis of MALT lymphoma. Our findings further suggest that the stabilized expression of API2-MALT1 products may continuously stimulate the NF-kappaB activating pathway, thus leading to MALT lymphomagenesis.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido 0608638, Japan	Aichi Cancer Center; Hokkaido University	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.		Asaka, Masahiro/A-5948-2012	Tsuzuki, Shinobu/0000-0002-3209-3550; Kasugai, Yumiko/0000-0003-4764-4455; Suzuki, Ritsuro/0000-0002-5974-7614				Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hozak RR, 2000, MOL CELL BIOL, V20, P1877, DOI 10.1128/MCB.20.5.1877-1885.2000; Huang HK, 2000, J BIOL CHEM, V275, P26661; Inagaki H, 2001, AM J PATHOL, V158, P699, DOI 10.1016/S0002-9440(10)64012-6; Isaacson PG, 1999, SEMIN HEMATOL, V36, P139; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; Kalla J, 2000, LEUKEMIA, V14, P1967, DOI 10.1038/sj.leu.2401918; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; McAllister-Lucas LM, 2001, J BIOL CHEM, V276, P30589, DOI 10.1074/jbc.M103824200; Morgan JA, 1999, CANCER RES, V59, P6205; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; Ott G, 1997, CANCER RES, V57, P3944; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Remstein ED, 2000, AM J PATHOL, V156, P1183, DOI 10.1016/S0002-9440(10)64988-7; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Suzuki H, 1999, BLOOD, V94, P3270, DOI 10.1182/blood.V94.9.3270.421a44b_3270_3271; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yonezumi M, 2001, BRIT J HAEMATOL, V115, P588, DOI 10.1046/j.1365-2141.2001.03158.x; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767	27	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8085	8092		10.1038/sj.onc.1207002	http://dx.doi.org/10.1038/sj.onc.1207002			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603249				2022-12-28	WOS:000186403400003
J	Araki, K; Nakajima, Y; Eto, K; Ikeda, MA				Araki, K; Nakajima, Y; Eto, K; Ikeda, MA			Distinct recruitment of E2F family members to specific E2F-binding sites mediates activation and repression of the E2F1 promoter	ONCOGENE			English	Article						E2F1; cell cycle; transcription; E2F; corepressor	CELL-CYCLE REGULATION; TRANSCRIPTION FACTOR E2F; B-MYB TRANSCRIPTION; IN-VIVO; REGULATED TRANSCRIPTION; FUNCTIONAL INTERACTION; THYMIDINE KINASE; RESPONSIVE GENES; MAMMALIAN CDC6; S-PHASE	The activity of E2F transcription factors plays a crucial role in mammalian cell-cycle progression and is controlled by physical association with the pocket proteins (pRb and its related p107 and p130). The E2F1 promoter, which contains two overlapping E2F-binding sites, is activated at the G1/S transition in an E2F-dependent manner. Mutational experiments have shown that the distal E2F-binding site on the E2F1 promoter is required for transcriptional repression in the G0 phase, whereas the proximal E2F-binding site contributes to transcriptional activation at the G1/S boundary. Consistent with these results, chromatin immunoprecipitation assays have revealed that the E2F4/p130 repressor complex specifically binds to the distal E2F-binding site, whereas E2F1 and E2F3 activators preferentially bind to the proximal E2F-binding site. The assays also showed that the specific binding of E2F4/p130 complex to the distal site was dramatically impaired by a mutation introduced into the contiguous repression site ( cell Cycle gene Homology Region; CHR). Taken together, these findings indicate that the two E2F-binding sites play distinct roles in the regulation of E2F1 transcription by interacting with different sets of E2F members and cooperating with the contiguous repressor element.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Craniofacial Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Grad Sch, Sect Oral Surg, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							Bennett JD, 1996, ONCOGENE, V13, P1073; Botz J, 1996, MOL CELL BIOL, V16, P3401; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; DOU QP, 1992, P NATL ACAD SCI USA, V89, P3256, DOI 10.1073/pnas.89.8.3256; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rotheneder H, 1999, J MOL BIOL, V293, P1005, DOI 10.1006/jmbi.1999.3213; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Takahashi Y, 2000, GENE DEV, V14, P804; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wu LL, 2000, MOL CELL BIOL, V20, P7059, DOI 10.1128/MCB.20.19.7059-7067.2000; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	42	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7632	7641		10.1038/sj.onc.1206840	http://dx.doi.org/10.1038/sj.onc.1206840			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576826				2022-12-28	WOS:000186113000011
J	Bartley, PA; Keough, RA; Lutwyche, JK; Gonda, TJ				Bartley, PA; Keough, RA; Lutwyche, JK; Gonda, TJ			Regulation of the gene encoding glutathione S-transferase M1 (GSTM1) by the Myb oncoprotein	ONCOGENE			English	Article						Myb; transactivation; glutathione S-transferase; promoter	C-MYB; GROWTH-FACTORS; MYELOID CELLS; V-MYB; EXPRESSION; TRANSFORMATION; APOPTOSIS; PROTEIN; DIFFERENTIATION; PROMOTER	The identification of Myb 'target' genes will not only aid in the understanding of how overexpression of Myb, or expression of activated forms of Myb, leads to cellular transformation but will also shed light on its role in normal cells. Using a combination of an estrogen-regulated Myb-transformed cell line (ERMYB) and PCR-based subtractive hybridization, we have identified the gene (GSTM1) encoding the detoxification enzyme glutathione S-transferase M1 as being transcriptionally upregulated by Myb. Functional analysis of the GSTM1 promoter using reporter assays indicated that both the DNA binding and transactivation domains of Myb were required for transcriptional activation. Mutational analysis of consensus Myb-binding sites (MBS) in the promoter and electrophoretic mobility gel shift analysis indicated that one of the three potential MBS can bind Myb protein, and is the primary site involved in the regulation of this promoter by Myb.	Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; University of Adelaide	Gonda, TJ (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.		Gonda, Thomas J/A-3620-2012					Bartley PA, 2001, BLOOD CELL MOL DIS, V27, P409, DOI 10.1006/bcmd.2001.0398; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVOIE L, 1992, J BIOL CHEM, V267, P3632; MACMILLAN EM, 1994, BLOOD, V83, P209; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1995, ONCOGENE, V11, P2113; REINHART J, 1993, ARCH BIOCHEM BIOPHYS, V303, P383, DOI 10.1006/abbi.1993.1299; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sattler M, 1999, BLOOD, V93, P2928; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Vanhaecke T, 2000, BIOCHEM PHARMACOL, V60, P1491, DOI 10.1016/S0006-2952(00)00446-9; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8	33	11	11	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7570	7575		10.1038/sj.onc.1207136	http://dx.doi.org/10.1038/sj.onc.1207136			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576818				2022-12-28	WOS:000186113000003
J	Clarke, R; Liu, MC; Bouker, KB; Gu, ZP; Lee, RY; Zhu, YL; Skaar, TC; Gomez, B; O'Brien, K; Wang, Y; Hilakivi-Clarke, L				Clarke, R; Liu, MC; Bouker, KB; Gu, ZP; Lee, RY; Zhu, YL; Skaar, TC; Gomez, B; O'Brien, K; Wang, Y; Hilakivi-Clarke, L			Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling	ONCOGENE			English	Review						tamoxifen; Faslodex; ICI 182,780; estrogen receptor; coregulator	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; REGULATORY FACTOR-I; PROTEIN-KINASE-C; TRANSCRIPTION FACTOR IRF-1; TAMOXIFEN-INDUCED APOPTOSIS; HORMONE-INDEPENDENT GROWTH; MESSENGER-RNA EXPRESSION; LIGAND-BINDING DOMAIN	Antiestrogens include agents such as tamoxifen, toremifene, raloxifene, and fulvestrant. Currently, tamoxifen is the only drug approved for use in breast cancer chemoprevention, and it remains the treatment of choice for most women with hormone receptor positive, invasive breast carcinoma. While antiestrogens have been available since the early 1970s, we still do not fully understand their mechanisms of action and resistance. Essentially, two forms of antiestrogen resistance occur: de novo resistance and acquired resistance. Absence of estrogen receptor (ER) expression is the most common de novo resistance mechanism, whereas a complete loss of ER expression is not common in acquired resistance. Antiestrogen unresponsiveness appears to be the major acquired resistance phenotype, with a switch to an antiestrogen-stimulated growth being a minor phenotype. Since antiestrogens compete with estrogens for binding to ER, clinical response to antiestrogens may be affected by exogenous estrogenic exposures. Such exposures include estrogenic hormone replacement therapies and dietary and environmental exposures that directly or indirectly increase a tumor's estrogenic environment. Whether antiestrogen resistance can be conferred by a switch from predominantly ERalpha to ERbeta expression remains unanswered, but predicting response to antiestrogen therapy requires only measurement of ERalpha expression. The role of altered receptor coactivator or corepressor expression in antiestrogen resistance also is unclear, and understanding their roles may be confounded by their ubiquitous expression and functional redundancy. We have proposed a gene network approach to exploring the mechanistic aspects of antiestrogen resistance. Using transcriptome and proteome analyses, we have begun to identify candidate genes that comprise one component of a larger, putative gene network. These candidate genes include NFkappaB, interferon regulatory factor- 1, nucleophosmin, and the X-box binding protein-1. The network also may involve signaling through ras and MAPK, implicating crosstalk with growth factors and cytokines. Ultimately, signaling affects the expression/function of the proliferation and/ or apoptotic machineries.	Georgetown Univ, Sch Med, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Med, Vincent T Lombardi Canc Res Ctr, Washington, DC 20057 USA; Celera Genom, Rockville, MD 20850 USA; Indiana Univ, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA; Catholic Univ Amer, Dept Elect Engn & Comp Sci, Washington, DC 20064 USA	Georgetown University; Georgetown University; Indiana University System; Indiana University-Purdue University Indianapolis; Catholic University of America	Clarke, R (corresponding author), Georgetown Univ, Sch Med, Dept Oncol, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	clarker@georgetown.edu	Skaar, Todd/ABD-7827-2021; Clarke, Robert/A-6485-2008	Clarke, Robert/0000-0002-9278-0854	NATIONAL CANCER INSTITUTE [P30CA051008, R01CA058022, P50CA058185, R01CA089950] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA 58185-10, R01 CA/AG 58022-10, R10 CA 089950-02, P30 CA 51008-14] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAMDAL S, 1984, CANCER-AM CANCER SOC, V53, P2525, DOI 10.1002/1097-0142(19840601)53:11<2525::AID-CNCR2820531126>3.0.CO;2-8; ADLERCREUTZ H, 1995, ENVIRON HEALTH PERSP, V103, P103, DOI 10.2307/3432518; Agarwal R, 2000, BIOCHEM PHARMACOL, V60, P1051, DOI 10.1016/S0006-2952(00)00385-3; Alberts SR, 1996, CANCER-AM CANCER SOC, V78, P764; Allred CD, 2001, CANCER RES, V61, P5045; ANZANO MA, 1994, CANCER RES, V54, P4614; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; Azorsa DO, 2001, BREAST CANCER RES TR, V70, P89, DOI 10.1023/A:1012972808558; Bachleitner-Hofmann T, 2002, CLIN CANCER RES, V8, P3427; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BARNES S, 1994, ADV EXP MED BIOL, V354, P135; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Beatson G., 1896, LANCET, V2, P104, DOI DOI 10.1016/S0140-6736(01)72307-0; BECKMANN R, 1992, EUR J BIOCHEM, V210, P45, DOI 10.1111/j.1432-1033.1992.tb17388.x; Berger T, 2000, J CELL SCI, V113, P3603; Bishop CM, 1998, IEEE T PATTERN ANAL, V20, P281, DOI 10.1109/34.667885; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 1998, J BIOL CHEM, V273, P33817, DOI 10.1074/jbc.273.50.33817; BOCKER T, 1995, MODERN PATHOL, V8, P226; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bouker KB, 2000, ENVIRON HEALTH PERSP, V108, P701, DOI 10.2307/3434722; Bouker Kerrie B., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P761; Bouras T, 2001, CANCER RES, V61, P903; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Bradlow HL, 1999, ANN NY ACAD SCI, V889, P204, DOI 10.1111/j.1749-6632.1999.tb08736.x; Brankin B, 1998, CANCER EPIDEM BIOMAR, V7, P1109; BRUNNER N, 1993, CANCER RES, V53, P3229; Brunner N, 1997, CANCER RES, V57, P3486; BRUNNER N, 1993, CANCER RES, V53, P283; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BUCKLEY MMT, 1989, DRUGS, V37, P451, DOI 10.2165/00003495-198937040-00004; Burow ME, 1998, CANCER RES, V58, P4940; Buzdar A, 2001, CLIN CANCER RES, V7, P2620; Buzdar A, 1996, J CLIN ONCOL, V14, P2000, DOI 10.1200/JCO.1996.14.7.2000; Byrne GJ, 2000, J NATL CANCER I, V92, P1329, DOI 10.1093/jnci/92.16.1329; Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5; Carroll JS, 2002, CANCER RES, V62, P3126; Castro-Rivera E, 2001, J BIOL CHEM, V276, P30853, DOI 10.1074/jbc.M103339200; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; Cavalieri EL, 2002, ANN NY ACAD SCI, V959, P341, DOI 10.1111/j.1749-6632.2002.tb02105.x; Chan CMW, 1999, CLIN CANCER RES, V5, P3460; Chan TW, 2001, CLIN CANCER RES, V7, P2545; Chapman NR, 2000, J BIOL CHEM, V275, P4719, DOI 10.1074/jbc.275.7.4719; Chlebowski RT, 2002, J CLIN ONCOL, V20, P3328, DOI 10.1200/JCO.2002.06.029; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; Clarke M, 1998, LANCET, V351, P1451; CLARKE P, 2001, BIOLOGIST, V48, P21; CLARKE R, 1989, J ENDOCRINOL, V122, P331, DOI 10.1677/joe.0.1220331; CLARKE R, 1990, J NATL CANCER I, V82, P1702, DOI 10.1093/jnci/82.21.1702; CLARKE R, 1992, J NATL CANCER I, V84, P1506, DOI 10.1093/jnci/84.19.1506; Clarke R, 2001, J STEROID BIOCHEM, V76, P71, DOI 10.1016/S0960-0760(00)00193-X; Clarke R, 2001, PHARMACOL REV, V53, P25; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; CLARKE R, 1990, ANN ONCOL, V1, P401, DOI 10.1093/oxfordjournals.annonc.a057790; CLARKE R, 1995, ENDOCR-RELAT CANCER, V2, P59, DOI 10.1677/erc.0.0020059; CLARKE R, 1996, TRENDS ENDOCRIN MET, V7, P25; CLARKE R, 1992, DRUG RESISTANCE ONCO, P501; Clarke SD, 2002, ANN NY ACAD SCI, V967, P283, DOI 10.1111/j.1749-6632.2002.tb04284.x; Clarkson RWE, 1999, J MAMMARY GLAND BIOL, V4, P165, DOI 10.1023/A:1018725207969; CLARYSSE A, 1985, EUR J CANCER CLIN ON, V21, P545, DOI 10.1016/0277-5379(85)90077-X; Clauss IM, 1996, NUCLEIC ACIDS RES, V24, P1855, DOI 10.1093/nar/24.10.1855; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; COLE MP, 1971, BRIT J CANCER, V25, P270, DOI 10.1038/bjc.1971.33; Collins BM, 1997, STEROIDS, V62, P365, DOI 10.1016/S0039-128X(96)00246-2; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Connor CE, 2001, CANCER RES, V61, P2917; Contente S, 1999, MOL CELL BIOCHEM, V194, P79, DOI 10.1023/A:1006913122261; Conze D, 2001, CANCER RES, V61, P8851; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cuny M, 2000, CANCER RES, V60, P1077; DAI P, 2003, UNPUB; Das A, 2001, J BIOL CHEM, V276, P3279, DOI 10.1074/jbc.M008454200; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Davies GC, 1999, OBSTET GYNECOL, V93, P558, DOI 10.1016/S0029-7844(98)00476-1; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; deGraffenried LA, 2003, ANN ONCOL, V14, P1051, DOI 10.1093/annonc/mdg291; Delgado M, 1999, J IMMUNOL, V162, P4685; Depypere HT, 2000, EUR J CANCER, V36, pS73; DeVincenzo R, 1996, INT J CANCER, V68, P340, DOI 10.1002/(SICI)1097-0215(19961104)68:3<340::AID-IJC12>3.0.CO;2-C; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dotzlaw H, 1999, CANCER RES, V59, P529; Dowsett M, 1997, J STEROID BIOCHEM, V61, P261; Drew PD, 1995, J INTERF CYTOK RES, V15, P1037, DOI 10.1089/jir.1995.15.1037; Dumont JA, 1996, CELL GROWTH DIFFER, V7, P351; *EBCTCG, 1992, LANCET, V399, P1; Egeblad M, 2000, INT J CANCER, V86, P617, DOI 10.1002/(SICI)1097-0215(20000601)86:5<617::AID-IJC3>3.3.CO;2-Q; Ellis M, 2002, CLIN CANCER RES, V8, P1155; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; ENCARNACION CA, 1993, BREAST CANCER RES TR, V26, P237, DOI 10.1007/BF00665801; Escalante CR, 1998, NATURE, V391, P103, DOI 10.1038/34224; ETIENNE MC, 1989, BRIT J CANCER, V60, P30, DOI 10.1038/bjc.1989.214; Fattman CL, 1998, CANCER LETT, V130, P103, DOI 10.1016/S0304-3835(98)00121-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Freedman M, 2001, J NATL CANCER I, V93, P51, DOI 10.1093/jnci/93.1.51; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fuqua SAW, 2001, J MAMMARY GLAND BIOL, V6, P407, DOI 10.1023/A:1014782813943; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Glaeser M, 2001, HORM METAB RES, V33, P121, DOI 10.1055/s-2001-14938; GOSS PE, 1995, CLIN CANCER RES, V1, P287; GOTTARDIS MM, 1989, CANCER RES, V49, P4765; Grady D, 2002, JAMA-J AM MED ASSOC, V288, P49, DOI 10.1001/jama.288.1.49; Graham JD, 2000, J STEROID BIOCHEM, V74, P255, DOI 10.1016/S0960-0760(00)00101-1; Gu Z., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P573; Gu ZP, 2002, CANCER RES, V62, P3428; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Hardman WE, 2001, CLIN CANCER RES, V7, P2041; Harris HA, 2002, STEROIDS, V67, P379, DOI 10.1016/S0039-128X(01)00194-5; Hehner SP, 1999, J IMMUNOL, V163, P5617; HERBST AL, 1964, CANC CHEMOTHER REP, V443, P39; HERRERA JE, 1995, NUCLEIC ACIDS RES, V23, P3974, DOI 10.1093/nar/23.19.3974; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584; Hilakivi-Clarke L, 2002, J STEROID BIOCHEM, V80, P163, DOI 10.1016/S0960-0760(01)00184-4; HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372; HILAKIVICLARKE L, 1999, BREAST CANC MOL GENE, P537; Hoffman B, 2002, ONCOGENE, V21, P3414, DOI 10.1038/sj.onc.1205400; HONIG SF, 1996, DIS BREAST, P669; Hopp TA, 1998, J MAMMARY GLAND BIOL, V3, P73, DOI 10.1023/A:1018726418931; Howell A, 2001, CLIN CANCER RES, V7, p4369S; Howell A, 1996, BRIT J CANCER, V74, P300, DOI 10.1038/bjc.1996.357; HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1; HSIEH C, 1994, EUR J CANCER, V30A, P969, DOI 10.1016/0959-8049(94)90125-2; Hsieh CY, 1998, CANCER RES, V58, P3833; Huang RP, 1997, INT J CANCER, V72, P102, DOI 10.1002/(SICI)1097-0215(19970703)72:1<102::AID-IJC15>3.0.CO;2-L; HULKA BS, 1995, LANCET, V346, P883, DOI 10.1016/S0140-6736(95)92713-1; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HUOVINEN R, 1993, INT J CANCER, V55, P685, DOI 10.1002/ijc.2910550429; HWANG PLH, 1987, BIOCHEM J, V243, P359, DOI 10.1042/bj2430359; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Jiang PS, 1999, BIOCHEM BIOPH RES CO, V257, P865, DOI 10.1006/bbrc.1999.0551; JIANG SY, 1992, MOL ENDOCRINOL, V6, P2167, DOI 10.1210/me.6.12.2167; Joensuu H, 2000, BREAST CANCER RES TR, V63, P225, DOI 10.1023/A:1006465732143; Johnston SRD, 2001, CLIN CANCER RES, V7, p4376S; Ju YH, 2002, CANCER RES, V62, P2474; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KARNIK PS, 1994, CANCER RES, V54, P349; Katchamart S, 2001, COMP BIOCHEM PHYS C, V129, P377, DOI 10.1016/S1532-0456(01)00217-4; Keane MM, 1996, CANCER RES, V56, P4791; Kenny FS, 2001, INT J CANCER, V92, P342, DOI 10.1002/ijc.1213; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kinsinger LS, 2002, ANN INTERN MED, V137, P59, DOI 10.7326/0003-4819-137-1-200207020-00017; Kirchhoff S, 1999, EUR J BIOCHEM, V261, P546, DOI 10.1046/j.1432-1327.1999.00308.x; KIRKMAN H, 1972, PROG EXP TUMOR RES, V16, P201; Kishimoto T, 1998, CELL GROWTH DIFFER, V9, P337; KISTNER R W, 1960, Surg Forum, V10, P725; Koh KK, 1999, CIRCULATION, V100, P1851, DOI 10.1161/01.CIR.100.18.1851; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Kurokawa H, 2000, CANCER RES, V60, P5887; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; KYPRIANOU N, 1991, CANCER RES, V51, P162; LACASSAGNE A, 1932, CR HEBD ACAD SCI, V195, P639; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Leclercq G, 2002, J STEROID BIOCHEM, V80, P259, DOI 10.1016/S0960-0760(02)00026-2; Lee AH, 2000, BIOCHEM J, V350, P131, DOI 10.1042/0264-6021:3500131; Lee KC, 2001, TRENDS ENDOCRIN MET, V12, P191, DOI 10.1016/S1043-2760(01)00392-7; Leygue E, 1998, CANCER RES, V58, P3197; Liao DJ, 2000, ENDOCR-RELAT CANCER, V7, P143, DOI 10.1677/erc.0.0070143; Liberopoulos E, 2002, ONCOLOGY-BASEL, V62, P115, DOI 10.1159/000048256; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; LITHERLAND S, 1988, CANCER TREAT REV, V15, P183, DOI 10.1016/0305-7372(88)90002-3; Liu CT, 1998, CANCER GENE THER, V5, P3; Liu H, 2002, J BIOL CHEM, V277, P9189, DOI 10.1074/jbc.M108335200; Liu MM, 2002, J BIOL CHEM, V277, P24353, DOI 10.1074/jbc.M201829200; Liu WH, 1999, INT J CANCER, V83, P765, DOI 10.1002/(SICI)1097-0215(19991210)83:6<765::AID-IJC12>3.0.CO;2-J; LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803; Lu LJW, 2000, CANCER RES, V60, P4112; Luboshits G, 1999, CANCER RES, V59, P4681; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Mandlekar S, 2000, CANCER RES, V60, P6601; Mandlekar S, 2000, CANCER RES, V60, P5995; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MARTIN PM, 1978, ENDOCRINOLOGY, V103, P1860, DOI 10.1210/endo-103-5-1860; Maruyama S, 2001, J STEROID BIOCHEM, V78, P177, DOI 10.1016/S0960-0760(01)00083-8; MCCORMICK DL, 1986, CARCINOGENESIS, V7, P193, DOI 10.1093/carcin/7.2.193; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McMichael-Phillips DF, 1998, AM J CLIN NUTR, V68, p1431S, DOI 10.1093/ajcn/68.6.1431S; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; MILLER MA, 1984, ENDOCRINOLOGY, V114, P296, DOI 10.1210/endo-114-1-296; Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200; Molino A, 1997, BREAST CANCER RES TR, V45, P241, DOI 10.1023/A:1005769925670; Montano MM, 1997, P NATL ACAD SCI USA, V94, P2581, DOI 10.1073/pnas.94.6.2581; Mori K, 1999, J CELL BIOCHEM, V74, P211, DOI 10.1002/(SICI)1097-4644(19990801)74:2<211::AID-JCB7>3.0.CO;2-U; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Murphy LC, 1998, J STEROID BIOCHEM, V65, P175, DOI 10.1016/S0960-0760(98)00012-0; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NARDULLI AM, 1995, MOL ENDOCRINOL, V9, P1064, DOI 10.1210/me.9.8.1064; *NAT TOX PROGR, 2002, 10 US DEP HLTH HUM S; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Nicholson RI, 2001, ENDOCR-RELAT CANCER, V8, P175, DOI 10.1677/erc.0.0080175; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOMURA Y, 1990, JNCI-J NATL CANCER I, V82, P1146, DOI 10.1093/jnci/82.13.1146; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Nozawa Y, 1996, J PATHOL, V178, P48; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; Okubo T, 1998, CANCER LETT, V122, P9, DOI 10.1016/S0304-3835(97)00359-5; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; OSBORNE CK, 1987, EUR J CANCER CLIN ON, V23, P1189; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; Petrakis NL, 1996, CANCER EPIDEM BIOMAR, V5, P785; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; Planas-Silva MD, 2001, CANCER RES, V61, P3858; PLOTKIN D, 1978, JAMA-J AM MED ASSOC, V240, P2644, DOI 10.1001/jama.240.24.2644; Powles T, 1998, LANCET, V352, P98; Pyrhonen S, 1999, BREAST CANCER RES TR, V56, P133; RAUGHT B, 1994, MOL CELL BIOL, V14, P1752, DOI 10.1128/MCB.14.3.1752; Reckless J, 1997, CIRCULATION, V95, P1542; Reimold AM, 2000, GENE DEV, V14, P152; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Robertson JFR, 2001, BRIT J CANCER, V85, P11, DOI 10.1054/bjoc.2001.1982; ROOS W, 1983, J NATL CANCER I, V71, P55; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; ROWLANDS MG, 1995, BIOCHEM PHARMACOL, V50, P723, DOI 10.1016/0006-2952(95)00186-4; Rubinstein YR, 1998, FEBS LETT, V431, P268, DOI 10.1016/S0014-5793(98)00774-1; SANCEAU J, 1995, J BIOL CHEM, V270, P27920, DOI 10.1074/jbc.270.46.27920; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Santell RC, 1997, J NUTR, V127, P263, DOI 10.1093/jn/127.2.263; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Saunders PTK, 2002, BRIT J CANCER, V86, P250, DOI 10.1038/sj/bjc/6600035; Schairer C, 1999, J NATL CANCER I, V91, P264, DOI 10.1093/jnci/91.3.264; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Schiff R, 2000, J NATL CANCER I, V92, P1926, DOI 10.1093/jnci/92.23.1926; SCHINKEL AH, 1991, CANCER RES, V51, P2628; Schwartz JA, 2002, J BIOL CHEM, V277, P13202, DOI 10.1074/jbc.M112215200; Sers C, 2002, ONCOGENE, V21, P2829, DOI 10.1038/sj.onc.1205377; SheenChen SM, 1997, BREAST CANCER RES TR, V43, P211, DOI 10.1023/A:1005736712307; Shiau AK, 2002, NAT STRUCT BIOL, V9, P359, DOI 10.1038/nsb787; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Skaar TC, 1998, J STEROID BIOCHEM, V67, P391, DOI 10.1016/S0960-0760(98)00142-3; SKAAR TC, 2000, P AM ASSOC CANC RES, V41, P428; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 2002, MOL CELL BIOL, V22, P525, DOI 10.1128/MCB.22.2.525-535.2002; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Speirs V, 1999, CANCER RES, V59, P5421; Speirs V, 1999, CANCER RES, V59, P525; Speirs V, 2002, J PATHOL, V197, P143, DOI 10.1002/path.1072; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stewart HJ, 1996, BRIT J CANCER, V74, P297, DOI 10.1038/bjc.1996.356; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan-Chiu E, 2003, J NATL CANCER I, V95, P302, DOI 10.1093/jnci/95.4.302; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, J CELL PHYSIOL, V173, P128, DOI 10.1002/(SICI)1097-4652(199711)173:2<128::AID-JCP8>3.0.CO;2-P; TAYLOR IW, 1983, CANCER RES, V43, P4007; Tchoudakova A, 1999, GEN COMP ENDOCR, V113, P388, DOI 10.1006/gcen.1998.7217; Tebar F, 2002, FEBS LETT, V517, P206, DOI 10.1016/S0014-5793(02)02624-8; Toillon RA, 2002, EXP CELL RES, V275, P31, DOI 10.1006/excr.2002.5490; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; Tremblay GB, 1998, CANCER RES, V58, P877; Trock B, 2001, J NUTR, V130, P690; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Tsai JC, 2000, AM J PHYSIOL-CELL PH, V279, pC1414, DOI 10.1152/ajpcell.2000.279.5.C1414; Tyulmenkov VV, 2000, MOL CELL ENDOCRINOL, V165, P151, DOI 10.1016/S0303-7207(00)00250-1; Varley CL, 1999, BIOCHEM BIOPH RES CO, V263, P627, DOI 10.1006/bbrc.1999.1431; Varma H, 2002, CANCER RES, V62, P3985; Veronesi U, 1998, LANCET, V352, P93; Veronesi U, 2003, J NATL CANCER I, V95, P160, DOI 10.1093/jnci/95.2.160; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG DR, 1994, J BIOL CHEM, V269, P30994; Wang TTY, 1996, CARCINOGENESIS, V17, P271, DOI 10.1093/carcin/17.2.271; WELCH JN, 2002, SIGNAL, V3, P4; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Winer EP, 2002, J CLIN ONCOL, V20, P3317, DOI 10.1200/JCO.2002.06.020; Wurtz JM, 1998, J MED CHEM, V41, P1803, DOI 10.1021/jm970406v; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yang NN, 1996, SCIENCE, V273, P1222, DOI 10.1126/science.273.5279.1222; Ye QP, 1996, CARCINOGENESIS, V17, P1747, DOI 10.1093/carcin/17.8.1747; YIM JH, 1997, HOKKAIDO IGAKU ZASSH, V71, P509; Zava DT, 1997, NUTR CANCER, V27, P31, DOI 10.1080/01635589709514498; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; ZYAD A, 1994, CANCER RES, V54, P825	297	371	391	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7316	7339		10.1038/sj.onc.1206937	http://dx.doi.org/10.1038/sj.onc.1206937			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576841				2022-12-28	WOS:000186112500006
J	Damaraju, VL; Damaraju, S; Young, JD; Baldwin, SA; Mackey, J; Sawyer, MB; Cass, CE				Damaraju, VL; Damaraju, S; Young, JD; Baldwin, SA; Mackey, J; Sawyer, MB; Cass, CE			Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy	ONCOGENE			English	Review						nucleoside transporters; anticancer nucleosides; polymorphisms; SNPs; drug resistance	SINGLE-NUCLEOTIDE POLYMORPHISMS; BORDER MEMBRANE-VESICLES; NECROSIS-FACTOR-ALPHA; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; RECOMBINANT HUMAN; PHASE-II; LEUKEMIA-CELLS; NITROBENZYLTHIOINOSINE-BINDING; RIBONUCLEOTIDE REDUCTASE	The clinical efficacy of anticancer nucleoside drugs depends on a complex interplay of transporters mediating entry of nucleoside drugs into cells, efflux mechanisms that remove drugs from intracellular compartments and cellular metabolism to active metabolites. Nucleoside transporters (NTs) are important determinants for salvage of preformed nucleosides and mediated uptake of antimetabolite nucleoside drugs into target cells. The focus of this review is the two families of human nucleoside transporters (hENTs, hCNTs) and their role in transport of cytotoxic chemotherapeutic nucleoside drugs. Resistance to anticancer nucleoside drugs is a major clinical problem in which NTs have been implicated. Single nucleotide polymorphisms ( SNPs) in drug transporters may contribute to interindividual variation in response to nucleoside drugs. In this review, we give an overview of the functional and molecular characteristics of human NTs and their potential role in resistance to nucleoside drugs and discuss the potential use of genetic polymorphism analyses for NTs to address drug resistance.	Cross Canc Inst, Dept Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Membrane Prot Res Grp, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Dept Oncol, Edmonton, AB T6G 2M7, Canada; Univ Alberta, Dept Physiol, Edmonton, AB T6G 2M7, Canada; Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Alberta; University of Alberta; University of Alberta; University of Alberta; University of Leeds	Cass, CE (corresponding author), Cross Canc Inst, Dept Oncol, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada.	carol.cass@cancerboard.ab.ca						ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Acimovic Y, 2002, MOL BIOL EVOL, V19, P2199, DOI 10.1093/oxfordjournals.molbev.a004044; BAKER CH, 1991, J MED CHEM, V34, P1879, DOI 10.1021/jm00110a019; BALDWIN S, 2003, PFLUGERS ARCH   0628; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Belanger K, 2002, J CLIN ONCOL, V20, P2567, DOI 10.1200/JCO.2002.12.047; BELT J, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P20; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; Blum JL, 1999, J CLIN ONCOL, V17, P485, DOI 10.1200/JCO.1999.17.2.485; BROCKMAN RW, 1977, BIOCHEM PHARMACOL, V26, P2193, DOI 10.1016/0006-2952(77)90275-1; Brookes AJ, 1999, GENE, V234, P177, DOI 10.1016/S0378-1119(99)00219-X; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cabrita MA, 2002, BIOCHEM CELL BIOL, V80, P623, DOI 10.1139/O02-153; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CARSON DA, 1992, P NATL ACAD SCI USA, V89, P2970, DOI 10.1073/pnas.89.7.2970; Cass, 1994, P AM ASSOC CANC RES, V35; Cass C E, 1999, Pharm Biotechnol, V12, P313; Cass CE, 1998, BIOCHEM CELL BIOL, V76, P761, DOI 10.1139/bcb-76-5-761; CASS CE, 1995, DRUG TRANSPORT ANTIM, P403; CATAPANO CV, 1991, CANCER RES, V51, P1829; Chandrasena G, 1997, BIOCHEM PHARMACOL, V53, P1909, DOI 10.1016/S0006-2952(97)00170-6; Chen R, 2000, BIOCHEM PHARMACOL, V60, P215, DOI 10.1016/S0006-2952(00)00334-8; CHEN SF, 1986, CANCER RES, V46, P3449; CHUN HG, 1991, J CLIN ONCOL, V9, P175, DOI 10.1200/JCO.1991.9.1.175; Clarke Marilyn L, 2002, Cancer Treat Res, V112, P27; Coe I, 2002, FEBS LETT, V517, P201, DOI 10.1016/S0014-5793(02)02622-4; Coe IR, 1997, GENOMICS, V45, P459, DOI 10.1006/geno.1997.4928; Crawford CR, 1998, J BIOL CHEM, V273, P5288, DOI 10.1074/jbc.273.9.5288; DAMARAJU S, 2002, GENOMIC APPROACHES C; DANHAUSER L, 1986, CANCER CHEMOTH PHARM, V18, P145; DELICADO EG, 1991, BIOCHEM J, V279, P651, DOI 10.1042/bj2790651; DIMOPOULOS MA, 1994, J CLIN ONCOL, V12, P2694, DOI 10.1200/JCO.1994.12.12.2694; Ecker Gerhard, 2002, Curr Opin Investig Drugs, V3, P1533; ELLISON RR, 1968, BLOOD, V32, P507, DOI 10.1182/blood.V32.4.507.507; ELLISON RR, 1967, CLIN PHARMACOL THER, V8, P800; FIDEU MD, 1992, NEUROCHEM RES, V17, P1099, DOI 10.1007/BF00967287; FIDEU MD, 1993, CELL MOL NEUROBIOL, V13, P493, DOI 10.1007/BF00711458; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; FRAM RJ, 1983, LEUKEMIA RES, V7, P243, DOI 10.1016/0145-2126(83)90014-0; FURTH JJ, 1968, CANCER RES, V28, P2061; Galmarini CM, 2002, BRIT J HAEMATOL, V117, P860, DOI 10.1046/j.1365-2141.2002.03538.x; Gati WP, 1998, LEUKEMIA LYMPHOMA, V32, P45, DOI 10.3109/10428199809059245; Genini D, 2000, BLOOD, V96, P3537; Giles FJ, 2003, J CLIN ONCOL, V21, P1050, DOI 10.1200/JCO.2003.04.023; Giles FJ, 2001, J CLIN ONCOL, V19, P762, DOI 10.1200/JCO.2001.19.3.762; Goh LB, 1995, ANTICANCER RES, V15, P2575; Goldman ID, 2002, CLIN CANCER RES, V8, P4; Gourdeau H, 2001, CANCER RES, V61, P7217; Graham KA, 2000, NUCLEOS NUCLEOT NUCL, V19, P415, DOI 10.1080/15257770008033018; Gray JH, 2003, CLIN PHARMACOL THER, V73, pP59, DOI 10.1016/S0009-9236(03)90574-1; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Grove KL, 1996, CANCER RES, V56, P4187; GROVE KL, 1995, CANCER RES, V55, P3008; Guida L, 2002, J BIOL CHEM, V277, P47097, DOI 10.1074/jbc.M207793200; GUTIERREZ MM, 1993, BIOCHIM BIOPHYS ACTA, V1149, P202, DOI 10.1016/0005-2736(93)90202-B; GUTIERREZ MM, 1992, BIOCHIM BIOPHYS ACTA, V1105, P1, DOI 10.1016/0005-2736(92)90156-G; GUTIERREZ MM, 1994, BIOCHEM PHARMACOL, V48, P2251, DOI 10.1016/0006-2952(94)00411-0; Hamajima Nobuyuki, 2002, J Epidemiol, V12, P229; Handa M, 2001, GENE, V262, P301, DOI 10.1016/S0378-1119(00)00555-2; HANDE KR, 1978, CANCER RES, V38, P579; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1988, CANCER RES, V48, P4024; Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282; Huang M, 2003, J PHARMACOL EXP THER, V304, P753, DOI 10.1124/jpet.102.044214; HUANG P, 1995, SEMIN ONCOL, V22, P19; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; Hyde RJ, 2001, MOL MEMBR BIOL, V18, P53, DOI 10.1080/09687680110033765; Iida A, 2001, J HUM GENET, V46, P590, DOI 10.1007/s100380170026; Illmer T, 2002, CANCER RES, V62, P4955; Ishikawa T, 1998, CANCER RES, V58, P685; Jennings LL, 2001, NEUROPHARMACOLOGY, V40, P722, DOI 10.1016/S0028-3908(00)00207-0; JONES KW, 1994, BRAIN RES, V660, P104, DOI 10.1016/0006-8993(94)90844-3; Kaye SB, 1998, BRIT J CANCER, V78, P1, DOI 10.1038/bjc.1998.747; Kichenin K, 2000, EUR J IMMUNOL, V30, P366, DOI 10.1002/1521-4141(200002)30:2<366::AID-IMMU366>3.0.CO;2-D; KING KM, 2003, P AM ASSOC CANC RES, V44, P1500; Kiss A, 2000, BIOCHEM J, V352, P363, DOI 10.1042/0264-6021:3520363; KUFE DW, 1980, J BIOL CHEM, V255, P8997; KWONG FYP, 1993, J BIOL CHEM, V268, P22127; Lamont EB, 1999, CLIN CANCER RES, V5, P2289; Lang TT, 2001, MOL PHARMACOL, V60, P1143, DOI 10.1124/mol.60.5.1143; Lassota Piotr, 1994, Archivum Immunologiae et Therapiae Experimentalis, V42, P17; LEE CW, 1991, BIOCHEM J, V274, P85, DOI 10.1042/bj2740085; LEE CW, 1994, BIOCHEM J, V300, P407, DOI 10.1042/bj3000407; Lindemalm S, 2003, HAEMATOLOGICA, V88, P324; Loewen SK, 1999, J BIOL CHEM, V274, P24475, DOI 10.1074/jbc.274.35.24475; Lu Xin, 2002, J Exp Ther Oncol, V2, P200, DOI 10.1046/j.1359-4117.2002.01035.x; Lum PY, 2000, CANCER CHEMOTH PHARM, V45, P273, DOI 10.1007/s002800050040; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1998, DRUG RESIST UPDATE, V1, P310, DOI 10.1016/S1368-7646(98)80047-2; Mackey JR, 2002, CLIN CANCER RES, V8, P110; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Mata JF, 2001, MOL PHARMACOL, V59, P1542, DOI 10.1124/mol.59.6.1542; MURRAY AW, 1971, ANNU REV BIOCHEM, V40, P811, DOI 10.1146/annurev.bi.40.070171.004115; Neff T, 1996, EXP HEMATOL, V24, P1340; Ngo LY, 2001, AM J PHYSIOL-GASTR L, V280, pG475, DOI 10.1152/ajpgi.2001.280.3.G475; Osato DH, 2003, PHARMACOGENETICS, V13, P297, DOI 10.1097/00008571-200305000-00010; Osses N, 1996, BIOCHEM J, V317, P843, DOI 10.1042/bj3170843; OWENS JK, 1992, CANCER RES, V52, P2389; PARKER WB, 1991, CANCER RES, V51, P2386; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Parker WB, 1999, MOL PHARMACOL, V55, P515; Parodi J, 2002, CIRC RES, V90, P570, DOI 10.1161/01.RES.0000012582.11979.8B; Paterson AR, 1993, P AM ASSOC CANC RES, V34, pA84; Patil SD, 1997, AM J PHYSIOL-GASTR L, V272, pG1314, DOI 10.1152/ajpgi.1997.272.6.G1314; Pennycooke M, 2001, BIOCHEM BIOPH RES CO, V280, P951, DOI 10.1006/bbrc.2000.4205; Pettitt AR, 1999, BRIT J HAEMATOL, V105, P986, DOI 10.1046/j.1365-2141.1999.01448.x; Pettitt AR, 1999, BRIT J HAEMATOL, V106, P1049; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; Possinger K, 1995, ANTI-CANCER DRUG, V6, P55, DOI 10.1097/00001813-199512006-00009; Ritzel MWL, 1998, MOL MEMBR BIOL, V15, P203; Ritzel MWL, 1997, AM J PHYSIOL-CELL PH, V272, pC707, DOI 10.1152/ajpcell.1997.272.2.C707; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Ritzel MWL, 2001, J BIOL CHEM, V276, P2914, DOI 10.1074/jbc.M007746200; Sachidanandam R, 2001, NATURE, V409, P928, DOI 10.1038/35057149; Sandoval A, 1996, CLIN CANCER RES, V2, P1731; Sankar N, 2002, NUCLEIC ACIDS RES, V30, P4339, DOI 10.1093/nar/gkf564; SCHACHTER JB, 1995, CELL SIGNAL, V7, P659, DOI 10.1016/0898-6568(95)00037-P; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schmoll HJ, 1999, SEMIN ONCOL, V26, P589; SenGupta DJ, 2002, BIOCHEMISTRY-US, V41, P1512, DOI 10.1021/bi015833w; SEYMOUR JF, 1994, BLOOD, V83, P2906, DOI 10.1182/blood.V83.10.2906.2906; Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002-9149(97)00256-7; SIROTNAK FM, 1983, CANCER RES, V43, P104; SOKOLOSKI JA, 1991, LEUKEMIA RES, V15, P1051, DOI 10.1016/0145-2126(91)90111-6; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; Soler C, 2000, J LEUKOCYTE BIOL, V67, P345, DOI 10.1002/jlb.67.3.345; Soler C, 2001, FASEB J, V15, P1979, DOI 10.1096/fj.01-0022com; Soler C, 2001, J BIOL CHEM, V276, P30043, DOI 10.1074/jbc.M101807200; Stadler WM, 1997, J CLIN ONCOL, V15, P3394, DOI 10.1200/JCO.1997.15.11.3394; Stam RW, 2003, BLOOD, V101, P1270, DOI 10.1182/blood-2002-05-1600; Strohman R, 2002, SCIENCE, V296, P701, DOI 10.1126/science.1070534; Sundaram M, 1998, J BIOL CHEM, V273, P21519, DOI 10.1074/jbc.273.34.21519; Sundaram M, 2001, J BIOL CHEM, V276, P45270, DOI 10.1074/jbc.M107169200; Sundaram M, 2001, BIOCHEMISTRY-US, V40, P8146, DOI 10.1021/bi0101805; Talbot DC, 2002, BRIT J CANCER, V86, P1367, DOI 10.1038/sj.bjc.6600261; Townsley CA, 2003, J CLIN ONCOL, V21, P1524, DOI 10.1200/JCO.2003.03.057; Vickers MF, 2002, BIOCHEM CELL BIOL, V80, P639, DOI 10.1139/O02-148; VICKERS MF, 2000, EMERGING THERAPEUTIC, V4, P515; VIJAYALAKSHMI D, 1988, J BIOL CHEM, V263, P19419; Visser F, 2002, J BIOL CHEM, V277, P395, DOI 10.1074/jbc.M105324200; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Wang J, 1997, AM J PHYSIOL-RENAL, V273, pF1058, DOI 10.1152/ajprenal.1997.273.6.F1058; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WILEY JS, 1983, EUR J CANCER CLIN ON, V19, P1067, DOI 10.1016/0277-5379(83)90029-9; Xie KC, 1996, CANCER RES, V56, P3030; YANG SW, 1992, J BIOL CHEM, V267, P2345; Yao SYM, 2002, J BIOL CHEM, V277, P24938, DOI 10.1074/jbc.M200966200; Yao SYM, 2001, MOL MEMBR BIOL, V18, P161, DOI 10.1080/09687680110048318; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; Young JD, 2001, CURR TOP MEMBR, V50, P329; ZIMMERMAN TP, 1987, J BIOL CHEM, V262, P5748	155	237	246	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7524	7536		10.1038/sj.onc.1206952	http://dx.doi.org/10.1038/sj.onc.1206952			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576856				2022-12-28	WOS:000186112500021
J	Townsend, DM; Tew, KD				Townsend, DM; Tew, KD			The role of glutathione-S-transferase in anti-cancer drug resistance	ONCOGENE			English	Review						GST; polymorphism; resistance; MAP kinase pathway	ETHACRYNIC-ACID; CHLORAMBUCIL RESISTANCE; PLASMODIUM-FALCIPARUM; SCHISTOSOMA-MANSONI; SIGNAL-TRANSDUCTION; TUMOR-CELLS; PHASE-I; P1-1; APOPTOSIS; PROTEIN	Glutathione-S-transferases (GSTs) are a family of Phase II detoxification enzymes that catalyse the conjugation of glutathione (GSH) to a wide variety of endogenous and exogenous electrophilic compounds. GSTs are divided into two distinct super-family members: the membrane-bound microsomal and cytosolic family members. Microsomal GSTs are structurally distinct from the cytosolic in that they homo- and heterotrimerize rather than dimerize to form a single active site. Microsomal GSTs play a key role in the endogenous metabolism of leukotrienes and prostaglandins. Human cytosolic GSTs are highly polymorphic and can be divided into six classes: alpha, mu, omega, pi, theta, and zeta. The pi and mu classes of GSTs play a regulatory role in the mitogen-activated protein (MAP) kinase pathway that participates in cellular survival and death signals via protein : protein interactions with c-Jun N-terminal kinase 1 (JNK1) and ASK1 (apoptosis signal-regulating kinase). JNK and ASK1 are activated in response to cellular stress. GSTs have been implicated in the development of resistance toward chemotherapy agents. It is plausible that GSTs serve two distinct roles in the development of drug resistance via direct detoxification as well as acting as an inhibitor of the MAP kinase pathway. The link between GSTs and the MAP kinase pathway provides a rationale as to why in many cases the drugs used to select for resistance are neither subject to conjugation with GSH, nor substrates for GSTs. GSTs have emerged as a promising therapeutic target because specific isozymes are overexpressed in a wide variety of tumors and may play a role in the etiology of other diseases, including neurodegenerative diseases, multiple sclerosis, and asthma. Some of the therapeutic strategies so far employed are described in this review.	Fox Chase Canc Ctr, Dept Pharmacol, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Tew, KD (corresponding author), Fox Chase Canc Ctr, Dept Pharmacol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	kd_tew@fccc.edu			NATIONAL CANCER INSTITUTE [T32CA119945, R01CA085660] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA085660, T32 CA119945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Baez S, 1997, BIOCHEM J, V324, P25, DOI 10.1042/bj3240025; Bakker J, 2002, J BIOL CHEM, V277, P22573, DOI 10.1074/jbc.M203009200; BLACK SM, 1990, BIOCHEM J, V268, P309, DOI 10.1042/bj2680309; BROWN GL, 2001, TLK286 PHASE 1 DOSE; CAPRON A, 1995, MEM I OSWALDO CRUZ, V90, P235, DOI 10.1590/S0074-02761995000200019; Capron A, 2001, INT ARCH ALLERGY IMM, V124, P9, DOI 10.1159/000053656; CarverMoore K, 1996, BLOOD, V88, P803; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Clapper M.L., 1990, J CELL PHARM, V1, P71; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; Davioud-Charvet E, 2001, J MED CHEM, V44, P4268, DOI 10.1021/jm010268g; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DECAMPO R, 1984, FREE RADIC BIOL, V6, P243; Dorion S, 2002, J BIOL CHEM, V277, P30792, DOI 10.1074/jbc.M203642200; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; FORD JM, 1991, CANCER LETT, V56, P85, DOI 10.1016/0304-3835(91)90198-Q; Gunnarsdottir S, 1999, J PHARMACOL EXP THER, V290, P950; HALL A, 1989, CANCER RES, V49, P6265; Harwaldt P, 2002, BIOL CHEM, V383, P821, DOI 10.1515/BC.2002.086; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Izbicka E, 1997, ANTI-CANCER DRUG, V8, P345, DOI 10.1097/00001813-199704000-00006; KAUVAR KM, 1996, GLUTATHIONE S TRANSF, P187; Kauvar LM, 1998, CHEM-BIOL INTERACT, V112, P225, DOI 10.1016/S0009-2797(97)00163-4; KAVANAGH JJ, 2002, EUR J CANC; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LYTTLE MH, 1994, J MED CHEM, V37, P1501, DOI 10.1021/jm00036a016; LYTTLE MH, 1994, J MED CHEM, V37, P189, DOI 10.1021/jm00027a024; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; McLellan LI, 1999, DRUG RESIST UPDATE, V2, P153, DOI 10.1054/drup.1999.0083; Morgan AS, 1998, CANCER RES, V58, P2568; Morgan AS, 1996, CANCER CHEMOTH PHARM, V37, P363, DOI 10.1007/s002800050398; Mulder TPJ, 1997, CANCER, V80, P873, DOI 10.1002/(SICI)1097-0142(19970901)80:5<873::AID-CNCR7>3.0.CO;2-M; NARE B, 1992, BIOCHEM PHARMACOL, V43, P1345, DOI 10.1016/0006-2952(92)90512-H; O'Brien ML, 1999, J PHARMACOL EXP THER, V291, P1348; Oakley AJ, 1997, FEBS LETT, V419, P32, DOI 10.1016/S0014-5793(97)01424-5; ODWYER PJ, 1991, CANCER RES, V51, P6059; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PAPADIMITRAKOPO.V, 2003, EUR J CANC; PETRINI M, 1993, BRIT J HAEMATOL, V85, P409, DOI 10.1111/j.1365-2141.1993.tb03187.x; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Ranson H, 1997, BIOCHEM J, V324, P97, DOI 10.1042/bj3240097; Rosario LA, 2000, MOL PHARMACOL, V58, P167, DOI 10.1124/mol.58.1.167; Rosen LS, 2003, CLIN CANCER RES, V9, P1628; Ruscoe JE, 2001, J PHARMACOL EXP THER, V298, P339; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SCHISSELBAUER JC, 1990, CANCER RES, V50, P3562; SHEN H, 1993, ARCH BIOCHEM BIOPHYS, V300, P137, DOI 10.1006/abbi.1993.1019; TANG AH, 1994, J BIOL CHEM, V269, P27876; TEW KD, 1994, CANCER RES, V54, P4313; Tew KD, 1996, MOL PHARMACOL, V50, P149; TEW KD, 1988, CANCER RES, V48, P3622; TIPPING E, 1978, BIOCHEM J, V169, P509, DOI 10.1042/bj1690509; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Xu XC, 1997, INFECT IMMUN, V65, P3867, DOI 10.1128/IAI.65.9.3867-3874.1997; Yin ZM, 2000, CANCER RES, V60, P4053	63	907	944	1	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7369	7375		10.1038/sj.onc.1206940	http://dx.doi.org/10.1038/sj.onc.1206940			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576844	Green Accepted			2022-12-28	WOS:000186112500009
J	Huang, HJ; Zegarro-Moro, OL; Benson, D; Tindall, DJ				Huang, HJ; Zegarro-Moro, OL; Benson, D; Tindall, DJ			Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells	ONCOGENE			English	Article						androgen receptor; Bcl-2; RB; transcription regulation; prostate cancer	HAMMERHEAD RIBOZYME; CYCLE PROGRESSION; TUMOR-MODEL; S-PHASE; GENE; APOPTOSIS; PROMOTER; RECEPTOR; OLIGODEOXYNUCLEOTIDES; INDEPENDENCE	The oncogene Bcl- 2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl- 2 overexpression may contribute to the androgen- refractory relapse of the disease. However, the molecular mechanism underlying androgenic regulation of Bcl- 2 in prostate cancer cells is understood poorly. In this study, we demonstrated that no androgen response element ( ARE) was identified in the androgen- regulated region of the P1 promoter of Bcl- 2 gene, whereas, we provided evidence that the androgenic effect is mediated by E2F1 protein through a putative E2F- binding site in the promoter. We further demonstrated that retinoblastoma ( RB) protein plays a critical role in androgen regulation of Bcl- 2. The phosphorylation levels of RB at serine residues 780 and 795 were decreased in LNCaP cells treated with androgens. Ectopic expression of a constitutively active form of RB inhibited expression of Bcl- 2. Knockdown of endogenous RB protein by an Rb small inference RNA ( siRNA) induced an increase in Bcl- 2 levels. Most importantly, the effect of androgens on Bcl- 2 was abolished completely by specific inhibition of RB function with a mutated E1A. Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclin-dependent kinase inhibitors ( CDKIs) p15INK4B and p27KIP1. Ectopic expression of p15INK4B and/ or p27KIP1 inhibited Bcl- 2 expression. Knockdown of endogenous p15INK4B or p27KIP1 protein with a pool of siRNAs diminished androgen- induced downregulation of Bcl- 2 expression. Therefore, our data indicate that androgens suppress Bcl- 2 expression through negatively modulating activities of the E2F site in the Bcl- 2 promoter by activating the CDKI- RB axis.	Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Tindall, DJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.	tindall.donald@mayo.edu			NATIONAL CANCER INSTITUTE [P50CA091956] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060920] Funding Source: NIH RePORTER; NCI NIH HHS [CA91956] Funding Source: Medline; NIDDK NIH HHS [DK60920] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agus DB, 1999, J NATL CANCER I, V91, P1869, DOI 10.1093/jnci/91.21.1869; Bruckheimer EM, 2003, J UROLOGY, V169, P1553, DOI 10.1097/01.ju.0000055140.91204.c7; Butler R, 2000, CELL GROWTH DIFFER, V11, P49; Cheema SK, 2003, J BIOL CHEM, V278, P19995, DOI 10.1074/jbc.M205865200; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cordon-Cardo C, 1998, JNCI-J NATL CANCER I, V90, P1284, DOI 10.1093/jnci/90.17.1284; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; Denmeade SR, 1996, PROSTATE, V28, P251; Dorai T, 1997, PROSTATE, V32, P246, DOI 10.1002/(SICI)1097-0045(19970901)32:4<246::AID-PROS4>3.0.CO;2-H; Dorai T, 1997, ANTICANCER RES, V17, P3307; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Gleave M, 1999, CLIN CANCER RES, V5, P2891; Gleave M, 1999, PROSTATE CANCER P D, V2, pS15, DOI 10.1038/sj.pcan.4500341; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Gomez-Manzano C, 2001, CANCER RES, V61, P6693; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haldar S, 1997, CANCER RES, V57, P229; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Huang H, 2002, CRIT REV EUKAR GENE, V12, P193, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i3.30; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 1999, CANCER RES, V59, P2981; Huggins C, 1941, CANCER RES, V1, P293; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kimura K, 2001, CANCER RES, V61, P5611; Krajewska M, 1996, AM J PATHOL, V148, P1567; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lapointe J, 1999, ENDOCRINOLOGY, V140, P416, DOI 10.1210/en.140.1.416; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Liu SL, 2000, ONCOGENE, V19, P3352, DOI 10.1038/sj.onc.1203675; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; Miyake H, 1999, CANCER RES, V59, P4030; MIYASHITA T, 1994, CANCER RES, V54, P3131; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; RAFFO AJ, 1995, CANCER RES, V55, P4438; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Tsihlias J, 2000, ONCOGENE, V19, P670, DOI 10.1038/sj.onc.1203369; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WESTIN P, 1995, AM J PATHOL, V146, P1368; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yang RM, 1998, J UROLOGY, V159, P941, DOI 10.1016/S0022-5347(01)63776-5; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	53	42	45	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2161	2176		10.1038/sj.onc.1207326	http://dx.doi.org/10.1038/sj.onc.1207326			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676836				2022-12-28	WOS:000220280900006
J	Chen, XY; Huang, LM; Kung, HJ; Ann, DK; Shih, HM				Chen, XY; Huang, LM; Kung, HJ; Ann, DK; Shih, HM			The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells	ONCOGENE			English	Article						Etk kinase; EGF-induced apoptosis; Statl activation	EPIDERMAL-GROWTH-FACTOR; FACTOR RECEPTOR GENE; FOCAL ADHESION KINASE; X-LINKED AGAMMAGLOBULINEMIA; TEC FAMILY; PHOSPHATIDYLINOSITOL 3'-KINASE; MEDIATED APOPTOSIS; SIGNALING PATHWAY; FACTOR-ALPHA; PH-DOMAIN	Etk/Bmx, a member of the Tec family of tyrosine kinases, mediates various signaling pathways and confers several cellular functions. In the present study, we have explored the functional role of Etk in mediating EGF-induced apoptosis, using MDA-MB-468 cell line as a model. We first demonstrated that EGF treatment induces Etk tyrosine phosphorylation in both HeLa and MDA-MB468 cells. Overexpression of Etk by recombinant adenovirus in MDA-MB-468 cells potentiates the extent of EGF-induced cell apoptosis. The observed Etk-enhanced MDA-MB-468 cell apoptosis is associated with the Stat1 activation, as demonstrated by electrophoresis mobility shift assays and reporter gene assays. By contrast, a kinase domain deletion mutant EtkDeltaK, functioning as a dominant-negative mutant, ameliorates EGF- induced Stat1 activation and apoptosis in MDA-MB-468 cells. To explore whether the activated Etk alone is sufficient for inducing apoptosis, a conditionally activated Etk (DeltaEtk-ER), a chimeric fusion protein of PH domain-truncated Etk and ligand-binding domain of estrogen receptor, was introduced into MDA-MB-468 cells. Upon beta-estradiol ligand activation, the DeltaEtk-ER could stimulate Stat1 activity and confer cell apoptosis independent of EGF treatment. Taken together, our findings indicate that Etk is a downstream signaling molecule of EGF receptor and suggest that Etk activation is essential for transducing the EGF- induced apoptotic signaling.	Natl Hlth Res Inst, Div Mol & Genom Med, Taipei 11529, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA; Univ So Calif, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	National Health Research Institutes - Taiwan; National Defense Medical Center; University of California System; University of California Davis; University of Southern California	Shih, HM (corresponding author), Natl Hlth Res Inst, Div Mol & Genom Med, 128,Sec2,Yen Chiu Yuan RD, Taipei 11529, Taiwan.	shihh@nhri.org.tw	Shih, Hsiu-Ming/S-7023-2018; Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207] Funding Source: Medline; NIDCR NIH HHS [R01 DE10742, DE14183] Funding Source: Medline; PHS HHS [91574] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE010742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014183] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; ARMSTRONG DK, 1994, CANCER RES, V54, P5280; August A, 2002, INT J BIOCHEM CELL B, V34, P1184, DOI 10.1016/S1357-2725(02)00068-7; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Chau CH, 2002, ONCOGENE, V21, P8817, DOI 10.1038/sj.onc.1206032; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; COSTA S, 1988, LANCET, V2, P1258; Czar MJ, 2001, BIOCHEM SOC T, V29, P863, DOI 10.1042/BST0290863; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DERYNCK R, 1987, CANCER RES, V47, P707; Ekman N, 2000, ONCOGENE, V19, P4151, DOI 10.1038/sj.onc.1203763; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Gulli LF, 1996, CELL GROWTH DIFFER, V7, P173; Hognason T, 2001, FEBS LETT, V491, P9, DOI 10.1016/S0014-5793(01)02166-4; Hsueh RC, 2000, ADV IMMUNOL, V75, P283, DOI 10.1016/S0065-2776(00)75007-3; Ibrahim SO, 1997, ANTICANCER RES, V17, P4539; Islam TC, 2000, J GENE MED, V2, P204; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Jui HY, 2000, J BIOL CHEM, V275, P41124, DOI 10.1074/jbc.M007772200; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KIKUCHI A, 1990, BRIT J DERMATOL, V123, P49, DOI 10.1111/j.1365-2133.1990.tb01823.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANO H, 1995, BLOOD, V85, P343; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Miller AT, 2002, CURR OPIN IMMUNOL, V14, P331, DOI 10.1016/S0952-7915(02)00345-X; Misra UK, 1998, CELL SIGNAL, V10, P441, DOI 10.1016/S0898-6568(97)00171-X; Pan S, 2002, MOL CELL BIOL, V22, P7512, DOI 10.1128/MCB.22.21.7512-7523.2002; Price JT, 1999, CANCER RES, V59, P5475; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rajantie I, 2001, MOL CELL BIOL, V21, P4647, DOI 10.1128/MCB.21.14.4647-4655.2001; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; RO J, 1988, CANCER RES, V48, P161; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SAINSBURY JRC, 1988, BRIT J CANCER, V58, P458, DOI 10.1038/bjc.1988.240; Satterthwaite AB, 1998, SEMIN IMMUNOL, V10, P309, DOI 10.1006/smim.1998.0123; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Smith CIE, 2001, BIOESSAYS, V23, P436, DOI 10.1002/bies.1062; Stephanou A, 2002, FASEB J, V16, P1841, DOI 10.1096/fj.02-0150fje; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Suhardja A, 2003, MICROSC RES TECHNIQ, V60, P70, DOI 10.1002/jemt.10245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Tsang DK, 1999, INT J ONCOL, V15, P519; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Vihinen M, 2000, FRONT BIOSCI-LANDMRK, V5, pD917, DOI 10.2741/vihinen; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu YM, 2001, J BIOL CHEM, V276, P17672, DOI 10.1074/jbc.M010964200; XU YH, 1984, P NATL ACAD SCI-BIOL, V81, P7308, DOI 10.1073/pnas.81.23.7308; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200	67	32	36	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1854	1862		10.1038/sj.onc.1207308	http://dx.doi.org/10.1038/sj.onc.1207308			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14676838				2022-12-28	WOS:000220129500007
J	Bourdeau, I; Antonini, SR; Lacroix, A; Kirschner, LS; Matyakhina, L; Lorang, D; Libutti, SK; Stratakis, CA				Bourdeau, I; Antonini, SR; Lacroix, A; Kirschner, LS; Matyakhina, L; Lorang, D; Libutti, SK; Stratakis, CA			Gene array analysis of macronodular adrenal hyperplasia confirms clinical heterogeneity and identifies several candidate genes as molecular mediators	ONCOGENE			English	Article; Proceedings Paper	84th Annual Meeting of the Endocrine-Society	JUN 19-22, 2002	SAN FRANCISCO, CA	Endocrine Soc		adrenal cortex; Cushing syndrome; macronodular hyperplasia; genetics	GASTRIC-INHIBITORY POLYPEPTIDE; DEPENDENT CUSHINGS-SYNDROME; SPORADIC ADRENOCORTICAL TUMORS; FAMILIAL ADENOMATOUS POLYPOSIS; GENOMIC HYBRIDIZATION ANALYSIS; ENDOCRINE NEOPLASIA TYPE-1; MEMBRANE HORMONE-RECEPTORS; ALPHA-CATENIN; CARNEY COMPLEX; HUMAN-DISEASE	Corticotropin (ACTH)-independent macronodular adrenal hyperplasia (AIMAH) is a heterogeneous condition in which cortisol secretion may be mediated by gastrointestinal peptide (GIP), vasopressin, catecholamines and other hormones. We studied the expression pro. le of AIMAH by genomic cDNA microarray analysis. Total RNA was extracted from eight tissues (three GIP-dependent) and compared to total RNA obtained from adrenal glands from 62 normal subjects. Genes had to be altered in 75% of the patients, and be up- or downregulated at a cutoff ratio of at least 2.0; 82 and 31 genes were found to be consistently up- and downregulated, respectively. Among the former were regulators of transcription, chromatin remodeling, and cell cycle and adhesion. Downregulated sequences included genes involved in immune responses and insulin signaling. Hierarchical clustering correlated with the two main AIMAH diagnostic groups: GIP-dependent and non-GIP-dependent. The genes encoding the 7B2 protein (SGNE1) and WNT1-inducible signaling pathway protein 2 (WISP2) were specifically overexpressed in the GIP-dependent AIMAH. For these, and six more genes, the data were validated by semiquantitative amplification in samples from a total of 32 patients (the original eight, six more cases of AIMAH, and 18 other adrenocortical hyperplasias and tumors) and the H295R adrenocortical cancer cell line. In conclusion, our data confirmed AIMAH's clinical heterogeneity by identifying molecularly distinct diagnostic subgroups. Several candidate genes that may be responsible for AIMAH formation and/or progression were also identified, suggesting pathways that affect the cell cycle, adhesion and transcription as possible mediators of adrenocortical hyperplasia.	NICHHD, Sect Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; CHUM, Hotel Dieu, Div Endocrinol, Montreal, PQ, Canada; NCI, Surg Branch, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Laval University; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stratakis, CA (corresponding author), NICHHD, Sect Genet & Endocrinol, Dev Endocrinol Branch, NIH, Bldg 10,Room 10N262,10 Ctr Dr MSC1862, Bethesda, MD 20892 USA.	stratakc@mail.nih.gov	Stratakis, Constantine/AAP-4745-2020; Lacroix, Andre/AAI-5645-2020; Antonini, Sonir RR/J-5264-2015; Levesque, Isabelle/A-1899-2012	Antonini, Sonir/0000-0003-4778-8803	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000642, Z01HD000642] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01SC010368] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; BAUMAN A, 1982, JAMA-J AM MED ASSOC, V248, P3140, DOI 10.1001/jama.248.23.3140; Bergeron F, 2002, FEBS LETT, V512, P259, DOI 10.1016/S0014-5793(02)02277-9; BERTHERAT J, 2002, END SOC 84 ANN M SAN; Bornstein SR, 1999, ANN INTERN MED, V130, P759, DOI 10.7326/0003-4819-130-9-199905040-00017; BOSTON BA, 1994, J CLIN ENDOCR METAB, V79, P890, DOI 10.1210/jc.79.3.890; Boulle N, 1998, J CLIN ENDOCR METAB, V83, P1713, DOI 10.1210/jc.83.5.1713; Bourdeau I, 2002, AM J HUM GENET, V71, P189; Bourdeau I, 2002, ANN NY ACAD SCI, V968, P240, DOI 10.1111/j.1749-6632.2002.tb04339.x; Bourdeau I, 2001, J CLIN ENDOCR METAB, V86, P5534, DOI 10.1210/jc.86.11.5534; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Figueiredo BC, 1999, J CLIN ENDOCR METAB, V84, P1116, DOI 10.1210/jc.84.3.1116; Fujita M, 2001, CANCER RES, V61, P7722; Giordano TJ, 2003, AM J PATHOL, V162, P521, DOI 10.1016/S0002-9440(10)63846-1; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; HAMWI GJ, 1957, NEW ENGL J MED, V257, P1153, DOI 10.1056/NEJM195712122572402; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Heikkila M, 2002, ENDOCRINOLOGY, V143, P4358, DOI 10.1210/en.2002-220275; Heppner C, 1999, J CLIN ENDOCR METAB, V84, P216, DOI 10.1210/jc.84.1.216; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kartheuser A, 1999, J MED GENET, V36, P65; Kikuchi E, 2000, BIOMED PHARMACOTHER, V54, p194S, DOI 10.1016/S0753-3322(00)80043-8; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kjellman M, 1996, CANCER RES, V56, P4219; Koch CA, 2000, MED KLIN, V95, P224, DOI 10.1007/PL00002112; Lacroix A, 2001, ENDOCR REV, V22, P75, DOI 10.1210/er.22.1.75; LACROIX A, 1992, NEW ENGL J MED, V327, P974, DOI 10.1056/NEJM199210013271402; Lacroix A, 1997, NEW ENGL J MED, V337, P1429, DOI 10.1056/NEJM199711133372004; Lebrethon MC, 1998, J CLIN ENDOCR METAB, V83, P4514, DOI 10.1210/jc.83.12.4514; Marchesa P, 1997, DIS COLON RECTUM, V40, P1023, DOI 10.1007/BF02050923; Mircescu H, 2000, J CLIN ENDOCR METAB, V85, P3531, DOI 10.1210/jc.85.10.3531; N'Diaye N, 1998, J CLIN ENDOCR METAB, V83, P2781, DOI 10.1210/jc.83.8.2781; N'Diaye N, 1999, J CLIN ENDOCR METAB, V84, P2616, DOI 10.1210/jc.84.8.2616; PANG S, 1981, PEDIATRICS, V68, P242; Park B, 2002, J BIOL CHEM, V277, P45361, DOI 10.1074/jbc.M202447200; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; RAINEY WE, 1994, MOL CELL ENDOCRINOL, V100, P45, DOI 10.1016/0303-7207(94)90277-1; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; REINCKE M, 1993, J CLIN ENDOCR METAB, V77, P1419, DOI 10.1210/jc.77.5.1419; Reincke M, 2000, EUR J CLIN INVEST, V30, P63, DOI 10.1046/j.1365-2362.2000.0300s3063.x; REZNIK Y, 1992, NEW ENGL J MED, V327, P981, DOI 10.1056/NEJM199210013271403; Saxena N, 2001, MOL CELL BIOCHEM, V228, P99, DOI 10.1023/A:1013338912642; Semenza GL, 2000, GENE DEV, V14, P1983; Sidhu S, 2002, J CLIN ENDOCR METAB, V87, P3467, DOI 10.1210/jc.87.7.3467; SKOGSEID B, 1992, J CLIN ENDOCR METAB, V75, P76, DOI 10.1210/jc.75.1.76; Stratakis CA, 1999, ANN INTERN MED, V131, P585, DOI 10.7326/0003-4819-131-8-199910190-00006; Stratakis CA, 2003, TRENDS ENDOCRIN MET, V14, P404, DOI 10.1016/j.tem.2003.08.005; Stratakis CA, 1998, HORM METAB RES, V30, P456, DOI 10.1055/s-2007-978914; Suwa T, 2003, J ENDOCRINOL, V178, P149, DOI 10.1677/joe.0.1780149; SUZUKI H, 1995, STEROIDS, V60, P42, DOI 10.1016/0039-128X(94)00025-8; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wakatsuki S, 1998, HUM PATHOL, V29, P302, DOI 10.1016/S0046-8177(98)90052-1; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; Zhao JM, 1999, AM J PATHOL, V155, P1039, DOI 10.1016/S0002-9440(10)65205-4; Zwermann O, 2000, EUR J ENDOCRINOL, V142, P689, DOI 10.1530/eje.0.1420689	64	100	104	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1575	1585		10.1038/sj.onc.1207277	http://dx.doi.org/10.1038/sj.onc.1207277			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14767469				2022-12-28	WOS:000189219500011
J	Cande, C; Vahsen, N; Kouranti, I; Schmitt, E; Daugas, E; Spahr, C; Luban, J; Kroemer, RT; Giordanetto, F; Garrido, C; Penninger, JM; Kroemer, G				Cande, C; Vahsen, N; Kouranti, I; Schmitt, E; Daugas, E; Spahr, C; Luban, J; Kroemer, RT; Giordanetto, F; Garrido, C; Penninger, JM; Kroemer, G			AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis	ONCOGENE			English	Article						mitochondria; Bcl-2	CELL-DEATH; GLYCOPROTEIN COMPLEX; ISOMERASE ACTIVITY; DNA-DEGRADATION; ENDONUCLEASE-G; INHIBITOR; BINDING; MITOCHONDRIA; QUANTITATION; REFINEMENT	Cyclophilin A (CypA) was determined to interact with apoptosis-inducing factor (AIF) by mass spectroscopy, coimmunoprecipitation, pull-down assays, and molecular modeling. During the initial, caspase-independent stage of chromatin condensation that accompanies apoptosis, AIF and CypA were found to coimmunolocalize in the nucleus. Recombinant AIF and CypA proteins synergized in vitro in the degradation of plasmid DNA, as well as in the capacity to induce DNA loss in purified nuclei. The apoptogenic cooperation between AIF and CypA did not rely on the CypA peptidyl-prolyl cis-trans isomerase activity. In Cyp-expressing cells, AIF overexpression augmented apoptotic chromatinolysis. The AIF-dependent large-scale DNA fragmentation was less pronounced in CypA knockout cells as compared to controls. AIF mutants lacking the CypA-binding domain were inefficient apoptosis sensitizers in transfection experiments. Moreover, AIF failed to sensitize CypA knockout cells to apoptosis induction, and this defect in the AIF response was reversed by reintroduction of the CypA gene into CypA-deficient cells. In summary, AIF and CypA collaborate in chromatinolysis.	Inst Gustave Roussy, CNRS, UMR8125, F-94805 Villejuif, France; Fac Med & Pharm, INSERM, U517, F-21033 Dijon, France; Amgen Inc, Amgen Ctr, Prot Sci, Thousand Oaks, CA 91320 USA; Columbia Univ, Dept Microbiol, New York, NY 10032 USA; Columbia Univ, Dept Med, New York, NY 10032 USA; Pharmacia, Mol Modeling & Design, I-20014 Nerviano, MI, Italy; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Austrian Acad Sci, Inst Mol Biotechnol, IMBA, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Amgen; Columbia University; Columbia University; Pfizer; University of Cambridge; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, UMR8125, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Garrido, carmen/G-1633-2018; Penninger, Josef M/I-6860-2013; Giordanetto, Fabrizio/E-2811-2012; Garrido, Carolina/GWM-5557-2022	KROEMER, Guido/0000-0002-9334-4405; Garrido, carmen/0000-0003-1368-1493; Penninger, Josef M/0000-0002-8194-3777; DAUGAS, Eric/0000-0001-7256-7979; Luban, Jeremy/0000-0001-5650-4054	NIAID NIH HHS [R01 AI036199, AI 36199] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aloy P, 1998, PROTEINS, V33, P535, DOI 10.1002/(SICI)1097-0134(19981201)33:4<535::AID-PROT6>3.3.CO;2-4; Ansari H, 2002, MOL CELL BIOL, V22, P6993, DOI 10.1128/MCB.22.20.6993-7003.2002; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Arnoult D, 2001, MOL BIOL CELL, V12, P3016, DOI 10.1091/mbc.12.10.3016; Bergsmedh A, 2002, CANCER RES, V62, P575; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 2001, J EXP MED, V194, P1097, DOI 10.1084/jem.194.8.1097; Colgan J, 2000, GENOMICS, V68, P167, DOI 10.1006/geno.2000.6295; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; de la Taille A, 1999, CANCER RES, V59, P5461; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hisatomi T, 2001, AM J PATHOL, V158, P1271, DOI 10.1016/S0002-9440(10)64078-3; Jackson RM, 1998, J MOL BIOL, V276, P265, DOI 10.1006/jmbi.1997.1519; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KE HM, 1992, J MOL BIOL, V228, P539, DOI 10.1016/0022-2836(92)90841-7; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lorenzo HK, 2000, METHOD ENZYMOL, V322, P198; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MONTAGUE JW, 1994, J BIOL CHEM, V269, P18877; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHMITT E, 2003, IN PRESS CANC RES; Spahr CS, 2000, ELECTROPHORESIS, V21, P1635, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1635::AID-ELPS1635>3.0.CO;2-1; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Widlak P, 2001, J BIOL CHEM, V276, P48404, DOI 10.1074/jbc.M108461200; Wyllie AH, 2001, P NATL ACAD SCI USA, V98, P11, DOI 10.1073/pnas.98.1.11; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221	50	214	225	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1514	1521		10.1038/sj.onc.1207279	http://dx.doi.org/10.1038/sj.onc.1207279			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716299				2022-12-28	WOS:000189219500004
J	Costa, FF; Verbisck, NV; Salim, ACM; Ierardi, DF; Pires, LC; Sasahara, RM; Sogayar, MC; Zanata, SM; Mackay, A; O'Hare, M; Soares, F; Simpson, AJG; Camargo, AA				Costa, FF; Verbisck, NV; Salim, ACM; Ierardi, DF; Pires, LC; Sasahara, RM; Sogayar, MC; Zanata, SM; Mackay, A; O'Hare, M; Soares, F; Simpson, AJG; Camargo, AA			Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors	ONCOGENE			English	Article						ADAM23; methylation; cell adhesion; downregulation; breast tumor	DNA METHYLATION; CELL-ADHESION; CPG ISLAND; METALLOPROTEASE DOMAIN; MEMBRANE-PROTEINS; SUPPRESSOR GENES; DISINTEGRIN-LIKE; CANCER; EXPRESSION; FAMILY	Altered cell adhesion is causally involved in tumor progression, and the identification of novel adhesion molecules altered in tumors is crucial for our understanding of tumor biology and for the development of new prognostic and therapeutic strategies. Here, we provide evidence for the epigenetic downregulation in breast tumors of the A Desintegrin And Metalloprotease domain 23 gene ( ADAM 23), a member of a new family of surface molecules with roles in cell - cell adhesion and/or cell matrix interactions. W e examined the mRNA expression and methylation status of the 50 upstream region of the ADAM23 gene in different breast tumor cell lines as well as in primary breast tumors. We found ADAM23 50 hypermethylation in eight out of 12 (66.7%) tumor cell lines and in nine out of 13 (69.2%) primary tumors. Promoter hypermethylation was strongly associated with reductions in both mRNA and protein expression, with a threshold of 40 - 60% of modified CpG dinucleotides being required for the complete silencing of ADAM23 mRNA expression. Treatment of MCF-7 and SKBR-3 cell lines with 5'-Aza-2'-deoxycytidine led to a reactivation of ADAM23 mRNA expression and a marked decrease in the methylation level. It is worth noting that primary breast tumors with a more advanced grade showed a higher degree of methylation, suggesting that the adhesion molecule ADAM23 may be downregulated during the progression of breast cancer.	Ludwig Inst Canc Res, Lab Mol Biol & Genom, BR-01509010 Sao Paulo, Brazil; Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; Univ Fed Parana, Neurobiol Lab, BR-80060000 Curitiba, Parana, Brazil; Univ Coll, Ludwig Inst Canc Res, Breast Canc Lab, London, England; Hosp ACCamargo, Dept Patol, Sao Paulo, Brazil	Ludwig Institute for Cancer Research; Universidade de Sao Paulo; Universidade Federal do Parana; Ludwig Institute for Cancer Research; University of London; University College London; A.C.Camargo Cancer Center	Camargo, AA (corresponding author), Ludwig Inst Canc Res, Lab Mol Biol & Genom, Rua Prof Antonio Prudente 109,4th Floor, BR-01509010 Sao Paulo, Brazil.	anamaria@compbio.ludwig.org.br	Zanata, Silvio/AAC-9670-2021; Camargo, Anamaria A/E-9388-2012; Verbisck, Newton Valerio/I-1356-2012; Simpson, Amelia/HGB-1823-2022; Sogayar, Mari C/B-3980-2017	Zanata, Silvio/0000-0003-2818-6954; Camargo, Anamaria A/0000-0002-6076-9597; Verbisck, Newton Valerio/0000-0001-9817-7223; Sogayar, Mari C/0000-0003-4805-4609; Soares, Fernando Augusto/0000-0003-1647-7842; Soares, Fernando/0000-0002-1212-9093				Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cavallaro U, 2001, BBA-REV CANCER, V1552, P39, DOI 10.1016/S0304-419X(01)00038-5; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Cousin H, 2000, DEV BIOL, V227, P197, DOI 10.1006/dbio.2000.9871; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Herren B, 2001, EXP CELL RES, V271, P152, DOI 10.1006/excr.2001.5353; Howard L, 1999, J BIOL CHEM, V274, P31693, DOI 10.1074/jbc.274.44.31693; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; McCulloch DR, 2000, MOL CELL ENDOCRINOL, V167, P11, DOI 10.1016/S0303-7207(00)00305-1; Moss ML, 2001, DRUG DISCOV TODAY, V6, P417, DOI 10.1016/S1359-6446(01)01738-X; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Radice D, 2003, PHARMACOECONOMICS, V21, P383, DOI 10.2165/00019053-200321060-00003; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sagane K, 1998, BIOCHEM J, V334, P93, DOI 10.1042/bj3340093; Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276; Suzuki A, 2000, ONCOGENE, V19, P5842, DOI 10.1038/sj.onc.1203986; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P350; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wu E, 1997, BIOCHEM BIOPH RES CO, V235, P437, DOI 10.1006/bbrc.1997.6714	36	51	54	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1481	1488		10.1038/sj.onc.1207263	http://dx.doi.org/10.1038/sj.onc.1207263			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14661055	Bronze			2022-12-28	WOS:000189035800016
J	Luoh, SW; Venkatesan, N; Tripathi, R				Luoh, SW; Venkatesan, N; Tripathi, R			Overexpression of the amplified Pip4k2 beta gene from 17q11-12 in breast cancer cells confers proliferation advantage	ONCOGENE			English	Article						tumor biology; breast cancer; gene amplification; gene expression; HER-2/Neu	IN-SITU HYBRIDIZATION; PHOSPHATIDYLINOSITOL PHOSPHATE KINASES; GROWTH-FACTOR RECEPTOR; HER-2/NEU GENE; N-MYC; INOSITIDE PHOSPHORYLATION; AMPLIFICATION STATUS; 11Q13 AMPLIFICATION; PUTATIVE ONCOGENE; PROGNOSTIC-FACTOR	Gene amplification is common in solid tumors and is associated with adverse prognosis, disease progression, and development of drug resistance. A small segment from chromosome 17q11-12 containing the HER-2/Neu gene is amplified in about 25% of breast cancer. HER-2/Neu amplification is associated with adverse prognosis and may predict response to chemotherapy and hormonal manipulation. Moreover, HER-2/Neu amplification may select patients for anti-HER-2/Neu-based therapy with Herceptin. We and others recently described a common sequence element from the HER-2/Neu region that was amplified in breast cancer cells. In addition, most, if not all, of the amplified genes from this region display overexpression. This raises the intriguing possibility that genes immediately adjacent to HER-2/Neu may influence the biological behavior of breast cancer carrying HER-2/ Neu amplification and serve as rational targets for therapy. By extracting sequence information from public databases, we have constructed a contig in bacterial artificial chromosomes (BACs) that extends from HER-2/ Neu to a phosphotidylinositol phosphate kinase (PIPK), Pip4k2beta from 17q11 - 12. Although a role of PI-3-kinase and AKT in cancer biology has been previously described, PIPK has not been previously implicated. We show that Pip4k2b, initially known as Pip5k2beta, is amplified in a subset of breast cancer cell lines and primary breast cancer samples that carry HER-2/ Neu amplification. Out of eight breast cancer cell lines with HER-2/ Neu amplification, three have concomitant amplification of the Pip4k2beta gene - UACC-812, BT-474 and ZR-75-30. Similarly, two out of four primary breast tumors with HER-2/ Neu amplification carry Pip4k2b gene amplification. Intriguingly, one tumor displays an increase in the gene copy number of Pip4k2b that is significantly more than that of HER-2/ Neu. Moreover, dual color FISH reveals that amplified Pip4k2b gene may exist in a distinct structure from that of HER-2/ Neu in ZR-75-30 cell line. These studies suggest that Pip4k2b may reside on an amplification maximum distinct from that of HER-2/Neu and serve as an independent target for amplification and selective retention. Pip4k2beta amplification is associated with overexpression at the RNA and protein level in breast cancer cell lines. Stable expression of Pip4k2b in breast cancer cell lines with and without HER-2/Neu amplification increases cell proliferation and anchorage-independent growth. The above observations implicate Pip4k2b in the development and/or progression of breast cancer. Our study suggests that Pip4k2b may be a distinct target for gene amplification and selective retention from 17q11-12.	Univ Calif Los Angeles, Med Ctr, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Cincinnati Vet Affairs Med Ctr, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Med, Div Hematol & Oncol, Cincinnati, OH 45267 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Luoh, SW (corresponding author), Oregon Hlth Sci Univ, Portland VA Med Ctr, RAD 47,3710 SW US Vet Hosp Rd, Portland, OR 97239 USA.							AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Arneson LS, 1999, J BIOL CHEM, V274, P17794, DOI 10.1074/jbc.274.25.17794; Barlund M, 2000, CANCER RES, V60, P5340; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Brien TP, 2000, HUM PATHOL, V31, P35, DOI 10.1016/S0046-8177(00)80195-1; Bringuier PP, 1996, ONCOGENE, V12, P1747; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishikawa T, 1997, AM J PATHOL, V151, P761; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kunz J, 2000, MOL CELL, V5, P1, DOI 10.1016/S1097-2765(00)80398-6; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LAMMIE GA, 1991, ONCOGENE, V6, P439; Luoh SW, 2002, CANCER GENET CYTOGEN, V136, P43, DOI 10.1016/S0165-4608(01)00657-4; Massion PP, 2002, CANCER RES, V62, P3636; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Mejillano M, 2001, J BIOL CHEM, V276, P1865, DOI 10.1074/jbc.M007271200; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nakajima M, 1999, CANCER, V85, P1894; Nessling M, 1998, GENE CHROMOSOME CANC, V23, P307, DOI 10.1002/(SICI)1098-2264(199812)23:4<307::AID-GCC5>3.0.CO;2-#; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PRESS MF, 1994, CANCER RES, V54, P5675; PRESS MF, 1993, CANCER RES, V53, P4960; PROCTOR AJ, 1991, ONCOGENE, V6, P789; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RAVDIN PM, 1995, GENE, V159, P19, DOI 10.1016/0378-1119(94)00866-Q; ROELOFS H, 1993, GENE CHROMOSOME CANC, V7, P74, DOI 10.1002/gcc.2870070203; Rolitsky CD, 1999, INT J GYNECOL PATHOL, V18, P138, DOI 10.1097/00004347-199904000-00007; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Ross JS, 1997, HUM PATHOL, V28, P827, DOI 10.1016/S0046-8177(97)90157-X; Rozenvayn N, 2001, J BIOL CHEM, V276, P22410, DOI 10.1074/jbc.M008184200; Rubie H, 1997, J CLIN ONCOL, V15, P1171, DOI 10.1200/JCO.1997.15.3.1171; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SZEPETOWSKI P, 1992, ONCOGENE, V7, P751; SZEPETOWSKI P, 1993, GENOMICS, V16, P745, DOI 10.1006/geno.1993.1257; THEILLET C, 1990, ONCOGENE, V5, P147; Thor AD, 1998, JNCI-J NATL CANCER I, V90, P1346, DOI 10.1093/jnci/90.18.1346; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Walch AK, 2000, MODERN PATHOL, V13, P814, DOI 10.1038/modpathol.3880143; Wu GJ, 2000, CANCER RES, V60, P5371; Wu GJ, 2001, CANCER RES, V61, P4951; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	67	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	2004	23	7					1354	1363		10.1038/sj.onc.1207251	http://dx.doi.org/10.1038/sj.onc.1207251			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14691457				2022-12-28	WOS:000189035800003
J	Liu, SL; Sugimoto, Y; Sorio, C; Tecchio, C; Lin, YC				Liu, SL; Sugimoto, Y; Sorio, C; Tecchio, C; Lin, YC			Function analysis of estrogenically regulated protein tyrosine phosphatase gamma (PTP gamma) in human breast cancer cell line MCF-7	ONCOGENE			English	Article						human breast; human breast cancer; protein tyrosine phosphatase gamma; overexpression; antisense; soft agar assay	EXPRESSION; GENE; CLONING; REGION; BRAIN; DOMAIN; CDNA; LUNG	Protein tyrosine phosphatase gamma (PTPgamma) is a member of the receptor-like family of tyrosine phosphatases and has been implicated as a tumor suppressor gene in kidney and lung cancers. Based on our previous findings, we hypothesize that PTPgamma is a potential estrogen-regulated tumor suppressor gene in human breast cancer. To examine the effects of PTPgamma on growth of MCF-7 human breast cancer cells and compare the estrogenic responses of human breast cells with different PTPgamma expression levels, we established several stably transfected MCF-7 cell lines expressing different levels of PTPgamma, which were confirmed by RT-PCR and immunostaining. In our work, we used the antisense construct to breakdown endogenous PTPgamma level in MCF-7 cells. The results from doubling time assay suggested that PTPgamma is capable of inhibiting MCF-7 breast cancer cell growth. We further demonstrated that PTPgamma is able to inhibit anchorage-independent growth of breast cancer cells in soft agar and reduce the estrogenic responses of MCF-7 cell proliferation to estradiol-17beta (E-2) and zeranol (Z, a nonsteroidal growth promoter with estrogenic activity). Our data suggest that PTPgamma may function as an important modulator in regulating the process of tumorigenesis in human breast.	Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Univ Verona, Dipartimento Patol, I-37134 Verona, Italy	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Verona	Lin, YC (corresponding author), Ohio State Univ, Coll Vet Med, Lab Reprod & Mol Endocrinol, 1900 Coffey Rd, Columbus, OH 43210 USA.	lin.15@osu.edu	Sorio, Claudio/F-2764-2018; Liu, Suling/N-2796-2013; tecchio, cristina/GRX-9586-2022; liu, suling/AAF-5249-2019; Sugimoto, Yasuro/AAR-1423-2021; Sugimoto, Yasuro/B-4004-2012	Sorio, Claudio/0000-0003-2739-4014; Liu, Suling/0000-0002-0475-0242; liu, suling/0000-0002-0475-0242; Sugimoto, Yasuro/0000-0002-5094-4347	NCI NIH HHS [CA 95915, CA 94718] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA095915, R21CA094718] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNEA G, 1993, MOL CELL BIOL, V13, P1497, DOI 10.1128/MCB.13.3.1497; GAITS F, 1995, BIOCHEM J, V311, P97, DOI 10.1042/bj3110097; KAPLAN R, 1990, P NATL ACAD SCI USA, V87, P7000, DOI 10.1073/pnas.87.18.7000; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Krop IE, 2001, P NATL ACAD SCI USA, V98, P9796, DOI 10.1073/pnas.171138398; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KRUEGER NX, 1992, P NATL ACAD SCI USA, V89, P7417, DOI 10.1073/pnas.89.16.7417; Kulp SK, 2000, BIOL REPROD, V62, P181; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LAFORGIA S, 1993, CANCER RES, V53, P3118; LEVY JB, 1993, J BIOL CHEM, V268, P10573; LIN YC, 1994, P AM ASS CANC RES 85, V35, pA607; Liu SL, 2002, BREAST CANCER RES TR, V71, P21, DOI 10.1023/A:1013343718942; LUBINSKI J, 1994, CANCER RES, V54, P3710; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Poliseno L, 2002, CANCER CHEMOTH PHARM, V50, P127, DOI 10.1007/s00280-002-0467-x; SHOCK LP, 1995, MOL BRAIN RES, V28, P110, DOI 10.1016/0169-328X(94)00190-P; Sorio C, 1997, BLOOD, V90, P49; SORIO C, 1995, CANCER RES, V55, P4855; TSUKAMOTO T, 1992, CANCER RES, V52, P3506; van Niekerk CC, 1999, CANCER LETT, V137, P61, DOI 10.1016/S0304-3835(98)00344-9; Zheng J, 2000, ANTICANCER RES, V20, P11	23	34	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1256	1262		10.1038/sj.onc.1207235	http://dx.doi.org/10.1038/sj.onc.1207235			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676845				2022-12-28	WOS:000188892200010
J	Guelen, L; Paterson, H; Gaken, J; Meyers, M; Farzaneh, F; Tavassoli, M				Guelen, L; Paterson, H; Gaken, J; Meyers, M; Farzaneh, F; Tavassoli, M			TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells	ONCOGENE			English	Article						apoptin; CAV; apoptosis; TAT-PTD; protein delivery; death effector	CHICKEN ANEMIA VIRUS; PROTEIN TRANSDUCTION; TUMOR-CELLS; MAMMALIAN-CELLS; INDUCTION; INDIVIDUALS; ACTIVATION; CASPASE-3; CYCLE; DNA	Apoptin has been described to induce apoptosis in various human cancer cell lines, but not in normal cells, thus making it an interesting candidate for the development of novel therapeutic strategies. Apoptin was generated and cloned into several mammalian expression vectors. Transfection or microinjection of apoptin cDNA resulted in its expression, initially in the cytoplasm with a filamentous pattern. Subsequently, apoptin entered the nucleus and efficiently induced apoptosis in several cancer cell lines. Nuclear localization was shown to be required for induction of apoptosis. Apoptin expression level was found to be an important determinant of the efficiency of induction of apoptosis. Surprisingly, expression of apoptin or GFP-apoptin cDNA induced apoptosis in some normal cells. When fused to the HIV-TAT protein transduction domain and delivered as a protein, TAT-apoptin was transduced efficiently (>90%) into normal and tumour cells. However, TAT-apoptin remained in the cytoplasm and did not kill normal 6689 and 1BR3 fibroblasts. In contrast TAT-apoptin migrated from the cytoplasm to the nucleus of Saos-2 and HSC-3 cancer cells resulting in apoptosis after 24 h. This study shows that apoptin is a powerful apoptosis-inducing protein with a potential for cancer therapy.	Guys Kings & St Thomas Sch Med & Dent, Rayne Inst, Dept Oral Med & Pathol, Head & Neck Oncol Grp, London, England; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England; Guys Kings & St Thomas Sch Med & Dent, Rayne Inst, Dept Mol Med, London, England	University of London; King's College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; King's College London	Tavassoli, M (corresponding author), GKT Sch Med & Dent, Head & Neck Oncol Grp, Rayne Inst, 123 Coldharbour Lane, London SE5 9NU, England.	mahvash.tavassoli@kcl.ac.uk	Farzaneh, Farzin/B-4902-2009	Farzaneh, Farzin/0000-0002-9275-2415				Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Danen-van Oorschot AAAM, 2000, J VIROL, V74, P7072, DOI 10.1128/JVI.74.15.7072-7078.2000; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Ford KG, 2001, GENE THER, V8, P1, DOI 10.1038/sj.gt.3301383; Gius DR, 1999, CANCER RES, V59, P2577; HOLME TC, 1990, EUR J SURG ONCOL, V16, P161; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MEEHAN BM, 1992, ARCH VIROL, V124, P301, DOI 10.1007/BF01309811; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; Noteborn MHM, 1998, MUTAT RES-FUND MOL M, V400, P447, DOI 10.1016/S0027-5107(98)00016-5; Oorschot AAAMD, 1999, LEUKEMIA, V13, pS75, DOI 10.1038/sj.leu.2401291; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710; Weber CH, 2001, TRENDS BIOCHEM SCI, V26, P475, DOI 10.1016/S0968-0004(01)01905-3; Zhang YH, 1999, CANCER RES, V59, P3010; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939; ZHUANG SM, 1995, LEUKEMIA, V9, pS118; ZHUANG SM, 1995, CANCER RES, V55, P486	28	120	150	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1153	1165		10.1038/sj.onc.1207224	http://dx.doi.org/10.1038/sj.onc.1207224			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14691460				2022-12-28	WOS:000188749900014
J	Kuang, CZ; Chen, Y				Kuang, CZ; Chen, Y			Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction	ONCOGENE			English	Article						TGF-beta; Smad4; mutations; cancer	GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; STRUCTURAL BASIS; L3 LOOP; PROTEINS; GENE; SUPPRESSOR; PROMOTER; RECEPTOR; SIGNAL	Smad4 is a critical component in transforming growth factor beta (TGF-beta) signaling and frequently mutated in pancreatic and colorectal cancers. Smad4 has two important functional domains, MH1 and MH2, that are involved in different biological processes. The MH1 domain comprises a DNA binding domain and the MH2 domain is mainly implicated in transcriptional activation and homo- and heteromeric complex formation among Smad proteins. In the present study, a total of nine Smad4 mutations at both MH1 and MH2 domains were analysed and all of them had a reduced activity to stimulate transcription of a TGF-beta-responsive reporter gene. All four MH1 mutations had a markedly reduced ability to bind a consensus Smad binding element by an in vitro assay using GST fusion proteins. Among the MH2 mutations, R497H, K507Q, and R515G mutations of Smad4 gave rise to a reduced DNA binding capacity. The R497H mutation had a slightly reduced interaction with Smad2 upon activation of TGF-beta receptor. However, the K507Q and R515G mutations greatly lost their ability to associate with Smad2. Using a GST pull-down assay, it was found that the Smad4 MH2 domain bearing R497H and R515G mutations had an enhanced interaction with the MH1 region of the Smad4 protein, indicating that an increased intramolecular interaction by these mutations may alleviate the DNA binding activity at the MH1 domain. Consistent with these observations, the MH2 domain with R497H mutation had an enhanced ability to inhibit TGF-beta receptor-mediated transcription. In addition, the full-length R497H mutation was able to antagonize TGF-beta signaling in a dominant-negative manner. Therefore, these studies revealed novel mechanisms by which the Smad4 mutations utilize to abrogate their functions in transducing the signaling of TGF-beta, which plays an important role in various stages of cancer formation.	Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA; Chinese Acad Sci, Inst Nutr Sci, Shanghai 200031, Peoples R China	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Chinese Academy of Sciences	Chen, Y (corresponding author), Indiana Univ, Sch Med, Dept Med & Mol Genet, 975 W Walnut St,IB130, Indianapolis, IN 46202 USA.	ychen3@iupui.edu			NIDDK NIH HHS [R01 DK55991] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055991] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Chacko BM, 2001, NAT STRUCT BIOL, V8, P248, DOI 10.1038/84995; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Li W, 2001, BIOCHEM BIOPH RES CO, V286, P1163, DOI 10.1006/bbrc.2001.5529; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Moren A, 2000, ONCOGENE, V19, P4396, DOI 10.1038/sj.onc.1203798; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xiao Z, 2003, ONCOGENE, V22, P1057, DOI 10.1038/sj.onc.1206212	29	19	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1021	1029		10.1038/sj.onc.1207219	http://dx.doi.org/10.1038/sj.onc.1207219			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647410				2022-12-28	WOS:000188749900001
J	Adriance, MC; Gendler, SJ				Adriance, MC; Gendler, SJ			Downregulation of Muc1 in MMTV-c-Neu tumors	ONCOGENE			English	Article						transmembrane mucin; erbB receptors; ErbB2; MUC1	HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; TRANSGENIC MICE; EXPRESSION; INDUCTION; MUTATIONS; ONCOGENE; RECEPTOR; DNA; PROTOONCOGENE	MUC1 is a tumor antigen, overexpressed in approximately 90% of human breast cancers. In normal glandular epithelia, MUC1 is expressed at the apical surface; however, in carcinomas an aberrantly glycosylated form of MUC1 is upregulated and expressed around the entire surface of the cell. Previously, we have shown that a lack of Muc1 significantly delays tumor progression and/or onset in MMTV-PyV-mT and MMTV-Wnt-1 transgenic mice. Here we show that, unlike the models mentioned above, a loss of Muc1 in MMTV-c-Neu mice (MMTV-c-Neu/Muc1(-/-)) altered neither mammary tumor onset nor progression. Moreover, characterization of MMTV-cNeu/Muc1(+/+) tumors revealed that Muc1 expression was repressed at the level of transcription. In contrast, normal mammary gland tissue adjacent to tumor tissue expressed Muc1 and pregnant mammary glands from c-Neu transgenic animals expressed high levels of Muc1. We found that transient transfection of activated ErbB2 into human embryonic kidney 293/MUC1 cells resulted in the repression of MUC1 expression. Further, transient transfection of activated ErbB2 resulted in the inhibition of Muc1 transcriptional activation in luciferase reporter assays. These data suggest that the activation of ErbB2, which only occurs in c-Neu tumors, selectively inhibits Muc1 expression.	Mayo Clin Scottsdale, Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Mayo Clin & Mayo Grad Sch Med, Dept Mol Biol & Biochem, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Mayo Clin & Mayo Grad Sch Med, Tumor Biol Program, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu			NCI NIH HHS [CA090205, CA064389] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA090205, R01CA064389] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akewanlop C, 2001, CANCER RES, V61, P4061; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; Croce MV, 2003, J HISTOCHEM CYTOCHEM, V51, P781, DOI 10.1177/002215540305100609; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kwong KY, 1998, MOL CARCINOGEN, V23, P62, DOI 10.1002/(SICI)1098-2744(199810)23:2<62::AID-MC2>3.0.CO;2-O; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; MCGUCKIN MA, 1995, HUM PATHOL, V26, P432, DOI 10.1016/0046-8177(95)90146-9; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; Nelson KL, 1996, J BIOL CHEM, V271, P18061, DOI 10.1074/jbc.271.30.18061; PEAT N, 1992, CANCER RES, V52, P1954; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; ROCHLITZ CF, 1989, CANCER RES, V49, P357; Rowse GJ, 1998, CANCER RES, V58, P2675; Rowse GJ, 1998, CANCER RES, V58, P315; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Scibetta AG, 2001, DNA CELL BIOL, V20, P265, DOI 10.1089/104454901750232463; Shiraga T, 2002, MOL MED, V8, P33, DOI 10.1007/BF03402001; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1991, J BIOL CHEM, V266, P15099; Turner BC, 1998, CANCER RES, V58, P5466; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; XING PX, 1989, IMMUNOL CELL BIOL, V67, P183, DOI 10.1038/icb.1989.29; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	32	7	10	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					697	705		10.1038/sj.onc.1207165	http://dx.doi.org/10.1038/sj.onc.1207165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737104				2022-12-28	WOS:000188304900008
J	Cannon, ML; Cesarman, E				Cannon, ML; Cesarman, E			The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells	ONCOGENE			English	Article						Kaposi's sarcoma-associated virus (KSHV); G protein-coupled receptor (GPCR); primary effusion lymphoma (PEL); signaling	SARCOMA-ASSOCIATED HERPESVIRUS; NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; SRC TYROSINE KINASE; KAPOSIS-SARCOMA; PHOSPHOLIPASE-C; DNA-SEQUENCES; HUMAN-HERPESVIRUS-8 ENCODES; VASCULAR-PERMEABILITY; CONSTITUTIVE ACTIVITY	Kaposi#39;s sarcoma-associated virus (KSHV) is the causative agent of Kaposi#39;s sarcoma (KS) and primary effusion lymphoma (PEL). The KSHV G protein-couple receptor (vGPCR) is a homologue of the human IL-8 receptor that signals constitutively, activates mitogen- and stress-activated kinases, and induces transcription via multiple transcription factors including AP-1 and NF#954;B. Furthermore, vGPCR causes cellular transformation in vitro and leads to KS-like tumors in transgenic mouse models. vGPCR has therefore become an exciting potential therapeutic target for KSHV-mediated disease, but its signaling properties need to be better understood in the context of KSHV-infected hematopoietic cells. We recently described a PEL cell line that expresses vGPCR via an inducible promoter and have shown that vGPCR has broad capabilities of affecting cellular and viral transcription patterns in this highly relevant cell type. To elucidate the predominant signaling pathways used by vGPCR in PEL cells, we have used reporter gene assays to measure vGPCR activity in the presence of various pharmacologic enzyme inhibitors and plasmid constructs. We show that vGPCR-induced activation of AP-1 and CREB is mediated cooperatively by a Gq-ERK-1#47;2 and a Gi#8211;PI3K-Src axis. Furthermore, unlike in other cell types, NF#954;B activation by vGPCR seems not to be substantially mediated by Gi or PI3K#47;Akt in PEL cells.Oncogene (2004) 23, 514#8211;523. doi:10.1038/sj.onc.1207021	Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA	Cornell University; Cornell University	Cannon, ML (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Int Med & Infect Dis, 1300 York Ave,Room A-421, New York, NY 10021 USA.	mlcannon@med.cornell.edu			NATIONAL CANCER INSTITUTE [R01CA073531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI053971] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA73531] Funding Source: Medline; NIAID NIH HHS [K08-AI53971-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Aoki Y, 1999, BLOOD, V94, P4247, DOI 10.1182/blood.V94.12.4247; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Arvanitakis L, 1998, TRENDS ENDOCRIN MET, V9, P27, DOI 10.1016/S1043-2760(98)00007-1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Burger M, 1999, J IMMUNOL, V163, P2017; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng EHY, 1997, P NATL ACAD SCI USA, V94, P690, DOI 10.1073/pnas.94.2.690; Chiou CJ, 2002, J VIROL, V76, P3421, DOI 10.1128/JVI.76.7.3421-3439.2002; CIVATI G, 1988, TRANSPLANT P, V20, P924; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Deng HY, 2002, J VIROL, V76, P8252, DOI 10.1128/JVI.76.16.8252-8264.2002; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dupin N, 2000, BLOOD, V95, P1406, DOI 10.1182/blood.V95.4.1406.004k26_1406_1412; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; Franceschi S, 1995, TUMORI, V81, P308, DOI 10.1177/030089169508100502; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, J EXP MED, V187, P801, DOI 10.1084/jem.187.5.801; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; Ho HH, 1999, J BIOL CHEM, V274, P31327, DOI 10.1074/jbc.274.44.31327; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Igishi T, 1998, BIOCHEM BIOPH RES CO, V244, P5, DOI 10.1006/bbrc.1998.8208; Jones KD, 1999, BLOOD, V94, P2871; Keller SA, 2000, BLOOD, V96, P2537; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Neipel F, 1997, J VIROL, V71, P839, DOI 10.1128/JVI.71.1.839-842.1997; Nicholas J, 1998, J Natl Cancer Inst Monogr, P79; Nicholas J, 1997, J VIROL, V71, P1963, DOI 10.1128/JVI.71.3.1963-1974.1997; Nicholas J, 1997, NAT MED, V3, P287, DOI 10.1038/nm0397-287; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; Pati S, 2003, J VIROL, V77, P5759, DOI 10.1128/JVI.77.10.5759-5773.2003; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Polson AG, 2002, CANCER RES, V62, P4525; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2000, MOL PHARMACOL, V57, P602, DOI 10.1124/mol.57.3.602; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Samaniego F, 1998, AM J PATHOL, V152, P1433; Sarid R, 1997, NAT MED, V3, P293, DOI 10.1038/nm0397-293; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; SHEPARD LW, 2001, J BIOL CHEM, V4, P4; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2000, CANCER RES, V60, P4873; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Wakeling MN, 2001, J GEN VIROL, V82, P1187, DOI 10.1099/0022-1317-82-5-1187; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Wong WW, 1998, AGENT ACTION SUPPL, V49, P5; WU DQ, 1992, J BIOL CHEM, V267, P1811; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Ziegler JL, 1996, INT J CANCER, V65, P200, DOI 10.1002/(SICI)1097-0215(19960117)65:2&lt;200::AID-IJC12&gt;3.0.CO;2-H; Zoeteweij JP, 2001, BLOOD, V97, P2374, DOI 10.1182/blood.V97.8.2374	77	61	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					514	523		10.1038/sj.onc.1207021	http://dx.doi.org/10.1038/sj.onc.1207021			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724579				2022-12-28	WOS:000188098300022
J	Choi, JA; Park, MT; Kang, CM; Um, HD; Bae, S; Lee, KH; Kim, TH; Kim, JH; Cho, CK; Lee, YS; Chung, HY; Lee, SJ				Choi, JA; Park, MT; Kang, CM; Um, HD; Bae, S; Lee, KH; Kim, TH; Kim, JH; Cho, CK; Lee, YS; Chung, HY; Lee, SJ			Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways	ONCOGENE			English	Article						12V-Ki-Ras; 12V-Ha-Ras; radiation-induced apoptosis; PI3K/Akt; Rac/p38 MAPK; Bax translocation	CYTOCHROME-C RELEASE; PHOSPHATIDYLINOSITOL 3-KINASE; CELLULAR-SURVIVAL; NIH-3T3 CELLS; CANCER CELLS; N-RAS; RESISTANCE; BAX; ONCOGENE; P38	It has been well known that Ras signaling is involved in various cellular processes, including proliferation, differentiation, and apoptosis. However, distinct cellular functions of Ras isozymes are not fully understood. Here we show the opposing roles of Ha-Ras and Ki-Ras genes in the modulation of cell sensitivity to ionizing radiation. Overexpression of active isoform of Ha-Ras (12V-Ha-Ras) in Rat2 cells increases resistance to the ionizing radiation. Constitutive activation of phosphoinositide-3-kinase (PI3K) and Akt is detected specifically in 12V-Ha-Ras-overexpressing cells. The specific PI3K inhibitor LY294002 inhibits PI3K/Akt signaling and potentiates the radiation-induced apoptosis, suggesting that activation of the PI3K/47;Akt signaling pathway is involved in the increased radio-resistance in cells overexpressing 12V-Ha-Ras. Overexpression of activated Ki-Ras (12V-Ki-Ras), on the other hand, markedly increases radiation sensitivity. The p38 mitogen-activated protein kinase (MAPK) activity is selectively enhanced by ionizing radiation in cells overexpressing 12V-Ki-Ras. The specific p38 MAPK inhibitor, PD169316, or dominant-negative p38 MAPK decreases radiation-induced cell death. We further show that the mechanism that underlies potentiation of cell death in cells overexpressing 12V-Ki-Ras involves Bax translocation to the mitochondrial membrane. Elevated Bax translocation following ionizing irradiation in 12V-Ki-Ras-overexpressing cells is completely inhibited by PD169316 or dominant-negative p38 MAPK. In addition, introduction of cells with RacN17, a dominant-negative mutant of Rac, resulted in a marked inhibition of radiation-induced Bax translocation and apoptotic cell death as well as p38 MAPK activation. Taken together, these findings explain the opposite effects of Ha-Ras and Ki-Ras on modulation of radiosensitivity, and suggest that differential activation of PI3K/Akt and Rac/p38 MAPK signaling by Ha-Ras and Ki-Ras may account for the opposing response to the ionizing radiation. These data provide an explanation for the diverse biological functions of Ras isozymes, and partly accounts for the differential response of transformed cells to anticancer treatments.	Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Lab Expt Pathol, Seoul 139706, South Korea; Korea Inst Radiol & Med Sci, Oncol Mol Lab, Seoul 139706, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Hanyang Univ, Coll Med, Dept Microbiol, Seoul 133791, South Korea	Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea Institute of Radiological & Medical Sciences; Korea University; Hanyang University	Lee, SJ (corresponding author), Korea Inst Radiol & Med Sci, Lab Radiat Effect, Seoul 139706, South Korea.	sjlee@kcchsun.kcch.re.kr	Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Chung, Hee Yong/0000-0001-7580-0537				Ayllon V, 2000, MOL MEMBR BIOL, V17, P65; Bache M, 2001, INT J CANCER, V96, P110, DOI 10.1002/ijc.1002; Belka C, 2000, ANTICANCER RES, V20, P3243; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOS JL, 1989, CANCER RES, V49, P4682; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Brooks DG, 2001, ONCOGENE, V20, P2144, DOI 10.1038/sj.onc.1204309; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Cheng GJ, 2001, ONCOGENE, V20, P7334, DOI 10.1038/sj.onc.1204928; Choi JA, 2001, INT J ONCOL, V19, P837; Chuang SM, 2000, CARCINOGENESIS, V21, P1423, DOI 10.1093/carcin/21.7.1423; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Cuda G, 2002, CIRCULATION, V105, P968, DOI 10.1161/hc0802.104324; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eom YW, 2001, BIOCHEM BIOPH RES CO, V285, P825, DOI 10.1006/bbrc.2001.5233; Fedorov YV, 2001, J CELL BIOL, V152, P1301, DOI 10.1083/jcb.152.6.1301; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Grana TM, 2002, CANCER RES, V62, P4142; Gupta AK, 2001, CANCER RES, V61, P4278; Gupta AK, 2000, RADIAT RES, V154, P64, DOI 10.1667/0033-7587(2000)154[0064:RMRRIN]2.0.CO;2; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; HERMENS AF, 1992, CANCER RES, V52, P3073; Hosoi Y, 1998, INT J CANCER, V78, P642, DOI 10.1002/(SICI)1097-0215(19981123)78:5<642::AID-IJC19>3.0.CO;2-3; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kunz M, 2001, CELL GROWTH DIFFER, V12, P137; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; MCKENNA WG, 1990, CANCER RES, V50, P97; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; Nagase M, 2001, BIOSCI BIOTECH BIOCH, V65, P1741, DOI 10.1271/bbb.65.1741; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Pan JX, 2001, J CLIN ENDOCR METAB, V86, P4731, DOI 10.1210/jc.86.10.4731; Pennisi E, 1997, SCIENCE, V275, P1567, DOI 10.1126/science.275.5306.1567; Pervaiz S, 2001, ONCOGENE, V20, P6263, DOI 10.1038/sj.onc.1204840; PIROLLO KF, 1993, RADIAT RES, V135, P234, DOI 10.2307/3578300; Prior IA, 2001, J CELL SCI, V114, P1603; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; Rosenzweig KE, 1997, CLIN CANCER RES, V3, P1149; Santillo M, 2001, CURR BIOL, V11, P614, DOI 10.1016/S0960-9822(01)00159-2; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoshino T, 2001, EUR J IMMUNOL, V31, P2702, DOI 10.1002/1521-4141(200109)31:9<2702::AID-IMMU2702>3.0.CO;2-8	62	50	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					9	20		10.1038/sj.onc.1206982	http://dx.doi.org/10.1038/sj.onc.1206982			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712206				2022-12-28	WOS:000187895300002
J	Weissman, JT; Ma, JN; Essex, A; Gao, Y; Burstein, ES				Weissman, JT; Ma, JN; Essex, A; Gao, Y; Burstein, ES			G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel G alpha i regulated pathway	ONCOGENE			English	Article						Rap; Ras; G-protein; receptor; proliferation; transformation	NUCLEOTIDE-EXCHANGE FACTOR; GROWTH-FACTOR RECEPTOR; SRC-DEPENDENT PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; CYCLIC-AMP; MAP KINASE; B-RAF; BETA(2)-ADRENERGIC RECEPTOR; BINDING PROTEINS; HUMAN PLATELETS	Ras proteins mediate the proliferative effects of G-protein-coupled receptors (GPCRs), but the role of Rap proteins in GPCR signaling is unclear. We have developed a novel cellular proliferation assay for examining signal transduction to Rap utilizing Ras/rap chimeras that respond selectively to Rap-specific exchange factors, but which stimulate cellular proliferation through Ras effectors. Both the D1 dopamine receptor (Gs-coupled) and the 5HT1E serotonin receptor (Gi-coupled) mediated cellular proliferation in a Ras/rap chimera-dependent manner. Responses to both receptors were PKA-independent. Both receptors activated Ras/rap and full-length Rap as measured by activation-specific probes. Pertussis toxin blocked Ras/rap-dependent responses to 5HT1E but not D1. Ras/rap-dependent responses to both receptors were insensitive to beta-gamma scavengers. Responses to 5HT1E, but not D1, were sensitive to inhibition by a dominant-negative C3G fragment, by the Src-like kinase inhibitors PP1 and PP2, and by a dominant-negative mutant of Src. Very similar data were obtained for two other Gi-coupled receptors, the D2 dopamine receptor and the alpha2C adrenergic receptor. A constitutively active mutant of Galphai2 also mediated Ras/rap-dependent responses. These data indicate that GPCRs coupled to pertussis-toxin-sensitive G-proteins activate Rap through a Galpha subunit, C3G, and Src-dependent pathway.	ACADIA Pharmaceut Inc, San Diego, CA 92121 USA		Burstein, ES (corresponding author), ACADIA Pharmaceut Inc, 3911 Sorrento Valley Blvd, San Diego, CA 92121 USA.	eburstein@acadia-pharm.com						ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Burstein ES, 1998, ONCOGENE, V17, P1617, DOI 10.1038/sj.onc.1202067; BURSTEIN ES, 1995, J BIOL CHEM, V270, P3141, DOI 10.1074/jbc.270.7.3141; Burstein ES, 1997, J NEUROCHEM, V68, P525; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao YL, 2001, J PHARMACOL EXP THER, V296, P426; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Guo FF, 2001, J BIOL CHEM, V276, P25568, DOI 10.1074/jbc.M101277200; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HATA Y, 1991, J BIOL CHEM, V266, P6571; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Lova P, 2003, J BIOL CHEM, V278, P131, DOI 10.1074/jbc.M204821200; Lova P, 2002, J BIOL CHEM, V277, P12009, DOI 10.1074/jbc.M111803200; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; M'Rabet L, 1998, BLOOD, V92, P2133, DOI 10.1182/blood.V92.6.2133.418k19_2133_2140; Maudsley S, 2000, J BIOL CHEM, V275, P9572, DOI 10.1074/jbc.275.13.9572; McLeod SJ, 1998, J BIOL CHEM, V273, P29218, DOI 10.1074/jbc.273.44.29218; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Schmitt JM, 2000, J BIOL CHEM, V275, P25342, DOI 10.1074/jbc.M003213200; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Seidel MG, 1999, J BIOL CHEM, V274, P25833, DOI 10.1074/jbc.274.36.25833; Smit MJ, 2002, METHOD ENZYMOL, V343, P430; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tsygankova OM, 2000, ONCOGENE, V19, P3609, DOI 10.1038/sj.onc.1203680; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wan Y, 1998, J BIOL CHEM, V273, P14533, DOI 10.1074/jbc.273.23.14533; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	51	30	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					241	249		10.1038/sj.onc.1207014	http://dx.doi.org/10.1038/sj.onc.1207014			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712229				2022-12-28	WOS:000187895300025
J	Pession, A; Martino, V; Tonelli, R; Beltramini, C; Locatelli, F; Biserni, G; Franzoni, M; Freccero, F; Montemurro, L; Pattacini, L; Paolucci, G				Pession, A; Martino, V; Tonelli, R; Beltramini, C; Locatelli, F; Biserni, G; Franzoni, M; Freccero, F; Montemurro, L; Pattacini, L; Paolucci, G			MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells	ONCOGENE			English	Article						MLL-AF9; cell growth; differentiation; expression; THP-1	FUSION GENE; HEMATOLOGICAL MALIGNANCIES; M-CSF; LEUKEMIA; MLL; LINE; PROTEIN; LEUKEMOGENESIS; MICE; ESTABLISHMENT	The MLL-AF9 oncogene - one of the most frequent MLL/HRX/ALL-1 rearrangements found in infantile and therapy-related leukaemias - originates from t(9;11) (p22;q23) and is mainly associated with monocytic acute myeloid leukaemia (AML-M5; FAB-classification). Here, we investigated the MLL-AF9 function by means of an antisense phosphorothioate-oligodeoxyribonucleotide (MLL-AF9-PS-ODNas) using the THP-1 AML-M5 cell line carrying t(9;11). Having confirmed that MLL-AF9-PS-ODNas induces strong inhibition of THP-1 cell growth, but only a moderate increase in apoptosis, we found that MLL-AF9-PS-ODNas did not induce morphofunctional terminal differentiation or restore M-CSF-, G-CSF- or GM-CSF-induced differentiation. Moreover, THP-1 cells showed the same phenotype with/without MLL-AF9-PS-ODNas. In THP-1 cells differentiated to mature macrophage-like cells by PMA/TPA or ATRA, MLL-AF9 expression was downregulated. Thus, in the monocytic lineage, MLL-AF9 may be expressed only in early phases and can induce deregulated amplification in both nonmalignant and malignant cells, maintaining the monocytic phenotype without blocking final maturation. Our findings suggest that: (1) as well as directly promoting cell growth, MLL-AF9 may also indirectly determine phenotype; (2) other leukaemogenic mutations associated with MLL-AF9-related leukaemias should be searched for mainly in processes of resistance to apoptosis (where MLL-AF9 may play only a limited role) and differentiation blockage (where MLL-AF9 may play no role).	Univ Bologna, Policlin S Orsola Malpighi, Dept Paediat, I-40138 Bologna, Italy; Univ Pavia, Policlin San Matteo, IRCCS, I-27100 Pavia, Italy; Univ Bologna, Policlin S Orsola Malpighi, Inst Haematol & Med Oncol LA Seragnoli, I-40138 Bologna, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Fondazione San Matteo; University of Pavia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Pession, A (corresponding author), Policlin S Orsola Malpighi, Dipartimento Sci Pediat Med & Chirurg, Unita Terapia Cellulare, Via Massarenti 11, I-40138 Bologna, Italy.		Pession, Andrea/O-3200-2013	Pession, Andrea/0000-0002-0379-9562				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; BRACH MA, 1990, VIRCHOWS ARCH B, V59, P54, DOI 10.1007/BF02899387; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Ennas MG, 1997, CANCER RES, V57, P2035; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Giles RV, 1998, NUCLEIC ACIDS RES, V26, P1567, DOI 10.1093/nar/26.7.1567; IIDA S, 1993, ONCOGENE, V8, P3085; Ikeda T, 1998, BIOCHEM BIOPH RES CO, V253, P265, DOI 10.1006/bbrc.1998.9702; Ikeda T, 1998, BLOOD, V91, P4543, DOI 10.1182/blood.V91.12.4543.412k27_4543_4553; Joh T, 1999, ONCOGENE, V18, P1125, DOI 10.1038/sj.onc.1202400; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Joh T, 1996, ONCOGENE, V13, P1945; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kawagoe H, 2001, LEUKEMIA, V15, P1743, DOI 10.1038/sj.leu.2402262; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; MATIKAINEN S, 1994, INT J CANCER, V57, P98, DOI 10.1002/ijc.2910570118; Niitsu N, 2001, ONCOGENE, V20, P375, DOI 10.1038/sj.onc.1204081; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Swansbury GJ, 1998, LEUKEMIA, V12, P792, DOI 10.1038/sj.leu.2401014; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	32	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8671	8676		10.1038/sj.onc.1207125	http://dx.doi.org/10.1038/sj.onc.1207125			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647461				2022-12-28	WOS:000186844900004
J	Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Oikawa, T				Suzuki, M; Yamada, T; Kihara-Negishi, F; Sakurai, T; Oikawa, T			Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression	ONCOGENE			English	Article						PU.1; MeCP2; Ets; co-repressor; transcriptional repression	DNA-BINDING PROTEIN; HISTONE DEACETYLASE; ERYTHROLEUKEMIA-CELLS; ACTIVATION DOMAIN; METHYLATED DNA; NUCLEAR-FACTOR; ACETYLATION; DIFFERENTIATION; HDAC1; SPI-1/PU.1	PU.1, a member of the Ets family of transcription factors, is implicated in hematopoietic cell differentiation through its interactions with other transcriptional factors and cofactors. To identify a novel protein(s) binding to PU.1, we carried out affinity purification using a column of Glutathione-Sepharose beads bound to GST-PU.1 fusion protein and isolated several individual proteins using murine erythroleukemia (MEL) cell extracts. Sequence analysis of these proteins revealed that one was MeCP2 a methyl CpG binding protein. GST-pull-down assay and immunoprecipitation assay showed that PU.1 bound directly to MeCP2 via its Ets domain and MeCP2 bound to PU.1 via either its amino terminal domain or transrepression domain. MeCP2 repressed transcriptional activity of PU.1 on a reporter construct with trimerized PU.1 binding sites. This downregulation was recovered in the presence of histone deacetylase inhibitor, trichostatin A (TSA). MeCP2 was integrated in PU.1-mSin3A-HDAC complex but not in PU.1-CBP complex. Chromatin immunoprecipitation (ChIP) assays showed that PU.1 and MeCP2 were collocated at the PU.1 binding site on the reporter construct and the PU.1 binding site of the intervening sequence 2 (IVS2) region in the intron of the beta-globin gene, which has been proposed to regulate expression of the gene, in undifferentiated MEL cells. The complex disappeared from the region during the course of erythroid differentiation of MEL cells. Our results suggest that MeCP2 acts as a corepressor of PU.1 probably due to facilitating complex formation with mSin3A and HDACs.	Sasaki Inst, Dept Cell Genet, Chiyoda Ku, Tokyo 1010062, Japan		Oikawa, T (corresponding author), Sasaki Inst, Dept Cell Genet, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chawla S, 1998, SCIENCE, V281, P1505, DOI 10.1126/science.281.5382.1505; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; Huang S, 2000, MOL CELL BIOL, V20, P2248, DOI 10.1128/MCB.20.6.2248-2259.2000; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Konishi Y, 1999, ONCOGENE, V18, P6795, DOI 10.1038/sj.onc.1203118; Mal A, 2001, EMBO J, V20, P1739, DOI 10.1093/emboj/20.7.1739; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; Rao E, 1997, J BIOL CHEM, V272, P6722, DOI 10.1074/jbc.272.10.6722; RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; TENEN DG, 1997, BLOOD, V90, P498; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	42	67	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8688	8698		10.1038/sj.onc.1207182	http://dx.doi.org/10.1038/sj.onc.1207182			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647463				2022-12-28	WOS:000186844900006
J	Gallego, MI; Bierie, B; Hennighausen, L				Gallego, MI; Bierie, B; Hennighausen, L			Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways	ONCOGENE			English	Article						breast cancer; transgenic mice; HGF; scatter factor; c-Met	HEPATOCYTE GROWTH-FACTOR; MET TYROSINE KINASE; NEGATIVE BREAST-CANCER; FACTOR SCATTER FACTOR; C-MET; BETA-CATENIN; GLAND DEVELOPMENT; FACTOR/SCATTER FACTOR; RECEPTOR MET; COLORECTAL-CANCER	Overexpression of hepatocyte growth factor (HGF), also called scatter factor (SIT), and its receptor c-Met are associated with poor prognosis for cancer patients. In particular, breast cancer cells can produce HGF that acts in a paracrine as well as in an autocrine manner. Therefore, HGF and c-Met are putative targets for cancer therapy. To explore HGF/c-Met signaling in breast cancer, we have generated transgenic mice expressing HGF specifically in mammary epithelium under the transcriptional control of the whey acidic protein (WAP) gene promoter. WAP-HGF transgenic females developed hyperplastic ductal trees and multifocal invasive tumors after several pregnancies, some of which progressed to lung metastases. Tumors produced HGF and displayed phosphorylated c-Met, which correlated with increased Akt as well as c-myc activation. A high growth rate, as demonstrated by Ki67 nuclear antigen staining, and a lack of progesterone receptor were characteristic of the tumors. Immunohistochemical analysis revealed areas of osteopontin (Opn) expression in WAP-HGF tumors and lung metastases in agreement with a previously reported role for Opn in invasive growth. We suggest that these mice may serve as a new breast cancer model for the evaluation of the effects of unscheduled HGF expression in breast cancer.	Fdn Marcelino Botin, Ctr Invest Energet Medioambientales & Tecnol, Project Breast Canc, Madrid 28042, Spain; NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gallego, MI (corresponding author), CIEMAT, Av Complutense 22,Edificio 7, E-28040 Madrid, Spain.			Gallego, Marta I./0000-0003-0143-2553; Hennighausen, Lothar/0000-0001-8319-9841	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK061000, ZIADK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aulmann S, 2002, BREAST CANCER RES TR, V74, P25, DOI 10.1023/A:1016061327812; Bieche I, 1999, INT J CANCER, V82, P908, DOI 10.1002/(SICI)1097-0215(19990909)82:6<908::AID-IJC22>3.0.CO;2-N; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Boon EMJ, 2002, CANCER RES, V62, P5126; Bowers DC, 2000, CANCER RES, V60, P4277; Camp RL, 1999, CANCER, V86, P2259, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2259::AID-CNCR13>3.0.CO;2-2; Cui XJ, 2003, MOL ENDOCRINOL, V17, P575, DOI 10.1210/me.2002-0318; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x; Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gallagher RCJ, 2002, ONCOGENE, V21, P6446, DOI 10.1038/sj.onc.1205892; Ghoussoub RAD, 1998, CANCER, V82, P1513, DOI 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7; Greenberg R, 2003, BREAST CANCER RES, V5, pR71, DOI 10.1186/bcr588; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Hogan B, 1994, MANIPULATING MOUSE E; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kamalati T, 1999, J MAMMARY GLAND BIOL, V4, P69, DOI 10.1023/A:1018756620265; Kang JY, 2003, CANCER RES, V63, P1101; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; KORDON EC, 1995, J VIROL, V69, P8066, DOI 10.1128/JVI.69.12.8066-8069.1995; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Medico E, 2001, CANCER RES, V61, P5861; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Monga SPS, 2002, CANCER RES, V62, P2064; Nakopoulou L, 2000, HISTOPATHOLOGY, V36, P313; Nemir M, 2000, J BIOL CHEM, V275, P969, DOI 10.1074/jbc.275.2.969; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; Oates AJ, 1996, ONCOGENE, V13, P97; Ocal IT, 2003, CANCER-AM CANCER SOC, V97, P1841, DOI 10.1002/cncr.11335; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; PITTIUS CW, 1988, P NATL ACAD SCI USA, V85, P5874, DOI 10.1073/pnas.85.16.5874; Pollard JW, 2001, BREAST CANCER RES, V3, P230, DOI 10.1186/bcr301; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; Rittling SR, 1997, CELL GROWTH DIFFER, V8, P1061; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Rudland PS, 2002, CANCER RES, V62, P3417; Schlotter CM, 2003, BREAST CANCER RES, V5, pR30, DOI 10.1186/bcr568; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; Stal O, 2003, BREAST CANCER RES, V5, pR37, DOI 10.1186/bcr569; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tuck AB, 1996, AM J PATHOL, V148, P225; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Walter KA, 2002, MOL CELL BIOL, V22, P2703, DOI 10.1128/MCB.22.8.2703-2715.2002; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Yant J, 1998, EXP CELL RES, V241, P476, DOI 10.1006/excr.1998.4028; Yoshida S, 2003, J INVEST DERMATOL, V120, P335, DOI 10.1046/j.1523-1747.2003.12039.x; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358	62	83	88	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8498	8508		10.1038/sj.onc.1207063	http://dx.doi.org/10.1038/sj.onc.1207063			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627990				2022-12-28	WOS:000186650300013
J	Kaufmann, SH; Vaux, DL				Kaufmann, SH; Vaux, DL			Alterations in the apoptotic machinery and their potential role in anticancer drug resistance	ONCOGENE			English	Review						apoptosis; caspases; carcinogenesis; Bcl-2; IAP; drug resistance; stress response	CHRONIC MYELOGENOUS LEUKEMIA; PROGRAMMED CELL-DEATH; BCL-2 ANTISENSE OLIGONUCLEOTIDE; CHRONIC LYMPHOCYTIC-LEUKEMIA; UBIQUITIN-PROTEIN LIGASE; ABL TYROSINE KINASE; CHEMOTHERAPY-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; X-LINKED INHIBITOR	Anticancer drugs can potentially kill cells in two fundamentally different ways, by interfering with cellular processes that are essential for maintenance of viability or by triggering an endogenous physiological cell death mechanism. Apoptosis is a form of physiological cell death mediated by caspases, a unique family of intracellular cysteine proteases. Zymogen forms of these proteases are found in virtually all somatic cells, but remain latent until their activation is induced by ligation of specific cell surface receptors (the so- called 'death receptors'), by mitochondrial alterations that allow release of cytochrome c and other intermembrane components, or possibly by other mechanisms. Most anticancer drugs activate the mitochondrial pathway. This apoptotic pathway is regulated by pro- and antiapoptotic members of the Bcl-2 family of proteins. Once activated, certain caspases might also be controlled by the inhibitor of apoptosis (IAP) proteins. Alterations in apoptotic pathway components or their regulators have been detected in a variety of cancers, suggesting that loss of the ability of cells to undergo apoptosis might contribute to carcinogenesis. Because cancer therapies such as radiation, glucocorticoids, and chemotherapeutic drugs exert their beneficial effects, at least in part, by inducing apoptosis of cancer cells, the same alterations in apoptotic pathways would be predicted to contribute to resistance. A key issue is whether the direct toxic activity of these treatments is of benefit when neoplastic cells contain changes that diminish their ability to undergo apoptosis.	Mayo Clin & Mayo Fdn, Div Oncol Res, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Mol Pharmacol, Rochester, MN 55905 USA; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Mayo Clinic; Mayo Clinic; Walter & Eliza Hall Institute	Kaufmann, SH (corresponding author), Mayo Clin & Mayo Fdn, Div Oncol Res, Guggenheim 1342C,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.Scott@Mayo.edu	Vaux, David L/C-7249-2013	Vaux, David L/0000-0003-2703-1651; Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Aebersold DM, 2001, INT J CANCER, V96, P41, DOI 10.1002/1097-0215(20010220)96:1<41::AID-IJC5>3.0.CO;2-F; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bai C, 2000, P NATL ACAD SCI USA, V97, P1230, DOI 10.1073/pnas.97.3.1230; Bairey O, 1999, CLIN CANCER RES, V5, P2860; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Boudard D, 2002, AM J HEMATOL, V70, P115, DOI 10.1002/ajh.10108; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brady HJM, 1996, EMBO J, V15, P1221, DOI 10.1002/j.1460-2075.1996.tb00463.x; Brown JM, 1999, CANCER RES, V59, P1391; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bullrich F, 1999, CANCER RES, V59, P24; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; CAMPOS L, 1994, BLOOD, V84, P595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chandra J, 1998, BLOOD, V92, P4220, DOI 10.1182/blood.V92.11.4220.423k49_4220_4229; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chi KN, 2001, CLIN CANCER RES, V7, P3920; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cotter Finbarr E., 1999, Seminars in Hematology, V36, P9; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eggert A, 2001, CANCER RES, V61, P1314; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Elnemr A, 2001, INT J ONCOL, V18, P311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Estrov Z, 1998, BLOOD, V92, P3090, DOI 10.1182/blood.V92.9.3090; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Green D R, 1994, Important Adv Oncol, P37; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; HANADA M, 1993, BLOOD, V82, P1820; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannun YA, 1997, BLOOD, V89, P1845, DOI 10.1182/blood.V89.6.1845; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASHIMOTO H, 1995, CLIN CANCER RES, V1, P369; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HK, 2000, J BIOL CHEM, V275, P26661; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Igata E, 1999, GENE, V238, P407, DOI 10.1016/S0378-1119(99)00348-0; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Irmler M, 1997, FEBS LETT, V406, P189, DOI 10.1016/S0014-5793(97)00271-8; Izquierdo M, 1999, EMBO J, V18, P156, DOI 10.1093/emboj/18.1.156; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kamihira S, 2001, BRIT J HAEMATOL, V114, P63, DOI 10.1046/j.1365-2141.2001.02902.x; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kaufmann SH, 2000, BIOESSAYS, V22, P1007, DOI 10.1002/1521-1878(200011)22:11<1007::AID-BIES7>3.3.CO;2-W; Keating MJ, 2002, SEMIN ONCOL, V29, P70, DOI 10.1053/sonc.2002.30142; Kipps TJ, 2002, SEMIN ONCOL, V29, P98, DOI 10.1053/sonc.2002.30146; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kohler T, 2002, ANTICANCER RES, V22, P1553; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kottke TJ, 2002, J BIOL CHEM, V277, P804, DOI 10.1074/jbc.M108419200; Kruh GD, 2003, ONCOGENE, V22, P7537, DOI 10.1038/sj.onc.1206953; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; La Rosee P, 2002, LEUKEMIA, V16, P1213, DOI 10.1038/sj.leu.2402555; LANEUVILLE P, 1994, CANCER RES, V54, P1360; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Li FZ, 1999, CANCER RES, V59, P3143; Li JL, 2001, ENDOCRINOLOGY, V142, P370, DOI 10.1210/en.142.1.370; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LI X, 1994, LEUKEMIA LYMPHOMA, V13, P65, DOI 10.3109/10428199409052678; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu R, 1999, AM J PATHOL, V155, P1861, DOI 10.1016/S0002-9440(10)65505-8; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lock RB, 1996, CANCER RES, V56, P4006; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; MARTIN DS, 1994, CANCER INVEST, V12, P296, DOI 10.3109/07357909409023028; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Martins LM, 1997, BLOOD, V90, P4283, DOI 10.1182/blood.V90.11.4283.4283_4283_4296; MATTHEWS DE, 1988, USING UNDERSTANDING; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Merritt AJ, 1997, ONCOGENE, V14, P2759, DOI 10.1038/sj.onc.1201126; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1995, J BIOL CHEM, V270, P26049, DOI 10.1074/jbc.270.44.26049; MIYASHITA T, 1992, CANCER RES, V52, P5407; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Mow BMF, 2002, BLOOD, V99, P664, DOI 10.1182/blood.V99.2.664; Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Newton K, 2001, ADV IMMUNOL, V76, P179, DOI 10.1016/S0065-2776(01)76020-8; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Pritchard DM, 1998, CANCER RES, V58, P5453; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; REED JC, 1990, CANCER RES, V50, P6565; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robles AI, 2001, CANCER RES, V61, P6660; Rudin CM, 2002, ANN ONCOL, V13, P539, DOI 10.1093/annonc/mdf124; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Seiter K, 1997, J CLIN ONCOL, V15, P44, DOI 10.1200/JCO.1997.15.1.44; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Shin MS, 2001, CANCER RES, V61, P4942; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Shuai K, 1996, ONCOGENE, V13, P247; Silke J, 2001, J CELL SCI, V114, P1821; Simonian PL, 1997, BLOOD, V90, P1208, DOI 10.1182/blood.V90.3.1208.1208_1208_1216; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith KGC, 1996, EMBO J, V15, P5167, DOI 10.1002/j.1460-2075.1996.tb00901.x; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Stoelcker B, 2000, AM J PATHOL, V156, P1171, DOI 10.1016/S0002-9440(10)64986-3; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tamm I, 2000, CLIN CANCER RES, V6, P1796; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Theodorakis P, 2002, CANCER RES, V62, P3373; Theodoropoulos PA, 1999, CANCER RES, V59, P4625; Thomas A, 1996, ONCOGENE, V12, P1055; Tillman DM, 1999, CLIN CANCER RES, V5, P425; Tolcher AW, 2001, SEMIN ONCOL, V28, P67, DOI 10.1016/S0093-7754(01)90158-7; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Villunger A, 1997, CANCER RES, V57, P3331; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Wachenfeld C, 2001, EUR J ENDOCRINOL, V145, P335, DOI 10.1530/eje.0.1450335; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Wang JL, 2000, CANCER RES, V60, P1498; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wu JW, 2001, MOL CELL, V8, P95, DOI 10.1016/S1097-2765(01)00282-9; WYLLIE AH, 1985, ANTICANCER RES, V5, P131; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yang LL, 2003, CANCER RES, V63, P831; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YIN DX, 1995, CANCER RES, V55, P4922; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zheng TS, 2000, EXP CELL RES, V256, P67, DOI 10.1006/excr.2000.4841; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	243	234	245	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7414	7430		10.1038/sj.onc.1206945	http://dx.doi.org/10.1038/sj.onc.1206945			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576849				2022-12-28	WOS:000186112500014
J	Mossink, MH; van Zon, A; Scheper, RJ; Sonneveld, P; Wiemer, EAC				Mossink, MH; van Zon, A; Scheper, RJ; Sonneveld, P; Wiemer, EAC			Vaults: a ribonucleoprotein particle involved in drug resistance?	ONCOGENE			English	Review						vault complex; multidrug resistance; LRP; MVP	ACUTE MYELOID-LEUKEMIA; LEVEL DOXORUBICIN RESISTANCE; PROTEIN MESSENGER-RNA; SHORT-TERM EXPOSURE; P-GLYCOPROTEIN PGP; MULTIDRUG-RESISTANCE; POLY(ADP-RIBOSE) POLYMERASE; INCREASED EXPRESSION; BREAST-CANCER; TELOMERASE ACTIVITY	Vaults are ribonucleoprotein particles found in the cytoplasm of eucaryotic cells. The 13 MDa particles are composed of multiple copies of three proteins: an M-r 100 000 major vault protein (MVP) and two minor vault proteins of M-r 193 000 (vault poly-(ADP-ribose) polymerase) and M-r 240 000 (telomerase-associated protein 1), as well as small untranslated RNA molecules of approximately 100 bases. Although the existence of vaults was first reported in the mid-1980s no function has yet been attributed to this organelle. The notion that vaults might play a role in drug resistance was suggested by the molecular identification of the lung resistance-related (LRP) protein as the human MVP. MVP/LRP was found to be overexpressed in many chemoresistant cancer cell lines and primary tumor samples of different histogenetic origin. Several, but not all, clinico-pathological studies showed that MVP expression at diagnosis was an independent adverse prognostic factor for response to chemotherapy. The hollow barrel-shaped structure of the vault complex and its subcellular localization indicate a function in intracellular transport. It was therefore postulated that vaults contributed to drug resistance by transporting drugs away from their intracellular targets and/or the sequestration of drugs. Here, we review the current knowledge on the vault complex and critically discuss the evidence that links vaults to drug resistance.	Erasmus MC, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Pathol, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam	Wiemer, EAC (corresponding author), Erasmus MC, Dept Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	e.wiemer@erasmusmc.nl		Wiemer, Erik/0000-0002-0673-7236				Abbondanza C, 1998, J CELL BIOL, V141, P1301, DOI 10.1083/jcb.141.6.1301; Arts HJG, 1999, CLIN CANCER RES, V5, P2798; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; Berger W, 2000, INT J CANCER, V88, P293, DOI 10.1002/1097-0215(20001015)88:2<293::AID-IJC23>3.0.CO;2-S; Borg AG, 1998, BRIT J HAEMATOL, V103, P1083, DOI 10.1046/j.1365-2141.1998.01111.x; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; CHUGANI DC, 1993, J CELL SCI, V106, P23; Damiani D, 1998, HAEMATOLOGICA, V83, P290; Den Boer ML, 1999, LEUKEMIA, V13, P2023, DOI 10.1038/sj.leu.2401576; den Boer ML, 1998, BLOOD, V91, P2092, DOI 10.1182/blood.V91.6.2092.2092_2092_2098; Dingemans AMC, 1996, ANN ONCOL, V7, P625; Filipits M, 1999, CLIN CANCER RES, V5, P2426; Filipits M, 1998, BLOOD, V91, P1508, DOI 10.1182/blood.V91.5.1508.1508_1508_1513; Filipits M, 2000, LEUKEMIA, V14, P68, DOI 10.1038/sj.leu.2401634; Goasguen JE, 1996, LEUKEMIA LYMPHOMA, V23, P567, DOI 10.3109/10428199609054866; Hamill DR, 1997, DEV BIOL, V190, P117, DOI 10.1006/dbio.1997.8676; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hart SM, 1997, EXP HEMATOL, V25, P1227; Herrmann C, 1999, J CELL BIOL, V144, P1163, DOI 10.1083/jcb.144.6.1163; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; Izquierdo MA, 1996, AM J PATHOL, V148, P877; Izquierdo MA, 1996, INT J CANCER, V65, P230; IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; Kakihara T, 1999, PEDIATR INT, V41, P641, DOI 10.1046/j.1442-200X.1999.t01-1-01144.x; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1990, MOL BIOL REP, V14, P121, DOI 10.1007/BF00360441; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1996, TRENDS CELL BIOL, V6, P174, DOI 10.1016/0962-8924(96)10014-3; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1998, J BIOL CHEM, V273, P8971, DOI 10.1074/jbc.273.15.8971; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2001, J CELL BIOL, V152, P157, DOI 10.1083/jcb.152.1.157; Kitazono M, 2001, INT J CANCER, V91, P126, DOI 10.1002/1097-0215(20010101)91:1<126::AID-IJC1018>3.0.CO;2-8; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Komarov PG, 1998, ONCOL RES, V10, P185; Kong LB, 2000, RNA, V6, P890, DOI 10.1017/S1355838200000157; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Lange C, 2000, BIOCHEM BIOPH RES CO, V278, P125, DOI 10.1006/bbrc.2000.3782; Laurencot CM, 1997, INT J CANCER, V72, P1021; Legrand O, 1998, LEUKEMIA, V12, P1367, DOI 10.1038/sj.leu.2401117; Leith CP, 1999, BLOOD, V94, P1086; Li JY, 1999, NEUROSCIENCE, V91, P1055, DOI 10.1016/S0306-4522(98)00622-8; Linn SC, 1997, INT J CANCER, V71, P787, DOI 10.1002/(SICI)1097-0215(19970529)71:5<787::AID-IJC16>3.0.CO;2-5; List AF, 1996, BLOOD, V87, P2464, DOI 10.1182/blood.V87.6.2464.bloodjournal8762464; Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000; Ma Q, 2001, BIOCHEM BIOPH RES CO, V289, P499, DOI 10.1006/bbrc.2001.5987; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meijer GA, 1999, J CLIN PATHOL, V52, P450, DOI 10.1136/jcp.52.6.450; Michieli M, 1997, BRIT J HAEMATOL, V96, P356, DOI 10.1046/j.1365-2141.1997.d01-2020.x; Michieli M, 1999, BRIT J HAEMATOL, V104, P328, DOI 10.1046/j.1365-2141.1999.01172.x; Moran E, 1997, EUR J CANCER, V33, P652, DOI 10.1016/S0959-8049(96)00501-1; Mossink MH, 2002, CANCER RES, V62, P7298; Mossink MH, 2002, GENE, V294, P225, DOI 10.1016/S0378-1119(02)00789-8; Ogretmen B, 2000, J PEDIAT HEMATOL ONC, V22, P45, DOI 10.1097/00043426-200001000-00009; Ohno N, 2001, BLOOD, V98, P1160, DOI 10.1182/blood.V98.4.1160; Oliver FJ, 1999, AM J HUM GENET, V64, P1282, DOI 10.1086/302389; Pallis M, 1999, BRIT J HAEMATOL, V104, P307, DOI 10.1046/j.1365-2141.1999.01157.x; Pohl G, 1999, ANTICANCER RES, V19, P5051; Raaijmakers HGP, 1998, BLOOD, V91, P1029, DOI 10.1182/blood.V91.3.1029.1029_1029_1036; RAMANI P, 1995, J PATHOL, V175, P13, DOI 10.1002/path.1711750104; Rimsza LM, 1999, LEUKEMIA LYMPHOMA, V34, P315, DOI 10.3109/10428199909050956; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; Sbodio JI, 2002, BIOCHEM J, V361, P451, DOI 10.1042/0264-6021:3610451; SCHADENDORF D, 1995, AM J PATHOL, V147, P1545; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCHEPER RJ, 1993, CANCER RES, V53, P1475; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Schroeijers AB, 2000, CANCER RES, V60, P1104; Schroeijers AB, 2002, J IMMUNOL, V168, P1572, DOI 10.4049/jimmunol.168.4.1572; Shall Sydney, 2002, Bioessays, V24, P197, DOI 10.1002/bies.10012; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Stephen AG, 2001, J BIOL CHEM, V276, P23217, DOI 10.1074/jbc.C100226200; Stoffler D, 1999, J MOL BIOL, V287, P741, DOI 10.1006/jmbi.1999.2637; Uozaki H, 1997, CANCER-AM CANCER SOC, V79, P2336, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; van Zon A, 2002, BIOCHEM BIOPH RES CO, V291, P535, DOI 10.1006/bbrc.2002.6472; van Zon A, 2001, J BIOL CHEM, V276, P37715, DOI 10.1074/jbc.M106055200; vanderPol JP, 1997, INVEST OPHTH VIS SCI, V38, P2523; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; Verovski VN, 1996, BRIT J CANCER, V73, P596, DOI 10.1038/bjc.1996.103; VERSANTVOORT CHM, 1995, INT J CANCER, V61, P375, DOI 10.1002/ijc.2910610317; Volm M, 1997, ANTI-CANCER DRUG, V8, P662, DOI 10.1097/00001813-199708000-00003; Volm M, 1997, ANTI-CANCER DRUG, V8, P931, DOI 10.1097/00001813-199711000-00003; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; Wyler B, 1997, BRIT J HAEMATOL, V97, P65, DOI 10.1046/j.1365-2141.1997.52649.x; Xu DW, 1999, BRIT J HAEMATOL, V106, P627, DOI 10.1046/j.1365-2141.1999.01611.x; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200	93	144	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7458	7467		10.1038/sj.onc.1206947	http://dx.doi.org/10.1038/sj.onc.1206947			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576851				2022-12-28	WOS:000186112500016
J	Hesson, L; Bieche, I; Krex, D; Criniere, E; Hoang-Xuan, K; Maher, ER; Latif, F				Hesson, L; Bieche, I; Krex, D; Criniere, E; Hoang-Xuan, K; Maher, ER; Latif, F			Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas	ONCOGENE			English	Article						methylation; gliomas; RASSF1A; BLU	TUMOR-SUPPRESSOR GENE; CARCINOMA IN-SITU; CELL LUNG-CANCER; PROMOTER HYPERMETHYLATION; CHROMOSOME 3P21.3; DUCTAL CARCINOMA; HUMAN NEOPLASIA; BREAST CANCERS; SLIT2 GENE; CPG ISLAND	RASSF1A is a major tumor suppressor gene located at 3p21.3. We investigated the role of aberrant promoter region hypermethylation of RASSF1A in a large series of adult gliomas. RASSF1A was frequently methylated in both primary tumors (36/63; 57%) and tumor cell lines (7/7; 100%). Hypermethylation of RASSF1A in glioma cell lines correlated with loss of expression and treatment with a demethylating agent-reactivated RASSF1A gene expression. Furthermore, re-expression of RASSF1A suppressed the growth of glioma cell line H4 in vitro. Next, we investigated whether other members of the RASSF gene family were also inactivated by methylation. NORE1B and RASSF3 were not methylated in gliomas, while NORE1A and RASSF5/AD037 demonstrated methylation in glioma cell lines but not in primary tumors. We then investigated the methylation status of three other candidate 3p21.3 tumor suppressor genes. CACNA2D2 and SEMA3B were not frequently methylated, but the BLU gene located just centromeric to RASSF1 was frequently methylated in glioma cell lines (7/7) and in 80% (35/44) of glioma tumors. In these tumor cell lines, BLU expression was restored after treatment with a demethylating agent. Loss of BLU gene expression in glioma tumors correlated with BLU methylation. There was no association between RASSF1A and BLU methylation. RASSF1A methylation increased with tumor grade, while BLU methylation was seen at similar frequencies in all grades. Our data implicate RASSF1A and BLU promoter methylation in the pathogenesis of adult gliomas, while other RASSF family members and CACNA2D2 and SEMA3B appear to have only minor roles. In addition, RASSF1A and BLU methylation appear to be independent and specific events and not due to region-wide changes in DNA methylation.	Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Ctr Rene Huguenin, INSERM, E0017, Lab Oncogenet, F-92210 St Cloud, France; Tech Univ Dresden, Univ Klinikum Carl Gustan Carus, Dept Neurosurg, D-01307 Dresden, Germany; Hop La Pitie Salpetriere, INSERM, U495, Paris, France; Federat Neurol Mazarin, Paris, France; Univ Birmingham, Canc Res UK Renal Mol Oncol Res Grp, Birmingham B15 2TG, W Midlands, England	University of Birmingham; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Technische Universitat Dresden; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Birmingham	Latif, F (corresponding author), Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	flatif@hgmp.mrc.ac.uk	Bièche, Ivan/O-7399-2017; Hesson, Luke/HDM-0311-2022; MAHER, EAMONN R/A-9507-2008; Krex, Dietmar/E-6833-2014; Hoang-Xuan, Khe/O-7527-2017	Bièche, Ivan/0000-0002-2430-5429; MAHER, EAMONN R/0000-0002-6226-6918; 				Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Agathanggelou A, 2003, CANCER RES, V63, P5344; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Bieche I, 2001, CANCER RES, V61, P1652; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dallol A, 2003, CANCER RES, V63, P1054; Dallol A, 2002, CANCER RES, V62, P5874; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 1998, CANCER RES, V58, P4515; FEINSTEIN PG, 1995, GENETICS, V140, P573; Harada K, 2002, CANCER RES, V62, P5897; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Honorio S, 2003, ONCOGENE, V22, P147, DOI 10.1038/sj.onc.1206057; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kuroki T, 2003, CANCER RES, V63, P3352; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lerman MI, 2000, CANCER RES, V60, P6116; Liu XQ, 2003, INT J CANCER, V106, P60, DOI 10.1002/ijc.11166; Louis DN, 2002, CANCER CELL, V1, P125, DOI 10.1016/S1535-6108(02)00040-5; Lusher ME, 2002, CANCER RES, V62, P5906; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Michelson RJ, 1999, J BIOL CHEM, V274, P30510, DOI 10.1074/jbc.274.43.30510; Mitic LL, 2000, AM J PHYSIOL-GASTR L, V279, pG250, DOI 10.1152/ajpgi.2000.279.2.G250; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Wolford JK, 1998, GENE, V212, P103, DOI 10.1016/S0378-1119(98)00141-3	40	94	109	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2408	2419		10.1038/sj.onc.1207407	http://dx.doi.org/10.1038/sj.onc.1207407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743209				2022-12-28	WOS:000220427700015
J	Gemignani, F; Moreno, V; Landi, S; Moullan, N; Chabrier, A; Gutierrez-Enriquez, S; Hall, J; Guino, E; Peinado, MA; Capella, G; Canzian, F				Gemignani, F; Moreno, V; Landi, S; Moullan, N; Chabrier, A; Gutierrez-Enriquez, S; Hall, J; Guino, E; Peinado, MA; Capella, G; Canzian, F			A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA	ONCOGENE			English	Article						TP53; colorectal cancer; polymorphism; mRNA levels	BREAST-CANCER; COMMON POLYMORPHISMS; OVARIAN-CANCER; P53 GENE; SEQUENCE; INFORMATION; PREDICTION; MUTATIONS; VARIANTS	We undertook a case-control study to examine the possible associations of the TP53 variants Arg>Pro at codon 72 and p53PIN3, a 16 bp insertion/duplication in intron 3, with the risk of colorectal cancer (CRC). The p53PIN3 A2 allele (16 bp duplication) was associated with an increased risk (OR 1.55, 95% CI 1.10-2.18, P = 0.012), of the same order of magnitude as that observed in previous studies for other types of cancer. The Pro72 allele was weakly associated with CRC (OR = 1.34, 95% CI 0.98-1.84, P = 0.066). The possible functional role of p53PIN3 was investigated by examining the TP53 mRNA transcripts in 15 lymphoblastoid cell lines with different genotypes. The possibility that the insertion/deletion could lead to alternatively spliced mRNAs was excluded. However, we found reduced levels of TP53 mRNA associated with the A2 allele. In conclusion, the epidemiological study suggests a role for p53PIN3 in tumorigenesis, supported by the in vitro characterization of this variant.	Int Agcy Res Canc, Genome Anal Grp, F-69372 Lyon, France; Univ Pisa, Dipartimento Sci Uomo & Ambiente, I-56100 Pisa, Italy; Inst Catala Oncol, Barcelona, Spain; Inst Recerca Oncol, Barcelona, Spain	World Health Organization; International Agency for Research on Cancer (IARC); University of Pisa; Catalan Institute of Oncology	Canzian, F (corresponding author), Int Agcy Res Canc, Genome Anal Grp, 150 Cours Albert Thomas, F-69372 Lyon, France.	canzian@iarc.fr	Canzian, Federico/I-2804-2014; Peinado, Miguel A./A-5591-2008; Moreno, Victor/A-1697-2010; Capella, Gabriel/I-1879-2015; hall, janet/G-1372-2013; Gutierrez, Sara/GXE-9832-2022	Peinado, Miguel A./0000-0002-4090-793X; Moreno, Victor/0000-0002-2818-5487; Capella, Gabriel/0000-0002-4669-7320; hall, janet/0000-0002-4397-6295; Landi, Stefano/0000-0001-8364-6357; GEMIGNANI, Federica/0000-0003-1297-0701; Guino, Elisabet/0000-0003-0093-2652; Gutierrez-Enriquez, Sara/0000-0002-1711-6101; Canzian, Federico/0000-0002-4261-4583				BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Cox DG, 2001, BIOINFORMATICS, V17, P738, DOI 10.1093/bioinformatics/17.8.738; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; Landi S, 2003, CANCER RES, V63, P3560; LAZAR V, 1993, ONCOGENE, V8, P1703; Powell BL, 2002, CARCINOGENESIS, V23, P311, DOI 10.1093/carcin/23.2.311; Rogan PK, 1998, HUM MUTAT, V12, P153, DOI 10.1002/(SICI)1098-1004(1998)12:3<153::AID-HUMU3>3.3.CO;2-O; RUNNEBAUM IB, 1995, LANCET, V345, P994, DOI 10.1016/S0140-6736(95)90745-9; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Tonisson N, 2002, P NATL ACAD SCI USA, V99, P5503, DOI 10.1073/pnas.082100599; Wang-Gohrke S, 2002, PHARMACOGENETICS, V12, P269, DOI 10.1097/00008571-200204000-00012; Wang-Gohrke S, 1999, BRIT J CANCER, V81, P179, DOI 10.1038/sj.bjc.6690669; Weston A, 1997, CANCER EPIDEM BIOMAR, V6, P105; Wu XF, 2002, JNCI-J NATL CANCER I, V94, P681	16	171	182	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1954	1956		10.1038/sj.onc.1207305	http://dx.doi.org/10.1038/sj.onc.1207305			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647431				2022-12-28	WOS:000220129500018
J	Dentelli, P; Rosso, A; Calvi, C; Ghiringhello, B; Garbarino, G; Camussi, G; Pegoraro, L; Brizzi, MF				Dentelli, P; Rosso, A; Calvi, C; Ghiringhello, B; Garbarino, G; Camussi, G; Pegoraro, L; Brizzi, MF			IL-3 affects endothelial cell-mediated smooth muscle cell recruitment by increasing TGF beta activity: potential role in tumor vessel stabilization	ONCOGENE			English	Article						tumor angiogenesis; IL-3; TGF beta; smooth muscle cells; endothelial cells	FIBROBLAST-GROWTH-FACTOR; CD4(+)CD25(+) T-CELLS; MATRIX METALLOPROTEINASES; INFILTRATING LYMPHOCYTES; VASCULAR DEVELOPMENT; ACTIVATION; CANCER; INTERLEUKIN-3; MIGRATION; BLOOD	Interleukin-3 (IL-3) express ion by tumor-infiltrating lymphocytes (TILs) and its effects on vessel assembly were evaluated. TILs from 'in situ' human breast cancers expressed CD4/CD25 antigens and IL-3. An injection of Matrigel containing SMC and IL-3 or basic-fibroblast growth factor ( bFGF) into SCID mice confirmed the neoangiogenetic effect of both factors. However, in response to IL-3, but not to bFGF, only few SMC became incorporated into the nascent vessels. To evaluate the possibility that signals emanated by the nascent vasculature in the presence of IL-3 may negatively regulate SMC recruitment, conditioned media ( CM) from IL-3-treated endothelial cells (EC) or SMC were tested for their biological effects on SMC and EC. CM from IL-3-treated SMC stimulated the migration of EC. In contrast, the migration of SMC was not affected by CM from IL-3-stimulated EC; however, it was greatly enhanced by blocking transforming growth factor beta (TGFbeta) activity. TGFbeta immunoenzymatic assay demonstrated the following: (i) the absence of TGFbeta activity in CM from IL-3-stimulated EC; (ii) a barely detectable TGFbeta activity in CM from IL-3-stimulated SMC; and (iii) the presence of TGFbeta activity in the supernatants of SMC stimulated with CM from IL-3-,but not from bFGF-stimulated EC. Increased TGFbeta mRNA expression was only detected in SMC stimulated with CM from IL-3-treated EC. Finally, the inhibitory signals induced by IL-3 in vivo were abrogated by the addition of the neutralizing TGFbeta antibody. Thus, the positive immunostaining for IL-3 by TILs in 'in situ' breast cancers sustains the possibility that early in tumor development, IL-3 can contribute to the chronic immaturity of these vessels.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Osped S Anna, Div Pathol, Turin, Italy	University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	Camussi, Giovanni/J-7624-2016; Brizzi, Maria Felice/J-7882-2016	Camussi, Giovanni/0000-0003-2795-232X; 				BALCH CM, 1990, ARCH SURG-CHICAGO, V125, P200; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bandyopadhyay A, 1999, CANCER RES, V59, P5041; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Brizzi MF, 1999, CIRC RES, V84, P785; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Brizzi MF, 1999, MOL BIOL CELL, V10, P3463, DOI 10.1091/mbc.10.10.3463; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; Dentelli P, 1999, J IMMUNOL, V163, P2151; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FINKE JH, 1990, CANCER RES, V50, P2363; Grosskreutz CL, 1999, MICROVASC RES, V58, P128, DOI 10.1006/mvre.1999.2171; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Ishida A, 2001, J CELL PHYSIOL, V188, P359, DOI 10.1002/jcp.1121; ITOH K, 1988, J EXP MED, V168, P1419, DOI 10.1084/jem.168.4.1419; Kenagy RD, 1997, CIRCULATION, V96, P3555; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KORPELAINEN EI, 1993, P NATL ACAD SCI USA, V90, P11137, DOI 10.1073/pnas.90.23.11137; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liyanage UK, 2002, J IMMUNOL, V169, P2756, DOI 10.4049/jimmunol.169.5.2756; McCaffrey TA, 2000, CYTOKINE GROWTH F R, V11, P103, DOI 10.1016/S1359-6101(99)00034-9; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Nunes I, 1996, INT J OBESITY, V20, pS4; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; PEOPLES GE, 1993, J IMMUNOL, V151, P5481; PEOPLES GE, 1995, P NATL ACAD SCI USA, V92, P6547, DOI 10.1073/pnas.92.14.6547; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Rowland-Goldsmith MA, 2001, CLIN CANCER RES, V7, P2931; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832; WIMPERIS JZ, 1989, BLOOD, V74, P1525; WINTZER HO, 1991, J CANCER RES CLIN, V117, P163, DOI 10.1007/BF01613141; Woo EY, 2001, CANCER RES, V61, P4766; Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333	49	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1681	1692		10.1038/sj.onc.1207290	http://dx.doi.org/10.1038/sj.onc.1207290			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14755254				2022-12-28	WOS:000220029300004
J	Sommerer, F; Vieth, M; Markwarth, A; Rohrich, K; Vomschloss, S; May, A; Ell, C; Stolte, M; Hengge, UR; Wittekind, C; Tannapfel, A				Sommerer, F; Vieth, M; Markwarth, A; Rohrich, K; Vomschloss, S; May, A; Ell, C; Stolte, M; Hengge, UR; Wittekind, C; Tannapfel, A			Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma	ONCOGENE			English	Article						BRAF; KRAS2; barrett; neoplasia	B-RAF; CANCER; GENE; ACTIVATION; CARCINOMA; ESOPHAGUS; PROGRESSION; MELANOMA; PROTEINS; PATHWAY	Activation of the Raf/MEK/ERK (MAPK) signal transduction cascade by RAS mutations has been found in a variety of human cancers. Mutations of BRAF provide an alternative route for activation of this signalling pathway. To determine the role of mutations in BRAF and KRAS2 in the neoplastic progression of Barrett's adenocarcinoma, we analysed both genes for common mutations. After microdissection, DNA of 19 Barrett's adenocarcinomas, 56 Barrett's intraepithelial neoplasias (n=29 low-grade intraepithelial neoplasia (LGIN) and n=27 high-grade intraepithelial neoplasia (HGIN)), 30 Barrett's mucosa without neoplasia and normal squamous, as well as gastric epithelium, were analysed for BRAF and KRAS2 mutation. Activating BRAF mutations were identified in 2/19 Barrett's adenocarcinomas (11%) and in 1/27 HGIN (4%). KRAS2 mutations were found in four out of 19 (21%) Barrett's adenocarcinomas examined and in three cases of HGIN (11%). In LGIN as well as in normal gastric or oesophageal mucosa, neither BRAF nor KRAS2 mutations were detected. All lesions with KRAS2 mutations had an intact BRAF gene. The status of mismatch-repair proteins was neither related to BRAF nor KRAS2 mutations. These data indicate that RAS or BRAF mutations are detected in about 32% of all Barrett's adenocarcinomas. We conclude that the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma.	Univ Leipzig, Inst Pathol, D-04103 Leipzig, Germany; Otto Von Guericke Univ, Inst Pathol, D-39120 Magdeburg, Germany; HSK Clin Wiesbaden, Clin Internal Med 2, D-65199 Wiesbaden, Germany; Klinikum Bayreuth, Inst Pathol, D-95445 Bayreuth, Germany; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany	Leipzig University; Otto von Guericke University; Klinikum Bayreuth; Heinrich Heine University Dusseldorf	Tannapfel, A (corresponding author), Univ Leipzig, Inst Pathol, Liebigstr 26, D-04103 Leipzig, Germany.	tana@medizin.uni-leipzig.de						Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; Arber N, 2000, GASTROENTEROLOGY, V118, P1045, DOI 10.1016/S0016-5085(00)70357-X; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Barrett MT, 1996, ONCOGENE, V13, P1867; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dunn JR, 2003, ONCOGENE, V22, P4134, DOI 10.1038/sj.onc.1206466; Fitzgerald RC, 2003, GUT, V52, P16, DOI 10.1136/gut.52.1.16; Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599; HAMILTON SR, 2000, PATHOLOGY GENETICS, P173; Kimura ET, 2003, CANCER RES, V63, P1454; Leder A, 2002, ONCOGENE, V21, P6657, DOI 10.1038/sj.onc.1205795; Liao YH, 2001, J BIOL CHEM, V276, P28478, DOI 10.1074/jbc.M101737200; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Morales CP, 2002, LANCET, V360, P1587, DOI 10.1016/S0140-6736(02)11569-8; Naoki K, 2002, CANCER RES, V62, P7001; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Ruschoff J, 1998, PATHOLOGE, V19, P269, DOI 10.1007/s002920050283; Satyamoorthy K, 2003, CANCER RES, V63, P756; Singer G, 2003, J NATL CANCER I, V95, P484, DOI 10.1093/jnci/95.6.484; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; Stahl J, 2000, ADV ANAT PATHOL, V7, P85, DOI 10.1097/00125480-200007020-00003; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tselepis C, 2002, ONCOGENE, V21, P6071, DOI 10.1038/sj.onc.1205731; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; Weber CK, 2001, CANCER RES, V61, P3595; Yuen ST, 2002, CANCER RES, V62, P6451	32	61	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					554	558		10.1038/sj.onc.1207189	http://dx.doi.org/10.1038/sj.onc.1207189			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724583				2022-12-28	WOS:000188098300026
J	Wang, Q; Wieder, R				Wang, Q; Wieder, R			All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells	ONCOGENE			English	Article						apoptosis; JNK; retinoic acid; Taxotere; breast cancer	ACTIVATED PROTEIN-KINASE; RECEPTOR-ALPHA; INDUCED APOPTOSIS; SIGNALING PATHWAYS; GROWTH-INHIBITION; TUMOR-CELLS; LNCAP CELLS; EXPRESSION; PHOSPHORYLATION; PROLIFERATION	Taxotere is a cytotoxin effective in treating breast and prostate cancer. It stabilizes microtubules and causes catastrophic cell cycle arrest in G2/M. Taxanes also initiate apoptosis by activating signal pathways, such as the jun N-terminal kinase (JNK) pathway. Strategies aimed at potentiating cell death signaling may improve their efficacy while lessening the potential side effects. We reported that all-trans retinoic acid (ATRA) potentiated taxane-mediated cell death. Here we investigated whether ATRA potentiates cell death signaling through the JNK pathway. Activation of JNK by Taxotere 0.01, 0.1 and 1.0 muM was observed at 24h in adherent cells and increased at 48h. Taxotere 0.001 muM-induced JNK activation started after 48h and increased at 72h. The timing and intensity of PARP cleavage was similar to that of JNK activation. JNK activation and PARP cleavage induced by 30 nM Taxotere at 48h were reversed by curcumin, PD169316 and SP600125, JNK inhibitors in order of progressive specificity. None of these inhibitors had an effect on p38 or ERK phosphorylation. All three inhibitors reversed Taxotere-induced phosphorylation of Bcl-2. ATRA induced JNK activation at 24, 48 and 72h. Incubating cells with ATRA 0.01 muM for 3 days prior to Taxotere treatment potentiated Taxotere-induced JNK activation 24 and 48h later, an effect sustained for 72h. Cytotoxicities from 3-day ATRA 0.01 muM incubations were synergistic with subsequent 1-h Taxotere 0.01, 0.1 and 1.0 muM incubations in breast cancer cell lines MCF-7 and MDA-MB-231 and in prostate cancer cell lines LNCaP and PC-3, and additive in breast cancer cell line SK-Br-3. These data demonstrate the potentiation of Taxotere-induced cell death by ATRA pretreatment in breast and prostate cancer cells, and support a mechanism through accentuated and sustained JNK activation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wieder, R (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, MSB I-596,185 S Orange Ave, Newark, NJ 07103 USA.	wiederro@umdnj.edu						Aapro M, 1996, ANTI-CANCER DRUG, V7, P33, DOI 10.1097/00001813-199608002-00009; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Butterfield L, 1997, J BIOL CHEM, V272, P10110; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Consolini R, 1998, J CLIN ONCOL, V16, P907, DOI 10.1200/JCO.1998.16.3.907; Cosulich S, 1996, CURR BIOL, V6, P1586, DOI 10.1016/S0960-9822(02)70779-3; DAWSON MI, 1995, CANCER RES, V55, P4446; Fenig E, 1997, CLIN CANCER RES, V3, P135; Fitzgerald P, 1997, CANCER RES, V57, P2642; Flicker SH, 1997, CANCER LETT, V115, P63, DOI 10.1016/S0304-3835(97)04715-0; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; GRECO WR, 1995, PHARMACOL REV, V47, P331; Grunt TW, 1998, BRIT J CANCER, V78, P79, DOI 10.1038/bjc.1998.446; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Jones HE, 1997, PROSTATE, V30, P174; Lee HY, 1999, MOL CELL BIOL, V19, P1973; Li MT, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-16; Liang JY, 1999, PROSTATE, V38, P228; Liu Y, 1996, MOL CELL BIOL, V16, P1138; Masuda M, 2002, JPN J CANCER RES, V93, P329, DOI 10.1111/j.1349-7006.2002.tb02176.x; Moos PJ, 1998, CELL GROWTH DIFFER, V9, P687; Moreno-Manzano V, 1999, J BIOL CHEM, V274, P20251, DOI 10.1074/jbc.274.29.20251; Nabholtz J M, 2000, Expert Opin Pharmacother, V1, P187, DOI 10.1517/14656566.1.2.187; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Petras J, 2000, LAT AM PERSPECT, V27, P3, DOI 10.1177/0094582X0002700501; Rishi AK, 1996, CANCER RES, V56, P5246; Schneider SM, 2000, CANCER RES, V60, P5479; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Shiah SG, 2001, MOL PHARMACOL, V59, P254, DOI 10.1124/mol.59.2.254; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; Sun SY, 1999, CANCER RES, V59, P2829; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Torres K, 1998, CANCER RES, V58, P3620; VANDERLEEDE BJM, 1995, MOL CELL ENDOCRINOL, V109, P77, DOI 10.1016/0303-7207(95)03487-R; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang H, 2001, FEBS LETT, V503, P91, DOI 10.1016/S0014-5793(01)02699-0; Wang Q, 2000, CANCER RES, V60, P2040; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wanner R, 2002, J MOL MED, V80, P61, DOI 10.1007/s00109-001-0288-0; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Wieder R, 1999, PRACT APPROACH SER, V215, P1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XC, 1997, CANCER RES, V57, P4992; Yang CPH, 2002, BBA-MOL CELL RES, V1590, P76, DOI 10.1016/S0167-4889(02)00200-8; Yokoo T, 1997, AM J PHYSIOL-RENAL, V273, pF206, DOI 10.1152/ajprenal.1997.273.2.F206; YOUNG CYF, 1994, PROSTATE, V25, P39, DOI 10.1002/pros.2990250106; Zhang YX, 1999, EXP CELL RES, V247, P233, DOI 10.1006/excr.1998.4350; Zheng A, 2000, ACTA HAEMATOL-BASEL, V103, P135, DOI 10.1159/000041036; Zou CP, 1998, CLIN CANCER RES, V4, P1345	56	51	58	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					426	433		10.1038/sj.onc.1207040	http://dx.doi.org/10.1038/sj.onc.1207040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724571				2022-12-28	WOS:000188098300013
J	Sampath, D; Rao, VA; Plunkett, W				Sampath, D; Rao, VA; Plunkett, W			Mechanisms of apoptosis induction by nucleoside analogs	ONCOGENE			English	Review						DNA damage; sensors; checkpoints; DNA repair	ACTIVATED PROTEIN-KINASE; S-PHASE CHECKPOINT; CHRONIC LYMPHOCYTIC-LEUKEMIA; DRUG-INDUCED APOPTOSIS; DAMAGE-INDUCED APOPTOSIS; HUMAN DNA-POLYMERASES; HAIRY-CELL LEUKEMIA; C-ABL; ARA-C; CYTOCHROME-C	Nucleoside analogs are structurally, metabolically, and pharmacodynamically related agents that nevertheless have diverse biological actions and therapeutic consequences. This class of agents affects the structural integrity of DNA, generally after incorporation during replication or DNA excision repair synthesis, leading to stalled replication forks and chain termination. The DNA damage sensors ATM, ATR and DNA-PK recognize these events. These and other protein kinases activate checkpoint pathways that arrest cell cycle progression, and also signal for DNA repair. In addition, if these survival mechanisms are overwhelmed by the damage caused, a third function of these sensors is to activate signaling pathways that initiate apoptotic processes. A review of the spectrum of responses that are activated by clinically relevant nucleoside analogs begins to provide a mechanistic basis for diverse outcomes in cell viability. Such information, when coupled with an understanding of the intrinsic apoptotic potential of a tumor cell type may provide a rational basis for the design of therapeutic strategies.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Plunkett, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd, Houston, TX 77030 USA.	wplunket@mdanderson.org	Sampath, Deepa/T-5069-2019; Sampath, Deepa/J-3298-2016; Rao, V Ashutosh/A-3569-2013	Rao, V Ashutosh/0000-0001-6817-8049; Sampath, Deepa/0000-0002-4366-8436	NATIONAL CANCER INSTITUTE [P01CA081534, R01CA028596, P01CA055164, P20CA081534, R01CA032839] Funding Source: NIH RePORTER; NCI NIH HHS [CA81534, CA55164, CA32839, CA28596] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achanta G, 2001, CANCER RES, V61, P8723; AGARWAL RP, 1982, PHARMACOL THERAPEUT, V17, P399, DOI 10.1016/0163-7258(82)90023-7; Akinaga S, 2000, ANTI-CANCER DRUG DES, V15, P43; Azuma A, 2001, MOL PHARMACOL, V59, P725, DOI 10.1124/mol.59.4.725; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Bermudez VP, 2003, P NATL ACAD SCI USA, V100, P1633, DOI 10.1073/pnas.0437927100; BIANCHI V, 1992, EXP CELL RES, V199, P120, DOI 10.1016/0014-4827(92)90469-O; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Bullock G, 1996, LEUKEMIA, V10, P1731; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Capasso H, 2002, J CELL SCI, V115, P4555, DOI 10.1242/jcs.00133; CARSON DA, 1988, ADV ENZYME REGUL, V27, P395, DOI 10.1016/0065-2571(88)90028-3; CARSON DA, 1978, CIBA F S, V68, P115; CARTER BZ, 2003, BLOOD; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHAN T, 1978, CELL, V14, P523, DOI 10.1016/0092-8674(78)90238-6; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHESON BD, 1997, NUCLEOSIDE ANAL CANC; Chreneik JE, 2003, J BIOL CHEM, V278, P12461, DOI 10.1074/jbc.M212930200; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COHEN A, 1976, NEW ENGL J MED, V295, P1449, DOI 10.1056/NEJM197612232952603; COHEN A, 1978, J CLIN INVEST, V61, P1405, DOI 10.1172/JCI109058; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Crews KR, 2002, J CLIN ONCOL, V20, P4217, DOI 10.1200/JCO.2002.10.006; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; Dearden CE, 2000, SEMIN ONCOL, V27, P22; Dewson G, 2003, ONCOGENE, V22, P2643, DOI 10.1038/sj.onc.1206326; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Eastman A, 2002, MOL CANCER THER, V1, P1067; Eggert A, 2001, CANCER RES, V61, P1314; ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979; Eucker J, 2002, ANTI-CANCER DRUG, V13, P907, DOI 10.1097/00001813-200210000-00002; Faderl Stefan, 2002, Cancer Chemother Biol Response Modif, V20, P37; Feng L, 2000, INT J MOL MED, V5, P597; Fink D, 1998, CLIN CANCER RES, V4, P1; Fu WN, 2003, ONCOGENE, V22, P451, DOI 10.1038/sj.onc.1206147; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; GIBLETT ER, 1972, LANCET, V2, P1067; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; Goodman GR, 2003, J CLIN ONCOL, V21, P891, DOI 10.1200/JCO.2003.05.093; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Grant S, 1998, ADV CANCER RES, V72, P197; Grem J L, 1999, Cancer Chemother Biol Response Modif, V18, P1; Grotzer MA, 2000, ONCOGENE, V19, P4604, DOI 10.1038/sj.onc.1203816; GUNJI H, 1991, CANCER RES, V51, P741; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; Harada K, 2002, CANCER RES, V62, P5897; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; HEIDELBERGER C, 1983, ADV ENZYMOL RAMB, V54, P57; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1990, MOL PHARMACOL, V38, P567; HENTOSH P, 1990, J BIOL CHEM, V265, P4033; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; HUANG P, 1991, CANCER RES, V51, P6110; HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844; HUANG P, 1990, J BIOL CHEM, V265, P16617; HUANG P, 1991, MOL PHARMACOL, V39, P449; Ibrado AM, 1996, CANCER RES, V56, P4743; INGRAHAM HA, 1982, MOL PHARMACOL, V21, P211; Johnson S A, 2001, Expert Opin Pharmacother, V2, P929, DOI 10.1517/14656566.2.6.929; Johnson SA, 2000, CLIN PHARMACOKINET, V39, P5, DOI 10.2165/00003088-200039010-00002; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kamiya K, 1996, J BIOL CHEM, V271, P19428, DOI 10.1074/jbc.271.32.19428; Kastan MB, 2000, COLD SPRING HARB SYM, V65, P521, DOI 10.1101/sqb.2000.65.521; Keating MJ, 1999, SEMIN ONCOL, V26, P107; Keating MJ, 1997, CLIN CANCER RES, V3, P2598; KEATING MJ, 1999, CLIN CANC RES 2, V3, P2598; KEITH FJ, 1995, LEUKEMIA, V9, P131; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kim CN, 1997, CANCER RES, V57, P3115; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Konopleva M, 2000, BLOOD, V95, P3929; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; KUFE DW, 1984, MOL PHARMACOL, V25, P322; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Leoni LM, 1998, P NATL ACAD SCI USA, V95, P9567, DOI 10.1073/pnas.95.16.9567; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu QH, 2000, GENE DEV, V14, P1448; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Massey A, 2001, CURR BIOL, V11, P1142, DOI 10.1016/S0960-9822(01)00272-X; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; O'Brien SM, 2001, J CLIN ONCOL, V19, P1414, DOI 10.1200/JCO.2001.19.5.1414; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OHNO Y, 1988, CANCER RES, V48, P1494; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8; PARKER WB, 1988, MOL PHARMACOL, V34, P485; Petak I, 2003, CELL DEATH DIFFER, V10, P211, DOI 10.1038/sj.cdd.4401132; Petak I, 2000, CLIN CANCER RES, V6, P4432; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; PINEDO HM, 1988, J CLIN ONCOL, V6, P1653, DOI 10.1200/JCO.1988.6.10.1653; Plunkett W, 1996, SEMIN ONCOL, V23, P3; Plunkett W, 2001, Cancer Chemother Biol Response Modif, V19, P21; PLUNKETT W, 1982, CANCER RES, V42, P2092; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Raina D, 2002, MOL PHARMACOL, V61, P1489, DOI 10.1124/mol.61.6.1489; Rao V. Ashutosh, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P797; Rao VA, 2003, CLIN CANCER RES, V9, P3204; Rodriguez CO, 2003, BLOOD, V102, P1842, DOI 10.1182/blood-2003-01-0317; Roos-Mattjus P, 2003, J BIOL CHEM, V278, P24428, DOI 10.1074/jbc.M301544200; Roos-Mattjus P, 2002, J BIOL CHEM, V277, P43809, DOI 10.1074/jbc.M207272200; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sampath D, 2000, CANCER RES, V60, P6408; Sandoval A, 1996, CLIN CANCER RES, V2, P1731; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Santoro A, 2000, J CLIN ONCOL, V18, P2615, DOI 10.1200/JCO.2000.18.13.2615; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Saven A, 1998, BLOOD, V92, P1918, DOI 10.1182/blood.V92.6.1918; SCHWEITZER BI, 1994, BIOCHEMISTRY-US, V33, P11460, DOI 10.1021/bi00204a008; SETO S, 1985, J CLIN INVEST, V75, P377, DOI 10.1172/JCI111710; SETO S, 1986, J IMMUNOL, V136, P2839; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shao RG, 1997, CANCER RES, V57, P4029; Shi Z, 2001, CANCER RES, V61, P1065; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; SNYDER RD, 1984, CHEM-BIOL INTERACT, V50, P1, DOI 10.1016/0009-2797(84)90127-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Storniolo AM, 1999, CANCER, V85, P1261, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1261::AID-CNCR7>3.0.CO;2-T; Sugimoto K, 2000, BRIT J HAEMATOL, V110, P819, DOI 10.1046/j.1365-2141.2000.02304.x; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSENG WC, 1982, MOL PHARMACOL, V21, P474; Ueki T, 2001, INT J CANCER, V91, P673, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1113>3.0.CO;2-U; Wang JL, 2002, CELL CYCLE, V1, P267, DOI 10.4161/cc.1.4.137; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Yamauchi T, 2001, CLIN CANCER RES, V7, P3580; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG SW, 1992, J BIOL CHEM, V267, P2345; Yin MB, 2002, BIOCHEM BIOPH RES CO, V295, P435, DOI 10.1016/S0006-291X(02)00683-6; Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045; Yoshida K, 2000, MOL CELL BIOL, V20, P5370, DOI 10.1128/MCB.20.15.5370-5380.2000; Yoshida K, 2002, MOL CELL BIOL, V22, P3292, DOI 10.1128/MCB.22.10.3292-3300.2002; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P4908, DOI 10.1021/bi00014a048; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu WG, 2001, CANCER RES, V61, P1327; Zinzani PL, 2000, J CLIN ONCOL, V18, P2603, DOI 10.1200/JCO.2000.18.13.2603; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	168	175	180	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9063	9074		10.1038/sj.onc.1207229	http://dx.doi.org/10.1038/sj.onc.1207229			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663485				2022-12-28	WOS:000187043600010
J	Ree, AH; Bratland, A; Nome, RV; Stokke, T; Fodstad, O				Ree, AH; Bratland, A; Nome, RV; Stokke, T; Fodstad, O			Repression of mRNA for the PLK cell cycle gene after DNA damage requires BRCA1	ONCOGENE			English	Article						BRCA1; polo-like kinase 1; cell cycle control; DNA damage; breast cancer	POLO-LIKE-KINASE; DOWN-REGULATION; CHECKPOINT; EXPRESSION; ATM; PROTEIN; PHOSPHORYLATION; PHOSPHATASE; REGULATORS; LINKAGE	DNA damage activates the G(2) cell cycle checkpoint to allow time for DNA repair before mitotic entry. The mechanism involves inhibition of the enzymatic activity for polo-like kinase 1 (Plk1), rendering Cdc25C with a basal phosphatase activity that is insufficient for converting Cdc2 to the fully active G(2)/M transition kinase. We found that cell cycle arrest at the G(2)/M boundary after ionizing radiation (IR) of breast carcinoma cells may involve repression of the gene for Plk1, PLK, mediated by the tumor-suppressor protein BRCA1. The p53-defective MT-1 cell line had an apparent accumulation of G(2)/M phase cells 12 h after irradiation. This response was preceded by a transient downregulation of PLK mRNA expression with a barely detectable level 6 h after exposure to IR but recovered after 12 h. A significantly lower fraction of irradiated BRCA1(-/-) HCC1937 cells arrested in the G(2)/M phase after 12 h, and the transient response of PLK mRNA was also considerably impaired. After reconstitution of wild-type BRCA1 in the HCC1937 cells however, downregulation of PLK mRNA as well as Plk1 protein expression after IR was restored. Moreover, the suppression of PLK mRNA expression 6 h after irradiation was completely abolished by the specific CHEK1 kinase inhibitor UCN-01, further indicating that the effector mechanism of DNA damage on PLK signals through BRCA1 and its downstream CHEK1. Our observations provide new information about the diversity of regulatory mechanisms governed by BRCA1 in DNA damage checkpoint control.	Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway; Norwegian Radium Hosp, Dept Biophys, N-0310 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo	Ree, AH (corresponding author), Norwegian Radium Hosp, Dept Tumor Biol, N-0310 Oslo, Norway.			Ree, Anne H./0000-0002-8264-3223				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; Deng CX, 2000, BIOESSAYS, V22, P728; Elez R, 2003, ONCOGENE, V22, P69, DOI 10.1038/sj.onc.1206038; Engebraaten O, 1999, INT J CANCER, V82, P219, DOI 10.1002/(SICI)1097-0215(19990719)82:2<219::AID-IJC12>3.0.CO;2-#; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Knecht R, 1999, CANCER RES, V59, P2794; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Tomlinson GE, 1998, CANCER RES, V58, P3237; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837	28	34	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8952	8955		10.1038/sj.onc.1207000	http://dx.doi.org/10.1038/sj.onc.1207000			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654792				2022-12-28	WOS:000186982200017
J	Wu, YZ; Zhang, XP; Zehner, ZE				Wu, YZ; Zhang, XP; Zehner, ZE			c-Jun and the dominant-negative mutant, TAM67, induce vimentin gene expression by interacting with the activator Sp1	ONCOGENE			English	Article						c-Jun; coactivator; Sp1; vimentin; dominantnegative TAM67	CANCER CELL-LINES; NF-KAPPA-B; BREAST-CANCER; TRANSCRIPTION FACTOR; EPITHELIAL-CELLS; TUMOR-CELLS; PROMOTER; OVEREXPRESSION; PHENOTYPE; MECHANISMS	Vimentin exhibits a complex pattern of developmental- and tissue-specific expression. Since it is aberrantly expressed in metastatic tumors, which have progressed through the epithelial-mesenchymal transition, it has been cited as a marker for tumor progression. Previous studies have indicated that the transcription factor activator protein (AP1) is important in tumor progression. The stable transformation of the MCF7 cell line with the oncogene c-Jun resulted in a cell line (MCF7Jun), which displayed a change in morphology, enhanced migratory and invasive properties, and metastatic behavior. Of the 21 genes whose expression levels were altered in the MCF7Jun cell line, the greatest change in expression occurred for the vimentin gene. Previously, tandem AP1 sites in the promoter were reported to be important for the serum and TPA inducibility of the vimentin gene. However, we find that the AP1 elements only contribute in part to c-Jun activation. Moreover, this activation can be duplicated in COS-1 or S2 cells by expression of c-Jun or TAM67, and is dependent only on the leucine-zipper region of c-Jun. Transient transfection analyses, electrophoretic mobility shift assays, DNA precipitation assays, and coimmunoprecipitation studies suggest that c-Jun is able to synergize with the activator protein Sp1 in binding to GC-box1 to enhance vimentin gene expression.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Zehner, ZE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus, Richmond, VA 23298 USA.				NHLBI NIH HHS [HL-45422] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045422] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakovic M, 2000, J LIPID RES, V41, P583; Blaine SA, 2001, J BIOL CHEM, V276, P42737, DOI 10.1074/jbc.M107773200; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chen JH, 1996, ONCOGENE, V13, P1667; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GILLES C, 1996, BREAST J, V2, P83; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Izmailova ES, 1999, GENE, V235, P69, DOI 10.1016/S0378-1119(99)00209-7; Izmailova ES, 1999, GENE, V230, P111, DOI 10.1016/S0378-1119(99)00046-3; Izmailova ES, 2000, J INTERF CYTOK RES, V20, P13, DOI 10.1089/107999000312694; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milde-Langosch K, 2001, BREAST CANCER RES TR, V67, P61, DOI 10.1023/A:1010623308275; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Rahmsdorf HJ, 1996, J MOL MED, V74, P725, DOI 10.1007/s001090050077; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; RITTLING SR, 1989, NUCLEIC ACIDS RES, V17, P1619, DOI 10.1093/nar/17.4.1619; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schneider I, 1972, J EMBRYOL EXP MORPH, V27, P363; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1989, CANCER RES, V49, P4258; STOVER DM, 1994, CANCER RES, V54, P3092; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wieczorek E, 2000, J BIOL CHEM, V275, P12879, DOI 10.1074/jbc.275.17.12879; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZHANG X, 2003, NUCLEIC ACIDS RES, V31, P1	33	45	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8891	8901		10.1038/sj.onc.1206898	http://dx.doi.org/10.1038/sj.onc.1206898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654785				2022-12-28	WOS:000186982200010
J	Del Bufalo, D; Trisciuoglio, D; Scarsella, M; Zangemeister-Wittke, U; Zupi, G				Del Bufalo, D; Trisciuoglio, D; Scarsella, M; Zangemeister-Wittke, U; Zupi, G			Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity	ONCOGENE			English	Article						bcl-2; antisense oligonucleotides; vascular endothelial growth factor; angiogenesis; melanoma	GROWTH-FACTOR EXPRESSION; PROTEIN-KINASE-A; BCL-2 OVEREXPRESSION; CARCINOMA-CELLS; IN-VIVO; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; TYROSINE KINASE; FACTOR RECEPTOR; TUMOR-GROWTH	We have recently reported that bcl-2 overexpression and hypoxia synergistically interact to modulate vascular endothelial growth factor (VEGF) and in vivo angiogenesis in tumour cells through VEGF mRNA stabilization and hypoxia-inducible factor 1-mediated transcriptional activity. Bcl-2 antisense treatment has shown promising clinical results in patients with malignant melanoma. In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. The antiangiogenic effect was determined in in vitro and in vivo angiogenesis assays. In particular, a reduction of hypoxia-induced VEGF secretion was observed after 4625 treatment, and the conditioned medium (CM) of bcl-2 overexpressing clones treated with 4625 and exposed to hypoxic conditions resulted in decreased endothelial cell proliferation when compared to CM of untreated control cells. In addition, we found that CM of 4625 antisense-treated bcl-2 transfectants inhibited in vivo vessel formation in matrigel plugs implanted subcutaneously in C57/B16 mice. Our findings confirm that bcl-2 plays a crucial role in melanoma angiogenesis and demonstrate for the first time that downregulation of bcl-2 by antisense treatment has potential to inhibit angiogenesis independent of its effect on cell survival. The use of 4625 in cancer therapy is suggested as an approach to facilitate simultaneously tumour cell apoptosis and inhibit tumour angiogenesis.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Zurich Hosp, Dept Oncol, CH-8091 Zurich, Switzerland	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Zurich; University Zurich Hospital	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi dOro 156, I-00158 Rome, Italy.	zupi@ifo.it	Del Bufalo, Donatella/AAC-1594-2021; trisciuoglio, daniela/AAL-4002-2021; trisciuoglio, Daniela/H-2131-2016; Del Bufalo, Donatella/K-8673-2016	Del Bufalo, Donatella/0000-0002-3148-6096; trisciuoglio, Daniela/0000-0002-7007-7914; Del Bufalo, Donatella/0000-0002-3148-6096; Scarsella, Marco/0000-0002-3386-9664				Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Biroccio A, 1999, INT J CANCER, V82, P125, DOI 10.1002/(SICI)1097-0215(19990702)82:1<125::AID-IJC21>3.0.CO;2-Q; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819; Del Bufalo D, 2002, EUR J CANCER, V38, P2455, DOI 10.1016/S0959-8049(02)00391-X; Del Bufalo D, 2002, MOL PHARMACOL, V61, P524, DOI 10.1124/mol.61.3.524; Del Bufalo D, 2001, J CELL BIOCHEM, V83, P473, DOI 10.1002/jcb.1245; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Fernandez A, 2001, J NATL CANCER I, V93, P208, DOI 10.1093/jnci/93.3.208; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; FOLKMAN J, 1986, CANCER RES, V46, P467; Fong TAT, 1999, CANCER RES, V59, P99; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P; Klagsbrun M, 1999, CHEM BIOL, V6, pR217, DOI 10.1016/S1074-5521(99)80081-7; Koty PP, 2002, MOL CELL BIOCHEM, V234, P125, DOI 10.1023/A:1015932615769; McCarthy M, 2001, LANCET, V357, P1593, DOI 10.1016/S0140-6736(00)04782-6; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Moses MA, 1997, STEM CELLS, V15, P180, DOI 10.1002/stem.150180; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nam NH, 2003, CURR DRUG TARGETS, V4, P159, DOI 10.2174/1389450033346966; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Nor JE, 2001, CANCER RES, V61, P2183; Olie RA, 2002, J INVEST DERMATOL, V118, P505, DOI 10.1046/j.0022-202x.2001.01677.x; Olie RA, 2002, BBA-GENE STRUCT EXPR, V1576, P101, DOI 10.1016/S0167-4781(02)00300-7; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Presta LG, 1997, CANCER RES, V57, P4593; Rak J, 2002, CANCER RES, V62, P1931; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Simoes-Wust AP, 2002, BREAST CANCER RES TR, V76, P157, DOI 10.1023/A:1020543004400; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Wang JH, 2002, CANCER-AM CANCER SOC, V94, P2745, DOI 10.1002/cncr.10520; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547	46	45	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8441	8447		10.1038/sj.onc.1206999	http://dx.doi.org/10.1038/sj.onc.1206999			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627985				2022-12-28	WOS:000186650300008
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Samara, R; Espinoza, LA; Hassa, PO; Hottiger, MO; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Samara, R; Espinoza, LA; Hassa, PO; Hottiger, MO; Smulson, ME			PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase	ONCOGENE			English	Article						PARP-1; E2F-1; DNA replication; promoter activity; gene expression; cell cycle; coactivator	POLY(ADP-RIBOSE) POLYMERASE BINDS; DEPENDENT TRANSCRIPTION; RIBOSE POLYMERASE; GENE-EXPRESSION; DISTINCT ROLES; CYCLIN-A; PROTEIN; P53; CDNA; IDENTIFICATION	The transcription factor E2F-1 is implicated in the activation of S-phase genes as well as, induction of apoptosis, and is regulated by interactions with Rb and by cell cycle-dependent alterations in E2F-1 abundance. We. earlier demonstrated a pivotal role for poly(ADP-ribose) polymerase-1 (PARP-1) in the regulation of E2F-1 expression and promoter activity during S-phase re-entry when quiescent cells re-enter the cell cycle. We now investigate the putative mechanism(s) by which PARP-1 may upregulate E2F-1 promoter activity during S-phase re-entry. DNase-1 footprint assays with purified PARP-1 showed that PARP-1 did not directly bind the E2F-1 promoter in a sequence-specific manner. In contrast to p53, a positive acceptor in poly(ADP-ribosyl)ation reactions, E2F-1 was not poly(ADP-ribosyl)ated by wild-type PARP-1 in vitro, indicating that PARP-1 does not exert a dual effect on F2F-1 transcriptional activation. Protein-binding reactions and coimmunoprecipitation experiments with purified PARP-1 and E2F-1, however, revealed that PARP-1 binds to E2F-1 in vitro. More significantly, physical association of PARP-1 and E2F-1 in vivo also occurred in wild-type fibroblasts 5h after re-entry into S phase, coincident with the increase in E2F-1 promoter activity and expression of E2F-1-responsive S-phase genes cyclin A and c-Myc. Mapping of the interaction domains revealed that full-length PARP-1 as well as PARP-1 mutants lacking either the catalytic active site or the DNA-binding domain equally bind E2F-1, whereas a PARP-1 mutant lacking the automodification domain does not, suggesting that the protein interaction site is located in this central domain. Finally, get shift analysis with end-blocked E2F-1 promoter sequence probes verified that the binding of PARP-1 to E2F-1 enhances binding to the E2F-1 promoter, indicating that PARP-1 acts as a positive cofactor of E2F-1-mediated transcription.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20057 USA; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	Georgetown University; University of Zurich	Simbulan-Rosenthal, CM (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,3900 Reservoir Rd NW, Washington, DC 20057 USA.	simbulac@georgetown.edu	Rosenthal, Dean S/J-2360-2014; Hottiger, Michael O./J-7747-2013; Simbulan-Rosenthal, Cynthia M./W-8429-2019	Hottiger, Michael O./0000-0002-7323-2270; Rosenthal, Dean/0000-0002-7624-0209; Simbulan-Rosenthal, Ph.D, Cynthia M./0000-0002-5070-0342	NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA25344, P01 CA74175] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Anderson MG, 2000, J VIROL, V74, P2169, DOI 10.1128/JVI.74.5.2169-2177.2000; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BUKI KG, 1995, J BIOL CHEM, V270, P3370, DOI 10.1074/jbc.270.7.3370; Butler AJ, 1999, MOL CELL BIOL, V19, P296; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHERNEY BW, 1987, P NATL ACAD SCI USA, V84, P8370, DOI 10.1073/pnas.84.23.8370; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; De Capoa A, 1999, FASEB J, V13, P89; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DESMARAIS Y, 1991, BIOCHIM BIOPHYS ACTA, V1078, P179, DOI 10.1016/0167-4838(91)99007-F; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Galande S, 1999, J BIOL CHEM, V274, P20521, DOI 10.1074/jbc.274.29.20521; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Johansson M, 1999, GENOMICS, V57, P442, DOI 10.1006/geno.1999.5799; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KAWAMITSU H, 1984, BIOCHEMISTRY-US, V23, P3771, DOI 10.1021/bi00311a032; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kim H, 1997, BIOCHEM J, V322, P469, DOI 10.1042/bj3220469; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; Lee D, 2002, ONCOGENE, V21, P5877, DOI 10.1038/sj.onc.1205723; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Oei SL, 1998, J BIOL CHEM, V273, P31644, DOI 10.1074/jbc.273.48.31644; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; Rosenthal DS, 1997, NUCLEIC ACIDS RES, V25, P1437, DOI 10.1093/nar/25.7.1437; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, ONCOGENE, V18, P5015, DOI 10.1038/sj.onc.1202900; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 1998, CANCER RES, V58, P3495; TANG A, 1989, ONCOGENE, V4, P401; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wesierska-Gadek J, 2003, J CELL BIOCHEM, V89, P220, DOI 10.1002/jcb.10521; Yamane K, 2001, ONCOGENE, V20, P2859, DOI 10.1038/sj.onc.1204408; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	65	81	85	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8460	8471		10.1038/sj.onc.1206897	http://dx.doi.org/10.1038/sj.onc.1206897			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627987				2022-12-28	WOS:000186650300010
J	Bertrand, P; Lambert, S; Joubert, C; Lopez, BS				Bertrand, P; Lambert, S; Joubert, C; Lopez, BS			Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cells	ONCOGENE			English	Article						Rad51; homologous recombination; tumorigenesis; centrosome; aneuploidy	INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; DIRECTED REPAIR; DNA-REPAIR; P53; EXPRESSION; PROTEIN; MOUSE; BRCA1; GENE; CYCLE	Rad51 protein plays a pivotal role in homologous recombination (HR), which is involved in double-strand break repair and in genome maintenance. Despite interactions with tumor suppressor proteins, the role of mammalian Rad51 and more generally of HR in tumor prevention is not clearly established. Indeed, both high and low frequencies of HR as well as high and low levels of RAD51 expression have been reported in tumors and in precancerous conditions. To address the question of the impact of HR on tumorigenesis, we used Chinese hamster ovary (CHO) p53-defective cell lines overexpressing the mouse MmRAD51, which stimulates HR ( we name these lines: Hyper-rec lines). In parallel, we used CHO cell lines expressing a RAD51 dominant-negative form that specifically inhibits gene conversion without affecting cell viability (Hypo-rec lines). These different lines were injected into nude mice to measure their tumorigenicity. Hypo-rec lines generated a higher frequency of tumors, which also exhibited faster growth, compared to control and Hyper-rec lines. Consistent with tumorigenicity, Hypo-rec cells exhibit spontaneous centrosome duplication defects and aneuploidy. These results are the first direct evidence of involvement of RAD51 in tumor repression.	CEA, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 6-68 Av Gen Leclerc, F-92265 Fontenay Aux Roses, France.	lopez@dsvidf.cea.fr	Lopez, Bernard S/O-7308-2017; lambert, sarah/K-7750-2017	Lopez, Bernard S/0000-0001-5088-0155; BERTRAND, Pascale/0000-0002-9019-742X; lambert, sarah/0000-0002-1403-3204				Ausubel F., 1999, CURRENT PROTOCOLS MO; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Flygare J, 1996, BBA-MOL CELL RES, V1312, P231, DOI 10.1016/0167-4889(96)00040-7; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lambert S, 2002, ONCOGENE, V21, P4065, DOI 10.1038/sj.onc.1205535; Lambert S, 2001, ONCOGENE, V20, P6627, DOI 10.1038/sj.onc.1204813; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levy-Lahad E, 2001, P NATL ACAD SCI USA, V98, P3232, DOI 10.1073/pnas.051624098; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Pihan GA, 1998, CANCER RES, V58, P3974; Raderschall E, 2002, CANCER RES, V62, P219; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sokal R. P., 1995, BIOMETRY PRINCIPLE P; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Wiese C, 2002, CANCER RES, V62, P1279; Wiesmuller L, 1996, J VIROL, V70, P737; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yoshikawa K, 2000, INT J CANCER, V88, P28, DOI 10.1002/1097-0215(20001001)88:1<28::AID-IJC5>3.0.CO;2-4	37	61	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7587	7592		10.1038/sj.onc.1206998	http://dx.doi.org/10.1038/sj.onc.1206998			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576820				2022-12-28	WOS:000186113000005
J	Debruyne, PR; Vermeulen, SJ; Berx, G; Pocard, M; da Rocha, ASC; Li, XD; Cirnes, L; Poupon, MF; van Roy, FM; Mareel, MM				Debruyne, PR; Vermeulen, SJ; Berx, G; Pocard, M; da Rocha, ASC; Li, XD; Cirnes, L; Poupon, MF; van Roy, FM; Mareel, MM			Functional and molecular characterization of the epithelioid to round transition in human colorectal cancer LoVo cells	ONCOGENE			English	Article						colorectal cancer; E-cadherin/catenin complex; invasion; morphotype	INVASION-SUPPRESSOR GENE; E-CADHERIN EXPRESSION; ALPHA-CATENIN; BETA-CATENIN; CPG ISLAND; ADHESION; GROWTH; METHYLATION; ACTIVATION; DIFFERENTIATION	In subclones of the human colon cancer LoVo cell line, there is a reproducible spontaneous transition from an epithelioid (E) to a round (R) morphotype. The E to R transition is associated with increased cell growth, absence of E-cadherin-dependent compaction in a slow aggregation assay, loss of contact inhibition of motility and directional migration in a wound filling motility assay. Furthermore, none of the E subclones from LoVo was invasive into chick heart fragments. This is in contrast to the R subclones that were either nonadherent or adherent and invasive. Macroarray analysis demonstrated transcriptional downregulation of plakoglobin in R type LoVo cells and this was confirmed at the level of the mRNA by quantitative RT-PCR. Western blotting showed lower expression of all components of the E-cadherin/catenin complex in R subclones. Interestingly, treatment of R subclones with the demethylating agent 5-aza-2'-deoxycytidine resulted in restoration of the E morphotype, higher expression of E-cadherin, but not plakoglobin mRNA, and higher expression of E-cadherin and plakoglobin at the protein level.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; VIB Univ Ghent, Dept Mol Biol, Mol Cell Biol Unit, B-9000 Ghent, Belgium; Inst Curie, CNRS, UMR Cytogenet Mol & Oncol 147, Sect Rech, F-75231 Paris 05, France; Univ Porto, Inst Mol Pathol & Immunol, P-4200 Oporto, Portugal	Ghent University; Ghent University Hospital; Flanders Institute for Biotechnology (VIB); Ghent University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universidade do Porto	Mareel, MM (corresponding author), Ghent Univ Hosp 1P7, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, De Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@rug.ac.be	van Roy, Frans M/C-6123-2009; Debruyne, Philip/AAU-6685-2021	van Roy, Frans M/0000-0003-4358-1039; Debruyne, Philip/0000-0001-5438-9697; Berx, Geert/0000-0001-5770-2458				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; AZNAVOORIAN S, 1990, J NATL CANCER I, V82, P1485, DOI 10.1093/jnci/82.18.1485; Bieche I, 1999, CANCER RES, V59, P2759; Boterberg T, 2001, Methods Mol Med, V58, P33, DOI 10.1385/1-59259-137-X:033; BOUKAMP P, 1993, J CELL BIOL, V120, P981, DOI 10.1083/jcb.120.4.981; Bracke M E, 2001, Methods Mol Med, V58, P91, DOI 10.1385/1-59259-137-X:091; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; BRATTAIN MG, 1981, CANCER RES, V41, P1751; Chen HY, 1997, J CELL SCI, V110, P345; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cowell HE, 1999, INT J CANCER, V80, P455; Daemi N, 2000, INT J CANCER, V85, P850, DOI 10.1002/(SICI)1097-0215(20000315)85:6<850::AID-IJC19>3.0.CO;2-B; Daemi N, 1995, INVAS METAST, V15, P103; DREWINKO B, 1976, CANCER RES, V36, P467; Dumortier J, 1998, DIFFERENTIATION, V63, P141, DOI 10.1046/j.1432-0436.1998.6330141.x; FISH EM, 1994, NEW ENGL J MED, V330, P1580; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; KINSELLA AR, 1994, CLIN EXP METASTAS, V12, P335, DOI 10.1007/BF01753841; Lehmann M, 1998, ENDOCRINOLOGY, V139, P3763, DOI 10.1210/en.139.9.3763; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Leroy A, 2000, FASEB J, V14, P1139, DOI 10.1096/fasebj.14.9.1139; MAREEL M, 1981, CELL BIOL INT REP, V5, P921, DOI 10.1016/0309-1651(81)90207-1; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; MAREEL M, 1979, VIRCHOWS ARCH B, V30, P95; MAREEL MM, 1986, NEW FRONTIERS MAMMAR, P351; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Orsulic S, 2000, J CELL SCI, V113, P1793; Pocard M, 2001, DIS COLON RECTUM, V44, P1106, DOI 10.1007/BF02234630; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; REMY L, 1992, INT J CANCER, V51, P204, DOI 10.1002/ijc.2910510207; Sgambato A, 1998, CANCER RES, V58, P3448; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TOMITA N, 1992, CANCER RES, V52, P6840; Tselepis C, 1998, P NATL ACAD SCI USA, V95, P8064, DOI 10.1073/pnas.95.14.8064; Van Hoorde L, 2000, INT J CANCER, V88, P751, DOI 10.1002/1097-0215(20001201)88:5<751::AID-IJC11>3.3.CO;2-2; VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902; vanHengel J, 1997, J CELL BIOL, V137, P1103, DOI 10.1083/jcb.137.5.1103; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VERMEULEN SJ, 1995, BRIT J CANCER, V72, P1447, DOI 10.1038/bjc.1995.528; Vermeulen SJ, 1999, CLIN EXP METASTAS, V17, P663, DOI 10.1023/A:1006724300022; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Wheeler JMD, 2001, GUT, V48, P367, DOI 10.1136/gut.48.3.367; ZAGOURAS P, 1995, P NATL ACAD SCI USA, V92, P6414, DOI 10.1073/pnas.92.14.6414	48	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7199	7208		10.1038/sj.onc.1206628	http://dx.doi.org/10.1038/sj.onc.1206628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562048				2022-12-28	WOS:000185955000011
J	Cromer, A; Carles, A; Millon, R; Ganguli, G; Chalmel, F; Lemaire, F; Young, J; Dembele, D; Thibault, C; Muller, D; Poch, O; Abecassis, J; Wasylyk, B				Cromer, A; Carles, A; Millon, R; Ganguli, G; Chalmel, F; Lemaire, F; Young, J; Dembele, D; Thibault, C; Muller, D; Poch, O; Abecassis, J; Wasylyk, B			Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis	ONCOGENE			English	Article						HNSCC; chromosomal location; prognosis; gene amplification	SQUAMOUS-CELL CARCINOMAS; LASER CAPTURE MICRODISSECTION; MOLECULAR CLASSIFICATION; EXPRESSION PROFILES; COPY NUMBER; BONE-MARROW; NECK; HEAD; AUTOTAXIN; AMPLIFICATION	Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer among men in the developed world. There is a need, for both clinical and scientific reasons, to find markers to identify patients with aggressive disease as early as possible, and to understand the events leading to malignant transformation and susceptibility to metastasis. We report the first large-scale gene expression analysis of a unique HNSCC location, the hypopharynx. Four normal and 34 tumour samples were analysed with 12 600 gene microarrays. Clusters of differentially expressed genes were identified in the chromosomal regions 3q27.3, 17q21.2-q21.31, 7q11.22-q22.1 and 11q13.1-q13.3, which, interestingly, have already been identified by comparative genomic hybridization (CGH) as major regions of gene amplification. We showed that six overexpressed genes (EIF4G1, DVL3, EPHB4, MCM7, BRMS1 and SART1) located in these regions are indeed amplified. We report 119 genes that are highly differentially expressed between 'early' tumours and normal samples. Of these, we validated by quantitative PCR six novel poorly characterized genes. These genes are potential new markers of HNSCC. Comparing patients with relatively nonaggressive and aggressive tumours (without or with clinical evidence of metastasis 3 years after surgery), we identified 164 differentially expressed genes potentially involved in the acquisition of metastatic potential. This study contributes to the understanding of HNSCC, staging patients into prognostic groups and identifying high-risk patients who may benefit from more aggressive treatment.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Ctr Paul Strauss, UPRES EA 34 30, F-67085 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UNICANCER; Centre Paul Strauss	Wasylyk, B (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 10142, F-67404 Illkirch Graffenstaden, France.	boh@igbmc.u-strasbg.fr	Chalmel, Frederic/M-1297-2016; Dembélé, Doulaye/O-6513-2017; Young, Julia/A-7219-2013; Chalmel, Frédéric/L-5360-2018; Chalmel, Frédéric/AAM-1079-2021; Indra, Gitali/G-2963-2016; Wasylyk, Bohdan/ABG-6778-2020	Dembélé, Doulaye/0000-0003-3879-6940; Chalmel, Frédéric/0000-0002-0535-3628; Chalmel, Frédéric/0000-0002-0535-3628; Wasylyk, Bohdan/0000-0002-1718-1237; Young, Julia/0000-0001-7219-7824; Thibault-Carpentier, Christelle/0000-0003-1562-1451				Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Belbin TJ, 2002, CANCER RES, V62, P1184; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Crawley JJ, 2002, GENOME BIOL, V3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El-Naggar AK, 2002, ONCOGENE, V21, P8206, DOI 10.1038/sj.onc.1206021; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Genden EM, 2003, ORAL ONCOL, V39, P207, DOI 10.1016/S1368-8375(02)00049-0; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Huang Q, 2002, GENE CHROMOSOME CANC, V34, P224, DOI 10.1002/gcc.10062; Hyman E, 2002, CANCER RES, V62, P6240; Kano M, 2003, PHYSIOL GENOMICS, V13, P31, DOI 10.1152/physiolgenomics.00116.2002; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kol S, 1997, J CLIN INVEST, V99, P2274, DOI 10.1172/JCI119403; LaTulippe E, 2002, CANCER RES, V62, P4499; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Lemaire F, 2003, BRIT J CANCER, V89, P1940, DOI 10.1038/sj.bjc.6601373; Li AH, 2001, CLIN CANCER RES, V7, P3298; Liu ET, 2003, CURR OPIN GENET DEV, V13, P97, DOI 10.1016/S0959-437X(03)00008-X; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Mendez E, 2002, CANCER, V95, P1482, DOI 10.1002/cncr.10875; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Muller D, 1997, EUR J CANCER, V33, P2203, DOI 10.1016/S0959-8049(97)00198-6; Murakami T, 2002, CANCER RES, V62, P7328; Nam SW, 2001, CANCER RES, V61, P6938; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Phillips JL, 2001, CANCER RES, V61, P8143; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Quon H, 2001, HEAD NECK-J SCI SPEC, V23, P147, DOI 10.1002/1097-0347(200102)23:2<147::AID-HED1010>3.0.CO;2-#; Redon R, 2001, CANCER RES, V61, P4122; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Taichman RS, 2002, CANCER RES, V62, P1832; Tao M, 2000, CYTOKINE, V12, P699, DOI 10.1006/cyto.2000.0666; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Villaret DB, 2000, LARYNGOSCOPE, V110, P374, DOI 10.1097/00005537-200003000-00008; Watanabe H, 2002, ORAL ONCOL, V38, P670, DOI 10.1016/S1368-8375(02)00006-4; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D	49	211	232	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2484	2498		10.1038/sj.onc.1207345	http://dx.doi.org/10.1038/sj.onc.1207345			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676830				2022-12-28	WOS:000220558000006
J	Nakamura, T; Furukawa, Y; Nakagawa, H; Tsunoda, T; Ohigashi, H; Murata, K; Ishikawa, O; Ohgaki, K; Kashimura, N; Miyamoto, M; Hirano, S; Kondo, S; Katoh, H; Nakamura, Y; Katagiri, T				Nakamura, T; Furukawa, Y; Nakagawa, H; Tsunoda, T; Ohigashi, H; Murata, K; Ishikawa, O; Ohgaki, K; Kashimura, N; Miyamoto, M; Hirano, S; Kondo, S; Katoh, H; Nakamura, Y; Katagiri, T			Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection	ONCOGENE			English	Article						pancreatic cancer; laser microbeam microdissection; cDNA microarray; gene expression profiles	HEPATOCELLULAR-CARCINOMA; COLORECTAL CARCINOMAS; MONOCLONAL-ANTIBODY; IDENTIFICATION; ADENOCARCINOMA; KINASE; CARCINOGENESIS; INHIBITORS; APOPTOSIS; DISCOVERY	To characterize molecular mechanism involved in pancreatic carcinogenesis, we analysed gene-expression profiles of 18 pancreatic tumors using a cDNA microarray representing 23 040 genes. As pancreatic ductal adenocarcinomas usually contain a low proportion of cancer cells in the tumor mass, we prepared 95% pure populations of pancreatic cancer cells by means of laser microbeam microdissection, and compared their expression profiles to those of similarly purified, normal pancreatic ductal cells. We identified 260 genes that were commonly upregulated and 346 genes that were downregulated in pancreatic cancer cells. Because of the high degree of purity in the cell populations, a large proportion of genes that we detected as upregulated or downregulated in pancreatic cancers were different from those reported in previous studies. Comparison of clinicopathological parameters with the expression profiles indicated that altered expression of 76 genes was associated with lymph-node metastasis and that of 168 genes with liver metastasis. In addition, expression levels of 30 genes were related to the recurrence of disease. These genome-wide expression profiles should provide useful information for finding candidate genes whose products might serve as specific tumor markers and/or as molecular targets for treatment of patients with pancreatic cancer.	Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan; Hokkaido Univ, Grad Sch Med, Div Canc Med, Kita Ku, Sapporo, Hokkaido 0608638, Japan; RIKEN, Inst Phys & Chem Res,SNP Res Ctr, Lab Med Informat, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg, Higashinari Ku, Osaka 5378511, Japan; Kyoto Police Hosp, Dept Surg, Kita Ku, Kyoto 6038142, Japan; Teine Keijinkai Hosp, Dept Surg, Teine Ku, Sapporo, Hokkaido 0068555, Japan	University of Tokyo; Hokkaido University; RIKEN; Osaka Medical Center for Cancer & Cardiovascular Diseases; Teine Keijinkai Hospital	Nakamura, Y (corresponding author), Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	yusuke@ims.u-tokyo.ac.jp	Tsunoda, Tatsuhiko/K-2061-2014; Kondo, Satoshi/B-1114-2008; Nakamura, toru/F-6901-2012	Tsunoda, Tatsuhiko/0000-0002-5439-7918; 				Brentnall TA, 1999, ANN INTERN MED, V131, P247, DOI 10.7326/0003-4819-131-4-199908170-00003; Chambers SK, 1997, CLIN CANCER RES, V3, P999; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Crnogorac-Jurcevic T, 2002, ONCOGENE, V21, P4587, DOI 10.1038/sj.onc.1205570; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gianni L, 2002, ONCOLOGY-BASEL, V63, P47, DOI 10.1159/000066197; Gjerdrum LM, 2001, J MOL DIAGN, V3, P105, DOI 10.1016/S1525-1578(10)60659-9; Goggins M, 2000, AM J PATHOL, V156, P1767, DOI 10.1016/S0002-9440(10)65047-X; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Guo HM, 2000, CANCER RES, V60, P888; Han HY, 2002, CANCER RES, V62, P2890; Hao D, 2002, CANCER INVEST, V20, P387, DOI 10.1081/CNV-120001184; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Ishiguro H, 2002, ONCOGENE, V21, P6387, DOI 10.1038/sj.onc.1205751; Ishiguro H, 2001, ONCOGENE, V20, P5062, DOI 10.1038/sj.onc.1204603; Kitahara O, 2001, CANCER RES, V61, P3544; Klejman A, 2002, ONCOGENE, V21, P5868, DOI 10.1038/sj.onc.1205724; Klinkenbijl JH, 1999, ANN SURG, V230, P776, DOI 10.1097/00000658-199912000-00006; Laheru D, 2001, CANCER J, V7, P324; Logsdon CD, 2003, CANCER RES, V63, P2649; Maney T, 1998, J CELL BIOL, V142, P787, DOI 10.1083/jcb.142.3.787; Ng IOL, 2000, CANCER RES, V60, P6581; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ono K, 2000, CANCER RES, V60, P5007; Rehwald U, 2003, BLOOD, V101, P420, DOI 10.1182/blood.V101.2.420; Rosenberg L, 2000, DRUGS, V59, P1071, DOI 10.2165/00003495-200059050-00004; Rozenblum E, 1997, CANCER RES, V57, P1731; Saito-Hisaminato A, 2002, DNA RES, V9, P35, DOI 10.1093/dnares/9.2.35; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Scanlan MJ, 2002, CANCER RES, V62, P4041; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sperti C, 1997, WORLD J SURG, V21, P195, DOI 10.1007/s002689900215; Violette S, 2003, INT J CANCER, V103, P185, DOI 10.1002/ijc.10788; Yagyu R, 2002, INT J ONCOL, V20, P1173; Yuan BZ, 1998, CANCER RES, V58, P2196	39	215	236	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2385	2400		10.1038/sj.onc.1207392	http://dx.doi.org/10.1038/sj.onc.1207392			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14767473				2022-12-28	WOS:000220427700013
J	Qiu, HQ; Miller, WT				Qiu, HQ; Miller, WT			Role of the Brk SH3 domain in substrate recognition	ONCOGENE			English	Article						Brk; tyrosine kinase; SH3 domain; SH2 domain; substrate	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; C-SRC; PROCESSIVE PHOSPHORYLATION; GASTROINTESTINAL-TRACT; FAMILY; PROTEIN; HCK; EXPRESSION; RNA	Breast tumor kinase ( Brk) is a nonreceptor tyrosine kinase that is overexpressed in a high percentage of breast carcinomas. Brk contains SH3, SH2, and tyrosine kinase catalytic domains in a similar arrangement as Src family kinases. In this study, we explored the roles of the SH3 and SH2 domains in Brk regulation and substrate binding. We introduced a series of mutations into Brk that were predicted to disrupt the intramolecular interactions involving the SH3 and SH2 domains. These mutant forms of Brk displayed higher activity than wild- type Brk when expressed in human embryonic kidney HEK293 cells. These studies also allowed us to pinpoint the intramolecular binding site for the SH3 domain. To examine substrate binding, we compared binding and phosphorylation of Sam68, a physiological substrate of Brk. These experiments showed that the SH3 domain plays a particularly important role in substrate recognition. We confirmed this conclusion using a series of synthetic peptides in which a substrate sequence was coupled to an SH3 or SH2 ligand. The SH3- binding substrate had a significantly lower K-m than a control, while no difference was observed between an SH2- binding substrate and a control. Taken together, our data suggest that SH3 interactions will govern phosphorylation of many substrates by Brk.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; LIU XQ, 1993, ONCOGENE, V8, P1119; Llor X, 1999, CLIN CANCER RES, V5, P1767; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; McPherson RA, 2000, ONCOGENE, V19, P3616, DOI 10.1038/sj.onc.1203678; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Serfas MS, 2003, ONCOL RES, V13, P409; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tian MX, 1997, MOL BIOL CELL, V8, P1183, DOI 10.1091/mbc.8.7.1183; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	42	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2216	2223		10.1038/sj.onc.1207339	http://dx.doi.org/10.1038/sj.onc.1207339			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676834				2022-12-28	WOS:000220280900011
J	de Marval, PLM; Macias, E; Conti, CJ; Rodriguez-Puebla, ML				de Marval, PLM; Macias, E; Conti, CJ; Rodriguez-Puebla, ML			Enhanced malignant tumorigenesis in Cdk4 transgenic mice	ONCOGENE			English	Article						CDK4; carcinogenesis; skin; cell-cycle; cyclin; papillomas	SKIN TUMOR-DEVELOPMENT; CYCLIN-DEPENDENT KINASES; SENCAR MOUSE SKIN; CELL-CYCLE; GERMLINE MUTATIONS; PREMALIGNANT PROGRESSION; HOMOZYGOUS DELETION; IN-VIVO; EXPRESSION; OVEREXPRESSION	In a previous study, we reported that overexpression of cyclin-dependent kinase-4 (CDK4) in mouse epidermis results in epidermal hyperplasia, hypertrophy and severe dermal fibrosis. In this study, we have investigated the susceptibility to skin tumor formation by forced expression of CDK4. Skin tumors from transgenic mice showed a dramatic increase in the rate of malignant progression to squamous cell carcinomas (SCC) in an initiation-promotion protocol. Histopathological analysis of papillomas from transgenic mice showed an elevated number of premalignant lesions characterized by dysplasia and marked atypia. Interestingly, transgenic mice also developed tumors in initiated but not promoted skin, demonstrating that CDK4 replaced the action of tumor promoters. These results suggest that expression of cyclin D1 upon ras activation synergizes with CDK4 overexpression. However, cyclin D1 transgenic mice and double transgenic mice for cyclin D1 and CDK4 did not show increased malignant progression in comparison to CDK4 transgenic mice. Biochemical analysis of tumors showed that CDK4 sequesters the CDK2 inhibitors p27(Kip1) and p21(Cip1), suggesting that indirect activation of CDK2 plays an important role in tumor development. These results indicate that, contrary to the general assumption, the catalytic subunit, CDK4, has higher oncogenic activity than cyclin D1, revealing a potential use of CDK4 as therapeutic target.	N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, Raleigh, NC 27606 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA	University of North Carolina; North Carolina State University; University of Texas System; UTMD Anderson Cancer Center	Rodriguez-Puebla, ML (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Mol Biomed Sci, 4700 Hillsborough St, Raleigh, NC 27606 USA.	marcelo_rodriguez-puebla@ncsu.edu			NATIONAL CANCER INSTITUTE [P01CA057596, R01CA042157, P30CA016672, R01CA090864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90864, P30 CA016672, R01 CA042157, CA 57596, CA 16672, R01 CA090864, CA 42157, R01 CA090864-02] Funding Source: Medline; NIEHS NIH HHS [P30 ES007784, ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALDAZ M, 1989, EXPT CLIN ASPECTS; An HX, 1999, AM J PATHOL, V154, P113, DOI 10.1016/S0002-9440(10)65257-1; BERENBLUM I, 1954, ADV CANCER RES, V2, P129, DOI 10.1016/S0065-230X(08)60493-5; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; CONTI C, 1992, CANC B, V54, P62; de Marval PLM, 2001, AM J PATHOL, V159, P369, DOI 10.1016/S0002-9440(10)61703-8; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jacks T, 1998, SCIENCE, V280, P1035, DOI 10.1126/science.280.5366.1035; Kanoe H, 1998, ANTICANCER RES, V18, P2317; Lam PYP, 2000, BRIT J NEUROSURG, V14, P28; Lazarov M, 2002, NAT MED, V8, P1105, DOI 10.1038/nm779; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; NEVINS JR, 1992, SCIENCE, V258, P424; Nikitakis NG, 2002, EXP MOL PATHOL, V73, P198, DOI 10.1006/exmp.2002.2465; OHTA M, 1994, CANCER RES, V54, P5269; Parry D, 1999, MOL CELL BIOL, V19, P1775; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Ramirez RD, 2003, ONCOGENE, V22, P433, DOI 10.1038/sj.onc.1206046; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLAGA T J, 1989, P1; SONODA Y, 1995, ONCOGENE, V11, P2145; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TOLFGARD R, 1985, CARCINOGENESIS, V6, P655; Tos APD, 2000, J PATHOL, V190, P531; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Weinberg RA, 1996, CYTOKINES MOL THER, V2, P105; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; YUSPA SH, 1990, ENVIRON HEALTH PERSP, V88, P193; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	61	41	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1863	1873		10.1038/sj.onc.1207309	http://dx.doi.org/10.1038/sj.onc.1207309			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647432	Green Accepted			2022-12-28	WOS:000220129500008
J	Shim, JS; Kim, DH; Kwon, HJ				Shim, JS; Kim, DH; Kwon, HJ			Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells	ONCOGENE			English	Article						histone deacetylase; transcriptional repression; plakoglobin; oncogene	BETA-CATENIN; TUMOR-SUPPRESSOR; GAMMA-CATENIN; EXPRESSION; INHIBITORS; DROSOPHILA; PROTEIN; AGENTS; CANCER; CARCINOGENESIS	Histone deacetylase ( HDAC) plays a key role in gene expression, by suppressing the transcription of a number of target genes. Identification of such genes is important for deciphering the functional role of HDAC. Here, using cancer gene-focused DNA microarray analysis, we identified plakoglobin as a new target gene of HDAC. Functional inhibition of HDAC by its specific inhibitors induced the expression of plakoglobin by eight-fold in human fibrosarcoma HT1080 cells. However, the expression of beta-catenin, which is closely related to plakoglobin, was not altered, implying the specific function of HDAC in plakoglobin expression. Using antiacetyl-H4 antibody, chromatin immunoprecipitation analysis revealed that the distal region ( - 945 similar to - 646) of the promoter of plakoglobin is responsible for the HDAC-mediated repression of the gene. Moreover, the induced expression of plakoglobin by the inhibition of HDAC activated the Tcf/ Lef-dependent luciferase reporter gene, a well-known downstream effector of the Wnt signaling pathway. Furthermore, transient transfection of plakoglobin also activated Tcf/ Lef reporter gene expression. Taken together, our results demonstrate that plakoglobin is a new target gene governed by HDAC, and that it acts as an oncogene in HT1080 cells.	Sejong Univ, Dept Biosci & Biotechnol, Inst Biosci, Seoul 143747, South Korea	Sejong University	Kwon, HJ (corresponding author), Sejong Univ, Dept Biosci & Biotechnol, Inst Biosci, 98 Kunja Dong, Seoul 143747, South Korea.	kwonhj@sejong.ac.kr	Shim, Joong Sup/O-2848-2016; Shim, Joong Sup/G-8383-2011; 권, 호정/AAS-3642-2021	Shim, Joong Sup/0000-0003-0167-7307; Shim, Joong Sup/0000-0003-0167-7307; 				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kim JH, 2002, JPN J CANCER RES, V93, P1378, DOI 10.1111/j.1349-7006.2002.tb01247.x; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kolligs FT, 2000, GENE DEV, V14, P1319; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Ogden SK, 2001, J BIOL CHEM, V276, P42057, DOI 10.1074/jbc.C100381200; Pantel K, 1998, J CLIN ONCOL, V16, P1407, DOI 10.1200/JCO.1998.16.4.1407; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Potter E, 2001, EUR J ENDOCRINOL, V145, P625, DOI 10.1530/eje.0.1450625; Richon VM, 2002, CLIN CANCER RES, V8, P662; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Simcha I, 1996, J CELL BIOL, V133, P199, DOI 10.1083/jcb.133.1.199; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VanLint C, 1996, GENE EXPRESSION, V5, P245; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963	30	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1704	1711		10.1038/sj.onc.1207289	http://dx.doi.org/10.1038/sj.onc.1207289			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14661058				2022-12-28	WOS:000220029300006
J	Yu, CR; Rahmani, M; Almenara, J; Sausville, EA; Dent, P; Grant, S				Yu, CR; Rahmani, M; Almenara, J; Sausville, EA; Dent, P; Grant, S			Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process	ONCOGENE			English	Article						leukemia; apoptosis; adaphostin; ROS; ERK; Akt	ACTIVATED PROTEIN-KINASE; CHRONIC MYELOGENOUS LEUKEMIA; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; IN-VIVO; GROWTH-FACTOR; MAP KINASES; PATHWAY; JNK; PHOSPHORYLATION	Effects of the tyrphostin tyrosine kinase inhibitor adaphostin (NSC 680410) have been examined in human leukemia cells ( Jurkat, U937) in relation to mitochondrial events, apoptosis, and perturbations in signaling and cell cycle regulatory events. Exposure of cells to adaphostin concentrations greater than or equal to0.75 muM for intervals greater than or equal to6 h resulted in a pronounced release of cytochrome c and AIF, activation of caspase-9, -8, and -3, and apoptosis. These events were accompanied by the caspase-independent downregulation of Raf-1, inactivation of MEK1/2, ERK, Akt, p70S6K, dephosphorylation of GSK-3, and activation of c-Jun-N-terminal kinase (JNK) and p38 MAPK. Adaphostin also induced cleavage and dephosphorylation of pRb on CDK2- and CDK4-specific sites, as well as the caspase-dependent downregulation of cyclin D-1. Inducible expression of a constitutively active MEK1 construct markedly diminished adaphostin-induced cytochrome c and AIF release, JNK activation, and apoptosis in Jurkat cells. Ectopic expression of Raf-1 or constitutively activated ( myristolated) Akt also significantly attenuated adaphostin-induced apoptosis, but protection was less than that conferred by enforced activation of MEK. Lastly, antioxidants (e.g., L-N-acetylcysteine; L-NAC) opposed adaphostin-mediated mitochondrial dysfunction, Raf-1/ MEK/ERK downregulation, JNK activation, and apoptosis. However, in contrast to L-NAC, enforced activation of MEK failed to block adaphostin-mediated ROS generation. Together, these findings demonstrate that the tyrphostin adaphostin induces multiple perturbations in signal transduction pathways in human leukemia cells, particularly inactivation of the cytoprotective Raf-1/ MEK/ERK and Akt cascades, that culminate in mitochondrial injury, caspase activation, and apoptosis. They also suggest that adaphostin-related oxidative stress acts upstream of perturbations in these signaling pathways to trigger the cell death process.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA; NCI, Dev Therapeut Program, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.	stgrant@hsc.vcu.edu		Rahmani, Mohamed/0000-0002-3992-8039	NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753] Funding Source: NIH RePORTER; NCI NIH HHS [CA 93738, CA63753] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arguello F, 1998, BLOOD, V91, P2482; Avramis IA, 2002, CANCER CHEMOTH PHARM, V50, P479, DOI 10.1007/s00280-002-0507-6; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Carlson B, 1999, CANCER RES, V59, P4634; CHANDRA J, 2003, BLOOD; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Clarke PA, 2000, ONCOGENE, V19, P4125, DOI 10.1038/sj.onc.1203753; Dan S, 1998, CELL DEATH DIFFER, V5, P710, DOI 10.1038/sj.cdd.4400400; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; Inoshita S, 2002, J BIOL CHEM, V277, P43730, DOI 10.1074/jbc.M207951200; Jarvis WD, 1997, FEBS LETT, V412, P9, DOI 10.1016/S0014-5793(97)00705-9; Jia WT, 2003, BLOOD, V102, P1824, DOI 10.1182/blood-2002-12-3785; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200; Svingen PA, 2000, CLIN CANCER RES, V6, P237; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wolf C, 2001, FEBS LETT, V488, P154, DOI 10.1016/S0014-5793(00)02403-0; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yu CR, 2003, CANCER RES, V63, P1822; Yu CR, 2003, CANCER RES, V63, P2118; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143	45	61	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1364	1376		10.1038/sj.onc.1207248	http://dx.doi.org/10.1038/sj.onc.1207248			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14647418				2022-12-28	WOS:000189035800004
J	Attardi, LD; de Vries, A; Jacks, T				Attardi, LD; de Vries, A; Jacks, T			Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer	ONCOGENE			English	Article						p53; cell cycle arrest; apoptosis; chemotherapeutics; DNA damage	CELL-CYCLE ARREST; P53; APOPTOSIS; P21; PHOSPHORYLATION; RADIATION	The p53 tumor suppressor protein inhibits proliferation by inducing either cell cycle arrest or apoptosis in response to cellular stresses. Mouse embryo fibroblasts (MEFs) provide a primary cell model system in which to examine both functions of p53. MEFs treated with gamma-rays undergo p53-dependent G1 arrest, while oncogene-expressing METs treated with a variety of DNA-damaging agents undergo p53-dependent apoptosis. Although the p53-dependent G1 arrest checkpoint response to gamma-rays in MEFs has been well characterized, the response to other DNA-damaging agents has not. Here, we examine the effects of commonly utilized chemotherapeutics, including doxorubicin, etoposide, and cisplatin, on cell cycle arrest in MEFs, and we define the p53 dependence of these effects. In addition, we examine the response of MEFs to ultraviolet light (UVC), as a representative agent acting by inducing pyrimidine dimers. Although p53 is clearly activated by all the agents examined, as measured by p21 induction, there are surprising differences in the activities of these agents. For example, doxorubicin but not cisplatin can effectively induce a p53-dependent G1 arrest. UVC, in contrast, induces a p53-independent G1 arrest response. Thus, the exact response of cells to DNA damage depends on the specific agent used.	Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Natl Inst Publ Hlth, Lab Toxicol Pathol & Genet, NL-3720 BA Bilthoven, Netherlands; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Stanford University; Stanford University; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Attardi, LD (corresponding author), Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.	attardi@stanford.edu						Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Attardi LD, 2000, GENE DEV, V14, P704; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chang D, 1999, CELL GROWTH DIFFER, V10, P155; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; ODWYER PJ, 1997, PRINCIPLES PRACTICE, P419; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; STEWART CF, 1997, PRINCIPLES PRACTICE, P452; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALDMAN T, 1995, CANCER RES, V55, P5187; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	22	90	90	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					973	980		10.1038/sj.onc.1207026	http://dx.doi.org/10.1038/sj.onc.1207026			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749764				2022-12-28	WOS:000188486600013
J	Bos, R; van Diest, PJ; van der Groep, P; Greijer, AE; Hermsen, MA; Heijnen, I; Meijer, GA; Baak, JPA; Pinedo, HM; van der Wall, E; Shvarts, A				Bos, R; van Diest, PJ; van der Groep, P; Greijer, AE; Hermsen, MA; Heijnen, I; Meijer, GA; Baak, JPA; Pinedo, HM; van der Wall, E; Shvarts, A			Protein expression of B-cell lymphoma gene 6 (BCL-6) in invasive breast cancer is associated with cyclin D-1 and hypoxia-inducible factor-1 alpha (HIF-1 alpha)	ONCOGENE			English	Article						BCL-6; HIF-1 alpha; cyclin D-1; oncogenes; breast cancer	D1; DIFFERENTIATION; OVEREXPRESSION	B-cell lymphoma gene (BCL-6) upregulation contributes to immortalization of mouse embryo fibroblast and primary B cells via upregulation of cyclin D-1. As cyclin D-1 overexpression is a common phenomenon in different cancers, BCL-6 protein overexpression may not be restricted to lymphomas. In this study, expression of BCL-6 was investigated by immunohistochemistry on paraffin-embedded specimens from 150 breast cancer patients and 10 specimens of normal breast tissue. The results showed BCL-6 overexpression (greater than or equal to10% of cells) in 24/150 (16%) breast cancer patients, whereas in normal breast low expression (<1%) of BCL-6 was observed. In linear regression analysis BCL-6 expression was associated with cyclin D-1 (r = 0.197, P = 0.016). Further, in chi(2) analyses, BCL-6-positivity was associated with overexpression of p53 (P = 0.016), and hypoxia-inducible factor-1 alpha (P < 0.001). Involvement of BCL-6 in breast carcinogenesis is further underscored by comparative genomic hybridization analysis that showed gains at the BCL-6 locus (3q27) in 14/86 (16%) breast cancer tissues. The cases with amplification in BCL-6 showed an increased (25%) incidence of BCL-6 protein overexpression. Thus, this study is the first to show that BCL-6 oncogene activation plays a role in cancers other than lymphomas.	Vrije Univ Amsterdam Med Ctr, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands; SiR Hosp, Dept Pathol, Stavanger, Norway	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Shvarts, A (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	a.shvarts@vumc.nl	Bos, Reinhard/AAS-1726-2020	Meijer, Gerrit/0000-0003-0330-3130; Bos, Reinhard/0000-0003-1094-5596				Bindra RS, 2002, CANCER RES, V62, P3014; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; de Jong JS, 1999, J CLIN PATHOL-MOL PA, V52, P78, DOI 10.1136/mp.52.2.78; Dunphy CH, 2001, LEUKEMIA LYMPHOMA, V41, P585, DOI 10.3109/10428190109060349; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Hermsen MAJA, 1998, J PATHOL, V186, P356; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Ree HJ, 2003, HUM PATHOL, V34, P610, DOI 10.1016/S0046-8177(03)00086-8; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; vanDiest PJ, 1997, AM J PATHOL, V150, P705; VANDIEST PJ, 1992, HUM PATHOL, V23, P603, DOI 10.1016/0046-8177(92)90313-R; Ye BH, 2000, CANCER INVEST, V18, P356, DOI 10.3109/07357900009012179; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Zhong H, 1999, CANCER RES, V59, P5830	19	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8948	8951		10.1038/sj.onc.1206995	http://dx.doi.org/10.1038/sj.onc.1206995			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654791				2022-12-28	WOS:000186982200016
J	Brummer, T; Naegele, H; Reth, M; Misawa, Y				Brummer, T; Naegele, H; Reth, M; Misawa, Y			Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf	ONCOGENE			English	Article						B-Raf; feedback phosphorylation; ERK; B-cell antigen receptor; DT40; MEK-inhibitor UO126	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; CELL ANTIGEN RECEPTOR; COMPLETE CODING SEQUENCE; NERVE GROWTH-FACTOR; JUN NH2-TERMINAL KINASE; NEGATIVE REGULATION; POSITIVE FEEDBACK; TYROSINE KINASES; STRUCTURAL BASIS	The extracellular signal-regulated kinase (ERK) pathway plays an important role during the development and activation of B lymphocytes. We have recently shown that B-Raf is a dominant ERK activator in B-cell antigen receptor signalling. We now show that B-Raf is hyperphosphorylated upon BCR engagement and undergoes a prominent electrophoretic mobility shift. This shift correlates with ERK activation and is prevented by the MEK inhibitor U0126. Syk-deficient DT40 B cells display neither dual ERK phosphorylation nor a mobility shift of B-Raf upon BCR engagement. The inducible expression of a constitutively active B-Raf in this mutant line restores dual ERK phosphorylation and the mobility shift of endogenous B-Raf, indicating that these two events are connected to each other. By site-directed mutagenesis studies, we demonstrate that the shift is due to an ERK2-mediated feedback phosphorylation of serine/threonine residues within an evolutionary conserved SPKTP motif at the C-terminus of B-Raf. Replacement of these residues by negatively charged amino acids causes a constitutive mobility shift and a reduction of PC12 cell differentiation. We discuss a model in which ERK-mediated phosphorylation of the SPKTP motif is involved in negative feedback regulation of B-Raf.	Univ Freiburg, Dept Mol Immunol, D-79108 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; Max Planck Society	Misawa, Y (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	ym8n@virginia.edu	Brummer, Tilman/B-6218-2016; Brummer, Tilman/AAA-9428-2020	Brummer, Tilman/0000-0003-4387-7905; Brummer, Tilman/0000-0003-4387-7905				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; Brummer T, 2002, EMBO J, V21, P5611, DOI 10.1093/emboj/cdf588; Bruyns E, 1998, J EXP MED, V188, P561, DOI 10.1084/jem.188.3.561; CALOGERAKI I, 1993, BIOCHEM BIOPH RES CO, V193, P1324, DOI 10.1006/bbrc.1993.1770; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrell JE, 2002, CURR OPIN CELL BIOL, V14, P140, DOI 10.1016/S0955-0674(02)00314-9; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Gold MR, 2000, CURR TOP MICROBIOL, V245, P77; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hashimoto A, 1998, J EXP MED, V188, P1287, DOI 10.1084/jem.188.7.1287; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Iritani BM, 1997, EMBO J, V16, P7019, DOI 10.1093/emboj/16.23.7019; Jaiswal RK, 1996, J BIOL CHEM, V271, P23626, DOI 10.1074/jbc.271.39.23626; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KOENEN M, 1988, ONCOGENE, V2, P179; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; LEE RM, 1992, J BIOL CHEM, V267, P1088; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MacNicol MC, 2000, J BIOL CHEM, V275, P3803, DOI 10.1074/jbc.275.6.3803; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Papin C, 1998, J BIOL CHEM, V273, P24939, DOI 10.1074/jbc.273.38.24939; Papin C, 1996, ONCOGENE, V12, P2213; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shirakata Y, 1999, J IMMUNOL, V163, P6589; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SPRENGER F, 1993, MOL CELL BIOL, V13, P1163, DOI 10.1128/MCB.13.2.1163; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; Toran-Allerand CD, 1999, FRONT NEUROENDOCRIN, V20, P97, DOI 10.1006/frne.1999.0177; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; UEKI K, 1994, J BIOL CHEM, V269, P15756; Wartmann M, 1997, J BIOL CHEM, V272, P3915, DOI 10.1074/jbc.272.7.3915; WILLIAMS NG, 1993, P NATL ACAD SCI USA, V90, P5772, DOI 10.1073/pnas.90.12.5772; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; Xu R, 1999, J IMMUNOL, V163, P1110; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yung Y, 1997, FEBS LETT, V408, P292, DOI 10.1016/S0014-5793(97)00442-0; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zhang Y, 1996, NUCLEIC ACIDS RES, V24, P543, DOI 10.1093/nar/24.4.543; ZHUO S, 1993, J BIOL CHEM, V268, P17754; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322	67	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8823	8834		10.1038/sj.onc.1207185	http://dx.doi.org/10.1038/sj.onc.1207185			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654779				2022-12-28	WOS:000186982200003
J	Rizzuto, R; Pinton, P; Ferrari, D; Chami, M; Szabadkai, G; Magalhaes, PJ; Di Virgilio, F; Pozzan, T				Rizzuto, R; Pinton, P; Ferrari, D; Chami, M; Szabadkai, G; Magalhaes, PJ; Di Virgilio, F; Pozzan, T			Calcium and apoptosis: facts and hypotheses	ONCOGENE			English	Review						mitochondria; Bcl-2; cell death; endoplasmic reticulum	PROTEIN-KINASE-C; OUTER MITOCHONDRIAL-MEMBRANE; ELECTRON-TRANSPORT CHAIN; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; PERMEABILITY TRANSITION; CYTOCHROME-C; BCL-2 FAMILY; CA2+ CONCENTRATION; NUCLEAR-ENVELOPE	Although longstanding experimental evidence has associated alterations of calcium homeostasis to cell death, only in the past few years the role of calcium in the signaling of apoptosis has been extensively investigated. In this review, we will summarize the current knowledge, focusing on (i) the effect of the proteins of the Bcl-2 family on ER Ca2+ levels, (ii) the action of the proteolytic enzymes of apoptosis on the Ca2+ signaling machinery, (iii) the ensuing alterations on the signaling patterns of extracellular stimuli, and (iv) the intracellular targets of 'apoptotic' Ca2+ signals, with special emphasis on the mitochondria and cytosolic Ca2+-dependent enzymes.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Study Inflammat, I-44100 Ferrara, Italy; Univ Padua, Dept Biomed Sci, I-35100 Padua, Italy	University of Ferrara; University of Ferrara; University of Padua	Rizzuto, R (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I-44100 Ferrara, Italy.	r.rizzuto@unife.it	DI VIRGILIO, Francesco/O-4634-2019; Pinton, Paolo/J-8025-2012; Di Virgilio, Francesco/J-3754-2018; Rizzuto, Rosario/B-6312-2008; Chami, Mounia/S-6471-2019; Ferrari, Davide/F-5644-2015	DI VIRGILIO, Francesco/0000-0003-3566-1362; Pinton, Paolo/0000-0001-7108-6508; Di Virgilio, Francesco/0000-0003-3566-1362; Chami, Mounia/0000-0003-1498-7187; Ferrari, Davide/0000-0002-5727-9204; Szabadkai, Gyorgy/0000-0002-3006-3577; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Camello P, 1996, J PHYSIOL-LONDON, V490, P585, DOI 10.1113/jphysiol.1996.sp021169; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; DEGIORGI F, 2002, FASEB J; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Glazner GW, 2000, J NEUROSCI, V20, P3641, DOI 10.1523/JNEUROSCI.20-10-03641.2000; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Konishi H, 1999, BIOCHEM BIOPH RES CO, V264, P840, DOI 10.1006/bbrc.1999.1579; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kruman I, 1998, J NEUROSCI RES, V51, P293, DOI 10.1002/(SICI)1097-4547(19980201)51:3<293::AID-JNR3>3.0.CO;2-B; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Lee ST, 1999, ONCOGENE, V18, P3520, DOI 10.1038/sj.onc.1202716; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lynch K, 2000, ENDOCRINOLOGY, V141, P4209, DOI 10.1210/en.141.11.4209; Ma TS, 1999, CELL CALCIUM, V26, P25, DOI 10.1054/ceca.1999.0049; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; MARTIKAINEN P, 1991, CANCER RES, V51, P4693; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mizuno K, 1997, EUR J BIOCHEM, V250, P7, DOI 10.1111/j.1432-1033.1997.00007.x; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Nomura M, 1999, CANCER RES, V59, P5542; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shchepina LA, 2002, ONCOGENE, V21, P8149, DOI 10.1038/sj.onc.1206053; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Skarka L, 2002, PHYSIOL RES, V51, P425; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; TANAKA S, 1993, J BIOL CHEM, V268, P10920; Teranishi F, 2003, BIOCHEM BIOPH RES CO, V303, P940, DOI 10.1016/S0006-291X(03)00447-9; Tidball JG, 2000, INT J BIOCHEM CELL B, V32, P1, DOI 10.1016/S1357-2725(99)00095-3; Tombal B, 1999, CELL CALCIUM, V25, P19, DOI 10.1054/ceca.1998.0005; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Vieira HLA, 1999, CELL MOL LIFE SCI, V56, P971, DOI 10.1007/s000180050486; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wertz IE, 2000, J BIOL CHEM, V275, P11470, DOI 10.1074/jbc.275.15.11470; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoon Y, 2001, CURR BIOL, V11, pR67, DOI 10.1016/S0960-9822(01)00011-2; Zhu WJ, 1996, EMBO J, V15, P4130, DOI 10.1002/j.1460-2075.1996.tb00788.x; Zirpel L, 1998, J NEUROPHYSIOL, V79, P2288, DOI 10.1152/jn.1998.79.5.2288	94	364	388	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8619	8627		10.1038/sj.onc.1207105	http://dx.doi.org/10.1038/sj.onc.1207105			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634623				2022-12-28	WOS:000186720000007
J	Jiang, Y; Zhang, YK; Lees, E; Seghezzi, W				Jiang, Y; Zhang, YK; Lees, E; Seghezzi, W			AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer	ONCOGENE			English	Article						mitotic spindle checkpoint; mitotic kinase; cell cycle	ANAPHASE-PROMOTING COMPLEX; CENTROSOME AMPLIFICATION; KINASE AURORA2/AIK; DROSOPHILA-AURORA; BINDING DOMAIN; PROTEIN BUBR1; B KINASE; A KINASE; CANCERS; MITOSIS	AuroraA, a mitotic kinase, is reported to be amplified and overexpressed in a variety of human tumors. Active mutants of AuroraA can transform mouse fibroblasts and form tumors in nude mice. However, the mechanism behind this oncogenic potential remains elusive. In this study, we investigated the consequences of AuroraA overexpression and showed that increased AuroraA levels compromise the mitotic spindle checkpoint triggered by nocodazole, a microtubule polymerization inhibitor. This is accomplished by disrupting the proper assembly of the mitotic checkpoint complex at the level of the Cdc20-BubR1 interaction. As a result, the spindle checkpoint complex fails to form and cells progress through mitosis without proper arrest in response to nocodazole. This ability to override the mitotic spindle checkpoint was found to be independent of AuroraA kinase activity. We conclude that maintenance of a functional balance between AuroraA and mitotic checkpoint proteins is essential for the proper progression through mitosis. This study therefore offers a possible explanation of how deregulation of AuroraA can contribute to genetic instability and tumorigenesis.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA; Prot Design Labs Inc, Fremont, CA 94555 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Seghezzi, W (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.	wolfgang.seghezzi@dnax.org						Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Bernard M, 1998, GENOMICS, V53, P406, DOI 10.1006/geno.1998.5522; Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; CHAN CSM, 1993, GENETICS, V135, P677; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; Giet R, 2000, EXP CELL RES, V258, P145, DOI 10.1006/excr.2000.4903; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hernando E, 2001, INT J CANCER, V95, P223, DOI 10.1002/1097-0215(20010720)95:4<223::AID-IJC1038>3.0.CO;2-L; Hixon ML, 2000, FRONT BIOSCI, V5, pD50, DOI 10.2741/Hixon; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kallio MJ, 2002, CURR BIOL, V12, P900, DOI 10.1016/S0960-9822(02)00887-4; Khan SH, 1998, CANCER RES, V58, P396; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Murata-Hori M, 2002, MOL BIOL CELL, V13, P1099, DOI 10.1091/mbc.01-09-0467; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Reis RM, 2001, ACTA NEUROPATHOL, V101, P297; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Sen S, 2002, JNCI-J NATL CANCER I, V94, P1320; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Zhang YK, 2001, MOL CELL BIOL, V21, P5190, DOI 10.1128/MCB.21.15.5190-5199.2001; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	40	52	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8293	8301		10.1038/sj.onc.1206873	http://dx.doi.org/10.1038/sj.onc.1206873			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614453				2022-12-28	WOS:000186541500008
J	Huang, HL; Fang, LW; Lu, SP; Chou, CK; Luh, TY; Lai, MZ				Huang, HL; Fang, LW; Lu, SP; Chou, CK; Luh, TY; Lai, MZ			DNA-damaging reagents induce apoptosis through reactive oxygen species-dependent Fas aggregation	ONCOGENE			English	Article						Fas; DNA damage; ROS; mitochondria; apoptosis	DEATH DOMAIN; CELL-DEATH; MEDIATED APOPTOSIS; T-LYMPHOCYTES; ACTIVATION; LIGAND; PROTEIN; MITOCHONDRIA; MECHANISM; EXPRESSION	DNA-damaging reagents may kill tumor cells through the generation of reactive oxygen species (ROS). Cytotoxic reagents may also induce apoptosis of cancer cells in Fas-FADD-dependent manners. In this study, we explored the possible link between these two apparently distinct pathways in T leukemia cell Jurkat. Our results demonstrated that gamma-irradiation, similar to cisplatin, induced apoptosis by triggering Fas aggregation and activating FADD-caspase-8 apoptotic cascade. The absence of caspase-8 or Fas greatly reduced the sensitivity to apoptosis mediated by DNA-damaging agents. In addition, apoptosis induced by cisplatin and gamma-irradiation, but not by Fas, was inhibited by ROS scavengers, including N-acetyl cysteine, MnTBAP, and C-60. Importantly, these ROS scavengers effectively prevented the clustering of Fas receptor induced by cisplatin and gamma-irradiation. Our results suggest that cisplatin and gamma-irradiation promote ROS production, which in turn contributes to Fas receptor aggregation and cell death. The novel coupling between ROS and Fas clustering likely plays a significant role in apoptosis triggered by DNA-damaging reagents in Fas-expressing leukemia cells.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Natl Def Med Sch, Grad Inst Life Sci, Taipei, Taiwan; Natl Yang Ming Univ, Dept Life Sci, Taipei, Taiwan; Acad Sinica, Inst Chem, Taipei, Taiwan	Academia Sinica - Taiwan; National Defense Medical Center; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Lai, MZ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mblai@ccvax.sinica.edu.tw	Lai, Ming-Zong/AAA-4408-2021	Luh, Tien-Yau/0000-0002-0415-6454; Lai, Ming-Zong/0000-0002-3237-4803				Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Aronis A, 2003, CELL DEATH DIFFER, V10, P335, DOI 10.1038/sj.cdd.4401150; Bauer MKA, 1998, J BIOL CHEM, V273, P8048, DOI 10.1074/jbc.273.14.8048; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Costa GL, 2000, J IMMUNOL, V164, P3581, DOI 10.4049/jimmunol.164.7.3581; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Dugan LL, 1997, P NATL ACAD SCI USA, V94, P9434, DOI 10.1073/pnas.94.17.9434; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hsu SC, 1998, BLOOD, V91, P2658, DOI 10.1182/blood.V91.8.2658.2658_2658_2663; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; Jayanthi S, 1999, MOL BRAIN RES, V72, P158, DOI 10.1016/S0169-328X(99)00216-8; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Lavastre V, 2002, J IMMUNOL, V168, P1419, DOI 10.4049/jimmunol.168.3.1419; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Malins DC, 2002, P NATL ACAD SCI USA, V99, P5937, DOI 10.1073/pnas.082111199; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Simizu S, 1998, J BIOL CHEM, V273, P26900, DOI 10.1074/jbc.273.41.26900; Stegh AH, 2000, MOL CELL BIOL, V20, P5665, DOI 10.1128/MCB.20.15.5665-5679.2000; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Um HD, 1996, J IMMUNOL, V156, P3469; van Wetering S, 2002, J CELL SCI, V115, P1837; Wang J, 2001, J BIOL CHEM, V276, P47763, DOI 10.1074/jbc.C100415200; Wang XD, 2001, GENE DEV, V15, P2922; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yeh JH, 1998, J EXP MED, V188, P1795, DOI 10.1084/jem.188.10.1795	49	139	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8168	8177		10.1038/sj.onc.1206979	http://dx.doi.org/10.1038/sj.onc.1206979			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603257				2022-12-28	WOS:000186403400011
J	Turner, SD; Tooze, R; Maclennan, K; Alexander, DR				Turner, SD; Tooze, R; Maclennan, K; Alexander, DR			Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase	ONCOGENE			English	Article						NPM-ALK; lymphoma; mouse model; Jun kinase	NON-HODGKINS-LYMPHOMA; RECEPTOR TYROSINE KINASE; ANAPLASTIC LYMPHOMA; C-JUN; T-CELL; SIGNAL-TRANSDUCTION; HELICOBACTER-PYLORI; NH2-TERMINAL KINASE; GENE REARRANGEMENT; EXPRESSION	Anaplastic large-cell lymphoma is associated with a chromosomal translocation generating an oncogenic fusion protein: the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). We have generated several independent lines of human NPM-ALK transgenic mice using the haematopoietic cell-specific Vav promoter. Lymphomas develop in two transgenic lines in which the Vav promoter regulates NPM-ALK expression. The transgenic line with higher copy number displays an early-onset phenotype in which all mice succumb to aggressive lymph node tumours with intestinal involvement, whereas the second line displays late-onset tumour development in the spleen and/or liver. Lymphomas from both lines are phenotypically distinct and display B-lineage characteristics with aberrant coexpression of myeloid markers. The NPM-ALK kinase is active in primary tumour tissue and forms a multimeric complex with tyrosine-phosphorylated proteins, that is, Shc. Jun and ERK kinase activities in tumours are elevated by up to 30-fold and fivefold, respectively, in comparison with sIgM-stimulated primary B cells. The new transgenic models provide a system for investigating the oncogenic events mediated by NPM-ALK in situ and a physiologically relevant context for developing tyrosine kinase inhibitor therapies of potential use in the clinic.	Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England; St James Univ Hosp, Canc Med Unit, Leeds LS9 7TF, W Yorkshire, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Saint James's University Hospital	Alexander, DR (corresponding author), Babraham Inst, Mol Immunol Programme, Lab Lymphocyte Signalling & Dev, Cambridge CB2 4AT, England.	denis.alexander@bbsrc.ac.uk	Turner, Suzanne Dawn/K-4405-2013	Turner, Suzanne Dawn/0000-0002-8439-4507; Tooze, Reuben/0000-0003-2915-7119				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Bost F, 1999, MOL CELL BIOL, V19, P1938; Chan PK, 1997, NUCLEIC ACIDS RES, V25, P1225, DOI 10.1093/nar/25.6.1225; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Corcoran AE, 1998, NATURE, V391, P904, DOI 10.1038/36122; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; Falini B, 2002, BLOOD, V99, P409, DOI 10.1182/blood.V99.2.409; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; HESTDAL K, 1991, J IMMUNOL, V147, P22; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jaffe ES, 2001, TUMOURS HAEMATOPOIET; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kanda M, 2001, LEUKEMIA LYMPHOMA, V42, P639, DOI 10.3109/10428190109099324; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LANIER LL, 1995, LEUCOCYTE TYPING, V5, P1398; Li YS, 1996, IMMUNITY, V5, P527, DOI 10.1016/S1074-7613(00)80268-X; Maes B, 2001, ANN ONCOL, V12, P853, DOI 10.1023/A:1011195708834; Mason DY, 1998, CANCER RES, V58, P1057; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1995, BLOOD, V86, P647; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Ogilvy S, 2003, J IMMUNOL, V171, P1792, DOI 10.4049/jimmunol.171.4.1792; Ogilvy S, 1999, BLOOD, V94, P1855; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; ONCIU M, 2003, IN PRESS BLOOD; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Pulford K, 1997, BLOOD, V89, P1394, DOI 10.1182/blood.V89.4.1394; Rabbitts TH, 1998, NEW ENGL J MED, V338, P192, DOI 10.1056/NEJM199801153380311; Sanderson RD, 2002, ANN HEMATOL, V81, P125, DOI 10.1007/s00277-002-0437-8; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Sebestyen A, 1999, BRIT J HAEMATOL, V104, P412, DOI 10.1046/j.1365-2141.1999.01211.x; STEWART M, 1993, INT J CANCER, V53, P1023; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; Weisenburger DD, 2001, AM J HEMATOL, V67, P172, DOI 10.1002/ajh.1102; Yang YM, 2003, CLIN CANCER RES, V9, P391; ZHUMABEKOV T, 1995, J IMMUNOL METHODS, V185, P133, DOI 10.1016/0022-1759(95)00124-S; ZUKERBERG LR, 1991, AM J PATHOL, V139, P475	56	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7750	7761		10.1038/sj.onc.1207048	http://dx.doi.org/10.1038/sj.onc.1207048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586401				2022-12-28	WOS:000186240200005
J	Motti, ML; Boccia, A; Belletti, B; Bruni, P; Troncone, G; Cito, L; Monaco, M; Chiappetta, G; Baldassarre, G; Palombini, L; Fusco, A; Viglietto, G				Motti, ML; Boccia, A; Belletti, B; Bruni, P; Troncone, G; Cito, L; Monaco, M; Chiappetta, G; Baldassarre, G; Palombini, L; Fusco, A; Viglietto, G			Critical role of cyclin D3 in TSH-dependent growth of thyrocytes and in hyperproliferative diseases of the thyroid gland	ONCOGENE			English	Article						cyclin D3; thyroid; TSH; p27(kip1)	CELL-CYCLE; FRTL-5 CELLS; IN-VITRO; CULTURED THYROCYTES; RAT; EXPRESSION; THYROTROPIN; PROLIFERATION; RECEPTOR; STIMULATION	We report that cyclin D3 is rate limiting for G1 progression in thyroid follicular cells and that its constitutive upregulation by chronic stimulation of the TSH/cAMP pathway plays a role in human and experimental hyperproliferative diseases of the thyroid gland. These conclusions are supported by in vitro and in vivo studies. In rat thyrocytes (PC Cl 3 cells), cyclin D3 expression is enhanced in response to activation of the TSH/cAMP pathway. Interference with the expression of G1 cyclins (in particular cyclin D3) by the antisense methodology strongly reduced TSH-dependent proliferation of PC Cl 3 cells, indicating that proper progression through G1 requires cyclin D3. Accordingly, PC Cl 3 cells engineered to overexpress cyclin D3 (PC- D3 cells) show enhanced growth rate and elude hormone-dependence and contact inhibition. Using an animal experimental model of thyroid stimulation, we demonstrate that cyclin D3 is a key mediator of TSH-dependent proliferation of thyroid follicular cells also in vivo. Cyclin D3 protein levels were higher in the thyrocytes from glands of propylthiouracil-treated rats compared with control animals. The increase in cyclin D3 expression occurred after the propylthiouracil-induced increase in TSH levels and preceded the burst of cell proliferation. Finally, we found that cyclin D3 protein is expressed in a fraction of human goiters but it is strongly overexpressed in most follicular adenomas.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Sci Morfol & Funz, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Naples Federico II	Viglietto, G (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol L Calif, CNR, Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	viglietto@sun.ceos.na.cnr.it	Belletti, Barbara/J-2028-2018; Baldassarre, Gustavo/K-1350-2016; Viglietto, Giuseppe/AAC-2852-2019	Belletti, Barbara/0000-0003-2249-0285; Baldassarre, Gustavo/0000-0002-9750-8825; Viglietto, Giuseppe/0000-0003-2327-7515; Fusco, Alfredo/0000-0003-3332-5197				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BERLINGIERI MT, 1990, BIOCHEM BIOPH RES CO, V173, P172, DOI 10.1016/S0006-291X(05)81037-X; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Carneiro C, 1998, ONCOGENE, V16, P1455, DOI 10.1038/sj.onc.1201662; Coppee F, 1998, ONCOGENE, V17, P631, DOI 10.1038/sj.onc.1201966; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234; Depoortere F, 1998, J CELL BIOL, V140, P1427, DOI 10.1083/jcb.140.6.1427; Dremier S, 2002, ANN NY ACAD SCI, V968, P106, DOI 10.1111/j.1749-6632.2002.tb04330.x; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Florio T, 2001, MOL ENDOCRINOL, V15, P1838, DOI 10.1210/me.15.10.1838; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; HEDINGER C, 1993, INT HISTOLOGICAL CLA; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; Kimura T, 1999, EUR J ENDOCRINOL, V140, P94, DOI 10.1530/eje.0.1400094; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; Medina DL, 1999, ENDOCRINOLOGY, V140, P87, DOI 10.1210/en.140.1.87; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Pedrinola F, 2001, THYROID, V11, P15, DOI 10.1089/10507250150500612; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; ROGNONI JB, 1984, ACTA ENDOCRINOL-COP, V105, P40, DOI 10.1530/acta.0.1050040; Saiz AD, 2002, J PATHOL, V198, P157, DOI 10.1002/path.1185; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; Shaughnessy J, 2001, BLOOD, V98, P217, DOI 10.1182/blood.V98.1.217; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SMEDS S, 1983, LAB INVEST, V48, P285; Sonoki T, 2001, BLOOD, V98, P2837, DOI 10.1182/blood.V98.9.2837; Viglietto G, 1999, EUR J ENDOCRINOL, V140, P597, DOI 10.1530/eje.0.1400597; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILSON JD, 1989, THYROID TXB ENDOCRIN; WOLLMAN SH, 1978, ENDOCRINOLOGY, V103, P2306, DOI 10.1210/endo-103-6-2306; WYNFORDTHOMAS D, 1982, J ENDOCRINOL, V94, P131, DOI 10.1677/joe.0.0940131; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036	37	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7576	7586		10.1038/sj.onc.1207055	http://dx.doi.org/10.1038/sj.onc.1207055			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576819				2022-12-28	WOS:000186113000004
J	Freemantle, SJ; Spinella, MJ; Dmitrovsky, E				Freemantle, SJ; Spinella, MJ; Dmitrovsky, E			Retinoids in cancer therapy and chemoprevention: promise meets resistance	ONCOGENE			English	Review						retinoids; retinoid resistance; acute promyelocytic leukemia; chemoprevention	ACUTE-PROMYELOCYTIC-LEUKEMIA; ACID-RECEPTOR-BETA; HUMAN EMBRYONAL CARCINOMA; CELL LUNG-CANCER; PML-RAR-ALPHA; HISTONE-DEACETYLASE INHIBITORS; ACUTE MYELOID-LEUKEMIA; BINDING PROTEIN-II; INDUCED GROWTH ARREST; BREAST-CANCER	Retinoids ( natural and synthetic derivatives of vitamin A) signal potent differentiation and growth-suppressive effects in diverse normal, premalignant, and malignant cells. A strong rationale exists for the use of retinoids in cancer treatment and chemoprevention based on preclinical, epidemiological, and early clinical findings. Despite the success of all-trans-retinoic acid (RA)-based differentiation therapy in acute promyelocytic leukemia (APL), the broad promise of retinoids in the clinic has not yet been realized. In addition to the expected limited activity of any single therapeutic agent, translation of retinoid activities from the laboratory to the clinic has met with intrinsic or acquired retinoid resistance. Evidence suggests that solid tumors develop intrinsic resistance to retinoids during carcinogenesis. In contrast, relapse of APL is often associated with acquired resistance to retinoid maturation induction. This review discusses what is known about retinoid resistance mechanisms in cancer therapy and chemoprevention. Strategies to overcome this resistance will be discussed, including combination therapy with other differentiation-inducing, cytotoxic or chromatin-remodeling agents, as well as the use of receptor-selective and nonclassical retinoids. Opportunities exist in the post-genomic era to bypass resistance to classical retinoids by identifying target genes and associated pathways that directly mediate the antineoplastic effects of retinoids. In this regard, the retinoids are useful pharmacological tools to reveal important pathways targeted in cancer therapy and chemoprevention.	Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Dartmouth College	Freemantle, SJ (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03756 USA.	sarah.freemantle@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [R01CA062275, K01CA075154, R01CA087546] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 62275, R01 CA 87546, R01 CA062275, K01 CA 75154-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albanell J, 1996, CANCER RES, V56, P1503; Bender CM, 1998, CANCER RES, V58, P95; Benedetti L, 1997, BLOOD, V90, P1175, DOI 10.1182/blood.V90.3.1175.1175_1175_1185; Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Berg WJ, 1999, CLIN CANCER RES, V5, P1671; Berg WJ, 2000, SEMIN ONCOL, V27, P234; Blaner W.S., 1999, HANDB EXP PHARM, P117; Brabender J, 2002, CLIN CANCER RES, V8, P438; Brigati C, 1999, LEUKEMIA RES, V23, P105, DOI 10.1016/S0145-2126(98)00145-3; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Budhu AS, 2002, MOL CELL BIOL, V22, P2632, DOI 10.1128/MCB.22.8.2632-2641.2002; Calleja E M, 2000, Curr Oncol Rep, V2, P519, DOI 10.1007/s11912-000-0105-x; Carapeti M, 1998, BLOOD, V91, P3127, DOI 10.1182/blood.V91.9.3127.3127_3127_3133; Castillo L, 1997, CLIN CANCER RES, V3, P2137; Cheer S M, 2000, Am J Clin Dermatol, V1, P307, DOI 10.2165/00128071-200001050-00005; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; COMIC M, 1994, LEUKEMIA, V8, P914; Conley B, 2000, J CLIN ONCOL, V18, P275, DOI 10.1200/JCO.2000.18.2.275; Cote S, 1998, ANTI-CANCER DRUG, V9, P743; Cote S, 1997, ANTI-CANCER DRUG, V8, P56; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; DELVA L, 1993, BLOOD, V82, P2175; Demary K, 2001, ENDOCRINOLOGY, V142, P2600, DOI 10.1210/en.142.6.2600; DERMIME S, 1993, BLOOD, V82, P1573; Dimberg A, 2002, BLOOD, V99, P2199, DOI 10.1182/blood.V99.6.2199; Dokmanovic M, 2002, CANCER BIOL THER, V1, P24, DOI 10.4161/cbt.1.1.35; Dragnev KH, 2001, ANN NY ACAD SCI, V952, P13, DOI 10.1111/j.1749-6632.2001.tb02724.x; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Esteller M, 2002, CANCER RES, V62, P5902; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Ferrara FF, 2001, CANCER RES, V61, P2; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Gallagher RE, 2002, LEUKEMIA, V16, P1940, DOI 10.1038/sj.leu.2402719; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GUERNSEY DL, 1988, INT J CANCER, V42, P576, DOI 10.1002/ijc.2910420419; Hayashi K, 2001, DIFFERENTIATION, V68, P13, DOI 10.1046/j.1432-0436.2001.068001013.x; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Heald P, 2000, Clin Lymphoma, V1 Suppl 1, pS45, DOI 10.3816/CLM.2000.s.009; Hong Waun Ki, 1994, P597; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Houldsworth J, 2002, CELL GROWTH DIFFER, V13, P257; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Khuri FR, 2000, SEMIN SURG ONCOL, V18, P100, DOI 10.1002/(SICI)1098-2388(200003)18:2<100::AID-SSU3>3.3.CO;2-0; Kitareewan S, 2002, P NATL ACAD SCI USA, V99, P3806, DOI 10.1073/pnas.052011299; Kitareewan S, 1999, ONCOGENE, V18, P5747, DOI 10.1038/sj.onc.1202981; KITAREEWAN S, 2003, RETINOIDS CANC PREVE, V1; Kizaki M, 1996, BLOOD, V87, P725, DOI 10.1182/blood.V87.2.725.bloodjournal872725; Kwong J, 2002, CLIN CANCER RES, V8, P131; LAMPRON C, 1995, DEVELOPMENT, V121, P539; Lemon B, 2001, NATURE, V414, P924, DOI 10.1038/414924a; LI YP, 1994, BLOOD, V83, P3298; Lian Z, 2001, BLOOD, V98, P513, DOI 10.1182/blood.V98.3.513; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; LIPPMAN SM, 1995, CANCER RES, V55, P16; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; Lubbert M, 2000, CURR TOP MICROBIOL, V249, P135; Matsushita H, 1998, BLOOD, V91, P2452, DOI 10.1182/blood.V91.7.2452.2452_2452_2458; Maurer BJ, 2000, JNCI-J NATL CANCER I, V92, P1897, DOI 10.1093/jnci/92.23.1897; McCaffery P, 2000, CYTOKINE GROWTH F R, V11, P233, DOI 10.1016/S1359-6101(00)00002-2; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MILLER WH, 1990, ONCOGENE, V5, P511; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; MOASSER MM, 1994, ONCOGENE, V9, P833; MOGHAL N, 1995, MOL CELL BIOL, V15, P3945; Moon Richard C., 1994, P573; MOORE DM, 1994, SEMIN HEMATOL, V31, P31; Mori J, 1999, JPN J CANCER RES, V90, P660, DOI 10.1111/j.1349-7006.1999.tb00798.x; Naar AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nason-Burchenal K, 1998, ONCOGENE, V17, P1759, DOI 10.1038/sj.onc.1202075; NasonBurchenal K, 1997, DIFFERENTIATION, V61, P321, DOI 10.1046/j.1432-0436.1997.6150321.x; NASONBURCHENAL K, 1999, HANDB EXP PHARM, V139, P301; NASONBURCHENAL K, 1996, MOL BIOL CANC, P1547; Nau H, 1999, HANDB EXP PHARM, V139, P153; Nehme A, 2001, BRIT J CANCER, V84, P1571, DOI 10.1054/bjoc.2001.1818; Nervi C, 1998, BLOOD, V92, P2244; Njar VCO, 2002, MINI-REV MED CHEM, V2, P261, DOI 10.2174/1389557023406223; Nowfar S, 2002, BREAST CANCER RES TR, V72, P33, DOI 10.1023/A:1014912919470; Ozpolat B, 2002, LEUKEMIA LYMPHOMA, V43, P933, DOI 10.1080/10428190290021678; Ozpolat B, 2001, J BIOL REG HOMEOS AG, V15, P107; PAIETTA E, 1994, LEUKEMIA, V8, P968; Palmisano WA, 2000, CANCER RES, V60, P5954; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; Pendino F, 2002, LEUKEMIA, V16, P826, DOI 10.1038/sj.leu.2402470; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; Privalsky ML, 2001, CURR TOP MICROBIOL, V254, P117; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rastinejad F, 2001, CURR OPIN STRUC BIOL, V11, P33, DOI 10.1016/S0959-440X(00)00165-2; Reid GK, 2002, CURR OPIN MOL THER, V4, P130; Reynolds CP, 2001, HEMATOL ONCOL CLIN N, V15, P867, DOI 10.1016/S0889-8588(05)70256-2; Reynolds CP, 2000, MED PEDIATR ONCOL, V35, P597, DOI 10.1002/1096-911X(20001201)35:6<597::AID-MPO23>3.0.CO;2-B; Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068; ROBERTSON KA, 1992, BLOOD, V80, P1885; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Silverman LR, 2002, J CLIN ONCOL, V20, P2429, DOI 10.1200/JCO.2002.04.117; Sirchia SM, 2002, CANCER RES, V62, P2455; Slack James L., 1999, Current Opinion in Oncology, V11, P9, DOI 10.1097/00001622-199901000-00003; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Suh N, 2002, CLIN CANCER RES, V8, P3270; Suh YA, 2002, CANCER RES, V62, P3945; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Takeshita A, 2000, BRIT J HAEMATOL, V108, P90, DOI 10.1046/j.1365-2141.2000.01823.x; Tallman Martin S, 2002, Curr Oncol Rep, V4, P381, DOI 10.1007/s11912-002-0031-1; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; TESTA U, 1994, CANCER RES, V54, P4508; Torrisi R, 2000, Curr Oncol Rep, V2, P263, DOI 10.1007/s11912-000-0077-x; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Urnov FD, 2001, CURR TOP MICROBIOL, V254, P1; Van Heusden J, 2002, BRIT J CANCER, V86, P605, DOI 10.1038/sj.bjc.6600056; VANDERBURG B, 1993, MOL CELL ENDOCRINOL, V91, P149, DOI 10.1016/0303-7207(93)90267-N; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang DL, 2000, CLIN CANCER RES, V6, P3636; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826; Widschwendter M, 1997, CANCER RES, V57, P4158; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; XU XC, 1994, CANCER RES, V54, P3580; Yoshida H, 1996, CANCER RES, V56, P2945; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zhou DC, 1998, CANCER RES, V58, P5770; Zujewski J, 2002, ENVIRON MOL MUTAGEN, V39, P264, DOI 10.1002/em.10054	148	256	271	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7305	7315		10.1038/sj.onc.1206936	http://dx.doi.org/10.1038/sj.onc.1206936			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576840				2022-12-28	WOS:000186112500005
J	Ferber, MJ; Thorland, EC; Brink, AA; Rapp, AK; Phillips, LA; McGovern, R; Gostout, BS; Cheung, TH; Chung, TKH; Fu, WY; Smith, DI				Ferber, MJ; Thorland, EC; Brink, AA; Rapp, AK; Phillips, LA; McGovern, R; Gostout, BS; Cheung, TH; Chung, TKH; Fu, WY; Smith, DI			Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma	ONCOGENE			English	Article						common fragile sites; cervical cancer; human papillomavirus; viral integration; c-myc	COMMON FRAGILE SITES; VIRAL INTEGRATION; E2 PROTEIN; CELLS; HPV16; CLONING; GENE; DNA; PHOSPHORYLATION; PROTOONCOGENE	The development of cervical cancer is highly associated with human papillomavirus (HPV) infection. Greater than 99% of all cervical tumors contain HPV DNA. Integration of high-risk HPV has been temporally associated with the acquisition of a malignant phenotype. Recent work from our lab has shown that HPV16, the most common high-risk HPV associated with cervical carcinoma, preferentially integrates at loci containing human common fragile sites (CFSs). CFSs are regions of genomic instability that have also been associated with deletions, translocations, and gene amplification during cancer development. The current work shows that HPV18, the second most prevalent high-risk HPV type found in cervical tumors, preferentially targets the CFSs. We identified 27 unique HPV18 integrations in cervical tumors, of which 63% ( P<0.001) occur in CFSs. However, the distribution of HPV18 integrations found were profoundly different from those found for HPV16. Specifically, 30% of all HPV18 integrations occurred within the chromosomal band 8q24 near the c-myc proto-oncogene. None of the HPV16 integrations occurred in this region. Previous low-resolution mapping suggested that c-myc may be a target of HPV integration. Our data at nucleotide resolution confirm that in HPV18-positive cervical tumors, the region surrounding c-myc is indeed a hot spot of viral integration. These results demonstrate that CFSs are preferred sites of integration for HPV18 in cervical tumors. In addition, we have identified multiple cellular genes that have been disrupted by HPV18 integration in cervical tumors. Our results suggest that the sites of HPV18 integration are nonrandom and may play an important role in the development of cervical tumors.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Obstet & Gynaecol, Rochester, MN 55905 USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Mayo Clinic; Mayo Clinic; Chinese University of Hong Kong; Prince of Wales Hospital	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		CHUNG, Tony/0000-0002-6362-8546	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082; Bechtold V, 2003, J VIROL, V77, P2021, DOI 10.1128/JVI.77.3.2021-2028.2003; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Boyer SN, 1996, CANCER RES, V56, P4620; Brink AATP, 2002, CANCER GENET CYTOGEN, V134, P145, DOI 10.1016/S0165-4608(01)00620-3; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHO KR, 1998, GENETIC BASIS HUMAN, P631; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenspan DL, 1997, CANCER RES, V57, P4692; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koopman LA, 1999, CANCER RES, V59, P5615; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; LAZO PA, 1989, CANCER RES, V49, P4305; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Macville M, 1999, CANCER RES, V59, P141; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pillutla RC, 1998, GENOMICS, V54, P351, DOI 10.1006/geno.1998.5604; POPESCU NC, 1989, CANCER GENET CYTOGEN, V42, P157, DOI 10.1016/0165-4608(89)90084-8; POPESCU NC, 1990, HUM GENET, V84, P383; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Ratsch A, 2002, EXP CELL RES, V273, P12, DOI 10.1006/excr.2001.5429; Sarkar G, 1993, PCR Methods Appl, V2, P318; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwartz SM, 2001, J CLIN ONCOL, V19, P1906, DOI 10.1200/JCO.2001.19.7.1906; SHAH KV, 1996, FIELDS VIROLOGY, P2077; SIMMONS DL, 1992, J IMMUNOL, V148, P267; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; Zimonjic DB, 1997, CANCER RES, V57, P1166	57	134	142	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7233	7242		10.1038/sj.onc.1207006	http://dx.doi.org/10.1038/sj.onc.1207006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562053				2022-12-28	WOS:000185955000016
J	Tagawa, H; Karnan, S; Kasugai, Y; Tuzuki, S; Suzuki, R; Hosokawa, Y; Seto, M				Tagawa, H; Karnan, S; Kasugai, Y; Tuzuki, S; Suzuki, R; Hosokawa, Y; Seto, M			MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8	ONCOGENE			English	Article						MASL1; lymphoma; oncogene; 8p23; translocation; amplification	NON-HODGKIN-LYMPHOMA; CHROMOSOME 8P; FREQUENT LOSS; CYCLIN D1; CANCER; GENE; LYMPHOMA/LEUKEMIA; CARCINOMA; SEQUENCES; PRAD1	Genetic amplification at chromosome 8p23.1 has been reported in some solid tumors. Translocation of 8p23.1 has also been reported in hematological malignancies and head and neck squamous cell cancer. In an attempt to clarify whether this translocation is implicated in lymphomagenesis, we performed FISH analysis of the immunoblastic B-cell lymphoma cell line OCI-LY8, which has chromosome translocation at 8p23.1, with various BAC clones. We found split signals on BAC, RP11-18L2 where the MASL1 gene is located. This translocation was found to produce a chimeric transcript of MASL1 exon 1 with a cryptic exon from the genome region at 14q21. Our study indicates that MASL1 is not only a target gene for genomic amplification but also for chromosomal translocation. Since tumorigenic activity of the MASL1 has not been proven, its in vitro transforming activity was studied and in vivo nude mice assay were performed. Although no in vitro transforming activity was detected by focus formation, the in vivo tumorigenesis assay with nude mice showed that both MASL1 and chimeric MASL1 possess tumorigenic activity. This suggests that MASL1 is an important oncogene not only for solid tumors but also for hematologic malignancies.	Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Aichi Cancer Center	Seto, M (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Med, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	mseto@aichi-cc.jp		Kasugai, Yumiko/0000-0003-4764-4455; Suzuki, Ritsuro/0000-0002-5974-7614				Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P328, DOI 10.1002/(SICI)1098-2264(199812)23:4<328::AID-GCC8>3.0.CO;2-M; CHANG H, 1992, J CLIN INVEST, V89, P1014, DOI 10.1172/JCI115642; EMI M, 1992, CANCER RES, V52, P5368; Gilhuis HJ, 2000, CLIN NEUROL NEUROSUR, V102, P203, DOI 10.1016/S0303-8467(00)00112-8; Jin YS, 2001, CANCER GENET CYTOGEN, V130, P111, DOI 10.1016/S0165-4608(01)00476-9; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOMATSU H, 1994, BLOOD, V84, P1226; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; Mehra S, 2002, GENE CHROMOSOME CANC, V33, P225, DOI 10.1002/gcc.10025; Nupponen NN, 2000, MICROSC RES TECHNIQ, V51, P456, DOI 10.1002/1097-0029(20001201)51:5<456::AID-JEMT8>3.0.CO;2-H; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Sakabe T, 1999, CANCER RES, V59, P511; Sakakura C, 1999, GENE CHROMOSOME CANC, V24, P299, DOI 10.1002/(SICI)1098-2264(199904)24:4<299::AID-GCC2>3.0.CO;2-U; SETO M, 1992, ONCOGENE, V7, P1401; SIN C, 1979, P NATL ACAD SCI USA, V76, P5714; Stock C, 2000, GENE CHROMOSOME CANC, V28, P329, DOI 10.1002/1098-2264(200007)28:3<329::AID-GCC11>3.0.CO;2-F; Sunwoo JB, 1996, GENE CHROMOSOME CANC, V16, P164, DOI 10.1002/(SICI)1098-2264(199607)16:3<164::AID-GCC2>3.0.CO;2-X; Tagawa H, 2002, GENE CHROMOSOME CANC, V34, P175, DOI 10.1002/gcc.10057; Tanner MM, 1998, AM J PATHOL, V153, P191, DOI 10.1016/S0002-9440(10)65560-5; TWEEDDALE ME, 1987, BLOOD, V69, P1307; Wong N, 2000, HUM PATHOL, V31, P771, DOI 10.1053/hupa.2000.7625	22	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2576	2581		10.1038/sj.onc.1207352	http://dx.doi.org/10.1038/sj.onc.1207352			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691450				2022-12-28	WOS:000220558000016
J	Bar, J; Cohen-Noyman, E; Geiger, B; Oren, M				Bar, J; Cohen-Noyman, E; Geiger, B; Oren, M			Attenuation of the p53 response to DNA damage by high cell density	ONCOGENE			English	Article						p53; cell density; microenvironment; DNA damage; apoptosis	TUMOR-SUPPRESSOR; BETA-CATENIN; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; APOPTOTIC RESPONSE; CONTACT INHIBITION; GROWTH SUPPRESSION; E-CADHERIN; S-PHASE; CYCLE	The p53 tumor suppressor is critical for preventing cancer progression. Numerous observations suggest that p53 function can be modulated by the cells' microenvironment. We addressed specifically the impact of cell crowding on the induction of p53 by DNA damage. We report that cell crowding attenuates markedly p53 upregulation, transcriptional activation and subsequent p53- dependent apoptosis following exposure to genotoxic stress. The p53 protein remains short- lived in confluent cultures regardless of the extent of DNA damage, even though it undergoes efficient phosphorylation on the mouse equivalent of human p53 serine 15. This inhibitory effect of cell crowding is not a secondary consequence of density-dependent cell cycle arrest ( contact inhibition). Microscopic examination indicates that dense cultures display prominent cadherin- mediated cell - cell junctions, and only poor cell - matrix focal adhesions, whereas sparse cells possess conspicuous matrix adhesions and essentially no cell - cell contacts. High- density cell culture might recapitulate the microenvironment of cells in a living organism, where the response of p53 to DNA damage is reported to be low in some organs and ages. The impact of cell density on p53 activation may have important bearings on the involvement of p53 in tumor suppression and the cellular response to anticancer therapy.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, POB26, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il	Bar, Jair/AAS-5743-2021	Bar, Jair/0000-0002-1224-3646; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bachelder RE, 1999, J BIOL CHEM, V274, P20733, DOI 10.1074/jbc.274.29.20733; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAUPT Y, 1995, ONCOGENE, V10, P1563; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Hussain SP, 2001, LUNG CANCER, V34, pS7, DOI 10.1016/S0169-5002(01)00339-7; Ilic D, 1998, J CELL BIOL, V143, P547; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Komarova EA, 1997, CANCER RES, V57, P5217; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Levenberg S, 1999, ONCOGENE, V18, P869, DOI 10.1038/sj.onc.1202396; Levenberg S, 1998, J CELL SCI, V111, P347; Lewis JM, 2002, P NATL ACAD SCI USA, V99, P3627, DOI 10.1073/pnas.062698499; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; MacCallum DE, 1996, ONCOGENE, V13, P2575; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nigro JM, 1997, CANCER RES, V57, P3635; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; RITTLING SR, 1992, ONCOGENE, V7, P935; Rubin H, 2001, CANCER RES, V61, P799; Sadot E, 2002, J CELL SCI, V115, P2771; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SHAULSKY G, 1990, ONCOGENE, V5, P1707; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557; von Schlippe M, 2000, J CELL SCI, V113, P425; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang WJ, 2002, J CELL BIOL, V159, P169, DOI 10.1083/jcb.200204050; Wilson JW, 1998, AM J PATHOL, V153, P899, DOI 10.1016/S0002-9440(10)65631-3; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	75	39	40	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2128	2137		10.1038/sj.onc.1207325	http://dx.doi.org/10.1038/sj.onc.1207325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14755247	Bronze			2022-12-28	WOS:000220280900002
J	Arnott, CH; Scott, KA; Moore, RJ; Robinson, SC; Thompson, RG; Balkwill, FR				Arnott, CH; Scott, KA; Moore, RJ; Robinson, SC; Thompson, RG; Balkwill, FR			Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development	ONCOGENE			English	Article						TNFR1; TNFR2; keratinocyte; GM-CSF; MMP-9; c-jun	NECROSIS-FACTOR RECEPTOR; DEFICIENT LIVER-REGENERATION; FACTOR-KAPPA-B; MOUSE SKIN; C-JUN; TRANSGENIC MICE; CARCINOGENESIS; CELLS; LIGAND; P55	Keratinocyte-derived TNF-alpha acts as an endogenous tumour promoter and can also regulate AP-1 activity in mouse epidermis. To gain further insight into TNF-alpha signalling during skin tumour formation, mice deficient in TNFR1 (TNFR1(-/-) mice) or TNFR2 (TNFR2(-/-) mice) were subjected to chemical carcinogenesis. Tumour multiplicity was significantly reduced in TNFR1(-/-) and TNFR2(-/-) mice compared to wild-type (wt) mice, suggesting that both receptors have protumour activity. However, TNFR1(-/-) mice were markedly more resistant to tumour development than TNFR2(-/-) mice indicating that TNFR1 is the major mediator of TNF-alpha-induced tumour formation. TNFR1 and TNFR2 were both expressed in wt epidermis during tumour promotion and by primary keratinocytes in vitro. TPA-induced c-Jun expression was transient in TNFR1(-/-) and TNFR2(-/-) compared to wt epidermis and this was reflected by reduced induction of the AP-1-responsive genes granulocyte/macrophage-colony stimulating factor, matrix metalloproteinase-9 and matrix metalloproteinase-3. The se genes were differentially regulated in TNFR1(-/-) compared to TNFR2(-/-) epidermis, suggesting that the TNF-alpha receptors act independently via different AP-1 complexes to transduce TNF-alpha signals during tumour promotion. In addition, TNFR2 cooperated with TNFR1 to optimise TNFR1-mediated TNF-alpha bioactivity on keratinocytes in vitro. Our data provide further insight into TNF-alpha signalling in malignancy and provide some rationale for the use of TNF-alpha antagonists in the treatment of cancer.	Barts & London Queen Marys Sch Med & Dent, John Vane Sci Ctr, Canc Res UK Translat Oncol Lab, London EC1M 6BQ, England	Cancer Research UK; University of London; Queen Mary University London	Scott, KA (corresponding author), Barts & London Queen Marys Sch Med & Dent, John Vane Sci Ctr, Canc Res UK Translat Oncol Lab, Charterhouse Sq, London EC1M 6BQ, England.	kate.scott@cancer.org.uk		Balkwill, Frances/0000-0002-5587-9759				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnott CH, 2002, ONCOGENE, V21, P4728, DOI 10.1038/sj.onc.1205588; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan FKM, 2000, EUR J IMMUNOL, V30, P652; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; Hulboy DL, 2001, MOL CELL BIOL, V21, P5478, DOI 10.1128/MCB.21.16.5478-5487.2001; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kitakata H, 2002, CANCER RES, V62, P6682; Knight B, 2000, J EXP MED, V192, P1809, DOI 10.1084/jem.192.12.1809; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Littlejohn AF, 2003, BIOCHEM PHARMACOL, V65, P91, DOI 10.1016/S0006-2952(02)01443-0; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Mann A, 2001, CANCER RES, V61, P2311; Medvedev AE, 1996, J BIOL CHEM, V271, P9778, DOI 10.1074/jbc.271.16.9778; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mori R, 2002, FASEB J, V16, P963, DOI 10.1096/fj.01-0776com; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Mukhopadhyay A, 2001, J BIOL CHEM, V276, P31906, DOI 10.1074/jbc.M105252200; Papathoma AS, 2001, MOL CARCINOGEN, V31, P74, DOI 10.1002/mc.1042; Peschon JJ, 1998, J IMMUNOL, V160, P943; Pinckard JK, 1997, J BIOL CHEM, V272, P10784; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; Rutberg SE, 1996, ONCOGENE, V13, P167; Scott KA, 2003, MOL CANCER THER, V2, P445; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Suganuma M, 1999, CANCER RES, V59, P4516; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yamada Y, 1998, AM J PATHOL, V152, P1577; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhong SP, 2001, CANCER RES, V61, P4084; Zhuang LH, 1999, J IMMUNOL, V162, P1440	43	152	157	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1902	1910		10.1038/sj.onc.1207317	http://dx.doi.org/10.1038/sj.onc.1207317			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14661063				2022-12-28	WOS:000220129500012
J	Fan, YJ; Rayet, B; Gelinas, C				Fan, YJ; Rayet, B; Gelinas, C			Divergent C-terminal transactivation domains of Rel/NF-kappa B proteins are critical determinants of their oncogenic potential in lymphocytes	ONCOGENE			English	Article						NF-kappa B; Rel; cancer; transformation; transcription	HODGKIN/REED-STERNBERG CELLS; CHICKEN SPLEEN-CELLS; DISEASE TUMOR-CELLS; V-REL; DNA-BINDING; TRANSCRIPTION FACTORS; BREAST-CANCER; CYTOPLASMIC RETENTION; TRANSFORMING ACTIVITY; SELECTIVE ACTIVATION	rel/nf-kappaB genes are amplified, overexpressed, or constitutively activated in many human hematopoietic tumors; however, the molecular mechanisms by which they contribute to tumorigenesis remain to be determined. Here, we explored the oncogenic potential of cellular Rel/NF-kappaB proteins in vitro and in vivo. We show that overexpression of wild-type mouse and human c-rel genes suffices to malignantly transform primary spleen cells in stringent soft agar assays and produce fatal tumors in vivo. In contrast relA and a constitutively active form of IKKbeta did not. Importantly, a hybrid RelA protein with its C-terminal transactivation domain substituted by that of v-Rel was potently oncogenic in vitro and in vivo. The transactivation domain of v-Rel selectively conferred an oncogenic phenotype upon the Rel homology domain (RHD) of RelA, but not to the more divergent RHDs of p50/NF-kappaB1, p52/NF-kappaB2, or RelB. Collectively, our results highlight important differences in the intrinsic oncogenic activity of mammalian c-Rel and RelA proteins, and indicate that critical determinants of their differential oncogenicity reside in their divergent transactivation domains. These findings provide experimental evidence for a role of mammalian Rel/NF-kappaB factors in leukemia/lymphomagenesis in an in vivo animal model, and are consistent with the implication of c-rel in many human lymphomas.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Gelinas, C (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu			NCI NIH HHS [CA54999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DOUGHERTY JP, 1989, J VIROL, V63, P3209, DOI 10.1128/JVI.63.7.3209-3212.1989; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; Fujii M, 1996, ONCOGENE, V12, P2193; Gapuzan MER, 2002, ONCOGENE, V21, P2484, DOI 10.1038/sj.onc.1205333; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Heinlein CA, 1999, J BIOL CHEM, V274, P16147, DOI 10.1074/jbc.274.23.16147; Hinz M, 2002, J EXP MED, V196, P605, DOI 10.1084/jem.20020062; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; HOFFMANN A, 2003, IN PRESS EMBO J, V22; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; KUCHARCZAK J, IN PRESS ONCOGENE; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; LU D, 1991, ONCOGENE, V6, P1235; MCDONNELL PC, 1992, ONCOGENE, V7, P163; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Ricca A, 2001, BRIT J CANCER, V85, P1914, DOI 10.1054/bjoc.2001.2174; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Sonenshein GE, 1997, SEMIN CANCER BIOL, V8, P113, DOI 10.1006/scbi.1997.0062; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297; White DW, 1996, ONCOGENE, V13, P891; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; Zurovec M, 1998, ONCOGENE, V16, P3133, DOI 10.1038/sj.onc.1201860	84	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1030	1042		10.1038/sj.onc.1207221	http://dx.doi.org/10.1038/sj.onc.1207221			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647412				2022-12-28	WOS:000188749900002
J	Luo, Q; Li, J; Cenkci, B; Kretzner, L				Luo, Q; Li, J; Cenkci, B; Kretzner, L			Autorepression of c-myc requires both initiator and E2F-binding site elements and cooperation with the p107 gene product	ONCOGENE			English	Article						transcriptional repression; c-Myc; Mxi1; p107; initiator; E2F binding sites	TRANSCRIPTIONAL REPRESSION; NEGATIVE AUTOREGULATION; RETINOBLASTOMA PROTEIN; GROWTH SUPPRESSION; CELL-PROLIFERATION; TRANS-ACTIVATION; IN-VIVO; PROMOTER; MAX; E2F	Myc proteins are transcriptional activators, but also repress transcription through initiator (Inr) elements. Repression requires the conserved Myc Box II, but the cis-acting element(s) required for c-myc autorepression have eluded definition. Since the gene has a candidate Inr at the P2 promoter, we tested whether Myc autorepression operates through the Inr/BoxII mechanism. Overexpression of c-Myc but not a Box II deletion mutation represses both c-myc P2 reporter genes and endogenous c-myc, as does Mxi1 expression. Only 45 nucleotides surrounding the P2 start suffice to mediate autorepression, but Myc and Mxi1 also downregulate P2 Inr mutations, suggesting other core promoter sequence requirements for autorepression. We tested the importance of conserved E2F sites, based on known Myc interaction with the pRb-related p107 and on the transrepressive effects of Rb family proteins. Myc, Mxi1, and p107 repress c-myc somewhat less well in the absence of E2F binding sites, while an E2F + Inr double mutation is not repressed at all by these gene products. Further, Myc repression at the c-myc P2 core promoter is augmented by p107, but not by pRb or p130, nor by p107 lacking the conserved pocket domain. Our data suggest that Myc autorepression requires both the c-myc Inr and E2F sites in cis, as well as p107 in trans. Consistent with this, we found that retrovirally transduced c-Myc cannot downregulate endogenous c-myc in p107-null fibroblasts, and show evidence that both Myc and p107 are present in a complex assembled at the c-myc P2 core promoter.	Univ S Dakota, Sch Med, Dept Cellular & Mol Biol, Div Basic Biomed Sci, Vermillion, SD 57069 USA	University of South Dakota	Kretzner, L (corresponding author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.	lkretzner@coh.org						AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIPP M, 1989, ONCOGENE, V4, P535; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; MANGO SE, 1989, MOL CELL BIOL, V9, P3482, DOI 10.1128/MCB.9.8.3482; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; Peters MA, 1998, CRIT REV EUKAR GENE, V8, P277, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.30; Roy AL, 2001, GENE, V274, P1, DOI 10.1016/S0378-1119(01)00625-4; Smale ST, 1998, COLD SPRING HARB SYM, V63, P21, DOI 10.1101/sqb.1998.63.21; SPENCER CA, 1991, ADV CANCER RES, V56, P1; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Starostik P, 1996, MOL CELL BIOL, V16, P3606; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693; Wang JYJ, 1997, CURR OPIN GENET DEV, V7, P39, DOI 10.1016/S0959-437X(97)80107-4; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	46	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1088	1097		10.1038/sj.onc.1207225	http://dx.doi.org/10.1038/sj.onc.1207225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14716294				2022-12-28	WOS:000188749900007
J	Young, AP; Longmore, GD				Young, AP; Longmore, GD			Differences in stability of repressor complexes at promoters underlie distinct roles for Rb family members	ONCOGENE			English	Article						Rb; E2F; p130; p107; tumor suppression; repressor complex stability	RETINOBLASTOMA PROTEIN-PHOSPHORYLATION; E2F-INDUCED S-PHASE; CELL-CYCLE; HISTONE H3; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; E2F PROTEINS; TGF-BETA; LYSINE 9; IN-VIVO	Oncogenic transformation of cells can induce the cyclin-dependent kinase inhibitor, p16, which leads to hypophosphorylation and activation of retinoblastoma (Rb). Rb is capable of causing permanent growth arrest, which may underlie its role as a tumor suppressor. We show that repression by Rb at E2F target gene promoters involves the establishment of a stable repressor complex that is not displaced by the overexpression of E2F-1. Rather than displacing Rb, excess E2F-1 instead recruits more Rb, leading to direct transcriptional repression. In contrast, the Rb family members, p130 and p107, which have not been demonstrated to be tumor suppressors, bind preferentially to target promoters in the absence of growth factors and in proliferating cells, respectively, and these repressor complexes are displaceable by E2F-1. Heterochromatin protein 1 (HP1), which interacts with Rb, is associated with these distinct repressor complexes and follows a similar pattern of stability/displaceability. Efficient growth arrest by p16/Rb is dependent on histone H3 lysine 9 methylation, which provides a binding site for HP1. We propose that these differences in the stability of repressor complexes at promoters may, in part, underlie the different roles of Rb vs p130 and p107 in cell cycle regulation and tumor suppression.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	glongmor@im.wustl.edu			NATIONAL CANCER INSTITUTE [R01CA085839] Funding Source: NIH RePORTER; NCI NIH HHS [CA 85839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Calbo J, 2002, J BIOL CHEM, V277, P50263, DOI 10.1074/jbc.M209181200; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dai CY, 2000, ONCOGENE, V19, P1613, DOI 10.1038/sj.onc.1203438; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LIPINSKI MM, 1999, P NATL ACAD SCI USA, V92, P6289; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Palmero I, 1996, CANCER SURV, V27, P351; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Takahashi Y, 2000, GENE DEV, V14, P804; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	53	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					814	823		10.1038/sj.onc.1207187	http://dx.doi.org/10.1038/sj.onc.1207187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737116				2022-12-28	WOS:000188304900020
J	Guo, GZ; Wang, TL; Gao, Q; Tamae, D; Wong, P; Chen, T; Chen, WC; Shively, JE; Wong, JYC; Li, JJ				Guo, GZ; Wang, TL; Gao, Q; Tamae, D; Wong, P; Chen, T; Chen, WC; Shively, JE; Wong, JYC; Li, JJ			Expression of ErbB2 enhances radiation-induced NF-kappa B activation	ONCOGENE			English	Article						NF-kappa B; ErbB2; breast cancer; radioresistance	HUMAN-BREAST-CANCER; GROWTH-FACTOR RECEPTOR; IONIZING-RADIATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; MONOCLONAL-ANTIBODY; TNF-ALPHA; CYCLIN B1; TRAIL/APO2L-INDUCED APOPTOSIS; SIGNALING PATHWAY	Her-2/neu (ErbB2) oncogene, the second member of the epidermal growth factor receptor (EGFR) family, encodes a transmembrane tyrosine kinase receptor in Her-2-positive tumors. Accumulating evidences demonstrate that signaling networks activated by EGFR and transcription factor NF-kappaB are associated with cell response to ionizing radiation (IR). The present study shows that overexpression of ErbB2 enhanced NF-kappaB activation induced by IR in human breast carcinoma MCF-7 cells transfected with ErbB2 genes (MCF-7/ErbB2). Stable transfection of dominant-negative mutant IkappaB (MCF-7/ErbB2/mIkappaB) or treatment with anti-ErbB2 antibody, Herceptin, inhibited NF-kappaB activation and radiosensitized MCF-7/ErbB2 cells. Consistent with NF-kappaB regulation, basal and IR-induced Akt, a kinase downstream of ErbB2, was activated in MCF-7/ErbB2 cells and inhibited by Herceptin. To identify specific genes affected by ErbB2-mediated NF-kappaB activation, a group of IR-responsive elements Cyclin B1, Cyclin D1, Bcl-2, Bcl/XL, BAD and BAX were evaluated. Basal levels of prosurvival elements Cyclin B1, Cyclin D1, Bcl-2 and Bcl/XL but not apoptotic BAD and BAX were upregulated in MCF-7/ErbB2 cells with striking enhancements in Bcl-2 and Bcl/XL. IR further induced Cyclin B1 and Cyclin D1 expression that was reduced by Herceptin. Bcl-2 kept a high steady level after Herceptin+IR treatment and, in contrast to control MCF-7/Vector cells, Bcl/XL was inhibited in MCF-7/ErbB2 cells by Herceptin+IR treatment. However, all four prosurvival proteins were downregulated by inhibition of NF-kappaB in MCF-7/ErbB/mIkappaB cells. These results thus provide evidence suggesting that overexpression of ErbB2 is able to enhance NF-kappaB response to IR, and that a specific prosurvival network downstream of NF-kappaB is triggered by treatments using anti-ErbB2 antibody combined with radiation.	City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, Duarte, CA 91010 USA; Biorad Labs, Life Sci Grp, Hercules, CA 94547 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Li, JJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Oncol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	jjli@coh.org		Li, Jian Jian/0000-0003-3694-9675				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Beetz A, 2000, INT J RADIAT BIOL, V76, P1443, DOI 10.1080/09553000050176207; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Bradbury CM, 2001, CANCER RES, V61, P7689; Chen XF, 2002, CANCER RES, V62, P1213; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Daosukho C, 2002, ONCOGENE, V21, P3603, DOI 10.1038/sj.onc.1205448; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Fornace AJ, 1999, GENE EXPRESSION, V7, P387; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Granville DJ, 2000, BLOOD, V95, P256; Grdina DJ, 2002, SEMIN RADIAT ONCOL, V12, P103, DOI 10.1053/srao.2002.31383; Guo GZ, 2003, MOL CELL BIOL, V23, P2362, DOI 10.1128/MCB.23.7.2362-2378.2003; Gupta AK, 2001, CANCER RES, V61, P4278; Hallahan DE, 1998, CANCER RES, V58, P5484; Hassan KA, 2002, CANCER RES, V62, P6414; Hassan KA, 2001, CLIN CANCER RES, V7, P2458; HAYMAN MJ, 1991, CANCER CELL-MON REV, V3, P302; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Herscher LL, 1999, ONCOLOGY-NY, V13, P11; Kato T, 2000, HEAD NECK-J SCI SPEC, V22, P748, DOI 10.1002/1097-0347(200012)22:8<748::AID-HED2>3.3.CO;2-Y; Kurland JF, 2001, INT J CANCER, V96, P327, DOI 10.1002/ijc.1040; Kurokawa H, 2001, CLIN CANCER RES, V7, p4436s; Kurokawa L, 2001, CLIN CANCER RES, V7, p4436S; LABUDDA K, 1995, VIROLOGY, V206, P269, DOI 10.1016/S0042-6822(95)80042-5; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, CLIN CANCER RES, V7, P682; Lee S, 2002, CANCER RES, V62, P5703; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li ZK, 2001, RADIAT RES, V155, P543, DOI 10.1667/0033-7587(2001)155[0543:EGAIMH]2.0.CO;2; Liang K, 2003, MOL CANCER THER, V2, P353; Locke JE, 2002, INT J RADIAT BIOL, V78, P493, DOI [10.1080/095530002317577312, 10.1080/09553000110120355]; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; McBride William H, 2002, Mil Med, V167, P66; Miyake H, 1998, ONCOGENE, V16, P933, DOI 10.1038/sj.onc.1201602; Miyakoshi J, 2000, BRIT J CANCER, V82, P28; Pegram M, 2000, SEMIN ONCOL, V27, P13; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; Pietras RJ, 1999, CANCER RES, V59, P1347; Ravi R, 2002, CANCER RES, V62, P1583; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Raziuddin A, 1997, J BIOL CHEM, V272, P15715, DOI 10.1074/jbc.272.25.15715; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; Schmidt M, 2001, GYNECOL ONCOL, V80, P145, DOI 10.1006/gyno.2000.6040; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Sherman L, 1999, ONCOGENE, V18, P6692, DOI 10.1038/sj.onc.1203055; Slamon D J, 1990, Cancer Invest, V8, P253, DOI 10.3109/07357909009017573; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soria JC, 2000, CANCER RES, V60, P4000; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047	70	78	82	3	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					535	545		10.1038/sj.onc.1207149	http://dx.doi.org/10.1038/sj.onc.1207149			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724581				2022-12-28	WOS:000188098300024
J	Krams, M; Parwaresch, R; Sipos, B; Heidorn, K; Harms, D; Rudolph, P				Krams, M; Parwaresch, R; Sipos, B; Heidorn, K; Harms, D; Rudolph, P			Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis	ONCOGENE			English	Article						c-kit; transcription; neuroblastoma; differentiation; prognosis	STEM-CELL FACTOR; TRANSCRIPTASE MESSENGER-RNA; TYROSINE KINASE; TELOMERASE ACTIVITY; INTERSTITIAL-CELLS; SIGNALING PATHWAYS; PROGENITOR CELLS; LUNG-CARCINOMA; HUMAN TISSUES; SURVIVAL	Expression of the c-kit proto-oncogene product in neuroblastomas has been reported, but its clinical relevance is unclear. We determined the expression of c-kit by immunohistochemistry in a series of 155 neuroblastomas with long-term follow-up. The specificity of the reaction was verified by Western blot analysis and quantitative RT-PCR, and exon 11 of the kit gene was screened for mutations by PCR and capillary electrophoresis. No mutations were detected, and transcription of the kit gene correlated with protein expression. c-kit expression was associated with lower tumor stages and a low rate of MYCN amplification. More importantly, it coincided with tumor differentiation (P < 0.0001), and portended a favorable outcome with a relative risk of 0.18 (P < 0.0001). In a multivariate analysis of event-free survival, loss of c-kit (relative risk 4.25, P < 0.0001) was an independent prognostic factor next to INSS stage 4 and before MYCN amplification. It is concluded that c-kit is transcriptionally regulated in neuroblastomas. Its expression likely identifies a subset of neuroblastomas with conserved capacity for differentiation, which may represent the embryonal variety of the disease. Assessment of c-kit may improve prognostic models for neuroblastoma and provide a basis for new therapy concepts.	Univ Kiel, Dept Pediat Pathol, D-24098 Kiel, Germany; Univ Kiel, Dept Hematopathol, D-24098 Kiel, Germany; Univ Kiel, Dept Gen Pathol, D-24098 Kiel, Germany	University of Kiel; University of Kiel; University of Kiel	Rudolph, P (corresponding author), Univ Kiel, Dept Pathol, Michaelisstr 11, D-24105 Kiel, Germany.	prudolph@path.uni-kiel.de						Arber DA, 1998, HUM PATHOL, V29, P498, DOI 10.1016/S0046-8177(98)90066-1; Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; BECK D, 1995, BLOOD, V86, P3132, DOI 10.1182/blood.V86.8.3132.bloodjournal8683132; Berthold F, 1997, EUR J CANCER, V33, P2092, DOI 10.1016/S0959-8049(97)00237-2; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; COHEN PS, 1994, BLOOD, V84, P3465; De Sepulveda P, 1999, EMBO J, V18, P904; DiPaola RS, 1997, CANCER GENE THER, V4, P176; Hayashi S, 1995, DNA Res, V2, P211, DOI 10.1093/dnares/2.5.211; HIRATA T, 1993, DEVELOPMENT, V119, P49; Hirota Seiichi, 2001, International Journal of Clinical Oncology, V6, P1, DOI 10.1007/PL00012072; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; Hornick JL, 2002, AM J CLIN PATHOL, V117, P188; HUANG EJ, 1992, MOL BIOL CELL, V3, P349, DOI 10.1091/mbc.3.3.349; IDA JA, 1993, J NEUROSCI RES, V36, P596, DOI 10.1002/jnr.490360512; Jahn T, 2002, ONCOGENE, V21, P4508, DOI 10.1038/sj.onc.1205559; JOSHI VV, 1992, CANCER-AM CANCER SOC, V69, P2197, DOI 10.1002/1097-0142(19920415)69:8<2197::AID-CNCR2820690829>3.0.CO;2-X; Kapur R, 2001, BLOOD, V97, P1975, DOI 10.1182/blood.V97.7.1975; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Krams M, 2002, CANCER, V94, P854, DOI 10.1002/cncr.10256.abs; Krams M, 2003, AM J PATHOL, V162, P1019, DOI 10.1016/S0002-9440(10)63896-5; Krams M, 2001, AM J PATHOL, V159, P1925, DOI 10.1016/S0002-9440(10)63039-8; LAMMIE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1417, DOI 10.1177/42.11.7523489; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; MAEDA H, 1992, DEVELOPMENT, V116, P369; Makhlouf HR, 2002, AM J SURG PATHOL, V26, P493, DOI 10.1097/00000478-200204000-00012; MIYAZAWA K, 1995, BLOOD, V85, P641, DOI 10.1182/blood.V85.3.641.bloodjournal853641; Montone KT, 1997, MODERN PATHOL, V10, P939; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NATALI PG, 1992, CANCER RES, V52, P6139; Robinson LLL, 2001, MOL HUM REPROD, V7, P845, DOI 10.1093/molehr/7.9.845; Rudolph P, 2002, VIRCHOWS ARCH, V441, P238, DOI 10.1007/s00428-002-0673-2; Schwartz S, 1999, LEUKEMIA LYMPHOMA, V34, P85, DOI 10.3109/10428199909083383; Shimada H, 1999, CANCER, V86, P364, DOI 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.3.CO;2-Z; Sipos B, 2002, INT J CANCER, V102, P592, DOI 10.1002/ijc.10753; Smithey BE, 2002, AM J SURG PATHOL, V26, P486, DOI 10.1097/00000478-200204000-00011; Timeus F, 1997, EXP HEMATOL, V25, P1253; Torihashi S, 1999, GASTROENTEROLOGY, V117, P140, DOI 10.1016/S0016-5085(99)70560-3; TSUURA Y, 1994, VIRCHOWS ARCH, V424, P135; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x	42	40	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					588	595		10.1038/sj.onc.1207145	http://dx.doi.org/10.1038/sj.onc.1207145			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724587				2022-12-28	WOS:000188098300030
J	Huang, MC; Lee, HY; Yeh, CC; Kong, Y; Zaloudek, CJ; Goetzl, EJ				Huang, MC; Lee, HY; Yeh, CC; Kong, Y; Zaloudek, CJ; Goetzl, EJ			Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA(2))	ONCOGENE			English	Article						vascular endothelial growth factor; urokinase-type plasminogen activator; lysophospholipids; lipid mediators; ovarian cancer	VASCULAR-PERMEABILITY FACTOR; PROSTATE-CANCER CELLS; SIGNAL-TRANSDUCTION; FACTOR VEGF; LYSOPHOSPHOLIPASE-D; ASCITES-FORMATION; SPLICE VARIANTS; EXPRESSION; TUMORS; GENE	The lipid growth factor lysophosphatidic acid (LPA) is produced by ovarian cancer cells in quantities sufficient to attain concentrations of up to 10 muM. An autocrine circuit was demonstrated when ovarian cancer cells, but not normal ovarian surface epithelial cells, were proven to express LPA(2) (Edg-4) and LPA(3) (Edg-7) G protein-coupled receptors for LPA. Human LPA(2) now has been expressed transgenically in C57BL/6 mouse ovaries under direction of the alpha-inhibin large promoter. Human LPA(2) mRNA and protein were detected in all transgenic (TG) mouse ovaries at levels far higher than in other tissues and at least fivefold higher than in cultured lines of human ovarian cancer cells, with the expected sex cord-stromal distribution. Most LPA(2) TG ovaries produced significantly higher levels than non-TG ovaries of type A, but not type B, vascular endothelial growth factor (VEGF), isomers of VEGF-A, and urokinase-type plasminogen activator (uPA). Many LPA(2) TG ovaries had elevated expression of VEGF receptors 1 and 2, and a depressed level of type 2 PA inhibitor. Thus, the LPA-LPA(2) circuit regulates ovarian cells both directly and through increases in protein growth factor systems.	Univ Calif San Francisco, Med Ctr, Dept Med Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med Microbiol & Immunol, UB8B,Box 0711,533 Parnassus Ave, San Francisco, CA 94143 USA.	egoetzl@itsa.ucsf.edu		Lee, Hsinyu/0000-0002-1477-0183				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Dolezalova H, 2003, J CELL BIOCHEM, V88, P732, DOI 10.1002/jcb.10394; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fujimoto J, 1998, CANCER-AM CANCER SOC, V83, P2528, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2528::AID-CNCR18>3.0.CO;2-N; Fujita T, 2003, CANCER LETT, V192, P161, DOI 10.1016/S0304-3835(02)00713-9; Gerber HP, 2000, CANCER RES, V60, P6253; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Goetzl EJ, 1999, CANCER RES, V59, P5370; Hazelton D, 1999, CLIN CANCER RES, V5, P823; Hsu SY, 1996, ENDOCRINOLOGY, V137, P4837, DOI 10.1210/en.137.11.4837; Hu LM, 2002, AM J PATHOL, V161, P1917, DOI 10.1016/S0002-9440(10)64467-7; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang MC, 2002, BBA-MOL CELL BIOL L, V1582, P161, DOI 10.1016/S1388-1981(02)00151-8; KANANEN K, 1995, MOL ENDOCRINOL, V9, P616, DOI 10.1210/me.9.5.616; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Luo JC, 1998, CANCER RES, V58, P2652; Mesiano S, 1998, AM J PATHOL, V153, P1249, DOI 10.1016/S0002-9440(10)65669-6; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Neufeld G, 1996, CANCER METAST REV, V15, P153, DOI 10.1007/BF00437467; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Orre M, 1999, INT J CANCER, V84, P101, DOI 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5; Qi C, 1998, J CELL PHYSIOL, V174, P261, DOI 10.1002/(SICI)1097-4652(199802)174:2<261::AID-JCP13>3.0.CO;2-F; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877; Stimpfl M, 2002, CLIN CANCER RES, V8, P2253; TIGYI G, 2002, MOL CELLULAR BIOL LI, V1582, P1; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xie YH, 2002, J BIOL CHEM, V277, P32516, DOI 10.1074/jbc.M203864200; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Xu Yan, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P23, DOI 10.2174/1568008033340414; Yukita A, 2000, ANTICANCER RES, V20, P155; Zebrowski BK, 1999, ANN SURG ONCOL, V6, P373, DOI 10.1007/s10434-999-0373-0; Zhang L, 2002, BIOCHEM BIOPH RES CO, V292, P860, DOI 10.1006/bbrc.2002.6710; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	42	51	54	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					122	129		10.1038/sj.onc.1206986	http://dx.doi.org/10.1038/sj.onc.1206986			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712217				2022-12-28	WOS:000187895300013
J	Bhalla, KN				Bhalla, KN			Microtubule-targeted anticancer agents and apoptosis	ONCOGENE			English	Review						microtubule; apoptosis; taxanes; Bcl-2	TAXOL-INDUCED APOPTOSIS; ACTIVATED PROTEIN-KINASE; PACLITAXEL-INDUCED APOPTOSIS; BREAST-CANCER CELLS; BETA-TUBULIN GENE; NF-KAPPA-B; BAX CONFORMATIONAL CHANGE; BCL-2 FAMILY-MEMBERS; HUMAN LEUKEMIA-CELLS; CYTOCHROME-C	Over the past decade, significant progress has been made in our understanding of the biology of microtubule (MT) assembly into the mitotic spindle during mitosis and the molecular signaling and execution of the various pathways to apoptosis. In the same period, the microtubule-targeted tubulin-polymerizing agents (MTPAs), notably paclitaxel and taxotere, have come to occupy a central role in the treatment of a variety of human epithelial cancers. Following their binding to B-tubulin, MTPAs inhibit MT dynamic instability, cell cycle G2/M phase transition and mitotic arrest of cancer cells. MTPA-induced anti-MT and cell cycle effects trigger the molecular signaling for the mitochondrial pathway of apoptosis. This triggering is orchestrated through different molecular links and determined by the threshold for apoptosis that is set and controlled diversely in various cancer types. The complexity and regulatory potential of the links and the apoptosis threshold are integral to the transformed biology of the cancer cell. The emerging understanding of this biology and how it is influenced by treatment with MTPAs has highlighted novel strategies to further enhance the antitumor activity and overcome resistance to MTPA-induced apoptosis in cancer cells.	Univ S Florida, Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Bhalla, KN (corresponding author), Univ S Florida, Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr,MRC 3 East,Room 3056, Tampa, FL 33612 USA.	bhallakn@moffitt.usf.edu		Bhalla, Kapil/0000-0001-5209-5126				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alli E, 2002, CANCER RES, V62, P6864; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALI P, 2003, COMMUNICATION; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; Benimetskaya L, 2001, MOL PHARMACOL, V60, P1296, DOI 10.1124/mol.60.6.1296; BHALLA K, 1993, LEUKEMIA, V7, P563; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cassinelli G, 2001, INT J CANCER, V92, P738, DOI 10.1002/1097-0215(20010601)92:5<738::AID-IJC1249>3.0.CO;2-2; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen JG, 2002, CANCER RES, V62, P1935; Clark AS, 2002, MOL CANCER THER, V1, P707; Datta R, 2000, J BIOL CHEM, V275, P31733, DOI 10.1074/jbc.M910231199; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; DEL PL, 1997, SCIENCE, V278, P687; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; Dent P, 2001, CLIN CANCER RES, V7, P775; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Derry WB, 1998, CANCER RES, V58, P1177; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DEVERAUX Q, 1997, GENE DEV, V13, P239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dogterom M, 1997, SCIENCE, V278, P856, DOI 10.1126/science.278.5339.856; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Dumontet C, 1996, CANCER RES, V56, P1091; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; Fang GF, 1998, CANCER RES, V58, P3202; Fedier A, 2003, INT J ONCOL, V22, P1169; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Fuino L, 2003, MOL CANCER THER, V2, P971; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Giet R, 1999, J CELL SCI, V112, P3591; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo F, 2002, BLOOD, V99, P3419, DOI 10.1182/blood.V99.9.3419; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1998, CANCER RES, V58, P1609; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Hawkins DS, 1996, CANCER RES, V56, P892; He LF, 2001, MOL CANCER THER, V1, P3; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hu LM, 2002, CANCER RES, V62, P1087; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang Y, 2001, ONCOL RES, V13, P113; Huang Y, 2002, MOL PHARMACOL, V61, P105, DOI 10.1124/mol.61.1.105; Huang Y, 1997, BREAST CANCER RES TR, V42, P73, DOI 10.1023/A:1005777219997; Huang Y, 2000, CANCER RES, V60, P4426; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Iancu C, 2000, CANCER RES, V60, P3537; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Isaacs JS, 2003, CANCER CELL, V3, P213, DOI 10.1016/S1535-6108(03)00029-1; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jordan M. A., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P1, DOI 10.2174/1568011023354290; Jordan MA, 1996, CANCER RES, V56, P816; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Kim CN, 1997, CANCER RES, V57, P3115; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Kowalski RJ, 1997, J BIOL CHEM, V272, P2534; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lamendola DE, 2003, ANTICANCER RES, V23, P681; Lee FYF, 2001, CLIN CANCER RES, V7, P1429; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Lee S, 2002, CANCER RES, V62, P5703; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; Maeno K, 2003, CANCER LETT, V198, P89, DOI 10.1016/S0304-3835(03)00279-9; Martello LA, 2003, CANCER RES, V63, P1207; MAY WS, 1994, J BIOL CHEM, V269, P26865; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Miller KD, 1999, CANCER INVEST, V17, P121; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Nguyen DM, 1999, J THORAC CARDIOV SUR, V118, P908, DOI 10.1016/S0022-5223(99)70061-9; Nicoletti MI, 2001, CLIN CANCER RES, V7, P2912; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; OConnor PM, 1997, CANCER RES, V57, P4285; OHTA S, 1993, INT CONGR SER, V1026, P209; Olie RA, 2000, CANCER RES, V60, P2805; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Paez Juan, 2003, Cancer Treat Res, V115, P145; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; Perkins C, 1998, CANCER RES, V58, P4561; Perkins CL, 2000, CANCER RES, V60, P1645; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; RAO S, 1994, J BIOL CHEM, V269, P3132; Rao S, 1999, J BIOL CHEM, V274, P37990, DOI 10.1074/jbc.274.53.37990; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rodi DJ, 1999, J MOL BIOL, V285, P197, DOI 10.1006/jmbi.1998.2303; Roghi C, 1998, J CELL SCI, V111, P557; Rosen EM, 2003, J CELL PHYSIOL, V196, P19, DOI 10.1002/jcp.10257; Rowinsky E.K., 2001, CANC CHEMOTHERAPY BI, P329; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Sale S, 2002, MOL CANCER THER, V1, P215; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; Sasaki H, 2000, CANCER RES, V60, P5659; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Schandl C. A., 1996, Cellular Pharmacology, V3, P367; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shingu T, 2003, CANCER RES, V63, P4044; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Solit DB, 2003, CANCER RES, V63, P2139; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Stachel SJ, 2001, CURR PHARM DESIGN, V7, P1277, DOI 10.2174/1381612013397410; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; Tai YT, 1999, CANCER RES, V59, P2121; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; TANG C, 1994, LEUKEMIA, V8, P1960; Tassin AM, 1999, BIOL CELL, V91, P343, DOI 10.1016/S0248-4900(99)80095-1; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Thangaraju M, 2000, J BIOL CHEM, V275, P33487, DOI 10.1074/jbc.M005824200; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Vasey PA, 1996, MOL PHARMACOL, V50, P1536; Vilenchik M, 2002, CANCER RES, V62, P2175; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Wall NR, 2003, CANCER RES, V63, P230; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG H, 2003, COMMUNICATION; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang SJ, 1999, BIOCHEM BIOPH RES CO, V259, P67, DOI 10.1006/bbrc.1999.0669; Wang TH, 2000, CANCER, V88, P2619, DOI 10.1002/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wittmann S, 2003, CANCER RES, V63, P93; WITTMANN S, 2003, COMMUNICATION; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yamaguchi H, 2002, CANCER RES, V62, P466; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 1996, ONCOGENE, V13, P1359; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	211	377	417	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9075	9086		10.1038/sj.onc.1207233	http://dx.doi.org/10.1038/sj.onc.1207233			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663486				2022-12-28	WOS:000187043600011
J	Coombes, MM; Briggs, KL; Bone, JR; Clayman, GL; El-Naggar, AK; Dent, SYR				Coombes, MM; Briggs, KL; Bone, JR; Clayman, GL; El-Naggar, AK; Dent, SYR			Resetting the histone code at CDKN2A in HNSCC by inhibition of DNA methylation	ONCOGENE			English	Article						squamous cell carcinoma; head and neck; chromatin; acetylation	DEACETYLASE INHIBITORS; LYSINE-9 METHYLATION; X-CHROMOSOME; CANCER-CELLS; GENE; H3; CHROMATIN; HETEROCHROMATIN; REPRESSOR; BINDING	Head and neck squamous cell carcinoma (HNSCC) is the fifth most frequent cancer in the US. Several genetic and epigenetic alterations are associated with HNSCC tumorigenesis, including inactivation of CDKN2A, which encodes the p16 tumor suppressor, in cell lines and primary tumors by DNA methylation. Reactivation of tumor suppressor genes by DNA-demethylating agents and histone deacetylase (HDAC) inhibitors shows therapeutic promise for other cancers. Therefore, we investigated the ability of these agents to reactivate p16 in Tu159 HNSCC cells. Treatment of cells with 5-aza-2' deoxycytidine (5-aza-dC) increases CDKN2A expression and slightly increases histone H3 acetylation at this gene. No reactivation of CDKN2A is observed upon treatment with the HDAC inhibitor trichostatin A (TSA), but synergistic reactivation of CDKN2A is observed upon sequential treatment of Tu159 cells with both 5-aza-dC and TSA. Silencing of CDKN2A in Tu159 cells is correlated with increased methylation of histone H3 at lysine 9 and decreased methylation at lysine 4 relative to the upstream p15 gene promoter. Interestingly, global levels of H3-K9 methylation are decreased upon treatment with 5-aza-dC. Together these data indicate that DNA methylation is a dominant epigenetic mark for silencing of CDKN2A in Tu159 tumor cells. Moreover, changes in DNA methylation can reset the histone code by impacting multiple H3 modifications.	Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Dent, SYR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.	syr@mdacc.tmc.edu	Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269				Bachman KE, 2001, J BIOL CHEM, V276, P32282, DOI 10.1074/jbc.M104661200; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Baylin SB, 1998, ADV CANCER RES, V72, P141; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; Bird A, 2001, SCIENCE, V294, P2113, DOI 10.1126/science.1066726; Burgess-Beusse B, 2002, P NATL ACAD SCI USA, V99, P16433, DOI 10.1073/pnas.162342499; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Carapeti M, 1999, CANCER GENET CYTOGEN, V113, P70, DOI 10.1016/S0165-4608(99)00007-2; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598; Czermin B, 2001, EMBO REP, V2, P915, DOI 10.1093/embo-reports/kve210; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Edmondson DG, 2002, J BIOL CHEM, V277, P29496, DOI 10.1074/jbc.M200651200; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ElNaggar AK, 1997, AM J PATHOL, V151, P1767; Enders GH, 1996, ONCOGENE, V12, P1239; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Goldman Michael A., 2002, Trends in Genetics, V18, P390, DOI 10.1016/S0168-9525(02)02735-X; Gonzalez MV, 1997, J CLIN PATHOL, V50, P509, DOI 10.1136/jcp.50.6.509; Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; HERMAN JG, 1995, CANCER RES, V55, P4525; Herman JG, 2000, CURR TOP MICROBIOL, V249, P35; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Johnson LM, 2002, CURR BIOL, V12, P1360, DOI 10.1016/S0960-9822(02)00976-4; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lachner M, 2002, CURR BIOL, V12, pR434, DOI 10.1016/S0960-9822(02)00919-3; Lai S, 1999, LAB INVEST, V79, P255; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mermoud JE, 2002, CURR BIOL, V12, P247, DOI 10.1016/S0960-9822(02)00660-7; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Reed AL, 1996, CANCER RES, V56, P3630; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Schutte M, 1997, CANCER RES, V57, P3126; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; Turker MS, 2002, ONCOGENE, V21, P5388, DOI 10.1038/sj.onc.1205599; Wade PA, 1998, COLD SPRING HARB SYM, V63, P435, DOI 10.1101/sqb.1998.63.435; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702; Wolffe A. P., 1999, CHROMATIN STRUCTURE; Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	79	41	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8902	8911		10.1038/sj.onc.1207050	http://dx.doi.org/10.1038/sj.onc.1207050			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654786				2022-12-28	WOS:000186982200011
J	Trauzold, A; Schmiedel, S; Sipos, B; Wermann, H; Westphal, S; Roder, C; Klapper, W; Arlt, A; Lehnert, L; Ungefroren, H; Johannes, FJ; Kalthoff, H				Trauzold, A; Schmiedel, S; Sipos, B; Wermann, H; Westphal, S; Roder, C; Klapper, W; Arlt, A; Lehnert, L; Ungefroren, H; Johannes, FJ; Kalthoff, H			PKC mu prevents CD95-mediated apoptosis and enhances proliferation in pancreatic tumour cells	ONCOGENE			English	Article						pancreatic cancer; apoptosis resistance; protein kinase C; death receptor	PROTEIN-KINASE-C; TELOMERASE ACTIVITY; CANCER-CELLS; ADENOCARCINOMA CELLS; PROTEOLYTIC CLEAVAGE; MEDIATED APOPTOSIS; MOLECULAR-CLONING; PHORBOL ESTERS; DNA-SYNTHESIS; ACTIVATION	Loss of growth control and a marked resistance to apoptosis are considered major mechanisms driving tumour progression. Protein kinases C (PKC) have been shown to be important in the regulation of proliferation and apoptosis. In this report, we investigated the role of the PKC-like kinase PKCmu in the control of these processes in pancreatic adenocarcinoma cells. We demonstrate that in these cells, PKCmu expression strongly correlates with resistance to CD95-induced apoptosis. Inhibition of PKCmu with Goe6983 sensitized resistant cells to CD95-induced apoptosis. In CD95-sensitive Colo357 cells, forced overexpression of PKCmu strongly reduced CD95-mediated apoptosis, an effect that could be reversed by pretreatment with Goe6983. In addition, PKCmu overexpression led to a strongly enhanced cell growth and to a significant increase of telomerase activity. In an attempt to identify the signalling pathways affected by PKCmu, we identified the antiapoptotic proteins c-FLIPL and survivin to be strongly upregulated in PKCmu over-expressing cells. Immunohistochemical analysis of pancreatic tumour tissue of 48 patients and 10 normal pancreatic tissues revealed marked overexpression of PKCmu in tumours. In conclusion, we showed that PKCmu controls proliferative, as well as anti-apoptotic, signalling pathways and therefore plays an important role in acquiring the malignant phenotype of pancreatic tumours.	Univ Kiel, Clin Gen Surg & Thorac Surg, D-24105 Kiel, Germany; Univ Kiel, Inst Pathol, D-24105 Kiel, Germany; Univ Kiel, Inst Hematopathol, D-24105 Kiel, Germany; Univ Kiel, Lymph Node Registry, D-24105 Kiel, Germany; Univ Kiel, Dept Med 1, Lab Mol Gastroenterol, D-24105 Kiel, Germany; Fraunhofer Inst Interfacial Engn, D-70569 Stuttgart, Germany	University of Kiel; University of Kiel; University of Kiel; University of Kiel; University of Kiel; Fraunhofer Gesellschaft	Kalthoff, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Arnold Heller Str 7, D-24105 Kiel, Germany.		Klapper, Wolfram/S-6314-2016; Kalthoff, Holger/B-1618-2010; Roeder, Christian/F-1068-2010; Klapper, Wolfram/D-2516-2010; Arlt, Alexander/G-7308-2019; Trauzold, Anna/P-4398-2014	Roeder, Christian/0000-0001-7881-9110; Arlt, Alexander/0000-0002-6160-1059; 				Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Belair CD, 1997, P NATL ACAD SCI USA, V94, P13677, DOI 10.1073/pnas.94.25.13677; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Elnemr A, 2001, INT J ONCOL, V18, P311; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Guha S, 2002, CANCER RES, V62, P1632; Hall-Jackson CA, 1998, BRIT J CANCER, V78, P641, DOI 10.1038/bjc.1998.554; Hamilton HB, 1996, J NEUROSURG, V85, P329, DOI 10.3171/jns.1996.85.2.0329; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Hayano RS, 1999, EUR PHYS J A, V6, P99, DOI 10.1007/s100500050322; Heasley LE, 2001, ONCOGENE, V20, P1563, DOI 10.1038/sj.onc.1204183; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hiyama E, 1997, CANCER RES, V57, P326; Holt SE, 1996, MOL CELL BIOL, V16, P2932; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Johannes FJ, 1998, EUR J BIOCHEM, V257, P47, DOI 10.1046/j.1432-1327.1998.2570047.x; Kim YW, 2001, EXP MOL MED, V33, P156, DOI 10.1038/emm.2001.27; KLAPPER W, 1998, BIOCHIM BIOPHYS ACTA, V8, P2; Krammer P H, 1999, Adv Immunol, V71, P163; Krupp G, 1997, NUCLEIC ACIDS RES, V25, P919, DOI 10.1093/nar/25.4.919; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li H, 1998, J BIOL CHEM, V273, P33436, DOI 10.1074/jbc.273.50.33436; Palmantier R, 2001, CANCER RES, V61, P2445; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Rennecke J, 1999, INT J CANCER, V80, P98, DOI 10.1002/(SICI)1097-0215(19990105)80:1<98::AID-IJC19>3.3.CO;2-4; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Ryder NM, 2001, J CELL PHYSIOL, V186, P53, DOI 10.1002/1097-4652(200101)186:1<53::AID-JCP1004>3.0.CO;2-Q; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Satoh K, 2001, CANCER, V92, P271, DOI 10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Ungefroren H, 1998, CANCER RES, V58, P1741; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Yu CC, 2001, BIOCHEM J, V355, P459, DOI 10.1042/0264-6021:3550459; Zhukova E, 2001, J BIOL CHEM, V276, P40298, DOI 10.1074/jbc.M106512200	48	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8939	8947		10.1038/sj.onc.1207001	http://dx.doi.org/10.1038/sj.onc.1207001			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654790				2022-12-28	WOS:000186982200015
J	Wang, SL; El-Deiry, WS				Wang, SL; El-Deiry, WS			TRAIL and apoptosis induction by TNF-family death receptors	ONCOGENE			English	Review						tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); tumor necrosis factor receptor family; p53; apoptosis; cancer therapy	CYTOTOXIC LIGAND TRAIL; PROTEASOME INHIBITOR PS-341; DRUG-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; NF-KAPPA-B; DECOY RECEPTORS; HUMAN-MELANOMA; MEDIATED APOPTOSIS; ANTITUMOR-ACTIVITY; HUMAN HEPATOCYTES	Tumor necrosis factor-related apoptosis-inducing ligand or Apo2 ligand (TRAIL/Apo2L) is a member of the tumor necrosis factor (TNF) family of ligands capable of initiating apoptosis through engagement of its death receptors. TRAIL selectively induces apoptosis of a variety of tumor cells and transformed cells, but not most normal cells, and therefore has garnered intense interest as a promising agent for cancer therapy. TRAIL is expressed on different cells of the immune system and plays a role in both T-cell- and natural killer cell-mediated tumor surveillance and suppression of suppressing tumor metastasis. Some mismatch-repair-deficient tumors evade TRAIL-induced apoptosis and acquire TRAIL resistance through different mechanisms. Death receptors, members of the TNF receptor family, signal apoptosis independently of the p53 tumor-suppressor gene. TRAIL treatment in combination with chemo- or radiotherapy enhances TRAIL sensitivity or reverses TRAIL resistance by regulating the downstream effectors. Efforts to identify agents that activate death receptors or block specific effectors may improve therapeutic design. In this review, we summarize recent insights into the apoptosis-signaling pathways stimulated by TRAIL, present our current understanding of the physiological role of this ligand and the potential of its application for cancer therapy and prevention.	Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; Pennsylvania Medicine	El-Deiry, WS (corresponding author), Univ Penn, Sch Med, Dept Med, 415 Curie Blvd,CRB437A, Philadelphia, PA 19104 USA.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266				Abdollahi T, 2003, CANCER RES, V63, P4521; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Armeanu S, 2003, CANCER RES, V63, P2369; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Bodmer JL, 2000, J BIOL CHEM, V275, P20632, DOI 10.1074/jbc.M909721199; Burns TF, 2001, J BIOL CHEM, V276, P37879; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eggert A, 2001, CANCER RES, V61, P1314; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frese S, 2003, ONCOGENE, V22, P5427, DOI 10.1038/sj.onc.1206842; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; HARPER N, 2003, IN PRESS J BIOL CHEM; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; Holen I, 2002, CANCER RES, V62, P1619; Hunt A, 2001, SCIENCE, V293, P1784, DOI 10.1126/science.1065206; Hymowitz SG, 1999, MOL CELL, V4, P563, DOI 10.1016/S1097-2765(00)80207-5; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lee JW, 2002, NEOPLASIA, V4, P312, DOI 10.1038/sj.neo.7900245; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Mariani SM, 1998, EUR J IMMUNOL, V28, P1492, DOI 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Mongkolsapaya J, 1999, NAT STRUCT BIOL, V6, P1048; Monleon I, 2001, J IMMUNOL, V167, P6736, DOI 10.4049/jimmunol.167.12.6736; Nagane M, 2001, APOPTOSIS, V6, P191, DOI 10.1023/A:1011336726649; Ozoren N, 2000, CANCER RES, V60, P6259; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Ravi R, 2002, CANCER RES, V62, P1583; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmaltz C, 2002, NAT MED, V8, P1433, DOI 10.1038/nm797; Seki N, 2003, CANCER RES, V63, P207; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; WANG S, 2003, IN PRESS P NATL ACAD; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	75	660	692	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 24	2003	22	53					8628	8633		10.1038/sj.onc.1207232	http://dx.doi.org/10.1038/sj.onc.1207232			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634624				2022-12-28	WOS:000186720000008
J	Oksvold, MP; Thien, CBF; Widerberg, J; Chantry, A; Huitfeldt, HS; Langdon, WY				Oksvold, MP; Thien, CBF; Widerberg, J; Chantry, A; Huitfeldt, HS; Langdon, WY			Serine mutations that abrogate ligand-induced ubiquitination and internalization of the EGF receptor do not affect c-Cbl association with the receptor	ONCOGENE			English	Article						receptor tyrosine kinase; endocytosis; down-regulation; ubiquitination	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; DOWN-REGULATION; THREONINE PHOSPHORYLATION; RING FINGER; TRAFFICKING; PATHWAY; GRB2; SITE; DESENSITIZATION	In the present study, we examined EGF-induced internalization, degradation and trafficking of the epidermal growth factor receptor (EGFR) mutated at serines 1046, 1047, 1057 and 1142 located in its cytoplasmic carboxyterminal region. We found the serine-mutated EGFR to be inhibited in EGF-induced internalization and degradation in NIH3T3 cells. We therefore tested the hypothesis that these mutations affect ligand-induced c-Cbl association with the receptor, leading to inhibited receptor ubiquitination. EGF was unable to induce ubiquitination of the serine-mutated EGFR, yet EGF-induced phosphorylation of the c-Cbl-binding site at tyrosine 1045, and c-Cbl-EGFR association, was unaffected. To compare the relevance of these serine residues with tyrosine 1045 in their regulation of c-Cbl binding and receptor ubiquitination, we analysed an EGFR mutated at tyrosine 1045 (Y1045F). EGF-induced c-Cbl-EGFR binding was partially inhibited, and receptor ubiquitination was abrogated in cells expressing Y1045F-EGFR. In contrast, ligand-induced internalization and degradation of the Y1045F mutant was similar to that of wild-type EGFR. Together, our data indicate that the serine residues and tyrosine 1045 are essential for EGF-induced receptor ubiquitination, but only the serine residues are critical for EGFR internalization and degradation.	Univ Oslo, Rikshosp, Inst Pathol, Lab Toxicopathol, N-0027 Oslo, Norway; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Pathol, Nedlands, WA 6009, Australia	University of Oslo; National Hospital Norway; University of East Anglia; University of Western Australia	Oksvold, MP (corresponding author), Univ Oslo, Rikshosp, Inst Pathol, Lab Toxicopathol, N-0027 Oslo, Norway.		Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Clague MJ, 2001, J CELL SCI, V114, P3075; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Courbard JR, 2002, J BIOL CHEM, V277, P45267, DOI 10.1074/jbc.M206460200; COVERS R, 1998, J BIOL CHEM, V273, P16426; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; ECCLES SA, 1994, INVAS METAST, V14, P337; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HELIN K, 1991, J BIOL CHEM, V266, P8363; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Levkowitz G, 2000, J BIOL CHEM, V275, P35532, DOI 10.1074/jbc.M002661200; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; LUND KA, 1990, J BIOL CHEM, V265, P20517; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SORKIN A, 1992, J BIOL CHEM, V267, P8672; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Tebar F, 2002, MOL BIOL CELL, V13, P2057, DOI 10.1091/mbc.01-12-0571; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WILEY HS, 1991, J BIOL CHEM, V266, P11083; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	41	48	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8509	8518		10.1038/sj.onc.1207117	http://dx.doi.org/10.1038/sj.onc.1207117			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627991				2022-12-28	WOS:000186650300014
J	Johnston, JB; Kabore, AF; Strutinsky, J; Hu, XJ; Paul, JT; Kropp, DM; Kuschak, B; Begleiter, A; Gibson, SB				Johnston, JB; Kabore, AF; Strutinsky, J; Hu, XJ; Paul, JT; Kropp, DM; Kuschak, B; Begleiter, A; Gibson, SB			Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia	ONCOGENE			English	Article						apoptosis; death receptors; chronic lymphocytic leukemia; TRAIL; chemotherapeutic drugs	TRAIL-INDUCED APOPTOSIS; LIGAND-INDUCED APOPTOSIS; MULTIPLE-MYELOMA; IN-VITRO; TRAIL/APO2L-INDUCED APOPTOSIS; DRUG-RESISTANCE; CYTOTOXIC DRUGS; TUMOR-CELLS; EXPRESSION; ACTIVATION	The standard treatments for chronic lymphocytic leukemia (CLL) include the alkylating agent chlorambucil (CLB) and the nucleoside analog fludarabine (F-ara-AMP, Flu). Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) is a death receptor ligand that induces apoptosis preferentially in tumors. However, CLL cells seem to be resistant to TRAIL-induced apoptosis. The TRAIL apoptotic signaling pathway has also been implicated in genotoxin-induced apoptosis through upregulation of TRAIL death receptors DR4 and DR5. In the present study, we demonstrate that the treatment of primary CLL cells with CLB or Flu increases the mRNA, protein and cell surface expression levels of DR4 and DR5 in a dose-dependent manner. In contrast to CLL cells, drug treatment fails to increase significantly the expression of DR4 or DR5 in normal lymphocytes. CLL cells are, however, resistant to TRAIL-induced apoptosis compared to B-cell lines. In contrast, combinational treatment using CLB or Flu with TRAIL (100 ng/ml) gave a synergistic apoptotic response. Furthermore, TRAIL is readily detectable on the cell surface of CLL cells, but TRAIL expression fails to increase following drug treatment. Preventing TRAIL from interacting with DR4 and DR5 decreases CLB-induced apoptosis in CLL cells. A similar, but less marked effect is observed with Flu. These findings indicate the involvement of the TRAIL apoptotic pathway in the mechanism of action of chemotherapy, and this mechanism could be utilized to sensitize CLL cells to TRAIL-induced apoptosis.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada; Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0V9, Canada	University of Manitoba; University of Manitoba; University of Manitoba; University of Manitoba	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.			Gibson, Spencer/0000-0003-0119-732X				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Begleiter A, 1996, LEUKEMIA LYMPHOMA, V23, P187, DOI 10.3109/10428199609054821; BEGLEITER A, 1995, LEUKEMIA, V9, P1875; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; Dighiero G, 2000, NEW ENGL J MED, V343, P1799, DOI 10.1056/NEJM200012143432410; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Friesen C, 1999, LEUKEMIA, V13, P1854, DOI 10.1038/sj.leu.2401333; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; Genini D, 2000, BLOOD, V96, P3537; Genini D, 2000, J BIOL CHEM, V275, P29, DOI 10.1074/jbc.275.1.29; Gibson EM, 2002, CANCER RES, V62, P488; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gottardi D, 1996, BRIT J HAEMATOL, V94, P612, DOI 10.1046/j.1365-2141.1996.d01-1856.x; Guan BX, 2002, ONCOGENE, V21, P3121, DOI 10.1038/sj.onc.1205430; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Johnston JB, 1997, LEUKEMIA LYMPHOMA, V26, P435, DOI 10.3109/10428199709050881; JOHNSTON JB, 1999, WINTROBES CLIN HEMAT, P2405; Jones DT, 2001, BLOOD, V98, P2800, DOI 10.1182/blood.V98.9.2800; Kim EJ, 2001, INT J ONCOL, V18, P187; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Lens D, 1997, BRIT J HAEMATOL, V99, P848, DOI 10.1046/j.1365-2141.1997.4723278.x; Levesque MC, 2001, LEUKEMIA, V15, P1305, DOI 10.1038/sj.leu.2402192; Lincz LF, 2001, LEUKEMIA, V15, P1650, DOI 10.1038/sj.leu.2402251; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Menzel T, 1996, BLOOD, V87, P1056, DOI 10.1182/blood.V87.3.1056.bloodjournal8731056; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mitsiades N, 2002, BLOOD, V99, P2162, DOI 10.1182/blood.V99.6.2162; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Pepper C, 1999, BRIT J HAEMATOL, V107, P611, DOI 10.1046/j.1365-2141.1999.01726.x; Plasilova M, 2002, LEUKEMIA, V16, P67, DOI 10.1038/sj.leu.2402338; Rai KR, 2000, NEW ENGL J MED, V343, P1750, DOI 10.1056/NEJM200012143432402; Ravi R, 2002, CANCER RES, V62, P1583; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sankar M, 1998, LEUKEMIA, V12, P510, DOI 10.1038/sj.leu.2400973; SAYERS TJ, 2003, BLOOD, V13, P13; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Solary E, 2000, LEUKEMIA, V14, P1833, DOI 10.1038/sj.leu.2401902; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Vrhovac R, 1998, BLOOD, V91, P4694, DOI 10.1182/blood.V91.12.4694.412k09_4694_4700; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; Werner AB, 2002, J BIOL CHEM, V277, P40760, DOI 10.1074/jbc.M204351200; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Zhao HX, 1998, BLOOD, V92, P1031	49	51	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8356	8369		10.1038/sj.onc.1207004	http://dx.doi.org/10.1038/sj.onc.1207004			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614459				2022-12-28	WOS:000186541500014
J	Umehara, S; Higashi, H; Ohnishi, N; Asaka, M; Hatakeyama, M				Umehara, S; Higashi, H; Ohnishi, N; Asaka, M; Hatakeyama, M			Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma	ONCOGENE			English	Article						H. pylori; CagA; MALT lymphoma; B cell; apoptosis	ATROPHIC GASTRITIS; GENE-EXPRESSION; ULCER DISEASE; LOW-GRADE; IN-VITRO; T(11-18)(Q21-Q21); PHOSPHORYLATION; TRANSLOCATION; STRAINS; KINASE	Helicobacter pylori (H. pylori) is a causative agent of gastrointestinal diseases such as atrophic gastritis and gastroduodenal ulcer. Infection of cagA-positive H. pylori is also associated with gastric carcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. The cagA gene product CagA is directly injected into the bacteria-attached host cells via the bacterial type IV secretion system. The translocated CagA deregulates intracellular signaling pathways and thereby initiates pathogenesis. In this work, we examined the biological effects of CagA on B cells, from which MALT lymphoma arises. Ectopic expression of CagA in interleukin 3-dependent B cells inhibited cell proliferation by suppressing the JAK-STAT signaling. CagA was also capable of preventing hydroxyurea-induced B-cell apoptosis through inhibiting p53 accumulation. In contrast to the effects of CagA in gastric epithelial cells, the observed CagA activities in B cells were independent of its tyrosine phosphorylation. Our results indicate that CagA possesses both phosphorylation-dependent and -independent activities in mammalian cells and that biological impacts of CagA depend on cell-type context. As a result of B-cell growth inhibition, CagA may diminish anti-H. pylori immune responses. Furthermore, CagA may play a role in the development of MALT lymphoma by impairing p53-dependent apoptosis.	Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Grad Sch Sci, Sapporo, Hokkaido 0600815, Japan; Hokkaido Univ, Dept Gastroenterol, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan	Hokkaido University; Hokkaido University; Hokkaido University	Hatakeyama, M (corresponding author), Hokkaido Univ, Inst Med Genet, Div Mol Oncol, Kita Ku, Kita-15,Nishi-7, Sapporo, Hokkaido 0600815, Japan.		Higashi, Hideaki/F-6872-2012; OHNISHI, Naomi/F-6914-2012; Asaka, Masahiro/A-5948-2012	OHNISHI, Naomi/0000-0002-2382-3152; 				Auer IA, 1997, ANN ONCOL, V8, P979, DOI 10.1023/A:1008202303666; Baens M, 2000, AM J PATHOL, V156, P1433, DOI 10.1016/S0002-9440(10)65012-2; BLASER MJ, 1995, CANCER RES, V55, P2111; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Du MQ, 2002, LANCET ONCOL, V3, P97, DOI 10.1016/S1470-2045(02)00651-4; Eck M, 1997, GASTROENTEROLOGY, V112, P1482, DOI 10.1016/S0016-5085(97)70028-3; Flores-Morales A, 1998, MOL CELL ENDOCRINOL, V138, P1, DOI 10.1016/S0303-7207(98)00054-9; Gartel AL, 2003, EXP CELL RES, V283, P17, DOI 10.1016/S0014-4827(02)00020-4; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Hoshikawa Y, 1998, ANAL BIOCHEM, V261, P211, DOI 10.1006/abio.1998.2742; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; KUIPERS EJ, 1995, ALIMENT PHARM THERAP, V9, P59; Kuipers EJ, 1997, ALIMENT PHARM THER, V11, P71, DOI 10.1046/j.1365-2036.11.s1.5.x; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Ott G, 1997, CANCER RES, V57, P3944; Palacios C, 2000, ONCOGENE, V19, P3556, DOI 10.1038/sj.onc.1203683; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sheu BS, 1999, DIGEST DIS SCI, V44, P868, DOI 10.1023/A:1026627707103; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Tsutsumi R, 2003, J BIOL CHEM, V278, P3664, DOI 10.1074/jbc.M208155200; Wang X, 2000, APMIS, V108, P503, DOI 10.1034/j.1600-0463.2000.d01-89.x; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F	29	72	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8337	8342		10.1038/sj.onc.1207028	http://dx.doi.org/10.1038/sj.onc.1207028			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614457				2022-12-28	WOS:000186541500012
J	Seminario, MC; Precht, P; Wersto, RP; Gorospe, M; Wange, RL				Seminario, MC; Precht, P; Wersto, RP; Gorospe, M; Wange, RL			PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression	ONCOGENE			English	Article						PTEN; proliferation; cell cycle; apoptosis	TUMOR-SUPPRESSOR PTEN; ANTIGEN RECEPTOR; CARCINOMA-CELLS; PHOSPHATASE-ACTIVITY; GROWTH ARREST; APOPTOSIS; ACTIVATION; PATHWAY; SIZE; STIMULATION	The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27(KIP1) expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.	NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA; NIA, Flow Cytometry Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wange, RL (corresponding author), NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, 5600 Nathan Shock Dr,MSC-12, Baltimore, MD 21224 USA.	wanger@grc.nia.nih.gov	Wange, Ronald/AAI-2505-2021	Wange, Ronald/0000-0001-9593-3572	NATIONAL INSTITUTE ON AGING [Z01AG000509] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; ALLEN GD, 1990, BIOPHARM DRUG DISPOS, V11, P477, DOI 10.1002/bdd.2510110603; Appleman LJ, 2002, J IMMUNOL, V168, P2729, DOI 10.4049/jimmunol.168.6.2729; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cheyney IW, 1999, CANCER RES, V59, P2318; Davies MA, 1999, CANCER RES, V59, P2551; DAVIES MA, 2002, CLIN CANCER RES, V8, P1695; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Furnari FB, 1998, CANCER RES, V58, P5002; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; GOLD R, 1993, J HISTOCHEM CYTOCHEM, V41, P1023, DOI 10.1177/41.7.8515045; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; NORDSTROM T, 1992, EXP CELL RES, V202, P487, DOI 10.1016/0014-4827(92)90103-F; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; Shan XC, 2001, MOL CELL BIOL, V21, P7137, DOI 10.1128/MCB.21.21.7137-7149.2001; Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Wang XD, 2000, J IMMUNOL, V164, P1934, DOI 10.4049/jimmunol.164.4.1934; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; Ward SG, 2001, CURR OPIN IMMUNOL, V13, P332, DOI 10.1016/S0952-7915(00)00223-5; Weng LP, 1999, CANCER RES, V59, P5808; Weng LP, 2001, HUM MOL GENET, V10, P251, DOI 10.1093/hmg/10.3.251; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Wersto RP, 1998, J VIROL, V72, P9491, DOI 10.1128/JVI.72.12.9491-9502.1998; WERSTO RP, 1995, CYTOMETRY, V20, P43, DOI 10.1002/cyto.990200108; Wishart MJ, 2002, TRENDS CELL BIOL, V12, P579, DOI 10.1016/S0962-8924(02)02412-1; Wu RC, 2000, MOL CELL BIOCHEM, V203, P59, DOI 10.1023/A:1007024624967; Xu Z, 2002, CELL GROWTH DIFFER, V13, P285; Yamada KM, 2001, J CELL SCI, V114, P2375; Zhang SM, 2000, J IMMUNOL, V165, P6270, DOI 10.4049/jimmunol.165.11.6270; Zhu XY, 2001, CANCER RES, V61, P4569	47	42	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2003	22	50					8195	8204		10.1038/sj.onc.1206872	http://dx.doi.org/10.1038/sj.onc.1206872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603260				2022-12-28	WOS:000186403400014
J	Sato, M; Girard, L; Sekine, I; Sunaga, N; Ramirez, RD; Kamibayashi, C; Minna, JD				Sato, M; Girard, L; Sekine, I; Sunaga, N; Ramirez, RD; Kamibayashi, C; Minna, JD			Increased expression and no mutation of the Flap endonuclease (FEN1) gene in human lung cancer	ONCOGENE			English	Article						Flap endonuclease 1 (FEN1); base excision repair; microsatellite instability; lung cancer	NONPOLYPOSIS COLORECTAL-CANCER; DNA-REPLICATION FORK; MICROSATELLITE INSTABILITY; CELL-LINES; EXCISION; REPAIR; PATHOGENESIS; CARCINOMAS; TUMORS; GENOME	The underlying molecular mechanisms leading to microsatellite alteration and mutations in human lung cancer remain unknown. Since Flap endonuclease1 (Fen1), which functions in the base excision repair system, has been shown to be involved in tumor progression of mouse models with microsatellite instability in a haplo-insufficient manner, we performed expression and mutation analyses for FEN1 in human lung cancer cell lines. Reverse transcriptase PCR analysis revealed that all 49 lung cancer cell lines ( 20 small cell lung cancers (SCLCs) and 29 non-small cell lung cancers (NSCLCs)) expressed FEN1. In addition, microarray analysis showed that FEN1 expression was elevated significantly by 1.65-fold ( P = 0.001) in SCLC cell lines compared to normal lung controls ( normal human lung cultures and immortalized normal human bronchial epithelial cell lines). FEN1 protein was abundantly expressed in all 23 lung cancer cell lines ( 10 SCLCs and 13 NSCLCs) and was expressed at lower levels in three of four normal lung epithelial culture controls. Direct sequencing of genomic DNAs revealed no FEN1 mutation in seven SCLCs and nine NSCLCs. As part of this analysis we discovered and sequenced a FEN1 pseudogene ( GenBank accession # AY249897) located at 1p22.2. This pseudogene is amplified from cDNA preparations contaminated with genomic DNA and must be taken into account in any FEN1 mutation analysis studies. Our results suggest that alterations of FEN1 are not likely to contribute to development of lung cancer.	Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Minna, JD (corresponding author), Univ Texas, SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res NB8 206, 6000 HarryHines Blvd, Dallas, TX 75390 USA.	John.Minna@UTsouthwestern.edu	Sato, MITSUO/I-7280-2014	Sato, MITSUO/0000-0001-5458-9576	NCI NIH HHS [P50CA70907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Bhattacharyya N, 1999, DNA CELL BIOL, V18, P549, DOI 10.1089/104454999315097; Boland CR, 1998, CANCER RES, V58, P5248; Charbonnier F, 2002, CANCER RES, V62, P848; Chen KH, 1998, NUCLEIC ACIDS RES, V26, P2001, DOI 10.1093/nar/26.8.2001; Girard L, 2000, CANCER RES, V60, P4894; GUGGENHEIMER RA, 1984, J BIOL CHEM, V259, P7815; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Kucherlapati M, 2002, P NATL ACAD SCI USA, V99, P9924, DOI 10.1073/pnas.152321699; LINDAHL T, 1971, EUR J BIOCHEM, V18, P407, DOI 10.1111/j.1432-1033.1971.tb01257.x; Peltomaki P, 1997, GASTROENTEROLOGY, V113, P1146, DOI 10.1053/gast.1997.v113.pm9322509; Phelps RM, 1996, J CELL BIOCHEM, P32; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thibodeau SN, 1996, CANCER RES, V56, P4836; Virmani AK, 2001, CLIN CANCER RES, V7, P1998; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 1998, J PATHOL, V186, P319; Wijnen J, 1998, NAT GENET, V20, P326, DOI 10.1038/3795; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	28	54	60	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7243	7246		10.1038/sj.onc.1206977	http://dx.doi.org/10.1038/sj.onc.1206977			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562054				2022-12-28	WOS:000185955000017
J	Morgan, WF				Morgan, WF			Is there a common mechanism underlying genomic instability, bystander effects and other nontargeted effects of exposure to ionizing radiation?	ONCOGENE			English	Article						genomic instability; bystander effects; death inducing effect; transgenerational effects	INDUCED CHROMOSOMAL INSTABILITY; INFLAMMATORY-TYPE RESPONSES; ALPHA-PARTICLE IRRADIATION; IN-VIVO; UNIRRADIATED CELLS; DOSE-RESPONSE; OXIDATIVE STRESS; APOPTOSIS; INDUCTION; TRANSMISSION	A number of nontargeted and delayed effects associated with radiation exposure have now been described. These include radiation-induced genomic instability, death-inducing and bystander effects, clastogenic factors and transgenerational effects. It is unlikely that these nontargeted effects are directly induced by cellular irradiation. Instead, it is proposed that some as yet to be identified secreted factor can be produced by irradiated cells that can stimulate effects in nonirradiated cells (death-inducing and bystander effects, clastogenic factors) and perpetuate genomic instability in the clonally expanded progeny of an irradiated cell. The proposed factor must be soluble and capable of being transported between cells by cell-to-cell gap junction communication channels. Furthermore, it must have the potential to stimulate cellular cytokines and/or reactive oxygen species. While it is difficult to imagine a role for such a secreted factor in contributing to transgenerational effects, the other nontargeted effects of radiation may all share a common mechanism.	Univ Maryland, Radiat Oncol Res Lab, Baltimore, MD 21201 USA; Univ Maryland, Greenebaum Canc Ctr, Dept Radiat Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Morgan, WF (corresponding author), Univ Maryland, Radiat Oncol Res Lab, 655 W Baltimore St,BRB 7-011, Baltimore, MD 21201 USA.				NCI NIH HHS [CA73924, CA 83872] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083872, R01CA073924] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Dubrova YE, 2000, MUTAT RES-FUND MOL M, V453, P17, DOI 10.1016/S0027-5107(00)00068-3; Dubrova YE, 1998, INT J RADIAT BIOL, V74, P689, DOI 10.1080/095530098140952; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; HUANG L, 2003, IN PRESS ONCOGENE RE; Iyer R, 2000, CANCER RES, V60, P1290; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P5557; Limoli CL, 1999, RADIAT RES, V151, P677, DOI 10.2307/3580206; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Little JB, 2002, RADIAT PROT DOSIM, V99, P159, DOI 10.1093/oxfordjournals.rpd.a006751; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Nagar S, 2003, CANCER RES, V63, P324; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Rugo RE, 2002, RADIAT RES, V158, P210, DOI 10.1667/0033-7587(2002)158[0210:XRCAPI]2.0.CO;2; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Smith LE, 2003, HEALTH PHYS, V85, P23, DOI 10.1097/00004032-200307000-00006; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Wright EG, 1998, INT J RADIAT BIOL, V74, P681, DOI 10.1080/095530098140943; Xue LY, 2002, P NATL ACAD SCI USA, V99, P13765, DOI 10.1073/pnas.182209699	37	170	183	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7094	7099		10.1038/sj.onc.1206992	http://dx.doi.org/10.1038/sj.onc.1206992			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557815				2022-12-28	WOS:000185903900015
J	Noble, JR; Zhong, ZH; Neumann, AA; Melki, JR; Clark, SJ; Reddel, RR				Noble, JR; Zhong, ZH; Neumann, AA; Melki, JR; Clark, SJ; Reddel, RR			Alterations in the p16(INK4a) and p53 tumor suppressor genes of hTERT-immortalized human fibroblasts	ONCOGENE			English	Article						telomerase; hTERT; immortalization p16INK4a; CDKN2A; TP53	MAMMARY EPITHELIAL-CELLS; LIFE-SPAN; TELOMERASE ACTIVITY; ASSOCIATION; EXPRESSION; RECONSTITUTION; INACTIVATION; QUANTITATION; METHYLATION; ELONGATION	Exogenous expression of the catalytic subunit of telomerase, hTERT, in a normal human foreskin fibroblast cell strain resulted in telomerase activity and an extended proliferative lifespan prior to a period of crisis. Three immortalized cell lines with stably maintained telomere lengths were established from cells that escaped crisis. Each of these cultures underwent a significant downregulation of p16(INK4a) expression due to gene deletion events. One cell line also acquired mutations in both alleles of the p53 tumor suppressor gene. Downregulation of p16(INK4a) and loss of wild-type p53 expression occurred after escape from crisis, so these mutations are most likely not required for immortalization of these cells but rather were selected for during continuous growth in vitro. These findings emphasize the need for caution in the use of hTERT-immortalized cells in studies of normal cell biology or in tissue engineering and the need to monitor for genetic instability and the accumulation of mutations in both the p16(INK4a)/pRb and p53 pathways.	Childrens Med Res Inst, Sydney, NSW 2145, Australia; Univ Sydney, Sydney Canc Ctr, Sydney, NSW 2006, Australia	Children's Medical Research Institute - Australia; University of Sydney; University of Sydney	Reddel, RR (corresponding author), Childrens Med Res Inst, 214 Hawkesbury Rd, Sydney, NSW 2145, Australia.	rreddel@cmri.usyd.edu.au	Reddel, Roger R/A-6635-2014; Clark, Susan J/U-7365-2019; Neumann, Axel/D-3319-2012; Clark, Susan J/B-2272-2008	Reddel, Roger R/0000-0002-6302-6107; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030				Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; Colgin LM, 2000, NEOPLASIA, V2, P426, DOI 10.1038/sj.neo.7900112; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; GIRARDI AJ, 1965, J CELL COMPAR PHYSL, V65, P69, DOI 10.1002/jcp.1030650110; Harland M, 2000, GENE CHROMOSOME CANC, V28, P45, DOI 10.1002/(SICI)1098-2264(200005)28:1<45::AID-GCC6>3.3.CO;2-6; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Holland EA, 1995, ONCOGENE, V11, P2289; Huschtscha LI, 1998, CANCER RES, V58, P3508; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kaul SC, 2003, EXP CELL RES, V286, P96, DOI 10.1016/S0014-4827(03)00101-0; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; McGregor F, 2002, CANCER RES, V62, P4757; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Noble JR, 1996, ONCOGENE, V13, P1259; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; Paul CL, 1996, BIOTECHNIQUES, V21, P126; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Reddel RR, 2000, CARCINOGENESIS, V21, P477, DOI 10.1093/carcin/21.3.477; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROONEY D, 1992, HUMAN CYTOGENETICS P, V1; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Toouli CD, 2002, ONCOGENE, V21, P128, DOI 10.1038/sj.onc.1205014; Tsutsui T, 2002, CARCINOGENESIS, V23, P2111, DOI 10.1093/carcin/23.12.2111; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; von Zglinicki T, 2002, TRENDS BIOCHEM SCI, V27, P339, DOI 10.1016/S0968-0004(02)02110-2; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 2002, NAT BIOTECHNOL, V20, P682, DOI 10.1038/nbt0702-682	44	39	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3116	3121		10.1038/sj.onc.1207440	http://dx.doi.org/10.1038/sj.onc.1207440			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14743210				2022-12-28	WOS:000220845200016
J	Oliveira, C; de Bruin, J; Nabais, S; Ligtenberg, M; Moutinho, C; Nagengast, FM; Seruca, R; van Krieken, H; Carneiro, F				Oliveira, C; de Bruin, J; Nabais, S; Ligtenberg, M; Moutinho, C; Nagengast, FM; Seruca, R; van Krieken, H; Carneiro, F			Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour	ONCOGENE			English	Article						E-cadherin; hereditary diffuse gastric cancer; HDGC; mutation; intragenic deletion; second hit	FAMILIAL GASTRIC-CANCER; E-CADHERIN GENE; GERMLINE MUTATIONS; BETA-CATENIN; CARCINOMA; METHYLATION; EXPRESSION; PATTERNS; CELLS	Mutations in CDH1, encoding E- cadherin, are the underlying genetic defect in approximately one- third of the hereditary diffuse gastric cancer ( HDGC) families described so far. Tumours arising in these families show abnormal or absence of E- cadherin expression, following the model of tumour suppressor gene inactivation. A single study has been reported showing inactivation of the CDH1 wild- type allele in tumour cells from HDGC families either by promoter methylation or by somatic mutation. In order to find the genetic alteration responsible for the presence of diffuse gastric cancers in four members of a Caucasian family, we have screened the coding sequence of CDH1 for germline mutations and searched for the second inactivating hit in the tumour samples. In this family, we have found a germline splice- site mutation in all members affected by gastric cancer and, in one tumour, a somatic deletion affecting at least exon 8 of CDH1. Our results show that a CDH1 intragenic deletion is the second hit inactivating the wild- type allele, in one of the tumours in this family.	Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal; Univ Med Ctr Nijmegen, Dept Pathol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Gastroenterol, NL-6500 HB Nijmegen, Netherlands; Univ Porto, Fac Med, P-4200465 Oporto, Portugal	Universidade do Porto; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Universidade do Porto	Oliveira, C (corresponding author), Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, P-4200465 Oporto, Portugal.	carlaol@ipatimup.pt	seruca, raquel/F-8187-2011; Ligtenberg, Marjolijn/N-9666-2013; Oliveira, Carla/F-8188-2011; Carneiro, Fatima/J-6432-2013; Nabais, Sérgio/AAQ-5859-2020; van Krieken, Joannes H J M/D-4138-2009; Carneiro, Fatima/AAV-8677-2021	Ligtenberg, Marjolijn/0000-0003-1290-1474; Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; van Krieken, Joannes H J M/0000-0001-6544-1040; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166				Avizienyte E, 2001, J MED GENET, V38, P49, DOI 10.1136/jmg.38.1.49; Caldas C, 1999, J MED GENET, V36, P873; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Dussaulx-Garin L, 2001, EUR J GASTROEN HEPAT, V13, P711, DOI 10.1097/00042737-200106000-00016; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Huber AH, 2001, J BIOL CHEM, V276, P12301, DOI 10.1074/jbc.M010377200; Humar B, 2002, HUM MUTAT, V19, P518, DOI 10.1002/humu.10067; Iida S, 1999, CLIN CANCER RES, V5, P1445; Jonsson BA, 2002, INT J CANCER, V98, P838, DOI 10.1002/ijc.10258; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; Machado JC, 2000, J PATHOL, V190, P437; Machado JC, 1998, INT J SURG PATHOL, V6, P135, DOI 10.1177/106689699800600302; Nabais S, 2003, INT J SURG PATHOL, V11, P1, DOI 10.1177/106689690301100102; Oliveira C, 2003, EXPERT REV MOL DIAGN, V3, P201; Oliveira C, 2002, HUM MUTAT, V19, P510, DOI 10.1002/humu.10068; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Shinmura K, 1999, CARCINOGENESIS, V20, P1127, DOI 10.1093/carcin/20.6.1127; Wang Y, 2003, JPN J CLIN ONCOL, V33, P17, DOI 10.1093/jjco/hyg002; Yabuta T, 2002, INT J CANCER, V101, P434, DOI 10.1002/ijc.10633; Yoon KA, 1999, J HUM GENET, V44, P177, DOI 10.1007/s100380050137	25	70	73	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2236	2240		10.1038/sj.onc.1207335	http://dx.doi.org/10.1038/sj.onc.1207335			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14661064				2022-12-28	WOS:000220280900014
J	Nagano, K; Masters, JR; Akpan, A; Yang, A; Corless, S; Wood, C; Hastie, C; Zvelebil, M; Cramer, R; Naaby-Hansen, S				Nagano, K; Masters, JR; Akpan, A; Yang, A; Corless, S; Wood, C; Hastie, C; Zvelebil, M; Cramer, R; Naaby-Hansen, S			Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons	ONCOGENE			English	Article						prostate cancer; interferon treatment; growth inhibitory effect of interferon	NUCLEAR RIBONUCLEOPROTEIN-K; HNRNP-K; ENDOPLASMIC-RETICULUM; IFN-GAMMA; C-SRC; CANCER; GENE; PHOSPHORYLATION; PATHWAYS; NMI	Protein expression and de novo synthesis in normal and prostate cancer cell lines derived from the same patient were compared by proteomic analysis, and the effects of INFalpha and INFgamma ( INF = interferon) determined. The expressions of several INF-inducible proteins, including MxA, Nmi, PA28a and IFP53, were downregulated in the cancer cells. INFgamma induced a more than twofold increase or decrease in the synthesis rates of almost twice as many proteins in the cancer cell line. The positive regulator of INF-induced transcription ISGF3gamma was upregulated in the cancer cells and inversely regulated by INFalpha and INFgamma in the normal and cancer cells. Moreover, ISGF3gamma's induction by INFgamma in the cancer cells was more enhanced by simultaneous stimulation with EGF, than its induction in the normal cells. In all, 31 differentially regulated proteins were identified by mass spectrometry analysis, several of which are involved in chaperone-assisted protein folding in the endoplasmic reticulum ( ER) or in regulated protein degradation. Our results suggest that the exclusion of proteins by the ER quality control system, crosstalk between the EGF- and INF-induced signalling pathways and the regulation of INF-inducible genes are all altered in the prostate cancer cells. The combination of upregulated activity in the growth-promoting PI3K/Akt pathway, suppression of Nmi and overexpression of hnRNP-K and c-myc proteins may explain why the prostate cancer cells were found to be more resistant to the growth inhibitory effects of INFgamma.	Royal Free & UCL, Ludwig Inst Canc Res, Sch Med, London W1W 7BS, England; Royal Free & UCL, Prostate Canc Res Ctr, Sch Med, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London, England	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London	Naaby-Hansen, S (corresponding author), Royal Free & UCL, Ludwig Inst Canc Res, Sch Med, Coutauld Bldg,91 Riding House St, London W1W 7BS, England.	soren@ludwig.ucl.ac.uk	Masters, John R/C-5694-2011; aukim-hastie, claire/A-7485-2011	Zvelebil, Marketa/0000-0001-8018-5591; Cramer, Rainer/0000-0002-8037-2511				Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090; Bao JX, 1996, ONCOGENE, V12, P2171; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Benvenuti S, 2002, MOL CELL PROTEOMICS, V1, P280, DOI 10.1074/mcp.M100028-MCP200; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Braddock DT, 2002, EMBO J, V21, P3476, DOI 10.1093/emboj/cdf352; Bright RK, 1997, CANCER RES, V57, P995; Da Silva N, 2002, BLOOD, V100, P3536, DOI 10.1182/blood.V100.10.3536; Delom F, 2001, J BIOL CHEM, V276, P21337, DOI 10.1074/jbc.M101086200; ENTWISTLE A, 1994, J MICROSC-OXFORD, V175, P238, DOI 10.1111/j.1365-2818.1994.tb03490.x; Frigerio L, 2000, CURR BIOL, V10, pR674, DOI 10.1016/S0960-9822(00)00680-1; Habelhah H, 2001, NAT CELL BIOL, V3, P325, DOI 10.1038/35060131; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Kuratsukuri K, 2000, UROL ONCOL, V5, P265, DOI 10.1016/S1078-1439(00)00086-7; MAKI RG, 1990, P NATL ACAD SCI USA, V87, P5658, DOI 10.1073/pnas.87.15.5658; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; Naaby-Hansen S, 2001, TRENDS PHARMACOL SCI, V22, P376, DOI 10.1016/S0165-6147(00)01663-1; NAABYHANSEN S, 2003, PROTEOMICS ANAL PROS, P277; Nakaya T, 2001, BIOCHEM BIOPH RES CO, V283, P1150, DOI 10.1006/bbrc.2001.4913; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Ostareck-Lederer A, 2002, MOL CELL BIOL, V22, P4535, DOI 10.1128/MCB.22.13.4535-4543.2002; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Quang CT, 2000, EMBO J, V19, P4565, DOI 10.1093/emboj/19.17.4565; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Roberts WW, 2001, UROLOGY, V57, P1033, DOI 10.1016/S0090-4295(01)00978-5; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sampath P, 2003, MOL CELL BIOL, V23, P1509, DOI 10.1128/MCB.23.5.1509-1519.2003; Scadden ADJ, 2001, METHOD ENZYMOL, V341, P126, DOI 10.1016/S0076-6879(01)41149-9; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Sueoka E, 1999, CANCER RES, V59, P1404; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; Vigneswaran N, 2000, HUM PATHOL, V31, P931, DOI 10.1053/hupa.2000.9035; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Wu YX, 2000, J CELL BIOCHEM, V79, P311, DOI 10.1002/1097-4644(20001101)79:2<311::AID-JCB140>3.0.CO;2-Z; Yu ZB, 2002, J BIOL CHEM, V277, P40247, DOI 10.1074/jbc.M207608200; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	45	47	49	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1693	1703		10.1038/sj.onc.1207297	http://dx.doi.org/10.1038/sj.onc.1207297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14647428				2022-12-28	WOS:000220029300005
J	Piccolo, E; Vignati, S; Maffucci, T; Innominato, PF; Riley, AM; Potter, BVL; Pandolfi, PP; Broggini, M; Iacobelli, S; Innocenti, P; Falasca, M				Piccolo, E; Vignati, S; Maffucci, T; Innominato, PF; Riley, AM; Potter, BVL; Pandolfi, PP; Broggini, M; Iacobelli, S; Innocenti, P; Falasca, M			Inositol pentakisphosphate promotes apoptosis through the PI3-K/Akt pathway	ONCOGENE			English	Article						phosphoinositide 3-kinase; pleckstrin homology domain; inositol polyphosphates; protein kinase B-Akt; apoptosis	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; LUNG-CANCER CELLS; PHOSPHOINOSITIDE 3-KINASE; DRUG-RESISTANCE; MEMBRANE; ACTIVATION; AKT; SPECIFICITY; PHOSPHATES	Phosphoinositide 3-kinase ( PI 3-K) is implicated in a wide array of biological and pathophysiological responses, including tumorigenesis, invasion and metastasis, therefore specific inhibitors of the kinase may prove useful in cancer therapy. We propose that specific inositol polyphosphates have the potential to antagonize the activation of PI 3-K pathways by competing with the binding of PtdIns(3,4,5) P-3 to pleckstrin homology (PH) domains. Here we show that Ins(1,3,4,5,6) P-5 inhibits the serine phosphorylation and the kinase activity of Akt/PKB. As a consequence of this inhibition, Ins(1,3,4,5,6) P-5 induces apoptosis in ovarian, lung and breast cancer cells. Overexpression of constitutively active Akt protects SKBR-3 cells from Ins(1,3,4,5,6) P-5-induced apoptosis. Furthermore, Ins(1,3,4,5,6) P-5 enhances the proapoptotic effect of cisplatin and etoposide in ovarian and lung cancer cells, respectively. These results support a role for Ins(1,3,4,5,6) P-5 as a specific inhibitor of the PI 3-K/Akt signalling pathway, that may sensitize cancer cells to the action of commonly used anticancer drugs.	UCL, Dept Med, Sackler Inst, Rayne Inst, London WC1E 6JJ, England; Univ G dAnnunzio, Dept Oncol & Neurosci, Sect Med Oncol, I-66100 Chieti, Italy; Mario Negri Inst Pharmacol Res, Mol Pharmacol Lab, Dept Oncol, I-20157 Milan, Italy; Univ Bath, Wolfson Lab Med Chem, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, Dept Pathol, New York, NY 10021 USA; Univ G dAnnunzio, Dept Surg Sci, I-66100 Chieti, Italy	University of London; King's College London; University College London; G d'Annunzio University of Chieti-Pescara; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Bath; Memorial Sloan Kettering Cancer Center; G d'Annunzio University of Chieti-Pescara	Falasca, M (corresponding author), UCL, Dept Med, Sackler Inst, Rayne Inst, 5 Univ St, London WC1E 6JJ, England.	m.falasca@ucl.ac.uk	Potter, Barry/AAX-4781-2020; broggini, massimo/AAA-6460-2020; Potter, Barry VL/A-1845-2012; Riley, Andrew M/F-3526-2013; Falasca, Marco/S-4020-2016	Riley, Andrew M/0000-0001-9003-3540; Falasca, Marco/0000-0002-9801-7235; BROGGINI, MASSIMO/0000-0002-8138-9358				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Berrie CP, 2000, FASEB J, V14, P2618, DOI 10.1096/fj.00-0096hyp; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Clark AS, 2002, MOL CANCER THER, V1, P707; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUKE RC, 1992, CURRENT PROTOCOLS IM; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Mills SJ, 2003, CHEM-EUR J, V9, P6207, DOI 10.1002/chem.200305207; Moore SM, 1998, CANCER RES, V58, P5239; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; Riley AM, 1998, J ORG CHEM, V63, P295, DOI 10.1021/jo9714425; Rintoul RC, 2002, CLIN SCI, V102, P417, DOI 10.1042/CS20010216; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Stein RC, 2001, ENDOCR-RELAT CANCER, V8, P237, DOI 10.1677/erc.0.0080237; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SZWERGOLD BS, 1987, BIOCHEM BIOPH RES CO, V149, P874, DOI 10.1016/0006-291X(87)90489-X; Takeuchi H, 1997, BBA-MOL CELL RES, V1359, P275, DOI 10.1016/S0167-4889(97)00109-2; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vikhanskaya F, 2002, INT REV CYTOL, V219, P157; Vincent SP, 2002, BIOORGAN MED CHEM, V10, P2825, DOI 10.1016/S0968-0896(02)00162-1; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450	54	81	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1754	1765		10.1038/sj.onc.1207296	http://dx.doi.org/10.1038/sj.onc.1207296			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14755253				2022-12-28	WOS:000220029300011
J	Yuan, BZ; Jefferson, AM; Baldwin, KT; Thorgeirsson, SS; Popescu, NC; Reynolds, SH				Yuan, BZ; Jefferson, AM; Baldwin, KT; Thorgeirsson, SS; Popescu, NC; Reynolds, SH			DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas	ONCOGENE			English	Article						DLC-1; tumor suppressor gene; non-small cell lung carcinoma; aberrant DNA methylation; tumorigenicity	ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CLINICAL IMPLICATIONS; RAS TRANSFORMATION; UNITED-STATES; RHOGAP; PATHOGENESIS; IMBALANCES; EXPRESSION	The deleted in liver cancer (DLC-1) gene at chromosome 8p21-22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth. Given the high frequency of deletion involving region 8p21-22 in human non-small cell lung carcinoma (NSCLC), we examined alterations of DLC-1 in a series of primary tumors and tumor cell lines and tested effects of DLC-1 on tumor cell growth. A significant decrease or absence of the DLC-1 mRNA expression was found in 95% of primary NSCLC (20/21) and 58% of NSCLC cell lines (11/19). Transcriptional silencing of DLC-1 was primarily associated with aberrant DNA methylation, rather than genomic deletion as 5-aza-2'-deoxycytidine induced reactivation of DLC-1 expression in 82% (9/11) NSCLC cell lines showing downregulated DLC-1. It was further evidenced by an aberrant DLC-1 promoter methylation pattern, which was detected by Southern blotting in 73% (8/11) of NSCLC cell lines with downregulation of the gene. The transfer of DLC-1 into three DLC-1 negative cell lines caused a significant inhibition in cell proliferation and/or a decrease in colony formation. Furthermore, stable transfer of DLC-1 abolished tumorigenicity in nude mice of two cell lines, suggesting that DLC-1 plays a role in NSCLC by acting as a bona. de new tumor suppressor gene.	NIOSH, Lab Genet Susceptibil, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuan, BZ (corresponding author), 1095 Willowdale Rd,Mailstop L-3014, Morgantown, WV 26505 USA.	bby1@cdc.gov			NATIONAL CANCER INSTITUTE [Z01BC010038, ZIABC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Belinsky SA, 2002, CANCER RES, V62, P2370; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Girard L, 2000, CANCER RES, V60, P4894; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P277, DOI 10.1093/jnci/93.4.277; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kurimoto F, 2001, INT J MOL MED, V8, P89; Minna JD, 2002, CANCER J, V8, pS41; Ng IOL, 2000, CANCER RES, V60, P6581; Niklinski J, 2001, EUR J CANCER PREV, V10, P213, DOI 10.1097/00008469-200106000-00004; Park SW, 2003, INT J ONCOL, V23, P133; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Soria JC, 2002, CANCER RES, V62, P351; Steenland K, 1996, AM J IND MED, V29, P474, DOI 10.1002/(SICI)1097-0274(199605)29:5<474::AID-AJIM6>3.0.CO;2-M; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Vecchione A, 2001, CLIN CANCER RES, V7, P1546; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wistuba II, 1999, CANCER RES, V59, P1973; Yin XL, 2002, CANCER GENET CYTOGEN, V134, P71, DOI 10.1016/S0165-4608(01)00611-2; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zheng SQL, 2003, MUTAT RES-FUND MOL M, V528, P45, DOI 10.1016/S0027-5107(03)00081-2; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	34	126	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1405	1411		10.1038/sj.onc.1207291	http://dx.doi.org/10.1038/sj.onc.1207291			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14661059				2022-12-28	WOS:000189035800007
J	Liu, WM; Powles, T; Shamash, J; Propper, D; Oliver, T; Joel, S				Liu, WM; Powles, T; Shamash, J; Propper, D; Oliver, T; Joel, S			Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity	ONCOGENE			English	Article						GM-CSF; Epo; apoptosis; chemosensitivity; receptors	COLONY-STIMULATING FACTOR; GM-CSF; IN-VITRO; RECEPTOR EXPRESSION; BCL-2 EXPRESSION; LEUKEMIA CELLS; DOUBLE-BLIND; BONE-MARROW; C-KIT; ERYTHROPOIETIN	The recombinant growth factors (GFs) erythropoietin (Epo) and granulocyte-macrophage colony stimulating factor (GM-CSF) have important roles in the management of cancer patients. However, the effects of these GFs at a cellular level are not well understood. We examined the effect of GFs alone, and in combination with cytotoxic chemotherapy, in a panel of seven cell lines. Flow cytometric analysis showed varying levels of receptor expression, which correlated with phosphorylated MAPK expression. Additionally, there were also concomitant increases in BCL-2 protein levels in those cells with high levels of MAPK activation. Although culturing cells with Epo or GM-CSF did not alter cell viability by themselves, GF pretreatment in cell lines expressing higher receptor levels resulted in a reduced magnitude of cell kill following exposure to cytotoxic IC50 concentrations of cisplatin. Subsequent co-culture with either the MEK inhibitor U0126 or the GM-CSF antagonist E21R negated this induced resistance to cytotoxic chemotherapy, confirming the importance of the GF receptor as well as MAPK in mediating these effects. These results suggest that the use of GFs during chemotherapy may be detrimental in those cancers expressing higher levels of the specific receptor. Conversely, our results also suggest that GFs are safe to use in chemotherapeutic regimens if the cancer cells do not overexpress the particular receptor.	St Bartholomews Hosp, Barry Reed Oncol Lab, New Drug Study Grp, London, England	University of London; Queen Mary University London	Liu, WM (corresponding author), Inst Canc Res, Haddow Labs, Med Sect, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	wai.liu@icr.ac.uk	Liu, Wai/B-7877-2008	Liu, Wai/0000-0001-7099-7510; Oliver, Tim/0000-0002-7879-8943				ABELS R, 1993, EUR J CANC S, V2, P2; Acs G, 2002, CANCER-AM CANCER SOC, V95, P969, DOI 10.1002/cncr.10787; Anderson P, 1997, MICROBIOL MOL BIOL R, V61, P33, DOI 10.1128/.61.1.33-46.1997; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BERDEL WE, 1989, BLOOD, V73, P80; BI SC, 1992, LEUKEMIA, V6, P839; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; BRADBURY D, 1994, LEUKEMIA, V8, P786; Bratthauer G L, 1999, Methods Mol Biol, V115, P203; CHERVENICK PA, 1971, BLOOD-J HEMATOL, V37, P131, DOI 10.1182/blood.V37.2.131.131; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Clark O, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-23; CLARKE BJ, 1977, P NATL ACAD SCI USA, V74, P1105, DOI 10.1073/pnas.74.3.1105; DASILVA JL, 1990, BLOOD, V75, P577; DeJong MO, 1997, STEM CELLS, V15, P275, DOI 10.1002/stem.150275; DEL PL, 1997, SCIENCE, V278, P687; Dempke W, 2000, ANTICANCER RES, V20, P5155; EVERSON MP, 1989, BLOOD, V74, P1472; Fallowfield L, 2002, BRIT J CANCER, V87, P1341, DOI 10.1038/sj.bjc.6600657; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fukumi S, 2000, MOL CELL BIOCHEM, V206, P43, DOI 10.1023/A:1007056727876; Galea HR, 2002, CLIN EXP IMMUNOL, V129, P247, DOI 10.1046/j.1365-2249.2002.01929.x; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gerharz CD, 2001, UROLOGY, V58, P821, DOI 10.1016/S0090-4295(01)01371-1; Hisakawa H, 2001, BLOOD, V98, P3618, DOI 10.1182/blood.V98.13.3618; Iversen PO, 1996, BLOOD, V88, P2634, DOI 10.1182/blood.V88.7.2634.bloodjournal8872634; Iversen PO, 1996, P NATL ACAD SCI USA, V93, P2785, DOI 10.1073/pnas.93.7.2785; Iversen PO, 1997, J BIOL CHEM, V272, P9877; Kapur R, 2001, J BIOL CHEM, V276, P1099, DOI 10.1074/jbc.M007442200; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KURZROCK R, 1991, LEUKEMIA, V5, P985; LAUGHLIN MJ, 1993, ANN HEMATOL, V67, P267, DOI 10.1007/BF01696346; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Liu WM, 1998, CANCER CHEMOTH PHARM, V41, P343, DOI 10.1007/s002800050749; Liu WM, 2002, EUR J CANCER, V38, P842, DOI 10.1016/S0959-8049(02)00016-3; Liu WM, 2002, BRIT J CANCER, V86, P1472, DOI 10.1038/sj.bjc.6600288; LOPEZ AF, 1992, EMBO J, V11, P909, DOI 10.1002/j.1460-2075.1992.tb05129.x; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LOTEM J, 1995, CELL GROWTH DIFFER, V6, P647; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MCCREDIE KB, 1971, SCIENCE, V171, P293, DOI 10.1126/science.171.3968.293; MCGUCKIN CP, 1995, EXP HEMATOL, V23, P14; ORAZI A, 1992, BLOOD, V79, P2610; Park SA, 2001, MOL BRAIN RES, V93, P18, DOI 10.1016/S0169-328X(01)00176-0; Pless M, 1997, BLOOD, V89, P3175, DOI 10.1182/blood.V89.9.3175; Ramshaw HS, 2002, EXP HEMATOL, V30, P1124, DOI 10.1016/S0301-472X(02)00903-7; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SEGER R, 1992, J BIOL CHEM, V267, P25628; SHABO Y, 1990, LEUKEMIA, V4, P797; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; STEWARD WP, 1993, LANCET, V342, P153, DOI 10.1016/0140-6736(93)91350-U; Vansteenkiste J, 2002, J NATL CANCER I, V94, P1211; Westenfelder C, 2000, KIDNEY INT, V58, P647, DOI 10.1046/j.1523-1755.2000.00211.x; Westphal G, 2002, TUMORI, V88, P150, DOI 10.1177/030089160208800214; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	57	48	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					981	990		10.1038/sj.onc.1207294	http://dx.doi.org/10.1038/sj.onc.1207294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647427				2022-12-28	WOS:000188486600014
J	Scapoli, L; Ramos-Nino, ME; Martinelli, M; Mossman, BT				Scapoli, L; Ramos-Nino, ME; Martinelli, M; Mossman, BT			Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for cell proliferation by asbestos	ONCOGENE			English	Article						mitogen-activated protein kinases; asbestos; activator protein-1	EPIDERMAL-GROWTH-FACTOR; FACTOR-RECEPTOR PROTEIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; PHOSPHORYLATION; EXPRESSION; APOPTOSIS; IDENTIFICATION; MECHANISMS; BMK1/ERK5	Crocidolite asbestos elicits oxidative stress and cell proliferation, but the signaling cascades linked to these outcomes are unclear. To determine the role of mitogen-activated protein kinases ( MAPK) in asbestos-induced cell signaling, we evaluated the effects of crocidolite asbestos, EGF and H2O2, on MAPK activation in murine lung epithelial cells (C10 line). In contrast to rapid and transient activation of extracellular signal-regulated kinase 5 (ERK5) by EGF or H2O2, asbestos caused protracted oxidant-dependent ERK5 activation that was inhibited by an Src kinase inhibitor (PP2), but not by an inhibitor of epidermal growth factor receptor ( EGFR) phosphorylation (AG1478). ERK1/2 activation by asbestos was inhibited by either PP2 or AG1478. To confirm the involvement of Src in ERK1/2 and ERK5 activation, a dominant-negative Src construct was used. These experiments showed that Src was essential for ERK1/2and also ERK5 phosphorylation by asbestos. Time frame studies indicated immediate activation of Src by asbestos fibers, whereas EGFR phosphorylation occurred subsequently. Data suggest that asbestos causes activation of ERK5 through an EGFR-independent pathway, whereas ERK1/ 2 activation is dependent on Src through a mechanism involving phosphorylation of the EGFR. Furthermore, Src, ERK1/ 2 and ERK5 activation are essential for cell proliferation by asbestos. The use of a dominant-negative ERK5 construct caused selective downregulation of c-jun expression, whereas inhibition of Src by PP2 or MEK1 by PD98059 caused decreases in c-fos, fra-1 and c-jun expression in asbestos-exposed C10 cells. These observations may have broad relevance to cell proliferation by carcinogenic mineral fibers and oxidants.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA	University of Vermont	Mossman, BT (corresponding author), Univ Vermont, Coll Med, Dept Pathol, 89 Beaumont Ave, Burlington, VT 05405 USA.	Brooke.Mossman@uvm.edu	Scapoli, Luca/C-6152-2008; Scapoli, Luca/I-7609-2019	Scapoli, Luca/0000-0003-4006-9910; Scapoli, Luca/0000-0003-4006-9910	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009213] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL67005] Funding Source: Medline; NIEHS NIH HHS [R01 ES/HL09213] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abe MK, 1999, MOL CELL BIOL, V19, P1301; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; BeruBe KA, 1996, AM J RESP CELL MOL, V15, P141, DOI 10.1165/ajrcmb.15.1.8679218; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Buder-Hoffmann S, 2001, AM J RESP CELL MOL, V24, P405, DOI 10.1165/ajrcmb.24.4.4290; CAMPBELL WJ, 1980, 8452 US BUR MIN; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kamp DW, 1995, TOXICOL PATHOL, V23, P689, DOI 10.1177/019262339502300606; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666, DOI 10.1164/ajrccm.157.5.9707141; MOSSMAN BT, 1990, SCIENCE, V247, P294, DOI 10.1126/science.2153315; Mossman BT, 1996, CANCER INVEST, V14, P466, DOI 10.3109/07357909609018904; Mossman BT, 2000, INHAL TOXICOL, V12, P307, DOI 10.1080/08958378.2000.11463240; Pache JC, 1998, AM J PATHOL, V152, P333; Ramos-Nino ME, 2003, CANCER RES, V63, P3539; Ramos-Nino ME, 2002, MOL CELL BIOCHEM, V234, P111, DOI 10.1023/A:1015924413043; Robledo RF, 2000, AM J PATHOL, V156, P1307, DOI 10.1016/S0002-9440(10)65001-8; Shukla A, 2001, CANCER RES, V61, P1791; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Wu WD, 2002, J BIOL CHEM, V277, P24252, DOI 10.1074/jbc.M200437200; Zanella CL, 1996, CANCER RES, V56, P5334; Zanella CL, 1999, AM J PHYSIOL-LUNG C, V277, pL684, DOI 10.1152/ajplung.1999.277.4.L684; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	32	77	82	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					805	813		10.1038/sj.onc.1207163	http://dx.doi.org/10.1038/sj.onc.1207163			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737115				2022-12-28	WOS:000188304900019
J	Whiteside, MA; Chen, DT; Desmond, RA; Abdulkadir, SA; Johanning, GL				Whiteside, MA; Chen, DT; Desmond, RA; Abdulkadir, SA; Johanning, GL			A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance	ONCOGENE			English	Article						lung cancer; drug resistance; gene expression profiling; mechanisms of drug action	CANCER CELL-LINES; PLASMINOGEN-ACTIVATOR; EXPRESSION PROFILES; LUNG-CANCER; DNA-REPAIR; STROMELYSIN-3; CHEMOSENSITIVITY; RADIATION; BRCA1; OVEREXPRESSION	In recent years, most cDNA microarray studies of chemotherapeutic drug resistance have not considered the temporal pattern of gene expression. The objective of this study was to examine systematically changes in gene expression of NCI-H226 and NCI-H2170 lung cancer cells treated weekly with IC10 doses of cisplatin. NCI-H226 lung cancer cells were treated weekly with an IC10 dose of cisplatin. Candidate genes with a fold change of 2.0 or more were identified from this study. A second experiment was conducted by exposing NCI-H2170 cells to cisplatin doses that were increased in week 4 and decreased in week 5. Overall, 44 genes were differentially expressed in both the NCI-H226 and NCI-H2170 cell lines. In the NCI-H2170 cell line, 24 genes had a twofold gene expression change from weeks 3 to 4. Real-time PCR found a significant correlation of the gene expression changes for seven genes of interest. This small time-ordered series identified novel genes associated with cisplatin resistance. This kind of analysis should be viewed as a first step towards building gene-regulatory networks.	Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA; NCI, Canc Prevent Fellowship Program, Bethesda, MD 20892 USA; Univ Alabama Birmingham, Biostat & Bioinformat Unit, Birmingham, AL USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Johanning, GL (corresponding author), Univ Alabama Birmingham, Dept Nutr Sci, Rm 404 Webb Bldg,1675 Univ Blvd, Birmingham, AL 35294 USA.	garyj@uab.edu						Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Amundson SA, 2000, CANCER RES, V60, P6101; ANDERSON IC, 1995, CANCER RES, V55, P4120; Anderson KM, 2002, ANTICANCER RES, V22, P75; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bolon I, 1997, AM J PATHOL, V150, P1619; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Boulay A, 2001, CANCER RES, V61, P2189; Brognard J, 2001, CANCER RES, V61, P3986; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Clave E, 1997, LEUKEMIA, V11, P114, DOI 10.1038/sj.leu.2400528; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; Dan S, 2002, CANCER RES, V62, P1139; De Larco JE, 2001, CANCER RES, V61, P2857; Delebecq TJ, 2000, CLIN CANCER RES, V6, P1086; Dunkern TR, 2001, MUTAT RES-DNA REPAIR, V486, P249, DOI 10.1016/S0921-8777(01)00095-7; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; Kudoh K, 2000, CANCER RES, V60, P4161; Lai WW, 2001, ANN THORAC SURG, V72, P1868, DOI 10.1016/S0003-4975(01)03207-6; Lamendola DE, 2003, CANCER RES, V63, P2200; Lee DH, 2003, CANCER RES, V63, P4648; Li QD, 2000, ANTICANCER RES, V20, P645; Mousses S, 2001, ONCOGENE, V20, P6718, DOI 10.1038/sj.onc.1204889; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Munster PN, 2002, CANCER RES, V62, P3132; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; Phelps RM, 1996, J CELL BIOCHEM, P32; PLUMB JA, 1989, CANCER RES, V49, P4435; Rajeevan MS, 2001, METHODS, V25, P443, DOI 10.1006/meth.2001.1266; Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439; Wang Y, 2000, GENE DEV, V14, P927; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhang JL, 1999, BIOCHEM J, V337, P231, DOI 10.1042/0264-6021:3370231	34	29	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					744	752		10.1038/sj.onc.1207164	http://dx.doi.org/10.1038/sj.onc.1207164			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737109				2022-12-28	WOS:000188304900013
J	Zhao, H; Dupont, J; Yakar, S; Karas, M; LeRoith, D				Zhao, H; Dupont, J; Yakar, S; Karas, M; LeRoith, D			PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells	ONCOGENE			English	Article						PTEN; IGF-IR; prostate cancer; protein synthesis; apoptosis	ADENOVIRAL-MEDIATED EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; INSULIN; RECEPTOR; ACTIVATION; PHOSPHORYLATION; DEGRADATION; METASTASIS; BREAST	PTEN is a tumor suppressor gene that is frequently mutated in human tumors. It functions primarily as a lipid phosphatase and plays a key role in the regulation of phosphatidylinositol-3'-kinase. PTEN appears to play a crucial role in modulating apoptosis by reducing the levels of PtdIns(3,4,5) P3, a phospholipid that activates AKT, a central regulator of apoptosis. To understand the role of PTEN in regulating cell proliferation and apoptosis, we stably overexpressed PTEN in PC3 cells, which are prostate cancer cells that lack PTEN. Overexpression of PTEN in two different clones inhibited cell proliferation and increased serum starvation-induced apoptosis, as compared to control cells. Interestingly, PTEN overexpression resulted in a 44 - 60% reduction in total insulin-like growth factor-I receptor (IGF-IR) protein levels and a 49 - 64% reduction in cell surface IGF-IR expression. [S-35] methionine pulse experiments in PC3 cells overexpressing PTEN demonstrated that these cells synthesize significantly lower levels of the IGF-IR precursor, whereas PTEN overexpression had no effect on IGF-IR degradation. Taken together, our results show that PTEN can regulate cell proliferation and apoptosis through inhibition of IGF-IR synthesis. These results have important implications for understanding the roles of PTEN and the IGF-IR in prostate cancer cell tumorigenesis.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Room 8D12,Bldg 10, Bethesda, MD 20892 USA.	derek@helix.nih.gov		Zhao, Hong/0000-0003-4616-3123				Beresford SA, 2001, J INTERF CYTOK RES, V21, P313, DOI 10.1089/107999001300177501; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chakraborty M, 2001, CANCER RES, V61, P7255; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Dong JT, 2001, CLIN CANCER RES, V7, P304; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Fernandez M, 2002, CLIN CANCER RES, V8, P1695; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang JH, 2002, ARTERIOSCL THROM VAS, V22, P745, DOI 10.1161/01.ATV.0000016358.05294.8D; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Koul D, 2002, INT J ONCOL, V21, P469; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ma Q, 2000, J BIOL CHEM, V275, P12676, DOI 10.1074/jbc.275.17.12676; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; REISS K, 1992, ONCOGENE, V7, P2243; Seely BL, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-15; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stambolic V, 2002, TRENDS PHARMACOL SCI, V23, P104, DOI 10.1016/S0165-6147(00)01984-2; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Tanno S, 2001, CANCER RES, V61, P589; Tomic-Carruthers N, 1998, BIOCHEM BIOPH RES CO, V244, P728, DOI 10.1006/bbrc.1998.8333; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wu YP, 2002, CANCER RES, V62, P1030; Yamada KM, 2001, J CELL SCI, V114, P2375	37	127	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					786	794		10.1038/sj.onc.1207162	http://dx.doi.org/10.1038/sj.onc.1207162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737113				2022-12-28	WOS:000188304900017
J	Miyagawa, S; Katsu, Y; Watanabe, H; Iguchi, T				Miyagawa, S; Katsu, Y; Watanabe, H; Iguchi, T			Estrogen-independent activation of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed neonatally to diethylstilbestrol	ONCOGENE			English	Article						mouse; diethylstilbestrol; vagina; erbBs signaling; estrogen receptor	AUTOCRINE GROWTH-FACTOR; GENITAL-TRACT; CROSS-TALK; IN-VITRO; MOLECULAR-MECHANISM; EPITHELIAL-CELLS; AMPHIREGULIN; REQUIREMENT; EXPRESSION; TAMOXIFEN	Growth factors and estrogen receptor (ER) signaling cooperate to play essential roles in cell proliferation, differentiation and tumor progression in mouse reproductive organs. Treatment of neonatal mice with diethylstilbestrol (DES) induces an estrogen-independent persistent proliferation and cornification of the vaginal epithelium, which results in cancerous lesions later in life. However, the mechanisms of the estrogen-dependent and -independent pathways essentially remain unknown. We characterized the expression of epidermal growth factor (EGF)-like growth factors (EGF, transforming growth factor alpha (TGF-alpha), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), amphiregulin (APR), epiregulin (EPR) and neuregulin (NRG) 1) and erbB receptors (EGF receptor (EGFR), erbB/neu, erbB3 and erbB4) in the vaginae of mice treated either neonatally (0-4 day) or as adults (55-59 day) with estrogens. EGFR and erbB2 were activated in the vaginal epithelium of mice by estrogen treatment. This activation was also encountered in vaginae from neonatally DES-exposed mice, along with the expression of EGF, TGF-alpha, HB-EGF, BTC, APR, EPR and NRG1. Immunohistochemical analysis indicated that erbB2 was primarily expressed in vaginal epithelium. Finally, we found that serine 118 and 167 located in the AF-1 domain of ERalpha were phosphorylated in these vaginae. AG825, AG1478 or ICI 182,780 administration blocked proliferation of vaginal epithelium induced by neonatal DES exposure. Thus, signal transduction via EGFR and erbB2 could be related to the estrogen-induced vaginal changes and persistent erbBs phosphorylation and sustained expression of EGF-like growth factors, leading to ERalpha activation that may result in cancerous lesions in vaginae from neonatally DES-exposed mice later in life.	Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST)	Iguchi, T (corresponding author), Okazaki Natl Res Inst, Ctr Integrat Biosci, 5-1 Higashiyama, Aichi 4448585, Japan.	taisen@nibb.ac.jp	Katsu, Yoshinao/F-9122-2012; WATANABE, Hajime/AAJ-8904-2021; Watanabe, Hajime/S-8957-2019; Iguchi, Taisen/AAL-4225-2021	Katsu, Yoshinao/0000-0003-2625-4626; Watanabe, Hajime/0000-0001-9657-6554				Atanaskova N, 2002, ONCOGENE, V21, P4000, DOI 10.1038/sj.onc.1205506; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Buckanan DL, 1998, ENDOCRINOLOGY, V139, P4345, DOI 10.1210/en.139.10.4345; CUNHA GR, 1977, DEV BIOL, V56, P52, DOI 10.1016/0012-1606(77)90154-3; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DAS SK, 1995, MOL ENDOCRINOL, V9, P691, DOI 10.1210/me.9.6.691; DIAUGUSTINE RP, 1988, ENDOCRINOLOGY, V122, P2355, DOI 10.1210/endo-122-6-2355; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DUNN TB, 1963, J NATL CANCER I, V31, P425; Falck L, 1996, ANAT REC, V245, P459; Forsberg J G, 1979, Natl Cancer Inst Monogr, P41; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; Herbst AL, 2000, GYNECOL ONCOL, V76, P147, DOI 10.1006/gyno.1999.5471; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGUCHI T, 1993, P SOC EXP BIOL MED, V204, P110, DOI 10.3181/00379727-204-43642; IGUCHI T, 1986, ACTA ANAT, V127, P110; IGUCHI T, 1992, INT REV CYTOL, V139, P1, DOI 10.1016/S0074-7696(08)61409-6; IGUCHI T, 1983, P NATL ACAD SCI-BIOL, V80, P3743, DOI 10.1073/pnas.80.12.3743; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kato S, 2000, GENES CELLS, V5, P593, DOI 10.1046/j.1365-2443.2000.00354.x; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Klotz DM, 2000, ENDOCRINOLOGY, V141, P3430, DOI 10.1210/en.141.9.3430; Kurokawa H, 2000, CANCER RES, V60, P5887; Lahooti H, 1995, J STEROID BIOCHEM, V55, P305, DOI 10.1016/0960-0760(95)00188-3; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; MARSELOS M, 1992, EUR J CANCER, V28A, P1182, DOI 10.1016/0959-8049(92)90482-H; MARSELOS M, 1993, EUR J CANCER, V29A, P149, DOI 10.1016/0959-8049(93)90597-9; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCLACHLAN JA, 1980, CANCER RES, V40, P3988; McLachlan JA, 2001, ENDOCR REV, V22, P319, DOI 10.1210/er.22.3.319; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; NELSON KG, 1992, ENDOCRINOLOGY, V131, P1657, DOI 10.1210/en.131.4.1657; NELSON KG, 1994, CELL GROWTH DIFFER, V5, P595; NELSON KG, 1991, P NATL ACAD SCI USA, V88, P21, DOI 10.1073/pnas.88.1.21; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; PASTAN I, 1983, TRENDS BIOCHEM SCI, V8, P250, DOI 10.1016/0968-0004(83)90351-1; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; Sato T, 1996, ANAT REC, V244, P374; Sato T, 2003, REPROD TOXICOL, V17, P289, DOI 10.1016/S0890-6238(03)00011-X; SATO T, 1996, P 10 INT C END SAN F, P1; TAKASUGI N, 1962, SCIENCE, V138, P438, DOI 10.1126/science.138.3538.438; TAKASUGI N, 1976, INT REV CYTOL, V44, P193, DOI 10.1016/S0074-7696(08)61650-2; TSAI PS, 1991, IN VITRO CELL DEV B, V27, P461; Yee D, 2000, J MAMMARY GLAND BIOL, V5, P107, DOI 10.1023/A:1009575518338	47	37	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					340	349		10.1038/sj.onc.1207207	http://dx.doi.org/10.1038/sj.onc.1207207			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647453				2022-12-28	WOS:000188098300003
J	Wang, XH; Ling, MT; Guan, XY; Tsao, SW; Cheung, HW; Lee, DT; Wong, YC				Wang, XH; Ling, MT; Guan, XY; Tsao, SW; Cheung, HW; Lee, DT; Wong, YC			Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells	ONCOGENE			English	Article						TWIST; taxol; cancer; resistance	SAETHRE-CHOTZEN-SYNDROME; HELIX TRANSCRIPTION FACTOR; CARCINOMA-CELLS; PROSTATE-CANCER; BCL-2 PHOSPHORYLATION; ALTERED EXPRESSION; SIGNALING PATHWAY; HUMAN OVARIAN; TUMOR-CELLS; PACLITAXEL	Taxol is one of the widely used chemotherapeutic drugs against many types of human cancer. While it is considered as one of the most effective anticancer drugs, treatment failure often occurs due to development of acquired resistance. Therefore, it is important to understand the molecular mechanisms responsible for the development of drug resistance. Although it is generally believed that taxol induces cell death through interfering with microtubules leading to mitotic arrest, recent evidence has suggested that taxol-induced cell death also occurs through pathways independent of either microtubule or mitotic arrest. In this study, we report the identification of a novel role for TWIST, a basic helix-loop-helix protein, which plays a central role in cell type determination and differentiation, during generation of acquired resistance to taxol in a nasopharyngeal carcinoma cell line, HNE1-T3, using comparative genome hybridization (CGH) and subsequent RT-PCR and Western blotting. We found that upregulation of TWIST was associated with cellular resistance to taxol but not other drugs with different mechanisms of action. The fact that increased TWIST protein levels were also associated with another microtubule-targeting anticancer drug, vincristine, in four types of human cancer including nasopharyngeal, bladder, ovarian and prostate, indicates that it may play a central role in the resistance to microtubule-disrupting agents. In addition, ectopic expression of TWIST into human cancer cells also led to increased resistance to both taxol and vincristine. Our results indicate a novel mechanism that leads to resistance to microtubule-disrupting anticancer drugs through upregulation of TWIST. Our evidence provides a therapeutic strategy to overcome acquired resistance through inactivation of TWIST expression in human cancer.	Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Med, Dept Clin Oncol, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Wang, XH (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, 1-F,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; ElGhouzzi V, 1997, NAT GENET, V15, P42; Funato N, 2001, MOL CELL BIOL, V21, P7416, DOI 10.1128/MCB.21.21.7416-7428.2001; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gu SU, 1983, CHINESE J CANCER, V2, P70; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Haldar S, 1996, CANCER RES, V56, P1253; Hjiantoniou E, 2003, BIOCHEM BIOPH RES CO, V300, P178, DOI 10.1016/S0006-291X(02)02804-8; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Huang Y, 2000, CANCER RES, V60, P4426; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; LIN CT, 1990, LAB INVEST, V62, P713; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Moos PJ, 1998, P NATL ACAD SCI USA, V95, P3896, DOI 10.1073/pnas.95.7.3896; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pajer P, 2003, ONCOGENE, V22, P665, DOI 10.1038/sj.onc.1206105; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Rauh-Adelmann C, 2000, MOL CARCINOGEN, V28, P236, DOI 10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; THISSE B, 1988, EMBO J, V7, P2175, DOI 10.1002/j.1460-2075.1988.tb03056.x; Urakami S, 2002, J UROLOGY, V168, P2444, DOI 10.1016/S0022-5347(05)64164-X; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Yousfi M, 2002, HUM MOL GENET, V11, P359, DOI 10.1093/hmg/11.4.359	36	189	206	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					474	482		10.1038/sj.onc.1207128	http://dx.doi.org/10.1038/sj.onc.1207128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724576				2022-12-28	WOS:000188098300018
J	Dazy, S; Damiola, F; Parisey, N; Beug, H; Gandrillon, O				Dazy, S; Damiola, F; Parisey, N; Beug, H; Gandrillon, O			The MEK-1/ERKs signalling pathway is differentially involved in the self-renewal of early and late avian erythroid progenitor cells	ONCOGENE			English	Article						MEK-1; self-renewal; TGF-alpha; erythropoiesis	P38 MAP KINASE; V-ERBA; STEM-CELLS; GLUCOCORTICOID-RECEPTOR; TYROSINE KINASE; C-KIT; APOPTOSIS; ACTIVATION; GROWTH; PROLIFERATION	Making decisions between self-renewal and differentiation is a central ability of stem cells. Elucidation of molecular networks governing this decision is therefore of prime importance. A model of choice to explore this question is represented by chicken erythroid progenitors, in which self-renewal versus differentiation as well as progenitor maturation are regulated by external factor combinations. We used this system to study whether similar or different signalling pathways were involved in the self-renewal of early, immature or more mature erythroid progenitors. We show that a transforming growth factor (TGF)-alpha-activated Ras/MEK-1/ERK1/2 pathway is strictly required for immature self-renewing cells but becomes fully dispensable when those cells are induced to differentiate. Consequently, pharmacological inhibition of this pathway led to spontaneous differentiation, only dependent on the presence of survival signals. Conversely, ectopic expression of a constitutive form of MEK-1 stimulates renewal and arrests differentiation process. Finally, we demonstrate that the ERK/MAPK signalling pathway is required in early but not in late primary erythroid progenitors, which can be turned into each other by different growth factor combinations specifically driving their renewal. To the best of our knowledge, this is the first description of a central role of ERK/MAPK signalling in regulating progenitor plasticity in the same cell type under different environmental conditions.	Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Signalisat & Ident Cellulaires, CNRS,UMR 5534, F-69622 Villeurbanne, France; Inst Mol Pathol, A-1030 Vienna, Austria	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Gandrillon, O (corresponding author), Univ Lyon 1, Ctr Genet Mol & Cellulaire, Lab Signalisat & Ident Cellulaires, CNRS,UMR 5534, Bat Gregoire Mendel,16 Rue Dubois, F-69622 Villeurbanne, France.	Gandrillon@cgmc.univ-lyon1.fr		Parisey, Nicolas/0000-0003-2439-3809; Damiola, Francesca/0000-0002-0238-1252				Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BAUER A, 2001, HEMATOPOIESIS DEV AP, P368; Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; BRUNET A, 1994, ONCOGENE, V9, P3379; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Dolznig H, 2002, CURR BIOL, V12, P1076, DOI 10.1016/S0960-9822(02)00930-2; Dolznig H, 2001, FASEB J, V15, P1442, DOI 10.1096/fj.00-0705fje; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; Gandrillon O, 1998, ONCOGENE, V16, P563, DOI 10.1038/sj.onc.1201550; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; HAYMAN MJ, 1993, CELL, V74, P157, DOI 10.1016/0092-8674(93)90303-8; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOWENZ E, 1987, MODERN TRENDS HUMA 7, V31, P199; LACOSTEELEAUME AS, 1994, EXP CELL RES, V213, P198, DOI 10.1006/excr.1994.1191; Lesault I, 2002, EMBO J, V21, P694, DOI 10.1093/emboj/21.4.694; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuzaki T, 2000, ONCOGENE, V19, P1500, DOI 10.1038/sj.onc.1203461; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Quang CT, 1997, EMBO J, V16, P5639, DOI 10.1093/emboj/16.18.5639; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; SAMARUT J, 1982, CELL, V28, P921, DOI 10.1016/0092-8674(82)90071-X; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Somervaille TCP, 2001, BLOOD, V98, P1374, DOI 10.1182/blood.V98.5.1374; STEINLEIN P, 1994, GROWTH FACTORS, V10, P1, DOI 10.3109/08977199409019599; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Tamir A, 2000, CELL GROWTH DIFFER, V11, P269; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; von Lindern M, 2001, ONCOGENE, V20, P3651, DOI 10.1038/sj.onc.1204494; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wessely O, 1999, BIOL CHEM, V380, P187, DOI 10.1515/BC.1999.027; Wessely O, 1997, EMBO J, V16, P267, DOI 10.1093/emboj/16.2.267; Witt O, 2000, BLOOD, V95, P2391, DOI 10.1182/blood.V95.7.2391.007k21_2391_2396; Zochodne B, 2000, ONCOGENE, V19, P2296, DOI 10.1038/sj.onc.1203590	52	23	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9205	9216		10.1038/sj.onc.1207049	http://dx.doi.org/10.1038/sj.onc.1207049			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681680				2022-12-28	WOS:000187400400002
J	Dean, NM; Bennett, CF				Dean, NM; Bennett, CF			Antisense oligonucleotide-based therapeutics for cancer	ONCOGENE			English	Article						antisense oligonucleotides; RNase H; siRNA; survivin	KINASE-C-ALPHA; SMALL INTERFERING RNAS; CULTURED-MAMMALIAN-CELLS; PEPTIDE NUCLEIC-ACID; ICAM-1 MESSENGER-RNA; DOUBLE-STRANDED-RNA; IN-VIVO STABILITY; PHOSPHOROTHIOATE OLIGONUCLEOTIDE; CAENORHABDITIS-ELEGANS; FULMINANT-HEPATITIS	There has been steady progress in antisense technology over the past 14 years. We now have a far better appreciation of the attributes and limitations of the technology. Antisense oligonucleotides have been used to selectively inhibit thousands of genes in mammalian cells, hundreds, if not thousands, of genes in rodents and other species and multiple genes in humans. There are over 20 antisense drugs currently in clinical trials, several of which are showing promising results. Like any other class of drugs in development, there will continue to be successes and failures in the clinic. Despite some disappointments with the technology, it appears to be a valid platform for both drug discovery and as an experimental tool for functionalizing genes. Advances in the medicinal chemistry and formulation of antisense oligonucleotides will further enhance their therapeutic and commercial potential.	ISIS Pharmaceut, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Bennett, CF (corresponding author), ISIS Pharmaceut, 2282 Faraday Ave, Carlsbad, CA 92008 USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; Agrawal S, 2002, INT J ONCOL, V21, P65; AGRAWAL S, 1995, BIOCHEM PHARMACOL, V50, P571, DOI 10.1016/0006-2952(95)00160-2; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Baker BF, 1997, J BIOL CHEM, V272, P11994, DOI 10.1074/jbc.272.18.11994; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Butler M, 1997, LAB INVEST, V77, P379; Butler M, 2000, J PHARMACOL EXP THER, V292, P489; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; CECH TR, 1994, NATURE, V372, P39, DOI 10.1038/372039a0; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Cook PD, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P29; COSSUM PA, 1993, J PHARMACOL EXP THER, V267, P1181; Crooke ST, 1999, BIOCHIM BIOPHYS ACTA, V1489, P30; De Backer MD, 2001, NAT BIOTECHNOL, V19, P235, DOI 10.1038/85677; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Flanagan WM, 1999, P NATL ACAD SCI USA, V96, P3513, DOI 10.1073/pnas.96.7.3513; Freier SM, 1997, NUCLEIC ACIDS RES, V25, P4429, DOI 10.1093/nar/25.22.4429; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; Geary RS, 1997, ANTI-CANCER DRUG DES, V12, P383; Geary RS, 2001, J PHARMACOL EXP THER, V296, P890; Gottschalk AR, 2001, CANCER RES, V61, P2105; Graham MJ, 1998, J PHARMACOL EXP THER, V286, P447; Harborth J, 2001, J CELL SCI, V114, P4557; Henry S, 2000, J PHARMACOL EXP THER, V292, P468; Henry SP, 1997, J PHARMACOL EXP THER, V281, P810; Henry SP, 1997, ANTISENSE NUCLEIC A, V7, P503, DOI 10.1089/oli.1.1997.7.503; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Kuss BJ, 2002, INT J CANCER, V98, P128, DOI 10.1002/ijc.10159; Larsen HJ, 1999, BBA-GENE STRUCT EXPR, V1489, P159, DOI 10.1016/S0167-4781(99)00145-1; Leaman DW, 2002, VIROLOGY, V292, P70, DOI 10.1006/viro.2001.1213; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Lee Y, 2003, CANCER RES, V63, P2802; Levin AA, 2001, ANTISENSE DRUG TECHNOLOGY: PRINCIPLES, STRATEGIES, AND APPLICATIONS, P201; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Lima WF, 2001, METHOD ENZYMOL, V341, P430, DOI 10.1016/S0076-6879(01)41168-2; Mani S, 2002, CLIN CANCER RES, V8, P1042; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; McMahon BM, 2002, ANTISENSE NUCLEIC A, V12, P65, DOI 10.1089/108729002760070803; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Miyake H, 2001, CLIN CANCER RES, V7, P4245; Mohammad R, 2002, CLIN CANCER RES, V8, P1277; MONIA BP, 1993, J BIOL CHEM, V268, P14514; Nemunaitis J, 1999, J CLIN ONCOL, V17, P3586, DOI 10.1200/JCO.1999.17.11.3586; Nylandsted J, 2002, CANCER RES, V62, P7139; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Rankin R, 2001, ANTISENSE NUCLEIC A, V11, P333, DOI 10.1089/108729001753231713; Sazani P, 2002, NAT BIOTECHNOL, V20, P1228, DOI 10.1038/nbt759; Sazani P, 2001, NUCLEIC ACIDS RES, V29, P3965, DOI 10.1093/nar/29.19.3965; Sewell KL, 2002, J PHARMACOL EXP THER, V303, P1334, DOI 10.1124/jpet.102.036749; Sheehan JP, 2001, BIOCHEMISTRY-US, V40, P4980, DOI 10.1021/bi002396x; Shen LJ, 2003, ANTISENSE NUCLEIC A, V13, P129, DOI 10.1089/108729003768247592; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; STEHELIN D, 1976, NATURE, V260, P70; Summerton J, 1999, BBA-GENE STRUCT EXPR, V1489, P141, DOI 10.1016/S0167-4781(99)00150-5; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Taylor J K, 1999, Curr Opin Drug Discov Devel, V2, P147; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Thallinger C, 2003, J INVEST DERMATOL, V120, P1081, DOI 10.1046/j.1523-1747.2003.12252.x; TORRENCE PF, 1993, P NATL ACAD SCI USA, V90, P1300, DOI 10.1073/pnas.90.4.1300; Tortora G, 2001, CLIN CANCER RES, V7, P2537; Urban G, 2001, J BIOL CHEM, V276, P27638, DOI 10.1074/jbc.M103512200; Verma UN, 2003, CLIN CANCER RES, V9, P1291; Vickers TA, 2003, J BIOL CHEM, V278, P7108, DOI 10.1074/jbc.M210326200; Vickers TA, 2001, NUCLEIC ACIDS RES, V29, P1293, DOI 10.1093/nar/29.6.1293; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; Wang H, 2002, INT J ONCOL, V21, P73; Weng D E, 2001, Curr Oncol Rep, V3, P141, DOI 10.1007/s11912-001-0014-7; Wengel J, 1999, ACCOUNTS CHEM RES, V32, P301, DOI 10.1021/ar980051p; Wu HJ, 1999, J BIOL CHEM, V274, P28270, DOI 10.1074/jbc.274.40.28270; Wu HJ, 1998, J BIOL CHEM, V273, P2532, DOI 10.1074/jbc.273.5.2532; Yu RZ, 2001, J PHARMACOL EXP THER, V296, P388; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zamore PD, 2002, SCIENCE, V296, P1265, DOI 10.1126/science.1072457; Zellweger T, 2001, J PHARMACOL EXP THER, V298, P934; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100; Zhang H, 2000, NAT BIOTECHNOL, V18, P862, DOI 10.1038/78475; Zhang H, 2003, J PHARMACOL EXP THER, V307, P24, DOI 10.1124/jpet.103.050435; ZHANG RW, 1995, BIOCHEM PHARMACOL, V50, P545, DOI 10.1016/0006-2952(95)00159-W; Zhao QY, 1996, BIOCHEM PHARMACOL, V51, P173, DOI 10.1016/0006-2952(95)02177-9	94	195	223	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 8	2003	22	56					9087	9096		10.1038/sj.onc.1207231	http://dx.doi.org/10.1038/sj.onc.1207231			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663487				2022-12-28	WOS:000187043600012
J	Ludwig, DL; Pereira, DS; Zhu, ZP; Hicklin, DJ; Bohlen, P				Ludwig, DL; Pereira, DS; Zhu, ZP; Hicklin, DJ; Bohlen, P			Monoclonal antibody therapeutics and apoptosis	ONCOGENE			English	Review						cancer; receptor tyrosine kinase; anti-angiogenesis; TRAIL; immunoglobulin; ErbB	ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMAS; FACTOR RECEPTOR BLOCKADE; HUMAN-BREAST-CANCER; COMPLEMENTARITY-DETERMINING REGIONS; PROTEIN-KINASE-A; PHASE I/II TRIAL; IN-VIVO; ANTITUMOR-ACTIVITY; TYROSINE KINASE	The potential for disease-specific targeting and low toxicity profiles have made monoclonal antibodies attractive therapeutic drug candidates. Antibody-mediated target cell killing is frequently associated with immune effector mechanisms such as antibody-directed cellular cytotoxicity, but they can also be induced by apoptotic processes. Antibody-directed mechanisms, including antigen crosslinking, activation of death receptors, and blockade of ligand-receptor growth or survival pathways, can elicit the induction of apoptosis in targeted cells. Depending on their mechanism of action, monoclonal antibodies can induce targeted cell-specific killing alone or can enhance target cell susceptibility to chemo- or radiotherapeutics by effecting the modulation of antiapoptotic pathways. This review will focus on the mechanisms by which antibodies are capable of eliciting programmed cell death either directly or indirectly within tumor cells.	ImClone Syst Inc, New York, NY 10014 USA	Eli Lilly	Ludwig, DL (corresponding author), ImClone Syst Inc, 180 Varick St, New York, NY 10014 USA.	dale@imclone.com						ALIMANDI M, 1995, ONCOGENE, V10, P1813; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814; Baetu TM, 2002, CYTOKINE GROWTH F R, V13, P199, DOI 10.1016/S1359-6101(02)00006-0; Bagshawe KD, 1996, ADV DRUG DELIVER REV, V22, P365, DOI 10.1016/S0169-409X(96)00443-7; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Baselga J, 2002, ONCOLOGIST, V7, P2; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Benini S, 2001, CLIN CANCER RES, V7, P1790; Bianco C, 2000, CLIN CANCER RES, V6, P4343; BOULIANNE GL, 1984, NATURE, V312, P643, DOI 10.1038/312643a0; Bruns CJ, 2002, INT J CANCER, V102, P101, DOI 10.1002/ijc.10681; Bruns CJ, 2000, CANCER, V89, P488, DOI 10.1002/1097-0142(20000801)89:3<488::AID-CNCR3>3.3.CO;2-O; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byrd JC, 2002, BLOOD, V99, P1038, DOI 10.1182/blood.V99.3.1038; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cardarelli PM, 2002, CANCER IMMUNOL IMMUN, V51, P15, DOI 10.1007/s00262-001-0247; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Bono JS, 2002, TRENDS MOL MED, V8, pS19, DOI 10.1016/S1471-4914(02)02306-7; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; Dearden C, 2002, BIODRUGS, V16, P283, DOI 10.2165/00063030-200216040-00004; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; DOUGALL WC, 1994, ONCOGENE, V9, P2109; Ekedahl J, 2002, EXP CELL RES, V279, P277, DOI 10.1006/excr.2002.5608; FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035; Findley HW, 1999, LEUKEMIA, V13, P147, DOI 10.1038/sj.leu.2401280; FischerColbrie J, 1997, ANTICANCER RES, V17, P613; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Ghetie MA, 2001, BLOOD, V97, P1392, DOI 10.1182/blood.V97.5.1392; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Glennie MJ, 2000, IMMUNOL TODAY, V21, P403, DOI 10.1016/S0167-5699(00)01669-8; Gupta VK, 2002, CANCER J, V8, P47, DOI 10.1097/00130404-200201000-00009; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoogenboom HR, 2000, IMMUNOL TODAY, V21, P371, DOI 10.1016/S0167-5699(00)01667-4; Hu LM, 2002, AM J PATHOL, V161, P1917, DOI 10.1016/S0002-9440(10)64467-7; Huang SM, 1999, INVEST NEW DRUG, V17, P259, DOI 10.1023/A:1006384521198; Huang SM, 2000, CLIN CANCER RES, V6, P2166; Huang SM, 1999, CANCER RES, V59, P1935; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Inoue K, 2000, CLIN CANCER RES, V6, P2635; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; Kandasamy K, 2002, CANCER RES, V62, P4929; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Keppler-Hafkemeyer A, 2000, INT J CANCER, V87, P86, DOI 10.1002/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; Kozin SV, 2001, CANCER RES, V61, P39; Kreitman R. J., 2001, Current Pharmaceutical Biotechnology, V2, P313, DOI 10.2174/1389201013378635; Kreitman RJ, 1999, BLOOD, V94, P3340, DOI 10.1182/blood.V94.10.3340.422k19_3340_3348; Kreitman RJ, 2000, J CLIN ONCOL, V18, P1622, DOI 10.1200/JCO.2000.18.8.1622; Lee S, 2002, CANCER RES, V62, P5703; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu BL, 2001, ONCOGENE, V20, P3726, DOI 10.1038/sj.onc.1204490; Mallat Z, 2000, BRIT J PHARMACOL, V130, P947, DOI 10.1038/sj.bjp.0703407; Maloney DG, 2001, ANTI-CANCER DRUG, V12, pS1; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; MAUNG ZT, 1994, BRIT J HAEMATOL, V88, P105, DOI 10.1111/j.1365-2141.1994.tb04984.x; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Mendelsohn J, 1997, CLIN CANCER RES, V3, P2703; Mendez MJ, 1997, NAT GENET, V15, P146, DOI 10.1038/ng0297-146; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Milas L, 2000, CLIN CANCER RES, V6, P701; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MIYASHITA T, 1993, BLOOD, V81, P151; Monks NR, 2001, BRIT J CANCER, V85, P764, DOI 10.1054/bjoc.2001.1947; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Napier MP, 2000, CLIN CANCER RES, V6, P765; NICHOLSON S, 1989, LANCET, V1, P182; Nor JE, 2001, CANCER RES, V61, P2183; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Overholser JP, 2000, CANCER, V89, P74, DOI 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Parrizas M, 1997, J BIOL CHEM, V272, P154; Pegram M, 1999, ONCOGENE, V18, P2241, DOI 10.1038/sj.onc.1202526; Peltenburg LTC, 2000, Q J NUCL MED, V44, P355; Penuel E, 2001, SEMIN ONCOL, V28, P36, DOI 10.1053/sonc.2001.29711; Pietras RJ, 1999, CANCER RES, V59, P1347; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; POSEY J, 2002, AM SOC CLIN ONCOL, V21, pA17; Press OW, 2000, BLOOD, V96, P2934; Presta Leonard G., 2002, Current Pharmaceutical Biotechnology, V3, P237, DOI 10.2174/1389201023378256; Prewett M, 1999, CANCER RES, V59, P5209; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rosen Lee S, 2002, Cancer Control, V9, P36; Rowan W, 1998, IMMUNOLOGY, V95, P427; Sasaki M, 2003, INT J ONCOL, V22, P181; Sato J D, 1983, Mol Biol Med, V1, P511; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schier R, 1996, J MOL BIOL, V263, P551, DOI 10.1006/jmbi.1996.0598; Senter PD, 2001, ADV DRUG DELIVER REV, V53, P247, DOI 10.1016/S0169-409X(01)00206-X; Shaheen RM, 2001, INT J ONCOL, V18, P221; Shan DM, 2000, CANCER IMMUNOL IMMUN, V48, P673, DOI 10.1007/s002620050016; Sheridan M T, 1997, Radiat Oncol Investig, V5, P180, DOI 10.1002/(SICI)1520-6823(1997)5:4<180::AID-ROI3>3.3.CO;2-Z; SHIBUYA M, 1990, ONCOGENE, V5, P519; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Sievers EL, 2000, CANCER CHEMOTH PHARM, V46, pS18, DOI 10.1007/PL00014043; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soffer SZ, 2001, J PEDIATR SURG, V36, P1177, DOI 10.1053/jpsu.2001.25747; TEDDER TE, 1994, IMMUNOL TODAY, V15, P450, DOI 10.1016/0167-5699(94)90276-3; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Tortora G, 1999, CLIN CANCER RES, V5, P875; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; van der Kolk LE, 2002, LEUKEMIA, V16, P1735, DOI 10.1038/sj.leu.2402559; Vaughan TJ, 1998, NAT BIOTECHNOL, V16, P535, DOI 10.1038/nbt0698-535; VOLM M, 1992, ANTICANCER RES, V12, P11; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Ward E S, 1995, Ther Immunol, V2, P77; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; Witzig TE, 1999, J CLIN ONCOL, V17, P3793, DOI 10.1200/JCO.1999.17.12.3793; Witzig TE, 2002, J CLIN ONCOL, V20, P2453, DOI 10.1200/JCO.2002.11.076; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Yakes FM, 2002, CANCER RES, V62, P4132; YARNOLD S, 1994, CANCER RES, V54, P506; Zhang LL, 2002, CANCER RES, V62, P2034; Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881	143	51	58	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9097	9106		10.1038/sj.onc.1207104	http://dx.doi.org/10.1038/sj.onc.1207104			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663488				2022-12-28	WOS:000187043600013
J	Cheng, SH; Hsia, CY; Leone, G; Liou, HC				Cheng, SH; Hsia, CY; Leone, G; Liou, HC			Cyclin E and Bcl-x(L) cooperatively induce cell cycle progression in c-Rel(-/-) B cells	ONCOGENE			English	Article						B cell; lymphoma; leukemia; Rel; cyclin E; Bcl-x(L)	NF-KAPPA-B; C-REL; RETINOBLASTOMA PROTEIN; ANTIGEN RECEPTOR; S-PHASE; TRANSCRIPTIONAL REGULATION; TRANSACTIVATION DOMAIN; REGULATED EXPRESSION; MECHANISMS CONTROL; INDUCED APOPTOSIS	Aberrant overexpression of the c-rel protooncogene is associated with lymphoid malignancy, while c-rel deletion produces severe lymphoproliferative defects and immunodeficiency. To investigate the mechanism of c-rel-induced proliferation and cell cycle progression in B lymphocytes, we have compared signaling events elicited through the BCR in c-rel(-/-) and wild-type B cells. BCR stimulation of c-rel(-/-) B cells fails to induce proper cyclin expression, resulting in G(1) phase arrest, but it is unclear whether these defects are in fact secondary events of decreased B-cell survival, since c-rel deletion also affects the expression of antiapoptotic genes such as bcl-x(L). Here, we use the bcl-x(L) transgene to correct the viability of c-rel-deficient B cells, and show that the inhibition of apoptosis does not necessarily confer hyperproliferation of B cells activated through the BCR. c-rel(-/-) B cells still fail to enter the S phase despite improved survival by bcl-x(L) overexpression, suggesting that c-Rel-associated cell cycle progression is dependent on more than just enhanced cell viability. Overexpression of cyclin E protein, however, can cooperate with Bcl-x(L) to restore cell cycle progression to c-rel(-/-) B cells via induction of the cyclin-CDK/Rb-E2F pathway. Furthermore, we show that c-Rel can directly regulate transcription of the e2f3a promoter/enhancer, which is then likely to lead to transcriptional activation of the cyclin E promoter by E2F3a. Hence, these studies provide clear evidence that control of lymphocyte proliferation via c-Rel is linked to a cyclin-dependent process, and suggest that c-Rel not only activates antiapoptotic signaling but also the induction of cell cycle progression.	Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, New York, NY 10021 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	Cornell University; University System of Ohio; Ohio State University	Liou, HC (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Immunol, 515 E 71st St,Room S-210, New York, NY 10021 USA.		Giuseppe Leone, Full Professor/I-9166-2019	Giuseppe Leone, Full Professor/0000-0002-7812-5300	NATIONAL CANCER INSTITUTE [R55CA068155, R01CA090405, R01CA068155] Funding Source: NIH RePORTER; NCI NIH HHS [CA 90405, CA 68155] Funding Source: Medline; PHS HHS [1 T32 A1 07621] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Aronica MA, 1999, J IMMUNOL, V163, P5116; BARTH TF, 2003, BLOOD, V2, P2; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Botz J, 1996, MOL CELL BIOL, V16, P3401; Caamano J, 2002, CLIN MICROBIOL REV, V15, P414, DOI 10.1128/CMR.15.3.414-429.2002; Carman JA, 1996, J IMMUNOL, V156, P4562; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Donovan CE, 1999, J IMMUNOL, V163, P6827; Duronio RJ, 1996, GENE DEV, V10, P2505, DOI 10.1101/gad.10.19.2505; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Ezhevsky SA, 2001, MOL CELL BIOL, V21, P4773, DOI 10.1128/MCB.21.14.4773-4784.2001; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Geng Y, 1996, ONCOGENE, V12, P1173; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 1996, ONCOGENE, V13, P1367; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hilliard BA, 2002, J CLIN INVEST, V110, P843, DOI 10.1172/JCI200215254; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Houldsworth J, 1996, BLOOD, V87, P25; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lavia P, 1999, BIOESSAYS, V21, P221; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Liou HC, 2002, J BIOCHEM MOL BIOL, V35, P537; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Mason N, 2002, J IMMUNOL, V168, P2590, DOI 10.4049/jimmunol.168.6.2590; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Tumang JR, 2002, CELL IMMUNOL, V217, P47, DOI 10.1016/S0008-8749(02)00513-0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yang H, 2002, TRANSPLANTATION, V74, P291, DOI 10.1097/00007890-200208150-00002; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	79	41	43	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8472	8486		10.1038/sj.onc.1206917	http://dx.doi.org/10.1038/sj.onc.1206917			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627988				2022-12-28	WOS:000186650300011
J	Eliopoulos, AG; Caamano, JH; Flavell, J; Reynolds, GM; Murray, PG; Poyet, JL; Young, LS				Eliopoulos, AG; Caamano, JH; Flavell, J; Reynolds, GM; Murray, PG; Poyet, JL; Young, LS			Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappa B2 to p52 via an IKK gamma/NEMO-independent signalling pathway	ONCOGENE			English	Article						LMP1; EBV; NF-kappa B2; signalling	NF-KAPPA-B; MEMBRANE-PROTEIN 1; LYMPHOTOXIN-BETA-RECEPTOR; LYMPHOCYTE GROWTH TRANSFORMATION; CYCLIN D1; SPLENIC MICROARCHITECTURE; TRANSCRIPTIONAL ACTIVITY; BCL-2 EXPRESSION; IMMUNE-RESPONSES; TRANSGENIC MICE	The oncogenic Epstein - Barr virus (EBV)-encoded latent infection membrane protein 1 (LMP1) constitutively activates the 'canonical' NF-kappaB pathway that involves the phosphorylation and degradation of IkappaBalpha downstream of the IkappaB kinases (IKKs). In this study, we show that LMP1 also promotes the proteasome-mediated proteolysis of p100 NF-kappaB2 resulting in the generation of active p52, which translocates to the nucleus in complex with the p65 and RelB NF-kappaB subunits. LMP1-induced NF-kappaB transactivation is reduced in nf-kb2(-/-) mouse embryo fibroblasts, suggesting that p100 processing contributes to LMP1-mediated NF-kappaB transcriptional effects. This pathway is likely to operate in vivo, as the expression of LMP1 in primary EBV-positive Hodgkin's lymphoma and nasopharyngeal carcinoma biopsies correlates with the nuclear accumulation of p52. Interestingly, while the ability of LMP1 to activate the canonical NF-kappaB pathway is impaired in cells lacking IKKgamma/NEMO, the regulatory subunit of the IKK complex, p100 processing remains unaffected. As a result, nuclear translocation of p52, but not p65, occurs in the absence of IKKgamma. These data point to the existence of a novel signalling pathway that regulates NF-kappaB in LMP1-expressingcells, and may thereby play a role in both oncogenic transformation and the establishment of persistent EBV infection.	Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, MRC, Ctr Immune Regulat, Birmingham B15 2TA, W Midlands, England; Univ Birmingham, Sch Med, Dept Pathol, Birmingham B15 2TA, W Midlands, England; Hop St Louis, INSERM, U532, Inst Rech Peau, F-75475 Paris 10, France	Cancer Research UK; University of Birmingham; University of Birmingham; University of Birmingham; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Eliopoulos, AG (corresponding author), Univ Birmingham, Sch Med, Canc Res UK Inst Canc Studies, Birmingham B15 2TA, W Midlands, England.	A.G.Eliopoulos@bham.ac.uk	Young, Lawrence S/B-7213-2009; Caamano, Jorge/O-7530-2019; Poyet, Jean-Luc/G-7114-2017; ELIOPOULOS, ARISTIDES/ABI-6632-2020; Caamano, Jorge/I-6778-2012; Reynolds, Gary/F-8641-2014; ELIOPOULOS, ARISTIDES/R-9449-2018	Young, Lawrence S/0000-0003-3919-4298; Caamano, Jorge/0000-0003-3530-7056; Poyet, Jean-Luc/0000-0002-3747-255X; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Caamano, Jorge/0000-0003-3530-7056; Reynolds, Gary/0000-0002-3250-0582; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Damania B, 2000, J VIROL, V74, P1593, DOI 10.1128/JVI.74.4.1593-1601.2000; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 2003, J VIROL, V77, P1316, DOI 10.1128/JVI.77.2.1316-1328.2003; Eliopoulos AG, 2002, J VIROL, V76, P4567, DOI 10.1128/JVI.76.9.4567-4579.2002; Eliopoulos AG, 2002, EMBO J, V21, P4831, DOI 10.1093/emboj/cdf478; Flavell JR, 2000, J CLIN PATHOL-MOL PA, V53, P145, DOI 10.1136/mp.53.3.145; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Garceau N, 2000, J EXP MED, V191, P381, DOI 10.1084/jem.191.2.381; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HUEN DS, 1995, ONCOGENE, V10, P549; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Lam N, 2003, EMBO J, V22, P3027, DOI 10.1093/emboj/cdg284; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsumoto M, 1996, SCIENCE, V271, P1289, DOI 10.1126/science.271.5253.1289; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; McFarland EDC, 1999, ONCOGENE, V18, P6959, DOI 10.1038/sj.onc.1203217; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PAINE E, 1995, J VIROL, V69, P4572, DOI 10.1128/JVI.69.7.4572-4576.1995; Perkins ND, 1997, INT J BIOCHEM CELL B, V29, P1433, DOI 10.1016/S1357-2725(97)00088-5; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453	69	84	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7557	7569		10.1038/sj.onc.1207120	http://dx.doi.org/10.1038/sj.onc.1207120			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576817				2022-12-28	WOS:000186113000002
J	Krynetski, E; Evans, WE				Krynetski, E; Evans, WE			Drug methylation in cancer therapy: lessons from the TPMT polymorphism	ONCOGENE			English	Review						thiopurine S-methyltransferase; pharmacogenetics	THIOPURINE S-METHYLTRANSFERASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; AZATHIOPRINE-INDUCED MYELOSUPPRESSION; GENOTYPE-PHENOTYPE CORRELATION; HEART-TRANSPLANT RECIPIENT; BIOCHEMICAL-PROPERTIES; GENETIC-POLYMORPHISM; CATALYTIC-ACTIVITY; MUTANT ALLELES; FUNCTIONAL-CHARACTERIZATION	The genetic polymorphism of thiopurine methyltransferase (TPMT) is one of the most developed examples of pharmacogenetics, spanning from molecular genetics to clinical diagnostics for individualizing thiopurine therapy (i.e. azathioprine, mercaptopurine, and thioguanine). Elucidation of the molecular mechanisms and biochemical consequences of TPMT deficiency demonstrates how pharmacogenetic traits can be identified, characterized, and translated to the bedside. Insights gained from studies of the TPMT polymorphism illustrate the potential of pharmacogenomics to optimize cancer therapy by avoiding toxic side effects in genetically distinct subgroups of patients.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Evans, WE (corresponding author), St Jude Childrens Res Hosp, Dept Pharmaceut Sci, 332 N Lauderdale St, Memphis, TN 38105 USA.	william.evans@stjude.org	Evans, William E./C-2069-2012	Evans, William E./0000-0002-9333-5322	NCI NIH HHS [CA 21765, R37 CA 36401] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036401, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN PW, 1971, BIOCHEM PHARMACOL, V20, P847, DOI 10.1016/0006-2952(71)90046-3; Alves S, 1999, PHARMACOGENETICS, V9, P257; Alves S, 2001, CLIN PHARMACOL THER, V70, P165, DOI 10.1067/mcp.2001.117284; Ando M, 2001, PHARMACOGENETICS, V11, P269, DOI 10.1097/00008571-200104000-00011; Bemi V, 1999, INT J CANCER, V82, P556, DOI 10.1002/(SICI)1097-0215(19990812)82:4<556::AID-IJC14>3.0.CO;2-Y; Black AJ, 1998, ANN INTERN MED, V129, P716, DOI 10.7326/0003-4819-129-9-199811010-00007; Brouwer C, 2001, LEUKEMIA, V15, P1792, DOI 10.1038/sj.leu.2402285; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Colombel JF, 2000, GASTROENTEROLOGY, V118, P1025, DOI 10.1016/S0016-5085(00)70354-4; Coulthard SA, 2000, BRIT J HAEMATOL, V110, P599, DOI 10.1046/j.1365-2141.2000.02218.x; Coulthard SA, 1998, BLOOD, V92, P2856, DOI 10.1182/blood.V92.8.2856.420k05_2856_2862; Cournoyer B, 1998, BBA-GENE STRUCT EXPR, V1397, P161, DOI 10.1016/S0167-4781(98)00020-7; de la Moureyre CSV, 1999, PHARMACOGENETICS, V9, P189; de la Moureyre CSV, 1998, HUM MUTAT, V12, P177, DOI 10.1002/(SICI)1098-1004(1998)12:3<177::AID-HUMU5>3.0.CO;2-E; de la Moureyre CSV, 1998, BRIT J PHARMACOL, V125, P879, DOI 10.1038/sj.bjp.0702152; DEININGER M, 1994, BIOCHEM PHARMACOL, V48, P2135, DOI 10.1016/0006-2952(94)90515-0; Dervieux T, 2001, CANCER RES, V61, P5810; ELION GB, 1989, IN VITRO CELL DEV B, V25, P321; Evans WE, 2001, J CLIN ONCOL, V19, P2293, DOI 10.1200/JCO.2001.19.8.2293; EVANS WE, 1991, J PEDIATR-US, V119, P985, DOI 10.1016/S0022-3476(05)83063-X; Fessing MY, 1998, EUR J BIOCHEM, V256, P510, DOI 10.1046/j.1432-1327.1998.2560510.x; Fessing MY, 1998, FEBS LETT, V424, P143, DOI 10.1016/S0014-5793(98)00159-8; Foster AP, 2000, J VET INTERN MED, V14, P552, DOI 10.1892/0891-6640(2000)014&lt;0552:DOTMAI&gt;2.3.CO;2; HASSOUN BS, 1995, RES COMMUN MOL PATH, V90, P133; HILL DL, 1969, BIOCHEMISTRY-US, V8, P122, DOI 10.1021/bi00829a017; Hon YY, 1999, HUM MOL GENET, V8, P371, DOI 10.1093/hmg/8.2.371; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Ishioka S, 1999, INTERNAL MED, V38, P944, DOI 10.2169/internalmedicine.38.944; Jang IJ, 1996, BRIT J CLIN PHARMACO, V42, P638, DOI 10.1111/j.1365-2125.1996.tb00061.x; JINNAH HA, 2000, METABOLIC MOL BASES; Krynetski EY, 1997, PHARM RES-DORDR, V14, P1672, DOI 10.1023/A:1012111325397; Krynetski EY, 2000, PHARMACOLOGY, V61, P136, DOI 10.1159/000028394; Krynetski EY, 1998, AM J HUM GENET, V63, P11, DOI 10.1086/301941; KRYNETSKI EY, 1995, MOL PHARMACOL, V47, P1141; KRYNETSKI EY, 1995, P NATL ACAD SCI USA, V92, P949, DOI 10.1073/pnas.92.4.949; KRYNETSKI EY, 1999, ANTICANCER DRUG TOXI, P392; Kubota T, 2001, BRIT J CLIN PHARMACO, V51, P475, DOI 10.1046/j.1365-2125.2001.01371.x; Kumagai K, 2001, PHARMACOGENETICS, V11, P275, DOI 10.1097/00008571-200104000-00012; LENNARD L, 1987, CLIN PHARMACOL THER, V41, P18, DOI 10.1038/clpt.1987.4; LENNARD L, 1990, LANCET, V336, P225, DOI 10.1016/0140-6736(90)91745-V; Liu MF, 2000, J BACTERIOL, V182, P6509, DOI 10.1128/JB.182.22.6509-6513.2000; Loennechen T, 1998, CLIN PHARMACOL THER, V64, P46, DOI 10.1016/S0009-9236(98)90021-2; Loennechen T, 2001, CLIN PHARMACOL THER, V70, P183, DOI 10.1067/mcp.2001.117445; Lowenthal A, 2001, EUR J CLIN PHARMACOL, V57, P43, DOI 10.1007/s002280100267; McDonald OG, 2002, PHARMACOGENETICS, V12, P93, DOI 10.1097/00008571-200203000-00003; MCLEOD HL, 1995, BLOOD, V85, P1897, DOI 10.1182/blood.V85.7.1897.bloodjournal8571897; MCLEOD HL, 1993, LANCET, V341, P1151, DOI 10.1016/0140-6736(93)93168-Z; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; MCLEOD HL, 1994, CLIN PHARMACOL THER, V55, P15, DOI 10.1038/clpt.1994.4; Olson TS, 1989, CURR OPIN CELL BIOL, V1, P1194, DOI 10.1016/S0955-0674(89)80071-7; Otterness D, 1997, CLIN PHARMACOL THER, V62, P60, DOI 10.1016/S0009-9236(97)90152-1; Otterness DM, 1998, J CLIN INVEST, V101, P1036, DOI 10.1172/JCI1004; ParkHah JO, 1996, CLIN PHARMACOL THER, V60, P68, DOI 10.1016/S0009-9236(96)90169-1; PIETERS R, 1992, INT J CANCER, V51, P213, DOI 10.1002/ijc.2910510208; Ranjard L, 2002, J BACTERIOL, V184, P3146, DOI 10.1128/JB.184.11.3146-3149.2002; Relling MV, 1999, JNCI-J NATL CANCER I, V91, P2001, DOI 10.1093/jnci/91.23.2001; Relling MV, 1999, LANCET, V354, P34, DOI 10.1016/S0140-6736(98)11079-6; REMY CN, 1967, BIOCHIM BIOPHYS ACTA, V138, P258, DOI 10.1016/0005-2787(67)90487-X; REMY CN, 1963, J BIOL CHEM, V238, P1078; Rossi AM, 2001, EUR J CLIN PHARMACOL, V57, P51, DOI 10.1007/s002280000246; Scerri L, 1999, ADV EXP MED BIOL, V455, P343; Schaeffeler E, 2001, CLIN CHEM, V47, P548; Schutz E, 2000, CLIN CHEM, V46, P1728; SCHUTZ E, 1993, LANCET, V341, P436, DOI 10.1016/0140-6736(93)93028-Y; Seki T, 2000, J HUM GENET, V45, P299, DOI 10.1007/s100380070020; Srivastava T, 2002, AM J MED GENET, V108, P219, DOI 10.1002/ajmg.10217; Szumlanski C, 1996, DNA CELL BIOL, V15, P17, DOI 10.1089/dna.1996.15.17; SZUMLANSKI CL, 1992, PHARMACOGENETICS, V2, P148, DOI 10.1097/00008571-199208000-00002; Tai HL, 1999, PHARMACOGENETICS, V9, P641, DOI 10.1097/01213011-199910000-00011; Tai HL, 1996, AM J HUM GENET, V58, P694; Tai HL, 1997, P NATL ACAD SCI USA, V94, P6444, DOI 10.1073/pnas.94.12.6444; Tatusov RL, 2001, NUCLEIC ACIDS RES, V29, P22, DOI 10.1093/nar/29.1.22; VANLOON JA, 1982, BIOCHEM GENET, V20, P637, DOI 10.1007/BF00483962; Weinshilboum R, 2001, DRUG METAB DISPOS, V29, P601; WEINSHILBOUM RM, 1980, AM J HUM GENET, V32, P651; WEINSHILBOUM RM, 1978, CLIN CHIM ACTA, V85, P323, DOI 10.1016/0009-8981(78)90311-X; WEINSHILBOUM RM, 1996, 2 THIOP S HAMB; White SD, 2000, J VET INTERN MED, V14, P499, DOI 10.1892/0891-6640(2000)014&lt;0499:TMIRBC&gt;2.3.CO;2; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WOODSON LC, 1982, J PHARMACOL EXP THER, V222, P174; WOODSON LC, 1983, BIOCHEM PHARMACOL, V32, P819, DOI 10.1016/0006-2952(83)90582-8; Yan L, 2000, CLIN PHARMACOL THER, V68, P210, DOI 10.1067/mcp.2000.108674; Yates CR, 1997, ANN INTERN MED, V126, P608, DOI 10.7326/0003-4819-126-8-199704150-00003	84	91	98	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7403	7413		10.1038/sj.onc.1206944	http://dx.doi.org/10.1038/sj.onc.1206944			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576848				2022-12-28	WOS:000186112500013
J	Meyers, M; Hwang, A; Wagner, MW; Bruening, AJ; Veigl, ML; Sedwick, WD; Boothman, DA				Meyers, M; Hwang, A; Wagner, MW; Bruening, AJ; Veigl, ML; Sedwick, WD; Boothman, DA			A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage	ONCOGENE			English	Review						fluorouracil; 5-fluoro-2 '-deoxyuridine; 5-fluoro-2 '-deoxycytidine; futile cycles of repair; DNA damage tolerance; colon cancer treatment	CELL-CYCLE CHECKPOINT; DEOXYURIDINE TRIPHOSPHATE NUCLEOTIDOHYDROLASE; HUMAN-COLON ADENOCARCINOMA; TARGET-DIRECTED THERAPIES; BREAST-CARCINOMA-CELLS; DOUBLE-STRAND BREAKS; LYMPHOMA S-49 CELLS; EXPLOIT HIGH-LEVELS; ADENINE BASE PAIR; KINASE C-ABL	The phenomenon of damage tolerance, whereby cells incur DNA lesions that are nonlethal, largely ignored, but highly mutagenic, appears to play a key role in carcinogenesis. Typically, these lesions are generated by alkylation of DNA or incorporation of base analogues. This tolerance is usually a result of the loss of specific DNA repair processes, most often DNA mismatch repair (MMR). The availability of genetically matched MMR deficient and - corrected cell systems allows dissection of the consequences of this unrepaired damage in carcinogenesis as well as the elucidation of cell cycle checkpoint responses and cell death consequences. Recent data indicate that MMR plays an important role in detecting damage caused by fluorinated pyrimidines (FPs) and represents a repair system that is probably not the primary system for detecting damage caused by these agents, but may be an important system for correcting key mutagenic lesions that could initiate carcinogenesis. In fact, clinical studies have shown that there is no benefit of FP-based adjuvant chemotherapy in colon cancer patients exhibiting microsatellite instability, a hallmark of MMR deficiency. MMR-mediated damage tolerance and futile cycle repair processes are discussed, as well as possible strategies using FPs to exploit these systems for improved anticancer therapy.	Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Gen Med Sci Oncol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Ireland Canc Ctr, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Boothman, DA (corresponding author), Case Western Reserve Univ, Dept Radiat Oncol, Lab Mol Stress Responses, Biomed Res Bldg 326 E,2109 Adelbert Rd, Cleveland, OH 44106 USA.	dab30@po.cwru.edu		Boothman, David/0000-0001-7474-9020	NATIONAL CANCER INSTITUTE [R01CA070788, R01CA067409, R01CA083196] Funding Source: NIH RePORTER; NCI NIH HHS [CA 83196-05, CA 70788, R01 CA 67409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; AEBERSOLD PM, 1979, CANCER RES, V39, P808; Agami R, 1999, NATURE, V399, P809; AU KG, 1992, J BIOL CHEM, V267, P12142; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEBENEK K, 1992, J BIOL CHEM, V267, P3589; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Berry SE, 2000, CANCER RES, V60, P5773; Berry SE, 1999, CANCER RES, V59, P1840; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; BOOTHMAN DA, 1987, CANCER RES, V47, P2354; BOOTHMAN DA, 1987, CANCER RES, V47, P2344; BOOTHMAN DA, 1985, MOL PHARMACOL, V27, P584; BOOTHMAN DA, 1988, MUTAT RES, V202, P393, DOI 10.1016/0027-5107(88)90201-1; Buermeyer AB, 1999, CANCER RES, V59, P538; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CARADONNA SJ, 1980, MOL PHARMACOL, V18, P513; CARADONNA SJ, 1984, J BIOL CHEM, V259, P5459; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; COLL M, 1989, NUCLEIC ACIDS RES, V17, P911, DOI 10.1093/nar/17.3.911; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Davis TW, 1998, CANCER RES, V58, P767; DIANOV GL, 1991, MOL GEN GENET, V225, P448, DOI 10.1007/BF00261686; DOMIN BA, 1993, BIOCHEM PHARMACOL, V46, P503, DOI 10.1016/0006-2952(93)90527-4; DOONG SL, 1988, J BIOL CHEM, V263, P4467; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; DUKER NJ, 1982, P NATL ACAD SCI-BIOL, V79, P4878, DOI 10.1073/pnas.79.16.4878; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELHAJJ HH, 1992, J BACTERIOL, V174, P4450, DOI 10.1128/JB.174.13.4450-4456.1992; FAZAKERLEY GV, 1987, J BIOMOL STRUCT DYN, V5, P639, DOI 10.1080/07391102.1987.10506417; FERNANDES DJ, 1986, CANCER RES, V46, P1741; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; FISHER EF, 1979, NUCLEIC ACIDS RES, V7, P401, DOI 10.1093/nar/7.2.401; Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; FREESE E, 1959, J MOL BIOL, V1, P87, DOI 10.1016/S0022-2836(59)80038-3; FRIEDKIN M, 1973, ADV ENZYMOL RAMB, V38, P235; GILL JE, 1974, BIOCHIM BIOPHYS ACTA, V335, P330, DOI 10.1016/0005-2787(74)90157-9; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; GLAZER RI, 1981, MOL PHARMACOL, V19, P117; GLICKMAN BW, 1982, MOL CELLULAR MECHANI, P65; Goel A, 2003, CANCER RES, V63, P1608; Gong JG, 1999, NATURE, V399, P806; GOULIAN M, 1980, J BIOL CHEM, V255, P630; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Grem JL, 1997, SEMIN RADIAT ONCOL, V7, P249, DOI 10.1016/S1053-4296(97)80023-9; GREM JL, 1989, BIOCHEM PHARMACOL, V38, P51, DOI 10.1016/0006-2952(89)90148-2; GREM JL, 1996, CANC CHEMOTHERAPY BI, P149; HABENER JF, 1988, P NATL ACAD SCI USA, V85, P1735, DOI 10.1073/pnas.85.6.1735; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; HAWN MT, 1995, CANCER RES, V55, P3721; HEIDELBERGER C, 1958, P SOC EXP BIOL MED, V97, P470; HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; INGRAHAM HA, 1982, MOL PHARMACOL, V21, P211; INGRAHAM HA, 1982, BIOCHEM BIOPH RES CO, V109, P746, DOI 10.1016/0006-291X(82)92003-4; INGRAHAM HA, 1980, CANCER RES, V40, P998; Jacob S, 2001, CANCER RES, V61, P6555; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Johnston P G, 1996, Cancer Chemother Biol Response Modif, V16, P1; JONES PA, 1976, CANCER RES, V36, P101; KANAMARU R, 1986, CANCER CHEMOTH PHARM, V17, P43, DOI 10.1007/BF00299864; Kane MF, 1997, CANCER RES, V57, P808; Karran P, 1996, CANCER SURV, V28, P69; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; KARRAN P, 1982, NATURE, V296, P868, DOI 10.1038/296868a0; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kashlan OB, 2002, BIOCHEMISTRY-US, V41, P462, DOI 10.1021/bi011653a; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; KAYSEN J, 1986, CANCER RES, V46, P4534; KOI M, 1994, CANCER RES, V54, P4308; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; KREMER AB, 1987, BIOCHEMISTRY-US, V26, P391, DOI 10.1021/bi00376a009; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 2001, PROG NUCLEIC ACID RE, V68, P365; KUFE DW, 1981, J BIOL CHEM, V256, P9802; KUFE DW, 1981, J BIOL CHEM, V256, P8885; Kunz BA, 1996, MUTAT RES-FUND MOL M, V355, P129, DOI 10.1016/0027-5107(96)00026-7; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; Lage H, 1999, J CANCER RES CLIN, V125, P156, DOI 10.1007/s004320050258; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; LONN U, 1989, CANCER RES, V49, P1085; LONN U, 1984, CANCER RES, V44, P3414; MAJOR PP, 1982, CANCER RES, V42, P3005; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; MAURO DJ, 1993, MOL PHARMACOL, V43, P854; MAYBAUM J, 1981, J BIOL CHEM, V256, P2126; McIntosh EM, 1997, ACTA BIOCHIM POL, V44, P159; MEKRAS JA, 1984, CANCER RES, V44, P2551; MEKRAS JA, 1985, CANCER RES, V45, P5270; Meyers M, 2001, CANCER RES, V61, P5193; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Muller A, 2002, CANCER INVEST, V20, P102, DOI 10.1081/CNV-120000371; Nehme A, 1999, BRIT J CANCER, V79, P1104, DOI 10.1038/sj.bjc.6690176; Nehme A, 1997, CANCER RES, V57, P3253; NEWMAN EM, 1982, P NATL ACAD SCI-BIOL, V79, P6419, DOI 10.1073/pnas.79.21.6419; NILSSON S, 1980, J BIOL CHEM, V255, P9552; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; Parikh SS, 2000, MUTAT RES-DNA REPAIR, V460, P183, DOI 10.1016/S0921-8777(00)00026-4; PARKER WB, 1987, CANCER RES, V47, P979; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHARD P, 1985, GENETIC CONSEQUENCES, P33; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; RICHARDS RG, 1984, ADV ENZYME REGUL, V22, P157, DOI 10.1016/0065-2571(84)90013-X; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; SANTI DV, 1972, P NATL ACAD SCI USA, V69, P1855, DOI 10.1073/pnas.69.7.1855; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SCHUETZ JD, 1984, CANCER RES, V44, P1358; SEDWICK WD, 1981, P NATL ACAD SCI-BIOL, V78, P917, DOI 10.1073/pnas.78.2.917; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SOWERS LC, 1989, J MOL BIOL, V205, P437, DOI 10.1016/0022-2836(89)90353-7; SOWERS LC, 1987, J BIOL CHEM, V262, P15436; SOWERS LC, 1988, J BIOL CHEM, V263, P14794; Stewart ZA, 2001, CHEM RES TOXICOL, V14, P243, DOI 10.1021/tx000199t; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; TAKAHASHI I, 1963, NATURE, V197, P794, DOI 10.1038/197794a0; Taverna P, 2001, MUTAT RES-DNA REPAIR, V485, P269, DOI 10.1016/S0921-8777(01)00076-3; van Laar JAM, 1998, EUR J CANCER, V34, P296, DOI 10.1016/S0959-8049(97)00366-3; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vikhanskaya F, 1999, CLIN CANCER RES, V5, P937; Wang Q, 2001, ONCOGENE, V20, P4640, DOI 10.1038/sj.onc.1204625; Wang Y, 2000, GENE DEV, V14, P927; WECKBECKER G, 1991, PHARMACOL THERAPEUT, V50, P367, DOI 10.1016/0163-7258(91)90051-M; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; YOSHIOKA A, 1987, J BIOL CHEM, V262, P8235; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	146	56	57	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7376	7388		10.1038/sj.onc.1206941	http://dx.doi.org/10.1038/sj.onc.1206941			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576845				2022-12-28	WOS:000186112500010
J	Shen, Q; Singh, P				Shen, Q; Singh, P			Identification of a novel SP3 binding site in the promoter of human IGFBP4 gene: Role of SP3 and AP-1 in regulating promoter activity in CaCo2 cells	ONCOGENE			English	Article						IGFBP4 promoter; Sp3 binding site; AP-1 binding site; colon cancer cells; c-Jun; JunD	GROWTH-FACTOR-II; SMOOTH-MUSCLE; DIFFERENTIAL EXPRESSION; PROTEIN-4 IGFBP-4; SP-FAMILY; TRANSCRIPTION; MECHANISMS; CLONING; ELEMENT; PROLIFERATION	Insulin-like growth factor binding protein 4 (IGFBP4/BP4) gene expression plays an important role in the transition from proliferation to differentiation of a human colon cancer cell line, CaCo2. We recently cloned and identified multiple cis elements (including putative binding sites for activator protein 1(AP-1) and specificity proteins (Sps) ) in the promoter of human BP4 gene, and measured a significant upregulation of the promoter activity in response to c-Jun. We therefore examined the role of the single AP-1 site (-869/-863) and other cis elements, in regulating the expression of hBP4 gene, in the current studies. Deletion of a 25 bp sequence from -872 to -848, which contains the AP-1 site, significantly reduced BP4 promoter activity by approximately 50%. Surprisingly, mutation of the AP-1 site did not produce significant alteration in the activity of the BP4 promoter. However, mutation of 7 bp (5'-TGCTGCA) at the 3' end of the AP-1 site resulted in significantly decreasing the promoter activity by > 50%. Proteins bound to the 25 bp probe (-872/-848) could be supershifted by antibodies specific for JunD and Sp3 in an EMSA. JunD binding was abolished on mutation of the AP-1 site and Sp3 binding was abolished on mutation of the 7 bp at -861/-855; binding of the purified Sp3 protein to the 25 bp probe was similarly abolished on mutation of the newly discovered Sp3 binding site (TGCTGCA). BP4 promoter activity was upregulated in insect cells in response to Sp3 expression, confirming a functional importance of the novel Sp3 binding site. These studies suggest that the Sp3 binding site, rather than the AP-1 site, may be playing a significant role in regulating the expression of IGFBP4 gene in CaCo2 cells.	Univ Texas, Med Branch, Dept Anat & Neurosci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Anat & Neurosci, 10-104 Med Res Bldg,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu		Shen, Qiang/0000-0002-1491-5434	NCI NIH HHS [CA 60087, CA 72992] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072992] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; Cohick WS, 2000, ENDOCRINOLOGY, V141, P4583, DOI 10.1210/en.141.12.4583; CONOVER CA, 1995, J BIOL CHEM, V270, P4395, DOI 10.1074/jbc.270.9.4395; Dai BS, 1997, ENDOCRINOLOGY, V138, P332, DOI 10.1210/en.138.1.332; Dai BS, 2001, J BIOL CHEM, V276, P6937, DOI 10.1074/jbc.M007789200; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; Duan CM, 1998, J BIOL CHEM, V273, P16836, DOI 10.1074/jbc.273.27.16836; Gao JG, 1996, MOL ENDOCRINOL, V10, P613, DOI 10.1210/me.10.6.613; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kao WY, 1997, J CELL BIOCHEM, V65, P231, DOI 10.1002/(SICI)1097-4644(199705)65:2<231::AID-JCB8>3.0.CO;2-V; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; Kutoh E, 1999, CANCER LETT, V136, P187, DOI 10.1016/S0304-3835(98)00321-8; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Li CG, 2000, BBA-GENE STRUCT EXPR, V1490, P213, DOI 10.1016/S0167-4781(99)00183-9; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; Maor SB, 2000, MOL GENET METAB, V69, P130, DOI 10.1006/mgme.1999.2958; Miyakoshi N, 2001, ENDOCRINOLOGY, V142, P2641, DOI 10.1210/en.142.6.2641; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; OGUCHI S, 1994, AM J PHYSIOL-GASTR L, V267, pG843, DOI 10.1152/ajpgi.1994.267.5.G843; Pan XL, 2000, J LAB CLIN MED, V136, P157, DOI 10.1067/mlc.2000.108149; Park JHY, 1996, J CELL PHYSIOL, V166, P396, DOI 10.1002/(SICI)1097-4652(199602)166:2<396::AID-JCP18>3.0.CO;2-9; Praz V, 2002, NUCLEIC ACIDS RES, V30, P322, DOI 10.1093/nar/30.1.322; Qin CH, 1999, ENDOCRINOLOGY, V140, P2501, DOI 10.1210/en.140.6.2501; Qin XZ, 1997, BBA-GENE STRUCT EXPR, V1350, P136, DOI 10.1016/S0167-4781(96)00220-5; Shen Q, 1998, GASTROENTEROLOGY, V114, pA1179; SHEN Q, 2001, P END SOC 83 ANN M D; SHEN Q, 1998, CANCER RES, V39, pA1225; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; Singh P, 1998, GASTROENTEROLOGY, V114, P1221, DOI 10.1016/S0016-5085(98)70428-7; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; Singh P, 2000, J CLIN LIGAND ASSAY, V23, P214; Singh P, 1996, ENDOCRINOLOGY, V137, P1764, DOI 10.1210/en.137.5.1764; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; SINGH P, 1994, CANCER RES, V54, P6563; Smith EP, 2001, ENDOCRINOLOGY, V142, P4420, DOI 10.1210/en.142.10.4420; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tseng L, 1997, ANN NY ACAD SCI, V828, P27, DOI 10.1111/j.1749-6632.1997.tb48521.x; Zarrilli R, 1999, GASTROENTEROLOGY, V116, P1358, DOI 10.1016/S0016-5085(99)70500-7; Zazzi H, 1998, GENOMICS, V49, P401, DOI 10.1006/geno.1998.5283; Zhang MY, 2002, J BIOL CHEM, V277, P21285, DOI 10.1074/jbc.M112082200; Zhu Q, 2000, J VIROL, V74, P6348, DOI 10.1128/JVI.74.14.6348-6357.2000	47	8	8	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2454	2464		10.1038/sj.onc.1207354	http://dx.doi.org/10.1038/sj.onc.1207354			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14767471				2022-12-28	WOS:000220558000003
J	Jiang, K; Delarue, FL; Sebti, SM				Jiang, K; Delarue, FL; Sebti, SM			EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation	ONCOGENE			English	Article						RhoB; Ras; EGFR; ErbB2; transformation; apoptosis	EPIDERMAL-GROWTH-FACTOR; GTP-BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; GERANYLGERANYLATED RHOB; CELL-GROWTH; GTPASES; FAMILY; KINASE; ONCOPROTEIN; PHENOTYPE	While some low molecular weight GTPases such as Ras and RhoA contribute to malignant transformation, a closely related family member, RhoB, has tumor-suppressive activity, but little is known about its regulation by oncogenes. In this study, we show that H-Ras, N-Ras, K-Ras, EGFR and ErbB2 but not v-Src suppress RhoB promoter transcriptional activity in NIH3T3 cells and human cancer cell lines derived from lung (A-549), pancreatic (Panc-1) and cervical (C33A) tumors. The EGFR and ErbB2 suppression of RhoB promoter activity is mediated by Ras. Furthermore, Ras suppresses basal as well as 5-fluorouracil (5-FU)-induced RhoB promoter activity and RhoB protein levels. Ectopic expression of RhoB, but not the closely related family member RhoA, antagonizes the ability of EGFR, ErbB2, H-Ras, N-Ras and K-Ras but not v-Src to transform NIH3T3 cells. Furthermore, RhoB, but not RhoA, inhibits colony formation and proliferation and induces anoikis in A-549 cells and Ras-transformed NIH3T3 cells. Finally, Ras-mediated resistance to 5-FU-induced apoptosis is reversed by RhoB. These results demonstrate that RhoB expression is negatively regulated by oncogenes that are prevalent in human cancers, and that ectopic expression of RhoB antagonizes the ability of these oncogenes to induce transformation. Taken together the data suggest that certain oncogenes suppress RhoB as one of the critical steps leading to malignant transformation.	Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, Tampa, FL 33612 USA; Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), Univ S Florida, Drug Discovery Program, H Lee Moffitt Canc Ctr & Res Inst, Dept Interdisciplinary Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	Sebti@moffitt.usf.edu			NATIONAL CANCER INSTITUTE [U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adnane J, 2002, CLIN CANCER RES, V8, P2225; ALIMANDI M, 1995, ONCOGENE, V10, P1813; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Du W, 1999, CANCER RES, V59, P5492; Du W, 1999, MOL CELL BIOL, V19, P1831; Forget MA, 2002, CLIN EXP METASTAS, V19, P9, DOI 10.1023/A:1013884426692; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Nakamura T, 1996, BIOCHEM BIOPH RES CO, V226, P688, DOI 10.1006/bbrc.1996.1415; Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Turkson J, 1999, MOL CELL BIOL, V19, P7519; VAN AL, 1997, GENE DEV, V11, P2295; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	25	59	61	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1136	1145		10.1038/sj.onc.1207236	http://dx.doi.org/10.1038/sj.onc.1207236			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14647415				2022-12-28	WOS:000188749900012
J	Saito, T; Tanaka, R; Wataba, K; Kudo, R; Yamasaki, H				Saito, T; Tanaka, R; Wataba, K; Kudo, R; Yamasaki, H			Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells	ONCOGENE			English	Article						connexin; estrogen; carcinogenesis; endometrial hyperplasia; gap junction; cell adhesion	EPIDERMAL-GROWTH-FACTOR; DOWN-REGULATION; STEROID-HORMONES; CONNEXIN GENES; CANCER-CELLS; MICROSATELLITE INSTABILITY; ISLAND METHYLATION; PROMOTER REGION; BETA-CATENIN; EXPRESSION	Stimulation of the endometrium by estrogens without the differentiating effect of progestins is the primary etiological factor associated with the development of endometrial hyperplasia and adenocarcinoma. However, the correlation between sex steroids and gap junctional intercellular communication (GJIC), which is considered to play an important role in the control of cell growth and differentiation, is not well known in endometrial carcinoma. In this study, we focused on the influence of estrogen and its receptor in connexin (Cx) expression and GJIC in endometrial carcinoma cells, established stable clone IK-ER1 overexpressing ER-alpha to transfect the expression vector and analysed them in various hormonal conditions. The growth of IK-ER1 was accelerated by 17beta-estradiol and the acceleration of the 5-bromo-25-deoxyuridine labeling index was observed. GJIC was assayed by scoring the number of dye-coupled cells after microinjecton of single cells with Lucifer-Yellow, and subcellular localization of Cx26 and Cx32 was analysed by immunocytochemistry. In the presence of estradiol, dye-coupled cells of IK-ER1 were significantly reduced compared to those without estradiol and the reduction was completely inhibited by adding ICI182.780, a pure antiestrogen substrate. Cxs were detected as only small spots by immunocytochemistry, and Western blotting showed that the expression was decreased. These results suggest that activation of ER-alpha by estrogen results in tumor progression by stimulating cell growth and suppressing GJIC via suppression of the expression of Cxs in endometrial carcinogenesis.	Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, Sapporo, Hokkaido 0608543, Japan; Kwansei Gakuin Univ, Sch Sci & Technol, Sanda 6691337, Japan	Sapporo Medical University; Kwansei Gakuin University	Saito, T (corresponding author), Sapporo Med Univ, Sch Med, Dept Obstet & Gynaecol, Chuo Ku, S-1,W-16, Sapporo, Hokkaido 0608543, Japan.	tsaito@sapmed.ac.jp						Al Moustafa AE, 2002, ONCOGENE, V21, P2634, DOI 10.1038/sj.onc.1205351; Ali SH, 2000, CANCER RES, V60, P7094; ANZAI Y, 1992, J STEROID BIOCHEM, V42, P449, DOI 10.1016/0960-0760(92)90256-I; Ashihara Koji, 2002, Medical Electron Microscopy, V35, P9, DOI 10.1007/s007950200001; BERCHUCK A, 1995, CANCER, V76, P2034, DOI 10.1002/1097-0142(19951115)76:10+<2034::AID-CNCR2820761321>3.0.CO;2-U; Darnel AD, 1999, J STEROID BIOCHEM, V70, P203, DOI 10.1016/S0960-0760(99)00116-8; Dubina MV, 2002, ONCOGENE, V21, P4992, DOI 10.1038/sj.onc.1205630; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Fukuchi T, 1998, CANCER RES, V58, P3526; Grummer R, 1999, ENDOCRINOLOGY, V140, P2509, DOI 10.1210/en.140.6.2509; Hanna EA, 1999, CARCINOGENESIS, V20, P1369, DOI 10.1093/carcin/20.7.1369; Heikaus S, 2002, J MOL ENDOCRINOL, V29, P239, DOI 10.1677/jme.0.0290239; Hirai A, 2003, AM J NEPHROL, V23, P172, DOI 10.1159/000070653; HOLINKA CF, 1986, CANCER RES, V46, P2771; Huang RC, 2002, CANCER RES, V62, P2806; JAMIL A, 1991, J MOL ENDOCRINOL, V6, P215, DOI 10.1677/jme.0.0060215; KAMIBAYASHI Y, 1995, CARCINOGENESIS, V16, P1287, DOI 10.1093/carcin/16.6.1287; KLEINMAN D, 1995, ENDOCRINOLOGY, V136, P2531, DOI 10.1210/en.136.6.2531; Klotz LO, 2002, CANCER RES, V62, P4922; KOHLER MF, 1993, AM J OBSTET GYNECOL, V169, P690, DOI 10.1016/0002-9378(93)90644-X; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Krutovskikh V, 1997, HISTOL HISTOPATHOL, V12, P761; KRUTOVSKIKH VA, 1991, CARCINOGENESIS, V12, P1701, DOI 10.1093/carcin/12.9.1701; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; Laird DW, 1999, CANCER RES, V59, P4104; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; Locke D, 1998, J PATHOL, V186, P343; Loncarek J, 2003, MOL CARCINOGEN, V36, P74, DOI 10.1002/mc.10102; LUKES AS, 1994, CANCER, V73, P2380, DOI 10.1002/1097-0142(19940501)73:9<2380::AID-CNCR2820730922>3.0.CO;2-G; MESNIL M, 1995, CANCER RES, V55, P629; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Nei H, 1999, MOL CARCINOGEN, V25, P207, DOI 10.1002/(SICI)1098-2744(199907)25:3<207::AID-MC7>3.3.CO;2-W; Nishida Masato, 2002, Hum Cell, V15, P104, DOI 10.1111/j.1749-0774.2002.tb00105.x; Nishimura M, 2003, CARCINOGENESIS, V24, P1615, DOI 10.1093/carcin/bgg121; Ozog MA, 2002, CANCER RES, V62, P3544; Parc YR, 2000, INT J CANCER, V86, P60, DOI 10.1002/(SICI)1097-0215(20000401)86:1<60::AID-IJC9>3.0.CO;2-3; PETROCELLI T, 1993, ENDOCRINOLOGY, V133, P284, DOI 10.1210/en.133.1.284; RISEK B, 1995, J CELL SCI, V108, P1017; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; Saito T, 1998, ONCOGENE, V17, P1673, DOI 10.1038/sj.onc.1202092; Saito T, 1997, INT J CANCER, V73, P479, DOI 10.1002/(SICI)1097-0215(19971114)73:4<479::AID-IJC4>3.0.CO;2-X; Saito T, 1997, CANCER RES, V57, P375; Saito T, 1997, BIOCHEM BIOPH RES CO, V231, P610, DOI 10.1006/bbrc.1997.6164; Saito T, 2001, INT J CANCER, V93, P317, DOI 10.1002/ijc.1350; SASAKI H, 1993, CANCER RES, V53, P1906; Singal R, 2000, ANTICANCER RES, V20, P59; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231; Thenot S, 1999, MOL CELL ENDOCRINOL, V156, P85, DOI 10.1016/S0303-7207(99)00139-2; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Trosko James E., 1998, Frontiers in Bioscience, V3, pD208; Trosko JE, 2002, CURR DRUG TARGETS, V3, P465, DOI 10.2174/1389450023347371; Trosko JE, 2001, MUTAT RES-FUND MOL M, V480, P219, DOI 10.1016/S0027-5107(01)00181-6; Tsai H, 1996, BIOCHEM BIOPH RES CO, V227, P64, DOI 10.1006/bbrc.1996.1468; Wataba K, 2001, INT J CANCER, V91, P448, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1077>3.0.CO;2-F; WENTZ W B, 1974, Gynecologic Oncology, V2, P362, DOI 10.1016/0090-8258(74)90027-4; Willecke K, 1999, ANN NY ACAD SCI, V883, P302, DOI 10.1111/j.1749-6632.1999.tb08592.x; Yamasaki H, 1999, CANCER DETECT PREV, V23, P273, DOI 10.1046/j.1525-1500.1999.99037.x; Yamasaki H, 1996, CARCINOGENESIS, V17, P1199, DOI 10.1093/carcin/17.6.1199; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	60	22	24	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1109	1116		10.1038/sj.onc.1207215	http://dx.doi.org/10.1038/sj.onc.1207215			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762440				2022-12-28	WOS:000188749900009
J	Sidhu, SS; Mengistab, AT; Tauscher, AN; LaVail, J; Basbaum, C				Sidhu, SS; Mengistab, AT; Tauscher, AN; LaVail, J; Basbaum, C			The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions	ONCOGENE			English	Article						EMMPRIN; MMP; microvesicle	MATRIX METALLOPROTEINASE INDUCER; BREAST-CARCINOMA CELLS; MEMBRANE-VESICLES; IMMUNOGLOBULIN SUPERFAMILY; MEDIATED RELEASE; MOUSE BASIGIN; MEMBER; RECEPTOR; SURFACE; EXPRESSION	EMMPRIN is a transmembrane glycoprotein expressed at high levels by tumor cells. It has been identified as a tumor-derived factor that can stimulate matrix metalloproteinase expression in fibroblasts and hence facilitate tumor invasion and metastasis. Recent studies have shown that full-length EMMPRIN is released by tumor cells, but the mechanism of release remains unclear. Here, we show that EMMPRIN is released from the surface of NCI-H460 cells via microvesicle shedding. However, these vesicles are unstable and rapidly break down to release bioactive EMMPRIN. Although microvesicle shedding has been considered a constitutive process in tumor cells, our data show that it can be amplified upon cell exposure to PMA, elucidating at least one signalling cascade responsible for EMMPRIN release. This pathway is dependent on protein kinase C, calcium mobilization and mitogen-activated protein kinase kinase (MEK 1/2). Thus, the results outline a novel form of tumor-stromal interaction in which extracellular matrix degradation by fibroblasts is controlled through the microvesicular release of EMMPRIN from tumor cells.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Biomol Sci Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Program Biomed Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Neurosci Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Basbaum, C (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.	cbas@itsa.ucsf.edu		Sidhu, Sukhvinder/0000-0002-2999-4358	NHLBI NIH HHS [R0-1 HL 43762, P0-1 HL24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043762, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albanese J, 1998, BLOOD, V91, P3862; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Basbaum CB, 1996, CURR OPIN CELL BIOL, V8, P731, DOI 10.1016/S0955-0674(96)80116-5; Beer S, 1999, J CELL SCI, V112, P2667; BISWAS C, 1995, CANCER RES, V55, P434; Black P H, 1980, Adv Cancer Res, V32, P75, DOI 10.1016/S0065-230X(08)60361-9; Cassara D, 1998, J SUBMICR CYTOL PATH, V30, P45; Caudroy S, 1999, J HISTOCHEM CYTOCHEM, V47, P1575, DOI 10.1177/002215549904701209; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; DAINIAK N, 1991, BLOOD, V78, P264; Dalberg K, 2000, WORLD J SURG, V24, P334, DOI 10.1007/s002689910053; Dolo V, 1998, CANCER RES, V58, P4468; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; Dolo V, 1999, CLIN EXP METASTAS, V17, P131, DOI 10.1023/A:1006500406240; DOLO V, 1995, J SUBMICR CYTOL PATH, V27, P535; ELLIS SM, 1989, CANCER RES, V49, P3385; Fadool JM, 1996, BIOCHEM BIOPH RES CO, V229, P280, DOI 10.1006/bbrc.1996.1793; Ginestra A, 1999, ANTICANCER RES, V19, P3439; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Guo HM, 1997, J BIOL CHEM, V272, P24; Gutwein P, 2000, J BIOL CHEM, V275, P15490, DOI 10.1074/jbc.275.20.15490; Gutwein P, 2002, FASEB J, V16, P292, DOI 10.1096/fj.02-0430fje; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; KANEKURA T, 1991, CELL STRUCT FUNCT, V16, P23, DOI 10.1247/csf.16.23; KASINRERK W, 1992, J IMMUNOL, V149, P847; Kim CW, 2002, CANCER RES, V62, P6312; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Li RS, 2001, J CELL PHYSIOL, V186, P371, DOI 10.1002/1097-4652(2000)9999:999<000::AID-JCP1042>3.0.CO;2-8; Lim M, 1998, FEBS LETT, V441, P88, DOI 10.1016/S0014-5793(98)01474-4; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; MIYAUCHI T, 1995, J BIOCHEM-TOKYO, V118, P717, DOI 10.1093/oxfordjournals.jbchem.a124971; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rutter JL, 1997, J CELL BIOCHEM, V66, P322, DOI 10.1002/(SICI)1097-4644(19970901)66:3<322::AID-JCB5>3.3.CO;2-D; Salzer U, 2002, BLOOD, V99, P2569, DOI 10.1182/blood.V99.7.2569; SATTA N, 1994, J IMMUNOL, V153, P3245; Taraboletti G, 2002, AM J PATHOL, V160, P673, DOI 10.1016/S0002-9440(10)64887-0; Taylor D D, 1986, Dev Biol (N Y 1985), V3, P33; Taylor PM, 2002, ONCOGENE, V21, P5765, DOI 10.1038/sj.onc.1205702; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thorns C, 2002, ANTICANCER RES, V22, P1983; Vincent JP, 2002, TRENDS CELL BIOL, V12, P57, DOI 10.1016/S0962-8924(01)02227-9; Wang W, 2002, J CELL BIOL, V157, P1061, DOI 10.1083/jcb.200203014; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Wu LNY, 2002, J BIOL CHEM, V277, P5126, DOI 10.1074/jbc.M107899200; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	53	214	229	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					956	963		10.1038/sj.onc.1207070	http://dx.doi.org/10.1038/sj.onc.1207070			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749763				2022-12-28	WOS:000188486600011
J	Sulman, EP; White, PS; Brodeur, GM				Sulman, EP; White, PS; Brodeur, GM			Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34	ONCOGENE			English	Article						meningioma; tumor suppressor gene; chromosome 1	BASAL-CELL CARCINOMA; ALLELIC LOSSES; FORKHEAD GENE; HUMAN HOMOLOG; HRAD54 GENE; NF2 GENE; DELETION; MUTATIONS; REGION; MAPS	Meningioma is a frequently occurring tumor of the meninges surrounding the central nervous system. Loss of the short arm of chromosome 1 (1p) is the second most frequent chromosomal abnormality observed in these tumors. Previously, we identified a 3.7 megabase (Mb) region of consistent deletion on 1p33-p34 in a panel of 157 tumors. Loss of this region was associated with advanced disease and predictive for tumor relapse. In this report, a high-resolution integrated map of the region was constructed (CompView) to identify all markers in the smallest region of overlapping deletion (SRO). A regional somatic cell hybrid panel was used to more precisely localize those markers identified in CompView as within or overlapping the region. Additional deletion mapping using microsatellites localized to the region narrowed the SRO to approximately 2.8 Mb. The 88 markers remaining in the SRO were used to screen genomic databases to identify large-insert clones. Clones were assembled into a physical map of the region by PCR-based, sequence-tagged site (STS) content mapping. A sequence from clones was used to validate STS content by electronic PCR and to identify transcripts. A minimal tiling path of 43 clones was constructed across the SRO. Sequence data from the most current sequence assembly were used for further validation. A total of 59 genes were ordered within the SRO. In all, 17 of these were selected as likely candidates based on annotation using Gene Ontology Consortium terms, including the MUTYH, PRDX1, FOXD2, FOXE3, PTCH2, and RAD54L genes. This annotation of a putative tumor suppressor locus provides a resource for further analysis of meningioma candidate genes.	Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA; Temple Univ, Sch Med, Fels Inst Mol Biol & Canc Res, Philadelphia, PA 19140 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania	Brodeur, GM (corresponding author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Room 902,Abramson Res Ctr,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	brodeur@email.chop.edu		Sulman, Erik/0000-0003-4933-9120	NCI NIH HHS [CA-39771] Funding Source: Medline; NIMH NIH HHS [MH-60240] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060240] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ashburner M, 2001, GENOME RES, V11, P1425; Auburger G, 1996, GENOMICS, V31, P90, DOI 10.1006/geno.1996.0013; Bello MJ, 2000, CANCER GENET CYTOGEN, V116, P142, DOI 10.1016/S0165-4608(99)00122-3; BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1995, CANCER GENET CYTOGEN, V83, P160, DOI 10.1016/0165-4608(95)00064-V; BIECHE I, 1993, CANCER RES, V53, P1990; Blixt A, 2000, GENE DEV, V14, P245; Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649; Brooksbank C, 2003, NUCLEIC ACIDS RES, V31, P43, DOI 10.1093/nar/gkg066; Corman B, 1999, AM J HUM GENET, V64, P126, DOI 10.1086/302206; DOWNING JR, 1995, AM J PATHOL, V146, P626; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; Engle EC, 1997, AM J HUM GENET, V60, P1150; Ernstsson S, 1997, GENOMICS, V46, P78, DOI 10.1006/geno.1997.4986; EVANS DGR, 1992, Q J MED, V84, P603; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; JIMENEZLARA AM, 1992, CANCER GENET CYTOGEN, V63, P174; Jogi A, 2000, INT J ONCOL, V16, P943; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Lamszus K, 2000, J NEUROPATH EXP NEUR, V59, P504, DOI 10.1093/jnen/59.6.504; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Leone PE, 1999, ONCOGENE, V18, P2231, DOI 10.1038/sj.onc.1202531; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; Mathiesen T, 1996, NEUROSURGERY, V39, P2, DOI 10.1097/00006123-199607000-00002; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mendiola M, 1999, MOL CARCINOGEN, V24, P300, DOI 10.1002/(SICI)1098-2744(199904)24:4<300::AID-MC8>3.0.CO;2-G; Miller PR, 1999, CYTOGENET CELL GENET, V85, P157; Muller P, 1999, CLIN CANCER RES, V5, P3569; NAKASU S, 1987, SURG NEUROL, V27, P319, DOI 10.1016/0090-3019(87)90005-X; Niedermayer I, 1997, J NEUROPATH EXP NEUR, V56, P879, DOI 10.1097/00005072-199708000-00006; PROSPERI MT, 1993, J BIOL CHEM, V268, P11050; Prosperi MT, 1998, FEBS LETT, V423, P39, DOI 10.1016/S0014-5793(98)00057-X; Pruess M, 2003, NUCLEIC ACIDS RES, V31, P414, DOI 10.1093/nar/gkg105; Pruitt KD, 1997, GENOME RES, V7, P1118, DOI 10.1101/gr.7.12.1118; PYKETT MJ, 1994, CANCER RES, V54, P6340; Rasio D, 1997, CANCER RES, V57, P2378; REMPEL SA, 1993, CANCER RES, V53, P2386; ROBERTS L, 1991, SCIENCE, V254, P805, DOI 10.1126/science.1948063; Roberts T, 1996, ANN HUM GENET, V60, P213, DOI 10.1111/j.1469-1809.1996.tb00424.x; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; Santarius T, 2000, NEUROPATH APPL NEURO, V26, P67, DOI 10.1046/j.1365-2990.2000.00219.x; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Schutte BC, 2001, CYTOGENET CELL GENET, V92, P24; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Simon M, 1996, GENE CHROMOSOME CANC, V16, P265, DOI 10.1002/(SICI)1098-2264(199608)16:4<265::AID-GCC7>3.3.CO;2-F; SIMON M, 1995, CANCER RES, V55, P4696; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; Sulman EP, 1998, CANCER RES, V58, P3226; Vance JM, 1997, CYTOGENET CELL GENET, V78, P154; VENTER JC, 2001, J BIOL CHEM, V276, P43604; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; White PS, 1999, GENOME RES, V9, P978, DOI 10.1101/gr.9.10.978; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Zaphiropoulos PG, 1999, CANCER RES, V59, P787; Zulch KJ, 1979, HISTOLOGICAL TYPING; 1998, CURR BIOL, V8, pR510	61	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1014	1020		10.1038/sj.onc.1206623	http://dx.doi.org/10.1038/sj.onc.1206623			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749765				2022-12-28	WOS:000188486600019
J	Richardson, C; Stark, JM; Ommundsen, M; Jasin, M				Richardson, C; Stark, JM; Ommundsen, M; Jasin, M			Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability	ONCOGENE			English	Article						translocation; DNA double-strand break; homologous recombination; crossover; genome instability; aneuploidy; Rad51	INDUCED DNA-REPLICATION; ACUTE MYELOID-LEUKEMIA; MAMMALIAN-CELLS; HOMOLOGOUS RECOMBINATION; GENE CONVERSION; CHROMOSOMAL TRANSLOCATIONS; ATP HYDROLYSIS; ES CELLS; C-MYC; PROTEIN	Genomic instability is characteristic of tumor cells, and a strong correlation exists between abnormal karyotype and tumorigenicity. Increased expression of the homologous recombination and DNA repair protein Rad51 has been reported in immortalized and tumor cells, which could alter recombination pathways to contribute to the chromosomal rearrangements found in these cells. We used a genetic system to examine the potential for multiple double-strand breaks to lead to genome rearrangements in the presence of increased Rad51 expression. Analysis of repair revealed a novel class of products consistent with crossing over, involving gene conversion associated with an exchange of flanking markers leading to chromosomal translocations. Increased Rad51 also promoted aneuploidy and multiple chromosomal rearrangements. These data provide a link between elevated Rad51 protein levels, genome instability, and tumor progression.	Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, New York, NY 10032 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA	Columbia University; Cornell University; Memorial Sloan Kettering Cancer Center	Richardson, C (corresponding author), Columbia Univ Coll Phys & Surg, Inst Canc Genet, Dept Pathol, 1150 St Nicholas Ave, New York, NY 10032 USA.	car10@columbia.edu			NCI NIH HHS [P30 CA13696] Funding Source: Medline; NCRR NIH HHS [S10 RR10506, S10 RR13701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013696] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013701, S10RR010506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGUILERA A, 1989, GENETICS, V123, P683; Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; ANTONARAKIS SE, 2002, GENETIC BASIS HUMAN, P7; Arnaudeau C, 1999, J MOL BIOL, V289, P1231, DOI 10.1006/jmbi.1999.2856; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Bosco G, 1998, GENETICS, V150, P1037; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Cory S, 1999, CANCER RES, V59, p1685S; Flygare J, 2001, EXP CELL RES, V268, P61, DOI 10.1006/excr.2001.5265; Gibson L, 1996, ONCOGENE, V13, P665; Gloor GB, 1998, TRENDS GENET, V14, P43, DOI 10.1016/S0168-9525(97)01365-6; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Hut HMJ, 2003, MOL BIOL CELL, V14, P1993, DOI 10.1091/mbc.E02-08-0510; JASIN M, 1988, GENE DEV, V2, P1353, DOI 10.1101/gad.2.11.1353; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; Kim PM, 2001, NUCLEIC ACIDS RES, V29, P4352, DOI 10.1093/nar/29.21.4352; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Malkova A, 1996, P NATL ACAD SCI USA, V93, P7131, DOI 10.1073/pnas.93.14.7131; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morrison C, 1999, MOL CELL BIOL, V19, P6891; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; Raderschall E, 2002, J CELL SCI, V115, P153; Raderschall E, 2002, CANCER RES, V62, P219; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stark JM, 2003, MOL CELL BIOL, V23, P733, DOI 10.1128/MCB.23.2.733-743.2003; Stark JM, 2002, J BIOL CHEM, V277, P20185, DOI 10.1074/jbc.M112132200; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; SUPER HJG, 1993, BLOOD, V82, P3705; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tremblay A, 2000, MOL CELL BIOL, V20, P54, DOI 10.1128/MCB.20.1.54-60.2000; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yamamoto A, 1996, MOL GEN GENET, V251, P1; Yanez RJ, 1999, GENE THER, V6, P1282, DOI 10.1038/sj.gt.3300945	63	184	193	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					546	553		10.1038/sj.onc.1207098	http://dx.doi.org/10.1038/sj.onc.1207098			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724582				2022-12-28	WOS:000188098300025
J	Al-Mohanna, MA; Manogaran, PS; Al-Mukhalafi, Z; Al-Hussein, KA; Aboussekhra, A				Al-Mohanna, MA; Manogaran, PS; Al-Mukhalafi, Z; Al-Hussein, KA; Aboussekhra, A			The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin	ONCOGENE			English	Article						apoptosis; Bax; cisplatin; p16(INK4a); UV damage	CELL-CYCLE ARREST; P53-DEPENDENT APOPTOSIS; BAX EXPRESSION; RNA-POLYMERASE; GROWTH ARREST; DNA-REPAIR; P53; BCL-2; SKIN; P16(CDKN2A)	p16(INK4a) (hereafter referred to as p16), a major cyclin-dependent kinase (CDK) inhibitor, is the product of a tumor-suppressor gene that has been found inactivated in different cancer types. In the present study, we sought to investigate the role of p16 in apoptosis induced by ultraviolet light (the most important etiological cause of skin cancer) and cisplatin (an anticancer DNA damaging agent). It is clearly shown that p16-compromised osteosarcoma U2OS cell line and p16-/- mouse embryo fibroblasts are sensitive to UV-induced apoptosis, as compared to their respective isogenic p16-expressing cells (EH1, EH2) and p16 +/+, indicating that p16 protects cells from undergoing apoptosis in response to UV light. Importantly, this reduction in UV-mediated apoptosis was associated with downregulation of the proapoptotic Bax protein, with no effect on Bcl-2 expression, suggesting that this antiapoptotic role of p16 is mediated via the intrinsic-mitochondrial pathway. On the other hand, p16 sensitized cells to cisplatin-mediated apoptosis through Bcl-2 decline. Interestingly, only proliferating but not G1-arrested EH1 cells underwent apoptosis in response to the anticancer drug. These novel findings provide further insight into the role of p16 in carcinogenesis, and has potential implications for future therapy strategies.	King Faisal Specialist Hosp & Res Ctr, BMR, Riyadh 11211, Saudi Arabia	King Faisal Specialist Hospital & Research Center	Aboussekhra, A (corresponding author), King Faisal Specialist Hosp & Res Ctr, BMR, MBC 03,POB 3354, Riyadh 11211, Saudi Arabia.	aboussekhra@kfshrc.edu.sa						Abrahams PJ, 1998, MUTAT RES-DNA REPAIR, V407, P189, DOI 10.1016/S0921-8777(98)00009-3; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; Al-Mohanna MA, 2001, CARCINOGENESIS, V22, P573, DOI 10.1093/carcin/22.4.573; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Amundson SA, 2000, CANCER RES, V60, P6101; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; Canman CE, 1998, ONCOGENE, V16, P957, DOI 10.1038/sj.onc.1201612; Dunkern TR, 2001, ONCOGENE, V20, P6026, DOI 10.1038/sj.onc.1204754; EVANS DL, 1994, CANCER RES, V54, P1596; Gonzalez VM, 2001, MOL PHARMACOL, V59, P657, DOI 10.1124/mol.59.4.657; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grim J, 1997, CLIN CANCER RES, V3, P2415; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Ljungman M, 1996, ONCOGENE, V13, P823; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McKay BC, 1998, ONCOGENE, V17, P545, DOI 10.1038/sj.onc.1201963; Milligan A, 1998, MUTAT RES-FUND MOL M, V422, P43, DOI 10.1016/S0027-5107(98)00174-2; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Moriwaki SI, 1997, CANCER RES, V57, P4637; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Pavey S, 1999, CANCER RES, V59, P4185; Pavey S, 2002, CANCER RES, V62, P875; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SORENSON CM, 1988, CANCER RES, V48, P4484; SORENSON CM, 1988, CANCER RES, V48, P6703; Stone S, 1996, CANCER RES, V56, P3199; Tamm I, 2002, CANCER GENE THER, V9, P641, DOI 10.1038/sj.cgt.7700480; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zornig M., 2001, BIOCHIM BIOPHYS ACTA, V1551, P1	49	49	54	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					201	212		10.1038/sj.onc.1206927	http://dx.doi.org/10.1038/sj.onc.1206927			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712225				2022-12-28	WOS:000187895300021
J	Peterson, S; Bogenmann, E				Peterson, S; Bogenmann, E			The RET and TRKA pathways collaborate to regulate neuroblastoma differentiation	ONCOGENE			English	Article						neuroblastoma; neurotrophic factors; differentiation; TRKA; RET	NERVE GROWTH-FACTOR; NEUROTROPHIN RECEPTOR P75(NTR); MICE LACKING GDNF; SYMPATHETIC NEURONS; PROTEIN-SYNTHESIS; RETINOIC ACID; NEURAL CREST; C-RET; EXPRESSION; CELLS	Neuroblastoma (NB) is a childhood cancer that arises in the adrenal gland and often shows differentiated neuronal and glial elements. The RET receptor signal pathway is functional in most NB, while loss of nerve growth factor (NGF) receptor (trkA) gene expression correlates with an aggressive phenotype. Thus, we hypothesized that the RET and TRKA signal pathways collaborate to instruct NB differentiation, reminiscent of normal neuronal maturation. Here, we demonstrate that activation of the RET receptor by glial cell line-derived neurotrophic factor (GDNF) increases expression of the RET receptor complex in a panel of malignant human NB cell lines, indicative of a positive feedback mechanism. GDNF also induces growth cessation concomitant with an arrest of cells in the G(0)/G(1) phase of the cell cycle. Furthermore, GDNF synergizes with ciliary neurotrophic factor (CNTF) to enhance TRKA receptor expression, thereby strengthening the NGF-mediated differentiation signal. Differentiated NB cells downregulate expression of the amplified N-myc gene, concurrent with the arrest of cell proliferation, while expressing neuron-specific markers (i.e., SCG10). Interestingly, maintenance of differentiated NB cells in culture is independent of the trophic activity of GDNF, but depends on TRKA signaling, thereby re-enacting the differentiation of normal sympathoadrenal (SA) progenitor cells.	Childrens Hosp Los Angeles, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Bogenmann, E (corresponding author), Childrens Hosp Los Angeles, Div Hematol Oncol, Smith Res Tower,Mail Stop 57,4650 Sunset Blvd, Los Angeles, CA 90027 USA.	ebogenmann@chla.usc.edu			NINDS NIH HHS [R01 NS36978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036978] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Baldassarre G, 2002, ONCOGENE, V21, P1739, DOI 10.1038/sj.onc.1205226; Barnett MW, 2002, J CELL SCI, V115, P4495, DOI 10.1242/jcs.00114; Barone MV, 2001, ONCOGENE, V20, P6973, DOI 10.1038/sj.onc.1204886; Barrett GL, 2000, PROG NEUROBIOL, V61, P205, DOI 10.1016/S0301-0082(99)00056-8; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; BIEDLER JL, 1976, SCIENCE, V191, P185, DOI 10.1126/science.942798; Bogenmann E, 1998, ONCOGENE, V17, P2367, DOI 10.1038/sj.onc.1202160; Bogenmann E, 1996, INT J CANCER, V67, P379, DOI 10.1002/(SICI)1097-0215(19960729)67:3<379::AID-IJC12>3.0.CO;2-3; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Creedon DJ, 1997, P NATL ACAD SCI USA, V94, P7018, DOI 10.1073/pnas.94.13.7018; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Dechant G, 2002, NAT NEUROSCI, V5, P1131, DOI 10.1038/nn1102-1131; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; Fukuda T, 2002, J BIOL CHEM, V277, P19114, DOI 10.1074/jbc.M200643200; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Hishiki T, 1998, CANCER RES, V58, P2158; Hofstra RMW, 1996, HUM GENET, V97, P362, DOI 10.1007/BF02185773; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Krieglstein K, 1998, J NEUROSCI, V18, P9822; KUMAR S, 1970, J PEDIATR SURG, V5, P18, DOI 10.1016/0022-3468(70)90515-4; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; MATSUSHIMA H, 1992, INT J CANCER, V51, P250, DOI 10.1002/ijc.2910510214; MATSUSHIMA H, 1992, INT J CANCER, V51, P727, DOI 10.1002/ijc.2910510511; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATSUSHIMA H, 1993, ADV NEUROBLASTOMA RE, V4; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; Miyake M, 1994, Prog Clin Biol Res, V385, P163; Molliver DC, 1997, J COMP NEUROL, V381, P428, DOI 10.1002/(SICI)1096-9861(19970519)381:4<428::AID-CNE3>3.0.CO;2-4; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Natarajan D, 2002, DEVELOPMENT, V129, P5151; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Roux PP, 2002, PROG NEUROBIOL, V67, P203, DOI 10.1016/S0301-0082(02)00016-3; SANTORO M, 1990, ONCOGENE, V5, P1595; Seeger Robert C., 1993, P2172; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Torres M, 1996, ONCOGENE, V12, P77; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Tsui-Pierchala B, 2002, NEURON, V33, P261, DOI 10.1016/S0896-6273(01)00585-2; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Westermann F, 2002, CANCER LETT, V184, P127, DOI 10.1016/S0304-3835(02)00199-4	56	42	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					213	225		10.1038/sj.onc.1206980	http://dx.doi.org/10.1038/sj.onc.1206980			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712226				2022-12-28	WOS:000187895300022
J	Ader, I; Delmas, C; Bonnet, J; Rochaix, P; Favre, G; Toulas, C; Cohen-Jonathan-Moyal, E				Ader, I; Delmas, C; Bonnet, J; Rochaix, P; Favre, G; Toulas, C; Cohen-Jonathan-Moyal, E			Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts	ONCOGENE			English	Article						Rho; glioma; hypoxia; MMP; angiogenesis	FARNESYLTRANSFERASE INHIBITOR; H-RAS; TUMOR-GROWTH; CELL-LINES; NUDE-MICE; IN-VIVO; TRANSGENIC MICE; HELA-CELLS; ANGIOGENESIS; REGRESSION	We previously demonstrated in vitro that inhibiting the biological pathways of the small GTPase Rho radio-sensitizes the human glioma U87 cell line. The aim of this study was to determine if Rho might be involved in the control of in vivo radiosensitivity altogether by controlling cellular radioresistance and by modifying tumor micro-environment. We demonstrate here that the in vivo induction of the dominant negative of Rho, RhoBN19, in U87 xenografts induces a significant decrease of tumor cell survival after irradiation more important than the one we previously observed in vitro. This in vivo increased effect of RhoBN19 expression is due to the improvement of the tumor oxygenation associated with a significant decrease of the vessel density and of the metalloproteinase 2 (MMP2) expression. Moreover, in vitro RhoBN19 expression in U87 cells leads to the inhibition of MMP2 activity. Our results demonstrate for the first time that inhibiting Rho pathways modifies the in vivo radiosensitivity of human glioma cells by controlling intrinsic radioresistance, hypoxia and angiogenesis. These data strongly suggest that Rho should be a major determinant of cellular resistance to ionizing radiation.	Inst Claudius Regaud, Dept Radiotherapie, F-31052 Toulouse, France; Inst Claudius Regaud, Dept Innovat Therapeut & Oncol Mol, INSERM, U563, F-31052 Toulouse, France; Inst Claudius Regaud, Anat Pathol Lab, F-31052 Toulouse, France	UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Claudius Regaud; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud	Cohen-Jonathan-Moyal, E (corresponding author), Inst Claudius Regaud, Dept Radiotherapie, 20-24 Rue Pont St Pierre, F-31052 Toulouse, France.		Moyal, Elizabeth/A-9802-2015; Rochaix, Philippe/O-4710-2014; delmas, caroline/O-9241-2014; Toulas, Christine/P-3838-2014; Ader-Perarnau, Isabelle/F-7160-2017; FAVRE, Gilles/K-9189-2014	Moyal, Elizabeth/0000-0002-6593-9276; Rochaix, Philippe/0000-0001-6238-1599; Toulas, Christine/0000-0003-1261-1725; FAVRE, Gilles/0000-0002-2344-1883; ADER, isabelle/0000-0001-5103-8509				ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Ader I, 2002, ONCOGENE, V21, P5998, DOI 10.1038/sj.onc.1205746; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bernhard EJ, 1996, CANCER RES, V56, P1727; Bernhard EJ, 1998, CANCER RES, V58, P1754; Bernsen HJJA, 1999, J NEURO-ONCOL, V44, P129, DOI 10.1023/A:1006363215260; Bernsen HJJA, 1998, J NEURO-ONCOL, V38, P51, DOI 10.1023/A:1005957201431; Brizel DM, 1996, CANCER RES, V56, P941; Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6; Cohen-Jonathan E, 1999, RADIAT RES, V152, P404, DOI 10.2307/3580225; Cohen-Jonathan E, 2000, RADIAT RES, V154, P125, DOI 10.1667/0033-7587(2000)154[0125:FIPTAE]2.0.CO;2; Cohen-Jonathan E, 2001, CANCER RES, V61, P2289; Deb S, 1999, J NEUROSCI RES, V55, P44, DOI 10.1002/(SICI)1097-4547(19990101)55:1<44::AID-JNR6>3.0.CO;2-G; Delmas C, 2002, INT J CANCER, V100, P43, DOI 10.1002/ijc.10439; Esparza J, 1999, BLOOD, V94, P2754, DOI 10.1182/blood.V94.8.2754.420k09_2754_2766; Fenton BM, 1999, BRIT J CANCER, V79, P464, DOI 10.1038/sj.bjc.6690072; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; HOCKEL M, 1994, ADV EXP MED BIOL, V345, P445; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Itoh T, 1998, CANCER RES, V58, P1048; Kakeji Y, 1997, INVEST NEW DRUG, V15, P39, DOI 10.1023/A:1005718628223; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; Koike T, 2000, BIOCHEM BIOPH RES CO, V277, P43, DOI 10.1006/bbrc.2000.3630; Kunkel P, 2001, CANCER RES, V61, P6624; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; MADER S, 1993, P NATL ACAD SCI USA, V90, P5603, DOI 10.1073/pnas.90.12.5603; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; Nozue M, 1997, J SURG ONCOL, V66, P30, DOI 10.1002/(SICI)1096-9098(199709)66:1<30::AID-JSO7>3.0.CO;2-O; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; SUN JZ, 1995, CANCER RES, V55, P4243; TEICHER BA, 1995, INT J CANCER, V61, P732, DOI 10.1002/ijc.2910610523; Turcotte S, 2003, J CELL SCI, V116, P2247, DOI 10.1242/jcs.00427; Uchida S, 2000, BIOCHEM BIOPH RES CO, V269, P633, DOI 10.1006/bbrc.2000.2315; VAN AL, 1997, GENE DEV, V11, P2295; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Wolff JEA, 1997, KLIN PADIATR, V209, P275, DOI 10.1055/s-2008-1043962; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	41	48	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8861	8869		10.1038/sj.onc.1207095	http://dx.doi.org/10.1038/sj.onc.1207095			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654782				2022-12-28	WOS:000186982200007
J	Iha, H; Kibler, KV; Yedavalli, VRK; Peloponese, JM; Haller, K; Miyazato, A; Kasai, T; Jeang, KT				Iha, H; Kibler, KV; Yedavalli, VRK; Peloponese, JM; Haller, K; Miyazato, A; Kasai, T; Jeang, KT			Segregation of NF-kappa B activation through NEMO/IKK gamma by Tax and TNF alpha: implications for stimulus-specific interruption of oncogenic signaling	ONCOGENE			English	Article						Tax; HTLV-I; adult T-cell leukemia; NEMO/IKK gamma; TNF alpha; NF-kappa B; oncogenic transformation	T-CELL LEUKEMIA; VIRUS TYPE-1 TAX; SEVERE LIVER DEGENERATION; IKK-GAMMA; KINASE COMPLEX; DEFICIENT MICE; INCONTINENTIA PIGMENTI; MEDIATED ACTIVATION; SPINDLE CHECKPOINT; REGULATORY SUBUNIT	Nuclear factor-kappaB essential modulator (NEMO), also called IKKgamma, has been proposed as a 'universal' adaptor of the I-kappaB kinase (IKK) complex for stimuli such as proinflammatory cytokines, microbes, and the HTLV-I Tax oncoprotein. Currently, it remains unclear whether the many signals that activate NF-kappaB through NEMO converge identically or differently. We have adopted two approaches to answer this question. First, we generated and targeted intracellularly three NEMO-specific monoclonal antibodies (mAbs). These mAbs produced two distinct intracellular NF-kappaB inhibition profiles segregating TNFalpha from Tax activation. Second, using NEMO knockout mouse fibroblasts and 10 NEMO mutants, we found that different regions function in trans either to complement or to inhibit dominantly TNFalpha, IL-1beta, or Tax activation of NF-kappaB. For instance, NEMO (1-245 amino acids) supported Tax-mediated NF-kappaB activation, but did not serve TNFalpha- or IL-1beta signaling. Altogether, our findings indicate that while NEMO 'universally' adapts numerous NF-kappaB activators, it may do so through separable domains. We provide the first evidence that selective targeting of NEMO can abrogate oncogenic Tax signaling without affecting signals used for normal cellular metabolism.	NIAID, Mol Microbiol Lab, Mol Virol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Jeang, KT (corresponding author), Bldg 4,Room 306,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jeang, Kuan-Teh/A-2424-2008	Peloponese, Jean-Marie/0000-0002-9677-9703; Iha, Hidekatsu/0000-0002-0999-5636	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000547, ZIAAI000547] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Bai JR, 2003, J BIOL CHEM, V278, P1433, DOI 10.1074/jbc.M208297200; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016/S0014-5793(02)03590-1; Iha H, 2000, AIDS RES HUM RETROV, V16, P1633, DOI 10.1089/08892220050193074; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Marriott SJ, 2002, J BIOMED SCI, V9, P292, DOI 10.1159/000064998; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; MORI N, 1994, BLOOD, V84, P2904; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Ranson M, 2002, ONCOLOGY-BASEL, V63, P17, DOI 10.1159/000066203; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROTHWARF DM, 1999, SCI STKE, V26, pRE1; Rudolph D, 2000, GENE DEV, V14, P854; Scheidereit C, 1998, NATURE, V395, P225, DOI 10.1038/26121; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	67	57	58	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8912	8923		10.1038/sj.onc.1207058	http://dx.doi.org/10.1038/sj.onc.1207058			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654787	Bronze			2022-12-28	WOS:000186982200012
J	Sugioka, R; Shimizu, S; Funatsu, T; Tamagawa, H; Sawa, Y; Kawakami, T; Tsujimoto, Y				Sugioka, R; Shimizu, S; Funatsu, T; Tamagawa, H; Sawa, Y; Kawakami, T; Tsujimoto, Y			BH4-domain peptide from Bcl-x(L) exerts anti-apoptotic activity in vivo	ONCOGENE			English	Article						Bcl-x(L); BH4 domain; apoptosis; mitochondria; TAT	DEPENDENT ANION CHANNEL; BCL-2 PROTEIN FAMILY; CYTOCHROME-C; CELL-DEATH; BH4 DOMAIN; CASPASE ACTIVATION; GENE TRANSFECTION; CONSERVED DOMAINS; BAX; MITOCHONDRIA	The Bcl-2 family of proteins regulates apoptosis chiefly by controlling mitochondrial membrane permeability. It has previously been shown that the BH4 domain of Bcl-2/Bcl-x(L) is essential for the prevention of apoptotic mitochondrial changes, including the release of cytochrome c and apoptotic cell death. We have previously reported that BH4 peptide fused to the protein transduction domain of HIV-1 TAT protein (TAT-BH4) significantly inhibits etoposide-induced apoptosis in a cell line. This time, we investigated whether TAT-BH4 peptide was cytoprotective in ex vivo and in vivo rodent models. Intraperitoneal injection of TAT-BH4 peptide greatly inhibited X-ray-induced apoptosis in the small intestine of mice and partially suppressed Fas-induced fulminant hepatitis. In addition, this peptide markedly suppressed heart failure after ischemia-reperfusion injury in isolated rat heart, probably by preventing mitochondrial dysfunction. These findings demonstrate that TAT-BH4 peptide exerts antiapoptotic activity both in vivo and ex vivo, and imply that it may be a useful therapeutic agent for diseases involving mitochondrial dysfunction and apoptosis.	Osaka Univ, Lab Prot Architecton, Res Ctr Struct Biol, Suita, Osaka 5650871, Japan; Osaka Univ, Sch Med, Dept Surg, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, SORST, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, JST, CREST, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Sch Med, Mol Genet Lab, Dept Postgenomics & Dis, 2-2 Yamadaoka,Room B8, Suita, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hirotani M, 1999, J BIOL CHEM, V274, P20415, DOI 10.1074/jbc.274.29.20415; Hockenbery D M, 1992, Semin Immunol, V4, P413; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Macho A, 1999, ONCOGENE, V18, P7543, DOI 10.1038/sj.onc.1203095; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Park IW, 2001, J IMMUNOL, V167, P2766, DOI 10.4049/jimmunol.167.5.2766; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Schwarze SR, 2000, TRENDS CELL BIOL, V10, P290, DOI 10.1016/S0962-8924(00)01771-2; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; SHIMIZU S, 1994, TRANSPLANTATION, V57, P144, DOI 10.1097/00007890-199401000-00022; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1996, ONCOGENE, V12, P2251; SOLEM LE, 1993, TOXICOL APPL PHARM, V121, P50, DOI 10.1006/taap.1993.1128; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2000, GENE DEV, V14, P2060; Yamabe K, 1998, BIOCHEM BIOPH RES CO, V243, P217, DOI 10.1006/bbrc.1997.7925; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073	41	85	91	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8432	8440		10.1038/sj.onc.1207180	http://dx.doi.org/10.1038/sj.onc.1207180			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627984				2022-12-28	WOS:000186650300007
J	Crnkovic-Mertens, I; Hoppe-Seyler, F; Butz, K				Crnkovic-Mertens, I; Hoppe-Seyler, F; Butz, K			Induction of apoptosis in tumor cells by siRNA-mediated silencing of the livin/ML-IAP/KIAP gene	ONCOGENE			English	Article						RNA interference; inhibitors of apoptosis; chemotherapy; HeLa; melanoma	SMALL INTERFERING RNAS; POSITIVE CANCER-CELLS; MAMMALIAN-CELLS; IN-VIVO; PROTEIN FAMILY; IAP PROTEINS; EXPRESSION; INHIBITOR; DELIVERY; DEATH	Increased resistance to apoptosis is a hallmark of many tumor cells. The functional inhibition of specific antiapoptotic factors may provide a rational basis for the development of novel therapeutic strategies. We investigated here whether the RNA interference (RNAi) technology could be used to increase the apoptotic susceptibility of cancer cells. As a molecular target, we chose the antiapoptotic livin (ML-IAP, KIAP) gene, which is expressed in a subset of human tumors. We identified vector-borne small interfering (si)RNAs, which could efficiently block endogenous livin gene expression. Silencing of livin was associated with caspase-3 activation and a strongly increased apoptotic rate in response to different proapoptotic stimuli, such as doxorubicin, UV-irradiation, or TNFalpha. The effects were specific for Livin-expressing tumor cells. Our results (i) provide direct evidence that the intracellular interference with livin gene expression resensitizes human tumor cells to apoptosis, (ii) define the livin gene as a promising molecular target for therapeutic inhibition, and (iii) show that the livin gene is susceptible to efficient and specific silencing by the siRNA technology.	Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Butz, K (corresponding author), Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.			Hoppe-Seyler, Felix/0000-0002-1864-300X				Agami R, 2002, CURR OPIN CHEM BIOL, V6, P829, DOI 10.1016/S1367-5931(02)00378-2; Ashhab Y, 2001, FEBS LETT, V495, P56, DOI 10.1016/S0014-5793(01)02366-3; Borkhardt A, 2002, CANCER CELL, V2, P167, DOI 10.1016/S1535-6108(02)00129-0; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; BUTZ K, 1993, J VIROL, V67, P6476, DOI 10.1128/JVI.67.11.6476-6486.1993; Butz K, 1999, ONCOGENE, V18, P2381, DOI 10.1038/sj.onc.1202557; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gazzaniga P, 2003, ANN ONCOL, V14, P85, DOI 10.1093/annonc/mdg002; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lewis DL, 2002, NAT GENET, V32, P107, DOI 10.1038/ng944; Lin JH, 2000, BIOCHEM BIOPH RES CO, V279, P820, DOI 10.1006/bbrc.2000.4027; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morris MC, 2000, CURR OPIN BIOTECH, V11, P461, DOI 10.1016/S0958-1669(00)00128-2; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Rothbard JB, 2000, NAT MED, V6, P1253, DOI 10.1038/81359; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; SONG E, 2003, NAT MED, V10, P2002; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Tuschl T, 2002, NAT BIOTECHNOL, V20, P446, DOI 10.1038/nbt0502-446; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wilda M, 2002, ONCOGENE, V21, P5716, DOI 10.1038/sj.onc.1205653; Xia HB, 2002, NAT BIOTECHNOL, V20, P1006, DOI 10.1038/nbt739	48	81	125	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8330	8336		10.1038/sj.onc.1206973	http://dx.doi.org/10.1038/sj.onc.1206973			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614456				2022-12-28	WOS:000186541500011
J	Ricaud, S; Vernus, B; Duclos, M; Bernardi, H; Ritvos, O; Carnac, G; Bonnieu, A				Ricaud, S; Vernus, B; Duclos, M; Bernardi, H; Ritvos, O; Carnac, G; Bonnieu, A			Inhibition of autocrine secretion of myostatin enhances terminal differentiation in human rhabdomyosarcoma cells	ONCOGENE			English	Article						myostatin; rhabdomyosarcoma; autocrine secretion; inhibition of myostatin; inhibition of differentiation; MyoD activity	HUMAN ALVEOLAR RHABDOMYOSARCOMA; FIBROBLAST GROWTH-FACTOR; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; MUSCLE-CELLS; REGULATORY FACTORS; PROTEIN-SYNTHESIS; PROLIFERATION; MYOD; INDUCTION	Rhabdomyosarcomas (RMSs) are one of the most common solid tumor of childhood. Rhabdomyosarcoma (RMS) cells fail to both complete the skeletal muscle differentiation program and irreversibly exit the cell cycle as a consequence of an active repression exerted on the muscle-promoting factor MyoD. Myostatin is a negative regulator of normal muscle growth, we have thus studied its possible role in RMS cells. Here, we present evidence that overexpression of myostatin is a common feature of RMS since both subtypes of RMS (embryonal RD and alveolar Rh30 cells) express high levels of myostatin when compared to nontumoral skeletal muscle cells. Interestingly, we found that inactivation of myostatin through overexpression of antisense myostatin or of follistatin (a myostatin antagonist) constructs enhanced differentiation of RD cells. In addition, RD and Rh30 cells treated with blocking antimyostatin antibodies progress into the myogenic terminal differentiation program. Finally, our results suggest that high levels of myostatin could impair MyoD function in RMS cells. These results show that an autocrine myostatin loopcontributes to maintain RMS cells in an undifferentiating stage and suggest that new therapeutic approaches could be exploited for the treatment of RMS based on inactivation of myostatin protein.	INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 1, France; INRA, Rech Avicoles Stn, F-37380 Nouzilly, France; Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FIN-00014 Helsinki, Finland; Univ Helsinki, Programme Dev & Reprod Biol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; CNRS, FRE 2593, CRBM, F-34293 Montpellier 5, France	INRAE; INRAE; University of Helsinki; University of Helsinki; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Bonnieu, A (corresponding author), INRA, UMR Differenciat Cellulaire & Croissance 866, F-34060 Montpellier 1, France.		DUCLOS, Michel/AAQ-3957-2021; Bonnieu, Anne/ABA-7182-2020; Ritvos, Olli/GWC-2442-2022; Carnac, Gilles/N-6744-2018	DUCLOS, Michel/0000-0002-9305-3982; Carnac, Gilles/0000-0002-3518-8774; Bernardi, Henri/0000-0003-3570-8925; Ritvos, Olli/0000-0001-7017-6931				Alric S, 1998, ONCOGENE, V16, P273, DOI 10.1038/sj.onc.1201484; Artaza JN, 2002, J CELL PHYSIOL, V190, P170, DOI 10.1002/JCP.10044; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; DeGiovanni C, 1996, CANCER RES, V56, P3898; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5657, DOI 10.1093/nar/15.14.5657; Froeschle A, 1998, ONCOGENE, V16, P3369, DOI 10.1038/sj.onc.1201894; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gonzalez-Cadavid NF, 1998, P NATL ACAD SCI USA, V95, P14938, DOI 10.1073/pnas.95.25.14938; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; JIN P, 1991, J BIOL CHEM, V266, P1245; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Knudsen ES, 1998, CANCER RES, V58, P2042; Langley B, 2002, J BIOL CHEM, V277, P49831, DOI 10.1074/jbc.M204291200; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PIETTE J, 1990, NATURE, V345, P353, DOI 10.1038/345353a0; Puri PL, 2000, GENE DEV, V14, P574; Rios R, 2002, AM J PHYSIOL-CELL PH, V282, pC993, DOI 10.1152/ajpcell.00372.2001; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; SCHWEIGERER L, 1987, P NATL ACAD SCI USA, V84, P842, DOI 10.1073/pnas.84.3.842; SHAPIRO DN, 1993, CANCER RES, V53, P5108; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Taylor WE, 2001, AM J PHYSIOL-ENDOC M, V280, pE221, DOI 10.1152/ajpendo.2001.280.2.E221; Thies RS, 2001, GROWTH FACTORS, V18, P251; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; TONIN PN, 1991, CANCER RES, V51, P5100; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	44	23	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8221	8232		10.1038/sj.onc.1207177	http://dx.doi.org/10.1038/sj.onc.1207177			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614446				2022-12-28	WOS:000186541500001
J	Gupta, A; Inaba, S; Wong, OK; Fang, GW; Liu, JW				Gupta, A; Inaba, S; Wong, OK; Fang, GW; Liu, JW			Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1	ONCOGENE			English	Article						BCSG1; BubR1; mitotic checkpoint; yeast two-hybrid; aneuploidy; multinucleation	ANAPHASE-PROMOTING COMPLEX; KINETOCHORE LOCALIZATION; SYNUCLEIN-GAMMA; ABERRANT EXPRESSION; PROTEIN BUBR1; HBUBR1; CELLS; MAD2; PHOSPHORYLATION; APOPTOSIS	The abnormal expression of breast cancer-specific gene 1 (BCSG1) in malignant mammary epithelial cells is highly associated with the development and progression of breast cancer. A series of in vitro and in vivo studies performed in our laboratory and others have demonstrated that BCSG1 expression significantly stimulates proliferation, invasion, and metastasis of breast cancer cells. However, currently little is known about how BCSG1 exerts its oncogenic functions. To elucidate the cellular mechanisms underlying the effects of BCSG1 in breast cancer cells, we used a yeast two-hybrid system to screen for proteins that could associate with BCSG1. Through this screening, we identified the mitotic checkpoint protein BubR1 as a novel binding partner of BCSG1. The specific association of BCSG1 with BubR1 in breast cancer cells was demonstrated by immunoprecipitation and GST pull-down assays. Intriguingly, experiments conducted in four different cell lines all showed that exogenous expressions of BCSG1 consistently reduce the cellular levels of the BubR1 protein without affecting BubR1 mRNA expression. The tendency of endogenous BCSG1 expression coinciding with lower BubR1 protein levels was also observed in seven out of eight breast cancer cell lines. We further showed that the reducing effect of BCSG1 on BubR1 protein expression could be prevented by treating BCSG1-transfected cells with MG-132, a selective 26S proteasome inhibitor, implying that the proteasome machinery may be involved in the BCSG1-induced reduction of the BubR1 protein. Accompanied with a reduction of BubR1 protein level, BCSG1 expression resulted in multinucleation of breast cancer cells upon treatment with spindle inhibitor nocodazole, indicating an impaired mitotic checkpoint. Taken together, our novel findings suggest that BCSG1 may accelerate the progression of breast cancer at least in part by compromising the mitotic checkpoint control through inactivation of BubR1.	VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University	Liu, JW (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	Jingwen.Liu@med.va.gov			NCI NIH HHS [1R01CA83648-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083648] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Canman JC, 2002, J CELL SCI, V115, P3787, DOI 10.1242/jcs.00057; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; Chen RH, 2002, J CELL BIOL, V158, P487, DOI 10.1083/jcb.200204048; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gupta A, 2003, CANCER RES, V63, P664; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Jablonski SA, 1998, CHROMOSOMA, V107, P386, DOI 10.1007/s004120050322; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LU A, 2002, J BIOL CHEM, V12, P12; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Page AM, 1999, ANNU REV BIOCHEM, V68, P583, DOI 10.1146/annurev.biochem.68.1.583; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Shichiri M, 2002, CANCER RES, V62, P13; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Surguchov A, 2001, CELL MOTIL CYTOSKEL, V49, P218, DOI 10.1002/cm.1035; Tang ZY, 2001, DEV CELL, V1, P227, DOI 10.1016/S1534-5807(01)00019-3; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Taylor SS, 2001, J CELL SCI, V114, P4385; WANG YH, 1991, P NATL ACAD SCI USA, V88, P8779, DOI 10.1073/pnas.88.19.8779	33	83	93	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7593	7599		10.1038/sj.onc.1206880	http://dx.doi.org/10.1038/sj.onc.1206880			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576821				2022-12-28	WOS:000186113000006
J	Bertucci, F; Borie, N; Ginestier, C; Groulet, A; Charafe-Jauffret, E; Adelaide, J; Geneix, J; Bachelart, L; Finetti, P; Koki, A; Hermitte, F; Hassoun, J; Debono, S; Viens, P; Fert, V; Jacquemier, J; Birnbaum, D				Bertucci, F; Borie, N; Ginestier, C; Groulet, A; Charafe-Jauffret, E; Adelaide, J; Geneix, J; Bachelart, L; Finetti, P; Koki, A; Hermitte, F; Hassoun, J; Debono, S; Viens, P; Fert, V; Jacquemier, J; Birnbaum, D			Identification and validation of an ERBB2 gene expression signature in breast cancers	ONCOGENE			English	Article						breast cancer; DNA microarrays; ERBB2/HER2; FISH; gene expression; expression profiles; tissue microarrays	IN-SITU HYBRIDIZATION; MICROARRAY ANALYSIS; COPY NUMBER; MOLECULAR CLASSIFICATION; CLINICAL-SIGNIFICANCE; TISSUE MICROARRAYS; DNA AMPLIFICATION; HORMONE RECEPTORS; OVEREXPRESSION; CELL	ERBB2 is a transmembrane tyrosine kinase receptor encoded by a gene located in chromosome region 17q12. Overexpression of ERBB2, generally by way of gene amplification, plays a role in mammary oncogenesis. This alteration can be overcome by use of the humanized monoclonal antibody trastuzumab (Herceptint(TM)). Accurate determination of ERBB2 status is required for appropriate use of this targeted therapy and is currently analysed by immunohistochemistry (IHC) on tissue sections and/or fluorescence in situ hybridisation (FISH) on interphase chromosomes. W e have studied the gene expression profiles of a series of 213 breast tumours and 16 breast cancer cell lines with known ERBB2 status, using Ipsogen's DiscoveryChip microarrays with similar to9000 cDNAs. W e have identified 36 genes and expressed sequence tags that were differentially expressed in tumours and in cell lines with and without ERBB2 protein overexpression. This ERBB2-specific gene expression signature (GES) contained 29 overexpressed genes including the ERBB2 gene itself, five genes located in its immediate vicinity on 17q12, non-17q genes such as GATA4 and eight downregulated genes including oestrogen receptor alpha ( ER). Some correlations were validated at the protein level using IHC on tissue microarrays. The GES was able to distinguish ERBB2-negative and -positive cancer samples, as well as FISH-negative and FISH-positive ERBB2 2+ IHC samples.	Inst J Paoli I Calmettes, Dept Mol Oncol, F-13009 Marseille, France; INSERM, UMR117, IFR57, F-13258 Marseille, France; Inst J Paoli I Calmettes, Dept Med Oncol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France; IPSOGEN SA, Marseille, France; Inst J Paoli I Calmettes, Dept Biopathol, F-13009 Marseille, France	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC)	Birnbaum, D (corresponding author), Inst J Paoli I Calmettes, Dept Mol Oncol, 217 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Ginestier, Christophe/M-8828-2017; ADELAIDE, José JA/O-4390-2017; Charafe-Jauffret, emmanuelle/P-6009-2017; Finetti, Pascal/O-8669-2017	Ginestier, Christophe/0000-0002-7477-3837; ADELAIDE, José JA/0000-0003-4364-9857; Bertucci, Francois/0000-0002-0157-0959; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299; Birnbaum, Daniel/0000-0001-7920-9883; Finetti, Pascal/0000-0002-2674-3123				Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2; Arthur WT, 2002, BIOL RES, V35, P239, DOI 10.4067/S0716-97602002000200016; Bertucci F, 2003, LAB INVEST, V83, P305, DOI 10.1097/01.LAB.0000059936.28369.19; Bertucci F, 2003, INT J CANCER, V103, P565, DOI 10.1002/ijc.10867; Bertucci F, 2002, HUM MOL GENET, V11, P863, DOI 10.1093/hmg/11.8.863; Bertucci F, 2000, HUM MOL GENET, V9, P2981, DOI 10.1093/hmg/9.20.2981; Bilous M, 2003, MODERN PATHOL, V16, P173, DOI 10.1097/01.MP.0000052102.90815.82; Callagy G, 2003, DIAGN MOL PATHOL, V12, P27, DOI 10.1097/00019606-200303000-00004; Dressman MA, 2003, CANCER RES, V63, P2194; Frade R, 2002, ONCOGENE, V21, P861, DOI 10.1038/sj.onc.1205177; Garratt AN, 2003, TRENDS CARDIOVAS MED, V13, P80, DOI 10.1016/S1050-1738(02)00231-1; Gilde AJ, 2003, ACTA PHYSIOL SCAND, V178, P425, DOI 10.1046/j.1365-201X.2003.01161.x; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; GINESTIER C, IN PRESS J PATHOL; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; KESHGEGIAN AA, 1995, BREAST CANCER RES TR, V35, P201, DOI 10.1007/BF00668210; Konecny G, 2003, J NATL CANCER I, V95, P142, DOI 10.1093/jnci/95.2.142; Korsching E, 2002, LAB INVEST, V82, P1525, DOI 10.1097/01.LAB.0000038508.86221.B3; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Leyland-Jones B, 2002, LANCET ONCOL, V3, P137, DOI 10.1016/S1470-2045(02)00676-9; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; Oh JJ, 1999, NUCLEIC ACIDS RES, V27, P4008, DOI 10.1093/nar/27.20.4008; Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2; Pauletti G, 2000, J CLIN ONCOL, V18, P3651, DOI 10.1200/JCO.2000.18.21.3651; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; Platzer P, 2002, CANCER RES, V62, P1134; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Press MF, 2002, J CLIN ONCOL, V20, P3095, DOI 10.1200/JCO.2002.09.094; Rampaul RS, 2002, CRIT REV ONCOL HEMAT, V43, P231, DOI 10.1016/S1040-8428(01)00207-4; Revillion F, 1998, EUR J CANCER, V34, P791, DOI 10.1016/S0959-8049(97)10157-5; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Sabatti C, 2002, MATH BIOSCI, V176, P17, DOI 10.1016/S0025-5564(01)00102-X; Shen TL, 2002, J BIOL CHEM, V277, P29069, DOI 10.1074/jbc.M203085200; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Tan M, 1997, CANCER RES, V57, P1199; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TIWARI RK, 1991, ANTICANCER RES, V11, P1383; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; van de Vijver M, 2002, ONCOLOGY-BASEL, V63, P33, DOI 10.1159/000066199; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Willis S, 2003, GENE CHROMOSOME CANC, V36, P382, DOI 10.1002/gcc.10138; Wilson KS, 2002, AM J PATHOL, V161, P1171, DOI 10.1016/S0002-9440(10)64394-5; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; Yang RB, 2002, J BIOL CHEM, V277, P46364, DOI 10.1074/jbc.M207410200	56	90	101	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2564	2575		10.1038/sj.onc.1207361	http://dx.doi.org/10.1038/sj.onc.1207361			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14743203				2022-12-28	WOS:000220558000015
J	Melnikova, VO; Bolshakov, SV; Walker, C; Ananthaswamy, HN				Melnikova, VO; Bolshakov, SV; Walker, C; Ananthaswamy, HN			Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines	ONCOGENE			English	Article						melanoma; Braf; ras; ERK1/2; p53; INK4a/ARF	WILD-TYPE P53; HUMAN MELANOCYTIC LESIONS; HUMAN CUTANEOUS MELANOMA; HUMAN-MALIGNANT MELANOMA; MOUSE SKIN TUMORS; N-RAS MUTATIONS; ULTRAVIOLET-RADIATION; FAMILIAL MELANOMA; ONCOGENIC RAS; BRAF GENE	We have conducted an analysis of genetic alterations in spontaneous murine melanoma cell line B16F(0) and its two metastatic clones, B16F(1) and B16F(10) and the carcinogen-induced murine melanoma cell lines CM519, CM3205, and K1735. We found that unlike human melanomas, the murine melanoma cell lines did not have activating mutations in the Braf oncogene at exon 11 or 15. However, there were distinct patterns of alterations in the ras, Ink4a/Arf, and p53 genes in the two melanoma groups. In the spontaneous B16 melanoma cell lines, expression of p16(Ink4a) and p19(Arf) tumor suppressor proteins was lost as a consequence of a large deletion spanning Ink4a/Arf exons 1alpha, 1beta, and 2. In contrast, the carcinogen-induced melanoma cell lines expressed p16(Ink4a) but had inactivating mutations in either p19(Arf) (K1735) or p53 (CM519 and CM3205). Inactivation of p19(Arf) or p53 in carcinogen-induced melanomas was accompanied by constitutive activation of mitogen-activated protein kinases (MAPKs) and/or mutation-associated activation of N-ras. These results indicate that genetic alterations in p16(Ink4a)/p19(Arf), p53 and ras-MAPK pathways can cooperate in the development of murine melanoma.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Ananthaswamy, HN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, POB 301402,Unit 902, Houston, TX 77030 USA.	hanantha@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, R01CA046523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 46523] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ananthaswamy H N, 1998, J Investig Dermatol Symp Proc, V3, P52; Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Bastian BC, 1998, CANCER RES, V58, P2170; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; BOSARI S, 1995, AM J PATHOL, V147, P790; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brose MS, 2002, CANCER RES, V62, P6997; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Cohen J, 2003, J NATL CANCER I, V95, P625, DOI 10.1093/jnci/95.8.625; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; GANNON JV, 1991, NATURE, V349, P802; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Gorden A, 2003, CANCER RES, V63, P3955; Groth A, 2000, J BIOL CHEM, V275, P27473; Gruis NA, 1999, J INVEST DERM SYMP P, V4, P50, DOI 10.1038/sj.jidsp.5640181; Haluska FG, 1998, J CLIN ONCOL, V16, P670, DOI 10.1200/JCO.1998.16.2.670; Hartmann A, 1996, INT J CANCER, V67, P313, DOI 10.1002/(SICI)1097-0215(19960729)67:3<313::AID-IJC1>3.0.CO;2-U; HERLYN M, 1993, MOL CELLULAR BIOL ME; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JAFARI M, 1995, J CANCER RES CLIN, V121, P23, DOI 10.1007/BF01202725; Jhappan C, 2003, ONCOGENE, V22, P3099, DOI 10.1038/sj.onc.1206450; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRIPKE ML, 1979, JNCI-J NATL CANCER I, V63, P541, DOI 10.1093/jnci/63.3.541; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; Melnikova VO, 2003, ONCOGENE, V22, P5958, DOI 10.1038/sj.onc.1206595; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Monzon J, 1998, NEW ENGL J MED, V338, P879, DOI 10.1056/NEJM199803263381305; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Osaka M, 1996, MOL CARCINOGEN, V16, P126, DOI 10.1002/(SICI)1098-2744(199607)16:3<126::AID-MC2>3.0.CO;2-F; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Papp T, 1996, J CANCER RES CLIN, V122, P541, DOI 10.1007/BF01213550; PICCININ S, 1997, CLIN LAB MED, V20, P667; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Recio JA, 2002, CANCER RES, V62, P6724; Rigel DS, 2000, CA-CANCER J CLIN, V50, P215, DOI 10.3322/canjclin.50.4.215; Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200; ROMERDAHL CA, 1986, CANCER METAST REV, V5, P167, DOI 10.1007/BF00046429; Satyamoorthy K, 2003, CANCER RES, V63, P756; Schlamp CL, 1997, J NATL CANCER I, V89, P1530, DOI 10.1093/jnci/89.20.1530; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; SPARROW LE, 1995, MELANOMA RES, V5, P93, DOI 10.1097/00008390-199504000-00004; STONE S, 1995, CANCER RES, V55, P2988; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; vanElsas A, 1996, AM J PATHOL, V149, P883; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOLKENANDT M, 1991, PIGM CELL RES, V4, P35, DOI 10.1111/j.1600-0749.1991.tb00311.x; Weber A, 2003, ONCOGENE, V22, P4757, DOI 10.1038/sj.onc.1206705; WEISS J, 1993, INT J CANCER, V54, P693, DOI 10.1002/ijc.2910540427; Wong AK, 2000, CANCER METAST REV, V19, P121, DOI 10.1023/A:1026537423753; Xu XL, 2003, CANCER RES, V63, P4561; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhuang SM, 1997, CANCER RES, V57, P2710; Zhuang SM, 1998, ONCOGENE, V16, P803, DOI 10.1038/sj.onc.1201600	87	84	84	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2347	2356		10.1038/sj.onc.1207405	http://dx.doi.org/10.1038/sj.onc.1207405			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743208				2022-12-28	WOS:000220427700009
J	McMullen, M; Keller, R; Sussman, M; Pumiglia, K				McMullen, M; Keller, R; Sussman, M; Pumiglia, K			Vascular endothelial growth factor-mediated activation of p38 is dependent upon Src and RAFTK/Pyk2	ONCOGENE			English	Article						p38; VEGF; migration; RAFTK/Pyk2; Src	FOCAL ADHESION KINASE; PROTEIN-KINASE; TYROSINE KINASE; TRANSCRIPTION FACTOR; DIFFERENTIAL REGULATION; CELL-MIGRATION; NITRIC-OXIDE; VEGF; ANGIOGENESIS; CALCIUM	Vascular endothelial growth factor ( VEGF) induces activation of p38 mitogen-activated protein kinase ( MAPK) in primary endothelial cells and may be critical for VEGF-induced angiogenesis. We investigated the molecular basis for p38 activation in response to VEGF. The expression of a C-terminal splice variant of FAK, FRNK, had no affect on VEGF-induced activation of p38; however, expression of a dominant-negative RAFTK/ Pyk2 mutant led to a decrease in the activation of p38, but had no affect on extracellular signal-regulated kinase (ERK). Since calcium regulates RAFTK/ Pyk2, we investigated its role in p38 activity. Preincubation with EGTA suppressed p38 activation, while calcium ionophore induced p38 activity. Inhibition of phospholipase C ( PLC) resulted in complete inhibition of ERK, while having no affect on p38 activity. These data suggested a bifurcation in the regulation of MAPKs that occurs at the level of PLC and RAFTK/ Pyk2 activation. Src family kinases interact with RAFTK/ Pyk2. Inhibition of Src by either pharmacological or genetic means decreased p38 activity. Finally, we found that both Src and RAFTK/ Pyk2 were essential for endothelial cell migration. These data identified a novel regulatory network involving extracellular calcium, RAFTK/ Pyk2, Src and p38. This signaling network appears to be critical for VEGF-induced endothelial cell migration.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA; Cincinnati Childrens Hosp, Div Cardiol, Cincinnati, OH USA	Albany Medical College; Albany Medical College; Cincinnati Children's Hospital Medical Center	Pumiglia, K (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu	; Sussman, Mark/H-2284-2014	Pumiglia, Kevin/0000-0003-4655-0334; Sussman, Mark/0000-0002-0104-4799	NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081419, R01-CA-81419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Avraham HK, 2003, J BIOL CHEM, V278, P36661, DOI 10.1074/jbc.M301253200; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Blanquet PR, 2003, NEUROSCIENCE, V118, P477, DOI 10.1016/S0306-4522(02)00963-6; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Faehling M, 2002, FASEB J, V16, P1805, DOI 10.1096/fj.01-0938fje; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garnier-Raveaud S, 2001, GROWTH FACTORS, V19, P35, DOI 10.3109/08977190109001074; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Huser J, 1997, AM J PHYSIOL-CELL PH, V273, pC1775, DOI 10.1152/ajpcell.1997.273.5.C1775; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Ishii Y, 2001, LEUKEMIA RES, V25, P813, DOI 10.1016/S0145-2126(01)00026-1; Issbrucker K, 2002, FASEB J, V16, P262, DOI 10.1096/fj.02-0329fje; Jiang TY, 2003, J BIOL CHEM, V278, P15789, DOI 10.1074/jbc.M212525200; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Kawasaki K, 2003, MOL CELL BIOL, V23, P5726, DOI 10.1128/MCB.23.16.5726-5737.2003; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; Kumar S, 1999, J BIOL CHEM, V274, P30657, DOI 10.1074/jbc.274.43.30657; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; Lian JP, 1999, J IMMUNOL, V163, P4527; Lin Q, 1998, DEVELOPMENT, V125, P4565; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; McShan GD, 2002, INT J ONCOL, V21, P197; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nagashima KI, 2002, MOL BIOL CELL, V13, P4231, DOI 10.1091/mbc.E02-04-0181; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Paul R, 2001, NAT MED, V7, P222, DOI 10.1038/84675; Pocock TM, 2000, AM J PHYSIOL-HEART C, V279, pH1625, DOI 10.1152/ajpheart.2000.279.4.H1625; Pocock TM, 2001, J PHYSIOL-LONDON, V534, P479, DOI 10.1111/j.1469-7793.2001.00479.x; Rikitake Y, 2001, AM J PHYSIOL-HEART C, V281, pH266, DOI 10.1152/ajpheart.2001.281.1.H266; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sarkar S, 2002, LEUKEMIA LYMPHOMA, V43, P1663, DOI 10.1080/1042819021000003009; Seymour LW, 1996, LAB INVEST, V75, P427; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Suarez S, 2001, J CELL SCI, V114, P1229; Toutenhoofd SL, 2000, CELL CALCIUM, V28, P83, DOI 10.1054/ceca.2000.0136; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Zahalka MA, 2003, FASEB J, V17, P955, DOI 10.1096/fj.02-0960fje; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	59	59	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1275	1282		10.1038/sj.onc.1207243	http://dx.doi.org/10.1038/sj.onc.1207243			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676843				2022-12-28	WOS:000188892200012
J	Marsit, CJ; Liu, M; Nelson, HH; Posner, M; Suzuki, M; Kelsey, KT				Marsit, CJ; Liu, M; Nelson, HH; Posner, M; Suzuki, M; Kelsey, KT			Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival	ONCOGENE			English	Article						methylation; NSCLC; HNSCC; Fanconi anemia; BRCA	PROMOTER HYPERMETHYLATION; DNA METHYLATION; OVARIAN-TUMORS; BRCA1 PROMOTER; CPG ISLANDS; GENE; SUSCEPTIBILITY; EXPOSURE; BREAST; ASSOCIATION	Inactivation of the FANC-BRCA pathway via promoter methylation of the FANCF gene renders cells sensitive to DNA crosslinking agents, and has been identified in ovarian cancer cell lines and sporadic primary tumor tissues. We investigated epigenetic alterations in the FANC-BRCA pathway in head and neck squamous cell carcinomas (HNSCC) and non-small-cell lung cancers (NSCLC) using methylation-specific PCR. Promoter methylation of FANCF occurred in 15% (13/89) of HNSCCs and 14% (22/158) of NSCLCs. Methylation of BRCA1 occurred only in 6/158 NSCLC, and was limited to adenocarcinomas and large-cell carcinomas of the lung. No methylation of BRCA2 was detected. FANCF methylation was associated with a shorter duration of tobacco use (P=0.03) and a younger age of starting smoking (P = 0.06) in NSCLC, and with a greater number of years of alcohol drinking (P=0.02) in HNSCC. In adenocarcinomas of the lung, FANCF promoter methylation was a significant predictor of poor survival with a hazard ratio of 3.1 (95% Cl 1.2-7.9). This study demonstrates that inactivation of the FANC-BRCA pathway is relatively common in solid tumors and may be related to tobacco and alcohol exposure and survival of these patients.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	kelsey@hsph.harvard.edu	Kelsey, Karl T/I-1252-2014	Marsit, Carmen/0000-0003-4566-150X; Nelson, Heather/0000-0003-1901-9513	NCI NIH HHS [T32CA09078, CA78609] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078609, T32CA009078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alter BP, 1996, AM J HEMATOL, V53, P99, DOI 10.1002/(SICI)1096-8652(199610)53:2<99::AID-AJH7>3.3.CO;2-M; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; Baldwin RL, 2000, CANCER RES, V60, P5329; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Esteller M, 2001, CANCER RES, V61, P3225; Fang JY, 2001, J GASTROEN HEPATOL, V16, P960, DOI 10.1046/j.1440-1746.2001.02554.x; Gras E, 2001, CANCER-AM CANCER SOC, V92, P787, DOI 10.1002/1097-0142(20010815)92:4<787::AID-CNCR1384>3.0.CO;2-4; Hasegawa M, 2002, ONCOGENE, V21, P4231, DOI 10.1038/sj.onc.1205528; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; ISHIDA R, 1982, CANCER RES, V42, P4000; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020; Nelson HH, 1999, J NATL CANCER I, V91, P2032, DOI 10.1093/jnci/91.23.2032; Olshan AF, 1997, ONCOGENE, V14, P811, DOI 10.1038/sj.onc.1200892; Phelps RM, 1996, J CELL BIOCHEM, P32; Potter JD, 1999, JNCI-J NATL CANCER I, V91, P916, DOI 10.1093/jnci/91.11.916; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; ROTHMAN K, 1972, J CHRON DIS, V25, P711, DOI 10.1016/0021-9681(72)90006-9; SASAKI MS, 1973, CANCER RES, V33, P1829; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543	26	181	197	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1000	1004		10.1038/sj.onc.1207256	http://dx.doi.org/10.1038/sj.onc.1207256			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647419				2022-12-28	WOS:000188486600016
J	Hu, N; Wang, CY; Han, XY; He, LJ; Tang, ZZ; Giffen, C; Emmert-Buck, MR; Goldstein, AM; Taylor, PR				Hu, N; Wang, CY; Han, XY; He, LJ; Tang, ZZ; Giffen, C; Emmert-Buck, MR; Goldstein, AM; Taylor, PR			Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer	ONCOGENE			English	Article						familial; mutation; LOH; high risk; DNA sequencing	SQUAMOUS-CELL CARCINOMA; ALLELIC LOSS; SHANXI-PROVINCE; BREAST	Previous studies of esophageal squamous cell carcinoma (ESCC) have shown a high frequency of allelic loss on chromosome 13q, infrequent somatic mutations in BRCA2, and a suggested association between a positive family history (FH+) of upper gastrointestinal cancer and germline BRCA2 mutations. In all, 70 ESCC patients ( 44 FH+ and 26 FH-) were examined by direct full sequencing of germline DNA for BRCA2 mutations. In addition, 28 family members of three of these patients and 232 unrelated healthy blood bank donor controls were examined for the mutations identified in the 70 ESCC patients. Five BRCA2 germline mutations, including three not previously reported (N1600del, A2054P, and V2109I), were identified in six of 44 FH+ patients, but none of 26 FH- patients ( 14 vs 0%, P = 0.078), consistent with our previous findings (3/34 or 9% FH+ vs 0/22 or 0% FH-, P = 0.27). The cumulative frequency of BRCA2 germline mutations in ESCC patients in this and our previous study combined is 12%, with all mutations found in FH+ as opposed to FH- cases (9/78 or 12% FH+ vs 0/48 or 0% FH-, P = 0.013). We conclude that germline mutations in BRCA2 in ESCC patients from this high-risk area of China are more frequent in FH+ than FH- cases, suggesting that BRCA2 may play a role in genetic susceptibility to familial ESCC.	NCI, Canc Prevent Studies Branch, Bethesda, MD 20892 USA; Shanxi Canc Hosp, Taiyuan 030013, Shanxi, Peoples R China; Yangcheng Canc Hosp, Yangcheng 048100, Shanxi, Peoples R China; Informat Management Serv Inc, Silver Spring, MD 20904 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Information Management Services, Inc.	Taylor, PR (corresponding author), NCI, Canc Prevent Studies Branch, 6116 Execut Plaza,Suite 705, Bethesda, MD 20892 USA.	ptaylor@mail.nih.gov			DIVISION OF CANCER PREVENTION AND CONTROL [Z01CN000150] Funding Source: NIH RePORTER	DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; CARTER CL, 1992, J NATL CANCER I, V84, P771, DOI 10.1093/jnci/84.10.771; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Harada H, 1999, CANCER RES, V59, P3724; Hu N, 2002, CLIN CANCER RES, V8, P1121; Hu N, 2001, CLIN CANCER RES, V7, P883; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; HU N, 1991, EUR J CANCER, V27, P1336, DOI 10.1016/0277-5379(91)90116-U; Hu N, 2000, GENE CHROMOSOME CANC, V27, P217, DOI 10.1002/(SICI)1098-2264(200003)27:3<217::AID-GCC1>3.0.CO;2-A; Li G, 2001, GENE CHROMOSOME CANC, V31, P390, DOI 10.1002/gcc.1158; LI G, 1986, P 1 SIN AM HUM GEN W, P43; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Li M H, 1980, Adv Cancer Res, V33, P173; Liede A, 2002, HUM MUTAT, V20, P413, DOI 10.1002/humu.10154; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; *NAT CANC CONTR OF, 1980, INV CANC MORT CHIN; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; Pyne MT, 2000, J HUM GENET, V45, P351, DOI 10.1007/s100380070007; WANG YP, 1992, CANCER CAUSE CONTROL, V3, P107, DOI 10.1007/BF00051650; WU M, 1989, FAM CANC 1 INT RES C, P187; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Zhi XC, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9083	22	29	29	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					852	858		10.1038/sj.onc.1207150	http://dx.doi.org/10.1038/sj.onc.1207150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647438	Bronze			2022-12-28	WOS:000188304900025
J	Nieto, M; Samper, E; Fraga, MF; de Buitrago, GG; Esteller, M; Serrano, M				Nieto, M; Samper, E; Fraga, MF; de Buitrago, GG; Esteller, M; Serrano, M			The absence of p53 is critical for the induction of apoptosis by 5-aza-2 '-deoxycytidine	ONCOGENE			English	Article						p53; apoptosis; demethylation; 5-aza-2 '-deoxycytidine	DNA METHYLATION; MYELODYSPLASTIC SYNDROME; P53-DEPENDENT APOPTOSIS; MITOTIC CATASTROPHE; TUMOR SUPPRESSION; ONCOGENIC RAS; INK4A LOCUS; CELLS; MICE; METHYLTRANSFERASE	The absence of functional p53 has complex consequences on the cellular responses to cytotoxic drugs. Here, we have examined the role of p53 in the response to 5-aza-2'-deoxycytidine (5-aza-dC or decitabine). Primary mouse embryonic fibroblasts deficient for p53 undergo apoptosis after treatment with 5-aza-dC. When compared with other demethylating drugs or chemotherapeutic treatments, 5-aza-dC showed the highest selectivity ratio for triggering apoptosis in p53-deficient cells relative to wild-type cells. Moreover, the apoptotic efficacy of 5-aza-dC is proprietary of p53-deficient cells, not being observed in cells lacking other cell-cycle regulators, such as p19(ARF), p16(INK4a), p21(CIP1/WAF1), E2F-1, or E2F-2. Interestingly, treatment with 5-aza-dC results in the same degree of global genomic hypomethylation in wild-type and p53-null cells. However, wild-type cells activate p53 and arrest at G2/M, whereas p53-null cells accumulate severe chromosomal aberrations and undergo apoptosis. Significantly, the impact of p53-deficiency on the response to 5-aza-dC is not exclusive of primary non-neoplastic cells, but it is also present in neoplastically transformed cells. Finally, treatment of mice bearing genetically defined tumors with nontoxic doses of 5-aza-dC results in therapeutical responses only on tumors lacking p53, but not on tumors lacking p19(ARF). Together, our results put forward the hypothesis that the absence of p53 may determine a higher chemotherapeutic index for 5-aza-dC.	Spanish Natl Canc Ctr CNIO, Madrid 28029, Spain; Spanish Natl Ctr Biotechnol CNB, Dept Immunol & Oncol, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Serrano, M (corresponding author), Spanish Natl Canc Ctr CNIO, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Serrano, Manuel/H-2634-2015; Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014	Serrano, Manuel/0000-0001-7177-9312; Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093				Abad JL, 2002, J GENE MED, V4, P27, DOI 10.1002/jgm.242; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; DECABO SF, 1994, EXPERIENTIA, V50, P658; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fraga MF, 2002, ELECTROPHORESIS, V23, P1677, DOI 10.1002/1522-2683(200206)23:11&lt;1677::AID-ELPS1677&gt;3.0.CO;2-Z; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HARVEY M, 1993, ONCOGENE, V8, P2457; Hawkins DS, 1996, CANCER RES, V56, P892; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ianzini F, 1998, MUTAGENESIS, V13, P337, DOI 10.1093/mutage/13.4.337; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lackinger D, 2000, MUTAT RES-FUND MOL M, V457, P113, DOI 10.1016/S0027-5107(00)00133-0; LANZA F, 1995, STEM CELLS, V13, P445, DOI 10.1002/stem.5530130416; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Lin XH, 2001, CANCER RES, V61, P8611; Lin YF, 2003, DNA REPAIR, V2, P1, DOI 10.1016/S1568-7864(02)00183-0; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Mori N, 1995, LEUKEMIA RES, V19, P869, DOI 10.1016/0145-2126(95)00058-5; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Paz MF, 2003, CANCER RES, V63, P1114; Peller S, 1998, SEMIN CANCER BIOL, V8, P379, DOI 10.1006/scbi.1998.0100; Plumb JA, 2000, CANCER RES, V60, P6039; PURDIE CA, 1994, ONCOGENE, V9, P603; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ruiz-Vela A, 2002, FEBS LETT, V517, P133, DOI 10.1016/S0014-5793(02)02607-8; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; SCHEINBART LS, 1991, J RHEUMATOL, V18, P530; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stancheva I, 2001, EMBO J, V20, P1963, DOI 10.1093/emboj/20.8.1963; Stuppia L, 1997, CANCER GENET CYTOGEN, V98, P28, DOI 10.1016/S0165-4608(96)00413-X; Tang JL, 1998, ANTICANCER RES, V18, P3757; UELAND PM, 1982, PHARMACOL REV, V34, P223; VANGROENINGEN CJ, 1986, CANCER RES, V46, P4831; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	55	69	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					735	743		10.1038/sj.onc.1207175	http://dx.doi.org/10.1038/sj.onc.1207175			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737108				2022-12-28	WOS:000188304900012
J	Dermott, JM; Ha, JH; Lee, CH; Dhanasekaran, N				Dermott, JM; Ha, JH; Lee, CH; Dhanasekaran, N			Differential regulation of Jun N-terminal kinase and p38MAP kinase by G alpha(12)	ONCOGENE			English	Article						G protein; JNK; p38MAPK; MKK; cell proliferation	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; NH2-TERMINAL KINASE; SYNERGISTIC ACTIVATION; IN-VITRO; MKK4; TRANSFORMATION; SPECIFICITY; FIBROBLASTS; INHIBITION	Based on the findings that the overexpression of the wild-type Galpha(12) (Galpha(12)WT) result in the oncogenic transformation of NIH3T3 cells in a serum-dependent manner, a model system has been established in which the mitogenic and subsequent cell transformation pathways activated by Galpha(12) can be turned on or off by the addition or removal of serum. Using this model system, our previous studies have shown that the stimulation of Galpha(12)WT or the expression of an activated mutant of Galpha(12) (Galpha(12)QL) leads to increased cell proliferation and subsequent oncogenic transformation of NIH3T3 cells, as well as persistent activation of Jun N-terminal kinases (JNKs). In the present studies, we show that the stimulation of Galpha(12)WT or the expression of Galpha(12)QL results in a potent inhibition of p38MAPK, and that the mechanism by which Galpha(12) inhibits p38MAPK activity involves the dual specificity kinases upstream of p38MAPK. The results indicate that Galpha(12) attenuates the activation of MKK3 and MKK4, which are known to stimulate only p38MAPK or p38MAPK and JNK, respectively. The results also suggest that Galpha(12) activates JNKs specifically through the stimulation of the JNK-specific upstream kinase MKK7. These findings demonstrate for the first time that Galpha(12) differentially regulates JNK and p38MAPK by specifically activating MKK7, while inhibiting MKK3 and MKK4 in NIH3T3 cells. Since the stimulation of p38MAPK is often associated with apoptotic responses, our findings suggest that Galpha(12) stimulates cell proliferation and neoplastic transformation of NIH3T3 cells by attenuating p38MAPK-associated apoptotic responses, while activating the mitogenic responses through the stimulation of ERK- and JNK-mediated signaling pathways.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Hanyang Univ, Coll Med, Dept Pharmacol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Inst Biomed Sci, Seoul 133791, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Hanyang University; Hanyang University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.	danny001@temple.edu		HA, Ji Hee/0000-0002-6281-1904	NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avdi NJ, 2002, J BIOL CHEM, V277, P40687, DOI 10.1074/jbc.M204455200; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dermott JM, 2002, METHOD ENZYMOL, V344, P298; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; Dhanasekaran N, 1998, ONCOGENE, V17, P1447, DOI 10.1038/sj.onc.1202251; Fleming Y, 2000, BIOCHEM J, V352, P145, DOI 10.1042/0264-6021:3520145; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; JIANG H, 1993, FEBS LETT, V3, P319; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lisnock J, 2000, BIOCHEMISTRY-US, V39, P3141, DOI 10.1021/bi992410+; Meigs TE, 2001, P NATL ACAD SCI USA, V98, P519, DOI 10.1073/pnas.021350998; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; VARAPRASAD MVV, 1995, J BIOL CHEM, V270, P18655; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Weston CR, 2002, SCIENCE, V296, P2345, DOI 10.1126/science.1073344; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; Yamaguchi Y, 2002, CURR BIOL, V12, P1353, DOI 10.1016/S0960-9822(02)01034-5; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004	26	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					226	232		10.1038/sj.onc.1207009	http://dx.doi.org/10.1038/sj.onc.1207009			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712227				2022-12-28	WOS:000187895300023
J	Fernandis, AZ; Prasad, A; Band, H; Klosel, R; Ganju, RK				Fernandis, AZ; Prasad, A; Band, H; Klosel, R; Ganju, RK			Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells	ONCOGENE			English	Article						CXCR4; chemotaxis; chemoinvasion; focal adhesion; metastasis; signaling	FOCAL ADHESION PROTEINS; RECEPTOR CCR5 SIGNALS; TYROSINE PHOSPHORYLATION; CHEMOKINE RECEPTORS; FACTOR-I; MATRIX METALLOPROTEINASES; ALPHA-CHEMOKINE; TUMOR-GROWTH; KINASE; CBL	The chemokine-CXCL12 and its receptor, CXCR4, have recently been shown to play an important role in regulating the directional migration of breast cancer cells to sites of metastasis. In the present study, we showed that CXCL12 enhanced the chemotaxis, chemoinvasion and adhesive properties of breast cancer cells; parameters that are critical for development of metastasis. We have also evaluated the signaling mechanisms that regulate CXCL12-induced and CXCR4-mediated breast cancer cell motility and invasion. These studies revealed that CXCL12 induces the tyrosine phosphorylation of focal adhesion kinase (FAK) at residues 397 and 577, and of RAFTK/Pyk2 at residues 402 and 579/580. The cytoskeletal proteins paxillin and Crk, as well as tyrosine phosphatase SHP2 and adaptor protein Cbl, were also phosphorylated. CXCL12 induced the activation of PI 3-kinase, and increased its association with Cbl and SHP2. PI 3-kinase, RAFTK/Pyk2 and tyrosine phosphatase inhibitors significantly blocked CXCL12-induced chemotaxis and chemoinvasion. The role of SHP2 and Cbl in CXCL12-induced chemotaxis and chemoinvasion in breast cancer cells was further defined by transiently overexpressing wild-type SHP2, wild-type Cbl, dominant-negative SHP2, Cbl mutants 70Z/3 and G306E or double transfectants of the Cbl and SHP2 constructs. We found a novel role of Cbl in CXCL12-induced chemotaxis, which may be mediated through the activation and formation of a multimeric complex comprised of Cbl, SHP2 and PI 3-kinase. We also observed the activation of matrix metalloproteinases 2 and 9 upon CXCL12 stimulation. These studies provide new information regarding signaling pathways that may regulate CXCL12-induced metastasis in breast cancer cells.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; Biontex Labs GmbH, D-80807 Munich, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Inst Med,Div Expt Med, 4 Blackfan Circle,Room 343, Boston, MA 02115 USA.	rganju@bidmc.harvard.edu	Fernandis, Aaron/C-3718-2012					ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Arboleda MJ, 2003, CANCER RES, V63, P196; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Camacho SA, 2001, NAT IMMUNOL, V2, P523, DOI 10.1038/88720; Cass I, 2001, GYNECOL ONCOL, V80, P56, DOI 10.1006/gyno.2000.6027; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Duong LT, 2000, CELL MOTIL CYTOSKEL, V47, P174, DOI 10.1002/1097-0169(200011)47:3<174::AID-CM2>3.0.CO;2-N; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Feshchenko EA, 1999, ONCOGENE, V18, P3703, DOI 10.1038/sj.onc.1202672; Fournier TM, 2000, MOL BIOL CELL, V11, P3397, DOI 10.1091/mbc.11.10.3397; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Geminder H, 2001, J IMMUNOL, V167, P4747, DOI 10.4049/jimmunol.167.8.4747; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hilakivi-Clarke L, 2000, CANCER RES, V60, P4993; Huminiecki L, 2002, GENOMICS, V79, P547, DOI 10.1006/geno.2002.6745; Hyder SM, 2001, INT J CANCER, V92, P469, DOI 10.1002/ijc.1236; Inoue K, 2000, CANCER RES, V60, P2290; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; Janowska-Wieczorek A, 2000, EXP HEMATOL, V28, P1274, DOI 10.1016/S0301-472X(00)00532-4; Kim H, 1999, EXP CELL RES, V253, P78, DOI 10.1006/excr.1999.4706; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Luca M, 1997, AM J PATHOL, V151, P1105; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Manes S, 1999, MOL CELL BIOL, V19, P3125; Mashino K, 2002, CANCER RES, V62, P2937; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Mohle R, 2000, BRIT J HAEMATOL, V110, P563, DOI 10.1046/j.1365-2141.2000.02157.x; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Nabeshima K, 2002, PATHOL INT, V52, P255, DOI 10.1046/j.1440-1827.2002.01343.x; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Price John T, 2002, Expert Opin Ther Targets, V6, P217; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Saphner T, 1996, J CLIN ONCOL, V14, P2738, DOI 10.1200/JCO.1996.14.10.2738; Saxton TM, 1999, P NATL ACAD SCI USA, V96, P3790, DOI 10.1073/pnas.96.7.3790; Scaife RM, 2000, J CELL SCI, V113, P215; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Taichman RS, 2002, CANCER RES, V62, P1832; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Verbeek BS, 1998, FEBS LETT, V425, P145, DOI 10.1016/S0014-5793(98)00224-5; Wade R, 2002, ONCOGENE, V21, P96, DOI 10.1038/sj.onc.1205013; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Yoshie O, 2000, INT J HEMATOL, V72, P399; Youngs SJ, 1997, INT J CANCER, V71, P257, DOI 10.1002/(SICI)1097-0215(19970410)71:2<257::AID-IJC22>3.0.CO;2-D; Zhang XF, 2001, BLOOD, V97, P3342, DOI 10.1182/blood.V97.11.3342	64	230	242	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					157	167		10.1038/sj.onc.1206910	http://dx.doi.org/10.1038/sj.onc.1206910			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712221	Bronze			2022-12-28	WOS:000187895300017
J	Liu, T; Brouha, B; Grossman, D				Liu, T; Brouha, B; Grossman, D			Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells	ONCOGENE			English	Article						apoptosis; survivin; caspase; AIF; melanoma; mitochondria	CRYSTAL-STRUCTURE; PROTEIN SURVIVIN; DIRECT INHIBITOR; CYTOCHROME-C; CANCER; DEATH; EXPRESSION; GENE; IAP; AIF	The inhibitor of apoptosis (IAP) protein Survivin is expressed in most cancers and is a key factor in maintaining apoptosis resistance. Although several IAPs have been shown to act as direct inhibitors of caspases, the precise antiapoptotic function of Survivin remains controversial. To clarify the mechanism by which Survivin protects cells, we investigated the kinetics of apoptosis and apoptotic events following Survivin inhibition utilizing a melanoma cell line harboring a tetracycline-regulated Survivin dominant-negative mutant (Survivin-T34A). Blocking Survivin resulted in both caspase activation and apoptosis; however, the level of apoptosis was only partially reduced by caspase inhibition. Survivin blockade also resulted in mitochondrial events that preceded caspase activation, including depolarization and release of cytochrome c and Smac/DIABLO. Levels of other IAPs were not altered in Survivin-targeted cells, although modest cleavage of XIAP and Livin was observed. The earliest proapoptotic event observed in Survivin-targeted cells was nuclear translocation of mitochondrial apoptosis-inducing factor (AIF), known to trigger both apoptotic mitochondrial events and caspase-independent DNA fragmentation. These findings suggest that a key antiapoptotic function of Survivin relates to inhibition of mitochondrial and AIF-dependent apoptotic pathways, and its expression in melanoma and other cancers likely protects against both caspase-independent and -dependent apoptosis.	Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; Univ Utah, Dept Dermatol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Grossman, D (corresponding author), Univ Utah, Huntsman Canc Inst, Suite 5243,2000 Circle Hope, Salt Lake City, UT 84112 USA.	doug.grossman@hci.utah.edu			NIAMS NIH HHS [KO8AR48618, R01 AR050102-01A1, R01 AR050102, K08 AR048618, K08 AR048618-04] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050102, K08AR048618] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fortugno P, 2002, J CELL SCI, V115, P575; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 1999, LAB INVEST, V79, P1121; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Mahotka C, 1999, CANCER RES, V59, P6097; Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Reed JC, 2001, J CLIN INVEST, V108, P965, DOI 10.1172/JCI14123; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Reutelingsperger CPM, 1997, CELL MOL LIFE SCI, V53, P527, DOI 10.1007/s000180050067; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 1998, CANCER RES, V58, P5315; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	62	154	170	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					39	48		10.1038/sj.onc.1206978	http://dx.doi.org/10.1038/sj.onc.1206978			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712209	Green Accepted			2022-12-28	WOS:000187895300005
J	Gillgrass, A; Cardiff, RD; Sharan, N; Kannan, S; Muller, WJ				Gillgrass, A; Cardiff, RD; Sharan, N; Kannan, S; Muller, WJ			Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression	ONCOGENE			English	Article						epidermal growth factor receptor; Gab-1; waved-2; ErbB-2; transgenic	HUMAN-BREAST-CANCER; TRANSGENIC MICE; TYROSINE KINASE; PROTO-ONCOGENE; NEU ONCOGENE; TGF-ALPHA; INDUCTION; OVEREXPRESSION; AMPLIFICATION; TUMORIGENESIS	Activation of the epidermal growth factor receptor (EGFR) family is thought to play an important role in mammary tumorigenesis and metastasis. The potent transforming activity of the EGFR family is due to their ability to heterodimerize with each other in response to a number of mitogenic ligands. The formation of EGFR and ErbB-2 heterodimers has been recently implicated as an important factor in the induction of sporadic human breast cancers. To directly assess whether the catalytic activity of EGFR is required for ErbB-2 induction of mammary tumors, we have interbred transgenic mice expressing ErbB-2 oncogene under the transcriptional control of the mouse mammary tumor virus (MMTV) promoter/enhancer to a naturally occurring mouse mutant carrying a catalytically impaired EGFR (waved-2 mice). Although the female transgenic mice possessing mutant EGFR developed mammary tumors, the tumors occurred only after a delayed latency period, and were fewer in number. The impaired tumor phenotype was further correlated with debilitated phosphorylation of the Gab1 multisubstrate adapter. These observations provide evidence that efficient ErbB-2-induced mammary tumor progression requires EGFR-dependent activation of Gab1.	McMaster Univ, MOBIX, Hamilton, ON L8S 4K1, Canada; Univ Calif Davis, Davis, CA 95616 USA; McGill Univ, Dept Med, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada	McMaster University; University of California System; University of California Davis; McGill University; McGill University	Muller, WJ (corresponding author), McGill Univ, Royal Victoria Hosp, Dept Biochem, 687 Pne Ave W,Rm H-5-21, Montreal, PQ H3A 1A1, Canada.							Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rowse GJ, 1998, CANCER RES, V58, P2675; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; Tzahar E, 1996, MOL CELL BIOL, V16, P5276	22	23	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9151	9155		10.1038/sj.onc.1206983	http://dx.doi.org/10.1038/sj.onc.1206983			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668796				2022-12-28	WOS:000187149100005
J	Sumrejkanchanakij, P; Tamamori-Adachi, M; Matsunaga, Y; Eto, K; Ikeda, MA				Sumrejkanchanakij, P; Tamamori-Adachi, M; Matsunaga, Y; Eto, K; Ikeda, MA			Role of cyclin D1 cytoplasmic sequestration in the survival of postmitotic neurons	ONCOGENE			English	Article						cyclin D1; cyclin-dependent kinase; neuron; apoptosis; nuclear localization; terminal differentiation	DEPENDENT KINASE-ACTIVITY; PROGRAMMED CELL-DEATH; CDK INHIBITORS; NUCLEAR EXPORT; IN-VIVO; PHOSPHORYLATION; EXPRESSION; PROTEIN; DIFFERENTIATION; LOCALIZATION	Cyclin D-dependent kinases phosphorylate the retinoblastoma (Rb) protein and play a critical role in neuronal cell cycle control and apoptosis. Here we show that cyclin D1 became predominantly cytoplasmic as primary cortical progenitor cells underwent cell cycle withdrawal and terminal differentiation. Furthermore, ectopically expressed cyclin D1 sequestered in the cytoplasm of postmitotic neurons, whereas it efficiently entered the nucleus of proliferating progenitor cells. Cytoplasmic cyclin D1 were complexed with cyclin-dependent kinase 4 (CDK4), and also with CDK inhibitors, p27(KipI) or p21(CipI), which positively regulate assembly and nuclear accumulation of the cyclin D1-CDK4 complex. Although overexpression of p21CipI promoted cyclin D1 nuclear localization, inhibition of either glycogen synthase kinase 3beta- or CRM1-mediated cyclin D1 nuclear export did not, suggesting that the inhibition of its nuclear import, rather than the acceleration of nuclear export, contributes to cytoplasmic sequestration of cyclin D1 in postmitotic neurons. In differentiated progenitor cells, nuclear localization of ectopic cyclin D1 induced apoptosis, and the DNA-damaging compound camptothecin caused nuclear accumulation of endogenous cyclin D1, accompanied by Rb phosphorylation. These results indicate that nuclear accumulation of cyclin D1 is inhibited in postmitotic neurons and suggest a role of its subcellular localization in neuronal death and survival.	Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, Tokyo 1138549, Japan; Tokyo Med & Dent Univ, Dept Internal Med 2, Bunkyo Ku, Tokyo 1138549, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Ikeda, MA (corresponding author), Tokyo Med & Dent Univ, Grad Sch, Sect Mol Embryol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.							Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gill RM, 1998, EXP CELL RES, V244, P157, DOI 10.1006/excr.1998.4197; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; Ino H, 2001, J NEUROSCI, V21, P6086, DOI 10.1523/JNEUROSCI.21-16-06086.2001; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Takiguchi-Hayashi K, 1998, BRAIN RES, V801, P9, DOI 10.1016/S0006-8993(98)00496-X; TAMALE-SALI E G, 1992, Journal of Obstetrics and Gynaecology (Abingdon), V12, P19, DOI 10.3109/01443619209029911; Tamamori M, 1998, AM J PHYSIOL-HEART C, V275, pH2036, DOI 10.1152/ajpheart.1998.275.6.H2036; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; Timsit S, 1999, EUR J NEUROSCI, V11, P263, DOI 10.1046/j.1460-9568.1999.00434.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	36	104	106	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8723	8730		10.1038/sj.onc.1206870	http://dx.doi.org/10.1038/sj.onc.1206870			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647467				2022-12-28	WOS:000186844900010
J	Degterev, A; Boyce, M; Yuan, JY				Degterev, A; Boyce, M; Yuan, JY			A decade of caspases	ONCOGENE			English	Review						caspase; apoptosis; protease	INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; DEPENDENT PROTEIN-KINASE; FOCAL ADHESION KINASE; ICE-LIKE PROTEASE; ENDOPLASMIC-RETICULUM STRESS; FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; RADIATION-INDUCED APOPTOSIS	Caspases are a family of cysteine proteases that play important roles in regulating apoptosis. A decade of research has generated a wealth of information on the signal transduction pathways mediated by caspases, the distinct functions of individual caspases and the mechanisms by which caspases mediate apoptosis and a variety of physiological and pathological processes.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	jyuan@hms.harvard.edu		Boyce, Michael/0000-0002-2729-4876				Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Ahmad M, 1998, CANCER RES, V58, P5201; Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; An B, 1996, CANCER RES, V56, P438; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; BALIGA BC, 2002, J BIOL CHEM, V10, P10; Barrett AJ, 2001, BIOL CHEM, V382, P727, DOI 10.1515/BC.2001.088; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bilsland J, 2002, J NEUROSCI, V22, P2637, DOI 10.1523/JNEUROSCI.22-07-02637.2002; Blanchard H, 1999, STRUCTURE, V7, P1125, DOI 10.1016/S0969-2126(99)80179-8; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chai JJ, 2001, CELL, V107, P399, DOI 10.1016/S0092-8674(01)00544-X; Chan SL, 1999, J NEUROSCI RES, V57, P315, DOI 10.1002/(SICI)1097-4547(19990801)57:3<315::AID-JNR3>3.3.CO;2-R; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chautan M, 1999, CURR BIOL, V9, P967, DOI 10.1016/S0960-9822(99)80425-4; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Crouch DH, 1996, ONCOGENE, V12, P2689; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; Deaciuc IV, 2001, ALCOHOL CLIN EXP RES, V25, P935; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; DEL PL, 1997, SCIENCE, V278, P687; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; DOLLE RE, 1995, J MED CHEM, V38, P220, DOI 10.1021/jm00002a002; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eckhart L, 2000, BIOCHEM BIOPH RES CO, V277, P655, DOI 10.1006/bbrc.2000.3698; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Eddins MJ, 2002, ACTA CRYSTALLOGR D, V58, P299, DOI 10.1107/S0907444901018753; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Ekert PG, 1999, EMBO J, V18, P330, DOI 10.1093/emboj/18.2.330; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; ESTROV Z, 1995, BLOOD, V86, P4594, DOI 10.1182/blood.V86.12.4594.bloodjournal86124594; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Foo SY, 1999, TRENDS GENET, V15, P229; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; GRAYBILL TL, 1994, INT J PEPT PROT RES, V44, P173; Greidinger EL, 1996, FEBS LETT, V390, P299, DOI 10.1016/0014-5793(96)00678-3; Grobmyer SR, 1999, MOL MED, V5, P585, DOI 10.1007/BF03402071; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Hayashi Yoshio, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P399; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Henshall DC, 2000, NEUROLOGY, V55, P250, DOI 10.1212/WNL.55.2.250; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Hoglen NC, 2001, J PHARMACOL EXP THER, V297, P811; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Hotchkiss RS, 2000, NAT IMMUNOL, V1, P496, DOI 10.1038/82741; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; Hu SM, 1998, J BIOL CHEM, V273, P29648, DOI 10.1074/jbc.273.45.29648; Hunter CP, 1999, CURR BIOL, V9, pR440, DOI 10.1016/S0960-9822(99)80276-0; Inohara N, 1999, J BIOL CHEM, V274, P270, DOI 10.1074/jbc.274.1.270; Inoue H, 2001, J IMMUNOL, V166, P5801, DOI 10.4049/jimmunol.166.9.5801; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Johnston AM, 2000, ONCOGENE, V19, P4290, DOI 10.1038/sj.onc.1203784; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kabra NH, 2001, P NATL ACAD SCI USA, V98, P6307, DOI 10.1073/pnas.111158698; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kang SJ, 2002, CELL DEATH DIFFER, V9, P1115, DOI 10.1038/sj.cdd.4401087; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Koenig U, 2001, BIOCHEM BIOPH RES CO, V285, P1150, DOI 10.1006/bbrc.2001.5315; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Kulms D, 2002, CELL DEATH DIFFER, V9, P598, DOI 10.1038/sj.cdd.4401002; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; Lamkanfi M, 2002, CELL DEATH DIFFER, V9, P358, DOI 10.1038/sj.cdd.4400989; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lazebnik YA, 1995, J CELL SCI, P41; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Lee D, 2000, J BIOL CHEM, V275, P16007, DOI 10.1074/jbc.275.21.16007; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leonard JR, 2002, J NEUROPATH EXP NEUR, V61, P673, DOI 10.1093/jnen/61.8.673; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li HL, 1999, CURR OPIN CELL BIOL, V11, P261, DOI 10.1016/S0955-0674(99)80035-0; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin XY, 2000, J BIOL CHEM, V275, P39920, DOI 10.1074/jbc.M007255200; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Livingston DJ, 1997, J CELL BIOCHEM, V64, P19, DOI 10.1002/(SICI)1097-4644(199701)64:1<19::AID-JCB4>3.0.CO;2-2; Lockshin R A, 1965, J Insect Physiol, V11, P803, DOI 10.1016/0022-1910(65)90159-9; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; Lugovskoy AA, 1999, CELL, V99, P747, DOI 10.1016/S0092-8674(00)81672-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinon F, 2000, FEBS LETT, V468, P134, DOI 10.1016/S0014-5793(00)01212-6; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; MICHEAU O, 2002, J BIOL CHEM, V4, P4; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; Mootha VK, 2001, EMBO J, V20, P661, DOI 10.1093/emboj/20.4.661; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Namura S, 1998, J NEUROSCI, V18, P3659; Natori S, 1999, TRANSPLANTATION, V68, P89, DOI 10.1097/00007890-199907150-00018; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nicotera P, 1998, TOXICOL LETT, V103, P139; Nicotera P, 1999, BIOCHEM SOC SYMP, V66, P69, DOI 10.1042/bss0660069; Nishimura I, 2002, CELL DEATH DIFFER, V9, P199, DOI 10.1038/sj.cdd.4400931; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Orth K, 1996, J BIOL CHEM, V271, P20977, DOI 10.1074/jbc.271.35.20977; Orth R, 1997, J BIOL CHEM, V272, P8841; Pandey P, 2000, ONCOGENE, V19, P3941, DOI 10.1038/sj.onc.1203751; Park WS, 2002, ONCOGENE, V21, P2919, DOI 10.1038/sj.onc.1205394; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Pistritto G, 2002, CELL DEATH DIFFER, V9, P995, DOI 10.1038/sj.cdd.4401061; Pop C, 2001, BIOCHEMISTRY-US, V40, P14224, DOI 10.1021/bi011037e; Prasad SC, 1998, BIOCHEM BIOPH RES CO, V249, P332, DOI 10.1006/bbrc.1998.9137; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Randle JCR, 2001, EXPERT OPIN INV DRUG, V10, P1207, DOI 10.1517/13543784.10.7.1207; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Renatus M, 2000, STRUCT FOLD DES, V8, P789, DOI 10.1016/S0969-2126(00)00165-9; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; Riedl SJ, 2001, BIOCHEMISTRY-US, V40, P13274, DOI 10.1021/bi010574w; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Ross CA, 1999, PHILOS T ROY SOC B, V354, P1005, DOI 10.1098/rstb.1999.0452; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Rudel T, 1999, HERZ, V24, P236, DOI 10.1007/BF03044967; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sakahira H, 1999, CURR BIOL, V9, P543, DOI 10.1016/S0960-9822(99)80240-1; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schmeiser K, 1998, FEBS LETT, V433, P51, DOI 10.1016/S0014-5793(98)00850-3; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shao RG, 1997, J BIOL CHEM, V272, P31321, DOI 10.1074/jbc.272.50.31321; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Shiozaki EN, 2002, P NATL ACAD SCI USA, V99, P4197, DOI 10.1073/pnas.072544399; Siegmund B, 2002, BIOCHEM PHARMACOL, V64, P1, DOI 10.1016/S0006-2952(02)01064-X; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith DJ, 1997, J IMMUNOL, V158, P163; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; SORDET O, 2002, BLOOD, V8, P8; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; Stefanis L, 1998, J NEUROSCI, V18, P9204; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 2000, BBA-PROTEIN STRUCT M, V1477, P299, DOI 10.1016/S0167-4838(99)00281-2; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; Talanian RV, 2000, J MED CHEM, V43, P3351, DOI 10.1021/jm000060f; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; Tong X, 2000, INT J RADIAT BIOL, V76, P1387, DOI 10.1080/09553000050151664; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; U M, 2001, CELL DEATH DIFFER, V8, P377, DOI 10.1038/sj.cdd.4400819; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Van de Craen M, 1999, CELL DEATH DIFFER, V6, P1117, DOI 10.1038/sj.cdd.4400589; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; VOGT C, 1842, SOLOTHURN, P130; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Watabe M, 1999, ONCOGENE, V18, P5211, DOI 10.1038/sj.onc.1202901; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Watt W, 1999, STRUCTURE, V7, P1135, DOI 10.1016/S0969-2126(99)80180-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Wellington CL, 2002, J NEUROSCI, V22, P7862; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 2002, CANCER BIOL THER, V1, P407, DOI 10.4161/cbt.1.4.16; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	317	917	961	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8543	8567		10.1038/sj.onc.1207107	http://dx.doi.org/10.1038/sj.onc.1207107			25	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634618				2022-12-28	WOS:000186720000002
J	Horiguchi, K; Tomizawa, Y; Tosaka, M; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N				Horiguchi, K; Tomizawa, Y; Tosaka, M; Ishiuchi, S; Kurihara, H; Mori, M; Saito, N			Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors	ONCOGENE			English	Article						3p21.3; methylation; glioma; medulloblastoma; meningioma; schwannoma	PRIMITIVE NEUROECTODERMAL TUMORS; CHROMOSOME 3P; PROMOTER HYPERMETHYLATION; CPG ISLAND; LUNG; METHYLATION; BREAST; CELL; HETEROZYGOSITY; HYBRIDIZATION	The human Ras association domain family 1A (RASS-F1A) gene, recently isolated from the lung and breast tumor suppressor locus 3p21.3, is highly methylated in primary lung, breast, nasopharyngeal and other tumors, and re-expression of RASSF1A suppresses the growth of several types of cancer cells. Epigenetic inactivation of RASSF1A by promoter hypermethylation is also important in the development of several human cancers. The methylation status of the promoter region of RASSF1A was analysed in primary brain tumors and glioma cell lines by methylation-specific polymerase chain reaction. In primary brain tumors, 25 of 46 ( 54.3%) gliomas and five of five (100%) medulloblastomas showed RASSF1A methylation. In benign tumors, only one of 10 (10%) schwannomas and two of 12 (16.7%) meningiomas showed RASSF1A methylation. The RASSF1A promoter region was methylated in all four glioma cell lines. RASSF1A was re-expressed in all methylated cell lines after treatment with the demethylating agent 5-aza-2'-deoxycytidine. Methylation of the promoter CpG islands of the RASSF1A may play an important role in the pathogenesis of glioma and medulloblastoma.	Gunma Univ, Sch Med, Dept Neurosurg, Gunma 3718511, Japan; Gunma Univ, Sch Med, Dept Internal Med 1, Gunma 3718511, Japan	Gunma University; Gunma University	Horiguchi, K (corresponding author), Gunma Univ, Sch Med, Dept Neurosurg, 3-39-22 Showa Machi, Gunma 3718511, Japan.							Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; Avet-Loiseau H, 1999, BRIT J CANCER, V79, P1843, DOI 10.1038/sj.bjc.6690293; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; FULTS D, 1990, CANCER RES, V50, P5784; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kanno H, 1997, CANCER RES, V57, P1035; Kleihues P, 2000, PATHOLOGY GENETICS T; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; Lo KW, 2001, CANCER RES, V61, P3877; Lusher ME, 2002, CANCER RES, V62, P5906; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Mollerup S, 1999, CANCER RES, V59, P3317; Morrissey C, 2001, CANCER RES, V61, P7277; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; Toyooka S, 2001, CANCER RES, V61, P5727; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835	28	57	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7862	7865		10.1038/sj.onc.1207082	http://dx.doi.org/10.1038/sj.onc.1207082			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586413				2022-12-28	WOS:000186240200017
J	Ciechomska, I; Pyrzynska, B; Kazmierczak, P; Kaminska, B				Ciechomska, I; Pyrzynska, B; Kazmierczak, P; Kaminska, B			Inhibition of Akt kinase signalling and activation of Forkhead are indispensable for upregulation of FasL expression in apoptosis of glioma cells	ONCOGENE			English	Article						Akt signalling; Forkhead transcription factor; Fas/FasL; apoptosis; cyclosporin A; glioma cells	NF-KAPPA-B; AP-1 TRANSCRIPTION FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; LIGAND EXPRESSION; TUMOR-SUPPRESSOR; CYCLOSPORINE-A; T-CELLS; CAENORHABDITIS-ELEGANS	Activation of Akt signalling pathway is frequently found in glioma cells and may contribute to their resistance to undergo apoptosis in response to conventional therapies. We found that cyclosporin A (CsA) induces apoptosis of C6 glioma cells, which is associated with transcriptional activation of fasL. In the present paper, we investigated an involvement of Akt signalling in the regulation of FasL expression in CsA-induced apoptosis. We demonstrated that the level of active Akt decreases significantly after CsA treatment, which results in the decrease of Forkhead phosphorylation and its translocation to the nucleus. It correlated with an increase of binding to the Forkhead-responsive element FHRE from the FasL promoter, as demonstrated by gel-shift assays. Although treatment with LY294002, a specific inhibitor of PI3 K, decreased the phosphorylation of Akt and increased Fkhr translocation to the nucleus, these events were not sufficient to induce FasL expression and apoptosis of C6 glioma cells. Interference with Akt/Forkhead signalling by membrane-targeted Akt or removal of the FKHR-binding sites from the FasL promoter significantly abolished its activation. These results indicate that downregulation of Akt signalling and activation of Forkhead is a prerequisite for the induction of FasL promoter. It may be clinically important for pharmacological intervention in gliomas.	M Nencki Inst Expt Biol, Dept Cellular Biochem, Lab Transcript Regulat, PL-02093 Warsaw, Poland	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kaminska, B (corresponding author), M Nencki Inst Expt Biol, Dept Cellular Biochem, Lab Transcript Regulat, 3 Pasteur Str, PL-02093 Warsaw, Poland.		Kaminska, Bozena/H-4592-2011; Pyrzyńska, Beata/T-2187-2018; Kaminska, Bozena/B-2915-2014; Kaźmierczak, Piotr/AAD-7059-2021; Ciechomksa, Iwona/R-4706-2016	Kaminska, Bozena/0000-0002-2642-4616; Pyrzyńska, Beata/0000-0002-0490-618X; Kaźmierczak, Piotr/0000-0002-4060-3055; Ciechomksa, Iwona/0000-0002-8068-0020				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brownawell AM, 2001, MOL CELL BIOL, V21, P3534, DOI 10.1128/MCB.21.10.3534-3546.2001; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Galanis E, 2000, BRIT J CANCER, V82, P1371, DOI 10.1054/bjoc.1999.1075; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HERMANSON M, 1992, CANCER RES, V52, P3213; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Hosli P, 1998, ANN ONCOL, V9, P589; KAMINSKA B, 1994, EUR J NEUROSCI, V6, P1558, DOI 10.1111/j.1460-9568.1994.tb00546.x; Kaminska B, 1996, J NEUROSCI, V16, P3968; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kawaguchi S, 2000, NEUROSURGERY, V46, P431, DOI 10.1097/00006123-200002000-00030; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mittelstadt PR, 1998, MOL CELL BIOL, V18, P3744, DOI 10.1128/MCB.18.7.3744; Mosieniak G, 1998, J NEUROCHEM, V71, P134; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Ozes ON, 1999, NATURE, V401, P82; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Pyrzynska B, 2002, J BIOL CHEM, V277, P14102, DOI 10.1074/jbc.M104443200; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SAXENA A, 1992, ONCOGENE, V7, P243; Sharma K, 2000, PHARMACOL THERAPEUT, V88, P333, DOI 10.1016/S0163-7258(00)00096-6; Shinoura N, 1998, HUM GENE THER, V9, P1983, DOI 10.1089/hum.1998.9.14-1983; Sonoda Y, 2001, CANCER RES, V61, P6674; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; TACHIBANA O, 1995, CANCER RES, V55, P5528; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200	75	74	87	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7617	7627		10.1038/sj.onc.1207137	http://dx.doi.org/10.1038/sj.onc.1207137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576824				2022-12-28	WOS:000186113000009
J	Zafarana, G; Grygalewicz, B; Gillis, AJM; Vissers, LELM; van de Vliet, W; van Gurp, RJHLM; Stoop, H; Debiec-Rychter, M; Oosterhuis, JW; van Kessel, AG; Schoenmakers, EFPM; Looijenga, LHJ; Veltman, JA				Zafarana, G; Grygalewicz, B; Gillis, AJM; Vissers, LELM; van de Vliet, W; van Gurp, RJHLM; Stoop, H; Debiec-Rychter, M; Oosterhuis, JW; van Kessel, AG; Schoenmakers, EFPM; Looijenga, LHJ; Veltman, JA			12p-Amplicon structure analysis in testicular germ cell tumors of adolescents and adults by array CGH	ONCOGENE			English	Article						testicular germ cell tumors; 12-amplicon; array CGH; architecture; candidate genes	COMPARATIVE GENOMIC HYBRIDIZATION; CANDIDATE ONCOGENE; EXPRESSION; AMPLIFICATION; GENE; AMPLICON; CANCER; TARGET; 12P; IDENTIFICATION	All invasive testicular germ cell tumors of adolescents and adults ( TGCTs), that is, seminomas and nonseminomas, show gain of 12p sequences, mostly as isochromosomes. Although several candidate genes have been suggested, the relevant gene(s) have not been identified yet. About 10% of testicular seminomas, however, show a more restricted amplification of the 12p11.2-p12.1 region, in which the various amplicons show an apparent overlap, allowing for the shortest region of amplification overlap approach, aiming at the identification of pathogenetically relevant sequences residing in this region. Here we report on a high-resolution 12p-amplicon architecture analysis using microarray-based comparative genomic hybridization, the results of which were subsequently confirmed by fluorescent in situ hybridization studies. The 12p-specific microarray contained 63 positionally selected BAC clones, which are more or less evenly distributed over the short arm of chromosome 12 ( average spacing: less than 500 Kb), including 20 clones within the region of amplification. Out of a series of 17 seminomas, seven seminomas showed amplification of the whole amplicon region, of which three showed a dip in T/R value in the center of the amplified area. A more complex amplification pattern was found in the other 10 seminomas: three showed predominant amplification at the centromeric border; one mainly at the telomeric border; six showed a balanced amplification of both the centromeric and telomeric regions. The only nonseminoma investigated showed a structure in which the centromeric border was only amplified. These data support a mechanistic model in which at least two 12p genes, situated at the border regions of the amplicon, are positional candidates capable of actively supporting tumor progression in TGCTs.	Erasmus Univ, Med Ctr, Erasmus MC,Daniel den Hoed Canc Ctr, Pathol Lab Exp Pathooncol, Rotterdam, Netherlands; Katholieke Univ Leuven, Ctr Human Genet, Louvain, Belgium; Maria Sklodowska Curie Mem Canc Ctr & Inst, Cytogenet Lab, Warsaw, Poland; Univ Med Ctr Nijmegen, Dept Human Genet, Nijmegen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; KU Leuven; Radboud University Nijmegen	Looijenga, LHJ (corresponding author), Josephine Nefkens Inst, Room 430B,POB 1738, NL-3000 DR Rotterdam, Netherlands.	l.looijenga@erasmusmc.nl	Veltman, Joris A/F-5128-2010; van Kessel, Ad Geurts/A-2810-2010; Vissers, Lisenka ELM/A-2598-2015; Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Veltman, Joris A/0000-0002-3218-8250; Vissers, Lisenka ELM/0000-0001-6470-5497; Looijenga, Leendert/0000-0002-8146-1911; Grygalewicz, Beata/0000-0002-9592-5174; Zafarana, Gaetano/0000-0003-1391-4488				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Bourdon V, 2002, CANCER RES, V62, P6218; Guan XY, 2001, CANCER RES, V61, P3806; Heidenblad M, 2002, GENE CHROMOSOME CANC, V34, P211, DOI 10.1002/gcc.10063; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Looijenga LHJ, 2002, ANAL QUANT CYTOL, V24, P263; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Mostofi F K, 1985, Prog Clin Biol Res, V203, P1; MOUL JW, 1992, GENE CHROMOSOME CANC, V5, P109, DOI 10.1002/gcc.2870050204; MULDER MP, 1989, ONCOGENE, V4, P1345; Nonet GH, 2001, CANCER RES, V61, P1250; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; RIDANPAA M, 1993, ENVIRON HEALTH PERSP, V101, P185, DOI 10.2307/3431723; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; Schmidt BA, 2001, CANCER RES, V61, P4214; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Skotheim RI, 2002, CANCER RES, V62, P2359; SUIJKERBUIJK RF, 1994, CANCER GENET CYTOGEN, V78, P145, DOI 10.1016/0165-4608(94)90082-5; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; TELENIUS H, 1992, GENOMICS, V13, P718, DOI 10.1016/0888-7543(92)90147-K; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; Yasui K, 2001, GENE CHROMOSOME CANC, V32, P112, DOI 10.1002/gcc.1172; Zafarana G, 2002, CANCER RES, V62, P1822; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	36	56	57	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7695	7701		10.1038/sj.onc.1207011	http://dx.doi.org/10.1038/sj.onc.1207011			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576833				2022-12-28	WOS:000186113000018
J	Kruh, GD; Belinsky, MG				Kruh, GD; Belinsky, MG			The MRP family of drug efflux pumps	ONCOGENE			English	Review						ABC transporter; efflux; resistance	MULTIDRUG-RESISTANCE PROTEIN; ORGANIC ANION TRANSPORTER; CONJUGATE EXPORT PUMP; ATP-DEPENDENT TRANSPORT; CASSETTE SUPERFAMILY TRANSPORTER; CAUSE PSEUDOXANTHOMA ELASTICUM; KIDNEY PROXIMAL TUBULES; ACUTE MYELOID-LEUKEMIA; CHARGED AMINO-ACIDS; TUMOR-CELL-LINES	The MRP family is comprised of nine related ABC transporters that are able to transport structurally diverse lipophilic anions and function as drug efflux pumps. Investigations of this family have provided insights not only into cellular resistance mechanisms associated with natural product chemotherapeutic agents, antifolates and nucleotide analogs, but also into factors that influence drug distribution in the body, membrane systems that are involved in the extrusion of reduced folates, cysteinyl leukotrienes and bile acids, and the molecular basis of two hereditary conditions in humans. The review will describe the biochemical properties, drug resistance activities and potential in vivo functions of these unusual pumps.	Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Kruh, GD (corresponding author), Fox Chase Canc Ctr, Div Med Sci, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA 73728, CA 06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, U01CA073728, R01CA073728] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2002, J BIOL CHEM, V277, P38998, DOI 10.1074/jbc.M203262200; Allen JD, 2000, CANCER RES, V60, P5761; Assaraf YG, 2003, J BIOL CHEM, V278, P6680, DOI 10.1074/jbc.M209186200; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bankir L, 2002, AM J PHYSIOL-RENAL, V282, pF376, DOI 10.1152/ajprenal.00202.2001; Bartosz G, 1998, BIOL CHEM, V379, P1121, DOI 10.1515/bchm.1998.379.8-9.1121; Belinsky MG, 2002, CANCER RES, V62, P6172; Belinsky MG, 1998, J NATL CANCER I, V90, P1735, DOI 10.1093/jnci/90.22.1735; Belinsky MG, 1999, BRIT J CANCER, V80, P1342, DOI 10.1038/sj.bjc.6690527; Bera TK, 2002, P NATL ACAD SCI USA, V99, P6997, DOI 10.1073/pnas.102187299; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Bodo A, 2003, J BIOL CHEM, V278, P23529, DOI 10.1074/jbc.M303515200; BREUNINGER LM, 1995, CANCER RES, V55, P5342; Burger H, 2003, CLIN CANCER RES, V9, P827; Chen ZS, 1999, MOL PHARMACOL, V56, P1219, DOI 10.1124/mol.56.6.1219; Chen ZS, 2003, MOL PHARMACOL, V63, P351, DOI 10.1124/mol.63.2.351; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2003, CANCER RES, V63, P4048; Chen ZS, 1999, MOL PHARMACOL, V55, P921; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Chu XY, 1997, J PHARMACOL EXP THER, V281, P304; Ciaccio PJ, 1996, BIOCHEM BIOPH RES CO, V222, P111, DOI 10.1006/bbrc.1996.0706; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui YH, 1999, MOL PHARMACOL, V55, P929; Daoud R, 2000, BIOCHEMISTRY-US, V39, P15344, DOI 10.1021/bi0020574; Daoud R, 2001, J BIOL CHEM, V276, P12324, DOI 10.1074/jbc.M009782200; Daoud R, 2000, BIOCHEMISTRY-US, V39, P6094, DOI 10.1021/bi9922188; Dietrich CG, 2001, CARCINOGENESIS, V22, P805, DOI 10.1093/carcin/22.5.805; Donner MG, 2001, HEPATOLOGY, V34, P351, DOI 10.1053/jhep.2001.26213; DUBIN IN, 1954, MEDICINE, V33, P155, DOI 10.1097/00005792-195409000-00001; ELFERINK RPJ, 1989, J CLIN INVEST, V84, P476, DOI 10.1172/JCI114189; Evers R, 1996, J CLIN INVEST, V97, P1211, DOI 10.1172/JCI118535; Evers R, 2000, BRIT J CANCER, V83, P375, DOI 10.1054/bjoc.2000.1262; FERNANDES DJ, 1990, BIOCHEMISTRY-US, V29, P4235, DOI 10.1021/bi00469a028; Flens MJ, 1996, AM J PATHOL, V148, P1237; Gao M, 1998, J BIOL CHEM, V273, P10733, DOI 10.1074/jbc.273.17.10733; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Guo YP, 2003, J BIOL CHEM, V278, P29509, DOI 10.1074/jbc.M304059200; Gupta E, 1996, CANCER RES, V56, P1309; Haimeur A, 2002, J BIOL CHEM, V277, P41326, DOI 10.1074/jbc.M206228200; Harris MJ, 2001, J BIOL CHEM, V276, P20876, DOI 10.1074/jbc.M010566200; Hegedus T, 2003, BIOCHEM BIOPH RES CO, V302, P454, DOI 10.1016/S0006-291X(03)00196-7; Hinoshita E, 2000, CLIN CANCER RES, V6, P2401; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hirohashi T, 1998, MOL PHARMACOL, V53, P1068; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hirrlinger J, 2001, J NEUROCHEM, V76, P627, DOI 10.1046/j.1471-4159.2001.00101.x; Hooijberg JH, 2003, BIOCHEM PHARMACOL, V65, P765, DOI 10.1016/S0006-2952(02)01615-5; Hooijberg JH, 1999, CANCER RES, V59, P2532; Hopper E, 2001, CANCER LETT, V162, P181, DOI 10.1016/S0304-3835(00)00646-7; Ilias A, 2002, J BIOL CHEM, V277, P16860, DOI 10.1074/jbc.M110918200; INOKUCHI A, 2001, J BIOL CHEM, V4, P4; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; Ito K, 2001, AM J PHYSIOL-GASTR L, V281, pG1034, DOI 10.1152/ajpgi.2001.281.4.G1034; Ito K, 2001, MOL PHARMACOL, V59, P1077, DOI 10.1124/mol.59.5.1077; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito K, 2001, J BIOL CHEM, V276, P38108; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Jedlitschky G, 1996, CANCER RES, V56, P988; Jedlitschky G, 1997, BIOCHEM J, V327, P305, DOI 10.1042/bj3270305; Johnson DR, 2001, CANCER RES, V61, P1469; Kao HH, 2002, GENE, V286, P299, DOI 10.1016/S0378-1119(02)00461-4; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Karwatsky J, 2003, BIOCHEMISTRY-US, V42, P3286, DOI 10.1021/bi0268807; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kawabe T, 1999, FEBS LETT, V456, P327, DOI 10.1016/S0014-5793(99)00979-5; KITAMURA T, 1990, P NATL ACAD SCI USA, V87, P3557, DOI 10.1073/pnas.87.9.3557; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Kocher O, 1999, LAB INVEST, V79, P1161; Koike K, 1997, CANCER RES, V57, P5475; Konno T, 2003, J BIOL CHEM, V278, P22908, DOI 10.1074/jbc.M302868200; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1999, CANCER RES, V59, P175; KRISHNAMACHARY N, 1993, CANCER RES, V53, P3658; Kruh GD, 2001, J BIOENERG BIOMEMBR, V33, P493, DOI 10.1023/A:1012827221844; KRUH GD, 1995, J NATL CANCER I, V87, P1256, DOI 10.1093/jnci/87.16.1256; KRUH GD, 1994, CANCER RES, V54, P1649; Kuo MT, 1996, CANCER RES, V56, P3642; Lai LQ, 2002, BIOCHEM J, V361, P497, DOI 10.1042/0264-6021:3610497; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; Lee K, 2000, JNCI-J NATL CANCER I, V92, P1934, DOI 10.1093/jnci/92.23.1934; Lee K, 1998, CANCER RES, V58, P2741; Legare D, 2001, J BIOL CHEM, V276, P26301, DOI 10.1074/jbc.M102351200; Leier I, 1996, EUR J BIOCHEM, V242, P201, DOI 10.1111/j.1432-1033.1996.0201r.x; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2003, BIOCHEMISTRY-US, V42, P5214, DOI 10.1021/bi027076n; Leslie EM, 2003, DRUG METAB DISPOS, V31, P11, DOI 10.1124/dmd.31.1.11; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Lin ZP, 2002, MOL CANCER THER, V1, P1105; Loe DW, 2000, J PHARMACOL EXP THER, V293, P530; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1998, CANCER RES, V58, P5130; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Lorico A, 2002, BIOCHEM BIOPH RES CO, V291, P617, DOI 10.1006/bbrc.2002.6489; Lorico A, 1997, CANCER RES, V57, P5238; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; Manciu L, 2003, J BIOL CHEM, V278, P3347, DOI 10.1074/jbc.M207963200; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; MARQUARDT D, 1990, CANCER RES, V50, P1426; Masuda M, 1997, CANCER RES, V57, P3506; McAleer MA, 1999, J BIOL CHEM, V274, P23541, DOI 10.1074/jbc.274.33.23541; MCGRATH T, 1987, BIOCHEM BIOPH RES CO, V145, P1171, DOI 10.1016/0006-291X(87)91560-9; MCGRATH T, 1989, BIOCHEM PHARMACOL, V38, P3611, DOI 10.1016/0006-2952(89)90134-2; Miller DS, 2000, MOL PHARMACOL, V58, P1357, DOI 10.1124/mol.58.6.1357; Morikawa A, 2000, PHARM RES-DORDR, V17, P546, DOI 10.1023/A:1026412915168; Morrow CS, 1998, J BIOL CHEM, V273, P20114, DOI 10.1074/jbc.273.32.20114; Mottino AD, 2000, J PHARMACOL EXP THER, V293, P717; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nies AT, 2002, J UROLOGY, V167, P2271, DOI 10.1016/S0022-5347(05)65141-5; Nies AT, 2002, EUR J BIOCHEM, V269, P1866, DOI 10.1046/j.1432-1033.2002.02832.x; Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498; O'Brien M, 2000, J PHARMACOL EXP THER, V294, P480; Ohishi Y, 2002, CLIN CANCER RES, V8, P3767; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Paumi CM, 2001, J BIOL CHEM, V276, P7952, DOI 10.1074/jbc.M009400200; Plasschaert SLA, 2003, LEUKEMIA LYMPHOMA, V44, P85, DOI 10.1080/1042819021000040288; POTSCHKA H, 2003, J PHARM EXP THER; Qian YM, 2002, J BIOL CHEM, V277, P35225, DOI 10.1074/jbc.M206058200; Qian YM, 2001, J BIOL CHEM, V276, P6404, DOI 10.1074/jbc.M008251200; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900; Rappa G, 1997, CANCER RES, V57, P5232; Ren XQ, 2002, BIOCHEMISTRY-US, V41, P14132, DOI 10.1021/bi026443s; Ren XQ, 2001, J BIOL CHEM, V276, P23197, DOI 10.1074/jbc.M101554200; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROBBINS BL, 1995, MOL PHARMACOL, V47, P391; Rosenberg MF, 2001, J BIOL CHEM, V276, P16076, DOI 10.1074/jbc.M100176200; Rost D, 2002, AM J PHYSIOL-GASTR L, V282, pG720, DOI 10.1152/ajpgi.00318.2001; Ryu S, 2000, J BIOL CHEM, V275, P39617, DOI 10.1074/jbc.M005149200; Sakamoto H, 1999, CANCER LETT, V135, P113; Sanghani PC, 2000, PROTEIN EXPRES PURIF, V18, P36, DOI 10.1006/prep.1999.1173; Sauerbrey A, 2002, LEUKEMIA LYMPHOMA, V43, P875, DOI 10.1080/10428190290017024; Schaub TP, 1997, J AM SOC NEPHROL, V8, P1213; Scheffer GL, 2002, LAB INVEST, V82, P515, DOI 10.1038/labinvest.3780444; Scheffer GL, 2002, LAB INVEST, V82, P193, DOI 10.1038/labinvest.3780411; SCHNEIDER E, 1995, BRIT J CANCER, V71, P738, DOI 10.1038/bjc.1995.144; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schultz MJ, 2001, J IMMUNOL, V166, P4059, DOI 10.4049/jimmunol.166.6.4059; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Soroka CJ, 2001, HEPATOLOGY, V33, P783, DOI 10.1053/jhep.2001.23501; St-Pierre MV, 2000, AM J PHYSIOL-REG I, V279, pR1495, DOI 10.1152/ajpregu.2000.279.4.R1495; Steinbach D, 2003, CLIN CANCER RES, V9, P1083; Suzuki H, 2002, ADV DRUG DELIVER REV, V54, P1311, DOI 10.1016/S0169-409X(02)00075-3; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; Taniguchi K, 1996, CANCER RES, V56, P4124; Uchiumi T, 1998, BIOCHEM BIOPH RES CO, V252, P103, DOI 10.1006/bbrc.1998.9546; Uitto J, 2001, TRENDS MOL MED, V7, P13, DOI 10.1016/S1471-4914(00)01869-4; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; Van Aubel RAMH, 1999, MOL PHARMACOL, V56, P714; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; Vernhet L, 1999, FEBS LETT, V443, P321, DOI 10.1016/S0014-5793(98)01716-5; Vernhet L, 2001, BIOCHEM PHARMACOL, V61, P1387, DOI 10.1016/S0006-2952(01)00606-2; VERSANTVOORT CHM, 1995, BRIT J CANCER, V72, P82, DOI 10.1038/bjc.1995.281; Volk EL, 2000, CANCER RES, V60, P3514; Volk EL, 2002, CANCER RES, V62, P5035; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865; Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zelcer N, 2001, J BIOL CHEM, V276, P46400, DOI 10.1074/jbc.M107041200; Zelcer N, 2003, J BIOL CHEM, V278, P23538, DOI 10.1074/jbc.M303504200; Zeng H, 2001, CANCER RES, V61, P7225; Zeng H, 1999, CANCER RES, V59, P5964; Zeng H, 2000, CANCER RES, V60, P4779; Zhang DW, 2002, J BIOL CHEM, V277, P20934, DOI 10.1074/jbc.M201311200; Zhang DW, 2001, J BIOL CHEM, V276, P34966, DOI 10.1074/jbc.M105063200; Zhang DW, 2001, J BIOL CHEM, V276, P13231, DOI 10.1074/jbc.M010008200; Zurita A, 2003, BRIT J CANCER, V88, P879, DOI 10.1038/sj.bjc.6600803	184	501	528	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7537	7552		10.1038/sj.onc.1206953	http://dx.doi.org/10.1038/sj.onc.1206953			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576857				2022-12-28	WOS:000186112500022
J	Kontou, M; Will, RD; Adelfalk, C; Wittig, R; Poustka, A; Hirsch-Kauffmann, M; Schweiger, M				Kontou, M; Will, RD; Adelfalk, C; Wittig, R; Poustka, A; Hirsch-Kauffmann, M; Schweiger, M			Thioredoxin, a regulator of gene expression	ONCOGENE			English	Article						Fanconi anemia; GAPDH; redox potential; thioredoxin	NF-KAPPA-B; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; CHROMOSOMAL INSTABILITY; BIOLOGICAL-ACTIVITIES; CEREBELLAR NEURONS; REDOX REGULATION; REDUCTASE; CELLS; PHOSPHORYLATION; ACTIVATION	Cancer cells have high levels of thioredoxin ( Trx) and of glyceraldehyde 3- phosphate dehydrogenase ( GAPDH). Cells from patients with the cancer- prone disease Fanconi anemia ( FA) exhibit reduced Trx levels. We found the activity of GAPDH to correlate directly with the endogenous Trx content and mRNA transcripts for GAPDH and TRx reduced in FA cells. The treatment of cells with reduced human Trx stimulated the synthesis of GAPDH mRNA. Similarly, the transfection of cells with an expression plasmid for Trx increased GAPDH mRNA synthesis. Trx treatment of cells and subsequent analysis of the differential gene expression by human cDNA arrays containing about 50 000 different PCR products resulted in more than 300 up- or downregulated genes. Two representative genes, GAPDH and IkappaBalpha/ MAD- 3, were further investigated to confirm their stimulation by Trx. Trx besides being the major carrier of redox potential of cells is also a regulator of gene expression on the transcriptional level. By regulation via Trx, cells are able to adapt to the prevailing redox conditions. These findings also enlighten the pathophysiology of FA in the respect that the characteristic diminution of Trx that results in the dysregulation of gene expression is a basis for the major symptoms of this disease.	Free Univ Berlin, Inst Biochem, D-14195 Berlin, Germany; Deutsch Krebsforschungszentrum, Dept Mol Genome Anal, D-69120 Heidelberg, Germany	Free University of Berlin; Helmholtz Association; German Cancer Research Center (DKFZ)	Schweiger, M (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.	schweigm@molgen.mpg.de	Wittig, Rainer/AAT-5361-2021	Wittig, Rainer/0000-0002-3735-9370; Will, Rainer/0000-0001-6049-2690				Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; ASHMARINA LI, 1988, FEBS LETT, V231, P413, DOI 10.1016/0014-5793(88)80861-5; BAXI MD, 1995, J PHARMACOL TOX MET, V33, P121, DOI 10.1016/1056-8719(94)00127-P; Bertini R, 1999, J EXP MED, V189, P1783, DOI 10.1084/jem.189.11.1783; Boer JM, 2001, GENOME RES, V11, P1861, DOI 10.1101/gr.184501; BROT N, 1991, BIOFACTORS, V3, P91; DALTON TP, 1999, ANN REV PHARM TOXICO, V93, P67; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Dastoor Z, 2001, J CELL SCI, V114, P1643; DURRIEU C, 1987, ARCH BIOCHEM BIOPHYS, V252, P32, DOI 10.1016/0003-9861(87)90005-1; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUBER HE, 1987, J BIOL CHEM, V262, P16224; Ishitani R, 1996, J NEUROCHEM, V66, P928; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; Kerblat I, 1999, IMMUNOLOGY, V97, P62; Kontou M, 2003, BIOL CHEM, V384, P1501, DOI 10.1515/BC.2003.166; Kontou M, 2002, ONCOGENE, V21, P2406, DOI 10.1038/sj.onc.1205299; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Messmer UK, 1996, EUR J PHARMACOL, V302, P171, DOI 10.1016/0014-2999(96)00055-6; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MURONETZ VI, 1994, ARCH BIOCHEM BIOPHYS, V313, P253, DOI 10.1006/abbi.1994.1385; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Nakamura H, 1996, INT IMMUNOL, V8, P603, DOI 10.1093/intimm/8.4.603; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Pekkari K, 2000, J BIOL CHEM, V275, P37474, DOI 10.1074/jbc.M001012200; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; Powis G, 2001, ANNU REV PHARMACOL, V41, P261, DOI 10.1146/annurev.pharmtox.41.1.261; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Ramirez MH, 1999, BIOCHEM BIOPH RES CO, V264, P518, DOI 10.1006/bbrc.1999.1482; Reiss N, 1996, BIOCHEM MOL BIOL INT, V40, P1191; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P1181; SCHULTZ DE, 1996, J BIOL CHEM, V270, P2755; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SILBERSTEIN DS, 1993, J BIOL CHEM, V268, P9138; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Sumida Y, 2000, J HEPATOL, V33, P616, DOI 10.1034/j.1600-0641.2000.033004616.x; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Warburg O, 1943, BIOCHEM Z, V314, P399; WILLINGALETHEUNE J, 1989, J CELL SCI, V93, P651; Wittig R, 2002, CANCER RES, V62, P6698	45	14	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2146	2152		10.1038/sj.onc.1207334	http://dx.doi.org/10.1038/sj.onc.1207334			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14730345				2022-12-28	WOS:000220280900004
J	Sato, N; Fukushima, N; Matsubayashi, H; Goggins, M				Sato, N; Fukushima, N; Matsubayashi, H; Goggins, M			Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling	ONCOGENE			English	Article						hypomethylation; maspin; SERPINB5; S100P; microarray	TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; DNA METHYLATION; ABERRANT METHYLATION; CPG-ISLANDS; EPITHELIAL-CELLS; MULTIPLE GENES; DUCTAL ADENOCARCINOMA; PLASMINOGEN-ACTIVATOR; OVARIAN-CARCINOMA	DNA hypomethylation is one of the major epigenetic alterations in human cancers. We have previously shown that genes identified as hypomethylated in pancreatic cancer are expressed in pancreatic cancer cell lines, but not in normal pancreatic ductal epithelium and can be reexpressed in nonexpressing cells using 'epigenetic modifying agents' such as DNA methyltransferase inhibitors. To identify additional targets for aberrant hypomethylation in pancreatic cancer, we used oligonucleotide microarrays to screen for genes that displayed expression patterns associated with hypomethylation. This analysis identified a substantial number of candidates including previously reported hypomethylated genes. A subset of eight genes were selected for further methylation analysis, and two cancer-related genes, maspin and S100P, were found to be aberrantly hypomethylated in a large fraction of pancreatic cancer cell lines and primary pancreatic carcinomas. Combined treatment with 5-aza-2'-deoxycytidie and trichostatin A resulted in synergistic induction of maspin and S100P mRNA in MiaPaCa2 cells where both genes were methylated. Furthermore, there was an inverse correlation between methylation and mRNA expression level for maspin and S100P in a large panel of pancreatic cancer cell lines. We also found a significant difference in the methylation patterns of maspin and two previously identified hypomethylated genes (trefoil factor 2 and lipocalin 2) between pancreatic and breast cancer cell lines, suggesting cancer-type specificity for some hypomethylation patterns. Thus, our present results confirm that DNA hypomethylation is a frequent epigenetic event in pancreatic cancer, and suggest that gene expression pro. ling may help to identify potential targets affected by this epigenetic alteration.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA090709, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924, CA90709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goggins M, 1999, ANN ONCOL, V10, P4, DOI 10.1023/A:1008307913019; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Gupta A, 2003, CANCER RES, V63, P664; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.E02-09-0553; Liang G, 2002, CANCER RES, V62, P961; Logsdon CD, 2003, CANCER RES, V63, P2649; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maass N, 2001, CLIN CANCER RES, V7, P812; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; Mousses S, 2002, CANCER RES, V62, P1256; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Ryu B, 2002, CANCER RES, V62, P819; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	52	124	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1531	1538		10.1038/sj.onc.1207269	http://dx.doi.org/10.1038/sj.onc.1207269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716296				2022-12-28	WOS:000189219500006
J	Woo, CW; Lucarelli, E; Thiele, CJ				Woo, CW; Lucarelli, E; Thiele, CJ			NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number	ONCOGENE			English	Article						NGF; TrkA; N-myc; MAPK; neuroblastoma; cell cycle; p27; E2F	NERVE GROWTH-FACTOR; RETINOIC ACID; FACTOR RECEPTOR; NEURONAL DIFFERENTIATION; CYCLE ARREST; PC12 CELLS; FACTOR I; INDUCTION; PROTEINS; RAP1	In neuroblastoma (NB), expression of the TrkA receptor is correlated with good prognosis while N-myc amplification is correlated with poor prognosis. Decreased N-myc levels are key to controlling growth and inducing differentiation in NB cells. In this report, we detail mechanisms by which nerve growth factor (NGF) decreases N-myc levels in TrkA-transfected NB cells and its effect on NB cell proliferation. NGF induced a decrease in N-myc mRNA within 1 h of treatment that occurred in the presence of cycloheximide. The stability of N-myc mRNA was not affected by NGF, indicating a transcriptional control of N-myc mRNA by NGF. NGF but not brain-derived neurotrophic factor (BDNF) decreased N-myc levels demonstrating that p75 alone was not involved. The NGF-induced decrease in N-myc expression was blocked by the Trk tyrosine kinase (TK) antagonist K252a indicating that signals transduced by Trk TK downstream targets were involved. Pharmacologic inhibitors implicated the mitogen-activated protein kinase (MAPK) path. This was supported by the finding that expression of a constitutively activated component of the MAPK path, MAPK kinase (MEK), decreased N-myc levels. Alterations in the level of N-myc are known to alter NB cell cycle progression by affecting the levels of E2Fs and p27(kip1). Consistent with these findings, NGF decreased NB cell number and decreased cyclin E-dependent kinase activity via an increase in p27(kip1). Thus, our results indicate that the MAP kinase is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism. Furthermore, NGF affects the time required for 15N TrkA cells to complete a replication cycle by decreasing N-myc, E2Fs, cyclin E kinase activity and increasing p27(kip1) binding to cyclin E kinase.	NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thiele, CJ (corresponding author), NCI, Cell & Mol Biol Sect, Pediat Oncol Branch, NIH, Bldg 10 Rm 13N240,10 Ctr MSC-1928, Bethesda, MD 20892 USA.	thielec@mail.nih.gov	Lucarelli, Enrico/AAF-1612-2021; Enrico, Lucarelli/G-3588-2015	Lucarelli, Enrico/0000-0002-6681-6374; Enrico, Lucarelli/0000-0002-6681-6374				Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; Beier R, 2000, EMBO J, V19, P5813, DOI 10.1093/emboj/19.21.5813; Berns K, 2000, ONCOGENE, V19, P4822, DOI 10.1038/sj.onc.1203879; Billon N, 1996, ONCOGENE, V13, P2047; Bogenmann E, 1998, ONCOGENE, V17, P2367, DOI 10.1038/sj.onc.1202160; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; Bulseco DA, 2001, J CELL BIOCHEM, V81, P193, DOI 10.1002/1097-4644(20010401)81:1<193::AID-JCB1035>3.0.CO;2-B; Chambery D, 1999, CANCER RES, V59, P2898; CICCARONE V, 1989, CANCER RES, V49, P219; Dechant G, 2001, CELL TISSUE RES, V305, P229, DOI 10.1007/s004410100378; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Fan LJ, 2001, CANCER RES, V61, P1073; HARTMAN DS, 1994, J NEUROCHEM, V63, P1261; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; KNUDSON AG, 1980, NEW ENGL J MED, V302, P1254, DOI 10.1056/NEJM198005293022210; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LUCARELLI E, 1995, J BIOL CHEM, V270, P24725, DOI 10.1074/jbc.270.42.24725; Lutz W, 1996, ONCOGENE, V13, P803; MacNicol MC, 1999, J BIOL CHEM, V274, P13193, DOI 10.1074/jbc.274.19.13193; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUMOTO K, 1995, CANCER RES, V55, P1798; Matsuo T, 1998, ONCOGENE, V16, P3337, DOI 10.1038/sj.onc.1201830; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Misawa A, 2003, INT J CANCER, V104, P233, DOI 10.1002/ijc.10914; Misawa A, 2000, CANCER RES, V60, P64; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Nakamura M, 2003, CELL DEATH DIFFER, V10, P230, DOI 10.1038/sj.cdd.4401125; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Persengiev SP, 2001, ONCOGENE, V20, P5124, DOI 10.1038/sj.onc.1204663; POLUHA W, 1995, ONCOGENE, V10, P185; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; Strieder V, 2003, J BIOL CHEM, V278, P2983, DOI 10.1074/jbc.M207596200; Strieder V, 2002, CANCER LETT, V180, P107, DOI 10.1016/S0304-3835(02)00020-4; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; THIELE CJ, 1988, ONCOGENE, V3, P281; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; Veenstra TD, 1997, BIOCHEM BIOPH RES CO, V235, P15, DOI 10.1006/bbrc.1997.6718; WADA RK, 1992, ONCOGENE, V7, P711; Wittrock J, 2002, ANTICANCER RES, V22, P4205; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yang SH, 2002, MOL CELL BIOL, V22, P5036, DOI 10.1128/MCB.22.14.5036-5046.2002; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang XH, 1999, ANTICANCER RES, V19, P1641	59	25	30	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1522	1530		10.1038/sj.onc.1207267	http://dx.doi.org/10.1038/sj.onc.1207267			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14691455				2022-12-28	WOS:000189219500005
J	Machwe, A; Xiao, LR; Orren, DK				Machwe, A; Xiao, LR; Orren, DK			TRF2 recruits the Werner syndrome (WRN) exonuclease for processing of telomeric DNA	ONCOGENE			English	Article						telomeres; Werner syndrome; RecQ helicases; cellular senescence; aging; cancer	SYNDROME PROTEIN; MAMMALIAN TELOMERES; SYNDROME CELLS; IN-VITRO; REPLICATION; BINDING; LENGTH; CANCER; MAINTENANCE; HELICASES	The cancer-prone and premature aging disease Werner syndrome is due to loss of WRN gene function. Cells lacking WRN demonstrate genomic instability, including telomeric abnormalities and undergo premature senescence, suggesting defects in telomere metabolism. This notion is strongly supported by our finding of physical and functional interactions between WRN and TRF2, a telomeric repeat binding factor essential for proper telomeric structure. TRF2 binds to DNA substrates containing telomeric repeats and facilitates their degradation specifically by WRN exonuclease activity. WRN and TRF2 also interact directly in the absence of DNA. These results suggest that TRF2 recruits WRN for accurate processing of telomeric structures in vivo. Thus, our findings link problems in telomere maintenance to both carcinogenesis and specific features of aging.	Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA	University of Kentucky	Orren, DK (corresponding author), Univ Kentucky, Grad Ctr Toxicol, 326 HSRB,800 Rose St, Lexington, KY 40536 USA.	dkorre2@pop.uky.edu						Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Bianchi A, 1999, EMBO J, V18, P5735, DOI 10.1093/emboj/18.20.5735; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; de Lange T, 2002, ONCOGENE, V21, P532, DOI 10.1038/sj.onc.1205080; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kim S, 2002, ONCOGENE, V21, P503, DOI 10.1038/sj.onc.1205077; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lundblad V, 2002, ONCOGENE, V21, P522, DOI 10.1038/sj.onc.1205079; Machwe A, 2002, J BIOL CHEM, V277, P4492, DOI 10.1074/jbc.M108880200; MARTIN GM, 1970, LAB INVEST, V23, P86; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Orren DK, 2002, BIOCHEMISTRY-US, V41, P13483, DOI 10.1021/bi0266986; Oshima J, 2000, BIOESSAYS, V22, P894, DOI 10.1002/1521-1878(200010)22:10<894::AID-BIES4>3.0.CO;2-B; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Schulz VP, 1996, HUM GENET, V97, P750; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Stansel RM, 2001, EMBO J, V20, P5532; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630	32	97	99	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					149	156		10.1038/sj.onc.1206906	http://dx.doi.org/10.1038/sj.onc.1206906			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712220				2022-12-28	WOS:000187895300016
J	Eberle, J; Fecker, LF; Hossini, AM; Wieder, T; Daniel, PT; Orfanos, CE; Geilen, CC				Eberle, J; Fecker, LF; Hossini, AM; Wieder, T; Daniel, PT; Orfanos, CE; Geilen, CC			CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants	ONCOGENE			English	Article						CD95L/FasL; melanoma; transfection; apoptosis	CERAMIDE-MEDIATED APOPTOSIS; DRUG-INDUCED APOPTOSIS; FAS-LIGAND; SURFACE-ANTIGENS; TUMOR-REGRESSION; MONOCLONAL-ANTIBODY; DEATH RECEPTORS; GENE-EXPRESSION; CANCER CELLS; IN-VIVO	The significance of CD95/Fas ligand expression by melanoma cells has remained a controversial matter in recent years. On the other hand, CD95 activation may represent a powerful tool for eliminating tumor cells. Here, we demonstrate expression of CD95 in 15/17 human melanoma cell lines analysed, but complete lack of CD95 ligand (CD95L). Overexpression of CD95 in a tetracycline-inducible expression system enhanced melanoma cell sensitivity to CD95 ligation but was unable to trigger apoptosis by itself. In clear contrast, all melanoma cells tested responded with increased apoptosis to conditional expression of CD95L (2-10-fold), both after transient and after stable transfection. Activation of caspase-8, Bid cleavage, cytochrome c release and caspase-3 activation followed after CD95L induction indicating a functional CD95-signaling cascade. CD95L was also able to enhance the proapoptotic effect of chemotherapeutics applied in parallel. Nude mouse experiments revealed that tumorigenicity was lost when melanoma xenografts were triggered to express CD95L. In addition, further progression of pre-existing melanomas was inhibited and even regression was seen after induction of CD95L expression. Due to these data, transfection of CD95L proofs as a highly efficient tool against melanoma cells in vitro and in vivo, and targeted expression of CD95L may thus represent a suitable strategy for melanoma therapy.	Charite Univ Med Berlin, Dept Dermatol, D-14195 Berlin, Germany; Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Eberle, J (corresponding author), Charite Univ Med Berlin, Dept Dermatol, Campus Benjamin Franklin,Fabeckstr 60-62, D-14195 Berlin, Germany.			Eberle, Jurgen/0000-0001-8533-1519				Ambar BB, 1999, HUM GENE THER, V10, P1641, DOI 10.1089/10430349950017644; Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624; Aragane Y, 2000, J INVEST DERMATOL, V115, P1008, DOI 10.1046/j.1523-1747.2000.00164.x; Arai H, 1997, P NATL ACAD SCI USA, V94, P13862, DOI 10.1073/pnas.94.25.13862; BEAN MA, 1975, CANCER RES, V35, P2902; Behrens CK, 2001, J IMMUNOL, V166, P3240, DOI 10.4049/jimmunol.166.5.3240; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; BRUGGEN J, 1981, CANCER IMMUNOL IMMUN, V10, P121; Bullani RR, 2002, MELANOMA RES, V12, P263, DOI 10.1097/00008390-200206000-00010; CAREY TE, 1976, P NATL ACAD SCI USA, V73, P3278, DOI 10.1073/pnas.73.9.3278; Chappell DB, 1999, CANCER RES, V59, P59; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONEY LR, 1994, INT J CANCER, V58, P562, DOI 10.1002/ijc.2910580419; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; DHEIN J, 1992, J IMMUNOL, V149, P3166; EBERLE J, 1995, ARCH DERMATOL RES, V287, P421, DOI 10.1007/BF00373422; Eberle J, 2002, BRIT J CANCER, V86, P1957, DOI 10.1038/sj.bjc.6600351; EISINGER M, 1982, P NATL ACAD SCI-BIOL, V79, P2018, DOI 10.1073/pnas.79.6.2018; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Hedlund TE, 1999, CELL DEATH DIFFER, V6, P175, DOI 10.1038/sj.cdd.4400477; Helmbach H, 2001, INT J CANCER, V93, P617, DOI 10.1002/ijc.1378; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LOCKSHIN A, 1985, CANCER RES, V45, P345; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MARIANI SM, 1995, EUR J IMMUNOL, V25, P2303, DOI 10.1002/eji.1830250828; Muschen M, 2000, J MOL MED-JMM, V78, P312, DOI 10.1007/s001090000112; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Okamoto S, 1999, J SURG RES, V84, P77, DOI 10.1006/jsre.1999.5613; Park BJ, 1999, HUM GENE THER, V10, P889, DOI 10.1089/10430349950018292; Pruschy M, 2001, INT J RADIAT ONCOL, V49, P561, DOI 10.1016/S0360-3016(00)01480-2; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Redondo P, 2002, BRIT J DERMATOL, V147, P80, DOI 10.1046/j.1365-2133.2002.04745.x; Seino KI, 1997, NAT MED, V3, P165, DOI 10.1038/nm0297-165; Shinoura N, 2000, CANCER GENE THER, V7, P732, DOI 10.1038/sj.cgt.7700160; Sieg S, 1999, CELL IMMUNOL, V195, P89, DOI 10.1006/cimm.1999.1530; Strater J, 2001, CELL DEATH DIFFER, V8, P273, DOI 10.1038/sj.cdd.4400813; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Timmer T, 2002, J PATHOL, V196, P125, DOI 10.1002/path.1028; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378	54	55	58	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9131	9141		10.1038/sj.onc.1207228	http://dx.doi.org/10.1038/sj.onc.1207228			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668794				2022-12-28	WOS:000187149100003
J	Prokop, A; Wrasidlo, W; Lode, H; Herold, R; Lang, F; Henze, G; Dorken, B; Wieder, T; Daniel, PT				Prokop, A; Wrasidlo, W; Lode, H; Herold, R; Lang, F; Henze, G; Dorken, B; Wieder, T; Daniel, PT			Induction of apoptosis by enediyne antibiotic calicheamicin theta II proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner	ONCOGENE			English	Article						calicheamicin; apoptosis; caspase-3; Bax; Bcl-2; cytochrome c; mitochondria; BJAB; Jurkat; HCT116	DRUG-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; CYTOCHROME-C RELEASE; SQUAMOUS-CELL CARCINOMA; HUMAN-MELANOMA CELLS; GEMTUZUMAB OZOGAMICIN; DEATH RECEPTOR; IDENTIFIES PATIENTS; OCCURS DOWNSTREAM; BAX/BCL-2 RATIO	Calicheamicin thetaII is a member of the enediyne class of antitumor antibiotics that bind to DNA and induce apoptosis. These compounds differ, however, from conventional anticancer drugs as they bind in a sequence-specific manner noncovalently to DNA and cause sequence-selective oxidation of deoxyriboses and bending of the DNA helix. Calicheamicin is clinically employed as immunoconjugate to antibodies directed against, for example, CD33 in the case of gemtuzumab ozogamicin. Here, we show by the use of the unconjugated drug that calicheamicin-induced apoptosis is independent from death-receptor/FADD-mediated signals. Moreover, calicheamicin triggers apoptosis in a p53-independent manner as shown by the use of p53 knockout cells. Cell death proceeds via activation of mitochondrial permeability transition, cytochrome c release and activation of caspase-9 and -3. The overexpression of Bcl-x(L) or Bcl-2 strongly inhibited calicheamicin-induced apoptosis. Knockout of Bax abrogated cell death after calicheamicin treatment. Thus, the activation of mitochondria and execution of cell death occur through a fully Bax-dependent mechanism. Interestingly, caspase inhibition by the pancaspase-inhibitor zVAD-fmk interfered with mitochondrial activation by calicheamicin. This places caspase activation upstream of the mitochondria and indicates that calicheamicin-triggered apoptosis is enhanced through death receptor-independent activation of the caspase cascade, that is, an amplification loop that is required for full activation of the mitochondrial pathway.	Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Humboldt Univ, Univ Med Ctr Charite, Dept Gen pediat, D-13353 Berlin, Germany; Humboldt Univ, Univ Med Ctr Charite, Dept Pediat Oncol Hematol, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Daniel, PT (corresponding author), Humboldt Univ, Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch, D-13125 Berlin, Germany.			Herold, Ralf/0000-0002-8148-6748				Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bosanquet AG, 2002, LEUKEMIA, V16, P1035, DOI 10.1038/sj.leu.2402539; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Cortazzo M, 1996, CANCER RES, V56, P1199; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; DANIEL PT, 2003, IN PRESS ESSAYS BIOC, V39; de Vetten MP, 2000, BRIT J HAEMATOL, V111, P277, DOI 10.1046/j.1365-2141.2000.02402.x; DHEIN J, 1992, J IMMUNOL, V149, P3166; Distelhorst CW, 2002, CELL DEATH DIFFER, V9, P6, DOI 10.1038/sj.cdd.4400969; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Guner D, 2003, INT J CANCER, V103, P445, DOI 10.1002/ijc.10850; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hiatt A, 1994, Bioorg Med Chem, V2, P315, DOI 10.1016/S0968-0896(00)82187-2; Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Linenberger ML, 2001, BLOOD, V98, P988, DOI 10.1182/blood.V98.4.988; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAIESE WM, 1989, J ANTIBIOT, V42, P558, DOI 10.7164/antibiotics.42.558; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Mrozek A, 2003, CELL DEATH DIFFER, V10, P461, DOI 10.1038/sj.cdd.4401193; Nabhan C, 2002, CLIN LYMPHOMA, V2, pS19, DOI 10.3816/CLM.2002.s.004; Nicolaou KC, 1994, CHEM BIOL, V1, P57, DOI 10.1016/1074-5521(94)90041-8; NICOLAOU KC, 1994, ANGEW CHEM INT EDIT, V33, P183, DOI 10.1002/anie.199401831; NICOLAOU KC, 1993, P NATL ACAD SCI USA, V90, P3142, DOI 10.1073/pnas.90.8.3142; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Radetzki S, 2002, ONCOGENE, V21, P227, DOI 10.1038/sj/onc/1205010; Raisova M, 2000, FEBS LETT, V473, P27, DOI 10.1016/S0014-5793(00)01491-5; Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Roucou X, 2001, CELL DEATH DIFFER, V8, P875, DOI 10.1038/sj.cdd.4400910; Rudner J, 2002, APOPTOSIS, V7, P441, DOI 10.1023/A:1020087108926; Rudner J, 2001, J CELL SCI, V114, P4161; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Salzberg AA, 2000, BIOCHEMISTRY-US, V39, P7605, DOI 10.1021/bi992227g; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schor NF, 1999, BRAIN RES, V831, P125, DOI 10.1016/S0006-8993(99)01414-6; Sievers EL, 1999, BLOOD, V93, P3678, DOI 10.1182/blood.V93.11.3678; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; Sturm I, 2003, CELL DEATH DIFFER, V10, P477, DOI 10.1038/sj.cdd.4401194; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Thorson JS, 2000, CURR PHARM DESIGN, V6, P1841, DOI 10.2174/1381612003398564; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; van der Velden VHJ, 2001, BLOOD, V97, P3197, DOI 10.1182/blood.V97.10.3197; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wieder T, 1998, J BIOL CHEM, V273, P11025, DOI 10.1074/jbc.273.18.11025; Wieder T, 1997, FEBS LETT, V411, P260, DOI 10.1016/S0014-5793(97)00717-5; Wieder T, 2001, LEUKEMIA, V15, P1735, DOI 10.1038/sj.leu.2402284; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	71	47	51	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9107	9120		10.1038/sj.onc.1207196	http://dx.doi.org/10.1038/sj.onc.1207196			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14647446				2022-12-28	WOS:000187149100001
J	Ueda, J; Kajita, M; Suenaga, N; Fujii, K; Seiki, M				Ueda, J; Kajita, M; Suenaga, N; Fujii, K; Seiki, M			Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors	ONCOGENE			English	Article						MT1-MMP; MMP-2; CD44; tumor invasion	MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; CD44 CLEAVAGE; SURFACE; CANCER; ACTIVATION; PROGELATINASE; METASTASIS; CARCINOMA; ADHESION	Membrane-type 1 matrix metalloproteinase (MT1-MMP/MMP-14) has been believed a key enzyme in tumor invasion, because it is expressed in a variety of malignant human tumors, and overexpression of the enzyme enhances the ability of cellular invasiveness. However, it has not necessarily been clarified whether the endogenously expressed MT1-MMP in human tumors plays a critical role in their invasiveness. We used RNA silencing technology to downregulate the endogenous MT1-MMP expression in human tumor cells (fibrosarcoma HT1080 and gastric carcinoma MKN-28 cell lines), and evaluated the effect on the invasion of a reconstituted basement membrane (Matrigel). Transfection of a double-stranded RNA targeted to the MT1-MMP gene decreased the level of the enzyme to less than 10-20% without affecting production of other MMPs. According to the degree of silencing, activation of proMMP-2 was inhibited. CD44 shedding was also inhibited, but only in part. Decreased MT1-MMP levels were also reflected in reduced cell motility on hyaluronan (HA) and invasion in Matrigel. Thus, specific downregulation of MT1-MMP expression was sufficient to cause significant inhibition of the migration and invasion of tumor cells, even though other MMPs continued to be expressed.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Jikei Univ, Sch Med, Dept Orthopaed Surg, Minato Ku, Tokyo, Japan	University of Tokyo; Jikei University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Seiki, Motoharu/K-9443-2015					Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Goebeler M, 1996, J CELL SCI, V109, P1957; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; McCarthy M, 2001, J RENAL NUTR, V11, P115; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NAOT D, 1997, ADV CANCER RES, V71, P241; NOMURA H, 1995, CANCER RES, V55, P3263; Okada Y, 2000, VERH DEUT G, V84, P33; Okamoto I, 1999, J BIOL CHEM, V274, P25525, DOI 10.1074/jbc.274.36.25525; Okamoto I, 2002, AM J PATHOL, V160, P441, DOI 10.1016/S0002-9440(10)64863-8; Okamoto I, 1999, ONCOGENE, V18, P1435, DOI 10.1038/sj.onc.1202447; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato T, 1997, J CELL SCI, V110, P589; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; Sneath RJS, 1998, J CLIN PATHOL-MOL PA, V51, P191, DOI 10.1136/mp.51.4.191; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	36	116	121	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8716	8722		10.1038/sj.onc.1206962	http://dx.doi.org/10.1038/sj.onc.1206962			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647466				2022-12-28	WOS:000186844900009
J	Barnhart, BC; Lee, JC; Alappat, EC; Peter, ME				Barnhart, BC; Lee, JC; Alappat, EC; Peter, ME			The death effector domain protein family	ONCOGENE			English	Review						apoptosis; DD fold; cancer	TRAIL-INDUCED APOPTOSIS; NF-KAPPA-B; FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; INDUCED CELL-DEATH; REGULATES FAS/TNFR1-INDUCED APOPTOSIS; CHRONIC LYMPHOCYTIC-LEUKEMIA; DOMINANT INTERFERING MUTANT; NECROSIS-FACTOR RECEPTOR-1; INDUCED-PROXIMITY MODEL	Apoptosis signaling is regulated and executed by specialized proteins that often carry protein/protein interaction domains. One of these domains is the death effector domain (DED) that is predominantly found in components of the death-inducing signaling complex, which forms at the members of the death receptor family following their ligation. Both proapoptotic- and antiapoptotic-DED-containing proteins have been identified, which makes these proteins exquisitely suited to the regulation of apoptosis. Aside from their pivotal role in the control of the apoptotic program, DED-containing proteins have recently been demonstrated to exert their influence on other cellular processes as well, including cell proliferation. These data highlight the multiple roles for the members of this family, suggesting that they are suited to control both life and death decisions of cells. Additionally, because they can act proapoptotically, antiapoptotically, or in the regulation of the cell cycle, this family of proteins may be excellent candidates for cancer therapy targets.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago	Peter, ME (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	MPeter@uchicago.edu		Peter, Marcus Ernst/0000-0003-3216-036X; Lee, Justine C./0000-0002-8943-0837				Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Alcivar A, 2003, ONCOGENE, V22, P291, DOI 10.1038/sj.onc.1206099; Algeciras-Schimnich A, 1999, J IMMUNOL, V162, P5205; ALGECIRASSCHIMN.A, 2003, IN PRESS P NATL SCI; ALGECIRASSCHIMN.A, 2002, CASPASES LANDES BIOS, P123; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Barnhart BC, 2003, SEMIN IMMUNOL, V15, P185, DOI 10.1016/S1044-5323(03)00031-9; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang DW, 2003, EMBO J, V22, P4132, DOI 10.1093/emboj/cdg414; Chatterjee D, 2001, CANCER RES, V61, P7148; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi YH, 2001, J BIOL CHEM, V276, P25073, DOI 10.1074/jbc.M102941200; Chun HJ, 2002, NATURE, V419, P395, DOI 10.1038/nature01063; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; Condorelli G, 1999, ONCOGENE, V18, P4409, DOI 10.1038/sj.onc.1202831; Condorelli G, 2002, J BIOL CHEM, V277, P11013, DOI 10.1074/jbc.M110934200; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; Derfuss T, 2002, CURR TOP MICROBIOL, V269, P257; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Dong G, 2001, CANCER RES, V61, P4797; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Eggert A, 2000, MED PEDIATR ONCOL, V35, P603, DOI 10.1002/1096-911X(20001201)35:6<603::AID-MPO24>3.0.CO;2-1; Eggert A, 2001, CANCER RES, V61, P1314; Estelles A, 1999, DEV BIOL, V216, P16, DOI 10.1006/dbio.1999.9510; Fairbrother WJ, 2001, PROTEIN SCI, V10, P1911, DOI 10.1110/ps.13801; Fan LF, 1999, HUM GENE THER, V10, P2273, DOI 10.1089/10430349950016924; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750; Fulda S, 2000, CANCER RES, V60, P3947; Gervais FG, 2002, NAT CELL BIOL, V4, P95, DOI 10.1038/ncb735; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Griffith TS, 1998, J IMMUNOL, V161, P2833; Hackam AS, 2000, J BIOL CHEM, V275, P41299, DOI 10.1074/jbc.M008408200; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao CH, 2001, CANCER RES, V61, P1162; Harada K, 2002, CANCER RES, V62, P5897; Held J, 2001, DRUG RESIST UPDATE, V4, P243, DOI 10.1054/drup.2001.0208; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Hill JM, 2002, EMBO J, V21, P6494, DOI 10.1093/emboj/cdf641; Horrevoets AJG, 1999, BLOOD, V93, P3418, DOI 10.1182/blood.V93.10.3418.410k23_3418_3431; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hua ZC, 2003, IMMUNITY, V18, P513, DOI 10.1016/S1074-7613(03)00083-9; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Hueber AO, 2000, J BIOL CHEM, V275, P10453, DOI 10.1074/jbc.275.14.10453; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irisarri M, 2000, LEUKEMIA, V14, P2149, DOI 10.1038/sj.leu.2401954; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kaufmann M, 2002, FEBS LETT, V527, P250, DOI 10.1016/S0014-5793(02)03146-0; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kelly MM, 2002, CANCER BIOL THER, V1, P520, DOI 10.4161/cbt.1.5.169; Kim PKM, 2001, DRUG RESIST UPDATE, V4, P293, DOI 10.1054/drup.2001.0223; Kim PKM, 1996, J IMMUNOL, V157, P5461; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Kitsberg D, 1999, J NEUROSCI, V19, P8244; Koga S, 2001, ANTICANCER RES, V21, P1937; Komata T, 2001, INT J ONCOL, V19, P1015; Kondo S, 1998, HUM GENE THER, V9, P1599, DOI 10.1089/hum.1998.9.11-1599; Koonin EV, 1999, NATURE, V401, P662, DOI 10.1038/44317; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kubes M, 1998, J NEUROCHEM, V71, P1307; Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973; Lee JC, 2002, J CELL BIOL, V158, P1051, DOI 10.1083/jcb.200112124; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Leo CP, 1998, ENDOCRINOLOGY, V139, P4839, DOI 10.1210/en.139.12.4839; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu BL, 2002, J BIOL CHEM, V277, P30159, DOI 10.1074/jbc.M203566200; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 2002, ONCOGENE, V21, P6809, DOI 10.1038/sj.onc.1205853; Mandruzzato S, 1997, J EXP MED, V186, P785, DOI 10.1084/jem.186.5.785; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Ng PWP, 1999, J BIOL CHEM, V274, P10301, DOI 10.1074/jbc.274.15.10301; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Petak Istvan, 2001, Pathology and Oncology Research, V7, P95; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ramos JW, 2000, MOL BIOL CELL, V11, P2863, DOI 10.1091/mbc.11.9.2863; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Roth W, 2002, J BIOL CHEM, V277, P7501, DOI 10.1074/jbc.M110749200; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 2000, J IMMUNOL, V164, P1236, DOI 10.4049/jimmunol.164.3.1236; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schickling O, 2001, CELL DEATH DIFFER, V8, P1157, DOI 10.1038/sj.cdd.4400928; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Shin MS, 2002, ONCOGENE, V21, P4129, DOI 10.1038/sj.onc.1205527; Shivapurkar N, 2002, ONCOGENE, V21, P8510, DOI 10.1038/sj.onc.1205941; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Siegmund D, 2002, MOL MED, V8, P725, DOI 10.1007/BF03402036; Sprick MR, 2002, EMBO J, V21, P4520, DOI 10.1093/emboj/cdf441; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; Stegh AH, 2002, J BIOL CHEM, V277, P4351, DOI 10.1074/jbc.M108947200; Stegh Alexander H., 2001, Cardiology Clinics, V19, P13, DOI 10.1016/S0733-8651(05)70192-2; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Teitz T, 2001, J MOL MED, V79, P428, DOI 10.1007/s001090100233; Telliez JB, 2000, J MOL BIOL, V300, P1323, DOI 10.1006/jmbi.2000.3899; Thomas LR, 2002, J BIOL CHEM, V277, P34343, DOI 10.1074/jbc.M204169200; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Tschopp J, 1998, CURR OPIN GENET DEV, V8, P82, DOI 10.1016/S0959-437X(98)80066-X; Tsukamoto T, 2000, CANCER LETT, V149, P105, DOI 10.1016/S0304-3835(99)00350-X; Uzzo RG, 2001, CLIN CANCER RES, V7, P3276; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaughn DE, 1999, J MOL BIOL, V293, P439, DOI 10.1006/jmbi.1999.3177; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Walsh CM, 1998, IMMUNITY, V8, P439, DOI 10.1016/S1074-7613(00)80549-X; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wang L, 2001, P NATL ACAD SCI USA, V98, P13884, DOI 10.1073/pnas.241358198; Xiao C, 2002, J BIOL CHEM, V277, P25020, DOI 10.1074/jbc.M202946200; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zhan Y, 2002, CELL DEATH DIFFER, V9, P439, DOI 10.1038/sj.cdd.4401038; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhang J, 2001, J BIOL CHEM, V276, P29815, DOI 10.1074/jbc.M103838200; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zhang Y, 2000, J BIOL CHEM, V275, P35224, DOI 10.1074/jbc.M003329200; Zheng LX, 2001, J BIOL CHEM, V276, P31945, DOI 10.1074/jbc.M102799200; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zuzak TJ, 2002, EUR J CANCER, V38, P83, DOI 10.1016/S0959-8049(01)00355-0	163	82	85	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8634	8644		10.1038/sj.onc.1207103	http://dx.doi.org/10.1038/sj.onc.1207103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634625				2022-12-28	WOS:000186720000009
J	Cory, S; Huang, DCS; Adams, JM				Cory, S; Huang, DCS; Adams, JM			The Bcl-2 family: roles in cell survival and oncogenesis	ONCOGENE			English	Review						apoptosis; caspases; oncogenesis; mouse models; therapeutics	CYTOCHROME-C RELEASE; MITOCHONDRIAL OUTER-MEMBRANE; APOPTOSIS-INDUCING FACTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; SMALL-MOLECULE INHIBITORS; COLORECTAL-CANCER CELLS; MYC-INDUCED APOPTOSIS; NON-HODGKINS-LYMPHOMA; TRANSGENIC MICE; IN-VIVO	Apoptosis, the cell-suicide programme executed by caspases, is critical for maintaining tissue homeostasis, and impaired apoptosis is now recognized to be a key step in tumorigenesis. Whether a cell should live or die is largely determined by the Bcl-2 family of anti- and proapoptotic regulators. These proteins respond to cues from various forms of intracellular stress, such as DNA damage or cytokine deprivation, and interact with opposing family members to determine whether or not the caspase proteolytic cascade should be unleashed. This review summarizes current views of how these proteins sense stress, interact with their relatives, perturb organelles such as the mitochondrion and endoplasmic reticulum and govern pathways to caspase activation. It briefly explores how family members influence cell-cycle entry and outlines the evidence for their involvement in tumour development, both as oncoproteins and tumour suppressors. Finally, it discusses the promise of novel anticancer therapeutics that target these vital regulators.	Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Walter & Eliza Hall Institute	Cory, S (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	cory@wehi.edu.au	Cory, Suzanne/E-1642-2013; Adams, Jerry M/E-1199-2013; Huang, David C. S./C-7586-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA80188, CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540, R01CA080188] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; Adams JM, 2002, CURR OPIN CELL BIOL, V14, P715, DOI 10.1016/S0955-0674(02)00381-2; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ADAMS JM, 2003, IN PRESS GENES DEV; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; ASHKENAZI A, 2003, IN PRESS ONCOGENE; ASKEW DS, 1991, ONCOGENE, V6, P1915; Baell JB, 2002, BIOCHEM PHARMACOL, V64, P851, DOI 10.1016/S0006-2952(02)01148-6; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Banerjee D, 2001, Curr Opin Investig Drugs, V2, P574; Berns A, 2002, CANCER CELL, V1, P309, DOI 10.1016/S1535-6108(02)00063-6; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Borner C, 1996, J BIOL CHEM, V271, P12695, DOI 10.1074/jbc.271.22.12695; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Brown JM, 1999, CANCER RES, V59, P1391; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chattopadhyay A, 2001, ONCOGENE, V20, P4507, DOI 10.1038/sj.onc.1204584; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chin JW, 2001, ANGEW CHEM INT EDIT, V40, P3806, DOI 10.1002/1521-3773(20011015)40:20<3806::AID-ANIE3806>3.0.CO;2-B; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cochran AG, 2001, CURR OPIN CHEM BIOL, V5, P654, DOI 10.1016/S1367-5931(01)00262-9; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cory S, 1999, CANCER RES, V59, p1685S; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; CRESCENZI E, 2003, BIOCH J EPUO; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; del Peso L, 2000, J BIOL CHEM, V275, P27205; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Druker BJ, 2002, CANCER CELL, V1, P31, DOI 10.1016/S1535-6108(02)00025-9; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EGLE A, 2003, IN PRESS BLOOD; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; ELLIS RE, 1991, DEVELOPMENT, V112, P591; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Ernst JT, 2002, ANGEW CHEM INT EDIT, V41, P278, DOI 10.1002/1521-3773(20020118)41:2<278::AID-ANIE278>3.0.CO;2-A; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN G, 2003, IN PRESS ONCOGENE; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fairlie DP, 1998, CURR MED CHEM, V5, P29; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Gibbons DL, 1999, ONCOGENE, V18, P3870, DOI 10.1038/sj.onc.1202721; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Griffiths GJ, 2001, ONCOGENE, V20, P7668, DOI 10.1038/sj.onc.1204995; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Hajduk PJ, 1999, J MED CHEM, V42, P2315, DOI 10.1021/jm9901475; Hajduk PJ, 1997, SCIENCE, V278, P497, DOI 10.1126/science.278.5337.497; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hamasaki A, 1998, J EXP MED, V188, P1985, DOI 10.1084/jem.188.11.1985; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hara H, 2002, J IMMUNOL, V168, P2288, DOI 10.4049/jimmunol.168.5.2288; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; Harris CA, 2001, J BIOL CHEM, V276, P37754; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Hausmann G, 2000, J CELL BIOL, V149, P623, DOI 10.1083/jcb.149.3.623; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hildeman DA, 2002, IMMUNITY, V16, P759, DOI 10.1016/S1074-7613(02)00322-9; Hinds MG, 2003, EMBO J, V22, P1497, DOI 10.1093/emboj/cdg144; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Honarpour N, 2001, NEUROSCIENCE, V106, P263, DOI 10.1016/S0306-4522(01)00275-5; Horvitz HR, 1999, CANCER RES, V59, p1701S; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; Imaizumi K, 1999, J BIOL CHEM, V274, P7975, DOI 10.1074/jbc.274.12.7975; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JANIAK F, 1994, J BIOL CHEM, V269, P9842; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; JI WZ, 1995, CANCER RES, V55, P2876; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KAMADA S, 1995, CANCER RES, V55, P354; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1969, J PATHOL, V97, P557, DOI 10.1002/path.1710970314; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Knudson CM, 2001, CANCER RES, V61, P659; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Kondo S, 2000, CANCER RES, V60, P4328; Konopleva M, 2000, BLOOD, V95, P3929; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; KUNTZ ID, 1992, SCIENCE, V257, P1078, DOI 10.1126/science.257.5073.1078; Kutzki O, 2002, J AM CHEM SOC, V124, P11838, DOI 10.1021/ja026861k; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIMPENS J, 1995, BLOOD, V85, P2528, DOI 10.1182/blood.V85.9.2528.bloodjournal8592528; Lind EF, 1999, J IMMUNOL, V162, P5374; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LIU X, 2003, IN PRESS IMMUNITY; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; Lockshin RA, 2001, NAT REV MOL CELL BIO, V2, P545, DOI 10.1038/35080097; Lossos IS, 2000, BLOOD, V96, P635; Lugovskoy AA, 2002, J AM CHEM SOC, V124, P1234, DOI 10.1021/ja011239y; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MARVEL J, 1994, ONCOGENE, V9, P1117; Matolcsy A, 1996, BLOOD, V88, P3937, DOI 10.1182/blood.V88.10.3937.bloodjournal88103937; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Mazel S, 1996, J EXP MED, V183, P2219, DOI 10.1084/jem.183.5.2219; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Meehan T, 2001, CELL DEATH DIFFER, V8, P225, DOI 10.1038/sj.cdd.4400799; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nakashima T, 2000, CANCER RES, V60, P1229; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2001, CELL DEATH DIFFER, V8, P486, DOI 10.1038/sj.cdd.4400835; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pavlov EV, 2001, J CELL BIOL, V155, P725, DOI 10.1083/jcb.200107057; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Polster BM, 2001, J BIOL CHEM, V276, P37887; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Quinn L, 2003, EMBO J, V22, P3568, DOI 10.1093/emboj/cdg355; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ranger AM, 2003, P NATL ACAD SCI USA, V100, P9324, DOI 10.1073/pnas.1533446100; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rinkenberger JL, 2000, GENE DEV, V14, P23; Ross AJ, 1998, NAT GENET, V18, P251, DOI 10.1038/ng0398-251; Roucou X, 2002, BIOCHEM J, V368, P915, DOI 10.1042/BJ20020972; Ruffolo SC, 2003, J BIOL CHEM, V278, P25039, DOI 10.1074/jbc.M302930200; Rutledge SE, 2002, CURR OPIN CHEM BIOL, V6, P479, DOI 10.1016/S1367-5931(02)00352-6; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; SANDER CA, 1993, BLOOD, V82, P1994; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schepartz A, 1998, CURR OPIN CHEM BIOL, V2, P9, DOI 10.1016/S1367-5931(98)80029-X; Schimmer AD, 2001, CELL DEATH DIFFER, V8, P725, DOI 10.1038/sj.cdd.4400870; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; SHIBUE T, 2003, GENES DEV; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; SHORE G, 2003, ONCOGENE, V22, P8608; SHUKER SB, 1997, SCIENCE, V275, P983; Simpson NH, 1999, BIOTECHNOL BIOENG, V64, P174, DOI 10.1002/(SICI)1097-0290(19990720)64:2<174::AID-BIT6>3.0.CO;2-D; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TANAKA S, 1992, BLOOD, V79, P229; TASHIRO S, 1992, ONCOGENE, V7, P573; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; VILLUNGER A, 2003, IN PRESS SCIENCE; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; WANG YS, 1993, ONCOGENE, V8, P3427; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; YANO T, 1992, BLOOD, V80, P758; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZELENETZ AD, 1992, J EXP MED, V176, P1137, DOI 10.1084/jem.176.4.1137; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	306	1206	1333	0	108	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8590	8607		10.1038/sj.onc.1207102	http://dx.doi.org/10.1038/sj.onc.1207102			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634621				2022-12-28	WOS:000186720000005
J	Harmes, DC; Bresnick, E; Lubin, EA; Watson, JK; Heim, KE; Curtin, JC; Suskind, AM; Lamb, J; DiRenzo, J				Harmes, DC; Bresnick, E; Lubin, EA; Watson, JK; Heim, KE; Curtin, JC; Suskind, AM; Lamb, J; DiRenzo, J			Positive and negative regulation of Delta N-p63 promoter activity by p53 and Delta N-p63-alpha contributes to differential regulation of p53 target genes	ONCOGENE			English	Article						p53; p63; mammary epithelia; gene regulation	MAMMARY-GLAND; STEM-CELLS; NEOPLASTIC-CELLS; DNA-DAMAGE; P63; P73; EXPRESSION; APOPTOSIS; HOMOLOG; FAMILY	Mammary epithelial regeneration implies the existence of cellular progenitors with retained replicative capacity, prolonged lifespan and developmental potency. Evidence exists that DeltaN-p63 isoforms preserve these features by modulating p53 activity in basal epithelia. DeltaN-p63 mRNA levels decline at the onset of differentiation suggesting that its transcriptional regulation may contribute to the initiation of differentiation. To study transcriptional regulation of DeltaN-p63, a 10.3 kbp fragment containing the DeltaN-p63 promoter was isolated. We report here that DeltaN-p63 is a positive and negative transcriptional target of p53 and DeltaN-p63-alpha, respectively. Disruption of p53 activity or expression abolishes the expression of DeltaN-p63-alpha. This regulation is mediated by a p53-binding element sufficient to confer these activities to a heterologous promoter. Chromatin immune-precipitation indicates that, in asynchronously growing cells, p53 occupies this element. In response to DNA damage, DeltaN-p63-alpha is recruited to this element as transcription of DeltaN-p63 declines. Disruption of DeltaN-p63-alpha expression had differential effects on the transcriptional regulation of several p53-target genes. These findings indicate that p53 contributes to the preservation of basal epithelia by driving the expression of DeltaN-p63 isoforms. These studies also suggest that in response to genotoxic stress, DeltaN-p63-alpha mediates the silencing of its own promoter thereby altering the pattern of p53-target gene expression.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Hanover, NH 03755 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Dartmouth College; Dartmouth College; Dartmouth College; Harvard University; Dana-Farber Cancer Institute	DiRenzo, J (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.			/0000-0002-1702-6085				Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; DiRenzo J, 2002, CANCER RES, V62, P89; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Hall PA, 2000, CARCINOGENESIS, V21, P153, DOI 10.1093/carcin/21.2.153; Hennighausen L, 1998, GENE DEV, V12, P449, DOI 10.1101/gad.12.4.449; Hovey RC, 2002, J MAMMARY GLAND BIOL, V7, P17, DOI 10.1023/A:1015766322258; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Jerry DJ, 1999, J MAMMARY GLAND BIOL, V4, P177, DOI 10.1023/A:1018777224808; Jerry DJ, 2002, J DAIRY SCI, V85, P1103, DOI 10.3168/jds.S0022-0302(02)74171-4; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Li P, 1998, INT J EXP PATHOL, V79, P193, DOI 10.1046/j.1365-2613.1998.00068.x; Liefer KM, 2000, CANCER RES, V60, P4016; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; Masso-Welch PA, 2000, J MAMMARY GLAND BIOL, V5, P165, DOI 10.1023/A:1026491221687; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nylander K, 2002, J PATHOL, V198, P417, DOI 10.1002/path.1231; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; Smith GH, 2001, MICROSC RES TECHNIQ, V52, P190, DOI 10.1002/1097-0029(20010115)52:2<190::AID-JEMT1005>3.0.CO;2-O; Suliman Y, 2001, CANCER RES, V61, P6467; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; van Bokhoven H, 2002, TRENDS MOL MED, V8, P133, DOI 10.1016/S1471-4914(01)02260-2; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	37	70	71	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7607	7616		10.1038/sj.onc.1207129	http://dx.doi.org/10.1038/sj.onc.1207129			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576823				2022-12-28	WOS:000186113000008
J	Chipitsyna, G; Slonina, D; Siddiqui, K; Peruzzi, F; Skorski, T; Reiss, K; Sawaya, BE; Khalili, K; Amini, S				Chipitsyna, G; Slonina, D; Siddiqui, K; Peruzzi, F; Skorski, T; Reiss, K; Sawaya, BE; Khalili, K; Amini, S			HIV-1 Tat increases cell survival in response to cisplatin by stimulating Rad51 gene expression	ONCOGENE			English	Article						HIV-1; Tat; DNA repair	IMMUNODEFICIENCY-VIRUS TYPE-1; TNF-ALPHA; CHECKPOINT ACTIVATION; DNA-REPAIR; PROTEIN; TRANSCRIPTION; REPLICATION; P53; SYSTEM; DAMAGE	Tat is an early regulatory protein of human immunodeficiency virus type 1, which plays a central role in the pathogenesis of AIDS by stimulating transcription of the viral genome and impairing several important cellular pathways during the progression of the disease. Here, we investigated the effect of Tat on cell response to DNA damage. Our results indicate that Tat production causes a noticeable increase in the survival rate of PC12 cells upon their treatment with genotoxic agents. Single-cell gel electrophoresis studies revealed reduced DNA breakage in PC12-Tat cells upon cisplatin treatment relative to the control cells. Furthermore, cytogenetic data exhibited less chromosomal damage in Tat-producing cells after recovery from cisplatin treatment, corroborating electrophoretic data. Examination of several proteins involved in the control of DNA repair showed elevated levels of Rad51, a key regulator of homologous recombination in cells expressing Tat. On the other hand, the level of Ku70, one of the components of the nonhomologous end-joining repair pathway, was slightly decreased in cells expressing Tat. Using a fluorescence-based assay, we demonstrated that repair of DNA double-strand breaks via homologous recombination is increased in Tat-producing cells. The results from in vitro nonhomologous end-joining assay revealed a reduced ability of protein extract from PC12-Tat cells compared to PC12 cells in rejoining linearized DNA. These observations ascribe a new role for Tat in host genomic integrity, perhaps by affecting the expression of genes involved in DNA repair.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA; Coll Sci & Technol, Ctr Biotechnol, Dept Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Amini, S (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,015-96, Philadelphia, PA 19122 USA.	shohreh.amini@temple.edu	Peruzzi, Francesca/M-9804-2014	Slonina, Dorota/0000-0003-1225-2355	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040673] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS040673-02] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aguilera A, 2001, TRENDS GENET, V17, P318, DOI 10.1016/S0168-9525(01)02309-5; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bennasser Y, 2002, VIROLOGY, V303, P174, DOI 10.1006/viro.2002.1676; Berkhout B, 2002, J NEUROVIROL, V8, P134, DOI 10.1080/13550280290101102; Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Chen PQ, 1997, J BIOL CHEM, V272, P22385, DOI 10.1074/jbc.272.36.22385; Clark E, 2000, J VIROL, V74, P5040, DOI 10.1128/JVI.74.11.5040-5052.2000; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; Esposito G, 2002, J BIOL CHEM, V277, P50348, DOI 10.1074/jbc.M207170200; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Gonzalez E, 2001, J IMMUNOL, V166, P4560, DOI 10.4049/jimmunol.166.7.4560; GREEN MHL, 1994, MUTAT RES-DNAGING G, V316, P91, DOI 10.1016/0921-8734(94)90011-6; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kashanchi F, 2000, J VIROL, V74, P652, DOI 10.1128/JVI.74.2.652-660.2000; Kundu M, 1998, J BIOL CHEM, V273, P8130, DOI 10.1074/jbc.273.14.8130; Lambotte O, 2003, BRAIN PATHOL, V13, P95, DOI 10.1111/j.1750-3639.2003.tb00010.x; Lee SH, 2002, MOL CELLS, V13, P159; LI CJ, 1995, P NATL ACAD SCI USA, V92, P5461, DOI 10.1073/pnas.92.12.5461; Liang Chen, 2002, AIDS Reviews, V4, P41; Magnusson KP, 2000, GENE, V246, P247, DOI 10.1016/S0378-1119(00)00068-8; Mahieux R, 2001, J VIROL, V75, P1736, DOI 10.1128/JVI.75.4.1736-1743.2001; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Persaud D, 2003, J VIROL, V77, P1659, DOI 10.1128/JVI.77.3.1659-1665.2003; Peruzzi F, 2002, J NEUROVIROL, V8, P91, DOI 10.1080/13550280290167885; Phimister EG, 2003, NEW ENGL J MED, V348, P643, DOI 10.1056/NEJMcibr035051; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rappaport J, 1999, J LEUKOCYTE BIOL, V65, P458, DOI 10.1002/jlb.65.4.458; RAUTONEN N, 1994, AIDS, V8, P1504, DOI 10.1097/00002030-199410000-00023; Reynolds L, 2003, P NATL ACAD SCI USA, V100, P1615, DOI 10.1073/pnas.252770699; Sawaya BE, 2000, J BIOL CHEM, V275, P35209, DOI 10.1074/jbc.M005197200; Sawaya BE, 1998, J NEUROIMMUNOL, V87, P33, DOI 10.1016/S0165-5728(98)00044-7; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shi B, 1998, J NEUROVIROL, V4, P281, DOI 10.3109/13550289809114529; SINGH NP, 1994, INT J RADIAT BIOL, V66, P23, DOI 10.1080/09553009414550911; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3	38	31	33	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2664	2671		10.1038/sj.onc.1207417	http://dx.doi.org/10.1038/sj.onc.1207417			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755242				2022-12-28	WOS:000220714900008
J	Arrington, AS; Moore, MS; Butel, JS				Arrington, AS; Moore, MS; Butel, JS			SV40-positive brain tumor in scientist with risk of laboratory exposure to the virus	ONCOGENE			English	Article						brain tumor; meningioma; simian virus 40	LARGE T-ANTIGEN; REGULATORY REGION; TRANSGENIC MICE; SV40 GENOMES; SIMIAN-VIRUS-40; ASSOCIATION; MONKEYS; DISEASE; DNA; IDENTIFICATION	Simian virus 40 ( SV40) is a DNA tumor virus known to induce cancers in laboratory animals. There are numerous reports of the detection of SV40 DNA and/ or proteins in human malignancies of the same types as those induced by SV40 in animals, including brain cancers. However, known exposure to the virus has not yet been linked directly to cancer development in a specific individual. Here we describe the detection of SV40 sequences in the meningioma of a laboratory researcher who had a probable direct exposure to SV40 and subsequently developed a tumor positive for viral DNA sequences indistinguishable from those of the laboratory source. This case suggests a link between viral exposure and tumor development.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Butel, JS (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.	jbutel@bcm.tmc.edu		Butel, Janet/0000-0002-6876-3245	NCI NIH HHS [CA09197] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arrington AS, 2000, ANTICANCER RES, V20, P879; ARRINGTON AS, 2001, HUMAN POLYOMAVIRUSES, P461; Bocchetta M, 2000, P NATL ACAD SCI USA, V97, P10214, DOI 10.1073/pnas.170207097; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Butel JS, 1999, J INFECT DIS, V180, P884, DOI 10.1086/314915; BUTEL JS, 1994, METH MOL G, V4, P282; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; Griffiths DJ, 1998, DEV BIOL STAND, V94, P127; Huang KC, 1999, VIROLOGY, V262, P457, DOI 10.1006/viro.1999.9952; HWANG SP, 1980, VIROLOGY, V105, P196, DOI 10.1016/0042-6822(80)90167-1; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; KRIEG P, 1984, VIROLOGY, V138, P336, DOI 10.1016/0042-6822(84)90357-X; Lednicky JA, 1998, J VIROL, V72, P3980, DOI 10.1128/JVI.72.5.3980-3990.1998; Lednicky JA, 1997, J GEN VIROL, V78, P1697, DOI 10.1099/0022-1317-78-7-1697; Lednicky JA, 1997, INT J CANCER, V72, P791; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Lednicky JA, 2001, SEMIN CANCER BIOL, V11, P39, DOI 10.1006/scbi.2000.0345; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; Ling PD, 2003, J INFECT DIS, V187, P1571, DOI 10.1086/374739; Martini F, 2002, CANCER-AM CANCER SOC, V94, P1037, DOI 10.1002/cncr.10272; Newman JS, 1998, J NEUROVIROL, V4, P394, DOI 10.3109/13550289809114538; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1981, VIROLOGY, V112, P800, DOI 10.1016/0042-6822(81)90330-5; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; SHEIN HM, 1967, J NEUROPATH EXP NEUR, V26, P60, DOI 10.1097/00005072-196701000-00005; Stewart AR, 1998, J NEUROVIROL, V4, P182; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1	37	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2231	2235		10.1038/sj.onc.1207341	http://dx.doi.org/10.1038/sj.onc.1207341			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676832				2022-12-28	WOS:000220280900013
J	Lu, T; Sathe, SS; Swiatkowski, SM; Hampole, CV; Stark, GR				Lu, T; Sathe, SS; Swiatkowski, SM; Hampole, CV; Stark, GR			Secretion of cytokines and growth factors as a general cause of constitutive NF kappa B activation in cancer	ONCOGENE			English	Article						TGF beta 2; FGF5; microarrays; mutant 293 cells; ELISA	FACTOR-C EXPRESSION; TUMOR-NECROSIS-FACTOR; LYMPH-NODE METASTASIS; RECEPTOR ACTIVATOR; FACTOR-BETA; AUTOCRINE PRODUCTION; PANCREATIC-CANCER; LIGAND RANKL; II-RECEPTOR; KINASE	The constitutive activation of nuclear factor kappaB ( NFkappaB) helps a variety of tumors to resist apoptosis and desensitizes them to chemotherapy, but the causes are still largely unknown. W e have analysed this phenomenon in eight mutant cell lines derived from human 293 cells, selected for NFkappaB- dependent expression of a marker gene, and also in seven tumor- derived cell lines. Conditioned media from all of these cells stimulated the activation of NFkappaB ( up to 30- fold) in indicator cells carrying an NFkappaB- responsive reporter. Therefore, secretion of extracellular factors as the cause of constitutive activation seems to be general. The mRNAs encoding several different cytokines and growth factors were greatly overexpressed in the tumor and mutant cells. The pattern of overexpression was distinct in each cell line, indicating that the phenomenon is complex. Two secreted factors whose roles in the constitutive activation of NFkappaB are not well defined were investigated further as pure proteins: transforming growth factor beta2 ( TGFbeta2) and fibroblast growth factor 5 ( FGF5) were both highly expressed in some mutant clones and tumor cell lines, each activated NFkappaB alone, and the combination was synergistic. Our data indicate that a group of different factors, expressed at abnormally high levels, can contribute singly and synergistically to the constitutive activation of NFkappaB in all of the mutant and tumor cell lines we studied. Since several NFkappaB target genes encode secreted proteins that induce NFkappaB, autocrine loops are likely to be ubiquitously important in the constitutive activation of NFkappaB in cancer. We provide the first evidence of the general, complex, and synergistic activation of NFkappaB in tumor and mutant cell lines through the action of secreted factors and suggest that the same explanation is likely for the constitutive activation of NFkappaB in cancers.	Cleveland Clin Fdn, Lerner Res Inst NB21, Dept Mol Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stark, GR (corresponding author), Cleveland Clin Fdn, Lerner Res Inst NB21, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	starkg@ccf.org		Swiatkowski, Shannon/0000-0003-4110-268X				Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X; Arlt A, 2002, CANCER RES, V62, P910; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; BRACH MA, 1991, PATHOBIOLOGY, V59, P284, DOI 10.1159/000163664; Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090-4295(00)01122-5; Byrd VM, 1999, J IMMUNOL, V162, P5853; Chen TP, 1999, INT J CANCER, V82, P43; Chen TP, 1998, CANCER RES, V58, P4805; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; Coward WR, 2002, J IMMUNOL, V169, P5287, DOI 10.4049/jimmunol.169.9.5287; Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535-6108(02)00154-X; Furudoi A, 2002, ONCOLOGY-BASEL, V62, P157, DOI 10.1159/000048262; Furuta K, 1999, INT J CANCER, V81, P851, DOI 10.1002/(SICI)1097-0215(19990611)81:6<851::AID-IJC2>3.0.CO;2-D; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Held-Feindt J, 2002, INT J CANCER, V98, P352, DOI 10.1002/ijc.10207; Hermouet S, 2000, LEUKEMIA LYMPHOMA, V38, P39, DOI 10.3109/10428190009060317; Hishima T, 2000, AM J SURG PATHOL, V24, P742, DOI 10.1097/00000478-200005000-00014; Iacopetta BJ, 1999, J PATHOL, V187, P428, DOI 10.1002/(SICI)1096-9896(199903)187:4<428::AID-PATH264>3.0.CO;2-A; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Karkkainen MJ, 2000, ONCOGENE, V19, P5598, DOI 10.1038/sj.onc.1203855; Karkkainen MJ, 2002, NAT CELL BIOL, V4, pE2, DOI 10.1038/ncb0102-e2; Kascinski Barry, 2002, Cancer Treat Res, V107, P285; Klomp HJ, 2002, CLIN CANCER RES, V8, P823; Kornmann M, 1997, ONCOGENE, V15, P1417, DOI 10.1038/sj.onc.1201307; Koubek K, 1999, EUR J HAEMATOL, V63, P1; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; LU TB, UNPUB; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; McDermott RS, 2002, EUR CYTOKINE NETW, V13, P121; Mentlein R, 2002, J NEUROCHEM, V83, P747, DOI 10.1046/j.1471-4159.2002.01179.x; Michigami T, 2001, CANCER RES, V61, P1637; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992-1000.2002; O'Neill LAJ, 2002, MOL CELL, V10, P969, DOI 10.1016/S1097-2765(02)00754-2; OCONNELL MA, 1995, J BIOL CHEM, V270, P7399, DOI 10.1074/jbc.270.13.7399; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Roux S, 2002, AM J CLIN PATHOL, V117, P210; Sapi E, 1999, P SOC EXP BIOL MED, V220, P1, DOI 10.1046/j.1525-1373.1999.d01-1.x; SATHE SS, UNPUB; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Sezer O, 2002, BLOOD, V99, P4646, DOI 10.1182/blood-2002-01-0148; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takahashi A, 2002, ONCOLOGY-BASEL, V62, P121, DOI 10.1159/000048257; Ueda M, 2002, INT J CANCER, V98, P335, DOI 10.1002/ijc.10193; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamamoto H, 1998, J IMMUNOL, V161, P4753; Yonemura Y, 1999, CLIN CANCER RES, V5, P1823; Zhang N, 1999, J BIOL CHEM, V274, P12959, DOI 10.1074/jbc.274.19.12959	56	63	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2138	2145		10.1038/sj.onc.1207332	http://dx.doi.org/10.1038/sj.onc.1207332			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676835				2022-12-28	WOS:000220280900003
J	Schedin, PJ; Eckel-Mahan, KL; McDaniel, SM; Prescott, JD; Brodsky, KS; Tentler, JJ; Gutierrez-Hartmann, A				Schedin, PJ; Eckel-Mahan, KL; McDaniel, SM; Prescott, JD; Brodsky, KS; Tentler, JJ; Gutierrez-Hartmann, A			ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells	ONCOGENE			English	Article						Ese-1; ETS; breast cancer; EMT; 3D culture; cadherin	ETS TRANSCRIPTION FACTOR; BREAST-CANCER; MATRIX METALLOPROTEINASES; PROGNOSTIC MARKER; GENE-EXPRESSION; MESSENGER-RNA; MURINE ETS-1; DOMAIN; GLAND; GROWTH	ESX is an epithelial-restricted member of a large family of transcription factors known as the Ets family. ESX expression has been shown to be correlated with Her2/neu proto-oncogene amplification in highly aggressive breast cancers and induced by Her2/neu in breast cell lines, but its role in tumorigenesis is unknown. Previously, we have shown that ESX enhances breast cell survival in colony-formation assays. In order to determine whether ESX can act as a transforming gene, we stably transfected MCF-12A human mammary epithelial cells with the ESX expression vector, pCGN2-HA-ESX. The MCF-12A cell line is immortalized, but nontransformed, and importantly, these cells fail to express endogenous ESX protein. We used pCGN2-HA-Ets-2 and pSVRas expression vectors as positive controls for transformation. Like HA-Ets-2 and V12-Ras, stable expression of ESX induced EGF-independent proliferation, serum-independent MAPK phosphorylation and growth in soft agar. Additionally, stable ESX expression conferred increased cell adhesion, motility and invasion in two-dimensional and transwell filter assays, and an epithelial to mesenchymal morphological transition. In three-dimensional cultures, parental and vector control (pCGN2) cells formed highly organized duct-like structures with evidence of cell polarity, ECM adhesion-dependent proliferation and cell survival, and lack of cellular invasion into surrounding matrix. Remarkably, the ESX stable cells formed solid, disorganized structures, with lack of cell polarity, loss of adhesion junctions and cytokeratin staining and loss of dependence on ECM adhesion for cell proliferation and survival. In addition, ESX cells invaded the surrounding matrix, indicative of a transformed and metastatic phenotype. Taken together, these data show that ESX expression alone confers a transformed and in vitro metastatic phenotype to otherwise normal MCF-12A cells.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA; AMC Canc Res Ctr, Denver, CO 80214 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Colorado Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; AMC Cancer Research Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gutierrez-Hartmann, A (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box B-151, Denver, CO 80262 USA.	schedinp@amc.org; a.gutierrez-hartmann@uchsc.edu	Schedin, Pepper/C-2532-2009; Gutierrez-Hartmann, Arthur/F-1295-2011	Eckel-Mahan, Kristin/0000-0001-8201-1675; Schedin, Pepper/0000-0003-4244-987X	NCI NIH HHS [R01 CA85944, P30 CA 46934] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085944, P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BASSET P, 1993, BREAST CANCER RES TR, V24, P185, DOI 10.1007/BF01833259; Bemis LT, 2000, CANCER RES, V60, P3414; Benaud C, 1998, BREAST CANCER RES TR, V50, P97, DOI 10.1023/A:1006061115909; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; BERNHARDT G, 1992, J CANCER RES CLIN, V118, P35, DOI 10.1007/BF01192309; BLUM JL, 1989, ENVIRON HEALTH PERSP, V80, P71, DOI 10.2307/3430733; Bonneton C, 1999, CELL MOTIL CYTOSKEL, V43, P288, DOI 10.1002/(SICI)1097-0169(1999)43:4<288::AID-CM2>3.3.CO;2-P; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bradford AP, 2000, J BIOL CHEM, V275, P3100, DOI 10.1074/jbc.275.5.3100; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; CUNHA GR, 1994, CANCER, V74, P1030, DOI 10.1002/1097-0142(19940801)74:3+<1030::AID-CNCR2820741510>3.0.CO;2-Q; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; FALCO JP, 1990, J CLIN INVEST, V85, P1740, DOI 10.1172/JCI114630; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Ghadersohi A, 2001, CLIN CANCER RES, V7, P2731; Gilles C, 1997, CLIN EXP METASTAS, V15, P519, DOI 10.1023/A:1018427027270; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay ED, 1995, ACTA ANAT, V154, P8; Humphreys RC, 1996, DEVELOPMENT, V122, P4013; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Kordon EC, 1998, DEVELOPMENT, V125, P1921; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; LIU E, 1992, ONCOGENE, V7, P1027; Mitas M, 2002, BRIT J CANCER, V86, P899, DOI 10.1038/sj.bjc.6600190; Neznanov N, 1999, CANCER RES, V59, P4242; O'Hagan RC, 1998, ONCOGENE, V16, P301, DOI 10.1038/sj.onc.1201547; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Sapi E, 1998, CANCER RES, V58, P1027; Savagner P, 1994, Cancer Treat Res, V71, P229; Schedin P, 2000, J MAMMARY GLAND BIOL, V5, P211, DOI 10.1023/A:1026447506666; Shepherd T, 2001, J MAMMARY GLAND BIOL, V6, P129, DOI 10.1023/A:1009576801226; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040; Stossel TP, 1999, BIOCHEM SOC SYMP, V65, P267; Takaoka AS, 1998, J BIOL CHEM, V273, P33848, DOI 10.1074/jbc.273.50.33848; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang B, 1997, ANTICANCER RES, V17, P4387; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Weaver VM, 1996, BIOCHEM CELL BIOL, V74, P833, DOI 10.1139/o96-089	56	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1766	1779		10.1038/sj.onc.1207391	http://dx.doi.org/10.1038/sj.onc.1207391			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14767472				2022-12-28	WOS:000220029300012
J	Spurgers, KB; Coombes, KR; Meyn, RE; Gold, DL; Logothetis, CJ; Johnson, TJ; McDonnell, TJ				Spurgers, KB; Coombes, KR; Meyn, RE; Gold, DL; Logothetis, CJ; Johnson, TJ; McDonnell, TJ			A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells	ONCOGENE			English	Article						p53; bcl-2; apoptosis; cell cycle; transcriptome; genomics; adenovirus	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REPRESSION; P53-DEPENDENT APOPTOSIS; SUPEROXIDE-DISMUTASE; DEATH INDUCTION; DOWN-REGULATION; 26S PROTEASOME; BREAST-CANCER; BCL-2 FAMILY	The p53 protein can induce cell cycle arrest or apoptosis following activation in response to DNA damage. The function of p53 is largely mediated by regulating the expression of downstream target genes. Adenoviral- p53 gene transfer (Ad-p53) is currently being evaluated in clinical trials as a therapeutic intervention. Tumor response is likely to be influenced by context-dependent variables, such as expression of bcl-2. Bcl-2 is upregulated in a variety of neoplasms, and can inhibit p53-dependent apoptosis. It was therefore of interest to use a global genomic strategy to assess gene expression following Ad-p53 gene transfer and to determine if the expression of specific Ad-p53-responsive genes could be modulated in the context of bcl-2 gene deregulation. cDNA arrays were used to identify p53-responsive genes following Ad-p53 gene transfer in control and bcl-2-overexpressing PC3 prostate cancer cells. A total of 40 transcripts were significantly upregulated by Ad-p53 in both control and bcl-2-transfectant PC3 cells. Conversely, 19 transcripts were significantly repressed in both cell lines. These Adp53-responsive transcripts included previously identified p53 targets, known genes representing candidate p53 targets, and transcripts identified as expressed sequence tags. A subset of 15 transcripts was differentially modulated by Ad-p53 in the context of bcl-2. Some of these genes were also differentially modulated in LNCaP (wt p53) cells following DNA damage. These results document a number of potential p53 targets and mediators of therapeutically relevant genotoxic stress. The findings further suggest that bcl-2 may inhibit cell death at multiple points downstream of p53 activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tmcdonne@mdanderson.org		Coombes, Kevin/0000-0002-7630-2123	NATIONAL CANCER INSTITUTE [T32CA060440, P01CA078778, P50CA090270] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90270, P01 CA78778, CA60440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; [Anonymous], 2003, BIODRUGS, V17, P216; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Beham AW, 1998, INT J MOL MED, V1, P953; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruckheimer EM, 2000, ONCOGENE, V19, P5251, DOI 10.1038/sj.onc.1203881; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen SR, 2003, FREE RADICAL BIO MED, V34, P1315, DOI 10.1016/S0891-5849(03)00146-1; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dummer R, 2000, CANCER GENE THER, V7, P1069, DOI 10.1038/sj.cgt.7700214; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; HAINAUT P, 1993, CANCER RES, V53, P4469; HALL PA, 1993, ONCOGENE, V8, P203; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda T, 2002, CANCER BIOL THER, V1, P163, DOI 10.4161/cbt.63; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; ISAACS WB, 1991, CANCER RES, V51, P4716; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; KAIGHN ME, 1979, INVEST UROL, V17, P16; KASTAN MB, 1991, CANCER RES, V51, P6304; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lowe SW, 1999, CANC DRUG DISC DEV, V5, P21; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moul JV, 1999, EUR UROL, V35, P399, DOI 10.1159/000019916; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2000, CANCER RES, V60, P2805; Pagliaro LC, 2000, WORLD J UROL, V18, P148, DOI 10.1007/s003450050188; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Pollack A, 2003, CANCER-AM CANCER SOC, V97, P1630, DOI 10.1002/cncr.11230; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Robles AI, 2001, CANCER RES, V61, P6660; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schumacher G, 2001, INT J CANCER, V91, P159, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Swisher Stephen G, 2002, Surg Oncol Clin N Am, V11, P521, DOI 10.1016/S1055-3207(02)00028-5; Tanaka K, 1997, MOL BIOL REP, V24, P3, DOI 10.1023/A:1006876904158; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2003, CANCER GENE THER, V10, P224, DOI 10.1038/sj.cgt.7700562; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1994, CANCER GENE THER, V1, P5; Zhao RB, 2000, GENE DEV, V14, P981	97	12	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1712	1723		10.1038/sj.onc.1207293	http://dx.doi.org/10.1038/sj.onc.1207293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14647426				2022-12-28	WOS:000220029300007
J	Huang, AM; Montagna, C; Sharan, S; Ni, YJ; Ried, T; Sterneck, E				Huang, AM; Montagna, C; Sharan, S; Ni, YJ; Ried, T; Sterneck, E			Loss of CCAAT/enhancer binding protein delta promotes chromosomal instability	ONCOGENE			English	Article						C/EBP; tumor suppressor; mouse embryo fibroblast; chromosomal rearrangements; genomic instability	GROWTH-FACTOR-BETA; I GENE-TRANSCRIPTION; ARREST-SPECIFIC GENE; ALPHA C/EBP-ALPHA; MICE LACKING; ADIPOCYTE DIFFERENTIATION; CENTROSOME AMPLIFICATION; CELL-PROLIFERATION; MESSENGER-RNA; EXPRESSION	The transcription factor CCAAT/enhancer binding protein delta (Cebpd, also known as C/EBPdelta, CRP3, CELF, NF-IL6beta) is implicated in diverse cellular functions such as the acute phase response, adipocyte differentiation, learning and memory, and mammary epithelial cell growth control. Here, we report that lack of Cebpd causes genomic instability and centrosome amplifications in primary embryonic fibroblasts derived from 129S1 mice. Upon spontaneous immortalization, Cebpd-deficient fibroblasts acquire transformed features such as impaired contact inhibition and reduced serum dependence. These data identify a novel role for Cebpd in the maintenance of chromosomal stability and suggest a potential tumor suppressor function in vivo.	Regulat Cell Growth Lab, Frederick, MD 21702 USA; NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sterneck, E (corresponding author), Regulat Cell Growth Lab, POB B, Frederick, MD 21702 USA.	sterneck@ncifcrf.gov		Huang, A-Mei/0000-0003-3723-0443; Sterneck, Esta/0000-0001-7716-8766	NATIONAL CANCER INSTITUTE [Z01BC010307, ZIABC010307] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Billiard J, 2001, J BIOL CHEM, V276, P31238, DOI 10.1074/jbc.M103634200; Breed DR, 1997, ENDOCRINOLOGY, V138, P5527, DOI 10.1210/en.138.12.5527; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Choy L, 2003, J BIOL CHEM, V278, P9609, DOI 10.1074/jbc.M212259200; DAVISSON MT, 1994, GENE, V147, P157, DOI 10.1016/0378-1119(94)90060-4; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Evdokiou A, 1998, INT J CANCER, V75, P568, DOI 10.1002/(SICI)1097-0215(19980209)75:4<568::AID-IJC13>3.0.CO;2-5; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gigliotti AP, 2003, EXP BIOL MED, V228, P278, DOI 10.1177/153537020322800306; Gigliotti AP, 1998, J CELL PHYSIOL, V174, P232, DOI 10.1002/(SICI)1097-4652(199802)174:2<232::AID-JCP10>3.0.CO;2-E; Gigliotti AP, 1999, BREAST CANCER RES TR, V58, P57, DOI 10.1023/A:1006381906288; Glick A, 1999, P NATL ACAD SCI USA, V96, P14949, DOI 10.1073/pnas.96.26.14949; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Janssen RAJ, 1997, MOL BIOL CELL, V8, P897, DOI 10.1091/mbc.8.5.897; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kreidberg JA, 2000, CANC DRUG DISC DEV, P3; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146; O'Rourke JP, 1999, J BIOL CHEM, V274, P16582, DOI 10.1074/jbc.274.23.16582; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Reitmair AH, 1997, CANCER RES, V57, P3765; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Slomiany BA, 2000, MOL CELL BIOL, V20, P5986, DOI 10.1128/MCB.20.16.5986-5997.2000; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Takiguchi M, 1998, INT J EXP PATHOL, V79, P369, DOI 10.1046/j.1365-2613.1998.00082.x; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tessarollo L, 2000, METH MOL B, V158, P47; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Timchenko NA, 1999, NUCLEIC ACIDS RES, V27, P3621, DOI 10.1093/nar/27.17.3621; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; Wang HM, 2002, EMBO J, V21, P930, DOI 10.1093/emboj/21.5.930; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Welm AL, 2002, J BIOL CHEM, V277, P33848, DOI 10.1074/jbc.M204096200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zahnow CA, 2001, CANCER RES, V61, P261; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	62	64	64	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1549	1557		10.1038/sj.onc.1207285	http://dx.doi.org/10.1038/sj.onc.1207285			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716301				2022-12-28	WOS:000189219500008
J	Balachandran, R; Welsh, MJ; Day, BW				Balachandran, R; Welsh, MJ; Day, BW			Altered levels and regulation of stathmin in paclitaxel-resistant ovarian cancer cells	ONCOGENE			English	Article						stathmin; p21(WAF1); microtubules; p53	HUMAN BREAST-CANCER; MICROTUBULE DYNAMICS; DOWN-REGULATION; IN-VIVO; PROTEIN; EXPRESSION; PHOSPHORYLATION; TUBULIN; P53; ONCOPROTEIN-18	Two paclitaxel(Ptx)-resistant ovarian cancer cell lines, 1A9/Ptx-10 and 1A9/Ptx-22, isolated from the 1A9 cell line (a clone of the A2780 line) by continuous exposure to Ptx and verapamil, have point mutations in their major beta-tubulin gene and in one or both alleles of their TP53 gene. These cells were examined for alterations in cell cycle regulators and the tubulin-binding protein stathmin. Unlike parental cells, neither 1A9/Ptx-10 nor 1A9/Ptx-22 expressed detectable levels of p21(WAF1/Cip1), a putative transcriptional regulator of stathmin, but did overexpress stathmin and Bcl2. No differences were noted in the expression levels of proliferative cell nuclear antigen or tyrosine-phosphorylated p34(Cdc2). Ptx treatment altered little the expression of stathmin in the parental cell line, although it increased p21(WAF1/Cip1) levels several-fold. Infection of Ptx-resistant lines with a wild-type TP53-bearing adenovirus (AdWTp53) changed cell cycle distribution and increased the levels of p21(WAF1/Cip1), but caused no changes in stathmin levels. Microtubule drug resistance in ovarian carcinoma may be associated with altered p53/21(WAF1/Cip1) regulatory pathways for stathmin expression and function.	Univ Pittsburgh, Dept Pharmaceut Sci, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Day, BW (corresponding author), 721 Salk Hall,3501 Terrace St, Pittsburgh, PA 15261 USA.			Day, Billy/0000-0001-6208-9950	NCI NIH HHS [CA 78039] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alli E, 2002, CANCER RES, V62, P6864; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Cheon MS, 2001, J NEURAL TRANSM-SUPP, P281; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; DiPaolo G, 1996, J CELL BIOL, V133, P1383, DOI 10.1083/jcb.133.6.1383; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; EUSTACE W, 1995, FEBS LETT, V364, P309, DOI 10.1016/0014-5793(95)00416-7; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; Gavet O, 1998, J CELL SCI, V111, P3333; Giannakakou P, 2000, ONCOGENE, V19, P3078, DOI 10.1038/sj.onc.1203642; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Gradin HM, 1998, J CELL BIOL, V140, P131, DOI 10.1083/jcb.140.1.131; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; Howell B, 1999, J CELL SCI, V112, P3713; Hummert TW, 2000, J CELL BIOCHEM, V79, P150, DOI 10.1002/1097-4644(2000)79:1<150::AID-JCB140>3.3.CO;2-2; Iancu C, 2000, CANCER RES, V60, P3537; JI H, 1993, J BIOL CHEM, V268, P13396; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Johnsson A, 2000, BRIT J CANCER, V83, P1047, DOI 10.1054/bjoc.2000.1420; Katayose D, 1995, CLIN CANCER RES, V1, P889; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Liedtke W, 2002, AM J PATHOL, V160, P469, DOI 10.1016/S0002-9440(10)64866-3; MARKLUND U, 1994, J BIOL CHEM, V269, P30626; McNally FJ, 1996, CURR OPIN CELL BIOL, V8, P23, DOI 10.1016/S0955-0674(96)80044-5; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Mistry SJ, 2001, J BIOL CHEM, V276, P31209, DOI 10.1074/jbc.M011654200; Moreno FJ, 1998, MOL CELL BIOCHEM, V183, P201, DOI 10.1023/A:1006807814580; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Price DK, 2000, CANCER INVEST, V18, P722, DOI 10.3109/07357900009012204; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; ROWLANDS DC, 1995, LAB INVEST, V72, P100; Steinman RA, 2000, LEUKEMIA RES, V24, P601, DOI 10.1016/S0145-2126(00)00020-5; Vancompernolle K, 2000, J BIOL CHEM, V275, P33876, DOI 10.1074/jbc.M004785200; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213	45	53	65	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8924	8930		10.1038/sj.onc.1207060	http://dx.doi.org/10.1038/sj.onc.1207060			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654788				2022-12-28	WOS:000186982200013
J	Vit, JP; Rosselli, F				Vit, JP; Rosselli, F			Role of the ceramide-signaling pathways in ionizing radiation-induced apoptosis	ONCOGENE			English	Article						ionizing radiations; apoptosis; ceramide; DNA damage	ATAXIA-TELANGIECTASIA; CELL-DEATH; PROTEIN; ATM; P53; GROWTH; INHIBITION; CHECKPOINT; RESISTANCE; GENES	Ionizing radiations (IR) exposure leads to damage on several cellular targets. How signals from different targets are integrated to determine the cell fate remains a controversial issue. Understanding the pathway(s) responsible(s) for the cell killing effect of the IR exposure is of prime importance in light of using radiations as anticancer agent or as diagnostic tool. In this study, we have established that IR-induced cell damage initiates two independent signaling pathways that lead to a biphasic intracellular ceramide increase. A transitory increase of ceramide is observed within minutes after IR exposure as a consequence of DNA damage-independent acid sphingomyelinase activation. Several hours after irradiation, a second wave of ceramide accumulation is observed depending on the DNA damage-dependent activation of ceramide synthase, which requires a signaling pathway involving ATM. Importantly, we have demonstrated that the late ceramide accumulation is also dependent on the first one and is rate limiting for the apoptotic process induced by IR. In conclusion, our observations suggest that ceramide is a major determinant of the IR-induced apoptotic process at the cross-point of different signal transduction pathways.	Inst Gustave Roussy, IFR 54, CNRS, UPR 2169, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Rosselli, F (corresponding author), Inst Gustave Roussy, IFR 54, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	rosselli@vjf.cnrs.fr	vit, jean-philippe/Q-7286-2019; Filippo, Rosselli/AAO-6393-2020	Filippo, Rosselli/0000-0003-1080-5745; Vit, Jean-Philippe/0000-0001-5057-8554				BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Chmura SJ, 1997, CANCER RES, V57, P1270; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180; Duchaud E, 1996, CANCER RES, V56, P1400; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HAREL R, 1993, J BIOL CHEM, V268, P14476; HARPER JW, 1993, CELL, V75, P805; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANNA KK, 1993, ONCOGENE, V8, P3307; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Meijer AE, 1999, INT J RADIAT BIOL, V75, P709, DOI 10.1080/095530099140041; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Radford IR, 1999, INT J RADIAT BIOL, V75, P521, DOI 10.1080/095530099140168; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Takagi M, 1998, CANCER RES, V58, P4923; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Xanthoudakis S, 2000, NAT CELL BIOL, V2, pE163, DOI 10.1038/35023643; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	42	58	60	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8645	8652		10.1038/sj.onc.1207087	http://dx.doi.org/10.1038/sj.onc.1207087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647458	Bronze			2022-12-28	WOS:000186844900001
J	Agarwal, C; Singh, RP; Dhanalakshmi, S; Tyagi, AK; Tecklenburg, M; Sclafani, RA; Agarwal, R				Agarwal, C; Singh, RP; Dhanalakshmi, S; Tyagi, AK; Tecklenburg, M; Sclafani, RA; Agarwal, R			Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells	ONCOGENE			English	Article						cyclin-dependent kinase inhibitor; apoptosis; colon cancer; silibinin	FLAVONOID ANTIOXIDANT SILYMARIN; CANCER CELLS; PROTEIN-KINASE; DU145 CELLS; PROGNOSTIC-SIGNIFICANCE; P27(KIP1) PROTEIN; GROWTH-INHIBITION; COLORECTAL-CANCER; SILYBUM-MARIANUM; MAMMALIAN-CELLS	Silymarin, a defined mixture of natural flavonoid, has recently been shown to have potent cancer chemopreventive efficacy against colon carcinogenesis in rat model; however, the mechanism of such efficacy is not elucidated. Here, using pure active agent in silymarin, namely silibinin, we show its antiproliferative and apoptotic effects, and associated molecular alterations in human colon carcinoma HT-29 cells. Silibinin treatment of cells at 50-100 mug/ml doses resulted in a moderate to very strong growth inhibition in a dose- and a time-dependent manner, which was largely due to a G0/G1 arrest in cell cycle progression; higher dose and longer treatment time also caused a G2/M arrest. In mechanistic studies related its effect on cell cycle progression, silibinin treatment resulted in an upregulation of Kip1/p27 and Cip1/p21 protein as well as mRNA levels, and decreased CDK2, CDK4, cyclin E and cyclin D1 protein levels together with an inhibition in CDK2 and CDK4 kinase activities. In other studies, we observed that G2/M arrest by silibinin was associated with a decrease in cdc25C, cdc2/p34 and cyclin B1 protein levels, as well as cdc2/p34 kinase activity. In the studies assessing biological fate of silibinin-treated cells, silibinin-induced cell cycle arrest and growth inhibition were not associated with cellular differentiation, but caused apoptotic death. The quantitative apoptosis analysis showed up to 15% apoptotic cell death after 48 h of silibinin treatment. Interestingly, silibinin-induced apoptosis in HT-29 cells was independent of caspases activation, as all caspases inhibitor did not reverse silibinin-induced apoptosis. This observation was further confirmed by the findings showing a lack in caspases activity increase and caspases and PARP cleavage as well as a lack in cytochrome c release in cytosol following silibinin treatment of HT-29 cells. Additional studies conducted in mice showed that doses found effective in HT-29 cells are achievable in plasma, which increases the significance of the present findings and their possible translation in in vivo anticancer efficacy of silibinin against colon cancer. Together, these results identify molecular mechanisms of silibinin efficacy as a cell cycle regulator and apoptosis inducer in human colon carcinoma HT-29 cells, and justify further studies to investigate potential usefulness of this nontoxic agent in colon cancer prevention and intervention.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Univ Colorado Canc Ctr, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th St,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu		Sclafani, Robert/0000-0002-1100-6489; Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R03CA099079, R01CA064514, R29CA064514, R01CA091883] Funding Source: NIH RePORTER; NCI NIH HHS [CA91883, CA99079, CA64514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad N, 1998, BIOCHEM BIOPH RES CO, V247, P294, DOI 10.1006/bbrc.1998.8748; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DING QM, 1998, AM J PHYSIOL, V275, pC1191; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Flora K, 1998, AM J GASTROENTEROL, V93, P139, DOI 10.1111/j.1572-0241.1998.00139.x; GILFIX BM, 1985, J BIOL CHEM, V260, P4026; GRANA X, 1995, ONCOGENE, V11, P211; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo YP, 1997, CLIN CANCER RES, V3, P2269; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; HAHN G, 1968, ARZNEI-FORSCHUNG, V18, P698; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Jordan RCK, 1998, AM J PATHOL, V152, P585; Katiyar SK, 1997, JNCI-J NATL CANCER I, V89, P556, DOI 10.1093/jnci/89.8.556; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kitamura S, 1999, JPN J CANCER RES, V90, P75, DOI 10.1111/j.1349-7006.1999.tb00668.x; Kohno H, 2002, INT J CANCER, V101, P461, DOI 10.1002/ijc.10625; Lahiri-Chatterjee M, 1999, CANCER RES, V59, P622; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Moragoda L, 2001, ANTICANCER RES, V21, P873; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Samowitz WS, 2002, INT J CANCER, V99, P597, DOI 10.1002/ijc.10405; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Singh RP, 2002, CARCINOGENESIS, V23, P499, DOI 10.1093/carcin/23.3.499; Singh RP, 2002, CANCER RES, V62, P3063; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; TSAI LH, 1993, ONCOGENE, V8, P1593; Tyagi AK, 2002, CLIN CANCER RES, V8, P3512; VOGEL G, 1975, ARZNEIMITTEL-FORSCH, V25, P82; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1997, BIOCHEM BIOPH RES CO, V239, P334, DOI 10.1006/bbrc.1997.7375; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi XL, 1999, BIOCHEM BIOPH RES CO, V263, P528, DOI 10.1006/bbrc.1999.1398; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	51	198	212	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8271	8282		10.1038/sj.onc.1207158	http://dx.doi.org/10.1038/sj.onc.1207158			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614451				2022-12-28	WOS:000186541500006
J	Frelin, C; Imbert, V; Griessinger, E; Loubat, A; Dreano, M; Peyron, JF				Frelin, C; Imbert, V; Griessinger, E; Loubat, A; Dreano, M; Peyron, JF			AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells	ONCOGENE			English	Article						NF-kappa B; IKK2 inhibitor; TNF; apoptosis	NF-KAPPA-B; CANCER-THERAPY; ACTIVATION; DEATH; CHEMORESISTANCE; EXPRESSION; BLOCKING; BLOCKADE; PATHWAY; C-IAP2	NF-kappaB transcription factors promote survival in numerous cell types via induction of antiapoptotic genes. Pharmacological blockade of the IKK2 kinase with AS602868, a specific inhibitor that competes with ATP binding, prevented TNF-alpha-induced NF-kappaB activation in Jurkat leukemic T cells. While TNF-alpha by itself had no effect on Jurkat survival, the addition of AS602868 induced cell death, visualized by DNA fragmentation and sub-G1 analysis. A disruption of the mitochondrial potential followed by activation of caspases 9 and 3 was observed in cells treated by the combination TNF-alpha+AS602868. Quantitative real-time PCR demonstrated that AS602868 prevented TNF-alpha induction of the antiapoptotic genes coding for c-IAP-2, Bclx, Bfl-1/A1 and Traf-1. The use of a specific IKK2 inhibitor appears, therefore, as an interesting pharmaceutical strategy to increase the cell's sensitivity towards apoptotic effectors.	Fac Med Pasteur, INSERM, U526, UFR Genet & Signalisat Mol 50, F-06107 Nice 02, France; Fac Med Pasteur, INSERM, U364, UFR Genet & Signalisat Mol 50, F-06107 Nice, France; Serono Int SA, Geneva, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Merck & Company; Serono International S.A.	Peyron, JF (corresponding author), Fac Med Pasteur, INSERM, U526, UFR Genet & Signalisat Mol 50, F-06107 Nice 02, France.		Griessinger, Emmanuel/G-5574-2018; Imbert, Véronique/I-6093-2016; Jean-Francois, Peyron/AAA-9496-2022; Peyron, Jean-Francois/M-5682-2016	Imbert, Véronique/0000-0003-2103-6718; Jean-Francois, Peyron/0000-0001-6113-916X; Peyron, Jean-Francois/0000-0001-6113-916X				Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Busuttil V, 2002, ONCOGENE, V21, P3213, DOI 10.1038/sj.onc.1205433; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Foo SY, 1999, TRENDS GENET, V15, P229; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hideshima T, 2001, CANCER RES, V61, P3071; Jones BE, 2000, J BIOL CHEM, V275, P705, DOI 10.1074/jbc.275.1.705; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Pagliari LJ, 2000, MOL CELL BIOL, V20, P8855, DOI 10.1128/MCB.20.23.8855-8865.2000; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sugiyama H, 1999, J BIOL CHEM, V274, P19532, DOI 10.1074/jbc.274.28.19532; VAN AD, 1996, SCIENCE, V274, P787; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	35	68	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8187	8194		10.1038/sj.onc.1206963	http://dx.doi.org/10.1038/sj.onc.1206963			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603259				2022-12-28	WOS:000186403400013
J	Croce, M; De Ambrosis, A; Corrias, MV; Pistoia, V; Occhino, M; Meazza, R; Giron-Michel, J; Azzarone, B; Accolla, RS; Ferrini, S				Croce, M; De Ambrosis, A; Corrias, MV; Pistoia, V; Occhino, M; Meazza, R; Giron-Michel, J; Azzarone, B; Accolla, RS; Ferrini, S			Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells	ONCOGENE			English	Article						HLA class II; CIITA; neuroblastoma; promoter methylation	BARE-LYMPHOCYTE-SYNDROME; HISTOCOMPATIBILITY COMPLEX EXPRESSION; PROMOTER BINDING-PROTEIN; TRANSACTIVATOR CIITA; ANTIGEN PRESENTATION; DERMAL FIBROBLASTS; TROPHOBLAST CELLS; REGULATORY FACTOR; GENE-EXPRESSION; NF-Y	The HLA class II expression is controlled by the transcriptional activator CIITA. The transcription of CIITA is controlled by different promoters, among which promoter-IV is inducible by IFN-gamma. We analysed the regulation of HLA class II molecules by IFN-gamma in a large series of human neuroblastoma cell lines. No induction of surface or intracellular HLA class II molecules and of specific mRNA was observed, in all neuroblastomas, with the exception of a nonprototypic cell line, ACN. In a large subset of neuroblastomas IFN-gamma induced expression of CIITA mRNA, derived from promoter-IV, which was not methylated. In contrast, in another subset of neuroblastomas, CIITA was not inducible by IFN-gamma and CIITA promoter-IV was either completely or partially methylated. Interestingly, the use of DNA demethylating agents restored CIITA gene transcriptional activation by IFN-gamma, but not HLA class II expression. The defect of HLA class II was not related to alterations in RFX or NF-Y transcription factors, as suggested by EMSA or RFX gene transfection experiments. In addition, the transfection of a functional CIITA cDNA failed to induce HLA class II expression in typical neuroblastoma cells. Confocal microscopy and Western blot analysis suggested a defective nuclear translocation and/or reduced protein synthesis in CIITA-transfected NB cells. Altogether, these data point to multiple mechanisms preventing HLA class II expression in the neuroblastoma, either involving CIITA promoter-IV silencing, or acting at the CIITA post-transcriptional level.	Ist Nazl Ric Canc, I-16132 Genoa, Italy; Ist Giannina Gaslini, I-16148 Genoa, Italy; Univ Insubria, Dipartimento Sci Clin & Biol, I-21100 Varese, Italy; Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Insubria; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Ferrini, S (corresponding author), Ctr Biotecnol Avanzate, Largo Rosanna Benzi 10, I-16132 Genoa, Italy.		Azzarone, Bruno/AAH-9251-2019; Giron-Michel, Julien/Q-4503-2018; Corrias, Maria Valeria/E-4571-2011; Croce, Michela/AAA-8966-2020; Meazza, Raffaella/AAC-2425-2019; Giron-michel, Julien/GNP-7299-2022	Azzarone, Bruno/0000-0002-5962-3849; Giron-Michel, Julien/0000-0001-6613-6099; Corrias, Maria Valeria/0000-0002-7316-0772; Croce, Michela/0000-0003-4683-4951; Meazza, Raffaella/0000-0003-0242-3157; Giron-michel, Julien/0000-0001-6613-6099; Accolla, Roberto/0000-0003-2493-7378; Ferrini, Silvano/0000-0001-7254-2616				Accolla RS, 2002, EUR J IMMUNOL, V32, P2783, DOI 10.1002/1521-4141(2002010)32:10<2783::AID-IMMU2783>3.0.CO;2-E; ACCOLLA RS, 1986, J EXP MED, V164, P369, DOI 10.1084/jem.164.1.369; Antunes NL, 2000, J PEDIAT HEMATOL ONC, V22, P315, DOI 10.1097/00043426-200007000-00007; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Barbieri G, 2002, INT IMMUNOL, V14, P839, DOI 10.1093/intimm/dxf060; Blanck G, 1999, MICROBES INFECT, V1, P913, DOI 10.1016/S1286-4579(99)00226-9; BLANCK G, 1990, HUM IMMUNOL, V29, P150, DOI 10.1016/0198-8859(90)90078-4; BROCKER EB, 1984, J INVEST DERMATOL, V82, P244, DOI 10.1111/1523-1747.ep12260181; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; COOPER MJ, 1990, CANCER RES, V50, P3694; Corrias MV, 2001, TISSUE ANTIGENS, V57, P110, DOI 10.1034/j.1399-0039.2001.057002110.x; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GOBLIN S, 1997, IMMUNITY, V6, P601; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; KHAN R, 1988, J BIOL CHEM, V263, P14374; LAMPSON LA, 1990, J IMMUNOL, V144, P512; Lennon AM, 1997, IMMUNOGENETICS, V45, P266, DOI 10.1007/s002510050202; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Martin BK, 1999, J IMMUNOL, V162, P6663; Meazza R, 2003, EUR J IMMUNOL, V33, P1183, DOI 10.1002/eji.200323712; MORENO CS, 1995, J IMMUNOL, V155, P4313; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Naves R, 2002, INT IMMUNOL, V14, P481, DOI 10.1093/intimm/14.5.481; Nekrep N, 2000, MOL CELL BIOL, V20, P4455, DOI 10.1128/MCB.20.12.4455-4461.2000; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Redwine JM, 2001, AM J PATHOL, V159, P1219, DOI 10.1016/S0002-9440(10)62507-2; REITH W, 1988, CELL, V53, P897, DOI 10.1016/S0092-8674(88)90389-3; REITH W, 1994, P NATL ACAD SCI USA, V91, P554, DOI 10.1073/pnas.91.2.554; REITH W, 1989, P NATL ACAD SCI USA, V86, P4200, DOI 10.1073/pnas.86.11.4200; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Rodriguez AM, 1997, EUR J IMMUNOL, V27, P45, DOI 10.1002/eji.1830270108; Sartoris S, 1998, J IMMUNOL, V161, P814; SHEENCHEN SM, 1994, SURGERY, V116, P510; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; Ting JPY, 2002, CELL, V109, pS21, DOI 10.1016/S0092-8674(02)00696-7; Tosi G, 2002, EMBO J, V21, P5467, DOI 10.1093/emboj/cdf557; van den Elsen PJ, 2000, HUM IMMUNOL, V61, P850, DOI 10.1016/S0198-8859(00)00159-2; van der Stoep N, 2002, INT J CANCER, V97, P501, DOI 10.1002/ijc.1623	57	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7848	7857		10.1038/sj.onc.1207054	http://dx.doi.org/10.1038/sj.onc.1207054			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586411				2022-12-28	WOS:000186240200015
J	Usenko, T; Kukushkin, A; Pospelova, T; Pospelov, V				Usenko, T; Kukushkin, A; Pospelova, T; Pospelov, V			Transient expression of E1A and Ras oncogenes causes downregulation of c-fos gene transcription in nontransformed REF52 cells	ONCOGENE			English	Article						E1A and Ras; c-fos transcription; chromatin; HDAC inhibitors	CHROMATIN STRUCTURE; CHA-RAS; ACTIVATION; PROMOTER; SIGNAL; TRANSFORMATION; FIBROBLASTS; REPRESSION; PATHWAY	Stable transformation of rat embryo fibroblast (REF) cells with E1A and cHa-ras oncogenes leads to downmodulation of c-fos gene transcription. This repression is provided in part by the association of Elk-1 transcription factor with histone deacetylases mediated through effects of Ras on MAP-kinase cascades. Here, we focus on the primary effects of E1A and Ras displayed in transient transfection assay on the transactivating capability of Elk-1, which is a key transcription factor of c-fos gene regulation. Our data show that E1A is able to suppress serum-and Ras-induced stimulation of Gal-luc reporter activity by a full-length Gal-Elk1-428 fusion protein as well as the expression of c-fos promoter-driven luciferase constructs (fos-luc). The repression can be relieved by trichostatin A, a histone deacetylase ( HDAC) inhibitor, implying the involvement of HDACs and an inactive chromatin structure formed due to underacetylation of nucleosomal histones. Thus, upon transient transfection of E1A and Ras oncogenes in REF52 cells or their stable expression in E1A+cHa-ras cells, E1A contributes to the formation of inactive chromatin structure through association with p300/CBP histone acetyltransferases at c-fos promoters, whereas Ras mediates its effect through constitutive activation of the MAP/ERK kinase cascade, thereby promoting the recruitment of HDAC1 to the Elk-1 transcription factor. As a result, downregulation of c-fos gene transcription revealed in established E1A+Ras transformants is unlikely to be a consequence of cell transformation itself, but follows from primary effects of E1A and Ras on chromatin remodeling factors.	Russian Acad Sci, Inst Cytol, St Petersburg 194064, Russia	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Pospelov, V (corresponding author), Russian Acad Sci, Inst Cytol, Tikhoretzky Ave 4, St Petersburg 194064, Russia.		Kukushkin, Alexander/W-7241-2018					Abramova MV, 2003, BIOCHEM BIOPH RES CO, V306, P483, DOI 10.1016/S0006-291X(03)00996-3; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; Kessler R, 1999, ONCOGENE, V18, P1733, DOI 10.1038/sj.onc.1202484; Kukushkin AN, 2002, ONCOGENE, V21, P719, DOI 10.1038/sj.onc.1205118; Lee HY, 1998, ONCOGENE, V16, P3039, DOI 10.1038/sj.onc.1201843; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Pospelova TV, 1999, GENE EXPRESSION, V8, P19; WANG HG, 1993, J VIROL, V76, P476; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	15	8	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7661	7666		10.1038/sj.onc.1206975	http://dx.doi.org/10.1038/sj.onc.1206975			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576829				2022-12-28	WOS:000186113000014
J	Doyle, LA; Ross, DD				Doyle, LA; Ross, DD			Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2)	ONCOGENE			English	Review						cancer; drug resistance; ABC transporter; BCRP; ABCG2	BINDING CASSETTE TRANSPORTER; ACUTE MYELOID-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; EYE PIGMENT PRECURSORS; DROSOPHILA-WHITE GENE; HALF-TRANSPORTER; P-GLYCOPROTEIN; DRUG EFFLUX; MITOXANTRONE-RESISTANCE; GENOMIC ORGANIZATION	Observations of functional adenosine triphosphate (ATP)dependent drug efflux in certain multidrug-resistant cancer cell lines without overexpression of P-glycoprotein or multidrug resistance protein (MRP) family members suggested the existence of another ATP-binding cassette (ABC) transporter capable of causing cancer drug resistance. In one such cell line (MCF-7/AdrVp), the overexpression of a novel member of the G subfamily of ABC transporters was found. The new transporter was termed the breast cancer resistance protein ( BCRP), because of its identification in MCF-7 human breast carcinoma cells. BCRP is a 655 amino-acid polypeptide, formally designated as ABCG2. Like all members of the ABC G ( white) subfamily, BCRP is a half transporter. Transfection and enforced overexpression of BCRP in drug-sensitive MCF-7 or MDA-MB-231 cells recapitulates the drug-resistance phenotype of MCF-7/AdrVp cells, consistent with current evidence suggesting that functional BCRP is a homodimer. BCRP maps to chromosome 4q22, downstream from a TATA-less promoter. The spectrum of anticancer drugs effluxed by BCRP includes mitoxantrone, camptothecin-derived and indolocarbazole topoisomerase I inhibitors, methotrexate, flavopiridol, and quinazoline ErbB1 inhibitors. Transport of anthracyclines is variable and appears to depend on the presence of a BCRP mutation at codon 482. Potent and specific inhibitors of BCRP are now being developed, opening the door to clinical applications of BCRP inhibition. Owing to tissue localization in the placenta, bile canaliculi, colon, small bowel, and brain microvessel endothelium, BCRP may play a role in protecting the organism from potentially harmful xenobiotics. BCRP expression has also been demonstrated in pluripotential 'side population' stem cells, responsible for the characteristic ability of these cells to exclude Hoechst 33342 dye, and possibly for the maintenance of the stem cell phenotype. Studies are emerging on the role of BCRP expression in drug resistance in clinical cancers. More prospective studies are needed, preferably combining BCRP protein or mRNA quanti. cation with functional assays, in order to determine the contribution of BCRP to drug resistance in human cancers.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; Baltimore VA Med Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center	Doyle, LA (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	adoyle@umm.edu; dross@som.umaryland.edu			NCI NIH HHS [R01 CA 77545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott BL, 2002, BLOOD, V100, P4594, DOI 10.1182/blood-2002-01-0271; Abele R, 1999, BBA-BIOMEMBRANES, V1461, P405, DOI 10.1016/S0005-2736(99)00171-6; Allen JD, 2002, CANCER RES, V62, P2294; Allen JD, 2002, MOL CANCER THER, V1, P417; Allen JD, 1999, CANCER RES, V59, P4237; Allikmets R, 1998, CANCER RES, V58, P5337; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Baer MR, 2002, BLOOD, V100, p67A; Bailey-Dell KJ, 2001, BBA-GENE STRUCT EXPR, V1520, P234, DOI 10.1016/S0167-4781(01)00270-6; Bates SE, 2001, J BIOENERG BIOMEMBR, V33, P503, DOI 10.1023/A:1012879205914; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Brangi M, 1999, CANCER RES, V59, P5938; Bunting KD, 2002, STEM CELLS, V20, P11, DOI 10.1002/stem.200011; Chen HM, 1996, AM J HUM GENET, V59, P66; Chen WS, 2000, BIOCHEM PHARMACOL, V60, P413, DOI 10.1016/S0006-2952(00)00341-5; CHEN YN, 1990, J BIOL CHEM, V265, P10073; Cole R. J., 1981, HDB TOXIC FUNGAL MET, P355; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cooray HC, 2002, NEUROREPORT, V13, P2059, DOI 10.1097/00001756-200211150-00014; Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6; de Bruin M, 1999, CANCER LETT, V146, P117, DOI 10.1016/S0304-3835(99)00182-2; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; DIETEL M, 1990, CANCER RES, V50, P6100; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; DOYLE LA, 1995, BRIT J CANCER, V71, P52, DOI 10.1038/bjc.1995.11; Doyle LA, 1996, P AN M AM SOC CLIN, V15, P398; Eisenblatter T, 2002, BIOCHEM BIOPH RES CO, V293, P1273, DOI 10.1016/S0006-291X(02)00376-5; Ejendal KFK, 2002, CURR PROTEIN PEPT SC, V3, P503, DOI 10.2174/1389203023380521; Elferink RO, 2002, BBA-MOL BASIS DIS, V1586, P129; Erlichman C, 2001, CANCER RES, V61, P739; EWART GD, 1994, J BIOL CHEM, V269, P10370; Ewart GD, 1998, METHOD ENZYMOL, V292, P213; Faneyte IF, 2002, CLIN CANCER RES, V8, P1068; FUTSCHER BW, 1994, BIOCHEM PHARMACOL, V47, P1601, DOI 10.1016/0006-2952(94)90538-X; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Guo YL, 2003, STEM CELLS, V21, P15, DOI 10.1634/stemcells.21-1-15; Hausner Petr, 1999, Neoplasia (New York), V1, P356, DOI 10.1038/sj.neo.7900047; Hazlehurst LA, 1999, CANCER RES, V59, P1021; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Honjo Y, 2001, CANCER RES, V61, P6635; HONJO Y, 2001, 3 FEBS ADV LECT COUR; Honjo Yasumasa, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P778; Imai Y, 2002, MOL CANCER THER, V1, P611; Imai Y, 2002, JPN J CANCER RES, V93, P231, DOI 10.1111/j.1349-7006.2002.tb02162.x; Ishii M, 2000, ANTI-CANCER DRUG, V11, P353, DOI 10.1097/00001813-200006000-00005; IZQUIERDO MA, 2002, P AM ASSOC CANC RES, V43, P77; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kanzaki A, 2001, JPN J CANCER RES, V92, P452, DOI 10.1111/j.1349-7006.2001.tb01115.x; Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267; Kawabata S., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P930; Kim M, 2002, CLIN CANCER RES, V8, P22; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Knutsen T, 2000, GENE CHROMOSOME CANC, V27, P110, DOI 10.1002/(SICI)1098-2264(200001)27:1<110::AID-GCC14>3.0.CO;2-4; Komatani H, 2001, CANCER RES, V61, P2827; Kowalski P, 2002, CANCER GENE THER, V9, P579, DOI 10.1038/sj.cgt.7700471; Kowalski P, 2001, CANCER GENE THER, V8, P185, DOI 10.1038/sj.cgt.7700294; Kruijtzer CMF, 2002, J CLIN ONCOL, V20, P2943, DOI 10.1200/JCO.2002.12.116; Langmann T, 2000, BBA-GENE STRUCT EXPR, V1494, P175, DOI 10.1016/S0167-4781(00)00215-3; Laurand Armelle, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P647; Lechner A, 2002, BIOCHEM BIOPH RES CO, V293, P670, DOI 10.1016/S0006-291X(02)00275-9; Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.3.CO;2-W; Leith CP, 1999, BLOOD, V94, P1086; List AF, 1998, BLOOD, V92, p312A; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CLIN CANCER RES, V7, P935; Maliepaard M, 2001, CANCER RES, V61, P3458; MALIEPAARD M, 2000, P AM ASSOC CANC RES, V41, P268; Minderman H, 2002, CYTOMETRY, V48, P59, DOI 10.1002/cyto.10111; MINDERMAN H, 2002, P AM ASSOC CANC RES, V43, P493; Miyake K, 1999, CANCER RES, V59, P8; NAKAGAWA M, 1992, CANCER RES, V52, P6175; Nakanishi T, 2003, CLIN CANCER RES, V9, P3320; Nakatomi K, 2001, BIOCHEM BIOPH RES CO, V288, P827, DOI 10.1006/bbrc.2001.5850; Ozvegy C, 2001, BIOCHEM BIOPH RES CO, V285, P111, DOI 10.1006/bbrc.2001.5130; OZVEGY C, 2002, J BIOL CHEM, V8, P8; Perego P, 2001, CANCER RES, V61, P6034; Rabindran SK, 1998, CANCER RES, V58, P5850; Rabindran SK, 2000, CANCER RES, V60, P47; Rajendra Rajeev, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P777; Robey RW, 2001, CLIN CANCER RES, V7, P145; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Rocchi E, 2000, BIOCHEM BIOPH RES CO, V271, P42, DOI 10.1006/bbrc.2000.2590; Ross DD, 1999, J NATL CANCER I, V91, P429, DOI 10.1093/jnci/91.5.429; ROSS DD, 1995, BIOCHEM PHARMACOL, V50, P1673, DOI 10.1016/0006-2952(95)02069-1; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; Ross DD, 2000, LEUKEMIA, V14, P467, DOI 10.1038/sj.leu.2401694; Sargent JM, 2001, BRIT J HAEMATOL, V115, P257, DOI 10.1046/j.1365-2141.2001.03122.x; Sauerbrey A, 2002, BRIT J HAEMATOL, V118, P147, DOI 10.1046/j.1365-2141.2002.03550.x; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; SCHEFFER GL, 2002, J CLIN PATHOL, V60, P2589; SCHEFFER GL, 2000, CANCER RES, V55, P332; Schellens Jan H. M., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1154; Schlegel S., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P669; Schuetz John D., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P272; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Stein U, 2002, INT J CANCER, V97, P751, DOI 10.1002/ijc.10131; Steinbach D, 2002, LEUKEMIA, V16, P1443, DOI 10.1038/sj.leu.2402541; Sugimoto Y, 2003, MOL CANCER THER, V2, P105; Taipalensuu J, 2001, J PHARMACOL EXP THER, V299, P164; Takebayashi Y, 2001, INT J MOL MED, V7, P397; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; TAYLOR CW, 1991, BRIT J CANCER, V63, P923, DOI 10.1038/bjc.1991.202; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uchida N, 2002, EXP HEMATOL, V30, P862, DOI 10.1016/S0301-472X(02)00879-2; UEDA K, 1987, J BIOL CHEM, V262, P17432; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; van den Heuvel-Eibrink MM, 2000, INT J CLIN PHARM TH, V38, P94; Van Der Kolk DM, 2002, LEUKEMIA LYMPHOMA, V43, P685, DOI 10.1080/10428190290016773; van der Kolk DM, 2002, BLOOD, V99, P3763, DOI 10.1182/blood.V99.10.3763; van Hattum A. H., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P815; van Hattum AH, 2002, INT J CANCER, V100, P22, DOI 10.1002/ijc.10434; van Loevezijn A, 2001, BIOORG MED CHEM LETT, V11, P29, DOI 10.1016/S0960-894X(00)00588-6; Volk EL, 2000, CANCER RES, V60, P3514; Volk EL, 2002, CANCER RES, V62, P5035; Volk Erin L., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P780; Wang X, 2003, MOL PHARMACOL, V63, P65, DOI 10.1124/mol.63.1.65; Yang CH, 2000, BIOCHEM PHARMACOL, V60, P831, DOI 10.1016/S0006-2952(00)00396-8; Yoshikawa Megumi, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P777; Young AM, 2003, ADV DRUG DELIVER REV, V55, P125, DOI 10.1016/S0169-409X(02)00174-6; Zamber CP, 2003, PHARMACOGENETICS, V13, P19, DOI 10.1097/00008571-200301000-00004; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhou S, 2000, BLOOD, V96, p820A; ZHU QC, 1994, CANCER RES, V54, P4488	130	873	944	5	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7340	7358		10.1038/sj.onc.1206938	http://dx.doi.org/10.1038/sj.onc.1206938			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576842	Bronze			2022-12-28	WOS:000186112500007
J	de Silanes, IL; Fan, JS; Yang, XL; Zonderman, AB; Potapova, O; Pizer, ES; Gorospe, M				de Silanes, IL; Fan, JS; Yang, XL; Zonderman, AB; Potapova, O; Pizer, ES; Gorospe, M			Role of the RNA-binding protein HuR in colon carcinogenesis	ONCOGENE			English	Article						HuR; ELAV; colon cancer; mRNA turnover; carcinogenesis	MESSENGER-RNA; STABILITY FACTOR; EXPRESSION; CANCER; RICH; STABILIZATION; ELEMENT; GROWTH; ELAV; CONTAINS	Immunohistochemical analysis of paired tumor and normal tissue specimens revealed that the expression and cytoplasmic abundance of the RNA-binding protein HuR increased with malignancy, particularly in colon carcinomas. Interventions to modulate HuR expression in human RKO colon cancer cells altered gene expression profiles and identified beta-catenin mRNA as a novel HuR target. Subcutaneous injection of HuR-overexpressing RKO cells into nude mice produced signfiicantly larger tumors than those arising from control populations; conversely, RKO cells expressing reduced HuR through small interference RNA- or antisense HuR-based approaches developed significantly more slowly. We propose that HuR-regulated target mRNA expression contributes to colon cancer growth. Our results suggest a pivotal function for HuR in colon carcinogenesis.	NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Baltimore, MD 21224 USA; NIA, Res Resources Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; SUGEN Inc, Preclin Res & Translat Med, San Francisco, CA 94080 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Pfizer; Johns Hopkins University; Johns Hopkins Medicine	Gorospe, M (corresponding author), NIA, Cellular & Mol Biol Lab, Intramural Res Program, NIH, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	myriam-gorospe@nih.gov	Zonderman, Alan B/A-5807-2013; Lopez de Silanes, Isabel/K-4962-2015	Zonderman, Alan B/0000-0003-3530-2319; Zonderman, Alan B/0000-0002-6523-4778; Lopez de Silanes, Isabel/0000-0001-6762-9792	NATIONAL INSTITUTE ON AGING [ZIAAG000511, Z01AG000511] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antic D, 1997, AM J HUM GENET, V61, P273, DOI 10.1086/514866; Atasoy U, 1998, J CELL SCI, V111, P3145; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gorospe M, 1998, MOL CELL BIOL, V18, P1400, DOI 10.1128/MCB.18.3.1400; JOOSS KU, 1995, ONCOGENE, V10, P603; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Morrell CH, 1997, AM STAT, V51, P338, DOI 10.2307/2685902; Nabors LB, 2001, CANCER RES, V61, P2154; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SAS Institute Inc, 1999, SAS STAT US GUID VER; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; Tenenbaum SA, 2000, P NATL ACAD SCI USA, V97, P14085, DOI 10.1073/pnas.97.26.14085; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wang WG, 2001, MOL CELL BIOL, V21, P5889, DOI 10.1128/MCB.21.17.5889-5898.2001; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0	36	227	233	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7146	7154		10.1038/sj.onc.1206862	http://dx.doi.org/10.1038/sj.onc.1206862			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562043				2022-12-28	WOS:000185955000006
J	Amir, RE; Haecker, H; Karin, M; Ciechanover, A				Amir, RE; Haecker, H; Karin, M; Ciechanover, A			Mechanism of processing of the NF-kappa B2 p100 precursor: identification of the specific polyubiquitin chain-anchoring lysine residue and analysis of the role of NEDD8-modification on the SCF beta-TrCP ubiquitin ligase	ONCOGENE			English	Article						ubiquitin; processing; NF-kappa B2; p100; p52; NEDD8	NF-KAPPA-B; NEDD8; PROTEIN; E3; PHOSPHORYLATION; DEGRADATION; ACTIVATION; PATHWAY; SYSTEM; ALPHA	Processing of the NF-kappaB2 precursor p100 to the mature p52 subunit is regulated via a unique pathway. NF-kappaB-inducing kinase (NIK) induces IkappaB kinase alpha (IKKalpha)-mediated phosphorylation of specific serine residues in the C-terminal domain of p100, leading to recruitment of the SCFbeta-TrCP ubiquitin ligase. We identified a single lysine residue, K855, that serves as the ubiquitin-anchoring residue required for signal-induced processing of p100. In a reconstituted system containing purified components, p100-K855R could not be ubiquitinated. In a crude extract and cells, only residual, signal-independent ubiquitination and processing were retained. Importantly, K855 is located in a site homologous to K22 that serves as an ubiquitination site in IkappaBalpha. This suggests a common recognition mechanism for the two molecules. In contrast, p105, the p100 homologue, lacks a similar Lys residue. We also demonstrate that the NEDD8 pathway is essential for the SCFbeta-TrCP activity. In a reconstituted system, efficient ubiquitination of p100 required all three components of the pathway - E1, the UBC12 E2 and NEDD8. Experiments in reconstituted systems and in cells demonstrated that SCFbeta-TrCP, which contains a mutant Cul-1 that cannot be NEDDylated, cannot stimulate ubiquitination and processing. Similarly, dominant negative UBC12 inhibits, in a reversible manner, both ubiquitination and processing of p100.	Technion Israel Inst Technol, Fac Med, Dept Biochem, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Rappaport Family Inst Res Med Sci, IL-31096 Haifa, Israel; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of California System; University of California San Diego	Ciechanover, A (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, POB 9649, IL-31096 Haifa, Israel.	c_tzachy@netvision.net.il	Haecker, Hans/F-6826-2013; Ciechanover, Aaron J/C-9166-2017	Haecker, Hans/0000-0001-5971-0451; 				Amir RE, 2002, J BIOL CHEM, V277, P23253, DOI 10.1074/jbc.M200967200; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Kamitani T, 2001, J BIOL CHEM, V276, P46655, DOI 10.1074/jbc.M108636200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3	29	84	88	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2540	2547		10.1038/sj.onc.1207366	http://dx.doi.org/10.1038/sj.onc.1207366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676825				2022-12-28	WOS:000220558000011
J	Wang, N; Kudryavtseva, E; Ch'en, IL; McCormick, J; Sugihara, TM; Ruiz, R; Andersen, B				Wang, N; Kudryavtseva, E; Ch'en, IL; McCormick, J; Sugihara, TM; Ruiz, R; Andersen, B			Expression of an engrailed-LMO4 fusion protein in mammary epithelial cells inhibits mammary gland development in mice	ONCOGENE			English	Article						LMO4; mammary gland development; heregulin; engrailed fusion protein	LIM DOMAIN GENE; TRANSGENIC MICE; LOBULOALVEOLAR DEVELOPMENT; TRANSCRIPTION FACTORS; HOMEODOMAIN PROTEINS; BREAST-CANCER; GROWTH-FACTOR; LMO PROTEINS; DIFFERENTIATION; BINDING	LIM domain factors and associated cofactors are important developmental regulators in pattern formation and organogenesis. In addition, overexpression of two LIM-only factors (LMOs) causes acute lymphocytic leukemia. The more recently discovered LMO factor LMO4 is highly expressed in proliferating epithelial cells, and frequently overexpressed in breast carcinoma. Here we show that while LMO4 is expressed throughout mammary gland development, it is dramatically upregulated in mammary epithelial cells during midpregnancy. The LMO coactivator Clim2/Ldb1/NLI showed a similar expression pattern, consistent with the idea that LMO4 and Clim2 act as a complex in mammary epithelial cells. In MCF-7 cells, LMO4 transcripts were upregulated by heregulin, an activator of ErbB receptors that are known to be important in mammary gland development and breast cancer. To test the hypothesis that LMO4 plays roles in mammary gland development, we created an engrailed-LMO4 fusion protein. This fusion protein maintains the ability to interact with Clim2, but acts as a dominant repressor of both basal and activated transcription when recruited to a DNA-regulatory region. When the engrailed-LMO4 fusion protein was expressed under control of the MMTV promoter in transgenic mice, both ductular development in virgin mice and alveolar development in pregnant mice were inhibited. These results suggest that LMO4 plays a role in promoting mammary gland development.	Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Div Endocrinol & Metab, Irvine, CA 92697 USA; Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu			NIAMS NIH HHS [AR02080] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR002080] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Andersen B, 1997, GENE DEV, V11, P1873, DOI 10.1101/gad.11.14.1873; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Bao JX, 2000, DEVELOPMENT, V127, P425; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Chen CB, 2002, DEVELOPMENT, V129, P2401; Dasen JS, 1999, CELL, V97, P587, DOI 10.1016/S0092-8674(00)80770-9; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Gruvberger S, 2001, CANCER RES, V61, P5979; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; Herblot S, 2000, NAT IMMUNOL, V1, P138, DOI 10.1038/77819; Hollemann T, 1998, DEVELOPMENT, V125, P2425; Jones FE, 1999, ONCOGENE, V18, P3481, DOI 10.1038/sj.onc.1202698; Jones FE, 1996, CELL GROWTH DIFFER, V7, P1031; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; Kudoh T, 2001, P NATL ACAD SCI USA, V98, P7852, DOI 10.1073/pnas.141224098; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Li L, 2002, ONCOGENE, V21, P4900, DOI 10.1038/sj.onc.1205634; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Mead PE, 2001, DEVELOPMENT, V128, P2301; Montross WT, 2000, J CELL SCI, V113, P1759; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; Osada H., 1997, Leukemia (Basingstoke), V11, P307; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; Rabbitts TH, 1999, CANCER RES, V59, p1794S; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Rudland PS, 1998, BIOCHEM SOC SYMP, P1; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Sykes TG, 1998, DEVELOPMENT, V125, P4595; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637	52	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1507	1513		10.1038/sj.onc.1207288	http://dx.doi.org/10.1038/sj.onc.1207288			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14676840				2022-12-28	WOS:000189219500003
J	Regl, G; Kasper, M; Schnidar, H; Eichberger, T; Neill, GW; Ikram, MS; Quinn, AG; Philpott, MP; Frischauf, AM; Aberger, F				Regl, G; Kasper, M; Schnidar, H; Eichberger, T; Neill, GW; Ikram, MS; Quinn, AG; Philpott, MP; Frischauf, AM; Aberger, F			The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells	ONCOGENE			English	Article						hedgehog signalling; GLI proteins; keratinocytes; basal cell carcinoma; epidermal differentiation; cell cycle	SONIC HEDGEHOG; KERATINOCYTE DIFFERENTIATION; GENE-EXPRESSION; CYCLE PROGRESSION; UP-REGULATION; TARGET GENES; FLOOR PLATE; BASAL; PROLIFERATION; CARCINOMA	In stratified epidermis, activation of the Hh/Gli signal transduction pathway has been implicated in the control of cell proliferation and tumorigenesis. The zinc-finger transcription factor Gli2 has been identified as critical mediator of the Hh signal at the distal end of the pathway, but the molecular mechanisms by which Gli2 regulates cell proliferation or induces epidermal malignancies such as basal cell carcinoma are still unclear. Here, we provide evidence for a role of human GLI2 in antagonizing contact inhibition and epidermal differentiation. We show by gene expression pro. ling that activation of the GLI2 oncogene in human keratinocytes activates the transcription of a number of genes involved in cell cycle progression such as E2F1, CCND1, CDC2 and CDC45L, while it represses genes associated with epidermal differentiation. Analysis of the proliferative effect of GLI2 revealed that GLI2 is able to induce G1-S phase progression in contact-inhibited keratinocytes. Detailed time-course experiments identified E2F1 as early transcriptional target of GLI2. Further, we show that GLI2 expression in human keratinocytes results in a marked downregulation of epidermal differentiation markers. The data suggest a role for GLI2 in Hh-induced epidermal neoplasia by opposing epithelial cell cycle arrest signals and epidermal differentiation.	Salzburg Univ, Inst Genet, A-5020 Salzburg, Austria; Univ London, Barts & London Queen Mary Sch Med & Dent, Ctr Cutaneaous Res, London WC1E 7HU, England; AstraZeneca R&D Charnwood, Expt Med, Loughborough, Leics, England	Salzburg University; University of London; Queen Mary University London; AstraZeneca	Aberger, F (corresponding author), Salzburg Univ, Inst Genet, Hellbrunner Str 34, A-5020 Salzburg, Austria.	fritz.aberger@sbg.ac.at	Kasper, Maria/Q-6318-2016; Schnidar, Harald/C-7049-2009; Neill, Graham/C-9008-2012; Aberger, Fritz/B-6357-2012	Aberger, Fritz/0000-0003-2009-6305; Philpott, Michael/0000-0002-1255-4612; Kasper, Maria/0000-0002-6117-2717				Aberger F, 2001, GENOMICS, V77, P50, DOI 10.1006/geno.2001.6623; Arata Y, 2000, J BIOL CHEM, V275, P6337, DOI 10.1074/jbc.275.9.6337; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai CB, 2002, DEVELOPMENT, V129, P4753; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Bonifas JM, 2001, J INVEST DERMATOL, V116, P739, DOI 10.1046/j.1523-1747.2001.01315.x; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Chopra A, 1998, J INVEST DERMATOL, V110, P52, DOI 10.1046/j.1523-1747.1998.00089.x; Deng H, 1997, NAT BIOTECHNOL, V15, P1388, DOI 10.1038/nbt1297-1388; Ding Q, 1998, DEVELOPMENT, V125, P2533; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Garach-Jehoshua O, 1998, BRIT J DERMATOL, V139, P950; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jee SH, 2001, ONCOGENE, V20, P198, DOI 10.1038/sj.onc.1204076; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Matise MP, 1998, DEVELOPMENT, V125, P2759; Medvedev A, 1999, J BIOL CHEM, V274, P3887, DOI 10.1074/jbc.274.6.3887; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Morasso MI, 1996, J CELL BIOL, V135, P1879, DOI 10.1083/jcb.135.6.1879; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Nickoloff BJ, 2002, CELL DEATH DIFFER, V9, P842, DOI 10.1038/sj.cdd.4401036; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rutberg SE, 1996, ONCOGENE, V13, P167; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SAVOIA P, 1993, J INVEST DERMATOL, V101, P352, DOI 10.1111/1523-1747.ep12365531; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; Sheng H, 2002, CANCER RES, V62, P5308; Sherr CJ, 2000, CANCER RES, V60, P3689; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Takahashi H, 1997, J INVEST DERMATOL, V108, P843, DOI 10.1111/1523-1747.ep12292575; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Tuominen H, 1997, J CUTAN PATHOL, V24, P590, DOI 10.1111/j.1600-0560.1997.tb01089.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Varani J, 2000, BRIT J CANCER, V82, P657, DOI 10.1054/bjoc.1999.0978; Watanabe R, 1998, J BIOL CHEM, V273, P9651, DOI 10.1074/jbc.273.16.9651; Weiner HL, 2002, CANCER RES, V62, P6385; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9; Wetmore C, 2003, CURR OPIN GENET DEV, V13, P34, DOI 10.1016/S0959-437X(03)00002-9; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; ZETTERGREN JG, 1984, P NATL ACAD SCI-BIOL, V81, P238, DOI 10.1073/pnas.81.1.238	60	70	73	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1263	1274		10.1038/sj.onc.1207240	http://dx.doi.org/10.1038/sj.onc.1207240			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14691458				2022-12-28	WOS:000188892200011
J	Bossi, G; Mazzaro, G; Porrello, A; Crescenzi, M; Soddu, S; Sacchi, A				Bossi, G; Mazzaro, G; Porrello, A; Crescenzi, M; Soddu, S; Sacchi, A			Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy	ONCOGENE			English	Article						p53; gene therapy; tumor targeting; normal cells; retrovirus vector	HEMATOPOIETIC STEM-CELLS; SUPPRESSOR GENE; RETROVIRAL VECTORS; EXOGENOUS WT-P53; 32D CELLS; CANCER; DIFFERENTIATION; TRANSPLANTATION; EXPRESSION; ONCOGENES	The p53 oncosuppressor is strictly maintained in an inactive form under normal conditions, while it is post-translationally activated by a variety of stresses, enacting different protective biological functions. Since one critical issue in cancer gene therapy is tumor specificity, we asked whether the tight p53 regulation applies also to exogenously transferred p53. In principle, this type of regulation could allow p53 gene transfer in both normal and tumor cells to produce detrimental effects only in the latter ones. Here, we report that primary bone marrow cells infected with a p53 recombinant retrovirus and transplanted into irradiated mice reconstitute the hematopoietic system, with no detectable alterations in any of its compartments. Furthermore, simultaneous infection of leukemia and bone marrow cells depleted the neoplastic contamination, allowing lifelong, disease-free survival of 65% of the transplanted animals. These results show that exogenous p53 is controlled as tightly as the endogenous one, and opens the way to p53 gene therapy, without requiring tumor targeting.	Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, I-00158 Rome, Italy; Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS)	Soddu, S (corresponding author), Regina Elena Inst Canc Res, Dept Expt Oncol, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.	soddu@ifo.it; sacchi@ifo.it	Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/ABH-6846-2020; Soddu, Silvia/K-2467-2018; Soddu, Silvia/ABH-6774-2020; Crescenzi, Marco/J-3603-2018; Bossi, Gianluca/B-9394-2017	Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Soddu, Silvia/0000-0001-8526-0044; Crescenzi, Marco/0000-0003-0156-1494; Bossi, Gianluca/0000-0002-2947-1063	Telethon [GP0234Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALMOG N, 1997, BIOCHIM BIOPHYS ACTA, V1333, P1; Appella E, 2000, PATHOL BIOL, V48, P227; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BLANDINO G, 1995, ONCOGENE, V10, P731; BODINE DM, 1991, EXP HEMATOL, V19, P206; Bossi G, 2000, CANCER GENE THER, V7, P135, DOI 10.1038/sj.cgt.7700101; CLAYMAN GL, 1995, CANCER RES, V55, P1; D'Orazi G, 2000, J GENE MED, V2, P11; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; Favrot M, 1998, GENE THER, V5, P728, DOI 10.1038/sj.gt.3300661; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; Gorin NC, 2002, CURR OPIN ONCOL, V14, P152, DOI 10.1097/00001622-200203000-00003; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Harris CC, 1996, JNCI-J NATL CANCER I, V88, P1442, DOI 10.1093/jnci/88.20.1442; Heslop HE, 1995, BLOOD REV, V9, P220, DOI 10.1016/S0268-960X(95)90013-6; Karlsson S, 1997, J INTERN MED, V242, P95, DOI 10.1111/joim.1997.242.s740.95; KASTAN MB, 1991, CANCER RES, V51, P4279; LaCasse EC, 1999, BLOOD, V94, P2901; Martinelli R, 1997, ONCOGENE, V15, P607, DOI 10.1038/sj.onc.1201218; Mazzaro G, 1999, ONCOGENE, V18, P5831, DOI 10.1038/sj.onc.1202962; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nielsen LL, 1998, CANCER GENE THER, V5, P52; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Soddu S, 1996, MOL CELL BIOL, V16, P487; Soddu S, 1998, CYTOKINES CELL MOL T, V4, P177; TAKAHASHI T, 1992, CANCER RES, V52, P2340; Williams David A., 2000, Hematology Am Soc Hematol Educ Program, P376; WILLS KN, 1994, HUM GENE THER, V5, P1079, DOI 10.1089/hum.1994.5.9-1079; Yang SL, 1999, HUM GENE THER, V10, P123, DOI 10.1089/10430349950019255; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155	34	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					418	425		10.1038/sj.onc.1207042	http://dx.doi.org/10.1038/sj.onc.1207042			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724570				2022-12-28	WOS:000188098300012
J	Petrovics, G; Zhang, W; Makarem, M; Street, JP; Connelly, R; Sun, L; Sesterhenn, IA; Srikantan, V; Moul, JW; Srivastava, S				Petrovics, G; Zhang, W; Makarem, M; Street, JP; Connelly, R; Sun, L; Sesterhenn, IA; Srikantan, V; Moul, JW; Srivastava, S			Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients	ONCOGENE			English	Article						PCGEM1; prostate-specific gene; prostate cancer; high-risk patients; cell proliferation	VIRUS-INDUCED LYMPHOMAS; AFRICAN-AMERICAN; RETINOBLASTOMA PROTEIN; PHOSPHORYLATION; OVEREXPRESSION; INSERTIONS; RACEMASE; MARKERS; RNA	PCGEM1 is a novel, highly prostate tissue-specific, androgen-regulated gene. Here, we demonstrate that PCGEM1 expression is significantly higher in prostate cancer (CaP) cells of African-American men than in Caucasian-American men (P=0.0002). Further, increased PCGEM1 expression associates with normal prostate epithelial cells of CaP patients with a family history of CaP (P=0.0400). PCGEM1 overexpression in LNCaP and in NIH3T3 cells promotes cell proliferation and a dramatic increase in colony formation, suggesting a biological role of PCGEM1 in cell growth regulation. Taken together, the cell proliferation/colony formation-promoting functions of PCGEM1 and the association of its increased expression with high-risk CaP patients suggest the potential roles of PCGEM1 in CaP onset/progression, especially in these high-risk groups.	Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, US Mil Canc Inst, Bethesda, MD 20814 USA; Armed Forces Inst Pathol, Dept Genitourinary Pathol, Washington, DC 20306 USA; Walter Reed Army Med Ctr, Serv Urol, Washington, DC 20307 USA	Uniformed Services University of the Health Sciences - USA; United States Department of Defense; United States Department of Defense; United States Army; Walter Reed National Military Medical Center	Petrovics, G (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, 1530 E Jefferson St, Rockville, MD 20852 USA.	gpetrovics@cpdr.org		Petrovics, Gyorgy/0000-0003-3732-284X	NCI NIH HHS [1R01CA85596-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1994, MOL CELL BIOL, V14, P1743, DOI 10.1128/MCB.14.3.1743; Brantey MA, 2000, CANCER RES, V60, P4320; Brawley O W, 1998, Semin Urol Oncol, V16, P193; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Cussenot O, 2001, Eur J Intern Med, V12, P11, DOI 10.1016/S0953-6205(00)00136-9; de Kok JB, 2002, CANCER RES, V62, P2695; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Guo YP, 2000, PROSTATE, V42, P130, DOI 10.1002/(SICI)1097-0045(20000201)42:2<130::AID-PROS7>3.0.CO;2-3; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Luo J, 2002, CANCER RES, V62, P2220; Magee JA, 2001, CANCER RES, V61, P5692; MOUL JW, 1995, JAMA-J AM MED ASSOC, V274, P1277, DOI 10.1001/jama.274.16.1277; Nelson WG, 2001, ANN NY ACAD SCI, V952, P135, DOI 10.1111/j.1749-6632.2001.tb02734.x; Paris PL, 1999, CANCER EPIDEM BIOMAR, V8, P901; Platz EA, 2000, JNCI-J NATL CANCER I, V92, P2009, DOI 10.1093/jnci/92.24.2009; Powell I J, 1998, Semin Urol Oncol, V16, P221; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Small Eric J., 1998, Current Opinion in Oncology, V10, P244, DOI 10.1097/00001622-199805000-00012; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Szymanski M, 2002, GENOME BIOL, V3; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Taylor JA, 1996, CANCER RES, V56, P4108; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Welsh JB, 2001, CANCER RES, V61, P5974; Xu JF, 2002, NAT GENET, V32, P321, DOI 10.1038/ng994; Xu LL, 2000, J UROLOGY, V163, P972, DOI 10.1016/S0022-5347(05)67867-6; Yan H, 2002, NAT GENET, V30, P25, DOI 10.1038/ng799; Yang G, 2000, CLIN CANCER RES, V6, P3430	33	190	211	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					605	611		10.1038/sj.onc.1207069	http://dx.doi.org/10.1038/sj.onc.1207069			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724589				2022-12-28	WOS:000188098300032
J	Yoshida, K; Oyaizu, N; Dutta, A; Inoue, I				Yoshida, K; Oyaizu, N; Dutta, A; Inoue, I			The destruction box of human Geminin is critical for proliferation and tumor growth in human colon cancer cells	ONCOGENE			English	Article						Geminin; destruction box; DNA replication initiation; tumor growth	DNA-REPLICATION; CHECKPOINT; INHIBITION; COMPLEXES; ARREST; ORIP; CDT1; P53; PROTEINS; ANAPHASE	A domain-specific disruption was performed on the destruction box sequence of endogenous Geminin gene, an inhibitor of the DNA replication initiation complex, in a human cancer cell line HCT116 resulting in the formation of a protein that was stable in the G1 phase of the cell cycle. Although the total amount of Geminin in asynchronous cultures was not elevated, the G1-specific stabilization of Geminin, diminished chromatin loading of minichromosome maintenance complex, inhibited DNA replication, and resulted in the accumulation of cells in G1. The mutated Geminin suppressed in vivo tumorigenicity and in vitro cell growth. Cells carrying this mutation failed to support the replication of a plasmid bearing the oriP replicator of Epstein-Barr virus. The DNA damage checkpoint pathway was activated in the mutated cells with increased levels of p53 protein and its target, the p21 protein. All these deficits were rescued by overexpression of Cdt1, a replication initiator protein that binds to Geminin. Therefore, alteration of the cell cycle-dependent regulation of endogenous Geminin in human cells without increasing total protein level inhibits DNA replication and suppresses tumor growth.	Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, Tokyo, Japan; Univ Tokyo, Inst Med Sci, Dept Lab Med, Div Mol Pathol,Minato Ku, Tokyo, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Tokyo; University of Tokyo; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Yoshida, K (corresponding author), Univ Tokyo, Inst Med Sci, Div Genet Diag, Minato Ku, 4-6-1 Shirokanedai, Tokyo, Japan.	yoshidak@ims.u-tokyo.ac.jp	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Chaudhuri B, 2001, P NATL ACAD SCI USA, V98, P10085, DOI 10.1073/pnas.181347998; Chehab NH, 2000, GENE DEV, V14, P278; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dhar SK, 2001, CELL, V106, P287, DOI 10.1016/S0092-8674(01)00458-5; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Lei M, 2001, J CELL SCI, V114, P1447; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 2002, MOL BIOL CELL, V13, P3662, DOI 10.1091/mbc.E02-04-0199; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Shieh SY, 2000, GENE DEV, V14, P289; Shreeram S, 2002, ONCOGENE, V21, P6624, DOI 10.1038/sj.onc.1205910; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Yates JL, 2000, J VIROL, V74, P4512, DOI 10.1128/JVI.74.10.4512-4522.2000; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039	36	33	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					58	70		10.1038/sj.onc.1206987	http://dx.doi.org/10.1038/sj.onc.1206987			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712211				2022-12-28	WOS:000187895300007
J	Loffler, H; Syljuasen, RG; Bartkova, J; Worm, J; Lukas, J; Bartek, J				Loffler, H; Syljuasen, RG; Bartkova, J; Worm, J; Lukas, J; Bartek, J			Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines	ONCOGENE			English	Article						DNA damage; cell cycle checkpoints; Cdc25A; proteolysis; breast cancer	DNA-DAMAGE; S-PHASE; CYCLIN D1; C-MYC; CHECKPOINT; EXPRESSION; PROTEIN; GENE; ATM; OVEREXPRESSION	The rapid cell cycle arrest in response to DNA damage is mediated by degradation of the Cdc25A phosphatase, a proto-oncogene whose mRNA is frequently overexpressed in human tumours. Here, we study the occurrence and mechanisms of Cdc25A deregulation in human breast cancer cell lines. We demonstrate aberrantly elevated Cdc25A protein abundance and phosphatase activity in eight out of 15 cell lines, in some cases resulting in abrogation of the Cdc25A-mediated checkpoint response to ionizing radiation (IR), and this defect correlated with hypersensitivity to IR. Furthermore, we present evidence that deregulation of Cdc25A occurs predominantly on the post-transcriptional level, as overabundant Cdc25A protein was usually not accompanied by adequate mRNA overexpression. Instead, we demonstrate that aberrantly enhanced protein stability is an important mechanism underlying Cdc25A overabundance in a subset of breast cancer cell lines. Given the frequency of this mechanism, we propose that the DNA integrity checkpoint controlling Cdc25A protein stability might be a common target for deregulation in breast cancer.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mondesert O, 2002, BIOCHEM BIOPH RES CO, V295, P673, DOI 10.1016/S0006-291X(02)00739-8; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishioka K, 2001, BRIT J CANCER, V85, P412, DOI 10.1054/bjoc.2001.1934; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu WG, 1998, CANCER RES, V58, P4082; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8063	8071		10.1038/sj.onc.1206976	http://dx.doi.org/10.1038/sj.onc.1206976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603247				2022-12-28	WOS:000186403400001
J	Ando, K; Kanazawa, S; Tetsuka, T; Ohta, S; Jiang, X; Tada, T; Kobayashi, M; Matsui, N; Okamoto, T				Ando, K; Kanazawa, S; Tetsuka, T; Ohta, S; Jiang, X; Tada, T; Kobayashi, M; Matsui, N; Okamoto, T			Induction of Notch signaling by tumor necrosis factor in rheumatoid synovial fibroblasts	ONCOGENE			English	Article						rheumatoid arthritis; transformation; notch; Jagged; gene expression; TNF	NF-KAPPA-B; INTRACELLULAR DOMAIN; GENE-EXPRESSION; ARTHRITIS; ALPHA; ACTIVATION; KINASE; MICE; IL-6; SYNOVIOCYTES	Rheumatoid arthritis ( RA) is characterized by progressive inflammation associated with abberrant proliferation of synoviocytes. In order to explore the characteristics of rheumatoid synovial fibroblasts (RSF), we performed the comparative gene expression profile analysis between RSF and normal synovial. broblasts (NSF) upon tumor necrosis factor (TNF) stimulation. As an initial screening for the genes preferentially induced by TNF in RSF compared with NSF, we have adopted a cDNA array containing well-defined sets of genes responsible for cell growth, cell fate determination, and cellular invasiveness. Differentially expressed genes of interest were confirmed using real-time RT-PCR. We found that TNF induced the expression of Notch-1, Notch-4, and Jagged-2 in RSF. The expression of these proteins was detected in the RA synovial tissues. The nucleus of RA synoviocytes showed strong staining with anti-Notch-1 and Notch-4 antibody. TNF induced the nuclear translocation of Notch intracellular domain in RSF, indicating the elicitation of the Notch signaling. Notch-1, Notch-4, and Jagged-2 proteins were also detected in the developing synovium of mouse embryo. Thus, RSF may have re-acquired the primordial phenotype, accounting for the hyperproliferation and aggressive invasiveness, exhibiting tumor-like phenotype.	Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Med, Dept Orthoped, Nagoya, Aichi 4678601, Japan; Nagoya City Univ, Sch Nursing, Dept Pathol, Nagoya, Aichi 4678601, Japan	Nagoya City University; Nagoya City University; Nagoya City University	Okamoto, T (corresponding author), Nagoya City Univ, Sch Med, Dept Mol Genet, Mizuho Ku, 1 Kawasumi,Mizuho Cho, Nagoya, Aichi 4678601, Japan.							ALVAROGRACIA JM, 1991, J IMMUNOL, V146, P3365; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Constantin A, 2002, ARTHRITIS RHEUM, V46, P1754, DOI 10.1002/art.10336; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fassbender H G, 1980, Verh Dtsch Ges Pathol, V64, P193; FASSBENDER HG, 1983, J PATHOL, V139, P399, DOI 10.1002/path.1711390314; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Feldmann M, 2001, J CLIN INVEST, V107, P1353, DOI 10.1172/JCI13209; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Kajino S, 2000, ONCOGENE, V19, P2233, DOI 10.1038/sj.onc.1203560; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MullerLadner U, 1996, AM J PATHOL, V149, P1607; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; Nakazawa M, 2001, ARTHRITIS RHEUM-US, V44, P1545, DOI 10.1002/1529-0131(200107)44:7<1545::AID-ART278>3.0.CO;2-Q; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Okamoto T, 1997, CURR TOP CELL REGUL, V35, P149, DOI 10.1016/S0070-2137(97)80006-4; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Sen M, 2002, ARTHRITIS RHEUM, V46, P2867, DOI 10.1002/art.10593; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Suzuki M, 2000, FEBS LETT, V465, P23, DOI 10.1016/S0014-5793(99)01717-2; Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598; Watanabe N, 2002, BIOCHEM BIOPH RES CO, V294, P1121, DOI 10.1016/S0006-291X(02)00608-3; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Yoshida S, 1999, INT IMMUNOL, V11, P151, DOI 10.1093/intimm/11.2.151; Yoshida S, 1999, J IMMUNOL, V163, P351	31	93	100	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7796	7803		10.1038/sj.onc.1206965	http://dx.doi.org/10.1038/sj.onc.1206965			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586405				2022-12-28	WOS:000186240200009
J	Nawata, R; Yujiri, T; Nakamura, Y; Ariyoshi, K; Takahashi, T; Sato, Y; Oka, Y; Tanizawa, Y				Nawata, R; Yujiri, T; Nakamura, Y; Ariyoshi, K; Takahashi, T; Sato, Y; Oka, Y; Tanizawa, Y			MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappa B activation	ONCOGENE			English	Article						MEK kinase 1; Bcr-Abl; NF-kappa B	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; DNA-DAMAGE; GENE DISRUPTION; APOPTOSIS; TRANSFORMATION; EXPRESSION; CELLS; JUN; PROTEIN	Bcr-Abl tyrosine kinase, a chimeric oncoprotein responsible for chronic myelogenous leukemia, constitutively activates several signal transduction pathways that stimulate cell proliferation and prevent apoptosis in hematopoietic cells. The antiapoptotic function of Bcr-Abl is necessary for hematopoietic transformation, and also contributes to leukemogenesis. Herein, we show for the first time that cell transformation induced by Bcr-Abl leads to increased expression and kinase activity of MEK kinase 1 (MEKK1), which acts upstream of the c-Jun N-terminal kinase (JNK), extracellular signal regulated kinase (ERK) and NF-kappaB signaling pathways. Inhibition of MEKK1 activity using a dominant-negative MEKK1 mutant (MEKK1km) diminished the ability of Bcr-Abl to protect cells from genotoxin-induced apoptosis, but had no effect on the proliferation of Bcr-Abl-transformed cells. Expression of MEKK1km also reduced NF-kappaB activation, and inhibited antiapoptotic c-IAP1 and c-IAP2 mRNA expression in response to the genotoxin. By contrast, neither JNK nor ERK activation was affected. These results indicate that MEKK1 is a downstream target of Bcr-Abl, and that the antiapoptotic effect of Bcr-Abl in chronic myelogenous leukemia cells is mediated via the MEKK1-NF-kappaB pathway.	Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Yamaguchi 7558505, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet, Sendai, Miyagi 9808575, Japan	Yamaguchi University; Tohoku University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.		Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hirano T, 2002, ONCOGENE, V21, P5923, DOI 10.1038/sj.onc.1205643; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; ODA T, 1994, J BIOL CHEM, V269, P22925; Onishi M, 1996, EXP HEMATOL, V24, P324; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	38	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7774	7780		10.1038/sj.onc.1206901	http://dx.doi.org/10.1038/sj.onc.1206901			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586403				2022-12-28	WOS:000186240200007
J	Harmala-Brasken, AS; Mikhailov, A; Soderstrom, TS; Meinander, A; Holmstrom, TH; Damuni, Z; Eriksson, JE				Harmala-Brasken, AS; Mikhailov, A; Soderstrom, TS; Meinander, A; Holmstrom, TH; Damuni, Z; Eriksson, JE			Type-2A protein phosphatase activity is required to maintain death receptor responsiveness	ONCOGENE			English	Article						PP2A; inhibition; I-2(PP2A); calyculin A; receptor-induced apoptosis	OKADAIC ACID; CELL-TRANSFORMATION; MEDIATED APOPTOSIS; TUMOR PROMOTION; KINASE-ACTIVITY; 2A; EXPRESSION; INHIBITORS; CANCER; FAS	Type-2A protein phosphatase (PP2A) is a key regulator in many different cell signaling pathways and an important determinant in tumorigenesis. One of the signaling targets of PP2A is the mitogen-activated protein kinase (MAPK/ ERK) cascade. In this study, we wanted to determine whether PP2A could be involved in regulation of death receptor activity through its capacity to regulate MAPK/ ERK. To this end, we studied the effects of two different routes of protein phosphatase inhibition on death receptor-mediated apoptosis. We demonstrated that the apoptosis mediated by Fas, TNF-alpha, and TRAIL in U937 cells is suppressed by calyculin A, an inhibitor of type-1 and type-2A protein phosphatases. The inhibition of the protein phosphatase activity was shown to subsequently increase the MAPK activity in these cells, and the level of activation corresponded to the degree of suppression of cytokine-mediated apoptosis. A more physiological inhibitor, the intracellular PP2A inhibitor protein I-2(PP2A), protected transfected HeLa cells in a similar way from Fas-mediated apoptosis and induced activation of MAPK in I-2(PP2A) transfected cells. A corresponding inhibition could also be obtained by stable transfection with a constitutively active form of the MAPK kinase, MKK1 (also referred to as MEK1). The inhibitor-mediated protection was highly efficient in preventing early stages of apoptosis, as no caspase-8 cleavage occurred in these cells. The observed apoptosis suppression is likely to facilitate the tumor-promoting effect of a range of different type-2A protein phosphatase inhibitors, and could explain the reported tumor association of I-2(PP2A).	Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biol, FIN-20520 Turku, Finland; Univ Turku, Dept Biol, Physiol Anim Lab, FIN-20014 Turku, Finland; Glogozymes, Carlsbad, CA 92009 USA	Abo Akademi University; University of Turku; Abo Akademi University; Abo Akademi University; University of Turku	Eriksson, JE (corresponding author), Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, POB 123, FIN-20521 Turku, Finland.	john.eriksson@utu.fl	Meinander, Annika/E-9260-2017	Meinander, Annika/0000-0002-3878-2293				Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brautigan DL, 1997, ADV SEC MESS PHOSPH, V31, P113; BRAUTIGAN DL, 1993, MOL CELL BIOCHEM, V128, P121; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; ERIKSSON JE, 1990, BIOCHIM BIOPHYS ACTA, V1025, P60, DOI 10.1016/0005-2736(90)90190-Y; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; OHOKA Y, 1993, BIOCHEM BIOPH RES CO, V197, P916, DOI 10.1006/bbrc.1993.2566; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Quintaje SB, 1996, BIOCHEM BIOPH RES CO, V221, P539, DOI 10.1006/bbrc.1996.0632; Rosenberger SF, 1996, ONCOGENE, V12, P2301; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393	41	35	37	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7677	7686		10.1038/sj.onc.1207077	http://dx.doi.org/10.1038/sj.onc.1207077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576831				2022-12-28	WOS:000186113000016
J	Fojo, T; Bates, S				Fojo, T; Bates, S			Strategies for reversing drug resistance	ONCOGENE			English	Review						ABC transporters; p53; apoptosis; methylation; glutathione	P53 GENE-TRANSFER; PHASE-I TRIAL; CELL LUNG-CANCER; MEDIATED MULTIDRUG-RESISTANCE; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; HUMAN TUMOR-CELLS; P-GLYCOPROTEIN; ANTISENSE OLIGONUCLEOTIDES; BUTHIONINE SULFOXIMINE	Drug resistance, intrinsic or acquired, is a problem for all chemotherapeutic agents. In this review, we examine numerous strategies that have been tested or proposed to reverse drug resistance. Included among these strategies are approaches targeting the apoptosis pathway. Although the process of apoptosis is complex, it provides several potential sites for therapeutic intervention. A variety of targets and approaches are being pursued, including the suppression of proteins inhibiting apoptosis using antisense oligonucleotides (ASOs), and small molecules targeted at proteins that modulate apoptosis. An alternate strategy is based on numerous studies that have documented methylation of critical regions in the genome in human cancers. Consequently, efforts have been directed at re-expressing genes, including genes that affect drug sensitivity, using 5-azacytidine and 2'-deoxy-5-azacytidine (DAC, decitabine) as demethylating agents. While this strategy may be effective as a single modality, success will most likely be achieved if it is used to modulate gene expression in combination with other modalities such as chemotherapy. At a more basic level, attempts have been made to modulate glutathione (GSH) levels. Owing to its reactivity and high intracellular concentrations, GSH has been implicated in resistance to several chemotherapeutic agents. Several approaches designed to deplete intracellular GSH levels have been pursued including the use of buthionine-(S, R)-sulfoxime (BSO), a potent and specific inhibitor of gamma-glutamyl cysteine synthetase (gamma-GCS), the rate-limiting step in the synthesis of GSH, a hammerhead ribozyme against gamma-GCS mRNA to downregulate specifically its levels and targeting cJun expression to reduce GSH levels. Alternate strategies have targeted p53. The frequent occurrence of p53 mutations in human cancer has led to the development of numerous approaches to restore wild-type (wt) p53. The goals of these interventions are to either revert the malignant phenotype or enhance drug sensitivity. The approach most extensively investigated has utilized one of several viral vectors. An alternate approach, the use of small molecules to restore wt function to mutant p53, remains an option. Finally, the conceptually simplest mechanism of resistance is one that reduces intracellular drug accumulation. Such reduction can be effected by a variety of drug efflux pumps, of which the most widely studied is P-glycoprotein (Pgp). The first strategy utilized to inhibit Pgp function relied on the identication of nonchemotherapeutic agents as competitors. Other approaches have included the use of hammerhead ribozymes against the MDR-1 gene and MDR-1-targeted ASOs. Although modulation of drug resistance has not yet been proven to be an effective clinical tool, we have learned an enormous amount about drug resistance. Should we succeed, these pioneering basic and clinical studies will have paved the road for future developments.	NCI, Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fojo, T (corresponding author), NCI, Ctr Canc Res, Bldg 10,Room 12C103,9000 Rockville Pike, Bethesda, MD 20892 USA.	tfojo@helix.nih.gov	Bates, Susan/AFP-9514-2022		NATIONAL CANCER INSTITUTE [ZIABC010620, Z01BC010620, Z01SC006732, ZIASC006732] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Advani R, 1999, BLOOD, V93, P787, DOI 10.1182/blood.V93.3.787.403k30_787_795; Aebi S, 1997, CLIN CANCER RES, V3, P1763; Aina OH, 2002, BIOPOLYMERS, V66, P184, DOI 10.1002/bip.10257; Avendano C, 2002, CURR MED CHEM, V9, P159, DOI 10.2174/0929867023371175; BAILEY HH, 1994, J CLIN ONCOL, V12, P194, DOI 10.1200/JCO.1994.12.1.194; Bailey HH, 1998, CHEM-BIOL INTERACT, V112, P239, DOI 10.1016/S0009-2797(97)00164-6; BARTLETT NL, 1994, J CLIN ONCOL, V12, P835, DOI 10.1200/JCO.1994.12.4.835; BARTON CM, 1995, BRIT J CANCER, V71, P429, DOI 10.1038/bjc.1995.88; Bender CM, 1998, CANCER RES, V58, P95; Benderra Z, 2000, EUR J CANCER, V36, P428, DOI 10.1016/S0959-8049(99)00288-9; Bergelson JM, 1998, J VIROL, V72, P415, DOI 10.1128/JVI.72.1.415-419.1998; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Blagosklonny MV, 1998, INT J CANCER, V75, P933, DOI 10.1002/(SICI)1097-0215(19980316)75:6<933::AID-IJC17>3.0.CO;2-3; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Boulay JL, 2000, CANCER GENE THER, V7, P1215, DOI 10.1038/sj.cgt.7700227; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Bouvet M, 1998, CANCER RES, V58, P2288; Bradshaw DM, 1998, J CLIN ONCOL, V16, P3674, DOI 10.1200/JCO.1998.16.11.3674; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chan JYW, 1999, LIFE SCI, V65, P63, DOI 10.1016/S0024-3205(99)00219-2; Chan JYW, 2000, LIFE SCI, V67, P2117, DOI 10.1016/S0024-3205(00)00798-0; Childs S, 1998, CANCER RES, V58, P4160; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DAMERON KM, 1994, COLD SPRING HARB SYM, V59, P483, DOI 10.1101/SQB.1994.059.01.053; DANO K, 1973, BIOCHIM BIOPHYS ACTA, V323, P466, DOI 10.1016/0005-2736(73)90191-0; Dantzig AH, 1999, J PHARMACOL EXP THER, V290, P854; Dassow H, 2000, INT J CLIN PHARM TH, V38, P209; de Bruin M, 1999, CANCER LETT, V146, P117, DOI 10.1016/S0304-3835(99)00182-2; Dedoussis GVZ, 2001, EUR J CELL BIOL, V80, P608, DOI 10.1078/0171-9335-00193; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dix BR, 2001, J VIROL, V75, P5443, DOI 10.1128/JVI.75.12.5443-5447.2001; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Durant ST, 1999, CURR BIOL, V9, P51, DOI 10.1016/S0960-9822(99)80047-5; Fakhrai H, 1996, P NATL ACAD SCI USA, V93, P2909, DOI 10.1073/pnas.93.7.2909; Fechner H, 1999, GENE THER, V6, P1520, DOI 10.1038/sj.gt.3301030; FEDELI L, 1989, CANCER, V64, P1805, DOI 10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO;2-D; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Ferry DR, 1996, EUR J CANCER, V32A, P1070, DOI 10.1016/0959-8049(96)00091-3; FISHER GA, 1995, HEMATOL ONCOL CLIN N, V9, P363, DOI 10.1016/S0889-8588(18)30099-6; Fisher GA, 1996, EUR J CANCER, V32A, P1082, DOI 10.1016/0959-8049(96)00111-6; FORD JM, 1990, PHARMACOL REV, V42, P155; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gao ZQ, 1999, INT J CANCER, V82, P346, DOI 10.1002/(SICI)1097-0215(19990730)82:3<346::AID-IJC7>3.0.CO;2-#; Gartenhaus RB, 2002, CLIN CANCER RES, V8, P566; Germann UA, 1997, ANTI-CANCER DRUG, V8, P141, DOI 10.1097/00001813-199702000-00005; GLOVER AB, 1987, CANCER TREAT REP, V71, P737; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; Hamel E, 2002, BIOPOLYMERS, V66, P142, DOI 10.1002/bip.10255; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; HOLM PS, 1994, BRIT J CANCER, V70, P239, DOI 10.1038/bjc.1994.286; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Huesker M, 2002, HEPATOLOGY, V36, P874, DOI 10.1053/jhep.2002.35619; Irie A, 1997, Adv Pharmacol, V40, P207, DOI 10.1016/S1054-3589(08)60141-6; Jedlitschky G, 1996, CANCER RES, V56, P988; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; KERR DJ, 1986, CANCER CHEMOTH PHARM, V18, P239; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KIMURA S, 1995, CANCER RES, V55, P1379; Klasa RJ, 2002, ANTISENSE NUCLEIC A, V12, P193, DOI 10.1089/108729002760220798; KOBAYASHI H, 1994, CANCER RES, V54, P1271; Kornblau SM, 1997, J CLIN ONCOL, V15, P1796, DOI 10.1200/JCO.1997.15.5.1796; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Kowalski P, 2002, CANCER GENE THER, V9, P579, DOI 10.1038/sj.cgt.7700471; KRAMER RA, 1988, SCIENCE, V241, P694, DOI 10.1126/science.3399900; LAI GM, 1991, INT J CANCER, V49, P688, DOI 10.1002/ijc.2910490511; Laing NM, 1998, CANCER RES, V58, P1332; Lee EJ, 1999, J CLIN ONCOL, V17, P2831, DOI 10.1200/JCO.1999.17.9.2831; Lehnert M, 1996, EUR J CANCER, V32A, P862, DOI 10.1016/0959-8049(96)00004-4; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; LIST AF, 1993, J CLIN ONCOL, V11, P1652, DOI 10.1200/JCO.1993.11.9.1652; List AF, 2001, BLOOD, V98, P3212, DOI 10.1182/blood.V98.12.3212; Liu C, 1996, CLIN SCI, V91, P93, DOI 10.1042/cs0910093; Loe DW, 1998, CANCER RES, V58, P5130; Lorico A, 2002, BIOCHEM BIOPH RES CO, V291, P617, DOI 10.1006/bbrc.2002.6489; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUM BL, 1992, J CLIN ONCOL, V10, P1635, DOI 10.1200/JCO.1992.10.10.1635; Mackay HJ, 2000, J CLIN ONCOL, V18, P87, DOI 10.1200/JCO.2000.18.1.87; Maliepaard M, 2001, CLIN CANCER RES, V7, P935; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; MILLWARD MJ, 1993, BRIT J CANCER, V67, P1031, DOI 10.1038/bjc.1993.189; Mistry P, 2001, CANCER RES, V61, P749; Miyake H, 2000, INT J CANCER, V86, P855, DOI 10.1002/(SICI)1097-0215(20000615)86:6<855::AID-IJC15>3.3.CO;2-#; Miyake K, 1999, CANCER RES, V59, P8; MIYASHITA T, 1995, CELL, V80, P293; Moller MB, 1999, CLIN CANCER RES, V5, P1085; Momparler RL, 1997, LEUKEMIA, V11, P175, DOI 10.1038/sj.leu.2400550; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; Nagata J, 2002, INT J ONCOL, V21, P1021; Nagata J, 2001, BIOCHEM BIOPH RES CO, V286, P406, DOI 10.1006/bbrc.2001.5399; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemunaitis J, 2001, J CLIN ONCOL, V19, P289, DOI 10.1200/JCO.2001.19.2.289; Newman MJ, 2000, CANCER RES, V60, P2964; O'Neal WK, 1998, HUM GENE THER, V9, P1587, DOI 10.1089/hum.1998.9.11-1587; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2001, DRUG RESIST UPDATE, V4, P9, DOI 10.1054/drup.2001.0181; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Plumb JA, 2000, CANCER RES, V60, P6039; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rabindran SK, 2000, CANCER RES, V60, P47; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Relling MV, 1996, THER DRUG MONIT, V18, P350, DOI 10.1097/00007691-199608000-00006; Rizk NP, 1999, CANCER GENE THER, V6, P291, DOI 10.1038/sj.cgt.7700059; Robey R, 1999, BLOOD, V93, P306, DOI 10.1182/blood.V93.1.306.401k42_306_314; Rochlitz CF, 2001, SWISS MED WKLY, V131, P4; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rowinsky EK, 1998, J CLIN ONCOL, V16, P2964, DOI 10.1200/JCO.1998.16.9.2964; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Solary E, 1996, BLOOD, V88, P1198, DOI 10.1182/blood.V88.4.1198.bloodjournal8841198; Song S, 1998, DRUG METAB DISPOS, V26, P1128; Sorrentino BR, 2002, NAT REV CANCER, V2, P431, DOI 10.1038/nrc823; Sparreboom A, 1999, ANTI-CANCER DRUG, V10, P719, DOI 10.1097/00001813-199909000-00005; Stewart A, 2000, CLIN CANCER RES, V6, P4186; Stewart AJ, 1996, BIOCHEM PHARMACOL, V51, P461, DOI 10.1016/0006-2952(95)02220-1; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; Tamm I, 2001, LANCET, V358, P489, DOI 10.1016/S0140-6736(01)05629-X; Tango Y, 2002, HUM GENE THER, V13, P1373, DOI 10.1089/104303402760128595; TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811; TSURUO T, 1983, CANCER RES, V43, P2267; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; van Zuylen L, 2000, CLIN CANCER RES, V6, P1365; Vernhet L, 2000, TOXICOLOGY, V142, P127; Vulevic B, 2001, CANCER RES, V61, P3339; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; WILSON WH, 1995, J CLIN ONCOL, V13, P1985, DOI 10.1200/JCO.1995.13.8.1985; YAO KS, 1995, CANCER RES, V55, P4367; YAO KS, 1993, CANCER RES, V53, P3662; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547	141	302	331	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7512	7523		10.1038/sj.onc.1206951	http://dx.doi.org/10.1038/sj.onc.1206951			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576855				2022-12-28	WOS:000186112500020
J	Bothos, J; Summers, MK; Venere, M; Scolnick, DM; Halazonetis, TD				Bothos, J; Summers, MK; Venere, M; Scolnick, DM; Halazonetis, TD			The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains	ONCOGENE			English	Article						checkpoint; mitosis; ubiquitination; Chfr; Ubc13	UBIQUITIN LIGASE ACTIVITY; RING-FINGER DOMAIN; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; FHA DOMAIN; STRESS CHECKPOINT; DNA-REPAIR; CPG ISLAND; HYPERMETHYLATION; COMPLEX	We recently described a novel checkpoint pathway that functions early in mitosis to delay chromosome condensation in response to microtubule poisons. The only gene implicated so far in this checkpoint pathway is chfr, whose protein product contains a RING domain and has ubiquitin ligase activity in vitro. The significance of this activity in vivo is unclear. A recent report suggested that the Chfr protein targets itself for proteasome-dependent degradation in mitotic cells through autoubiquitination. However, we observe that in mitosis Chfr exhibits a phosphorylation-dependent electrophoretic mobility shift with no change in overall protein levels. Further analysis of its ubiquitin ligase activity revealed that Chfr can catalyse the formation of noncanonical Lys63-linked polyubiquitin chains with Ubc13-Mms2 acting as the ubiquitin-conjugating enzyme. Ubc13-Mms2 and Lys63-polyubiquitin chains are not associated with targeting proteins to the proteasome, but rather with signaling cellular stress. We propose that Chfr may have a role in signaling the presence of mitotic stress induced by microtubule poisons.	Univ Penn, Wistar Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Program, Philadelphia, PA 19104 USA; Univ Penn, Program Biochem & Biophys, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Halazonetis, TD (corresponding author), Univ Penn, Wistar Inst, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		Halazonetis, Thanos/D-7923-2011		NCI NIH HHS [CA09171, CA09677, CA89630] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089630, T32CA009677, T32CA009171] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; Chaturvedi P, 2002, CANCER RES, V62, P1797; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liao H, 1999, J MOL BIOL, V294, P1041, DOI 10.1006/jmbi.1999.3313; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Stavridi ES, 2002, STRUCTURE, V10, P891, DOI 10.1016/S0969-2126(02)00776-1; Torres-Ramos CA, 2002, MOL CELL BIOL, V22, P2419, DOI 10.1128/MCB.22.7.2419-2426.2002; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang P, 2000, J MOL BIOL, V302, P927, DOI 10.1006/jmbi.2000.4095; Xiao W, 2000, GENETICS, V155, P1633; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	27	79	85	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7101	7107		10.1038/sj.onc.1206831	http://dx.doi.org/10.1038/sj.onc.1206831			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562038				2022-12-28	WOS:000185955000001
J	Dai, Y; Rahmani, M; Grant, S				Dai, Y; Rahmani, M; Grant, S			Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappa B-dependent process	ONCOGENE			English	Article						apoptosis; proteasome inhibitor; flavopiridol; NF-kappa B; JNK	MULTIPLE-MYELOMA CELLS; BREAST-CARCINOMA CELLS; CYTOCHROME-C RELEASE; CANCER-THERAPY; TRANSCRIPTIONAL REPRESSION; SYNERGISTIC INDUCTION; ENDOTHELIAL-CELLS; DOWN-REGULATION; PS-341; MITOCHONDRIAL	Interactions between proteasome and cyclin-dependent kinase inhibitors have been examined in human leukemia cells in relation to induction of apoptosis. Simultaneous exposure (24 h) of U937 myelomonocytic leukemia cells to 100 nm flavopiridol and 300 nm MG-132 resulted in a marked increase in mitochondrial injury ( cytochrome c, Smac/DIABLO release, loss of DeltaPsim), caspase activation, and synergistic induction of cell death, accompanied by a marked decrease in clonogenic potential. Similar effects were observed with other proteasome inhibitors (e. g., Bortezomib (VELCADE(TM) bortezomib or injection), lactacystin, LLnL) and cyclin-dependent kinase inhibitors (e. g., roscovitine), as well as other leukemia cell types (e.g., HL-60, Jurkat, Raji). In U937 cells, synergistic interactions between MG-132 and. avopiridol were associated with multiple perturbations in expression/activation of signaling- and survival-related proteins, including downregulation of XIAP and Mcl-1, activation of JNK and p34(cdc2), and diminished expression of p21(CIP1). The lethal effects of MG-132/flavopiridol were not reduced in leukemic cells ectopically expressing Bcl-2, but were partially attenuated in cells ectopically expressing dominant-negative caspase-8 or CrmA. Flavopiridol/proteasome inhibitor-mediated lethality was also significantly diminished by agents and siRNA blocking JNK activation. Lastly, coadministration of MG-132 with. avopiridol resulted in diminished DNA binding of NF-kappaB. Notably, pharmacologic interruption of the NF-kappaB pathway (e. g., by BAY 11-7082, PDTC, or SN-50) or molecular dysregulation of NF-kappaB (i.e., in cells ectopically expressing an IkappaBalpha super-repressor) mimicked the actions of proteasome inhibitors in promoting flavopiridol-induced mitochondrial injury, JNK activation, and apoptosis. Together, these findings indicate that proteasome inhibitors strikingly lower the apoptotic threshold of leukemic cells exposed to pharmacologic CDK inhibitors, and suggest that interruption of the NF-kappaB cytoprotective pathway and JNK activation both play key roles in this phenomenon. They also raise the possibility that combining proteasome and CDK inhibitors could represent a novel antileukemic strategy.	Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Grant, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol Oncol, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA.		Dai, Yun/AAG-4040-2019	Dai, Yun/0000-0003-2285-0818; Rahmani, Mohamed/0000-0002-3992-8039	NCI NIH HHS [CA63753, CA93738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093738, R01CA063753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achenbach TV, 2000, J BIOL CHEM, V275, P32089, DOI 10.1074/jbc.M005267200; Adams J, 2002, TRENDS MOL MED, V8, pS49, DOI 10.1016/S1471-4914(02)02315-8; Adams J, 2002, CURR OPIN CHEM BIOL, V6, P493, DOI 10.1016/S1367-5931(02)00343-5; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436; Ao Y, 2001, ONCOGENE, V20, P2720, DOI 10.1038/sj.onc.1204352; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Carlson B, 1999, CANCER RES, V59, P4634; Carlson BA, 1996, CANCER RES, V56, P2973; Cartee L, 2002, MOL PHARMACOL, V61, P1313, DOI 10.1124/mol.61.6.1313; Cartee L, 2001, CANCER RES, V61, P2583; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Dai Y, 2001, CANCER RES, V61, P5106; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Decker RH, 2001, CELL DEATH DIFFER, V8, P715, DOI 10.1038/sj.cdd.4400868; Dong QG, 2002, ONCOGENE, V21, P6510, DOI 10.1038/sj.onc.1205848; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldberg AL, 2002, NAT MED, V8, P338, DOI 10.1038/nm0402-338; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Karp JE, 2003, CLIN CANCER RES, V9, P307; Kim DM, 2003, CANCER RES, V63, P621; Kitada S, 2000, BLOOD, V96, P393; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Motwani M, 1999, CLIN CANCER RES, V5, P1876; Ogiso Y, 2000, CANCER RES, V60, P2429; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Parker BW, 1998, BLOOD, V91, P458, DOI 10.1182/blood.V91.2.458.458_458_465; Porcile C, 2002, ANN NY ACAD SCI, V973, P402, DOI 10.1111/j.1749-6632.2002.tb04673.x; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rosato RR, 2002, MOL CANCER THER, V1, P253; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sandal T, 2002, ONCOLOGIST, V7, P73, DOI 10.1634/theoncologist.7-1-73; Sedlacek HH, 2001, CRIT REV ONCOL HEMAT, V38, P139, DOI 10.1016/S1040-8428(00)00124-4; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Soligo D, 2001, BRIT J HAEMATOL, V113, P126, DOI 10.1046/j.1365-2141.2001.02683.x; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tan C, 2002, CANCER RES, V62, P1083; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tang L, 2000, BIOCHEM PHARMACOL, V60, P1445, DOI 10.1016/S0006-2952(00)00463-9; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Vrana JA, 2001, BLOOD, V97, P2105, DOI 10.1182/blood.V97.7.2105; Wittmann S, 2003, CANCER RES, V63, P93; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamaguchi H, 2002, J BIOL CHEM, V277, P41604, DOI 10.1074/jbc.M207516200; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	65	121	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7108	7122		10.1038/sj.onc.1206863	http://dx.doi.org/10.1038/sj.onc.1206863			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562039				2022-12-28	WOS:000185955000002
J	O'Nions, J; Allday, MJ				O'Nions, J; Allday, MJ			Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2	ONCOGENE			English	Article						EBV; p21(WAF1/CIP1); CDK2; G1 arrest; genotoxins; B cells	HUMAN B-CELLS; GROWTH ARREST; DNA-DAMAGE; S-PHASE; APOPTOSIS; CYCLE; LYMPHOCYTES; P21; CHECKPOINTS; CANCER	Epstein-Barr virus (EBV) is involved in the pathogenesis of several B cell lymphoproliferations, but the precise contribution it makes to the aetiology of each remains unclear. In vitro, the virus has potent growth transforming activity and efficiently induces the continuous proliferation of normal human B cells. A comparison of EBV-infected primary B cells with an isogenic population induced to proliferate by CD40-ligand (CD40L) and IL4 has revealed that EBV can override - by a novel mechanism - the p53/pRb-mediated G1 checkpoint activated in normal B cells by a genotoxic stress. In cells responding to cisplatin, although p53 is stabilized and activated, EBV latent gene expression appears to inhibit the accumulation of newly synthesized p21(WAF1/CIP1) and the downregulation of cyclin D2 that occur in the normal cells. Consequently, in the EBV-infected cells, CDK2 remains active, hyperphosphorylation of pRb is maintained and the replication of damaged DNA can occur. Under conditions of severe genomic stress, this absence of p21(WAF1/CIP1) function can result in apoptosis; however, when damage is less sustained, genomic instability may arise and this in turn could contribute to the development of a variety of EBV-associated B cell malignancies.	Univ London Imperial Coll Sci Technol & Med, Dept Virol, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Wright Fleming Inst, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Virol, Norfolk Pl, London W2 1PG, England.							Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Cannell EJ, 1996, ONCOGENE, V13, P1413; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; GARRONE P, 1995, J EXP MED, V182, P1265, DOI 10.1084/jem.182.5.1265; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LINNDSTROM MS, 2002, CANC BIOL, V12, P381; LUI CW, 2003, SCIENCE, V299, P408; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; PALMERO I, 1993, ONCOGENE, V8, P1049; Parker GA, 2000, ONCOGENE, V19, P700, DOI 10.1038/sj.onc.1203327; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Rickinson A, 2001, PHILOS T ROY SOC B, V356, P595, DOI 10.1098/rstb.2000.0785; ROUSSET F, 1995, INT IMMUNOL, V7, P1243, DOI 10.1093/intimm/7.8.1243; Scott MT, 2002, EMBO J, V21, P6771, DOI 10.1093/emboj/cdf684; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; Speck SH, 2002, NAT MED, V8, P1086, DOI 10.1038/nm1002-1086; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; Spender LC, 2001, J VIROL, V75, P3537, DOI 10.1128/JVI.75.8.3537-3546.2001; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Thorley-Lawson DA, 1999, LIFE SCI, V65, P1433, DOI 10.1016/S0024-3205(99)00214-3; Thorley-Lawson DA, 2001, NAT REV IMMUNOL, V1, P75, DOI 10.1038/35095584; Timms JM, 2003, LANCET, V361, P217, DOI 10.1016/S0140-6736(03)12271-4; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Wade M, 2000, MOL CELL BIOL, V20, P1344, DOI 10.1128/MCB.20.4.1344-1360.2000; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	42	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7181	7191		10.1038/sj.onc.1206838	http://dx.doi.org/10.1038/sj.onc.1206838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562046				2022-12-28	WOS:000185955000009
J	Sansom, OJ; Zabkiewicz, J; Bishop, SM; Guy, J; Bird, A; Clarke, AR				Sansom, OJ; Zabkiewicz, J; Bishop, SM; Guy, J; Bird, A; Clarke, AR			MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine	ONCOGENE			English	Article						MBD4; mismatch repair; apoptosis; DNA methylation; p53	MISMATCH REPAIR PROTEIN; MED1 MBD4; CPG SITES; MICE; GENE; MUTATION; CANCER; CELLS; DEATH; P53	MBD4 was originally identified through its methyl binding domain, but has more recently been characterized as a thymine DNA glycosylase that interacts with the mismatch repair (MMR) protein MLH1. In vivo, MBD4 functions to reduce the mutability of methyl-CpG sites in the genome and mice deticient in MBD4 show increased intestinal tumorigenesis on an Apc(Min/)+ background. As MLH1 and other MMR proteins have been functionally linked to apoptosis, we asked whether MBD4 also plays a role in mediating the apoptotic response within the murine small intestine. Mice deficient for MBD4 showed significantly reduced apoptotic responses 6 h following treatment with a range of cytotoxic agents including gamma-irradiation, cisplatin, temozolomide and 5-fluorouracil (5-FU). This leads to increased clonogenic survival in vivo in Mbd4(-/-) mice following exposure to either 5-FU or cisplatin. We next analysed the apoptotic response to 5FU and temozolomide in doubly mutant Mbd4(-/-), Mlh1(-/-) mice but observed no additive decrease. The results imply that MBD4 and MLH1 lie in the same pathway and therefore that MMR-dependent apoptosis is mediated through MBD4. MBD4 deficiency also reduced the normal apoptotic response to gamma-irradiation, which we show is independent of Mlh1 status (at least in the murine small intestine), so suggesting that the reliance upon MBD4 may extend beyond MMR-mediated apoptosis. Our results establish a novel functional role for MBD4 in the cellular response to DNA damage and may have implications for its role in suppressing neoplasia.	Cardiff Univ, Cardiff Business Sch, Cardiff CF10 3US, S Glam, Wales; Univ Edinburgh, Wellcome Trust Ctr Cell Biol, Edinburgh EH9 3JR, Midlothian, Scotland	Cardiff University; University of Edinburgh	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Business Sch, POB 911, Cardiff CF10 3US, S Glam, Wales.		clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Sansom, Owen J./0000-0001-9540-3010; Guy, Jacky/0000-0002-8440-5667; Bird, Adrian/0000-0002-8600-0372; Clarke, Alan/0000-0002-4281-426X				Bader S, 1999, ONCOGENE, V18, P8044, DOI 10.1038/sj.onc.1203229; Bader S, 2000, BRIT J CANCER, V83, P1646, DOI 10.1054/bjoc.2000.1482; Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Drummond JT, 2001, NUCLEIC ACIDS RES, V29, P2234, DOI 10.1093/nar/29.11.2234; Fishel R, 1999, NAT MED, V5, P1239, DOI 10.1038/15191; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hendry JH, 1997, RADIAT RES, V148, P254, DOI 10.2307/3579610; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; IJIRI K, 1983, BRIT J CANCER, V47, P175, DOI 10.1038/bjc.1983.25; KARRAN P, 1992, NUCLEIC ACIDS RES, V20, P2933, DOI 10.1093/nar/20.12.2933; Meyers M, 2001, CANCER RES, V61, P5193; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Petronzelli F, 2000, J CELL PHYSIOL, V185, P473, DOI 10.1002/1097-4652(200012)185:3<473::AID-JCP19>3.0.CO;2-#; POTTEN CS, 1990, INT J RADIAT BIOL, V58, P925, DOI 10.1080/09553009014552281; Pritchard DM, 1998, CANCER RES, V58, P5453; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Riccio A, 1999, NAT GENET, V23, P266, DOI 10.1038/15443; Sansom OJ, 2000, MUTAT RES-FUND MOL M, V452, P149, DOI 10.1016/S0027-5107(00)00089-0; Sansom OJ, 2002, ONCOGENE, V21, P5934, DOI 10.1038/sj.onc.1205760; Sansom OJ, 2001, ONCOGENE, V20, P3580, DOI 10.1038/sj.onc.1204449; Screaton RA, 2003, P NATL ACAD SCI USA, V100, P5211, DOI 10.1073/pnas.0431215100; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911	27	77	81	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7130	7136		10.1038/sj.onc.1206850	http://dx.doi.org/10.1038/sj.onc.1206850			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562041				2022-12-28	WOS:000185955000004
J	Lorimore, SA; Coates, PJ; Wright, EG				Lorimore, SA; Coates, PJ; Wright, EG			Radiation-induced genomic instability and bystander effects: inter-related nontargeted effects of exposure to ionizing radiation	ONCOGENE			English	Review						radiation; genetic instability; bystander effects; clastogenic factors; inflammation	INDUCED CHROMOSOMAL INSTABILITY; IRRADIATED MAMMALIAN-CELLS; TRANSFERABLE CLASTOGENIC ACTIVITY; INFLAMMATORY-TYPE RESPONSES; MURINE HEMATOPOIETIC-CELLS; SISTER-CHROMATID EXCHANGES; ALPHA-PARTICLE IRRADIATION; APOPTOSIS IN-VIVO; A-BOMB SURVIVORS; DNA-DAMAGE	The paradigm of genetic alterations being restricted to direct DNA damage after exposure to ionizing radiation has been challenged by observations in which cells that are not exposed to ionizing radiation exhibit responses typically associated with direct radiation exposure. These effects are demonstrated in cells that are the descendants of irradiated cells (radiation-induced genomic instability) or in cells that are in contact with irradiated cells or receive certain signals from irradiated cells (radiation-induced bystander effects). There is accumulating evidence that radiation-induced genomic instability may be a consequence of, and in some cell systems may also produce, bystander interactions involving intercellular signalling, production of cytokines and free-radical generation. These processes are also features of inflammatory responses that are known to have the potential for both bystander-mediated and persisting damage as well as for conferring a predisposition to malignancy. Thus, radiation-induced genomic instability and untargeted bystander effects may reflect inter-related aspects of inflammatory-type responses to radiation-induced stress and injury and contribute to the variety of pathological consequences of radiation exposures.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland	University of Dundee	Wright, EG (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Coates, Philip J/H-6854-2019	Coates, Philip J/0000-0003-1518-6306				AUCLAIR C, 1990, ARCH BIOCHEM BIOPHYS, V278, P238, DOI 10.1016/0003-9861(90)90253-U; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; BABIOR BM, 1984, BLOOD, V64, P959; Babior BM, 2000, AM J MED, V109, P33, DOI 10.1016/S0002-9343(00)00481-2; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Belyakov OV, 2003, BRIT J CANCER, V88, P767, DOI 10.1038/sj.bjc.6600804; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Belyakov OV, 1999, INT J RADIAT BIOL, V75, P985, DOI 10.1080/095530099139746; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; BIRNBOIM HC, 1982, SCIENCE, V215, P1247, DOI 10.1126/science.6276978; Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Brenner DJ, 2002, RADIAT PROT DOSIM, V99, P283, DOI 10.1093/oxfordjournals.rpd.a006785; Brockhaus F, 1999, ONCOGENE, V18, P6403, DOI 10.1038/sj.onc.1203058; BROWN DC, 1994, INT J RADIAT BIOL, V66, P151, DOI 10.1080/09553009414551051; Brune B, 1996, BIOCHEM BIOPH RES CO, V229, P396, DOI 10.1006/bbrc.1996.1816; Burns TF, 2001, ONCOGENE, V20, P4601, DOI 10.1038/sj.onc.1204484; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; Chiba S, 2002, BONE MARROW TRANSPL, V29, P935, DOI 10.1038/sj.bmt.1703568; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Clutton SM, 1996, CELL DEATH DIFFER, V3, P141; COATES PJ, 2003, IN PRESS J PATHOL; Coen N, 2001, J PATHOL, V195, P293; Darveau R, 1999, NAT BIOTECHNOL, V17, P19, DOI 10.1038/5188; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; DIZDAROGLU M, 1993, CANCER RES, V53, P1269; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELKIND MM, 1959, NATURE, V184, P1293, DOI 10.1038/1841293a0; EMERIT I, 1994, FREE RADICAL BIO MED, V16, P99, DOI 10.1016/0891-5849(94)90246-1; EMERIT I, 1991, FREE RADICAL BIO MED, V10, P371, DOI 10.1016/0891-5849(91)90045-5; EMERIT I, 1994, J CANCER RES CLIN, V120, P558, DOI 10.1007/BF01221035; EMERIT I, 1990, METHOD ENZYMOL, V186, P555; Emerit I, 1997, MUTAT RES-FUND MOL M, V377, P239, DOI 10.1016/S0027-5107(97)00080-8; EMERIT I, 1995, HUM GENET, V96, P14, DOI 10.1007/BF00214180; Fei PW, 2002, CANCER RES, V62, P7316; Futaki M, 2001, TRENDS MOL MED, V7, P560, DOI 10.1016/S1471-4914(01)02178-5; Giles KM, 2000, BRIT J HAEMATOL, V109, P1, DOI 10.1046/j.1365-2141.2000.01805.x; GOH KO, 1968, RADIAT RES, V35, P171, DOI 10.2307/3572443; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gregory CD, 2000, CURR OPIN IMMUNOL, V12, P27, DOI 10.1016/S0952-7915(99)00047-3; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; Hall EJ, 2001, PHYS MEDICA, V17, P21; Harper K, 1997, EXP HEMATOL, V25, P263; Hayashi T, 2003, INT J RADIAT BIOL, V79, P129, DOI 10.1080/0955300021000038662; Hibner U, 1994, Cell Death Differ, V1, P33; HICKMAN AW, 1994, CANCER RES, V54, P5797; HOLLOWELL JG, 1967, J S C MED ASS, V63, P437; HOLMBERG K, 1995, INT J RADIAT BIOL, V68, P245, DOI 10.1080/09553009514551171; Holmberg K, 1998, INT J RADIAT BIOL, V73, P21, DOI 10.1080/095530098142671; Ishikawa Y, 2001, J Environ Pathol Toxicol Oncol, V20, P311; Iwamoto KS, 1999, CARCINOGENESIS, V20, P1283, DOI 10.1093/carcin/20.7.1283; Iyer R, 2000, CANCER RES, V60, P1290; Kadhim MA, 2001, RADIAT RES, V155, P122, DOI 10.1667/0033-7587(2001)155[0122:LTGIIH]2.0.CO;2; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; KADHIM MA, 1994, LANCET, V344, P987, DOI 10.1016/S0140-6736(94)91643-8; KADHIM MA, 2002, 49 ANN M RAD RES SOC, P84; Knudsen LE, 2001, MUTAT RES-FUND MOL M, V482, P83, DOI 10.1016/S0027-5107(01)00213-5; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Lehnert BE, 1997, ENVIRON HEALTH PERSP, V105, P1095, DOI 10.2307/3433515; Lehnert BE, 1997, CANCER RES, V57, P2164; LI CY, 1994, MOL CELL BIOL, V14, P4373, DOI 10.1128/MCB.14.7.4373; LI CY, 1992, MOL CARCINOGEN, V5, P270, DOI 10.1002/mc.2940050407; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P4048; Limoli CL, 1998, PHOTOCHEM PHOTOBIOL, V67, P233, DOI 10.1562/0031-8655(1998)067<0233:IOCAAD>2.3.CO;2; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; LITTLE JB, 1990, INT J RADIAT ONCOL, V19, P1425, DOI 10.1016/0360-3016(90)90354-M; LITTLEFIELD LG, 1969, RADIOLOGY, V93, P879, DOI 10.1148/93.4.879; LLOYD DC, 1985, INT J RADIAT BIOL, V47, P433, DOI 10.1080/713860600; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maeda H, 1998, BIOCHEMISTRY-MOSCOW+, V63, P854; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Meyn MS, 1997, CURR TOP MICROBIOL, V221, P71; Mohrenweiser HW, 2000, RADIAT RES, V154, P722; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Mothersill C, 2000, BRIT J CANCER, V82, P1740; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 2000, INT J RADIAT BIOL, V76, P799, DOI 10.1080/09553000050028959; Mothersill C, 2000, Radiats Biol Radioecol, V40, P615; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Mothersill C, 2001, CARCINOGENESIS, V22, P1465, DOI 10.1093/carcin/22.9.1465; Mothersill CE, 1999, CARCINOGENESIS, V20, P2273, DOI 10.1093/carcin/20.12.2273; Nagar S, 2003, CANCER RES, V63, P324; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nebert DW, 2000, CLIN CHEM LAB MED, V38, P857, DOI 10.1515/CCLM.2000.124; Neriishi K, 2001, INT J RADIAT BIOL, V77, P475, DOI 10.1080/09553000010024911; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; PANT GS, 1977, HIROSHIMA J MED SCI, V26, P149; PARCHMENT RE, 1992, CYTOTECHNOLOGY, V10, P93, DOI 10.1007/BF00570888; PARSONS WB, 1954, CANCER-AM CANCER SOC, V7, P179, DOI 10.1002/1097-0142(195401)7:1<179::AID-CNCR2820070120>3.0.CO;2-A; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; ROSIN MP, 1994, CANCER RES, V54, pS1929; SCOTT D, 1969, CELL TISSUE KINET, V2, P295, DOI 10.1111/j.1365-2184.1969.tb00239.x; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; SHACTER E, 1988, CARCINOGENESIS, V9, P2297, DOI 10.1093/carcin/9.12.2297; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Simons J. W. I. M., 1995, Critical Reviews in Oncogenesis, V6, P261; TAPPEL AL, 1973, FED PROC, V32, P1870; THOMPSON LH, 1969, INT J RADIAT BIOL RE, V15, P347, DOI 10.1080/09553006914550571; TROTT KR, 1970, INT J RADIAT BIOL RE, V17, P483, DOI 10.1080/09553007014550591; Uchimura E, 2000, J LEUKOCYTE BIOL, V67, P780, DOI 10.1002/jlb.67.6.780; Ullrich RL, 1998, INT J RADIAT BIOL, V74, P747, DOI 10.1080/095530098141023; Wallace M, 2001, ONCOGENE, V20, P3597, DOI 10.1038/sj.onc.1204496; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Watson GE, 2000, CANCER RES, V60, P5608; Watson GE, 1996, INT J RADIAT BIOL, V69, P175, DOI 10.1080/095530096146002; Watson GE, 2001, INT J RADIAT BIOL, V77, P409, DOI 10.1080/09553000010028476; WEITBERG AB, 1983, NEW ENGL J MED, V308, P26, DOI 10.1056/NEJM198301063080107; WEITZMAN SA, 1981, SCIENCE, V212, P546, DOI 10.1126/science.6259738; WEITZMAN SA, 1990, BLOOD, V76, P655; Wright EG, 2002, INT CONGR SER, V1236, P271, DOI 10.1016/S0531-5131(01)00773-7; Wright EG, 1999, J PATHOL, V187, P19, DOI 10.1002/(SICI)1096-9896(199901)187:1<19::AID-PATH233>3.0.CO;2-1; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798	138	174	190	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7058	7069		10.1038/sj.onc.1207044	http://dx.doi.org/10.1038/sj.onc.1207044			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557811				2022-12-28	WOS:000185903900011
J	Mothersill, C; Seymour, C				Mothersill, C; Seymour, C			Radiation-induced bystander effects, carcinogenesis and models	ONCOGENE			English	Article						radiation; carcinogenesis; bystander effects; chaos models; social evolution; autopoietic theory	INDUCED GENOMIC INSTABILITY; INFLAMMATORY-TYPE RESPONSES; UNIRRADIATED CELLS; IONIZING-RADIATION; IN-VIVO; CHROMOSOMAL INSTABILITY; IRRADIATED-CELLS; EXPOSURE; INITIATION; MECHANISM	Implications for carcinogenesis of radiation-induced bystander effects are both mechanistic and practical. They include induction of second cancers, perturbations to tissue social control and induction of genomic instability and delayed or immediate mutations in areas not receiving a direct deposition of energy. Bystander effects have consequences for DNA damage-mutation-cancer initiation paradigms of radiation carcinogenesis that provide the mechanistic justification for low-dose risk estimates. If carcinogenesis does not result from directly induced DNA mutations, then the carcinogenic initiation process may not simply relate to radiation dose. Modi. cation of the preclonal state through genetic and epigenetic mechanisms may occur. To deal with the complexity of these interactions, a 'chaotic' or 'bifurcation' model invoking autopoietic theory is proposed that could accommodate both beneficial (hormetic) and harmful effects of radiation at comparable doses. Carcinogenesis may then be thought of as the result of a disturbance of the genetic/epigenetic balance occurring within the organ. Ultimate clonality may reflect domination due to selection processes rather than the initiating damage.	Dublin Inst Technol, Radiat & Environm Sci Ctr, Dublin 8, Ireland; St Lukes Inst Canc Res, Dublin 6, Ireland	Technological University Dublin	Mothersill, C (corresponding author), McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON, Canada.	mothers@mcmaster.ca						Anderson GR, 2001, BIOESSAYS, V23, P1037, DOI 10.1002/bies.1149; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; Bedi GC, 1996, CANCER RES, V56, P2484; Goldberg Z, 2002, INT J ONCOL, V21, P337; GRANDJEAN V, UNPUB RAD RES; Kadhim MA, 2001, RADIAT RES, V155, P122, DOI 10.1667/0033-7587(2001)155[0122:LTGIIH]2.0.CO;2; Limoli CL, 1998, CANCER RES, V58, P3712; Loeb LA, 2001, CANCER RES, V61, P3230; Lorimore SA, 1998, P NATL ACAD SCI USA, V95, P5730, DOI 10.1073/pnas.95.10.5730; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maturana H.R., 1980, AUTOPOIESIS COGNITIO, V42; MATURANA HR, 1975, INT J MAN MACH STUD, V7, P313, DOI 10.1016/S0020-7373(75)80015-0; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mothersill C, 2002, RADIAT RES, V157, P526, DOI 10.1667/0033-7587(2002)157[0526:RBRILD]2.0.CO;2; Mothersill C, 2001, CARCINOGENESIS, V22, P1465, DOI 10.1093/carcin/22.9.1465; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; MOTHERSILL C, 2003, J EXP HAEMATOL; NOGUCHI S, 1995, CANCER LETT, V90, P57, DOI 10.1016/0304-3835(94)03678-C; Osterreicher J, 2003, STRAHLENTHER ONKOL, V179, P69, DOI 10.1007/s00066-003-1000-9; RAMBIHAR VS, 2000, NEW CHAOS BASED MED; Sedivy R, 2000, WIEN KLIN WOCHENSCHR, V112, P177; SEYMOUR C, 1992, MUTAT RES, V267, P19, DOI 10.1016/0027-5107(92)90107-D; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Seymour CB, 2000, RADIAT RES, V153, P508, DOI 10.1667/0033-7587(2000)153[0508:RCOBAT]2.0.CO;2; Varela F.J., 1979, PRINCIPLES BIOL AUTO; Watson GE, 2000, CANCER RES, V60, P5608; Werness BA, 1997, HUM PATHOL, V28, P626, DOI 10.1016/S0046-8177(97)90087-3	31	88	89	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7028	7033		10.1038/sj.onc.1206882	http://dx.doi.org/10.1038/sj.onc.1206882			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557807				2022-12-28	WOS:000185903900007
J	Van Gele, M; Boyle, GM; Cook, AL; Vandesompele, J; Boonefaes, T; Rottiers, P; Van Roy, N; De Paepe, A; Parsons, PG; Leonard, JH; Speleman, F				Van Gele, M; Boyle, GM; Cook, AL; Vandesompele, J; Boonefaes, T; Rottiers, P; Van Roy, N; De Paepe, A; Parsons, PG; Leonard, JH; Speleman, F			Gene-expression profiling reveals distinct expression patterns for classic versus variant Merkel cell phenotypes and new classifier genes to distinguish Merkel cell from small-cell lung carcinoma	ONCOGENE			English	Article						Merkel cell carcinoma; small-cell lung carcinoma; differential expression profiling; differential diagnosis; classic/variant	INTERMEDIATE-FILAMENT PROTEINS; SHORT ARM; KINASE-C; CANCER; LINES; IDENTIFICATION; DIFFERENTIATION; ADENOCARCINOMA; PROLIFERATION; ESTABLISHMENT	Merkel cell carcinoma (MCC) is a rare aggressive skin tumor which shares histopathological and genetic features with small-cell lung carcinoma (SCLC), both are of neuroendocrine origin. Comparable to SCLC, MCC cell lines are classified into two different biochemical subgroups designated as 'Classic' and 'Variant'. With the aim to identify typical gene-expression signatures associated with these phenotypically different MCC cell lines subgroups and to search for differentially expressed genes between MCC and SCLC, we used cDNA arrays to pro. le 10 MCC cell lines and four SCLC cell lines. Using significance analysis of microarrays, we defined a set of 76 differentially expressed genes that allowed unequivocal identification of Classic and Variant MCC subgroups. We assume that the differential expression levels of some of these genes reflect, analogous to SCLC, the different biological and clinical properties of Classic and Variant MCC phenotypes. Therefore, they may serve as useful prognostic markers and potential targets for the development of new therapeutic interventions specific for each subgroup. Moreover, our analysis identified 17 powerful classifier genes capable of discriminating MCC from SCLC. Real-time quantitative RT-PCR analysis of these genes on 26 additional MCC and SCLC samples confirmed their diagnostic classification potential, opening opportunities for new investigations into these aggressive cancers.	Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium; Queensland Inst Med Res, Melanoma Genom Grp, Brisbane, Qld 4006, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Flanders Interuniv Inst Biotechnol, Dept Mol Biomed Res, B-9000 Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium; Queensland Inst Med Res, Queensland Radium Inst Res Unit, Brisbane, Qld 4006, Australia	Ghent University; Ghent University Hospital; QIMR Berghofer Medical Research Institute; University of Queensland; Ghent University; QIMR Berghofer Medical Research Institute	Speleman, F (corresponding author), Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium.	franki.speleman@UGent.be	Leonard, Helen/F-2022-2013; Boyle, Glen/G-1347-2013; speleman, frank/AAR-5184-2020; Parsons, Peter G/H-8163-2015; Cook, Anthony/K-9489-2018; Vandesompele, Jo/W-3411-2018	Boyle, Glen/0000-0002-1385-529X; speleman, frank/0000-0002-6628-8559; Parsons, Peter G/0000-0002-0473-3346; Cook, Anthony/0000-0003-1770-7910; Vandesompele, Jo/0000-0001-6274-0184				Baumann KI, 2000, INT CONGR SER, V1187, P73; BENZIL DL, 1992, CANCER RES, V52, P2951; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0; Botchkarev VA, 1999, J INVEST DERMATOL, V113, P691; BROERS JLV, 1986, J CELL SCI, V83, P37; BROERS JLV, 1985, P NATL ACAD SCI USA, V82, P4409, DOI 10.1073/pnas.82.13.4409; Buchner K, 2000, J CANCER RES CLIN, V126, P1, DOI 10.1007/PL00008458; CARNEY DN, 1985, CANCER RES, V45, P2913; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; Cook AL, 2001, INT J CANCER, V93, P361; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fong KM, 1999, J THORAC CARDIOV SUR, V118, P1136, DOI 10.1016/S0022-5223(99)70121-2; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; GAZDAR AF, 1985, CANCER RES, V45, P2924; Goessling W, 2002, J CLIN ONCOL, V20, P588, DOI 10.1200/JCO.20.2.588; Halata Z, 2003, ANAT REC PART A, V271A, P225, DOI 10.1002/ar.a.10029; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Leonard JH, 1997, GENE CHROMOSOME CANC, V20, P93, DOI 10.1002/(SICI)1098-2264(199709)20:1<93::AID-GCC14>3.0.CO;2-G; Leonard JH, 2002, INT J CANCER, V101, P103, DOI 10.1002/ijc.10554; LEONARD JH, 1995, INT J RADIAT ONCOL, V32, P1401, DOI 10.1016/0360-3016(94)00610-W; LEONARD JH, 1995, INT J CANCER, V60, P100, DOI 10.1002/ijc.2910600115; LEONARD JH, 1993, INT J CANCER, V55, P803, DOI 10.1002/ijc.2910550519; Leonard JH, 2000, CANCER DETECT PREV, V24, P620; LEONARD JH, 1997, AUSTRALAS J DERMATOL, V38, P91; LEVIN NA, 1995, GENE CHROMOSOME CANC, V13, P175, DOI 10.1002/gcc.2870130307; Metz KA, 1998, GRAEF ARCH CLIN EXP, V236, P561, DOI 10.1007/s004170050121; Miller RW, 1999, CANCER EPIDEM BIOMAR, V8, P153; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moll I, 1996, J CUTAN PATHOL, V23, P109, DOI 10.1111/j.1600-0560.1996.tb01283.x; Pattyn F, 2003, NUCLEIC ACIDS RES, V31, P122, DOI 10.1093/nar/gkg011; Pedersen N, 2003, CANCER RES, V63, P1943; Petersen I, 1997, BRIT J CANCER, V75, P79, DOI 10.1038/bjc.1997.13; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; RATNER D, 1993, J AM ACAD DERMATOL, V29, P143, DOI 10.1016/0190-9622(93)70159-Q; RIED T, 1994, CANCER RES, V54, P1801; RONAN SG, 1993, J AM ACAD DERMATOL, V29, P715, DOI 10.1016/0190-9622(93)70236-M; ROSEN ST, 1987, LAB INVEST, V56, P302; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Schmidt U, 1998, AM J DERMATOPATH, V20, P346, DOI 10.1097/00000372-199808000-00004; Tazaki M, 2000, INT CONGR SER, V1187, P63; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Van Gele M, 1998, CANCER RES, V58, P1503; Van Gele M, 2002, INT J CANCER, V101, P137, DOI 10.1002/ijc.10591; Van Gele M, 2000, BRIT J CANCER, V82, P823; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang L, 2000, J SURG RES, V93, P108, DOI 10.1006/jsre.2000.5957	49	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2732	2742		10.1038/sj.onc.1207421	http://dx.doi.org/10.1038/sj.onc.1207421			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755241				2022-12-28	WOS:000220714900015
J	Garnis, C; Coe, BP; Zhang, LW; Rosin, MP; Lam, WL				Garnis, C; Coe, BP; Zhang, LW; Rosin, MP; Lam, WL			Overexpression of LRP12, a gene contained within an 8q22 amplicon identified by high-resolution array CGH analysis of oral squamous cell carcinomas	ONCOGENE			English	Article						head and neck; array CGH; 8q; premalignant	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; EXPRESSION; DISTINCT; NECK; HEAD	Chromosome 8q amplification is a common event observed in cancer. In this study, we used high-resolution array comparative genomic hybridization to resolve two neighboring regions on 8q that are both amplified in oral cancer. One region (at 8q24) contains the MYC oncogene, which is frequently overexpressed in many cancers, while the other region (at 8q22) represents a novel amplicon. The alignment of array comparative genomic hybridization profiles of 20 microdissected oral squamous cell carcinomas (OSCCs) revealed a similar to5 Mbp region of frequent copy number alteration. This region harbors 16 known genes. Gene expression analysis comparing 15 microdissected OSCC with 16 normal epithelium samples revealed overexpression specific to LRP12 but not the neighboring genes, dihydropyrimidinase and FOG2, suggesting that LRP12 may function as an oncogene in oral tumors.	British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; University of British Columbia; University of British Columbia	Garnis, C (corresponding author), British Columbia Canc Res Ctr, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	cgarnis@bccancer.bc.ca	Garnis, Cathie/A-3888-2009; Coe, Bradley/A-2878-2009; Zhang, Lewei/AAP-4757-2021	Zhang, Lewei/0000-0003-3594-598X; Coe, Bradley/0000-0001-8471-4016	NIDCR NIH HHS [R01 DE13124] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013124] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Battle MA, 2003, BIOCHEMISTRY-US, V42, P7270, DOI 10.1021/bi034081y; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dong SM, 2002, CLIN CANCER RES, V8, P2939; Garnis C, 2004, GENE CHROMOSOME CANC, V39, P93, DOI 10.1002/gcc.10294; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; KRAJINA Z, 1975, LARYNGOSCOPE, V85, P1155, DOI 10.1288/00005537-197507000-00006; LOWRY WS, 1975, LARYNGOSCOPE, V85, P1275, DOI 10.1288/00005537-197508000-00001; Martinez-Climent JA, 2003, BLOOD, V101, P3109, DOI 10.1182/blood-2002-07-2119; Ng IOL, 2000, ORAL ONCOL, V36, P484, DOI 10.1016/S1368-8375(00)00040-3; Paris PL, 2003, AM J PATHOL, V162, P763, DOI 10.1016/S0002-9440(10)63873-4; Qing J, 1999, ONCOGENE, V18, P335, DOI 10.1038/sj.onc.1202290; Rosin MP, 2000, CLIN CANCER RES, V6, P357; Veltman JA, 2003, CANCER RES, V63, P2872; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; Zhang LW, 1997, AM J PATHOL, V151, P323	16	53	55	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2582	2586		10.1038/sj.onc.1207367	http://dx.doi.org/10.1038/sj.onc.1207367			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676824				2022-12-28	WOS:000220558000017
J	Jones, GG; Reaper, PM; Pettitt, AR; Sherrington, PD				Jones, GG; Reaper, PM; Pettitt, AR; Sherrington, PD			The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes	ONCOGENE			English	Article						ATR; p53; lymphocytes; chronic lymphocytic leukaemia; cell cycle	NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; STRAND BREAKS; CHROMOSOMAL FRAGMENTATION; TARGETED DISRUPTION; P53 DYSFUNCTION; ATR PROTEIN; PHOSPHORYLATION	Chronic lymphocytic leukaemia (CLL) results from the accumulation of apoptosis-resistant clonal B cells that are arrested in G0/G1, and is heterogeneous with respect to clinical outcome. An aggressive form of the disease is identified by an impaired p53 response to ionizing radiation (IR). This is associated with inactivating mutations of either p53 or ATM, a regulator of p53 activated by IR-induced DNA damage. Since other forms of DNA damage activate p53 via ATR, a kinase closely related to ATM, abnormalities of the ATR-p53 pathway also have the potential to result in p53 dysfunction. We therefore tested cases of CLL for abnormal p53 responses to ultraviolet irradiation (UVC), a known activator of ATR, to screen for additional forms of p53 dysfunction. CLL cells and normal peripheral blood mononuclear cell (PBMC) preparations (predominantly noncycling lymphocytes) were treated with UVC and assessed for p53 responses. In all of the CLL cases and PBMC preparations tested, we were unable to detect p53 accumulation, phosphorylation or transcriptional consequences in response to UVC-induced DNA damage. The most likely explanation for the absence of UVC-induced p53 activation in CLL and normal lymphocytes was that, in contrast to other cell types, the UVC-induced ATR pathway was inactive. This notion was confirmed by showing that ATR protein was absent or undetectable in all of the cases of CLL and normal PBMCs screened. This was an unexpected finding because ATR was thought to be essential for the viability of somatic cells and for normal human and murine embryonic development. An obvious difference between the cell lines used as positive controls for ATR antibodies and the CLL cells/PBMCs was that the former were actively cycling while the latter were quiescent. We therefore hypothesized that the ATR-p53 pathway is selectively downregulated in noncycling lymphocytes. To test this, we induced cycling in the T-cell fraction of PBMC preparations and demonstrated that ATR protein expression was restored. Furthermore, p53 was upregulated and phosphorylated in response to UVC in these cells. Our data support the conclusion that the ATR-p53 pathway is suppressed in noncycling lymphocytes via ATR downregulation. We tentatively suggest that this repressed DNA damage response may have evolved to protect quiescent lymphocytes from the potential for p53-dependent apoptosis in the face of some forms of endurable genotoxic stress. If this is the case, DNA repair and genome stability might be compromised in quiescent lymphocytes with potentially negative consequences.	Royal Liverpool Univ Hosp, Dept Haematol, Liverpool L7 8XP, Merseyside, England; Univ Cambridge, Wellcome Trust Canc Res UK Inst Canc & Dev Biol, Cambridge CB2 1TN, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Cambridge	Sherrington, PD (corresponding author), Royal Liverpool Univ Hosp, Dept Haematol, Prescot St, Liverpool L7 8XP, Merseyside, England.	pds@liv.ac.uk						Abou-Zahr F, 1999, AM J MED GENET, V83, P388, DOI 10.1002/(SICI)1096-8628(19990423)83:5<388::AID-AJMG9>3.0.CO;2-1; Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Bogdanov KV, 1997, BRIT J HAEMATOL, V98, P869, DOI 10.1046/j.1365-2141.1997.2913109.x; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brown JM, 1999, CANCER RES, V59, P1391; BUTLER MG, 1987, AM J MED GENET, V27, P645, DOI 10.1002/ajmg.1320270318; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chanan-Khan Asher, 2003, Haematologica, V88, pECR14; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; Ford JM, 1997, J BIOL CHEM, V272, P28073, DOI 10.1074/jbc.272.44.28073; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Friedburg E.C., 1995, DNA REPAIR MUTAGENES; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Kapoor M, 2000, ONCOGENE, V19, P358, DOI 10.1038/sj.onc.1203300; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lawrence CW, 2001, BIOCHEM SOC T, V29, P187, DOI 10.1042/0300-5127:0290187; Lin K, 2002, BLOOD, V100, P1404, DOI 10.1182/blood-2001-11-0066; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; Lyons AB, 2000, J IMMUNOL METHODS, V243, P147, DOI 10.1016/S0022-1759(00)00231-3; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Mitchell JR, 2003, CURR OPIN CELL BIOL, V15, P232, DOI 10.1016/S0955-0674(03)00018-8; MunchPetersen B, 1997, MUTAT RES-DNA REPAIR, V383, P143, DOI 10.1016/S0921-8777(96)00054-7; NAKONA K, 2000, ONCOGENE, V19, P4283; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Peller S, 2003, HUM MUTAT, V21, P277, DOI 10.1002/humu.10190; Pettitt AR, 2003, BRIT J HAEMATOL, V121, P692, DOI 10.1046/j.1365-2141.2003.04336.x; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Pfeifer GP, 1997, PHOTOCHEM PHOTOBIOL, V65, P270, DOI 10.1111/j.1751-1097.1997.tb08560.x; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Starostik P, 1998, CANCER RES, V58, P4552; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tuck A, 2000, MUTAT RES-DNA REPAIR, V459, P73, DOI 10.1016/S0921-8777(99)00060-9; Tuck A, 1999, LEUKEMIA LYMPHOMA, V36, P169, DOI 10.3109/10428199909145961; Unsal-Kacmaz K, 2002, P NATL ACAD SCI USA, V99, P6673, DOI 10.1073/pnas.102167799; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang P, 1997, GENE CHROMOSOME CANC, V20, P282, DOI 10.1002/(SICI)1098-2264(199711)20:3<282::AID-GCC9>3.0.CO;2-Z; White E, 1999, NATURE, V399, P734, DOI 10.1038/21539; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	66	41	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1911	1921		10.1038/sj.onc.1207318	http://dx.doi.org/10.1038/sj.onc.1207318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755251				2022-12-28	WOS:000220129500013
J	Rodriguez, JA; Schuchner, S; Au, WWY; Fabbro, M; Henderson, BR				Rodriguez, JA; Schuchner, S; Au, WWY; Fabbro, M; Henderson, BR			Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1	ONCOGENE			English	Article						BARD1; BRCA1; nuclear export; cancer; apoptosis	CANCER-PREDISPOSING MUTATIONS; RING DOMAIN; TUMOR-SUPPRESSOR; CELL-CYCLE; IN-VIVO; GENE; PROTEIN; BREAST; IDENTIFICATION; BRCA1-BARD1	The breast cancer-associated protein, BARD1, colocalizes with BRCA1 in nuclear foci in the S phase and after DNA damage, and the two proteins form a stable heterodimer implicated in DNA repair, protein ubiquitination, and control of mRNA processing. BARD1 has a BRCA1-independent proapoptotic activity; however, little is known about its regulation. Here, we show that BARD1 localization and apoptotic activity are regulated by nuclear-cytoplasmic shuttling. We identified a functional CRM1-dependent nuclear export sequence (NES) near the N-terminal RING domain of BARD1. The NES forms part of the BRCA1 dimerization domain, and coexpression of BRCA1 resulted in masking of the NES and nuclear retention of BARD1. In transient expression assays, BARD1 apoptotic activity was stimulated by nuclear export, and both apoptotic function and nuclear export were markedly reduced by BRCA1. Similar findings were obtained for endogenous BARD1. Silencing BRCA1 expression by siRNA, or disrupting the endogenous BARD1/BRCA1 interaction by peptide competition caused a reduction in BARD1 nuclear localization and foci formation, and increased the level of cytoplasmic BARD1 correlating with increased apoptosis. Our findings suggest that BRCA1/BARD1 heterodimer formation is important for optimal nuclear targeting of BARD1 and its role in DNA repair and cell survival.	Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Henderson, BR (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Darcy Rd,POB 412, Westmead, NSW 2145, Australia.	beric_henderson@wmi.usyd.edu.au	Rodriguez, Jose Antonio/AAA-1125-2019	Rodriguez, Jose Antonio/0000-0002-2823-3733				Baer R, 2002, CURR OPIN GENET DEV, V12, P86, DOI 10.1016/S0959-437X(01)00269-6; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brzovic PS, 2001, J BIOL CHEM, V276, P41399, DOI 10.1074/jbc.M106551200; Brzovic PS, 2001, NAT STRUCT BIOL, V8, P833, DOI 10.1038/nsb1001-833; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Chiba N, 2002, CANCER RES, V62, P4222; Chiba N, 2001, J BIOL CHEM, V276, P38549, DOI 10.1074/jbc.M105227200; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Ghimenti C, 2002, GENE CHROMOSOME CANC, V33, P235, DOI 10.1002/gcc.1223; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Irminger-Finger I, 2001, MOL CELL, V8, P1255, DOI 10.1016/S1097-2765(01)00406-3; Irminger-Finger I, 1998, J CELL BIOL, V143, P1329, DOI 10.1083/jcb.143.5.1329; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; Kleiman FE, 2001, CELL, V104, P743, DOI 10.1016/S0092-8674(02)07059-9; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Spahn L, 2002, CANCER RES, V62, P4583; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108	28	62	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1809	1820		10.1038/sj.onc.1207302	http://dx.doi.org/10.1038/sj.onc.1207302			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647430				2022-12-28	WOS:000220129500002
J	Luo, AP; Kong, JP; Hu, GX; Liew, CC; Xiong, MM; Wang, XQ; Ji, JF; Wang, T; Zhi, HY; Wu, M; Liu, ZH				Luo, AP; Kong, JP; Hu, GX; Liew, CC; Xiong, MM; Wang, XQ; Ji, JF; Wang, T; Zhi, HY; Wu, M; Liu, ZH			Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray	ONCOGENE			English	Article						differentiation; calcium; cell envelope; esophageal squamous cell carcinoma; cDNA microarray	PROLINE-RICH PROTEINS; ANNEXIN-I; TERMINAL DIFFERENTIATION; TRANSCRIPTION FACTORS; CORNIFIED ENVELOPE; BARRIER FUNCTION; KERATIN 4; EXPRESSION; CANCER; OVEREXPRESSION	To identify genes that are differentially expressed in human esophageal squamous cell carcinoma (ESCC), we have developed a cDNA microarray representing 34 176 clones to analyse gene expression profiles in ESCC. A total of 77 genes ( including 31 novel genes) were downregulated, and 15 genes ( including one novel gene) were upregulated in cancer tissues compared with their normal counterparts. Immunohistochemistry and Northern blot analysis were carried out to verify the cDNA microarray results. It was revealed that genes involved in squamous cell differentiation were coordinately downregulated, including annexin I, small proline-rich proteins (SPRRs), calcium-binding S100 proteins (S100A8, S100A9), transglutaminase (TGM3), cytokeratins (KRT4, KRT13), gut-enriched Krupple-like factor ( GKLF) and cystatin A. Interestingly, most of the downregulated genes encoded Ca2+-binding or - modulating proteins that constitute the cell envelope (CE). Moreover, genes associated with invasion or proliferation were upregulated, including genes such as fibronectin, secreted protein acidic and rich in cystein ( SPARC), cathepsin B and KRT17. Functional analysis of the alteration in the expression of GKLF suggested that GKLF might be able to regulate the expression of SPRR1A, SPRR2A and KRT4 in ESCC. This study provides new insights into the role of squamous cell differentiation-associated genes in ESCC initiation and progression.	Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Peking Union Med Coll, Beijing 100021, Peoples R China; Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ Texas, Ctr Human Genet, Houston, TX 77030 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Texas System	Liu, ZH (corresponding author), Chinese Acad Med Sci, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China.	liuzh@pubem.cicams.ac.cn						Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; BANKSSCHLEGEL SP, 1986, CANCER RES, V46, P250; Bikle DD, 2001, MOL CELL ENDOCRINOL, V177, P161, DOI 10.1016/S0303-7207(01)00452-X; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Busatto G, 1998, J CLIN PATHOL-MOL PA, V51, P80, DOI 10.1136/mp.51.2.80; Chang S, 1999, Wei Sheng Yan Jiu, V28, P364; Dotto GP, 1999, CRIT REV ORAL BIOL M, V10, P442; Fischer DF, 1999, GENOMICS, V55, P88, DOI 10.1006/geno.1998.5622; Frey BM, 1999, FASEB J, V13, P2235, DOI 10.1096/fasebj.13.15.2235; Gebhardt C, 2002, ONCOGENE, V21, P4266, DOI 10.1038/sj.onc.1205521; Geboes K, 1978, Front Gastrointest Res, V3, P1; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hu YC, 2001, CLIN CANCER RES, V7, P2213; Ishizuka T, 2002, BIOCHEM BIOPH RES CO, V296, P152, DOI 10.1016/S0006-291X(02)00836-7; JANKOWSKI J, 1993, EUR J GASTROEN HEPAT, V5, P235, DOI 10.1097/00042737-199304000-00008; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Lam KY, 1997, INT J CANCER, V74, P212, DOI 10.1002/(SICI)1097-0215(19970422)74:2<212::AID-IJC13>3.0.CO;2-F; Li W, 1998, Wei Sheng Yan Jiu, V27, P69; Liew CC, 1997, MOL CELL BIOCHEM, V172, P81, DOI 10.1023/A:1006811403996; Lu JY, 2001, INT J CANCER, V91, P288, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1063>3.0.CO;2-S; Ma SH, 1997, GENE EXPRESSION, V6, P361; Marenholz I, 1996, GENOMICS, V37, P295, DOI 10.1006/geno.1996.0563; Montesano R, 1996, INT J CANCER, V69, P225, DOI 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0.CO;2-6; Moore RC, 1998, CELL MOTIL CYTOSKEL, V41, P168, DOI 10.1002/(SICI)1097-0169(1998)41:2<168::AID-CM7>3.0.CO;2-A; Nagasawa S, 2001, J SURG ONCOL, V78, P208, DOI 10.1002/jso.1152; Ness SL, 1998, J BIOL CHEM, V273, P23904, DOI 10.1074/jbc.273.37.23904; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Sark MWJ, 1998, J BIOL CHEM, V273, P24683, DOI 10.1074/jbc.273.38.24683; Seery JP, 2000, CURR BIOL, V10, P1447, DOI 10.1016/S0960-9822(00)00803-4; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEVEN AC, 1994, J CELL SCI, V107, P693; Suzuki H, 1997, CANCER INVEST, V15, P411, DOI 10.3109/07357909709047579; THIEL C, 1992, J CELL SCI, V103, P733; Turksen K, 2002, DEVELOPMENT, V129, P1775; van Dorst EBL, 1998, J CLIN PATHOL, V51, P679, DOI 10.1136/jcp.51.9.679; Wang Q, 2002, CANCER LETT, V179, P71, DOI 10.1016/S0304-3835(01)00846-1; Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818; Xu L, 2001, CANCER RES, V61, P3176; Xu Y, 2002, CANCER RES, V62, P3493; Yamazaki M, 1997, DNA SEQUENCE, V8, P71, DOI 10.3109/10425179709020888; Zhang WH, 2000, AM J HUM GENET, V67, P110, DOI 10.1086/302970	49	178	204	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1291	1299		10.1038/sj.onc.1207218	http://dx.doi.org/10.1038/sj.onc.1207218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647409				2022-12-28	WOS:000188892200014
J	Gao, J; Huang, HY; Pak, J; Cheng, J; Zhang, ZT; Shapiro, E; Pellicer, A; Sun, TT; Wu, XR				Gao, J; Huang, HY; Pak, J; Cheng, J; Zhang, ZT; Shapiro, E; Pellicer, A; Sun, TT; Wu, XR			p53 deficiency provokes urothelial proliferation and synergizes with activated Ha-ras in promoting urothelial tumorigenesis	ONCOGENE			English	Article						bladder cancer; p53; ras; oncogene; tumor suppressor gene	SUPERFICIAL BLADDER-CANCER; TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; C-TERMINAL DOMAIN; IN-SITU; NUCLEAR OVEREXPRESSION; MOLECULAR-GENETICS; TUMOR SUPPRESSION; ONCOGENIC RAS; EXPRESSION	Mutation and deletion of the p53 tumor suppressor gene are arguably the most prevalent among the multiple genetic alterations found in human bladder cancer, but these p53 defects are primarily associated with the advanced diseases, and their roles in bladder tumor initiation and in synergizing with oncogenes in tumor progression have yet to be defined. Using the mouse uroplakin II gene promoter, we have targeted into urothelium of transgenic mice a dominant-negative mutant of p53 that lacks the DNA-binding domain but retains the tetramerization domain. Urothelium-expressed p53 mutant binds to and stabilizes the endogenous wild-type p53, induces nuclear abnormality, hyperplasia and occasionally dysplasia, without eliciting frank carcinomas. Concurrent expression of the p53 mutant with an activated Ha-ras, the latter of which alone induces urothelial hyperplasia, fails to accelerate tumor formation. In contrast, the expression of the activated Ha-ras in the absence of p53, as accomplished by crossing the activated Ha-ras transgenic mice with the p53 knockout mice, results in early-onset bladder tumors that are either low-grade superficial papillary or high grade in nature. These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis.	Vet Affairs Med Ctr Manhattan, Urol Res Labs, New York, NY 10010 USA; NYU, Sch Med, Dept Urol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Wu, XR (corresponding author), Vet Affairs Med Ctr Manhattan, Urol Res Labs, 423 E 23 St,18th Floor,Room 18064 S, New York, NY 10010 USA.	xue-ru.wu@med.nyu.edu	Sun, Tung-Tien/J-4425-2015; MARTINEZ, ANTONIO PELLICER/C-4832-2015	Sun, Tung-Tien/0000-0002-6841-1063; Wu, Xue-Ru/0000-0001-6058-6291; Pellicer, Angel/0000-0002-5062-0692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK052206, R01DK056903] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52206, DK56903] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bowman T, 1996, GENE DEV, V10, P826, DOI 10.1101/gad.10.7.826; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Cheng J, 2003, CANCER RES, V63, P179; Cheng J, 2002, CANCER RES, V62, P4157; Cordon-Cardo C, 1994, Important Adv Oncol, P71; Cordon-Cardo C, 2000, SCAND J UROL NEPHROL, V34, P82, DOI 10.1080/003655900750169338; CordonCardo C, 1997, SEMIN SURG ONCOL, V13, P319, DOI 10.1002/(SICI)1098-2388(199709/10)13:5<319::AID-SSU5>3.0.CO;2-G; CordonCardo C, 1997, WORLD J UROL, V15, P112, DOI 10.1007/BF02201982; Cote RJ, 1998, CANCER RES, V58, P1090; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; Dahse R, 2000, ONCOL REP, V7, P931; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; Fradet Y, 2000, Curr Opin Urol, V10, P441, DOI 10.1097/00042307-200009000-00013; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gottifredi V, 2000, COLD SPRING HARB SYM, V65, P483, DOI 10.1101/sqb.2000.65.483; Grossman HB, 1998, CLIN CANCER RES, V4, P829; KIKUCHIYANOSHITA R, 1995, ONCOGENE, V11, P1339; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; KNOWLES MA, 1995, BRIT J UROL, V75, P57; KOSS LGS, 1992, J CELL BIOCHEM, V16, P23; Lacombe L, 1996, J CLIN ONCOL, V14, P2646, DOI 10.1200/JCO.1996.14.10.2646; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liebert M, 1996, Semin Urol Oncol, V14, P62; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; Llopis J, 2000, EUR UROL, V37, P644, DOI 10.1159/000020232; MESSING EM, 1992, SEMIN SURG ONCOL, V8, P285, DOI 10.1002/ssu.2980080507; Orntoft TF, 1998, UROL RES, V26, P223, DOI 10.1007/s002400050050; Pohar KS, 2002, CANCER PRECURSORS: EPIDEMIOLOGY, DETECTION, AND PREVENTION, P344, DOI 10.1007/0-387-21605-7_22; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Raghavan D, 2003, CANCER, V97, P2083, DOI 10.1002/cncr.11281; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Reiher F, 2002, J UROLOGY, V167, P1469, DOI 10.1016/S0022-5347(05)65347-5; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; SARKIS AS, 1994, J UROLOGY, V152, P388, DOI 10.1016/S0022-5347(17)32745-3; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; SPRUCK CH, 1994, CANCER RES, V54, P784; Theodorescu D, 2003, HISTOL HISTOPATHOL, V18, P259, DOI 10.14670/HH-18.259; Vageli D, 1996, CANCER LETT, V107, P241, DOI 10.1016/0304-3835(96)04372-8; ZAMBETTI GP, 1992, P NATL ACAD SCI USA, V89, P3952, DOI 10.1073/pnas.89.9.3952; Zhang ZT, 1999, CANCER RES, V59, P3512; Zhang ZT, 2001, ONCOGENE, V20, P1973, DOI 10.1038/sj.onc.1204315	52	46	47	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					687	696		10.1038/sj.onc.1207169	http://dx.doi.org/10.1038/sj.onc.1207169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737103				2022-12-28	WOS:000188304900007
J	Tomida, M; Saito, T				Tomida, M; Saito, T			The human hepatocyte growth factor (HGF) gene is transcriptionally activated by leukemia inhibitory factor through the Stat binding element	ONCOGENE			English	Article						human HGF promoter; LIF; Stat3	DNA-BINDING; CELL-LINES; DIFFERENTIATION; EXPRESSION; RECEPTOR; INDUCIBILITY; FIBROBLASTS; PROTEINS; CLONING; FAMILY	We found that human melanoma SEKI and neuroepithelioma NAGAI cells, which are known to secrete high concentrations of leukemia inhibitory factor (LIF), also secrete high levels of hepatocyte growth factor (HGF). We therefore examined the role of LIF in HGF expression and examined the human HGF promoter. The expression of both LIF and HGF mRNA is very low in HEK293 cells. Treatment of these cells with LIF stimulated the expression of HGF mRNA. The cis-acting regulatory element of the HGF promoter in SEKI and 293 cells was analysed by means of a transient expression assay. By deletion analysis, we showed that the region comprising the -181 to -73 bp was required for full activity of the HGF promoter in SEKI cells and for LIF responsiveness of 293 cells. This region contains putative consensus sequences for the Stat and NF-IL6 (C/EBP beta) transcription factors. The activity of the HGF promoter was abolished by mutation of the Stat site at -99/-91, while the activity only slightly decreased on mutation of the NF-IL6 site. Treatment with anti-LIF antibodies or interruption of Stat3 signaling by dominant-negative Stat3 also reduced the HGF promoter activity. Stat3 activation was constitutive in SEKI cells and induced on treatment of 293 cells with LIF. These results suggest that cytokines, growth factors and oncogenes (v-Src, etc.) that activate Stat3 are important regulators of HGF expression.	Saitama Canc Ctr, Div Res, Ina, Saitama 3620806, Japan; Saitama Small Enterprise Promot Corp, REDS Grp, Saitama Prefecture Collaborat Reg Entities Adv Te, Kawaguchi 3330844, Japan		Tomida, M (corresponding author), Saitama Canc Ctr, Div Res, 818 Komuro, Ina, Saitama 3620806, Japan.	tomida@cancer-c.pref.saitama.jp						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200; ISEKI H, 1995, JPN J CANCER RES, V86, P562, DOI 10.1111/j.1349-7006.1995.tb02435.x; Jiang JG, 1997, MOL CELL BIOL, V17, P5758, DOI 10.1128/MCB.17.10.5758; KAMOHARA H, 1994, RES COMMUN MOL PATH, V85, P131; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIU YH, 1994, J BIOL CHEM, V269, P4152; LOWE DG, 1989, DNA-J MOLEC CELL BIO, V8, P351, DOI 10.1089/dna.1.1989.8.351; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; Nakamura T, 1997, CANCER RES, V57, P3305; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMELZER CH, 1993, ARCH BIOCHEM BIOPHYS, V302, P484, DOI 10.1006/abbi.1993.1243; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; TAMURA M, 1993, J BIOL CHEM, V268, P8140; TOMIDA M, 1990, FEBS LETT, V268, P261, DOI 10.1016/0014-5793(90)81023-H; TOMIDA M, 1984, FEBS LETT, V178, P291, DOI 10.1016/0014-5793(84)80619-5; Tomida M, 1999, BLOOD, V93, P1934, DOI 10.1182/blood.V93.6.1934.406k05_1934_1941; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WARE CB, 1995, DEVELOPMENT, V121, P1283; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	37	26	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					679	686		10.1038/sj.onc.1207190	http://dx.doi.org/10.1038/sj.onc.1207190			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647442				2022-12-28	WOS:000188304900006
J	Liu, ZM; Chen, GG; Ng, EKW; Leung, WK; Sung, JJY; Chung, SCS				Liu, ZM; Chen, GG; Ng, EKW; Leung, WK; Sung, JJY; Chung, SCS			Upregulation of heme oxygenase-1 and p21 confers resistance to apoptosis in human gastric cancer cells	ONCOGENE			English	Article						gastric cancer; heme oxygenase-1; p21; p53; apoptosis	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; INHIBITS APOPTOSIS; GENE-EXPRESSION; TNF-ALPHA; CARCINOMA; PATHWAY; DEATH; HEAT-SHOCK-PROTEIN-70; OVEREXPRESSION	Both heme oxygenase-1 (HO-1) and p21(WAF1/Cip1) (p21) are involved in the pathogenesis of human cancer and their functions are closely associated with apoptosis. However, how these two molecules regulate apoptosis in human gastric cancer is unknown. In this study, we studied how HO-1 and p21 were regulated in two gastric cancer cell lines, MKN-45 with wild p53 and MKN-28 with mutant p53. The cells were treated with hemin and cadmium to induce HO-1. The result showed that HO-1 protein was significantly induced by hemin and cadmium in both cells tested. Following the HO-1 expression, p21 level was also markedly induced. The cells with increased HO-1 and p21 showed obviously resistantance to apoptotic stimuli. The levels of HO-1 and p21 induced were significantly inhibited by p38 mitogen-activated protein kinase (p38 MAPK) inhibitor (SB203580) and extracellular-regulated kinase (ERK) inhibitor (PD098059). Parallel to decreased HO-1 and p21 expression, the kinase inhibitors also significantly attenuated the resistance of the cells to apoptosis. The elevated HO-1 and p21 was further found to be associated with increase activity of the nuclear NF-kappaB and the inhibition of NF-kappaB led to the block of their induction. The elevated HO-1 and p21 were also demonstrated to be related to increased cellular inhibitor of caspase inbitory protein-2 (c-IAP2) and decreased caspapse-3 activity. It was noted that the above changes observed were not different between MKN-45 and MKN-28 cells, suggesting the functions of HO-1 and p21 were irrespective of the status of p53. In conclusion, we demonstrate that the resistance to apoptosis in gastric cancer cells with elevated HO-1 and p21 is independent of p53 status in a p38 MAPK- and ERK-mediated pathway with elevated c-IAP2 and decreased caspase-3 activity and that this pathway is sensitive to the inhibition of NF-kappaB.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; Sichuan Univ, W China Hosp, Inst Gasterointestinal Surg, Chengdu 610041, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Sichuan University	Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Shatin, Hong Kong, Peoples R China.	gchen@cuhk.edu.hk	Chen, George Gong/I-2757-2016; Lin, Hualiang/E-6622-2010; Sung, Joseph J. Y./R-3203-2018; Leung, Wai Keung/B-8140-2011; Ng, Enders Kwok-wai/E-8276-2016	Lin, Hualiang/0000-0002-2462-5158; Sung, Joseph J. Y./0000-0003-3125-5199; Leung, Wai Keung/0000-0002-5993-1059; Ng, Enders Kwok-wai/0000-0001-7219-5810				Baas IO, 1998, J CLIN PATHOL, V51, P662, DOI 10.1136/jcp.51.9.662; Baldus SE, 2001, SCAND J GASTROENTERO, V36, P975, DOI 10.1080/003655201750305512; Bortner CD, 2002, ANNU REV PHARMACOL, V42, P259, DOI 10.1146/annurev.pharmtox.42.083101.143836; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chellappan SP, 1998, CURR TOP MICROBIOL, V227, P57; Chen GG, 2002, LIFE SCI, V70, P2631, DOI 10.1016/S0024-3205(02)01510-2; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Craanen ME, 1999, J PATHOL, V189, P481, DOI 10.1002/(SICI)1096-9896(199912)189:4<481::AID-PATH482>3.0.CO;2-U; Davis JN, 2001, FREE RADICAL BIO MED, V30, P1293, DOI 10.1016/S0891-5849(01)00535-4; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; ELLEDGE RM, 1994, CANCER RES, V54, P3752; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Goodman AI, 1997, P SOC EXP BIOL MED, V214, P54; Helt CE, 2001, TOXICOL SCI, V63, P214, DOI 10.1093/toxsci/63.2.214; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Inguaggiato P, 2001, KIDNEY INT, V60, P2181, DOI 10.1046/j.1523-1755.2001.00046.x; Jobin C, 1998, J IMMUNOL, V160, P410; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maines MD, 1999, J PHARMACOL EXP THER, V291, P911; Maines MD, 1996, UROLOGY, V47, P727, DOI 10.1016/S0090-4295(96)00010-6; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MURPHY BJ, 1993, CANCER RES, V53, P2700; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; TAKAHASHI S, 1994, AM J CLIN PATHOL, V101, P519; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Wakana Y, 2002, ONCOL REP, V9, P1213; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu J, 2003, CARCINOGENESIS, V24, P243, DOI 10.1093/carcin/24.2.243; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yokozaki H, 2000, PATHOL INT, V50, P767, DOI 10.1046/j.1440-1827.2000.01117.x; Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200	43	147	158	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					503	513		10.1038/sj.onc.1207173	http://dx.doi.org/10.1038/sj.onc.1207173			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14647439				2022-12-28	WOS:000188098300021
J	Sharpless, NE; Ramsey, MR; Balasubramanian, P; Castrillon, DH; DePinho, RA				Sharpless, NE; Ramsey, MR; Balasubramanian, P; Castrillon, DH; DePinho, RA			The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis	ONCOGENE			English	Article						Rb; p14(ARF); p53; cdkn2a	MAMMARY EPITHELIAL-CELLS; HUMAN-DIPLOID FIBROBLASTS; TUMOR SUPPRESSION; INDUCED SENESCENCE; KERATINOCYTE SENESCENCE; GERMLINE MUTATION; FAMILIAL MELANOMA; INK4A LOCUS; IN-VIVO; INACTIVATION	Mounting genetic evidence suggests that each product of the Ink4/Arf locus, p16(INK4a) and p19(ARF), possesses tumor-suppressor activity (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001a). We report the generation and characterization of a p19(ARF)-specific knockout allele (p19(ARF)-/-) and direct comparison with mice and derivative cells deficient for p16(INK4a), both p16(INK4a) and p19(ARF), and p53. Like Ink4/Arf-/- murine embryo fibroblasts (MEFs), p19(ARF)-/- MEFs were highly susceptible to oncogenic transformation, exhibited enhanced subcloning efficiency at low density, and resisted both RAS- and culture-induced growth arrest. In contrast, the biological profile of p16(INK4a)-/- MEFs in these assays more closely resembled that of wild-type cells. In vivo, however, both p19(ARF)-/- and p16(INK4a)-/- animals were significantly more tumor prone than wild-type animals, but each less so than p53-/- or Ink4/Arf-/- animals, and with differing tumor spectra. These data confirm the predominant role of p19(ARF) over p16(INK4a) in cell culture-based assays of MEFs, yet also underscore the importance of the analysis of tumor suppressors across many cell types within the organism. The cancer-prone conditions of mice singly deficient for either p16(INK4a) or p19(ARF) agree with data derived from human cancer genetics, and reinforce the view that both gene products play significant and nonredundant roles in suppressing malignant transformation in vivo.	Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Genet, Chapel Hill, NC 27599 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Sharpless, NE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Ctr, Dept Med, CB 7295, Chapel Hill, NC 27599 USA.	NES@med.unc.edu		DePinho, Ronald/0000-0002-5625-577X; Ramsey, Matthew/0000-0003-2402-8502; Sharpless, Norman/0000-0001-7078-9455				Artandi SE, 2002, P NATL ACAD SCI USA, V99, P8191, DOI 10.1073/pnas.112515399; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Eischen CM, 2002, CANCER RES, V62, P2184; Festing M, 1998, MOUSE GENOME INFORMA; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793; Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273; Huot TJ, 2002, MOL CELL BIOL, V22, P8135, DOI 10.1128/MCB.22.23.8135-8143.2002; Huschtscha LI, 1998, CANCER RES, V58, P3508; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, SCIENCE, V264, P440; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kannan K, 2003, P NATL ACAD SCI USA, V100, P1221, DOI 10.1073/pnas.0336397100; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; Munro J, 1999, CANCER RES, V59, P2516; OLSON DC, 1993, ONCOGENE, V8, P2353; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 2002, CANCER RES, V62, P2761; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; SHARPLESS NE, 2003, IN PRESS ONCOGENE; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 2001, CELL, V106, P531, DOI 10.1016/S0092-8674(01)00486-X; STONE S, 1995, CANCER RES, V55, P2988; Sviderskaya EV, 2003, J NATL CANCER I, V95, P723, DOI 10.1093/jnci/95.10.723; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	46	145	157	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					379	385		10.1038/sj.onc.1207074	http://dx.doi.org/10.1038/sj.onc.1207074			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724566				2022-12-28	WOS:000188098300007
J	Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL				Xue, LY; Chiu, SM; Fiebig, A; Andrews, DW; Oleinick, NL			Photodamage to multiple Bcl-xL isoforms by photodynamic therapy with the phthalocyanine photosensitizer Pc 4	ONCOGENE			English	Article						Bcl-xL; Bcl-2; apoptosis; photodynamic; therapy; Pc 4	ENDOPLASMIC-RETICULUM; INDUCED APOPTOSIS; CELLS; BCL-X(L); OVEREXPRESSION; ONCOPROTEIN; RESISTANCE; INDUCTION; MEMBERS; FAMILY	The antiapoptotic oncoprotein Bcl-2 is now a recognized phototarget of photodynamic therapy (PDT) with the phthalocyanine Pc 4 and with other mitochondrion-targeting photosensitizers. Photodamage, observed on Western blots as the loss of the native 26-kDa Bcl-2 protein, is PDT dose dependent and occurs in multiple cell lines, in the cold, and immediately upon photoirradiation. In our initial study, no photochemical damage was observed to Bcl-xL, in spite of its similarity in size, sequence, location and function to Bcl-2. The original study used a commercial anti-Bcl-xS/L antibody. We have revisited this issue by examining Western blots developed using one of three epitope-specific anti-Bcl-xL antibodies from commercial sources, a polyclonal antibody generated to the entire protein, as well as the antibody used previously. All five Bcl-xL antibodies recognized bacterially expressed Bcl-xL, but not Bcl-2, whereas an anti-Bcl-2 antibody recognized Bcl-2 and not Bcl-xL. All five Bcl-xL antibodies recognized at least one protein migrating at similar to30 kDa; two of the antibodies recognized an additional band, migrating at similar to33 or similar to24 kDa. We now observe Pc 4-PDT-induced photo-damage to all Bcl-xL-related proteins, except the 33-kDa species, in several human cancer cell lines. The results indicate that, in addition to the expected quantitative differences that may reflect exposure of individual epitopes, the antibodies also detect proteins of different apparent molecular weights that may be distinct isoforms or post-translationally modified forms of Bcl-xL. No evidence for PDT-induced phosphorylation or degradation was observed. Bcl-xL localized to mitochondria was considerably more sensitive to photodamage than was Bcl-xL in the cytosol, indicating that as previously found for Bcl-2, Bcl-xL must be membrane localized to be photosensitive.	Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, CWRU Ireland Comprehens Canc Ctr, Cleveland, OH USA; McMaster Univ, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	Case Western Reserve University; Case Western Reserve University; McMaster University	Oleinick, NL (corresponding author), Case Western Reserve Univ, Sch Med BRB324, Dept Radiat Oncol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	nlo@po.cwru.edu		Andrews, David/0000-0002-9266-7157	NATIONAL CANCER INSTITUTE [R01CA083917, P01CA048735, P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83917, P01 CA48735, P30 CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; FANG W, 1994, J IMMUNOL, V153, P4388; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Granville DJ, 1999, BRIT J CANCER, V79, P95, DOI 10.1038/sj.bjc.6690017; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; He J, 1996, PHOTOCHEM PHOTOBIOL, V64, P845, DOI 10.1111/j.1751-1097.1996.tb01845.x; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kessel D, 1999, CELL DEATH DIFFER, V6, P28, DOI 10.1038/sj.cdd.4400446; Kessel D, 2001, PHOTOCHEM PHOTOBIOL, V74, P318, DOI 10.1562/0031-8655(2001)074<0318:ETBITT>2.0.CO;2; Kim HRC, 1999, CANCER RES, V59, P3429; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lam M, 2001, J BIOL CHEM, V276, P47379, DOI 10.1074/jbc.M107678200; Li XY, 2001, CANCER RES, V61, P1699; Liu QY, 1997, CLIN CANCER RES, V3, P2039; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Oleinick NL, 1998, RADIAT RES, V150, pS146, DOI 10.2307/3579816; OLEINICK NL, 1993, PHOTOCHEM PHOTOBIOL, V57, P242, DOI 10.1111/j.1751-1097.1993.tb02282.x; Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Srivastava M, 2001, J BIOL CHEM, V276, P15481, DOI 10.1074/jbc.M006920200; Trivedi NS, 2000, PHOTOCHEM PHOTOBIOL, V71, P634, DOI 10.1562/0031-8655(2000)071<0634:QAOPLI>2.0.CO;2; Usuda J, 2003, PHOTOCHEM PHOTOBIOL, V78, P1, DOI 10.1562/0031-8655(2003)078<0001:ABTPLO>2.0.CO;2; Usuda J, 2003, J BIOL CHEM, V278, P2021, DOI 10.1074/jbc.M205219200; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Ye QR, 2002, J EXP MED, V196, P87, DOI 10.1084/jem.20012084	32	53	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9197	9204		10.1038/sj.onc.1207019	http://dx.doi.org/10.1038/sj.onc.1207019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681679				2022-12-28	WOS:000187400400001
J	Franke, TF; Hornik, CP; Segev, L; Shostak, GA; Sugimoto, C				Franke, TF; Hornik, CP; Segev, L; Shostak, GA; Sugimoto, C			PI3K/Akt and apoptosis: size matters	ONCOGENE			English	Review						Akt; PI3K; PTEN; PDK2; apoptosis; genetic models	PROTEIN-KINASE-B; PLECKSTRIN HOMOLOGY DOMAIN; FORKHEAD TRANSCRIPTION FACTORS; GLYCOGEN-SYNTHASE KINASE-3; PROMOTES CELL-SURVIVAL; INHIBITS AKT/PKB ACTIVATION; SUPPRESSOR GENE-PRODUCT; SERINE-THREONINE KINASE; DEATH AGONIST BAD; AGE-1 PI3 KINASE	Recent research has examined Akt and Akt-related serine-threonine kinases in signaling cascades that regulate cell survival and are important in the pathogenesis of degenerative diseases and in cancer. W e seek to recapitulate the research that has helped to de. ne the current understanding of the role of the Akt pathway under normal and pathologic conditions, also in view of genetic models of Akt function. In particular, we will evaluate the mechanisms of Akt regulation and the role of Akt substrates in Akt-dependent biologic responses in the decisions of cell death and cell survival. Here, we hope to establish the mechanisms of apoptosis suppression by Akt kinase as a framework for a more general understanding of growth factor-dependent regulation of cell survival.	Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Columbia University	Franke, TF (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pharmacol, 630 W 168th St,PH7-W318, New York, NY 10032 USA.	tff5@columbia.edu						AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Astoul E, 1999, J CELL BIOL, V145, P1511, DOI 10.1083/jcb.145.7.1511; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Bacus SS, 2002, ONCOGENE, V21, P3532, DOI 10.1038/sj.onc.1205438; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Barthwal MK, 2003, J BIOL CHEM, V278, P3897, DOI 10.1074/jbc.M211598200; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bergmann A, 2002, DEV CELL, V3, P607, DOI 10.1016/S1534-5807(02)00328-3; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bertolotto C, 2000, J BIOL CHEM, V275, P37246, DOI 10.1074/jbc.M007732200; Bhave SV, 1999, J NEUROSCI, V19, P3277, DOI 10.1523/jneurosci.19-09-03277.1999; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Biondi RM, 2003, BIOCHEM J, V372, P1, DOI 10.1042/BJ20021641; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cairns P, 1997, CANCER RES, V57, P4997; Calleja V, 2003, BIOCHEM J, V372, P33, DOI 10.1042/BJ20030358; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cerezo A, 1998, MOL BIOL CELL, V9, P3107, DOI 10.1091/mbc.9.11.3107; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Clarke RB, 2003, BREAST CANCER RES, V5, P162, DOI 10.1186/bcr596; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 2002, DEV CELL, V3, P631, DOI 10.1016/S1534-5807(02)00326-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FRANKE TF, 1994, ONCOGENE, V9, P141; Franke TF, 2000, METHOD ENZYMOL, V322, P400; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita E, 1999, BIOCHEM BIOPH RES CO, V264, P550, DOI 10.1006/bbrc.1999.1387; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Graff JR, 2000, J BIOL CHEM, V275, P24500, DOI 10.1074/jbc.M003145200; Guan KL, 2000, J BIOL CHEM, V275, P27354; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Hinton HJ, 1999, J IMMUNOL, V162, P7002; Hodgkinson CP, 2002, BIOCHEMISTRY-US, V41, P10351, DOI 10.1021/bi026065r; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Hong M, 1997, J BIOL CHEM, V272, P19547, DOI 10.1074/jbc.272.31.19547; Hosoi Y, 1998, INT J CANCER, V78, P642, DOI 10.1002/(SICI)1097-0215(19981123)78:5<642::AID-IJC19>3.0.CO;2-3; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Imai S, 2003, LIFE SCI, V72, P2199, DOI 10.1016/S0024-3205(03)00092-4; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; JONES PF, 1991, CELL REGUL, V2, P1001, DOI 10.1091/mbc.2.12.1001; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kenerson HL, 2002, CANCER RES, V62, P5645; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim AH, 2003, J BIOL CHEM, V278, P29830, DOI 10.1074/jbc.M305349200; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kitada S, 1998, AM J PATHOL, V152, P51; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P817, DOI 10.1006/bbrc.1994.2738; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Krymskaya VP, 2003, CELL SIGNAL, V15, P729, DOI 10.1016/S0898-6568(03)00040-8; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kunstle G, 2002, MOL CELL BIOL, V22, P1513, DOI 10.1128/MCB.22.5.1513-1525.2002; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Lafon-Cazal M, 2002, EUR J NEUROSCI, V16, P575, DOI 10.1046/j.1460-9568.2002.02124.x; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Laine J, 2002, J BIOL CHEM, V277, P3743, DOI 10.1074/jbc.M107069200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin J, 2002, ONCOGENE, V21, P3082, DOI 10.1038/sj.onc.1205426; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Liu MY, 2002, CANCER RES, V62, P6475; Liu QR, 1999, GENE DEV, V13, P786, DOI 10.1101/gad.13.7.786; Liu WG, 1997, CANCER RES, V57, P5254; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Matsui T, 2003, CELL CYCLE, V2, P220, DOI 10.4161/cc.2.3.381; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Mok CL, 1999, J EXP MED, V189, P575, DOI 10.1084/jem.189.3.575; Munster PN, 2002, CANCER RES, V62, P3132; Myers MP, 1997, AM J HUM GENET, V61, P1234, DOI 10.1086/301659; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Nakatani K, 1999, J BIOL CHEM, V274, P21528, DOI 10.1074/jbc.274.31.21528; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Ng SSW, 2000, CANCER RES, V60, P5451; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Noselli S, 2000, SCIENCE, V290, P68, DOI 10.1126/science.290.5489.68; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Ookuma S, 2003, CURR BIOL, V13, P427, DOI 10.1016/S0960-9822(03)00108-8; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Page C, 2000, ANTICANCER RES, V20, P407; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Paradis S, 1999, GENE DEV, V13, P1438, DOI 10.1101/gad.13.11.1438; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pianetti S, 2002, CANCER RES, V62, P652; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; Plas DR, 2002, NAT IMMUNOL, V3, P515, DOI 10.1038/ni0602-515; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Potter CJ, 2003, BIOCHEM SOC T, V31, P584, DOI 10.1042/BST0310584; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Risinger JI, 1997, CANCER RES, V57, P4736; Rokudai S, 2002, MOL CELL BIOL, V22, P8695, DOI 10.1128/MCB.22.24.8695-8708.2002; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Salh B, 2002, INT J CANCER, V98, P148, DOI 10.1002/ijc.10147; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; Scheid MP, 2003, FEBS LETT, V546, P108, DOI 10.1016/S0014-5793(03)00562-3; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shi YJ, 2002, CANCER RES, V62, P5027; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; STAAL SP, 1977, P NATL ACAD SCI USA, V74, P3065, DOI 10.1073/pnas.74.7.3065; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Sutton G, 2002, J NEUROCHEM, V82, P1097, DOI 10.1046/j.1471-4159.2002.01031.x; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Weihl CC, 1999, J NEUROSCI, V19, P5360; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	266	945	1006	5	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					8983	8998		10.1038/sj.onc.1207115	http://dx.doi.org/10.1038/sj.onc.1207115			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663477				2022-12-28	WOS:000187043600002
J	Orr, GA; Verdier-Pinard, P; McDaid, H; Horwitz, SB				Orr, GA; Verdier-Pinard, P; McDaid, H; Horwitz, SB			Mechanisms of Taxol resistance related to microtubules	ONCOGENE			English	Review						resistance; Taxol; microtubule	BETA-TUBULIN GENE; GROWTH-FACTOR RECEPTOR; CANCER CELL-LINES; METASTATIC BREAST-CANCER; PROSTATE CARCINOMA-CELLS; HUMAN LEUKEMIA-CELLS; LUNG-CANCER; ALPHA-TUBULIN; DRUG-RESISTANCE; PROTEIN-KINASE	Since its approval by the FDA in 1992 for the treatment of ovarian cancer, the use of Taxol has dramatically increased. Although treatment with Taxol has led to improvement in the duration and quality of life for some cancer patients, the majority eventually develop progressive disease after initially responding to Taxol treatment. Drug resistance represents a major obstacle to improving the overall response and survival of cancer patients. This review focuses on mechanisms of Taxol resistance that occur directly at the microtubule, such as mutations, tubulin isotype selection and post-translational modi. cations, and also at the level of regulatory proteins. A review of tubulin structure, microtubule dynamics, the mechanism of action of Taxol and its binding site on the microtubule are included, so that the reader can evaluate Taxol resistance in context.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Horwitz, SB (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Verdier-Pinard, Pascal/0000-0002-6149-6578	NATIONAL CANCER INSTITUTE [R35CA039821, R01CA077263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI049749] Funding Source: NIH RePORTER; NCI NIH HHS [CA 39821, R01 CA077263, CA 77263] Funding Source: Medline; NIAID NIH HHS [AI 49749] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; BANERJEE A, 1990, J BIOL CHEM, V265, P1794; Banerjee A, 1998, BIOCHEM BIOPH RES CO, V245, P349, DOI 10.1006/bbrc.1998.8426; Bash-Babula J, 2002, CLIN CANCER RES, V8, P1057; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Blade K, 1999, J CELL SCI, V112, P2213; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bode CJ, 2002, BIOCHEMISTRY-US, V41, P3870, DOI 10.1021/bi0121611; BOLLAG DM, 1995, CANCER RES, V55, P2325; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; Burkhart C.A., 2001, BIOCHIM BIOPHYS ACTA, V1471, P1; CABRAL F, 1989, FASEB J, V3, P1593, DOI 10.1096/fasebj.3.5.2646163; CABRAL FR, 1986, ANN NY ACAD SCI, V466, P745, DOI 10.1111/j.1749-6632.1986.tb38456.x; CALVERT PM, 2001, P AM SOC CLIN ONCOL, V20; Cardone L, 2002, J MOL BIOL, V320, P663, DOI 10.1016/S0022-2836(02)00479-5; Carles G, 1999, BRIT J CANCER, V80, P1162, DOI 10.1038/sj.bjc.6690481; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chang W, 2001, J CELL SCI, V114, P2879; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; Chen JG, 2002, CANCER RES, V62, P1935; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; Dai Y, 2001, CANCER RES, V61, P5106; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Detrich HW, 2000, J BIOL CHEM, V275, P37038, DOI 10.1074/jbc.M005699200; Diaz JF, 1998, J BIOL CHEM, V273, P33803, DOI 10.1074/jbc.273.50.33803; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Downing KH, 1998, EUR BIOPHYS J BIOPHY, V27, P431, DOI 10.1007/s002490050153; Drukman S, 2002, INT J ONCOL, V21, P621; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Esteva FJ, 2002, J CLIN ONCOL, V20, P1800, DOI 10.1200/JCO.2002.07.058; FORERO LPA, 2002, P AM SOC CLIN ONCOL; Giannakakou P, 2000, P NATL ACAD SCI USA, V97, P2904, DOI 10.1073/pnas.040546297; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Gonzalez-Garay ML, 1999, J BIOL CHEM, V274, P23875, DOI 10.1074/jbc.274.34.23875; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Gruber D, 2001, CELL MOTIL CYTOSKEL, V49, P115, DOI 10.1002/cm.1026; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Hamel E, 1999, BIOCHEMISTRY-US, V38, P5490, DOI 10.1021/bi983023n; Han EKH, 2000, EUR J CANCER, V36, P1565, DOI 10.1016/S0959-8049(00)00145-3; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Hasegawa S, 2002, INT J CANCER, V101, P46, DOI 10.1002/ijc.10575; He LF, 2000, BIOCHEMISTRY-US, V39, P3972, DOI 10.1021/bi992518p; He LF, 2001, DRUG DISCOV TODAY, V6, P1153, DOI 10.1016/S1359-6446(01)02038-4; Hollenbeck P, 2001, CURR BIOL, V11, pR820, DOI 10.1016/S0960-9822(01)00494-8; Horwitz SB, 1997, J BIOL CHEM, V272, P8129, DOI 10.1074/jbc.272.13.8129; HORWITZ SB, 1986, ANN NY ACAD SCI, V466, P733, DOI 10.1111/j.1749-6632.1986.tb38455.x; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; Hu LM, 2002, CANCER RES, V62, P1087; Hung DT, 1996, CHEM BIOL, V3, P287, DOI 10.1016/S1074-5521(96)90108-8; Iancu C, 2000, CANCER RES, V60, P3537; Iancu C, 2001, J CELL SCI, V114, P909; Jaffrezou JP, 1995, ONCOL RES, V7, P517; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Kavallaris M, 1999, BRIT J CANCER, V80, P1020, DOI 10.1038/sj.bjc.6690507; Kavallaris M, 2001, CANCER RES, V61, P5803; Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642; Kelley MJ, 2001, J NATL CANCER I, V93, P1886, DOI 10.1093/jnci/93.24.1886; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; Kohonen-Corish MRJ, 2002, INT J CANCER, V101, P398, DOI 10.1002/ijc.10601; Kowalski RJ, 1997, MOL PHARMACOL, V52, P613, DOI 10.1124/mol.52.4.613; Laferriere NB, 1996, CELL MOTIL CYTOSKEL, V35, P188, DOI 10.1002/(SICI)1097-0169(1996)35:3<188::AID-CM2>3.3.CO;2-0; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; LEE MG, 1983, CELL, V33, P477; Li YK, 2000, BIOCHEMISTRY-US, V39, P281, DOI 10.1021/bi991936r; Long BH, 1998, CANCER RES, V58, P1111; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 2001, J MOL BIOL, V313, P1045, DOI 10.1006/jmbi.2001.5077; LU Q, 1994, J BIOL CHEM, V269, P2041; LU Q, 1993, CELL STRUCT FUNCT, V18, P173, DOI 10.1247/csf.18.173; Luduena RF, 1998, INT REV CYTOL, V178, P207; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; Martello LA, 2000, CLIN CANCER RES, V6, P1978; Martello LA, 2003, CANCER RES, V63, P1207; McDaid HM, 2002, CLIN CANCER RES, V8, P2035; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Meurer-Grob P, 2001, BIOCHEMISTRY-US, V40, P8000, DOI 10.1021/bi010343p; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Montgomery RB, 2000, J BIOL CHEM, V275, P17358, DOI 10.1074/jbc.M000966200; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Monzo M, 1999, J CLIN ONCOL, V17, P1786, DOI 10.1200/JCO.1999.17.6.1786; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nicoletti MI, 2001, CLIN CANCER RES, V7, P2912; Nishio K, 2001, CANCER, V91, P1494, DOI 10.1002/1097-0142(20010415)91:8<1494::AID-CNCR1157>3.0.CO;2-7; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; NYLANDER K, 1995, HISTOCHEM J, V27, P155; Oakley BR, 2000, TRENDS CELL BIOL, V10, P537, DOI 10.1016/S0962-8924(00)01857-2; OHTA S, 1994, JPN J CANCER RES, V85, P290, DOI 10.1111/j.1349-7006.1994.tb02096.x; Orr GA, 1998, METHOD ENZYMOL, V298, P238, DOI 10.1016/S0076-6879(98)98023-5; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Poruchynsky MS, 2001, BIOCHEM PHARMACOL, V62, P1469, DOI 10.1016/S0006-2952(01)00804-8; Pryor DE, 2002, BIOCHEMISTRY-US, V41, P9109, DOI 10.1021/bi020211b; Ranganathan S, 1998, BBA-GENE STRUCT EXPR, V1395, P237, DOI 10.1016/S0167-4781(97)00168-1; Ranganathan S, 1998, BRIT J CANCER, V77, P562, DOI 10.1038/bjc.1998.91; Ranganathan S, 2001, BRIT J CANCER, V85, P735, DOI 10.1054/bjoc.2001.1956; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; Rao S, 2001, BIOCHEMISTRY-US, V40, P2096, DOI 10.1021/bi002323d; Rao S, 1999, J BIOL CHEM, V274, P37990, DOI 10.1074/jbc.274.53.37990; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; Regnard C, 1999, J CELL SCI, V112, P4281; Sale S, 2002, J NATL CANCER I, V94, P776; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schmid-Alliana A, 1998, J BIOL CHEM, V273, P3394, DOI 10.1074/jbc.273.6.3394; Sharp DJ, 2000, NATURE, V407, P41, DOI 10.1038/35024000; SHINOHARAGOTOH Y, 1991, EXP CELL RES, V193, P161, DOI 10.1016/0014-4827(91)90551-5; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; Stanchi F, 2000, BIOCHEM BIOPH RES CO, V270, P1111, DOI 10.1006/bbrc.2000.2571; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; terHaar E, 1996, BIOCHEMISTRY-US, V35, P243, DOI 10.1021/bi9515127; Tolcher AW, 2001, ONCOLOGIST, V6, P40; Torres K, 1998, CANCER RES, V58, P3620; Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P11, DOI 10.1016/S0169-5002(01)00291-4; Verdier-Pinard P, 2003, BIOCHEMISTRY-US, V42, P5349, DOI 10.1021/bi027293o; WILDE CD, 1982, SCIENCE, V217, P549, DOI 10.1126/science.6178164; WILDE CD, 1982, NATURE, V297, P83, DOI 10.1038/297083a0; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhang CC, 1999, CANCER RES, V59, P3663; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658	138	564	585	9	100	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 20	2003	22	47					7280	7295		10.1038/sj.onc.1206934	http://dx.doi.org/10.1038/sj.onc.1206934			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576838	Green Accepted			2022-12-28	WOS:000186112500003
J	Pupa, SM; Argraves, SW; Forti, S; Casalini, P; Berno, V; Agresti, R; Aiello, P; Invernizzi, A; Baldassari, P; Otwal, W; Mortarini, R; Anichini, A; Menard, S				Pupa, SM; Argraves, SW; Forti, S; Casalini, P; Berno, V; Agresti, R; Aiello, P; Invernizzi, A; Baldassari, P; Otwal, W; Mortarini, R; Anichini, A; Menard, S			Immunological and pathobiological roles of fibulin-1 in breast cancer	ONCOGENE			English	Article						B and T lymphocytes; tumour antigen; SEREX; fibulin-1; breast cancer	EXTRACELLULAR-MATRIX; IMMUNE-RESPONSES; HUMAN OVARIAN; ELEVATED EXPRESSION; DENDRITIC CELLS; CARCINOMA; ANTIGEN; PROTEIN; IDENTIFICATION; ANTIBODY	Fibulin- 1 ( Fbln- 1) is an immunogenic breast cancer-related glycoprotein identified by serological analysis of cDNA expression library ( SEREX) strategy. Here, we show that dendritic cells from two breast cancer patients elicited a CD4(+)- mediated T- cell response to Fbln- 1 presentation. In both patients, an antibody response to Fbln- 1 was also found. By contrast, a Fbln- 1- seronegative patient and a weakly seropositive patient demonstrated no such T- cell response. Analysis of human breast cancers for Fbln- 1 RNA and protein expression revealed the presence of Fbln- 1C and - 1D variants. Fbln- 1 was detected in the cytoplasm and at the cell surface of different human breast carcinoma cell lines. Immunohistochemical analysis of 528 archival primary breast carcinomas showed the expression of Fbln- 1 in 35% of the cases. When the immunohistochemical findings were compared against pathobiological information associated with each specimen, an inverse relationship between Fbln- 1 and cathepsin D expression was observed ( P = 0.04). Furthermore, even though long- term survival was similar between Fbln- 1-positive and - negative cases, the survival of Fbln- 1- positive cases improved when a lymphoid infiltrate was present at the tumour site. Taken together, our findings of an Fbln-1-specific immunity and the improved survival associated with Fbln- 1 expression in the presence of lymphoid infiltration point to a role of Fbln- 1 in tumour immunosurveillance.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Gen Oncol Breast Unit B, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Menard, S (corresponding author), Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Mol Targeting Unit, Via Venezian 1, I-20133 Milan, Italy.	sylvie.menard@istitutotumori.mi.it	Berno, Valeria/AAN-3997-2020; menard, sylvie mm/C-7940-2011; Agresti, Roberto/AAB-6062-2019; Anichini, Andrea/K-1434-2016; Mortarini, Roberta/C-9483-2017; Pupa, Serenella/K-6388-2016	Berno, Valeria/0000-0001-5848-494X; Agresti, Roberto/0000-0003-4700-1951; Anichini, Andrea/0000-0001-5096-5538; Mortarini, Roberta/0000-0001-7732-0561; Pupa, Serenella/0000-0002-4592-6830				ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Clinton GM, 1996, P NATL ACAD SCI USA, V93, P316, DOI 10.1073/pnas.93.1.316; Du MJ, 2002, BIOCHEM BIOPH RES CO, V296, P962, DOI 10.1016/S0006-291X(02)02041-7; Forti S, 2002, BREAST CANCER RES TR, V73, P245, DOI 10.1023/A:1015854415746; Greene LM, 2003, BRIT J CANCER, V88, P871, DOI 10.1038/sj.bjc.6600802; Hayashido Y, 1998, INT J CANCER, V75, P654, DOI 10.1002/(SICI)1097-0215(19980209)75:4<654::AID-IJC26>3.0.CO;2-7; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; MARTIGNONE S, 1992, CLIN EXP METASTAS, V10, P379, DOI 10.1007/BF00133466; Menard S, 1999, BREAST CANCER RES TR, V55, P169; Moll F, 2002, ONCOGENE, V21, P1097, DOI 10.1038/sj.onc.1205171; Nakatsura T, 2002, EUR J IMMUNOL, V32, P826, DOI 10.1002/1521-4141(200203)32:3<826::AID-IMMU826>3.0.CO;2-Y; Niu Y, 2002, INT J CANCER, V98, P754, DOI 10.1002/ijc.10136; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Parmiani G, 2002, JNCI-J NATL CANCER I, V94, P805, DOI 10.1093/jnci/94.11.805; PEREIRA H, 1995, HISTOPATHOLOGY, V27, P219, DOI 10.1111/j.1365-2559.1995.tb00213.x; Pupa SM, 2003, J CELL BIOCHEM, V89, P647, DOI 10.1002/jcb.10563; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Pupa SM, 2002, ANN ONCOL, V13, P483, DOI 10.1093/annonc/mdf111; Qing J, 1997, ONCOGENE, V15, P2159, DOI 10.1038/sj.onc.1201385; ROARK EF, 1995, J HISTOCHEM CYTOCHEM, V43, P401, DOI 10.1177/43.4.7534784; Roger P, 1998, AM J PATHOL, V153, P1579, DOI 10.1016/S0002-9440(10)65746-X; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Sahin U, 1997, CURR OPIN IMMUNOL, V9, P709, DOI 10.1016/S0952-7915(97)80053-2; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Struss AK, 2001, ONCOGENE, V20, P4107, DOI 10.1038/sj.onc.1204552; Tran H, 1997, MATRIX BIOL, V15, P479, DOI 10.1016/S0945-053X(97)90021-4; Twal WO, 2001, J CELL SCI, V114, P4587; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703	33	39	41	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2153	2160		10.1038/sj.onc.1207323	http://dx.doi.org/10.1038/sj.onc.1207323			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14691454				2022-12-28	WOS:000220280900005
J	Shridhar, R; Zhang, J; Song, J; Booth, BA; Kevil, CG; Sotiropoulou, G; Fsloane, B; Keppler, D				Shridhar, R; Zhang, J; Song, J; Booth, BA; Kevil, CG; Sotiropoulou, G; Fsloane, B; Keppler, D			Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells	ONCOGENE			English	Article						cystatins; cathepsins; lysosomal proteases; protease inhibitors; tumor progression	CYSTEINE PROTEINASE-INHIBITOR; SQUAMOUS CARCINOMA-CELLS; CATHEPSIN-B; BREAST-CANCER; MAMMALIAN LEGUMAIN; PLASMINOGEN-ACTIVATOR; PROTEASE INHIBITORS; CHICKEN CYSTATIN; M/E EXPRESSION; TUMOR-CELLS	Proteases are involved in many aspects of tumor progression, including cell survival and proliferation, escape from immune surveillance, cell adhesion and migration, remodeling and invasion of the extracellular matrix. Several lysosomal cysteine proteases have been cloned and shown to be overexpressed in cancer; yet, despite the great potential for development of novel therapeutics, we still know little about the regulation of their proteolytic activity. Cystatins such as cystatin M are potent endogenous protein inhibitors of lysosomal cysteine proteases. Cystatin M is expressed in normal and premalignant human epithelial cells, but not in many cancer cell lines. Here, we examined the effects of cystatin M expression on malignant properties of human breast carcinoma MDA-MB-435S cells. Cystatin M was found to significantly reduce in vitro: cell proliferation, migration, Matrigel invasion, and adhesion to endothelial cells. Reduction of cell proliferation and adhesion to an endothelial cell monolayer were both independent of the inhibition of lysosomal cysteine proteases. In contrast, cell migration and matrix invasion seemed to rely on lysosomal cysteine proteases, as both recombinant cystatin M and E64 were able to block these processes. This study provides the first evidence that cystatin M may play important roles in safeguarding against human breast cancer.	LSUHSC, Sch Med, Dept Cellular Biol & Anat, Shreveport, LA 71130 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA; Univ Patras, Dept Pharm, Patras 26500, Greece; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Wayne State University; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; University of Patras; Barbara Ann Karmanos Cancer Institute; Wayne State University	Keppler, D (corresponding author), LSUHSC, Sch Med, Dept Cellular Biol & Anat, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.	dkeppl@lsuhsc.edu	Zhang, Jun/AAN-4970-2021; Kevil, Christopher/G-9318-2011; Keppler, Daniel/B-4309-2012	Zhang, Jun/0000-0001-7886-6187; Kevil, Christopher/0000-0003-0863-7260	NATIONAL CANCER INSTITUTE [R21CA091785, R01CA036481] Funding Source: NIH RePORTER; NCI NIH HHS [CA91785, CA36481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1994, METHOD ENZYMOL, V244, P685; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BELL ET, 1989, ARCH BIOCHEM BIOPHYS, V271, P359, DOI 10.1016/0003-9861(89)90285-3; Boike G, 1992, Melanoma Res, V1, P333, DOI 10.1097/00008390-199201000-00004; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 2002, CURR PHARM DESIGN, V8, P1639, DOI 10.2174/1381612023394179; Brunner N, 1994, Cancer Treat Res, V71, P299; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; DECLERCK YA, 1994, EUR J CANCER, V30A, P2170, DOI 10.1016/0959-8049(94)00460-M; Ekiel I, 1997, J MOL BIOL, V271, P266, DOI 10.1006/jmbi.1997.1150; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; Guo M, 2002, J BIOL CHEM, V277, P14829, DOI 10.1074/jbc.M108180200; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hulkower KI, 2000, EUR J BIOCHEM, V267, P4165, DOI 10.1046/j.1432-1327.2000.01458.x; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; Keppler D, 1997, MECH AGEING DEV, V98, P151, DOI 10.1016/S0047-6374(97)00080-8; Keppler D, 1996, ENZYME PROTEIN, V49, P94, DOI 10.1159/000468619; Keppler D, 1996, BIOCHEM CELL BIOL, V74, P799, DOI 10.1139/o96-086; KEPPLER D, 1994, BBA-MOL BASIS DIS, V1226, P117, DOI 10.1016/0925-4439(94)90018-3; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kevil CG, 2001, AM J PHYSIOL-CELL PH, V281, pC1442, DOI 10.1152/ajpcell.2001.281.5.C1442; KOBAYASHI H, 1992, CANCER RES, V52, P3610; Kolkhorst V, 1998, J CANCER RES CLIN, V124, P598, DOI 10.1007/s004320050221; Konduri SD, 2002, ONCOGENE, V21, P8705, DOI 10.1038/sj.onc.1205949; LABER B, 1989, FEBS LETT, V248, P162, DOI 10.1016/0014-5793(89)80453-3; LEUNGTACK J, 1990, EXP CELL RES, V188, P16, DOI 10.1016/0014-4827(90)90272-C; Lin R, 2002, MOL ENDOCRINOL, V16, P1243, DOI 10.1210/me.16.6.1243; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; LIOTTA LA, 1991, CANCER RES, V51, pS5054; Liu C, 2003, CANCER RES, V63, P2957; Liu ZD, 1997, BIOCHEM BIOPH RES CO, V231, P283, DOI 10.1006/bbrc.1997.6083; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; Mai JX, 2002, BIOL CHEM, V383, P1407, DOI 10.1515/BC.2002.159; Mason RW, 2002, BIOL CHEM, V383, P1113, DOI 10.1515/BC.2002.120; Merz GS, 1997, J CELL PHYSIOL, V173, P423; Ni J, 1997, J BIOL CHEM, V272, P10853; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PRICE JE, 1990, CANCER METAST REV, V8, P285, DOI 10.1007/BF00052605; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; REDWOOD SM, 1992, CANCER, V69, P1212; Roshy S, 2003, CANCER METAST REV, V22, P271, DOI 10.1023/A:1023007717757; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sameni M, 2000, NEOPLASIA, V2, P496, DOI 10.1038/sj.neo.7900116; Sexton PS, 1997, MELANOMA RES, V7, P97, DOI 10.1097/00008390-199704000-00002; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; SUN Q, 1989, EXP CELL RES, V180, P150, DOI 10.1016/0014-4827(89)90219-X; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; TAVERA C, 1992, BIOCHEM BIOPH RES CO, V182, P1082, DOI 10.1016/0006-291X(92)91842-E; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1; Villadangos JA, 1999, IMMUNOL REV, V172, P109, DOI 10.1111/j.1600-065X.1999.tb01360.x; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x	63	71	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2206	2215		10.1038/sj.onc.1207340	http://dx.doi.org/10.1038/sj.onc.1207340			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676833				2022-12-28	WOS:000220280900010
J	Feber, A; Clark, J; Goodwin, G; Dodson, AR; Smith, PH; Fletcher, A; Edwards, S; Flohr, P; Falconer, A; Roe, T; Kovacs, G; Dennis, N; Fisher, C; Wooster, R; Huddart, R; Foster, CS; Cooper, CS				Feber, A; Clark, J; Goodwin, G; Dodson, AR; Smith, PH; Fletcher, A; Edwards, S; Flohr, P; Falconer, A; Roe, T; Kovacs, G; Dennis, N; Fisher, C; Wooster, R; Huddart, R; Foster, CS; Cooper, CS			Amplification and overexpression of E2F3 in human bladder cancer	ONCOGENE			English	Article						E2F3 gene; bladder cancer; 6p22 amplicon	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL IMBALANCES; GENETIC ALTERATIONS; CELL-CYCLE; CARCINOMA; EXPRESSION; PROGRESSION; FUSION; TUMORS; PRCC	We demonstrate that, in human bladder cancer, amplification of the E2F3 gene, located at 6p22, is associated with overexpression of its encoded mRNA transcripts and high levels of expression of E2F3 protein. Immunohistochemical analyses of E2F3 protein levels have established that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress nuclear E2F3 protein, with the proportion of tumours containing over-expressed nuclear E2F3 increasing with tumour stage and grade. When considered together with the established role of E2F3 in cell cycle progression, these results suggest that the E2F3 gene represents a candidate bladder cancer oncogene that is activated by DNA amplification and overexpression.	Inst Canc Res, Sect Mol Carcinogenesis & Male Urol Canc Res, Sutton SM2 5NG, Surrey, England; Univ Liverpool, Dept Pathol & Mol Genet, Liverpool L69 3GA, Merseyside, England; Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England; Heidelberg Univ, Heidelberg Klinikum, D-69120 Heidelberg, Germany; Royal Marsden NHS Trust, London SW3 6JJ, England; Sanger Ctr, Cambridge CB10 1SA, England	University of London; Institute of Cancer Research - UK; University of Liverpool; Royal Marsden NHS Foundation Trust; Ruprecht Karls University Heidelberg; Royal Marsden NHS Foundation Trust; Wellcome Trust Sanger Institute	Cooper, CS (corresponding author), Inst Canc Res, Sect Mol Carcinogenesis & Male Urol Canc Res, Sutton SM2 5NG, Surrey, England.	colin.cooper@icr.ac.uk		Feber, Andrew/0000-0001-5282-0498; huddart, robert/0000-0003-3604-1990				Bruch J, 2000, CANCER RES, V60, P4526; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Cornford PA, 2000, CANCER RES, V60, P7099; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Hovey RM, 1998, CANCER RES, V58, P3555; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Humbert PO, 2000, GENE DEV, V14, P690; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Markl IDC, 1998, CANCER RES, V58, P5348; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Richter J, 1999, CANCER RES, V59, P5687; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Simon R, 2000, INT J ONCOL, V17, P1025; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Stein JP, 1998, J NATL CANCER I, V90, P1072, DOI 10.1093/jnci/90.14.1072; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Tomovska S, 2001, INT J ONCOL, V18, P1239; Veltman JA, 2003, CANCER RES, V63, P2872; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	29	135	145	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1627	1630		10.1038/sj.onc.1207274	http://dx.doi.org/10.1038/sj.onc.1207274			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716298				2022-12-28	WOS:000189219500017
J	Ogasawara, S; Maesawa, C; Yamamoto, M; Akiyama, Y; Wada, K; Fujisawa, K; Higuchi, T; Tomisawa, Y; Sato, N; Endo, S; Saito, K; Masuda, T				Ogasawara, S; Maesawa, C; Yamamoto, M; Akiyama, Y; Wada, K; Fujisawa, K; Higuchi, T; Tomisawa, Y; Sato, N; Endo, S; Saito, K; Masuda, T			Disruption of cell-type-specific methylation at the Maspin gene promoter is frequently involved in undifferentiated thyroid cancers	ONCOGENE			English	Article						maspin; methylation; thyroid cancer; differentiation; cell-type-specific expression	TUMOR-SUPPRESSOR GENE; BREAST-CARCINOMA; EPITHELIAL-CELLS; DNA METHYLATION; P53 MUTATIONS; EXPRESSION; HYPOMETHYLATION; MAMMARY; REGION	Cancer-associated DNA hypomethylation is as prevalent as cancer-linked hypermethylation, but the biological significance of DNA hypomethylation in carcinogenesis is less understood. The expression of Maspin (mammary serpin) in differentiated normal cells is regulated by epigenetic modi. cations in a cell-type-specific manner. Paradoxical Maspin expression due to epigenetic modification has been addressed in several cancer cell types. To elucidate the role of the Maspin gene in thyroid cancer, we studied methylation status in the promoter region and its expression in six human undifferentiated thyroid cancer cell lines and in specimens from 92 primary thyroid tumors, consisting of six follicular adenomas, 56 well-differentiated thyroid cancers (WDTCs), 17 poorly differentiated thyroid cancers (PDTCs) and 13 undifferentiated thyroid cancers (UDTCs). Three of the six cell lines overexpressed Maspin mRNA and its protein product, but the remaining three did not. The methylation status at the promoter region was inversely correlated with Maspin expression. In Maspin-negative cell lines, Maspin expression was induced by treatment with 5-aza-2'-deoxycytidine, a DNA demethylating agent. Immunoreactivity for Maspin protein was frequently detected in UDTCs (8/13, 62%) and PDTCs (7/17, 41%). Immunoreactivity for Maspin was diffusely positive in UDTCs, and was restricted to dedifferentiated components of the tumor in PDTCs. Positive immunoreactivity was infrequent in WDTCs (1/56, 2%), and all follicular adenomas and normal thyroid glands were completely negative. Their methylation status evaluated by the methylation-specific PCR method showed a good inverse correlation with their immunoreactivity in surgically resected specimens. Our data suggest that overexpression of Maspin by DNA hypomethylation is closely associated with morphological dedifferentiation in thyroid cancers.	Iwate Med Univ, Sch Med, Dept Surg 1, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Pathol, Morioka, Iwate 0208505, Japan; Iwate Med Univ, Sch Med, Dept Crit Care Med, Morioka, Iwate 0208505, Japan	Iwate Medical University; Iwate Medical University; Iwate Medical University	Ogasawara, S (corresponding author), Iwate Med Univ, Sch Med, Dept Surg 1, Uchimaru 19-1, Morioka, Iwate 0208505, Japan.	soga@iwate-med.ac.jp						Abraham S, 2003, J UROLOGY, V169, P1157, DOI 10.1097/01.ju.0000040245.70349.37; Akiyama Y, 2003, AM J PATHOL, V163, P1911, DOI 10.1016/S0002-9440(10)63549-3; BERLINGIERI MT, 1989, EXP CELL RES, V183, P277, DOI 10.1016/0014-4827(89)90388-1; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DELSENNO L, 1987, CANCER DETECT PREV, V10, P159; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Ehrlich M, 2002, ONCOGENE, V21, P6694, DOI 10.1038/sj.onc.1205890; Elisei R, 1998, CANCER, V83, P2185, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2185::AID-CNCR18>3.0.CO;2-4; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Frisk T, 2002, GENE CHROMOSOME CANC, V35, P74, DOI 10.1002/gcc.10098; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Graff JR, 1998, CANCER RES, V58, P2063; HEDINGER C, 1998, HISTOLOGIC TYPING TH; Ishiwata I, 1999, Hum Cell, V12, P37; ITO T, 1992, CANCER RES, V52, P1369; Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507; Maass N, 2001, CLIN CANCER RES, V7, P812; MATSUO K, 1993, J CLIN ENDOCR METAB, V77, P991, DOI 10.1210/jc.77.4.991; ROSAI J, 1994, TUMORS THYROID GLAND; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Venkataraman GM, 1999, J CLIN ENDOCR METAB, V84, P2449, DOI 10.1210/jc.84.7.2449; Wreesmann VB, 2002, AM J PATHOL, V161, P1549, DOI 10.1016/S0002-9440(10)64433-1; Xia WY, 2000, ONCOGENE, V19, P2398, DOI 10.1038/sj.onc.1203535; YOSHIDA M, 1992, CANCER RES, V52, P464; YOSHIMOTO K, 1992, CANCER RES, V52, P5061; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	34	44	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1117	1124		10.1038/sj.onc.1207211	http://dx.doi.org/10.1038/sj.onc.1207211			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14743202				2022-12-28	WOS:000188749900010
J	Schafer, B; Gschwind, A; Ullrich, A				Schafer, B; Gschwind, A; Ullrich, A			Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion	ONCOGENE			English	Article						EGFR; GPCR; transactivation; LPA; invasion; metalloprotemase	CELL-CARCINOMA-CELLS; EGF RECEPTOR; HB-EGF; TRANSFORMING GROWTH; AUTOCRINE GROWTH; BLADDER-CANCER; FACTOR-ALPHA; TRANSACTIVATION; CLEAVAGE; EXPRESSION	Signalling through G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTK) is involved in the regulation of essential cellular processes and its deregulation is associated with tumorigenesis in vitro and in vivo. We investigated pathophysiological processes that are regulated by GPCR pathways in human kidney and bladder cancer cell lines. Our results show that GPCR ligands induce tyrosine phosphorylation of the epidermal growth factor receptor (EGFR) as well as downstream signalling events such as recruitment of the adapter protein Shc and activation of the mitogen-activated protein kinases (MAPK) ERK1/2, JNK and p38. Moreover, we report that the EGFR transactivation signal involves the EGFR ligands amphiregulin, HB-EGF and TGFalpha as well as the metalloproteinases ADAM 10, 15 and 17, depending on the cellular system. Finally, we demonstrate that EGFR transactivation is part of a regulatory system that modulates the migratory and invasive behaviour of kidney and bladder cancer cells. In conclusion, our findings demonstrate that metalloproteinase-mediated transactivation of the EGFR is a key mechanism of the cellular signalling network that promotes MAPK activation as well as tumour cell migration and invasion in response to a variety of physiologically relevant GPCR ligands, and therefore represents a novel target for cancer intervention strategies.	Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Max Planck Society	Ullrich, A (corresponding author), Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany.	ullrich@biochem.mpg.de						Bue P, 1998, INT J CANCER, V76, P189, DOI 10.1002/(SICI)1097-0215(19980413)76:2<189::AID-IJC4>3.0.CO;2-T; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DeBoer WI, 1997, INT J CANCER, V71, P284, DOI 10.1002/(SICI)1097-0215(19970410)71:2<284::AID-IJC25>3.0.CO;2-G; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gerthoffer WT, 1996, J PHYSIOL-LONDON, V495, P597, DOI 10.1113/jphysiol.1996.sp021619; Ghanem MA, 2001, CANCER-AM CANCER SOC, V92, P3120, DOI 10.1002/1097-0142(20011215)92:12<3120::AID-CNCR10173>3.0.CO;2-2; Gildea JJ, 2002, CANCER RES, V62, P982; GILL GN, 1987, MOL CELL ENDOCRINOL, V51, P169, DOI 10.1016/0303-7207(87)90027-X; Gschwind A, 2002, CANCER RES, V62, P6329; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; ISHIKAWA J, 1989, INT J CANCER, V44, P1000, DOI 10.1002/ijc.2910440610; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Levine JS, 1997, AM J PHYSIOL-RENAL, V273, pF575, DOI 10.1152/ajprenal.1997.273.4.F575; Lummen G, 1997, N-S ARCH PHARMACOL, V356, P769, DOI 10.1007/PL00005117; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ritter CA, 2003, SEMIN ONCOL, V30, P3, DOI 10.1053/sonc.2003.50027; Ruck A, 1997, ANTICANCER RES, V17, P1925; Ruck A, 1998, ANTICANCER RES, V18, P1447; Sieuwerts AM, 1997, CLIN EXP METASTAS, V15, P53; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Uchiyama-Tanaka Y, 2001, KIDNEY INT, V60, P2153, DOI 10.1046/j.1523-1755.2001.00067.x; Van Brussel JP, 1999, BJU INT, V83, P902; Vogelzang NJ, 1998, LANCET, V352, P1691, DOI 10.1016/S0140-6736(98)01041-1; Wallasch C, 2002, BIOCHEM BIOPH RES CO, V295, P695, DOI 10.1016/S0006-291X(02)00740-4; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	34	214	220	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					991	999		10.1038/sj.onc.1207278	http://dx.doi.org/10.1038/sj.onc.1207278			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647423				2022-12-28	WOS:000188486600015
J	Liu, X; Yan, S; Zhou, TH; Terada, Y; Erikson, RL				Liu, X; Yan, S; Zhou, TH; Terada, Y; Erikson, RL			The MAP kinase pathway is required for entry into mitosis and cell survival	ONCOGENE			English	Article						MAP kinase pathway; Cdc2; Plk1; RNAi	POLO-LIKE KINASE; XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; ACTIVATED PROTEIN-KINASES; H3 PHOSPHORYLATION; G(2)/M TRANSITION; MAMMALIAN-CELLS; IN-VITRO; CYCLE; PLX1	In this communication, we examined the role of the MAP kinase pathway in the G2/M phase of the cell cycle. Activation of the Plk1 and MAP kinase pathways was initially evaluated in FT210 cells, which arrest at G2 phase at the restrictive temperature (39degreesC), due to a mutation in the cdc2 gene. Previous studies had shown that these cells enter mitosis at the nonpermissive temperature upon incubation with okadaic acid, a protein phosphatase 1 and 2A inhibitor. We show that treatment of FT210 cells at 39degreesC with okadaic acid activated Plk1, as shown by hyperphosphorylation and elevated protein kinase activity, and also induced activation of the MAP kinase pathway. The specific Mek inhibitor PD98059 antagonized the okadaic acid-induced activation of both Plk1 and MAP kinases. This suggests that activation of the MAP kinase pathway may contribute to the okadaic acid-induced activation of Plk1 in FT210 cells at 39degreesC. We also found that PD98059 strongly attenuated progression of HeLa cells through mitosis, and active Mek colocalizes with Plk1 at mitotic structures. To study the potential function of the MAP kinase pathway during mitosis, RNAi was used to specifically deplete five members of this pathway (Raf1, Mek1/2, Erk1/2). Each of these five protein kinases is required for cell proliferation and survival, and depletion of any of these proteins eventually leads to apoptosis. Treatment with Mek inhibitors also inhibited cell proliferation and caused apoptosis. A dramatic increase of Plk1 activities and a moderate increase of Cdc2 activities in Raf1-depleted cells indicate that Raf1-depleted cells arrest in the late G2 or M phase. Mek1 and Erk1 depletion also caused cell cycle arrest at G2, suggesting that these enzymes are required for the G2/M transition, whereas the loss of Mek2 or Erk2 caused arrest at G1.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Liu, X (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	liu13@fas.harvard.edu	zhou, tianhua/K-4908-2013	zhou, tianhua/0000-0002-1791-2124	NIGMS NIH HHS [GM59172] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059172] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gowdy PM, 1998, J CELL SCI, V111, P3401; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MILTENBERGER RJ, 1993, J BIOL CHEM, V268, P15674; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	48	135	141	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	2004	23	3					763	776		10.1038/sj.onc.1207188	http://dx.doi.org/10.1038/sj.onc.1207188			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737111				2022-12-28	WOS:000188304900015
J	Wang, Y; Lau, SH; Sham, JST; Wu, MC; Wang, T; Guan, XY				Wang, Y; Lau, SH; Sham, JST; Wu, MC; Wang, T; Guan, XY			Characterization of HBV integrants in 14 hepatocellular carcinomas: association of truncated X gene and hepatocellular carcinogenesis	ONCOGENE			English	Article						hepatitis B virus; integration; X gene; sequence	HEPATITIS-B-VIRUS; HEPATOMA-CELL LINE; TRANSGENIC MICE; TRANSCRIPTION FACTOR; DNA-REPAIR; IN-VIVO; PROTEIN; HEPATOCARCINOGENESIS; EXPRESSION; APOPTOSIS	Although the integration of hepatitis B virus (HBV) into human DNA has been found to be associated with the development of hepatocellular carcinoma (HCC), the molecular mechanism remains unclear. In order to obtain additional insight into the correlation of HBV integration and HCC development, integrated HBV in 14 primary HCC cases was isolated and characterized by sequencing analysis. Our findings in this study showed that: (1) none of the known cellular oncogene or tumor suppressor gene was affected by the HBV integration; (2) although the integration of HBV is random, the integration site was often within or close to human repetitive sequences; (3) integrated HBV may possess the capacity to transpose to another chromosome region through reintegration; (4) rearrangements of HBV sequence were observed in all the 14 integrants, involving (most frequently) X (12/14 integrants), P (8/14), S (7/14), and C (7/14) genes; and (5) 3'-deleted X gene and consequent C-terminal truncated X protein caused by HBV integration was observed in 10 cases. These deletions cause the losses of p53-dependent transcriptional repression binding site, transcription factor Sp1 binding site, and growth-suppressive effect domain, leading to cell proliferation and transformation. This finding suggests that 3'-deleted X gene caused by the HBV integration may play an important role in the HCC development.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Second Mil Med Univ, Eastern Hepatobilliary Surg Hosp, Shanghai, Peoples R China	University of Hong Kong; Naval Medical University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,Sch Chinese Med Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BEASLEY RP, 1981, LANCET, V2, P1129; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; GROZUACIK D, 2001, ONCOGENE, V20, P6233; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; JASPERS NGJ, 1995, CURR BIOL, V5, P700, DOI 10.1016/S0960-9822(95)00137-0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lee H, 1998, J BIOL CHEM, V273, P19786, DOI 10.1074/jbc.273.31.19786; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; MATSUBARA K, 1990, MOL BIOL MED, V7, P243; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; NATOLI G, 1994, ONCOGENE, V9, P2837; PETERSON MG, 1991, NATURE, V354, P369; Reifenberg K, 1997, J HEPATOL, V26, P119, DOI 10.1016/S0168-8278(97)80018-9; ROBINSON WS, 1994, ANNU REV MED, V45, P297; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Su TS, 1998, DNA CELL BIOL, V17, P415, DOI 10.1089/dna.1998.17.415; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TOKINO T, 1991, J VIROL, V65, P6761, DOI 10.1128/JVI.65.12.6761-6764.1991; Tu H, 2001, CANCER RES, V61, P7803; URANO Y, 1991, CANCER RES, V51, P1460; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WANG XW, 1995, CANCER RES, V55, P6012; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P339, DOI 10.1046/j.1440-1746.2000.02166.x; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985	32	89	101	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					142	148		10.1038/sj.onc.1206889	http://dx.doi.org/10.1038/sj.onc.1206889			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712219				2022-12-28	WOS:000187895300015
J	Fridman, JS; Lowe, SW				Fridman, JS; Lowe, SW			Control of apoptosis by p53	ONCOGENE			English	Review						P73; P53; P63; apoptosis; tumor suppressor	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; CELL-CYCLE ARREST; DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; MEDIATED APOPTOSIS; HUMAN CANCER; P53-INDUCED APOPTOSIS	The p53 tumor suppressor acts to integrate multiple stress signals into a series of diverse antiproliferative responses. One of the most important p53 functions is its ability to activate apoptosis, and disruption of this process can promote tumor progression and chemoresistance. p53 apparently promotes apoptosis through transcription-dependent and -independent mechanisms that act in concert to ensure that the cell death program proceeds efficiently. Moreover, the apoptotic activity of p53 is tightly controlled, and is influenced by a series of quantitative and qualitative events that influence the outcome of p53 activation. Interestingly, other p53 family members can also promote apoptosis, either in parallel or in concert with p53. Although incomplete, our current understanding of p53 illustrates how apoptosis can be integrated into a larger tumor suppressor network controlled by different signals, environmental factors, and cell type. Understanding this network in more detail will provide insights into cancer and other diseases, and will identify strategies to improve their therapeutic treatment.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Incyte Corp, Wilmington, DE 19880 USA	Cold Spring Harbor Laboratory; Incyte	Lowe, SW (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	lowe@cshl.edu			NCI NIH HHS [P30 CA008748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asher G, 2001, P NATL ACAD SCI USA, V98, P1188, DOI 10.1073/pnas.021558898; Attardi LD, 2000, GENE DEV, V14, P704; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARDEESY N, 1995, CANCER RES, V55, P215; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chang NS, 2003, J BIOL CHEM, V278, P9195, DOI 10.1074/jbc.M208373200; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; de Stanchina E, 2002, NAT CELL BIOL, V4, pE275, DOI 10.1038/ncb1202-e275; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Frantz S, 2001, NAT REV MOL CELL BIO, V2, P872, DOI 10.1038/35103049; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Green DR, 2001, NAT REV MOL CELL BIO, V2, P917, DOI 10.1038/35103104; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo Z, 2001, CANCER RES, V61, P8395; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hussain SP, 1998, CANCER RES, V58, P4023; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Maecker HL, 2000, CANCER RES, V60, P4638; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Matsuda K, 2002, CANCER RES, V62, P2883; Mattson MP, 2001, APOPTOSIS, V6, P69, DOI 10.1023/A:1009676112184; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Parant JM, 2003, HUM MUTAT, V21, P321, DOI 10.1002/humu.10186; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Petak I, 2000, CLIN CANCER RES, V6, P4432; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Prives C, 1999, J PATHOL, V187, P112; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robles AI, 2001, CANCER RES, V61, P6660; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soengas MS, 2000, NAT GENET, V26, P391, DOI 10.1038/82497; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wosik K, 2003, J NEUROCHEM, V85, P635, DOI 10.1046/j.1471-4159.2003.01674.x; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang CC, 1999, CANCER RES, V59, P3663; Zhang CC, 1998, ONCOGENE, V16, P1617, DOI 10.1038/sj.onc.1201658; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao RB, 2000, GENE DEV, V14, P981	134	1038	1105	4	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9030	9040		10.1038/sj.onc.1207116	http://dx.doi.org/10.1038/sj.onc.1207116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663481				2022-12-28	WOS:000187043600006
J	Falcone, G; Ciuffini, L; Gauzzi, MC; Provenzano, C; Strano, S; Gallo, R; Castellani, L; Alema, S				Falcone, G; Ciuffini, L; Gauzzi, MC; Provenzano, C; Strano, S; Gallo, R; Castellani, L; Alema, S			V-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels	ONCOGENE			English	Article						myogenesis; MyoD; cell cycle; tyrosine kinase; p300	CELL-CYCLE ARREST; HELIX-LOOP-HELIX; CHROMATIN REMODELING ENZYMES; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; QUAIL MYOTUBES; DNA-BINDING; MOLECULAR-MECHANISMS; GENE-TRANSCRIPTION; TYROSINE KINASE	The conversion of skeletal myoblasts to terminally differentiated myocytes is negatively controlled by several growth factors and oncoproteins. In this study, we have investigated the molecular mechanisms by which v-Src, a prototypic tyrosine kinase, perturbs myogenesis in primary avian myoblasts and in established murine C2C12 satellite cells. We determined the expression levels of the cell cycle regulators pRb, cyclin D1 and D3 and cyclin-dependent kinase inhibitors p21 and p27 in v-Src-transformed myoblasts and found that, in contrast to myogenin, they are normally modulated by differentiative cues, implying that v-Src affects myogenesis independent of cell proliferation. We then examined the levels of expression, DNA-binding ability and transcription-activation potentials of myogenic regulatory factors in transformed myoblasts and in myotubes after reactivation of a temperature-sensitive allele of v-Src. Our results reveal two distinct potential modes of repression targeted to myogenic factors. On the one hand, we show that v-Src reversibly inhibits the expression of MyoD and myogenin in C2C12 cells and of myogenin in quail myoblasts. Remarkably, these loci become resistant to activation of the kinase in the postmitotic compartment. On the other hand, we demonstrate that v-Src efficiently inhibits muscle gene expression by repressing the transcriptional activity of myogenic factors without affecting MyoD DNA-binding activity. Indeed, forced expression of MyoD and myogenin allows terminal differentiation of transformed myoblasts. Finally, we found that ectopic expression of the coactivator p300 restores transcription from extrachromosomal muscle-specific promoters.	CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Cassino, I-03043 Cassino, Italy; INFM, SezB, Cassino, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	gfalcone@ibc.cnr.it; alema@ibc.cnr.it	Gauzzi, Maria Cristina/N-7038-2017; strano, sabrina/B-6743-2013; Falcone, Germana/A-3735-2016; Strano, Sabrina/K-9654-2016	Gauzzi, Maria Cristina/0000-0002-2996-5231; strano, sabrina/0000-0002-6341-4230; Castellani, Loriana/0000-0002-8519-3504; Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 1996, J CELL SCI, V109, P1335; Chan HM, 2001, J CELL SCI, V114, P2363; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnson SE, 2002, J BIOL CHEM, V277, P28742, DOI 10.1074/jbc.M203680200; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; KIESS M, 1995, ONCOGENE, V10, P159; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; La Rocca SA, 2002, ONCOGENE, V21, P4838, DOI 10.1038/sj.onc.1205586; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; MARTELLI F, 1994, ONCOGENE, V9, P3579; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; PINNEY DF, 1995, DEV BIOL, V170, P21, DOI 10.1006/dbio.1995.1192; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WELHAM MJ, 1990, ONCOGENE, V5, P161; Winter B, 2000, J CELL SCI, V113, P4211; YOON HY, 1994, ONCOGENE, V9, P801; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	63	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8302	8315		10.1038/sj.onc.1206915	http://dx.doi.org/10.1038/sj.onc.1206915			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614454				2022-12-28	WOS:000186541500009
J	Kartasheva, NN; Lenz-Bauer, C; Hartmann, O; Schafer, H; Eilers, M; Dobbelstein, M				Kartasheva, NN; Lenz-Bauer, C; Hartmann, O; Schafer, H; Eilers, M; Dobbelstein, M			Delta Np73 can modulate the expression of various genes in a p53-independent fashion	ONCOGENE			English	Article						p53; p73; EGR1; NF-kappa B; c-MYC	WILD-TYPE P53; NF-KAPPA-B; P73 GENE; C-MYC; TRANSCRIPTION; MICROARRAY; INHIBITOR; CANCER; OVEREXPRESSION; NEUROBLASTOMA	DeltaNp73alpha is an isoform of the p53 homologue p73 that lacks an amino-terminal transactivation domain and antagonizes the induction of gene expression by p53. Here, we examined whether DeltaNp73alpha might also modulate cellular transcription in the absence of p53. The expression of DeltaNp73alpha in the p53-/- cell line H1299 reduced the mRNA levels of p21/CDKN1A, but did not affect other p53-responsive genes. Correspondingly, the p21/CDKN1A promoter was downregulated by DeltaNp73alpha in reporter assays, whereas other p53-responsive promoters were not inhibited. To identify additional genes that respond to DeltaNp73alpha in the absence of p53, microarrays carrying 4600 cDNA clones were hybridized. The expression of 30 genes was found to be altered more than threefold by overexpressed DeltaNp73alpha. For instance, DeltaNp73alpha increased the expression of EGR1 and CDC6, whereas it decreased the mRNA levels of c-MYC, cyclin A2/CCNA2, NF-kappaB1, ODC1, and RET finger protein/RFP. Semiquantitative reverse transcription-PCR confirmed these results and further revealed that the influence of DeltaNp73alpha on the regulation of these genes differs from other p73 isoforms and p53. We conclude that the impact of DeltaNp73alpha on gene expression is not limited to p53-responsive genes. Rather, DeltaNp73alpha can regulate the expression of a variety of genes independently of p53.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35033 Marburg, Germany; Univ Marburg, Inst Med Biometrie & Epidemiol, D-35037 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Philipps University Marburg; Philipps University Marburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.	dobbelst@mailer.uni-marburg.de		Dobbelstein, Matthias/0000-0001-5052-3967; Eilers, Martin/0000-0002-0376-6533				Abdulkadir SA, 2001, NAT MED, V7, P101, DOI 10.1038/83231; Adamson ED, 2002, TUMOR BIOL, V23, P93, DOI 10.1159/000059711; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Douc-Rasy S, 2002, AM J PATHOL, V160, P631, DOI 10.1016/S0002-9440(10)64883-3; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fontemaggi G, 2002, J BIOL CHEM, V277, P43359, DOI 10.1074/jbc.M205573200; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Koch P, 2001, CANCER RES, V61, P5941; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; Lagger G, 2003, MOL CELL BIOL, V23, P2669, DOI 10.1128/MCB.23.8.2669-2679.2003; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MOBERG KH, 1992, J CELL BIOCHEM, V49, P208, DOI 10.1002/jcb.240490213; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zaika AI, 1999, CANCER RES, V59, P3257; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179	44	34	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8246	8254		10.1038/sj.onc.1207138	http://dx.doi.org/10.1038/sj.onc.1207138			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614448				2022-12-28	WOS:000186541500003
J	Leu, CM; Wong, FH; Chang, CM; Huang, SF; Hu, CP				Leu, CM; Wong, FH; Chang, CM; Huang, SF; Hu, CP			Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways	ONCOGENE			English	Article						IL-6; esophageal carcinoma; apoptosis; MAPK; STAT3	PROSTATE-CANCER CELLS; GROWTH-FACTOR-I; SERINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; IMMUNE-RESPONSE; MYELOMA CELLS; RISK-FACTORS; EXPRESSION; RECEPTOR	The production of interleukin-6 (IL-6) has been discovered in a variety of human tumors. Here we report the expression of IL-6, IL-6 receptor alpha (IL- 6Ralpha), and gp130 in human esophageal carcinoma tissues. We further demonstrate that IL- 6 protects an esophageal carcinoma cell line CE48T/VGH from apoptosis induced by staurosporine. IL-6 stimulation induced a rapid phosphorylation of gp130 and STAT3, and a dominant-negative STAT3 completely abolished the antiapoptotic effect. IL-6 also activated ERK 1/2 in CE48T/VGH cells. Inhibition of the ERK activation by PD98059 and transfection of a dominant-negative ERK2 completely blocked the protection of IL- 6 against apoptosis. Thus, both STAT and MAP kinase pathways are responsible for the IL-6-delivered survival signal in human esophageal carcinoma cells. In contrast, PI3-K inhibitors only partially attenuated the effect of IL-6, suggesting that PI3-K does not play a major role in the antiapoptotic signal of IL- 6 in our system. To investigate whether IL- 6 could induce the production of antiapoptotic molecules, proteins of the Bcl-2 family were measured. While Bcl-2, Bcl- x(L),, and Bax were not affected, Mcl-1 was induced by IL-6 in human esophageal carcinoma cells. Our results suggest that IL- 6 may contribute to the progression of esophageal cancers in an autocrine or paracrine manner.	Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Microbiol & Immunol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Publ Hlth, Taipei 112, Taiwan; Natl Hlth Res Inst, Dept Intramural Res Affairs, Taipei, Taiwan; Natl Hlth Res Inst, Div Mol & Gen Med, Taipei, Taiwan; Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan	Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Health Research Institutes - Taiwan; National Health Research Institutes - Taiwan; Chang Gung Memorial Hospital	Hu, CP (corresponding author), Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 112, Taiwan.	cphu@vghtpe.gov.tw	Huang, Shiu-Feng Kathy/E-3977-2010; Chang, Chung-Ming/E-3945-2010					Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; BLOT WJ, 1994, SEMIN ONCOL, V21, P403; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; CHEN T, 2001, CANCER RES, V60, P2132; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Enzinger PC, 1999, SEMIN ONCOL, V26, P12; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gallo RL, 1997, J INVEST DERMATOL, V109, P597, DOI 10.1111/1523-1747.ep12337529; Halapi E, 1998, MED ONCOL, V15, P203, DOI 10.1007/BF02787202; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; HU CP, 1984, J NATL CANCER I, V72, P577; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Lauta VM, 2001, CYTOKINE, V16, P79, DOI 10.1006/cyto.2001.0982; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Ma YX, 1999, APMIS, V107, P514, DOI 10.1111/j.1699-0463.1999.tb01587.x; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; MEIR EV, 1990, CANCER RES, V50, P6683; Minshall C, 1996, J IMMUNOL, V156, P939; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Oka M, 1996, CANCER RES, V56, P2776; OKA M, 1995, J INTERF CYTOK RES, V15, P1005, DOI 10.1089/jir.1995.15.1005; Okamoto M, 1997, CANCER RES, V57, P141; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Ribeiro U, 1996, BRIT J SURG, V83, P1174, DOI 10.1002/bjs.1800830905; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Singleton JR, 1996, J BIOL CHEM, V271, P31791, DOI 10.1074/jbc.271.50.31791; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Takeda K, 1998, J IMMUNOL, V161, P4652; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WONG FH, 1994, CANCER INVEST, V12, P121, DOI 10.3109/07357909409024867; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200	46	137	147	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7809	7818		10.1038/sj.onc.1207084	http://dx.doi.org/10.1038/sj.onc.1207084			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586407				2022-12-28	WOS:000186240200011
J	Takahashi, M; Mutoh, M; Shoji, Y; Kamanaka, Y; Naka, M; Maruyama, T; Sugimura, T; Wakabayashi, K				Takahashi, M; Mutoh, M; Shoji, Y; Kamanaka, Y; Naka, M; Maruyama, T; Sugimura, T; Wakabayashi, K			Transfection of K-ras(Asp12) cDNA markedly elevates IL-1 beta- and lipopolysaccharide-mediated inducible nitric oxide synthase expression in rat intestinal epithelial cells	ONCOGENE			English	Article						inducible nitric oxide synthase; K-ras; rat; IL-1 beta; lipopolysaccharide	FACTOR-KAPPA-B; ACTIVATED PROTEIN-KINASE; ABERRANT CRYPT FOCI; ELEMENT-BINDING PROTEIN; ONCOGENIC RAS; PRIMARY ASTROCYTES; TUMOR-GROWTH; CYCLIN D1; COLON; CANCER	Activating mutations of K-ras are frequent in colon tumors and aberrant crypt foci, and may play important roles in colon carcinogenesis. Here, we investigated the effects of a K-ras codon 12 mutation on inducible nitric oxide synthase ( iNOS) expression. When rat intestinal epithelial cells (IEC-6) were transfected with K-ras(Asp12) cDNA, the iNOS expression linked to interleukin-1beta (IL-1beta) or lipopolysaccharide (LPS) treatment was markedly increased and prolonged. In contrast, it was only very faint and transient in cells transfected with the control vector or K-ras(WT). Electrophoretic mobility-shift assays demonstrated that NF-kappaB binding activity induced by IL-1beta or LPS was also increased in K-ras(Asp12)-transfected cells, along with the bindingof CREB-1, CREM-1, ATF-1, ATF-2, and Jun D to a cAMP-responsive element (CRE)-like site and the bindingof C/EBPbeta to a C/EBP-binding consensus site. Furthermore, the anchorage-independent growth of K-ras(Asp12)-transfected cells was markedly increased by IL-1beta or LPS treatment, and decreased by ONO-1714, an iNOS inhibitor. In addition, tumor growth in nude mice injected with K-ras(Asp12)-transfected cells was significantly suppressed by NOS inhibition with 50 p. p. m. ONO-1714 or 100 p. p. m. L-N-G-nitroarginine methyl ester. These results suggest that an activating mutation of K-ras can markedly enhance the iNOS expression mediated by IL-1beta or LPS, through the activation of promoters on NF-kappaB, C/EBP, and CRE-like sites, and that nitric oxide contributes to the colony formation and tumor growth of K-ras-transformed cells.	Natl Canc Ctr, Res Inst, Canc Prevent Basic Res Project, Chuo Ku, Tokyo 1040045, Japan; Ono Pharmaceut Co Ltd, Minase Res Inst, Shimamoto, Osaka 6188585, Japan	National Cancer Center - Japan; Ono Pharmaceutical Co Ltd	Takahashi, M (corresponding author), Natl Canc Ctr, Res Inst, Canc Prevent Basic Res Project, Chuo Ku, 1-1 Tsukiji 5 Chome, Tokyo 1040045, Japan.		Mutoh, Michihiro/AAB-1868-2022	Takahashi, Mami/0000-0001-5062-811X				Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ambs S, 1998, CANCER RES, V58, P334; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Bhat NR, 2002, J BIOL CHEM, V277, P29584, DOI 10.1074/jbc.M204994200; Bissonnette M, 2000, CANCER RES, V60, P4602; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Eberhardt W, 1998, J IMMUNOL, V160, P4961; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; ICHII S, 1993, ONCOGENE, V8, P2399; INOUE Y, 1991, JPN J CANCER RES, V82, P90, DOI 10.1111/j.1349-7006.1991.tb01751.x; IRITANI A, 1986, Bulletin of Tokyo Medical and Dental University, V33, P35; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jiang BB, 2001, ARTERIOSCL THROM VAS, V21, P1915, DOI 10.1161/hq1201.099424; Kawamori T, 2000, CANCER LETT, V148, P33, DOI 10.1016/S0304-3835(99)00310-9; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Keinanen R, 1999, GENE, V234, P297, DOI 10.1016/S0378-1119(99)00196-1; Kiechle FL, 1996, ANN CLIN LAB SCI, V26, P501; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; Mifflin RC, 2002, AM J PHYSIOL-CELL PH, V282, pC824, DOI 10.1152/ajpcell.00388.2001; Naka M, 2000, BIOCHEM BIOPH RES CO, V270, P663, DOI 10.1006/bbrc.2000.2474; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rao CV, 1999, CARCINOGENESIS, V20, P641, DOI 10.1093/carcin/20.4.641; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, CANCER RES, V61, P2670; Singh K, 1996, J BIOL CHEM, V271, P1111, DOI 10.1074/jbc.271.2.1111; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Takahashi M, 2000, CARCINOGENESIS, V21, P1319, DOI 10.1093/carcin/21.7.1319; Takahashi M, 1997, CANCER RES, V57, P1233; Tannous M, 2001, BIOCHEM PHARMACOL, V62, P1459, DOI 10.1016/S0006-2952(01)00818-8; Thomsen LL, 1997, CANCER RES, V57, P3300; Vickers SM, 1999, ARCH SURG-CHICAGO, V134, P245, DOI 10.1001/archsurg.134.3.245; YAMASHITA N, 1995, GASTROENTEROLOGY, V108, P434, DOI 10.1016/0016-5085(95)90071-3	40	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7667	7676		10.1038/sj.onc.1207051	http://dx.doi.org/10.1038/sj.onc.1207051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576830				2022-12-28	WOS:000186113000015
J	Lee, S; Roy, F; Galmarini, CM; Accardi, R; Michelon, J; Viller, A; Cros, E; Dumontet, C; Sylla, BS				Lee, S; Roy, F; Galmarini, CM; Accardi, R; Michelon, J; Viller, A; Cros, E; Dumontet, C; Sylla, BS			Frameshift mutation in the Dok1 gene in chronic lymphocytic leukemia	ONCOGENE			English	Article						Dok1; chronic lymphocytic leukemia; frameshift mutation; NLS; Lck; tyrosine phosphorylation	RASGAP-BINDING PROTEIN; GTPASE-ACTIVATING PROTEIN; TYROSINE PHOSPHORYLATION; NEGATIVE REGULATION; MOLECULAR-CLONING; DOCKING PROTEIN; P62(DOK) DOK1; V-SRC; KINASE; APOPTOSIS	B-cell chronic lymphocytic leukemia (B-CLL) is a malignant disease characterized by an accumulation of monoclonal CD5+ mature B cells, with a high percentage of cells arrested in the G0/G1 phase of the cell cycle, and a particular resistance toward apoptosis-inducing agents. Dok1 ( downstream of tyrosine kinases) is an abundant Ras-GTPase-activating protein (Ras-GAP)-associated tyrosine kinase substrate, which negatively regulates cell proliferation, downregulates MAP kinase activation and promotes cell migration. The gene encoding Dok1 maps to human chromosome 2p13, a region previously found to be rearranged in B-CLL. We have screened the Dok1 gene for mutations from 46 individuals with B-CLL using heteroduplex analysis. A four-nucleotide GGCC deletion in the coding region was found in the leukemia cells from one patient. This mutation causes a frameshift leading to protein truncation at the carboxyl-terminus, with the acquisition of a novel amino-acid sequence. In contrast to the wild-type Dok1 protein, which has cytoplasmic/membrane localization, the mutant Dok1 is a nuclear protein containing a functional bipartite nuclear localization signal. Whereas overexpression of wild-type Dok1 inhibited PDGF-induced MAP kinase activation, this inhibition was not observed with the mutant Dok1. Furthermore the mutant Dok1 forms heterodimers with Dok1 wild type and the association can be enhanced by Lck-mediated tyrosine-phosphorylation. This is the first example of a Dok1 mutation in B-CLL and the data suggest that Dok1 might play a role in leukemogenesis.	Int Agcy Res Canc, F-69008 Lyon, France; INSERM, U590, F-69008 Lyon, France; Hospices Civils Lyon, F-69008 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon	Sylla, BS (corresponding author), Int Agcy Res Canc, 150 Cours Albert Thomas, F-69008 Lyon, France.	sylla@iarc.fr		Galmarini, Carlos Maria/0000-0001-5494-6617; Dumontet, Charles/0000-0003-1875-134X				ABTS H, 1991, LEUKEMIA RES, V15, P987, DOI 10.1016/0145-2126(91)90103-Z; Bhat A, 1998, J BIOL CHEM, V273, P32360, DOI 10.1074/jbc.273.48.32360; Cai DS, 2003, J BIOL CHEM, V278, P25323, DOI 10.1074/jbc.M212430200; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cheng GF, 2002, J VIROL, V76, P9434, DOI 10.1128/JVI.76.18.9434-9445.2002; Cong F, 1999, MOL CELL BIOL, V19, P8314; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; ELROUBY S, 1993, BLOOD, V82, P3452; Favre C, 2003, GENES IMMUN, V4, P40, DOI 10.1038/sj.gene.6363891; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hall A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [citeulike-article-id:691774, DOI 10.1021/BK-1999-0734.CH008]; Hosooka T, 2001, MOL CELL BIOL, V21, P5437, DOI 10.1128/MCB.21.16.5437-5446.2001; Hubert P, 2000, EUR J IMMUNOGENET, V27, P145, DOI 10.1046/j.1365-2370.2000.00203.x; INABA T, 1991, LEUKEMIA, V5, P719; JUCKER M, 1991, LEUKEMIA, V5, P528; Kato I, 2002, J IMMUNOL, V168, P629, DOI 10.4049/jimmunol.168.2.629; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Lemay S, 2000, MOL CELL BIOL, V20, P2743, DOI 10.1128/MCB.20.8.2743-2754.2000; Liang XQ, 2002, J BIOL CHEM, V277, P13732, DOI 10.1074/jbc.M200277200; Martelli MP, 2001, J BIOL CHEM, V276, P45654, DOI 10.1074/jbc.M105777200; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; NEET K, 1995, MOL CELL BIOL, V15, P4908; Nelms K, 1998, GENOMICS, V53, P243, DOI 10.1006/geno.1998.5514; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Nemorin JG, 2001, J IMMUNOL, V166, P4408, DOI 10.4049/jimmunol.166.7.4408; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; RICHARDSON AL, 1992, ONCOGENE, V7, P961; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Schaffner C, 1999, BLOOD, V94, P748, DOI 10.1182/blood.V94.2.748.414k02_748_753; SCHROEDER HW, 1994, IMMUNOL TODAY, V15, P288, DOI 10.1016/0167-5699(94)90009-4; Shah K, 2002, CHEM BIOL, V9, P35, DOI 10.1016/S1074-5521(02)00086-8; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; SONNIER JA, 1983, NEW ENGL J MED, V309, P590, DOI 10.1056/NEJM198309083091005; Stankovic T, 1999, LANCET, V353, P26, DOI 10.1016/S0140-6736(98)10117-4; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; van Dijk TB, 2000, BLOOD, V96, P3406; VonKnethen A, 1997, LEUKEMIA LYMPHOMA, V26, P551; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Wick MJ, 2001, J BIOL CHEM, V276, P42843, DOI 10.1074/jbc.M102116200; Wyatt W, 2000, BLOOD, V96, p367A; Yamakawa N, 2002, EMBO J, V21, P1684, DOI 10.1093/emboj/21.7.1684; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YOFFE G, 1990, J PEDIATR-US, V116, P114, DOI 10.1016/S0022-3476(05)81658-0; Zhao MM, 2001, J EXP MED, V194, P265, DOI 10.1084/jem.194.3.265	52	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2287	2297		10.1038/sj.onc.1207385	http://dx.doi.org/10.1038/sj.onc.1207385			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14730347				2022-12-28	WOS:000220427700002
J	Wada, M; Yazumi, S; Takaishi, S; Hasegawa, K; Sawada, M; Tanaka, H; Ida, H; Sakakura, C; Ito, K; Ito, Y; Chiba, T				Wada, M; Yazumi, S; Takaishi, S; Hasegawa, K; Sawada, M; Tanaka, H; Ida, H; Sakakura, C; Ito, K; Ito, Y; Chiba, T			Frequent loss of RUNX3 gene expression in human bile duct and pancreatic cancer cell lines	ONCOGENE			English	Article						RUNX3; bile duct cancer; pancreatic cancer; methylation	INTRAHEPATIC CHOLANGIOCARCINOMA; MULTIPLE GENES; ADENOCARCINOMA; GROWTH; HYPERMETHYLATION; HYBRIDIZATION; METHYLATION; MUTATIONS; PEBP2/CBF; DOMAIN	RUNX3, a Runt domain transcription factor involved in TGF-beta signaling, is a candidate tumor-suppressor gene localized in 1p36, a region commonly deleted in a wide variety of human tumors, including those of the stomach, bile duct, and pancreas. Recently, frequent inactivation of RUNX3 has been demonstrated in human gastric carcinomas. In this study, to examine the involvement of RUNX3 abnormalities in tumorigenesis of bile duct as well as pancreatic cancers, we investigated not only the expression but also methylation status of RUNX3 in 10 human bile duct and 12 pancreatic cancer cell lines. Seven (70%) of the bile duct and nine (75%) of the pancreatic cancer cell lines exhibited no expression of RUNX3 by both Northern blot analysis and the reverse transcriptase polymerase chain reaction. All of the 16 cell lines that did not express RUNX3 also showed methylation of the promoter CpG island of the gene, whereas the six cell lines that showed RUNX3 expression were not methylated or only partially methylated in the RUNX3 promoter region. Moreover, treatment with the methylation inhibitor 5'-aza-2'-deoxycitidine activated RUNX3 mRNA expression in all of 16 cancer cell lines that originally lacked RUNX3 expression. Finally, hemizygous deletion of RUNX3, as detected by fluorescence in situ hybridization, was found in 15 of the 16 cancer cell lines that lacked RUNX3 expression. These data suggest that the inactivation of RUNX3 plays an important role in bile duct and pancreatic carcinogenesis, and that methylation is a common mechanism by which the gene is inactivated.	Kyoto Univ, Grad Sch Internal Med, Dept Gastroenterol & Hepatol, Kyoto 6068507, Japan; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Natl Univ Singapore, Oncol Res Inst, Singapore 117609, Singapore; Kyoto Prefectural Univ Med, Dept Digest Surg, Kyoto 6028566, Japan	Kyoto University; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National University of Singapore; Kyoto Prefectural University of Medicine	Chiba, T (corresponding author), Kyoto Univ, Grad Sch Internal Med, Dept Gastroenterol & Hepatol, Kyoto 6068507, Japan.	cteya@kuhp.kyoto-u.ac.jp						BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BISGAARD HC, 1991, J CELL PHYSIOL, V147, P333, DOI 10.1002/jcp.1041470220; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Eng C, 2000, NAT GENET, V24, P101, DOI 10.1038/72730; Goggins M, 1999, ANN ONCOL, V10, P4, DOI 10.1023/A:1008307913019; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; HERMAN JG, 2000, MODERN PATHOL, V13, P627; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Kang YK, 2000, MODERN PATHOL, V13, P627, DOI 10.1038/modpathol.3880108; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; LOGSDON CD, 1992, AM J PHYSIOL, V262, pG364, DOI 10.1152/ajpgi.1992.262.2.G364; PARSONS R, 1995, CANCER RES, V55, P5548; Schleger C, 2000, J PATHOL, V191, P27, DOI 10.1002/(SICI)1096-9896(200005)191:1<27::AID-PATH582>3.0.CO;2-J; Schnall SF, 1996, SEMIN ONCOL, V23, P220; Schutte M, 1997, CANCER RES, V57, P3126; Takenoshita S, 1998, CARCINOGENESIS, V19, P803, DOI 10.1093/carcin/19.5.803; Ueki T, 2000, CANCER RES, V60, P1835; Weith A, 1996, CYTOGENET CELL GENET, V72, P114; Yazumi S, 2000, INT J CANCER, V86, P782; YOSHIDA S, 1995, CANCER RES, V55, P2756	25	87	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2401	2407		10.1038/sj.onc.1207395	http://dx.doi.org/10.1038/sj.onc.1207395			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743205				2022-12-28	WOS:000220427700014
J	Nielsen, FC; Jager, AC; Lutzen, A; Bundgaard, JR; Juel, L; Rasmussen, LJ				Nielsen, FC; Jager, AC; Lutzen, A; Bundgaard, JR; Juel, L; Rasmussen, LJ			Characterization of human exonuclease 1 in complex with mismatch repair proteins, subcellular localization and association with PCNA	ONCOGENE			English	Article						hEXO1; hMSH2; hMLH1; PCNA; DNA mismatch repair; HNPCC	CELL NUCLEAR ANTIGEN; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE EXO1; NUCLEOTIDE EXCISION-REPAIR; MEIOTIC CROSSING-OVER; DNA POLYMERASE-DELTA; COLORECTAL-CANCER; WERNER-SYNDROME; S-PHASE; REPLICATION FACTORIES	Human exonuclease 1 ( hEXO1) has been implicated in DNA mismatch repair (MMR), replication, and recombination, but the nature of its interaction with these cellular processes is still ambiguous. We show that hEXO1 colocalizes with proliferating cell nuclear antigen ( PCNA) at DNA replication sites and that the C-terminal region of hEXO1 is sufficient for this localization. We also show that both hMLH1-hPMS2 (MutLalpha) and hMLH1 hEXO1 complexes are formed in a reaction mixture containing all three proteins. Moreover, hEXO1 50 double-stranded exonuclease activity on a homoduplex substrate but not on a substrate containing a G/T mismatch was inhibited by complex formation with hMSH2-hMSH6 (MutSalpha) or MutLalpha. Taken together, the results support a model in which hEXO1 plays a role in events at the replication sites as well as a functional role in the MMR and/or recombination processes.	Roskilde Univ Ctr, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark; Rigshosp, Dept Clin Biochem, DK-2100 Copenhagen, Denmark	Roskilde University; Rigshospitalet; University of Copenhagen	Rasmussen, LJ (corresponding author), Roskilde Univ Ctr, Dept Chem & Life Sci, DK-4000 Roskilde, Denmark.	ljr@ruc.dk	Nielsen, Finn Cilius/AAA-4926-2020	Rasmussen, Lene Juel/0000-0001-6864-963X				Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Argueso JL, 2002, GENETICS, V160, P909; Baker SM, 1998, CANCER RES, V58, P1087; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; de Wind N, 2001, CURR BIOL, V11, pR545, DOI 10.1016/S0960-9822(01)00338-4; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Digilio FA, 1996, DEV BIOL, V178, P90, DOI 10.1006/dbio.1996.0200; Drotschmann K, 1999, P NATL ACAD SCI USA, V96, P2970, DOI 10.1073/pnas.96.6.2970; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Fiorentini P, 1997, MOL CELL BIOL, V17, P2764, DOI 10.1128/MCB.17.5.2764; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Genschel J, 2002, J BIOL CHEM, V277, P13302, DOI 10.1074/jbc.M111854200; Heyer J, 1999, ONCOGENE, V18, P5325, DOI 10.1038/sj.onc.1203036; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Hsieh P, 2001, MUTAT RES-DNA REPAIR, V486, P71, DOI 10.1016/S0921-8777(01)00088-X; Jager AC, 2001, ONCOGENE, V20, P3590, DOI 10.1038/sj.onc.1204467; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Kawamura K, 2000, ANAL QUANT CYTOL, V22, P107; Khazanehdari KA, 2000, CHROMOSOMA, V109, P94, DOI 10.1007/s004120050416; Kirkpatrick DT, 2000, GENETICS, V156, P1549; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kondo E, 2001, NUCLEIC ACIDS RES, V29, P1695, DOI 10.1093/nar/29.8.1695; Leach FS, 1996, CANCER RES, V56, P235; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lee BI, 1999, NUCLEIC ACIDS RES, V27, P4114, DOI 10.1093/nar/27.20.4114; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Marra G, 1996, ONCOGENE, V13, P2189; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; Nielsen FC, 2002, J CELL SCI, V115, P2087; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rasmussen LJ, 2000, MUTAT RES-DNA REPAIR, V460, P41, DOI 10.1016/S0921-8777(00)00012-4; Rasmussen LJ, 2000, EXP CELL RES, V257, P127, DOI 10.1006/excr.2000.4865; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Rothstein R, 2000, GENE DEV, V14, P1; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; Smith BT, 2001, MOL CELL, V8, P1197, DOI 10.1016/S1097-2765(01)00402-6; Sokolsky T, 2000, GENETICS, V155, P589; Somanathan S, 2001, J CELL BIOCHEM, V81, P56, DOI 10.1002/1097-4644(20010401)81:1<56::AID-JCB1023>3.0.CO;2-#; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sun XM, 2002, CANCER RES, V62, P6026; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2002, DNA REPAIR, V1, P895, DOI 10.1016/S1568-7864(02)00114-3; Tsubouchi H, 2000, MOL BIOL CELL, V11, P2221, DOI 10.1091/mbc.11.7.2221; Wang Y, 2000, GENE DEV, V14, P927; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; Wu Y, 2001, GASTROENTEROLOGY, V120, P1580, DOI 10.1053/gast.2001.25117	74	63	69	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1457	1468		10.1038/sj.onc.1207265	http://dx.doi.org/10.1038/sj.onc.1207265			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14676842				2022-12-28	WOS:000189035800013
J	Lucca, C; Vanoli, F; Cotta-Ramusino, C; Pellicioli, A; Liberi, G; Haber, J; Foiani, M				Lucca, C; Vanoli, F; Cotta-Ramusino, C; Pellicioli, A; Liberi, G; Haber, J; Foiani, M			Checkpoint-mediated control of replisome-fork association and signalling in response to replication pausing	ONCOGENE			English	Article						checkpoint; genome instability; chromosome replication; ATM pathway; Rad53	DOUBLE-STRAND BREAKS; DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-A; HOMOLOG MEC1; G2/M ARREST; DAMAGE; PROGRESSION; PHOSPHORYLATION	The replication checkpoint controls the integrity of replicating chromosomes by stabilizing stalled forks, thus preventing the accumulation of abnormal replication and recombination intermediates that contribute to genome instability. Checkpoint-defective cells are susceptible to rearrangements at chromosome fragile sites when replication pauses, and certain human cancer prone diseases suffer checkpoint abnormalities. It is unclear as to how the checkpoint stabilizes stalled forks and how cells sense replication blocks. We have analysed the checkpoint contribution in controlling replisome-fork association when replication pauses. We show that in yeast wild-type cells, stalled forks exhibit stable replisome complexes and the checkpoint sensors Ddc1 and Ddc2, thus activating Rad53 checkpoint kinase. Ddc1/Ddc2 recruitment on stalled forks and Rad53 activation are influenced by the single-strand-binding protein replication factor A (RFA). rad53 forks exhibit a defective association with DNA polymerases alpha, epsilon and delta. Further, in rad53 mutants, stalled forks progressively generate abnormal structures that turn into checkpoint signals by accumulating RFA, Ddc1 and Ddc2. We suggest that, following replication blocks, checkpoint activation mediated by RFA-ssDNA. laments stabilizes stalled forks by controlling replisome - fork association, thus preventing unscheduled recruitment of recombination enzymes that could otherwise cause the pathological processing of the forks.	Ist FIRC Oncol Mol, I-20141 Milan, Italy; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	IFOM - FIRC Institute of Molecular Oncology; University of Milan; Brandeis University	Foiani, M (corresponding author), Ist FIRC Oncol Mol, Via Adamello 16, I-20141 Milan, Italy.	foiani@ifom-firc.it	LIBERI, GIORDANO/AAY-7273-2020; Foiani, Marco/M-8234-2014; Pellicioli, Achille/B-8765-2017	LIBERI, GIORDANO/0000-0003-3160-2242; Foiani, Marco/0000-0003-4795-834X; Pellicioli, Achille/0000-0002-1528-9009; Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020056, R01GM061766, R01GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20056, GM61766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cimprich KA, 2003, CURR BIOL, V13, pR231, DOI 10.1016/S0960-9822(03)00158-1; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kornberg A., 1992, DNA REPLICATION; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee SE, 2001, CURR BIOL, V11, P1053, DOI 10.1016/S0960-9822(01)00296-2; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marini F, 1997, EMBO J, V16, P639, DOI 10.1093/emboj/16.3.639; Melo JA, 2001, GENE DEV, V15, P2809; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Paciotti V, 2000, GENE DEV, V14, P2046; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Umezu K, 1998, GENETICS, V148, P989; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	128	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1206	1213		10.1038/sj.onc.1207199	http://dx.doi.org/10.1038/sj.onc.1207199			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647447				2022-12-28	WOS:000188892200004
J	Zheng, YH; Shi, Y; Tian, CH; Jiang, CS; Jin, HJ; Chen, JJ; Almasan, A; Tang, H; Chen, Q				Zheng, YH; Shi, Y; Tian, CH; Jiang, CS; Jin, HJ; Chen, JJ; Almasan, A; Tang, H; Chen, Q			Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide	ONCOGENE			English	Article						apoptosis; arsenic trioxide; Bcl-2 proteins; cytochrome c; VDAC	ACUTE PROMYELOCYTIC LEUKEMIA; BCL-2 FAMILY; CASPASE ACTIVATION; CELL APOPTOSIS; BAX; MODULATION; MEMBRANE; PROTEIN; MEGACHANNEL; YEAST	The precise molecular mechanism underlying arsenic trioxide (As2O3)-induced apoptosis is a subject of extensive study. Here, we show that clinically relevant doses of As2O3 can induce typical apoptosis in IM-9, a multiple myeloma cell line, in a Bcl-2 inhibitable manner. We confirmed that As2O3 directly induced cytochrome c (cyto c) release from isolated mouse liver mitochondria via the mitochondrial permeability transition pore, and we further identified the voltage-dependent anion channel (VDAC) as a biological target of As2O3 responsible for eliciting cyto c release in apoptosis. First, pretreatment of the isolated mitochondria with an anti-VDAC antibody specifically prevented As2O3-induced cyto c release. Second, in proteoliposome experiments, VDAC by itself was sufficient to mediate As2O3-induced cyto c release, which could be specifically inhibited by Bcl-X-L. Third, As2O3 induced mitochondria membrane potential (DeltaPsim) reduction and cyto c release only in the VDAC-expressing, but not in the VDAC-deficient yeast strain. Finally, we found that As2O3 induced the increased expression and homodimerization of VDAC in IM-9 cells, but not in Bcl-2 overexpressing cells, suggesting that VDAC homodimerization could potentially determine its gating capacity to cyto c, and Bcl-2 blockage of VDAC homodimerization represents a novel mechanism for its inhibition of apoptosis.	Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, State Key lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China; Chinese Acad Sci, Inst Microbiol, Ctr Mol Immunol, Beijing 100080, Peoples R China; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy of Sciences; Institute of Microbiology, CAS; Cleveland Clinic Foundation	Chen, Q (corresponding author), Chinese Acad Sci, Inst Zool, Lab Apoptosis & Canc Biol, State Key lab Biomembrane & Membrane Biotechnol, Beijing 100080, Peoples R China.	chenq@panda.ioz.ac.cn	Almasan, Alex/C-2715-2008; Tian, Changhai/AAD-4856-2019; yang, zheng/HGC-7753-2022	Almasan, Alex/0000-0002-8916-6650; Chen, Quan/0000-0001-7539-8728	NCI NIH HHS [R01 CA081504, R01 CA081504-05, CA82858, CA81504, R01 CA082858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KC, 2002, CANCER J, V8, P12, DOI 10.1097/00130404-200201000-00003; Aposhian HV, 1997, ANNU REV PHARMACOL, V37, P397, DOI 10.1146/annurev.pharmtox.37.1.397; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; BERNARDI P, 1984, BIOCHIM BIOPHYS ACTA, V766, P277, DOI 10.1016/0005-2728(84)90242-1; Chen GQ, 1996, BLOOD, V88, P1052; Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chen Q, 1998, BLOOD, V92, P4545, DOI 10.1182/blood.V92.12.4545.424k41_4545_4553; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Colombini M, 1996, Ion Channels, V4, P169; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costantini P, 1996, J BIOL CHEM, V271, P6746, DOI 10.1074/jbc.271.12.6746; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; DEPINTO V, 1992, J BIOENERG BIOMEMBR, V24, P21, DOI 10.1007/BF00769526; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KRAUSE J, 1986, BIOCHIM BIOPHYS ACTA, V860, P690, DOI 10.1016/0005-2736(86)90568-7; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; Mannella CA, 1998, J STRUCT BIOL, V121, P207, DOI 10.1006/jsbi.1997.3954; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, BIOMED PHARMACOTHER, V52, P248, DOI 10.1016/S0753-3322(98)80009-7; Matsuyama S, 1999, CURR OPIN MICROBIOL, V2, P618, DOI 10.1016/S1369-5274(99)00031-4; Miller WH, 2002, CANCER RES, V62, P3893; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Perkins C, 2000, BLOOD, V95, P1014, DOI 10.1182/blood.V95.3.1014.003k04_1014_1022; PETRONILLI V, 1993, J BIOL CHEM, V268, P21939; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Rousselot P, 1999, CANCER RES, V59, P1041; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Shi Y, 2003, BIOCHEM BIOPH RES CO, V305, P989, DOI 10.1016/S0006-291X(03)00871-4; Shi Y, 2003, BIOCHEM BIOPH RES CO, V303, P475, DOI 10.1016/S0006-291X(03)00359-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Song JM, 1998, J BIOL CHEM, V273, P24406, DOI 10.1074/jbc.273.38.24406; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Takagi-Morishita Y, 2003, BIOL REPROD, V68, P1178, DOI 10.1095/biolreprod.102.007997; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wang XD, 2001, GENE DEV, V15, P2922; Wang ZG, 1998, BLOOD, V92, P1497, DOI 10.1182/blood.V92.5.1497.417k41_1497_1504; Xia T, 2002, CHINESE SCI BULL, V47, P553, DOI 10.1360/02tb9127; Xia T, 2002, FEBS LETT, V510, P62, DOI 10.1016/S0014-5793(01)03228-8; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762	69	150	163	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1239	1247		10.1038/sj.onc.1207205	http://dx.doi.org/10.1038/sj.onc.1207205			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647451	Green Accepted			2022-12-28	WOS:000188892200008
J	Serresi, M; Piccinini, G; Pierpaoli, E; Fazioli, F				Serresi, M; Piccinini, G; Pierpaoli, E; Fazioli, F			A ligand-inducible anaplastic lymphoma kinase chimera is endocytosis impaired	ONCOGENE			English	Article						internalization; EGFR-ALK chimera; downregulation; receptor degradation	EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; MOLECULAR CHARACTERIZATION; ERBB RECEPTORS; C-CBL; ALK; PROTEIN; GENE; ACTIVATION; PHOSPHORYLATION	Ligand-induced membrane trafficking of the anaplastic lymphoma kinase (ALK) was studied using a chimeric receptor in which the extracellular and transmembrane domain of ALK was substituted for the corresponding regions of epidermal growth factor receptor (EGFR). Wild-type EGFR, EGFR/ALK and an EGFR/ALK kinase negative mutant were independently expressed in mouse NR6 fibroblasts. The capacity of EGFR/ALK to mediate [I-125]-EGF internalization, receptor degradation and downregulation, which has never been previously described, was assayed. The rate of [I-125]-EGF-induced internalization mediated by the cytoplasmic domain of ALK was reduced several fold compared with the wildtype EGFR. The low rate of EGF internalization promoted by EGFR/ALK correlated with an impaired degradation and downregulation of the receptor and indicate that ALK is not subject to traditional mechanisms used to regulate receptor tyrosine kinase function. Accordingly, ALK-activated intracellular domain does not associate in vivo with c-cbl and does not undergo ligand-mediated ubiquitination. The current study provides new insight into the function and regulation of ALK suggesting that the relative long membrane residence of activated ALK might confers a more potent and prolonged signaling activity. Indeed NR6-EGFR/ALK cells exhibited a similar to3-fold increase in a maximal mitogenic response than NR6-EGFR.	Univ Ancona, Inst Clin Med, Cellular & Mol Biol Lab, I-60020 Ancona, Italy	Marche Polytechnic University	Fazioli, F (corresponding author), Univ Ancona, Inst Clin Med, Cellular & Mol Biol Lab, Via Tronto 10-A, I-60020 Ancona, Italy.	fazioli@mta01.univpm.it	Pierpaoli, Elisa/J-5996-2016	Pierpaoli, Elisa/0000-0003-4612-7317				Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Hernandez L, 1999, BLOOD, V94, P3265; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kholodenko BN, 2002, TRENDS CELL BIOL, V12, P173, DOI 10.1016/S0962-8924(02)02251-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lamant L, 1999, BLOOD, V93, P3088; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; LONARDO F, 1990, New Biologist, V2, P992; LUND KA, 1990, J BIOL CHEM, V265, P15713; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; Pandit SD, 1997, J BIOL CHEM, V272, P2199; Piccinini G, 2002, J BIOL CHEM, V277, P22231, DOI 10.1074/jbc.M111145200; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Slupianek A, 2001, CANCER RES, V61, P2194; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1993, ONCOGENE, V8, P3021; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Waterman H, 1998, J BIOL CHEM, V273, P13819, DOI 10.1074/jbc.273.22.13819; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; Weber D, 2000, CANCER RES, V60, P5284; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083	49	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1098	1108		10.1038/sj.onc.1207227	http://dx.doi.org/10.1038/sj.onc.1207227			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14691459				2022-12-28	WOS:000188749900008
J	Coupier, I; Baldeyron, U; Rousseau, A; Mosseri, V; Pages-Berhouet, S; Caux-Moncoutier, V; Papadopoulo, D; Stoppa-Lyonnet, D				Coupier, I; Baldeyron, U; Rousseau, A; Mosseri, V; Pages-Berhouet, S; Caux-Moncoutier, V; Papadopoulo, D; Stoppa-Lyonnet, D			Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations	ONCOGENE			English	Article						BRCA1 heterozygous carriers; missense mutation; DNA end-joining; double-strand break repair	OVARIAN-CANCER FAMILIES; DAMAGE RESPONSE; GENE; SUSCEPTIBILITY; REARRANGEMENTS; ASSOCIATION; RAD51; RISK	Germ-line mutations of the BRCA1 and BRCA2 genes, when they lead to a truncated protein, confer a high risk of breast and ovarian cancer. However, the role of BRCA1 missense mutations in cancer predisposition is unclear. Functional assays may be very helpful to more clearly define the biological effect of these mutations, and could therefore be useful in clinical practice. A recent study using a Host Cell End-Joining assay showed that a truncating mutation results in impaired fidelity of DSB repair by DNA end-joining. In the present study, we examined the fidelity of DSB repair in four lymphoblastoid cell lines with BRCA1 missense mutations. The fidelity of DNA end-joining was impaired in the four cell lines studied compared to the normal control cell line. The fidelity of end-joining was similar to that of a truncated mutation control cell line for one cell line and slightly higher for the other cell lines.	Inst Curie, Serv Genet Oncol, Med Sect, F-75248 Paris 05, France; Inst Curie, INSERM, U509, Sect Rech, Paris, France; Inst Curie, CNRS, UMR 218, Sect Rech, F-75231 Paris, France; Inst Curie, Serv Biostat, Med Sect, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Stoppa-Lyonnet, D (corresponding author), Inst Curie, Serv Genet Oncol, Med Sect, 26 Rue Ulm, F-75248 Paris 05, France.	dominique.stoppa-lyonnet@curie.net	Baldeyron, Céline/F-6990-2019	Baldeyron, Céline/0000-0003-2311-1523				Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Casilli F, 2002, HUM MUTAT, V20, P218, DOI 10.1002/humu.10108; Chen JJ, 1999, CANCER RES, V59, p1752S; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Fleming MA, 2003, P NATL ACAD SCI USA, V100, P1151, DOI 10.1073/pnas.0237285100; Foray N, 1999, ONCOGENE, V18, P7334, DOI 10.1038/sj.onc.1203165; Gad S, 2002, ONCOGENE, V21, P6841, DOI 10.1038/sj.onc.1205685; Huyton T, 2000, MUTAT RES-DNA REPAIR, V460, P319, DOI 10.1016/S0921-8777(00)00034-3; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Rothfuss A, 2000, CANCER RES, V60, P390; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	26	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					914	919		10.1038/sj.onc.1207191	http://dx.doi.org/10.1038/sj.onc.1207191			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647443				2022-12-28	WOS:000188486600006
J	Hobbs, SS; Cameron, EM; Hammer, RP; Le, ATD; Gallo, RM; Blommell, EN; Coffing, SL; Chang, H; Riese, DJ				Hobbs, SS; Cameron, EM; Hammer, RP; Le, ATD; Gallo, RM; Blommell, EN; Coffing, SL; Chang, H; Riese, DJ			Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase	ONCOGENE			English	Article						heregulins; neuregulins; ErbB4; HER4	EPIDERMAL-GROWTH-FACTOR; CONSTITUTIVELY ACTIVE ERBB4; FACTOR-ALPHA; DIFFERENTIATION FACTOR; EXTRACELLULAR DOMAIN; CELLULAR-RESPONSE; CRYSTAL-STRUCTURE; HIGH-AFFINITY; EGF RECEPTOR; FAMILY	The neuregulins (NRGs) are members of the epidermal growth factor (EGF) family of peptide growth factors. These hormones are agonists for the ErbB family of receptor tyrosine kinases, a family that includes the epidermal growth factor receptor (EGFR/ErbB1), ErbB2/ Neu/HER2, ErbB3/HER3, and ErbB4/HER4. We recently observed that the EGF family hormone NRG2beta is a potent agonist for ErbB4. In contrast, NRG2alpha, a splicing isoform of the same gene that encodes NRG2beta, is a poor ErbB4 agonist. We hypothesized that carboxyl-terminal residues of NRG2beta are critical for stimulation of ErbB4 tyrosine phosphorylation and coupling to downstream signaling events. Here, we demonstrate that the substitution of a lysine residue for Phe45 in NRG2beta results in reduced ligand potency. We also demonstrate that substitution of a phenylalanine for Lys45 in NRG2alpha: results in increased ligand potency. Finally, analyses of the gain-of-function NRG2alpha Chg5 mutant demonstrate that Gln43, Met47, Asn49, and Phe50 regulate ligand efficacy. Thus, these data indicate that carboxyl-terminal residues of NRG2beta are critical for activation of ErbB4 signaling. Moreover, these NRG2alpha: and NRG2beta mutants reveal new insights into models for ligand-induced ErbB family receptor tyrosine phosphorylation and coupling to downstream signaling events.	Purdue Univ, Dept Med Chem & Mol Pharmacol, Sch Pharm, W Lafayette, IN 47907 USA; Louisiana State Univ, Dept Chem, Baton Rouge, LA 70803 USA; Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Louisiana State University System; Louisiana State University; Bristol-Myers Squibb	Riese, DJ (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Sch Pharm, 201 S Univ St,HANS 114, W Lafayette, IN 47907 USA.	driese@purdue.edu	Riese, David/AAF-3581-2020	Riese, David/0000-0002-8823-5802	NCI NIH HHS [F33CA085049, R21CA089274, R21CA080770] Funding Source: Medline; NIGMS NIH HHS [T32GM008737] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F33CA085049, R21CA089274, R21CA080770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008737] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Feroz K, 2002, CELL SIGNAL, V14, P793, DOI 10.1016/S0898-6568(02)00019-0; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; Gullick WJ, 2001, ENDOCR-RELAT CANCER, V8, P75, DOI 10.1677/erc.0.0080075; Halgren TA, 1999, J COMPUT CHEM, V20, P720, DOI 10.1002/(SICI)1096-987X(199905)20:7<720::AID-JCC7>3.0.CO;2-X; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; Hobbs SS, 2002, ONCOGENE, V21, P8442, DOI 10.1038/sj.onc.1205960; HOYT DW, 1994, BIOCHEMISTRY-US, V33, P11928; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1992, BIOCHEMISTRY-US, V31, P11928, DOI 10.1021/bi00162a036; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Miura K, 2002, BIOCHEM BIOPH RES CO, V294, P1040, DOI 10.1016/S0006-291X(02)00585-5; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Penington DJ, 2002, CELL GROWTH DIFFER, V13, P247; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Riese DJ, 1998, J BIOL CHEM, V273, P11288, DOI 10.1074/jbc.273.18.11288; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sherrill JM, 1996, BIOCHEMISTRY-US, V35, P5705, DOI 10.1021/bi9602268; Sherrill JM, 1997, BIOCHEMISTRY-US, V36, P12890, DOI 10.1021/bi971418l; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Williams EE, 2003, CANCER LETT, V192, P67, DOI 10.1016/S0304-3835(02)00690-0; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	36	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					883	893		10.1038/sj.onc.1207250	http://dx.doi.org/10.1038/sj.onc.1207250			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661053				2022-12-28	WOS:000188486600003
J	Courtois, S; de Fromentel, CC; Hainaut, P				Courtois, S; de Fromentel, CC; Hainaut, P			p53 protein variants: structural and functional similarities with p63 and p73 isoforms	ONCOGENE			English	Review						p53 family; isoform; regulation; alternative splicing; degradation	ALTERNATIVELY SPLICED FORM; TUMOR-SUPPRESSOR GENE; DNA-BINDING ACTIVITY; WILD-TYPE P53; TRANSACTIVATION FUNCTION; PROTEOLYTIC CLEAVAGE; TERMINAL DOMAIN; NORMAL-CELLS; DAMAGED DNA; SAM DOMAIN	Since its discovery in 1979, many studies have reported that the p53 tumour suppressor protein could be expressed in the form of products smaller than those predicted by the full-length amino-acid sequence. These products differ from full-length p53 in their N- or C-terminal regions, but generally conserve the central, DNA-binding domain. They appear to be expressed at rather low levels and to be restricted to particular cell types and/or physiological circumstances, suggesting that they play very narrow and specific roles. Several mechanisms have been proposed to explain their timely occurrence, including alternative splicing, internal initiation of translation or proteolytic cleavage. A precise assessment of the various 'p53 isoforms' reveals striking similarities with several isoforms of the p53 homologous proteins p63 or p73, suggesting that regulated production of specific, N- or C-terminal variants may be a 'trademark' of all family members. In this review, we summarize the published evidence on the structure, mode of production, expression and function of the p53 isoforms, and discuss their properties in the light of recent data on the structure and function of p63/p73 isoforms.	Int Agcy Res Canc, Unit Mol Carcinogenesis, F-69372 Lyon 08, France; Ctr Leon Berard, INSERM, U590, F-69373 Lyon 08, France	World Health Organization; International Agency for Research on Cancer (IARC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Hainaut, P (corresponding author), Int Agcy Res Canc, Unit Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012; de Fromentel, Claude Caron/Y-9715-2019	Hainaut, Pierre/0000-0002-1303-1610; de Fromentel, Claude Caron/0000-0001-7566-3958				Ahn J, 2001, NAT STRUCT BIOL, V8, P730, DOI 10.1038/nsb0901-730; Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; Barraille P, 1999, BIOCHEM BIOPH RES CO, V257, P84, DOI 10.1006/bbrc.1999.0334; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; BRAIN R, 1994, ONCOGENE, V9, P1775; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flaman JM, 1996, ONCOGENE, V12, P813; FOULKES NS, 1992, CELL, V68, P411, DOI 10.1016/0092-8674(92)90178-F; Ghioni P, 2002, MOL CELL BIOL, V22, P8659, DOI 10.1128/MCB.22.24.8659-8668.2002; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishimoto O, 2002, CANCER RES, V62, P636; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; Laverdiere M, 2000, NUCLEIC ACIDS RES, V28, P1489, DOI 10.1093/nar/28.6.1489; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Molinari M, 1996, ONCOGENE, V13, P2077; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rehberger PA, 1997, CELL GROWTH DIFFER, V8, P851; Sadji-Ouatas Z, 2002, BIOCHEM J, V364, P881, DOI 10.1042/BJ20020349; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Stiewe T, 2002, CANCER RES, V62, P3598; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; WILL K, 1995, NUCLEIC ACIDS RES, V23, P4023, DOI 10.1093/nar/23.20.4023; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Wolkowicz R, 1997, PATHOL BIOL, V45, P785; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	59	87	91	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					631	638		10.1038/sj.onc.1206929	http://dx.doi.org/10.1038/sj.onc.1206929			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737098				2022-12-28	WOS:000188304900001
J	Treff, NR; Pouchnik, D; Dement, GA; Britt, RL; Reeves, R				Treff, NR; Pouchnik, D; Dement, GA; Britt, RL; Reeves, R			High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human breast cancer cells	ONCOGENE			English	Article						HMGA1; MCF-7 cells; Ras/ERK; caveolin; KIT ligand; cholesterol	GLOBAL GENE-EXPRESSION; CHROMOSOMAL-PROTEINS; IN-VIVO; HMG-I/Y; CHEMOTHERAPEUTIC INTERVENTION; TRANSDUCTION CASCADE; MALIGNANT PHENOTYPE; HMGI(Y) PROTEINS; EPITHELIAL-CELLS; GASTRIC CANCERS	High-mobility group (HMG) A1 proteins are gene regulatory factors whose overexpression is frequently observed in naturally occurring human cancers. The overexpression of transgenic HMGA1 proteins in cells results in neoplastic transformation and promotes progression to malignant cellular phenotypes. To understand the underlying molecular and biological events involved in these phenomena, we used oligonucleotide microarray analyses to generate an HMGA1a-induced expression profile for approximately 22 000 genes. This gene expression profile was generated using a well-characterized transgenic human MCF-7 mammary adenocarcinoma cell line in which overexpression of transgenic HMGA1 promotes a transition to a more malignant and metastatic phenotype. Microarray expression analyses, together with independent quantitative real-time reverse transcriptase polymerase chain reaction results, indicate that HMGA1a regulates genes involved in the Ras-extracellular signal-related kinase (Ras/ERK) mitogenic signaling pathway, including KIT ligand and caveolins 1 and 2. We also found that many cholesterol biosynthesis genes were decreased in cells overexpressing HMGA1a. Cholesterol depletion, decreased caveolin, and increased KIT ligand expression, are all independently associated with the activation of Ras/ERK signaling. Upon further analysis, we found that sensitivity to epidermal growth factor activation of ERK phosphorylation was significantly higher, and that cholesterol was significantly depleted, in cells overexpressing HMGA1a. The cumulative evidence indicates that one likely mechanism by which the HMGA1a protein promotes malignant changes in cells is through increased sensitivity to the activation of the Ras/ERK signaling pathway.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Reeves, R (corresponding author), Washington State Univ, Sch Mol Biosci, POB 644660, Pullman, WA 99164 USA.	reevesr@mail.wsu.edu	Kim, Seongman/N-6910-2014		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046352, T32GM008336] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-46352, T-32 GM008336] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe N, 2000, CANCER RES, V60, P3117; Bandiera A, 1998, CANCER RES, V58, P426; Banks GC, 2000, BIOCHEMISTRY-US, V39, P8333, DOI 10.1021/bi000378+; Beckerbauer L, 2000, CHEM BIOL, V7, P805, DOI 10.1016/S1074-5521(00)00028-4; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; Brandt S, 2003, ANTICANCER RES, V23, P223; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; BUSTIN M, 1996, PROG NUCL ACIDS RES, V54, P25; Caceres-Cortes JR, 2001, CANCER RES, V61, P6281; Charpentier AH, 2000, CANCER RES, V60, P5977; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Daoud SS, 2003, CANCER RES, V63, P2782; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Fedele M, 1996, CANCER RES, V56, P1896; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; Giannini G, 1999, CANCER RES, V59, P2484; Giannini G, 2000, BRIT J CANCER, V83, P1503, DOI 10.1054/bjoc.2000.1494; HEIDER JG, 1978, J LIPID RES, V19, P514; Hilger RA, 2002, ONKOLOGIE, V25, P511, DOI 10.1159/000068621; Janowski BA, 2002, P NATL ACAD SCI USA, V99, P12675, DOI 10.1073/pnas.202471599; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; Kaneda A, 2002, INT J CANCER, V100, P57, DOI 10.1002/ijc.10464; Kolch Walter, 2002, Expert Opin Pharmacother, V3, P709, DOI 10.1517/14656566.3.6.709; KOPP A, 1995, CANCER RES, V55, P4512; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lee S, 2002, CANCER LETT, V184, P197, DOI 10.1016/S0304-3835(02)00197-0; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; LUNDBERG K, 1989, BIOCHIM BIOPHYS ACTA, V1009, P277, DOI 10.1016/0167-4781(89)90113-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nam ES, 2003, HISTOPATHOLOGY, V42, P466, DOI 10.1046/j.1365-2559.2003.01618.x; OGRAM SA, 1995, J BIOL CHEM, V270, P14235, DOI 10.1074/jbc.270.23.14235; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; PIERANTONI GM, 2003, BIOCHEM J, V15, P145; Rajeswari MR, 2001, CANCER LETT, V173, P93, DOI 10.1016/S0304-3835(01)00688-7; RAM TG, 1993, CANCER RES, V53, P2655; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 1999, METHOD ENZYMOL, V304, P155; Reeves R, 2001, GENE, V277, P63, DOI 10.1016/S0378-1119(01)00689-8; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; REEVES R, 1990, J BIOL CHEM, V265, P8573; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Scala S, 2000, P NATL ACAD SCI USA, V97, P4256, DOI 10.1073/pnas.070029997; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Tallini G, 1999, ADV ANAT PATHOL, V6, P237, DOI 10.1097/00125480-199909000-00001; TAMIMI Y, 1993, CANCER RES, V53, P5512; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; Weinstein-Oppenheimer CR, 2000, PHARMACOL THERAPEUT, V88, P229, DOI 10.1016/S0163-7258(00)00085-1; Wood LJ, 2000, MOL CELL BIOL, V20, P5490, DOI 10.1128/MCB.20.15.5490-5502.2000; Wood LJ, 2000, CANCER RES, V60, P4256; Zhang W, 2000, CANCER RES, V60, P6757	60	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					777	785		10.1038/sj.onc.1207167	http://dx.doi.org/10.1038/sj.onc.1207167			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737112				2022-12-28	WOS:000188304900016
J	Mingo-Sion, AM; Marietta, PM; Koller, E; Wolf, DM; Van Den Berg, CL				Mingo-Sion, AM; Marietta, PM; Koller, E; Wolf, DM; Van Den Berg, CL			Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells	ONCOGENE			English	Article						JNK; proliferation; apoptosis; cell cycle; stress signaling	N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; INSULIN-RECEPTOR SUBSTRATE-1; GROWTH SUPPRESSION; CYCLE ARREST; JUN; PHOSPHORYLATION; CHECKPOINT; EXPRESSION; PATHWAY	c-Jun N-terminal kinase (JNK) is activated by diverse cell stimuli, including stress, growth factors, and cytokines. Traditionally, activation of JNK by stress treatment is thought to induce cell death. However, our recent data indicate that JNK's ability to sensitize cells to apoptosis may be, in part, cell cycle dependent. Here, we show that the majority of both paclitaxel- and UV-induced apoptosis can be inhibited by the pharmacological JNK inhibitor, SP600125, in MCF-7 cells. However, inhibition of JNK does little to reverse doxorubicin-induced apoptosis in MCF-7 cells or doxorubicin- and UV-mediated death in MDA MB-231 cells. SP treatment causes G2/M arrest of three breast cancer cell lines and results in the endoreduplication (cellular DNA content >4N) of MCF-7 and MDA MB-231 cells. These effects on cell cycle and apoptosis are not significantly altered by the inhibition of p53, indicating that JNK is functioning independently of p53. Lastly, inhibition of JNK using both SP and antisense oligonucleotides targeted to JNK1 and JNK2 reduced proliferation of all three breast cancer cell lines. Taken together, these results suggest that the activation of JNK is important for the induction of apoptosis following stresses that function at different cell cycle phases, and that basal JNK activity is necessary to promote proliferation and maintain diploidy in breast cancer cells.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; ISIS Pharmaceut, Carlsbad, CA 92008 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Isis Pharmaceuticals Inc	Van Den Berg, CL (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, 4200 E 9th Ave,Campus Box C238, Denver, CO 80262 USA.	carla.vandenberg@UCHSC.edu						Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; Bacus SS, 2001, ONCOGENE, V20, P147, DOI 10.1038/sj.onc.1204062; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; BAND V, 1990, CANCER RES, V50, P7351; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haq R, 2002, CANCER RES, V62, P5076; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hildesheim J, 2002, CANCER RES, V62, P7305; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Jin SQ, 2000, J BIOL CHEM, V275, P16602, DOI 10.1074/jbc.M000284200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; MacCorkle-Chosnek RA, 2001, BIOCHEM BIOPH RES CO, V289, P173, DOI 10.1006/bbrc.2001.5948; Mamay CL, 2003, ONCOGENE, V22, P602, DOI 10.1038/sj.onc.1206186; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Motwani M, 2000, CLIN CANCER RES, V6, P924; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Patel R, 1998, J CELL SCI, V111, P2247; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woodgett JR, 1996, CANCER SURV, V27, P127; Xue Y, 2003, MOL CARCINOGEN, V36, P38, DOI 10.1002/mc.10096; Yang Q, 2000, J BIOL CHEM, V275, P36892, DOI 10.1074/jbc.M005319200	42	138	143	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					596	604		10.1038/sj.onc.1207147	http://dx.doi.org/10.1038/sj.onc.1207147			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724588				2022-12-28	WOS:000188098300031
J	Versteeg, HH; Spek, CA; Richel, DJ; Peppelenbosch, MP				Versteeg, HH; Spek, CA; Richel, DJ; Peppelenbosch, MP			Coagulation factors VIIa and Xa inhibit apoptosis and anoikis	ONCOGENE			English	Article						apoptosis; anoikis; MAP kinase; PI3 kinase; active-site-blocked FVIIa	FACTOR CYTOPLASMIC DOMAIN; TISSUE FACTOR EXPRESSION; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; KINASE PATHWAY; UP-REGULATION; ACTIVATION; METASTASIS; SURVIVAL	The molecular mechanisms enabling cancer cells to survive loss-of-adhesion-induced apoptosis in the early phases of metastasis remain largely obscure. Interestingly, the overexpression of tissue factor (TF) on tumor cells is associated with successful metastasis and it has now become clear that coagulation factor VIIa (FVIIa), the natural binding partner of TF induces signal transduction in TF-expressing cells. Hence, we investigated the effects of FVIIa-TF interaction on cell survival. We observed that FVIIa, at physiologically relevant concentrations, inhibits cell death and caspase-3 activation induced by serum deprivation and loss of adhesion (lack of integrin signaling) in TF-overexpressing cells, but not in non-TF-expressing cells. This FVIIa effect was not dependent on the formation of the downstream coagulation products FXa or thrombin and was inhibited using an active site-blocked form of FVIIa (FVIIai). FVIIa incubation resulted in the prolonged activation of both the phosphatidylinositide-3-(OH) kinase and p42/p44 MAP kinase pathways, and studies employing pharmacological inhibitors revealed that both the pathways are required for FVIIa-induced cell survival and inhibition of caspase-3 activity. Finally, TF:FVIIa-induced FXa generation dramatically increased cell survival. We propose that FVIIa-induced cell survival may explain why overexpression of TF is associated with successful metastasis.	Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Med Oncol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Versteeg, HH (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, G2-105,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	h.h.versteeg@amc.uva.nl	Versteeg, Henri/G-1783-2018; Spek, Arnold/AAC-5866-2019	Versteeg, Henri/0000-0003-4294-175X; Spek, Arnold/0000-0002-2149-4068; Peppelenbosch, Maikel/0000-0001-9112-6028				Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Camerer E, 1999, J BIOL CHEM, V274, P32225, DOI 10.1074/jbc.274.45.32225; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; Hamada K, 1996, CANCER, V77, P1877, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1877::AID-CNCR18>3.0.CO;2-X; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mueller BM, 1998, J CLIN INVEST, V101, P1372, DOI 10.1172/JCI930; MUELLER BM, 1992, P NATL ACAD SCI USA, V89, P11832, DOI 10.1073/pnas.89.24.11832; Pendurthi UR, 2000, J BIOL CHEM, V275, P14632, DOI 10.1074/jbc.275.19.14632; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Riewald M, 2001, P NATL ACAD SCI USA, V98, P7742, DOI 10.1073/pnas.141126698; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; Seto S, 2000, CANCER, V88, P295, DOI 10.1002/(SICI)1097-0142(20000115)88:2<295::AID-CNCR8>3.0.CO;2-U; Shigemori C, 1998, THROMB HAEMOSTASIS, V80, P894; Sorensen BB, 1999, J BIOL CHEM, V274, P21349, DOI 10.1074/jbc.274.30.21349; Ueda C, 2001, J GASTROENTEROL, V36, P848, DOI 10.1007/s005350170008; Versteeg HH, 2000, J BIOL CHEM, V275, P28750, DOI 10.1074/jbc.M907635199; Versteeg HH, 2003, J THROMB HAEMOST, V1, P1012, DOI 10.1046/j.1538-7836.2003.00205.x; Versteeg HH, 2001, THROMB HAEMOSTASIS, V86, P1353; Versteeg HH, 2002, J BIOL CHEM, V277, P27065, DOI 10.1074/jbc.M110325200; Vrana JA, 1996, CANCER RES, V56, P5063; Wang XL, 2002, J BIOL CHEM, V277, P23620, DOI 10.1074/jbc.M202242200	26	88	95	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	2004	23	2					410	417		10.1038/sj.onc.1207066	http://dx.doi.org/10.1038/sj.onc.1207066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724569				2022-12-28	WOS:000188098300011
J	Moller, A; Sirma, H; Hofmann, TG; Staege, H; Gresko, E; Ludi, KS; Klimczak, E; Droge, W; Will, H; Schmitz, ML				Moller, A; Sirma, H; Hofmann, TG; Staege, H; Gresko, E; Ludi, KS; Klimczak, E; Droge, W; Will, H; Schmitz, ML			Sp100 is important for the stimulatory effect of homeodomain-interacting protein kinase-2 on p53-dependent gene expression	ONCOGENE			English	Article						HIPK2; Sp100; p53; PML nuclear body	PRIMARY BILIARY-CIRRHOSIS; NUCLEAR-BODIES; TRANSCRIPTIONAL ACTIVITY; P53; PML; LOCALIZATION; CELLS; DOMAINS; PHOSPHORYLATION; COMPONENTS	HIPK2 shows overlapping localization with p53 in promyelocytic leukemia (PML) nuclear bodies (PML-NBs) and functionally interacts with p53 to increase gene expression. Here we demonstrate that HIPK2 and the PML-NB resident protein Sp100 synergize for the activation of p53-dependent gene expression. Sp100 and HIPK2 interact and partially colocalize in PML-NBs. The cooperation of HIPK2 and Sp100 for the induction of p21(Waf1) is completely dependent on the presence of p53 and the kinase function of HIPK2. Downregulation of Sp100 levels by expression of siRNA does not interfere with p53-mediated transcription, but obviates the enhancing effect of HIPK2. In summary, these experiments reveal a novel function for Sp100 as a coactivator for HIPK2-mediated p53 activation.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; German Canc Res Ctr, Div Immunochem G0200, D-69120 Heidelberg, Germany; Heinrich Pette Inst Expt Virol & Immunol, Dept Gen Virol, D-20251 Hamburg, Germany	University of Bern; Helmholtz Association; German Cancer Research Center (DKFZ); Heinrich Pette Institute	Schmitz, ML (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.		Schmitz, M. Lienhard/D-9328-2017; Möller, Andreas/O-1063-2015	Schmitz, M. Lienhard/0000-0002-6984-7192; Möller, Andreas/0000-0002-8618-6998				Bloch DB, 2000, MOL CELL BIOL, V20, P6138, DOI 10.1128/MCB.20.16.6138-6146.2000; Borden KLB, 2002, MOL CELL BIOL, V22, P5259, DOI 10.1128/MCB.22.15.5259-5269.2002; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Ecsedy JA, 2003, MOL CELL BIOL, V23, P950, DOI 10.1128/MCB.23.3.950-960.2003; EL DW, 1993, CELL, V75, P817; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eskiw CH, 2002, BIOCHEM CELL BIOL, V80, P301, DOI 10.1139/O02-079; Greenwood E, 2002, NAT REV CANCER, V2, P5, DOI 10.1038/nrc715; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Kondo S, 2003, P NATL ACAD SCI USA, V100, P5431, DOI 10.1073/pnas.0530308100; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Moller A, 2003, CANCER RES, V63, P4310; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; Negorev D, 2001, J CELL SCI, V114, P59; Rogalla P, 2000, GENOMICS, V63, P117, DOI 10.1006/geno.1999.6008; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Sourvinos G, 2002, EMBO J, V21, P4989, DOI 10.1093/emboj/cdf458; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Vogel A, 2002, J MOL MED, V80, P201, DOI 10.1007/s00109-001-0306-2; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	30	33	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8731	8737		10.1038/sj.onc.1207079	http://dx.doi.org/10.1038/sj.onc.1207079			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647468				2022-12-28	WOS:000186844900011
J	Breckenridge, DG; Germain, M; Mathai, JP; Nguyen, M; Shore, GC				Breckenridge, DG; Germain, M; Mathai, JP; Nguyen, M; Shore, GC			Regulation of apoptosis by endoplasmic reticulum pathways	ONCOGENE			English	Review						calcium; BCL-2; caspase; mitochondria	UNFOLDED PROTEIN RESPONSE; CYTOCHROME-C RELEASE; BCL-X-L; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; STRESS-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; ER STRESS; MITOCHONDRIAL APOPTOSIS; SIGNAL-TRANSDUCTION	Apoptotic programmed cell death pathways are activated by a diverse array of cell extrinsic and intrinsic signals, most of which are ultimately coupled to the activation of effector caspases. In many instances, this involves an obligate propagation through mitochondria, causing egress of critical proapoptotic regulators to the cytosol. Central to the regulation of the mitochondrial checkpoint is a complex three-way interplay between members of the BCL-2 family, which are comprised of an antiapoptotic subgroup including BCL-2 itself, and the proapoptotic BAX, BAK and BH3-domain-only subgroups. Constituents of all three of these BCL-2 classes, however, also converge on the endoplasmic reticulum ( ER), an organelle whose critical contributions to apoptosis is only now becoming apparent. In addition to propagating death-inducing stress signals itself, the ER also contributes in a fundamental way to Fas-mediated apoptosis and to p53-dependent pathways resulting from DNA damage and oncogene expression. Mobilization of ER calcium stores can initiate the activation of cytoplasmic death pathways as well as sensitize mitochondria to direct proapoptotic stimuli. Additionally, the existence of BCL-2-regulated initiator procaspase activation complexes at the ER membrane has also been described. Here, we review the potential underlying mechanisms involved in these events and discuss pathways for ER-mitochondrial crosstalk pertinent to a number of cell death stimuli.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Adachi T, 1996, EMBO J, V15, P1534, DOI 10.1002/j.1460-2075.1996.tb00497.x; Alberici A, 1999, J BIOL CHEM, V274, P30764, DOI 10.1074/jbc.274.43.30764; Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bourdon JC, 2002, J CELL BIOL, V158, P235, DOI 10.1083/jcb.200203006; Boya P, 2002, CELL DEATH DIFFER, V9, P465, DOI 10.1038/sj.cdd.4401006; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Breckenridge DG, 2002, P NATL ACAD SCI USA, V99, P4331, DOI 10.1073/pnas.072088099; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Carlberg M, 1996, CARCINOGENESIS, V17, P2589, DOI 10.1093/carcin/17.12.2589; CAVALLI AL, 2002, AM J PHYSIOL-CELL PH, V6, P6; Chang SH, 2000, AM J PATHOL, V156, P637, DOI 10.1016/S0002-9440(10)64768-2; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Diaz F, 2000, CELL CALCIUM, V27, P315, DOI 10.1054/ceca.2000.0126; Distelhorst CW, 1996, ONCOGENE, V12, P2051; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fujita E, 2002, CELL DEATH DIFFER, V9, P1108, DOI 10.1038/sj.cdd.4401080; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Herrera PL, 2000, P NATL ACAD SCI USA, V97, P279, DOI 10.1073/pnas.97.1.279; Higgins ME, 2001, J LIPID RES, V42, P1939; Hirota J, 1999, J BIOL CHEM, V274, P34433, DOI 10.1074/jbc.274.48.34433; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ichimiya M, 1998, AM J PHYSIOL-CELL PH, V275, pC832, DOI 10.1152/ajpcell.1998.275.3.C832; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Johnson VL, 2000, J CELL SCI, V113, P2941; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lilliehook C, 2002, MOL CELL NEUROSCI, V19, P552, DOI 10.1006/mcne.2001.1096; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Mattson MP, 2001, BIOESSAYS, V23, P733, DOI 10.1002/bies.1103; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; Muriel MP, 2000, J COMP NEUROL, V426, P297, DOI 10.1002/1096-9861(20001016)426:2<297::AID-CNE10>3.0.CO;2-O; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Nguyen M, 2000, MOL CELL BIOL, V20, P6731, DOI 10.1128/MCB.20.18.6731-6740.2000; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; NUTT LK, 2001, J BIOL CHEM, V6, P6; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pan Z, 2001, J BIOL CHEM, V276, P32257, DOI 10.1074/jbc.M100178200; Passer BJ, 1999, J BIOL CHEM, V274, P24007, DOI 10.1074/jbc.274.34.24007; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; PU Y, 2002, BIOCH BIOPHYS REV CO, V279, P762; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Rudner J, 2001, J CELL SCI, V114, P4161; Ruiz-Vela A, 1999, EMBO J, V18, P4988, DOI 10.1093/emboj/18.18.4988; Ruiz-Vela A, 2001, J EXP MED, V194, P247, DOI 10.1084/jem.194.3.247; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; Torgler CN, 1997, CELL DEATH DIFFER, V4, P263, DOI 10.1038/sj.cdd.4400239; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Utz PJ, 1998, J BIOL CHEM, V273, P35362, DOI 10.1074/jbc.273.52.35362; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; Walter J, 1999, P NATL ACAD SCI USA, V96, P1391, DOI 10.1073/pnas.96.4.1391; WANG B, 2003, IN PRESS J BIOL CHEM, V278; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WELLER M, 1995, EXP CELL RES, V221, P395, DOI 10.1006/excr.1995.1390; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wu F, 1999, EUR J CANCER, V35, P1155, DOI 10.1016/S0959-8049(99)00099-4; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Zeng YS, 2000, NEUROSCI RES, V37, P113, DOI 10.1016/S0168-0102(00)00107-3; Zhu LP, 1999, J BIOL CHEM, V274, P33267, DOI 10.1074/jbc.274.47.33267; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	127	604	645	3	91	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8608	8618		10.1038/sj.onc.1207108	http://dx.doi.org/10.1038/sj.onc.1207108			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634622				2022-12-28	WOS:000186720000006
J	Kim, E; Gunther, W; Yoshizato, K; Meissner, H; Zapf, S; Nusing, RM; Yamamoto, H; Van Meir, EG; Deppert, W; Giese, A				Kim, E; Gunther, W; Yoshizato, K; Meissner, H; Zapf, S; Nusing, RM; Yamamoto, H; Van Meir, EG; Deppert, W; Giese, A			Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1	ONCOGENE			English	Article						invasion genes; glioma; p53; ets-1; thromboxane synthase; transcription	HUMAN COLON-CANCER; GROWTH-FACTOR; CELL-GROWTH; PLASMINOGEN-ACTIVATOR; GLIOBLASTOMA CELLS; INDUCE APOPTOSIS; EPITHELIAL-CELLS; DOWN-REGULATION; BREAST-CANCER; HUMAN GLIOMAS	Cancer formation and progression is a complex process determined by several mechanisms that promote cell growth, invasiveness, neo-angiogenesis, and render neoplastic cells resistant to apoptosis. The tumor suppressor p53 and the proto-oncogenic factor ets-1 are important regulators of such mechanisms. While it is well established that p53 and ets-1 influence various aspects of cell behavior by regulating the transcription of specific genes, little is known about the functional relationship between these transcription factors. We found that the gene encoding thromboxane synthase (TXSA), which we recently identified as a factor promoting invasion and resistance to apoptosis in gliomas, is a novel target gene for both p53 and ets-1. We demonstrate that p53 and ets-1 coregulate TXSA in an antagonistic and interrelated manner, with ets-1 being a potent transcriptional activator and p53 inhibiting ets-1-dependent transcription. Negative interference with ets-1 transcription requires functional p53 and is lost in mutant p53 proteins. We show that ets-1 and p53 associate physically in vitro and in vivo and that their interaction, rather than a direct binding of p53 to the TXSA promoter, is required for transcriptional repression of TXSA by wild-type p53. An important implication of our findings is that the loss of p53-mediated negative control over ets-1-dependent transcription may lead to the acquisition of an invasive phenotype in tumor cells.	Univ Hosp Lubeck, Dept Neurosurg, D-23538 Lubeck, Germany; Univ Hosp Eppendorf, Dept Neurosurg, Hamburg, Germany; Univ Childrens Hosp, Ctr Sci Res, Marburg, Germany; Inst Neurosurg & Neurores, Chicago, IL USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Neurosurg, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Dept Tumor Virol, D-2000 Hamburg, Germany	University of Lubeck; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Emory University; Emory University; Heinrich Pette Institute; University of Hamburg	Giese, A (corresponding author), Univ Hosp Lubeck, Dept Neurosurg, Ratzeburger Allee 160, D-23538 Lubeck, Germany.			Van Meir, Erwin G./0000-0003-2444-7707				Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Behrens P, 2001, J PATHOL, V194, P43, DOI 10.1002/path.844; BENNETT A, 1986, PROG LIPID RES, V25, P539, DOI 10.1016/0163-7827(86)90109-8; BENNETT A, 1977, LANCET, V2, P624; BENNETT A, 1987, GUT, V28, P315, DOI 10.1136/gut.28.3.315; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; CASTELLI MG, 1989, CANCER RES, V49, P1505; Daniel TO, 1999, CANCER RES, V59, P4574; Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fenrick R, 2000, MOL CELL BIOL, V20, P5828, DOI 10.1128/MCB.20.16.5828-5839.2000; Fritsche M, 1998, MOL CELL ENDOCRINOL, V143, P143, DOI 10.1016/S0303-7207(98)00140-3; Giese A, 1999, Neuro Oncol, V1, P3, DOI 10.1093/neuonc/1.1.3; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gohler T, 2002, J BIOL CHEM, V277, P41192, DOI 10.1074/jbc.M202344200; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Jayaraman G, 1999, J BIOL CHEM, V274, P17869, DOI 10.1074/jbc.274.25.17869; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 2003, BIOCHEM CELL BIOL, V81, P141, DOI 10.1139/o03-046; Kita D, 2001, CANCER RES, V61, P7985; Kitange G, 2000, CANCER, V89, P2292, DOI 10.1002/1097-0142(20001201)89:11<2292::AID-CNCR18>3.0.CO;2-0; Kurzel F, 2002, ACTA NEUROCHIR, V144, P71, DOI 10.1007/s701-002-8276-9; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; McDonough W, 1998, J NEUROPATH EXP NEUR, V57, P449, DOI 10.1097/00005072-199805000-00008; MIYATA A, 1994, EUR J BIOCHEM, V224, P273, DOI 10.1111/j.1432-1033.1994.00273.x; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nakada M, 1999, J NEUROPATH EXP NEUR, V58, P329, DOI 10.1097/00005072-199904000-00003; Nie DT, 2000, BIOCHEM BIOPH RES CO, V267, P245, DOI 10.1006/bbrc.1999.1840; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Pica F, 1996, J PHARMACOL EXP THER, V277, P1793; Pradono P, 2002, CANCER RES, V62, P63; Reisdorff J, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015617.39974.FB; Ristimaki A, 1997, CANCER RES, V57, P1276; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; SANO H, 1995, CANCER RES, V55, P3785; Sato Y, 2001, ANN NY ACAD SCI, V947, P117; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Valter MM, 1999, CANCER RES, V59, P5608; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang XJ, 1997, J RADIAT RES, V38, P179, DOI 10.1269/jrr.38.179; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Wasylyk C, 2002, MOL CELL BIOL, V22, P2687, DOI 10.1128/MCB.22.8.2687-2702.2002; Watabe T, 1998, INT J CANCER, V77, P128, DOI 10.1002/(SICI)1097-0215(19980703)77:1<128::AID-IJC20>3.0.CO;2-9; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yamamoto H, 2000, CANCER RES, V60, P134; Yoshizato K, 2002, NEUROSURGERY, V50, P343, DOI 10.1097/00006123-200202000-00021; ZHOU Y, 2002, J BIOL CHEM, V25, P25	70	45	45	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7716	7727		10.1038/sj.onc.1207155	http://dx.doi.org/10.1038/sj.onc.1207155			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586398				2022-12-28	WOS:000186240200002
J	Muntoni, A; Fleming, J; Gordon, KE; Hunter, K; McGregor, F; Parkinson, EK; Harrison, PR				Muntoni, A; Fleming, J; Gordon, KE; Hunter, K; McGregor, F; Parkinson, EK; Harrison, PR			Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-beta: but p53 mutations are not necessarily required	ONCOGENE			English	Article						head and neck cancer; preneoplasia; immortalization; RAR-beta; INK4A; telomerase	KERATINOCYTE SENESCENCE; REPLICATIVE SENESCENCE; P16(INK4A); TELOMERASE; INACTIVATION; ACQUISITION; PROTEINS	Our previous work showed that acquisition of immortality at the dysplasia stage of oral cancer progression was consistently associated with four changes: loss of retinoic acid receptor (RAR)-beta and p16(INK4A) expression, p53 mutations and activation of telomerase. One atypical dysplasia (D17) that underwent delayed senescence after an extended lifespan showed loss of RAR-beta and p16(INK4A)/ p14(ARF) expression, but retained functional wild-type p53 and telomerase was not activated. We now demonstrate that retroviral delivery of hTERT results in telomere lengthening and immortalization of D17 without loss of functional wild-type p53 activity. In contrast, the expression of hTERT in two other typical mortal dyplasia cultures (that retain RAR-beta and p16(INK4A) expression) does not extend their lifespan, even though telomeres are lengthened.	CRC Beatson Labs, Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Harrison, PR (corresponding author), CRC Beatson Labs, Beatson Inst Canc Res, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	p.r.harrison@beatson.gla.ac.uk	Hunter, Keith D/B-5670-2009; Hunter, Keith/M-9784-2019	Hunter, Keith/0000-0002-7873-0877				Campisi J, 2000, IN VIVO, V14, P183; Ghose A, 2001, CANCER RES, V61, P7479; Gordon KE, 2003, CANCER RES, V63, P458; Kresty LA, 2002, CANCER RES, V62, P5295; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; McGregor F, 1997, CANCER RES, V57, P3886; McGregor F, 2002, CANCER RES, V62, P4757; Morris M, 2002, ONCOGENE, V21, P4277, DOI 10.1038/sj.onc.1205492; Munro J, 1999, CANCER RES, V59, P2516; Munro J, 2001, ONCOGENE, V20, P3541, DOI 10.1038/sj.onc.1204460; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Papadimitrakopoulou V, 1997, ONCOGENE, V14, P1799, DOI 10.1038/sj.onc.1201010; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stewart SA, 2002, ONCOGENE, V21, P627, DOI 10.1038/sj.onc.1205062; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; XU XC, 1994, CANCER RES, V54, P3580	24	25	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2003	22	49					7804	7808		10.1038/sj.onc.1207085	http://dx.doi.org/10.1038/sj.onc.1207085			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586406				2022-12-28	WOS:000186240200010
J	Xie, YT; Tornkvist, M; Aalto, Y; Nilsson, G; Girnita, L; Nagy, B; Knuutila, S; Larsson, O				Xie, YT; Tornkvist, M; Aalto, Y; Nilsson, G; Girnita, L; Nagy, B; Knuutila, S; Larsson, O			Gene expression profile by blocking the SYT-SSX fusion gene in synovial sarcoma cells. Identification of XRCC4 as a putative SYT-SSX target gene	ONCOGENE			English	Article						microarray; antisense; SYT-SSX; synovial sarcoma	TRANSLOCATION; SYT-SSX1; PROTEINS; REPAIR; CANCER; D1	Increasing evidence suggests that the SYT-SSX fusion gene plays an important role in synovial sarcoma development and progression. However, very little is known about the downstream targets of SYT-SSX. In this study, we used antisense oligonucleotides to block the expression of the SYT-SSX fusion gene in synovial sarcoma cells. By comparing SYT-SSX inhibited cells with noninhibited cells, the gene expression pro. le was analysed using cDNA microarray and established by real-time PCR. Herewith, using a filter containing 1176 cancer-relevant genes, we found that the DNA repair gene XRCC4 and the DNA mismatch repair gene MSH2 were downregulated, whereas the gene encoding for the serine/threonine protein kinase PRK (also known as CNK), and the macrophage inhibitory cytokine MICI ( also known as PLAB) were upregulated after the inhibition of SYT-SSX. In comparison, expression of the XRCC4 gene was undergoing the strongest alteration. Consistently, the protein expression of XRCC4 was found to be decreased after SYT-SSX inhibition, whereas there were no detectable changes for the other gene products. Our study provides some clues to elucidate the signaling pathways of the SYT-SSX fusion gene, as well as it demonstrates a valuable model system for search for other SYT-SSX targets.	Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Karolinska Hosp, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Peking Univ, Sch Oncol, Beijing Canc Hosp, Dept Surg, Beijing, Peoples R China; Karolinska Hosp, Dept Orthoped, SE-17176 Stockholm, Sweden	University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital; Peking University; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland.		Nagy, Balint/F-6943-2012; Girnita, Leonard/A-4168-2008	Girnita, Leonard/0000-0003-0280-9500				Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DELEEUW B, 1995, HUM MOL GENET, V4, P1097; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Inagaki H, 2000, MODERN PATHOL, V13, P482, DOI 10.1038/modpathol.3880083; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Ladanyi M, 2001, ONCOGENE, V20, P5755, DOI 10.1038/sj.onc.1204601; Myers KJ, 2000, TRENDS PHARMACOL SCI, V21, P19, DOI 10.1016/S0165-6147(99)01420-0; Nagai M, 2001, P NATL ACAD SCI USA, V98, P3843, DOI 10.1073/pnas.061036798; Nilsson G, 1999, CANCER RES, V59, P3180; Roth DB, 2000, NATURE, V404, P823, DOI 10.1038/35009180; Skytting B, 1999, J NATL CANCER I, V91, P974, DOI 10.1093/jnci/91.11.974; Thaete C, 1999, HUM MOL GENET, V8, P585, DOI 10.1093/hmg/8.4.585; Xie YT, 2002, ONCOGENE, V21, P5791, DOI 10.1038/sj.onc.1205700; Xie YT, 2002, CANCER RES, V62, P3861	19	20	21	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7628	7631		10.1038/sj.onc.1207153	http://dx.doi.org/10.1038/sj.onc.1207153			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576825				2022-12-28	WOS:000186113000010
J	Siddik, ZH				Siddik, ZH			Cisplatin: mode of cytotoxic action and molecular basis of resistance	ONCOGENE			English	Review						cisplatin; mode of action; drug resistance; mechanism	DNA MISMATCH REPAIR; NUCLEOTIDE EXCISION-REPAIR; GLUTATHIONE-S-TRANSFERASE; CANCER CELL-LINES; ADENOSINE-TRIPHOSPHATASE ATP7B; SIGNAL-TRANSDUCTION PATHWAY; TUMOR-SUPPRESSOR GENE; OVARIAN-CARCINOMA; INDUCED APOPTOSIS; DRUG-RESISTANCE	Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/ Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature de. ning the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Siddik, ZH (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 104,1515 Holcombe Blvd, Houston, TX 77030 USA.	zsiddik@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA077332, R01CA082361] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82361, CA 77332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aebi S, 1996, CANCER RES, V56, P3087; Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; ALIOSMAN F, 1993, CANCER RES, V53, P5663; ANDREWS PA, 1988, CANCER RES, V48, P68; ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149; Anthoney DA, 1996, CANCER RES, V56, P1374; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ARTEAGA CL, 1994, CANCER RES, V54, P3758; Asselin E, 2001, CANCER RES, V61, P1862; Baekelandt MM, 2000, ANTICANCER RES, V20, P1061; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Beale PJ, 2000, BRIT J CANCER, V82, P436; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; Bible KC, 2000, CLIN CANCER RES, V6, P661; Blanc C, 2000, CANCER RES, V60, P4386; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cabelguenne A, 2000, J CLIN ONCOL, V18, P1465, DOI 10.1200/JCO.2000.18.7.1465; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chaney SG, 1996, JNCI-J NATL CANCER I, V88, P1346, DOI 10.1093/jnci/88.19.1346; Chaney SG, 1999, J INORG BIOCHEM, V77, P71, DOI 10.1016/S0162-0134(99)00149-X; CHAO CCK, 1991, CANCER RES, V51, P601; CHIAO C, 1995, CANCER RES, V55, P3576; CHIBA T, 1995, FASEB J, V9, pA523; Cocker HA, 2001, BRIT J CANCER, V85, P1746, DOI 10.1054/bjoc.2001.2145; Cui W, 2000, MOL CARCINOGEN, V29, P219, DOI 10.1002/1098-2744(200012)29:4<219::AID-MC1004>3.0.CO;2-D; Cui YH, 1999, MOL PHARMACOL, V55, P929; D'Incalci M, 1998, EUR J CANCER, V34, P1749, DOI 10.1016/S0959-8049(98)00191-9; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; Daubeuf S, 2002, BIOCHEM PHARMACOL, V64, P207, DOI 10.1016/S0006-2952(02)01118-8; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Deng XY, 2002, BIOCHEM BIOPH RES CO, V296, P792, DOI 10.1016/S0006-291X(02)00948-8; Dent P, 2001, CLIN CANCER RES, V7, P775; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1988, BIOCHEMISTRY-US, V27, P4730, DOI 10.1021/bi00413a022; EASTMAN A, 1987, BIOCHEM PHARMACOL, V36, P4177, DOI 10.1016/0006-2952(87)90581-8; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; EISENHAUER E, 1990, CARBOPLATIN CURRENT, P133; El-Khateeb M, 1999, J INORG BIOCHEM, V77, P13, DOI 10.1016/S0162-0134(99)00146-4; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Faivre S, 1999, ANN ONCOL, V10, P1125, DOI 10.1023/A:1008334215414; Fan JG, 1997, BIOCHEM PHARMACOL, V53, P1203, DOI 10.1016/S0006-2952(97)00101-9; FAN SJ, 1995, CANCER RES, V55, P1649; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; FAN SJ, 1994, CANCER RES, V54, P5824; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; Ferreira CG, 2000, CLIN CANCER RES, V6, P203; Ferry KV, 2000, BIOCHEM PHARMACOL, V60, P1305, DOI 10.1016/S0006-2952(00)00441-X; Fink D, 1996, CANCER RES, V56, P4881; Fink D, 1998, CLIN CANCER RES, V4, P1; FRAVAL HNA, 1979, CANCER RES, V39, P1793; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Furuta T, 2002, CANCER RES, V62, P4899; Gallagher WM, 1997, ONCOGENE, V14, P185; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; Gebauer G, 2000, INT J ONCOL, V16, P321; Giaccone G, 2000, DRUGS, V59, P9, DOI 10.2165/00003495-200059004-00002; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Gong JG, 1999, NATURE, V399, P806; GORE ME, 1989, BRIT J CANCER, V60, P767, DOI 10.1038/bjc.1989.356; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hagopian GS, 1999, CLIN CANCER RES, V5, P655; HAMAGUCHI K, 1993, CANCER RES, V53, P5225; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hawkins DS, 1996, CANCER RES, V56, P892; Hayakawa J, 2000, CANCER RES, V60, P5988; HE G, 2001, P AM ASSOC CANC RES, V42, P901; He Q, 2000, P NATL ACAD SCI USA, V97, P5768, DOI 10.1073/pnas.100108697; HEIGERBERNAYS WJ, 1990, BIOCHEMISTRY-US, V29, P8461, DOI 10.1021/bi00488a037; Hengstler JG, 1999, CANCER RES, V59, P3206; Henkels KM, 1999, CANCER RES, V59, P3077; Henkels KM, 1997, CANCER RES, V57, P4488; Herod JJO, 1996, CANCER RES, V56, P2178; Hershberger PA, 2002, MOL CANCER THER, V1, P821; HILLS CA, 1989, BRIT J CANCER, V59, P527, DOI 10.1038/bjc.1989.108; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Holford J, 1998, INT J CANCER, V77, P94, DOI 10.1002/(SICI)1097-0215(19980703)77:1<94::AID-IJC15>3.3.CO;2-Y; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Hung MC, 1999, SEMIN ONCOL, V26, P51; Husain A, 1998, CANCER RES, V58, P1120; Ikeguchi M, 2002, APOPTOSIS, V7, P23, DOI 10.1023/A:1013556727182; IZQUIERDO MA, 1995, JNCI-J NATL CANCER I, V87, P1230; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JENNERWEIN MM, 1989, CHEM-BIOL INTERACT, V70, P39, DOI 10.1016/0009-2797(89)90061-6; JENNERWEIN MM, 1991, MUTAT RES, V254, P89, DOI 10.1016/0921-8777(91)90044-P; Johnson SW, 1997, CANCER RES, V57, P850; Jordan P, 2000, CELL MOL LIFE SCI, V57, P1229, DOI 10.1007/PL00000762; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; KASAHARA K, 1991, CANCER RES, V51, P3237; KASTAN MB, 1991, CANCER RES, V51, P6304; Katano K, 2002, CANCER RES, V62, P6559; Kelland LR, 2000, DRUGS, V59, P1, DOI 10.2165/00003495-200059004-00001; KELLAND LR, 1992, CANCER RES, V52, P1710; KELLAND LR, 1993, CRIT REV ONCOL HEMAT, V15, P191, DOI 10.1016/1040-8428(93)90042-3; KELLAND LR, 1992, CANCER RES, V52, P3857; Kelland LR, 1999, J INORG BIOCHEM, V77, P111, DOI 10.1016/S0162-0134(99)00141-5; KELLAND LR, 1995, J MED CHEM, V38, P3016, DOI 10.1021/jm00016a004; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Koike K, 1997, CANCER RES, V57, P5475; Kolfschoten GM, 2000, GYNECOL ONCOL, V76, P362, DOI 10.1006/gyno.1999.5689; Komatsu M, 2000, CANCER RES, V60, P1312; KONDO S, 1995, ONCOGENE, V10, P2001; Kool M, 1997, CANCER RES, V57, P3537; LAI GM, 1988, BIOCHEM PHARMACOL, V37, P4597, DOI 10.1016/0006-2952(88)90325-5; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; LARMINAT F, 1994, NUCLEIC ACIDS RES, V22, P3005, DOI 10.1093/nar/22.15.3005; LEE KB, 1993, CARCINOGENESIS, V14, P2177, DOI 10.1093/carcin/14.10.2177; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Lin XJ, 2000, MOL PHARMACOL, V58, P1222, DOI 10.1124/mol.58.6.1222; Lin XJ, 2001, CANCER RES, V61, P1508; Makin GWJ, 2001, EMBO J, V20, P6306, DOI 10.1093/emboj/20.22.6306; MAMENTA EL, 1994, CANCER RES, V54, P3500; Mandic A, 2001, MELANOMA RES, V11, P11, DOI 10.1097/00008390-200102000-00002; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Marx D, 1998, EUR J CANCER, V34, P845, DOI 10.1016/S0959-8049(97)10169-1; Mayer F, 2002, CANCER RES, V62, P2758; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; MISTRY P, 1991, BRIT J CANCER, V64, P215, DOI 10.1038/bjc.1991.279; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Miyake H, 1999, J UROLOGY, V162, P2176, DOI 10.1016/S0022-5347(05)68155-4; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Mossink MH, 2002, CANCER RES, V62, P7298; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MURPHY D, 1991, BRIT J CANCER, V63, P711, DOI 10.1038/bjc.1991.160; Nagatani G, 2001, CANCER RES, V61, P1592; Nakayama K, 2002, INT J CANCER, V101, P488, DOI 10.1002/ijc.10608; Nehme A, 1997, CANCER RES, V57, P3253; O'Connor P M, 1996, Prog Cell Cycle Res, V2, P165; OConnor PM, 1997, CANCER RES, V57, P4285; Ono Y, 2001, MOL UROL, V5, P25, DOI 10.1089/109153601750124267; Oren M, 2002, ANN NY ACAD SCI, V973, P374, DOI 10.1111/j.1749-6632.2002.tb04669.x; Ormerod MG, 1996, CANCER CHEMOTH PHARM, V37, P463, DOI 10.1007/s002800050413; OZOLS RF, 1991, CANCER TREAT REV, V18, P77, DOI 10.1016/0305-7372(91)90027-W; OZOLS RF, 1984, ANN INTERN MED, V100, P19, DOI 10.7326/0003-4819-100-1-19; OZOLS RF, 1992, HEMATOL ONCOL CLIN N, V6, P879; OZOLS RF, 1988, PLATINUM OTHER METAL, P197; Pan B, 2002, BIOCHEM PHARMACOL, V63, P1699, DOI 10.1016/S0006-2952(02)00841-9; Perego P, 1996, CANCER RES, V56, P556; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PINTO AL, 1984, BIOCHIM BIOPHYS ACTA, V780, P167; PRESTAYKO AW, 1979, CANCER TREAT REV, V6, P17, DOI 10.1016/S0305-7372(79)80057-2; Qin LF, 2002, CANCER LETT, V175, P27, DOI 10.1016/S0304-3835(01)00720-0; Reed E, 1998, CANCER TREAT REV, V24, P331, DOI 10.1016/S0305-7372(98)90056-1; Reles A, 2001, CLIN CANCER RES, V7, P2984; RICHON VM, 1987, CANCER RES, V47, P2056; Righetti SC, 1999, CELL GROWTH DIFFER, V10, P473; Righetti SC, 1996, CANCER RES, V56, P689; Roberts JJ, 1980, CISPLATIN CURRENT ST, P57; Roberts Josephine A., 1983, PLATINUM GOLD OTHER, P3; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakamoto M, 2001, Hum Cell, V14, P305; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; SARKIS AS, 1995, J CLIN ONCOL, V13, P1384, DOI 10.1200/JCO.1995.13.6.1384; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SCHILDER RJ, 1990, INT J CANCER, V45, P416, DOI 10.1002/ijc.2910450306; SCHILDER RJ, 1992, CANCER INVEST, V10, P307, DOI 10.3109/07357909209032755; SCHMIDT W, 1993, CANCER RES, V53, P799; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Segal-Bendirdjian E, 1998, CELL DEATH DIFFER, V5, P390, DOI 10.1038/sj.cdd.4400357; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Shapiro GI, 1998, MOL CELL BIOL, V18, P378, DOI 10.1128/MCB.18.1.378; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; SHEIBANI N, 1989, BIOCHEMISTRY-US, V28, P3120, DOI 10.1021/bi00433a055; Shen DW, 2000, J CELL PHYSIOL, V183, P108, DOI 10.1002/(SICI)1097-4652(200004)183:1<108::AID-JCP13>3.3.CO;2-W; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Shiga H, 1999, CLIN CANCER RES, V5, P4097; Siddik ZH, 1998, CANCER RES, V58, P698; Siddik ZH, 1999, J INORG BIOCHEM, V77, P65, DOI 10.1016/S0162-0134(99)00144-0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; SMITH CD, 1993, CANCER RES, V53, P1343; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; SORENSON CM, 1988, CANCER RES, V48, P6703; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; TEICHER BA, 1987, CANCER RES, V47, P388; TEICHER BA, 1991, INT J CANCER, V47, P252, DOI 10.1002/ijc.2910470214; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; Vaisman A, 1998, CANCER RES, V58, P3579; VANDERZEE AGJ, 1995, J CLIN ONCOL, V13, P70, DOI 10.1200/JCO.1995.13.1.70; VANTVEER LJ, 1988, ONCOGENE, V2, P157; Wada H, 1999, EXP HEMATOL, V27, P99, DOI 10.1016/S0301-472X(98)00027-7; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Woessmann W, 2002, CANCER CHEMOTH PHARM, V50, P397, DOI 10.1007/s00280-002-0502-y; WOLF CR, 1987, INT J CANCER, V39, P695, DOI 10.1002/ijc.2910390607; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yeh PY, 2002, BIOCHEM PHARMACOL, V63, P1423, DOI 10.1016/S0006-2952(02)00908-5; Yoshida M, 1998, ONCOL REP, V5, P1281; YOSHIDA M, 1994, CANCER RES, V54, P3468; Zdraveski ZZ, 2002, J BIOL CHEM, V277, P1255, DOI 10.1074/jbc.M105382200; Zhang LS, 1996, ONCOGENE, V12, P571; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BHP, 2002, SEMIN ONCOL, V29, P62, DOI 10.1053/sonc.2002.34057; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	224	2497	2579	20	608	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7265	7279		10.1038/sj.onc.1206933	http://dx.doi.org/10.1038/sj.onc.1206933			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576837				2022-12-28	WOS:000186112500002
J	Ro, TB; Holt, RU; Brenne, AT; Hjorth-Hansen, H; Waage, A; Hjertner, O; Sundan, A; Borset, M				Ro, TB; Holt, RU; Brenne, AT; Hjorth-Hansen, H; Waage, A; Hjertner, O; Sundan, A; Borset, M			Bone morphogenetic protein-5,-6 and-7 inhibit growth and induce apoptosis in human myeloma cells	ONCOGENE			English	Article						BMP-5; BMP-6; BMP-7; myeloma; apoptosis	HEMATOPOIETIC STEM-CELLS; MULTIPLE-MYELOMA; OSTEOGENIC PROTEIN-1; SERINE/THREONINE KINASE; SIGNALING PATHWAYS; I RECEPTORS; ACTIVIN; DIFFERENTIATION; EXPRESSION; CANDIDATE	Previously, bone morphogenetic protein (BMP)-2 and -4 have been shown to inhibit proliferation and induce apoptosis in human myeloma cells. BMP-2 and -4 belong to a subgroup of BMPs using the BMP receptors Alk-3 or -6. In this study, we examined the effects on human myeloma cells of BMP-6 and -7, members of a different BMP subgroup, which mainly utilize Alk-2 as their receptor. All cell lines examined expressed mRNA for the BMP-6 and -7 receptor Alk-2. We did not detect transcripts for the BMP-2 and -4 receptors Alk-3 or Alk-6 in INA-6 and RPMI-8226 cells by RT-PCR. Accordingly, the intracellular signalling molecules Smad-1, -5 and -8 were not phosphorylated by BMP-4 in INA-6 and RPMI-8226 cells. The expression patterns of various BMP receptors in the myeloma cell lines explained the differences in responses to the various BMPs. Alk-2-expressing cell lines responded with growth inhibition and apoptosis to BMP-6 and -7, whereas cell lines lacking both Alk-3 and -6 were resistant to BMP-4. Soluble Alk-3 and -6 were able to neutralize the BMP-4 effects in BMP-4-responsive cell lines. All BMPs reduced viability in more than 70% of purified primary myeloma cell samples. BMPs have intriguing antitumor effects in vitro. Importantly, myeloma cells not responsive to BMP-2 and -4 may still be sensitive to BMP-6 or -7. It is possible that therapeutic use of BMP or BMP analogues could have an impact on both myeloma bone disease and myeloma cell growth.	Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, MTFS, N-7489 Trondheim, Norway; St Olavs Hosp, Dept Hematol, N-7005 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Ro, TB (corresponding author), Norwegian Univ Sci & Technol, Dept Canc Res & Mol Med, MTFS, N-7489 Trondheim, Norway.	torstein.ro@medisin.ntnu.no	Waage, Anders/D-7705-2013; Borset, Magne/AAY-1713-2021; Rø, Torstein/I-2340-2013	Ro, Torstein/0000-0002-5258-500X; Borset, Magne/0000-0001-5179-2835				Beck HN, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-12; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Brenne AT, 2002, BLOOD, V99, P3756, DOI 10.1182/blood.V99.10.3756; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Ebisawa T, 1999, J CELL SCI, V112, P3519; Franzen A, 2001, BIOCHEM BIOPH RES CO, V285, P773; Friedlaender GE, 2001, J BONE JOINT SURG AM, V83A, pS151; Gazitt Y, 1999, LEUKEMIA, V13, P1817, DOI 10.1038/sj.leu.2401501; Gilboa L, 2000, MOL BIOL CELL, V11, P1023, DOI 10.1091/mbc.11.3.1023; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hallahan AR, 2003, NAT MED, V9, P1033, DOI 10.1038/nm904; Hjertner O, 2001, BLOOD, V97, P516, DOI 10.1182/blood.V97.2.516; JACKSON N, 1989, CLIN EXP IMMUNOL, V75, P93; JERNBERGWIKLUND H, 1991, EUR J HAEMATOL, V46, P231; Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011; Kim IY, 2000, CANCER RES, V60, P2840; NISHIHARA T, 1993, BIOCHEM BIOPH RES CO, V197, P985, DOI 10.1006/bbrc.1993.2576; Nohe A, 2002, J BIOL CHEM, V277, P5330, DOI 10.1074/jbc.M102750200; Paine-Saunders S, 2002, J BIOL CHEM, V277, P2089, DOI 10.1074/jbc.M109151200; Rodriguez-Leon J, 1999, NAT CELL BIOL, V1, P125, DOI 10.1038/10098; Seidel C, 2000, BLOOD, V95, P388, DOI 10.1182/blood.V95.2.388; SHIMA Y, 1995, BLOOD, V85, P757, DOI 10.1182/blood.V85.3.757.bloodjournal853757; Tarte K, 2003, BLOOD, V102, P592, DOI 10.1182/blood-2002-10-3161; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Urashima M, 1996, BLOOD, V87, P1928; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Wach S, 2001, ONCOGENE, V20, P7761, DOI 10.1038/sj.onc.1204962; Wozney J M, 1989, Prog Growth Factor Res, V1, P267, DOI 10.1016/0955-2235(89)90015-X; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zavadil J, 1997, LEUKEMIA, V11, P1187, DOI 10.1038/sj.leu.2400750; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	36	96	104	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3024	3032		10.1038/sj.onc.1207386	http://dx.doi.org/10.1038/sj.onc.1207386			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14691444				2022-12-28	WOS:000220845200006
J	Kim, PKM; Armstrong, M; Liu, Y; Yan, P; Bucher, B; Zuckerbraun, BS; Gambotto, A; Billiar, TR; Yim, JH				Kim, PKM; Armstrong, M; Liu, Y; Yan, P; Bucher, B; Zuckerbraun, BS; Gambotto, A; Billiar, TR; Yim, JH			IRF-1 expression induces apoptosis and inhibits tumor growth in mouse mammary cancer cells in vitro and in vivo	ONCOGENE			English	Article						interferon regulatory factor-1 (IRF-1); apoptosis; breast cancer; caspase	REGULATORY FACTOR-I; TRANSCRIPTION FACTOR IRF-1; HUMAN BREAST-CANCER; IFN-GAMMA; GENE-EXPRESSION; NITRIC-OXIDE; ACTIVATION; INDUCTION; CARCINOMA; FAMILY	Interferon regulatory factor-1 (IRF-1) is a nuclear transcription factor that mediates interferon and other cytokine effects and appears to have antitumor activity in vitro and in vivo in cancer cells. We have constructed a recombinant adenoviral vector (Ad-IRF-1) that infects mammary cells with high efficiency and results in high levels of functional IRF-1 protein in transfected cells. Overexpression of IRF-1 in two mouse breast cancer cell lines, C3-L5 and TS/A, resulted in apoptosis in these cell lines as assessed by Annexin V staining. The involvement of caspases was confirmed by significant inhibition of apoptosis by a caspase inhibitor, and by demonstration of caspase-3 activity, cleavage of caspase-3, and PARP cleavage. Interestingly, the growth of nonmalignant breast cell lines C127I and NMuMG did not appear to be inhibited by IRF-1 overexpression. Suppression of growth for breast cancer cell lines in vivo was demonstrated by both preinfection of breast cancer cells ex vivo and by intratumoral injection of Ad-IRF-1 into established tumors in their natural hosts. The mechanism of apoptosis may involve the transcriptional upregulation of bak, caspase-8, and caspase-7 expression. These data support the antitumor potential of IRF-1 and the use of agents that increase IRF-1 in breast cancer.	Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yim, JH (corresponding author), Univ Pittsburgh, Med Ctr, Dept Surg, 497 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	yimjh@msx.upmc.edu	Yim, John/R-7555-2019					Baselga J, 2002, CANCER CELL, V1, P319, DOI 10.1016/S1535-6108(02)00066-1; BOUKER KB, 2002, CLIN CANC RES S, V5, P53; BRODT P, 1985, INT J CANCER, V35, P265, DOI 10.1002/ijc.2910350220; CHANG CH, 1992, IMMUNOGENETICS, V35, P378; Chapman RS, 2000, ONCOGENE, V19, P6386, DOI 10.1038/sj.onc.1204016; Doherty GM, 2001, ANN SURG, V233, P623, DOI 10.1097/00000658-200105000-00005; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GELLER DA, 1993, SURGERY, V114, P235; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; KASHIWABA M, 1994, J CANCER RES CLIN, V120, P727, DOI 10.1007/BF01194271; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881; Kirkwood JM, 2001, J CLIN ONCOL, V19, P2370, DOI 10.1200/JCO.2001.19.9.2370; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kroger A, 2002, J INTERF CYTOK RES, V22, P5, DOI 10.1089/107999002753452610; Kroger A, 2003, ONCOGENE, V22, P1045, DOI 10.1038/sj.onc.1206260; Kroger A, 2001, CANCER RES, V61, P2609; Lee SH, 2003, ONCOGENE, V22, P381, DOI 10.1038/sj.onc.1206133; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; NANNI P, 1983, CLIN EXP METASTAS, V1, P373, DOI 10.1007/BF00121199; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.3.CO;2-X; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; O'Connell P, 1998, JNCI-J NATL CANCER I, V90, P697, DOI 10.1093/jnci/90.9.697; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Paulson TG, 1999, GENOME RES, V9, P482; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sangfelt O, 2001, MED ONCOL, V18, P3, DOI 10.1385/MO:18:1:3; Skaar TC, 1998, J STEROID BIOCHEM, V67, P391, DOI 10.1016/S0960-0760(98)00142-3; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; Takahashi Y, 2000, SURGERY, V128, P345, DOI 10.1067/msy.2000.107415; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Ulrich E, 1997, GENOMICS, V44, P195, DOI 10.1006/geno.1997.4858; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yim JH, 1999, J INTERF CYTOK RES, V19, P723, DOI 10.1089/107999099313569; Yim JH, 1997, J IMMUNOL, V158, P1284	52	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1125	1135		10.1038/sj.onc.1207023	http://dx.doi.org/10.1038/sj.onc.1207023			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762441				2022-12-28	WOS:000188749900011
J	Staber, PB; Linkesch, W; Zauner, D; Beham-Schmid, C; Guelly, C; Schauer, S; Sill, H; Hoefler, G				Staber, PB; Linkesch, W; Zauner, D; Beham-Schmid, C; Guelly, C; Schauer, S; Sill, H; Hoefler, G			Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia	ONCOGENE			English	Article						AML; relapse; proliferation; RAF/MEK/ERK; c-DNA subtraction; c-DNA microarray	ACUTE MYELOGENOUS LEUKEMIA; RESISTANCE PROTEIN BCRP; N-RAS; P-GLYCOPROTEIN; CLINICAL-SIGNIFICANCE; NUCLEAR ANTIGEN; C-FOS; RELAPSE; MUTATIONS; CANCER	Recurrent disease following high-dose chemotherapy is a major problem in patients with acute myeloid leukemia (AML). To identify its characteristics, we performed expression profiling in blasts from untreated AML and relapse, using a specific cDNA microarray comprising 4128 genes generated by cDNA subtraction supplemented with cancer-associated genes. Expression analysis of 18 AML bone marrow specimens showed that recurrent AML is commonly associated with the mRNA expression changes in a set of 58 genes. Increased cellular proliferation was indicated by the overexpression of the transferrin receptor, proliferating cell nuclear antigen, and G1 cyclins. An immunohistochemical study for Ki-67-positive blasts in 18 paired bone marrow biopsy samples confirmed a highly significant (P < 0.0001) increase in the proliferation fraction at relapse. In addition, we found enhanced activation of the RAF/MEK/ERK cascade as mRNAs of MKP-1, c-jun, c-fos, and egr-1 were significantly increased at relapse. Immunohistochemistry and immunoblotting analyses for biphosphorylated ERK1/2 protein provide additional evidence for enhanced activation of the RAF/MEK/ERK pathway. The degree of increase is significantly correlated with the increased proliferation. Furthermore, the genes identified provide a rationale for further studies on predictive diagnosis and therapeutic intervention.	Karl Franzens Univ Graz, Univ Hosp, Dept Pathol, A-8036 Graz, Austria; Graz Univ, Dept Internal Med, Div Hematol, Graz, Austria	University of Graz; University of Graz	Hoefler, G (corresponding author), Karl Franzens Univ Graz, Univ Hosp, Dept Pathol, Auenbruggerpl 25, A-8036 Graz, Austria.	gerald.hoefler@uni-graz.at	Hoefler, Gerald/B-7006-2008; Sill, Heinz/AAV-4643-2021; Staber, Philipp Bernhard/ADK-1536-2022; Hoefler, Gerald/H-1796-2016	Sill, Heinz/0000-0003-0993-4371; Staber, Philipp Bernhard/0000-0001-6729-7708; Hoefler, Gerald/0000-0002-9056-3063				APPELBAUM FR, 2001, ACUTE MYELOID LEUKEM, P62; Baer MR, 2001, BLOOD, V97, P3574, DOI 10.1182/blood.V97.11.3574; BORELLA L, 1979, BLOOD, V54, P64; BOS JL, 1987, BLOOD, V69, P1237; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ESTEY E, 1995, LEUKEMIA, V9, P972; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; Gale RP, 1996, LEUKEMIA, V10, P13; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; GARSON OM, 1989, CANCER GENET CYTOGEN, V40, P187, DOI 10.1016/0165-4608(89)90024-1; GERDES J, 1984, J IMMUNOL, V133, P1710; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOLDIE JH, 1983, CANCER TREAT REP, V67, P923; GUERCI A, 1995, BLOOD, V85, P2147, DOI 10.1182/blood.V85.8.2147.bloodjournal8582147; HARTIGAN JA, 1973, ANNU REV BIOPHYS BIO, V2, P81, DOI 10.1146/annurev.bb.02.060173.000501; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Hur M, 2001, CLIN LAB HAEMATOL, V23, P173, DOI 10.1046/j.1365-2257.2001.00389.x; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kiyoi H, 1999, BLOOD, V93, P3074; Lee JT, 2002, LEUKEMIA, V16, P486, DOI 10.1038/sj/leu/2402460; Leith CP, 1999, BLOOD, V94, P1086; MARIE JP, 1991, BLOOD, V78, P586; MUSTO P, 1990, TUMORI, V76, P353, DOI 10.1177/030089169007600410; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Padua RA, 1998, LEUKEMIA, V12, P887, DOI 10.1038/sj.leu.2401044; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PUI CH, 1986, BLOOD, V68, P1306; RADICH JP, 1990, BLOOD, V76, P801; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; TERADA N, 1993, EXP CELL RES, V204, P260, DOI 10.1006/excr.1993.1032; van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496; van den Heuvel-Eibrink MM, 2001, BLOOD, V97, P3605, DOI 10.1182/blood.V97.11.3605; van der Kolk DM, 2002, BLOOD, V99, P3763, DOI 10.1182/blood.V99.10.3763; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343	40	58	64	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 29	2004	23	4					894	904		10.1038/sj.onc.1207192	http://dx.doi.org/10.1038/sj.onc.1207192			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14749762				2022-12-28	WOS:000188486600004
J	Joseph, MK; Solomon, LR; Petros, AM; Cai, J; Simmer, RL; Zhang, HC; Rosenberg, S; Ng, SC				Joseph, MK; Solomon, LR; Petros, AM; Cai, J; Simmer, RL; Zhang, HC; Rosenberg, S; Ng, SC			Divergence of Genbank and human tumor Bcl-2 sequences and implications for binding affinity to key apoptotic proteins	ONCOGENE			English	Article						Bcl-2; apoptosis; BH3 region; fluorescence anisotropy; Genbank sequences	T(14-18) CHROMOSOMAL TRANSLOCATION; CELL-DEATH; ANTISENSE OLIGONUCLEOTIDES; FOLLICULAR LYMPHOMA; STRUCTURAL-ANALYSIS; DISTINCT; BCL-X(L); CANCER; FAMILY; DOMAIN	Heterodimerization of antiapoptotic and pro-apoptotic Bcl-2 family of proteins provides an important mechanism for apoptosis regulation. Knowledge about key amino acids in the binding groove of native Bcl-2 contributing to this interaction will greatly facilitate the design of Bcl-2-specific inhibitors. There are two different Bcl-2 sequences, M13994 and M14745, in Genbank. Chimeric proteins Bcl-2( 1) and Bcl-2( 2) derived from the above sequences, although similar in structure, showed different binding affinities to Bak and Bad BH3 peptides (Petros et al., 2001). In this study, we show that the Bcl-2( 1) sequence in normal and tumor human tissue samples differs from M13994 and M14745, and contains P59, T96, R110, S117 and G237. The actual sequence in the binding pocket matches the Bcl-2 - Ig fusion sequence X06487, originally identified in a t(14: 18) translocation of the Bcl-2 gene, associated with follicular lymphoma. The possible effects of the observed amino acid differences compared to M13994 and M14745 were investigated by combining structural data with fluorescence anisotropy. G110R substitution confers on Bcl-2( 1) substantially increased binding affinity to Bak, Bad and Bax BH3 peptides, demonstrating that R110 is a key contributor to the BH3 binding affinity of Bcl-2. Although NMR structure did not predict R110 involvement in binding to these BH3 peptides, fluorescence anisotropy data clearly points to a critical role for this residue in binding to proapoptotic Bcl-2 family members.	Abbott Labs, Global Pharmaceut Res Div, Canc Res, Abbott Pk, IL 60064 USA	Abbott Laboratories	Joseph, MK (corresponding author), Abbott Labs, Global Pharmaceut Res Div, Canc Res, Abbott Pk, IL 60064 USA.	mary.joseph@abbott.com						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Antonsson B, 2001, CELL TISSUE RES, V306, P347, DOI 10.1007/s00441-001-0472-0; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BELLI B, 2003, AACR ANN M WASH DC; Berghella AM, 1998, CANCER BIOTHER RADIO, V13, P225, DOI 10.1089/cbr.1998.13.225; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COTTER FE, 1994, ONCOGENE, V9, P3049; Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NGAN BY, 1988, NEW ENGL J MED, V318, P1638, DOI 10.1056/NEJM198806233182502; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Petrovic AS, 1998, BLOOD, V91, P3952, DOI 10.1182/blood.V91.10.3952.3952_3952_3961; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; ZHANG HC, 1995, BIOCHEM BIOPH RES CO, V208, P950, DOI 10.1006/bbrc.1995.1426; Zhang HC, 2002, ANAL BIOCHEM, V307, P70, DOI 10.1016/S0003-2697(02)00028-3	23	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	2004	23	3					835	838		10.1038/sj.onc.1207141	http://dx.doi.org/10.1038/sj.onc.1207141			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737118				2022-12-28	WOS:000188304900022
J	Pennati, M; Binda, M; Colella, G; Zoppe', M; Folini, M; Vignati, S; Valentini, A; Citti, L; De Cesare, M; Pratesi, G; Giacca, M; Daidone, MG; Zaffaroni, N				Pennati, M; Binda, M; Colella, G; Zoppe', M; Folini, M; Vignati, S; Valentini, A; Citti, L; De Cesare, M; Pratesi, G; Giacca, M; Daidone, MG; Zaffaroni, N			Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells	ONCOGENE			English	Article						survivin; ribozyme; prostate cancer; apoptosis; tumorigenicity	HUMAN-MELANOMA CELLS; DOWN-REGULATION; GENE-THERAPY; TUMOR-GROWTH; DEATH; PHOSPHORYLATION; PROGRESSION; RESISTANCE; RECEPTOR; BCL-2	Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which has been implicated in inhibition of apoptosis and control of mitotic progression. The finding that survivin is overexpressed in most human tumors but absent in normal adult tissues has led to the proposal of survivin as a promising therapeutic target for anticancer therapies. We decided to evaluate the effects of a ribozyme-based strategy for survivin inhibition in androgen-independent human prostate cancer cells. We constructed a Moloney-based retroviral vector expressing a ribozyme targeting the 3' end of the CUA(110) triplet in survivin mRNA, encoded as a chimeric RNA within adenoviral VA1 RNA. Polyclonal cell populations obtained by infection with the retroviral vector of two androgen-independent human prostate cancer cell lines (DU145 and PC-3) were selected for the study. Ribozyme-expressing prostate cancer cells were characterized by a significant reduction of survivin expression compared to parental cells transduced with a control ribozyme; the cells became polyploid, underwent caspase-9-dependent apoptosis and showed an altered pattern of gene expression, as detected by oligonucleotide array analysis. Survivin inhibition also increased the susceptibility of prostate cancer cells to cisplatin-induced apoptosis and prevented tumor formation when cells were xenografted in athymic nude mice. These findings suggest that manipulation of the antiapoptotic survivin pathway may provide a novel approach for the treatment of androgen-independent prostate cancer.	Ist Nazl Studio & Cura Tumori, Dipartimento Oncol Sperimentale, I-20133 Milan, Italy; CNR, Ist Fisiol Clin, I-56100 Pisa, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); International Center for Genetic Engineering & Biotechnology (ICGEB)	Zaffaroni, N (corresponding author), Ist Nazl Tumori, Dipartimento Oncol Sperimentale, Unita Operat 10, Via Venezian 1, I-20133 Milan, Italy.	nadia.zaffaroni@istitutotumori.mi.it	Zaffaroni, Nadia/J-8178-2016; Folini, Marco/B-9607-2017; De Cesare, Michelandrea/M-6667-2017; Daidone, Maria Grazia/E-9232-2017; Giacca, Mauro/J-9287-2016; Pennati, Marzia/K-2554-2016	Zaffaroni, Nadia/0000-0002-4669-0890; Folini, Marco/0000-0002-1811-4407; De Cesare, Michelandrea/0000-0001-9687-0753; Daidone, Maria Grazia/0000-0002-4786-1321; Giacca, Mauro/0000-0003-2927-7225; Pennati, Marzia/0000-0002-6181-2681; Colella, Gennaro/0000-0001-9132-8375; ZOPPE', Monica/0000-0003-4590-0718				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asanuma K, 2000, JPN J CANCER RES, V91, P1204, DOI 10.1111/j.1349-7006.2000.tb00906.x; Cagnon L, 2000, ANTISENSE NUCLEIC A, V10, P251, DOI 10.1089/108729000421439; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Denmeade SR, 1996, PROSTATE, V28, P251; Dennis LK, 2000, PROSTATE, V42, P247; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Giodini A, 2002, CANCER RES, V62, P2462; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Honda T, 2001, ANTICANCER RES, V21, P3141; Howell SB, 2000, MOL UROL, V4, P225; Kore AR, 1998, NUCLEIC ACIDS RES, V26, P4116, DOI 10.1093/nar/26.18.4116; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lewin AS, 2001, TRENDS MOL MED, V7, P221, DOI 10.1016/S1471-4914(01)01965-7; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; McEleny KR, 2002, PROSTATE, V51, P133, DOI 10.1002/pros.10061; Mendoza-Maldonado R, 2002, CANCER GENE THER, V9, P71, DOI 10.1038/sj/cgt/7700410; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Olie RA, 2000, CANCER RES, V60, P2805; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Pennati M, 2002, J CLIN INVEST, V109, P285; Prislei S, 1997, RNA, V3, P677; Somia NV, 2000, J VIROL, V74, P4420, DOI 10.1128/JVI.74.9.4420-4424.2000; Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wall NR, 2003, CANCER RES, V63, P230; Workman P, 1998, BRIT J CANCER, V77, P1; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3	37	77	92	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					386	394		10.1038/sj.onc.1207071	http://dx.doi.org/10.1038/sj.onc.1207071			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724567				2022-12-28	WOS:000188098300008
J	Vargiu, P; De Abajo, R; Garcia-Ranea, JA; Valencia, A; Santisteban, P; Crespo, P; Bernal, J				Vargiu, P; De Abajo, R; Garcia-Ranea, JA; Valencia, A; Santisteban, P; Crespo, P; Bernal, J			The small GTP-binding protein, Rhes, regulates signal transduction from G protein-coupled receptors	ONCOGENE			English	Article						Ras; thyroid hormone; striatum; adrenergic receptor; PC12 cells	RAS SUPERFAMILY MEMBER; BETA(2)-ADRENERGIC RECEPTOR; ACTIVATION; IDENTIFICATION; DEXRAS1; BLOCKS; CELLS; GENE; DISRUPTION; DEFICIENCY	The Ras homolog enriched in striatum, Rhes, is the product of a thyroid hormone-regulated gene during brain development. Rhes and the dexamethasone-induced Dexras1 define a novel distinct subfamily of proteins within the Ras family, characterized by an extended variable domain in the carboxyl terminal region. We have carried this study because there is a complete lack of knowledge on Rhes signaling. We show that in PC12 cells, Rhes is targeted to the plasma membrane by farnesylation. We demonstrate that about 30% of the native Rhes protein is bound to GTP and this proportion is unaltered by typical Ras family nucleotide exchange factors. However, Rhes is not transforming in murine fibroblasts. We have also examined the role of Rhes in cell signaling. Rhes does not stimulate the ERK pathway. By contrast, it binds to and activates PI3K. On the other hand, we demonstrate that Rhes impairs the activation of the cAMP/PKA pathway by thyroid-stimulating hormone, and by an activated beta2 adrenergic receptor by a mechanism that suggests uncoupling of the receptor to its cognate heterotrimeric complex. Overall, our results provide the initial insights into the role in signal transduction of this novel Ras family member.	CSIC, Inst Invest Biomed Alverto Sols, E-28029 Madrid, Spain; Univ Autonoma Madrid, Madrid 28029, Spain; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Bernal, J (corresponding author), CSIC, Inst Invest Biomed Alverto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	jbernal@iib.uam.es	Santisteban, Pilar/E-7829-2016; Bernal, Juan/J-6086-2014; Valencia, Alfonso/I-3127-2015; Crespo, Piero/M-3273-2014	Santisteban, Pilar/0000-0002-2758-796X; Bernal, Juan/0000-0002-5867-4951; Valencia, Alfonso/0000-0002-8937-6789; Garcia Ranea, Juan Antonio/0000-0003-0327-1837; Crespo, Piero/0000-0003-2825-7783				Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; Bauer B, 1999, J BIOL CHEM, V274, P17763, DOI 10.1074/jbc.274.25.17763; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chan SLF, 2002, BRIT J PHARMACOL, V136, P31, DOI 10.1038/sj.bjp.0704680; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; DELONG GR, 1985, DEV MED CHILD NEUROL, V27, P317; Falk JD, 1999, J NEUROSCI RES, V57, P782, DOI 10.1002/(SICI)1097-4547(19990915)57:6<782::AID-JNR3>3.0.CO;2-9; Fang M, 2000, NEURON, V28, P183, DOI 10.1016/S0896-6273(00)00095-7; FARRELL FX, 1993, BIOCHEM J, V289, P349, DOI 10.1042/bj2890349; Foster R, 1996, MOL CELL BIOL, V16, P2689; Graham TE, 2001, ENDOCRINOLOGY, V142, P2631, DOI 10.1210/en.142.6.2631; Graham TE, 2002, J BIOL CHEM, V277, P10876, DOI 10.1074/jbc.M110397200; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; Kemppainen RJ, 1998, J BIOL CHEM, V273, P3129, DOI 10.1074/jbc.273.6.3129; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; MELLON PL, 1990, NEURON, V5, P1, DOI 10.1016/0896-6273(90)90028-E; Mott HR, 1997, BIOCHEMISTRY-US, V36, P3640, DOI 10.1021/bi962790o; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; Park J, 1997, J MOL BIOL, V273, P349, DOI 10.1006/jmbi.1997.1288; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; St Croix B, 2000, SCIENCE, V289, P1197; Takesono A, 2002, J BIOL CHEM, V277, P13827, DOI 10.1074/jbc.M201064200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vargiu P, 2001, MOL BRAIN RES, V94, P1, DOI 10.1016/S0169-328X(01)00140-1; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WITTINGHOFER A, 1995, GUIDEBOOK SMALL GTPA, P20	36	73	76	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					559	568		10.1038/sj.onc.1207161	http://dx.doi.org/10.1038/sj.onc.1207161			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724584				2022-12-28	WOS:000188098300027
J	Hu, L; Lau, SH; Tzang, CH; Wen, JM; Wang, WS; Xie, D; Huang, MH; Wang, Y; Wu, MC; Huang, JF; Zeng, WF; Sham, JST; Yang, MS; Guan, XY				Hu, L; Lau, SH; Tzang, CH; Wen, JM; Wang, WS; Xie, D; Huang, MH; Wang, Y; Wu, MC; Huang, JF; Zeng, WF; Sham, JST; Yang, MS; Guan, XY			Association of Vimentin overexpression and hepatocellular carcinoma metastasis	ONCOGENE			English	Article						Vimentin; hepatocellular carcinoma; metastasis; microarray	TISSUE MICROARRAY; BREAST-CARCINOMA; EXPRESSION; PROTEIN; CELLS; CLUSTERIN; CANCER; RNA	The poor prognosis of hepatocellular carcinoma (HCC) has been associated with recurrence and metastasis. Recently, we established a pair of HCC cell lines from a primary (H2-P) and its matched metastatic (H2-M) HCC tumors. A high density of cDNA microarray with 9184 human cDNA was used to identify the differentially expressed genes between H2-P and H2-M. Comparing with H2-P, eight upregulated and six downregulated genes were detected in H2-M. One interesting finding is the overexpression of Vimentin (VIM), a well-defined intermediate filament, which has been linked to a more aggressive status in various tumors. The correlation of overexpression of VIM and HCC metastasis was studied by immunohistochemistry using a tissue microarray with 200 primary HCCs and 60 pairs of primary and matched metastatic HCC samples. Tissue microarray demonstrated that the overexpression of VIM was significantly associated with HCC metastasis (P<0.01). This finding strongly suggests that the overexpression of VIM may play an important role in the metastasis of HCC.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China; Sun Yat Sen Univ, Affiliated Hosp 1, Dept Hepatobilliary Surg, Guangzhou, Peoples R China; Second Mil Med Univ, Eastern Hepatobilliary Surg Hosp, Shanghai, Peoples R China	University of Hong Kong; City University of Hong Kong; Sun Yat Sen University; Sun Yat Sen University; Naval Medical University	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,1-F,Sch Chinese Med Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Yang, Mengsu/I-5750-2015; Guan, Xin-Yuan/A-3639-2009; /A-3639-2009	Yang, Mengsu/0000-0003-2083-2296; Guan, Xin-Yuan/0000-0002-4485-6017; /0000-0003-1874-9805				Aguayo A, 2001, SEMIN ONCOL, V28, P503, DOI 10.1053/sonc.2001.26953; Aldamassi M., 2001, PRACTICAL GUIDE MICR; BENZEEV A, 1985, CANCER RES, V45, P2632; Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; DOMAGALA W, 1994, EUR J CANCER, V30A, P1527, DOI 10.1016/0959-8049(94)00288-G; FAN C, 1995, ONCOLOGY, V52, P498; Gilles C, 1999, J CELL SCI, V112, P4615; Gilles C, 1996, J PATHOL, V180, P175, DOI 10.1002/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Guan XY, 1996, NAT GENET, V12, P10, DOI 10.1038/ng0196-10; Hendrix MJC, 1997, AM J PATHOL, V150, P483; Iwatsuki H, 1999, ACTA HISTOCHEM, V101, P369, DOI 10.1016/S0065-1281(99)80038-5; Lang SH, 2002, PROSTATE, V52, P253, DOI 10.1002/pros.10088; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lelievre V, 2001, J BIOL CHEM, V276, P43668, DOI 10.1074/jbc.M107341200; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Qin LX, 1999, CANCER RES, V59, P5662; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Tang ZY, 2001, WORLD J GASTROENTERO, V7, P445; THOMASSALGAR S, 1994, J BIOL CHEM, V269, P17879; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Wang Y, 2002, J PATHOL, V197, P610, DOI 10.1002/path.1150; Wen JM, 2002, CANCER GENET CYTOGEN, V135, P91, DOI 10.1016/S0165-4608(01)00636-7	24	180	201	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					298	302		10.1038/sj.onc.1206483	http://dx.doi.org/10.1038/sj.onc.1206483			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14647434				2022-12-28	WOS:000187895300031
J	Lahortiga, I; Agirre, X; Belloni, E; Vazquez, I; Larrayoz, MJ; Gasparini, P; Coco, FL; Pelicci, PG; Calasanz, MJ; Odero, MD				Lahortiga, I; Agirre, X; Belloni, E; Vazquez, I; Larrayoz, MJ; Gasparini, P; Coco, FL; Pelicci, PG; Calasanz, MJ; Odero, MD			Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells	ONCOGENE			English	Article						PRDM16/MEL1; RPN1; 1p36; 3q21; MDS (RAEB)	ACUTE MYELOID-LEUKEMIA; HEMATOLOGIC MALIGNANCIES; EVI1 EXPRESSION; GENE; 3Q21; IDENTIFICATION; MDS1/EVI1; 1P36.3; METHYLTRANSFERASES; REARRANGEMENTS	Patients with myeloid malignancies and either the 3q21q26 syndrome or t(1;3)(p36;q21) have been reported to share similar clinicopathological features and a common molecular mechanism for leukemogenesis. Overexpression of MDS1/EVI1 (3q26) or MEL1/PRDM16 (1p36), both members of the PR-domain family, has been directly implicated in the malignant transformation of this subset of neoplasias. The breakpoints in both entities are outside the genes, and the 3q21 region, where RPN1 is located, seems to act as an enhancer. MEL1 has been reported to be expressed in leukemia cells with t(1;3) and in the normal uterus and fetal kidney, but neither in bone marrow (BM) nor in other tissues, suggesting that this gene is specific to t(1;3)-positive MDS/AML. We report the molecular characterization of a t(1;3)(p36;q21) in a patient with MDS (RAEB-2). In contrast to previous studies, we demonstrate that MEL1, the PR-containing form, and MEL1S, the PR-lacking form, are widely expressed in normal tissues, including BM. The clinicopathological features and the breakpoint on 1p36 are different from cases previously described, and MEL1 is not overexpressed, suggesting a heterogeneity in myeloid neoplasias with t(1;3).	Univ Navarra, Dept Genet, Pamplona 31008, Spain; FIRC, Inst Mol Oncol, Milan, Italy; European Inst Oncol, Milan, Italy; Univ Tor Vergata, Dipartimento Biopatol & Diagnost Immagini, Rome, Italy	University of Navarra; IFOM - FIRC Institute of Molecular Oncology; IRCCS European Institute of Oncology (IEO); University of Rome Tor Vergata	Odero, MD (corresponding author), Univ Navarra, Dept Genet, C Irunlarrea S-N, Pamplona 31008, Spain.	modero@unav.es	Gasparini, Patrizia/Q-7626-2016; Pelicci, Pier Giuseppe/AAL-6572-2020; Calasanz, MJ/R-5813-2016; Agirre, Xabier/ABE-4110-2020; belloni, elena/H-9909-2013; Odero/ABG-9860-2020	Gasparini, Patrizia/0000-0002-9548-3724; Calasanz, MJ/0000-0002-0374-3008; Odero/0000-0002-8858-2054; Belloni, Elena/0000-0003-3214-0780	Telethon [TGM03Z03, TGM06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Du Y, 2001, CANCER RES, V61, P8094; FICHELSON S, 1992, LEUKEMIA, V6, P93; Huang S, 2002, NAT REV CANCER, V2, P469, DOI 10.1038/nrc819; Huang Shi, 1999, Frontiers in Bioscience, V4, pd528, DOI 10.2741/Huang; Langabeer SE, 2001, BRIT J HAEMATOL, V112, P208, DOI 10.1046/j.1365-2141.2001.02569.x; Mochizuki N, 2000, BLOOD, V96, P3209, DOI 10.1182/blood.V96.9.3209.h8003209_3209_3214; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; Nishikata I, 2003, BLOOD, V102, P3323, DOI 10.1182/blood-2002-12-3944; Odero MD, 2001, GENE CHROMOSOME CANC, V31, P134, DOI 10.1002/gcc.1127; Pekarsky Y, 1997, CANCER RES, V57, P3914; Rynditch A, 1997, GENE, V193, P49, DOI 10.1016/S0378-1119(97)00076-0; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; SECKERWALKER LM, 1995, BRIT J HAEMATOL, V91, P490, DOI 10.1111/j.1365-2141.1995.tb05329.x; Shimizu S, 2000, GENE CHROMOSOME CANC, V27, P229, DOI 10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0; Soderholm J, 1997, LEUKEMIA, V11, P352, DOI 10.1038/sj.leu.2400584; van Doorn-Khosrovani SBV, 2003, BLOOD, V101, P837, DOI 10.1182/blood-2002-05-1459; Vinatzer U, 2003, GENE CHROMOSOME CANC, V36, P80, DOI 10.1002/gcc.10144; Wieser R, 2002, LEUKEMIA LYMPHOMA, V43, P59, DOI 10.1080/10428190210196; Xinh PT, 2003, GENE CHROMOSOME CANC, V36, P313, DOI 10.1002/gcc.10176	19	24	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					311	316		10.1038/sj.onc.1206923	http://dx.doi.org/10.1038/sj.onc.1206923			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712237	Green Published			2022-12-28	WOS:000187895300034
J	Bertholon, J; Wang, Q; Falette, N; Verny, C; Auclair, J; Chassot, C; Navarro, C; Saurin, JC; Puisieux, A				Bertholon, J; Wang, Q; Falette, N; Verny, C; Auclair, J; Chassot, C; Navarro, C; Saurin, JC; Puisieux, A			Chfr inactivation is not associated to chromosomal instability in colon cancers	ONCOGENE			English	Article						Chfr; hypermethylation; chromosome instability; breast cancer; colon cancer	COMPARATIVE GENOMIC HYBRIDIZATION; MITOTIC STRESS CHECKPOINT; CELL-LINES; BREAST-CANCER; COLORECTAL-CANCER; CPG ISLAND; CENTROSOME AMPLIFICATION; MULTIPLE MUTATIONS; LUNG-CANCER; GENES	Numerous observations suggest that chromosome instability is caused by mitotic abnormalities such as errors in the partitioning of chromosomes. Chfr was recently defined as a central component of a new mitotic checkpoint that delays chromosome condensation in response to mitotic stress. Chfr was shown to be frequently inactivated in several human neoplasms, including colon, lung and esophageal cancers. To test whether Chfr inactivation may lead or participate to chromosomal instability (CIN), we analysed the genetic and epigenetic status of the gene in a large panel of primary colon and breast cancers, as well as in colon and breast cancer cell lines displaying either a microsatellite instability or a CIN. Our results confirm that Chfr is frequently inactivated in colon cancers, through a mechanism of hypermethylation of the promoter sequences. In contrast, the loss of Chfr expression appears to be a rare event in breast cancers. Furthermore, our data demonstrate that Chfr inactivation is not associated with CIN in these frequent types of human cancers.	Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, F-69373 Lyon 08, France; Fac Pharm Lyon, F-69373 Lyon, France; Hop Edouard Herriot, Federat Special Digest, F-69437 Lyon 03, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CHU Lyon	Puisieux, A (corresponding author), Ctr Leon Berard, INSERM, U590, Unite Oncol Mol, 28 Rue Laennec, F-69373 Lyon 08, France.			PUISIEUX, Alain/0000-0002-9938-3798				Ahuja N, 1997, CANCER RES, V57, P3370; Bunz F, 2002, CANCER RES, V62, P1129; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duval A, 2002, ANN GENET-PARIS, V45, P71, DOI 10.1016/S0003-3995(02)01115-2; Forozan F, 2000, CANCER RES, V60, P4519; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Jackson AL, 1998, SEMIN CANCER BIOL, V8, P421, DOI 10.1006/scbi.1998.0113; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kytola S, 2000, GENE CHROMOSOME CANC, V28, P308, DOI 10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; Luker KE, 2001, CANCER RES, V61, P6540; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Rummukainen J, 2001, CANCER GENET CYTOGEN, V126, P1, DOI 10.1016/S0165-4608(00)00387-3; Sato M, 2000, JPN J CANCER RES, V91, P504, DOI 10.1111/j.1349-7006.2000.tb00974.x; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Sen S, 2000, CURR OPIN ONCOL, V12, P82, DOI 10.1097/00001622-200001000-00014; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Tsushimi T, 2001, CANCER GENET CYTOGEN, V126, P34, DOI 10.1016/S0165-4608(00)00391-5; Wang Q, 2003, ONCOGENE, V22, P1486, DOI 10.1038/sj.onc.1206224; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	32	30	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8956	8960		10.1038/sj.onc.1207078	http://dx.doi.org/10.1038/sj.onc.1207078			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654793				2022-12-28	WOS:000186982200018
J	Shinozaki, T; Nota, A; Taya, Y; Okamoto, K				Shinozaki, T; Nota, A; Taya, Y; Okamoto, K			Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export	ONCOGENE			English	Article						p53; Mdm2; ATR	RING-FINGER DOMAIN; PROTEIN-KINASE; DEPENDENT PHOSPHORYLATION; DNA; ACTIVATION; CHECKPOINT; AKT; REPLICATION; DEGRADATION; UBIQUITINATION	Mdm2 oncoprotein plays a major role in inhibiting the p53 tumor suppressor protein. Here, we investigate phosphorylation of Mdm2 at serine 407 (S407). S407 is phosphorylated in cells after treatment with camptothecin (CPT) or hydroxyurea, inhibitors of DNA replication. S407 phosphorylation after CPT treatment is induced upon cell cycle arrest during S phase and prevented if entry into S phase of cell cycle is blocked. We found that a major kinase responsible for S407 phosphorylation is ATR, a DNA damage checkpoint protein that induces cell cycle arrest and promotes DNA repair in response to impaired DNA replication; induction of S407 phosphorylation is enhanced after expression of wild-type ATR, while it is inhibited by a dominant-negative form of ATR. Further, S407 is specifically phosphorylated by ATR in vitro. Substitution of S407 with aspartate (S407D), but not with alanine (S407A), promotes nuclear localization of p53. Taken together, our data indicate that S407 phosphorylation of Mdm2 by ATR reduces Mdm2-dependent export of p53 from nuclei to cytoplasm.	Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tokyo 1040045, Japan; Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki, Japan	National Cancer Center - Japan; Japan Science & Technology Agency (JST)	Okamoto, K (corresponding author), Natl Canc Ctr, Res Inst, Div Radiobiol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	kojokamo@gan2.res.ncc.go.jp						Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Blattner C, 2002, MOL CELL BIOL, V22, P6170, DOI 10.1128/MCB.22.17.6170-6182.2002; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brown EJ, 2000, GENE DEV, V14, P397; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hay TJ, 2000, FEBS LETT, V478, P183, DOI 10.1016/S0014-5793(00)01850-0; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Juven-Gershon T, 1999, MOL MED, V5, P71, DOI 10.1007/BF03402141; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu QH, 2000, GENE DEV, V14, P1448; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Shieh SY, 2000, GENE DEV, V14, P289; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Taya Yoichi, 2003, Methods Mol Biol, V223, P17; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang HY, 2002, CANCER RES, V62, P2483; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	63	59	61	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8870	8880		10.1038/sj.onc.1207176	http://dx.doi.org/10.1038/sj.onc.1207176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654783				2022-12-28	WOS:000186982200008
J	Mettus, RV; Rane, SG				Mettus, RV; Rane, SG			Characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice	ONCOGENE			English	Article						cyclin-dependent kinase 4; pancreas; fertility	CELL; DEFICIENT; DYSFUNCTION	Cyclin-dependent kinase 4 (Cdk4) and Cdk6, and later Cdk2, in association with their specific cyclin partners, regulate the G1 to S phase cell cycle transition of mammalian cells by phosphorylation of retinoblastoma (Rb) family proteins. Phosphorylation of Rb results in the release of S-phase specific transcription factors; cell cycle-promoting gene expression, and advancement of the cell cycle. Loss of Cdk4 by homologous-targeted disruption leads to a delay in S-phase entry in serum-stimulated mouse embryo fibroblast (MEF) cultures. Homozygous Cdk4-deficient mice display defects in weight gain, fertility and hypoproliferation of specific endocrine cells of the pituitary and pancreas, the latter of which results in a diabetes-like phenotype. In contrast, inheritance of the p16(Ink4a)-insensitive Cdk4(R24C) mutation leads to spontaneous transformation of MEF cultures in vitro and, in vivo, hyperproliferative disorders that progress to cancer. In this manuscript, we report characterization of the abnormal pancreatic development, reduced growth and infertility in Cdk4 mutant mice. We observe that, whereas Cdk4 is dispensable for early pancreatic development, normal Cdk4 expression is critical for optimal growth of the organism. Also, we observe that loss of Cdk4 may result in insulin insensitivity, implicating an additional role of Cdk4 in beta-cell function, in addition to its role in beta-cell proliferation. Further, we demonstrate that loss of Cdk4 leads to an age-dependent defect in spermatogenesis and disruption in the timing of the estrus cycle. Taken together, our results indicate that the overall defects in growth, fertility and pancreatic development in Cdk4-deficient mice may be a combination of cell-type specific defects and altered glucose metabolism, as a result of defects in postnatal pancreatic development.	NCI, Cell Cycle & Human Dis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Rane, SG (corresponding author), NCI, Cell Cycle & Human Dis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA.	sushil_rane@nih.gov			NCI NIH HHS [K22CA90790-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMANN RP, 1976, BIOL REPROD, V15, P586, DOI 10.1095/biolreprod15.5.586; Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; BENTON L, 1995, J STEROID BIOCHEM, V53, P61, DOI 10.1016/0960-0760(95)00022-R; Bouwens L, 1996, VIRCHOWS ARCH, V427, P553; Edlund H, 2002, NAT REV GENET, V3, P524, DOI 10.1038/nrg841; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Mauvais-Jarvis F, 2002, CLIN ENDOCRINOL, V57, P1, DOI 10.1046/j.1365-2265.2002.01563.x; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; Moons DS, 2002, ENDOCRINOLOGY, V143, P647, DOI 10.1210/en.143.2.647; MURRAY FT, 1985, HORM METAB RES, V17, P495, DOI 10.1055/s-2007-1013588; Murray J, 2001, COMB CHEM HIGH T SCR, V4, P265; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Rane SG, 2000, FRONT BIOSCI, V5, pD1, DOI 10.2741/Rane; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sherr CJ, 2000, CANCER RES, V60, P3689; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	24	74	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8413	8421		10.1038/sj.onc.1206888	http://dx.doi.org/10.1038/sj.onc.1206888			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627982				2022-12-28	WOS:000186650300005
J	Ohno, H; Hirabayashi, S; Kansaku, A; Yao, I; Tajima, M; Nishimura, W; Ohnishi, H; Mashima, H; Fujita, T; Omata, M; Hata, Y				Ohno, H; Hirabayashi, S; Kansaku, A; Yao, I; Tajima, M; Nishimura, W; Ohnishi, H; Mashima, H; Fujita, T; Omata, M; Hata, Y			Carom: a novel membrane-associated guanylate kinase-interacting protein with two SH3 domains	ONCOGENE			English	Article						epithelial junctions; MAGI-1; CASK; SH3; PDZ	TIGHT JUNCTION PROTEIN; CELL-ADHESION; PDZ DOMAIN; BASOLATERAL MEMBRANE; EPITHELIAL-CELLS; KIDNEY-CELLS; MAGI-1; CASK/LIN-2; BINDS; LOCALIZATION	MAGI-1 and CASK are membrane-associated guanylate kinases of epithelial junctions. MAGI-1 is localized at tight junctions in polarized epithelial cells, whereas CASK is localized along the lateral membranes. We obtained the KIAA0769 gene product through the yeast two-hybrid screening using MAGI-1 as a bait and named it Carom. Carom has a coiled-coil domain in the middle region, and two src homology 3 domains and a PSD-95/Dlg-A/ZO-1 (PDZ)-binding motif in the C-terminal region. Carom binds to the fifth PDZ domain of MAGI-1 and the calmodulin kinase domain of CASK in vitro. MAGI-1 and CASK bind to the distinct sequences in the C-terminal region of Carom, but still compete with each other for Carom binding. The study using a stable transformant of Madine Darby canine kidney (MDCK) cells expressing GFP-Carom revealed that Carom was partially overlapped by MAGI-1 in MDCK cells, which have not yet established mature cell junctions, but became separated from MAGI-1 and colocalized with CASK in polarized cells. Carom was highly resistant to Triton X-100 extractions and recruited CASK to the Triton X-100-insoluble structures. Carom is a binding partner of CASK, which interacts with CASK in polarized epithelial cells and may link it to the cytoskeleton.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Univ Tokyo, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo, Japan; Jichi Med Sch, Dept Gastroenterol, Minami Kawachi, Tochigi 32904, Japan; Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); University of Tokyo; Jichi Medical University; University of Tokyo	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.		Nishimura, Wataru/R-9215-2019	Nishimura, Wataru/0000-0002-8068-1277				ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BIERDERER T, 2001, J BIOL CHEM, V276, P47869; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Christensen EI, 2002, NAT REV MOL CELL BIO, V3, P258, DOI 10.1038/nrm778; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Dimitratos SD, 1997, MECH DEVELOP, V63, P127, DOI 10.1016/S0925-4773(97)00668-0; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fallon L, 2002, J BIOL CHEM, V277, P486, DOI 10.1074/jbc.M109806200; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Hata Y, 1996, J NEUROSCI, V16, P2488; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Irie M, 1999, ONCOGENE, V18, P2811, DOI 10.1038/sj.onc.1202652; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARINEZESTRADA OM, 2001, J BIOL CHEM, V276, P9291; Maximov A, 2002, J NEUROSCI, V22, P6939; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Ohno H, 2002, ONCOGENE, V21, P7042, DOI 10.1038/sj.onc.1205852; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Patrie KM, 2002, J BIOL CHEM, V277, P30183, DOI 10.1074/jbc.M203072200; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; STEVENSON BR, 1986, J CELL BIOL, V103, P755, DOI 10.1083/jcb.103.3.755; Tabuchi K, 2002, J NEUROSCI, V22, P4264, DOI 10.1523/JNEUROSCI.22-11-04264.2002	35	19	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 20	2003	22	52					8422	8431		10.1038/sj.onc.1206996	http://dx.doi.org/10.1038/sj.onc.1206996			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627983				2022-12-28	WOS:000186650300006
J	Liu, LT; Peng, JP; Chang, HC; Hung, WC				Liu, LT; Peng, JP; Chang, HC; Hung, WC			RECK is a target of Epstein-Barr virus latent membrane protein 1	ONCOGENE			English	Article						RECK; Epstein-Barr virus; latent membrane protein 1; extracellular signal-regulated kinases; small interference RNA	MEMBRANE-PROTEIN 1; CANCER-CELL INVASION; NASOPHARYNGEAL CARCINOMA; EXTRACELLULAR-MATRIX; B-CELLS; EXPRESSION; ACTIVATION; MATRIX-METALLOPROTEINASE-9; TRANSFORMATION; METASTASIS	Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) has been suggested to be involved in tumor metastasis. However, the molecular mechanism of LMP1-induced metastasis is largely unknown. In this study, we investigated the effect of LMP1 on the expression of RECK, a metastasis suppressor gene, in an EBV-negative nasopharyngeal carcinoma (NPC) cell line. Our data demonstrated that LMP1 induced downregulation of RECK via transcription repression in TW04 cells. In addition, we found that LMP1 acted via an Sp1 site to inhibit RECK promoter activity. We next studied the signaling pathway that mediated the effect of LMP1 on RECK expression. Our results showed that LMP1 potently stimulated the activity of extracellular signal-regulated kinases (ERKs) and inhibition of ERK activity by PD98059 antagonized LMP1-induced downregulation of RECK. Conversely, the c-Jun N-terminal kinase inhibitor SP600125 and p38(HOG) kinase inhibitor SB203580 had little effect. We also found that the expression of LMP1 increased the invasive ability of TW04 cells. The importance of RECK in LMP1-induced invasiveness was supported by three observations. First, restoration of RECK expression by PD98059 reduced LMP1-induced release of active MMP-9. Second, suppression of PD98059-induced RECK expression by small interference RNA abolished the inhibitory action of PD98059 on LMP1-induced invasiveness. Third, coexpression of RECK with LMP1 in TW04 cells effectively suppressed cell invasiveness induced by LMP1. Taken together, these results suggest that LMP1 inhibits RECK expression via the ERK/Sp1 signaling pathway and this inhibition is a critical step for LMP1-induced tumor metastasis.	Kaohsiung Med Univ, Sch Technol Med Sci, Kaohsiung 807, Taiwan; Kaohsiung Med Univ, Dept Physiol, Kaohsiung, Taiwan; Cang Gung Univ, Chang Gung Mem Hosp, Dept Otolaryngol, Kaohsiung Med Ctr, Kaohsiung, Taiwan; Kaohsiung Med Univ, Grad Inst Med, Kaohsiung, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Chang Gung Memorial Hospital; Kaohsiung Medical University	Hung, WC (corresponding author), Kaohsiung Med Univ, Sch Technol Med Sci, No 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.			Liu, Li-Teh/0000-0002-7993-7263				DERRICO A, 1991, MODERN PATHOL, V4, P239; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; Horikawa T, 2000, CANCER-AM CANCER SOC, V89, P715, DOI 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9; HU LF, 1995, EUR J CANCER, V31A, P658, DOI 10.1016/0959-8049(94)00468-K; KIEFF E, 1995, NEW ENGL J MED, V333, P724, DOI 10.1056/NEJM199509143331110; KIEFF E, 1990, VIROLOGY, P1889; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; LIN CT, 1990, LAB INVEST, V62, P713; LIN CT, 1993, LAB INVEST, V68, P716; Liu LT, 2003, CANCER RES, V63, P3069; MILLER G, 1990, VIROLOGY, P1921; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; PALLESEN G, 1991, J PATHOL, V165, P289, DOI 10.1002/path.1711650404; Pan MR, 2002, J BIOL CHEM, V277, P32775, DOI 10.1074/jbc.M202334200; PENG M, 1992, ONCOGENE, V7, P1775; Roberts ML, 1998, VIROLOGY, V240, P93, DOI 10.1006/viro.1997.8901; Sasahara RM, 1999, BIOCHEM BIOPH RES CO, V264, P668, DOI 10.1006/bbrc.1999.1552; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1991, AM J PATHOL, V139, P1259; Yang XH, 2000, ONCOGENE, V19, P2002, DOI 10.1038/sj.onc.1203515; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621	31	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	2003	22	51					8263	8270		10.1038/sj.onc.1207157	http://dx.doi.org/10.1038/sj.onc.1207157			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614450				2022-12-28	WOS:000186541500005
J	Delia, D; Fontanella, E; Ferrario, C; Chessa, L; Mizutani, S				Delia, D; Fontanella, E; Ferrario, C; Chessa, L; Mizutani, S			DNA damage-induced cell-cycle phase regulation of p53 and p21(waf1) in normal and ATM-defective cells	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA; INDUCED PHOSPHORYLATION; RADIOSENSITIZING AGENT; CHECKPOINT; APOPTOSIS; INHIBITION; G(1); DISSOCIATION; ARREST	The ATM-dependent accumulation of p53 and induction of p21(waf1) are key events for G1 cell-cycle checkpoint arrest following DNA damage. In ATM-null AT cells, even though the p53 and p21(waf1) responses are kinetically delayed and quantitatively reduced, the G1 checkpoint is virtually disrupted, suggesting that these proteins arrive too late in G1 to enforce the arrest. As the precise mechanism remains unclear, we examined the response to DNA double-strand breaks generated by gamma-radiation (IR), to determine if ATM deficiency affects the cell-cycle phase regulation of these molecules. We find that, after irradiation, whereas normal LCL-N cells markedly increase their levels of p53 in all phases of the cell cycle, AT cells fail to show any p53 increase in the G1 phase. In addition, whereas in LCL-N p21(waf1) is induced in G1 and G2-M, in AT cells this induction is partly seen in G2-M, but not in G1, indicating a different cell-cycle phase regulation of p53 and p21(waf1) as a result of ATM deficiency. The levels and catalytic activity of the p53-targeting kinases ATR and DNA-PK in LCL-N and AT cells are very similar throughout the cell cycle, both before and after IR, thus excluding a phase-specific activity for these kinases. Collectively, our findings demonstrate that, in ATM-deficient cells, the p53-dependent p21(waf1) response to DNA damage is not only quantitatively reduced, but also specifically suppressed in the G1 phase, thus providing a mechanistic explanation for the severe disruption of the G1 checkpoint in AT cells.	Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; IFOM, I-20139 Milan, Italy; Osped S Andrea, I-00189 Rome, Italy; Tokyo Med & Dent Univ, Postgrad Med Sch, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138519, Japan	Fondazione IRCCS Istituto Nazionale Tumori Milan; IFOM - FIRC Institute of Molecular Oncology; Sapienza University Rome; Azienda Ospedaliera Sant'Andrea; Tokyo Medical & Dental University (TMDU)	Delia, D (corresponding author), Ist Nazl Tumori, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.				Telethon [GP0205Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; CANMAN CE, 1994, CANCER RES, V54, P5054; Chehab NH, 2000, GENE DEV, V14, P278; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Delia D, 2000, BRIT J CANCER, V82, P1938; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Goi K, 1997, CANCER RES, V57, P1895; Jhappan C, 2000, MOL CELL BIOL, V20, P4075, DOI 10.1128/MCB.20.11.4075-4083.2000; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Takagi M, 1998, CANCER RES, V58, P4923; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yoshida M, 2002, INT J RADIAT BIOL, V78, P503, DOI [10.1080/095530002317577321, 10.1080/09553000210123685]	28	34	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7866	7869		10.1038/sj.onc.1207086	http://dx.doi.org/10.1038/sj.onc.1207086			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586414				2022-12-28	WOS:000186240200018
J	Zhang, JM; Liu, LM; Pfeifer, GP				Zhang, JM; Liu, LM; Pfeifer, GP			Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene	ONCOGENE			English	Article						TIG1; retinoic acid receptor beta; estrogen receptor; RASSF1A; DNA methylation; prostate cancer	TUMOR-SUPPRESSOR GENE; CPG ISLAND; SHORT ARM; ESTROGEN-RECEPTOR; DNA METHYLATION; LUNG-CANCER; SMALL-CELL; HYPERMETHYLATION; EXPRESSION; PROMOTER	Methylation of CpG islands and associated gene silencing may lead to malignant progression, but the mechanisms of CpG island methylation in cancer are unknown. The tazarotene- induced gene 1 ( TIG1), also known as retinoid acid ( RA) receptor- responsive 1 gene was first identified as an RA- responsive gene and was shown to be downregulated in prostate cancer. Here, we show that this downregulation is caused by the methylation of the promoter and CpG island of TIG1. TIG1 was methylated in 26 of 50 ( 52%) primary prostate cancers, but was not methylated in normal tissues or benign hyperplasias. Three of four tumors that metastasized, five of six that were poorly differentiated and all that were assigned a Gleason score higher than 8 ( 7/ 7) were methylated in the promoter of TIG1. The samples with peripheral invasion were more frequently methylated ( 21/ 32, 66%) than tissues without peripheral invasion ( 5/ 18, 28%). In addition, Gleason 7 - 10 cancers ( 21/ 30, 70%) were significantly more frequently methylated compared with Gleason 4 - 6 cancers ( 4/ 18, 22%) ( P < 0.01). The retinoic acid receptor beta ( RAR- beta) gene was frequently methylated as well ( 42/ 50, 84%). When TIG1 showed methylation, RAR- beta was also methylated ( 25/ 26 samples). In almost all samples where RAR- beta was not methylated, TIG1 was also in an unmethylated state ( 14/ 15 samples). The methylation of TIG1 and RAR- beta was positively correlated ( r = 0.35; P = 0.017). It is possible that the methylation of the retinoid response gene TIG1 occurred in response to the methylation and inactivation of RAR- beta. These observations may contribute to our understanding of mechanistic events leading to CpG island methylation in cancer.	City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Pfeifer, GP (corresponding author), City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA.	gpfeifer@coh.org			NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOEHM MF, 1995, J MED CHEM, V38, P3146, DOI 10.1021/jm00016a018; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; DE LUCA LM, 1991, FASEB J, V5, P2924; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Esteller M, 2002, CANCER RES, V62, P5902; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FISHER GJ, 1995, J INVEST DERMATOL, V105, P80, DOI 10.1111/1523-1747.ep12313352; HOSOE S, 1994, LUNG CANCER-J IASLC, V10, P297, DOI 10.1016/0169-5002(94)90659-9; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; HOWELL JM, 1967, BRIT J NUTR, V21, P373, DOI 10.1079/BJN19670038; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Lau KM, 2000, CANCER RES, V60, P3175; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Li LC, 2000, CANCER RES, V60, P702; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lotan R, 2002, J NATL CANCER I, V94, P469; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAESTRO R, 1993, CANCER RES, V53, P5775; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; Nagpal S, 1996, J INVEST DERMATOL, V106, P269, DOI 10.1111/1523-1747.ep12340668; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nelson JB, 1997, CANCER RES, V57, P35; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; Nwosu V, 2001, HUM MOL GENET, V10, P2313, DOI 10.1093/hmg/10.20.2313; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Ozen M, 2000, ANTICANCER RES, V20, P1905; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Picard E, 1999, J NATL CANCER I, V91, P1059, DOI 10.1093/jnci/91.12.1059; PIENTA KJ, 1993, CANCER RES, V53, P224; POLLARD M, 1991, CANCER RES, V51, P3610; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; STEARNS ME, 1993, CANCER RES, V53, P3073; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; Wei MH, 1996, CANCER RES, V56, P1487; WOLBACH SB, 1978, NUTR REV, V36, P16	50	59	70	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2241	2249		10.1038/sj.onc.1207328	http://dx.doi.org/10.1038/sj.onc.1207328			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14691453				2022-12-28	WOS:000220280900015
J	Carloni, V; Mazzocca, A; Ravichandran, KS				Carloni, V; Mazzocca, A; Ravichandran, KS			Tetraspanin CD81 is linked to ERK/MAPKinase signaling by Shc in liver tumor cells	ONCOGENE			English	Article						phosphatidylinositol-4 phosphate; phosphatidylinositol-4; kinase; cell growth	PHOSPHOTYROSINE-BINDING DOMAIN; SUPERFAMILY TM4SF PROTEINS; PLASMA-MEMBRANE; LIPID RAFTS; B-CELLS; COMPLEXES; ADHESION; TAPA-1; MIGRATION; FAMILY	Tetraspanins is a large family of membrane proteins that are implicated in cell proliferation, differentiation and tumor invasion. Specifically, the tetraspanin CD81 has been involved in cell proliferation but the mechanism is unknown. Here, we show that CD81 clustering stimulates ERK/MAPKinase activity and tyrosine phosphorylation of the adapter protein Shc in Huh7 cancer cells. In addition, overexpression of CD81 in HepG2 cells, NIH3T3 cells, and murine. broblasts GD25 lacking the beta1 family of integrins induces cell proliferation and ERK/MAPKinase activation. Linked with this event, we observed an increase in CD81-associated type II phosphatidylinositol 4-kinase activity. A mutant in the PTB domain of Shc failed to interact with phosphoinositides and localize to the plasma membrane thus blocking CD81-induced ERK/MAPKinase activation. Therefore, we conclude that CD81 stimulates synthesis of phosphoinositides with the recruitment of Shc to the plasma membrane via PTB domain, and this sequence of events induces activation of ERK/MAPKinase. These findings define a novel mechanism of ERK/MAPKinase activation and tumor cell proliferation.	Univ Florence, Dipartimento Med Interna, I-50134 Florence, Italy; Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA USA; Univ Virginia, Dept Microbiol, Charlottesville, VA USA	University of Florence; University of Virginia; University of Virginia	Carloni, V (corresponding author), Univ Florence, Dipartimento Med Interna, Viale Morgagni 85, I-50134 Florence, Italy.	v.carloni@dfc.unifi.it		MAZZOCCA, Antonio/0000-0003-0940-7352				Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; Berditchevski F, 2001, J CELL SCI, V114, P4143; Claas C, 2001, J BIOL CHEM, V276, P7974, DOI 10.1074/jbc.M008650200; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; LEVY S, 1991, J BIOL CHEM, V266, P14597; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1998, P NATL ACAD SCI USA, V95, P2458, DOI 10.1073/pnas.95.5.2458; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Mazzocca A, 2002, J HEPATOL, V37, P322, DOI 10.1016/S0168-8278(02)00175-7; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Owens DM, 2001, CANCER RES, V61, P5248; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; SCHICK MR, 1993, J IMMUNOL, V151, P4090; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Wang YD, 2002, ONCOGENE, V21, P2584, DOI 10.1038/sj.onc.1205355; Wei YJ, 2002, J BIOL CHEM, V277, P46586, DOI 10.1074/jbc.M206860200; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yauch RL, 2000, BIOCHEM J, V351, P629, DOI 10.1042/0264-6021:3510629; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	34	62	66	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 26	2004	23	8					1566	1574		10.1038/sj.onc.1207287	http://dx.doi.org/10.1038/sj.onc.1207287			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14676841				2022-12-28	WOS:000189219500010
J	He, Q; Huang, Y; Sheikh, MS				He, Q; Huang, Y; Sheikh, MS			Bax deficiency affects caspase-2 activation during ultraviolet radiation-induced apoptosis	ONCOGENE			English	Article						caspase-2; ultraviolet radiation; Bax deficiency; colon cancer cells	FAMILY-MEMBERS; CELL-DEATH; MITOCHONDRIA; REQUIREMENT; FAS/APO-1; RECEPTORS; SULINDAC; PATHWAY	There has been a considerable debate as to whether caspase-2 is an initiator or effector caspase. Recently, a new model of intrinsic pathway of apoptosis has been proposed, which suggests caspase-2 to be an initiator caspase. For example, ultraviolet radiation (UV) and other DNA damage-inducing agents were shown to first activate caspase-2 and then regulate the mitochondrial and postmitochondrial events. Active caspase-2 was found to engage mitochondria by promoting Bax translocation to the mitochondria. Consequently, Bax was proposed to play a central role in bridging the active caspase-2 with mitochondria by affecting mitochondrial permeability, cytochrome c release into the cytosol and caspase- 9 activation. In the present study, we investigated the role of Bax in UV-induced apoptosis and caspase- 2 activation. Our results indicate that UV-induced apoptosis and caspase- 2 activation were diminished in Bax-deficient cells, suggesting that Bax appears to play an important role in UV-induced apoptosis as well as caspase- 2 activation, and that it also appears to reside upstream of caspase-2. Bax deficiency also affected the activation of caspase- 3 and - 8 and abolished caspase- 9 activation during UV-induced apoptosis, suggesting that the absence of caspase- 9 activation may affect caspase- 2, - 3 and - 8 activation in Bax-deficient cells. Based on our results, we propose that activation of caspases is not a linear cascade of events, but is rather connected via complex feedback loops.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Sheikh, MS (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	sheikhm@mail.upstate.edu			NCI NIH HHS [CA86945, CA89043] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA089043, R01CA086945] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Fujita E, 2001, CELL DEATH DIFFER, V8, P335, DOI 10.1038/sj.cdd.4400824; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; He Q, 2002, ONCOGENE, V21, P6032, DOI 10.1038/sj.onc.1205897; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang Y, 2001, CANCER RES, V61, P6918; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Sitailo LA, 2002, J BIOL CHEM, V277, P19346, DOI 10.1074/jbc.M200401200; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang XD, 2001, GENE DEV, V15, P2922; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989	25	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1321	1325		10.1038/sj.onc.1207212	http://dx.doi.org/10.1038/sj.onc.1207212			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647455				2022-12-28	WOS:000188892200018
J	Maeda, O; Usami, N; Kondo, M; Takahashi, M; Goto, H; Shimokata, K; Kusugami, K; Sekido, Y				Maeda, O; Usami, N; Kondo, M; Takahashi, M; Goto, H; Shimokata, K; Kusugami, K; Sekido, Y			Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line	ONCOGENE			English	Article						plakoglobin; beta-catenin; malignant mesothelioma; transcriptional activity; Wnt signaling cascade	3P21.3 HOMOZYGOUS DELETION; HUMAN LUNG-CANCER; MALIGNANT MESOTHELIOMA; CYCLIN D1; MUTATIONS; PATHWAY; TARGET; APC; GROWTH; GENE	beta-Catenin is an essential element for the transcriptional activation of target genes in the Wnt signaling cascade and is also a cell adhesion molecule that couples with cadherins. Although plakoglobin (gamma-catenin), a closely related homologue of beta-catenin, is also known to be a cell adhesion molecule, its function as a transcriptional factor has not been revealed in detail. Using a human malignant mesothelioma cell line, NCI-H28, in which we have identified a homozygous deletion of the beta-catenin gene, we studied whether plakoglobin has a T-cell factor/ lymphocyte enhancer factor (TCF/LEF) family-dependent transcriptional activity. Transfection with the wildtype plakoglobin expression vector induced accumulation of plakoglobin in the nucleus. Immunoprecipitation assay with cotransfection of plakoglobin and either TCF-4 or LEF-1 detected binding of plakoglobin to TCF-4 or LEF-1. Luciferase reporter assay demonstrated transcriptional activity of the wild-type plakoglobin when transfected with TCF/LEF, although plakoglobin showed less activity than beta-catenin. Exogenous plakoglobin was also shown to promote entrance of exogenous beta-catenin into the nuclei. Furthermore, small interfering RNA directed against plakoglobin suppressed expression of endogenous plakoglobin and its transcriptional activity, suggesting that endogenous plakoglobin has a weak transcriptional activity. These results suggest that plakoglobin can activate the Wnt signaling cascade directly without interaction of beta-catenin, and that plakoglobin has multiple functions as a transcriptional activator and a cell adhesion molecule like beta-catenin.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668560, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668560, Japan.	ysekido@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; Kondo, Masashi/I-7378-2014; TAKAHASHI, Masahide/I-7244-2014; Sekido, Yoshitaka/P-9756-2015	Takahashi, Masahide/0000-0002-2803-2683; Sekido, Yoshitaka/0000-0002-2428-3848				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Clements WM, 2002, CANCER RES, V62, P3503; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Kolligs FT, 2000, GENE DEV, V14, P1319; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SEKIDO Y, 1994, CANCER RES, V54, P4988; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sparks AB, 1998, CANCER RES, V58, P1130; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	33	124	126	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					964	972		10.1038/sj.onc.1207254	http://dx.doi.org/10.1038/sj.onc.1207254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661054				2022-12-28	WOS:000188486600012
J	Kusam, S; Vasanwala, FH; Dent, AL				Kusam, S; Vasanwala, FH; Dent, AL			Transcriptional repressor BCL-6 immortalizes germinal center-like B cells in the absence of p53 function	ONCOGENE			English	Article						B-cell lymphoma; BCL-6; germinal center; CD40; p53	LYMPHOMA; EXPRESSION; GENE; DIFFERENTIATION; APOPTOSIS; ABERRATIONS; SURVIVAL; BLIMP-1	Chromosomal rearrangements in non-Hodgkin's B-cell lymphoma implicate BCL-6 as an oncogene, yet direct evidence for BCL-6 acting as an oncogene in B cells has been lacking. Here, we show that BCL-6 can immortalize primary B cells, but only in the absence of p53 tumor suppressor function. The expression of BCL-6 led to greatly increased B-cell proliferation, particularly in response to CD40 stimulation. Furthermore, BCL-6-infected p53-deficient B cells gave rise to immortalized cell lines that could be maintained by CD40 stimulation. We found that in primary mouse B cells, BCL-6 repressed expression of the Blimp-1, p27kip1, and cyclin D2 target genes. BCL-6 did not markedly repress the PDCD2 and BCL-XL target genes. The BCL-6 immortalized cell lines had a phenotype consistent with germinal center B cells, they expressed the germinal center-specific M17 gene, and a significant fraction of the cells stained positive with PNA. Our data indicate that BCL-6 may act to maintain B cells in a germinal center-like state, and repression of Blimp-1 by BCL-6 may be particularly crucial for stabilization of the germinal center phenotype. Our data also suggest that disruption of the p53 pathway may be crucial for the development of BCL-6- expressing B-cell lymphomas.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46208 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Dent, AL (corresponding author), Indiana Univ, Sch Med, Dept Microbiol & Immunol, 1044 W Walnut St,R4 302, Indianapolis, IN 46202 USA.	adent2@iupui.edu						Akasaka T, 2000, J CLIN ONCOL, V18, P510, DOI 10.1200/JCO.2000.18.3.510; Albagli-Curiel O, 2003, ONCOGENE, V22, P507, DOI 10.1038/sj.onc.1206152; Baron BW, 2002, P NATL ACAD SCI USA, V99, P2860, DOI 10.1073/pnas.042702599; Bellido M, 2002, HAEMATOLOGICA, V87, P908; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Cervenak L, 2001, IMMUNOL LETT, V78, P89, DOI 10.1016/S0165-2478(01)00239-5; CHRISTOPH T, 1994, INT IMMUNOL, V6, P1203, DOI 10.1093/intimm/6.8.1203; DALLAFAVERA R, 1994, ANN ONCOL, V5, pS55, DOI 10.1093/annonc/5.suppl_1.S55; Dent AL, 2002, CRIT REV ONCOL HEMAT, V41, P1, DOI 10.1016/S1040-8428(01)00164-0; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fanzo JC, 2003, J EXP MED, V197, P303, DOI 10.1084/jem.20020717; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; HATZ P, 1994, J BIOL CHEM, V269, P16802; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Messika EJ, 1998, J EXP MED, V188, P515, DOI 10.1084/jem.188.3.515; Moller MB, 1999, LEUKEMIA, V13, P453, DOI 10.1038/sj.leu.2401315; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shvarts A, 2002, GENE DEV, V16, P681, DOI 10.1101/gad.929302; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Staudt L M, 1999, Int Rev Immunol, V18, P381, DOI 10.3109/08830189909088490; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; Volpe G, 1996, GENE CHROMOSOME CANC, V16, P21, DOI 10.1002/(SICI)1098-2264(199605)16:1<21::AID-GCC3>3.0.CO;2-5; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; Yu DN, 2002, ONCOGENE, V21, P1922, DOI 10.1038/sj.onc.1205244	29	37	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					839	844		10.1038/sj.onc.1207065	http://dx.doi.org/10.1038/sj.onc.1207065			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737119	Bronze			2022-12-28	WOS:000188304900023
J	Mateo-Lozano, S; Tirado, OM; Notario, V				Mateo-Lozano, S; Tirado, OM; Notario, V			Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation	ONCOGENE			English	Article						mTOR; rapamycin; EWS/FLI-1; Ewing's sarcoma	TRANSFORMING-GROWTH-FACTOR; II RECEPTOR; EWS-FLI1; FAMILY; EXPRESSION; TARGET; EWS; ONCOPROTEINS; PATHWAY	Ewing's sarcoma (ES) is the prototype of a family of tumors (ESFT) of neuroectodermal origin formed by small, round cells with limited neural differentiation, which arise most frequently within bones in children or adolescents. The proliferation of ESFT cells is highly dependent on the establishment of, and signaling through several growth factor-mediated autocrine loops. The mammalian target of rapamycin (mTOR) is a central regulator of translation and cell proliferation, involved in the cellular response to various nutritional, stress and mitogenic effectors. As mTOR has recently been associated with certain human cancers, we investigated the possibility that mTOR played a role in the regulation of ES cell proliferation. Results showed that ES cell lines carrying EWS/FLI-1 alleles of different types expressed different levels of total and phosphorylated mTOR protein. We demonstrate that rapamycin, an mTOR inhibitor, efficiently blocked the proliferation of all cell lines by promoting cell cycle arrest at the G(1) phase. This was paralleled by the downregulation of the levels of the EWS/FLI-1 proteins, regardless of their fusion type, and the concomitant restoration of the expression of the TGF-beta type 2 receptor (TGFbeta RII), which is known to be repressed by several EWS-ETS fusion proteins. The expression of a rapamycin-resistant mTOR construct prevented both the proliferation blockade and the EWS/FLI-1 downregulation. These data demonstrate that mTOR signaling plays a central role in ES cell pathobiology and strongly suggest that the use of rapamycin as a cytostatic agent may be an efficient tool for the treatment of ES patients.	Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Washington, DC 20057 USA	Georgetown University	Notario, V (corresponding author), Georgetown Univ, Med Ctr, Dept Radiat Med, Expt Carcinogenesis Lab, Res Bldg,Room E215,3970 Reservoir Rd NW, Washington, DC 20057 USA.	notariov@georgetown.edu	/AAB-6461-2022; /AFP-0764-2022; Tirado, Oscar Martínez/R-9604-2019	Tirado, Oscar Martínez/0000-0002-4666-2822; Mateo, Silvia/0000-0002-2365-1573	NATIONAL CANCER INSTITUTE [P30CA051008, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA74175, P30-CA51008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Aryee DNT, 2000, LAB INVEST, V80, P1833, DOI 10.1038/labinvest.3780194; Benini S, 2001, CLIN CANCER RES, V7, P1790; Daniels G A, 2001, Expert Rev Anticancer Ther, V1, P211, DOI 10.1586/14737140.1.2.211; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Elit Laurie, 2002, Curr Opin Investig Drugs, V3, P1249; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Im YH, 2000, CANCER RES, V60, P1536; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Kovar H, 2001, CANCER RES, V61, P5992; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Lin PP, 1999, CANCER RES, V59, P1428; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Matsumoto Y, 2001, BRIT J CANCER, V84, P768, DOI 10.1054/bjoc.2000.1652; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sausville EA, 1999, PHARMACOL THERAPEUT, V82, P285, DOI 10.1016/S0163-7258(98)00062-X; Scotlandi K, 1998, CANCER RES, V58, P4127; Seufferlein T, 1996, CANCER RES, V56, P3895; Shah SA, 2001, J SURG RES, V97, P123, DOI 10.1006/jsre.2001.6145; Toretsky JA, 1999, CANCER RES, V59, P5745; Uren A, 2003, ONCOGENE, V22, P2334, DOI 10.1038/sj.onc.1206330; van der Poel HG, 2003, UROL RES, V30, P380, DOI 10.1007/s00240-002-0282-1; Visner GA, 2003, CIRCULATION, V107, P911, DOI 10.1161/01.CIR.0000048191.75585.60; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; Zwerner JP, 2001, ONCOGENE, V20, P626, DOI 10.1038/sj.onc.1204133	35	78	96	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9282	9287		10.1038/sj.onc.1207081	http://dx.doi.org/10.1038/sj.onc.1207081			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681687				2022-12-28	WOS:000187400400010
J	Morito, N; Yoh, K; Itoh, K; Hirayama, A; Koyama, A; Yamamoto, M; Takahashi, S				Morito, N; Yoh, K; Itoh, K; Hirayama, A; Koyama, A; Yamamoto, M; Takahashi, S			Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels	ONCOGENE			English	Article						Nrf2; oxidative stress; apoptosis; fas; TNF-receptor I	TUMOR-NECROSIS-FACTOR; PLANAR AROMATIC-COMPOUNDS; OXIDATIVE STRESS; INDUCIBLE EXPRESSION; APOPTOSIS; MICE; DEPLETION; IDENTIFICATION; ACETAMINOPHEN; ELEMENTS	Nrf2 is a basic leucine zipper transcriptional activator that is essential for the coordinate transcriptional induction of various antioxidant drug-metabolizing enzymes. Numerous studies have firmly established Nrf2's importance in protection from oxidative stress and certain chemical insults. Given the protective function of Nrf2, surprisingly few studies have focused on the relationship between Nrf2 and apoptosis. Therefore, we analysed how Nrf2 influences Fas signaling using Nrf2-deficient T cells. At a concentration of 1 mug/ml, the anti-Fas antibody induced 60% of cell death in Nrf2-deficient cultured thymocytes while, using the same treatment, only 40% of Nrf2 wildtype thymocytes died (P < 0.05). Nrf2 deficiency enhances the sensitivity of Fas-mediated apoptosis in T cells. Next we examined the effect of Nrf2 deficiency during hepatocellular apoptosis in vivo. In comparison to wildtype mice, Nrf2-deficient mice displayed more severe hepatitis after induction with the anti-Fas antibody or tumor necrosis factor (TNF)-alpha. The enhanced sensitivity to anti-Fas or TNF-alpha stimulation was restored by preadministration of glutathione ethyl monoester, a compound capable of passing the cell membrane and upregulating the intracellular levels of glutathione. The results indicated that Nrf2 activity regulates the sensitivity of death signals by means of intracellular glutathione levels.	Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Lab Anim Resource Ctr, Tsukuba, Ibaraki 3058575, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; University of Tsukuba	Takahashi, S (corresponding author), Univ Tsukuba, Inst Basic Med Sci, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	satoruta@md.tsukuba.ac.jp	Itoh, Ken/B-9506-2013; Yamamoto, Masayuki/A-4873-2010; Hirayama, Aki/G-7842-2017	Itoh, Ken/0000-0002-5518-0729; Yamamoto, Masayuki/0000-0002-9073-9436; Hirayama, Aki/0000-0001-5777-4208				Anderson M E, 1997, Adv Pharmacol, V38, P65; Chan D, 2000, AUSTRALAS J AGEING, V19, P26; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chen TS, 2000, MECH AGEING DEV, V120, P127, DOI 10.1016/S0047-6374(00)00214-1; Chiba T, 1996, EUR J IMMUNOL, V26, P1164, DOI 10.1002/eji.1830260530; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; DROGE W, 1994, FASEB J, V8, P1131; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hentze H, 1999, HEPATOLOGY, V30, P177, DOI 10.1002/hep.510300111; Hentze H, 2000, AM J PATHOL, V156, P2045, DOI 10.1016/S0002-9440(10)65076-6; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JONES TW, 1986, ARCH TOXICOL, P259; Kotlo KU, 2003, ONCOGENE, V22, P797, DOI 10.1038/sj.onc.1206077; Leist M, 1996, MOL MED, V2, P109, DOI 10.1007/BF03402207; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEISTER A, 1992, BIOCHEM PHARMACOL, V44, P1905, DOI 10.1016/0006-2952(92)90091-V; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Srivastava SK, 2000, CANCER LETT, V153, P35, DOI 10.1016/S0304-3835(00)00333-5; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UHLIG S, 1992, LIFE SCI, V51, P1083, DOI 10.1016/0024-3205(92)90509-N; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xu Y, 1998, GASTROENTEROLOGY, V115, P1229, DOI 10.1016/S0016-5085(98)70095-2; Yoh K, 2001, KIDNEY INT, V60, P1343, DOI 10.1046/j.1523-1755.2001.00939.x; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	40	90	96	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9275	9281		10.1038/sj.onc.1207024	http://dx.doi.org/10.1038/sj.onc.1207024			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681686	Green Submitted, Bronze			2022-12-28	WOS:000187400400009
J	Durr, M; Harder, F; Merkel, A; Bug, G; Henschler, R; Muller, AM				Durr, M; Harder, F; Merkel, A; Bug, G; Henschler, R; Muller, AM			Chimaerism and erythroid marker expression after microinjection of human acute myeloid leukaemia cells into murine blastocysts	ONCOGENE			English	Article						acute myeloid leukaemia (AML); embryonic microenvironment	TERATOCARCINOMA CELLS; EMBRYONAL CARCINOMA; RETINOIC ACID; MOUSE EMBRYOS; STEM-CELLS; DIFFERENTIATION; FUSION; CANCER; LINES; LIVER	It has been suggested that the embryonic microenvironment can control the survival and the transformed phenotype of tumour cells. Here, we addressed the hypothesis that the murine embryonic microenvironment can induce the differentiation of human tumour cells. To examine such interactions, we injected human leukaemic cells into preimplantation murine blastocysts at embryonic day 3.5 of gestation (E3.5). Microinjection of human KG-1 myeloid leukaemia cells and primary human acute myeloid leukaemia (AML) cells led to the generation of chimaeric embryos and adults. We observed that in E12.5 murine embryos, KG-1 cells were preferentially detected in yolk sac and peripheral blood, while primary AML cells mainly seeded the aorta gonad mesonephros region of chimaeric embryos. Analysis of the donor contribution in 15 different adult tissues showed that progeny of primary AML cells seeded to various haematopoietic and non-haematopoietic tissues. Chimaeric embryos and adults showed no apparent tumour formation. Furthermore, analysis of chimaeric E12.5 embryos revealed that the progeny of human KG-1 cells activated erythroid-specific human globin and glycophorin A expression. In summary, our data indicate that human AML cells activate markers of erythroid differentiation after injection into early murine embryos.	Univ Wurzburg, Inst Med Radiat & Cell Res MSZ, D-97078 Wurzburg, Germany; Red Cross Blood Ctr, Inst Transfus Med & Immune Haematol, D-60528 Frankfurt, Germany; Univ Frankfurt, Dept Med 3, D-60590 Frankfurt, Germany	University of Wurzburg; Goethe University Frankfurt	Muller, AM (corresponding author), Univ Wurzburg, Inst Med Radiat & Cell Res MSZ, Versbacherstr 5,D-2, D-97078 Wurzburg, Germany.		Bug, Gesine/H-8827-2013					Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; BARKER JE, 1970, NATURE, V228, P1305, DOI 10.1038/2281305a0; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; DRACH J, 1993, CANCER RES, V53, P2100; Geiger H, 1998, CELL, V93, P1055, DOI 10.1016/S0092-8674(00)81210-6; GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307; GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0; Harder F, 2002, BLOOD, V99, P719, DOI 10.1182/blood.V99.2.719; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549; JUNGHAHN I, 2001, BLOOD, V98; Kirchhof N, 2002, CELLS TISSUES ORGANS, V171, P77, DOI 10.1159/000057693; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KOEFFLER HP, 1981, CANCER RES, V41, P919; Li L, 2003, CANCER RES, V63, P2733; Lichtenberger C, 1999, J IMMUNOL METHODS, V227, P75, DOI 10.1016/S0022-1759(99)00076-9; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; MINTZ B, 1975, TERATOMAS DIFFERENTI, P59; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; OUTRAM S, 1988, LEUKEMIA RES, V12, P651, DOI 10.1016/0145-2126(88)90099-9; PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0; PIERCE GB, 1979, P NATL ACAD SCI USA, V76, P6649, DOI 10.1073/pnas.76.12.6649; PIERCE GB, 1982, CANCER RES, V42, P1082; PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBINSON J, 1981, NATURE, V289, P68, DOI 10.1038/289068a0; ROSSANT J, 1985, EXP CELL RES, V156, P213, DOI 10.1016/0014-4827(85)90275-7; SACHS L, 1980, J NATL CANCER I, V65, P675, DOI 10.1093/jnci/65.4.675; SAITO H, 1985, BLOOD, V66, P1233; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Stevens L C, 1967, Adv Morphog, V6, P1; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WATERS BK, 1986, J EMBRYOL EXP MORPH, V98, P99; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	43	22	27	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9185	9191		10.1038/sj.onc.1207134	http://dx.doi.org/10.1038/sj.onc.1207134			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668800				2022-12-28	WOS:000187149100009
J	Nilsson, JA; Cleveland, JL				Nilsson, JA; Cleveland, JL			Myc pathways provoking cell suicide and cancer	ONCOGENE			English	Review						Myc; apoptosis; Arf; p53; Bcl-2; death receptors; cancer	ARF TUMOR-SUPPRESSOR; APOPTOSIS-INDUCING LIGAND; WILD-TYPE P53; BCL-X-L; ATM-DEPENDENT PHOSPHORYLATION; PUTATIVE TRANSFORMING GENE; NERVE GROWTH-FACTOR; S-PHASE ENTRY; C-MYC; N-MYC	A paradox for the cancer biology field has been the revelation that oncogenes, once thought to simply provide advantages to a cancer cell, actually put it at dire risk of cell suicide. Myc is the quintessential oncogene in this respect, as in normal cells it is required for cell cycle traverse, whereas in cancers it is overexpressed and functions as the angiogenic switch. Nonetheless, Myc overexpression kills normal cells dead in their tracks. Here we review Myc-induced pathways that contribute to the apoptotic response. Molecular analysis of Myc-induced tumors has established that some of these apoptotic pathways are essential checkpoints that guard the cell from cancer, as they are selectively bypassed during tumorigenesis. The precise mechanism(s) by which Myc targets these pathways are largely unresolved, but we propose that they involve crosstalk and feedback regulatory loops between arbiters of cell death.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Nilsson, Jonas/E-5346-2013	Nilsson, Jonas/0000-0003-0346-6837				Abrahams VM, 2003, MOL BIOTECHNOL, V25, P19, DOI 10.1385/MB:25:1:19; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Alarcon-Vargas D, 2002, ONCOGENE, V21, P4384, DOI 10.1038/sj.onc.1205543; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; Alt JR, 2003, EMBO J, V22, P1442, DOI 10.1093/emboj/cdg133; Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; ASHE PC, 2003, BIOL PSYCHIAT, V27, P199; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bellmeyer A, 2003, DEV CELL, V4, P827, DOI 10.1016/S1534-5807(03)00160-6; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brummelkamp TR, 2002, J BIOL CHEM, V277, P6567, DOI 10.1074/jbc.M110492200; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629; Burns TF, 2003, CANCER BIOL THER, V2, P431, DOI 10.4161/cbt.2.4.478; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Cameron ER, 2000, CELL DEATH DIFFER, V7, P80, DOI 10.1038/sj.cdd.4400630; Carlson H, 2002, ONCOGENE, V21, P3827, DOI 10.1038/sj.onc.1205476; CAVALIERI F, 1987, MOL CELL BIOL, V7, P3554, DOI 10.1128/MCB.7.10.3554; Channavajhala P, 2002, ONCOGENE, V21, P5280, DOI 10.1038/sj.onc.1205640; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen MK, 1999, J SURG RES, V84, P82, DOI 10.1006/jsre.1999.5614; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen O, 1999, J CELL BIOL, V146, P141; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Condorelli F, 2001, MOL CELL BIOL, V21, P3025, DOI 10.1128/MCB.21.9.3025-3036.2001; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/0300-5127:0290696; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 1999, MOL CELL BIOL, V19, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; de Alboran IM, 2001, IMMUNITY, V14, P45, DOI 10.1016/S1074-7613(01)00088-7; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DEL PL, 1997, SCIENCE, V278, P687; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Fridman JS, 2003, CANCER RES, V63, P5703; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Godfried MB, 2002, ONCOGENE, V21, P2097, DOI 10.1038/sj.onc.1205259; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Green DR, 2003, IMMUNOL REV, V193, P70, DOI 10.1034/j.1600-065X.2003.00051.x; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Groth A, 2000, J BIOL CHEM, V275, P27473; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; Hahn P, 2003, INVEST OPHTH VIS SCI, V44, P3598, DOI 10.1167/iovs.02-1113; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; Hurlin PJ, 2003, EMBO J, V22, P4584, DOI 10.1093/emboj/cdg442; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iaccarino I, 2003, CELL DEATH DIFFER, V10, P599, DOI 10.1038/sj.cdd.4401211; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Iritani BM, 2002, EMBO J, V21, P4820, DOI 10.1093/emboj/cdf492; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jacobs JJL, 2000, NAT GENET, V26, P291, DOI 10.1038/81583; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JACOBSEN KA, 1994, BLOOD, V84, P2784; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; James M C, 2000, Prog Cell Cycle Res, V4, P71; JEFFERS JR, 2003, CANC CELL, V4; Jiang M, 2003, GENE DEV, V17, P832, DOI 10.1101/gad.252603; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kandasamy K, 2003, CANCER RES, V63, P1712; Kasibhatla S, 2000, CURR BIOL, V10, P1205, DOI 10.1016/S0960-9822(00)00727-2; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; Kime L, 2003, BIOCHEM J, V370, P291, DOI 10.1042/BJ20021679; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Klefstrom J, 2002, J BIOL CHEM, V277, P43224, DOI 10.1074/jbc.M206967200; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kogel D, 2003, EUR J CANCER, V39, P249, DOI 10.1016/S0959-8049(02)00477-X; KOHL NE, 1983, CELL, V35, P359, DOI 10.1016/0092-8674(83)90169-1; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lawlor MA, 2001, J CELL SCI, V114, P2903; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li Qun, 2002, Current Topics in Medicinal Chemistry, V2, P939, DOI 10.2174/1568026023393318; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lindstrom MS, 2003, ONCOGENE, V22, P4993, DOI 10.1038/sj.onc.1206659; Lindstrom MS, 2001, ONCOGENE, V20, P2171, DOI 10.1038/sj.onc.1204303; Lingbeek ME, 2002, J BIOL CHEM, V277, P26120, DOI 10.1074/jbc.M200403200; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LUNA RMD, 1995, NATURE, V378, P203; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Marcu KB, 1997, CURR TOP MICROBIOL, V224, P47; MARUYAMA K, 1987, ONCOGENE, V1, P361; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Matsuzaki Y, 1997, BLOOD, V89, P853, DOI 10.1182/blood.V89.3.853; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOENS CB, 1992, GENE DEV, V6, P691, DOI 10.1101/gad.6.5.691; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; NILSSON JA, 2003, IN PRESS MOL CELL BI; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; PEDUTO EL, 1999, INT J CANCER, V81, P772; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Popescu NC, 2002, J CELL MOL MED, V6, P151, DOI 10.1111/j.1582-4934.2002.tb00183.x; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Rathmell JC, 2002, NAT IMMUNOL, V3, P932, DOI 10.1038/ni834; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; RENAN MJ, 1989, CANCER LETT, V47, P1, DOI 10.1016/0304-3835(89)90170-5; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rosenfeld ME, 2000, AM J PATHOL, V156, P997, DOI 10.1016/S0002-9440(10)64967-X; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Rounbehler RJ, 2002, CANCER RES, V62, P3276; Rounbehler RJ, 2001, ONCOGENE, V20, P5341, DOI 10.1038/sj.onc.1204691; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAWAI S, 1991, NEW BIOL, V3, P861; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; SCHWAB M, 1984, NATURE, V308, P288, DOI 10.1038/308288a0; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sedger LM, 2002, EUR J IMMUNOL, V32, P2246, DOI 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; SHEINESS DK, 1980, VIROLOGY, V105, P415, DOI 10.1016/0042-6822(80)90042-2; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shiraki K, 1997, P NATL ACAD SCI USA, V94, P6420, DOI 10.1073/pnas.94.12.6420; Shurin GV, 1998, NAT IMMUN, V16, P263, DOI 10.1159/000069452; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; STANTON BR, 1990, MOL CELL BIOL, V10, P6755, DOI 10.1128/MCB.10.12.6755; STEWART M, 1993, INT J CANCER, V53, P1023; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Strand S, 1998, MOL MED TODAY, V4, P63, DOI 10.1016/S1357-4310(97)01191-X; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takamizawa S, 2000, J PEDIATR SURG, V35, P375, DOI 10.1016/S0022-3468(00)90044-7; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tonini GP, 2003, CANCER LETT, V197, P69, DOI 10.1016/S0304-3835(03)00081-8; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wang Z, 2001, J Vet Sci, V2, P167; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei MC, 2000, GENE DEV, V14, P2060; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wen RR, 2001, MOL CELL BIOL, V21, P678, DOI 10.1128/MCB.21.2.678-689.2001; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu Q, 2002, J BIOL CHEM, V277, P13059, DOI 10.1074/jbc.M111403200; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	303	348	364	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					9007	9021		10.1038/sj.onc.1207261	http://dx.doi.org/10.1038/sj.onc.1207261			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663479				2022-12-28	WOS:000187043600004
J	Takayama, S; Reed, JC; Homma, S				Takayama, S; Reed, JC; Homma, S			Heat-shock proteins as regulators of apoptosis	ONCOGENE			English	Article						heat-shock proteins; Hsp27; Hsp70; Hsp90; apoptosis	CYTOCHROME-C RELEASE; KAPPA-B ACTIVATION; INDUCED CELL-DEATH; N-TERMINAL KINASE; BCL-2-BINDING PROTEIN; INTERACTING PROTEIN; CHAPERONE FUNCTION; HSP90 FUNCTION; J-DOMAIN; IN-VIVO	Heat-shock proteins are produced in response to different types of stress conditions making cells resistant to stress-induced cell damage. Under normal conditions, heat-shock proteins play numerous roles in cell function, including modulating protein activity by changing protein conformation, promoting multiprotein complex assembly/disassembly, regulating protein degradation within the proteasome pathway, facilitating protein translocation across organellar membranes, and ensuring proper folding of nascent polypeptide chains during protein translation. When cells are stressed, a common response is to undergo cell death by one of two pathways, either 'necrosis' or 'apoptosis'. Recently, both routes to cell death have been revealed to share similar mechanisms, with heat-shock proteins and their cofactors responsible for inhibiting both apoptotic and necrotic pathways. We therefore briefly summarize recent reports showing molecular evidence of cell death regulation by heat-shock proteins and their cochaperones.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Takayama, S (corresponding author), Burnham Inst, La Jolla, CA 92037 USA.			Homma, Sachiko/0000-0001-6563-8521				Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen F, 2003, J BIOL CHEM, V278, P6848, DOI 10.1074/jbc.M212021200; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chittenden T, 2002, CANCER CELL, V2, P165, DOI 10.1016/S1535-6108(02)00128-9; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; DanenVanOorschot AAAM, 1997, APOPTOSIS, V2, P395, DOI 10.1023/A:1026409808732; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Demonacos C, 2001, MOL CELL, V8, P71, DOI 10.1016/S1097-2765(01)00277-5; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Eversole-Cire P, 2000, INVEST OPHTH VIS SCI, V41, P1953; Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000; Gao TY, 2002, J BIOL CHEM, V277, P31585, DOI 10.1074/jbc.M204335200; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Gjoerup O, 2000, J VIROL, V74, P864, DOI 10.1128/JVI.74.2.864-874.2000; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Imai Y, 2002, MOL CELL, V10, P55, DOI 10.1016/S1097-2765(02)00583-X; IWAKI K, 1993, CIRCULATION, V87, P2023, DOI 10.1161/01.CIR.87.6.2023; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; KAWAGOE J, 1993, BRAIN RES, V621, P121, DOI 10.1016/0006-8993(93)90306-8; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KERMER P, 2003, IN PRESS BRIAN PATHO; Kim S, 2002, NAT CELL BIOL, V4, P826, DOI 10.1038/ncb863; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kurisu J, 2003, GENES CELLS, V8, P189, DOI 10.1046/j.1365-2443.2003.00625.x; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Lee MY, 2002, EXP NEUROL, V175, P338, DOI 10.1006/exnr.2002.7903; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Miki K, 2002, MOL CELL BIOL, V22, P2536, DOI 10.1128/MCB.22.8.2536-2543.2002; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Okubo S, 2001, CIRCULATION, V103, P877, DOI 10.1161/01.CIR.103.6.877; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Ozes ON, 1999, NATURE, V401, P82; Pagliuca MG, 2003, FEBS LETT, V541, P11, DOI 10.1016/S0014-5793(03)00274-6; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; Pfanner N, 1999, CURR BIOL, V9, pR720, DOI 10.1016/S0960-9822(99)80467-9; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Sakahira H, 2002, J BIOL CHEM, V277, P3364, DOI 10.1074/jbc.M110071200; Sakamoto H, 2002, J BIOL CHEM, V277, P45770, DOI 10.1074/jbc.M207485200; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Syken J, 1999, P NATL ACAD SCI USA, V96, P8499, DOI 10.1073/pnas.96.15.8499; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Terada S, 1997, CYTOTECHNOLOGY, V25, P17, DOI 10.1023/A:1007954103572; Thress K, 2001, EMBO J, V20, P1033, DOI 10.1093/emboj/20.5.1033; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Xanthoudakis S, 1999, EMBO J, V18, P2049, DOI 10.1093/emboj/18.8.2049; Xiang SL, 2001, BIOCHEM BIOPH RES CO, V287, P932, DOI 10.1006/bbrc.2001.5685; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zhang XD, 2002, CURR OPIN STRUC BIOL, V12, P231, DOI 10.1016/S0959-440X(02)00315-9	93	373	390	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 8	2003	22	56					9041	9047		10.1038/sj.onc.1207114	http://dx.doi.org/10.1038/sj.onc.1207114			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663482				2022-12-28	WOS:000187043600007
J	Altieri, DC				Altieri, DC			Survivin, versatile modulation of cell division and apoptosis in cancer	ONCOGENE			English	Review						survivin; apoptosis; cell cycle; cancer; checkpoint	MESSENGER-RNA EXPRESSION; NORMAL CORD BLOOD; PROTEIN SURVIVIN; GENE-EXPRESSION; PROGNOSTIC-SIGNIFICANCE; REGULATED EXPRESSION; CASPASE ACTIVATION; ANTIAPOPTOSIS GENE; ENDOTHELIAL-CELLS; CRYSTAL-STRUCTURE	Survivin is a member of the inhibitor of apoptosis (IAP) gene family that has attracted attention from several viewpoints of basic and translational research. Its cell cycle-regulated expression at mitosis and association with the mitotic apparatus have been of interest to cell biologists studying faithful segregation of sister chromatids and timely separation of daughter cells. Investigators interested in mechanisms of apoptosis have found survivin an evolving challenge: while survivin inhibits apoptosis in vitro and in vivo, this pathway may be more selective as compared to cytoprotection mediated by other IAPs. Finally, basic and translational researchers in cancer biology have converged on survivin as a pivotal cancer gene, not simply for its sharp expression in tumors and not in normal tissues, but also for the potential exploitation of this pathway in cancer diagnosis and therapy. The objective of the present contribution is to line up current evidence and emerging concepts on the multifaceted functions of survivin in cell death and cell division, and how this pathway is being pursued for novel cancer therapeutic strategies.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, 364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu			NCI NIH HHS [CA78810, CA90917] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090917, R01CA078810] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Adida C, 2000, BRIT J HAEMATOL, V111, P196, DOI 10.1046/j.1365-2141.2000.02328.x; Adida C, 1998, LANCET, V351, P882, DOI 10.1016/S0140-6736(05)70294-4; Adida C, 1998, AM J PATHOL, V152, P43; Adida C, 2000, BLOOD, V96, P1921; Allen SM, 2003, CANCER RES, V63, P567; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Andersen MH, 2001, CANCER RES, V61, P869; Andersen MH, 2002, HISTOL HISTOPATHOL, V17, P669, DOI 10.14670/HH-17.669; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Badie C, 2000, MOL CELL BIOL, V20, P2358, DOI 10.1128/MCB.20.7.2358-2366.2000; Badran A, 2003, INT J ONCOL, V22, P59; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bao RD, 2002, J NATL CANCER I, V94, P522; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chantalat L, 2000, MOL CELL, V6, P183, DOI 10.1016/S1097-2765(00)00019-8; Chen J, 2003, J BIOL CHEM, V278, P486, DOI 10.1074/jbc.M211119200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Choi KS, 2003, CANCER GENE THER, V10, P87, DOI 10.1038/sj.cgt.7700531; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Fukuda S, 2002, BLOOD, V100, P2463, DOI 10.1182/blood.V100.7.2463; Fukuda S, 2001, BLOOD, V98, P2091, DOI 10.1182/blood.V98.7.2091; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Gianani R, 2001, HUM PATHOL, V32, P119, DOI 10.1053/hupa.2001.21897; Giodini A, 2002, CANCER RES, V62, P2462; Grabowski P, 2003, BRIT J CANCER, V88, P115, DOI 10.1038/sj.bjc.6600696; Gradilone A, 2003, J CLIN ONCOL, V21, P306, DOI 10.1200/JCO.2003.08.066; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Grossman D, 1999, J INVEST DERMATOL, V113, P1076, DOI 10.1046/j.1523-1747.1999.00776.x; Grossman D, 2001, P NATL ACAD SCI USA, V98, P635, DOI 10.1073/pnas.230450097; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Hausladen DA, 2003, J UROLOGY, V170, P230, DOI 10.1097/01.ju.0000063685.29339.24; Hirohashi Y, 2002, CLIN CANCER RES, V8, P1731; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Ikeguchi M, 2002, BRIT J CANCER, V87, P883, DOI 10.1038/sj.bjc.6600546; Ikeguchi M, 2002, CLIN CANCER RES, V8, P3131; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Jiang XY, 2001, J CELL BIOCHEM, V83, P342, DOI 10.1002/jcb.1228; Jones G, 2000, J BIOL CHEM, V275, P22157, DOI 10.1074/jbc.M000369200; Kajiwara Y, 2003, CANCER-AM CANCER SOC, V97, P1077, DOI 10.1002/cncr.11122; Kallio MJ, 2001, FASEB J, V15, P2721, DOI 10.1096/fj.01-0280fje; Kamihira S, 2001, BRIT J HAEMATOL, V114, P63, DOI 10.1046/j.1365-2141.2001.02902.x; Kanwar JR, 2001, J NATL CANCER I, V93, P1541, DOI 10.1093/jnci/93.20.1541; Kappler M, 2001, INT J CANCER, V95, P360, DOI 10.1002/1097-0215(20011120)95:6<360::AID-IJC1063>3.0.CO;2-1; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kato J, 2001, INT J CANCER, V95, P92; Kawasaki H, 1998, CANCER RES, V58, P5071; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Koch CA, 2002, EUR J ENDOCRINOL, V146, P381, DOI 10.1530/eje.0.1460381; Kuttler F, 2002, LEUKEMIA, V16, P726, DOI 10.1038/sj.leu.2402427; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Li FZ, 1999, CANCER RES, V59, P3143; Lu CD, 1998, CANCER RES, V58, P1808; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Mahotka C, 1999, CANCER RES, V59, P6097; Mahotka C, 2002, CELL DEATH DIFFER, V9, P1334, DOI 10.1038/sj.cdd.4401091; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Mesri M, 2001, AM J PATHOL, V158, P1757, DOI 10.1016/S0002-9440(10)64131-4; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Monzo M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100; Muchmore SW, 2000, MOL CELL, V6, P173, DOI 10.1016/S1097-2765(00)00018-6; Murphy CR, 2002, DEV DYNAM, V225, P597, DOI 10.1002/dvdy.10194; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Olie RA, 2000, CANCER RES, V60, P2805; Ota T, 2002, CANCER RES, V62, P5168; Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102; Pennati M, 2003, J INVEST DERMATOL, V120, P648, DOI 10.1046/j.1523-1747.2003.12082.x; Rodriguez JA, 2002, EXP CELL RES, V275, P44, DOI 10.1006/excr.2002.5492; Rohayem J, 2000, CANCER RES, V60, P1815; Saitoh Y, 1999, INT J ONCOL, V15, P137; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645; Satoh K, 2001, CANCER, V92, P271, DOI 10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0; Sausville EA, 2002, TRENDS MOL MED, V8, pS32, DOI 10.1016/S1471-4914(02)02308-0; Schmidt SM, 2003, BLOOD, V102, P571, DOI 10.1182/blood-2002-08-2554; Schmitz M, 2000, CANCER RES, V60, P4845; Schwartz GK, 2002, J CLIN ONCOL, V20, P2157, DOI 10.1200/JCO.2002.08.080; Shankar SL, 2001, J NEUROCHEM, V79, P426, DOI 10.1046/j.1471-4159.2001.00596.x; Shannon KB, 2002, CURR BIOL, V12, pR458, DOI 10.1016/S0960-9822(02)00945-4; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Silke J, 2001, J CELL SCI, V114, P1821; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Song Z, 2003, J BIOL CHEM; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614; Tamm I, 1998, CANCER RES, V58, P5315; Tanaka K, 2000, CLIN CANCER RES, V6, P127; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Wall NR, 2003, CANCER RES, V63, P230; Wang HW, 2002, EMBO J, V21, P2602, DOI 10.1093/emboj/21.11.2602; Wang XD, 2001, GENE DEV, V15, P2922; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Williams NS, 2003, CLIN CANCER RES, V9, P931; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4; Xia CY, 2002, MOL CANCER THER, V1, P687; Yagihashi A, 2001, CLIN CHEM, V47, P1729; Yamamoto T, 2002, EUR J CANCER, V38, P2316, DOI 10.1016/S0959-8049(02)00247-2; Yoshida H, 2001, INT J ONCOL, V19, P537; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zaffaroni N, 2002, CELL MOL LIFE SCI, V59, P1406, DOI 10.1007/s00018-002-8518-3; Zhang JY, 2003, CANCER EPIDEM BIOMAR, V12, P136; Zhang T, 2001, CANCER RES, V61, P8664; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192	132	744	837	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2003	22	53					8581	8589		10.1038/sj.onc.1207113	http://dx.doi.org/10.1038/sj.onc.1207113			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	745YX	14634620				2022-12-28	WOS:000186720000004
J	Whitmarsh, RJ; Saginario, C; Zhuo, Y; Hilgenfeld, E; Rappaport, EF; Megonigal, MD; Carroll, M; Liu, M; Osheroff, N; Cheung, NKV; Slater, DJ; Ried, T; Knutsen, T; Blair, IA; Felix, CA				Whitmarsh, RJ; Saginario, C; Zhuo, Y; Hilgenfeld, E; Rappaport, EF; Megonigal, MD; Carroll, M; Liu, M; Osheroff, N; Cheung, NKV; Slater, DJ; Ried, T; Knutsen, T; Blair, IA; Felix, CA			Reciprocal DNA topoisomerase II cleavage events at 5 '-TATTA-3 ' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing	ONCOGENE			English	Article						t(9;11) translocation; DNA topoisomerase II; secondary leukemia; etoposide; etoposide catechol; etoposide quinone	ACUTE MYELOID-LEUKEMIA; BALANCED CHROMOSOME-ABERRATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; SECONDARY ACUTE-LEUKEMIA; CLUSTER REGION; MYELODYSPLASTIC SYNDROMES; RELIGATION REACTION; TRANSLOCATION; GENE; COMPLEX	Few t(9;11) translocations in DNA topoisomerase II inhibitor-related leukemias have been studied in detail and the DNA damage mechanism remains controversial. We characterized the der(11) and der(9) genomic breakpoint junctions in a case of AML following etoposide and doxorubicin. Etoposide-, etoposide metabolite- and doxorubicin-induced DNA topoisomerase II cleavage was examined in normal homologues of the MLL and AF-9 breakpoint sequences using an in vitro assay. Induction of DNA topoisomerase II cleavage complexes in CEM and K562 cell lines was investigated using an in vivo complex of enzyme assay. The translocation occurred between identical 5'-TATTA-3' sequences in MLL intron 8 and AF-9 intron 5 without the gain or loss of bases. The 5'-TATTA-3' sequences were reciprocally cleaved by DNA topoisomerase II in the presence of etoposide, etoposide catechol or etoposide quinone, creating homologous 4-base 5' overhangs that would anneal to form both breakpoint junctions without any processing. der(11) and der(4) translocation breakpoints in a treatment-related ALL at the same site in MLL are consistent with a damage hotspot. Etoposide and both etoposide metabolites induced DNA topoisomerase II cleavage complexes in the hematopoietic cell lines. These results favor the model in which the chromosomal breakage leading to MLL translocations in DNA topoisomerase II inhibitor-related leukemias is a consequence of DNA topoisomerase II cleavage.	Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Hosp Univ Penn, Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Josephy Stokes Jr Res Inst, Philadelphia, PA 19104 USA; NCI, Genet Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Memorial Sloan Kettering Cancer Center; Vanderbilt University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Jefferson University	Felix, CA (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Rm 902B,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	felix@email.chop.edu	Rappaport, Eric/GRO-4051-2022; Blair, Ian A/B-3320-2010		NATIONAL CANCER INSTITUTE [R01CA077683, R01CA080175, R01CA085469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER; NCI NIH HHS [CA77683, CA85469, CA80175] Funding Source: Medline; NIGMS NIH HHS [GM33944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Atlas M, 1998, LEUKEMIA, V12, P1895, DOI 10.1038/sj.leu.2401223; BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; Ben-Yehuda M, 2002, BLOOD, V100, p324A; Betti CJ, 2003, CANCER RES, V63, P1377; Betti CJ, 2001, CANCER RES, V61, P4550; Blanco JG, 2001, P NATL ACAD SCI USA, V98, P10338, DOI 10.1073/pnas.181199898; Bloomfield CD, 2002, GENE CHROMOSOME CANC, V33, P362, DOI 10.1002/gcc.10046; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Bromberg KD, 2003, J BIOL CHEM, V278, P7406, DOI 10.1074/jbc.M212056200; Bromberg KD, 2001, BIOCHEMISTRY-US, V40, P8410, DOI 10.1021/bi010681q; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Byl JAW, 2001, BIOCHEMISTRY-US, V40, P712, DOI 10.1021/bi0021838; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P4553, DOI 10.1093/nar/18.15.4553; CHARRON M, 1991, CHROMOSOMA, V100, P97, DOI 10.1007/BF00418242; Daheron L, 2001, GENE CHROMOSOME CANC, V31, P382, DOI 10.1002/gcc.1157; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1995, CANCER RES, V55, P4287; Felix CA, 1999, MOL DIAGN, V4, P269, DOI 10.1016/S1084-8592(99)80002-2; Felix CA, 1997, BLOOD, V90, P4679, DOI 10.1182/blood.V90.12.4679.4679_4679_4686; Felix CA, 2001, MED PEDIATR ONCOL, V36, P525, DOI 10.1002/mpo.1125; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Fortune JM, 2000, PROG NUCLEIC ACID RE, V64, P221, DOI 10.1016/S0079-6603(00)64006-0; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; KAUFMANN SH, 1998, BIOCHIM BIOPHYS ACTA, V1400, P196; Langer T, 2003, GENE CHROMOSOME CANC, V36, P393, DOI 10.1002/gcc.10167; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lovett BD, 2001, BIOCHEMISTRY-US, V40, P1159, DOI 10.1021/bi002361x; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; LOZZIO BB, 1979, LEUKEMIA RES, V3, P363, DOI 10.1016/0145-2126(79)90033-X; Megonigal MD, 1997, P NATL ACAD SCI USA, V94, P11583, DOI 10.1073/pnas.94.21.11583; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; Megonigal MD, 1998, P NATL ACAD SCI USA, V95, P6413, DOI 10.1073/pnas.95.11.6413; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; NEGRINI M, 1993, CANCER RES, V53, P4489; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; POMMIER Y, 1993, CAUSES CONSEQUENCES, P277; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Raffini LJ, 2002, P NATL ACAD SCI USA, V99, P4568, DOI 10.1073/pnas.062066799; RAFFINI LJ, 2002, P ANR M 2002; RATAIN MJ, 1987, BLOOD, V70, P1412; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; ROSS JA, 2003, AM SOC CLIN ONCOL, V3, P243; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; SANDOVAL C, 1993, J CLIN ONCOL, V11, P1039, DOI 10.1200/JCO.1993.11.6.1039; SECKERWALKER LM, 1985, MED PEDIATR ONCOL, V13, P48, DOI 10.1002/mpo.2950130112; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Slater DJ, 2002, ONCOGENE, V21, P4706, DOI 10.1038/sj.onc.1205572; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; SUBRAMANIAN D, 1995, CANCER RES, V55, P2097; SUBRAMANIAN D, 2001, DNA TOPOISOMERASE 2; Super HG, 1997, GENE CHROMOSOME CANC, V20, P185, DOI 10.1002/(SICI)1098-2264(199710)20:2<185::AID-GCC9>3.0.CO;2-#; UZMAN BG, 1966, CANCER, V19, P1725, DOI 10.1002/1097-0142(196611)19:11<1725::AID-CNCR2820191142>3.0.CO;2-T; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WEH HJ, 1986, J CLIN ONCOL, V4, P1518, DOI 10.1200/JCO.1986.4.10.1518; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014; Zhou RH, 1997, CANCER RES, V57, P4699; Zinkevich Vitaly, 2000, Molecular Biology Today, V1, P29	69	48	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 20	2003	22	52					8448	8459		10.1038/sj.onc.1207052	http://dx.doi.org/10.1038/sj.onc.1207052			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	744UB	14627986				2022-12-28	WOS:000186650300009
J	Pendaries, V; Verrecchia, F; Michel, S; Mauviel, A				Pendaries, V; Verrecchia, F; Michel, S; Mauviel, A			Retinoic acid receptors interfere with the TGF-beta/Smad signaling pathway in a ligand-specific manner	ONCOGENE			English	Article						transforming growth factor-beta; nuclear receptors; RAR; Smad; promoter region; gene expression	GROWTH-FACTOR-BETA; CANCER-CELL-LINES; TRANSCRIPTION FACTORS; HL-60 CELLS; PROMOTER; SMAD; GENE; DIFFERENTIATION; PROLIFERATION; ELEMENTS	Transforming growth factor-beta (TGF-beta) and retinoic acid (RA) are important regulators of cell growth and differentiation. The TGF-beta receptors utilize Smad proteins to transduce signals intracellularly and regulate transcription of target genes, either directly or in combination with other sequence-specific transcription factors. Two classes of nuclear receptors, the retinoic acid receptors (RARs) and the retinoic X receptors, are involved in mediating transcriptional responses to RA. Given the known interactions between the TGF-beta and RAR pathways, we have investigated the role played by RAR ligands in modulating functional interactions between Smad3 and RARs. Using transient cell transfection experiments with an artificial Smad3/Smad4-dependent reporter construct, we demonstrate that RAR overexpression enhances Smad-driven transactivation, an effect that requires both Smad3 and Smad4. We provide evidence that RAR effect on Smad3/Smad4-driven transcription is prevented by natural and synthetic RAR agonists, and potentiated by synthetic RAR antagonists. The activity of two TGF-beta-responsive human gene promoter constructs was regulated in a parallel fashion. Using both mammalian two-hybrid and immunoprecipitation/Western methods, we demonstrate a direct interaction between the region DEF of RARgamma and the MH2 domain of Smad3, inhibited by RAR agonists and enhanced by their antagonists. We propose that RARs may function as coactivators of the Smad pathway in the absence of RAR agonists or in the presence of their antagonists, a phenomenon that contrasts with their known role as agonist-activated transcriptional regulators of RA-dependent genes.	Univ Paris 07, Inst Rech Peau, Hop St Louis, INSERM,U532, F-75475 Paris 10, France; Galderma R&D, F-06902 Sophia Antipolis, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Galderma R&D SNC	Mauviel, A (corresponding author), Univ Paris 07, Inst Rech Peau, Hop St Louis, INSERM,U532, Pavillon Bazin,Ave Claude Vellefaux, F-75475 Paris 10, France.		MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554; Mauviel, Alain/0000-0002-0438-2793				Allenby G, 1995, Hum Exp Toxicol, V14, P226; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Borger DR, 2000, VIROLOGY, V270, P397, DOI 10.1006/viro.2000.0282; Cao ZH, 2003, BLOOD, V101, P498, DOI 10.1182/blood-2002-05-1549; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; CHIPUK JE, 2001, J BIOL CHEM, V13, P13; Datto M, 2000, CYTOKINE GROWTH F R, V11, P37, DOI 10.1016/S1359-6101(99)00027-1; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Defacque H, 1997, LEUKEMIA, V11, P221, DOI 10.1038/sj.leu.2400568; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fink SP, 2003, ONCOGENE, V22, P1317, DOI 10.1038/sj.onc.1206128; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Jetten AM, 2001, PROG NUCLEIC ACID RE, V69, P205, DOI 10.1016/S0079-6603(01)69048-2; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; La P, 2003, ONCOGENE, V22, P198, DOI 10.1038/sj.onc.1206100; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda T, 2001, J BIOL CHEM, V276, P42908, DOI 10.1074/jbc.M105316200; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nunes I, 1996, CANCER RES, V56, P495; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; Reiss M, 1999, MICROBES INFECT, V1, P1327, DOI 10.1016/S1286-4579(99)00251-8; ROBERTS AB, 1992, CANCER SURV, V14, P205; Rodeck U, 1999, CANCER RES, V59, P547; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Toma S, 1998, INT J CANCER, V78, P86, DOI 10.1002/(SICI)1097-0215(19980925)78:1<86::AID-IJC14>3.0.CO;2-3; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317	42	62	68	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8212	8220		10.1038/sj.onc.1206913	http://dx.doi.org/10.1038/sj.onc.1206913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603262				2022-12-28	WOS:000186403400016
J	Uematsu, K; He, BA; You, L; Xu, ZD; McCormick, F; Jablons, DM				Uematsu, K; He, BA; You, L; Xu, ZD; McCormick, F; Jablons, DM			Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression	ONCOGENE			English	Article						Dishevelled (Dvl); Wnt signaling; non small cell lung cancer; siRNA	BETA-CATENIN; SIGNALING PATHWAY; P53; CARCINOMAS; EXPRESSION; MUTATIONS; PROTEINS; SIAH-1; SUBSET	Non small cell lung cancer (NSCLC) is the leading cause of cancer deaths in the United States and worldwide. Unfortunately, standard therapies remain inadequate. An increased understanding of the molecular biology of lung cancer biology is required to develop more effective new therapies. In this report, we show that the Wnt pathway is activated through Dishevelled (Dvl) overexpression in NSCLC. Analysis of freshly resected tumors and lung cancer cell lines demonstrate that Dvl-3, a critical mediator of Wnt signaling, is overexpressed. Specifically, Dvl-3 was overexpressed significantly in 75% of fresh NSCLC microdissected samples compared to control paired matched normal lung samples. To evaluate the biological significance of Wnt signaling and, in particular, Dvl function in lung cancer, we transfected siRNA ( designed to inhibit selectively human Dvl-1, - 2, and - 3), to the NSCLC cell line H1703, which is known to have beta-catenin-mediated Tcf-dependent transcriptional activity. Here, we demonstrate that Dvl-specific siRNA treatment in H1703 decreases significantly Dvl and beta-catenin expression, resulting in reduction of Tcf-dependent transcriptional activity, and, importantly, growth inhibition. Taken together, these data support the novel hypothesis that Dvl overexpression is critical to Wnt signaling activation and cell growth in NSCLC.	Univ Calif San Francisco, UCSF Canc Ctr, Thorac Oncol Lab, San Francisco, CA 94115 USA; Nippon Med Coll, Dept Internal Med 4, Tokyo 1138602, Japan	University of California System; University of California San Francisco; UCSF Medical Center; Nippon Medical School	Jablons, DM (corresponding author), Univ Calif San Francisco, UCSF Canc Ctr, Thorac Oncol Lab, Campus Box 1674,1600 Divisadero St,Suite 322C, San Francisco, CA 94115 USA.							Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; Brognard J, 2002, CELL DEATH DIFFER, V9, P893, DOI 10.1038/sj.cdd.4401054; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; Hommura F, 2002, CANCER-AM CANCER SOC, V94, P752, DOI 10.1002/cncr.10213; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; MINNA JD, 1998, HARRISONS PRINCIPLES, V14, P522; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Polakis P, 2000, GENE DEV, V14, P1837; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; You Liang, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P609	18	267	279	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7218	7221		10.1038/sj.onc.1206817	http://dx.doi.org/10.1038/sj.onc.1206817			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562050				2022-12-28	WOS:000185955000013
J	Azzam, EI; de Toledo, SM; Little, JB				Azzam, EI; de Toledo, SM; Little, JB			Oxidative metabolism, gap junctions and the ionizing radiation-induced bystander effect	ONCOGENE			English	Article						bystander response; ionizing radiation; alpha-particles; gap-junction intercellular communication; oxidative stress	SISTER-CHROMATID EXCHANGES; FIBROBLAST-GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; TUMOR-NECROSIS-FACTOR; TISSUE-CULTURE MODEL; VERY-LOW FLUENCES; ALPHA-PARTICLES; INTERCELLULAR COMMUNICATION; SIGNAL-TRANSDUCTION; MAMMALIAN-CELLS	Evidence accumulated over the past two decades has indicated that exposure of cell populations to ionizing radiation results in significant biological effects occurring in both the irradiated and nonirradiated cells in the population. This phenomenon, termed the 'bystander response', has been shown to occur both in vitro and in vivo and has been postulated to impact both the estimation of risks of exposure to low doses/low fluences of ionizing radiation and radiotherapy. Several mechanisms involving secreted soluble factors, oxidative metabolism and gap-junction intercellular communication have been proposed to regulate the radiation-induced bystander effect. Our current knowledge of the biochemical and molecular events involved in the latter two processes is reviewed in this article.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07103 USA; Harvard Univ, Sch Med, Radiobiol Lab, Boston, MA USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard Medical School	Azzam, EI (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, 185 S Orange Ave, Newark, NJ 07103 USA.				NATIONAL CANCER INSTITUTE [R01CA092262] Funding Source: NIH RePORTER; NCI NIH HHS [1R01-CA92262-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; AZZAM EI, 2003, IN PRESS CANC RES; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; BEDFORD JS, 1974, BRIT J RADIOL, V47, P687, DOI 10.1259/0007-1285-47-562-687; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Bruzzone R, 1996, BIOESSAYS, V18, P709, DOI 10.1002/bies.950180906; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; Chipman JK, 2003, TOXICOL SCI, V71, P146, DOI 10.1093/toxsci/71.2.146; CHUAQUI CA, 1987, RADIAT PHYS CHEM, V30, P365; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; D'Angio CT, 2000, MOL GENET METAB, V71, P371, DOI 10.1006/mgme.2000.3074; De Maio A, 2002, J CELL PHYSIOL, V191, P269, DOI 10.1002/jcp.10108; DOBLE BW, 1995, MOL CELL BIOCHEM, V143, P81, DOI 10.1007/BF00925930; Dowling-Warriner CV, 2000, NEUROSCIENCE, V95, P859; Echetebu CO, 1999, MOL HUM REPROD, V5, P757, DOI 10.1093/molehr/5.8.757; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; EMERIT I, 1995, FREE RADICAL BIO MED, V18, P985, DOI 10.1016/0891-5849(94)00220-E; Feinendegen LE, 2002, HUM EXP TOXICOL, V21, P85, DOI 10.1191/0960327102ht216oa; Fernandez-Cobo M, 1999, CYTOKINE, V11, P216, DOI 10.1006/cyto.1998.0422; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Gabbita SP, 2000, ARCH BIOCHEM BIOPHYS, V376, P1, DOI 10.1006/abbi.1999.1685; Goldberg GS, 1999, NAT CELL BIOL, V1, P457, DOI 10.1038/15693; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; HOLLOWELL JG, 1968, P SOC EXP BIOL MED, V129, P240; Hosoi Y, 2001, INT J CANCER, V96, P270, DOI 10.1002/ijc.1030; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Huo LH, 2001, RADIAT RES, V156, P521, DOI 10.1667/0033-7587(2001)156[0521:HMIIBC]2.0.CO;2; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Iyer R, 2000, CANCER RES, V60, P1290; John SA, 1999, J BIOL CHEM, V274, P236, DOI 10.1074/jbc.274.1.236; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kasper M, 1996, HISTOCHEM CELL BIOL, V106, P419; Khan MA, 1998, INT J RADIAT ONCOL, V40, P467, DOI 10.1016/S0360-3016(97)00736-0; Kojima T, 1997, CELL STRUCT FUNCT, V22, P347, DOI 10.1247/csf.22.347; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lehnert BE, 1997, CANCER RES, V57, P2164; Liu K, 1997, RADIAT RES, V147, P437, DOI 10.2307/3579500; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; Lorimore SA, 2001, ONCOGENE, V20, P7085, DOI 10.1038/sj.onc.1204903; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Lyng FM, 2001, BIOCHEM SOC T, V29, P350; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; Mothersill C, 2000, BRIT J CANCER, V82, P1740; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Ohba K, 1998, GUT, V43, P575, DOI 10.1136/gut.43.4.575; Paulson AF, 2000, J CELL SCI, V113, P3037; PETKAU A, 1978, PHOTOCHEM PHOTOBIOL, V28, P765, DOI 10.1111/j.1751-1097.1978.tb07015.x; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; PRICE BD, 1992, CANCER RES, V52, P3814; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; RUBANYI GM, 1991, BIOCHEM BIOPH RES CO, V181, P1392, DOI 10.1016/0006-291X(91)92093-Y; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Schulze-Osthoff Klaus, 1997, P239; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; SHERMAN MP, 1993, BIOCHEM BIOPH RES CO, V191, P1301, DOI 10.1006/bbrc.1993.1359; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Suchyna TM, 1999, BIOPHYS J, V77, P2968, DOI 10.1016/S0006-3495(99)77129-8; Tonon R, 2002, BIORHEOLOGY, V39, P153; Trosko JE, 1997, STEM CELLS, V15, P59; UCHIDA A, 1989, IMMUNOPHARM IMMUNOT, V11, P507, DOI 10.3109/08923978909005381; Vance MM, 1999, RADIAT RES, V152, P544, DOI 10.2307/3580152; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Weill D, 1996, J INTERF CYTOK RES, V16, P395, DOI 10.1089/jir.1996.16.395; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Wink DA, 1996, CURR TOP CELL REGUL, V34, P159, DOI 10.1016/S0070-2137(96)80006-9; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	90	240	255	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7050	7057		10.1038/sj.onc.1206961	http://dx.doi.org/10.1038/sj.onc.1206961			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557810				2022-12-28	WOS:000185903900010
J	Dubrova, YE				Dubrova, YE			Radiation-induced transgenerational instability	ONCOGENE			English	Article						instability; mutation; radiation; germline; mouse; cancer	INDUCED GENOMIC INSTABILITY; INDUCED CHROMOSOMAL INSTABILITY; PATERNAL X-IRRADIATION; LUNG-TUMOR INDUCTION; F-1 MICE BORN; IONIZING-RADIATION; 2 GENERATIONS; GERM-LINE; MALE-RATS; MINISATELLITE MUTATIONS	To date, the analysis of mutation induction has provided an irrefutable evidence for an elevated germline mutation rate in the parents directly exposed to ionizing radiation and a number of chemical mutagens. However, the results of numerous publications suggest that radiation may also have an indirect effect on genome stability, which is transmitted through the germ line of irradiated parents to their offspring. This review describes the phenomenon of transgenerational instability and focuses on the data showing increased cancer incidence and elevated mutation rates in the germ line and somatic tissues of the offspring of irradiated parents. The possible mechanisms of transgenerational instability are also discussed.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Leicester	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020	Dubrova, Yuri/0000-0001-5281-7539				AUROUX MR, 1988, J ANDROL, V9, P153; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber R, 2000, MUTAT RES-FUND MOL M, V457, P79, DOI 10.1016/S0027-5107(00)00130-5; Baulch JE, 2001, MUTAGENESIS, V16, P17, DOI 10.1093/mutage/16.1.17; Bois P, 1998, GENOMICS, V49, P122, DOI 10.1006/geno.1998.5228; BRANDRIFF B, 1981, SCIENCE, V211, P1431, DOI 10.1126/science.7466400; Burruel VR, 1997, MUTAT RES-FUND MOL M, V381, P59, DOI 10.1016/S0027-5107(97)00148-6; Carls N, 1999, CARCINOGENESIS, V20, P2351, DOI 10.1093/carcin/20.12.2351; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; Cattanach BM, 1998, MUTAT RES-FUND MOL M, V403, P1, DOI 10.1016/S0027-5107(97)00322-9; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Daher A, 1998, CARCINOGENESIS, V19, P1553, DOI 10.1093/carcin/19.9.1553; Dickinson HO, 2002, INT J CANCER, V99, P437, DOI 10.1002/ijc.10385; Dubrova YE, 2000, MUTAT RES-FUND MOL M, V453, P17, DOI 10.1016/S0027-5107(00)00068-3; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Dubrova YE, 2002, MUTAT RES-FUND MOL M, V499, P143, DOI 10.1016/S0027-5107(01)00284-6; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FOMENKO LA, 2001, BIOL BULL, V28, P419; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GENEROSO WM, 1979, P NATL ACAD SCI USA, V76, P435, DOI 10.1073/pnas.76.1.435; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; HALES BF, 1992, TERATOLOGY, V45, P671, DOI 10.1002/tera.1420450612; Harrouk W, 2000, MUTAT RES-DNA REPAIR, V461, P229, DOI 10.1016/S0921-8777(00)00053-7; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Hoyes KP, 2001, RADIAT RES, V156, P488, DOI 10.1667/0033-7587(2001)156[0488:TEOPPC]2.0.CO;2; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; Kropacova K, 2002, J RADIAT RES, V43, P125, DOI 10.1269/jrr.43.125; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; Luke GA, 1997, MUTAGENESIS, V12, P147, DOI 10.1093/mutage/12.3.147; LUNING KG, 1976, MUTAT RES, V34, P539, DOI 10.1016/0027-5107(76)90229-3; LYON MF, 1986, GENETIC TOXICOLOGY B, P449; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Nakanishi M, 2001, INT J RADIAT BIOL, V77, P687, DOI 10.1080/095530000110047537; NAPALKOV NP, 1989, PERINATAL MULTIGENRA; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; NOMURA T, 1983, MUTAT RES, V121, P59, DOI 10.1016/0165-7992(83)90087-8; Pearce MS, 2002, J R STAT SOC A STAT, V165, P523; Pils S, 1999, MUTAT RES-FUND MOL M, V429, P85, DOI 10.1016/S0027-5107(99)00101-3; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Rakyan VK, 2001, BIOCHEM J, V356, P1, DOI 10.1042/0264-6021:3560001; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; RODERICK TH, 1963, RADIAT RES, V20, P631, DOI 10.2307/3571354; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Tawn EJ, 2000, MUTAT RES-GEN TOX EN, V465, P45, DOI 10.1016/S1383-5718(99)00210-7; TURUSOV VS, 1990, CANCER LETT, V55, P227, DOI 10.1016/0304-3835(90)90123-F; Ullrich RL, 1999, RADIAT RES, V152, P170, DOI 10.2307/3580090; Vance MM, 2002, INT J RADIAT BIOL, V78, P513, DOI [10.1080/095530002317577330, 10.1080/09553000110112444]; Vilarino-Guell C, 2003, MUTAT RES-FUND MOL M, V526, P63, DOI 10.1016/S0027-5107(03)00016-2; VOROBTSOVA IE, 1993, MUTAT RES, V287, P207, DOI 10.1016/0027-5107(93)90013-6; Vorobtsova IE, 2000, MUTAGENESIS, V15, P33, DOI 10.1093/mutage/15.1.33; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Wiley LM, 1997, RADIAT RES, V148, P145, DOI 10.2307/3579571; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yu YJ, 2001, CANCER RES, V61, P1820; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429	70	123	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7087	7093		10.1038/sj.onc.1206993	http://dx.doi.org/10.1038/sj.onc.1206993			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557814				2022-12-28	WOS:000185903900014
J	Kumari, A; Schultz, N; Helleday, T				Kumari, A; Schultz, N; Helleday, T			p53 protects from replication-associated DNA double-strand breaks in mammalian cells	ONCOGENE			English	Article						RAD51; p53; mouse embryonic fibroblasts; stalled DNA replication forks; DNA double-strand breaks; etoposide; hydroxyurea; thymidine	WILD-TYPE P53; INTRACHROMOSOMAL HOMOLOGOUS RECOMBINATION; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE POOLS; HOLLIDAY JUNCTIONS; MUTANT P53; SYNAPTONEMAL COMPLEXES; EMBRYONIC LETHALITY; HUMAN RAD51; C-ABL; DAMAGE	Genetic instability caused by mutations in the p53 gene is generally thought to be due to a loss of the DNA damage response that controls checkpoint functions and apoptosis. Cells with mutant p53 exhibit high levels of homologous recombination (HR). This could be an indirect consequence of the loss of DNA damage response or p53 could have a direct role in HR. Here, we report that p53-/- mouse embryonic fibroblasts (MEFs) exhibit higher levels of the RAD51 protein and increased level of spontaneous RAD51 foci Agents that stall replication forks, for example, hydroxyurea (HU), potently induce HR repair and RAD51 foci. To test if the increase in RAD51 foci in p53-/- MEFs was due to an increased level of damage during replication, we measured the formation of DNA double-strand breaks (DSBs) in p53+/+ and p53-/- MEFs following treatments with HU. We found that HU induced DSBs only in p53-/- MEFs, indicating that p53 is involved in a pathway to protect stalled replication forks from being collapsed into a substrate for HR. Also, p53 is upregulated in response to agents that inhibit DNA replication, which supports our hypothesis. Finally, we observed that the DSBs produced in p53-/- MEFs did not result in a permanent arrest of replication and that they were repaired. Altogether, we suggest that the effect of p53 on HR and RAD51 levels and foci can be explained by the idea that p53 suppresses formation of recombinogenic lesions.	Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England; Stockholm Univ, Arrhenius Lab, Dept Genet & Cellular Toxicol, S-10691 Stockholm, Sweden	University of Sheffield; Stockholm University	Helleday, T (corresponding author), Univ Sheffield, Sch Med, Inst Canc Studies, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	t.helleday@sheffield.ac.uk	Helleday, Thomas/D-5224-2013; Schultz, Niklas/AFQ-8244-2022	Helleday, Thomas/0000-0002-7384-092X				Arnaudeau C, 2001, J MOL BIOL, V307, P1235, DOI 10.1006/jmbi.2001.4564; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BIANCHI V, 1986, J BIOL CHEM, V261, P6037; BJURSELL G, 1973, J BIOL CHEM, V248, P3904; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; Chehab NH, 2000, GENE DEV, V14, P278; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Flygare J, 1998, FEBS LETT, V427, P247, DOI 10.1016/S0014-5793(98)00433-5; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; Janz C, 2002, ONCOGENE, V21, P5929, DOI 10.1038/sj.onc.1205757; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lundin C, 2003, J MOL BIOL, V328, P521, DOI 10.1016/S0022-2836(03)00313-9; Lundin C, 2002, MOL CELL BIOL, V22, P5869, DOI 10.1128/MCB.22.16.5869-5878.2002; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Raderschall E, 2002, J CELL SCI, V115, P153; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2002, ONCOGENE, V21, P488, DOI 10.1038/sj.onc.1205040; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Shieh SY, 2000, GENE DEV, V14, P289; Shu ZG, 1999, MOL CELL BIOL, V19, P8686; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Subramanian D, 2002, NUCLEIC ACIDS RES, V30, P2427, DOI 10.1093/nar/30.11.2427; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Willers H, 2000, INT J RADIAT BIOL, V76, P1055; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Yang Q, 2002, J BIOL CHEM, V277, P31980, DOI 10.1074/jbc.M204111200; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang H, 1999, CANCER RES, V59, P3021; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	46	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2324	2329		10.1038/sj.onc.1207379	http://dx.doi.org/10.1038/sj.onc.1207379			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14743204				2022-12-28	WOS:000220427700006
J	Pucci, S; Bonanno, E; Pichiorri, F; Angeloni, C; Spagnoli, LG				Pucci, S; Bonanno, E; Pichiorri, F; Angeloni, C; Spagnoli, LG			Modulation of different clusterin isoforms in human colon tumorigenesis	ONCOGENE			English	Article						clusterin/ApoJ; colon carcinoma; progression marker; tumor progression; clusterin isoforms	PROGRAMMED CELL-DEATH; EXPRESSION; PROTEIN; GENE; APOPTOSIS; PROSTATE; BREAST; RAT; OVEREXPRESSION; CARCINOMA	Clusterin is a ubiquitous secretory heterodimeric disulfide-linked glycoprotein, which is implicated in several physiological processes, including immune regulation, cell adhesion and morphological transformation, lipid transportation, tissue remodelling, membrane recycling and cell-cell interactions. A large number of studies have focused their interest on clusterin gene products as mediators of cell cycle progression and cell death induction, although data on the different isoforms and their role in the different cell processes are still obscure. Recently, an increased clusterin expression in breast cancer has been reported. In order to elucidate the role of clusterin in tumor progression and whether one of its isoforms is preferentially expressed in tumorigenesis, we examined its presence throughout the different steps of human colon carcinoma, one of the best-characterized models of human tumor progression. The immunohistochemical observation of 30 bioptic and surgical colon specimens demonstrated a cell compartment clusterin translocation from the nucleus to the cytoplasm directly related to tumor progression. In fact, a nuclear localization found in healthy colonic mucosa is consistent with the involvement of the proapoptotic nuclear form in the regulation of cell cycle progression and in cell death induction. The progression towards high-grade and metastatic carcinoma leads to cytoplasmic clusterin distribution. Protein extracts from freshly isolated cells of the same patients confirm in high-grade carcinomas with metastatic nodes the complete loss of the proapoptotic nuclear form and a cytoplasmic overexpression of the highly glycosylated form. Data obtained from in vitro experiments confirm that this form is released in the extracellular space and corresponded to the fully glycosylated one. These data suggest that the controversial data on clusterin function in tumors may be related to the pattern shift of its isoform production. As the secreted form of clusterin is correlated to cell matrix formation, cell membrane remodeling and cell-cell adhesion, the overexpression of this form in highly aggressive tumors and metastatic nodes could be a potential new prognostic and predictive marker for colon carcinoma aggressiveness.	Univ Roma Tor Vergata, Dept Biopathol, I-00133 Rome, Italy	University of Rome Tor Vergata	Pucci, S (corresponding author), Univ Roma Tor Vergata, Dept Biopathol, Via Montpellier 1, I-00133 Rome, Italy.	Sabina.Pucci@uniroma2.it; spagnoli@uniroma2.it		Spagnoli, Luigi Giusto/0000-0002-0684-5501; bonanno, elena/0000-0002-0222-0141; Pucci, Sabina/0000-0002-2418-6482				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARONOW BJ, 1993, P NATL ACAD SCI USA, V90, P725, DOI 10.1073/pnas.90.2.725; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; Bettuzzi S, 2002, ONCOGENE, V21, P4328, DOI 10.1038/sj.onc.1205594; BURKEY BF, 1991, J LIPID RES, V32, P1039; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fratelli M, 1996, BBA-MOL CELL RES, V1311, P71, DOI 10.1016/0167-4889(95)00192-1; FRENCH LE, 1992, J CLIN INVEST, V90, P1919, DOI 10.1172/JCI116069; Ho SM, 1998, AM J PATHOL, V153, P131, DOI 10.1016/S0002-9440(10)65553-8; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lakins J, 1998, J BIOL CHEM, V273, P27887, DOI 10.1074/jbc.273.43.27887; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Miyake H, 2001, CLIN CANCER RES, V7, P4245; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; O'Sullivan J, 2003, CELL DEATH DIFFER, V10, P914, DOI 10.1038/sj.cdd.4401254; Pucci S, 2001, ONCOGENE, V20, P739, DOI 10.1038/sj.onc.1204148; Reddy KB, 1996, BIOCHEMISTRY-US, V35, P309, DOI 10.1021/bi951880a; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Rigas B, 2001, CANCER RES, V61, P8381; WONG P, 1993, J BIOL CHEM, V268, P5021; Yang CR, 1999, NUCLEIC ACIDS RES, V27, P2165, DOI 10.1093/nar/27.10.2165; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Zellweger T, 2001, NEOPLASIA, V3, P360, DOI 10.1038/sj.neo.7900174; Zhou W, 2002, LIFE SCI, V72, P11, DOI 10.1016/S0024-3205(02)02183-5	25	184	196	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2004	23	13					2298	2304		10.1038/sj.onc.1207404	http://dx.doi.org/10.1038/sj.onc.1207404			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806IN	14755245	Green Published			2022-12-28	WOS:000220427700003
J	Sheahan, S; Bellamy, COC; Treanor, L; Harrison, DJ; Prost, S				Sheahan, S; Bellamy, COC; Treanor, L; Harrison, DJ; Prost, S			Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes	ONCOGENE			English	Article						polyploidy; proliferation; liver; carcinogenesis; regeneration	KINASE INHIBITOR P21; CELL-CYCLE; INDUCED APOPTOSIS; GENE-EXPRESSION; INDUCTION; GROWTH; POLYPLOIDY; PATHWAY; ROLES; MICE	Using Cre-Lox technology to inducibly delete Rb from wild-type, p21- and/or p53-deficient primary hepatocytes, we investigated the role of p53, p21 and pRb in the regulation of liver cell proliferation, polyploidization and death. These cellular decisions are critical to maintaining liver cell replacement in disease, and in determining the likelihood of carcinogenesis in chronic liver injury. Clearly, the present study shows a complex interplay between p53, p21 and pRb, which regulates the likelihood of hepatocytes stimulated from quiescence, to proliferate, undergo polyploidy or die. It reveals that these proteins act both in concert and independently, demonstrating that a small set of key cellular players is common to diverse cell decisions of fundamental importance to disease.	Univ Edinburgh, Sch Mol & Clin Med, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Prost, S (corresponding author), Univ Edinburgh, Sch Mol & Clin Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	s.prost@ed.ac.uk		harrison, david/0000-0001-9041-9988; prost, sandrine/0000-0002-0140-7115				Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; Bellamy COC, 1997, FASEB J, V11, P591, DOI 10.1096/fasebj.11.7.9212083; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DOTTO GP, 2000, BIOCHIM BIOPHYS ACTA, V1471, P43; Fotedar R, 1999, ONCOGENE, V18, P3652, DOI 10.1038/sj.onc.1202693; Goke R, 2001, DIGESTION, V64, P75, DOI 10.1159/000048843; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Javelaud D, 2002, J BIOL CHEM, V277, P37949, DOI 10.1074/jbc.M204497200; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; NURSE P, 1991, NATURE, V354, P356, DOI 10.1038/354356a0; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Prost S, 1998, J BIOL CHEM, V273, P33327, DOI 10.1074/jbc.273.50.33327; Prost S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.16.e80; PURDIE CA, 1994, ONCOGENE, V9, P603; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Silver DP, 2001, MOL CELL, V8, P233, DOI 10.1016/S1097-2765(01)00295-7; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2000, CANCER INVEST, V18, P148, DOI 10.3109/07357900009038246; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tsai KY, 2002, CURR BIOL, V12, P159, DOI 10.1016/S0960-9822(01)00659-5; Tsao YP, 1999, J VIROL, V73, P4983, DOI 10.1128/JVI.73.6.4983-4990.1999; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vooijs M, 2002, CANCER RES, V62, P1862; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	56	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1489	1497		10.1038/sj.onc.1207280	http://dx.doi.org/10.1038/sj.onc.1207280			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647424				2022-12-28	WOS:000189219500001
J	Gu, J; Zhang, LD; Swisher, SG; Liu, JS; Roth, JA; Fang, BL				Gu, J; Zhang, LD; Swisher, SG; Liu, JS; Roth, JA; Fang, BL			Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis	ONCOGENE			English	Article						lung cancer; real-time PCR; p53; apoptosis; siRNA	P53-DEPENDENT APOPTOSIS; P53-INDUCED APOPTOSIS; BINDING PROTEIN; BCL-2 FAMILY; P53 PROTEIN; BAX; TRANSCRIPTION; SEQUENCE; DEATH; PUMA	The p53 gene is the most frequently mutated gene in human cancers. Loss of functional p53 leads to impaired responses of cancer cells to apoptosis induction and to poor prognosis in patients with certain types of cancer. Cancer gene therapies using ectopic expression of wildtype p53 to force cancer cells through the apoptotic pathway have been tested extensively preclinically and clinically, and genes in various cell lines have been reported to be regulated upon ectopic p53 overexpression. However, the effect of p53 on many other p53-dependent and apoptosis-related genes remains unclear, as does the mechanism of p53-induced apoptosis in human cancers. In this study, we used real-time reverse transcription polymerase chain reaction to evaluate the changes in expression of various p53-dependent and apoptosis-related genes in five human non-small-cell lung cancer cell lines with varying p53 statuses after adenoviral p53 treatment. We found that Ad/p53 induced the expression of the proapoptotic genes PUMA, Bak, Bax, and Fas in a cell type- and time-dependent manner. Among these genes, PUMA was upregulated the most dramatically and broadly. However, when a specific siRNA construct against PUMA was employed, we observed no attenuation of apoptosis in H1299 cells. Our data suggest that Ad-p53 induces the expression of a variety of proapoptotic genes and that lack of induction in one of these genes does not block Ad/p53-mediated cell killing in human lung cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fang, BL (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bfang@mdanderson.org	Gu, Jian/Q-4780-2018	Gu, Jian/0000-0003-3499-0973	NATIONAL CANCER INSTITUTE [R01CA092487, R01CA098582, P01CA078778] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 098582-01A1, R01 CA 092487-01A1, 2P50-CA70970-04, P01 CA78778-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; EL DW, 1993, CELL, V75, P817; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 2002, TRENDS MOL MED, V8, pS38, DOI 10.1016/S1471-4914(02)02309-2; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MIYASHITA T, 1995, CELL, V80, P293; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemunaitis J, 2000, J CLIN ONCOL, V18, P609, DOI 10.1200/JCO.2000.18.3.609; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; QUINLAN DC, 1992, CANCER RES, V52, P4828; Reinke V, 1997, ONCOGENE, V15, P1527, DOI 10.1038/sj.onc.1201316; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Xiang H, 1998, J NEUROSCI, V18, P1363; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; ZHANG WW, 1993, BIOTECHNIQUES, V15, P868; Zhao RB, 2000, GENE DEV, V14, P981	39	17	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1300	1307		10.1038/sj.onc.1207239	http://dx.doi.org/10.1038/sj.onc.1207239			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14676844				2022-12-28	WOS:000188892200015
J	Wang, SH; Mezosi, E; Wolf, JM; Cao, ZY; Utsugi, S; Gauger, PG; Doherty, GM; Baker, JR				Wang, SH; Mezosi, E; Wolf, JM; Cao, ZY; Utsugi, S; Gauger, PG; Doherty, GM; Baker, JR			IFN gamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression	ONCOGENE			English	Article						Bak; thyroid cancer; apoptosis; IFN gamma; TRAIL	FAS-MEDIATED APOPTOSIS; INTERFERON-GAMMA; FOLLICULAR CELLS; CYTOCHROME-C; BCL-2 FAMILY; CANCER-CELLS; DEATH; LIGAND; PATHWAY; RELEASE	TRAIL preferentially induces apoptosis in tumor cells and virus-infected cells. Unlike other tumor necrosis factor family members, TRAIL does not kill cells from most normal tissues and has thus been proposed as a promising new cancer treatment. Our study demonstrated that IFNgamma combined with TRAIL can trigger apoptosis in vitro in several resistant thyroid tumor cell lines, such as thyroid anaplastic carcinoma cells (ARO cells), while either agent alone exerts only a minimal effect. We further tested this effect on a mouse thyroid tumor model, when in vivo tumor growth was also significantly inhibited by this combination. The mechanism of how IFNgamma sensitized thyroid carcinoma cells to TRAIL-induced apoptosis was investigated by screening global gene alterations in ARO cells treated with IFNgamma. Microarray data revealed that a proapoptotic gene, Bak, is markedly upregulated by IFNgamma, and this was confirmed by RNase protection assay. Western blot analysis also showed a significant increase in Bak at the protein level. Upregulation of Bak and sensitization for apoptosis by IFNgamma was blocked by overexpression of antisense Bak in ARO cells. Furthermore, overexpression of Bak sensitized ARO cell to TRAIL-induced apoptosis without the need for IFNgamma pretreatment. This suggests that Bak is a regulatory molecule involved in IFNgamma-facilitated TRAIL-mediated apoptosis in thyroid cancer cells.	Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Ctr Biol Nanotechnol, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Baker, JR (corresponding author), Univ Michigan, Med Ctr, Dept Med, Ann Arbor, MI 48109 USA.	jbakerjr@umich.edu	Gauger, Paul/W-8176-2019	Doherty, Gerard/0000-0002-1685-9552	NIDDK NIH HHS [P60DK20572, DK58771] Funding Source: Medline; PHS HHS [R01 A137141] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ain KB, 1998, THYROID, V8, P715, DOI 10.1089/thy.1998.8.715; Ain KB, 2000, THYROID, V10, P587, DOI 10.1089/thy.2000.10.587; Beatty GL, 2001, IMMUNOL RES, V24, P201, DOI 10.1385/IR:24:2:201; Bonavida B, 1999, INT J ONCOL, V15, P793; Braga-Basaria M, 2003, J CLIN ENDOCR METAB, V88, P1947, DOI 10.1210/jc.2002-021863; Bretz JD, 1999, J BIOL CHEM, V274, P23627, DOI 10.1074/jbc.274.33.23627; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; Caturegli P, 2000, P NATL ACAD SCI USA, V97, P1719, DOI 10.1073/pnas.020522597; de Metz J, 2000, THYROID, V10, P87, DOI 10.1089/thy.2000.10.87; Egle A, 1996, EUR J IMMUNOL, V26, P3119, DOI 10.1002/eji.1830261244; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fulda S, 2002, ONCOGENE, V21, P2295, DOI 10.1038/sj.onc.1205255; Jelinek DF, 1997, J CLIN INVEST, V99, P447, DOI 10.1172/JCI119179; Kandasamy K, 2003, CANCER RES, V63, P1712; Kayagaki N, 1999, J IMMUNOL, V162, P2639; KILLINGER WA, 1992, ANN THORAC SURG, V53, P472, DOI 10.1016/0003-4975(92)90271-5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2001, B ACAD NAT MED PARIS, V185, P1135, DOI 10.1016/S0001-4079(19)34476-0; Kumar-Sinha C, 2002, J BIOL CHEM, V277, P575, DOI 10.1074/jbc.M107795200; Langaas V, 2001, ANTICANCER RES, V21, P3733; LEE YS, 1988, CANCER RES, V48, P559; Mitsiades N, 2000, CANCER RES, V60, P4122; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Poulaki V, 2002, AM J PATHOL, V161, P643, DOI 10.1016/S0002-9440(10)64220-4; Ruiz-Ruiz C, 2002, BIOCHEM J, V365, P825, DOI 10.1042/BJ20020184; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shin EC, 2001, CANCER IMMUNOL IMMUN, V50, P23, DOI 10.1007/s002620000166; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Voigt W, 2000, CLIN CANCER RES, V6, P2087; Wang SH, 1999, ENDOCRINOLOGY, V140, P1649, DOI 10.1210/en.140.4.1649; Wang SH, 2002, J IMMUNOL, V168, P2470, DOI 10.4049/jimmunol.168.5.2470; Wang SH, 2001, THYROID, V11, P725, DOI 10.1089/10507250152484556; Yano H, 1996, J HEPATOL, V25, P454, DOI 10.1016/S0168-8278(96)80204-2; Yeung SCJ, 2000, CANCER RES, V60, P650	39	31	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					928	935		10.1038/sj.onc.1207213	http://dx.doi.org/10.1038/sj.onc.1207213			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647456				2022-12-28	WOS:000188486600008
J	Mallette, FA; Goumard, S; Gaumont-Leclerc, MF; Moiseeva, O; Ferbeyre, G				Mallette, FA; Goumard, S; Gaumont-Leclerc, MF; Moiseeva, O; Ferbeyre, G			Human fibroblasts require the Rb family of tumor suppressors, but not p53, for PML-induced senescence	ONCOGENE			English	Article						senescence; nuclear bodies; E6; E7; Rb; p53; PML	PAPILLOMAVIRUS TYPE-16 E7; HUMAN-DIPLOID FIBROBLASTS; CELL-CYCLE ARREST; ONCOGENIC RAS; RETINOBLASTOMA PROTEIN; REPLICATIVE SENESCENCE; PREMATURE SENESCENCE; TELOMERASE ACTIVITY; G(1) CONTROL; IMMORTALIZATION	Cellular senescence is a permanent cell cycle arrest that can be triggered by a variety of stresses including short telomeres and activated oncogenes. Promyelocytic leukemia protein (PML) is a central component of the senescence response, and is able to trigger the process when overexpressed in human diploid fibroblasts (HDFs). Senescence induced by PML in HDFs is characterized by a modest increase in p53 levels and activity, the accumulation of hypophosphorylated Rb and a reduced expression of E2F-dependent genes. To dissect the p53 and Rb family requirements for PML-induced senescence, we used the oncoproteins E6 and E7 from human papillomavirus type 16. We found that the coexpression of E6 and E7 inhibited the growth arrest and senescence induced by PML. In addition, these viral oncoproteins blocked the formation of PML bodies and excluded both p53 and Rb from PML bodies. Expression of dominant-negative p53 alone failed to block PML-induced senescence and expression of E6 only delayed the process. On the other hand, expression of E7 was sufficient to block PML-induced senescence, while an E7 mutant unable to bind Rb did not. Together, these data indicate that PML-induced senescence engages the Rb tumor-suppressor pathway predominantly.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	Universite de Montreal	Ferbeyre, G (corresponding author), Univ Montreal, Dept Biochim, E-515,CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	g.ferbeyre@umontreal.ca	Moiseeva, Olga/Q-4848-2016; Ferbeyre, Gerardo/A-1569-2010; Mallette, Frédérick A./J-6646-2019	Mallette, Frédérick A./0000-0001-7932-0338				Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2000, GENE DEV, V14, P2015; Franco EL, 2001, CAN MED ASSOC J, V164, P1017; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P10978, DOI 10.1073/pnas.97.20.10978; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Haq R, 2002, CANCER RES, V62, P5076; Hara E, 1996, MOL CELL BIOL, V16, P859; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Heidebrecht HJ, 2001, LAB INVEST, V81, P1163, DOI 10.1038/labinvest.3780328; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Medcalf ASC, 1996, CANCER RES, V56, P4582; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; Rheinwald JG, 2002, MOL CELL BIOL, V22, P5157, DOI 10.1128/MCB.22.14.5157-5172.2002; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 2001, CURR OPIN CELL BIOL, V13, P748, DOI 10.1016/S0955-0674(00)00278-7; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wells SI, 2000, EMBO J, V19, P5762, DOI 10.1093/emboj/19.21.5762; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	53	77	78	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					91	99		10.1038/sj.onc.1206886	http://dx.doi.org/10.1038/sj.onc.1206886			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712214				2022-12-28	WOS:000187895300010
J	Chelbi-alix, MK; Bobe, P; Benoit, G; Canova, A; Pine, R				Chelbi-alix, MK; Bobe, P; Benoit, G; Canova, A; Pine, R			Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1	ONCOGENE			English	Article						interferon; IRF-1; Stat1; apoptosis; APL	ACUTE PROMYELOCYTIC LEUKEMIA; SIGNALING CROSS-TALK; I-TRANSFORMED-CELLS; TRANS-RETINOIC ACID; PML-RAR-ALPHA; APL CELLS; REGULATORY FACTOR-1; IFN-GAMMA; NB4 CELLS; KAPPA-B	Arsenic trioxide (As2O3) can induce clinical remission in patients with acute promyelocytic leukemia (APL), including those who have relapsed after treatment with all-trans-retinoic acid (RA). In vitro studies with the APL-derived NB4 cell line showed that As2O3 exerts a dose-dependent dual effect, which induces apoptosis at 1 muM, whereas at a lower concentration of 0.1 muM, a partial differentiation of APL is observed. In non-APL cells, interferon (IFN) alpha and 1 muM As2O3 act synergistically to induce apoptosis. In this report, we show that in NB4 cells and in two RA-resistant NB4-derived cell lines, NB4-R1 and NB4-R2, IFNalpha or IFNgamma combined with 0.1 muM As2O3 lead to an increased maturation effect. Moreover, IFNgamma alone is able to differentiate RA-sensitive and -resistant cells with a higher maturation effect on NB4-R2 cells. In contrast, all these cells underwent apoptosis in the presence of the cytokine and a higher concentration of As2O3. IFNgamma boosted As2O3-induced apoptosis in APL cells as tested by TUNEL, Annexin V staining and activation of caspase 3. As2O3 differently altered IFN-induced gene products; it downregulated PML/RARalpha and PML, did not alter PKR and Stat1, and upregulated interferon regulatory family (IRF)-1. Synergism by IFNgamma and arsenic on IRF-1 expression is mediated by a composite element in the IRF-1 promoter that includes an IFNgamma-activation site (GAS) overlapped by a nonconsensus site for nuclear factor kappa B (NFkappaB). Arsenic has no effect on NFkappaB, whereas it enhances the activation of Stat1 by IFNgamma in NB4 cells leading to an increase in IRF-1 expression.	Inst Lwoff, UPR9045, F-94801 Villejuif, France; Hop St Louis, INSERM, U496, F-75010 Paris, France; Publ Hlth Res Inst, Newark, NJ 07103 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Chelbi-alix, MK (corresponding author), Inst Lwoff, UPR9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.			BENOIT, Gerard/0000-0001-9462-6570; Bobe, Pierre/0000-0002-8835-6786				Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Chen GQ, 1997, BLOOD, V89, P3345; Chen Z, 1997, PHARMACOL THERAPEUT, V76, P141, DOI 10.1016/S0163-7258(97)00090-9; DANIEL MT, 1993, BLOOD, V82, P1858; de The H, 2001, ONCOGENE, V20, P7136, DOI 10.1038/sj.onc.1204851; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Foss GS, 1999, J BIOL CHEM, V274, P35196, DOI 10.1074/jbc.274.49.35196; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; Gil J, 2000, APOPTOSIS, V5, P107, DOI 10.1023/A:1009664109241; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KROGER A, 2002, J INTERFERON CYTOKIN, V1, P5; LANOTTE M, 1991, BLOOD, V77, P1080; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; Ohmori Y, 1997, J BIOL CHEM, V272, P14899, DOI 10.1074/jbc.272.23.14899; Pelicano L, 1999, ONCOGENE, V18, P3944, DOI 10.1038/sj.onc.1202802; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; Percario ZA, 1999, CELL GROWTH DIFFER, V10, P263; Pine R, 1997, NUCLEIC ACIDS RES, V25, P4346, DOI 10.1093/nar/25.21.4346; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stadler M, 1995, ONCOGENE, V11, P2565; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TANIGUCHI T, 1997, BIOCHIM BIOPHYS ACTA, V1333, P9; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yoshida H, 1996, CANCER RES, V56, P2945; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978; Zhu Q, 2002, BLOOD, V99, P1014	43	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2003	22	57					9121	9130		10.1038/sj.onc.1207090	http://dx.doi.org/10.1038/sj.onc.1207090			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	752FJ	14668793				2022-12-28	WOS:000187149100002
J	Kucharczak, J; Simmons, MJ; Fan, YJ; Gelinas, C				Kucharczak, J; Simmons, MJ; Fan, YJ; Gelinas, C			To be, or not to be: NF-kappa B is the answer - role of Rel/NF-kappa B in the regulation of apoptosis	ONCOGENE			English	Review						Rel; NF-kappa B; apoptosis; transcription factor; tumor necrosis factor; lymphocyte; neurodegenerative disease; hepatocyte; cancer therapy	NECROSIS-FACTOR-ALPHA; INDUCED CELL-DEATH; CALPAIN-MEDIATED DEGRADATION; RECEPTOR-INDUCED APOPTOSIS; SEVERE LIVER DEGENERATION; BRUTONS TYROSINE KINASE; E1A SENSITIZES CELLS; CHICKEN SPLEEN-CELLS; VIRUS TYPE-1 TAX; BCL-X-L	During their lifetime, cells encounter many life or death situations that challenge their very own existence. Their survival depends on the interplay within a complex yet precisely orchestrated network of proteins. The Rel/NF-kappaB signaling pathway and the transcription factors that it activates have emerged as critical regulators of the apoptotic response. These proteins are best known for the key roles that they play in normal immune and inflammatory responses, but they are also implicated in the control of cell proliferation, differentiation, apoptosis and oncogenesis. In recent years, there has been remarkable progress in understanding the pathways that activate the Rel/NF-kappaB factors and their role in the cell's decision to either flight or surrender to apoptotic challenge. Whereas NF-kappaB is most commonly involved in suppressing apoptosis by transactivating the expression of antiapoptotic genes, it can promote programmed cell death in response to certain death-inducing signals and in certain cell types. This review surveys our current understanding of the role of NF-kappaB in the apoptotic response and focuses on many developments since this topic was last reviewed in Oncogene 4 years ago. These recent findings shed new light on the activity of NF-kappaB as a critical regulator of apoptosis in the immune, hepatic, epidermal and nervous systems, on the mechanisms through which it operates and on its role in tissue development, homoeostasis and cancer.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Grad Program Biochem & Mol Biol, Piscataway, NJ USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu		KUCHARCZAK, Jerome/0000-0001-7722-8490	NATIONAL CANCER INSTITUTE [R29CA054999, R01CA054999, R01CA083937] Funding Source: NIH RePORTER; NCI NIH HHS [CA83937, CA54999] Funding Source: Medline; NIGMS NIH HHS [GM08360] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Anto RJ, 2003, J BIOL CHEM, V278, P25490, DOI 10.1074/jbc.M301790200; Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Bannerman DD, 2002, J CLIN INVEST, V109, P419, DOI 10.1172/JCI14774; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bernard D, 2001, CANCER RES, V61, P2656; Bernard D, 2001, FREE RADICAL BIO MED, V31, P943, DOI 10.1016/S0891-5849(01)00668-2; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bhakar AL, 2002, J NEUROSCI, V22, P8466; BILYEU JD, 2003, UNPUB; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; BURSTEIN E, 2003, IN PRESS CURR OPIN C, V15; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; CAVIN LG, 2003, IN PRESS HEPATOLOGY; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang I, 2003, DIABETES, V52, P1169, DOI 10.2337/diabetes.52.5.1169; Chaudhary PM, 2000, ONCOGENE, V19, P4451, DOI 10.1038/sj.onc.1203812; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen XF, 2003, CANCER RES, V63, P1059; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; CHENG S, 2003, IN PRESS ONCOGENE; Chiarugi A, 2002, MOL BRAIN RES, V109, P179, DOI 10.1016/S0169-328X(02)00558-2; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cogswell PC, 2003, J BIOL CHEM, V278, P2963, DOI 10.1074/jbc.M209995200; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Cusack JC, 2001, CANCER RES, V61, P3535; Cusack JC, 2000, CANCER RES, V60, P2323; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; DSOUZA BN, 2003, UNPUB; Duckett CS, 2002, J CLIN INVEST, V109, P579, DOI 10.1172/JCI200215197; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; Edelstein LC, 2003, MOL CELL BIOL, V23, P2749, DOI 10.1128/MCB.23.8.2749-2761.2003; Esslinger CW, 1997, J IMMUNOL, V158, P5075; FAN Y, 2003, IN PRESS ONCOGENE; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Foehr ED, 2000, J BIOL CHEM, V275, P34021, DOI 10.1074/jbc.C000507200; Foehr ED, 2000, J NEUROSCI, V20, P7556; Franzoso G, 2003, CELL DEATH DIFFER, V10, P13, DOI 10.1038/sj.cdd.4401154; Fujioka S, 2003, ONCOGENE, V22, P1365, DOI 10.1038/sj.onc.1206323; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gerondakis S, 2001, NAT IMMUNOL, V2, P377, DOI 10.1038/87669; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P89; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Goodkin ML, 2003, J VIROL, V77, P7261, DOI 10.1128/JVI.77.13.7261-7280.2003; Green DR, 2003, MOL CELL, V11, P551, DOI 10.1016/S1097-2765(03)00107-2; Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guo Q, 1998, J BIOL CHEM, V273, P12341, DOI 10.1074/jbc.273.20.12341; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hacker H, 2002, CANCER CELL, V2, P431, DOI 10.1016/S1535-6108(02)00213-1; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Hanson JL, 2003, J BIOL CHEM, V278, P34910, DOI 10.1074/jbc.M304189200; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harper N, 2003, J BIOL CHEM, V278, P25534, DOI 10.1074/jbc.M303399200; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; He ZM, 2000, CANCER RES, V60, P1845; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hinata K, 2003, ONCOGENE, V22, P1955, DOI 10.1038/sj.onc.1206198; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hsia CY, 2002, INT IMMUNOL, V14, P905, DOI 10.1093/intimm/dxf055; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Hu WH, 2000, J BIOL CHEM, V275, P10838, DOI 10.1074/jbc.275.15.10838; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; IVANOV VN, 1995, INT IMMUNOL, V7, P1709, DOI 10.1093/intimm/7.11.1709; Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000; Javelaud D, 2002, INT J CANCER, V98, P193, DOI 10.1002/ijc.10192; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; Johnson BW, 1999, J BIOL CHEM, V274, P18552, DOI 10.1074/jbc.274.26.18552; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kasof GM, 2001, ONCOGENE, V20, P7965, DOI 10.1038/sj.onc.1204985; KATO T, 2003, IN PRESS MOL CELL; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Kim DS, 2002, IMMUNITY, V16, P9, DOI 10.1016/S1074-7613(02)00264-9; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Lademann U, 2001, CELL DEATH DIFFER, V8, P265, DOI 10.1038/sj.cdd.4400805; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Lenz HJ, 2003, CANCER TREAT REV, V29, P41, DOI 10.1016/S0305-7372(03)00082-3; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liao CL, 2001, J VIROL, V75, P7828, DOI 10.1128/JVI.75.17.7828-7839.2001; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; Lin BH, 1999, CELL DEATH DIFFER, V6, P570, DOI 10.1038/sj.cdd.4400528; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Lopez M, 2003, J IMMUNOL, V170, P2409, DOI 10.4049/jimmunol.170.5.2409; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malewicz M, 2003, J BIOL CHEM, V278, P32825, DOI 10.1074/jbc.M304000200; Mao XR, 2002, J BIOL CHEM, V277, P44911, DOI 10.1074/jbc.M204292200; Marianneau P, 1997, J VIROL, V71, P3244, DOI 10.1128/JVI.71.4.3244-3249.1997; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin P, 2002, EMBO J, V21, P4049, DOI 10.1093/emboj/cdf407; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matsui K, 1998, J IMMUNOL, V161, P3469; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Medici MA, 2003, J BIOL CHEM, V278, P36059, DOI 10.1074/jbc.M306198200; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Middleton G, 2000, J CELL BIOL, V148, P325, DOI 10.1083/jcb.148.2.325; Mir SS, 2000, BLOOD, V96, P4307; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Mitchell TC, 2002, ANN NY ACAD SCI, V975, P132, DOI 10.1111/j.1749-6632.2002.tb05947.x; Mitchell TC, 2002, ANN NY ACAD SCI, V975, P114, DOI 10.1111/j.1749-6632.2002.tb05946.x; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Moerman AM, 1999, MOL BRAIN RES, V67, P303, DOI 10.1016/S0169-328X(99)00091-1; Morrison RS, 1996, J NEUROSCI, V16, P1337; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; Nakai M, 2000, J NEUROCHEM, V74, P647, DOI 10.1046/j.1471-4159.2000.740647.x; Nakamura Y, 2002, MOL CELL BIOL, V22, P5563, DOI 10.1128/MCB.22.15.5563-5574.2002; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; Ni H, 2001, BRIT J HAEMATOL, V115, P279, DOI 10.1046/j.1365-2141.2001.03102.x; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nitta T, 2003, CELL SIGNAL, V15, P423, DOI 10.1016/S0898-6568(02)00141-9; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Okazaki T, 2003, BIOCHEM BIOPH RES CO, V300, P807, DOI 10.1016/S0006-291X(02)02932-7; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PANTA GR, 2003, UNPUB; PAPA S, 2003, UNPUB; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pizzi M, 2002, J BIOL CHEM, V277, P20717, DOI 10.1074/jbc.M201014200; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; Portis T, 2001, BLOOD, V98, P1200, DOI 10.1182/blood.V98.4.1200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Qin ZH, 1999, J NEUROSCI, V19, P4023; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Ravi R, 1998, CANCER RES, V58, P882; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rayet B, 2003, MOL CELL BIOL, V23, P1520, DOI 10.1128/MCB.23.5.1520-1533.2003; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Reuther JY, 1999, J BIOL CHEM, V274, P20664, DOI 10.1074/jbc.274.29.20664; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Reuther-Madrid JY, 2002, MOL CELL BIOL, V22, P8175, DOI 10.1128/MCB.22.23.8175-8183.2002; Richardson P, 2003, CANCER TREAT REV, V29, P33, DOI 10.1016/S0305-7372(03)00080-X; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rodriguez CI, 2002, J VIROL, V76, P3936, DOI 10.1128/JVI.76.8.3936-3942.2002; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rudolph D, 2000, GENE DEV, V14, P854; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Sabroe I, 2003, J IMMUNOL, V170, P5268, DOI 10.4049/jimmunol.170.10.5268; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Schwarz EM, 1998, J VIROL, V72, P5654, DOI 10.1128/JVI.72.7.5654-5660.1998; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Sheehy AM, 1999, J BIOL CHEM, V274, P8708, DOI 10.1074/jbc.274.13.8708; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Shou Y, 2002, J NEUROCHEM, V81, P842, DOI 10.1046/j.1471-4159.2002.00880.x; Siegmund D, 2001, J BIOL CHEM, V276, P43708, DOI 10.1074/jbc.M106421200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; Taub R, 1998, HEPATOLOGY, V27, P1445, DOI 10.1002/hep.510270538; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Tietze MK, 2000, CANCER GENE THER, V7, P1315, DOI 10.1038/sj.cgt.0241; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Tumang JR, 1998, EUR J IMMUNOL, V28, P4299, DOI 10.1002/(SICI)1521-4141(199812)28:12<4299::AID-IMMU4299>3.0.CO;2-Y; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Verschelde C, 2003, CELL DEATH DIFFER, V10, P1059, DOI 10.1038/sj.cdd.4401265; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Walczak H, 2000, CANCER RES, V60, P3051; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; White DW, 1996, ONCOGENE, V13, P891; WHITE DW, 1995, ONCOGENE, V10, P857; Wilkinson KD, 2003, NATURE, V424, P738, DOI 10.1038/424738a; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu M, 1996, MOL CELL BIOL, V16, P5015; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wu MX, 2003, APOPTOSIS, V8, P11, DOI 10.1023/A:1021688600370; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Yan MH, 2002, CURR BIOL, V12, P409, DOI 10.1016/S0960-9822(02)00687-5; Yang F, 2003, J IMMUNOL, V170, P5630, DOI 10.4049/jimmunol.170.11.5630; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yoo NJ, 2002, BIOCHEM BIOPH RES CO, V299, P652, DOI 10.1016/S0006-291X(02)02714-6; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Yu ZF, 2000, J MOL NEUROSCI, V15, P31, DOI 10.1385/JMN:15:1:31; Zazzeroni F, 2003, NATURE, V424, P742, DOI 10.1038/424742a; ZAZZERONI F, 2003, IN PRESS BLOOD, V102; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zong WX, 1997, ONCOGENE, V15, P971, DOI 10.1038/sj.onc.1201266	329	608	674	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 8	2003	22	56					8961	8982		10.1038/sj.onc.1207230	http://dx.doi.org/10.1038/sj.onc.1207230			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663476				2022-12-28	WOS:000187043600001
J	Paronetto, MP; Venables, JP; Elliott, DJ; Geremia, R; Rossi, P; Sette, C				Paronetto, MP; Venables, JP; Elliott, DJ; Geremia, R; Rossi, P; Sette, C			tr-kit promotes the formation of a multimolecular complex composed by Fyn, PLC gamma 1 and Sam68	ONCOGENE			English	Article						tyrosine kinase; SH3; RNA; adaptor proteins; signal transduction	RNA-BINDING PROTEIN; FAMILY TYROSINE KINASES; C-KIT; SIGNAL-TRANSDUCTION; EGG ACTIVATION; TRUNCATED FORM; SH3 DOMAINS; MOUSE EGGS; SRC; PHOSPHORYLATION	tr-kit is a truncated form of the tyrosine kinase receptor c-kit expressed in the haploid phase of spermatogenesis. Upon microinjection, tr-kit triggers metaphase-to-anaphase transition in mouse eggs by the sequential activation of Fyn and PLCgamma1. Here, we show that tr-kit promotes the interaction of several tyrosine-phosphorylated proteins with the SH3 domain of PLCgamma1. Western blot analysis indicates that one of these proteins is Sam68, an RNA-binding protein that is known to interact with and be phosphorylated by Src-like kinases in mitosis. tr-kit promotes the association of Sam68 with PLCgamma1 and Fyn in a multimolecular complex, as demonstrated by co-immunoprecipitation of the phosphorylated forms of these proteins using antibodies directed to anyone of the partners of the complex. Expression of tr-kit potentiates the interaction of endogenous Sam68 also with the SH3 domain of Fyn. Further more, the subcellular localization of Sam68 is affected by tr-kit through activation of Fyn in live cells. Lastly, we show that interaction with the SH3 domain of Fyn triggers the release of Sam68 from bound RNA. Thus, our data suggest that tr-kit promotes the formation of a multimolecular complex composed of Fyn, PLCgamma1 and Sam68, which allows phosphorylation of PLCgamma1 by Fyn, and may modulate RNA metabolism.	Univ Roma Tor Vergata, Sect Anat, Dipartimento Sanita Pubbl & Biol Cellulare, I-00133 Rome, Italy; Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	University of Rome Tor Vergata; Newcastle University - UK	Sette, C (corresponding author), Univ Roma Tor Vergata, Sect Anat, Dipartimento Sanita Pubbl & Biol Cellulare, Via Montpellier 1, I-00133 Rome, Italy.		Rossi, Pellegrino/AAA-7072-2019; Sette, Claudio/S-4307-2019; Paronetto, Maria Paola/A-9578-2012	Sette, Claudio/0000-0003-2864-8266; Paronetto, Maria Paola/0000-0001-5324-0903; ROSSI, PELLEGRINO/0000-0003-4796-327X; GEREMIA, Raffaele/0000-0001-9056-6603; Elliott, David/0000-0002-6930-0699				Albanesi C, 1996, DEVELOPMENT, V122, P1291; BESMER P, 1993, DEVELOPMENT, P125; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; Lang V, 1999, J IMMUNOL, V162, P7224; Lee MH, 2001, GENE DEV, V15, P2408, DOI 10.1101/gad.915901; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Li JL, 2002, J VIROL, V76, P8374, DOI 10.1128/JVI.76.16.8374-8382.2002; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Matter N, 2002, NATURE, V420, P691, DOI 10.1038/nature01153; Oh B, 2000, DEVELOPMENT, V127, P3795; Oneyama C, 2002, ONCOGENE, V21, P2037, DOI 10.1038/sj.onc.1205271; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Sette C, 1998, J CELL BIOL, V142, P1063, DOI 10.1083/jcb.142.4.1063; Sette C, 1997, DEVELOPMENT, V124, P2267; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; SORRENTINO V, 1991, ONCOGENE, V6, P149; Takaoka A, 1997, CANCER LETT, V115, P257, DOI 10.1016/S0304-3835(97)04746-0; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TOYOTA M, 1994, CANCER RES, V54, P272; Venables JP, 1999, HUM MOL GENET, V8, P959, DOI 10.1093/hmg/8.6.959; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010; Zhang YY, 2003, EMBO J, V22, P1801, DOI 10.1093/emboj/cdg171	33	46	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8707	8715		10.1038/sj.onc.1207016	http://dx.doi.org/10.1038/sj.onc.1207016			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647465	Bronze			2022-12-28	WOS:000186844900008
J	Wischhusen, J; Naumann, U; Ohgaki, H; Rastinejad, F; Weller, M				Wischhusen, J; Naumann, U; Ohgaki, H; Rastinejad, F; Weller, M			CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death	ONCOGENE			English	Article						p53; glioma; CP-31398; conformation; drug engineering	WILD-TYPE P53; IN-VITRO; P53-INDUCED APOPTOSIS; CANCER-CELLS; MUTANT P53; DNA-DAMAGE; GENE; EXPRESSION; DRUG; PROTEIN	CP-31398 is a prototype small molecule that stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53. Here, we report that CP-31398 induces p53 reporter gene activity and p21 expression in all of 11 glioma cell lines harboring wild-type or mutant p53, but not in p53-null LN-308 cells. Upon prolonged exposure to CP-31398, all glioma cell lines undergo caspase-independent and bcl-x(L)-insensitive cell death with EC50 concentrations of 10-36 muM. By comparing p53 wild-type U87MG and p53-null LN-308 cells expressing the temperature-sensitive p53(V135A) mutant, we delineate two pathways of CP-31398-induced cell death: an early, p53-dependent pathway that requires (new p53) protein synthesis and a late, p53-independent pathway characterized by aurintricarboxylic acid -sensitive calcium release and epiphenomenal free radical formation. Post-transcriptional repression of p53 synthesis by an intracellularly transcribed short interfering RNA confirmed the presence of these two pathways of cell death. These observations point out some of the liabilities of CP-31398 as a prototype p53-based therapeutic and de. ne a rationale for further refinement of small molecules that specifically target the p53 pathway, but lack the p53-independent effects.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Int Agcy Res Canc, F-69372 Lyon 08, France; Pfizer Inc, Global Res & Dev, Canc Drug Discovery Grp, Groton, CT 06340 USA	Eberhard Karls University of Tubingen; World Health Organization; International Agency for Research on Cancer (IARC); Pfizer	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany.	michael.weller@uni-tuebingen.de		Weller, Michael/0000-0002-1748-174X				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385-299X(97)00047-0; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; Kaku S, 2001, BIOCHEM BIOPH RES CO, V280, P204, DOI 10.1006/bbrc.2000.4060; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Naumann U, 2001, CANCER RES, V61, P5833; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Schmidt F, 2001, EUR J PHARMACOL, V412, P21, DOI 10.1016/S0014-2999(00)00923-7; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WELLER M, 1992, BRAIN RES, V594, P160, DOI 10.1016/0006-8993(92)91043-E; Weller M, 1998, INT J CANCER, V79, P640; Wick W, 1999, J PHARMACOL EXP THER, V289, P1306; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	34	125	129	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8233	8245		10.1038/sj.onc.1207198	http://dx.doi.org/10.1038/sj.onc.1207198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614447				2022-12-28	WOS:000186541500002
J	Liu, LM; Tommasi, S; Lee, DH; Dammann, R; Pfeifer, GP				Liu, LM; Tommasi, S; Lee, DH; Dammann, R; Pfeifer, GP			Control of microtubule stability by the RASSF1A tumor suppressor	ONCOGENE			English	Article						RASSF1A; mitosis; DNA methylation; microtubules; taxol	FREQUENT EPIGENETIC INACTIVATION; HUMAN-CHROMOSOME 3P21.3; PROMOTER HYPERMETHYLATION; CPG ISLAND; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; BREAST CANCERS; BLADDER-CANCER; MITOTIC BLOCK; K-RAS	The RAS association domain family 1A ( RASSF1A) gene is silenced by DNA methylation in over 50% of all solid tumors of different histological types. However, the biochemical function of the RASSF1A protein is unknown. We show that RASSF1A colocalizes with microtubules in interphase and decorates spindles and centrosomes during mitosis. RASSF1A has a strong cytoprotective activity against the microtubule-destabilizing drug nocodazole, and against cold-treatment in vivo. Conversely, loss of RASSF1 in RASSF1(-/-) mouse embryonic fibroblasts renders the cells more sensitive to nocodazole-induced depolymerization of microtubules. The domain required for both microtubule association and stabilization was mapped to a 169 amino-acid fragment that contains the RAS association domain. Overexpression of RASSF1A induces mitotic arrest at metaphase with aberrant mitotic cells reminiscent of such produced by the microtubule-stabilizing drug paclitaxel (taxol), including monopolar spindles, or complete lack of a mitotic spindle. Altered microtubule stability in cells lacking RASSF1A is likely to affect spindle assembly and chromosome attachment, processes that need to be carefully controlled to protect cells from genomic instability and transformation. In addition, knowledge of the microtubule-targeting function of RASSF1 may aid in the development of new anticancer drugs.	City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Humangenet & Med Biol, D-06097 Halle Saale, Germany	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg	Pfeifer, GP (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.			Tommasi, Stella/0000-0001-6897-4985	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBONDANZO SJ, 1993, METHOD ENZYMOL, V225, P803; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Byun DS, 2001, CANCER RES, V61, P7034; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan MWY, 2003, INT J CANCER, V104, P611, DOI 10.1002/ijc.10971; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1992, J CELL SCI, V102, P401; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2003, CANCER RES, V63, P1888; Kuzmin I, 2002, CANCER RES, V62, P3498; Lee MG, 2001, CANCER RES, V61, P6688; Lerman MI, 2000, CANCER RES, V60, P6116; Li YC, 2000, GENETICS, V156, P995; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Lo KW, 2001, CANCER RES, V61, P3877; Lotti LV, 2002, GENE CHROMOSOME CANC, V35, P193, DOI 10.1002/gcc.10105; Lusher ME, 2002, CANCER RES, V62, P5906; Maruyama R, 2001, CANCER RES, V61, P8659; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Morrissey C, 2001, CANCER RES, V61, P7277; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P422, DOI 10.1016/S0968-0004(96)30038-8; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schagdarsurengin U, 2003, ONCOGENE, V22, P1866, DOI 10.1038/sj.onc.1206338; Segal M, 2001, BIOESSAYS, V23, P307, DOI 10.1002/bies.1044; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Spugnardi M, 2003, CANCER RES, V63, P1639; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Wagner KJ, 2002, ONCOGENE, V21, P7277, DOI 10.1038/sj.onc.1205922; Zhang YJ, 2002, MOL CARCINOGEN, V35, P85, DOI 10.1002/mc.10076; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	53	160	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8125	8136		10.1038/sj.onc.1206984	http://dx.doi.org/10.1038/sj.onc.1206984			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603253				2022-12-28	WOS:000186403400007
J	Hoornaert, I; Marynen, P; Goris, J; Sciot, R; Baens, M				Hoornaert, I; Marynen, P; Goris, J; Sciot, R; Baens, M			MAPK phosphatase DUSP16/MKP-7, a candidate tumor suppressor for chromosome region 12p12-13, reduces BCR-ABL-induced transformation	ONCOGENE			English	Article						tumor suppressor gene; MAPK phosphatase; chromosome 12p12-13; transformation	ACUTE LYMPHOBLASTIC-LEUKEMIA; DUAL-SPECIFICITY PHOSPHATASES; LUNG-CARCINOMA CELLS; SIGNAL-TRANSDUCTION; KINASE PHOSPHATASE; PROSTATE-CANCER; FREQUENT LOSS; GENE FAMILY; JUN KINASE; SHORT ARM	Recurrent chromosome 12p deletions are associated with distinct tumor types and suggest the presence of a tumor suppressor gene (TSG). Previously, we mapped an EST with similarity to a protein tyrosine phosphatase to the minimally deleted region for all these neoplasms. The corresponding gene, DUSP16/MKP-7, was recently shown to code for a mitogen-activated protein kinase phosphatase, suggestive for a function as tumor suppressor. Overexpression of DUSP16 in BCR-ABL-transformed Rat-1. broblasts reduces their transforming capacity in vitro and in vivo via downregulation of BCR-ABL-induced JNK activation. A role for DUSP16 as a regulator of JNK signaling was further demonstrated via overexpression in Ba/F3 cells, which increased their antiapoptosis. However, no inactivating mutations could be detected in leukemia patients hemizygous for DUSP16, and the effect of hemizygosity on DUSP16 expression level could not be assessed due to the variability of DUSP16 transcript levels observed in leukaemia cell lines and in patients. Taken together, the functional data point to a context-dependent role for DUSP16 on cell transformation and apoptosis, reflecting the dual role of JNK, and therefore suggest that DUSP16 might be haploinsufficient for tumor suppression.	Katholieke Univ Leuven VIB, Dept Human Genet, Human Genome Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Mol Cell Biol, Div Biochem, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Dept Pathol, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven; KU Leuven; KU Leuven	Baens, M (corresponding author), Katholieke Univ Leuven VIB, Dept Human Genet, Human Genome Lab, Herestr 49, B-3000 Louvain, Belgium.	Mathijs.Baens@med.kuleuven.ac.be		sciot, raf/0000-0003-2244-5839				Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Baens M, 1999, GENOMICS, V56, P40, DOI 10.1006/geno.1998.5685; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Cools J, 2002, BLOOD, V99, P1776, DOI 10.1182/blood.V99.5.1776; Cortez D, 1997, ONCOGENE, V15, P2333, DOI 10.1038/sj.onc.1201400; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200; Hatta Y, 1997, BRIT J CANCER, V75, P1256, DOI 10.1038/bjc.1997.214; Hetet G, 2000, Hematol J, V1, P42, DOI 10.1038/sj.thj.6200008; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Huang CS, 1999, J BIOL CHEM, V274, P29672, DOI 10.1074/jbc.274.42.29672; Kibel AS, 1998, CANCER RES, V58, P5652; Kibel AS, 2000, J UROLOGY, V164, P192, DOI 10.1016/S0022-5347(05)67493-9; Kibel AS, 1999, GENE CHROMOSOME CANC, V25, P270, DOI 10.1002/(SICI)1098-2264(199907)25:3<270::AID-GCC9>3.3.CO;2-Q; Latil A, 2001, GENE CHROMOSOME CANC, V31, P199; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Montpetit A, 2002, EUR J HUM GENET, V10, P62, DOI 10.1038/sj.ejhg.5200766; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Nesbit MA, 1997, GENOMICS, V42, P284, DOI 10.1006/geno.1997.4737; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Raynaud S, 1996, BLOOD, V87, P2891, DOI 10.1182/blood.V87.7.2891.bloodjournal8772891; Romana SP, 1996, LEUKEMIA, V10, P167; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; Spirin KS, 1996, CANCER RES, V56, P2400; Stegmaier K, 1996, CANCER RES, V56, P1413; Takeuchi S, 1996, CANCER RES, V56, P738; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Wlodarska I, 1996, CYTOGENET CELL GENET, V72, P229, DOI 10.1159/000134197; Xiao L, 2000, CANCER RES, V60, P400	42	42	43	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7728	7736		10.1038/sj.onc.1207089	http://dx.doi.org/10.1038/sj.onc.1207089			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586399				2022-12-28	WOS:000186240200003
J	Boon, K; Edwards, JB; Siu, IM; Olschner, D; Eberhart, CG; Marra, MA; Strausberg, RL; Riggins, GJ				Boon, K; Edwards, JB; Siu, IM; Olschner, D; Eberhart, CG; Marra, MA; Strausberg, RL; Riggins, GJ			Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes	ONCOGENE			English	Article						medulloblastoma; tumor-associated antigens; SAGE; bioinformatics	INDEPENDENT PROGNOSTIC MARKER; CENTRAL-NERVOUS-SYSTEM; PATIENT SURVIVAL; GLIOMA-CELLS; IN-VIVO; EXPRESSION; CANCER; CD24; ANTIGEN	Over 1.4 million transcript tags expressed in 20 different human medulloblastomas were counted using serial analysis of gene expression. Digital gene expression profiles in the medulloblastoma were compared to multiple regions of the normal human brain, revealing 30 transcripts with high expression in multiple tumors and little or no expression in the normal cerebellum and other adult and pediatric brain regions. Using independent medulloblastoma samples and normal tissue, real-time PCR verified eight of nine selected genes as candidate tumor-associated antigens. Differential protein expression for CD24, prolactin and Topo2A was further confirmed by immunohistochemical analysis using medulloblastoma and normal brain sections and a tissue microarray. The genes highly expressed in the medulloblastoma include PRAME, a cancer-testis antigen and potential targets for immunotherapy.	Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; BC Canc Agcy, Sequencing Ctr, Vancouver, BC, Canada; NCI, Off Canc Genom, Bethesda, MD 20892 USA	Duke University; Johns Hopkins University; British Columbia Cancer Agency; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Center for Cancer Genomics (CCG)	Riggins, GJ (corresponding author), Mason Lord Ctr Tower,5th Floor,Bhns Hopkins Beyvi, Baltimore, MD 21224 USA.		Marra, Marco A/B-5987-2008	Marra, Marco A/0000-0001-7146-7175	NCI NIH HHS [U01 CA88128] Funding Source: Medline; PHS HHS [S98-146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anadon R, 2001, BRAIN RES, V894, P255, DOI 10.1016/S0006-8993(01)02024-8; Boon K, 2002, P NATL ACAD SCI USA, V99, P11287, DOI 10.1073/pnas.152324199; Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fogel M, 1999, CANCER LETT, V143, P87, DOI 10.1016/S0304-3835(99)00195-0; GARSON JA, 1989, BRIT J CANCER, V59, P889, DOI 10.1038/bjc.1989.188; Gure AO, 2000, INT J CANCER, V85, P726, DOI 10.1002/(SICI)1097-0215(20000301)85:5<726::AID-IJC21>3.0.CO;2-F; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Holden JA, 1999, MODERN PATHOL, V12, P1094; Ikeda H, 1997, IMMUNITY, V6, P199, DOI 10.1016/S1074-7613(00)80426-4; Kanemura Y, 2001, DIFFERENTIATION, V68, P141, DOI 10.1046/j.1432-0436.2001.680208.x; Kirkin AF, 2002, CANCER INVEST, V20, P222, DOI 10.1081/CNV-120001150; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kristiansen G, 2003, BRIT J CANCER, V88, P231, DOI 10.1038/sj.bjc.6600702; Kristiansen G, 2002, AM J PATHOL, V161, P1215, DOI 10.1016/S0002-9440(10)64398-2; Lal A, 1999, CANCER RES, V59, P5403; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Senner V, 1999, J NEUROPATH EXP NEUR, V58, P795, DOI 10.1097/00005072-199908000-00002; Siu I.-Mei, 2001, Gene Expression Patterns, V1, P33, DOI 10.1016/S1567-133X(01)00006-0; St Croix B, 2000, SCIENCE, V289, P1197; Steinbach D, 2002, CANCER GENET CYTOGEN, V133, P118, DOI 10.1016/S0165-4608(01)00570-2; Vassal G, 2003, CANCER CHEMOTH PHARM, V51, P385, DOI 10.1007/s00280-003-0584-1; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484	25	62	71	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7687	7694		10.1038/sj.onc.1207043	http://dx.doi.org/10.1038/sj.onc.1207043			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576832				2022-12-28	WOS:000186113000017
J	Rasheed, ZA; Rubin, EH				Rasheed, ZA; Rubin, EH			Mechanisms of resistance to topoisomerase I-targeting drugs	ONCOGENE			English	Review						topoisomerase I; camptothecin; topotecan; irinotecan; drug resistance	TERNARY CLEAVABLE COMPLEX; HUMAN-COLON-CANCER; HUMAN TUMOR-CELLS; BREAST-CANCER; WERNER-SYNDROME; HUMAN LIVER; DNA-DAMAGE; CAMPTOTHECIN RESISTANCE; CELLULAR ACCUMULATION; MULTIDRUG-RESISTANCE	DNA topoisomerases are a class of enzymes that alter the topology of DNA and are targets of several anticancer drugs. Camptothecins (CPTs) are a relatively new family of compounds that specifically target topoisomerase I (Top1). These compounds 'poison' Top1 by binding to the Top1 - DNA complex in a manner that prevents the religation of DNA. Topotecan and irinotecan are two CPTs that are approved for the treatment of a variety of malignancies, including colorectal, ovarian, and small cell lung cancers, as well as myeloid malignancies. Although CPTs have proven to be effective anticancer drugs, resistance is still a critical clinical problem. The mechanisms underlying de novo and acquired clinical resistance to CPTs and the newer classes of Top1 poisons are unclear. However, based on preclinical studies, it is likely that clinical resistance to these drugs is the result of: ( 1) inadequate accumulation of drug in the tumor, ( 2) resistance-conferring alterations in Top1, or ( 3) alterations in the cellular response to the Top1 - CPT interaction. This review will focus on the current knowledge regarding mechanisms of resistance to CPTs and other Top1-targeting drugs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol & Cellular Pharmacol, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Rasheed, ZA (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol & Cellular Pharmacol, Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08901 USA.	rasheeze@umdnj.edu						Ahmed F, 1999, ANTICANCER RES, V19, P2067; Allen JD, 2002, CANCER RES, V62, P2294; Allen JD, 1999, CANCER RES, V59, P4237; Bailly C, 1999, BIOCHEMISTRY-US, V38, P8605, DOI 10.1021/bi983052y; Bearden DT, 2001, PHARMACOTHERAPY, V21, p224S, DOI 10.1592/phco.21.16.224S.33997; BENEDETTI P, 1993, CANCER RES, V53, P4343; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Brangi M, 1999, CANCER RES, V59, P5938; Buckwalter CA, 1996, CANCER RES, V56, P1674; Byrne Lee James, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P415; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chang JY, 2002, CANCER RES, V62, P3716; CHEN AY, 1991, CANCER RES, V51, P6039; Ciotti M, 1999, BIOCHEM BIOPH RES CO, V260, P199, DOI 10.1006/bbrc.1999.0453; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; Cummings J, 2002, BIOCHEM PHARMACOL, V63, P607, DOI 10.1016/S0006-2952(01)00812-7; Cusack JC, 2001, CANCER RES, V61, P3535; Danks MK, 1998, CANCER RES, V58, P20; Danks MK, 1996, CANCER RES, V56, P1664; DARPA P, 1990, CANCER RES, V50, P6919; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; ENG WK, 1988, MOL PHARMACOL, V34, P755; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; Faneyte IF, 2002, CLIN CANCER RES, V8, P1068; Fiorani Paola, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P717; FUJIMORI A, 1995, CANCER RES, V55, P1339; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GIOVANELLA BC, 1989, SCIENCE, V246, P1046, DOI 10.1126/science.2555920; GOLDWASSER F, 1995, CANCER RES, V55, P2116; Gounder Murugesan K., 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P805; Gupta E, 2000, ANTICANCER RES, V20, P1013; GUPTA E, 1998, CANC THER, V1, P292; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Hanioka N, 2001, XENOBIOTICA, V31, P687, DOI 10.1080/00498250110057341; HARKER WG, 1995, CANCER RES, V55, P1707; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; Honjo Y, 2001, CANCER RES, V61, P6635; HOUGHTON PJ, 1995, CANCER CHEMOTH PHARM, V36, P393; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huinink WTB, 1997, J CLIN ONCOL, V15, P2183, DOI 10.1200/JCO.1997.15.6.2183; Humerickhouse R, 2000, CANCER RES, V60, P1189; Kanzaki A, 2001, JPN J CANCER RES, V92, P452, DOI 10.1111/j.1349-7006.2001.tb01115.x; Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267; Kerrigan JE, 2001, BIOCHEMISTRY-US, V40, P9792, DOI 10.1021/bi010913l; Khanna R, 2000, CANCER RES, V60, P4725; Koike K, 1997, CANCER RES, V57, P5475; Komatani H, 2001, CANCER RES, V61, P2827; Komatani H, 1999, CANCER RES, V59, P2701; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Ma J, 1998, BRIT J CANCER, V77, P1645, DOI 10.1038/bjc.1998.270; Maliepaard M, 1999, CANCER RES, V59, P4559; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Meijer M, 2002, J BIOL CHEM, V277, P4050, DOI 10.1074/jbc.M109383200; MIRSKI SEL, 1995, CANCER RES, V55, P2129; MO YY, 2001, J BIOL CHEM, V14, P14; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nieves-Neira W, 1999, INT J CANCER, V82, P396, DOI 10.1002/(SICI)1097-0215(19990730)82:3<396::AID-IJC13>3.0.CO;2-Z; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Ohashi N, 1996, JPN J CANCER RES, V87, P1280, DOI 10.1111/j.1349-7006.1996.tb03144.x; Pandit B, 2001, CANCER CHEMOTH PHARM, V48, P312, DOI 10.1007/s002800100352; Park SY, 2002, CANCER RES, V62, P459; Perego P, 2001, CANCER RES, V61, P6034; Pichierri P, 2001, CARCINOGENESIS, V22, P1781, DOI 10.1093/carcin/22.11.1781; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Rajendra R, 2003, CANCER RES, V63, P3228; Rallabhandi P, 2002, J BIOL CHEM, V277, P40020, DOI 10.1074/jbc.M200388200; Rasheed ZA, 2002, EXP CELL RES, V277, P152, DOI 10.1006/excr.2002.5550; RASHEED ZA, 2000, P AM ASSOC CANC RES, V41, P210; Rasheed Zeshaan A., 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P1156; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Reid RJD, 1997, J BIOL CHEM, V272, P12091, DOI 10.1074/jbc.272.18.12091; Reid RJD, 1999, P NATL ACAD SCI USA, V96, P11440, DOI 10.1073/pnas.96.20.11440; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; Rothenberg ML, 1996, J CLIN ONCOL, V14, P1128, DOI 10.1200/JCO.1996.14.4.1128; RUBIN E, 1995, CLIN CANCER RES, V1, P269; RUBIN E, 1994, J BIOL CHEM, V269, P2433; Saleem A, 2000, ANN NY ACAD SCI, V922, P46; SALEEM A, 2002, P AM ASS CANC RES S, V43, P74; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Simon JA, 2000, CANCER RES, V60, P328; SMITH PJ, 1989, INT J RADIAT BIOL, V55, P217, DOI 10.1080/09553008914550271; SQUIRES S, 1993, CANCER RES, V53, P2012; Stewart L., 2001, P AM ASS CANC RES S, V42, P80; Takahashi T, 1997, JPN J CANCER RES, V88, P1211, DOI 10.1111/j.1349-7006.1997.tb00351.x; Takatani H, 1997, JPN J CANCER RES, V88, P160, DOI 10.1111/j.1349-7006.1997.tb00361.x; Takenaga N, 2002, DRUG METAB DISPOS, V30, P494, DOI 10.1124/dmd.30.5.494; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P299, DOI 10.1016/S0169-5002(01)00425-1; Urasaki Y, 2001, CANCER RES, V61, P1964; Urasaki Y, 2001, CANCER RES, V61, P504; Valkov NI, 2000, BRIT J HAEMATOL, V108, P331; VANWARDENBURG R, 2002, P AM ASSOC CANC RES, V43, P793; WALL ME, 1995, CANCER RES, V55, P753; Walowsky C, 1999, J BIOL CHEM, V274, P7302, DOI 10.1074/jbc.274.11.7302; WALTON MI, 1993, CANCER RES, V53, P1853; Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.3.CO;2-R; Wang HY, 2002, CANCER RES, V62, P2483; Wang J C, 1985, Harvey Lect, V81, P93; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LF, 1997, CANCER RES, V57, P1516; Wessel I, 1997, CANCER RES, V57, P4451; Wierdl M, 2001, CANCER RES, V61, P5078; Woo MH, 2002, J BIOL CHEM, V277, P3813, DOI 10.1074/jbc.M110484200; Yang CH, 2000, BIOCHEM PHARMACOL, V60, P831, DOI 10.1016/S0006-2952(00)00396-8; Zamboni WC, 1998, CLIN CANCER RES, V4, P743; Zhang XW, 2000, ANTI-CANCER DRUG, V11, P747, DOI 10.1097/00001813-200010000-00012; Zhang YK, 1999, INT J CANCER, V83, P790, DOI 10.1002/(SICI)1097-0215(19991210)83:6<790::AID-IJC15>3.0.CO;2-6	119	137	148	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7296	7304		10.1038/sj.onc.1206935	http://dx.doi.org/10.1038/sj.onc.1206935			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576839				2022-12-28	WOS:000186112500004
J	Yanamandra, N; Gumidyala, KV; Waldron, KG; Gujrati, M; Olivero, WC; Dinh, D; Rao, JS; Mohanam, S				Yanamandra, N; Gumidyala, KV; Waldron, KG; Gujrati, M; Olivero, WC; Dinh, D; Rao, JS; Mohanam, S			Blockade of cathepsin B expression in human glioblastoma cells is associated with suppression of angiogenesis	ONCOGENE			English	Article						cathepsin B; angiogenesis; glioblastoma; antisense	ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS CARCINOMA-CELLS; HUMAN BRAIN-TUMORS; IN-VITRO; CYSTEINE PROTEINASES; INVASIVE PROPERTIES; VEGF EXPRESSION; DOWN-REGULATION; ENZYME-ACTIVITY; IV COLLAGENASE	The cysteine proteinase cathepsin B has been implicated in tumor progression by virtue of its increased mRNA and protein levels, as well as its localization at the invading front of the tumor. In this study, we examined whether blocking cathepsin B expression in human glioblastoma SNB19 cells affects angiogenesis. Stable transfectants of human glioblastoma cells with a plasmid containing antisense cathepsin B cDNA showed decreased migration rates in wound- and spheroid- migration assays. Analysis showed a reduction in VEGF protein and MMP- 9 activity in the cathepsin B antisense cDNA- transfected cells. Regarding angiogenesis in vitro, we found that the conditioned medium of glioblastoma cells with downregulated cathepsin B expression reduced cell - cell interaction of human microvascular endothelial cells, resulting in the disruption of capillary- like network formation. Furthermore, a marked reduction in microvasculature development was seen in an in vivo dorsal air sac assay of glioblastoma cells with downregulated cathepsin B expression. Taken together, these results provide evidence that inhibition of cathepsin B expression can suppress glioblastoma- induced neovascularization.	Univ Illinois, Coll Med, Program Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Mohanam, S (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	smohanam@uic.edu			NATIONAL CANCER INSTITUTE [R01CA076350, R01CA075557, R01CA085216, R01CA092393] Funding Source: NIH RePORTER; NCI NIH HHS [CA76350, CA75557, CA92393, CA85216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE T, 1993, J CLIN INVEST, V92, P54, DOI 10.1172/JCI116599; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CAO LQ, 1994, GENE, V139, P163, DOI 10.1016/0378-1119(94)90750-1; Chandrasekar N, 2003, ONCOGENE, V22, P392, DOI 10.1038/sj.onc.1206164; Chandrasekar N, 2000, CLIN EXP METASTAS, V18, P337, DOI 10.1023/A:1010833730407; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; Coulibaly S, 1999, INT J CANCER, V83, P526, DOI 10.1002/(SICI)1097-0215(19991112)83:4<526::AID-IJC15>3.3.CO;2-D; Creemers LB, 1998, MATRIX BIOL, V16, P575, DOI 10.1016/S0945-053X(98)90068-3; Demchik LL, 1999, INT J DEV NEUROSCI, V17, P483, DOI 10.1016/S0736-5748(99)00011-8; GARRIDO T, 1995, BRIT J CANCER, V71, P770, DOI 10.1038/bjc.1995.149; GUINEC N, 1993, BIOL CHEM H-S, V374, P1135, DOI 10.1515/bchm3.1993.374.7-12.1135; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hamano Y, 2003, CANCER CELL, V3, P589, DOI 10.1016/S1535-6108(03)00133-8; Hizel C, 1998, ONCOL REP, V5, P31; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; IacobuzioDonahue CA, 1997, J BIOL CHEM, V272, P29190, DOI 10.1074/jbc.272.46.29190; Kachra Z, 1999, CLIN EXP METASTAS, V17, P555, DOI 10.1023/A:1006760632766; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; Kruger S, 1999, CANCER RES, V59, P6010; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Lopes MBS, 2003, MICROSC RES TECHNIQ, V60, P225, DOI 10.1002/jemt.10260; Lorenzo K, 2000, CANCER RES, V60, P4070; Machein MR, 2000, J NEURO-ONCOL, V50, P109, DOI 10.1023/A:1006416003964; MIKKELSEN T, 1995, J NEUROSURG, V83, P285, DOI 10.3171/jns.1995.83.2.0285; Miyoshi C, 2001, IN VIVO, V15, P233; Mohanam S, 2001, ONCOGENE, V20, P3665, DOI 10.1038/sj.onc.1204480; Mohanam S, 1997, ONCOGENE, V14, P1351, DOI 10.1038/sj.onc.1200963; NAKAO H, 1989, INT J BIOCHEM, V21, P739; Nirmala C, 2000, INT J CANCER, V88, P766, DOI 10.1002/1097-0215(20001201)88:5<766::AID-IJC13>3.0.CO;2-Y; Rao JS, 1996, CLIN EXP METASTAS, V14, P12, DOI 10.1007/BF00157681; RAO JS, 1993, CANCER RES, V53, P2208; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; SLOANE BF, 1994, J CELL SCI, V107, P373; SPIESS E, 1994, J HISTOCHEM CYTOCHEM, V42, P917, DOI 10.1177/42.7.8014475; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Szpaderska AM, 2001, CANCER RES, V61, P3493; Venetsanakos E, 2002, EXP CELL RES, V273, P21, DOI 10.1006/excr.2001.5424; Virgintino D, 2003, HISTOCHEM CELL BIOL, V119, P227, DOI 10.1007/s00418-003-0510-y; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wesseling P, 1997, J NEURO-ONCOL, V32, P253, DOI 10.1023/A:1005746320099	43	72	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2224	2230		10.1038/sj.onc.1207338	http://dx.doi.org/10.1038/sj.onc.1207338			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14730346				2022-12-28	WOS:000220280900012
J	Hasskarl, J; Duensing, S; Manuel, E; Munger, K				Hasskarl, J; Duensing, S; Manuel, E; Munger, K			The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers	ONCOGENE			English	Article						centrosomes; ID1 protein; genomic instability; cancer	SENESCENT HUMAN FIBROBLASTS; SQUAMOUS-CELL CARCINOMA; MAMMALIAN-CELLS; DNA-BINDING; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; GENOMIC INSTABILITY; PANCREATIC-CANCER; G(1) PROGRESSION; BREAST-CANCER	ID1 is a member of the inhibitor of DNA binding/differentiation ( ID) family of dominant negative helix loop-helix transcription factors. ID-proteins have been implicated in the control of differentiation and transcriptional modulation of various cell cycle regulators and high levels of ID1 expression are frequently detected in various cancer types. However, it is unclear whether ID1 is a marker of highly proliferative cancer cells or whether it directly contributes to the tumor phenotype. A detailed analysis of ID1-expressing human cells revealed that a fraction of ID1 localizes to centrosomes. Ectopic expression of ID1 in primary cells and tumor cell lines resulted in accumulation of cells with abnormal centrosome numbers. There was no evidence for centrosomal localization or induction of centrosome abnormalities by the other ID family members. Hence, ID1 may contribute to oncogenesis not only by inhibiting transcriptional activity of basic helix-loop-helix transcription factors and abrogate differentiation but also by subverting centrosome duplication.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur,NRB 958C, Boston, MA 02115 USA.	karl_munger@hms.harvard.edu	Hasskarl, Jens/E-8980-2011	Manuel, Edwin/0000-0002-4602-7060; Munger, Karl/0000-0003-3288-9935	NCI NIH HHS [R01 CA66980] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Andres-Barquin PJ, 1999, EXP CELL RES, V247, P347, DOI 10.1006/excr.1998.4360; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BIGGS JR, 1995, J CELL PHYSIOL, V164, P249, DOI 10.1002/jcp.1041640205; Bounpheng MA, 1999, FASEB J, V13, P2257, DOI 10.1096/fasebj.13.15.2257; BOVERI T, 1914, FRAGEENTSTEHUNG MALI; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; D'Assoro AB, 2001, MARC MALPIG SYMP SER, V7, P103; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; DEED RW, 1993, ONCOGENE, V8, P599; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; Deed RW, 1997, MOL CELL BIOL, V17, P6815, DOI 10.1128/MCB.17.12.6815; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, CANCER RES, V61, P2356; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; HARA E, 1994, J BIOL CHEM, V269, P2139; Hasskarl J, 2000, J MOL MED-JMM, V78, P94, DOI 10.1007/s001090000083; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hu YC, 2001, CLIN CANCER RES, V7, P2213; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kebebew E, 2000, SURGERY, V128, P952, DOI 10.1067/msy.2000.111082; Kleeff J, 1998, CANCER RES, V58, P3769; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Langlands K, 2000, CANCER RES, V60, P5929; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; Lauricella M, 2001, FEBS LETT, V499, P191, DOI 10.1016/S0014-5793(01)02553-4; Lin CQ, 2000, CANCER RES, V60, P1332; Lingle WL, 1999, AM J PATHOL, V155, P1941, DOI 10.1016/S0002-9440(10)65513-7; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Maruyama H, 1999, AM J PATHOL, V155, P815, DOI 10.1016/S0002-9440(10)65180-2; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; Matsumura ME, 2002, J BIOL CHEM, V277, P7293, DOI 10.1074/jbc.M108986200; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Mueller C, 2002, CIRCULATION, V105, P2423, DOI 10.1161/01.CIR.0000016047.19488.91; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nehlin JO, 1997, BIOCHEM BIOPH RES CO, V231, P628, DOI 10.1006/bbrc.1997.6152; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Pagliuca A, 2000, CANCER RES, V60, P1376; Paoletti A, 1996, J CELL SCI, V109, P3089; PESCE S, 1993, MOL CELL BIOL, V13, P7874, DOI 10.1128/MCB.13.12.7874; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Piboonniyom SO, 2003, CANCER RES, V63, P476; Polsky D, 2001, CANCER RES, V61, P6008; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schindl M, 2001, CANCER RES, V61, P5703; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Takai N, 2001, CANCER LETT, V165, P185, DOI 10.1016/S0304-3835(01)00433-5; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Wu CL, 1996, MOL CELL BIOL, V16, P3698; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9	72	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1930	1938		10.1038/sj.onc.1207310	http://dx.doi.org/10.1038/sj.onc.1207310			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14755252				2022-12-28	WOS:000220129500015
J	Hildesheim, J; Belova, GI; Tyner, SD; Zhou, XW; Vardanian, L; Fornace, AJ				Hildesheim, J; Belova, GI; Tyner, SD; Zhou, XW; Vardanian, L; Fornace, AJ			Gadd45a regulates matrix metalloproteinases by suppressing Delta Np63 alpha and beta-catenin via p38 MAP kinase and APC complex activation	ONCOGENE			English	Article						Gadd45a; beta-catenin; Delta Np63 alpha; keratinocyte; UV	P63 EXPRESSION; P53 HOMOLOG; CYCLIN D1; SKIN; CANCER; MATRILYSIN; APOPTOSIS; PHOSPHORYLATION; PROTEIN; TARGET	The p53-regulated growth arrest and DNA damage-inducible gene product Gadd45a has been recently identified as a key factor protecting the epidermis against ultraviolet radiation (UVR)-induced skin tumors by activating p53 via the stress mitogen-activated protein kinase ( MAPK) signaling pathway. Herein we identify Gadd45a as an important negative regulator of two oncogenes commonly over-expressed in epithelial tumors: the p53 homologue DeltaNp63alpha and beta-catenin. DeltaNp63alpha is one of the several p63 isoforms and is the predominant species expressed in basal epidermal keratinocytes. DeltaNp63alpha lacks the N-terminal transactivation domain and behaves as a dominant-negative factor blocking expression of several p53-effector genes. DeltaNp63alpha also associates with and blocks activation of the adenomatous polyposis coli (APC) destruction complex that targets free cytoplasmic beta-catenin for degradation. While most beta-catenin protein is localized to the cell membrane and is involved in cell-cell adhesion, accumulation of free cytoplasmic beta-catenin will translocate into the nucleus where it functions in a bipartite transcription factor complex, whose targets include invasion and metastasis promoting endopeptidases, matrix metalloproteinases (MMP). We show that Gadd45a not only directly associates with two components of the APC complex, namely protein phosphatase 2A (PP2A) and glycogen synthase kinase 3beta (GSK3beta) but also promotes GSK3b dephosphorylation at Ser9, which is essential for GSK3b activation, and resultant activation of the APC destruction complex. We demonstrate that lack of Gadd45a not only prevents DeltaNp63alpha suppression and GSK3b dephosphorylation but also prevents free cytoplasmic beta-catenin degradation after UV irradiation. The inability of Gadd45a-null keratinocytes to suppress beta-catenin may contribute to the resulting observation of increased MMP expression and activity along with significantly faster keratinocyte migration in Matrigel in vitro and accelerated wound closure in vivo. Furthermore, epidermal keratinocytes treated with p38 MAPK inhibitors, both in vivo and in vitro, behave very similarly to Gadd45a-null keratinocytes after UVR. Similarly, Trp53-null mice are unable to attenuate DeltaNp63alpha expression in epidermal keratinocytes after such stress. These findings demonstrate a dependence on Gadd45a-mediated p38 MAPK and p53 activation for proper modulation of DeltaNp63alpha, GSK3beta, and beta-catenin after irradiation. Taken together, our results indicate that Gadd45a is able to repress DeltaNp63alpha, beta-catenin, and consequently MMP expression by two means: by maintaining UVR-induced p38 MAPK and p53 activation and also by associating with the APC complex. This implicates Gadd45a in the negative regulation of cell migration, and invasion.	NCI, Gene Response Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Fornace, AJ (corresponding author), NCI, Gene Response Sect, Ctr Canc Res, NIH, Bldg 37,Rm 6144,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	af6z@nih.gov	Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hildesheim J, 2002, CANCER RES, V62, P7305; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; KARELINA TV, 1994, J INVEST DERMATOL, V103, P482, DOI 10.1111/1523-1747.ep12395596; Kusukawa J, 1996, ORAL ONCOL, V32B, P217, DOI 10.1016/0964-1955(96)00016-4; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Li G, 1996, AM J PATHOL, V148, P1113; Liefer KM, 2000, CANCER RES, V60, P4016; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Park BJ, 2000, CANCER RES, V60, P3370; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Polakis P, 2000, GENE DEV, V14, P1837; POWELL WC, 1993, CANCER RES, V53, P417; PYKE C, 1992, CANCER RES, V52, P1336; Quinn AG, 1997, BRIT J HOSP MED, V58, P261; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Sakanaka C, 2002, J BIOCHEM, V132, P697, DOI 10.1093/oxfordjournals.jbchem.a003276; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tsukifuji R, 1999, BRIT J CANCER, V80, P1087, DOI 10.1038/sj.bjc.6690468; Urist MJ, 2002, AM J PATHOL, V161, P1199, DOI 10.1016/S0002-9440(10)64396-9; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; YAMAMOTO H, 1995, INT J CANCER, V61, P218, DOI 10.1002/ijc.2910610213; Yamasawa K, 2002, CLIN CANCER RES, V8, P2563; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	50	54	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 11	2004	23	10					1829	1837		10.1038/sj.onc.1207301	http://dx.doi.org/10.1038/sj.onc.1207301			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	801XV	14647429				2022-12-28	WOS:000220129500004
J	Kauraniemi, P; Hautaniemi, S; Autio, R; Astola, J; Monni, O; Elkahloun, A; Kallioniemi, A				Kauraniemi, P; Hautaniemi, S; Autio, R; Astola, J; Monni, O; Elkahloun, A; Kallioniemi, A			Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines	ONCOGENE			English	Article						HER2; herceptin; amplification; breast cancer; cDNA microarray	MONOCLONAL-ANTIBODY; C-FOS; MUTATIONS; KIT; CHEMOTHERAPY; TRASTUZUMAB; ACTIVATION; ESTROGEN; EFFICACY; AMPLICON	Herceptin is a humanized monoclonal antibody targeted against the extracellular domain of the HER2 oncogene, which is amplified and overexpressed in 10-34% of breast cancers. Herceptin therapy provides effective treatment in HER2-positive metastatic breast cancer, although a favorable treatment response is not achieved in all cases. Here, we show that Herceptin treatment induces a dose-dependent growth reduction in breast cancer cell lines with HER2 amplification, whereas nonamplified cell lines are practically resistant. Time-course analysis of global gene expression patterns in amplified and nonamplified cell tines indicated a major change in transcript levels between 24 and 48 h of Herceptin treatment. A step-wise gene selection algorithm revealed a set of 439 genes whose temporal expression profiles differed most between the amplified and nonamplified cell lines. The discriminatory power of these genes was confirmed by both hierarchical clustering and self-organizing map analyses. In the amplified cell lines, the Herceptin treatment induced the expression of several genes involved in RNA processing and DNA repair, while cell adhesion mediators and known oncogenes, such as e-FOS and c-KIT, were downregulated. These results provide additional clues to the downstream effects of blocking the HER2 pathway in breast cancer and may provide new targets for more effective treatment.	Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33520 Tampere, Finland; Tampere Univ Hosp, FIN-33520 Tampere, Finland; Tampere Univ Technol, Inst Signal Proc, FIN-33101 Tampere, Finland; Univ Helsinki, Biomedicum Helsinki, Biomedicum Biochip Ctr, FIN-00290 Helsinki, Finland; NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA	Tampere University; Tampere University; Tampere University Hospital; Tampere University; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Kallioniemi, A (corresponding author), Univ Tampere, Inst Med Technol, Canc Genet Lab, FIN-33520 Tampere, Finland.	anne.kallioniemi@uta.fi	Astola, Jaakko T/G-4297-2014; Autio, Reija/D-2037-2014; Hautaniemi, Sampsa/CAG-0362-2022; Hautaniemi, Sampsa/A-3122-2009	Hautaniemi, Sampsa/0000-0002-7749-2694; Hautaniemi, Sampsa/0000-0002-7749-2694; Astola, Jaakko/0000-0002-2750-5311; Autio, Reija/0000-0002-6519-2715				Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Duan RQ, 2002, BIOCHEM BIOPH RES CO, V294, P384, DOI 10.1016/S0006-291X(02)00499-0; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Hautaniemi S, 2003, MACH LEARN, V52, P45, DOI 10.1023/A:1023941307670; HAUTANIEMI S, 2003, STRATEGY IDENTIFYING; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kohonen T., 2001, SELF ORG MAPS, DOI [DOI 10.1007/978-3-642-56927-2, 10.1007/978-3-642-56927-2, DOI 10.1007/978-3-642-56927-2_1]; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Molina MA, 2001, CANCER RES, V61, P4744; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Mousses S, 2000, PRACT APPROACH SER, P113; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Vesanto J., 2000, SOM TOOLBOX MATLAB 5; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; WILDING G, 1988, CANCER RES, V48, P802; Yakes FM, 2002, CANCER RES, V62, P4132; Yang YH, 2001, PROC SPIE, V4266, P141, DOI 10.1117/12.427982	27	53	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					1010	1013		10.1038/sj.onc.1207200	http://dx.doi.org/10.1038/sj.onc.1207200			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647448				2022-12-28	WOS:000188486600018
J	Cleaves, R; Wang, QF; Friedman, AD				Cleaves, R; Wang, QF; Friedman, AD			C/EBP alpha p30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding	ONCOGENE			English	Article						C/EBP alpha; AML; leukemia; differentiation; cell cycle	PROTEIN-ALPHA; TRANSCRIPTION FACTOR; GRANULOCYTIC DIFFERENTIATION; MURINE MYELOPEROXIDASE; GENE-EXPRESSION; GROWTH ARREST; C-MYB; INDUCTION; PROLIFERATION; PU.1	Heterozygous mutations of the CEBPA gene are present in 5% of acute myeloid leukemia (AML) cases and often lead to the expression of an N-terminally truncated, 30 kDa isoform, C/EBPalphap30, from an internal translation start site. We have assessed the effect of C/EBPalphap30 on granulopoiesis utilizing C/EBPalphap30-ER, containing the estradiol receptor ligand-binding domain. In contrast to C/EBPalpha-ER, C/EBPalphap30-ER did not induce 32Dcl3 myeloid cell differentiation in IL-3. However, both isoforms, when expressed at high levels, were capable of inhibiting E2F activity in 32Dcl3 cells and of slowing their G1 to S progression. C/EBPalphap30 repressed expression of the endogenous G-CSF receptor several-fold. To facilitate investigation of the effect of C/EBPalphap30-ER on granulopoiesis downstream of G-CSF signalling, we coexpressed exogenous G-CSF receptor. C/EBPalphap30-ER/GR cells expressed several granulocytic markers in G-CSF and demonstrated nuclear maturation. Rat C/EBPalpha-ER and C/EBPalphap30-ER, expressed in 293T cells, bound the C/EBP site from the NE gene with similar affinity, as did human C/EBPalpha and C/EBPalphap30. In contrast, C/EBPalphap30 bound the C/EBP sites in the PU.1 or GR gene with 3-6-fold reduced affinity. Thus, the selective inhibition of GR expression by C/EBPalphap30-ER is due in part to its variable affinity for C/EBP sites. Variation in affinity for selected cis elements among isoforms may affect the biology of basic region-leucine zipper (bZIP) proteins.	Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Friedman, AD (corresponding author), Johns Hopkins Univ, Div Pediat Oncol, Sidney Kimmel Comprehens Canc Ctr, Canc Res Bldg,Rm 253,1650 Orleans St, Baltimore, MD 21231 USA.	afriedm2@jhem.jhmi.edu			NHLBI NIH HHS [R01 HL51388] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051388] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An MR, 1996, MOL CELL BIOL, V16, P2295; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Calkhoven CF, 2000, GENE DEV, V14, P1920; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Friedman AD, 1996, CANCER RES, V56, P3250; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Iwasaki-Arai J, 2002, BLOOD, V100, p61A; JOHANSEN LM, 2003, IN PRESS BLOOD; Keeshan K, 2003, BLOOD, V102, P1267, DOI 10.1182/blood-2003-02-0477; Kummalue T, 2003, J LEUKOCYTE BIOL, V74, P464, DOI 10.1189/jlb.1202622; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Liu HT, 2003, BLOOD, V101, P3885, DOI 10.1182/blood-2002-07-2212; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; RAUGHT B, 1995, MOL ENDOCRINOL, V9, P1223, DOI 10.1210/me.9.9.1223; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; SCOTT LM, 1992, BLOOD, V80, P1725; Smith LT, 1996, BLOOD, V88, P1234, DOI 10.1182/blood.V88.4.1234.bloodjournal8841234; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; Theilgaard-Moench K, 2002, BLOOD, V100, p298A; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Wang QF, 2003, ONCOGENE, V22, P2548, DOI 10.1038/sj.onc.1206360; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wang W, 2001, LEUKEMIA, V15, P779, DOI 10.1038/sj.leu.2402094; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang P, 1998, J EXP MED, V188, P1173, DOI 10.1084/jem.188.6.1173	43	34	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					716	725		10.1038/sj.onc.1207172	http://dx.doi.org/10.1038/sj.onc.1207172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737106				2022-12-28	WOS:000188304900010
J	Eszlinger, M; Krohn, K; Frenzel, R; Kropf, S; Tonjes, A; Paschke, R				Eszlinger, M; Krohn, K; Frenzel, R; Kropf, S; Tonjes, A; Paschke, R			Gene expression analysis reveals evidence for inactivation of the TGF-beta signaling cascade in autonomously functioning thyroid nodules	ONCOGENE			English	Article						thyroid; TSH receptor; signal transduction; transforming growth factor beta 1; sialyltransferase 1	GROWTH-FACTOR-BETA; HUMAN THYROTROPIN RECEPTOR; TSH RECEPTOR; MUTATIONS; CELLS; COLD; PROLIFERATION; MECHANISM; ADENOMAS; PATHWAY	Molecular eventsthat lead to the development of autonomously functioning thyroid nodules (AFTNs) are somatic mutations of the thyrotropin receptor (TSHR) in approximately 60% of the nodules and less frequently, somatic mutations in the G(s)alpha protein. However, AFTNs without known mutations indicate that other causes remain to be identified. Moreover, the impact of constitutively activating TSHR mutations on the signal transduction network of the thyroid epithelial cell is unknown. We therefore investigated gene expression in 15 AFTNs and their surrounding tissue using Affymetrix GeneChips. Most prominently, data analysis revealed a changed pattern of gene expression in the TGF-beta signaling cascade and 25 differentially regulated genes in AFTNs, including thyroid peroxidase, type I iodothyronine deiodinase and sialyltransferase ( SIAT) 1. Strikingly coexpression of SIAT 1 and TSHR in COS-7 cells increased TSH binding and cell surface expression of the TSHR. Moreover, differences in gene expression patterns for AFTNs with and without TSHR mutations indicate specific alterations of signal transduction in AFTNs without TSHR mutations. These results suggest that AFTNs with TSHR mutations harbor further mechanisms of forward stimulation. Furthermore, they give important leads to elucidate the molecular etiology of AFTNs without TSHR mutations.	Univ Leipzig, Dept Med 3, D-04103 Leipzig, Germany; Interdisciplinary Ctr Clin Res, D-04103 Leipzig, Germany; Univ Magdeburg, Inst Biometr & Med Informat, D-39120 Magdeburg, Germany	Leipzig University; Otto von Guericke University	Paschke, R (corresponding author), Univ Leipzig, Dept Med 3, Ph Rosenthal Str 27, D-04103 Leipzig, Germany.	pasr@medizin.uni-leipzig.de		Eszlinger, Markus/0000-0002-4732-2934				Arturi F, 1998, EXP CLIN ENDOCR DIAB, V106, P234, DOI 10.1055/s-0029-1211982; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; COLLETTA G, 1989, CANCER RES, V49, P3457; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Eszlinger M, 2001, J CLIN ENDOCR METAB, V86, P4834, DOI 10.1210/jc.86.10.4834; Eszlinger M, 2001, THYROID, V11, P125, DOI 10.1089/105072501300042767; Fuhrer D, 1999, THYROID, V9, P757, DOI 10.1089/thy.1999.9.757; Gartner R, 1997, THYROID, V7, P633, DOI 10.1089/thy.1997.7.633; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; GRUBECKLOEBENSTEIN B, 1989, J CLIN INVEST, V83, P764, DOI 10.1172/JCI113955; Hedinger CE., 1988, HISTOLOGICAL TYPING; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Krohn K, 1999, THYROID, V9, P241, DOI 10.1089/thy.1999.9.241; LIBERT F, 1989, BIOCHEM BIOPH RES CO, V165, P1250, DOI 10.1016/0006-291X(89)92736-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lutz M, 2002, CELL SIGNAL, V14, P977, DOI 10.1016/S0898-6568(02)00058-X; Miyazono K, 1997, INT J HEMATOL, V65, P97; Neumann S, 2001, MOL ENDOCRINOL, V15, P1294, DOI 10.1210/me.15.8.1294; Oda Y, 1999, J CLIN ENDOCR METAB, V84, P2119, DOI 10.1210/jc.84.6.2119; PANG XP, 1992, ENDOCRINOLOGY, V131, P45, DOI 10.1210/en.131.1.45; Park ES, 2000, MOL ENDOCRINOL, V14, P662, DOI 10.1210/mend.14.5.0458; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; SANDROCK D, 1993, ACTA ENDOCRINOL-COP, V128, P51, DOI 10.1530/acta.0.1280051; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; TATON M, 1993, MOL CELL ENDOCRINOL, V95, P13, DOI 10.1016/0303-7207(93)90024-E; Trulzsch B, 1999, BIOTECHNIQUES, V27, P266, DOI 10.2144/99272bm10; Trulzsch B, 2001, J MOL MED, V78, P684, DOI 10.1007/s001090000170; TSUSHIMA T, 1988, ENDOCRINOLOGY, V123, P1187, DOI 10.1210/endo-123-2-1187; Vanvooren V, 2001, EUR J ENDOCRINOL, V144, P605, DOI 10.1530/eje.0.1440605; Vicencio AG, 2002, J APPL PHYSIOL, V93, P1123, DOI 10.1152/japplphysiol.00031.2002; Voigt C, 2000, FEBS LETT, V486, P208, DOI 10.1016/S0014-5793(00)02302-4; Westfall P.H., 1993, RESAMPLING BASED MUL; Wonerow P, 2000, CLIN ENDOCRINOL, V53, P461, DOI 10.1046/j.1365-2265.2000.01119.x; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	42	32	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					795	804		10.1038/sj.onc.1207186	http://dx.doi.org/10.1038/sj.onc.1207186			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737114				2022-12-28	WOS:000188304900018
J	Wu, MC; Ho, SM				Wu, MC; Ho, SM			PMP24, a gene identified by MSRF, undergoes DNA hypermethylation-associated gene silencing during cancer progression in an LNCaP model	ONCOGENE			English	Article						peroxisome; androgen independency; prostate neoplasm; epigenetic regulation of gene expression; 5-aza-2 '-deoxycytidine; bisulfite genomic sequencing	HUMAN PROSTATE-CANCER; ARBITRARILY PRIMED-PCR; HUMAN TUMOR-CELLS; CPG ISLAND; METHYLATION DIFFERENCES; EPIGENETIC REGULATION; EPITHELIAL-CELLS; MEMBRANE-PROTEIN; SUPPRESSOR GENE; RECEPTOR GENE	Transcriptional silencing of antitumor genes via CpG island methylation could be a mechanism mediating prostate cancer (PCa) progression from an androgen-sensitive (AS) to an androgen-insensitive (AI) state. We have used the (m) under bar ethylation-(s) under bar ensitive (r) under bar estriction (f) under bar ingerprinting (MSRF) technique to identify novel CpG-rich sequences that are differentially methylated between the genome of the AS PCa cell line LNCaP and that of an AI subline LNCaPCS generated by maintaining LNCaP in medium with charcoal-stripped (CS) serum for over 30 passages. One such sequence identified was located on a 5' CpG island that was found to span part of the promoter, exon 1, and part of intron 1 of the (p) under bar eroxisomal (m) under bar embrane (p) under bar rotein 24 kDa (PMP24) gene. Using semiquantitative RT-PCR and bisulfite genomic sequencing, we established an inverse relationship between mRNA expression and methylation of the 5' CpG island of PMP24. PMP24 mRNA was absent in LNCaPCS and the androgen receptor-negative PC-3 cell line; both exhibited dense methylation in the said CpG island. In contrast, PMP24 mRNA was expressed in LNCaP and normal prostatic epithelial cells (NPrECs) whose PMP24 5' CpG island remained unmethylated. Treatment of LNCaPCS and PC-3 with the demethylating agent 5-aza-2'-deoxycytidine (5-AZAdC) reactivated PMP24 mRNA expression. Transient transfection of PMP24 into LNCaPCS and PC-3 cells induced a significant reduction in cell growth and soft-agar colony formation potential, suggesting that PMP24 gene product has antitumor properties. These results demonstrate the utility of MSRF in the identification of novel, differentially methylated DNA sequences in the genome and suggest that hypermethylation-mediated silencing of PMP24 is an epigenetic event involved in PCa progression to androgen independence.	Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Grad Sch Biomed Sci, Interdisciplinary Grad Program, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Ho, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Surg, Div Urol, Rm 504,Lazare Res Bldg,364 Plantat St, Worcester, MA 01605 USA.	Shuk-Mei.Ho@umassmed.edu			NCI NIH HHS [CA94221, CA62269] Funding Source: Medline; NIDDK NIH HHS [DK61084] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094221, R01CA062269] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BRYANT DD, 1995, BIOCHEM MOL MED, V55, P22, DOI 10.1006/bmme.1995.1027; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Davies Catherine S, 2002, Methods Mol Biol, V200, P43; Eckert JH, 2003, REV PHYSIOL BIOCH P, V147, P75, DOI 10.1007/s10254-003-0007-z; El Yaagoubi M, 1998, BIOCHEM MOL BIOL INT, V46, P321; Esteller M, 2000, CANCER RES, V60, P129; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gonzalgo ML, 1997, CANCER RES, V57, P594; GRAFF JR, 1995, CANCER RES, V55, P5195; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; HAYATSU H, 1970, J AM CHEM SOC, V92, P724, DOI 10.1021/ja00706a062; Huang THM, 1997, CANCER RES, V57, P1030; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jarrard DF, 1997, CLIN CANCER RES, V3, P2121; Jarrard DF, 1998, CANCER RES, V58, P5310; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Johnson TL, 2001, PLANT PHYSIOL, V127, P731, DOI 10.1104/pp.010262; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kibel AS, 2001, PROSTATE, V48, P248, DOI 10.1002/pros.1104; Kohno T, 1998, HUM GENET, V102, P258, DOI 10.1007/s004390050689; Kuzmin I, 2002, CANCER RES, V62, P3498; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; Lau KM, 2000, CANCER RES, V60, P3175; Lauer C, 1999, CARCINOGENESIS, V20, P985, DOI 10.1093/carcin/20.6.985; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Liang GG, 2002, METHODS, V27, P150, DOI 10.1016/S1046-2023(02)00068-3; Liang GN, 2000, CANCER RES, V60, P4907; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Lou W, 1999, CANCER RES, V59, P2329; MARSHALL KG, 1995, JAMA-J AM MED ASSOC, V274, P607, DOI 10.1001/jama.1995.03530080023020; Masters C, 1998, MOL CELL BIOCHEM, V187, P85, DOI 10.1023/A:1006863123068; Mobley JA, 2003, CANCER EPIDEM BIOMAR, V12, P775; Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Nelson JB, 1997, CANCER RES, V57, P35; Newling DWW, 1996, EUR UROL, V29, P69; Reguenga C, 1999, BBA-GENE STRUCT EXPR, V1445, P337, DOI 10.1016/S0167-4781(99)00061-5; Robbins SE, 1996, PROSTATE, V29, P362; Salem CE, 2000, INT J CANCER, V87, P179, DOI 10.1002/1097-0215(20000715)87:2<179::AID-IJC4>3.0.CO;2-X; SALMON SE, 1978, NEW ENGL J MED, V298, P1321, DOI 10.1056/NEJM197806152982401; SCHER HI, 1995, UROLOGY, V46, P142, DOI 10.1016/S0090-4295(99)80182-4; Schmitt JF, 2002, MOL ENDOCRINOL, V16, P213, DOI 10.1210/me.16.2.213; Singal R, 2001, CANCER RES, V61, P4820; Singh S, 2003, CANCER RES, V63, P2306; Syed V, 2001, CANCER RES, V61, P6768; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Taplin ME, 2001, J CLIN ENDOCR METAB, V86, P3467, DOI 10.1210/jc.86.8.3467; Tekur S, 2001, MOL CARCINOGEN, V30, P1, DOI 10.1002/1098-2744(200101)30:1<1::AID-MC1008>3.0.CO;2-X; Toyota M, 1999, CANCER RES, V59, P2307; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; Verkaik NS, 1999, INT J CANCER, V80, P439; WANG RYH, 1980, NUCLEIC ACIDS RES, V8, P4777, DOI 10.1093/nar/8.20.4777; Zheng SL, 2001, HUM GENET, V108, P430, DOI 10.1007/s004390100513	58	28	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					250	259		10.1038/sj.onc.1207076	http://dx.doi.org/10.1038/sj.onc.1207076			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712230				2022-12-28	WOS:000187895300026
J	Liu, BY; Kim, YC; Leatherberry, V; Cowin, P; Alexander, CM				Liu, BY; Kim, YC; Leatherberry, V; Cowin, P; Alexander, CM			Mammary gland development requires syndecan-1 to create a beta-catenin/TCF-responsive mammary epithelial subpopulation	ONCOGENE			English	Article						Wnt-1; syndecan; mouse mammary gland; beta-catenin	HEPARAN-SULFATE PROTEOGLYCANS; SIGNAL-TRANSDUCTION; COLORECTAL-CANCER; WNT/BETA-CATENIN; TGF-BETA; WNT; WINGLESS; DROSOPHILA; PATHWAYS; PROTEIN	Mice with a null mutation in the cell surface heparan sulfate (HS) proteoglycan, syndecan-1 (Sdc1), develop almost normally, but resist mammary tumor development in response to Wnt-1. Here, we test the hypothesis that Sdc1 promotes Wnt-1- induced tumor development by interacting with the Wnt cell surface signaling complex. Thus, the response of Sdc1 -/- mammary epithelial cells (mecs) to the intracellular, activated Wnt signal transducer, DeltaNbeta-catenin, was assayed both in vitro and in vivo, to test whether beta-catenin/TCF transactivation was Sdc1-independent. Surprisingly, we found that the expression of a canonical Wnt pathway reporter, TOP-FLASH, was reduced by 50% in both unstimulated Sdc1-/- mecs and in stimulated cells responding to Wnt1 or DeltaNbeta-catenin. Tumor development in response to DeltaNbeta-catenin was also significantly delayed on a Sdc1-/- background. Furthermore, the average beta-catenin/TCF transactivation per cell was normal in Sdc1-/- mec cultures, but the number of responsive cells was reduced by 50%. Sdc1-/- mecs show compensatory changes that maintain the number of HS chains, hence these experiments cannot test the coreceptor activity of HS for Wnt signaling. We propose that TCF-dependent transactivational activity is suppressed in 50% of cells in Sdc1-/- glands, and conclude that the major effect of Sdc1 does not map to the activity of the Wnt signaling complex, but to another pathway to create or stabilize the beta-catenin/TCF-responsive tumor precursor cells in mouse mammary gland.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10016 USA	University of Wisconsin System; University of Wisconsin Madison; New York University	Alexander, CM (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.			Kim, Young Chul/0000-0002-6782-2186; Cowin, Pamela/0000-0002-1827-1154	NCI NIH HHS [P30 CA14520, T32 CA09135, CA 90877-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA090877, P30CA014520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Baeg GH, 2001, DEVELOPMENT, V128, P87; Baeg GH, 2000, CURR OPIN CELL BIOL, V12, P575, DOI 10.1016/S0955-0674(00)00134-4; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Behrens J, 2000, J CELL SCI, V113, P911; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; Brantjes H, 2002, BIOL CHEM, V383, P255, DOI 10.1515/BC.2002.027; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Clevers H, 2000, NAT GENET, V24, P206, DOI 10.1038/73396; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; EMERMAN JT, 1988, ADV CELL CULT, V6, P137; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Ornitz DM, 2000, BIOESSAYS, V22, P108, DOI 10.1002/(SICI)1521-1878(200002)22:2<108::AID-BIES2>3.0.CO;2-M; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Polakis P, 2000, GENE DEV, V14, P1837; Rasmussen SB, 2000, METHODS MAMMARY GLAN; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0	38	54	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9243	9253		10.1038/sj.onc.1207217	http://dx.doi.org/10.1038/sj.onc.1207217			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681683				2022-12-28	WOS:000187400400006
J	Cox, AD; Der, CJ				Cox, AD; Der, CJ			The dark side of Ras: regulation of apoptosis	ONCOGENE			English	Article						Ras; apoptosis; signal transduction; small GTPase	NF-KAPPA-B; GTPASE-ACTIVATING PROTEIN; INTESTINAL EPITHELIAL-CELLS; FAS-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; ONCOGENIC RAS; SIGNALING PATHWAY; DOWN-REGULATION; R-RAS; CELLULAR-TRANSFORMATION	Mutational activation of Ras promotes oncogenesis by disrupting a multitude of normal cellular processes. Perhaps, best characterized and understood are the mechanisms by which oncogenic Ras promotes deregulated cell cycle progression and uncontrolled cellular proliferation. However, it is now clear that oncogenic Ras can also deregulate processes that control apoptosis. In light of the diversity of downstream effector targets known to facilitate Ras function, it is perhaps not surprising that Ras regulation of cell survival is complex, involving the balance and interplay of multiple signaling networks. While our understanding of these events is still far from complete, and is complicated by cell type and signaling context differences, several important mechanisms have begun to emerge. We review the role and mechanism of specific effectors in regulating the antiapoptotic (Raf, phosphatidylinositol 3-kinase and Tiam1) and apoptotic (Nore1 and RASSF1) actions of oncogenic Ras, and discuss the possibility that the effector actions of p120RasGAP make a significant contribution to Ras regulation of apoptotic events.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Radiat Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA.			Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA069577, U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978, CA69577, CA67771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balachandran S, 2001, J VIROL, V75, P3474, DOI 10.1128/JVI.75.7.3474-3479.2001; Barradas M, 1999, EMBO J, V18, P6362, DOI 10.1093/emboj/18.22.6362; Bazarov AV, 2001, CANCER RES, V61, P1178; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DeChant AK, 2002, ONCOGENE, V21, P5268, DOI 10.1038/sj.onc.1205648; Denis GV, 2003, J BIOL CHEM, V278, P5775, DOI 10.1074/jbc.M210202200; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Du W, 1999, CANCER RES, V59, P5492; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Feig LA, 2002, CURR BIOL, V12, pR259, DOI 10.1016/S0960-9822(02)00787-X; Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; Fritz G, 2001, J BIOL CHEM, V276, P3115, DOI 10.1074/jbc.M005058200; Gigoux V, 2002, J BIOL CHEM, V277, P23742, DOI 10.1074/jbc.C200121200; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Guan KL, 2000, J BIOL CHEM, V275, P27354; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Hueber AO, 1998, TRENDS GENET, V14, P364, DOI 10.1016/S0168-9525(98)01520-0; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Leblanc V, 1999, ONCOGENE, V18, P4884, DOI 10.1038/sj.onc.1202855; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Malliri A, 2002, NATURE, V417, P867, DOI 10.1038/nature00848; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Mazzoni IE, 1999, J NEUROSCI, V19, P9716; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Osada M, 1999, MOL CELL BIOL, V19, P6333; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rong R, 2002, ONCOGENE, V21, P1062, DOI 10.1038/sj.onc.1205154; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; Suzuki J, 1998, FEBS LETT, V437, P112, DOI 10.1016/S0014-5793(98)01213-7; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Terada K, 2000, BIOCHEM BIOPH RES CO, V267, P449, DOI 10.1006/bbrc.1999.1955; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; Trentin GA, 2001, J BIOL CHEM, V276, P13087, DOI 10.1074/jbc.M009267200; Tsuchida T, 2000, CANCER GENE THER, V7, P373, DOI 10.1038/sj.cgt.7700136; Tsuneoka M, 2000, ONCOGENE, V19, P115, DOI 10.1038/sj.onc.1203232; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; Tu SS, 2002, BIOCHEMISTRY-US, V41, P12350, DOI 10.1021/bi026167h; von Gise A, 2001, MOL CELL BIOL, V21, P2324, DOI 10.1128/MCB.21.7.2324-2336.2001; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wen LP, 1998, CELL DEATH DIFFER, V5, P729, DOI 10.1038/sj.cdd.4400409; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Yang JY, 2002, J BIOL CHEM, V277, P14641, DOI 10.1074/jbc.M111540200; Yang JY, 2001, MOL CELL BIOL, V21, P5346, DOI 10.1128/MCB.21.16.5346-5358.2001; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	93	349	363	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 8	2003	22	56					8999	9006		10.1038/sj.onc.1207111	http://dx.doi.org/10.1038/sj.onc.1207111			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	751GC	14663478				2022-12-28	WOS:000187043600003
J	Gryz, EA; Meakin, SO				Gryz, EA; Meakin, SO			Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-dependent, but not nerve growth factor-independent, differentiation and cell cycle arrest in the human neuroblastoma cell line, SY5Y	ONCOGENE			English	Article						nerve growth factor; TrkA; tyrosine kinase receptor; kinase activation; activation loop; neurotrophins; mutagenesis; neuroblastomas; neuronal tumors; signalling	PC12 CELLS; NEURONAL DIFFERENTIATION; FACTOR RECEPTOR; N-MYC; SIGNALING ENDOSOMES; NEURITE OUTGROWTH; KINASE ACTIVATION; PROTEIN-KINASE; MESSENGER-RNA; EXPRESSION	TrkA is the receptor tyrosine kinase (RTK) for nerve growth factor (NGF) and stimulates NGF-dependent cell survival and differentiation in primary neurons and also differentiation of neuroblastomas and apoptosis of medulloblastomas. We have previously shown that aspartic acid and glutamic acid substitution (AspGlu and GluAsp) of the activation loop tyrosines in TrkA (Tyr(683) and Tyr(684)) supports NGF-independent neuritogenesis and cell survival in PC12 cell-derived nnr5 cells. In this study, the AspGlu and GluAsp mutant Trks have been analysed for their ability to support NGF-independent and NGF-dependent neuritogenesis, proliferation and cell signalling in the human neuroblastoma cell line, SY5Y. We find that the AspGlu and GluAsp mutant Trks support NGF-dependent, but not NGF-independent, autophosphorylation, neuritogenic responses and/or inhibit cell cycle progression. The NGF-dependent neuritogenic responses are lower for the mutant Trks (approximately 30-60% for AspGlu and 50-60% for GluAsp), relative to wild-type TrkA. While both the AspGlu and GluAsp mutant Trks support NGF-dependent transient phosphorylation of Shc, PLCgamma-1, AKT, FRS2, SH2B as well as prolonged MAP kinase activation, the GluAsp mutant induces stronger NGF-dependent tyrosine phosphorylation of FRS2 and SH2B, as well as a stronger reduction in bromodeoxyuridine (BrdU) incorporation. Collectively, these data suggest that neither absolute levels of receptor autophosphorylation, high levels of TrkA expression nor the activation of a specific signalling pathway is dominant and absolutely essential for neuritogenesis and cell cycle arrest of SY5Y cells.	John P Robarts Res Inst, Cell Biol Grp, Lab Neural Signalling, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Cell Biol Grp, Lab Neural Signalling, 100 Perth Dr, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	41	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8774	8785		10.1038/sj.onc.1206890	http://dx.doi.org/10.1038/sj.onc.1206890			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647472				2022-12-28	WOS:000186844900015
J	Hideshima, T; Hayashi, T; Chauhan, D; Akiyama, M; Richardson, P; Anderson, K				Hideshima, T; Hayashi, T; Chauhan, D; Akiyama, M; Richardson, P; Anderson, K			Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines	ONCOGENE			English	Article						multiple myeloma; JNK; growth arrest; p21; NF-kappa B	N-TERMINAL KINASE; PROTEASOME INHIBITOR PS-341; MARROW STROMAL CELLS; KAPPA-B; THERAPEUTIC APPLICATIONS; MOLECULAR-MECHANISMS; INDUCED APOPTOSIS; DRUG-RESISTANCE; PLASMA-CELLS; INTERLEUKIN-6	Although c-Jun NH2-terminal kinase (JNK) is activated by treatment with therapeutic agents, the biologic sequelae of inhibiting constitutive activation of JNK has not yet been clarified. In this study, we examine the biologic effect of JNK inhibition in multiple myeloma (MM) cell lines. JNK-specific inhibitor SP600125 induces growth inhibition via induction of G1 or G2/M arrest in U266 and MM.1S multiple myeloma cell lines, respectively. Neither exogenous IL-6 nor insulin-like growth factor-1 (IGF-1) overcome SP600125-induced growth inhibition, and IL-6 enhances SP600125-induced G2/M phase in MM.1S cells. Induction of growth arrest is mediated by upregulation of p27(Kip1), without alteration of p53 and JNK protein expression. Importantly, SP600125 inhibits growth of MM cells adherent to bone marrow stromal cells (BMSCs). SP600125 induces NF-kappaB activation in a dose-dependent fashion, associated with phosphorylation of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha. In contrast, SP600125 does not affect phosphorylation of STAT3, Akt, and/or ERK. IKK-specific inhibitor PS-1145 inhibits SP600125-induced NF-kappaB activation and blocks the protective effect of SP600125 against apoptosis. Our data therefore demonstrate for the first time that inhibiting JNK activity induces growth arrest and activates NF-kappaB in MM cells.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, K (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA050947, P01CA078378] Funding Source: NIH RePORTER; NCI NIH HHS [P0-1 CA78378, R0-1 CA50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chauhan D, 2003, J BIOL CHEM, V278, P17593, DOI 10.1074/jbc.C300076200; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen Y, 2001, J BIOL CHEM, V276, P8350, DOI 10.1074/jbc.M008431200; FREUND GG, 1993, J IMMUNOL, V151, P1811; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; HIDESHIMA T, 2003, UNPUB CANC RES; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Mitsiades CS, 2002, BLOOD, V100, p170A; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4079, DOI 10.1182/blood.V99.11.4079; Ogata A, 1997, J IMMUNOL, V159, P2212; Pearce AK, 2001, TRENDS CELL BIOL, V11, P426, DOI 10.1016/S0962-8924(01)02119-5; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Tu YP, 2000, CANCER RES, V60, P6763; UCHIYAMA H, 1993, BLOOD, V82, P3712; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1	29	65	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8797	8801		10.1038/sj.onc.1206919	http://dx.doi.org/10.1038/sj.onc.1206919			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647474				2022-12-28	WOS:000186844900017
J	Lebedeva, IV; Sarkar, D; Su, ZZ; Kitada, S; Dent, P; Stein, CA; Reed, JC; Fisher, PB				Lebedeva, IV; Sarkar, D; Su, ZZ; Kitada, S; Dent, P; Stein, CA; Reed, JC; Fisher, PB			Bcl-2 and Bcl-x(L) differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7, mda-7/IL-24	ONCOGENE			English	Review						cancer gene therapy; prostate cancer; Bcl-2 protein family; apoptosis; mda-7/IL-24	HUMAN ADENOVIRUS TYPE-5; IN-VIVO; GROWTH ARREST; UP-REGULATION; DNA-DAMAGE; IMMUNOHISTOCHEMICAL ANALYSIS; CLONOGENIC SURVIVAL; ANDROGEN-ABLATION; CARCINOMA-CELLS; OVER-EXPRESSION	Subtraction hybridization identified melanoma differentiation associated gene-7, mda-7, in the context of terminally differentiated human melanoma cells. Based on its structure, cytokine-like properties and proposed mode of action, mda-7 has now been classified as IL-24. When expressed by means of a replication-incompetent adenovirus, Ad. mda-7 induces apoptosis in a broad range of cancer cells, without inducing harmful effects in normal fibroblast or epithelial cells. These unique properties of mda-7/IL-24 suggest that this gene will prove beneficial for cancer gene therapy. We now demonstrate that Ad. mda-7 decreases viability by induction of apoptosis in hormone-responsive (LNCaP) and hormone-independent (DU-145 and PC-3) human prostate carcinomas, without altering growth or survival in early-passage normal human prostate epithelial cells (HuPEC). Ad. mda-7 causes G(2)/M arrest and apoptosis in LNCaP (p53-wildtype), DU-145 (p53 mutant, Bax-negative) and PC-3 (p53-negative) prostate carcinomas, but not in HuPEC. Apoptosis induction correlated with changes in the ratio of pro- to antiapoptotic Bcl-2 protein family members. A potential functional role for changes in bcl-2 family gene expression in Ad. mda-7-induced apoptosis was suggested by the finding that forced overexpression of bcl-xL or bcl-2 differentially diminished the apoptotic effect of Ad. mda-7 in prostate carcinomas. These results confirm that induction of apoptosis by the mda-7/IL-24 gene in prostate cancer cells is Bax- and p53-independent and is mediated by mitochondrial pathways involving bcl-2 family gene members. The mda-7/IL-24 gene represents a new class of cancer-specific apoptosis-inducing genes with obvious potential for the targeted gene-based therapy of human prostate cancer.	Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, New York, NY 10032 USA; Burnham Inst, La Jolla, CA 92037 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Urol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, New York, NY 10032 USA	Columbia University; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University; Columbia University; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, Dept Pathol, BB-1501,630 W 168th St, New York, NY 10032 USA.		Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NATIONAL CANCER INSTITUTE [R01CA035675, R01CA088906, R01CA097318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [BC98-0148, CA97318, CA88906, CA35675] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 2002, CELL DEATH DIFFER, V9, P1240, DOI 10.1038/sj.cdd.4401097; Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amundson SA, 2000, CANCER RES, V60, P6101; Bai XZ, 1999, INT J ONCOL, V14, P785; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Beham AW, 1998, INT J MOL MED, V1, P953; BERCHEM GJ, 1995, CANCER RES, V55, P735; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Biederer C, 2002, J MOL MED-JMM, V80, P163, DOI 10.1007/s00109-001-0295-1; Cao XX, 2002, MOL MED, V8, P869, DOI 10.1007/BF03402093; Chadbourne DE, 2001, POPTRONICS, V2, P3; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Curiel DT, 2000, CANCER GENE THER, V7, P1197, DOI 10.1038/sj.cgt.7700222; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; FALCKPEDERSEN E, 1994, MOL PHARMACOL, V45, P684; FISHER PB, 1985, J INTERFERON RES, V5, P11, DOI 10.1089/jir.1985.5.11; FISHER PB, 1985, PHARMACOL THERAPEUT, V27, P143, DOI 10.1016/0163-7258(85)90067-1; Gazdar AF, 2001, P NATL ACAD SCI USA, V98, P10028, DOI 10.1073/pnas.191379998; Gilbert MS, 1996, J CELL PHYSIOL, V168, P114; Gopalkrishnan RV, 2001, J CELL PHYSIOL, V189, P245, DOI 10.1002/jcp.10023; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Haldar S, 1996, CANCER RES, V56, P1253; Hall SJ, 1999, CANCER GENE THER, V6, P54, DOI 10.1038/sj.cgt.7700004; Herman JR, 1999, HUM GENE THER, V10, P1239, DOI 10.1089/10430349950018229; Huang F, 1999, ONCOGENE, V18, P3546, DOI 10.1038/sj.onc.1202715; Hull GW, 2000, CLIN CANCER RES, V6, P4101; Ibrado AM, 1997, CANCER RES, V57, P1109; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P41; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Jin RJ, 2000, CANCER GENE THER, V7, P1537, DOI 10.1038/sj.cgt.7700266; Kajiwara T, 1999, INT J UROL, V6, P520, DOI 10.1046/j.1442-2042.1999.00102.x; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Ko SC, 1996, HUM GENE THER, V7, P1683, DOI 10.1089/hum.1996.7.14-1683; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lebedeva I, 2000, CANCER RES, V60, P6052; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; LEON JA, 1994, PHARMACOL THERAPEUT, V61, P237, DOI 10.1016/0163-7258(94)90065-5; Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2; Li XY, 2001, CANCER RES, V61, P1699; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Liu QY, 1997, CLIN CANCER RES, V3, P2039; Lock RB, 1996, CANCER RES, V56, P4006; Lowe SL, 2001, GENE THER, V8, P1363, DOI 10.1038/sj.gt.3301531; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; Matsubara S, 2001, CANCER RES, V61, P6012; MAY WS, 1994, J BIOL CHEM, V269, P26865; McConkey DJ, 1996, CANCER RES, V56, P5594; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Miyake H, 2001, INT J UROL, V8, P337, DOI 10.1046/j.1442-2042.2001.00311.x; Nasu Y, 1999, GENE THER, V6, P338, DOI 10.1038/sj.gt.3300834; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pataer A, 2002, CANCER RES, V62, P2239; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Pramudji C, 2001, CLIN CANCER RES, V7, P4272; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed J C, 1996, Behring Inst Mitt, P72; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; Rodriguez R, 1997, CANCER RES, V57, P2559; Rots M G, 2000, Cancer Gene Ther, V7, P1507, DOI 10.1038/sj.cgt.7700253; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sarkar D, 2002, BIOTECHNIQUES, P30; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shalev M, 2000, J UROLOGY, V163, P1747, DOI 10.1016/S0022-5347(05)67534-9; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 1999, P NATL ACAD SCI USA, V96, P15115, DOI 10.1073/pnas.96.26.15115; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; Sweeney P, 2000, WORLD J UROL, V18, P121, DOI 10.1007/s003450050183; Tang DG, 1998, CANCER RES, V58, P3466; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; VOLKERT FC, 1983, VIROLOGY, V125, P175, DOI 10.1016/0042-6822(83)90072-7; Xie XM, 2001, CANCER RES, V61, P6795; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009	108	118	134	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8758	8773		10.1038/sj.onc.1206891	http://dx.doi.org/10.1038/sj.onc.1206891			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647471				2022-12-28	WOS:000186844900014
J	Niwa, O				Niwa, O			Induced genomic instability in irradiated germ cells and in the offspring; reconciling discrepancies among the human and animal studies	ONCOGENE			English	Article						radiation; genomic instability; minisatellite; transgenerational	MINISATELLITE MUTATION-RATE; EYED UNSTABLE MUTATION; F-1 MICE BORN; IONIZING-RADIATION; DOSE-RESPONSE; HUMAN SPERM; TEST SYSTEM; X-RAYS; MOUSE; INDUCTION	Many studies confirmed that radiation induces genomic instability in whole-body systems. However, the results of the studies are not always consistent with each other. Attempts are made in the present review to resolve the discrepancies. Many of the studies in human and experimental animals utilize the length change mutation of minisatellite sequences as a marker of genomic instability. Minisatellite sequences frequently change their length, and the data obtained by conventional Southern blotting give rather qualitative information, which is sometimes difficult to scrutinize quantitatively. This is the problem inevitably associated with the study of minisatellite mutations and the source of some conflicts among studies in humans and mice. Radiation induction of genomic instability has also been assessed in whole-body experimental systems, using other markers such as the mouse pink-eyed unstable allele and the specific pigmentation loci of medaka fish (Oryzias latipes). Even though there are some contradictions, all these studies have demonstrated that genomic instability is induced in the germ cells of irradiated parents, especially of males, and in offspring born to them. Among these, transmission of genomic instability to the second generation of irradiated parents is limited to the mouse minisatellite system, and awaits further clarification in other experimental systems.	Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Niwa, O (corresponding author), Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Yoshida Konoe, Kyoto 6068501, Japan.	tsimura@house.rbc.kyoto-u.ac.jp						Adler ID, 1996, MUTAT RES-FUND MOL M, V352, P169, DOI 10.1016/0027-5107(95)00223-5; AUERBACH C, 1976, MUTAT RES, P270; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber R, 2000, MUTAT RES-FUND MOL M, V457, P79, DOI 10.1016/S0027-5107(00)00130-5; Bishop AJR, 2000, MUTAT RES-FUND MOL M, V457, P31, DOI 10.1016/S0027-5107(00)00118-4; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Bridges BA, 2001, RADIAT RES, V156, P631, DOI 10.1667/0033-7587(2001)156[0631:RAGMAR]2.0.CO;2; BRILLIANT MH, 1994, MAMM GENOME, V5, pS104; Buard J, 2000, GENOMICS, V65, P95, DOI 10.1006/geno.2000.6161; Buard J, 1998, EMBO J, V17, P3495, DOI 10.1093/emboj/17.12.3495; Cho C, 2003, BIOL REPROD, V69, P211, DOI 10.1095/biolreprod.102.015115; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; CROMPTON NEA, 1990, RADIAT RES, V124, P300, DOI 10.2307/3577843; Dubrova YE, 2000, MUTAT RES-FUND MOL M, V453, P17, DOI 10.1016/S0027-5107(00)00068-3; Dubrova YE, 1998, INT J RADIAT BIOL, V74, P689, DOI 10.1080/095530098140952; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 1997, MUTAT RES-FUND MOL M, V381, P267; Dubrova YE, 1996, NATURE, V380, P683, DOI 10.1038/380683a0; Dubrova YE, 2002, AM J HUM GENET, V71, P801, DOI 10.1086/342729; Dubrova YE, 2002, SCIENCE, V295, P1037, DOI 10.1126/science.1068102; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FAN YJ, 1995, INT J RADIAT BIOL, V68, P177, DOI 10.1080/09553009514551081; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P59; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; Goodhead DT, 1999, J RADIAT RES, V40, P1, DOI 10.1269/jrr.40.S1; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; HILL CK, 1984, INT J RADIAT BIOL, V46, P11, DOI 10.1080/09553008414551011; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; Jeffreys AJ, 1997, CLIN SCI, V93, P383, DOI 10.1042/cs0930383; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; JEFFREYS AJ, 1997, HUM MOL GENET, P136; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Kiuru A, 2003, RADIAT RES, V159, P651, DOI 10.1667/0033-7587(2003)159[0651:HMMATO]2.0.CO;2; KODAIRA M, 1995, AM J HUM GENET, V57, P1275; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Livshits LA, 2001, RADIAT RES, V155, P74, DOI 10.1667/0033-7587(2001)155[0074:COCCWD]2.0.CO;2; Mannazzu I, 2002, APPL ENVIRON MICROB, V68, P5437, DOI 10.1128/AEM.68.11.5437-5444.2002; Martini E, 2002, MOL CELL, V9, P700, DOI 10.1016/S1097-2765(02)00512-9; May CA, 2000, MUTAT RES-FUND MOL M, V453, P67, DOI 10.1016/S0027-5107(00)00085-3; MITANI K, 1990, J BIOL CHEM, V265, P15203; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; *NAT AC SCI, 1990, 5 BEIRR NAT AC SCI N; NEEL JV, 1990, AM J HUM GENET, V46, P1053; Nikjoo H, 1999, J RADIAT RES, V40, P85, DOI 10.1269/jrr.40.S85; Niwa O, 1996, J RADIAT RES, V37, P217, DOI 10.1269/jrr.37.217; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Radman M, 2001, NATURE, V413, P115, DOI 10.1038/35093178; Rassoulzadegan M, 2002, EMBO J, V21, P440, DOI 10.1093/emboj/21.3.440; Richard GF, 2000, EMBO REP, V1, P122, DOI 10.1093/embo-reports/kvd031; RUSSELL LB, 1991, MUTAT RES, V262, P101, DOI 10.1016/0165-7992(91)90114-J; RUSSELL LB, 1990, BANBURY REPORT, V34, P271; RUSSELL WL, 1982, P NATL ACAD SCI-BIOL, V79, P542, DOI 10.1073/pnas.79.2.542; Russell WL, 1998, GENETICS, V148, P1567; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; Sankaranarayanan K, 2000, MUTAT RES-FUND MOL M, V453, P107, DOI 10.1016/S0027-5107(00)00108-1; Satoh C, 1996, NATURE, V383, P226, DOI 10.1038/383226a0; Schiestl RH, 1997, P NATL ACAD SCI USA, V94, P4576, DOI 10.1073/pnas.94.9.4576; SCHIESTL RH, 1994, SCIENCE, V266, P1573, DOI 10.1126/science.7985029; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SHIMA A, 1991, P NATL ACAD SCI USA, V88, P2545, DOI 10.1073/pnas.88.6.2545; Shimada A, 1998, MUTAT RES-FUND MOL M, V399, P149, DOI 10.1016/S0027-5107(97)00253-4; Shimada A, 2001, MUTAT RES-GEN TOX EN, V495, P33, DOI 10.1016/S1383-5718(01)00193-0; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; *UN SCI COMM, 2000, UN SCI COMM EFF AT R; *UN SCI COMM, 1993, UN SCI COMM EFF AT R; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yokomori K, 2003, CURR TOP MICROBIOL, V274, P79; Zheng NJ, 2000, ENVIRON MOL MUTAGEN, V36, P134, DOI 10.1002/1098-2280(2000)36:2<134::AID-EM8>3.0.CO;2-D	73	41	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7078	7086		10.1038/sj.onc.1207037	http://dx.doi.org/10.1038/sj.onc.1207037			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557813				2022-12-28	WOS:000185903900013
J	Fishman, P; Bar-Yehuda, S; Ohana, G; Barer, F; Ochaion, A; Erlanger, A; Madi, L				Fishman, P; Bar-Yehuda, S; Ohana, G; Barer, F; Ochaion, A; Erlanger, A; Madi, L			An agonist to the A(3) adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B	ONCOGENE			English	Article						A(3) adenosine receptor; CF101; colon carcinoma; beta-catenin; GSK-3 beta	BIOCHEMICAL-CHARACTERIZATION; PROGNOSTIC MARKER; SIGNALING PATHWAY; CANCER-THERAPY; CELL GROWTH; MELANOMA; TUMOR; PHOSPHORYLATION; OVEREXPRESSION; ACTIVATION	A(3) adenosine receptor (A(3)AR) activation with the specific agonist CF101 has been shown to inhibit the development of colon carcinoma growth in syngeneic and xenograft murine models. In the present study, we looked into the effect of CF101 on the molecular mechanisms involved in the inhibition of HCT-116 colon carcinoma in mice. In tumor lesions derived from CF101-treated mice, a decrease in the expression level of protein kinase A (PKA) and an increase in glycogen synthase kinase-3beta (GSK-3beta) was observed. This gave rise to downregulation of beta-catenin and its transcriptional gene products cyclin D1 and c-Myc. Further mechanistic studies in vitro revealed that these responses were counteracted by the selective A(3)AR antagonist MRS 1523 and by the GSK-3beta inhibitors lithium and SB216763, confirming that the observed effects were A(3)AR and GSK-3beta mediated. CF101 downregulated PKB/Akt expression level, resulting in a decrease in the level and DNA-binding capacity of NF-kappaB, both in vivo and in vitro. Furthermore, the PKA and PKB/Akt inhibitors H89 and Worthmannin mimicked the effect of CF101, supporting their involvement in mediating the response to the agonist. This is the first demonstration that A(3)AR activation induces colon carcinoma growth inhibition via the modulation of the key proteins GSK-3beta and NF-kappaB.	Can Fite Biopharma Ltd, IL-49170 Kiryat Matalon, Petach Tikva, Israel; Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr, Felsenstein Med Res Ctr,Lab Clin & Tumor Immunol, Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fishman, P (corresponding author), Can Fite Biopharma Ltd, IL-49170 Kiryat Matalon, Petach Tikva, Israel.	pnina@canfite.co.il						Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Chana JS, 2002, BRIT J PLAST SURG, V55, P623, DOI 10.1054/bjps.2002.3964; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Fishman P, 2003, ANTICANCER RES, V23, P2077; Fishman P, 2002, ANTI-CANCER DRUG, V13, P437, DOI 10.1097/00001813-200206000-00001; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Gessi S, 2001, BRIT J PHARMACOL, V134, P116, DOI 10.1038/sj.bjp.0704254; Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO;2-5; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755; Lovig T, 2002, SCAND J GASTROENTERO, V37, P1184, DOI 10.1080/003655202760373407; Madi L, 2003, J BIOL CHEM, V278, P42121, DOI 10.1074/jbc.M301243200; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Masuda M, 2002, CANCER RES, V62, P3351; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nguyen DC, 2003, INT J ONCOL, V22, P1285; Ohana G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/sj.bjc.6601315; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; Schulte G, 2002, MOL PHARMACOL, V62, P1137, DOI 10.1124/mol.62.5.1137; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Suh BC, 2001, BRIT J PHARMACOL, V134, P132, DOI 10.1038/sj.bjp.0704218; Trincavelli ML, 2002, MOL PHARMACOL, V62, P1373, DOI 10.1124/mol.62.6.1373; Trincavelli ML, 2002, BBA-MOL CELL RES, V1591, P55, DOI 10.1016/S0167-4889(02)00248-3; VanWardenburg RCAM, 1997, INT J CANCER, V73, P544, DOI 10.1002/(SICI)1097-0215(19971114)73:4<544::AID-IJC15>3.3.CO;2-C	33	85	94	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2465	2471		10.1038/sj.onc.1207355	http://dx.doi.org/10.1038/sj.onc.1207355			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14691449				2022-12-28	WOS:000220558000004
J	Liu, MT; Chen, YR; Chen, SC; Hu, CY; Lin, CS; Chang, YT; Wang, WB; Chen, JY				Liu, MT; Chen, YR; Chen, SC; Hu, CY; Lin, CS; Chang, YT; Wang, WB; Chen, JY			Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells	ONCOGENE			English	Article						Epstein-Barr virus LMP1; DNA repair; micronucleus formation	TUMOR-SUPPRESSOR GENE; NASOPHARYNGEAL CARCINOMA; P53 GENE; EXCISION-REPAIR; POINT MUTATION; MICE LACKING; IN-VITRO; PROTEIN; CHROMOSOME; EXPRESSION	The latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is a viral oncogene and it is essential for the transformation of resting B cells by the virus. The protein acts as a ligand-less membrane receptor and triggers numerous cellular signaling pathways. Cellular transformation frequently has been associated with genomic instability. To investigate whether EBV LMP1 induces chromosomal aberrations, micronucleus (MN) formation was examined in LMP1-expressing epithelial cells. The expression of wild-type LMP1 enhanced both spontaneous and bleomycin-induced MN formation. MN formation may be induced by inactivation of DNA repair and, therefore, we investigated the effect of LMP1 on DNA repair, using a host cell reactivation (HCR) assay. In the HCR assay, LMP1 reduced the capacity for DNA repair of both NPC-TW01 (p53-wild-type) and H1299 (p53-defficient) cells. As reduction of DNA repair by LMP1 occurs in p53-wild-type and p53-defficient cells, it seems that LMP1 can repress DNA repair in a p53-independent manner. Inactivation of DNA repair may render cells sensitive to DNA-damaging agents. In this study, H1299 cells harboring LMP1 were shown to be more sensitive to UV and bleomycin than those with a vector control. Using various deletion mutants of EBV LMP1 to determine the regions of LMP1 required to enhance MN formation, inhibit DNA repair and sensitize cells to DNA-damaging agents, we found that the region a. a. 189-222 (located within the CTAR1 domain) was responsible for sensitizing cells to UV and bleomycin, as well as for enhancing MN formation and repressing DNA repair. Based on these results, we suggest that disruption of DNA repair by LMP-1 results in an accumulation of unrepaired DNA and consequent genomic instability, which may contribute to the oncogenesis of LMP1 in human epithelial cells.	Natl Hlth Res Inst, Taipei 114, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Health Research Institutes - Taiwan; National Taiwan University	Chen, JY (corresponding author), Natl Hlth Res Inst, 3F 109,Sect 6,Min Chuan E Rd, Taipei 114, Taiwan.	cjy@nhri.org.tw	Lin, Chang-Shen/X-2189-2019; Chen, Jen-Yang/D-2085-2010; Lin, Chang-Shen/D-5140-2009	Lin, Chang-Shen/0000-0001-7415-2187; 				AARONSON SA, 1970, NATURE, V228, P359, DOI 10.1038/228359a0; AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ABRAHAMS PJ, 1976, MUTAT RES, V35, P13, DOI 10.1016/0027-5107(76)90164-0; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; ATHAS WF, 1991, CANCER RES, V51, P5786; BLANCO M, 1973, MUTAT RES, V17, P293, DOI 10.1016/0027-5107(73)90001-8; Butel JS, 1996, TRENDS MICROBIOL, V4, P119, DOI 10.1016/0966-842X(96)81529-0; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; Chang Y, 2002, HEAD NECK-J SCI SPEC, V24, P143, DOI 10.1002/hed.10039; CHEN JY, 1985, J MED VIROL, V17, P47, DOI 10.1002/jmv.1890170107; CHEN JY, 1989, J MED VIROL, V27, P269, DOI 10.1002/jmv.1890270403; CHEN JY, 1982, CHINESE J MICROBIOLO, V15, P255; Chen MR, 2001, J MED VIROL, V64, P51, DOI 10.1002/jmv.1017; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; Chien YC, 2001, NEW ENGL J MED, V345, P1877, DOI 10.1056/NEJMoa011610; Cho EY, 2003, CANCER EPIDEM BIOMAR, V12, P1100; Cleaver JE, 1989, METABOLIC BASIS INHE, V6th, P2949; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Duensing S, 2002, CANCER RES, V62, P7075; Fenech M, 2002, DRUG DISCOV TODAY, V7, P1128, DOI 10.1016/S1359-6446(02)02502-3; Floettmann JL, 1998, ONCOGENE, V17, P2383, DOI 10.1038/sj.onc.1202144; Gualandi G, 2001, MUTAGENESIS, V16, P203, DOI 10.1093/mutage/16.3.203; Gulley ML, 1998, HUM PATHOL, V29, P252, DOI 10.1016/S0046-8177(98)90044-2; HEDDLE JA, 1973, MUTAT RES, V18, P187, DOI 10.1016/0027-5107(73)90035-3; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HSU TY, 1992, J MED VIROL, V38, P214, DOI 10.1002/jmv.1890380311; HUANG DP, 1991, CANCER GENET CYTOGEN, V54, P91, DOI 10.1016/0165-4608(91)90035-S; HUANG DP, 1989, INT J CANCER, V43, P936, DOI 10.1002/ijc.2910430535; HUEN DS, 1995, ONCOGENE, V10, P549; JACOB F, 1953, COLD SPRING HARB SYM, V18, P101, DOI 10.1101/SQB.1953.018.01.019; KAMADA N, 1992, CANCER RES, V52, P1481; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KLOCKER H, 1986, EUR J CELL BIOL, V39, P346; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LEHMANN AR, 1985, NUCLEIC ACIDS RES, V13, P2087, DOI 10.1093/nar/13.6.2087; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; LIN CT, 1990, LAB INVEST, V62, P713; Liu MY, 1998, J MED VIROL, V56, P179, DOI 10.1002/(SICI)1096-9071(199811)56:3<179::AID-JMV1>3.0.CO;2-4; Liu MY, 1997, J MED VIROL, V52, P262, DOI 10.1002/(SICI)1096-9071(199707)52:3&lt;262::AID-JMV5&gt;3.0.CO;2-0; LIU MY, 1989, J MED VIROL, V28, P101, DOI 10.1002/jmv.1890280209; LO KW, 1992, ANTICANCER RES, V12, P1957; LO KW, 1995, CANCER RES, V55, P2039; Lu JJY, 1996, J GEN VIROL, V77, P1883, DOI 10.1099/0022-1317-77-8-1883; Lung ML, 1998, CANCER LETT, V133, P89, DOI 10.1016/S0304-3835(98)00209-2; LYTLE CD, 1972, INT J RADIAT BIOL RE, V22, P159, DOI 10.1080/716100000; Macera MJ, 1996, AM J HEMATOL, V52, P53, DOI 10.1002/(SICI)1096-8652(199605)52:1&lt;53::AID-AJH9&gt;3.0.CO;2-5; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARUYAMA K, 1990, CANCER RES, V50, pS5697; MATSUOKA A, 1992, MUTAT RES, V272, P223, DOI 10.1016/0165-1161(92)91535-Y; MITSUDOMI T, 1992, ONCOGENE, V7, P171; OLD LJ, 1966, P NATL ACAD SCI USA, V56, P1699, DOI 10.1073/pnas.56.6.1699; PARRY JM, 1987, MUTAT RES, V181, P267, DOI 10.1016/0027-5107(87)90104-7; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; PROTICSABLJIC M, 1985, P NATL ACAD SCI USA, V82, P6622, DOI 10.1073/pnas.82.19.6622; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Shao JY, 2001, ANTICANCER RES, V21, P3021; SMITH ML, 1995, ONCOGENE, V10, P1053; SPRUCK CH, 1992, CANCER RES, V52, P4787; STERNES KL, 1989, MUTAGENESIS, V4, P425, DOI 10.1093/mutage/4.6.425; Stopper H, 1997, MUTAT RES-DNA REPAIR, V383, P107, DOI 10.1016/S0921-8777(96)00049-3; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; SUN Y, 1995, ONCOGENE, V10, P785; THODAY JM, 1951, BRIT J RADIOL, V24, P572, DOI 10.1259/0007-1285-24-286-572; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VANDEREB AJ, 1967, BIOCHEM BIOPH RES CO, V28, P284, DOI 10.1016/0006-291X(67)90442-1; ZENG Y, 1982, INT J CANCER, V29, P139, DOI 10.1002/ijc.2910290204	75	82	83	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2004	23	14					2531	2539		10.1038/sj.onc.1207375	http://dx.doi.org/10.1038/sj.onc.1207375			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14716302				2022-12-28	WOS:000220558000010
J	Lee, LF; Louie, MC; Desai, SJ; Yang, J; Chen, HW; Evans, CP; Kung, HJ				Lee, LF; Louie, MC; Desai, SJ; Yang, J; Chen, HW; Evans, CP; Kung, HJ			Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK	ONCOGENE			English	Article						interleukin-B; androgen-independence; migration; LNCAP; Src; focal adhesion kinase	PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; CARCINOMA-CELLS; RECEPTOR TRANSACTIVATION; CHEMOKINE RECEPTORS; GENE-EXPRESSION; OVARIAN-CANCER; IN-VITRO; ACTIVATION; PATHWAY	Interleukin- 8 ( IL- 8), a chemokine implicated in the metastasis and angiogenesis of a variety of cancers, has been reported to be overexpressed in prostate cancer. In this study, we ascribe a new role for IL- 8 in prostate cancer progression using LNCaP cells. We demonstrate that IL- 8 activates the androgen receptor and confers androgen- independent growth, while serving as a potent chemotactic factor. Our evaluation of the possible signal pathways involved in androgen- independence and cell migration shows that the tyrosine kinases Src and FAK ( focal adhesion kinase) are involved in IL- 8- induced signaling. Pharmacological and genetic inhibitors of Src and FAK interfere with IL- 8- induced cell migration, while only the Src inhibitor was able to repress androgen-independent growth. This suggests that both growth and migration depend on the activity of Src, whereas cell migration also requires the activation of FAK. Our evidence that IL- 8- induced androgen- independent growth is, at least in part, due to androgen receptor activation includes ( 1) an inhibitor of androgen receptor activity diminishes cell growth; ( 2) androgen receptor transactivation potential is augmented by IL- 8 and ( 3) androgen receptor is recruited to the promoter of prostate specific antigen ( PSA) upon IL- 8 treatment, based on chromatin immunoprecipitation experiments. Taken together, our data suggest that in addition to its role in metastasis and angiogenesis, IL- 8 may also serve as a facilitator for androgen- independent transition of prostate cancers. To our knowledge, this is the first report about the tyrosine kinase signals and androgen receptor activation induced by IL- 8 in prostate cancer cells. The observation that IL- 8 mediates its growth and chemotactic effects via Src and FAK suggests the potential use for tyrosine kinase inhibitors at early stage of prostate cancer development.	Univ Calif Davis, Dept Biol Chem, Sacramento, CA 95817 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA	University of California System; University of California Davis; Stanford University; University of California System; University of California Davis	Kung, HJ (corresponding author), Univ Calif Davis, Ctr Canc, Res III,UCDMC,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NATIONAL CANCER INSTITUTE [R37CA039207, R01CA082073, P30CA093373, U01CA057179, R01CA057179, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK060748] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57179, P30 CA93373, CA82073, CA39207] Funding Source: Medline; NIDDK NIH HHS [DK52695, K08 DK60748] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balbay MD, 1999, CLIN CANCER RES, V5, P783; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen TS, 2000, CANCER RES, V60, P2132; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1994, CANCER RES, V54, P5474; Dai J, 2002, CLIN CANCER RES, V8, P2399; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Debes JD, 2002, CANCER RES, V62, P5632; Feniger-Barish R, 2003, BIOCHEMISTRY-US, V42, P2874, DOI 10.1021/bi026783d; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Gioeli D, 2002, J BIOL CHEM, V277, P29304, DOI 10.1074/jbc.M204131200; Greene GF, 1997, AM J PATHOL, V150, P1571; Herrera CA, 2002, INT J ONCOL, V20, P5; Hunger-Glaser I, 2003, J BIOL CHEM, V278, P22631, DOI 10.1074/jbc.M210876200; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kanda N, 2001, J INVEST DERMATOL, V117, P274, DOI 10.1046/j.1523-1747.2001.01422.x; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Lee SO, 2003, CLIN CANCER RES, V9, P370; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Luttrell LM, 2002, J CELL SCI, V115, P455; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MATSUSHIMA K, 1992, CHEM IMMUNOL, V51, P236; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; MOORE BB, 1999, AM J PATHOL, V162, P5511; Onuffer JJ, 2002, TRENDS PHARMACOL SCI, V23, P459, DOI 10.1016/S0165-6147(02)02064-3; Papakonstanti EA, 2003, MOL ENDOCRINOL, V17, P870, DOI 10.1210/me.2002-0253; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Patel BJ, 2000, J UROLOGY, V164, P1420, DOI 10.1016/S0022-5347(05)67210-2; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Reiland J, 1999, PROSTATE, V41, P78; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHADENDORF D, 1993, J IMMUNOL, V151, P2667; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sumitomo M, 2000, J CLIN INVEST, V106, P1399, DOI 10.1172/JCI10536; Torring N, 2000, ANTICANCER RES, V20, P91; Tremblay L, 1996, INT J CANCER, V68, P164, DOI 10.1002/(SICI)1097-0215(19961009)68:2<169::AID-IJC4>3.0.CO;2-W; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Veltri RW, 1999, UROLOGY, V53, P139, DOI 10.1016/S0090-4295(98)00455-5; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wen Y, 2000, CANCER RES, V60, P6841; Xia L, 2002, J BIOL CHEM, V277, P35422, DOI 10.1074/jbc.M203940200; Xiao DM, 2003, CELL SIGNAL, V15, P945, DOI 10.1016/S0898-6568(03)00059-7; Xu L, 1998, HUM GENE THER, V9, P2699, DOI 10.1089/hum.1998.9.18-2699; Yang L, 2003, BIOCHEM BIOPH RES CO, V305, P462, DOI 10.1016/S0006-291X(03)00792-7; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458	52	146	157	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2197	2205		10.1038/sj.onc.1207344	http://dx.doi.org/10.1038/sj.onc.1207344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14767470				2022-12-28	WOS:000220280900009
J	Li, CX; Chi, SM; He, NG; Zhang, XL; Guicherit, O; Wagner, R; Tyring, S; Xie, JW				Li, CX; Chi, SM; He, NG; Zhang, XL; Guicherit, O; Wagner, R; Tyring, S; Xie, JW			IFN alpha induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling	ONCOGENE			English	Article						hedgehog; smoothened; BCCs; PDGFR alpha; INF alpha; MEK; Fas	PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; MEDIATED APOPTOSIS; HUMAN HOMOLOG; PATCHED GENE; SOMATIC MUTATIONS; NEVUS SYNDROME; ONCOGENIC RAS; CARCINOMA; SKIN	Basal cell carcinoma (BCC), the most common form of human cancer, is understood to be associated with activation of the sonic hedgehog pathway, through loss-of-function mutations of tumor suppressor PTCH1 or gain-of-function mutations of smoothened. Interferon (IFN)-based therapy is quite effective in BCC treatment, but the molecular basis is not well understood. Here we report a novel mechanism by which IFNalpha mediates apoptosis in BCCs. In the presence of IFNalpha, we observed increased apoptosis in a BCC cell line ASZ001, in which PTC is null, and therefore with constitutive activation of the sonic hedgehog pathway. We demonstrate that SMO agonist Ag-1.4 mediates activation of extracellular signal-regulated kinase (Erk) phosphorylation, which is abrogated by IFNalpha in sonic hedgehog responsive C3H10T1/2 cells. In transient transfection experiments, we demonstrate that IFNalpha inhibits Erk phosphorylation and serum response element activation induced by expression of SMO, Gli1, PDGFRalpha and activated Raf, but not activated mitogen-activated Erk-regulating kinase (Mek), suggesting that IFNalpha targets mainly on Mek function. We further show that IFNalpha induces expression of Fas in BCC cells through interfering with Mek function. The role of the Fas-L/Fas signaling axis in IFNalpha-mediated apoptosis is demonstrated by the fact that addition of Fas-L neutralizing antibodies, just as caspase-8 inhibitor Z-IETD-FMK, effectively prevents IFNalpha-mediated apoptosis. Thus, our data indicate that IFNalpha-based BCC therapy induces Fas expression and apoptosis through interfering with Mek function.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; Curis Inc, Cambridge, MA 02138 USA; Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77555 USA; Xijing Hosp, Dept Dermatol, Xian 710032, Peoples R China	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Air Force Military Medical University	Xie, JW (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA.	jinxie@utmb.edu						Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; Buechner SA, 1997, J CLIN INVEST, V100, P2691, DOI 10.1172/JCI119814; CHIMENTI S, 1995, DERMATOLOGY, V190, P214, DOI 10.1159/000246688; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; Epstein E, 2001, MED PEDIATR ONCOL, V36, P555, DOI 10.1002/mpo.1129; Fenton RG, 1998, CANCER RES, V58, P3391; Filipowicz E, 2002, CANCER, V94, P814, DOI 10.1002/cncr.10277; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; GROB JJ, 1988, LANCET, V1, P878; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hottiger MO, 1999, GENE THER, V6, P1929, DOI 10.1038/sj.gt.3301036; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; Larner A, 1996, BIOTHERAPY, V8, P175, DOI 10.1007/BF01877202; Lee SH, 1998, BRIT J DERMATOL, V139, P186; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Reifenberger J, 1998, CANCER RES, V58, P1798; Romerio F, 2002, FASEB J, V16, P1680, DOI 10.1096/fj.02-0120fje; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Vander Straten M, 2000, Adv Dermatol, V16, P299; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 2001, P NATL ACAD SCI USA, V98, P9255, DOI 10.1073/pnas.151173398; Xie JW, 1997, CANCER RES, V57, P2369; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Xie JW, 1997, GENE CHROMOSOME CANC, V18, P305	34	52	57	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1608	1617		10.1038/sj.onc.1207273	http://dx.doi.org/10.1038/sj.onc.1207273			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14647422				2022-12-28	WOS:000189219500015
J	Li, YW; Rao, PK; Wen, R; Song, Y; Muir, D; Wallace, P; van Horne, SJ; Tennekoon, GI; Kadesch, T				Li, YW; Rao, PK; Wen, R; Song, Y; Muir, D; Wallace, P; van Horne, SJ; Tennekoon, GI; Kadesch, T			Notch and Schwann cell transformation	ONCOGENE			English	Article						Notch; NICD; Schwann; neurofibromatosis; MPNST; p53	TRANSCRIPTION FACTOR SOX10; NERVE SHEATH TUMORS; NEUROFIBROMATOSIS TYPE-1; PERIPHERAL-NERVE; NEOPLASTIC TRANSFORMATION; INTRACELLULAR DOMAIN; SIGNALING PATHWAY; PROGENITOR CELLS; HUMAN HOMOLOG; BONE-MARROW	Benign plexiform neurofibromas in NF1 patients can transform spontaneously into malignant peripheral nerve sheath tumors (MPNSTs). Although mutations in the p53 gene have been found in a subset of MPNSTs and mouse models support a role for p53 mutations in malignant conversion, we found that each of three Schwann cell lines derived from human MPNSTs possessed active p53. One of the lines expressed the Notch intracellular domain (NICD), indicative of ongoing Notch signaling. Consistent with a role in malignancy, NICD was able to transform primary rat Schwann cells. Transformation was robust NICD-transduced cells generated tumors in nude rats and was associated with the loss of markers associated with Schwann cell differentiation. These data suggest that aberrant Notch signaling may contribute to the conversion of benign neurofibromas to MPNSTs.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurol & Pediat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA; Univ Florida, Coll Med, Div Neurol, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kadesch, T (corresponding author), Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA.	kadesch@mail.med.upenn.edu			NEI NIH HHS [R01 EY12727] Funding Source: Medline; NIGMS NIH HHS [R01 GM58228] Funding Source: Medline; NINDS NIH HHS [R01 NS21700] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012727] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058228] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021700] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allman D, 2002, CELL, V109, pS1, DOI 10.1016/S0092-8674(02)00689-X; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Beatus P, 1999, DEVELOPMENT, V126, P3925; Birindelli S, 2001, LAB INVEST, V81, P833, DOI 10.1038/labinvest.3780293; Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DAVIS JB, 1990, J CELL BIOL, V110, P1353, DOI 10.1083/jcb.110.4.1353; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; delaPompa J, 1997, DEVELOPMENT, V124, P1139; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; Gutmann DH, 2001, HUM MOL GENET, V10, P747, DOI 10.1093/hmg/10.7.747; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Jehn BM, 1999, J IMMUNOL, V162, P635; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kourea HP, 1999, AM J PATHOL, V155, P1855, DOI 10.1016/S0002-9440(10)65504-6; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535-6108(03)00140-5; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Muir D, 2001, AM J PATHOL, V158, P501, DOI 10.1016/S0002-9440(10)63992-2; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; RAO P, 2003, IN PRESS MOL CELL BI; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Ross DA, 2001, MOL CELL BIOL, V21, P7537, DOI 10.1128/MCB.21.22.7537-7544.2001; Rutkowski JL, 2000, HUM MOL GENET, V9, P1059, DOI 10.1093/hmg/9.7.1059; Small D, 2003, J BIOL CHEM, V278, P16405, DOI 10.1074/jbc.M300464200; Soriano JV, 2000, INT J CANCER, V86, P652; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanigaki K, 2001, NEURON, V29, P45, DOI 10.1016/S0896-6273(01)00179-9; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wang SL, 2000, NEURON, V27, P197, DOI 10.1016/S0896-6273(00)00028-3; Wang SL, 1998, NEURON, V21, P63, DOI 10.1016/S0896-6273(00)80515-2; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	51	33	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2004	23	5					1146	1152		10.1038/sj.onc.1207068	http://dx.doi.org/10.1038/sj.onc.1207068			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	770UV	14762442				2022-12-28	WOS:000188749900013
J	Zou, WG; Luo, CX; Zhang, ZL; Liu, J; Gu, JF; Pei, ZF; Qian, C; Liu, XY				Zou, WG; Luo, CX; Zhang, ZL; Liu, J; Gu, JF; Pei, ZF; Qian, C; Liu, XY			A novel oncolytic adenovirus targeting to telomerase activity in tumor cells with potent	ONCOGENE			English	Article						oncolytic adenovirus; E1A gene; hTERT promoter; telomerase; cancer	REPLICATION-COMPETENT ADENOVIRUS; SUICIDE GENE-THERAPY; EXPRESSING BACTERIAL NITROREDUCTASE; REVERSE-TRANSCRIPTASE PROMOTER; CATALYTIC SUBUNIT HTERT; HUMAN CANCER-CELLS; HUMAN BONE-MARROW; PROSTATE-CANCER; HEPATOCELLULAR-CARCINOMA; BAX GENE	Telomerase is a therapeutic target for cancer. Human telomerase reverse transcriptase (hTERT), the catalytic subunit of the telomerase, is transcriptionaly upregulated exclusively in about 90#37; of cancer cells. Previous studies have demonstrated that hTERT promoter can control the expression of exogenous genes to the telomerase-positive cancer cells, thus hTERT promoter is an excellent candidate for generating cancer-specific oncolytic adenovirus. In this study, we devised a novel oncolytic adenovirus (Ad.TERT) by replacing the normal E1A regulatory elements with hTERT promoter. Ad.TERT displays cancer-specific E1A expression, virus replication and cytolysis in in vitro experiments. In animal experiments, intratumoral administration of Ad.TERT demonstrates potent antitumoral efficacy at least in two xenograft models (Bcap37 and BEL7404). Ad.TERT was targeted by the telomerase activity in cancer cells and has potent antitumoral efficacy in vivo, and since telomerase activity is a wide-ranged tumor marker, Ad.TERT could be a powerful therapeutic agent for a variety of cancers.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China; Univ Navarra, Sch Med, Dept Med, E-31080 Pamplona, Spain	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; University of Navarra	Liu, XY (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	xyliu@sibs.ac.cn	zhang, zl/D-9716-2012					Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Bilsland AE, 2003, ONCOGENE, V22, P370, DOI 10.1038/sj.onc.1206168; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Curiel DT, 2000, CLIN CANCER RES, V6, P3395; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Freytag SO, 1998, HUM GENE THER, V9, P1323, DOI 10.1089/hum.1998.9.9-1323; Gu J, 2000, CANCER RES, V60, P5359; Gu J, 2002, ONCOGENE, V21, P4757, DOI 10.1038/sj.onc.1205582; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hernandez-Alcoceba R, 2002, HUM GENE THER, V13, P1737, DOI 10.1089/104303402760293574; HORWITZ MS, 1996, FIELDS VIROLOGY, P2149; Ichikawa T, 2001, CANCER RES, V61, P5336; Jakubczak JL, 2003, CANCER RES, V63, P1490; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirch HC, 2002, ONCOGENE, V21, P7991, DOI 10.1038/sj.onc.1205965; Kirn D, 2001, NAT MED, V7, P781, DOI 10.1038/89901; Komata T, 2002, ONCOGENE, V21, P656, DOI 10.1038/sj.onc.1205072; Kruyt FAE, 2002, HUM GENE THER, V13, P485, DOI 10.1089/10430340252809784; Kurihara T, 2000, J CLIN INVEST, V106, P763, DOI 10.1172/JCI9180; Li YH, 2001, CANCER RES, V61, P6428; Lin TY, 2002, ONCOGENE, V21, P8020, DOI 10.1038/sj.onc.1205926; Liu J, 2002, INT J ONCOL, V21, P661; Matsubara S, 2001, CANCER RES, V61, P6012; MCKINNON RD, 1982, GENE, V19, P33, DOI 10.1016/0378-1119(82)90186-X; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Motoi F, 2000, HUM GENE THER, V11, P223, DOI 10.1089/10430340050015978; Nakamura Y, 1999, MOL CARCINOGEN, V26, P312, DOI 10.1002/(SICI)1098-2744(199912)26:4<312::AID-MC10>3.3.CO;2-1; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; Plumb JA, 2001, ONCOGENE, V20, P7797, DOI 10.1038/sj.onc.1204954; Post DE, 2003, ONCOGENE, V22, P2065, DOI 10.1038/sj.onc.1206464; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; Rodriguez R, 1997, CANCER RES, V57, P2559; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Takakura M, 1999, CANCER RES, V59, P551; Tsukuda K, 2002, CANCER RES, V62, P3438; Wang JH, 2002, BIOCHEM BIOPH RES CO, V290, P1454, DOI 10.1006/bbrc.2002.6373; Watanabe T, 1996, BLOOD, V87, P5032, DOI 10.1182/blood.V87.12.5032.bloodjournal87125032; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Wildner O, 1999, GENE THER, V6, P57, DOI 10.1038/sj.gt.3300810; Yasumoto S, 1996, ONCOGENE, V13, P433; Yu DC, 1999, CANCER RES, V59, P4200; Yu DC, 2001, CANCER RES, V61, P517	46	53	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					457	464		10.1038/sj.onc.1207033	http://dx.doi.org/10.1038/sj.onc.1207033			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724574				2022-12-28	WOS:000188098300016
J	Cencig, S; Nanbru, C; Le, SY; Gueydan, C; Huez, G; Kruys, V				Cencig, S; Nanbru, C; Le, SY; Gueydan, C; Huez, G; Kruys, V			Mapping and characterization of the minimal internal ribosome entry segment in the human c-myc mRNA 5 ' untranslated region	ONCOGENE			English	Article						translation; IRES; proto-oncogene; c-myc	SITE-MEDIATED TRANSLATION; 5' UNTRANSLATED REGION; GROWTH-FACTOR; CELL-CYCLE; ALTERNATIVE TRANSLATION; PROTEIN-SYNTHESIS; INITIATION; TRANSCRIPTION; BINDING; IDENTIFICATION	The human c-myc proto-oncogene is transcribed from four alternative promoters generating transcripts with 5' untranslated regions of various lengths. These transcripts encode two proteins, c-Myc1 and c-Myc2, from two initiation codons, CUG and AUG, respectively. We and others have previously demonstrated that the region of c-myc transcripts between nucleotides (nt) -363 and -94 upstream from the CUG start codon contained an internal ribosome entry site leading to the cap-independent translation of c-myc open reading frames (ORFs). Here, we mapped a 50-nt sequence (-143 -94), which is sufficient to promote internal translation initiation of c-myc ORFs. Interestingly, this 50-nt element can be further dissected into two segments of 14 nt, each capable of activating internal translation initiation. We also demonstrate that this 50-nt element acts as the ribosome landing site from which the preinitiation ribosomal complex scans the mRNA until the CUG or AUG start codons.	Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, B-6041 Gosselies, Belgium; NCI, Lab Expt & Computat Biol, Ctr Canc Res, NIH, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kruys, V (corresponding author), Free Univ Brussels, Inst Biol & Med Mol, Chim Biol Lab, Rue Profs Jeener & Brachet 12, B-6041 Gosselies, Belgium.	vkruys@ulb.ac.be	Kruys, Veronique I/N-6613-2018	Kruys, Veronique/0000-0002-3144-5403; Gueydan, Cyril/0000-0003-3097-7667				Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1994, GENE DEV, V8, P2441, DOI 10.1101/gad.8.20.2441; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Holcik M, 2003, MOL CELL BIOL, V23, P280, DOI 10.1128/MCB.23.1.280-288.2003; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; JACKSON RJ, 1988, NATURE, V334, P292, DOI 10.1038/334292a0; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; Kim JH, 2003, MOL CELL BIOL, V23, P708, DOI 10.1128/MCB.23.2.708-720.2003; KRUYS V, 1993, J EXP MED, V177, P1383, DOI 10.1084/jem.177.5.1383; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Mitchell SA, 2003, MOL CELL, V11, P757, DOI 10.1016/S1097-2765(03)00093-5; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; Owens GC, 2001, P NATL ACAD SCI USA, V98, P1471, DOI 10.1073/pnas.98.4.1471; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Ryan KM, 1996, BIOCHEM J, V314, P713, DOI 10.1042/bj3140713; Sella O, 1999, MOL CELL BIOL, V19, P5429; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Subkhankulova T, 2001, BIOCHEM J, V359, P183, DOI 10.1042/0264-6021:3590183; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	48	16	18	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					267	277		10.1038/sj.onc.1207017	http://dx.doi.org/10.1038/sj.onc.1207017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712232				2022-12-28	WOS:000187895300028
J	Kim, B; van Golen, CM; Feldman, EL				Kim, B; van Golen, CM; Feldman, EL			Insulin-like growth factor-I signaling in human neuroblastoma cells	ONCOGENE			English	Article						insulin-like growth factor I; neuroblastoma; Shc; insulin receptor substrate; FAK; paxillin	FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; NEURAL CREST; DIFFERENTIAL REGULATION; HEMATOPOIETIC-CELLS; PREVENTS APOPTOSIS; MEDIATED SURVIVAL; BREAST-CANCER	Neuroblastoma is a heterogeneous tumor consisting of N (neuronal) and S (stromal) cells. We report that more tumorigenic and motile N cells express higher levels of IGF-I receptor (IGF-IR) than less tumorigenic, more adherent S cells. Shc, one of the two major docking partners of IGF-IR, is equally expressed in N and S cell lines. IGF-I treatment phosphorylates Shc in N cells, but only weakly activates Shc in S cells. Expression of the second partner, insulin receptor substrate (IRS), is cell type specific. S cells exclusively express IRS-1 that undergoes sustained phosphorylation by IGF-I. In contrast, N cells express IRS-2 that is transiently phosphorylated by IGF-I. Downstream of IRS-2 and Shc, IGF-I treatment results in strong activation of Akt and MAPK in N cells and activation of both pathways is required for IGF-I-mediated differentiation. Only IGF-IR activation of phosphatidylinositol-3 kinase is required for tumor edge ruffling in N and S cells, with stimulation of focal adhesion kinase (FAK) and paxillin. This detailed understanding of the 'biochemical signature' of N and S cells provides the background needed to target and disrupt specific IGF signaling pathways in an attempt to develop more effective therapies.	Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kim, B (corresponding author), Univ Michigan, Dept Neurol, 4414 Kresge III,200 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bhumsoo@umich.edu		Feldman, Eva/0000-0002-9162-2694	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038849, R01NS036778] Funding Source: NIH RePORTER; NINDS NIH HHS [NS36778, NS38849] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON DJ, 1993, ANNU REV NEUROSCI, V16, P129, DOI 10.1146/annurev.ne.16.030193.001021; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; CICCARONE V, 1989, CANCER RES, V49, P219; Corvi R, 1997, J NEURO-ONCOL, V31, P25, DOI 10.1023/A:1005721027709; DECLERCK YA, 1987, CANCER RES, V47, P6505; DEMEYTS P, 1994, HORM RES, V42, P152, DOI 10.1159/000184188; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Encinas M, 1999, J NEUROCHEM, V73, P1409, DOI 10.1046/j.1471-4159.1999.0731409.x; FAVROT MC, 1991, INT J CANCER, V49, P347, DOI 10.1002/ijc.2910490306; Feldman EL, 1997, NEUROBIOL DIS, V4, P201, DOI 10.1006/nbdi.1997.0156; FLICKINGER KS, 1994, EXP CELL RES, V213, P156, DOI 10.1006/excr.1994.1185; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frappaz D, 2000, J CLIN ONCOL, V18, P468, DOI 10.1200/JCO.2000.18.3.468; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; Greene MW, 2003, J BIOL CHEM, V278, P8199, DOI 10.1074/jbc.M209153200; Guo HB, 2002, CANCER RES, V62, P6837; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Ivankovic-Dikic I, 2000, NAT CELL BIOL, V2, P574, DOI 10.1038/35023515; Judware R, 1995, ONCOGENE, V11, P2599; Kim B, 1997, J BIOL CHEM, V272, P21268, DOI 10.1074/jbc.272.34.21268; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kim B, 1998, ENDOCRINOLOGY, V139, P4881, DOI 10.1210/en.139.12.4881; Kim BS, 1998, J NEUROCHEM, V71, P1333; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Leventhal PS, 1997, TRENDS ENDOCRIN MET, V8, P1, DOI 10.1016/S1043-2760(96)00202-0; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu XD, 1998, CANCER RES, V58, P5432; Meyer G, 2002, J NEUROCHEM, V83, P490, DOI 10.1046/j.1471-4159.2002.01185.x; Meyer GE, 2001, ONCOGENE, V20, P7542, DOI 10.1038/sj.onc.1204927; Miller TM, 1997, J BIOL CHEM, V272, P9847; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Ogihara T, 1997, J BIOL CHEM, V272, P12868, DOI 10.1074/jbc.272.19.12868; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pederson TM, 2001, DIABETES, V50, P24, DOI 10.2337/diabetes.50.1.24; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSS RA, 1985, CANCER RES, V45, P1628; ROSS RA, 1995, CELL GROWTH DIFFER, V6, P449; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Russell JW, 1998, J NEUROBIOL, V36, P455, DOI 10.1002/(SICI)1097-4695(19980915)36:4<455::AID-NEU1>3.0.CO;2-V; Salgia R, 1999, ONCOGENE, V18, P67, DOI 10.1038/sj.onc.1202273; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; Scibelli A, 2003, VET RES, V34, P193, DOI 10.1051/vetres:2002066; Seiler AEM, 2001, J NEUROCHEM, V76, P573, DOI 10.1046/j.1471-4159.2001.00025.x; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Singleton JR, 1996, CANCER RES, V56, P4522; Thomas JW, 1999, J BIOL CHEM, V274, P36684, DOI 10.1074/jbc.274.51.36684; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2000, J BIOL CHEM, V275, P25451, DOI 10.1074/jbc.M002271200; van Golen CM, 2001, CELL GROWTH DIFFER, V12, P371; Van Golen CM, 2000, J CELL PHYSIOL, V182, P24, DOI 10.1002/(SICI)1097-4652(200001)182:1<24::AID-JCP3>3.0.CO;2-6; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Waters SB, 1996, TRENDS CELL BIOL, V6, P1, DOI 10.1016/0962-8924(96)81024-5; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; YOSHIHARA T, 1992, INT J CANCER, V51, P620, DOI 10.1002/ijc.2910510419; Yu H, 1999, JNCI-J NATL CANCER I, V91, P151, DOI 10.1093/jnci/91.2.151; Zumkeller W, 1999, HORM METAB RES, V31, P138, DOI 10.1055/s-2007-978711	77	69	69	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2004	23	1					130	141		10.1038/sj.onc.1206924	http://dx.doi.org/10.1038/sj.onc.1206924			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712218				2022-12-28	WOS:000187895300014
J	Imai, T; Adachi, S; Nishijo, K; Ohgushi, M; Okada, M; Yasumi, T; Watanabe, K; Nishikomori, R; Nakayama, T; Yonehara, S; Toguchida, J; Nakahata, T				Imai, T; Adachi, S; Nishijo, K; Ohgushi, M; Okada, M; Yasumi, T; Watanabe, K; Nishikomori, R; Nakayama, T; Yonehara, S; Toguchida, J; Nakahata, T			FR901228 induces tumor regression associated with induction of Fas ligand and activation of Fas signaling in human osteosarcoma cells	ONCOGENE			English	Article						histone deacetylase inhibitor; osteosarcoma; apoptosis; Fas ligand; Fas	HISTONE DEACETYLASE INHIBITOR; CHROMOBACTERIUM-VIOLACEUM NO-968; ACUTE PROMYELOCYTIC LEUKEMIA; COLON-CANCER CELLS; MEDIATED APOPTOSIS; DEPSIPEPTIDE FR901228; IN-VITRO; ADJUVANT CHEMOTHERAPY; MONOCLONAL-ANTIBODY; OSTEOGENIC-SARCOMA	We investigated the antitumor effects of FR901228, a HDAC inhibitor, on human osteosarcoma cells, in vitro and in vivo to explore its possible utility in the treatment of pediatric bone cancers. FR901228 caused marked growth inhibition with a 50% inhibitory concentration of 1.2-7.3 nM and induction of apoptosis in all eight osteosarcoma cell lines tested. These effects of FR901228 were also observed in vivo xenograft models on BALB/c nude mice, and treatment with 5.6 mg/kg/day resulting in a >70% reduction in the mean final tumor volume compared with the mean initial tumor volume. TUNEL assays demonstrated extensive apoptosis in tumor sections of mice treated with FR901228. Induction of apoptosis was preceded by increased expression of Fas ligand ( FasL) mRNA, resulting in expression of membrane-bound FasL, which was followed by sequential activation of caspase-8 and -3. The level of apoptosis induction was reduced using a neutralizing anti-FasL antibody and overexpression of either the dominant-negative FADD or the viral FLICE inhibitory protein. Furthermore, treatment with a suboptimal dose of FR901228 greatly sensitized osteosarcoma cells to agonistic anti-Fas antibody-mediated apoptosis. These findings suggest that FR901228 is a highly promising antitumor agent against osteosarcoma, inducing apoptosis by the activation of the Fas/FasL system.	Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Inst Frontier Med Sci, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Kyoto University	Adachi, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.		Nishikomori, Ryuta/AAM-5771-2020; Nishikomori, Ryuta/N-4039-2018	Nishikomori, Ryuta/0000-0002-9407-6158; Nishikomori, Ryuta/0000-0002-9407-6158; Yasumi, Takahiro/0000-0003-3257-5071				Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Aron JL, 2003, BLOOD, V102, P652, DOI 10.1182/blood-2002-12-3794; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; BERON G, 1985, EUR PAEDIATR HAEMAT, V2, P77, DOI 10.3109/08880018509141211; Bonnotte B, 1998, CELL DEATH DIFFER, V5, P480, DOI 10.1038/sj.cdd.4400371; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMWELL VHC, 1992, J CLIN ONCOL, V10, P1579, DOI 10.1200/JCO.1992.10.10.1579; Cuisset L, 1998, BIOCHEM BIOPH RES CO, V246, P760, DOI 10.1006/bbrc.1998.8698; Debatin KM, 1999, DRUG RESIST UPDATE, V2, P85, DOI 10.1054/drup.1999.0073; EILBER F, 1987, J CLIN ONCOL, V5, P21, DOI 10.1200/JCO.1987.5.1.21; Fellenberg J, 1997, INT J CANCER, V72, P536, DOI 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 1998, INT J CANCER, V76, P105; Gastman BR, 1999, CANCER RES, V59, P5356; Glick RD, 1999, CANCER RES, V59, P4392; Gore SD, 2000, EXPERT OPIN INV DRUG, V9, P2923, DOI 10.1517/13543784.9.12.2923; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamada T, 1999, INT J ONCOL, V15, P1125; Haruyama H, 2002, BIOL PHARM BULL, V25, P1537, DOI 10.1248/bpb.25.1537; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Himelstein Bruce P., 1998, Current Opinion in Oncology, V10, P326, DOI 10.1097/00001622-199807000-00009; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; ISHII S, 1982, INT ORTHOP, V6, P215; Jaboin J, 2002, CANCER RES, V62, P6108; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; Klisovic DD, 2003, INVEST OPHTH VIS SCI, V44, P2390, DOI 10.1167/iovs.02-1052; Kosugi H, 2001, JPN J CANCER RES, V92, P529, DOI 10.1111/j.1349-7006.2001.tb01126.x; Kwon SH, 2002, J BIOL CHEM, V277, P2073, DOI 10.1074/jbc.M106699200; Lafleur EA, 2001, CANCER RES, V61, P4066; LINK MP, 1991, CLIN ORTHOP RELAT R, P8; Lynch MP, 1998, J CELL BIOCHEM, V68, P31; MARINA NM, 1992, CANCER-AM CANCER SOC, V70, P2722, DOI 10.1002/1097-0142(19921201)70:11<2722::AID-CNCR2820701125>3.0.CO;2-S; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5; Mizutani Y, 1997, CANCER, V79, P1180, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1180::AID-CNCR17>3.0.CO;2-W; Murakami H, 2002, CANCER LETT, V182, P203, DOI 10.1016/S0304-3835(02)00096-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; OhYama T, 2000, MICROBIOL IMMUNOL, V44, P289, DOI 10.1111/j.1348-0421.2000.tb02498.x; Ozaki T, 2003, J CLIN ONCOL, V21, P334, DOI 10.1200/JCO.2003.01.142; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Prakash S, 2001, INVEST NEW DRUG, V19, P1, DOI 10.1023/A:1006489328324; Richon VM, 2002, CLIN CANCER RES, V8, P662; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; ROSEN G, 1979, CANCER-AM CANCER SOC, V43, P2163, DOI 10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S; Sandor V, 2002, CLIN CANCER RES, V8, P718; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; Sasakawa Y, 2002, BIOCHEM PHARMACOL, V64, P1079, DOI 10.1016/S0006-2952(02)01261-3; Seki K, 2000, CANCER CHEMOTH PHARM, V45, P199, DOI 10.1007/s002800050030; Shen J, 2003, MOL ENDOCRINOL, V17, P743, DOI 10.1210/me.2002-0122; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UEDA H, 1994, J ANTIBIOT, V47, P301; UEDA H, 1994, J ANTIBIOT, V47, P315; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wang LH, 1998, ANTICANCER RES, V18, P321; Wang RX, 1998, ONCOGENE, V17, P1503, DOI 10.1038/sj.onc.1202059; Weiser TS, 2001, J IMMUNOTHER, V24, P151, DOI 10.1097/00002371-200103000-00010; Wu XX, 2000, CANCER RES, V60, P2912; Yonehara S, 2002, CYTOKINE GROWTH F R, V13, P393, DOI 10.1016/S1359-6101(02)00024-2; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	76	60	66	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	2003	22	58					9231	9242		10.1038/sj.onc.1207184	http://dx.doi.org/10.1038/sj.onc.1207184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14647441	Green Submitted			2022-12-28	WOS:000187400400005
J	Dinulescu, DM; Wood, LJ; Shen, L; Loriaux, M; Corless, CL; Gross, AW; Ren, RB; Deininger, MWN; Druker, BJ				Dinulescu, DM; Wood, LJ; Shen, L; Loriaux, M; Corless, CL; Gross, AW; Ren, RB; Deininger, MWN; Druker, BJ			c-CBL is not required for leukemia induction by Bcr-Abl in mice	ONCOGENE			English	Article						c-Cbl; Bcr-Abl; leukemia; CML	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PHILADELPHIA-CHROMOSOME; TYROSINE PHOSPHORYLATION; MYELOPROLIFERATIVE DISEASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR	Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are required for Bcr-Abl to transform cells. The multifunctional protein c-Cbl is one of the most prominently tyrosine-phosphorylated proteins in Bcr-Abl-expressing cells. Using cell lines and mice with homozygous disruption of the c-CBL locus, we investigated the role of this protein for Bcr-Abl-driven transformation. We find that although c-Cbl(-/-) fibroblast cell lines show a deficit in Bcr-Abl transformation compared to wild-type (Wt) cells, this deficit was less pronounced in c-Cbl(-/-) B cells derived from murine bone marrow. Most importantly, in a transplantation model of CML, Bcr-Abl was capable of inducing fatal leukemia in mice in the absence of c-Cbl protein. Our results indicate that c-Cbl is dispensable for Bcr-Abl-induced leukemo-genesis in mice.	Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol & Med Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Inst Canc, Div Hematol Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Sch Nursing, Dept Primary Care, Portland, OR 97239 USA; VA Med Ctr, Dept Pathol, Portland, OR 97239 USA; Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Brandeis University	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol & Med Oncol, L592,3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	drukerb@ohsu.edu		Wood, Lisa/0000-0003-1145-3649; Druker, Brian/0000-0001-8331-8206				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DEKLEIN A, 1986, BLOOD, V68, P1369; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE RP, 1988, LEUKEMIA, V2, P321; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gaston I, 2000, EXP HEMATOL, V28, P77, DOI 10.1016/S0301-472X(99)00130-7; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLDMAN A, 1998, CELLS LAB MANUAL; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEANE MM, 1995, ONCOGENE, V10, P2367; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okuda K, 1996, ONCOGENE, V13, P1147; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Rader AE, 2001, CANCER CYTOPATHOL, V93, P269, DOI 10.1002/cncr.9041; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Sattler M, 1996, ONCOGENE, V12, P839; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	67	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8852	8860		10.1038/sj.onc.1206892	http://dx.doi.org/10.1038/sj.onc.1206892			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654781				2022-12-28	WOS:000186982200006
J	Baust, H; Schoke, A; Brey, A; Gern, U; Los, M; Schmid, RM; Rottinger, EM; Seufferlein, T				Baust, H; Schoke, A; Brey, A; Gern, U; Los, M; Schmid, RM; Rottinger, EM; Seufferlein, T			Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-kappa B independent mechanisms	ONCOGENE			English	Article						gliotoxin and radiosensitizing; NF-kappa B; XIAP; survivin; JNK	PROTEIN-KINASE PATHWAY; IONIZING-RADIATION; PERSISTENT ACTIVATION; 26S PROTEASOME; APOPTOSIS; INHIBITION; GENE; P53; SENSITIVITY; EXPRESSION	Radioresistance markedly impairs the efficacy of tumor radiotherapy and may involve antiapoptotic signal transduction pathways that prevent radiation-induced cell death. A common cellular response to genotoxic stress induced by radiation is the activation of the nuclear factor kappa B (NF-kappaB). NF-kappaB activation in turn can lead to an inhibition of radiation-induced apoptotic cell death. Thus, inhibition of NF-kappaB activation is commonly regarded as an important strategy to abolish radioresistance. Among other compounds, the fungal metabolite gliotoxin (GT) has been reported to be a highly selective inhibitor of NF-kappaB activation. Indeed, low doses of GT were sufficient to significantly enhance radiation-induced apoptosis in HL-60 cells. However, this effect turned out to be largely independent of NF-kappaB activation since radiation of HL-60 cells with clinically relevant doses of radiation induced only a marginal increase in NF-kappaB activity, and selective inhibition of NF-kappaB by SN50 did not result in a marked enhancement of GT-induced apoptosis. GT induced activation of JNKs, cytochrome c release from the mitochondria and potently stimulated the caspase cascade inducing cleavage of caspases -9, -8, -7 and -3. Furthermore, cleavage of the antiapoptotic protein X-linked IAP and downregulation of the G2/M-specific IAP-family member survivin were observed during GT-induced apoptosis. Finally, the radiation-induced G2/M arrest was markedly reduced in GT-treated cells most likely due to the rapid induction of apoptosis. Our data demonstrate that various other pathways apart from the NF-kappaB signaling complex can sensitize tumor cells to radiation and propose a novel mechanism for radio-sensitization by GT, the interference with the G2/M checkpoint that is important for repair of radiation-induced DNA damage in p53-deficient tumor cells.	Univ Ulm, Dept Radiat Oncol, D-89081 Ulm, Germany; Univ Ulm, Dept Internal Med, D-89081 Ulm, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munich, Dept Internal Med 2, D-81675 Munich, Germany	Ulm University; Ulm University; University of Munster; University of Munich	Baust, H (corresponding author), Univ Ulm, Dept Radiat Oncol, Robert Koch Str 6, D-89070 Ulm, Germany.	heinrich.baust@medizin.uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018	Los, Marek/0000-0001-9518-1411				Aldridge DR, 1998, CANCER RES, V58, P2817; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Bratton DL, 1999, J BIOL CHEM, V274, P28113, DOI 10.1074/jbc.274.40.28113; Bristow RG, 1996, RADIOTHER ONCOL, V40, P197, DOI 10.1016/0167-8140(96)01806-3; Chaudhary PM, 1999, J BIOL CHEM, V274, P19211, DOI 10.1074/jbc.274.27.19211; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; EICHNER RD, 1988, J BIOL CHEM, V263, P3772; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hazzalin CA, 1998, MOL CELL BIOL, V18, P1844, DOI 10.1128/MCB.18.4.1844; Hida A, 2000, IMMUNOLOGY, V99, P553, DOI 10.1046/j.1365-2567.2000.00985.x; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; KERR JFR, 1972, J PATHOL, V107, P217, DOI 10.1002/path.1711070309; Kroll M, 1999, CHEM BIOL, V6, P689, DOI 10.1016/S1074-5521(00)80016-2; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Pajonk F, 2001, RADIOTHER ONCOL, V59, P203, DOI 10.1016/S0167-8140(01)00311-5; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; POWELL SN, 1995, CANCER RES, V55, P1643; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSSELL KJ, 1995, CANCER RES, V55, P1639; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; Seufferlein T, 1999, GASTROENTEROLOGY, V116, P1441, DOI 10.1016/S0016-5085(99)70509-3; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Waring P, 1996, GEN PHARMACOL, V27, P1311, DOI 10.1016/S0306-3623(96)00083-3; WARING P, 1990, J BIOL CHEM, V265, P14476; WILSON RE, 1993, ONCOGENE, V8, P3229; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yuan ZQ, 2002, J BIOL CHEM, V277, P29973, DOI 10.1074/jbc.M203636200; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	50	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 27	2003	22	54					8786	8796		10.1038/sj.onc.1206969	http://dx.doi.org/10.1038/sj.onc.1206969			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647473	Green Published			2022-12-28	WOS:000186844900016
J	Kioi, M; Yamamoto, K; Higashi, S; Koshikawa, N; Fujita, K; Miyazaki, K				Kioi, M; Yamamoto, K; Higashi, S; Koshikawa, N; Fujita, K; Miyazaki, K			Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model	ONCOGENE			English	Article						matrilysin; matrix metalloproteinases; metastasis; colon carcinoma; E-cadherin	MATRIX-DEGRADING METALLOPROTEINASE; ANCHORAGE-INDEPENDENT GROWTH; HUMAN COLORECTAL CANCERS; E-CADHERIN; CARCINOMA-CELLS; EXTRACELLULAR-MATRIX; TUMOR INVASION; EXPRESSION; CLEAVAGE; INTEGRIN	Matrilysin (MMP-7) is thought to contribute to invasive growth and metastasis of colon carcinoma and many other human cancers. The present study demonstrates that treatment of human colon carcinoma cells with active matrilysin induces cell aggregation in vitro and promotes liver metastasis in nude mice. When two kinds of colon carcinoma cell lines were incubated with active matrilysin, this enzyme efficiently bound to the cell surface and induced loose cell aggregation, which led to E-cadherin-mediated tight cell aggregation. Synthetic MMP inhibitors inhibited both the membrane binding of matrilysin and matrilysin-induced cell aggregation, while TIMP-2 inhibited only the cell aggregation. Two other active MMPs, stromelysin and gelatinase A, neither bound to cell membrane nor induced cell aggregation. Tumor cells in loose cell aggregates could reaggregate even after they were freed from matrilysin and dispersed. When injected into the spleen of nude mice, the tumor cells in the stable aggregates produced much larger metastatic nodules in the livers than control cells and those in the loose aggregates. These results suggest that matrilysin may enhance metastatic potential of tumor cells by processing a cell surface protein(s) and thereby inducing loose and then tight aggregation of tumor cells.	Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, Yokohama, Kanagawa 2440813, Japan; Yokohama City Univ, Sch Med, Dept Oral Maxillofacial Surg, Kanazawa Ku, Yokohama, Kanagawa 2360008, Japan	Yokohama City University; Yokohama City University	Miyazaki, K (corresponding author), Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Totsuka Ku, 641-12 Maioka Cho, Yokohama, Kanagawa 2440813, Japan.		Yamamoto, Kazuhiro/AAD-9650-2019; Koshikawa, Naohiko/S-7306-2017	Koshikawa, Naohiko/0000-0002-4539-888X; Kioi, Mitomu/0000-0002-7981-3340				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252; Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Belaaouaj AA, 2000, J BIOL CHEM, V275, P27123; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BROWNER MF, 1995, BIOCHEMISTRY-US, V34, P6602, DOI 10.1021/bi00020a004; Caterson B, 2000, MATRIX BIOL, V19, P333, DOI 10.1016/S0945-053X(00)00078-0; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; Davies G, 2001, CLIN CANCER RES, V7, P3289; Gearing AJH, 2002, IMMUNOL LETT, V81, P41, DOI 10.1016/S0165-2478(01)00333-9; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Hasegawa S, 1998, INT J CANCER, V76, P812, DOI 10.1002/(SICI)1097-0215(19980610)76:6<812::AID-IJC8>3.0.CO;2-0; Higashi S, 2003, J BIOL CHEM, V278, P14020, DOI 10.1074/jbc.M212264200; Higashi S, 1999, J BIOL CHEM, V274, P10497, DOI 10.1074/jbc.274.15.10497; INCH WR, 1970, GROWTH, V34, P271; Inohara H, 1996, CANCER RES, V56, P4530; Ishikawa T, 1996, CANCER LETT, V107, P5, DOI 10.1016/0304-3835(96)04336-4; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Kondo K, 1998, CANCER RES, V58, P2014; Mitsiades N, 2001, CANCER RES, V61, P577; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MONZ B, 1994, ONCOL REP, V1, P1177; Mueller S, 2000, CANCER RES, V60, P156; MuellerKlieser W, 1997, AM J PHYSIOL-CELL PH, V273, pC1109, DOI 10.1152/ajpcell.1997.273.4.C1109; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nagashima Y, 1997, INT J CANCER, V72, P441, DOI 10.1002/(SICI)1097-0215(19970729)72:3<441::AID-IJC11>3.0.CO;2-F; Noe V, 2001, J CELL SCI, V114, P111; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; Olive PL, 1997, CANCER RES, V57, P5528; SEMPLE TU, 1978, CANCER RES, V38, P1345; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takeda T, 2000, MOL BIOL CELL, V11, P3219, DOI 10.1091/mbc.11.9.3219; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; UMENISHI F, 1990, J BIOCHEM-TOKYO, V108, P537, DOI 10.1093/oxfordjournals.jbchem.a123238; vonBredow DC, 1997, EXP CELL RES, V236, P341, DOI 10.1006/excr.1997.3711; Welch AR, 1996, BIOCHEMISTRY-US, V35, P10103, DOI 10.1021/bi9601969; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; YOSHIMOTO M, 1993, INT J CANCER, V54, P614, DOI 10.1002/ijc.2910540415; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	44	84	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8662	8670		10.1038/sj.onc.1207181	http://dx.doi.org/10.1038/sj.onc.1207181			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647460				2022-12-28	WOS:000186844900003
J	Repovic, P; Fears, CY; Gladson, CL; Benveniste, EN				Repovic, P; Fears, CY; Gladson, CL; Benveniste, EN			Oncostatin-M induction of vascular endothelial growth factor expression in astroglioma cells	ONCOGENE			English	Article						oncostatin-M; VEGF; angiogenesis; astroglioma	HYPOXIA-INDUCIBLE FACTOR-1; NECROSIS-FACTOR-ALPHA; IN-VITRO; GENE-TRANSCRIPTION; SIGNALING PATHWAY; NERVOUS-SYSTEM; FACTOR VEGF; ASTROCYTES; RECEPTOR; INTERLEUKIN-6	Oncostatin-M (OSM), a hematopoietic cytokine, and vascular endothelial growth factor (VEGF), a quintessential angiogenic signal, are coexpressed in development, cancer and inflammation. Here, we report that OSM treatment of human astroglioma cell lines increases VEGF levels by similar tothreefold. Interleukin-1beta (IL-1beta), in combination with OSM, induces up to sevenfold higher VEGF expression, without significantly inducing VEGF on its own. Specifically examining the OSM contribution to VEGF expression, neutralizing antibodies to OSM receptor subunits gp130 and OSMRbeta, but not LIFRbeta, inhibited OSM induction of VEGF, indicating that the OSM-specific receptor OSMRbeta/gp130 transduces the OSM signal for VEGF synthesis. OSM induction of VEGF promoter activity maps to the (-1171, -786) region of the VEGF promoter, which contains a STAT-3-binding site. STAT-3 is indeed essential for this response, since overexpression of a dominant-negative STAT-3 blocks OSM induction of VEGF promoter activity, as well as endogenous VEGF expression. Finally, we demonstrate that OSM is expressed in glioblastoma multiforme tumor biopsies, a particularly malignant form of brain tumor. This novel mechanism of VEGF regulation in astroglioma cells may be active in pathophysiological states where both OSM and IL-1beta are present.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, MCLM 395,1918 Univ Blvd, Birmingham, AL 35294 USA.		Repovic, Pavle/AAV-1594-2020		NCI NIH HHS [CA59958, CA97110, CA97247] Funding Source: Medline; NIMH NIH HHS [MH63650] Funding Source: Medline; NINDS NIH HHS [NS39954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059958, P50CA097247, R01CA097110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hao CH, 2002, ACTA NEUROPATHOL, V103, P171; Hecker TP, 2002, CANCER RES, V62, P2699; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; Lilja A, 2001, INT J ONCOL, V19, P495; Ma ZD, 2001, J IMMUNOL, V167, P5150, DOI 10.4049/jimmunol.167.9.5150; Modur V, 1997, J CLIN INVEST, V100, P158, DOI 10.1172/JCI119508; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Mukouyama YS, 1998, IMMUNITY, V8, P105, DOI 10.1016/S1074-7613(00)80463-X; Murphy M, 1997, PROG NEUROBIOL, V52, P355, DOI 10.1016/S0301-0082(97)00020-8; Nagashima G, 2002, CLIN NEUROL NEUROSUR, V104, P125, DOI 10.1016/S0303-8467(01)00197-4; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Pietsch T, 1997, ACTA NEUROPATHOL, V93, P109, DOI 10.1007/s004010050591; RADKA SF, 1993, J IMMUNOL, V150, P5195; Repovic P, 2003, GLIA, V42, P433, DOI 10.1002/glia.10182; Repovic P, 2002, J NEUROSCI, V22, P5334; Ruprecht K, 2001, J NEUROPATH EXP NEUR, V60, P1087, DOI 10.1093/jnen/60.11.1087; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Schaefer LK, 2000, CYTOKINE, V12, P1647, DOI 10.1006/cyto.2000.0774; Shono T, 2001, CANCER RES, V61, P4375; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228; TISCHER E, 1991, J BIOL CHEM, V266, P11947; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Van Wagoner NJ, 2000, J NEUROCHEM, V75, P563, DOI 10.1046/j.1471-4159.2000.0750563.x; Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835; Xu L, 2002, J BIOL CHEM, V277, P11368, DOI 10.1074/jbc.M108347200; Yao Y, 2001, ACTA NEUROCHIR, V143, P159, DOI 10.1007/s007010170122	41	53	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8117	8124		10.1038/sj.onc.1206922	http://dx.doi.org/10.1038/sj.onc.1206922			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603252				2022-12-28	WOS:000186403400006
J	Shah, NP; Sawyers, CL				Shah, NP; Sawyers, CL			Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias	ONCOGENE			English	Review						tyrosine kinase inhibitor; BCR-ABL; imatinib; gleevec; mutation	CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; KINASE INHIBITOR STI571; ABL TYROSINE KINASE; CYTOGENETIC RESPONSES; POSITIVE CELLS; GENE MUTATION; BLAST CRISIS; STI-571; DOMAIN	Philadelphia chromosome-associated leukemias are among the most well-understood human malignancies. The importance of BCR-ABL enzymatic activity in the proliferation of the leukemic clone has been confirmed by the high response rates of these leukemias to the ABL-selective tyrosine kinase inhibitor STI571, even in advanced disease phases, which are characterized by increased genetic heterogeneity. Disease relapse has been observed in a subset of patients who had initially responded to STI571. Evidence suggests that BCR-ABL activity is restored in the majority of these cases of acquired resistance. Molecular studies of resistant leukemia cells isolated from patients have implicated BCR-ABL kinase domain point mutation as the most common mechanism of resistance. Additionally, genomic amplification of the BCR-ABL gene can occasionally be detected. This review will highlight mechanisms of STI571 resistance in clinical samples as well as preclinical models.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med & Mol Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sawyers, CL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Sawyers, Charles/G-5327-2016					Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; GambacortiPasserini C, 1997, BLOOD CELL MOL DIS, V23, P380, DOI 10.1006/bcmd.1997.0155; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; GRAEBER T, UNPUB; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hochhaus A, 2001, SCIENCE, V293, P2163; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Jorgensen HG, 2002, BLOOD, V99, P713, DOI 10.1182/blood.V99.2.713; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Nagar B, 2002, CANCER RES, V62, P4236; NOWELL PC, 1960, SCIENCE, V132, P1497; Ricci C, 2002, CANCER RES, V62, P5995; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505	23	178	184	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 20	2003	22	47					7389	7395		10.1038/sj.onc.1206942	http://dx.doi.org/10.1038/sj.onc.1206942			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KL	14576846				2022-12-28	WOS:000186112500011
J	Young, AP; Nagarajan, R; Longmore, GD				Young, AP; Nagarajan, R; Longmore, GD			Mechanisms of transcriptional regulation by Rb-E2F segregate by biological pathway	ONCOGENE			English	Article						E2F; Rb; biological pathways	CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; DNA-REPLICATION; REPRESS TRANSCRIPTION; MICROARRAY ANALYSIS; COMPLEX-FORMATION; GROWTH-REGULATION; FACTOR E2F1; EXPRESSION	The E2F family of transcription factors are critical regulators of the cell cycle and have also been implicated in apoptosis, development, DNA damage checkpoints, and differentiation. Retinoblastoma (Rb) proteins interact with E2F to regulate transcription, and several mechanisms have been proposed for Rb-E2F transcriptional regulation. We designed microarray-based experiments to characterize the relative contributions of each mechanism, and unexpectedly, we found that distinct functional gene groups show preference for one mechanism over the others. We propose that such a distribution may provide signaling specificity to enable regulatory proteins to turn on or off entire pathways that determine cell fate.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Longmore, GD (corresponding author), Washington Univ, Sch Med, Dept Med, 4940 Parkview Pl, St Louis, MO 63110 USA.				NCI NIH HHS [CA 85839] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085839] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Geng Y, 1996, ONCOGENE, V12, P1173; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; Koziczak M, 2001, EUR J BIOCHEM, V268, P4969, DOI 10.1046/j.0014-2956.2001.02428.x; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma YH, 2002, ARCH BIOCHEM BIOPHYS, V399, P212, DOI 10.1006/abbi.2002.2761; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NEUMAN E, 1994, MOL CELL BIOL, V14, P6017; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Reed SI, 1997, CANCER SURV, V29, P7; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Suzuki A, 2000, MOL CELL, V5, P217, DOI 10.1016/S1097-2765(00)80418-9; Takahashi Y, 2000, GENE DEV, V14, P804; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; WADE M, 1992, MOL CELL BIOL, V12, P4364, DOI 10.1128/MCB.12.10.4364; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	42	73	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 16	2003	22	46					7209	7217		10.1038/sj.onc.1206804	http://dx.doi.org/10.1038/sj.onc.1206804			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562049				2022-12-28	WOS:000185955000012
J	Herzog, CR; Bodon, N; Pittman, B; Maronpot, RR; Massey, TE; Anderson, MW; You, M; Devereux, TR				Herzog, CR; Bodon, N; Pittman, B; Maronpot, RR; Massey, TE; Anderson, MW; You, M; Devereux, TR			Carcinogen-specific targeting of chromosome 12 for loss of heterozygosity in mouse lung adenocarcinomas: implications for chromosome instability and tumor progression	ONCOGENE			English	Article						loss of heterozygosity; chromosome instability; lung carcinogenesis; chromosome 12	HOMOLOGOUS RECOMBINATION; GENETIC ALTERATIONS; ALLELIC LOSSES; HIGH-FREQUENCY; DNA-DAMAGE; CANCER; SELECTION; MICE; SUSCEPTIBILITY; MECHANISMS	Genotoxic carcinogens exert their tumorigenic effects in part by inducing genomic instability. We recently showed that loss of heterozygosity (LOH) on chromosome 12 associates significantly with the induction of chromosome instability (CIN) by the likely human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and vinyl carbamate (VC) during mouse lung carcinogenesis. Here, we demonstrate the carcinogen specificity of this event and its effect on lung tumor evolution. LOH on chromosome 12 was observed in 45% of NNK-induced, 59% of VC-induced, 58% of aflatoxin B1 (AFB1)-induced, 14% of N-ethyl-N-nitrosourea (ENU)-induced and 12% of spontaneous lung adenocarcinomas. The frequency of LOH in each of the carcinogen-induced groups, except ENU, was significantly higher than in the spontaneous group (P<0.001). Deletion mapping revealed four potential candidate regions of 1-4 centiMorgans suspected to contain targeted tumor suppressor genes, with at least one expected to have a role in CIN. The relationship between LOH on chromosome 12 and additional chromosomal alterations occurring during lung tumor progression was also examined. LOH on chromosomes 1 and 14 were moderately frequent during malignant progression in tumors from all treatment groups, occurring in 21-35 and 18-33% of tumors. However, these alterations showed significant concurrence with LOH on chromosome 12 in VC-, NNK- and AFB1-induced tumors (P<0.05). The results suggest that a carcinogen-selective mechanism of lung cancer induction involves the frequent inactivation of genes on chromosome 12, including a stability gene that evidently promotes the evolutionary selection of additional chromosomal alterations during malignant progression.	Inst Canc Prevent, Valhalla, NY 10595 USA; NIEHS, Res Triangle Pk, NC 27709 USA; Queens Univ, Kingston, ON K7L 3N6, Canada; Univ Cincinnati, Cincinnati, OH 45267 USA; Washington Univ, St Louis, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Queens University - Canada; University System of Ohio; University of Cincinnati; Washington University (WUSTL)	Herzog, CR (corresponding author), Inst Canc Prevent, Valhalla, NY 10595 USA.	cherzog@ifcp.us			NATIONAL CANCER INSTITUTE [P30CA017613] Funding Source: NIH RePORTER; NCI NIH HHS [CA17613] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON LM, 1978, CANCER LETT, V5, P55, DOI 10.1016/S0304-3835(78)80011-1; Ballering LAP, 1997, ENVIRON MOL MUTAGEN, V30, P321, DOI 10.1002/(SICI)1098-2280(1997)30:3<321::AID-EM11>3.0.CO;2-F; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1; Bishop AJR, 2000, CANCER RES, V60, P395; BRANCH P, 1995, CANCER RES, V55, P2304; BRANSTETTER DG, 1987, CANCER RES, V47, P348; Breivik J, 1999, SEMIN CANCER BIOL, V9, P245, DOI 10.1006/scbi.1999.0123; Breivik J, 2001, P NATL ACAD SCI USA, V98, P5379, DOI 10.1073/pnas.101137698; Cheng KC, 1997, CURR TOP MICROBIOL, V221, P5; Claij N, 2003, CANCER RES, V63, P2062; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; DIPPLE A, 1995, CARCINOGENESIS, V16, P437, DOI 10.1093/carcin/16.3.437; Fijneman RJA, 1998, CANCER RES, V58, P4794; Girard L, 2000, CANCER RES, V60, P4894; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Hecht SS, 1999, MUTAT RES-FUND MOL M, V424, P127, DOI 10.1016/S0027-5107(99)00014-7; HECHT SS, 1978, J NATL CANCER I, V60, P819, DOI 10.1093/jnci/60.4.819; HEGI ME, 1994, CANCER RES, V54, P6257; Herzog CR, 1997, J CELL BIOCHEM, P49; Herzog CR, 2002, CANCER RES, V62, P6424; Herzog CR, 1999, MOL CARCINOGEN, V25, P92, DOI 10.1002/(SICI)1098-2744(199906)25:2<92::AID-MC3>3.0.CO;2-2; Herzog CR, 1996, MOL CARCINOGEN, V16, P83, DOI 10.1002/(SICI)1098-2744(199606)16:2<83::AID-MC4>3.0.CO;2-O; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pataer A, 1997, CANCER RES, V57, P2904; Powell SN, 2002, MOL CELL, V10, P1262, DOI 10.1016/S1097-2765(02)00789-X; Ricordy R, 2002, MUTAGENESIS, V17, P241, DOI 10.1093/mutage/17.3.241; Sargent LM, 2002, CANCER RES, V62, P1152; SHEN HM, 1995, CARCINOGENESIS, V16, P419, DOI 10.1093/carcin/16.2.419; Sipowicz MA, 1997, CANCER LETT, V117, P87, DOI 10.1016/S0304-3835(97)00208-5; Tam AS, 1999, CANCER RES, V59, P3634; TRUSHIN N, 1994, CANCER RES, V54, P1205; Wong MP, 2002, CANCER RES, V62, P4464	41	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2004	23	17					3033	3039		10.1038/sj.onc.1207431	http://dx.doi.org/10.1038/sj.onc.1207431			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	812NC	14755239				2022-12-28	WOS:000220845200007
J	Philipp-Staheli, J; Kim', KH; Liggitt, D; Gurley, KE; Longton, G; Kemp, CJ				Philipp-Staheli, J; Kim', KH; Liggitt, D; Gurley, KE; Longton, G; Kemp, CJ			Distinct roles for p53, p27(Kip1), and p21(Cip1) during tumor development	ONCOGENE			English	Article						tumor suppressor gene; lymphoma; sarcoma haploinsufficiency; epistasis	DEPENDENT KINASE INHIBITOR; CELL-CYCLE ARREST; MAMMARY-CANCER MODEL; CDK INHIBITOR; MICE LACKING; P53-DEFICIENT MICE; P27; EXPRESSION; TUMORIGENESIS; DEGRADATION	Mutations in p53 and reduced expression of the Cdk inhibitor P27(Kip1) are frequently observed in a wide variety of human cancers, but it is not known whether alterations in these tumor suppressors interact to influence tumor progression. To address this, we measured tumor latency and spectrum in p53 and p27 single and compound mutant mice. p53-/- (null) mice developed T-cell lymphomas and soft-tissue sarcomas, while p27-/- mice developed adenomas of the pituitary and lung, but with much longer latency. The latency for tumor development in p53-/- p27-/- and p53 -/- p27 +/- compound mutant mice was significantly reduced, by 15-30%, compared to single mutant p53-/- mice. The tumor spectrum in the compound mutants was similar to that of p53-/- mice, and additional tumors of diverse histotypes. In tumors from p53-/- mice, p27 protein levels were reduced to a greater extent than were mRNA levels, indicating that p27 is downregulated in tumors at the transcriptional as well as post-transcriptional levels. In contrast, mice deficient in another Cdk inhibitor p21(Cip1), which is also a transcriptional target and effector of p53, showed only a marginal increase in tumor predisposition in response to ENU treatment. Thus, downregulation of p27 is a common feature in p53-/- tumors. Germline deletion of one or both alleles of p27 accelerates tumor development and associated mortality in p53-/- mice, indicating potent synergy between loss of p27 and p53. Although p21 is functionally similar to both p53 and p27, it plays a lesser role in tumor suppression. These results further highlight the highly cooperative nature of p27 and its central role in tumor suppression.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, C1-015,1100 Fairview Ave N, Seattle, WA 98109 USA.	cjkemp@fhcrc.org			NCI NIH HHS [CA70414] Funding Source: Medline; NIEHS NIH HHS [ES011045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES011045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Bearss DJ, 2002, CANCER RES, V62, P2077; Blain SW, 2002, NAT MED, V8, P1076, DOI 10.1038/nm1002-1076; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BULLRICH F, 1995, CANCER RES, V55, P1199; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2000, BLOOD, V95, P619, DOI 10.1182/blood.V95.2.619; Ciaparrone M, 1998, CANCER RES, V58, P114; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDIERY WS, 2001, NAT CELL BIOL, V3, P71; Erlanson M, 1998, BLOOD, V92, P770; Esposito V, 1997, CANCER RES, V57, P3381; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson RJ, 2003, CANCER RES, V63, P3021; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jones JM, 1999, CELL GROWTH DIFFER, V10, P213; Kalbfleish J., 1980, STAT ANAL FAILURE TI; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maronpot R, 1999, PATHOLOGY MOUSE; Martin-Caballero J, 2001, CANCER RES, V61, P6234; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; Masciullo V, 1999, CANCER RES, V59, P3790; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Moller MB, 2000, LEUKEMIA LYMPHOMA, V39, P19, DOI 10.3109/10428190009053535; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; PIETENPOL JA, 1995, CANCER RES, V55, P1206; Piva R, 1999, J NEUROPATH EXP NEUR, V58, P691, DOI 10.1097/00005072-199907000-00002; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Quintanilla-Martinez L, 1998, AM J PATHOL, V153, P175, DOI 10.1016/S0002-9440(10)65558-7; SanchezBeato M, 1997, AM J PATHOL, V151, P151; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; Singh SP, 1998, CANCER RES, V58, P1730; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; TIMME TL, 1994, BIOTECHNIQUES, V17, P462; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Yang WC, 2001, CANCER RES, V61, P565; Yasui W, 1997, JPN J CANCER RES, V88, P625, DOI 10.1111/j.1349-7006.1997.tb00428.x	63	53	56	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					905	913		10.1038/sj.onc.1207220	http://dx.doi.org/10.1038/sj.onc.1207220			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647411				2022-12-28	WOS:000188486600005
J	Denys, H; Jadidizadeh, A; Nik, SA; Van Dam, K; Aerts, S; Alman, BA; Cassiman, JJ; Tejpar, S				Denys, H; Jadidizadeh, A; Nik, SA; Van Dam, K; Aerts, S; Alman, BA; Cassiman, JJ; Tejpar, S			Identification of IGFBP-6 as a significantly downregulated gene by beta-catenin in desmoid tumors	ONCOGENE			English	Article						beta-catenin; IGFBP-6; expression profile; desmoid; target genes	AGGRESSIVE FIBROMATOSIS; CELL-PROLIFERATION; EXPRESSION; MUTATIONS; BINDING; CANCER; ACTIVATION; TARGET	Desmoid tumors (aggressive fibromatosis) are locally invasive soft tissue tumors in which beta-catenin-mediated TCF-3-dependent transcription is activated. To provide more insight into the pathophysiology of these tumors, expression profiles were generated using oligonucleotide arrays (Affymetrix). In total, 69 differentially expressed genes were identified in desmoids compared to normal fibroblasts (fascia) from the same patients. The differential expression of a selection of genes was confirmed using RT-PCR and Northern blotting. We further evaluated the insulin-like growth factor-binding protein 6 (IGFBP-6), a gene that was consistently downregulated in all desmoids tested. Promotor studies and electromobility shift assays revealed two functional beta-catenin/TCF-responsive elements in the human IGFBP-6 promoter. These findings suggest that IGFBP-6 is directly downregulated by the beta-catenin/TCF complex in desmoid tumors, and imply a role for the IGF axis in the proliferation of desmoid tumors.	Catholic Univ Louvain, Ctr Human Genet, B-3000 Louvain, Belgium; Univ Louvain, Dept Elect Engn, B-3001 Heverlee, Belgium; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON M5G 1X8, Canada	Universite Catholique Louvain; Universite Catholique Louvain; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Tejpar, S (corresponding author), Catholic Univ Louvain, Ctr Human Genet, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	Sabine.Tejpar@med.kuleuven.ac.be	Aerts, Stein/A-1100-2009; Nik, Saeid Amini/B-6640-2014	Aerts, Stein/0000-0002-8006-0315; Nik, Saeid Amini/0000-0002-9185-9456				Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Alman BA, 1997, AM J PATHOL, V151, P329; Bach LA, 1999, HORM METAB RES, V31, P226, DOI 10.1055/s-2007-978723; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Cui HM, 2002, CANCER RES, V62, P6442; CULLEN KJ, 1992, MOL ENDOCRINOL, V6, P91, DOI 10.1210/me.6.1.91; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; Eccles DM, 1996, AM J HUM GENET, V59, P1193; Fujita M, 2000, CANCER RES, V60, P6683; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim EJ, 2002, J CELL PHYSIOL, V190, P92, DOI 10.1002/jcp.10045; Li C, 1998, AM J PATHOL, V153, P709, DOI 10.1016/S0002-9440(10)65614-3; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; ROGHANI M, 1991, GROWTH REGULAT, V1, P125; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Saito T, 2001, J PATHOL, V195, P222, DOI 10.1002/path.942; SINGH P, 1994, AM J PHYSIOL-GASTR L, V267, pG608, DOI 10.1152/ajpgi.1994.267.4.G608; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tejpar S, 2001, BRIT J CANCER, V85, P98, DOI 10.1054/bjoc.2001.1857; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	28	31	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					654	664		10.1038/sj.onc.1207160	http://dx.doi.org/10.1038/sj.onc.1207160			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737101				2022-12-28	WOS:000188304900004
J	Maru, D; Wu, TT; Canada, A; Houlihan, PS; Hamilton, SR; Rashid, A				Maru, D; Wu, TT; Canada, A; Houlihan, PS; Hamilton, SR; Rashid, A			Loss of chromosome 18q and DPC4 (Smad4) mutations in appendiceal adenocarcinomas	ONCOGENE			English	Article						appendix; adenocarcinoma; chromosome 18q loss; beta-catenin; DPC4	TUMOR-SUPPRESSOR GENE; COLORECTAL-CANCER; FREQUENT LOSS; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; GASTRIC-CANCER; COLON-CANCER; ALLELIC LOSS; CARCINOMAS; DCC	Appendiceal adenocarcinomas are uncommon, and the genetic alterations present in these tumors are not well characterized. We studied genetic alterations including loss of chromosome 18q ( location of DCC, DPC4, and JV-18 genes), and mutations of the DPC4 (SMAD4) and beta-catenin genes in 28 appendiceal adenocarcinomas, consisting of 17 mucinous and 11 nonmucinous carcinomas. Chromosome 18q loss was present in 57% (12/21) of appendiceal carcinomas including 54% (7/13) of mucinous and 63% (5/8) of nonmucinous carcinomas. Mutation of the DPC4 gene was present in 14% ( three of 22) of the carcinomas occurring in one tumor with chromosome 18q loss and in two with unassessed chromosome 18q status. beta-catenin gene mutation was present in 0%( 0 of 25) of the carcinomas. Chromosome 18q loss status was not associated with any clinicopathological features. The presence of chromosome 18q loss and DPC4 mutations in appendiceal adenocarcinomas suggests involvement of DPC4 and nearby genes on chromosome 18q ( DCC and/or JV-18) in the pathogenesis of appendiceal adenocarcinomas.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Rashid, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	arashid@mdacc.tmc.edu						Blaker H, 2002, ONCOGENE, V21, P158, DOI 10.1038/sj.onc.1205041; Blons H, 2002, ONCOGENE, V21, P5016, DOI 10.1038/sj.onc.1205626; CARR NJ, 2000, PATHOLOGY GENETICS T, P94; Dai JL, 1998, CANCER RES, V58, P4592; DEVILEE P, 1991, ONCOGENE, V6, P311; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Font A, 2001, DIS COLON RECTUM, V44, P549, DOI 10.1007/BF02234328; Fujii H, 1997, AM J PATHOL, V151, P1447; GAO X, 1993, CANCER RES, V53, P2723; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; HOHNE MW, 1992, CANCER RES, V52, P2616; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kabbani W, 2002, MODERN PATHOL, V15, P599, DOI 10.1038/modpathol.3880572; Kanazawa T, 2002, INT J CANCER, V102, P225, DOI 10.1002/ijc.10690; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kremmidiotis G, 1998, GENOMICS, V49, P467, DOI 10.1006/geno.1998.5281; Kytola S, 2002, GENE CHROMOSOME CANC, V34, P325, DOI 10.1002/gcc.10081; Lanza G, 1998, INT J CANCER, V79, P390, DOI 10.1002/(SICI)1097-0215(19980821)79:4<390::AID-IJC14>3.3.CO;2-M; Lassus H, 2001, AM J PATHOL, V159, P35, DOI 10.1016/S0002-9440(10)61670-7; Lei JY, 1996, ONCOGENE, V13, P2459; LYSS AP, 1988, SEMIN ONCOL, V15, P129; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; McCusker ME, 2002, CANCER, V94, P3307, DOI 10.1002/cncr.10589; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Moskaluk CA, 1997, AM J PATHOL, V150, P1547; Powell SM, 1997, CANCER RES, V57, P4221; Rashid A, 2001, CANCER RES, V61, P3406; Roth S, 2000, BRIT J CANCER, V83, P1015, DOI 10.1054/bjoc.2000.1387; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sparks AB, 1998, CANCER RES, V58, P1130; Szych C, 1999, AM J PATHOL, V154, P1849, DOI 10.1016/S0002-9440(10)65442-9; Takagi Y, 1996, GASTROENTEROLOGY, V111, P1369, DOI 10.1053/gast.1996.v111.pm8898652; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; UCHINO S, 1992, CANCER RES, V52, P3099; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	42	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					859	864		10.1038/sj.onc.1207194	http://dx.doi.org/10.1038/sj.onc.1207194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14647445				2022-12-28	WOS:000188304900026
J	Lamalice, L; Houle, F; Jourdan, G; Huot, J				Lamalice, L; Houle, F; Jourdan, G; Huot, J			Phosphorylation of tyrosine 1214 on VEGFR2 is required for VEGF-induced activation of Cdc42 upstream of SAPK2/p38	ONCOGENE			English	Article						VEGF; VEGFR2; SAPK2/p38; Cdc42	ENDOTHELIAL GROWTH-FACTOR; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE PATHWAYS; FOCAL ADHESION KINASE; ACTIN-BASED MOTILITY; CELL-MIGRATION; DNA-SYNTHESIS; PAF SYNTHESIS; P38 MAPK; RECEPTOR	Activation of the tyrosine kinase receptor vascular endothelial growth factor receptor 2 (VEGFR2) by VEGF leads to the activation of stress-activated protein kinase (SAPK)2/p38 and then to actin polymerization and reorganization into stress fibers in endothelial cells. In turn, this triggers endothelial cell migration. Yet, nothing is known about the molecular mechanisms that couple VEGFR2 to SAPK2/p38. Here, we found that VEGF increased by twofold the activity of the small GTPase Cdc42 and that the expression of two different constitutively active forms of Cdc42 (Cdc42 V12 and Cdc42 L61) led to a marked increase in the formation of stress fibers that was sensitive to SAPK/p38 inhibition by SB203580. Moreover, the expression of a dominant-negative form of Cdc42 (Cdc42 N17) inhibited the activation of SAPK2/p38 and of its direct target MAP kinase-activated protein kinase 2. These results indicate that Cdc42 is upstream of SAPK2/p38 in response to the activation of VEGFR2 by VEGF. In contrast, we found that neither RhoA nor Rac was involved in the SAPK2/p38-mediated actin reorganization induced by VEGF. Using a site-specific mutant of the major autophosphorylation site Y1214 on VEGFR2, we found that the mutant Y1214F inhibited the activation of both Cdc42 and SAPK2/p38 in response to VEGF. We conclude that phosphorylation of Y1214 on VEGFR2 is required to trigger the sequential activation of Cdc42 and SAPK2/p38 and to drive the SAPK2/p38-mediated actin remodeling in stress fibers in endothelial cells exposed to VEGF.	Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada	Laval University	Huot, J (corresponding author), Univ Laval, Hotel Dieu Quebec, Ctr Rech Cancerol, 9 Rue McMahon, Quebec City, PQ G1R 2J6, Canada.	Jacques.Huot@phc.ulaval.ca						Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Barleon B, 1997, CANCER RES, V57, P5421; BARRY ST, 1994, J CELL SCI, V107, P2033; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Clerk A, 2001, MOL CELL BIOL, V21, P1173, DOI 10.1128/MCB.21.4.1173-1184.2001; Dechert MA, 2001, AM J PHYSIOL-CELL PH, V281, pC123, DOI 10.1152/ajpcell.2001.281.1.C123; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Ferrara N, 1996, Curr Opin Nephrol Hypertens, V5, P35, DOI 10.1097/00041552-199601000-00008; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 2000, Z KARDIOL, V89, P206, DOI 10.1007/s003920050472; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Masson-Gadais B, 2003, CELL STRESS CHAPERON, V8, P37, DOI 10.1379/1466-1268(2003)8<37:IVRFVA>2.0.CO;2; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Mudgett JS, 2000, P NATL ACAD SCI USA, V97, P10454, DOI 10.1073/pnas.180316397; Nakamura M, 2002, PATHOL INT, V52, P331, DOI 10.1046/j.1440-1827.2002.01367.x; Pai KS, 2002, J NEUROCHEM, V80, P715, DOI 10.1046/j.0022-3042.2001.00761.x; Pai KS, 2001, J BIOL CHEM, V276, P32642, DOI 10.1074/jbc.M104212200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; Polverini Peter J, 2002, J Dent Educ, V66, P962; Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781; Renkema GH, 2002, MOL CELL BIOL, V22, P6719, DOI 10.1128/MCB.22.19.6719-6725.2002; Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107; Ridley AJ, 1999, NAT CELL BIOL, V1, pE64, DOI 10.1038/11034; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Sato Y, 2000, ANN NY ACAD SCI, V902, P201; SEETHARAM L, 1995, ONCOGENE, V10, P135; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Van Trappen PO, 2002, BRIT J CANCER, V87, P537, DOI 10.1038/sj.bjc.6600471; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; ZENG H, 2002, J BIOL CHEM, V19, P19; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	166	171	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2004	23	2					434	445		10.1038/sj.onc.1207034	http://dx.doi.org/10.1038/sj.onc.1207034			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	763QH	14724572				2022-12-28	WOS:000188098300014
J	Meadows, KN; Bryant, P; Vincent, PA; Pumiglia, KM				Meadows, KN; Bryant, P; Vincent, PA; Pumiglia, KM			Activated Ras induces a proangiogenic phenotype in primary endothelial cells	ONCOGENE			English	Article						angiogenesis; VEGF; Erk; migration; PI3K; proliferation; Ras	THYROID EPITHELIAL-CELLS; WILD-TYPE P53; GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLE ARREST; TUMOR ANGIOGENESIS; COOPERATING ONCOGENES; ACTIN REORGANIZATION; NEURITE OUTGROWTH	Angiogenic factors alter endothelial cell phenotype to promote the formation of new blood vessels, a process critical for a number of normal and pathological conditions. Ras is required for the induction of the angiogenic phenotype in response to vascular endothelial growth factor (VEGF). However, VEGF generates many signals, several of which are not dependent upon Ras activation. Our current study investigates the sufficiency of Ras activation for driving angiogenic responses. An activated Ras(V12) mutant induces prominent membrane ruffling, branching morphogenesis on three-dimensional collagen, DNA synthesis, and cell migration in primary endothelial cells. An upregulation of PI3K/AKT, Erk, and Jnk signaling pathways accompany these phenotypic changes. The inhibition of Erk blocked cell proliferation, but only partially attenuated migration. Blocking PI3K had no effect on DNA synthesis, but caused a modest reduction in cell migration. Lastly, Jnk played a significant role in both the proliferation and migration response. These effects of Ras(V12) are not the result of increased autocrine secretion of VEGF. These data suggest that the acquisition of activating Ras mutations can lead to a proangiogenic conversion in the phenotype of primary endothelial cells. Furthermore, these data raise the possibility that chronic Ras activation in endothelial cells may be sufficient to promote angiogenesis and the development of vascular anomalies.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Albany Medical College; Albany Medical College	Pumiglia, KM (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.	pumiglk@mail.amc.edu		Pumiglia, Kevin/0000-0003-4655-0334	NCI NIH HHS [R01 CA081419, R01-CA-81419] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07194] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081419] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; FOX PL, 1994, ONCOGENE, V9, P3519; Fox SB, 1996, J PATHOL, V179, P232, DOI 10.1002/(SICI)1096-9896(199607)179:3<232::AID-PATH505>3.0.CO;2-A; Ghosh PK, 2002, NAT CELL BIOL, V4, P894, DOI 10.1038/ncb873; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gitler AD, 2003, NAT GENET, V33, P75, DOI 10.1038/ng1059; Goi T, 1999, MOL CELL BIOL, V19, P1731; Goncharova EA, 2002, AM J PHYSIOL-LUNG C, V283, pL354, DOI 10.1152/ajplung.00010.2002; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; Hong HHL, 2000, TOXICOL PATHOL, V28, P529, DOI 10.1177/019262330002800404; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MacKenzie KL, 2002, ONCOGENE, V21, P4200, DOI 10.1038/sj.onc.1205425; MARION MJ, 1991, MOL CARCINOGEN, V4, P450, DOI 10.1002/mc.2940040607; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03; Pal S, 2001, CANCER RES, V61, P6952; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rak J, 2000, CANCER RES, V60, P490; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Soga N, 2001, CELL COMMUN ADHES, V8, P1, DOI 10.3109/15419060109080703; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; Spyridopoulos I, 2002, BASIC RES CARDIOL, V97, P117, DOI 10.1007/s003950200001; Suzuki E, 2002, HYPERTENS RES, V25, P773; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zhang LL, 2000, CANCER RES, V60, P3655; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	64	75	77	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					192	200		10.1038/sj.onc.1206921	http://dx.doi.org/10.1038/sj.onc.1206921			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712224				2022-12-28	WOS:000187895300020
J	Nakagawachi, T; Soejima, H; Urano, T; Zhao, W; Higashimoto, K; Satoh, Y; Matsukura, S; Kudo, S; Kitajima, Y; Harada, H; Furukawa, K; Matsuzaki, H; Emi, M; Nakabeppu, Y; Miyazaki, K; Sekiguchi, M; Mukai, T				Nakagawachi, T; Soejima, H; Urano, T; Zhao, W; Higashimoto, K; Satoh, Y; Matsukura, S; Kudo, S; Kitajima, Y; Harada, H; Furukawa, K; Matsuzaki, H; Emi, M; Nakabeppu, Y; Miyazaki, K; Sekiguchi, M; Mukai, T			Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer	ONCOGENE			English	Article						MGMT; DNA methylation; histone modification; histone methylation; chromatin; gene silencing	O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; DNA METHYLATION; BINDING-PROTEIN; PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; LYSINE-9 METHYLATION; CHROMATIN-STRUCTURE; H3 LYSINE-9; REPAIR; TRANSCRIPTION	O6-methylguanine-DNA methyltransferase (MGMT) repairs the cytotoxic and mutagenic O6-alkylguanine produced by alkylating agents such as chemotherapeutic agents and mutagens. Recent studies have shown that in a subset of tumors, MGMT expression is inversely linked to hypermethylation of the CpG island in the promoter region; however, how the epigenetic silencing mechanism works, as it relates to hypermethylation, was still unclear. To understand the mechanism, we examined the detailed methylation status of the whole island with bisulfite-sequencing in 19 MGMT non-expressed cancer cell lines. We found two highly methylated regions in the island. One was upstream of exon 1, including minimal promoter, and the other was downstream, including enhancer. Reporter gene assay showed that methylation of both the upstream and downstream regions suppressed luciferase activity drastically. Chromatin immunoprecipitation assay revealed that histone H3 lysine 9 was hypermethylated throughout the island in the MGMT negative line, whereas acetylation on H3 and H4 and methylation on H3 lysine 4 were at significantly high levels outside the minimal promoter in the MGMT-expressed line. Furthermore, MeCP2 preferentially bound to the CpG-methylated island in the MGMT negative line. Given these results, we propose a model for gene silencing of MGMT that is dependent on the epigenetic state in cancer.	Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, Saga 8498501, Japan; Nagoya Univ, Grad Sch Med, Dept Biochem 2, Nagoya, Aichi, Japan; Hokkaido Inst Publ Hlth, Sapporo, Hokkaido, Japan; Saga Med Sch, Dept Surg, Saga, Japan; Int Med Ctr Japan Res Inst, Dept Pathol, Div Histol, Tokyo, Japan; RIKEN, Spring 8, Harima Inst, Synchrotron Radiat Res Network,Membrane Dynam Pro, Tokyo, Japan; Nippon Med Coll, Inst Gerontol, Dept Mol Biol, Tokyo, Japan; Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Fukuoka 812, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan	Saga University; Nagoya University; Saga University; National Center for Global Health & Medicine - Japan; RIKEN; Nippon Medical School; Kyushu University; Japan Science & Technology Agency (JST)	Soejima, H (corresponding author), Saga Med Sch, Dept Biomol Sci, Div Mol Biol & Genet, 5-1-1 Nabeshima, Saga 8498501, Japan.	soejimah@post.saga-med.ac.jp	Nakabeppu, Yusaku/A-8902-2011	Nakabeppu, Yusaku/0000-0002-6739-242X; Urano, Takeshi/0000-0003-3383-3554; Soejima, Hidenobu/0000-0001-5076-6563				Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Becker K, 1996, CANCER RES, V56, P3244; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Chen FY, 1997, P NATL ACAD SCI USA, V94, P4348, DOI 10.1073/pnas.94.9.4348; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; Danam RP, 1999, MOL CARCINOGEN, V24, P85, DOI 10.1002/(SICI)1098-2744(199902)24:2<85::AID-MC2>3.0.CO;2-C; Danam RP, 2001, INT J ONCOL, V18, P1187; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, CANCER RES, V60, P2368; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HARRIS LC, 1994, NUCLEIC ACIDS RES, V22, P4614, DOI 10.1093/nar/22.22.4614; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herfarth KKF, 1999, MOL CARCINOGEN, V24, P90, DOI 10.1002/(SICI)1098-2744(199902)24:2<90::AID-MC3>3.0.CO;2-B; Hsieh CL, 1997, MOL CELL BIOL, V17, P5897, DOI 10.1128/MCB.17.10.5897; Irvine RA, 2002, MOL CELL BIOL, V22, P6689, DOI 10.1128/MCB.22.19.6689-6696.2002; Jackson JP, 2002, NATURE, V416, P556, DOI 10.1038/nature731; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Matsukura S, 2003, BRIT J CANCER, V88, P521, DOI 10.1038/sj.bjc.6600743; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mukai T, 2002, ONCOGENE, V21, P9033, DOI 10.1038/sj.onc.1206095; Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Nguyen CT, 2002, CANCER RES, V62, P6456; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; OLSSON M, 1980, J BIOL CHEM, V255, P569; Patel SA, 1997, MOL CELL BIOL, V17, P5813, DOI 10.1128/MCB.17.10.5813; Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009; PEGG AE, 1983, J BIOL CHEM, V258, P2327; Peters AHFM, 2002, NAT GENET, V30, P77, DOI 10.1038/ng789; Pieper RO, 1996, J BIOL CHEM, V271, P13916, DOI 10.1074/jbc.271.23.13916; Qian XLC, 1997, CANCER RES, V57, P3672; Roder K, 2002, J BIOL CHEM, V277, P30543, DOI 10.1074/jbc.M111891200; Sakumi K, 1997, CANCER RES, V57, P2415; Satoh Y, 2003, J BIOCHEM, V133, P303, DOI 10.1093/jb/mvg041; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Tamaru H, 2001, NATURE, V414, P277, DOI 10.1038/35104508; URANO T, 1993, ONCOGENE, V8, P1371; VONWRONSKI MA, 1992, ONCOL RES, V4, P167; Watts GS, 1997, MOL CELL BIOL, V17, P5612, DOI 10.1128/MCB.17.9.5612; Whitehall VLJ, 2001, CANCER RES, V61, P827; Xin ZH, 2001, AM J HUM GENET, V69, P1389, DOI 10.1086/324469	52	138	145	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8835	8844		10.1038/sj.onc.1207183	http://dx.doi.org/10.1038/sj.onc.1207183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14647440				2022-12-28	WOS:000186982200004
J	Vlaeminck-Guillem, V; Vanacker, JM; Verger, A; Tomavo, N; Stehelin, D; Laudet, V; Duterque-Coquillaud, M				Vlaeminck-Guillem, V; Vanacker, JM; Verger, A; Tomavo, N; Stehelin, D; Laudet, V; Duterque-Coquillaud, M			Mutual repression of transcriptional activation between the ETS-related factor ERG and estrogen receptor	ONCOGENE			English	Article						nuclear receptors; orphan receptors; ETS proteins; transcription factors; repression	CREB-BINDING-PROTEIN; NUCLEAR RECEPTORS; GLUCOCORTICOID-RECEPTOR; ANDROGEN RECEPTOR; STEROID-HORMONE; GENE-EXPRESSION; DNA-BINDING; FUNCTIONAL INTERFERENCE; FAMILY; DOMAIN	Transcription factors are known to interact with each other to modulate their transcriptional activity. In this study, we found that the transcriptional activity of human Erg (one of the Ets family-transcription factors) was repressed by several nuclear receptors, including human estrogen receptor ERalpha, nonsteroid receptors and orphan receptors. Conversely, Erg inhibited ERalpha-dependent transcription. These reciprocal functional interactions extended to other nuclear receptors such as thyroid hormone and retinoic acid receptors, as well as to Fli1, an ERG-related ETS factor. Although similarly inhibited by overexpression of the orphan nuclear receptors ERR1 and RORalpha, ERG activity was unaffected by either REV-ERBalpha1 or COUP-TFII. The antagonism between ERG and ERalpha did not depend on DNA binding inhibition or direct protein-protein interactions. Repression of ERalpha-dependent transcription required the carboxyterminal and aminoterminal transactivation domains of Erg whereas the carboxyterminal AF-2 domain of ERalpha was necessary for repression of Erg activity. Reciprocal inhibition between Erg and ERalpha was not alleviated by overexpressing CBP, SRC-1 or RIP 140, three nuclear coactivator proteins. A negative cross-talk observed between Erg and ERa expands their potential range of regulation and may be relevant in vivo, particularly in endothelial, urogenital and cartilaginous tissues where both factors are expressed.	Inst Biol Lille, CNRS, UMR 8526, F-59021 Lille, France; Ecole Normale Super Lyon, CNRS, UMR 5665, Lyon, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)	Duterque-Coquillaud, M (corresponding author), Inst Biol Lille, CNRS, UMR 8526, BP 447,1 Rue Calmette, F-59021 Lille, France.			verger, alexis/0000-0002-0299-2344; Duterque-Coquillaud, Martine/0000-0003-3943-5629				Aurrekoetxea-Hernandez K, 2000, J VIROL, V74, P4988, DOI 10.1128/JVI.74.11.4988-4998.2000; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Chang CY, 1999, MOL CELL BIOL, V19, P8226; COMMITTEE NRN, 1999, CELL, V97, P161; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Darby TG, 1997, ONCOGENE, V15, P3067, DOI 10.1038/sj.onc.1201503; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Dwivedi PP, 2000, J BIOL CHEM, V275, P47, DOI 10.1074/jbc.275.1.47; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; Glass CK, 2000, GENE DEV, V14, P121; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; INCE BA, 1993, J BIOL CHEM, V268, P14026; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; Lee JS, 1996, MOL CELL BIOL, V16, P4312; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; LIBERMANN TA, 1993, MOL CELL BIOL, V13, P5957, DOI 10.1128/MCB.13.10.5957; Lopez GN, 1999, MOL ENDOCRINOL, V13, P897, DOI 10.1210/me.13.6.897; Luo GY, 2000, MOL ENDOCRINOL, V14, P114, DOI 10.1210/me.14.1.114; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Pettersson K, 1997, MOL ENDOCRINOL, V11, P1486, DOI 10.1210/me.11.10.1486; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; Potthoff SJ, 1996, MOL ENDOCRINOL, V10, P1095, DOI 10.1210/me.10.9.1095; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Simpson S, 1997, ONCOGENE, V14, P2149, DOI 10.1038/sj.onc.1201058; Takahashi T, 2000, ONCOGENE, V19, P134, DOI 10.1038/sj.onc.1203228; Tolon RM, 2000, MOL CELL BIOL, V20, P8793, DOI 10.1128/MCB.20.23.8793-8802.2000; Vanacker JM, 1999, MOL ENDOCRINOL, V13, P764, DOI 10.1210/me.13.5.764; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Yang C, 1998, MOL CELL BIOL, V18, P2218, DOI 10.1128/MCB.18.4.2218; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	57	7	8	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8072	8084		10.1038/sj.onc.1207094	http://dx.doi.org/10.1038/sj.onc.1207094			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603248				2022-12-28	WOS:000186403400002
